PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ojuka, EO; Jones, TE; Han, DH; Chen, M; Holloszy, JO				Ojuka, EO; Jones, TE; Han, DH; Chen, M; Holloszy, JO			Raising Ca2+ in L6 myotubes mimics effects of exercise on mitochondrial biogenesis in muscle	FASEB JOURNAL			English	Article						PPAR gamma coactivator 1; mitochondrial transcription factor A; NRF-1; NRF-2	ACTIVATED PROTEIN-KINASE; TRANSCRIPTIONAL COACTIVATOR PGC-1; RAT SKELETAL-MUSCLE; GENE-EXPRESSION; BIOCHEMICAL ADAPTATION; SARCOPLASMIC-RETICULUM; EPITROCHLEARIS MUSCLE; ENERGY-METABOLISM; NUCLEAR; CELLS	Skeletal muscle adapts to endurance exercise with an increase in mitochondria. Muscle contractions generate numerous potential signals. To determine which of these stimulates mitochondrial biogenesis, we are using L6 myotubes. Using this model we have found that raising cytosolic Ca2+ induces an increase in mitochondria. In this study, we tested the hypothesis that raising cytosolic Ca2+ in L6 myotubes induces increased expression of PGC-1, NRF-1, NRF-2, and mtTFA, factors that have been implicated in mitochondrial biogenesis and in the adaptation of muscle to exercise. Raising cytosolic Ca2+ by exposing L6 myotubes to caffeine for 5 h induced significant increases in PGC-1 and mtTFA protein expression and in NRF-1 and NRF-2 binding to DNA. These adaptations were prevented by dantrolene, which blocks Ca2+ release from the SR. Exposure of L6 myotubes to caffeine for 5 h per day for 5 days induced significant increases in mitochondrial marker enzyme proteins. Our results show that the adaptive response of L6 myotubes to an increase in cytosolic Ca2+ mimics the stimulation of mitochondrial biogenesis by exercise. They support the hypothesis that an increase in cytosolic Ca2+ is one of the signals that mediate increased mitochondrial biogenesis in muscle.	Washington Univ, Sch Med, Dept Med, Sect Appl Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Holloszy, JO (corresponding author), Washington Univ, Sch Med, Dept Med, Sect Appl Physiol, Campus Box 8113,4566 Scott Ave, St Louis, MO 63110 USA.	jhollosz@im.wustl.edu			NIA NIH HHS [AG00425, AG00078] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG000425, R01AG000425, R56AG000425] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; BIANCHI CP, 1961, J GEN PHYSIOL, V44, P845, DOI 10.1085/jgp.44.5.845; BOOTH FW, 1977, J BIOL CHEM, V252, P416; BOOTH FW, 1997, HDB PHYSL 12, P1075; BRAIDOTTI G, 1993, J BIOL CHEM, V268, P1109; CONSTABLE SH, 1987, AM J PHYSIOL, V253, pC316, DOI 10.1152/ajpcell.1987.253.2.C316; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; DAVIES KJA, 1981, ARCH BIOCHEM BIOPHYS, V209, P539, DOI 10.1016/0003-9861(81)90312-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY GA, 1987, J BIOL CHEM, V262, P9109; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; Freyssenet D, 1999, J BIOL CHEM, V274, P9305, DOI 10.1074/jbc.274.14.9305; Gordon JW, 2001, J APPL PHYSIOL, V90, P389, DOI 10.1152/jappl.2001.90.1.389; Goto M, 2000, BIOCHEM BIOPH RES CO, V274, P350, DOI 10.1006/bbrc.2000.3134; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; HOLLOSZY JO, 1979, AM J PHYSIOL, V236, pR180, DOI 10.1152/ajpregu.1979.236.3.R180; HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278; Holmes BF, 1999, J APPL PHYSIOL, V87, P1990, DOI 10.1152/jappl.1999.87.5.1990; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; LAWRENCE JC, 1983, AM J PHYSIOL, V244, pC348, DOI 10.1152/ajpcell.1983.244.5.C348; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Li B, 1999, J BIOL CHEM, V274, P17534, DOI 10.1074/jbc.274.25.17534; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; MURAKAMI S, 1998, J PLASMA FUSION RES, V1, P122; OHIRA Y, 1987, AM J PHYSIOL, V253, pC639, DOI 10.1152/ajpcell.1987.253.5.C639; Ojuka EO, 2000, J APPL PHYSIOL, V88, P1072, DOI 10.1152/jappl.2000.88.3.1072; Ojuka EO, 2002, AM J PHYSIOL-ENDOC M, V283, pE1040, DOI 10.1152/ajpendo.00242.2002; Ojuka EO, 2002, AM J PHYSIOL-ENDOC M, V282, pE1008, DOI 10.1152/ajpendo.00512.2001; PALADE P, 1987, J BIOL CHEM, V262, P6142; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; REN JM, 1993, AM J PHYSIOL, V264, pC146, DOI 10.1152/ajpcell.1993.264.1.C146; Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3; SHOUBRIDGE EA, 1985, BIOCHEM J, V232, P125, DOI 10.1042/bj2320125; Terada S, 2002, BIOCHEM BIOPH RES CO, V296, P350, DOI 10.1016/S0006-291X(02)00881-1; Terada S, 2001, J APPL PHYSIOL, V90, P2019, DOI 10.1152/jappl.2001.90.6.2019; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; VANWINKLE WB, 1976, SCIENCE, V193, P1130, DOI 10.1126/science.959824; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Zheng DH, 2001, J APPL PHYSIOL, V91, P1073, DOI 10.1152/jappl.2001.91.3.1073	43	161	177	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					675	681		10.1096/fj.02-0951com	http://dx.doi.org/10.1096/fj.02-0951com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665481				2022-12-28	WOS:000182580100013
J	Takahashi, K; Saishin, Y; Saishin, Y; Silva, RL; Oshima, Y; Oshima, S; Melia, M; Paszkiet, B; Zerby, D; Kadan, MJ; Liau, G; Kaleko, M; Connelly, S; Luo, TC; Campochiaro, PA				Takahashi, K; Saishin, Y; Saishin, Y; Silva, RL; Oshima, Y; Oshima, S; Melia, M; Paszkiet, B; Zerby, D; Kadan, MJ; Liau, G; Kaleko, M; Connelly, S; Luo, TC; Campochiaro, PA			Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment	FASEB JOURNAL			English	Article						blood-retinal barrier; diabetic retinopathy; macular edema; ocular neovascularization; vascular endothelial growth factor	ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; MEDIATED GENE-TRANSFER; ADENOVIRAL VECTORS; TUMOR-GROWTH; ANGIOGENESIS; INHIBITION; MICE; ANGIOSTATIN; METASTASES	Endostatin, a proteolytic fragment of collagen XVIII, is an endogenous inhibitor of tumor angiogenesis that also inhibits choroidal neovascularization. In this study, we assessed the effects of increased intraocular expression of endostatin on vascular endothelial growth factor (VEGF)induced changes in the retina. After subretinal injection of a pair of gutless adenoviral vectors (AGV) designed to provide tamoxifen-inducible expression of endostatin, diffuse endostatin immunoreactivity was induced thoroughout the retina by administration of tamoxifen. Induction of endostatin in double transgenic mice with doxycycline-induced expression of VEGF in the retina resulted in significant suppression of leakage of intravascular [H-3]mannitol into the retina. The ability of endostatin to reduce VEGF-induced retinal vascular permeability was confirmed by using [H-3]mannitol leakage and two other parameters, fluorescein leakage and retinal thickness, after subretinal injection of a bovine immunodeficiency lentiviral vector coding for endostatin (BIV-vectored endostatin, or BIVendostatin). Subretinal injection of BIVendostatin resulted in more discrete, less intense staining for endostatin in the retina than that seen with the inducible AGV system, which suggested lower levels and allowed visualization of sites where endostatin was concentrated. Endostatin staining outlined retinal blood vessels, which suggested endostatin binding to a component of vessel walls. More prolonged or higher level expression of VEGF in the retina resulted in neovascularization and retinal detachment, both of which were also significantly reduced by BIVendostatin. These data suggest that endostatin may be an endogenous inhibitor of vasopermeability as well as neovascularization. In patients with diabetic retinopathy, endostatin gene transfer may provide a way to decrease the risk of three causes of visual loss: macular edema, neovascularization, and retinal detachment.	Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; Adv Vis Therapies Inc, Rockville, MD 20854 USA	Johns Hopkins University; Johns Hopkins University	Campochiaro, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Maumenee 719,600 N Wolfe St, Baltimore, MD 21287 USA.	pcampo@jhmi.edu						Ackley BD, 2001, J CELL BIOL, V152, P1219, DOI 10.1083/jcb.152.6.1219; AGRESTI A, 1990, J AM STAT ASSOC, V85, P453, DOI 10.2307/2289783; Ando A, 2002, J CELL PHYSIOL, V191, P116, DOI 10.1002/jcp.10083; BLANKS JC, 1986, J COMP NEUROL, V254, P543, DOI 10.1002/cne.902540407; Blezinger P, 1999, NAT BIOTECHNOL, V17, P343, DOI 10.1038/7895; Chang MA, 2000, INVEST OPHTH VIS SCI, V41, P4281; Chen QR, 1999, CANCER RES, V59, P3308; Das A, 1999, ARCH OPHTHALMOL-CHIC, V117, P498; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Derevjanik NL, 2002, INVEST OPHTH VIS SCI, V43, P2462; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Dixelius J, 2002, CANCER RES, V62, P1944; Feldman AL, 2000, CANCER RES, V60, P1503; Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Hackett SF, 2000, J CELL PHYSIOL, V184, P275, DOI 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.3.CO;2-Z; Hackett SF, 2002, J CELL PHYSIOL, V192, P182, DOI 10.1002/jcp.10128; Hanai J, 2002, J BIOL CHEM, V277, P16464, DOI 10.1074/jbc.M112274200; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kim YM, 2002, J BIOL CHEM, V277, P27872, DOI 10.1074/jbc.M202771200; Kim YM, 2000, CANCER RES, V60, P5410; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; Kuo CJ, 2001, J CELL BIOL, V152, P1233, DOI 10.1083/jcb.152.6.1233; KURITZ SJ, 1988, ANNU REV PUBL HEALTH, V9, P123, DOI 10.1146/annurev.pu.09.050188.001011; Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684; Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158; MacDonald NJ, 2001, J BIOL CHEM, V276, P25190, DOI 10.1074/jbc.M100743200; MAIONE TE, 1990, SCIENCE, V247, P77, DOI 10.1126/science.1688470; Matukonis M, 2002, HUM GENE THER, V13, P1293, DOI 10.1089/104303402760128522; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994; Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428; Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114; Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2; Okamoto N, 1997, AM J PATHOL, V151, P281; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6; Polito A, 2002, AM J OPHTHALMOL, V134, P240, DOI 10.1016/S0002-9394(02)01528-3; Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408; Reddy PS, 2002, MOL THER, V5, P63, DOI 10.1006/mthe.2001.0510; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Sauter BV, 2000, P NATL ACAD SCI USA, V97, P4802, DOI 10.1073/pnas.090065597; Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com; Takahashi K, 2002, HUM GENE THER, V13, P1305, DOI 10.1089/104303402760128531; Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180; Toietta G, 2002, MOL THER, V5, P204, DOI 10.1006/mthe.2002.0532; Urbich C, 2002, FASEB J, V16, P706, DOI 10.1096/fj.01-0637fje; Xu L, 2001, MOL THER, V3, P262, DOI 10.1006/mthe.2000.0254; Yamada E, 2001, HISTOL HISTOPATHOL, V16, P87, DOI 10.14670/HH-16.87; Yin GY, 2002, MOL THER, V5, P547, DOI 10.1006/mthe.2002.0590; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4	55	108	119	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					896	+		10.1096/fj.02-0824fje	http://dx.doi.org/10.1096/fj.02-0824fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670875				2022-12-28	WOS:000181892600007
J	Koike, H; Morishita, R; Iguchi, S; Aoki, M; Matsumoto, K; Nakamura, T; Yokoyama, C; Tanabe, T; Ogihara, T; Kaneda, Y				Koike, H; Morishita, R; Iguchi, S; Aoki, M; Matsumoto, K; Nakamura, T; Yokoyama, C; Tanabe, T; Ogihara, T; Kaneda, Y			Enhanced angiogenesis and improvement of neuropathy by cotransfection of human hepatocyte growth factor and prostacyclin synthase gene	FASEB JOURNAL			English	Article						peripheral arterial disease; vasodilation; angiogenesis; gene therapy; diabetes	PERIPHERAL ARTERIAL-DISEASE; NERVE-CONDUCTION-VELOCITY; HUMAN DIABETIC-NEUROPATHY; LIMB ISCHEMIA MODEL; BLOOD-FLOW; POTENTIAL ROLE; PHVEGF(165); EXPRESSION; RATS; HGF	The current therapeutic angiogenesis strategy to treat ischemic disease by using angiogenic growth factors has been limited to use of a single gene. However, as vasodilator substances such as prostacyclin are widely used for the treatment of peripheral arterial disease, it might be useful to combine angiogenesis with vasodilation of new vessels. In a mouse hind limb ischemia model, cotransfection of the hepatocyte growth factor (HGF) gene with the prostacyclin synthase gene demonstrated a further increase in blood flow and capillary density compared with a single gene. Even in the rabbit ischemia model, cotransfection of HGF plasmid with the prostacyclin synthase gene demonstrated a further increase in angiogenic activity compared with HGF alone. Because peripheral neuropathy due to diabetes is common for significant morbidity, we examined the hypothesis that experimental diabetic neuropathy can be reversed by HGF and prostacyclin synthase genes. Severe peripheral neuropathy, characterized by significant slowing of nerve conduction velocity compared with nondiabetic control animals, was ameliorated. Overall, cotransfection of the prostacyclin synthase and HGF genes is more effective than single-gene transfection to stimulate angiogenesis, and it significantly improved neuropathy. These data provide important information relating to the clinical application of therapeutic angiogenesis to treat peripheral arterial disease.	Osaka Univ, Sch Med, Div Gene Therapy Sci, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Dept Geriatr Med, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Oncol,Div Biochem, Suita, Osaka 565, Japan; Natl Cardiovasc Res Ctr, Dept Pharmacol, Suita, Osaka, Japan	Osaka University; Osaka University; Osaka University; National Cerebral & Cardiovascular Center - Japan	Morishita, R (corresponding author), Osaka Univ, Sch Med, Div Gene Therapy Sci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	morishit@geriat.med.osaka-u.ac.jp	Matsumoto, Kunio/D-8441-2015	Matsumoto, Kunio/0000-0002-6532-4482				Aoki M, 2000, GENE THER, V7, P417, DOI 10.1038/sj.gt.3301104; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; CAMERON NE, 1991, AM J PHYSIOL, V261, pE1, DOI 10.1152/ajpendo.1991.261.1.E1; Davey F, 2000, MOL CELL NEUROSCI, V15, P79, DOI 10.1006/mcne.1999.0803; DORMANDY J, 1989, J CARDIOVASC SURG, V30, P50; DYCK PJ, 1989, NEUROLOGY, V39, P111, DOI 10.1212/WNL.39.1.111; HARA S, 1995, BIOCHEM BIOPH RES CO, V216, P862, DOI 10.1006/bbrc.1995.2701; Hayashi S, 1999, CIRCULATION, V100, P301; HIRST DG, 1979, BRIT J CANCER, V39, P159, DOI 10.1038/bjc.1979.26; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; Isner JM, 1998, J VASC SURG, V28, P964, DOI 10.1016/S0741-5214(98)70022-9; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; MALIK RA, 1989, DIABETOLOGIA, V32, P92, DOI 10.1007/BF00505180; Melian EB, 2002, DRUGS, V62, P107, DOI 10.2165/00003495-200262010-00005; MIYATA A, 1994, BIOCHEM BIOPH RES CO, V200, P1728, DOI 10.1006/bbrc.1994.1652; Miyazawa T, 1998, J CEREBR BLOOD F MET, V18, P345, DOI 10.1097/00004647-199804000-00001; Morishita R, 1999, HYPERTENSION, V33, P1379, DOI 10.1161/01.HYP.33.6.1379; Morishita R, 1997, DIABETOLOGIA, V40, P1053, DOI 10.1007/s001250050787; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakano N, 1998, HYPERTENSION, V32, P444, DOI 10.1161/01.HYP.32.3.444; Rajagopalan S, 2001, CIRCULATION, V104, P753, DOI 10.1161/hc3201.095192; RALEVIC V, 1991, CIRCULATION, V84, P1, DOI 10.1161/01.CIR.84.1.1; Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468; RUTHERFORD RB, 1986, J VASC SURG, V4, P80; Schratzberger P, 2000, NAT MED, V6, P405, DOI 10.1038/74664; STANLEY EF, 1981, EXP NEUROL, V71, P497, DOI 10.1016/0014-4886(81)90027-3; STEVENS EJ, 1994, DIABETOLOGIA, V37, P43, DOI 10.1007/BF00428776; Szczeklik A, 1980, Adv Prostaglandin Thromboxane Res, V7, P687; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Taniyama Y, 2001, CIRCULATION, V104, P2344, DOI 10.1161/hc4401.098470; Taniyama Y, 2001, GENE THER, V8, P181, DOI 10.1038/sj.gt.3301379; TESFAYE S, 1993, DIABETOLOGIA, V36, P1266, DOI 10.1007/BF00400804; TESFAYE S, 1992, DIABETOLOGIA, V35, P155, DOI 10.1007/BF00402548; Todaka T, 1999, STROKE, V30, P419, DOI 10.1161/01.STR.30.2.419; TUCK RR, 1984, BRAIN, V107, P935, DOI 10.1093/brain/107.3.935; Van Belle E, 1998, CIRCULATION, V97, P381; Vincent KA, 2000, CIRCULATION, V102, P2255; WHITELEY SJ, 1985, EXP NEUROL, V89, P314, DOI 10.1016/0014-4886(85)90092-5; YAMADA C, 1995, BIOMED RES-TOKYO, V16, P105; Yang XM, 1998, J NEUROSCI, V18, P8369; YOUNG MJ, 1995, DIABETOLOGIA, V38, P1051, DOI 10.1007/s001250050390	42	44	56	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					779	+		10.1096/fj.02-0754fje	http://dx.doi.org/10.1096/fj.02-0754fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586736				2022-12-28	WOS:000181456900026
J	Kuijpers, MJE; Schulte, V; Bergmeier, W; Lindhout, T; Brakebusch, C; Offermanns, S; Fassler, R; Heemskerk, JWM; Nieswandt, B				Kuijpers, MJE; Schulte, V; Bergmeier, W; Lindhout, T; Brakebusch, C; Offermanns, S; Fassler, R; Heemskerk, JWM; Nieswandt, B			Complementary roles of platelet glycoprotein VI and integrin alpha 2 beta 1 in collagen-induced thrombus formation in flowing whole blood ex vivo	FASEB JOURNAL			English	Article						collagen receptors; flow model; phosphatidylserine; platelet aggregation; whole blood perfusion	VON-WILLEBRAND-FACTOR; RECEPTOR GAMMA-CHAIN; COUPLED RECEPTORS; PHOSPHOLIPASE-C; IB INTERACTION; CA2+ ENTRY; ACTIVATION; ADHESION; MOUSE; KINASE	Platelets interact vigorously with subendothelial collagens that are exposed by injury or pathological damage of a vessel wall. The collagen-bound platelets trap other platelets to form aggregates, and they expose phosphatidylserine (PS) required for coagulation. Both processes are implicated in the formation of vaso-occlusive thrombi. We previously demonstrated that the immunoglobulin receptor glycoprotein VI (GPVI), but not integrin alpha2beta1, is essential in priming platelet-collagen interaction and subsequent aggregation. Here, we report that these receptors have yet a complementary function in ex vivo thrombus formation during perfusion of whole blood over collagen. With mice deficient in GPVI or blocking antibodies, we found that GPVI was indispensable for collagen-dependent Ca2+ mobilization, exposure of PS, and aggregation of platelets. Deficiency of integrin beta1 reduces the GPVI-evoked responses but still allows the formation of loose platelet aggregates. By using mice deficient in Galpha(q) or specific thromboxane A(2) and ADP antagonists, we show that these autocrine agents mediated aggregation but not collagen-induced Ca2+ mobilization or PS exposure. Collectively, these data indicate that integrin alpha2beta1 facilitates the central function of GPVI in the platelet activation processes that lead to thrombus formation, whereas the autocrine thromboxane A(2) and ADP serve mainly to trigger aggregate formation.	Univ Maastricht, CARIM, Dept Biochem & Human Biol, NL-6200 MD Maastricht, Netherlands; Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Germany; Max Planck Inst Biochem, Dept Mol Med, D-82152 Martinsried, Germany; Heidelberg Univ, Dept Pharmacol, D-69120 Heidelberg, Germany	Maastricht University; Maastricht University Medical Centre (MUMC); University of Wurzburg; Max Planck Society; Ruprecht Karls University Heidelberg	Heemskerk, JWM (corresponding author), Univ Maastricht, CARIM, Dept Biochem, POB 616, NL-6200 MD Maastricht, Netherlands.	jwm.heemskerk@bioch.unimaas.nl	Kuijpers, Marijke/AAN-9876-2021; Heemskerk, Johan/AAM-8323-2021; Offermanns, Stefan/L-3313-2017	Heemskerk, Johan/0000-0002-2848-5121; Offermanns, Stefan/0000-0001-8676-6805; Brakebusch, Cord/0000-0002-9342-1634				ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; Briede JJ, 2001, THROMB HAEMOSTASIS, V85, P509, DOI 10.1055/s-0037-1615613; Chen JC, 2002, AM J PATHOL, V161, P337, DOI 10.1016/S0002-9440(10)64185-5; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; COLLER BS, 1989, BLOOD, V74, P182; Furihata K, 2001, ARTERIOSCL THROM VAS, V21, P1857, DOI 10.1161/hq1001.096643; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Hechler B, 1998, BLOOD, V92, P152, DOI 10.1182/blood.V92.1.152.413k27_152_159; Heemskerk JWM, 2002, THROMB HAEMOSTASIS, V88, P186; Heemskerk JWM, 1997, BLOOD, V90, P2615, DOI 10.1182/blood.V90.7.2615.2615_2615_2625; Heemskerk JWM, 2001, J PHYSIOL-LONDON, V535, P625, DOI 10.1111/j.1469-7793.2001.00625.x; HEEMSKERK JWM, 1994, EUR J BIOCHEM, V223, P543, DOI 10.1111/j.1432-1033.1994.tb19023.x; Heemskerk JWM, 1999, THROMB HAEMOSTASIS, V81, P782; Jackson SP, 2000, TRENDS CARDIOVAS MED, V10, P192, DOI 10.1016/S1050-1738(00)00062-1; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Kehrel B, 1998, BLOOD, V91, P491; Moroi M, 1997, THROMB HAEMOSTASIS, V78, P439; Moroi M, 1997, BLOOD, V90, P4413; Moroz LL, 2000, NITR OXIDE BIO MED, V2, P1; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Nieswandt B, 2001, BLOOD, V97, P3829, DOI 10.1182/blood.V97.12.3829; Nieswandt B, 2001, J EXP MED, V193, P459, DOI 10.1084/jem.193.4.459; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Pasquet JM, 2000, EMBO J, V19, P2793, DOI 10.1093/emboj/19.12.2793; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Potocnik AJ, 2000, IMMUNITY, V12, P653, DOI 10.1016/S1074-7613(00)80216-2; Roest M, 2000, BLOOD, V96, P1433, DOI 10.1182/blood.V96.4.1433.h8001433_1433_1437; Ruggeri ZM, 2001, HEMOSTASIS THROMBOSI, P683; SAELMAN EUM, 1994, BLOOD, V83, P3240, DOI 10.1182/blood.V83.11.3240.bloodjournal83113240; Savage B, 1999, BLOOD, V94, P2704, DOI 10.1182/blood.V94.8.2704.420k41_2704_2715; Siljander P, 2001, ARTERIOSCL THROM VAS, V21, P618, DOI 10.1161/01.ATV.21.4.618; Storey RF, 2000, BRIT J HAEMATOL, V110, P925, DOI 10.1046/j.1365-2141.2000.02208.x; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Turner NA, 2001, BLOOD, V98, P3340, DOI 10.1182/blood.V98.12.3340; Verkleij MW, 1998, BLOOD, V91, P3808; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276; Wu YP, 2000, ARTERIOSCL THROM VAS, V20, P1661, DOI 10.1161/01.ATV.20.6.1661; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	44	121	129	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					685	+		10.1096/fj.02-0381fje	http://dx.doi.org/10.1096/fj.02-0381fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586747				2022-12-28	WOS:000181456900019
J	Miller, G; Lahrs, S; DeMatteo, RP				Miller, G; Lahrs, S; DeMatteo, RP			Overexpression of interleukin-12 enables dendritic cells to activate NK cells and confer systemic antitumor immunity	FASEB JOURNAL			English	Article						immunity; cytokines; tumor	NATURAL-KILLER-CELLS; INTERFERON-GAMMA PRODUCTION; NF-KAPPA-B; IFN-GAMMA; ANTIMETASTATIC ACTIVITY; RECOMBINANT IL-12; TUMOR-REGRESSION; RECEPTOR; MACROPHAGE; EXPRESSION	Dendritic cells (DC) are initiators of T cell-mediated immunity. However, less is known about the relationship between DC and natural killer (NK) cells, and direct evidence of their interaction in vivo is scarce. Interleukin (IL)-12 is an activator of both DC and NK cells. We postulated that secretion of IL-12 by DC would enable them to activate NK cells. Bone marrow-derived DC propagated only in granulocyte macrophage colony-stimulating factor did not activate NK cells. In contrast, DC engineered to express IL-12 markedly stimulated NK cells as determined by coculture experiments in vitro, assays of NK cells isolated from treated animals, and survival experiments in a systemic tumor model. Activation depended on both DC-NK cellular interaction and secretion of IL-12. Adoptive transfer of DC expressing IL-12 to mice markedly increased NK cell interferon-gamma production and lytic activity in vivo. Treated mice were also protected against B16 melanoma hepatic metastases. The in vivo effects on NK cells were DC-specific. Administration of IL-12 protein alone or melanoma cells or fibroblasts engineered to secrete IL-12 were only weakly activating. Our findings demonstrate that IL-12 expression by DC enables them to activate NK cells and provide evidence for a substantial DC-NK relationship in vivo.	Mem Sloan Kettering Canc Ctr, Hepatobiliary Serv, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	DeMatteo, RP (corresponding author), Mem Sloan Kettering Canc Ctr, Hepatobiliary Serv, 1275 York Ave, New York, NY 10021 USA.	dematter@mskcc.org						Ahuja SS, 1998, J IMMUNOL, V161, P868; Amakata Y, 2001, CLIN EXP IMMUNOL, V124, P214, DOI 10.1046/j.1365-2249.2001.01550.x; Atkins MB, 1997, CLIN CANCER RES, V3, P409; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BRUNDA MJ, 1993, J EXP MED, V178, P1223, DOI 10.1084/jem.178.4.1223; CHAN SH, 1992, J IMMUNOL, V148, P92; COHEN J, 1995, SCIENCE, V270, P908; DAndrea A, 1996, J EXP MED, V184, P789, DOI 10.1084/jem.184.2.789; DeMatteo RP, 1997, J VIROL, V71, P5330, DOI 10.1128/JVI.71.7.5330-5335.1997; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; Fernandez NC, 1999, NAT MED, V5, P405, DOI 10.1038/7403; Furumoto K, 2000, INT J CANCER, V87, P665, DOI 10.1002/1097-0215(20000901)87:5<665::AID-IJC8>3.0.CO;2-F; GATELY MK, 1994, INT IMMUNOL, V6, P157, DOI 10.1093/intimm/6.1.157; Gerosa F, 2002, J EXP MED, V195, P327, DOI 10.1084/jem.20010938; Grohmann U, 1998, IMMUNITY, V9, P315, DOI 10.1016/S1074-7613(00)80614-7; Hendrzak JA, 1996, CURR TOP MICROBIOL, V213, P65; Heufler C, 1996, EUR J IMMUNOL, V26, P659, DOI 10.1002/eji.1830260323; Hirschowitz EA, 2000, GENE THER, V7, P1112, DOI 10.1038/sj.gt.3301210; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jenne L, 2000, CANCER RES, V60, P4446; Kelly JJ, 1998, FASEB J, V12, pA14; Kikuchi T, 2000, CANCER RES, V60, P6391; Kim KD, 1999, ARCH PHARM RES, V22, P340, DOI 10.1007/BF02979055; KLEIN E, 1993, CURR OPIN IMMUNOL, V5, P714, DOI 10.1016/0952-7915(93)90126-D; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; Kodama T, 1999, EUR J IMMUNOL, V29, P1390, DOI 10.1002/(SICI)1521-4141(199904)29:04<1390::AID-IMMU1390>3.3.CO;2-3; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; MANETTI R, 1994, J EXP MED, V179, P1273, DOI 10.1084/jem.179.4.1273; Maruo S, 1997, J LEUKOCYTE BIOL, V61, P346, DOI 10.1002/jlb.61.3.346; Melero I, 1999, GENE THER, V6, P1779, DOI 10.1038/sj.gt.3301010; Morelli AE, 2000, J VIROL, V74, P9617, DOI 10.1128/JVI.74.20.9617-9628.2000; Nagayama H, 2000, J IMMUNOL, V165, P59, DOI 10.4049/jimmunol.165.1.59; NASTALA CL, 1994, J IMMUNOL, V153, P1697; Ng P, 2000, HUM GENE THER, V11, P693; Nishioka Y, 2001, EUR J IMMUNOL, V31, P2633, DOI 10.1002/1521-4141(200109)31:9<2633::AID-IMMU2633>3.0.CO;2-2; Nouri-Shirazi M, 2000, J IMMUNOL, V165, P3797, DOI 10.4049/jimmunol.165.7.3797; OGarra A, 1995, RES IMMUNOL, V146, P466, DOI 10.1016/0923-2494(96)83017-3; Ohteki T, 1999, J EXP MED, V189, P1981, DOI 10.1084/jem.189.12.1981; Piccioli D, 2002, J EXP MED, V195, P335, DOI 10.1084/jem.20010934; TAHARA H, 1994, CANCER RES, V54, P182; Wilkinson VL, 1996, J IMMUNOL METHODS, V189, P15, DOI 10.1016/0022-1759(95)00223-5; Zitvogel L, 1995, RES IMMUNOL, V146, P628, DOI 10.1016/0923-2494(96)83041-0; Zitvogel L, 2002, J EXP MED, V195, pf9, DOI 10.1084/jem.20012040; ZITVOGEL L, 1996, ANN NY ACAD SCI, V795, P84	44	38	43	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					728	+		10.1096/fj.02-0900fje	http://dx.doi.org/10.1096/fj.02-0900fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594171				2022-12-28	WOS:000181456900004
J	Campbell, CH; Bulayeva, N; Brown, DB; Gametchu, B; Watson, CS				Campbell, CH; Bulayeva, N; Brown, DB; Gametchu, B; Watson, CS			Regulation of the membrane estrogen receptor-alpha: role of cell density, serum, cell passage number, and estradiol	FASEB JOURNAL			English	Article						estrogens; nongenomic effects of steroids; rapid; nuclear receptors	PITUITARY-TUMOR CELLS; MESSENGER-RNA EXPRESSION; ACTIVATED PROTEIN-KINASE; NITRIC-OXIDE SYNTHASE; BREAST-CANCER-CELLS; RAT PITUITARY; PLASMA-MEMBRANE; GLUCOCORTICOID RECEPTOR; MCF-7 CELLS; EPITHELIAL-CELLS	We used modified immunocytochemical conditions to quantify a membrane form of estrogen receptor-alpha (mERalpha) in a rat pituitary tumor cell line, GH(3)/B6/F10. We studied the regulation of mERalpha vs. levels of intracellular ERalpha (iERalpha) using our 96-well plate immunoassay. The anti-ERalpha antibody C542 was used to label the ERalpha (via conjugated alkaline phosphatase) in fixed permeabilized (for iERalpha) vs. nonpermeabilized cells (for mERalpha). Expression of mERalpha was highest at low cell densities (<1000 cells/well) and decreased significantly at densities where cellular processes touched, whereas the more abundant iER alpha increased with increasing cell density over the same range. Serum starvation for 48 h caused increases in mER alpha, whereas iER alpha levels showed no significant changes. A large decline in mER alpha and iER alpha levels with cell passage number was observed. Minutes after nM 17 beta-estradiol (E(2)) treatment, a portion of the cells rounded up and detached from the culture plate, whereas nM cholesterol had no such effect. Although E(2) treatment did not change mER alpha levels, the antigen was reorganized from a fine particulate to aggregation into asymmetric large granules of staining. That common culturing conditions favor down-regulation of mER alpha may explain the relatively few reports of this protein in other experimental systems.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA	University of Texas System; University of Texas Medical Branch Galveston; Medical College of Wisconsin	Watson, CS (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.	cswatson@utmb.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010987, T32ES007254] Funding Source: NIH RePORTER; NIEHS NIH HHS [T32 ES007254, R01 ES010987, 5232ES07254] Funding Source: Medline; PHS HHS [32481] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Agarwal VR, 2000, MOL CELL ENDOCRINOL, V162, P9, DOI 10.1016/S0303-7207(00)00227-6; Beresford N, 2000, TOXICOL APPL PHARM, V162, P22, DOI 10.1006/taap.1999.8817; BRUBAKER KD, 1994, BIOCHEM BIOPH RES CO, V200, P899, DOI 10.1006/bbrc.1994.1535; BRUNNER N, 1993, CANCER RES, V53, P283; Campbell CH, 2001, STEROIDS, V66, P727, DOI 10.1016/S0039-128X(01)00106-4; Carlson KE, 1997, BIOCHEMISTRY-US, V36, P14897, DOI 10.1021/bi971746l; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; Chen FH, 1999, J CELL BIOCHEM, V74, P430, DOI 10.1002/(SICI)1097-4644(19990901)74:3<430::AID-JCB11>3.0.CO;2-5; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; CLANCY AN, 1994, NEUROENDOCRINOLOGY, V59, P553; DePasquale JA, 1998, HISTOCHEM CELL BIOL, V110, P485, DOI 10.1007/s004180050310; Diba F, 2001, J CELL BIOCHEM, V81, P149, DOI 10.1002/1097-4644(20010401)81:1<149::AID-JCB1031>3.3.CO;2-N; DUFY B, 1979, SCIENCE, V204, P509, DOI 10.1126/science.107590; ERICKSON CA, 1976, EXP CELL RES, V99, P375, DOI 10.1016/0014-4827(76)90595-4; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FRIEND KE, 1995, P NATL ACAD SCI USA, V92, P4367, DOI 10.1073/pnas.92.10.4367; GAMETCHU B, 1987, SCIENCE, V236, P456, DOI 10.1126/science.3563523; GARCIASEGURA LM, 1989, DEV BRAIN RES, V47, P298, DOI 10.1016/0165-3806(89)90186-7; GERSCHENSON LE, 1981, J STEROID BIOCHEM, V14, P959, DOI 10.1016/0022-4731(81)90203-X; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; Heinrich CA, 1999, ENDOCRINE, V10, P67, DOI 10.1385/ENDO:10:1:67; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Iruela-Arispe ML, 1999, MICROCIRCULATION, V6, P127, DOI 10.1038/sj.mn.7300061; KATZENELLENBOGEN BS, 1987, CANCER RES, V47, P4355; KE FC, 1990, J NEUROCHEM, V54, P467, DOI 10.1111/j.1471-4159.1990.tb01895.x; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LOTTERING ML, 1992, CANCER RES, V52, P5926; MacLusky NJ, 1997, NEUROCHEM RES, V22, P1395, DOI 10.1023/A:1022027408234; Matsuzaki S, 2000, FERTIL STERIL, V73, P1219, DOI 10.1016/S0015-0282(00)00527-6; MCGINNIS MY, 1981, NEUROENDOCRINOLOGY, V33, P158, DOI 10.1159/000123222; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Mitchner NA, 1999, ENDOCRINOLOGY, V140, P2651, DOI 10.1210/en.140.6.2651; MURPHY CS, 1989, EUR J CANCER CLIN ON, V25, P1777, DOI 10.1016/0277-5379(89)90348-9; NAKHLA AM, 1984, ENDOCRINOLOGY, V115, P121, DOI 10.1210/endo-115-1-121; Norfleet AM, 1999, ENDOCRINOLOGY, V140, P3805, DOI 10.1210/en.140.8.3805; Norfleet AM, 2000, FASEB J, V14, P157, DOI 10.1096/fasebj.14.1.157; Norman AW, 1999, STEROIDS, V64, P120, DOI 10.1016/S0039-128X(98)00091-9; PAPPAS TC, 1994, ENDOCRINE, V2, P813; PAPPAS TC, 1995, ENDOCRINE, V3, P743, DOI 10.1007/BF03000207; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; Pawlowski S, 2000, TOXICOL IN VITRO, V14, P531, DOI 10.1016/S0887-2333(00)00048-5; Pelletier G, 1999, BIOL REPROD, V61, P1249, DOI 10.1095/biolreprod61.5.1249; PIETRAS RJ, 1979, J STEROID BIOCHEM, V11, P1471, DOI 10.1016/0022-4731(79)90124-9; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; PIETRAS RJ, 1975, NATURE, V253, P357, DOI 10.1038/253357a0; PIETRAS RJ, 1979, J CELL PHYSIOL, V98, P145, DOI 10.1002/jcp.1040980116; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Shughure PJ, 1998, STEROIDS, V63, P498, DOI 10.1016/S0039-128X(98)00054-3; Singh M, 1999, J NEUROSCI, V19, P1179; Soji T, 1997, MICROSC RES TECHNIQ, V39, P138, DOI 10.1002/(SICI)1097-0029(19971015)39:2<138::AID-JEMT5>3.0.CO;2-H; SZEGO CM, 1984, INT REV CYTOL, V88, P1, DOI 10.1016/S0074-7696(08)62759-X; SZEGO CM, 1988, AM J PHYSIOL, V254, P775; Watson CS, 1999, EXP PHYSIOL, V84, P1013, DOI 10.1111/j.1469-445X.1999.01903.x; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; WATSON CS, 1995, ENVIRON HEALTH PERSP, V103, P41, DOI 10.2307/3432507; Watson CS, 1999, STEROIDS, V64, P5, DOI 10.1016/S0039-128X(98)00107-X; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; ZYZEK E, 1981, BIOCHEM BIOPH RES CO, V102, P1151, DOI 10.1016/S0006-291X(81)80132-5	59	35	37	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2002	16	14					1917	1927		10.1096/fj.02-0182com	http://dx.doi.org/10.1096/fj.02-0182com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12468456	Green Accepted			2022-12-28	WOS:000180574300012
J	Kraus, J; Borner, C; Hollt, V				Kraus, J; Borner, C; Hollt, V			Distinct palindromic extensions of the 5 '-TTC...GAA-3 ' motif allow STAT6 binding in vivo	FASEB JOURNAL			English	Article						transcription regulation; cytokine; cytokine response element; interleukin-4	INTERLEUKIN-4-INDUCED TRANSCRIPTION FACTOR; GERMLINE EPSILON-PROMOTER; NF-KAPPA-B; GENE-EXPRESSION; DNA-BINDING; FACTOR DECOY; SITES; IL-4; ACTIVATION; ELEMENTS	STATs (signal transducers and activators of transcription) are transcription factors downstream of cytokine and growth factor signals. All of the seven different STATs bind to regulatory promoter elements with the common core motif 5'-TTC(N)(2-4)GAA-3'. A key question is how the different STAT factors recognize "their" response elements, that is, what distinguishes for example STAT1 from STAT6 binding sites. In vivo, binding of the different STATs to DNA elements is highly specific and disruption of the genes for the different STAT factors is accompanied with distinct, non-overlaping phenotypical effects. As a first step towards discrimination of target sequences for the various STATs, we determined requirements for binding sites for STAT6. In functional assays, six sequences were identified. These have palindromic extensions of the core motif in common (underlined): 5'-TTTCNNNGAAA-3', 5'-CTTCNNNGAAG-3', 5'-TTTCNNNNGAAA-3', 5'-CTTCNNNNGAAG-3', 5'-TTCCNNGGAA3' and 5'-TTCANNTGAA-3'. Different approaches and mutational analysis demonstrated the functionality of these sequences and high specific binding to STAT6. (I) These elements mediate transcriptional induction by interleukin-(IL)-4, IL-13, IL-15, and platelet-derived growth factor. (II) When used as "decoy" oligonucleotides, they bind STAT6 and disrupt its function in vivo, attenuating (a) STAT6/IL-4-mediated reporter gene transcription and (b) STAT6/IL-4-mediated induction of mu-opioid receptor mRNA of Raji cells.	Univ Magdeburg, Inst Pharmacol & Toxicol, Dept Pharmacol & Toxicol, D-39120 Magdeburg, Germany	Otto von Guericke University	Kraus, J (corresponding author), Univ Magdeburg, Inst Pharmacol & Toxicol, Dept Pharmacol & Toxicol, 44 Leipzigerstr, D-39120 Magdeburg, Germany.	juergen.kraus@medizin.uni-magdeburg.de						Bianchi M, 1999, EUR J NEUROSCI, V11, P1501, DOI 10.1046/j.1460-9568.1999.00563.x; BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; Cattaneo E, 1999, TRENDS NEUROSCI, V22, P365, DOI 10.1016/S0166-2236(98)01378-2; Conrad DJ, 2000, AM J RESP CELL MOL, V22, P226, DOI 10.1165/ajrcmb.22.2.3786; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; KANG C, 1993, BIOTECHNIQUES, V15, P659; Khew-Goodall Y, 1999, ARTERIOSCL THROM VAS, V19, P1421, DOI 10.1161/01.ATV.19.6.1421; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; Kraus J, 2001, J BIOL CHEM, V276, P43901, DOI 10.1074/jbc.M107543200; Lee DK, 1999, BIOCHEM J, V337, P59, DOI 10.1042/0264-6021:3370059; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Matsukura S, 1999, J IMMUNOL, V163, P6876; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Morishita R, 1998, CIRC RES, V82, P1023, DOI 10.1161/01.RES.82.10.1023; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; Ohmori Y, 1996, J IMMUNOL, V157, P2058; Richards ML, 1997, J IMMUNOL, V158, P263; Schaffer A, 1999, J IMMUNOL, V162, P5327; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Wang LH, 2000, BLOOD, V95, P1249, DOI 10.1182/blood.V95.4.1249.004k39_1249_1257; XU MZ, 1992, EMBO J, V11, P145, DOI 10.1002/j.1460-2075.1992.tb05037.x	27	39	40	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2002	16	14					304	+		10.1096/fj.02-0482fje	http://dx.doi.org/10.1096/fj.02-0482fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475891				2022-12-28	WOS:000180574300024
J	Iannaccone, P; Morley, S; Skimina, T; Mullins, J; Landini, G				Iannaccone, P; Morley, S; Skimina, T; Mullins, J; Landini, G			Cord-like mosaic patches in the adrenal cortex are fractal: Implications for growth and development	FASEB JOURNAL			English	Article						organogenesis; chimeras; mosaic pattern; adrenal cortex; fractals	EXCHANGE FACTOR; EXPRESSION; GEOMETRY; LIVER; MIGRATION; PATTERNS; BUD5	Organogenesis proceeds rapidly and faithfully during fetal development. The process includes generation of parenchyma, followed by organization into functional tissues. The method by which the growth of organ parenchyma is regulated is not known, but insight into this regulation has been obtained by studying mosaic tissues of experimental chimeras and transgenic mosaics. The patterns revealed by this procedure offer an indication of how the parenchyma was generated. In the liver, the pattern appears as islands of one cell type in a sea of the other cell type, while in the adrenal cortex the pattern is one of alternating cords of one cell type adjacent to the other cell type. We have established previously that mosaic patches in the liver are fractal. The fractal dimensions of patches in the liver are consistent with an iterative, recursive growth model with simple stereotypical division rules. Here we report that the patches in mosaic adrenal cortex of the mouse and rat are also fractal and that the fractal dimension of the surface of the patches is lower than that in the liver. Fetal development and fractal dimensions of adrenal cortical mosaic patches are consistent with an algorithmic cell division model in which parenchymal growth is constrained to edges of growth centers forcing cord structures to form. Fractal analysis of the geometry of mosaic patches in tissues of experimental chimeras is helpful in constructing hypotheses of organ growth.	Northwestern Univ, Sch Med, Dept Pediat, Childrens Mem Inst Educ & Res, Evanston, IL 60201 USA; Univ Edinburgh, Royal Infirm NHS Trust, Dept Reprod & Dev Sci, Clin Biochem Sect, Edinburgh, Midlothian, Scotland; Univ Edinburgh, Sch Med, Mol Physiol Grp, Edinburgh, Midlothian, Scotland; Univ Birmingham, Sch Dent, Oral Pathol Unit, Birmingham, W Midlands, England	Northwestern University; University of Edinburgh; University of Edinburgh; University of Birmingham	Iannaccone, P (corresponding author), Northwestern Univ, Sch Med, Dept Pediat, Childrens Mem Inst Educ & Res, 2300 Childrens Plaza,No 204, Evanston, IL 60201 USA.	pmi@nwu.edu	Morley, Steve/AAY-9985-2020	Landini, Gabriel/0000-0002-9689-0989; Morley, Steven/0000-0002-7355-3349				Bass WT, 1998, HISTOCHEM J, V30, P657, DOI 10.1023/A:1003597010707; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; IANNACCONE PM, 1987, DEVELOPMENT, V99, P187; IANNACCONE PM, 1987, J EXP ZOOL, V243, P217, DOI 10.1002/jez.1402430207; IANNACCONE PM, 1990, FASEB J, V4, P1508, DOI 10.1096/fasebj.4.5.2307328; KHOKHA MK, 1994, DEV BIOL, V165, P545, DOI 10.1006/dbio.1994.1274; Landini G, 2000, FASEB J, V14, P823, DOI 10.1096/fasebj.14.5.823; MANDELBROT B, 1967, SCIENCE, V156, P636, DOI 10.1126/science.156.3775.636; Marston AL, 2001, CURR BIOL, V11, P803, DOI 10.1016/S0960-9822(01)00230-5; MICHAELS L, 1991, AM J ANAT, V191, P280, DOI 10.1002/aja.1001910307; Mitani F, 1999, ENDOCRINOLOGY, V140, P3342, DOI 10.1210/en.140.7.3342; Mitani F, 1998, ENDOCR RES, V24, P983, DOI 10.3109/07435809809032721; Morley SD, 1996, ENDOCR RES, V22, P631, DOI 10.1080/07435809609043757; Morley SD, 1996, MOL ENDOCRINOL, V10, P585, DOI 10.1210/me.10.5.585; NG YK, 1992, DEV BIOL, V151, P419, DOI 10.1016/0012-1606(92)90182-G; WEINBERG WC, 1985, SCIENCE, V227, P524, DOI 10.1126/science.3966159; WEINBERG WC, 1985, HYBRIDOMA, V4, P27, DOI 10.1089/hyb.1985.4.27	17	20	20	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					41	+		10.1096/fj.02-0451fje	http://dx.doi.org/10.1096/fj.02-0451fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475906				2022-12-28	WOS:000180218500028
J	Panyam, J; Zhou, WZ; Prabha, S; Sahoo, SK; Labhasetwar, V				Panyam, J; Zhou, WZ; Prabha, S; Sahoo, SK; Labhasetwar, V			Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery	FASEB JOURNAL			English	Article						intracellular delivery; gene therapy; antiproliferative effect; sustained release; restenosis	BIOLOGICALLY-ACTIVE PROTEINS; SMOOTH-MUSCLE-CELLS; BIODEGRADABLE NANOSPHERES; INTRACELLULAR DELIVERY; MOLECULAR-MECHANISMS; BREFELDIN-A; IN-VIVO; LIPOSOMES; PEPTIDE; CULTURE	The endo-lysosomal escape of drug carriers is crucial to enhancing the efficacy of their macromolecular payload, especially the payloads that are susceptible to lysosomal degradation. Current vectors that enable the endo-lysosomal escape of macromolecules such as DNA are limited by their toxicity and by their ability to carry only limited classes of therapeutic agents. In this paper, we report the rapid (<10 min) endo-lysosomal escape of biodegradable nanoparticles (NPs) formulated from the copolymers of poly( DL-lactide-co-glycolide) (PLGA). The mechanism of rapid escape is by selective reversal of the surface charge of NPs (from anionic to cationic) in the acidic endolysosomal compartment, which causes the NPs to interact with the endo-lysosomal membrane and escape into the cytosol. PLGA NPs are able to deliver a variety of therapeutic agents, including macromolecules such as DNA and low molecular weight drugs such as dexamethasone, intracellularly at a slow rate, which results in a sustained therapeutic effect. PLGA has a number of advantages over other polymers used in drug and gene delivery including biodegradability, biocompatibility, and approval for human use granted by the U. S. Food and Drug Administration. Hence PLGA is well suited for sustained intracellular delivery of macromolecules.	Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Nebraska Med Ctr 986025, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Labhasetwar, V (corresponding author), Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Nebraska Med Ctr 986025, 600 S 42nd St, Omaha, NE 68198 USA.	vlabhase@unmc.edu	Labhasetwar, Vinod/J-9660-2016; Sanjeeb, Sahoo/ABF-3419-2020	Labhasetwar, Vinod/0000-0001-7950-1542; Panyam, Jayanth/0000-0002-8656-2244	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL057234] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 57234] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adcock IM, 2000, PULM PHARMACOL THER, V13, P115, DOI 10.1006/pupt.2000.0243; Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3; Belanger AJ, 2001, CARDIOVASC RES, V51, P749, DOI 10.1016/S0008-6363(01)00329-7; BENNETT MR, 1995, CIRC RES, V77, P1136, DOI 10.1161/01.RES.77.6.1136; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Clark PR, 1999, CURR OPIN MOL THER, V1, P158; Cohen H, 2000, GENE THER, V7, P1896, DOI 10.1038/sj.gt.3301318; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; Davda J, 2002, INT J PHARM, V233, P51, DOI 10.1016/S0378-5173(01)00923-1; Gicquiaux H, 2002, J BIOL CHEM, V277, P6645, DOI 10.1074/jbc.M107224200; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Guzman LA, 1996, CIRCULATION, V94, P1441, DOI 10.1161/01.CIR.94.6.1441; Labhasetwar V, 1999, COLLOID SURFACE B, V16, P281, DOI 10.1016/S0927-7765(99)00079-X; LABHASETWAR V, 1997, PHARM NEWS, V4, P28; Langer R, 1997, PHARMACEUT RES, V14, P840, DOI 10.1023/A:1012131329148; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Liu F, 2002, J CONTROL RELEASE, V78, P259, DOI 10.1016/S0168-3659(01)00494-1; Maheshwari A, 2000, MOL THER, V2, P121, DOI 10.1006/mthe.2000.0105; Makino K, 1986, J Microencapsul, V3, P195, DOI 10.3109/02652048609031573; Moghimi SM, 2001, PHARMACOL REV, V53, P283; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; PANYAM J, 2002, IN PRESS J DRUG TARG; Peters PJ, 2001, TRAFFIC, V2, P885, DOI 10.1034/j.1600-0854.2001.21204.x; Riezman H, 1997, CELL, V91, P731, DOI 10.1016/S0092-8674(00)80461-4; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Shitara Y, 1998, J CONTROL RELEASE, V55, P35, DOI 10.1016/S0168-3659(98)00025-X; STOLNIK S, 1995, COLLOID SURFACE A, V97, P235, DOI 10.1016/0927-7757(95)03081-N; Suh H, 1998, PHARMACEUT RES, V15, P1495, DOI 10.1023/A:1011982428413; Tachibana R, 1998, BIOCHEM BIOPH RES CO, V251, P538, DOI 10.1006/bbrc.1998.9460; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; WAGNER M, 1994, J CELL SCI, V107, P933; Wattiaux R, 2000, ADV DRUG DELIVER REV, V41, P201, DOI 10.1016/S0169-409X(99)00066-6	33	827	895	7	198	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1217	10.1096/fj.02-0088com	http://dx.doi.org/10.1096/fj.02-0088com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153989				2022-12-28	WOS:000177814000030
J	Kato, K; Ito, H; Kamei, K; Iwamoto, I; Inaguma, Y				Kato, K; Ito, H; Kamei, K; Iwamoto, I; Inaguma, Y			Innervation-dependent phosphorylation and accumulation of crystallin and Hsp27 as insoluble complexes in disused muscle	FASEB JOURNAL			English	Article						molecular chaperone; phospho-specific antibodies; nerve activity	ALPHA-B-CRYSTALLIN; RAT SKELETAL-MUSCLE; HEAT-SHOCK PROTEIN; P38 MAP KINASE; ALEXANDERS-DISEASE; IDENTIFICATION; STRESS; GENE; PURIFICATION; CONTRACTION	Levels and phosphorylation states of the two small molecular chaperones, alphaB-crystallin and Hsp27, in disused rat soleus muscles were determined by Western blot analysis of extracts with antibodies recognizing each of the two proteins and their phosphorylated serine residues. Increased phosphorylation and relocalization to insoluble fractions were found within a few days of hindlimb suspension. High phosphorylation of alphaB-crystallin at Ser-59 (and to a certain extent, at Ser45) and of Hsp27 at Ser-15 and Ser-85, along with phosphorylated, active states of p38 and p44/42 mitogen-activated protein kinases were maintained during hind-limb suspension but promptly returned to control levels within a 5-day recovery period. These results are similar to those observed with U373 MG glioma cells exposed to proteasome inhibitors (16). However, the responses of alphaB-crystallin and Hsp27 in suspended soleus muscles did not appear with ipsilateral transection of the sciatic nerve trunk, indicating mediation by nerve activity. The fact that ubiquitinated proteins accumulated in the insoluble fractions of suspended soleus muscle further suggests participation of alphaB-crystallin and Hsp27 in quality control of proteins in disused soleus muscle, with involvement of nerve activity-dependent processes.	Aichi Human Serv ctr, Inst Dev Res, Dept Biochem, Kasugai, Aichi 4800392, Japan		Kato, K (corresponding author), Aichi Human Serv ctr, Inst Dev Res, Dept Biochem, 713-8 Kamiya, Kasugai, Aichi 4800392, Japan.	kato@inst-hsc.pref.aichi.jp		Ito, Hidenori/0000-0002-6527-477X				Aronson D, 1998, AM J PHYSIOL-CELL PH, V275, pC555, DOI 10.1152/ajpcell.1998.275.2.C555; Aronson D, 1997, J BIOL CHEM, V272, P25636, DOI 10.1074/jbc.272.41.25636; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; Beall AC, 1997, J BIOL CHEM, V272, P11283; BLOEMENDAL H, 1981, ANAL BIOCHEM, V117, P327, DOI 10.1016/0003-2697(81)90787-9; Boppart MD, 2001, AM J PHYSIOL-CELL PH, V280, pC352, DOI 10.1152/ajpcell.2001.280.2.C352; CHIESA R, 1987, J BIOL CHEM, V262, P1438; COOPER LF, 1994, J BIOL CHEM, V269, P7869; FURUNO K, 1990, J BIOL CHEM, V265, P8550; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; Goodyear LJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE403, DOI 10.1152/ajpendo.1996.271.2.E403; INAGUMA Y, 1993, J BIOCHEM-TOKYO, V114, P378, DOI 10.1093/oxfordjournals.jbchem.a124184; Inaguma Y, 2001, EUR J CELL BIOL, V80, P741, DOI 10.1078/0171-9335-00203; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; Ito H, 2002, J BIOCHEM, V131, P593, DOI 10.1093/oxfordjournals.jbchem.a003139; Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; Kato K, 1998, J BIOL CHEM, V273, P28346, DOI 10.1074/jbc.273.43.28346; KATO K, 1994, J BIOL CHEM, V269, P11274; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; Kato K, 1996, J BIOL CHEM, V271, P26989, DOI 10.1074/jbc.271.43.26989; Kato K, 2001, J NEUROCHEM, V76, P730, DOI 10.1046/j.1471-4159.2001.00038.x; KATO K, 1994, J BIOL CHEM, V269, P15302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; QUAXJEUKEN Y, 1985, P NATL ACAD SCI USA, V82, P5819, DOI 10.1073/pnas.82.17.5819; Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457; Sherwood DJ, 1999, AM J PHYSIOL-ENDOC M, V276, pE870, DOI 10.1152/ajpendo.1999.276.5.E870; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Taillandier D, 1996, BIOCHEM J, V316, P65, DOI 10.1042/bj3160065; UOSHIMA K, 1993, BIOCHEM BIOPH RES CO, V197, P1388, DOI 10.1006/bbrc.1993.2631; Verschuure P, 2002, J MOL CELL CARDIOL, V34, P117, DOI 10.1006/jmcc.2001.1493; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; VOORTER CEM, 1986, EUR J BIOCHEM, V160, P203; Widegren U, 1998, FASEB J, V12, P1379, DOI 10.1096/fasebj.12.13.1379	40	40	41	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1432	+		10.1096/fj.02-0129fje	http://dx.doi.org/10.1096/fj.02-0129fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205038				2022-12-28	WOS:000177813100008
J	Caricasole, A; Bruno, V; Cappuccio, I; Melchiorri, D; Copani, A; Nicoletti, F				Caricasole, A; Bruno, V; Cappuccio, I; Melchiorri, D; Copani, A; Nicoletti, F			A novel rat gene encoding a Humanin-like peptide endowed with broad neuroprotective activity	FASEB JOURNAL			English	Article						Alzheimer's disease; Rattin; neurodegeneration	METABOTROPIC GLUTAMATE RECEPTORS; FAMILIAL ALZHEIMERS-DISEASE; RESCUE FACTOR HUMANIN; IN-VITRO; BETA; TOXICITY; ACTIVATION; PROTEIN; NEURONS	We report the identification of a novel rat cDNA encoding a peptide homologous to Humanin, a secreted peptide that specifically protects against neuronal cell death induced by beta-amyloid peptide (Abeta) or by mutations causing early-onset familial Alzheimer's disease. The rat gene, which we termed Rattin, encodes a peptide of 38 residues (15 residues longer than Humanin) showing 73% identity in the conserved region to Humanin. The expression profile of the 1.6-kb Rattin transcript is comparable to that displayed by Humanin, with significant expression levels in the central nervous system and in cardiac and skeletal muscle. The full-length Rattin peptide and its 1-25 fragment were equally effective as Humanin in protecting rat- and mouse-cultured cortical neurons against Abeta-induced toxicity. However, Rattin was much more effective than Humanin against excitotoxic neuronal death induced by a toxic pulse with NMDA. Rattin and its short fragment were protective against excitotoxic death not only when coapplied with NMDA, but also when added to the cultures after the NMDA pulse. Neither Rattin not Humanin could affect neuronal apoptosis by trophic deprivation induced in cultured cerebellar granule cells depleted of extracellular potassium. This suggests that Rattin is the prototype of a novel class of peptides, phylogenetically related to Humanin, endowed with protective activity not only against Abeta but also toward excitotoxic neuronal death. The identification of Rattin may be instrumental for the development of novel pharmacological strategies aimed at enhancing the production of endogenous Humanin-like peptides.	Univ Roma La Sapienza, Inst Human Physiol & Pharmacol Vittorio Erspamer, Dept Human Physiol & Pharmacol, I-00185 Rome, Italy; Univ Catania, Dept Pharmaceut Sci, I-95124 Catania, Italy; INM Neuromed, Pozzilli, Italy	Sapienza University Rome; University of Catania; IRCCS Neuromed	Caricasole, A (corresponding author), Univ Roma La Sapienza, Inst Human Physiol & Pharmacol Vittorio Erspamer, Dept Human Physiol & Pharmacol, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	andrea.caricasole@uniroma1.it	Nicoletti, Ferdinando/T-4898-2019; Nicoletti, Ferdinando/K-4410-2016; bruno, Valeria/F-3146-2012; Nicoletti, Ferdinando/A-2446-2010	bruno, Valeria/0000-0003-4231-0739; NICOLETTI, Ferdinando/0000-0003-3366-7269; Nicoletti, Ferdinando/0000-0003-0917-443X				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Bruno V, 2000, J NEUROSCI, V20, P6413, DOI 10.1523/JNEUROSCI.20-17-06413.2000; Caricasole A, 2000, BBA-GENE STRUCT EXPR, V1517, P63, DOI 10.1016/S0167-4781(00)00260-8; Copani A, 1999, FASEB J, V13, P2225, DOI 10.1096/fasebj.13.15.2225; COPANI A, 1995, MOL PHARMACOL, V47, P890; DUGAN LL, 1994, ANN NEUROL, V35, pS17, DOI 10.1002/ana.410350707; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; Exley C, 1996, BIOCHEM J, V314, P709, DOI 10.1042/bj3140709; Fagarasan MO, 1996, MOL PSYCHIATR, V1, P398; Fassbender K, 2001, NATURWISSENSCHAFTEN, V88, P261; GALLO V, 1987, EUR J PHARMACOL, V138, P293, DOI 10.1016/0014-2999(87)90448-1; Garnier J, 1996, METHOD ENZYMOL, V266, P540; GEORGEHYSLOP PH, 2000, BIOL PSYCHIAT, V47, P183; Hashimoto Y, 2001, J NEUROSCI, V21, P9235, DOI 10.1523/JNEUROSCI.21-23-09235.2001; Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498; Hashimoto Y, 2001, BIOCHEM BIOPH RES CO, V283, P460, DOI 10.1006/bbrc.2001.4765; IVERSEN LL, 1995, BIOCHEM J, V311, P1; Melchiorri D, 2001, EUR J NEUROSCI, V13, P1694, DOI 10.1046/j.1460-9568.2001.01549.x; Nabeshima Toshitaka, 1998, Journal of Toxicological Sciences, V23, P177; Neve RL, 2001, BIOCHEM SOC SYMP, V67, P37; Nicoletti F, 1986, Funct Neurol, V1, P345; OLSHANSKY SJ, 1993, SCI AM, V268, P46, DOI 10.1038/scientificamerican0493-46; PIKE CJ, 1991, EUR J PHARM-MOLEC PH, V207, P367, DOI 10.1016/0922-4106(91)90014-9; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; ROELEN BAJ, 1994, DEV BIOL, V166, P716, DOI 10.1006/dbio.1994.1350; ROSE KGM, 2001, METHODS TOXICOLOGY, P40; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; Zoghbi HY, 2000, CURR OPIN NEUROBIOL, V10, P655, DOI 10.1016/S0959-4388(00)00135-5	31	46	54	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1331	+		10.1096/fj.02-0018fje	http://dx.doi.org/10.1096/fj.02-0018fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154011				2022-12-28	WOS:000176683900025
J	Yang, YL; Yu, XD				Yang, YL; Yu, XD			Regulation of apoptosis: the ubiquitous way	FASEB JOURNAL			English	Review						ubiquitination; caspase; IAP; ring finger protein; ubiquitin protein ligase (E3)	TRAIL-INDUCED APOPTOSIS; PROTEIN LIGASE ACTIVITY; PROGRAMMED CELL-DEATH; BCL-2 FAMILY MEMBERS; X-LINKED INHIBITOR; SOCS-BOX MOTIF; SERINE-PROTEASE; MEDIATES UBIQUITINATION; MITOCHONDRIAL RELEASE; DEPENDENT DEGRADATION	Ubiquitin is a ubiquitously expressed 76 amino acid protein that can be covalently attached to target proteins, leading to their ubiquitination. Many ubiquitinated proteins are degraded by the proteasome, a 2000 kDa ATP-dependent proteolytic complex. Numerous studies have demonstrated that the ubiquitination and proteasome system plays an important role in controlling the levels of various cellular proteins and therefore regulates basic cellular processes such as cell cycle progression, signal transduction, and cell transformation. Ubiquitination also directly affects the function and location of target proteins. Recent studies found that ubiquitination-mediated degradation and change in activity regulate many molecules of the cell death machinery, such as p53, caspases, and Bcl-2 family members. Ring finger-containing members of the IAP (inhibitor of apoptosis) family proteins themselves can function as ubiquitin protein ligases to ubiquitinate their target proteins or promote autoubiquitination. It has been demonstrated that degradation of the IAP proteins is required for apoptosis to occur in some systems, indicating apoptosis proceeds by activating death pathways as well as eliminating "roadblocks" through ubiquitination. These new findings also suggest that ubiquitination is one of the major mechanisms that regulate apoptotic cell death and could be a unique target for therapeutic intervention.	NCI, Regulat Cell Growth Lab, Ctr Canc Res, NIH, Frederick, MD 21702 USA; Inst Basic Med Sci, Dept Cell Biol, Beijing 100850, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yang, YL (corresponding author), NCI, Regulat Cell Growth Lab, Ctr Canc Res, NIH, 1050 Boyles St,Bldg 560,Room 22-45, Frederick, MD 21702 USA.	yangyili@ncifcrf.gov						Almond JB, 2002, LEUKEMIA, V16, P433, DOI 10.1038/sj.leu.2402417; AVAVIND L, 2000, CURR BIOL, V10, pR132; Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Becker K, 1997, FEBS LETT, V412, P102, DOI 10.1016/S0014-5793(97)00758-8; Bonavida B, 1999, INT J ONCOL, V15, P793; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Buchberger A, 2001, J MOL BIOL, V307, P17, DOI 10.1006/jmbi.2000.4462; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Coscoy L, 2001, J CELL BIOL, V155, P1265, DOI 10.1083/jcb.200111010; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; DELIC J, 1993, MOL CELL BIOL, V13, P4875, DOI 10.1128/MCB.13.8.4875; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Finch RA, 2002, CANCER RES, V62, P3221; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Griffith TS, 1998, J IMMUNOL, V161, P2833; Grimm LM, 1996, EMBO J, V15, P3835, DOI 10.1002/j.1460-2075.1996.tb00757.x; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hays R, 2002, NAT CELL BIOL, V4, P425, DOI 10.1038/ncb794; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hirsch T, 1998, J IMMUNOL, V161, P35; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang HK, 2000, J BIOL CHEM, V275, P26661; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lalioti VS, 2002, J BIOL CHEM, V277, P19783, DOI 10.1074/jbc.M110294200; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li SC, 2002, J BIOL CHEM, V277, P26912, DOI 10.1074/jbc.M200726200; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Nguyen LT, 1999, IMMUNITY, V11, P379, DOI 10.1016/S1074-7613(00)80113-2; Okura T, 1996, J IMMUNOL, V157, P4277; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; Palaga T, 2002, NAT CELL BIOL, V4, pE149, DOI 10.1038/ncb0602-e149; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Richter BWM, 2001, MOL CELL BIOL, V21, P4292, DOI 10.1128/MCB.21.13.4292-4301.2001; Riemenschneider MJ, 1999, CANCER RES, V59, P6091; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Rotin D, 2001, AM J PHYSIOL-RENAL, V281, pF391, DOI 10.1152/ajprenal.2001.281.3.F391; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Ryu SW, 2001, BIOCHEM BIOPH RES CO, V286, P1027, DOI 10.1006/bbrc.2001.5505; Ryu SW, 2000, BIOCHEM BIOPH RES CO, V279, P6, DOI 10.1006/bbrc.2000.3882; Sadoul R, 1996, EMBO J, V15, P3845, DOI 10.1002/j.1460-2075.1996.tb00758.x; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHWARTZ LM, 1990, NEURON, V5, P411, DOI 10.1016/0896-6273(90)90080-Y; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Tenev T, 2002, EMBO J, V21, P5118, DOI 10.1093/emboj/cdf530; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Uren AG, 1999, P NATL ACAD SCI USA, V96, P10170, DOI 10.1073/pnas.96.18.10170; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Verhagen AM, 2001, GENOME BIOL, V2; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Weiss T, 1998, J IMMUNOL, V161, P3136; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wing JP, 2002, NAT CELL BIOL, V4, P451, DOI 10.1038/ncb800; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	117	167	178	2	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					790	799		10.1096/fj.02-0654rev	http://dx.doi.org/10.1096/fj.02-0654rev			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724336				2022-12-28	WOS:000183165000003
J	Veldman, RJ; Mita, A; Cuvillier, O; Garcia, V; Klappe, K; Medin, JA; Campbell, JD; Carpentier, S; Kok, JW; Levade, T				Veldman, RJ; Mita, A; Cuvillier, O; Garcia, V; Klappe, K; Medin, JA; Campbell, JD; Carpentier, S; Kok, JW; Levade, T			The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs	FASEB JOURNAL			English	Article						apoptosis; ceramide; GM95 melanoma cells; multidrug resistance	DAUNORUBICIN-INDUCED APOPTOSIS; MULTIDRUG-RESISTANCE; CERAMIDE GLYCOSYLATION; EXPRESSION; PROTEIN; ACTIVATION; SPHINGOLIPIDS; BIOSYNTHESIS; INHIBITION; METABOLISM	Conversion of ceramide, a putative mediator of anticancer drug-induced apoptosis, into glucosylceramide, by the action of glucosylceramide synthase (GCS), has been implicated in drug resistance. Herein, we compared GM95 mouse melanoma cells deficient in GCS activity, with cells stably transfected with a vector encoding GCS (GM95/GCS). Enzymatic and metabolic analysis demonstrated that GM95/GCS cells expressed a fully functional enzyme, resulting in normal ceramide glycosylation. However, cytotoxicity assays, as well as caspase activation and cytochrome c release studies, did not reveal any difference between the two cell lines with respect to their sensitivity toward doxorubicin, vinblastine, paclitaxel, cytosine arabinoside, or short-chain ceramide analogs. Administration of doxorubicin resulted in ceramide accumulation in both cell lines, with similar kinetics and amplitude. Although glucosylceramide formation was detected in doxorubicin-treated GM95/GCS cells, metabolism of drug-induced ceramide did not appear to be instrumental in cell survival. Furthermore, N-(n-butyl)deoxynojirimycin, a potent and non-toxic GCS inhibitor, had no chemosensitizing effect on wild-type melanoma cells. Altogether, both genetic and pharmacological alterations of the cellular ceramide glycosylation capacity failed to sensitize melanoma cells to anticancer drugs, therefore moderating the importance of ceramide glucosylation in drug-resistance mechanisms.	CHU Rangueil, INSERM, U466,Lab Biochim, Inst Louis Bugnard, F-31059 Toulouse 9, France; Univ Groningen, Fac Med Sci, Dept Membrane Cell Biol, NL-9713 AV Groningen, Netherlands; Univ Toronto, Ontario Canc Inst, Div Expt Therapeut, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M1, Canada	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Groningen; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Levade, T (corresponding author), CHU Rangueil, INSERM, U466,Lab Biochim, Inst Louis Bugnard, 1 Ave Jean Poulhes,TSA 50032, F-31059 Toulouse 9, France.	levade@toulouse.inserm.fr	CUVILLIER, Olivier/S-1631-2019; CUVILLIER, Olivier/B-2567-2009; GARCIA, Virginie/W-8313-2019; Levade, Thierry/O-8948-2014	CUVILLIER, Olivier/0000-0003-3346-375X; CUVILLIER, Olivier/0000-0003-3346-375X; GARCIA, Virginie/0000-0002-9761-7036; 				BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; Borst P, 2000, BBA-MOL CELL BIOL L, V1486, P128, DOI 10.1016/S1388-1981(00)00053-6; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Bourteele S, 1998, J BIOL CHEM, V273, P31245, DOI 10.1074/jbc.273.47.31245; CARMICHAEL J, 1987, CANCER RES, V47, P936; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Cuvillier O, 2001, CELL DEATH DIFFER, V8, P162, DOI 10.1038/sj.cdd.4400793; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Di Sano F, 2002, CELL DEATH DIFFER, V9, P693, DOI 10.1038/sj.cdd.4401040; Ferraro C, 2000, CELL DEATH DIFFER, V7, P197, DOI 10.1038/sj.cdd.4400595; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; ICHIKAWA S, 1994, P NATL ACAD SCI USA, V91, P2703, DOI 10.1073/pnas.91.7.2703; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Jaffrezou JP, 1998, FASEB J, V12, P999, DOI 10.1096/fasebj.12.11.999; Kok JW, 2000, INT J CANCER, V87, P172, DOI 10.1002/1097-0215(20000715)87:2<172::AID-IJC3>3.0.CO;2-K; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Liu YY, 2000, J BIOL CHEM, V275, P7138, DOI 10.1074/jbc.275.10.7138; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Liu YY, 2001, FASEB J, V15, P719, DOI 10.1096/fj.00-0223com; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lucci A, 1998, ANTICANCER RES, V18, P475; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nielsen D, 2001, INT J RADIAT ONCOL, V51, P1050, DOI 10.1016/S0360-3016(01)01719-9; NOZUE M, 1988, INT J CANCER, V42, P734, DOI 10.1002/ijc.2910420518; PLATT FM, 1994, J BIOL CHEM, V269, P8362; Sietsma H, 2000, CLIN CANCER RES, V6, P942; Sietsma H, 2001, J MEMBRANE BIOL, V181, P153, DOI 10.1007/s00232-001-0033-1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNOW K, 1991, BRIT J CANCER, V63, P17, DOI 10.1038/bjc.1991.7; STRUM JC, 1994, J BIOL CHEM, V269, P15493; Tepper AD, 2000, J BIOL CHEM, V275, P34810, DOI 10.1074/jbc.M005142200; Tu YP, 1998, CANCER RES, V58, P256; van der Kolk DM, 1999, ADV EXP MED BIOL, V457, P187; van Meer G, 2000, BBA-MOL CELL BIOL L, V1486, P145, DOI 10.1016/S1388-1981(00)00054-8; Veldman RJ, 2002, FASEB J, V16, P1111, DOI 10.1096/fj.01-0863fje; WANG E, 1991, J BIOL CHEM, V266, P14486	44	40	44	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1144	+		10.1096/fj.02-1053fje	http://dx.doi.org/10.1096/fj.02-1053fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692077				2022-12-28	WOS:000182580100037
J	Wan, RQ; Camandola, S; Mattson, MP				Wan, RQ; Camandola, S; Mattson, MP			Intermittent fasting and dietary supplementation with 2-deoxy-D-glucose improve functional and metabolic cardiovascular risk factors in rats	FASEB JOURNAL			English	Article						caloric restriction; cardiovascular disease; glucose metabolism; stress response	CALORIC RESTRICTION; INSULIN-RESISTANCE; BLOOD-PRESSURE; FOOD-RESTRICTION; LIFE-SPAN; VOLUNTARY EXERCISE; DIABETES-MELLITUS; FISCHER-344 RATS; BRAIN-DAMAGE; BODY-WEIGHT	Hypertension and insulin resistance syndrome are risk factors for cardiovascular disease, and it is therefore important to identify interventions that can reduce blood pressure and improve glucose metabolism. We performed experiments aimed at determining whether intermittent fasting (IF) can improve cardiovascular health and also tested the hypothesis that beneficial effects of IF can be mimicked by dietary supplementation with 2-deoxy-D-glucose (2DG) a non-metabolizable glucose analog. Four-month-old male rats were implanted with telemetry probes to allow continuous monitoring of heart rate, blood pressure, physical activity, and body temperature. Rats were then maintained for 6 months on one of three different dietary regimens: ad libitum feeding, IF, or 2DG supplementation. Rats on the IF regimen consumed 30% less food over time and had reduced body weights compared with rats fed ad libitum, whereas rats on the 2DG regimen did not reduce their food intake and maintained their body weight. Heart rate and blood pressure were significantly decreased within 1 month in rats on IF and 2DG diets and were maintained at reduced levels thereafter. Body temperature was significantly decreased in group IF, but not in group 2DG. Levels of serum glucose and insulin were significantly decreased in rats maintained on IF and 2DG-supplemented diets, suggesting that IF and 2DG diets affect insulin sensitivity in a similar manner. Finally, rats in groups IF and 2DG exhibited increased levels of plasma adrenocorticotropin and corticosterone, indicating that these diets induced a stress response. We conclude that reductions in blood pressure, heart rate, and insulin levels, similar to or greater than those obtained with regular physical exercise programs, can be achieved by IF and by dietary supplementation with 2DG by a mechanism involving stress responses.	NIA, Neurosci Lab, Gerontol Res Ctr, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Mattson, MP (corresponding author), NIA, Neurosci Lab, Gerontol Res Ctr, GRC 4F01,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	mattsonm@grc.nia.nih.gov	Mattson, Mark P/F-6038-2012		NATIONAL INSTITUTE ON AGING [Z01AG000312, ZIAAG000315, ZIAAG000314, Z01AG000314, Z01AG000315, ZIAAG000312] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANSON M, 2003, IN PRESS P NATL ACAD; Arakawa K, 1999, CLIN EXP HYPERTENS, V21, P797, DOI 10.3109/10641969909061009; BRAUN LT, 1991, NURS CLIN N AM, V26, P135; Bruce-Keller AJ, 1999, ANN NEUROL, V45, P8, DOI 10.1002/1531-8249(199901)45:1<8::AID-ART4>3.0.CO;2-V; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Davidson RT, 2002, AM J PHYSIOL-ENDOC M, V282, pE270, DOI 10.1152/ajpendo.00232.2001; Duan WZ, 1999, J NEUROSCI RES, V57, P195, DOI 10.1002/(SICI)1097-4547(19990715)57:2&lt;195::AID-JNR5&gt;3.0.CO;2-P; Duan WZ, 2001, J NEUROCHEM, V76, P619, DOI 10.1046/j.1471-4159.2001.00071.x; Dwarakanath B. S., 1999, Indian Journal of Experimental Biology, V37, P865; Ehrenfried JA, 1996, ANN SURG, V223, P592, DOI 10.1097/00000658-199605000-00015; FURLAN R, 1993, CARDIOVASC RES, V27, P482, DOI 10.1093/cvr/27.3.482; GAO P, 1992, TOXICOL LETT, V61, P233, DOI 10.1016/0378-4274(92)90150-I; GOODRICK CL, 1982, GERONTOLOGY, V28, P233, DOI 10.1159/000212538; GOODRICK CL, 1990, MECH AGEING DEV, V55, P69, DOI 10.1016/0047-6374(90)90107-Q; Grassi G, 1998, CIRCULATION, V97, P2037, DOI 10.1161/01.CIR.97.20.2037; Hall DM, 2000, FASEB J, V14, P78, DOI 10.1096/fasebj.14.1.78; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Henriksen EJ, 2002, J APPL PHYSIOL, V93, P788, DOI 10.1152/japplphysiol.01219.2001; HERLIHY JT, 1992, AM J PHYSIOL, V263, pH1021, DOI 10.1152/ajpheart.1992.263.4.H1021; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; HUGHES TA, 1984, AM J MED, V77, P7, DOI 10.1016/0002-9343(84)90429-7; KALANT N, 1988, MECH AGEING DEV, V46, P89, DOI 10.1016/0047-6374(88)90117-0; KAPLAN O, 1990, CANCER RES, V50, P544; Kinnick TR, 2002, J APPL PHYSIOL, V93, P805, DOI 10.1152/japplphysiol.00236.2002; Klebanov S, 1997, AM J PHYSIOL-HEART C, V273, pH2333, DOI 10.1152/ajpheart.1997.273.5.H2333; KUSHIRO T, 1991, HYPERTENSION, V17, P965, DOI 10.1161/01.HYP.17.6.965; Lee J, 2002, J NEUROCHEM, V80, P539, DOI 10.1046/j.0022-3042.2001.00747.x; NELSON JF, 1995, NEUROBIOL AGING, V16, P837, DOI 10.1016/0197-4580(95)00072-M; Reusch JEB, 2002, AM J CARDIOL, V90, p19G; Roberts SB, 2001, J GERONTOL A-BIOL, V56, P66, DOI 10.1093/gerona/56.suppl_1.66; Roth GS, 2001, ANN NY ACAD SCI, V928, P305; Shahid SK, 2000, CORONARY ARTERY DIS, V11, P103, DOI 10.1097/00019501-200003000-00003; Stewart KJ, 2002, JAMA-J AM MED ASSOC, V288, P1622, DOI 10.1001/jama.288.13.1622; SUZUKI K, 1995, EUR J APPL PHYSIOL O, V71, P240, DOI 10.1007/BF00854985; THOMAS J, 1993, J GERONTOL, V48, pB151, DOI 10.1093/geronj/48.4.B151; VanNess JM, 1999, BRAIN RES, V821, P263, DOI 10.1016/S0006-8993(99)01058-6; Visscher TLS, 2001, ANNU REV PUBL HEALTH, V22, P355, DOI 10.1146/annurev.publhealth.22.1.355; Wachsman JT, 1996, MUTAT RES-FUND MOL M, V350, P25, DOI 10.1016/0027-5107(95)00087-9; Wallis EJ, 2002, HEART, V88, P306, DOI 10.1136/heart.88.3.306; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; Wilmore JH, 2001, MED SCI SPORT EXER, V33, P107; YOUNG JB, 1978, METABOLISM, V27, P1711, DOI 10.1016/0026-0495(78)90256-1; YOUNG JB, 1982, J CHRON DIS, V35, P879, DOI 10.1016/0021-9681(82)90118-7; Yu BP, 2001, ANN NY ACAD SCI, V928, P39; Yu ZF, 1999, J NEUROSCI RES, V57, P830, DOI 10.1002/(SICI)1097-4547(19990915)57:6&lt;830::AID-JNR8&gt;3.0.CO;2-2	45	102	105	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1133	+		10.1096/fj.02-0996fje	http://dx.doi.org/10.1096/fj.02-0996fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709404				2022-12-28	WOS:000182580100026
J	Lee, SY; Andoh, T; Murphy, DL; Chiueh, CC				Lee, SY; Andoh, T; Murphy, DL; Chiueh, CC			17 beta-estradiol activates ICI 182,780-sensitive estrogen receptors and cyclic GMP-dependent thioredoxin expression for neuroprotection	FASEB JOURNAL			English	Article						cognition; human SH-SY5Y neuroblastoma cell; MnSOD; NOS1/nNOS	NITRIC-OXIDE SYNTHASE; STRESS-INDUCED APOPTOSIS; SIGNAL-REGULATED KINASE; OXIDATIVE STRESS; PROTEIN-KINASE; DOPAMINERGIC-NEURONS; CELL-DEATH; MAMMALIAN THIOREDOXIN; S-NITROSOGLUTATHIONE; NEUROTROPHIC FACTOR	Clinical studies suggest that estrogen may improve cognition in Alzheimer's patients. Basic experiments demonstrate that 17beta-estradiol protects against neurodegeneration in both cell and animal models. In the present study, a human SH-SY5Y cell model was used to investigate molecular mechanisms underlying the receptor-mediated neuroprotection of physiological concentrations of 17beta-estradiol. 17beta-Estradiol (<10 nM) concomitantly increased neuronal nitric oxide synthase (NOS1) expression and cell viability. 17 beta-Estradiol-induced neuroprotection was blocked by the receptor antagonist ICI 182,780, also prevented by inhibitors of NOS1 (7-nitroindazole), guanylyl cyclase (LY 83,583), and cGMP-dependent protein kinase (PKG) (Rp-8-pCPT-cGMPs). In addition to the expression of NOS1 and MnSOD, 17 beta-estradiol increased the expression of the redox protein thioredoxin (Trx), which was blocked by the inhibition of either cGMP formation or PKG activity. The expression of heme oxygenase 2 and brain-derived neurotrophic factor was not altered. Estrogen receptor-enhanced cell viability against oxidative stress may be linked to Trx expression because the Trx reductase inhibitor, 5,5'-dithio-bis(2-nitrobenzoic acid) significantly reduced the cytoprotective effect of 17 beta-estradiol. Furthermore, Trx (1 mu M) inhibited lipid peroxidation, proapoptotic caspase-3, and cell death during oxidative stress caused by serum deprivation. We conclude that cGMP-dependent expression of Trx--the redox protein with potent antioxidative and antiapoptotic properties--may play a pivotal role in estrogen-induced neuroprotection.	NIMH, Clin Sci Lab, NIH, Bethesda, MD 20892 USA; Penn State Univ, Milton S Hershey Med Ctr, Dept Anat & Neurosci, Coll Med, Hershey, PA 17033 USA; Toyama Med & Pharmaceut Univ, Dept Appl Pharmacol, Fac Pharmaceut Sci, Toyama 9300194, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Toyama	Chiueh, CC (corresponding author), NIMH, Clin Sci Lab, NIH, 10-3D-41, Bethesda, MD 20892 USA.	chiueh@helix.nih.gov		Lee, Sang/0000-0003-3911-8316				Andoh T, 2000, FASEB J, V14, P2144; Andoh T, 2003, J BIOL CHEM, V278, P885, DOI 10.1074/jbc.M209914200; Andoh T, 2002, ANN NY ACAD SCI, V962, P1, DOI 10.1111/j.1749-6632.2002.tb04051.x; Andoh T, 2002, J BIOL CHEM, V277, P9655, DOI 10.1074/jbc.M110701200; Asthana S, 2001, NEUROLOGY, V57, P605, DOI 10.1212/WNL.57.4.605; Bai J, 2002, NEUROSCI LETT, V321, P81, DOI 10.1016/S0304-3940(02)00058-7; Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535; Belcher SM, 1999, DEV BRAIN RES, V115, P57, DOI 10.1016/S0165-3806(99)00050-4; Belcher SM, 2001, J PHARMACOL EXP THER, V299, P408; Berco M, 2001, J SOC GYNECOL INVEST, V8, P245, DOI 10.1016/S1071-5576(01)00111-3; Beyer C, 2000, J NEUROSCI RES, V59, P107, DOI 10.1002/(SICI)1097-4547(20000101)59:1<107::AID-JNR13>3.0.CO;2-W; Bidmon HJ, 2001, J CHEM NEUROANAT, V22, P167, DOI 10.1016/S0891-0618(01)00126-0; Bolli R, 2001, J MOL CELL CARDIOL, V33, P1897, DOI 10.1006/jmcc.2001.1462; Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646; Chiueh CC, 1999, ANN NY ACAD SCI, V890, P301, DOI 10.1111/j.1749-6632.1999.tb08007.x; CHIUEH CC, 2001, MAPPING PROGR ALZHEI, P447; Culmsee C, 1999, J CEREBR BLOOD F MET, V19, P1263, DOI 10.1097/00004647-199911000-00011; Das KC, 1997, AM J RESP CELL MOL, V17, P713, DOI 10.1165/ajrcmb.17.6.2809; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.98.4.1952; Duran MG, 2000, OBSTET GYNECOL, V95, P284, DOI 10.1016/S0029-7844(99)00567-0; Estevez AG, 1998, J NEUROSCI, V18, P3708; FILLIT H, 1986, PSYCHONEUROENDOCRINO, V11, P337, DOI 10.1016/0306-4530(86)90019-3; Garcia-Duran M, 1999, CIRC RES, V85, P1020; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Goetz RM, 1999, P NATL ACAD SCI USA, V96, P2788, DOI 10.1073/pnas.96.6.2788; Green P S, 2000, Novartis Found Symp, V230, P202, DOI 10.1002/0470870818.ch15; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Greene K, 1997, WOMEN POLIT, V17, P17, DOI 10.1300/J014v17n03_02; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; Harms C, 2001, J NEUROSCI, V21, P2600, DOI 10.1523/JNEUROSCI.21-08-02600.2001; Hawkins V, 1999, J BIOMED SCI, V6, P433, DOI 10.1159/000025419; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; Horimoto H, 2000, J SURG RES, V92, P56, DOI 10.1006/jsre.2000.5845; Howard SA, 2001, EXP NEUROL, V168, P385, DOI 10.1006/exnr.2000.7619; Howell A, 2000, CANCER-AM CANCER SOC, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; Ivanova T, 2001, J NEUROSCI RES, V66, P221, DOI 10.1002/jnr.1214; Jover T, 2002, J NEUROSCI, V22, P2115, DOI 10.1523/JNEUROSCI.22-06-02115.2002; Khaldi A, 2002, ANN NY ACAD SCI, V962, P53, DOI 10.1111/j.1749-6632.2002.tb04055.x; Kim H, 2001, NEUROSCI LETT, V302, P58, DOI 10.1016/S0304-3940(01)01659-7; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Kuntz MA, 1997, J BIOL CHEM, V272, P27949, DOI 10.1074/jbc.272.44.27949; Kuroki Y, 2001, EUR J NEUROSCI, V13, P472, DOI 10.1046/j.0953-816x.2000.01409.x; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; McEwen B, 2001, P NATL ACAD SCI USA, V98, P7093, DOI 10.1073/pnas.121146898; Murad F, 1994, Adv Pharmacol, V26, P19, DOI 10.1016/S1054-3589(08)60049-6; Nethrapalli IS, 2001, ENDOCRINOLOGY, V142, P5145, DOI 10.1210/en.142.12.5145; Nuedling S, 2001, FEBS LETT, V502, P103, DOI 10.1016/S0014-5793(01)02675-8; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Pantazis NJ, 1998, J NEUROCHEM, V70, P1826; Patrone C, 2000, ENDOCRINOLOGY, V141, P1839, DOI 10.1210/en.141.5.1839; Pelligrino DA, 1998, NEUROREPORT, V9, P3285, DOI 10.1097/00001756-199810050-00026; Rauhala P, 2000, ANN NY ACAD SCI, V899, P238; Rauhala P, 1998, FASEB J, V12, P165, DOI 10.1096/fasebj.12.2.165; Rauhala P, 1996, SYNAPSE, V23, P58, DOI 10.1002/(SICI)1098-2396(199605)23:1<58::AID-SYN7>3.0.CO;2-G; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sahlin L, 1997, BIOL REPROD, V57, P1056, DOI 10.1095/biolreprod57.5.1056; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Samuels A, 2001, BONE, V29, P24, DOI 10.1016/S8756-3282(01)00471-9; Sawada H, 2000, FASEB J, V14, P1202, DOI 10.1096/fasebj.14.9.1202; Sawada H, 2002, NEUROPHARMACOLOGY, V42, P1056, DOI 10.1016/S0028-3908(02)00049-7; Sawada H, 2000, NEUROSCI BIOBEHAV R, V24, P143, DOI 10.1016/S0149-7634(99)00059-7; Shao LE, 2002, ANN NY ACAD SCI, V962, P140, DOI 10.1111/j.1749-6632.2002.tb04064.x; Shumaker SA, 1998, CONTROL CLIN TRIALS, V19, P604, DOI 10.1016/S0197-2456(98)00038-5; Simpkins JW., 1997, AM J MED, V103, p19S, DOI 10.1016/s0002-9343(97)00260-x; Singh M, 2000, J NEUROSCI, V20, P1694; Singh M, 2001, ENDOCRINE, V14, P407, DOI 10.1385/ENDO:14:3:407; Singleton JR, 1996, CANCER RES, V56, P4522; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Stoltzner SE, 2001, NEUROREPORT, V12, P2797, DOI 10.1097/00001756-200109170-00009; Takagi Y, 1999, P NATL ACAD SCI USA, V96, P4131, DOI 10.1073/pnas.96.7.4131; Takuma K, 2001, J BIOL CHEM, V276, P48093, DOI 10.1074/jbc.M108622200; Tanaka T, 2000, FREE RADICAL RES, V33, P851, DOI 10.1080/10715760000301361; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Urushitani M, 2000, J NEUROSCI RES, V61, P443, DOI 10.1002/1097-4547(20000815)61:4<443::AID-JNR11>3.0.CO;2-W; Wade CB, 2001, ENDOCRINOLOGY, V142, P2336, DOI 10.1210/en.142.6.2336; Wang L, 2001, P NATL ACAD SCI USA, V98, P2792, DOI 10.1073/pnas.041617498; WANG L, 2002, SCI STKE, V138, P1; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; Wirtz-Brugger F, 2000, NEUROSCIENCE, V99, P737, DOI 10.1016/S0306-4522(00)00243-8; Wise PM, 2002, TRENDS ENDOCRIN MET, V13, P229, DOI 10.1016/S1043-2760(02)00611-2; Wise PM, 2001, ENDOCRINOLOGY, V142, P969, DOI 10.1210/en.142.3.969; Xia S, 2002, NEUROBIOL DIS, V9, P282, DOI 10.1006/nbdi.2002.0478	90	73	76	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					947	+		10.1096/fj.02-0807fje	http://dx.doi.org/10.1096/fj.02-0807fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626428				2022-12-28	WOS:000181892600021
J	Nencioni, L; Iuvara, A; Aquilano, K; Ciriolo, MR; Cozzolino, F; Rotilio, G; Garaci, E; Palamara, AT				Nencioni, L; Iuvara, A; Aquilano, K; Ciriolo, MR; Cozzolino, F; Rotilio, G; Garaci, E; Palamara, AT			Influenza A virus replication is dependent on an antioxidant pathway that involves GSH and Bcl-2	FASEB JOURNAL			English	Article						orthomyxovirus; redox state; glutathione; viral persistence	NF-KAPPA-B; OXIDATIVE STRESS; INDUCED APOPTOSIS; GLUTATHIONE DEFICIENCY; EPITHELIAL-CELLS; SENDAI-VIRUS; BCL-2-EXPRESSING CELLS; REDOX REGULATION; HIV REPLICATION; GENE-EXPRESSION	Growing evidence indicates that viral replication is regulated by the redox state of the host cell. We demonstrate that cells of different origins display differential permissivity for influenza A virus replication, depending on their intracellular redox power as reflected by Bcl-2 expression and glutathione (GSH) content. Bcl-2 expressing cells were found to have higher intracellular levels of GSH and to produce lower amounts of virus than Bcl-2 negative cells. Two different steps in the virus life-cycle were involved in Bcl-2/GSH mediated viral inhibition: 1) expression of late viral proteins (in particular hemagglutinin and matrix); and 2) nuclear-cytoplasmic translocation of viral ribonucleoproteins (vRNPs). Buthionine-sulfoximine-induced inhibition of GSH synthesis in Bcl-2 expressing cells caused an increase in the expression of late viral proteins but did not restore vRNP export to the cytoplasm. Collectively, our findings show that both Bcl-2 expression and GSH content contribute to the host cell's ability to down-regulate influenza virus replication, although their effects are exerted at different stages of the viral life-cycle. In certain cell populations, this form of down-regulation might conceivably favor the establishment of persistent viral infection.	Univ Roma La Sapienza, Fac Pharm, Inst Microbiol, I-00185 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Rome, Italy; Univ Roma Tor Vergata, Dept Biol, Rome, Italy; Univ G DAnnunzio, Inst Biomed Sci, Chieti, Italy; CNR, INeMM, Rome, Italy	Sapienza University Rome; University of Rome Tor Vergata; University of Rome Tor Vergata; G d'Annunzio University of Chieti-Pescara; Consiglio Nazionale delle Ricerche (CNR)	Palamara, AT (corresponding author), Univ Roma La Sapienza, Fac Pharm, Inst Microbiol, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	annateresa.palamara@uniroma1.it	Ciriolo, Maria Rosa/K-6572-2016; AQUILANO, KATIA/K-8888-2016; Nencioni, Lucia/K-5988-2016; GARACI, ENRICO/AAB-3349-2021	AQUILANO, KATIA/0000-0002-5905-9870; Nencioni, Lucia/0000-0003-4427-4823; PALAMARA, ANNA TERESA/0000-0001-8330-4381; Cozzolino, Federico/0000-0002-2800-640X; Ciriolo, Maria Rosa/0000-0002-7863-9029				Aillet F, 1998, J VIROL, V72, P9698, DOI 10.1128/JVI.72.12.9698-9705.1998; Aslund F, 1999, CELL, V96, P751, DOI 10.1016/S0092-8674(00)80584-X; Banki K, 1998, J BIOL CHEM, V273, P11944, DOI 10.1074/jbc.273.19.11944; Barbaro G, 1996, AM J GASTROENTEROL, V91, P2569; Beck MA, 2000, ANN NY ACAD SCI, V917, P906; Boya P, 1999, J HEPATOL, V31, P808, DOI 10.1016/S0168-8278(99)80281-5; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BUHL R, 1989, LANCET, V2, P1294; Bui M, 2000, J VIROL, V74, P1781, DOI 10.1128/JVI.74.4.1781-1786.2000; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; Casola A, 2001, J BIOL CHEM, V276, P19715, DOI 10.1074/jbc.M101526200; Choi J, 2000, J BIOL CHEM, V275, P3693, DOI 10.1074/jbc.275.5.3693; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Ciriolo MR, 1997, J BIOL CHEM, V272, P2700, DOI 10.1074/jbc.272.5.2700; De Rosa SC, 2000, EUR J CLIN INVEST, V30, P915, DOI 10.1046/j.1365-2362.2000.00736.x; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; Elbim C, 1999, J VIROL, V73, P4561, DOI 10.1128/JVI.73.6.4561-4566.1999; Flory E, 2000, J BIOL CHEM, V275, P8307, DOI 10.1074/jbc.275.12.8307; GARACI E, 1992, BIOCHEM BIOPH RES CO, V188, P1090, DOI 10.1016/0006-291X(92)91343-O; Garaci E, 1997, J LEUKOCYTE BIOL, V62, P54, DOI 10.1002/jlb.62.1.54; Gaudernak E, 2002, J VIROL, V76, P6004, DOI 10.1128/JVI.76.12.6004-6015.2002; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Gu Y, 2001, VIROLOGY, V286, P62, DOI 10.1006/viro.2001.0998; HENNET T, 1992, J GEN VIROL, V73, P39, DOI 10.1099/0022-1317-73-1-39; Herzenberg LA, 1997, P NATL ACAD SCI USA, V94, P1967, DOI 10.1073/pnas.94.5.1967; HIERHOLZER JC, 1993, J CLIN MICROBIOL, V31, P1504, DOI 10.1128/JCM.31.6.1504-1510.1993; HINSHAW VS, 1994, J VIROL, V68, P3667, DOI 10.1128/JVI.68.6.3667-3673.1994; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jan JT, 2000, J VIROL, V74, P8680, DOI 10.1128/JVI.74.18.8680-8691.2000; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kaul P, 2000, J INFECT DIS, V181, P1885, DOI 10.1086/315504; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LAMB RA, 2001, VIROLOGY, P1487; Lee M, 2001, FREE RADICAL BIO MED, V31, P1550, DOI 10.1016/S0891-5849(01)00633-5; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; Liao CL, 1997, J VIROL, V71, P5963, DOI 10.1128/JVI.71.8.5963-5971.1997; Liao CL, 1998, J VIROL, V72, P9844, DOI 10.1128/JVI.72.12.9844-9854.1998; Lin KI, 1999, J BIOL CHEM, V274, P13650, DOI 10.1074/jbc.274.19.13650; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUKACS N, 1985, J VIROL, V53, P166; Macchia I, 1999, INT J IMMUNOPHARMACO, V21, P185, DOI 10.1016/S0192-0561(98)00080-0; May B.V.J., 1991, VIROLOGY PRACTICAL A, P119; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Meredith MJ, 1998, BIOCHEM BIOPH RES CO, V248, P458, DOI 10.1006/bbrc.1998.8998; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; Mileva M, 2000, TOXICOL LETT, V114, P39, DOI 10.1016/S0378-4274(99)00265-9; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; Mori I, 1999, J NEUROVIROL, V5, P355, DOI 10.3109/13550289909029476; Nucci C, 2000, EXP EYE RES, V70, P215, DOI 10.1006/exer.1999.0782; O'Neill RE, 1998, EMBO J, V17, P288, DOI 10.1093/emboj/17.1.288; Olsen CW, 1996, J VIROL, V70, P663, DOI 10.1128/JVI.70.1.663-666.1996; Palamara AT, 1996, AIDS RES HUM RETROV, V12, P1373, DOI 10.1089/aid.1996.12.1373; Palamara AT, 1996, BIOCHEM BIOPH RES CO, V228, P579, DOI 10.1006/bbrc.1996.1701; PALAMARA AT, 1995, ANTIVIR RES, V27, P237, DOI 10.1016/0166-3542(95)00008-A; Palamara AT, 1996, AIDS RES HUM RETROV, V12, P1537, DOI 10.1089/aid.1996.12.1537; Pekosz A, 1996, J VIROL, V70, P5329, DOI 10.1128/JVI.70.8.5329-5335.1996; Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098; RAVENHOLT RT, 1982, LANCET, V2, P860; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RODRIGUEZBOULAN E, 1983, METHOD ENZYMOL, V98, P486; Scallan MF, 1997, J VIROL, V71, P1583, DOI 10.1128/JVI.71.2.1583-1590.1997; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Su HL, 2001, VIROLOGY, V282, P141, DOI 10.1006/viro.2000.0820; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; Torcia M, 2001, J BIOL CHEM, V276, P39027, DOI 10.1074/jbc.M102970200; UBOL S, 1994, P NATL ACAD SCI USA, V91, P5202, DOI 10.1073/pnas.91.11.5202; VIDAL S, 1989, J VIROL, V63, P892, DOI 10.1128/JVI.63.2.892-900.1989; Voehringer DW, 2000, ANTIOXID REDOX SIGN, V2, P537, DOI 10.1089/15230860050192314; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; VOGEL U, 1994, VIROLOGY, V198, P227, DOI 10.1006/viro.1994.1025; Waris G, 2001, MOL CELL BIOL, V21, P7721, DOI 10.1128/MCB.21.22.7721-7730.2001	77	100	107	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					758	+		10.1096/fj.02-0508fje	http://dx.doi.org/10.1096/fj.02-0508fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594179				2022-12-28	WOS:000181456900013
J	Drake, PMW; Chargelegue, D; Vine, ND; Van Dolleweerd, CJ; Obregon, P; Ma, JKC				Drake, PMW; Chargelegue, D; Vine, ND; Van Dolleweerd, CJ; Obregon, P; Ma, JKC			Transgenic plants expressing antibodies: a model for phytoremediation	FASEB JOURNAL			English	Article						hydroponic medium; recombinant antibody; transgenic plants	MONOCLONAL-ANTIBODIES; TOBACCO PLANTS; IMMUNOGLOBULIN; DOMAINS; PROTEIN; CHAINS; GENE	The feasibility of using antibody expressing transgenic plants either to neutralize bioactive molecules in the rhizosphere, or to accumulate and concentrate the molecules in leaves has been demonstrated in a model system consisting of hydroponic Nicotiana plant cultures expressing a murine monoclonal IgG1. Two transgenic plant types were used; in the first, functional antibody was rhizosecreted and shown to bind with antigen in the surrounding medium to form an immune complex. In the second, a transmembrane sequence retained monoclonal antibody in the plants, on the plasma membrane. Antigen added to the nutrient medium around the roots of mIgG plants was transported within 24 h to the topmost leaves of the plant where it was sequestered as an immune complex by binding to antibody on the cell membrane. Concentration of immune complex in the leaf tissue remained constant over a 72 h period after removal of antigen from nutrient medium. Free antigen was not detected in the leaves of wild-type plants. The two strategies of rhizosecretion-mediated binding and sequestration in leaf tissue could potentially be used in the phytoremediation of any pollutant for which it is possible to generate a monoclonal antibody.	Guys Hosp, GKT Dent Inst, Dept Oral Med & Pathol, Immunol Unit, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Ma, JKC (corresponding author), Guys Hosp, GKT Dent Inst, Dept Oral Med & Pathol, Immunol Unit, 28th Floor,Guys Tower,London Bridge, London SE1 9RT, England.	julian.ma@kcl.ac.uk		Ma, Julian/0000-0003-0767-0042; Drake, Pascal/0000-0002-6181-0600; van Dolleweerd, Craig/0000-0002-1380-6930				BENVENUTO E, 1991, PLANT MOL BIOL, V17, P865, DOI 10.1007/BF00037067; BILES CL, 1991, PLANT PHYSIOL, V96, P597, DOI 10.1104/pp.96.2.597; DENEVE M, 1993, TRANSGENIC RES, V2, P227, DOI 10.1007/BF01977353; Frigerio L, 2000, PLANT PHYSIOL, V123, P1483, DOI 10.1104/pp.123.4.1483; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; Kramer U, 1996, NATURE, V379, P635, DOI 10.1038/379635a0; Kramer U, 2001, APPL MICROBIOL BIOT, V55, P661, DOI 10.1007/s002530100631; MA JKC, 1995, SCIENCE, V268, P716, DOI 10.1126/science.7732380; MA JKC, 1994, EUR J IMMUNOL, V24, P131, DOI 10.1002/eji.1830240120; MAITI IB, 1989, PLANT PHYSIOL, V91, P1020, DOI 10.1104/pp.91.3.1020; Meagher RB, 2000, CURR OPIN PLANT BIOL, V3, P153, DOI 10.1016/S1369-5266(99)00054-0; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; OWEN M, 1992, BIO-TECHNOL, V10, P790, DOI 10.1038/nbt0792-790; PAN AH, 1994, MOL GEN GENET, V242, P666, DOI 10.1007/BF00283421; Ryland JR, 2000, J MICROBIOL BIOTECHN, V10, P449; SMITH R, 1989, ORAL MICROBIOL IMMUN, V4, P153, DOI 10.1111/j.1399-302X.1989.tb00243.x; Vine ND, 2001, PLANT MOL BIOL, V45, P159, DOI 10.1023/A:1006477231006; Vonier PM, 1996, ENVIRON HEALTH PERSP, V104, P1318, DOI 10.2307/3432968; Wongsamuth R, 1997, BIOTECHNOL BIOENG, V54, P401, DOI 10.1002/(SICI)1097-0290(19970605)54:5&lt;401::AID-BIT1&gt;3.0.CO;2-I; YAMAWAKIKATAOKA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2623, DOI 10.1073/pnas.79.8.2623	20	18	18	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					1855	1860		10.1096/fj.02-0148com	http://dx.doi.org/10.1096/fj.02-0148com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12468448				2022-12-28	WOS:000180574300004
J	[Anonymous]				[Anonymous]			Combating diabetes	FASEB JOURNAL			English	Editorial Material																			0	0	0	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					1853	1853		10.1096/fj.02-0974bkt	http://dx.doi.org/10.1096/fj.02-0974bkt			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12468445	Bronze			2022-12-28	WOS:000180574300001
J	Lynn, FC; Thompson, SA; Pospisilik, JA; Ehses, JA; Hinke, SA; Pamir, N; McIntosh, CHS; Pederson, RA				Lynn, FC; Thompson, SA; Pospisilik, JA; Ehses, JA; Hinke, SA; Pamir, N; McIntosh, CHS; Pederson, RA			A novel pathway for regulation of glucose-dependent insulinotropic polypeptide receptor expression in beta-cells	FASEB JOURNAL			English	Article						PPAR alpha; type 2 diabetes; Zucker rats; INS(832/13) cells; gastric inhibitory polypeptide	GASTRIC-INHIBITORY POLYPEPTIDE; RAT; GIP; ALPHA; STIMULATION; RELEASE; GENE; DESENSITIZATION; INTOLERANCE; ANTAGONIST	Glucose-dependent insulinotropic polypeptide (GIP) is secreted postprandially and acts in concert with glucose to stimulate insulin secretion from the pancreas. Here, we describe a novel pathway for the regulation of GIP receptor (GIPR) expression within clonal beta-cell lines, pancreatic islets, and in vivo. High (25 mM) glucose was able to significantly reduce GIPR mRNA levels in INS(832/13) cells after only 6 h. In contrast, palmitic acid (2 mM) and WY 14643 (100 muM) stimulated approximate doublings of GIPR expression in INS(832/13) cells under low (5.5 mM), but not high (25 mM), glucose conditons, suggesting that fat can regulate GIPR expression via PPARalpha in a glucose-dependent manner. Both MK-886, an antagonist of PPARalpha, and a dominant negative form of PPARalpha transfected into INS(832/13) cells caused a significant reduction in GIPR expression in low, but not high, glucose conditions. Finally, in hyperglycemic clamped rats, there was a 70% reduction in GIPR expression in the islets and a 71% reduction in GIP-stimulated insulin secretion from the perfused pancreas. Thus, evidence is presented that the GIPR is controlled at normoglycemia by the fatty acid load on the islet; however, when exposed to hyperglycemic conditions, the GIPR is down-regulated, which may contribute to the decreased responsiveness to GIP that is observed in type 2 diabetes.	Univ British Columbia, Fac Med, Dept Physiol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Pederson, RA (corresponding author), Univ British Columbia, Fac Med, Dept Physiol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	pederson@interchange.ubc.ca	Hinke, Simon/R-7120-2019; Ehses, Jan/AAK-1635-2020; Pamir, Nathalie/H-5234-2013	Ehses, Jan/0000-0001-9066-7607; Pamir, Nathalie/0000-0002-2074-888X; Lynn, Francis/0000-0001-9318-1063				AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; BECK B, 1983, REGUL PEPTIDES, V7, P3, DOI 10.1016/0167-0115(83)90276-8; Beguin P, 1999, EMBO J, V18, P4722, DOI 10.1093/emboj/18.17.4722; BLAKE AD, 1987, BIOCHEM J, V245, P357, DOI 10.1042/bj2450357; DAlessio D, 1997, HORM METAB RES, V29, P297, DOI 10.1055/s-2007-979039; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Ding WG, 1997, DIABETES, V46, P615, DOI 10.2337/diabetes.46.4.615; Ehses JA, 2001, J BIOL CHEM, V276, P23667, DOI 10.1074/jbc.M103023200; Freeman WM, 1999, BIOTECHNIQUES, V26, P112, DOI 10.2144/99261rv01; Gervois P, 1999, MOL ENDOCRINOL, V13, P1535, DOI 10.1210/me.13.9.1535; Hinke SA, 2000, J ENDOCRINOL, V165, P281, DOI 10.1677/joe.0.1650281; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Holst JJ, 1997, DIABETOLOGIA, V40, P984, DOI 10.1007/s001250050779; HSU MH, 1995, MOL PHARMACOL, V48, P559; Kehrer JP, 2001, BIOCHEM J, V356, P899, DOI 10.1042/0264-6021:3560899; KIEFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585, DOI 10.1210/en.136.8.3585; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Laybutt R, 2001, DIABETES, V50, pS180, DOI 10.2337/diabetes.50.2007.S180; Lynn FC, 2001, DIABETES, V50, P1004, DOI 10.2337/diabetes.50.5.1004; McClenaghan NH, 1996, DIABETES, V45, P1132, DOI 10.2337/diabetes.45.8.1132; McIntosh CHS, 1996, ACTA PHYSIOL SCAND, V157, P361, DOI 10.1046/j.1365-201X.1996.44267000.x; McIntosh CHS, 1999, ENDOCRINOLOGY, V140, P398, DOI 10.1210/en.140.1.398; Miyawaki K, 1999, P NATL ACAD SCI USA, V96, P14843, DOI 10.1073/pnas.96.26.14843; NAUCK M, 1986, DIABETOLOGIA, V29, P46, DOI 10.1007/BF02427280; NAUCK MA, 1993, J CLIN INVEST, V91, P301, DOI 10.1172/JCI116186; OBEN J, 1991, J ENDOCRINOL, V130, P267, DOI 10.1677/joe.0.1300267; PEDERSON RA, 1975, DIABETES, V24, P1050, DOI 10.2337/diabetes.24.12.1050; PEDERSON RA, 1976, ENDOCRINOLOGY, V99, P780, DOI 10.1210/endo-99-3-780; PEDERSON RA, 1982, REGUL PEPTIDES, V5, P53, DOI 10.1016/0167-0115(82)90075-1; Prentki M, 1997, DIABETOLOGIA, V40, pS32, DOI 10.1007/s001250051395; Roduit R, 2000, J BIOL CHEM, V275, P35799, DOI 10.1074/jbc.M006001200; Schinner S, 2002, J BIOL CHEM, V277, P1941, DOI 10.1074/jbc.M109718200; Schirra J, 1998, J CLIN INVEST, V101, P1421, DOI 10.1172/JCI1349; Scrocchi LA, 1996, NAT MED, V2, P1254, DOI 10.1038/nm1196-1254; Trumper A, 2001, MOL ENDOCRINOL, V15, P1559, DOI 10.1210/me.15.9.1559; Tseng CC, 1996, J CLIN INVEST, V98, P2440, DOI 10.1172/JCI119060; Tseng CC, 1999, AM J PHYSIOL-ENDOC M, V276, pE1049, DOI 10.1152/ajpendo.1999.276.6.E1049; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; Wang MY, 1999, J BIOL CHEM, V274, P17541, DOI 10.1074/jbc.274.25.17541; WHEELER MB, 1995, ENDOCRINOLOGY, V136, P4629, DOI 10.1210/en.136.10.4629; Zhou YT, 1998, P NATL ACAD SCI USA, V95, P8898, DOI 10.1073/pnas.95.15.8898	41	71	78	2	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					91	+		10.1096/fj.02-0243fje	http://dx.doi.org/10.1096/fj.02-0243fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475913				2022-12-28	WOS:000180218500017
J	Shi, H; Norman, AW; Okamura, WH; Sen, A; Zemel, MB				Shi, H; Norman, AW; Okamura, WH; Sen, A; Zemel, MB			1 alpha,25-dihydroxyvitamin D-3 inhibits uncoupling protein 2 expression in human adipocytes	FASEB JOURNAL			English	Article						intracellular calcium; membrane vitamin D receptor; nuclear vitamin D receptor; thermogenesis	CYTOSOLIC-FREE CALCIUM; VITAMIN-D-RECEPTOR; INSULIN-RESISTANCE; INTRACELLULAR CALCIUM; ADIPOSE DIFFERENTIATION; BIOLOGICAL RESPONSES; MEMBRANE-RECEPTOR; AGOUTI REGULATION; GENE; OBESITY	We recently demonstrated that suppressing 1alpha,25-(OH)(2)-D-3 by increasing dietary calcium decreases adipocyte intracellular Ca2+ ([Ca2+](i)), stimulates lipolysis, and inhibits lipogenesis. High calcium diets also increase core temperature and white adipose tissue uncoupling protein 2 (UCP2) expression in aP2-agouti transgenic mice. Accordingly, we have evaluated the role of 1alpha,25-(OH)(2)-D-3 in regulating human adipocyte UCP2 expression. Treatment of human adipocytes for 48 h with 1 nM 1alpha,25-(OH)(2)-D-3 inhibited UCP2 mRNA and protein levels by 50% (P<0.002) and completely blocked isoproterenol- or fatty acid-stimulated two- to threefold increases in UCP2 expression. However, a specific agonist for the membrane vitamin D receptor (mVDR), 1 alpha,25-dihydroxylumisterol(3), was unable to inhibit basal, isoproterenol-stimulated, or fatty acid-stimulated UCP2 expression, whereas a specific mVDR antagonist, 1 beta,25-dihydroxyvitamin D-3, was unable to prevent the 1 alpha,25-(OH)(2)-D-3 inhibition of UCP2 expression. In contrast, nuclear vitamin D receptor (nVDR) knockout via antisense oligodeoxynucleotide (ODN) prevented the inhibitory effect of 1 alpha,25-(OH)(2)-D-3 on adipocyte UCP2 expression and protein levels. These data indicate that 1 alpha,25-(OH)2-D3 exerts an inhibitory effect on adipocyte UCP2 expression via the nVDR. Thus, suppression of 1 alpha,25-(OH)(2)-D-3 and consequent up-regulation of UCP2 may contribute to our previous observation of increased thermogenesis in mice fed with high calcium diets.	Univ Tennessee, Knoxville, TN 37996 USA; Univ Calif Riverside, Riverside, CA 92521 USA; Zen Bio, Res Triangle Pk, NC 27709 USA	University of Tennessee System; University of Tennessee Knoxville; University of California System; University of California Riverside	Zemel, MB (corresponding author), Univ Tennessee, 1215 W Cumberland Ave,229, Knoxville, TN 37996 USA.	mzemel@utk.edu		Zemel, Michael/0000-0003-4104-5750				ANDERSEN T, 1988, METABOLISM, V37, P425, DOI 10.1016/0026-0495(88)90041-8; BARAN DT, 1991, J BONE MINER RES, V6, P1269; Baran DT, 2000, J CELL BIOCHEM, V78, P34, DOI 10.1002/(SICI)1097-4644(20000701)78:1<34::AID-JCB4>3.3.CO;2-Q; BARGERLUX MJ, 1995, CALCIFIED TISSUE INT, V57, P161, DOI 10.1007/BF00298438; BELL NH, 1985, J CLIN INVEST, V76, P370, DOI 10.1172/JCI111971; BYYNY RL, 1992, AM J HYPERTENS, V5, P459, DOI 10.1093/ajh/5.7.459; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; Dace A, 1997, BIOCHEM BIOPH RES CO, V232, P771, DOI 10.1006/bbrc.1997.6372; Davies KM, 2000, J CLIN ENDOCR METAB, V85, P4635, DOI 10.1210/jc.85.12.4635; DeLuca HF, 1998, NUTR REV, V56, pS4; DRAZNIN B, 1988, J CLIN INVEST, V82, P1848, DOI 10.1172/JCI113801; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; Fleet JC, 1999, NUTR REV, V57, P60, DOI 10.1111/j.1753-4887.1999.tb01779.x; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Hida Y, 1998, LIFE SCI, V62, pPL205, DOI 10.1016/S0024-3205(98)00059-9; Kajikawa M, 1999, ENDOCRINOLOGY, V140, P4706, DOI 10.1210/en.140.10.4706; Kawada T, 1996, INT J OBESITY, V20, pS52; Kim JH, 1997, AM J PHYSIOL-ENDOC M, V272, pE379, DOI 10.1152/ajpendo.1997.272.3.E379; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenoir C, 1996, ENDOCRINOLOGY, V137, P4268, DOI 10.1210/en.137.10.4268; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; LI YC, 1998, BONE, V23, pS263; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; Nemere I, 1998, J BONE MINER RES, V13, P1353, DOI 10.1359/jbmr.1998.13.9.1353; NEMERE I, 1994, J BIOL CHEM, V269, P23750; NORMAN AW, 1980, SCIENCE, V209, P823, DOI 10.1126/science.6250216; NORMAN AW, 1993, J BIOL CHEM, V268, P20022; Norman AW, 1997, MOL ENDOCRINOL, V11, P1518, DOI 10.1210/me.11.10.1518; Norman AW, 1998, J BONE MINER RES, V13, P1360, DOI 10.1359/jbmr.1998.13.9.1360; Querfeld U, 1999, J AM SOC NEPHROL, V10, P2158; RESNICK L, 1999, PROG CARDIOVASC DIS, V4; Sanchez M, 1997, HYPERTENSION, V29, P531, DOI 10.1161/01.HYP.29.1.531; SHAN J, 1993, AM J HYPERTENS, V6, P983, DOI 10.1093/ajh/6.12.983; Shi H, 2001, FASEB J, V15, P2751, DOI 10.1096/fj.01-0584fje; Shi H, 2001, FASEB J, V15, P291; Shi H, 2000, PHYSIOL GENOMICS, V3, P75, DOI 10.1152/physiolgenomics.2000.3.2.75; Shi H, 1999, FASEB J, V13, P1833, DOI 10.1096/fasebj.13.13.1833; TANAKA Y, 1986, ENDOCRINOLOGY, V118, P1971, DOI 10.1210/endo-118-5-1971; TORNQUIST K, 1989, ENDOCRINOLOGY, V124, P2765, DOI 10.1210/endo-124-6-2765; TU M, 1999, BIOCHEM BIOPH RES CO, V265, P326; Xue BZ, 1998, FASEB J, V12, P1391, DOI 10.1096/fasebj.12.13.1391; Yamada M, 1998, FEBS LETT, V432, P65, DOI 10.1016/S0014-5793(98)00835-7; YOSHIDA S, 1999, J PHYS MESOMECH, V2, P5; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733; Zemel MB, 2000, FASEB J, V14, P1132, DOI 10.1096/fasebj.14.9.1132	47	108	125	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13	1				1808	+		10.1096/fj.02-0255fje	http://dx.doi.org/10.1096/fj.02-0255fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223452				2022-12-28	WOS:000181189100011
J	Wong, LF; Polson, JW; Murphy, D; Paton, JFR; Kasparov, S				Wong, LF; Polson, JW; Murphy, D; Paton, JFR; Kasparov, S			Genetic and pharmacological dissection of pathways involved in the angiotensin II-mediated depression of baroreflex function	FASEB JOURNAL			English	Article						hypertension; nucleus of the solitary tract; adenoviral gene transfer; calcium signaling	NITRIC-OXIDE SYNTHASE; NUCLEUS-TRACTUS-SOLITARII; PROTEIN-KINASE-C; SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; BRAIN-STEM; RAT; ACTIVATION; HYPERTENSION	Heart failure and hypertension are associated with increases in angiotensin II (ANG II) activity. One brain area where ANG II effects may be particularly important in these situations is the nucleus of the solitary tract (NTS). Located in the dorsomedial medulla, the NTS is the termination site of baroreceptor afferents and is essential for mediating the baroreflex. In hypertensive animals the baroreflex is impaired; this may be reversed by antagonizing ANG II AT(1) receptors in the NTS. Recently, we showed that the baroreflex depressant action of ANG II in the NTS is mediated by activation of endothelial nitric oxide synthase (eNOS) and enhanced release of GABA. Using conventional pharmacological tools and a range of adenoviral-mediated expression of dominant negative proteins, we have determined the intracellular pathway(s) in the NTS by which ANG II activates eNOS. Our data indicate that ANG II acting in the NTS depresses the baroreflex via a G(q) protein-mediated activation of phospholipase C, which through 1,4,5-inositol triphosphate causes release of calcium from the IP3-sensitive intracellular stores and calcium-calmodulin formation. In contrast, multiple site disruption of a pathway leading to eNOS activation via the serine/threonine kinase Akt was ineffective.	Univ Bristol, Dept Physiol, Bristol BS8 1TD, Avon, England; Univ Bristol, Bristol Royal Infirm, Univ Res Ctr Neuroendocrinol, Bristol BS2 8HW, Avon, England	University of Bristol; Bristol Royal Infirmary; University of Bristol	Kasparov, S (corresponding author), Univ Bristol, Dept Physiol, Univ Walk, Bristol BS8 1TD, Avon, England.	sergey.kasparov@bristol.ac.uk	Murphy, David/C-3967-2012; Kasparov, Sergey/C-4932-2014; Kasparov, Sergey/AAH-5286-2019; Paton, Julian/AAM-2121-2020	Murphy, David/0000-0003-2946-0353; Kasparov, Sergey/0000-0002-1824-1764; Kasparov, Sergey/0000-0002-1824-1764; 				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; CAJARAVILLE MP, 1993, HISTOL HISTOPATHOL, V8, P537; CAMPBELL DJ, 1995, HYPERTENSION, V25, P1014, DOI 10.1161/01.HYP.25.5.1014; CASTO R, 1986, AM J PHYSIOL, V250, pR193, DOI 10.1152/ajpregu.1986.250.2.R193; CAULFIELD M, 1994, NEW ENGL J MED, V330, P1629, DOI 10.1056/NEJM199406093302301; Cummins MM, 2000, IMMUNOL CELL BIOL, V78, P375, DOI 10.1046/j.1440-1711.2000.00932.x; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fang X, 2000, J NEUROCHEM, V75, P614, DOI 10.1046/j.1471-4159.2000.0750614.x; Ferguson AV, 2000, EXP PHYSIOL, V85, p153S, DOI 10.1111/j.1469-445X.2000.tb00019.x; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Govers R, 2001, AM J PHYSIOL-RENAL, V280, pF193, DOI 10.1152/ajprenal.2001.280.2.F193; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; HEAGERTY AM, 1993, J HUM HYPERTENS, V7, P383; HEALY DP, 1989, BRAIN RES, V489, P1; HIRATA K, 1995, HYPERTENSION, V25, P180, DOI 10.1161/01.HYP.25.2.180; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; Kasparov S, 1999, J PHYSIOL-LONDON, V521, P227, DOI 10.1111/j.1469-7793.1999.00227.x; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; Luoh HF, 1998, BRAIN RES, V782, P73, DOI 10.1016/S0006-8993(97)01198-0; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MICHELINI LC, 1990, HYPERTENSION S1, V15, P145; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Mollnau H, 2002, CIRC RES, V90, pE58, DOI 10.1161/01.RES.0000012569.55432.02; Pan SJ, 2001, AM J PHYSIOL-CELL PH, V281, pC17, DOI 10.1152/ajpcell.2001.281.1.C17; Paton JFR, 2001, J PHYSIOL-LONDON, V531, P445, DOI 10.1111/j.1469-7793.2001.0445i.x; Paton JFR, 1999, J PHYSIOL-LONDON, V521, P213, DOI 10.1111/j.1469-7793.1999.00213.x; Paton JFR, 1996, J NEUROSCI METH, V65, P63, DOI 10.1016/0165-0270(95)00147-6; Paton JFR, 2000, J AUTONOM NERV SYST, V80, P117, DOI 10.1016/S0165-1838(00)00077-1; PHILLIPS MI, 1977, NATURE, V270, P445, DOI 10.1038/270445a0; SENANAYAKE PD, 1994, PEPTIDES, V15, P919; Seyedabadi M, 2001, HYPERTENSION, V38, P1087, DOI 10.1161/hy1101.096054; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; Stanarius A, 1997, ACTA HISTOCHEM, V99, P411, DOI 10.1016/S0065-1281(97)80034-7; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TERUYA H, 1995, J HYPERTENS, V13, P883, DOI 10.1097/00004872-199508000-00009; Teschemacher AG, 2000, J NEUROSCI, V20, P4776; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; WONG LF, 2001, SOC NEUR ABSTR, V27, P8374; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871	42	48	48	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1595	1601		10.1096/fj.02-0099com	http://dx.doi.org/10.1096/fj.02-0099com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374782				2022-12-28	WOS:000179167600041
J	Udagawa, T; Fernandez, A; Achilles, EG; Folkman, J; D'Amato, RJ				Udagawa, T; Fernandez, A; Achilles, EG; Folkman, J; D'Amato, RJ			Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy	FASEB JOURNAL			English	Article						angiogenesis; dormant tumors; occult cancers	ENDOTHELIAL GROWTH-FACTOR; CARCINOMA-CELLS; BREAST-CANCER; IN-VIVO; INHIBITOR; RAS; EXPRESSION; METASTASES; INDUCTION; ONCOGENES	Some human tumor lines do not form visible tumors when inoculated into immunosuppressed mice. The fate of these human tumor lines was followed by transfecting them with green fluorescence protein before inoculating them into mice. Although the tumor lines failed to grow progressively, they formed small dormant microscopic foci maintained at constant mass by balanced proliferation and apoptosis. Transfecting the cells with either VEGF(165) or activated c-Ha-ras induced loss of dormancy, which correlated with a shift in the angiogenic balance toward increased vascularity with reduced tumor cell apoptosis. These results support a model in which loss of dormancy is controlled in part by a switch to an angiogenic phenotype. These tumor lines may serve as models for investigating the cellular mechanisms controlling dormancy and identifying those factors that promote the loss of balanced proliferation and apoptosis. Finally, these models may prove useful in the design and testing of therapies directed toward eradicating dormant tumors and preventing tumor recurrence.	Harvard Univ, Sch Med, Childrens Hosp, Dept Surg,Div Surg Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA; Hosp Leon, Unidad Invest, Leon 24071, Spain; Univ Hamburg, Univ Hamburg Hosp, Dept Hepatobiliary Surg, Hamburg, Germany	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Universidad de Leon; Hospital de Leon; University of Hamburg; University Medical Center Hamburg-Eppendorf	D'Amato, RJ (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Dept Surg,Div Surg Res, Enders 1022,300 Longwood Ave, Boston, MA 02115 USA.	robert.damato@tch.harvard.edu			NATIONAL CANCER INSTITUTE [K01CA087013] Funding Source: NIH RePORTER; NCI NIH HHS [1 K01 CA87013-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achilles EG, 2001, J NATL CANCER I, V93, P1075, DOI 10.1093/jnci/93.14.1075; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Badgley CE, 1941, ARCH SURG-CHICAGO, V43, P541, DOI 10.1001/archsurg.1941.01210160002001; Barnhill RL, 1998, ARCH DERMATOL, V134, P991, DOI 10.1001/archderm.134.8.991; Bayko L, 1998, Angiogenesis, V2, P203, DOI 10.1023/A:1009275307663; BECKWITH JB, 1963, AM J PATHOL, V43, P1089; BILLIAU A, 1977, ANTIMICROB AGENTS CH, V12, P11, DOI 10.1128/AAC.12.1.11; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Califano J, 1999, J NATL CANCER I, V91, P599, DOI 10.1093/jnci/91.7.599; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; CHOI BH, 1981, ACTA NEUROPATHOL, V254, P269; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; CROWLEY NJ, 1992, ARCH SURG-CHICAGO, V127, P1303; DEMICHELI R, 1994, J NATL CANCER I, V86, P45; Fernandez A, 2001, J NATL CANCER I, V93, P208, DOI 10.1093/jnci/93.3.208; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Galdemard C, 2000, J BIOL CHEM, V275, P17364, DOI 10.1074/jbc.M909316199; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GOUSTIN AS, 1986, CANCER RES, V46, P1015; HARACH HR, 1985, CANCER-AM CANCER SOC, V56, P531, DOI 10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3; Holmgren L, 1998, ONCOGENE, V17, P819, DOI 10.1038/sj.onc.1201993; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Huntsman DG, 2001, NEW ENGL J MED, V344, P1904, DOI 10.1056/NEJM200106213442504; Kimura W, 1998, CANCER, V82, P1839, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1839::AID-CNCR5>3.0.CO;2-I; Lu KH, 2000, J CLIN ONCOL, V18, P2728, DOI 10.1200/JCO.2000.18.14.2728; Meijers-Heijboer H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; Mizuno I, 1998, Rinsho Ketsueki, V39, P670; MONTIE JE, 1989, CANCER, V63, P381, DOI 10.1002/1097-0142(19890115)63:2<381::AID-CNCR2820630230>3.0.CO;2-O; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Orel SG, 1999, RADIOLOGY, V212, P543, DOI 10.1148/radiology.212.2.r99au40543; Rak J, 1996, EUR J CANCER, V32A, P2438, DOI 10.1016/S0959-8049(96)00396-6; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 2000, J INVEST DERM SYMP P, V5, P24, DOI 10.1046/j.1087-0024.2000.00012.x; Sheibani N, 1996, CANCER LETT, V107, P45, DOI 10.1016/0304-3835(96)04341-8; STOLL BA, 1982, PROLONGED ARREST CAN, V1, P59; SWEENEY TM, 1991, CANCER METAST REV, V10, P245, DOI 10.1007/BF00050795; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Tokunaga T, 1998, J NATL CANCER I, V90, P400, DOI 10.1093/jnci/90.5.400; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Yadav M, 1996, ANTICANCER RES, V16, P1787	48	103	107	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2002	16	11					1361	1370		10.1096/fj.01-0813com	http://dx.doi.org/10.1096/fj.01-0813com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12205027				2022-12-28	WOS:000178441800010
J	Babiychuk, EB; Monastyrskaya, K; Burkhard, FC; Wray, S; Draeger, A				Babiychuk, EB; Monastyrskaya, K; Burkhard, FC; Wray, S; Draeger, A			Modulating signaling events in smooth muscle: cleavage of annexin 2 abolishes its binding to lipid rafts	FASEB JOURNAL			English	Article						5 '-nucleotidase; microdomains; contraction; protein kinase C; RhoA; compartmentalization; annexins	CONTRACTILE PROPERTIES; MEMBRANE DYNAMICS; LIPOCORTIN-I; G-PROTEINS; CELLS; PROTEOLYSIS; PHOSPHORYLATION; CHROMATOGRAPHY; MICRODOMAINS; TRANSDUCTION	Cell membrane compartmentalization, which is believed to involve association of cholesterol- and glycosphingolipid-enriched membrane rafts, represents an important means of transmitting information across the plasma membrane. We have previously shown that raft association is mediated by the Ca2+ dependent binding of annexin 2 to the plasma membrane. In the present study, we demonstrate that the association of annexins 1 and 2 with the smooth muscle cell membrane can be terminated by their proteolytic cleavage. This proteolysis is thought to be triggered by calpain and occurs at non-raft regions of the plasma membrane. It is critically dependent on the intracellular concentration of free Ca2+ and requires an intact contractile apparatus. Annexins 1 and 2 interact with different membrane microcompartments-the former with non-raft, glycerolipid regions, the latter preferentially with membrane rafts. We demonstrate that PKC and RhoA, major signaling molecules that regulate smooth muscle contraction, are spatially segregated and interact with distinct membrane microcompartments. Proteolysis abolishes annexin binding to the plasma membrane and might result in rearrangement of membrane constituents followed by the interruption of segregation-dependent signaling events.	Univ Bern, Inst Anat, Dept Cell Biol, CH-3012 Bern, Switzerland; Taras Schevchenko Kiev Univ, Inst Physiol, Kiev, Ukraine; Univ Bern, Dept Urol, CH-3012 Bern, Switzerland; Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Bern; Ministry of Education & Science of Ukraine; Taras Shevchenko National University Kiev; University of Bern; University of Liverpool	Draeger, A (corresponding author), Univ Bern, Inst Anat, Dept Cell Biol, Buhlstr 26, CH-3012 Bern, Switzerland.	draeger@ana.unibe.ch	Babiychuk, Eduard/AAV-7223-2021; wray, susan/B-1197-2009; Burkhard, Fiona/AAE-4524-2020	Wray, Susan/0000-0002-0086-1359; Monastyrskaya, Katia/0000-0003-2042-1139; Babiychuk, Eduard/0000-0003-1786-0085; Burkhard, Fiona/0000-0002-8271-014X				Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; ANDO Y, 1989, J BIOL CHEM, V264, P6948; Babiychuk EB, 1999, J BIOL CHEM, V274, P35191, DOI 10.1074/jbc.274.49.35191; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CHUAH SY, 1989, J BIOL CHEM, V264, P21160; Cuervo AM, 2000, J BIOL CHEM, V275, P33329, DOI 10.1074/jbc.M005655200; Ehler E, 1996, CELL MOTIL CYTOSKEL, V34, P288, DOI 10.1002/(SICI)1097-0169(1996)34:4<288::AID-CM4>3.0.CO;2-4; Filipenko NR, 2001, J BIOL CHEM, V276, P5310, DOI 10.1074/jbc.M009710200; Fiske CH, 1925, J BIOL CHEM, V66, P375; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; Horowitz A, 1996, PHYSIOL REV, V76, P967, DOI 10.1152/physrev.1996.76.4.967; Jost M, 1997, J CELL SCI, V110, P221; Jostarndt-Fogen K, 1998, HISTOCHEM CELL BIOL, V110, P273, DOI 10.1007/s004180050289; Kohler A, 1999, ANAT EMBRYOL, V200, P313, DOI 10.1007/s004290050282; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu L, 1995, BIOCHEM MOL BIOL INT, V36, P373; MACALA LJ, 1983, J LIPID RES, V24, P1243; Movitz C, 2000, BBA-BIOMEMBRANES, V1468, P231, DOI 10.1016/S0005-2736(00)00261-3; Movitz C, 1999, BBA-BIOMEMBRANES, V1416, P101, DOI 10.1016/S0005-2736(98)00212-0; Nath R, 2000, BIOCHEM BIOPH RES CO, V274, P16, DOI 10.1006/bbrc.2000.3070; NORTH AJ, 1993, J CELL BIOL, V120, P1159, DOI 10.1083/jcb.120.5.1159; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Petrie RJ, 2000, J IMMUNOL, V165, P1220, DOI 10.4049/jimmunol.165.3.1220; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sjolin C, 1996, BBA-BIOMEMBRANES, V1281, P227, DOI 10.1016/0005-2736(96)00018-1; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Sowa G, 2001, P NATL ACAD SCI USA, V98, P14072, DOI 10.1073/pnas.241409998; Thyberg J, 1996, INT REV CYTOL, V169, P183, DOI 10.1016/S0074-7696(08)61987-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsao FHC, 1998, AM J RESP CELL MOL, V18, P120, DOI 10.1165/ajrcmb.18.1.2808; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080	35	64	64	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1177	10.1096/fj.02-0070com	http://dx.doi.org/10.1096/fj.02-0070com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153985				2022-12-28	WOS:000177814000026
J	Bootman, MD; Collins, TJ; Mackenzie, L; Roderick, HL; Berridge, MJ; Peppiatt, CM				Bootman, MD; Collins, TJ; Mackenzie, L; Roderick, HL; Berridge, MJ; Peppiatt, CM			2-Aminoethoxydiphenyl borate (2-APB) is a reliable blocker of store-operated Ca2+ entry but an inconsistent inhibitor of InsP(3)-induced Ca2+ release	FASEB JOURNAL			English	Review							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CALCIUM-RELEASE; TRISPHOSPHATE RECEPTOR; ARACHIDONIC-ACID; ACINAR-CELLS; CHANNELS; ACTIVATION; MECHANISM; INS(1,4,5)P-3; MODULATOR	Since its introduction to Ca2+ signaling in 1997, 2-aminoethoxydiphenyl borate (2-APB) has been used in many studies to probe for the involvement of inositol 1,4,5-trisphosphate receptors in the generation of Ca2+ signals. Due to reports of some nonspecific actions of 2-APB, and the fact that its principal antagonistic effect is on Ca2+ entry rather than Ca2+ release, this compound may not have the utility first suggested. However, 2-APB has thrown up some interesting results, particularly with respect to store-operated Ca2+ entry in nonexcitable cells. These data indicate that although it must be used with caution, 2-APB can be useful in probing certain aspects of Ca2+ signaling.	Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Bootman, MD (corresponding author), Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England.	martin.bootman@bbsrc.ac.uk	Bootman, Martin/AAB-3330-2019	Bootman, Martin/0000-0002-6447-3451; Peppiatt-Wildman, Claire/0000-0002-4406-8571; Roderick, Hywel/0000-0001-7065-3523				Ascher-Landsberg J, 1999, BIOCHEM BIOPH RES CO, V264, P979, DOI 10.1006/bbrc.1999.1602; Bakowski D, 2001, J PHYSIOL-LONDON, V532, P55, DOI 10.1111/j.1469-7793.2001.0055g.x; BERRIDGE MJ, 1995, RYANODINE RECEPTORS, P119; Bishara NB, 2002, BRIT J PHARMACOL, V135, P119, DOI 10.1038/sj.bjp.0704465; Bootman MD, 2001, SEMIN CELL DEV BIOL, V12, P3, DOI 10.1006/scdb.2000.0211; Bramich NJ, 2001, AM J PHYSIOL-HEART C, V281, pH1771, DOI 10.1152/ajpheart.2001.281.4.H1771; Braun FJ, 2001, J BIOL CHEM, V276, P1063, DOI 10.1074/jbc.M008348200; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; Chorna-Ornan I, 2001, J NEUROSCI, V21, P2622, DOI 10.1523/JNEUROSCI.21-08-02622.2001; Collins TJ, 2001, J BIOL CHEM, V276, P26411, DOI 10.1074/jbc.M101101200; De Smet P, 1999, CELL CALCIUM, V26, P9; Diver JM, 2001, CELL CALCIUM, V30, P323, DOI 10.1054/ceca.2001.0239; Dobryndeva Y, 2001, MOL PHARMACOL, V60, P541; Dyachok O, 2001, J CELL SCI, V114, P2179; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; Estrada M, 2001, J BIOL CHEM, V276, P22868, DOI 10.1074/jbc.M100118200; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Gregory RB, 2001, BIOCHEM J, V354, P285, DOI 10.1042/0264-6021:3540285; Gysembergh A, 1999, AM J PHYSIOL-HEART C, V277, pH2458, DOI 10.1152/ajpheart.1999.277.6.H2458; Hamada T, 1999, NEUROSCI LETT, V263, P125, DOI 10.1016/S0304-3940(99)00111-1; Hauser NC, 2001, COMPAR FUNCT GENOM, V2, P69, DOI 10.1002/cfg.73; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; Hirst GDS, 2001, J PHYSIOL-LONDON, V535, P165, DOI 10.1111/j.1469-7793.2001.00165.x; Imaeda K, 2000, BRIT J PHARMACOL, V131, P1121, DOI 10.1038/sj.bjp.0703689; Iwasaki H, 2001, RECEPTOR CHANNEL, V7, P429; Jezior JR, 2001, BRIT J PHARMACOL, V134, P78, DOI 10.1038/sj.bjp.0704241; Jonas S, 1997, ANN NY ACAD SCI, V825, P389, DOI 10.1111/j.1749-6632.1997.tb48449.x; Kukkonen JP, 2001, CELL CALCIUM, V30, P117, DOI 10.1054/ceca.2001.0219; Li WH, 1997, TETRAHEDRON, V53, P12017, DOI 10.1016/S0040-4020(97)00714-X; Luo DL, 2001, J BIOL CHEM, V276, P20186, DOI 10.1074/jbc.M100327200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2002, J BIOL CHEM, V277, P6915, DOI 10.1074/jbc.M107755200; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Missiaen L, 2001, CELL CALCIUM, V29, P111, DOI 10.1054/ceca.2000.0163; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Pal S, 2001, CELL CALCIUM, V30, P285, DOI 10.1054/ceca.2001.0236; Potocnik SJ, 2001, BRIT J PHARMACOL, V134, P247, DOI 10.1038/sj.bjp.0704270; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Scherer EQ, 2001, J MEMBRANE BIOL, V182, P183, DOI 10.1007/s00232-001-0041-1; Sergeant GP, 2001, AM J PHYSIOL-CELL PH, V280, pC1349, DOI 10.1152/ajpcell.2001.280.5.C1349; Silverman-Gavrila LB, 2001, EUR J CELL BIOL, V80, P379, DOI 10.1078/0171-9335-00175; SMITH PM, 1994, BIOCHEM J, V299, P37, DOI 10.1042/bj2990037; Taylor CW, 1998, TRENDS PHARMACOL SCI, V19, P370, DOI 10.1016/S0165-6147(98)01243-7; Tesfai Y, 2001, BIOCHEM J, V358, P717, DOI 10.1042/0264-6021:3580717; Thomas D, 2000, CURR BIOL, V10, P8, DOI 10.1016/S0960-9822(99)00258-4; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Wu J, 2000, MOL PHARMACOL, V58, P1368, DOI 10.1124/mol.58.6.1368; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596	51	597	610	3	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1145	10.1096/fj.02-0037rev	http://dx.doi.org/10.1096/fj.02-0037rev			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153982	Green Accepted			2022-12-28	WOS:000177814000023
J	Doolan, GK; Panchal, RG; Fonnes, EL; Clarke, AL; Williams, DA; Petrou, S				Doolan, GK; Panchal, RG; Fonnes, EL; Clarke, AL; Williams, DA; Petrou, S			Fatty acid augmentation of the cardiac slowly activating delayed rectifier current (I-Ks) is conferred by hminK	FASEB JOURNAL			English	Article						KvLQT1; free fatty acids; arrhythmias; electrophysiology	ARACHIDONIC-ACID; N-3; SUPPRESSION; MODULATION; K(V)LQT1; PROTEINS; CHANNELS; ADULT; FORM	The mechanism by which dietary fatty acids confer protection against cardiac arrhythmias and sudden cardiac death is not resolved. Here, we study the effects of several known cardioprotective and arrhythmogenic fatty acids on the slowly activating delayed rectifier potassium current (I-Ks), which is responsible for the repolarization phase of the cardiac action potential. cRNAs encoding either or both of the two subunits, KvLQT1 and hminK, that together produce I-Ks, were injected into Xenopus oocytes, and the effects of various fatty acids were determined. Docosahexaenoic acid (DHA) significantly augmented I-Ks as did the short-chained fully saturated lauric acid, and to a lesser extent the cis-unsaturated oleic acid. Eicosapentaenoic acid (EPA) was without significant effect on current magnitude, although it reduced the rate of activation. These results suggest that not all "antiarrhythmic" fatty acids target the same channel. To examine the role of hminK in this response, KvLQT1 was expressed alone. In this case, DHA, lauric acid, and oleic acid did not augment current, suggesting that hminK confers fatty acid sensitivity to I-Ks.	Univ Melbourne, Dept Physiol, Parkville, Vic 3010, Australia	University of Melbourne	Petrou, S (corresponding author), Univ Melbourne, Dept Physiol, Parkville, Vic 3010, Australia.	spetrou@unimelb.edu.au	Petrou, Steven/M-8332-2013; Panchal, Rekha/None	Petrou, Steven/0000-0002-4960-6375; Panchal, Rekha/0000-0001-8621-9078				AKHTAR M, 1990, CIRCULATION, V81, P1123, DOI 10.1161/01.CIR.81.3.1123; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Billman GE, 1997, LIPIDS, V32, P1161, DOI 10.1007/s11745-997-0149-2; Busch AE, 1997, BRIT J PHARMACOL, V122, P187, DOI 10.1038/sj.bjp.0701434; CHARNOCK JS, 1985, ANN NUTR METAB, V29, P279, DOI 10.1159/000176983; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Damron DS, 1997, AM J PHYSIOL-HEART C, V272, pH350, DOI 10.1152/ajpheart.1997.272.1.H350; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; HOCK CE, 1987, AM J PHYSIOL, V252, pH554, DOI 10.1152/ajpheart.1987.252.3.H554; Kang JX, 1997, P NATL ACAD SCI USA, V94, P2724, DOI 10.1073/pnas.94.6.2724; Kang JX, 2000, AM J CLIN NUTR, V71, p202S, DOI 10.1093/ajcn/71.1.202S; Leaf A, 2001, J MEMBRANE BIOL, V184, P263, DOI 10.1007/s00232-001-0095-0; Leifert WR, 1999, J PHYSIOL-LONDON, V520, P671, DOI 10.1111/j.1469-7793.1999.00671.x; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MCLENNAN PL, 1990, AM J CLIN NUTR, V51, P53, DOI 10.1093/ajcn/51.1.53; MCLENNAN PL, 1993, AM J CLIN NUTR, V58, P666, DOI 10.1093/ajcn/58.5.666; MCLENNAN PL, 1989, AUST NZ J MED, V19, P1, DOI 10.1111/j.1445-5994.1989.tb01662.x; MEVES H, 1994, PROG NEUROBIOL, V43, P175, DOI 10.1016/0301-0082(94)90012-4; Pepe S, 1996, J NUTR, V126, P34, DOI 10.1093/jn/126.1.34; PETROU S, 1994, J GEN PHYSIOL, V103, P471, DOI 10.1085/jgp.103.3.471; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Singh MP, 1999, IEEE INTERNET COMPUT, V3, P4, DOI 10.1109/MIC.1999.793453; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; Unsold B, 2000, PFLUG ARCH EUR J PHY, V441, P368, DOI 10.1007/s004240000434; VanderVusse GJ, 1997, PROSTAG LEUKOTR ESS, V57, P85, DOI 10.1016/S0952-3278(97)90497-X; Wilde AAM, 1999, J AM COLL CARDIOL, V33, P327, DOI 10.1016/S0735-1097(98)00578-6; Xiao YF, 2000, AM J PHYSIOL-HEART C, V279, pH35, DOI 10.1152/ajpheart.2000.279.1.H35; Xiao YF, 1997, P NATL ACAD SCI USA, V94, P4182, DOI 10.1073/pnas.94.8.4182	28	37	37	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1662	+		10.1096/fj.02-0084fje	http://dx.doi.org/10.1096/fj.02-0084fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206993				2022-12-28	WOS:000177814000004
J	Hong, F; Lee, J; Song, JW; Lee, SJ; Ahn, H; Cho, JJ; Ha, J; Kim, SS				Hong, F; Lee, J; Song, JW; Lee, SJ; Ahn, H; Cho, JJ; Ha, J; Kim, SS			Cyclosporine blocks muscle differentiation by inducing oxidative stress and by inhibiting the peptidylprolyl-cis-trans-isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporine-induced cytotoxicity	FASEB JOURNAL			English	Article						reactive oxygen species (ROS); allogenic myoblast transplantation; FK-506; adaptive response; calcineurin	INDUCED NEPHROTOXICITY; IMMUNOPHILIN LIGAND; IN-VITRO; CELLS; ALLOTRANSPLANTATION; IMMUNOSUPPRESSION; TRANSPLANTATION; CYCLOPHOSPHAMIDE; EXPRESSION; MYOPATHY	Allogenic myoblast transplantation (AMT) is under investigation for treatment of severe genetic myopathies. Data regarding the role of cyclosporine (CsA) and FK-506 in AMT have shown that CsA is less effective than FK-506. For this study, we investigated mechanisms of CsA toxicity during AMT and showed that a high level of reactive oxygen species (ROS) generated by CsA, mediated partly by inhibition of the peptidylprolyl-cis-trans-isomerase (PPIase)-like activity of cyclophilin A (CypA), blocked differentiation and induced apoptosis at an early stage of muscle differentiation. Inhibition of the PPIase-like activity of CypA alone also blocked muscle differentiation. However, CsA toxicity did not depend on the inhibition of calcineurin activity during muscle differentiation. Together, these data suggest that CsA-mediated inhibition of the PPIase-like activity of CypA and the high level of ROS generation contributed to the low efficacy of CsA in AMT. In addition, we showed that a reduction of oxidative stress protected cells from CsA-induced apoptosis, and myoblasts that had survived after preexposure to CsA not only proliferated and differentiated reversibly but also gained resistance to subsequent CsA exposure. Thus, administration of antioxidants or overexpression of CypA either exogenously or endogenously during CsA treatment has the potential to improve the success of this treatment in AMT.	Kyung Hee Univ, Sch Med, Dept Mol Biol, Seoul 130701, South Korea; Kyung Hee Univ, Sch Med, Dept Anat, Seoul 130701, South Korea; Kyung Hee Univ, Sch Med, Dept Microbiol, Seoul 130701, South Korea; Dongseo Univ, Dept Biotechnol, Pusan 617716, South Korea; Korea Canc Ctr Hosp, Lab Radiat Effect, Seoul 139706, South Korea	Kyung Hee University; Kyung Hee University; Kyung Hee University; Dongseo University; National Cancer Center - Korea (NCC)	Kim, SS (corresponding author), Kyung Hee Univ, Sch Med, Dept Mol Biol, Seoul 130701, South Korea.	sgskim@khu.ac.kr	Kim, Sung Soo/S-2540-2017	Kim, Sung Soo/0000-0002-6817-7668				Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; ALEJANDRO DSJ, 1994, J AM SOC NEPHROL, V5, P153; Andreeva L, 1999, INT J EXP PATHOL, V80, P305, DOI 10.1046/j.1365-2613.1999.00128.x; ARELLANO F, 1991, LANCET, V337, P915, DOI 10.1016/0140-6736(91)90245-K; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; Biring MS, 1998, J APPL PHYSIOL, V84, P1967, DOI 10.1152/jappl.1998.84.6.1967; Buetler TM, 2000, TRENDS PHARMACOL SCI, V21, P288, DOI 10.1016/S0165-6147(00)01508-X; de Lema GP, 1998, LIFE SCI, V62, P1745, DOI 10.1016/S0024-3205(98)00136-2; Doyle V, 1999, BIOCHEM J, V341, P127, DOI 10.1042/0264-6021:3410127; FERNANDEZSOLA J, 1990, LANCET, V335, P362; Friday BB, 2000, J CELL BIOL, V149, P657, DOI 10.1083/jcb.149.3.657; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GILL RG, 1995, CELL TRANSPLANT, V4, P361, DOI 10.1016/0963-6897(95)00019-T; GOY JJ, 1989, LANCET, V1, P1446; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Hamilton GS, 1998, J MED CHEM, V41, P5119, DOI 10.1021/jm980307x; HARDIMAN O, 1993, NEUROLOGY, V43, P1432, DOI 10.1212/WNL.43.7.1432; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; HOKANSON JF, 1995, AM J RESP CRIT CARE, V151, P1848, DOI 10.1164/ajrccm.151.6.7767529; Hovland AR, 1999, NEUROCHEM INT, V35, P229, DOI 10.1016/S0197-0186(99)00065-0; Jaschke A, 1998, J MOL BIOL, V277, P763, DOI 10.1006/jmbi.1998.1644; KARPATI G, 1993, ANN NEUROL, V34, P8, DOI 10.1002/ana.410340105; KINOSHITA I, 1995, MUSCLE NERVE, V18, P1217; KINOSHITA I, 1994, MUSCLE NERVE, V17, P1407, DOI 10.1002/mus.880171210; Kumar KV, 1999, TRANSPLANTATION, V67, P1065, DOI 10.1097/00007890-199904150-00022; LABRECQUE C, 1992, TRANSPLANT P, V24, P2889; LAW PK, 1988, MUSCLE NERVE, V11, P525, DOI 10.1002/mus.880110602; Lee JP, 1999, P NATL ACAD SCI USA, V96, P3251, DOI 10.1073/pnas.96.6.3251; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Leonardi A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1512; LIU J, 1991, BIOCHEMISTRY-US, V30, P2306, DOI 10.1021/bi00223a003; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; Longoni B, 2001, FASEB J, V15, P731, DOI 10.1096/fj.00-0163com; Matsuda S, 2000, IMMUNOPHARMACOLOGY, V47, P119, DOI 10.1016/S0162-3109(00)00192-2; Naidu MUR, 1999, NEPHRON, V81, P60, DOI 10.1159/000045247; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; RUSH DN, 1991, CLIN BIOCHEM, V24, P101, DOI 10.1016/0009-9120(91)90399-Y; SHAW LM, 1990, CLIN CHEM, V36, P1841; Skuk D, 2000, MICROSC RES TECHNIQ, V48, P213, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<213::AID-JEMT9>3.0.CO;2-Z; SZABO I, 1991, J BIOL CHEM, V266, P3376; TEGZESS AM, 1988, TRANSPLANT P, V20, P530; Tran TT, 2000, J BIOL CHEM, V275, P35708, DOI 10.1074/jbc.M005636200; VILQUIN JT, 1995, NEUROMUSCULAR DISORD, V5, P511, DOI 10.1016/0960-8966(95)00011-B; WANG CY, 1994, TRANSPLANTATION, V58, P940, DOI 10.1097/00007890-199410270-00014; Wolf A, 1997, J PHARMACOL EXP THER, V280, P1328; Zhong Z, 1999, MOL PHARMACOL, V56, P455, DOI 10.1124/mol.56.3.455; Zhong Z, 1998, AM J PHYSIOL-RENAL, V275, pF595, DOI 10.1152/ajprenal.1998.275.4.F595; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	48	96	99	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10					1633	+		10.1096/fj.02-0060fje	http://dx.doi.org/10.1096/fj.02-0060fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207006				2022-12-28	WOS:000177814000022
J	Farre, L; Casanova, I; Guerrero, S; Trias, M; Capella, G; Mangues, R				Farre, L; Casanova, I; Guerrero, S; Trias, M; Capella, G; Mangues, R			Heterotopic implantation alters the regulation of apoptosis and the cell cycle and generates a new metastatic site in a human pancreatic tumor xenograft model	FASEB JOURNAL			English	Article						implantation site; carcinoma; metastases	HUMAN COLON-CANCER; ORGAN ENVIRONMENT; DRUG-RESISTANCE; MOUSE MODEL; GROWTH; PROTEIN; PROGRESSION; EXPRESSION; SURVIVAL; LIVER	Differences in growth and in response to antineoplastic drugs between s.c. and orthotopically implanted tumors in nude mice and between the primary tumor and the metastases in human tumors suggest that implantation site may alter the molecular regulation of tumor cells. We assessed the influence of implantation site on cell cycle and apoptotic regulation and the possible contribution of the implantation site in directing the choice of metastatic site by comparing the behavior of tumor aliquots of two human pancreatic xenografts (NP18 and NP9) implanted in the organ where the tumor grows (orthotopically), in heterotopic sites (the site of metastases (liver), and in nonmetastatic sites (subcutis and colon). We observed that implantation site changes tumor growth by altering apoptotic or cell cycle regulation in a tumor-specific manner. In the NP18 tumor it occurs by altering apoptotic induction and activation of the Bad/Bcl-X-L/caspase-3 pathway through AKT and Erk regulation, but in the NP9 tumor by changing the activation and/or expression of the proteins that regulate the cell cycle (Erk, PCNA, and cyclin B1). We also observed that implantation site alters the metastatic pattern of the NP9 tumor, originating a new metastatic site.	Hosp Santa Cruz & San Pablo, Inst Recerca, E-08025 Barcelona, Spain; Hosp Santa Cruz & San Pablo, Dept Surg, E-08025 Barcelona, Spain; Inst Catala Oncol, Lab Recerca Translac, Barcelona, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Catalan Institute of Oncology	Mangues, R (corresponding author), Hosp Sant Pau, Inst Recerca, Avda Sant Antoni M Claret 167, Barcelona, Spain.	rmangues@santpau.es	CASANOVA RIGAT, ISOLDA/I-5393-2014; Capella, Gabriel/I-1879-2015; Mangues, Ramon/J-6396-2014	CASANOVA RIGAT, ISOLDA/0000-0002-1196-4724; Capella, Gabriel/0000-0002-4669-7320; Mangues, Ramon/0000-0003-2661-9525; Farre, Lourdes/0000-0002-3168-1940				Bae J, 2001, APOPTOSIS, V6, P319, DOI 10.1023/A:1011319901057; BALDREE LA, 1993, AM J KIDNEY DIS, V1, P1; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; Chambers AF, 2000, ADV CANCER RES, V79, P91, DOI 10.1016/S0065-230X(00)79003-8; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Compagni A, 2000, BRIT J CANCER, V83, P1; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; DONG ZY, 1994, JNCI-J NATL CANCER I, V86, P913, DOI 10.1093/jnci/86.12.913; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; FIDLER IJ, 1994, CANCER METAST REV, V13, P209, DOI 10.1007/BF00689637; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hay E.D., 1991, CELL BIOL EXTRACELLU, DOI 10.1007/978-1-4615-3770-0; Hulleman E, 2001, CELL MOL LIFE SCI, V58, P80, DOI 10.1007/PL00000780; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; KERBEL RS, 1994, J CELL BIOCHEM, V56, P37, DOI 10.1002/jcb.240560108; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuo TH, 1995, P NATL ACAD SCI USA, V92, P12085, DOI 10.1073/pnas.92.26.12085; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; NICOLSON GL, 1993, EXP CELL RES, V204, P171, DOI 10.1006/excr.1993.1022; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Pocard M, 1998, ANTICANCER RES, V18, P2743; Pocard M, 1996, IN VIVO, V10, P463; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rashidi B, 2000, CLIN CANCER RES, V6, P2556; Rashidi B, 2000, ANTICANCER RES, V20, P715; Reyes G, 1996, CANCER RES, V56, P5713; Ruggeri BA, 1998, MOL CARCINOGEN, V21, P81, DOI 10.1002/(SICI)1098-2744(199802)21:2<81::AID-MC1>3.0.CO;2-R; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; SLACK NH, 1975, BRIT J CANCER, V32, P78, DOI 10.1038/bjc.1975.135; Tarafa G, 2000, ONCOGENE, V19, P546, DOI 10.1038/sj.onc.1203353; TOGO S, 1995, CANCER RES, V55, P681; Wagner M, 2001, GENE DEV, V15, P286, DOI 10.1101/gad.184701; White MK, 2001, LEUKEMIA, V15, P1011, DOI 10.1038/sj.leu.2402143; WILMANNS C, 1992, INT J CANCER, V52, P98, DOI 10.1002/ijc.2910520118; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335	39	11	13	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2002	16	9					975	982		10.1096/fj.01-0973com	http://dx.doi.org/10.1096/fj.01-0973com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087058				2022-12-28	WOS:000177813100028
J	Saaristo, A; Veikkola, T; Enholm, B; Hytonen, M; Arola, J; Pajusola, K; Turunen, P; Jeltsch, M; Karkkainen, MJ; Kerjaschki, D; Bueler, H; Yla-Herttuala, S; Alitalo, K				Saaristo, A; Veikkola, T; Enholm, B; Hytonen, M; Arola, J; Pajusola, K; Turunen, P; Jeltsch, M; Karkkainen, MJ; Kerjaschki, D; Bueler, H; Yla-Herttuala, S; Alitalo, K			Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes	FASEB JOURNAL			English	Article						lymphangiogenesis; VEGF; VEGFR-2; VEGFR-3; angiopoietin 1	ENDOTHELIAL GROWTH-FACTOR; GENE-TRANSFER; FACTOR RECEPTOR-3; TRANSGENIC MICE; IN-VIVO; EXPRESSION; LYMPHANGIOGENESIS; THERAPY; ANGIOPOIETIN-1; LYMPHEDEMA	Vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) are important regulators of blood and lymphatic vessel growth and vascular permeability. The VEGF-C/VEGFR-3 signaling pathway is crucial for lymphangiogenesis, and heterozygous inactivating missense mutations of the VEGFR-3 gene are associated with hereditary lymphedema. However, VEGF-C can have potent effects on blood vessels because its receptor VEGFR-3 is expressed in certain blood vessels and because the fully processed form of VEGF-C also binds to the VEGFR-2 of blood vessels. To characterize the in vivo effects of VEGF-C on blood and lymphatic vessels, we have overexpressed VEGF-C via adenovirus- and adeno-associated virus-mediated transfection in the skin and respiratory tract of athymic nude mice. This resulted in dose-dependent enlargement and tortuosity of veins, which, along with the collecting lymphatic vessels were found to express VEGFR-2. Expression of angiopoietin 1 blocked the increased leakiness of the blood vessels induced by VEGF-C whereas vessel enlargement and lymphangiogenesis were not affected. However, angiogenic sprouting of new blood vessels was not observed in response to AdVEGF-C or AAV-VEGF-C. These results show that virally produced VEGF-C induces blood vessel changes, including vascular leak, but its angiogenic potency is much reduced compared with VEGF in normal skin.	Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Biomedicum Helsinki, Ludwig Inst Canc Res, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Otorhinolaryngol, FIN-00014 Helsinki, Finland; Univ Kuopio, AI Virtanen Inst, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Med, FIN-70211 Kuopio, Finland; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland; Univ Vienna, Dept Pathol, A-1090 Vienna, Austria	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Eastern Finland; University of Eastern Finland; University of Zurich; University of Vienna	Alitalo, K (corresponding author), Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Lab, POB 63 Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	Kari.Alitalo@Helsinki.FI	Jeltsch, Michael/I-5340-2012; Alitalo, Kari K/J-5013-2014; Büeler, Hansruedi/J-6965-2017	Jeltsch, Michael/0000-0003-2890-7790; Alitalo, Kari K/0000-0002-7331-0902; Büeler, Hansruedi/0000-0002-4892-7177; Yla-Herttuala, Seppo/0000-0001-7593-2708				Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Enholm B, 2001, CIRC RES, V88, P623, DOI 10.1161/01.RES.88.6.623; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Flotte TR, 2001, CHEST, V120, p124S, DOI 10.1378/chest.120.3_suppl.124S; Hiltunen MO, 2000, CIRCULATION, V102, P2262; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; JUSSILA L, 2002, IN PRESS PHYSL REV; Kadambi A, 2001, CANCER RES, V61, P2404; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karkkainen MJ, 2002, NAT CELL BIOL, V4, pE2, DOI 10.1038/ncb0102-e2; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Kubo H, 2000, BLOOD, V96, P546; Laitinen M, 1998, HUM GENE THER, V9, P1481, DOI 10.1089/hum.1998.9.10-1481; Laitinen M, 1997, HUM GENE THER, V8, P1737, DOI 10.1089/hum.1997.8.15-1737; Li XR, 2001, INT J BIOCHEM CELL B, V33, P421, DOI 10.1016/S1357-2725(01)00027-9; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Monahan PE, 2000, MOL MED TODAY, V6, P433, DOI 10.1016/S1357-4310(00)01810-4; Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com; Paterna JC, 2000, GENE THER, V7, P1304, DOI 10.1038/sj.gt.3301221; Pepper MS, 2001, CLIN CANCER RES, V7, P462; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Puumalainen AM, 1998, HUM GENE THER, V9, P1769, DOI 10.1089/hum.1998.9.12-1769; Ristimaki A, 1998, J BIOL CHEM, V273, P8413, DOI 10.1074/jbc.273.14.8413; Saaristo A, 2000, AM J PATHOL, V157, P7, DOI 10.1016/S0002-9440(10)64510-5; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Skobe M, 2001, AM J PATHOL, V159, P893, DOI 10.1016/S0002-9440(10)61765-8; Sundberg C, 2001, AM J PATHOL, V158, P1145, DOI 10.1016/S0002-9440(10)64062-X; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Veikkola T, 2000, CANCER RES, V60, P203; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; Weninger W, 1999, LAB INVEST, V79, P243; Witzenbichler B, 1998, AM J PATHOL, V153, P381, DOI 10.1016/S0002-9440(10)65582-4; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	42	121	130	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2002	16	9					1041	1049		10.1096/fj.01-1042com	http://dx.doi.org/10.1096/fj.01-1042com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087065				2022-12-28	WOS:000177813100035
J	Fannon, M; Forsten-Williams, K; Dowd, CJ; Freedman, DA; Folkman, J; Nugent, MA				Fannon, M; Forsten-Williams, K; Dowd, CJ; Freedman, DA; Folkman, J; Nugent, MA			Binding inhibition of angiogenic factors by heparan sulfate proteoglycans in aqueous humor: potential mechanism for maintenance of an avascular environment	FASEB JOURNAL			English	Article						VEGF; endothelial cell; bFGF; heparin binding; computational model	FIBROBLAST GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; HIGH-AFFINITY; BASEMENT-MEMBRANE; BFGF BINDING; TGF-BETA; NEOVASCULARIZATION; PURIFICATION; MITOGENESIS; RECEPTORS	Aqueous humor is a clear fluid, primarily a blood filtrate, which circulates through the anterior chamber of the eye and bathes the cornea. We explored the possibility that components in the aqueous humor play a direct part in maintaining the avascular environment of the cornea. We report here that heparan sulfate proteoglycan (HSPG) was found in bovine aqueous humor and that it directly inhibits binding of basic fibroblast growth factor and vascular endothelial growth factor to cell-surface heparan sulfate. We demonstrate that this holds true for all heparin binding proteins tested but not for epidermal growth factor, which does not bind heparin. Furthermore, we show, with mathematical modeling, that the concentration of HSPG in aqueous humor ( 4 mug/ml), when combined with the clearance of aqueous humor from the eye due to circulation, is sufficient to block the binding of heparin binding growth factors to corneal endothelium. This mechanism suggests a physiological process to control bioavailability of angiogenic growth factors in the cornea.	Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Virginia Polytech Inst & State Univ, Dept Chem Engn, Blacksburg, VA 24061 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Virginia Polytechnic Institute & State University; Boston University; Boston University	Fannon, M (corresponding author), Childrens Hosp, Dept Surg, 300 Longwood Ave, Boston, MA 02115 USA.	michael.fannon@tch.harvard.edu		Nugent, Matthew/0000-0002-8630-4712				AUSPRUNK DH, 1978, LAB INVEST, V38, P284; Brown CT, 1999, J BIOL CHEM, V274, P7111, DOI 10.1074/jbc.274.11.7111; BROWN RA, 1988, ANN RHEUM DIS, V47, P881, DOI 10.1136/ard.47.11.881; BRUBAKER RF, 1991, INVEST OPHTH VIS SCI, V32, P3145; CASTELLOT JJ, 1985, J CELL PHYSIOL, V124, P13, DOI 10.1002/jcp.1041240104; Collen A, 2000, CANCER RES, V60, P6196; DANIELSON KG, 1992, MATRIX, V12, P22, DOI 10.1016/S0934-8832(11)80101-0; Dowd CJ, 1999, J BIOL CHEM, V274, P5236, DOI 10.1074/jbc.274.8.5236; Fannon M, 2000, BIOCHEMISTRY-US, V39, P1434, DOI 10.1021/bi991895z; Fannon M, 1996, J BIOL CHEM, V271, P17949, DOI 10.1074/jbc.271.30.17949; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V881, P46, DOI 10.1016/0304-4165(86)90095-4; Forsten K E, 1994, J Comput Biol, V1, P15; FORSTEN KE, 1994, MOL IMMUNOL, V31, P739, DOI 10.1016/0161-5890(94)90148-1; Forsten KE, 1997, J CELL PHYSIOL, V172, P209, DOI 10.1002/(SICI)1097-4652(199708)172:2<209::AID-JCP8>3.0.CO;2-S; Forsten KE, 2000, J THEOR BIOL, V205, P215, DOI 10.1006/jtbi.2000.2064; Funaki H, 2001, INVEST OPHTH VIS SCI, V42, P1193; GALLAGHER JT, 1990, BIOCHEM SOC T, V18, P207, DOI 10.1042/bst0180207; GIMBRONE MA, 1973, J NATL CANCER I, V50, P219, DOI 10.1093/jnci/50.1.219; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; Hayasaka K, 1998, LIFE SCI, V63, P1089, DOI 10.1016/S0024-3205(98)00205-7; HONDERMARCK H, 1992, DEV BRAIN RES, V68, P247, DOI 10.1016/0165-3806(92)90067-7; Huang SH, 1996, EXP EYE RES, V62, P481, DOI 10.1006/exer.1996.0058; Krufka A, 1996, BIOCHEMISTRY-US, V35, P11131, DOI 10.1021/bi960125+; LIOTE F, 1991, REV RHUM, V58, pS51; Liu DF, 2002, P NATL ACAD SCI USA, V99, P568, DOI 10.1073/pnas.012578299; Loughnan MS, 1996, AUST NZ J OPHTHALMOL, V24, P289, DOI 10.1111/j.1442-9071.1996.tb01596.x; MALI M, 1993, J BIOL CHEM, V268, P24215; Moulton KS, 1999, CIRCULATION, V99, P1726, DOI 10.1161/01.CIR.99.13.1726; Namiki Mari, 1994, Nippon Ganka Gakkai Zasshi, V98, P334; NGUYEN M, 1993, J NATL CANCER I, V85, P241, DOI 10.1093/jnci/85.3.241; NUGENT MA, 1993, CIRC RES, V73, P1051, DOI 10.1161/01.RES.73.6.1051; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; NUGENT MA, 1994, INV OPHTHAL VIS SCI, V34, P3049; Ornstein DL, 2001, INT J HEMATOL, V73, P157, DOI 10.1007/BF02981932; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Schechter J, 2000, EXP EYE RES, V70, P777, DOI 10.1006/exer.2000.0837; Sheibani N, 2000, BIOCHEM BIOPH RES CO, V267, P257, DOI 10.1006/bbrc.1999.1903; Sperinde GV, 2000, BIOCHEMISTRY-US, V39, P3788, DOI 10.1021/bi992243d; Sperinde GV, 1998, BIOCHEMISTRY-US, V37, P13153, DOI 10.1021/bi980600z; Thompson RW, 1990, GROWTH FACTORS, V3, P221, DOI 10.3109/08977199009043906; Tripathi RC, 1997, EXP EYE RES, V64, P335, DOI 10.1006/exer.1996.0215; TRIPATHI RC, 1992, EXP EYE RES, V54, P447, DOI 10.1016/0014-4835(92)90056-X; Wallentin N, 1998, INVEST OPHTH VIS SCI, V39, P1410; Whalen GF, 1989, GROWTH FACTORS, V1, P157, DOI 10.3109/08977198909029125; Whitelock J, 2001, Methods Mol Biol, V171, P27; YANG VC, 1985, J BIOL CHEM, V260, P1849; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	49	34	35	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					902	+		10.1096/fj.02-0935fje	http://dx.doi.org/10.1096/fj.02-0935fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626427				2022-12-28	WOS:000181892600020
J	Vitadello, M; Penzo, D; Petronilli, V; Michieli, G; Gomirato, S; Menabo, R; Di Lisa, F; Gorza, L				Vitadello, M; Penzo, D; Petronilli, V; Michieli, G; Gomirato, S; Menabo, R; Di Lisa, F; Gorza, L			Overexpression of the stress-protein Grp94 reduces cardiomyocyte necrosis due to calcium overload and simulated ischemia	FASEB JOURNAL			English	Article						endoplasmic reticulum proteins; cell resistance to injury; myocyte death; gene transfer	GLUCOSE-REGULATED PROTEIN; MITOCHONDRIAL PERMEABILITY TRANSITION; ENDOPLASMIC-RETICULUM CHAPERONES; HEAT-SHOCK PROTEINS; CELL-DEATH; MOLECULAR CHAPERONES; CLINICAL-APPLICATIONS; ATRIAL-FIBRILLATION; EPITHELIAL-CELLS; CA2+	Increase in free intracellular calcium [Ca2+](i) plays a crucial role in cardiomyocyte ischemic injury. Here we demonstrate that overexpression of the sarcoplasmic-reticulum stress-protein Grp94 reduces myocyte necrosis due to calcium overload or simulated ischemia. Selective three-to eightfold Grp94 increase, with no change in Grp78 or calreticulin amount, was achieved by stable transfection of skeletal C2C12 and cardiac H9c2 muscle cells. After exposure to the calcium ionophore A23187, LDH release from five different Grp94-overexpressing clones of either C2C12 and H9c2 origin was significantly lower than that of control ones and [Ca2+](i) increase was significantly delayed. The number of necrotic cells, evaluated by propidium iodide uptake, was reduced when cells from the Grp94-overexpressing H9c2 clone were exposed to conditions simulating ischemia. Experiments performed in neonatal rat cardiomyocytes cotransfected with grp94 and the green fluorescent protein (GFP) cDNAs validated the protective effect of Grp94 overexpression. A lower percentage of propidium-iodide positive/GFP-fluorescent myocytes co-expressing exogenous Grp94, with respect to myocytes expressing GFP alone, was observed after exposure to either A23187 (6.6% vs. 14.0%, respectively) or simulated ischemia (8.5% vs. 17.7%, respectively). In conclusion, the selective increase in Grp94 protects cardiomyocytes from both ischemia and calcium overload counteracting [Ca2+](i) elevations.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Inst Neurosci, I-35121 Padua, Italy; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Dept Biochem, I-35121 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; University of Padua	Gorza, L (corresponding author), Univ Padua, Dept Biomed Sci, Via G Colombo 3, I-35121 Padua, Italy.	lgorza@bio.unipd.it	Petronilli, Valeria/C-3558-2015	Petronilli, Valeria/0000-0003-4026-6404; GORZA, LUISA/0000-0003-4897-400X; Di Lisa, Fabio/0000-0001-9757-8818				Ausma J, 2000, J MOL CELL CARDIOL, V32, P355, DOI 10.1006/jmcc.1999.1090; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; Bolli R, 2000, CIRC RES, V87, P972, DOI 10.1161/01.RES.87.11.972; Bush KT, 1999, AM J PHYSIOL-RENAL, V277, pF211, DOI 10.1152/ajprenal.1999.277.2.F211; CARROZZA JP, 1992, CIRC RES, V71, P1334, DOI 10.1161/01.RES.71.6.1334; Cornelussen RN, 1996, AM J PHYSIOL-HEART C, V271, pH1938, DOI 10.1152/ajpheart.1996.271.5.H1938; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; ENTMAN ML, 1991, FASEB J, V5, P2529, DOI 10.1096/fasebj.5.11.1868978; GORZA L, 1993, DEV BIOL, V156, P253, DOI 10.1006/dbio.1993.1074; Gorza L, 2000, FASEB J, V14, P461, DOI 10.1096/fasebj.14.3.461; Gorza L, 1996, CIRCULATION, V93, P1896, DOI 10.1161/01.CIR.93.10.1896; KANG HS, 1991, J BIOL CHEM, V266, P5643; KOCH G, 1986, J CELL SCI, V86, P217; Kuznetsov G, 1996, P NATL ACAD SCI USA, V93, P8584, DOI 10.1073/pnas.93.16.8584; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; LEWIS MJ, 1985, J BIOL CHEM, V260, P3050; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; MARBAN E, 1990, CIRC RES, V66, P1255, DOI 10.1161/01.RES.66.5.1255; MARBER MS, 1993, J MOL CELL CARDIOL, V25, P1119, DOI 10.1006/jmcc.1993.1124; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; McDonough JL, 1999, CIRC RES, V84, P9; MIYATA H, 1992, CIRC RES, V71, P605, DOI 10.1161/01.RES.71.3.605; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Qian T, 1999, TOXICOL APPL PHARM, V154, P117, DOI 10.1006/taap.1998.8580; Reddy RK, 1999, J BIOL CHEM, V274, P28476, DOI 10.1074/jbc.274.40.28476; Snoeckx LHEH, 2001, PHYSIOL REV, V81, P1461, DOI 10.1152/physrev.2001.81.4.1461; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; VandenHoek TL, 1996, AM J PHYSIOL-HEART C, V270, pH1334, DOI 10.1152/ajpheart.1996.270.4.H1334; Vitadello M, 1998, BIOCHEM J, V332, P351, DOI 10.1042/bj3320351; Vitadello M, 2001, CIRCULATION, V103, P2201; Zhao J, 1998, J BIOL CHEM, V273, P23072, DOI 10.1074/jbc.273.36.23072	38	100	103	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					923	+		10.1096/fj.02-0644fje	http://dx.doi.org/10.1096/fj.02-0644fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670879				2022-12-28	WOS:000181892600010
J	Chauhan, SD; Seggara, G; Vo, PA; MacAllister, RJ; Hobbs, AJ; Ahluwalia, A				Chauhan, SD; Seggara, G; Vo, PA; MacAllister, RJ; Hobbs, AJ; Ahluwalia, A			Protection against lipopolysaccharide-induced endothelial dysfunction in resistance and conduit vasculature of iNOS knockout mice	FASEB JOURNAL			English	Article						nitric oxide; resistance arteries; inflammation; vasorelaxation; sepsis	NITRIC-OXIDE SYNTHASE; L-ARGININE; ENDOTOXIN-SHOCK; SUPEROXIDE; RAT; HYPOREACTIVITY; EXPRESSION; REACTIVITY; PHYSIOLOGY; PULMONARY	Endothelial dysfunction is a characteristic of, and may be pathogenic in, inflammatory cardiovascular diseases, including sepsis. The mechanism underlying inflammation-induced endothelial dysfunction may be related to the expression and activity of inducible nitric oxide synthase (iNOS). This possibility was investigated in isolated resistance (mesenteric) and conduit (aorta) arteries taken from lipopolysaccharide (LPS)-treated (12.5 mg/kg i.v.) or saline-treated iNOS knockout (KO) and wild-type (WT) mice. LPS pretreatment (for 15 h, but not 4 h) profoundly suppressed responses to acetylcholine (ACh) and significantly reduced sensitivity to the NO donor spermine-NONOate (SPER-NO) in aorta and mesenteric arteries of WT mice. This effect was temporally associated with iNOS protein expression in both conduit and resistance arteries and with a 10-fold increase in plasma NOx levels. In contrast, no elevation of plasma NOx was observed in LPS-treated iNOS KO animals, and arteries dissected from these animals did not express iNOS or display hyporeactivity to ACh or SPER-NO. The mechanism underlying this phenomenon may be suppression of eNOS expression, as observed in arteries of WT animals, that was absent in arteries of iNOS KO animals. These results clearly demonstrate that iNOS induction plays an integral role in mediation of the endothelial dysfunction associated with sepsis in both resistance and conduit arteries.	Barts & London Queen Marys Sch Med & Dent, London EC1M 6BQ, England; UCL, Ctr Clin Pharmacol, London WC1E 6JJ, England; Univ Valencia, Dept Physiol, Valencia, Spain; UCL, Wolfson Inst Biomed Res, London WC1, England	University of London; Queen Mary University London; University of London; University College London; University of Valencia; University of London; University College London	Ahluwalia, A (corresponding author), Barts & London Queen Marys Sch Med & Dent, Charterhouse Sq, London EC1M 6BQ, England.	a.ahluwalia@qmul.ac.uk	Segarra, Gloria/L-2495-2017	Segarra, Gloria/0000-0003-3069-2717; Hobbs, Adrian/0000-0002-3589-7108; AHLUWALIA, Amrita/0000-0001-7626-6399				Anstey NM, 1996, J EXP MED, V184, P557, DOI 10.1084/jem.184.2.557; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Boyle WA, 2000, CIRC RES, V87, pE18; Brandes RP, 1999, HYPERTENSION, V33, P1243, DOI 10.1161/01.HYP.33.5.1243; BUGA GM, 1993, CIRC RES, V73, P808, DOI 10.1161/01.RES.73.5.808; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; FLEMING I, 1991, BRIT J PHARMACOL, V103, P1047, DOI 10.1111/j.1476-5381.1991.tb12298.x; GRUNFELD S, 1995, HYPERTENSION, V26, P854, DOI 10.1161/01.HYP.26.6.854; HALES CA, 1981, J CLIN INVEST, V68, P497, DOI 10.1172/JCI110281; HALPERN W, 1977, J PHYSIOL-LONDON, V265, pP21; Hamilton CA, 1997, ATHEROSCLEROSIS, V133, P77, DOI 10.1016/S0021-9150(97)00114-7; Hingorani AD, 2000, CIRCULATION, V102, P994, DOI 10.1161/01.CIR.102.9.994; Hoang L, 1998, BBA-BIOMEMBRANES, V1369, P335, DOI 10.1016/S0005-2736(97)00237-X; Hollenberg SM, 2000, CIRC RES, V86, P774, DOI 10.1161/01.RES.86.7.774; HOM GJ, 1995, J PHARMACOL EXP THER, V272, P452; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Hussain MB, 1999, BRIT J PHARMACOL, V128, P1082, DOI 10.1038/sj.bjp.0702874; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; JULOUSCHAEFFER G, 1990, AM J PHYSIOL, V259, pH1038, DOI 10.1152/ajpheart.1990.259.4.H1038; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; Mombouli JV, 1999, J MOL CELL CARDIOL, V31, P61, DOI 10.1006/jmcc.1998.0844; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULVANY MJ, 1977, CIRC RES, V41, P19, DOI 10.1161/01.RES.41.1.19; O'Brien AJ, 2001, BRIT J PHARMACOL, V133, P351, DOI 10.1038/sj.bjp.0704079; PerezVizcaino F, 1996, J VASC RES, V33, P249, DOI 10.1159/000159152; PETROS A, 1994, CARDIOVASC RES, V28, P34, DOI 10.1093/cvr/28.1.34; Rees DD, 1998, BRIT J PHARMACOL, V124, P540, DOI 10.1038/sj.bjp.0701815; WHITWORTH PW, 1989, CIRC SHOCK, V27, P111; Yamashita T, 2000, CIRCULATION, V101, P931, DOI 10.1161/01.CIR.101.8.931; Zhou MA, 1997, BBA-GEN SUBJECTS, V1335, P182, DOI 10.1016/S0304-4165(96)00139-0	31	111	112	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					773	+		10.1096/fj.02-0668fje	http://dx.doi.org/10.1096/fj.02-0668fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586741				2022-12-28	WOS:000181456900033
J	Kaasik, A; Veksler, V; Boehm, E; Novotova, M; Ventura-Clapier, R				Kaasik, A; Veksler, V; Boehm, E; Novotova, M; Ventura-Clapier, R			From energy store to energy flux: a study in creatine kinase deficient fast skeletal muscle	FASEB JOURNAL			English	Article						permeabilized fibers; energy cross talk; mitochondrial respiration; myofilaments; sarcoplasmic reticulum	SARCOPLASMIC-RETICULUM; OXIDATIVE-PHOSPHORYLATION; IN-SITU; MITOCHONDRIAL-FUNCTION; ADENYLATE KINASE; MICE DEFICIENT; CELLS; MYOFIBRILLAR; HEART; ADAPTATIONS	Fast-twitch skeletal muscle of mice deficient in cytosolic and mitochondrial creatine kinase isoforms (CK-/-) lack burst activity but can sustain prolonged contractile activity, suggesting that adaptive mechanisms can regulate local adenine nucleotide turnover. We investigated whether direct energy and signal channeling between mitochondria and sarcoplasmic reticulum (SR) or myofilaments may exist that compensate for the lack of CK isoenzymes. Oxidative capacity of fast-twitch muscle was increased twofold in CK-/- mice. Energy cross talk between organelles was studied in muscle fibers with permeabilized sarcolemma. Energy supply to SR was estimated by analyzing the tension transient induced by caffeine and energy supply to myofilaments was estimated by the relaxation of rigor tension, both under different conditions of energy supply. In normal mice, ATP directly produced by mitochondria was not able to sustain calcium uptake and to relax rigor tension as efficiently as ATP produced by bound CK. However, in CK-/- mice, mitochondria ability to provide ATP for calcium uptake and relaxation of rigor tension was dramatically enhanced, suggesting a direct ATP/ADP channeling between sites of energy production (mitochondria) and energy utilization in CK-/- mice. These results demonstrate two possible patterns of energy transport in muscle cells: energy store with phosphocreatine and energy flux through mitochondria.	Univ Paris Sud, INSERM, U446, F-92296 Chatenay Malabry, France; Slovak Acad Sci, Bratislava, Slovakia	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Slovak Academy of Sciences	Ventura-Clapier, R (corresponding author), Univ Paris Sud, INSERM, U446, F-92296 Chatenay Malabry, France.	Renee.Ventura@cep.u-psud.fr	Kaasik, Allen/I-2738-2015; Novotova, Marta/D-2578-2009	Ventura-Clapier, Renee/0000-0002-7488-4123; Veksler, Vladimir/0000-0002-8869-9594; Kaasik, Allen/0000-0002-4850-3198				Bigard AX, 1998, J MOL CELL CARDIOL, V30, P2391, DOI 10.1006/jmcc.1998.0798; Boehm E, 1998, J MOL CELL CARDIOL, V30, P901, DOI 10.1006/jmcc.1998.0692; Boehm E, 2000, J MOL CELL CARDIOL, V32, P891, DOI 10.1006/jmcc.2000.1130; Dahlstedt AJ, 2000, FASEB J, V14, P982, DOI 10.1096/fasebj.14.7.982; Dahlstedt AJ, 2001, J PHYSIOL-LONDON, V533, P639, DOI 10.1111/j.1469-7793.2001.00639.x; Dahlstedt AJ, 2001, J PHYSIOL-LONDON, V533, P379, DOI 10.1111/j.1469-7793.2001.0379a.x; de Groof AJC, 2002, J BIOL CHEM, V277, P5275, DOI 10.1074/jbc.M108157200; de Groof AJC, 2001, FEBS LETT, V506, P73, DOI 10.1016/S0014-5793(01)02879-4; de Groof AJC, 2001, MUSCLE NERVE, V24, P1188, DOI 10.1002/mus.1131; Dzeja PP, 1996, J BIOL CHEM, V271, P12847, DOI 10.1074/jbc.271.22.12847; Dzeja PP, 1998, MOL CELL BIOCHEM, V184, P169, DOI 10.1023/A:1006859632730; Gorselink M, 2001, AM J PHYSIOL-ENDOC M, V281, pE619, DOI 10.1152/ajpendo.2001.281.3.E619; Hochachka PW, 1999, P NATL ACAD SCI USA, V96, P12233, DOI 10.1073/pnas.96.22.12233; Janssen E, 2000, EMBO J, V19, P6371, DOI 10.1093/emboj/19.23.6371; Kaasik A, 2001, CIRC RES, V89, P153, DOI 10.1161/hh1401.093440; Kay L, 2000, J BIOL CHEM, V275, P6937, DOI 10.1074/jbc.275.10.6937; KHUCHUA Z, 1994, BBA-BIOENERGETICS, V1188, P373, DOI 10.1016/0005-2728(94)90058-2; KORGE P, 1994, AM J PHYSIOL, V267, pC357, DOI 10.1152/ajpcell.1994.267.2.C357; Kraft T, 2000, J MUSCLE RES CELL M, V21, P691, DOI 10.1023/A:1005623002979; LEVITSKII D O, 1977, Biokhimiya, V42, P1766; Mannella CA, 1998, BIOFACTORS, V8, P225, DOI 10.1002/biof.5520080309; Minajeva A, 1996, PFLUG ARCH EUR J PHY, V432, P904, DOI 10.1007/s004240050214; Novotova M, 2002, EUR J CELL BIOL, V81, P101, DOI 10.1078/0171-9335-00230; PETTE D, 1992, REV PHYSIOL BIOCH P, V120, P115, DOI 10.1007/BFb0036123; Qin WN, 1999, HISTOCHEM J, V31, P357, DOI 10.1023/A:1003748108062; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; Saks VA, 1998, MOL CELL BIOCHEM, V184, P81, DOI 10.1023/A:1006834912257; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; Saks VA, 2001, BIOCHEM J, V356, P643, DOI 10.1042/0264-6021:3560643; SAKS VA, 1980, J BIOL CHEM, V255, P755; Steeghs K, 1998, MOL CELL BIOCHEM, V184, P183, DOI 10.1023/A:1006811717709; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VEKSLER VI, 1995, J BIOL CHEM, V270, P19921, DOI 10.1074/jbc.270.34.19921; Ventura-Clapier R, 1998, MOL CELL BIOCHEM, V184, P231, DOI 10.1023/A:1006840508139; VENTURACLAPIER R, 1995, J BIOL CHEM, V270, P19914, DOI 10.1074/jbc.270.34.19914; VENTURACLAPIER R, 1994, MOL CELL BIOCHEM, V133, P125, DOI 10.1007/BF01267952; Wallimann T, 1985, Cell Muscle Motil, V6, P239; Watchko JF, 1996, PEDIATR RES, V40, P53, DOI 10.1203/00006450-199607000-00010; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; XU KY, 1995, CIRC RES, V77, P88, DOI 10.1161/01.RES.77.1.88	41	39	39	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2								10.1096/fj.02-0684fje	http://dx.doi.org/10.1096/fj.02-0684fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586739				2022-12-28	WOS:000181456900031
J	Mayr, D; Amann, G; Siefert, C; Diebold, J; Anderegg, B				Mayr, D; Amann, G; Siefert, C; Diebold, J; Anderegg, B			Does endometriosis really have premalignant potential? A clonal analysis of laser-microdissected tissue	FASEB JOURNAL			English	Article						PGK-1; X-chromosome inactivation; methylation pattern; HUMARA	X-CHROMOSOME INACTIVATION; POLYMERASE CHAIN-REACTION; ANDROGEN-RECEPTOR GENE; CLEAR-CELL-CARCINOMA; ABERRANT CRYPT FOCI; DIFFERENTIAL METHYLATION; OVARIAN ENDOMETRIOSIS; LOCUS DXS255; CYSTS; HETEROZYGOSITY	Since 1925, epidemiological and histological evidence for an association between endometriosis and ovarian neoplasia has accumulated. Recently, publications assaying the clonality of a given cell population have implied endometriosis has premalignant properties. However, the human androgen receptor used as a marker in these studies is of highly questionable reliability due to the instability of its methylation pattern in nonmalignant cells and during the course of malignancy. Therefore, we decided to readdress the question of clonality of endometriotic foci by using an alternative assay based on a polymorphism of the phosphoglycerate kinase-1 gene. We overcame the limitation to using ovarian cysts (a problem encountered in other studies) by laser-microdissecting defined tissue fractions of interest. From the 13/29 informative patients, a total of 32 endometriotic samples from various sites was assayed. Only 2/32 samples from different patients bore monoclonal tissue. With one of those cases, we present the first direct evidence of the two morphological endometric compartments comprising a single biphasic developmental unit. Neither monoclonal patient was characterized by any outstanding clinical parameters, including neoplasia. Individual endometriotic foci from the only patient in this study with neoplasia was assayed as being polyclonal. Therefore, former studies stating endometriosis as premalignant have to be cautiously reinterpreted.	Univ Munich, Dept Pathol, D-80337 Munich, Germany	University of Munich	Anderegg, B (corresponding author), Arcturus GmbH, Waldecker Str 9, D-64546 Morfelden Walldorf, Germany.	banderegg@arctureurope.com						ALLEN RC, 1992, AM J HUM GENET, V51, P1229; Bischoff FZ, 2000, HUM REPROD UPDATE, V6, P37, DOI 10.1093/humupd/6.1.37; BOYD Y, 1990, GENOMICS, V7, P182, DOI 10.1016/0888-7543(90)90539-7; BRALY PS, 1993, CANCER-AM CANCER SOC, V71, P1621, DOI 10.1002/cncr.2820710429; BROWN RM, 1990, GENOMICS, V7, P215, DOI 10.1016/0888-7543(90)90543-4; Buller RE, 1999, JNCI-J NATL CANCER I, V91, P339, DOI 10.1093/jnci/91.4.339; CORNER GW, 1950, AM J OBSTET GYNECOL, V59, P760; Diaz-Cano SJ, 2001, DIAGN MOL PATHOL, V10, P24, DOI 10.1097/00019606-200103000-00005; DUMANOIR S, 1995, CYTOMETRY, V19, P27, DOI 10.1002/cyto.990190105; FIALKOW PJ, 1976, BIOCHIM BIOPHYS ACTA, V458, P283, DOI 10.1016/0304-419X(76)90003-2; Fujimoto J, 1999, STEROIDS, V64, P526, DOI 10.1016/S0039-128X(99)00025-2; GILLILAND DG, 1991, P NATL ACAD SCI USA, V88, P6848, DOI 10.1073/pnas.88.15.6848; Henegariu O, 2001, CYTOMETRY, V43, P101, DOI 10.1002/1097-0320(20010201)43:2<101::AID-CYTO1024>3.0.CO;2-8; Jang SJ, 2000, CANCER RES, V60, P864; Jiang XX, 1998, CANCER RES, V58, P1707; Jiang XX, 1996, CANCER RES, V56, P3534; Jimbo H, 1997, AM J PATHOL, V150, P1173; Jimbo H, 1999, FERTIL STERIL, V72, P1142, DOI 10.1016/S0015-0282(99)00416-1; KURMAN RJ, 1972, CANCER-AM CANCER SOC, V29, P1653, DOI 10.1002/1097-0142(197206)29:6<1653::AID-CNCR2820290633>3.0.CO;2-E; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MAYR D, 2002, IN PRESS MOD PATHOL; MOSTOUFIZADEH M, 1980, Clinical Obstetrics and Gynecology, V23, P951; MUTTER GL, 1995, NUCLEIC ACIDS RES, V23, P1411; MUTTER GL, 1995, AM J PATHOL, V146, P501; Nishida M, 2000, GYNECOL OBSTET INVES, V50, P18, DOI 10.1159/000052874; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Sakurazawa N, 2000, CANCER RES, V60, P3165; Sampson JA, 1925, ARCH SURG-CHICAGO, V10, P1, DOI 10.1001/archsurg.1925.01120100007001; Sato N, 2000, CANCER RES, V60, P7052; SCULLY RE, 1967, CANCER-AM CANCER SOC, V20, P1405, DOI 10.1002/1097-0142(196709)20:9<1405::AID-CNCR2820200907>3.0.CO;2-B; SCULLY RE, 1966, CLIN OBSTET GYNECOL, V9, P381; SEROV SF, 1973, INT HISTOLOGICAL CLA, V9, P51; Siu IM, 1999, CANCER RES, V59, P63; SYMONDS DA, 1988, CANCER, V61, P2511, DOI 10.1002/1097-0142(19880615)61:12<2511::AID-CNCR2820611220>3.0.CO;2-Y; TANAKA N, 1998, ACTA OBSTET GYNAECOL, V50, P765; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806; Yano T, 1999, GYNECOL OBSTET INVES, V47, P41, DOI 10.1159/000052858; YEN PH, 1984, P NATL ACAD SCI-BIOL, V81, P1759, DOI 10.1073/pnas.81.6.1759	40	27	29	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					693	+		10.1096/fj.02-0562fje	http://dx.doi.org/10.1096/fj.02-0562fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594178				2022-12-28	WOS:000181456900015
J	Michaelis, UR; Fisslthaler, B; Medhora, M; Harder, D; Fleming, I; Busse, R				Michaelis, UR; Fisslthaler, B; Medhora, M; Harder, D; Fleming, I; Busse, R			Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor	FASEB JOURNAL			English	Article						AG 1478; Akt; cyclin D1; endothelial cell proliferation; endothelium-derived hyperpolarizing factor	ARTERIAL SMOOTH-MUSCLE; EGF-RECEPTOR; 11,12-EPOXYEICOSATRIENOIC ACID; SIGNAL-TRANSDUCTION; ARACHIDONIC-ACID; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; BINDING PROTEIN; CELL-MIGRATION; EXPRESSION	Cytochrome P450 (CYP) epoxygenase products, such as 11,12-epoxyeicosatrienoic acid (EET), stimulate endothelial cell proliferation. We set out to identify the signal transduction cascade linking EET generation to enhanced proliferation and angiogenesis. In human endothelial cells overexpressing CYP 2C9, cell number was increased compared with control cells and was inhibited by the CYP 2C9 inhibitor, sulfaphenazole. CYP 2C9 overexpression was associated with the activation of Akt and an increase in cyclin D1 expression, effects that were abolished by the epidermal growth factor (EGF) receptor inhibitor, AG1478, which also prevented the CYP 2C9-induced increase in cell proliferation. Stimulation of EGF receptor overexpressing cells with 11,12-EET or transfection of these cells with CYP 2C9 enhanced the tyrosine phosphorylation of the EGF receptor. Endothelial tube formation in a fibrin gel was significantly enhanced (6-fold) in CYP 2C9 overexpressing cells and was comparable with the tube formation induced by EGF. In the chick chorioallantoic membrane, 11,12-EET stimulated vessel formation (3.5-fold) and induced vessel convergence, an effect that was abolished by cotreatment with either an EGF receptor-neutralizing antibody or AG1478. These results indicate that CYP 2C9-derived EETs stimulate angiogenesis by a mechanism involving the activation of the EGF receptor.	Univ Frankfurt Klinikum, Inst Kardiovask Physiol, D-60590 Frankfurt, Germany; Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Medical College of Wisconsin	Fleming, I (corresponding author), Univ Frankfurt Klinikum, Inst Kardiovask Physiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	fleming@em.uni-frankfurt.de	Fleming, Ingrid/AAB-6123-2022; Fleming, Ingrid/L-1225-2014	Fleming, Ingrid/0000-0003-1881-3635; Fleming, Ingrid/0000-0003-1881-3635				Augustin HG, 2001, CIRC RES, V89, P645, DOI 10.1161/res.89.8.645; Bauersachs J, 2002, CARDIOVASC RES, V54, P669, DOI 10.1016/S0008-6363(02)00257-2; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CAPDEVILA J, 1981, P NATL ACAD SCI-BIOL, V78, P5362, DOI 10.1073/pnas.78.9.5362; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Chen JK, 1999, J BIOL CHEM, V274, P4764, DOI 10.1074/jbc.274.8.4764; Chen JK, 2002, P NATL ACAD SCI USA, V99, P6029, DOI 10.1073/pnas.092671899; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; Chen JK, 1998, J BIOL CHEM, V273, P29254, DOI 10.1074/jbc.273.44.29254; Chen JR, 2000, J BIOL CHEM, V275, P13789, DOI 10.1074/jbc.275.18.13789; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Fisslthaler B, 2000, HYPERTENSION, V36, P270, DOI 10.1161/01.HYP.36.2.270; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; Fisslthaler B, 2001, HYPERTENSION, V38, P1427, DOI 10.1161/hy1201.096532; FLEMING I, 1995, CIRC RES, V76, P522, DOI 10.1161/01.RES.76.4.522; Fleming I, 2001, PFLUG ARCH EUR J PHY, V442, P511, DOI 10.1007/s004240100565; Fleming I, 2001, CIRC RES, V88, P44, DOI 10.1161/01.RES.88.1.44; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gallo O, 2001, NEOPLASIA, V3, P53, DOI 10.1038/sj.neo.7900127; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hoebel BG, 1998, EUR J PHARMACOL, V346, P115, DOI 10.1016/S0014-2999(98)00118-6; Imig JD, 1999, HYPERTENSION, V33, P408, DOI 10.1161/01.HYP.33.1.408; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Li PL, 1997, HYPERTENSION, V29, P262, DOI 10.1161/01.HYP.29.1.262; Li PL, 2002, AM J PHYSIOL-HEART C, V282, pH1229, DOI 10.1152/ajpheart.00736.2001; Li PL, 1999, CIRC RES, V85, P349, DOI 10.1161/01.RES.85.4.349; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; LIN JHC, 1996, ENDOTHELIUM, V4, P219; Mancy A, 1996, BIOCHEMISTRY-US, V35, P16205, DOI 10.1021/bi961950t; Munzenmaier DH, 2000, AM J PHYSIOL-HEART C, V278, pH1163, DOI 10.1152/ajpheart.2000.278.4.H1163; Muthalif MM, 2001, PROSTAG OTH LIPID M, V65, P33, DOI 10.1016/S0090-6980(01)00112-5; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; Node K, 2001, J BIOL CHEM, V276, P15983, DOI 10.1074/jbc.M100439200; Potente M, 2002, J BIOL CHEM, V277, P15671, DOI 10.1074/jbc.M110806200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Qi XJ, 2002, UROL RES, V30, P48, DOI 10.1007/s00240-001-0223-4; Roman RJ, 2002, PHYSIOL REV, V82, P131, DOI 10.1152/physrev.00021.2001; Russell KS, 1999, AM J PHYSIOL-HEART C, V277, pH2205, DOI 10.1152/ajpheart.1999.277.6.H2205; SCHWARTZMAN M, 1985, NATURE, V314, P620, DOI 10.1038/314620a0; Sun JX, 2002, CIRC RES, V90, P1020, DOI 10.1161/01.RES.0000017727.35930.33; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; Vernia S, 2001, ADV EXP MED BIOL, V500, P209; Vernia S, 2001, FEBS LETT, V488, P59, DOI 10.1016/S0014-5793(00)02388-7; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; West DC, 2001, METH MOLEC MED, V46, P107, DOI 10.1385/1-59259-143-4:107; Wong PYK, 2000, PROSTAG OTH LIPID M, V62, P321, DOI 10.1016/S0090-6980(00)00079-4; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	54	146	148	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					770	+		10.1096/fj.02-0640fje	http://dx.doi.org/10.1096/fj.02-0640fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586744				2022-12-28	WOS:000181456900027
J	Zhang, PS; Chan, SL; Fu, WM; Mendoza, M; Mattson, MP				Zhang, PS; Chan, SL; Fu, WM; Mendoza, M; Mattson, MP			TERT suppresses apoptotis at a premitochondrial step by a mechanism requiring reverse transcriptase activity and 14-3-3 protein binding ability	FASEB JOURNAL			English	Article						cancer; cytochrome c; etoposide; mitochondria; site-directed mutagenesis	TELOMERASE ACTIVITY; 14-3-3 PROTEINS; CELL-PROLIFERATION; CATALYTIC SUBUNIT; HELA-CELLS; LIFE-SPAN; NEURONS; INHIBITION; EXPRESSION; STAUROSPORINE	The catalytic subunit of telomerase (TERT) is a reverse transcriptase (RT) that adds a six-base DNA repeat onto chromosome ends and prevents their shortening during successive cell divisions. Telomerase is associated with cell immortality and cancer, which may by related to the ability of TERT to prevent apoptosis by stabilizing telomeres. However, fundamental information concerning the antiapoptotic function of TERT is lacking, including whether RT activity and/or nuclear localization are required and where telomerase acts to suppress the cell death process. Here, we show that overexpression of wild-type human TERT in HeLa cells, and in a cells lacking TERT but containing the telomerase RNA template, increases their resistance to apoptosis induced by the DNA damaging agent etoposide or the bacterial alkaloid staurosporine. In contrast, TERT mutants with disruptions of either the RT domain or a 14-3-3 binding domain fail to protect cells against apoptosis, and overexpression of TERT in cells lacking the telomerase RNA template is also ineffective in preventing apoptosis. Additional findings show that TERT suppresses apoptosis at an early step before release of cytochrome c and apoptosis-inducing factor from mitochondria. We conclude that both RT activity and 14-3-3 protein binding ability are required for the antiapoptotic function of TERT in tumor cells and that TERT can suppress a nuclear signal(s) that is an essential component of apoptotic cascades triggered by diverse stimuli.	NIA, Neurosci Lab, Gerontol Res Ctr, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University	Mattson, MP (corresponding author), NIA, Neurosci Lab, Gerontol Res Ctr, GRC 4F01,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	mattsonm@grc.nia.nih.gov	Mattson, Mark P/F-6038-2012		NATIONAL INSTITUTE ON AGING [Z01AG000317, Z01AG000313, ZIAAG000317, ZIAAG000314, ZIAAG000313, Z01AG000314] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Bernard B, 2001, CELL DEATH DIFFER, V8, P234, DOI 10.1038/sj.cdd.4400796; BLASCO MA, 2001, ADV CELL AGING GERON, V8, P151; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Capranico G, 1999, Cancer Chemother Biol Response Modif, V18, P125; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.0.CO;2-K; Coultas L, 2000, APOPTOSIS, V5, P491, DOI 10.1023/A:1009617727938; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Harley CB, 1997, CANCER SURV, V29, P263; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Herrera E, 2000, EMBO J, V19, P472, DOI 10.1093/emboj/19.3.472; Herrera E, 1999, EMBO J, V18, P1172, DOI 10.1093/emboj/18.5.1172; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klapper W, 2001, J NEUROSCI RES, V64, P252, DOI 10.1002/jnr.1073.abs; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Krupp G, 1997, NUCLEIC ACIDS RES, V25, P919, DOI 10.1093/nar/25.4.919; Lauber K, 2001, J BIOL CHEM, V276, P29772, DOI 10.1074/jbc.M101524200; Lee CC, 2001, PHARMACEUT RES, V18, P846, DOI 10.1023/A:1011048831698; Lock RB, 1997, CANCER CHEMOTH PHARM, V39, P399, DOI 10.1007/s002800050590; Lu CB, 2001, DEV BRAIN RES, V131, P167, DOI 10.1016/S0165-3806(01)00237-1; MacManus J P, 1996, Hum Cell, V9, P197; Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200; Melek M, 1996, BIOESSAYS, V18, P301, DOI 10.1002/bies.950180408; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Oh H, 2001, P NATL ACAD SCI USA, V98, P10308, DOI 10.1073/pnas.191169098; Ranger AM, 2001, NAT GENET, V28, P113, DOI 10.1038/88815; Reddel RR, 2001, RADIAT RES, V155, P194, DOI 10.1667/0033-7587(2001)155[0194:ALOTIH]2.0.CO;2; Reddy VG, 2001, BIOCHEM BIOPH RES CO, V282, P409, DOI 10.1006/bbrc.2001.4593; Ren JG, 2001, FEBS LETT, V488, P133, DOI 10.1016/S0014-5793(00)02397-8; Rowley PT, 2000, ANTICANCER RES, V20, P4419; Rudolph KL, 2000, SCIENCE, V287, P1253, DOI 10.1126/science.287.5456.1253; Sachsinger J, 2001, CANCER RES, V61, P5580; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Tafani M, 2001, CANCER RES, V61, P2459; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yegorov YE, 1996, FEBS LETT, V389, P115, DOI 10.1016/0014-5793(96)00533-9; Zaugg K, 2001, CANCER RES, V61, P732; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu HY, 2000, J NEUROCHEM, V75, P117, DOI 10.1046/j.1471-4159.2000.0750117.x; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	51	69	83	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					767	+		10.1096/fj.02-0603fje	http://dx.doi.org/10.1096/fj.02-0603fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594176				2022-12-28	WOS:000181456900009
J	Zhao, H; Miller, M; Pfeiffer, K; Buras, JA; Stahl, GL				Zhao, H; Miller, M; Pfeiffer, K; Buras, JA; Stahl, GL			Anoxia and reoxygenation of human endothelial cells decreases ceramide glucosyltransferase expression and activates caspases	FASEB JOURNAL			English	Article						HUVEC; caspase activity; ischemia/reperfusion; apoptosis; glucosylceramide synthase	CARDIAC MYOCYTES; ISCHEMIA/REPERFUSION INJURY; GENE-EXPRESSION; ROCK-I; APOPTOSIS; GLUCOSYLCERAMIDE; STRESS; REPERFUSION; SPHINGOSINE; CLEAVAGE	Endothelial oxidative stress induces cellular activation and sometimes death. Endothelial death can occur via necrosis or apoptosis. Understanding the mechanisms involved in cellular activation and death may lead to therapeutics designed to increase death or preserve cellular function. In the present study, brief periods of anoxia (3 h) followed by varying lengths of reoxygenation (0-5 h) lead to a time-dependent increase in human umbilical vein endothelial cell (HUVEC) caspase activity. Furthermore, ROCK-1 cleavage, which is dependent on caspase-3 activity, was also increased in cells undergoing oxidative stress compared with normoxic cells. Microarray data demonstrated that glucosylceramide synthase (GCS; glucosylceramide transferase), but not acid sphingomyelinase, was modulated by anoxia and reoxygenation. We confirmed that GCS mRNA and protein expression were significantly decreased in a time-dependent fashion following oxidative stress by real-time polymerase chain reaction and Western blot, respectively. Treatment of normoxic cells with the GCS-specific inhibitor, D,L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), increased caspase activity to the same degree as cells undergoing oxidative stress. Fumonisin B-1, the N-acyl-sphinganine dehydrogenase (e.g., ceramide synthase) inhibitor significantly attenuated caspase activity in HUVECs undergoing oxidative stress. These data suggest that alterations in GCS expression following brief periods of oxidative stress in human endothelial cells lead to increased caspase activity.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Hosp Med Ctr, Dept Emergency Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Stahl, GL (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Thorn 705,75 Francis St, Boston, MA 02115 USA.	gstahl@zeus.bwh.harvard.edu		Stahl, Gregory/0000-0002-4805-8119				BALLOU LR, 1992, IMMUNOL TODAY, V13, P339, DOI 10.1016/0167-5699(92)90167-6; Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; Bielawska AE, 1997, AM J PATHOL, V151, P1257; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Collard CD, 1997, CIRCULATION, V96, P326; Cordis GA, 1998, J PHARMACEUT BIOMED, V16, P1189, DOI 10.1016/S0731-7085(97)00260-4; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Hofmann K, 1999, TRENDS BIOCHEM SCI, V24, P227, DOI 10.1016/S0968-0004(99)01410-3; Huwiler A, 2001, BIOCHEM BIOPH RES CO, V284, P404, DOI 10.1006/bbrc.2001.4941; INOKUCHI JI, 1989, J CELL PHYSIOL, V141, P573, DOI 10.1002/jcp.1041410316; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Leverrier Y, 2001, NAT CELL BIOL, V3, pE91, DOI 10.1038/35070151; Lin CC, 2000, AM J CHINESE MED, V28, P87, DOI 10.1142/S0192415X00000118; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; Matsushita H, 2000, CIRC RES, V86, P974, DOI 10.1161/01.RES.86.9.974; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; PATARROYO M, 1990, IMMUNOL REV, V114, P67, DOI 10.1111/j.1600-065X.1990.tb00562.x; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Scarabelli T, 2001, CIRCULATION, V104, P253, DOI 10.1161/01.CIR.104.3.253; Scarabelli TM, 2002, CIRC RES, V90, P745, DOI 10.1161/01.RES.0000015224.07870.9A; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Slowik MR, 1996, CIRC RES, V79, P736, DOI 10.1161/01.RES.79.4.736; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Vakeva AP, 1998, CIRCULATION, V97, P2259, DOI 10.1161/01.CIR.97.22.2259; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang NP, 2001, CIRC RES, V88, P1223, DOI 10.1161/hh1201.093162; Watanabe R, 1998, J BIOL CHEM, V273, P9651, DOI 10.1074/jbc.273.16.9651; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085	34	17	22	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					723	+		10.1096/fj.02-0806fje	http://dx.doi.org/10.1096/fj.02-0806fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586734				2022-12-28	WOS:000181456900021
J	Nikolovski, J; Kim, BS; Mooney, DJ				Nikolovski, J; Kim, BS; Mooney, DJ			Cyclic strain inhibits switching of smooth muscle cells to an osteoblast-like phenotype	FASEB JOURNAL			English	Article						tissue engineering; mechanical strain; calcification; osteopontin; matrix gla protein	MESSENGER-RNA EXPRESSION; EXTRACELLULAR-MATRIX; VASCULAR CELLS; OSTEOPONTIN; TISSUE; CALCIFICATION; PROTEIN; DIFFERENTIATION; PROLIFERATION; ATHEROSCLEROSIS	Ectopic calcification is commonly associated with cardiovascular disease, injury, aging, and biomaterial implantation. We hypothesized that the normal mechanical environment of smooth muscle cells (SMCs) inhibits a phenotypic switch to a pattern of gene expression more typical for bone and inducive for calcification. This hypothesis was tested using a 3-D engineered smooth muscle tissue model subjected to cyclic mechanical strain. This simplified model maintained a 3-D tissue architecture while eliminating systemic effects as can be seen with in vivo models. All engineered tissues were found to express bone-associated genes (osteopontin, matrix gla protein, alkaline phosphatase, and the transcription factor CBFA-1). Strikingly, however, expression of these genes was down-regulated in tissues exposed to cyclic strain at all time points ranging from 5 to 150 days. Furthermore, long-term strain played a protective role in regard to calcification, as unstrained tissues exhibited increased calcium deposition with respect to strained tissues. The results of this study suggest that without an appropriate mechanical environment, SMCs in 3-D culture undergo a phenotypic conversion to an osteoblast-like pattern of gene expression. This finding has significant implications for the mechanisms underlying a variety of cardiovascular diseases and indicates the broad utility of engineered tissue models in basic biology studies.	Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Hanyang Univ, Dept Chem Engn, Seoul 133791, South Korea	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Hanyang University	Mooney, DJ (corresponding author), Univ Michigan, Dept Chem Engn, 2300 Hayward Ave,3074 HH Dow, Ann Arbor, MI 48109 USA.	mooneyd@umich.edu	Byung-Soo, Kim/O-2352-2013	Byung-Soo, Kim/0000-0001-5210-7430; Mooney, David/0000-0001-6299-1194				BOSTROM K, 1993, J CLIN INVEST, V91, P1800, DOI 10.1172/JCI116391; Bostrom KI, 2000, Z KARDIOL, V89, P69; CARON JM, 1985, J CELL BIOL, V101, P1763, DOI 10.1083/jcb.101.5.1763; Crosby AH, 1996, MAMM GENOME, V7, P149, DOI 10.1007/s003359900037; Cunningham JJ, 2002, BIOTECHNIQUES, V32, P876, DOI 10.2144/02324rr05; Cunningham JJ, 2002, ANN BIOMED ENG, V30, P927, DOI 10.1114/1.1500408; DEMER LL, 1995, CIRCULATION, V92, P2029, DOI 10.1161/01.CIR.92.8.2029; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; GADEAU AP, 1993, ARTERIOSCLER THROMB, V13, P120, DOI 10.1161/01.ATV.13.1.120; Giachelli C M, 2001, Z Kardiol, V90 Suppl 3, P31; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; Girton TS, 2000, J BIOMECH ENG-T ASME, V122, P216, DOI 10.1115/1.429652; HAO H, 1995, ARTERIOSCL THROM VAS, V15, P1474, DOI 10.1161/01.ATV.15.9.1474; Hoerstrup SP, 2000, CIRCULATION, V102, P44; Iizuka K, 2001, BIOCHEM BIOPH RES CO, V283, P493, DOI 10.1006/bbrc.2001.4796; Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10; KANDA K, 1994, CELL TRANSPLANT, V3, P481, DOI 10.1177/096368979400300605; Kaspar D, 2000, J BIOMECH, V33, P45, DOI 10.1016/S0021-9290(99)00171-2; Kim BS, 2000, J BIOMECH ENG-T ASME, V122, P210, DOI 10.1115/1.429651; Kim BS, 1998, BIOTECHNOL BIOENG, V57, P46; Kim BS, 1999, EXP CELL RES, V251, P318, DOI 10.1006/excr.1999.4595; Kim BS, 1999, NAT BIOTECHNOL, V17, P979, DOI 10.1038/13671; L'Heureux N, 2001, FASEB J, V15, P515, DOI 10.1096/fj.00-0283com; Lee DA, 1998, J ORTHOP RES, V16, P726, DOI 10.1002/jor.1100160615; Lehoux S, 1998, HYPERTENSION, V32, P338, DOI 10.1161/01.HYP.32.2.338; Li CH, 2000, CELL SIGNAL, V12, P435, DOI 10.1016/S0898-6568(00)00096-6; MANOLAGAS SC, 1981, J BIOL CHEM, V256, P7115; Meyer U, 1999, J CRANIO MAXILL SURG, V27, P222, DOI 10.1016/S1010-5182(99)80033-X; Meyer U, 2001, BRIT J ORAL MAX SURG, V39, P22, DOI 10.1054/bjom.2000.0549; Mills I, 1997, J CELL PHYSIOL, V170, P228, DOI 10.1002/(SICI)1097-4652(199703)170:3<228::AID-JCP2>3.0.CO;2-Q; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Parhami F, 2001, Z Kardiol, V90 Suppl 3, P27; Pei M, 2002, FASEB J, V16, P1691, DOI 10.1096/fj.02-0083fje; Proudfoot D, 1998, ARTERIOSCL THROM VAS, V18, P379, DOI 10.1161/01.ATV.18.3.379; Putnam AJ, 1998, J CELL SCI, V111, P3379; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sato R, 1998, POSITIVITY, V2, P1, DOI 10.1023/A:1009728507209; Seliktar D, 2000, ANN BIOMED ENG, V28, P351, DOI 10.1114/1.275; SHANAHAN CM, 1994, J CLIN INVEST, V93, P2393, DOI 10.1172/JCI117246; SHIOI A, 1995, ARTERIOSCL THROM VAS, V15, P2003, DOI 10.1161/01.ATV.15.11.2003; Sikavitsas VI, 2002, J BIOMED MATER RES, V62, P136, DOI 10.1002/jbm.10150; STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157; Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070; Stock UA, 2001, J CELL BIOCHEM, V81, P220, DOI 10.1002/1097-4644(20010501)81:2<220::AID-JCB1037>3.0.CO;2-O; Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166; WATSON KE, 1994, J CLIN INVEST, V93, P2106, DOI 10.1172/JCI117205; Wozniak M, 2000, J BONE MINER RES, V15, P1731, DOI 10.1359/jbmr.2000.15.9.1731; Yamamoto M, 1997, HISTOCHEM CELL BIOL, V107, P279, DOI 10.1007/s004180050113	49	54	57	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					455	+		10.1096/fj.02-0459fje	http://dx.doi.org/10.1096/fj.02-0459fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12514116	Green Submitted			2022-12-28	WOS:000181453700017
J	Tralhao, JG; Schaefer, L; Micegova, M; Evaristo, C; Schonherr, E; Kayal, S; Veiga-Fernandes, H; Danel, C; Iozzo, RV; Kresse, H; Lemarchand, P				Tralhao, JG; Schaefer, L; Micegova, M; Evaristo, C; Schonherr, E; Kayal, S; Veiga-Fernandes, H; Danel, C; Iozzo, RV; Kresse, H; Lemarchand, P			In vivo selective and distant killing of cancer cells, using adenovirus-mediated decorin gene transfer	FASEB JOURNAL			English	Article						decorin; apoptosis; tumor; proteoglycan	TUMOR-SUPPRESSOR GENE; DOWN-REGULATION; TRANSGENE EXPRESSION; GROWTH SUPPRESSION; APOPTOSIS; THERAPY; INHIBITION; P53; PROTEOGLYCANS; TUMORIGENICITY	Decorin is a well-known, ubiquitous proteoglycan that is a normal component of the ECM. Upon transgenic expression of decorin, tumor cells with diverse histogenetic background overexpress p21(WAF1), a potent inhibitor of cyclin-dependent kinase activity, become arrested in G1, and fail to generate tumors in immunocompromised animals. Because decorin is a secreted protein, it has been recently suggested that decorin could act as an autocrine and paracrine regulator of tumor growth. Here, we demonstrate that adenovirus (Ad)-mediated transfer and expression of human decorin cDNA induced in vivo apoptosis of xenograft tumor cells in nude mice. This oncolytic activity was observed when the Ad vector encoding the decorin cDNA was injected intratumorally (i.t.) or i.v. Importantly, i.t. injection of the decorin Ad vector led to growth inhibition of the injected tumor associated with similar growth inhibition of a distant contralateral tumor, demonstrating a distant decorin antitumoral effect. Immunochemistry against human decorin and decorin quantitation in tumors confirmed that decorin migrated to the tumor distant site. Furthermore, decorin effect was specific to tumor cells, because neither apoptosis nor growth inhibition were observed in nontumoral human cells such as hepatocytes, endothelial cells, and fibroblasts, despite p21 overexpression.	Univ Paris 05, Fac Necker Enfants Malad, INSERM, E0016, Paris, France; Univ Munster, Dept Internal Med, D-4400 Munster, Germany; Univ Munster, Inst Physiol Chem & Pathobiochem, D-4400 Munster, Germany; Fac Necker Enfants Malad, INSERM, U411, Paris, France; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Munster; University of Munster; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Jefferson University	Lemarchand, P (corresponding author), Fac Med, INSERM, U533, 1 Rue Gaston Veil, F-44035 Nantes 1, France.	patricia.lemarchand@nantes.inserm.fr	Iozzo, Renato/AAS-1980-2020; lemarchand, patricia/C-3247-2011; Evaristo, Cesar/O-8430-2016	lemarchand, patricia/0000-0002-5330-2008; Tralhao, Jose/0000-0002-5641-6975; Veiga-Fernandes, Henrique/0000-0001-6216-1836; Schaefer, Liliana/0000-0002-3318-3005; Iozzo, Renato/0000-0002-5908-5112; Evaristo, Cesar/0000-0002-2281-1045				Addison CL, 1998, GENE THER, V5, P1400, DOI 10.1038/sj.gt.3300731; Benchoua A, 2002, J BIOL CHEM, V277, P34217, DOI 10.1074/jbc.M203941200; Bui LA, 1997, HUM GENE THER, V8, P2173, DOI 10.1089/hum.1997.8.18-2173; Claudio PP, 2000, CANCER RES, V60, P372; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Danel C, 1998, HUM GENE THER, V9, P1487, DOI 10.1089/hum.1998.9.10-1487; EASTHAM JA, 1995, CANCER RES, V55, P5151; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Evdokiou A, 2002, INT J CANCER, V99, P491, DOI 10.1002/ijc.10376; Ghaneh P, 2001, GENE THER, V8, P199, DOI 10.1038/sj.gt.3301394; Griscelli F, 1998, P NATL ACAD SCI USA, V95, P6367, DOI 10.1073/pnas.95.11.6367; HOSONO S, 1991, ONCOGENE, V6, P237; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; Jacotot E, 2000, PATHOL BIOL, V48, P271; Ji L, 1999, CANCER RES, V59, P3333; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kolb M, 2001, AM J PHYSIOL-LUNG C, V280, pL1327, DOI 10.1152/ajplung.2001.280.6.L1327; Kolb M, 2001, AM J RESP CRIT CARE, V163, P770, DOI 10.1164/ajrccm.163.3.2006084; Kuo CJ, 2001, P NATL ACAD SCI USA, V98, P4605, DOI 10.1073/pnas.081615298; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEMARCHAND P, 1992, P NATL ACAD SCI USA, V89, P6482, DOI 10.1073/pnas.89.14.6482; Li H, 2001, HUM GENE THER, V12, P515, DOI 10.1089/104303401300042429; Marshall E, 1999, SCIENCE, V286, P2244, DOI 10.1126/science.286.5448.2244; Mercer DF, 2001, NAT MED, V7, P927, DOI 10.1038/90968; Nash MA, 1999, CANCER RES, V59, P6192; Nielsen LL, 1998, HUM GENE THER, V9, P681, DOI 10.1089/hum.1998.9.5-681; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Park KH, 2001, LUNG CANCER-J IASLC, V31, P149, DOI 10.1016/S0169-5002(00)00195-1; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Sauter BV, 2000, P NATL ACAD SCI USA, V97, P4802, DOI 10.1073/pnas.090065597; Schaefer L, 2001, FASEB J, V15, P559; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; Steiner MS, 2000, CANCER RES, V60, P4419; STROM SC, 1982, J NATL CANCER I, V68, P771; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; Worgall S, 1997, HUM GENE THER, V8, P37, DOI 10.1089/hum.1997.8.1-37; Zaretzky FR, 1999, INFECT IMMUN, V67, P5352, DOI 10.1128/IAI.67.10.5352-5360.1999; Zhao JS, 1999, AM J PHYSIOL-LUNG C, V277, pL412, DOI 10.1152/ajplung.1999.277.2.L412	47	99	118	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					464	+		10.1096/fj.02-0534fje	http://dx.doi.org/10.1096/fj.02-0534fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12631584	Green Submitted, Green Accepted, Green Published			2022-12-28	WOS:000181453700013
J	Hannon, R; Croxtall, JD; Getting, SJ; Roviezzo, F; Yona, S; Paul-Clark, MJ; Gavins, FNE; Perretti, M; Morris, JF; Buckingham, JC; Flower, RJ				Hannon, R; Croxtall, JD; Getting, SJ; Roviezzo, F; Yona, S; Paul-Clark, MJ; Gavins, FNE; Perretti, M; Morris, JF; Buckingham, JC; Flower, RJ			Aberrant inflammation and resistance to glucocorticoids in Annexin 1(-/-) Mouse	FASEB JOURNAL			English	Article						neutrophil activation; cell adhesion molecules; phagocytosis; cytokines; edema	LIPOCORTIN-I; RECOMBINANT LIPOCORTIN-1; GENE-EXPRESSION; LAVAGE FLUID; PAW EDEMA; MECHANISM; AUTOANTIBODIES; DEXAMETHASONE; PHAGOCYTOSIS; MACROPHAGES	The 37-kDa protein annexin 1 (Anx-1; lipocortin 1) has been implicated in the regulation of phagocytosis, cell signaling, and proliferation and is postulated to be a mediator of glucocorticoid action in inflammation and in the control of anterior pituitary hormone release. Here, we report that mice lacking the Anx-1 gene exhibit a complex phenotype that includes an altered expression of other annexins as well as of COX-2 and cPLA(2). In carrageenin- or zymosan-induced inflammation, Anx-1(-/-) mice exhibit an exaggerated response to the stimuli characterized by an increase in leukocyte emigration and IL-1beta generation and a partial or complete resistance to the antiinflammatory effects of glucocorticoids. Anx-1(-/-) polymorphonuclear leucocytes exhibited increased spontaneous migratory behavior in vivo whereas in vitro, leukocytes from Anx-1(-/-) mice had reduced cell surface CD 11b (MAC-1) but enhanced CD62L (L-selectin) expression and Anx-1(-/-) macrophages exhibited anomalies in phagocytosis. There are also gender differences in activated leukocyte behavior in the Anx-1(-/-) mice that are not seen in the wild-type animals, suggesting an interaction between sex hormones and inflammation in Anx-1(-/-) animals.	Univ London, Queen Mary, William Harvey Res Inst, Dept Biochem Pharmacol, London EC1M 6BQ, England; Univ Naples Federico II, Dipartimento Farmacol Sperimentale Federico II, Naples, Italy; Univ Oxford, Dept Human Anat & Genet, Oxford OX1 3QX, England; Imperial Coll Sch Med, Div Neurosci & Psychol Med, London W12 0NN, England	University of London; Queen Mary University London; University of Naples Federico II; University of Oxford; Imperial College London	Flower, RJ (corresponding author), Univ London, Queen Mary, William Harvey Res Inst, Dept Biochem Pharmacol, Charterhouse Sq, London EC1M 6BQ, England.	r.j.flower@qmul.ac.uk	Yona, Simon/ABE-6572-2020; Gavins, Felicity N. E./AAU-6010-2020	Gavins, Felicity N. E./0000-0001-7008-5423; Yona, Simon/0000-0002-3984-2008				Ahn SH, 1997, CLIN EXP METASTAS, V15, P151, DOI 10.1023/A:1018452810915; Ajuebor MN, 1999, J IMMUNOL, V162, P1685; Akama Hideto, 1995, Materia Medica Polona, V27, P75; Barnes PJ, 2001, ALLERGY, V56, P928, DOI 10.1034/j.1398-9995.2001.00001.x; Bastian Boris C., 1993, Journal of Dermatological Science, V6, P225, DOI 10.1016/0923-1811(93)90043-O; Brichory FM, 2001, P NATL ACAD SCI USA, V98, P9824, DOI 10.1073/pnas.171320598; CIRINO G, 1989, P NATL ACAD SCI USA, V86, P3428, DOI 10.1073/pnas.86.9.3428; Collins HL, 1997, J CELL SCI, V110, P191; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; CROXTALL JD, 1992, P NATL ACAD SCI USA, V89, P3571, DOI 10.1073/pnas.89.8.3571; Croxtall JD, 2002, BRIT J PHARMACOL, V135, P511, DOI 10.1038/sj.bjp.0704474; Cuzzocrea S, 1997, J IMMUNOL, V159, P5089; DASILVA JAP, 1993, J ENDOCRINOL, V136, P389, DOI 10.1677/joe.0.1360389; DAVIDSON J, 1991, BRIT J PHARMACOL, V102, P7, DOI 10.1111/j.1476-5381.1991.tb12122.x; DECATERINA R, 1993, J APPL PHYSIOL, V75, P2368, DOI 10.1152/jappl.1993.75.6.2368; Diakonova M, 1997, J CELL SCI, V110, P1199; EBERHARD DA, 1994, AM J PATHOL, V145, P640; ELDERFIELD AJ, 1992, J NEUROIMMUNOL, V39, P91, DOI 10.1016/0165-5728(92)90178-N; Ferreira SH, 1997, BRIT J PHARMACOL, V121, P883, DOI 10.1038/sj.bjp.0701211; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; GARCIAGONZALEZ A, 1992, SEMIN ARTHRITIS RHEU, V22, P139, DOI 10.1016/0049-0172(92)90014-5; Getting SJ, 1997, BRIT J PHARMACOL, V120, P1075, DOI 10.1038/sj.bjp.0701029; GOULDING NJ, 1990, LANCET, V335, P1416, DOI 10.1016/0140-6736(90)91445-G; GOULDING NJ, 1989, ANN RHEUM DIS, V48, P843, DOI 10.1136/ard.48.10.843; Goulding NJ, 1998, INFLAMM RES, V47, pS158; GunteskiHamblin AM, 1996, AM J PHYSIOL-HEART C, V270, pH1091, DOI 10.1152/ajpheart.1996.270.3.H1091; Harricane MC, 1996, CELL BIOL INT, V20, P193, DOI 10.1006/cbir.1996.0024; Hawkins TE, 1999, MOL CELL BIOL, V19, P8028; HENRIQUES MGMO, 1987, BRAZ J MED BIOL RES, V20, P243; Herr C, 2001, MOL CELL BIOL, V21, P4119, DOI 10.1128/MCB.21.13.4119-4128.2001; Hogan B, 1994, MANIPULATING MOUSE E; HORLICK KR, 1991, GENOMICS, V10, P365, DOI 10.1016/0888-7543(91)90321-5; KITAJIMA Y, 1991, J INVEST DERMATOL, V97, P1032, DOI 10.1111/1523-1747.ep12492494; Kusumawati A, 2001, CELL BIOL INT, V25, P809, DOI 10.1006/cbir.2000.0704; La M, 2001, FASEB J, V15, P2247, DOI 10.1096/fj.01-0196com; Le Cabec V, 2000, INFECT IMMUN, V68, P4736, DOI 10.1128/IAI.68.8.4736-4745.2000; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; Lindahl M, 1999, ELECTROPHORESIS, V20, P881, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<881::AID-ELPS881>3.0.CO;2-6; MEERS P, 1992, BIOCHEMISTRY-US, V31, P6372, DOI 10.1021/bi00143a003; MEERS P, 1993, BIOCHEMISTRY-US, V32, P1390, DOI 10.1021/bi00056a026; Mikuniya T, 1998, SARCOIDOSIS VASC DIF, V15, P38; MULLA A, 2001, IN PRESS J ENDOCRINO; Newman SP, 1997, ADV EXP MED BIOL, V407, P249; PEPINSKY RB, 1991, METHOD ENZYMOL, V198, P260; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; Perretti M, 1996, BRIT J PHARMACOL, V117, P1145, DOI 10.1111/j.1476-5381.1996.tb16709.x; Philip JG, 2001, BRIT J PHARMACOL, V134, P887, DOI 10.1038/sj.bjp.0704324; PODGORSKI MR, 1992, J RHEUMATOL, V19, P1668; Rand JH, 1999, NEW ENGL J MED, V340, P1035, DOI 10.1056/NEJM199904013401310; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RELTON JK, 1991, J EXP MED, V174, P305, DOI 10.1084/jem.174.2.305; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHOHAT M, 1989, AM J MED GENET, V34, P163, DOI 10.1002/ajmg.1320340205; SMITH FB, 1995, J VASC INVEST, V1, P79; SMITH SF, 1990, ENVIRON HEALTH PERSP, V85, P135, DOI 10.2307/3430676; Srivastava M, 2000, CELL BIOL INT, V24, P475, DOI 10.1006/cbir.2000.0511; STEVENS TRJ, 1993, CLIN SCI, V84, P381, DOI 10.1042/cs0840381; Strausbaugh HJ, 2001, J IMMUNOL, V166, P6294, DOI 10.4049/jimmunol.166.10.6294; Sun HT, 2001, AM J MED GENET, V103, P81, DOI 10.1002/1096-8628(20010915)103:1<81::AID-AJMG1505>3.0.CO;2-T; TAYLOR AD, 1993, NEUROENDOCRINOLOGY, V58, P430, DOI 10.1159/000126572; TAYLOR AD, 1995, J ENDOCRINOL, V147, P533, DOI 10.1677/joe.0.1470533; TAYLOR AD, 1995, NEUROENDOCRINOLOGY, V62, P19, DOI 10.1159/000126984; Tsao FHC, 1998, AM J RESP CELL MOL, V18, P120, DOI 10.1165/ajrcmb.18.1.2808; VIOLETTE SM, 1990, J CELL PHYSIOL, V142, P70, DOI 10.1002/jcp.1041420110; VISHWANATH BS, 1993, J CLIN INVEST, V92, P1974, DOI 10.1172/JCI116791; Yang YH, 1999, ARTHRITIS RHEUM, V42, P1538, DOI 10.1002/1529-0131(199907)42:7<1538::AID-ANR29>3.0.CO;2-3	66	292	306	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					253	+		10.1096/fj.02-0239fje	http://dx.doi.org/10.1096/fj.02-0239fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475898				2022-12-28	WOS:000180574300020
J	Kumanovics, A; Levin, G; Blount, P				Kumanovics, A; Levin, G; Blount, P			Family ties of gated pores: evolution of the sensor module	FASEB JOURNAL			English	Article						MscL; TPTE; transient receptor potential; tyrosine phosphatases; voltage-gated channel	COMPLETE GENOME SEQUENCE; VOLTAGE SENSOR; GENE; CHANNEL; PROTEIN; IDENTIFICATION; DATABASE; MSCL; ACTIVATION; HOMOLOGY	The six-transmembrane channels are thought to be composed of two modules: pore and sensor. Whereas the modular design of the pore has been established, the modularity of the sensor remains hypothetical. As a first step toward establishing the modularity of this region, we searched for genes where the sensor is found independent of the pore and have identified new members of the sensor superfamily. Analysis of these sensors reveals a motif shared among not only these newly discovered members and voltage-gated, transient receptor potential, and polycystin channel sensors, but also MscL, a bacterial mechanosensitive channel. Mutational analyses presented here and in previous studies demonstrate that highly conserved residues within this motif are required for normal channel activity; mutations of residues within this motif in different subfamilies lead to consistent channel phenotypes. Previous studies have demonstrated that peptides containing this motif and the adjacent conserved transmembrane domain elicit channel activities when reconstituted into lipid membranes. These data provide evidence for the modularity of the sensor, imply a model for its evolution, suggest a common origin for mechano- and voltage-sensing, and may offer a glimpse of the properties of the first sensor/channel.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Immunol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Blount, P (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, Harry Hines Blvd, Dallas, TX 75390 USA.	Paul.Blount@UTSouthwestern.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK060818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061028] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60818] Funding Source: Medline; NIGMS NIH HHS [R01 GM061028, GM61028] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], [No title captured]; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Blount P, 1999, Methods Enzymol, V294, P458; Blount P, 1999, TRENDS MICROBIOL, V7, P420, DOI 10.1016/S0966-842X(99)01594-2; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Chen HM, 1999, HUM GENET, V105, P399, DOI 10.1007/s004390051122; Enklaar T, 2000, GENOMICS, V67, P179, DOI 10.1006/geno.2000.6234; Gil Z, 1999, P NATL ACAD SCI USA, V96, P14594, DOI 10.1073/pnas.96.25.14594; GROSS GJ, 1993, BIOPHYS J, V64, pA313; GROVE A, 1993, PROTEIN SCI, V2, P1918, DOI 10.1002/pro.5560021113; Gu CX, 2001, BIOPHYS J, V80, P2678, DOI 10.1016/S0006-3495(01)76237-6; Guipponi H, 2000, HUM GENET, V107, P127, DOI 10.1007/s004390000343; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hong KH, 2000, J GEN PHYSIOL, V115, P51, DOI 10.1085/jgp.115.1.51; Hunter JJ, 1998, GENOMICS, V54, P116, DOI 10.1006/geno.1998.5549; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; Jones SE, 2000, BIOCHEM BIOPH RES CO, V279, P208, DOI 10.1006/bbrc.2000.3921; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; Li-Smerin YY, 2000, J GEN PHYSIOL, V115, P33, DOI 10.1085/jgp.115.1.33; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; MCKEMY DD, 2002, NATURE, V416, P53; MILKMAN R, 1994, P NATL ACAD SCI USA, V91, P3510, DOI 10.1073/pnas.91.9.3510; Moe PC, 2000, J BIOL CHEM, V275, P31121, DOI 10.1074/jbc.M002971200; Oghalai JS, 2000, SCIENCE, V287, P658, DOI 10.1126/science.287.5453.658; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Perozo E, 2001, J GEN PHYSIOL, V118, P193, DOI 10.1085/jgp.118.2.193; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; PETROV AG, 1994, EUR BIOPHYS J BIOPHY, V23, P1, DOI 10.1007/BF00192201; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PLANELLSCASES R, 1995, P NATL ACAD SCI USA, V92, P9422, DOI 10.1073/pnas.92.20.9422; Prawitt D, 2000, HUM MOL GENET, V9, P203, DOI 10.1093/hmg/9.2.203; Reynolds DM, 1999, J AM SOC NEPHROL, V10, P2342; SALKOFF L, 1995, NEURON, V15, P489, DOI 10.1016/0896-6273(95)90137-X; SANSOM MSP, 1991, PROG BIOPHYS MOL BIO, V55, P139, DOI 10.1016/0079-6107(91)90004-C; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Snel B, 2000, TRENDS GENET, V16, P9, DOI 10.1016/S0168-9525(99)01924-1; Somlo S, 2001, CURR BIOL, V11, pR356, DOI 10.1016/S0960-9822(01)00193-2; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Walker SM, 2001, BIOCHEM J, V360, P277, DOI 10.1042/0264-6021:3600277	45	56	59	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1623	1629		10.1096/fj.02-0238hyp	http://dx.doi.org/10.1096/fj.02-0238hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374785				2022-12-28	WOS:000179167600044
J	Obreja, O; Rathee, PK; Lips, KS; Distler, C; Kress, M				Obreja, O; Rathee, PK; Lips, KS; Distler, C; Kress, M			IL-10 potentiates heat-activated currents in rat sensory neurons: involvement of IL-1RI, tyrosine kinase, and protein kinase C	FASEB JOURNAL			English	Article						hyperalgesia; inflammation; cytokines; nociceptor	TUMOR-NECROSIS-FACTOR; GENE-RELATED PEPTIDE; INTERLEUKIN-1 RECEPTOR; RELEASE; SENSITIZATION; EXPRESSION; IRAK; HYPERALGESIA; BRADYKININ; INDUCTION	Interleukin 1beta (IL-1beta) is a proinflammatory cytokine that maintains thermal hyperalgesia and facilitates the release of calcitonin gene-related peptide from rat cutaneous nociceptors in vivo and in vitro. Brief applications of IL-1beta to nociceptive neurons yielded a potentiation of heat-activated inward currents (meat) and a shift of activation threshold toward lower temperature without altering intracellular calcium levels. The IL-1 beta-induced heat sensitization was not dependent on G-protein-coupled receptors but was mediated by activation of protein kinases. The nonspecific protein kinase inhibitor staurosporine, the specific protein kinase C inhibitor bisindolyhnaleimide BIM1, and the protein tyrosine kinase inhibitor genistein reduced the sensitizing effect of IL-1beta whereas negative controls were ineffective. RT-PCR and in situ hybridization revealed IL-1RI but not RII expression in neurons rather than surrounding satellite cells in rat dorsal root ganglia. IL-1beta acts on sensory neurons to increase their susceptibility for noxious heat via an IL-1RI/PTK/ PKC-dependent mechanism.	Univ Erlangen Nurnberg, Inst Physiol & Expt Pathophysiol, D-91054 Erlangen, Germany; Univ Giessen, Inst Anat & Zellbiol, Giessen, Germany	University of Erlangen Nuremberg; Justus Liebig University Giessen	Kress, M (corresponding author), Univ Erlangen Nurnberg, Inst Physiol & Expt Pathophysiol, Univ Str 17, D-91054 Erlangen, Germany.	kress@physiologiel.uni-erlangen.de		Kress, Michaela/0000-0002-8921-7470; Obreja, Otilia/0000-0002-0230-7538				Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Barber LA, 1996, J NEUROCHEM, V67, P72; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Cesare P, 1996, P NATL ACAD SCI USA, V93, P15435, DOI 10.1073/pnas.93.26.15435; Cesare P, 1999, NEURON, V23, P617, DOI 10.1016/S0896-6273(00)80813-2; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; Copray JCVM, 2001, J NEUROIMMUNOL, V118, P203, DOI 10.1016/S0165-5728(01)00324-1; Cunha JM, 2000, BRIT J PHARMACOL, V130, P1418, DOI 10.1038/sj.bjp.0703434; CUNNINGHAM ET, 1993, IMMUNOL TODAY, V14, P171; Dittert I, 1998, J NEUROSCI METH, V82, P195, DOI 10.1016/S0165-0270(98)00051-X; EASTGATE JA, 1988, LANCET, V2, P706; EIZIRIK DL, 1995, MOL CELL ENDOCRINOL, V111, P159, DOI 10.1016/0303-7207(95)03561-K; FERREIRA SH, 1988, NATURE, V334, P698, DOI 10.1038/334698a0; FREIDIN M, 1992, P NATL ACAD SCI USA, V89, P10440, DOI 10.1073/pnas.89.21.10440; Fu LW, 1999, J PHYSIOL-LONDON, V521, P249, DOI 10.1111/j.1469-7793.1999.00249.x; FUKUOKA H, 1994, BRAIN RES, V657, P133, DOI 10.1016/0006-8993(94)90960-1; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GUY GR, 1995, EUR J BIOCHEM, V229, P503, DOI 10.1111/j.1432-1033.1995.0503k.x; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Inoue A, 1999, J NEUROCHEM, V73, P2206; KHASAR SG, 1993, NEUROSCI LETT, V153, P215, DOI 10.1016/0304-3940(93)90325-F; KOLTZENBURG M, 1992, NEUROSCIENCE, V46, P465, DOI 10.1016/0306-4522(92)90066-B; Kress M, 1999, J NEUROPHYSIOL, V81, P2612, DOI 10.1152/jn.1999.81.6.2612; KUMAZAWA T, 1987, PAIN, V28, P255, DOI 10.1016/0304-3959(87)90120-5; KUMAZAWA T, 1991, J NEUROPHYSIOL, V66, P1819, DOI 10.1152/jn.1991.66.6.1819; NAKAMURA H, 1988, EUR J PHARMACOL, V149, P49, DOI 10.1016/0014-2999(88)90040-4; Opree A, 2000, J NEUROSCI, V20, P6289, DOI 10.1523/JNEUROSCI.20-16-06289.2000; PERKINS MN, 1994, NEUROPHARMACOLOGY, V33, P657, DOI 10.1016/0028-3908(94)90171-6; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; RZYMKIEWICZ DM, 1995, KIDNEY INT, V47, P1354, DOI 10.1038/ki.1995.191; Saade NE, 1998, J NEUROIMMUNOL, V91, P171, DOI 10.1016/S0165-5728(98)00176-3; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Sauer SK, 2001, EUR J NEUROSCI, V14, P1203, DOI 10.1046/j.0953-816x.2001.01741.x; Sauer SK, 1999, NEUROSCIENCE, V92, P319, DOI 10.1016/S0306-4522(98)00731-3; Sommer C, 1999, NEUROSCI LETT, V270, P25, DOI 10.1016/S0304-3940(99)00450-4; Souter AJ, 2000, PAIN, V86, P63, DOI 10.1016/S0304-3959(99)00315-2; Sweitzer SM, 1999, BRAIN RES, V829, P209, DOI 10.1016/S0006-8993(99)01326-8; Takii T, 1999, EUR CYTOKINE NETW, V10, P237; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Watkins LR, 1999, CYTOKINES PAIN; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Zeilhofer HU, 1996, J NEUROPHYSIOL, V76, P2834, DOI 10.1152/jn.1996.76.5.2834	45	183	191	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1497	1503		10.1096/fj.02-0101com	http://dx.doi.org/10.1096/fj.02-0101com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374772				2022-12-28	WOS:000179167600031
J	Kohno, T; Wada, A; Igarashi, Y				Kohno, T; Wada, A; Igarashi, Y			N-glycans of sphingosine 1-phosphate receptor Edg-1 regulate ligand-induced receptor internalization	FASEB JOURNAL			English	Article						Edg-1; G-protein-coupled receptor; glycosylation; sphingosine 1-phosphate; membrane microdomain	PROTEIN-COUPLED RECEPTOR; MOLECULAR-CLONING; LINKED GLYCOSYLATION; SIGNAL-TRANSDUCTION; SPHINGOSINE-1-PHOSPHATE; EXPRESSION; SYSTEM; GENE; ACTIVATION; INHIBITION	Endothelial differentiation gene-1 product (Edg-1) is a G-protein-coupled receptor (GPCR) for the platelet derived bioactive lipid mediator sphingosine 1-phosphate (Sph-1-P). Recent studies have shown that in response to Sph-1-P, Edg-1 mediates various signaling pathways through downstream signaling molecules, such as MAP kinase and calcium, via heterotrimeric G-proteins. We found for the first time that Edg-1 is glycosylated in its amino-terminal extracellular portion, and further identified the specific glycosylation site as asparagine 30 by creating a nonglycosylated mutant of Edg-1 (N30D-Edg-1) and transfecting it into cell lines. The nonglycosylated mutant receptors, resembling their wild-type controls, were predominantly expressed in the plasma membrane. Although there was no difference in ligand binding ability and ligand-induced MAP kinase activation in the wild-type and mutant receptors, nonglycosylated Edg-1 was much less responsive for ligand-induced internalization. Unlike the wild-type receptor, which was associated with the caveolae, nonglycosylated N30D-Edg-1 was dispersed broadly in the membrane fractions separated by sucrose density gradient centrifugation, suggesting that internalization and microdomain localization of N-glycosylated Edg-1 might be related. Although the precise molecular mechanism of the internalization of the N-glycosylated Edg-1 localized in the microdomain remains to be examined, the present study suggested that the presence of N-linked glycan in the receptor may play a regulatory role in the receptor dynamics in ligand-stimulated mammalian cells.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Sapporo, Hokkaido 060, Japan	Hokkaido University	Igarashi, Y (corresponding author), Nishi 6,Kita 12,Kita Ku, Sapporo, Hokkaido 0600812, Japan.	yigarash@pharm.hokudai.ac.jp		Kohno, Takayuki/0000-0002-1782-3578				An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Chun J, 1999, ADV EXP MED BIOL, V469, P357; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Gao-Uozumi CX, 2000, GLYCOBIOLOGY, V10, P1209, DOI 10.1093/glycob/10.11.1209; Glickman M, 1999, MOL CELL NEUROSCI, V14, P141, DOI 10.1006/mcne.1999.0776; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P627, DOI 10.1023/A:1011086929064; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; HLA T, 1990, J BIOL CHEM, V265, P9308; Hla T, 1999, BIOCHEM PHARMACOL, V58, P201; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; Igarashi Y, 1998, ANN NY ACAD SCI, V845, P19, DOI 10.1111/j.1749-6632.1998.tb09659.x; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Liu CH, 1999, MOL BIOL CELL, V10, P1179, DOI 10.1091/mbc.10.4.1179; MACLENNAN AJ, 1994, MOL CELL NEUROSCI, V5, P201, DOI 10.1006/mcne.1994.1024; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; Ono M, 1999, CANCER RES, V59, P2335; Ray K, 1998, J BIOL CHEM, V273, P34558, DOI 10.1074/jbc.273.51.34558; RUSSO D, 1991, MOL ENDOCRINOL, V5, P29, DOI 10.1210/mend-5-1-29; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Ulloa-Aguirre A, 1999, ARCH MED RES, V30, P420, DOI 10.1016/S0188-0128(99)00041-X; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	33	67	68	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2002	16	9					983	992		10.1096/fj.01-0809com	http://dx.doi.org/10.1096/fj.01-0809com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087059				2022-12-28	WOS:000177813100029
J	Deplancke, B; Gaskins, HR				Deplancke, B; Gaskins, HR			Hydrogen sulfide induces serum-independent cell cycle entry in nontransformed rat intestinal epithelial cells	FASEB JOURNAL			English	Article						IEC-18; colorectal cancer; ulcerative colitis; epithelial hyperproliferation; microarray analysis	ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR-BETA; ULCERATIVE-COLITIS; COLORECTAL-CANCER; CARDIAC MYOCYTES; GENE-EXPRESSION; UP-REGULATION; COLON-CANCER; C-JUN; METABOLIC INHIBITION	Hydrogen sulfide (H2S), produced by commensal sulfate-reducing bacteria, is an environmental insult that potentially contributes to chronic intestinal epithelial disorders. We tested the hypothesis that exposure of nontransformed intestinal epithelial cells (IEC-18) to the reducing agent sodium hydrogen sulfide (NaHS) activates molecular pathways that underlie epithelial hyperplasia, a phenotype common to both ulcerative colitis (UC) and colorectal cancer. Exposure of IEC-18 cells to NaHS rapidly increased the NADPH/NADP ratio, reduced the intracellular redox environment, and inhibited mitochondrial respiratory activity. The addition of 0.2-5 mM NaHS for 4 h increased the IEC-18 proliferative cell fraction (P<0.05), as evidenced by analysis of the cell cycle and proliferating cell nuclear antigen expression, while apoptosis occurred only at the highest concentration of NaHS. Thirty minutes of NaHS exposure increased (P<0.05) c-Jun mRNA concentrations, consistent with the observed activation of mitogen activated protein kinases (MAPK). Microarray analysis confirmed an increase (P<0.05) in MAPK-mediated proliferative activity, likely reflecting the reduced redox environment of NaHS-treated cells. These data identify functional pathways by which H2S may initiate epithelial dysregulation and thereby contribute to UC or colorectal cancer. Thus, it becomes crucial to understand how genetic background may affect epithelial responsiveness to this bacterial-derived environmental insult.	Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA; Univ Illinois, Dept Anim Sci, Urbana, IL 61801 USA; Univ Illinois, Dept Vet Pathobiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Gaskins, HR (corresponding author), Univ Illinois, Div Nutr Sci, 1207 W Gregory Dr, Urbana, IL 61801 USA.	hgaskins@uiuc.edu	Deplancke, Bart/B-3250-2008	Deplancke, Bart/0000-0001-9935-843X; Gaskins, H. Rex/0000-0002-1249-535X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK057940] Funding Source: NIH RePORTER; NIDDK NIH HHS [R21 DK057940-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; AUSSERER WA, 1994, MOL CELL BIOL, V14, P5032, DOI 10.1128/MCB.14.8.5032; Babidge W, 1998, MOL CELL BIOCHEM, V181, P117, DOI 10.1023/A:1006838231432; Baserga R, 1997, ENDOCRINE, V7, P99, DOI 10.1007/BF02778073; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; CHRISTL SU, 1995, Z GASTROENTEROL, V33, P408; Christl SU, 1996, DIGEST DIS SCI, V41, P2477, DOI 10.1007/BF02100146; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; Dagsgaard C, 2001, J BIOL CHEM, V276, P7593, DOI 10.1074/jbc.M009180200; Das M, 2001, J BIOL CHEM, V276, P15631, DOI 10.1074/jbc.M010690200; De Laurenzi V, 2000, ANN NY ACAD SCI, V926, P90; Deb SP, 2002, FRONT BIOSCI, V7, pD235, DOI 10.2741/deb; DEPLANCKE B, 2003, IN PRESS EXP BIOL ME; DIETRICH DR, 1993, CRIT REV TOXICOL, V23, P77, DOI 10.3109/10408449309104075; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Esco MA, 2001, J CELL SCI, V114, P4033; EVANS CL, 1967, Q J EXP PHYSIOL CMS, V52, P231, DOI 10.1113/expphysiol.1967.sp001909; FLORIN T, 1991, GUT, V32, P766, DOI 10.1136/gut.32.7.766; Furne J, 2001, BIOCHEM PHARMACOL, V62, P255, DOI 10.1016/S0006-2952(01)00657-8; GIBSON GR, 1996, FEMS MICROBIOL ECOL, V86, P101; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; GONZALEZFLECHA B, 1993, J CLIN INVEST, V91, P456, DOI 10.1172/JCI116223; Griffiths EJ, 1998, BIOCHEM PHARMACOL, V56, P173, DOI 10.1016/S0006-2952(98)00016-1; Guo YS, 2001, J BIOL CHEM, V276, P22941, DOI 10.1074/jbc.M101801200; HAGUE A, 1995, INT J CANCER, V60, P400, DOI 10.1002/ijc.2910600322; Hardy RG, 2000, BRIT MED J, V321, P886, DOI 10.1136/bmj.321.7265.886; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Hoffmann A, 2001, J CELL PHYSIOL, V188, P33, DOI 10.1002/jcp.1092; Ierardi E, 2001, DIGEST DIS SCI, V46, P1083, DOI 10.1023/A:1010774331331; Isaksen MF, 1996, MAR ECOL PROG SER, V137, P187, DOI 10.3354/meps137187; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jung F, 2001, BIOCHEM BIOPH RES CO, V286, P419, DOI 10.1006/bbrc.2001.5406; Kanazawa K, 1996, CANCER-AM CANCER SOC, V77, P1701, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1701::AID-CNCR42>3.3.CO;2-E; Kang HS, 2001, CELL IMMUNOL, V213, P34, DOI 10.1006/cimm.2001.1861; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kirlin WG, 1999, FREE RADICAL BIO MED, V27, P1208, DOI 10.1016/S0891-5849(99)00145-8; Ladoux A, 2000, J BIOL CHEM, V275, P39914, DOI 10.1074/jbc.M006512200; Levitt MD, 1999, J CLIN INVEST, V104, P1107, DOI 10.1172/JCI7712; Liu YC, 1998, FEBS LETT, V441, P200, DOI 10.1016/S0014-5793(98)01549-X; Loftus EV, 2000, GUT, V46, P336, DOI 10.1136/gut.46.3.336; Magee EA, 2000, AM J CLIN NUTR, V72, P1488; Manthey CL, 1998, J LEUKOCYTE BIOL, V64, P409, DOI 10.1002/jlb.64.3.409; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Masys DR, 2001, BIOINFORMATICS, V17, P319, DOI 10.1093/bioinformatics/17.4.319; Matsuda N, 1998, BIOCHEM BIOPH RES CO, V249, P350, DOI 10.1006/bbrc.1998.9151; OBITABOT ET, 1993, J SURG RES, V55, P575, DOI 10.1006/jsre.1993.1187; PANDEY S, 1995, J CELL BIOCHEM, V58, P135, DOI 10.1002/jcb.240580203; Pellizzaro C, 2002, CARCINOGENESIS, V23, P735, DOI 10.1093/carcin/23.5.735; Pitcher MCL, 1995, GUT, V36, pA63; POCHART P, 1992, FEMS MICROBIOL LETT, V98, P225; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; POWELL MA, 1986, SCIENCE, V233, P563, DOI 10.1126/science.233.4763.563; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Qiao L, 1997, BBA-MOL CELL RES, V1359, P222, DOI 10.1016/S0167-4889(97)00102-X; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; Rhodes JM, 2002, TRENDS MOL MED, V8, P10, DOI 10.1016/S1471-4914(01)02194-3; ROEDIGER WEW, 1984, J CLIN PATHOL, V37, P704, DOI 10.1136/jcp.37.6.704; Roediger WEW, 1997, DIGEST DIS SCI, V42, P1571, DOI 10.1023/A:1018851723920; ROEDIGER WEW, 1993, GASTROENTEROLOGY, V104, P802, DOI 10.1016/0016-5085(93)91016-B; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Schuchmann S, 2000, FREE RADICAL BIO MED, V28, P235, DOI 10.1016/S0891-5849(99)00226-9; Scott PH, 1998, AM J RESP CRIT CARE, V158, P958, DOI 10.1164/ajrccm.158.3.9712130; SEGAL I, 1988, INT J COLORECTAL DIS, V3, P222, DOI 10.1007/BF01660719; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Smith J, 2000, P NATL ACAD SCI USA, V97, P10032, DOI 10.1073/pnas.170209797; Sodhi CP, 2001, DIABETES, V50, P1482, DOI 10.2337/diabetes.50.6.1482; WEBSTER KA, 1994, CIRC RES, V74, P679, DOI 10.1161/01.RES.74.4.679; Welsh DJ, 2001, AM J RESP CRIT CARE, V164, P282, DOI 10.1164/ajrccm.164.2.2008054; WHITAKER JE, 1991, BIOCHEM BIOPH RES CO, V175, P387, DOI 10.1016/0006-291X(91)91576-X; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; YAO A, 1995, J CLIN INVEST, V96, P69, DOI 10.1172/JCI118081	76	148	154	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1310	+		10.1096/fj.02-0883fje	http://dx.doi.org/10.1096/fj.02-0883fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738807				2022-12-28	WOS:000183165000039
J	Johnston, JD; Cagampang, FRA; Stirland, JA; Carr, AJF; White, MRH; Davis, JRE; Loudon, ASI				Johnston, JD; Cagampang, FRA; Stirland, JA; Carr, AJF; White, MRH; Davis, JRE; Loudon, ASI			Evidence for an endogenous per1- and ICER-independent seasonal timer in the hamster pituitary gland	FASEB JOURNAL			English	Article						clock gene; melatonin; pars tuberalis; refractoriness; photoperiod; circadian	OVINE PARS TUBERALIS; DECODING PHOTOPERIODIC TIME; SUPRACHIASMATIC NUCLEUS; PROLACTIN SECRETION; GENE-EXPRESSION; SIBERIAN HAMSTERS; MELATONIN SIGNAL; SYRIAN-HAMSTERS; PINEAL-GLAND; DOPAMINE	Most mammals use changing annual day-length cycles to regulate pineal melatonin secretion and thereby drive many physiological rhythms including reproduction, metabolism, immune function, and pelage. Prolonged exposure to short winter day lengths results in refractoriness, a spontaneous reversion to long-day physiological status. Despite its critical role in the timing of seasonal rhythms, refractoriness remains poorly understood. The aim of this study was therefore to describe cellular and molecular mechanisms driving the seasonal secretion of a key hormone, prolactin, in refractory Syrian hamsters. We used recently developed single cell hybridization and reporter assays to show that this process is initiated by timed reactivation of endocrine signaling from the pars tuberalis (PT) region of the pituitary gland, a well-defined melatonin target site, causing renewed activation of prolactin gene expression. This timed signaling is independent of per1 clock gene expression in the suprachiasmatic nuclei and PT and of melatonin secretion, which continue to track day length. Within the PT, there is also a continued short day-like profile of ICER expression, suggesting that the change in hormone secretion is independent of cAMP signaling. Our data thus identify the PT as a key anatomical structure involved in endogenous seasonal timing mechanisms, which breaks from prevailing day length-induced gene expression.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Liverpool, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England; Univ Manchester, Sch Med, Manchester M13 9PL, Lancs, England	University of Manchester; University of Liverpool; University of Manchester	Loudon, ASI (corresponding author), Univ Manchester, Sch Biol Sci, 3-614 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	andrew.loudon@man.ac.uk	Cagampang, Felino/AAG-5141-2019; Johnston, Jonathan/AAS-6969-2021; Davis, Julian R/G-8943-2014; Jansen, Heiko T./A-5770-2008; Yoong, Elizabeth/AAF-1297-2019; Johnston, Jonathan D/H-6363-2011	Cagampang, Felino/0000-0003-4404-9853; Davis, Julian R/0000-0003-0838-0557; Jansen, Heiko T./0000-0003-0178-396X; Johnston, Jonathan D/0000-0001-8083-9794; Carr, Amanda-Jayne/0000-0002-5469-0030; White, Michael/0000-0002-3617-3232; Loudon, Andrew/0000-0003-3648-445X				BADURA LL, 1994, NEUROENDOCRINOLOGY, V59, P49, DOI 10.1159/000126637; BADURA LL, 1992, J EXP ZOOL, V261, P27, DOI 10.1002/jez.1402610105; BARTNESS TJ, 1993, J PINEAL RES, V15, P161; BITTMAN EL, 1978, SCIENCE, V202, P648, DOI 10.1126/science.568311; Bockers TM, 1997, ENDOCRINOLOGY, V138, P4101, DOI 10.1210/en.138.10.4101; CURLEWIS JD, 1992, REPROD FERT DEVELOP, V4, P1, DOI 10.1071/RD9920001; Freeman DA, 2001, P NATL ACAD SCI USA, V98, P6447, DOI 10.1073/pnas.111140398; Goldman BD, 2001, J BIOL RHYTHM, V16, P283, DOI 10.1177/074873001129001980; Gwinner E., 1986, CIRCANNUAL RHYTHMS, Vfirst; Hazlerigg DG, 2001, J BIOL RHYTHM, V16, P326, DOI 10.1177/074873001129002042; Hazlerigg DG, 1996, J NEUROENDOCRINOL, V8, P489, DOI 10.1046/j.1365-2826.1996.04971.x; HAZLERIGG DG, 1993, ENDOCRINOLOGY, V132, P285, DOI 10.1210/en.132.1.285; Jagota A, 2000, NAT NEUROSCI, V3, P372, DOI 10.1038/73943; LINCOLN GA, 1994, J NEUROENDOCRINOL, V6, P251, DOI 10.1111/j.1365-2826.1994.tb00580.x; Lincoln GA, 2002, J NEUROENDOCRINOL, V14, P36, DOI 10.1046/j.0007-1331.2001.00734.x; LINCOLN GA, 1995, J NEUROENDOCRINOL, V7, P637, DOI 10.1111/j.1365-2826.1995.tb00802.x; Lincoln GA, 2000, BIOL REPROD, V62, P432, DOI 10.1095/biolreprod62.2.432; MAYWOOD ES, 1993, J ENDOCRINOL, V136, P65, DOI 10.1677/joe.0.1360065; MAYWOOD ES, 1995, ENDOCRINOLOGY, V136, P144, DOI 10.1210/en.136.1.144; Messager S, 2001, NEUROREPORT, V12, P579, DOI 10.1097/00001756-200103050-00029; Messager S, 2000, EUR J NEUROSCI, V12, P2865, DOI 10.1046/j.1460-9568.2000.00174.x; Messager S, 1999, P NATL ACAD SCI USA, V96, P9938, DOI 10.1073/pnas.96.17.9938; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Morgan PJ, 2000, J NEUROENDOCRINOL, V12, P287; Morgan PJ, 1998, J NEUROENDOCRINOL, V10, P319, DOI 10.1046/j.1365-2826.1998.00232.x; Morgan PJ, 1996, ENDOCRINOLOGY, V137, P4018, DOI 10.1210/en.137.9.4018; Mrugala M, 2000, AM J PHYSIOL-REG I, V278, pR987, DOI 10.1152/ajpregu.2000.278.4.R987; NICHOLLS TJ, 1988, PHYSIOL REV, V68, P133, DOI 10.1152/physrev.1988.68.1.133; Nuesslein-Hildesheim B, 2000, EUR J NEUROSCI, V12, P2856, DOI 10.1046/j.1460-9568.2000.00173.x; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; ROLLAG MD, 1980, P SOC EXP BIOL MED, V165, P330, DOI 10.3181/00379727-165-40981; Schwartz WJ, 2001, J BIOL RHYTHM, V16, P302, DOI 10.1177/074873001129002024; STEGER RW, 1991, BIOL REPROD, V44, P76, DOI 10.1095/biolreprod44.1.76; Stirland JA, 2001, J NEUROENDOCRINOL, V13, P147, DOI 10.1046/j.1365-2826.2001.00611.x; SUMOVA A, 1995, P NATL ACAD SCI USA, V92, P7754, DOI 10.1073/pnas.92.17.7754; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Takasuka N, 1998, ENDOCRINOLOGY, V139, P1361, DOI 10.1210/en.139.3.1361; von Gall C, 2002, NAT NEUROSCI, V5, P234, DOI 10.1038/nn806; Yagita K, 2000, FEBS LETT, V465, P79, DOI 10.1016/S0014-5793(99)01724-X	39	47	48	0	3428	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					810	815		10.1096/fj.02-0837com	http://dx.doi.org/10.1096/fj.02-0837com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724339				2022-12-28	WOS:000183165000006
J	Kojima, K; Bonassar, LJ; Roy, AK; Mizuno, H; Cortiella, J; Vacanti, CA				Kojima, K; Bonassar, LJ; Roy, AK; Mizuno, H; Cortiella, J; Vacanti, CA			A composite tissue-engineered trachea using sheep nasal chondrocyte and epithelial cells	FASEB JOURNAL			English	Article						chondrocytes; polyglycolic acid (PGA); hydrogel; tracheal replacement	HUMAN SEPTAL CARTILAGE; AGE-DEPENDENCE; RECONSTRUCTION; BONE	This study evaluates the feasibility of producing a composite engineered tracheal equivalent composed of cylindrical cartilaginous structures with lumens lined with nasal epithelial cells. Chondrocytes and epithelial cells isolated from sheep nasal septum were cultured in Ham's F12 media. After 2 wk, chondrocyte suspensions were seeded onto a matrix of polyglycolic acid. Cell-polymer constructs were wrapped around silicon tubes and cultured in vitro for 1 wk, followed by implanting into subcutaneous pockets on the backs of nude mice. After 6 wk, epithelial cells were suspended in a hydrogel and injected into the embedded cartilaginous cylinders following removal of the silicon tube. Implants were harvested 4 wk later and analyzed. The morphology of implants resembles that of native sheep trachea. H&E staining shows the presence of mature cartilage and formation of a pseudo-stratified columnar epithelium, with a distinct interface between tissue-engineered cartilage and epithelium. Safranin-O staining shows that tissue-engineered cartilage is organized into lobules with round, angular lacunae, each containing a single chondrocyte. Proteoglycan and hydroxyproline contents are similar to native cartilage. This study demonstrates the feasibility of recreating the cartilage and epithelial portion of the trachea using tissue harvested in a single procedure. This has the potential to facilitate an autologous repair of segmental tracheal defects.	Univ Massachusetts, Sch Med, Ctr Tissue Engn, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester	Vacanti, CA (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Anesthesiol,Lab Tissue Engn, 75 Francis St, Boston, MA 02115 USA.	cvacanti@partners.org	Bonassar, Lawrence J/C-2103-2016	Bonassar, Lawrence J/0000-0003-1094-6433				Banis JC, 1996, PLAST RECONSTR SURG, V98, P1046, DOI 10.1097/00006534-199611000-00019; Cavadas PC, 1998, PLAST RECONSTR SURG, V101, P937, DOI 10.1097/00006534-199804040-00008; Enobakhare BO, 1996, ANAL BIOCHEM, V243, P189, DOI 10.1006/abio.1996.0502; KIM YJ, 1988, ANAL BIOCHEM, V174, P168, DOI 10.1016/0003-2697(88)90532-5; Mukaida T, 1998, ANN THORAC SURG, V66, P205, DOI 10.1016/S0003-4975(98)00154-4; NAKANISHI R, 1993, J THORAC CARDIOV SUR, V106, P1081, DOI 10.1016/S0022-5223(19)33981-9; NEVILLE WE, 1982, INT SURG, V67, P229; Okumura N, 1992, ASAIO J, V38, pM555, DOI 10.1097/00002480-199207000-00096; OSADA H, 1994, J CARDIOVASC SURG, V35, P165; Rotter N, 2002, ARCH BIOCHEM BIOPHYS, V403, P132, DOI 10.1016/S0003-9861(02)00263-1; Rotter N, 2002, BIOMATERIALS, V23, P3087, DOI 10.1016/S0142-9612(02)00031-5; Rotter N, 2001, ARCH OTOLARYNGOL, V127, P1248, DOI 10.1001/archotol.127.10.1248; SPANGENBERG KM, 1998, TISSUE ENG, V4, P476; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; Treppo S, 2000, J ORTHOP RES, V18, P739, DOI 10.1002/jor.1100180510; VACANTI CA, 1994, OTOLARYNG CLIN N AM, V27, P263; VACANTI CA, 1994, CLIN PLAST SURG, V21, P445; VACANTI CA, 1994, J PEDIATR SURG, V29, P201, DOI 10.1016/0022-3468(94)90318-2; van Veenendaal MB, 2000, EUR J PEDIATR, V159, P8, DOI 10.1007/s004310050002	19	87	93	1	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					823	828		10.1096/fj.02-0462com	http://dx.doi.org/10.1096/fj.02-0462com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724341				2022-12-28	WOS:000183165000008
J	Asanuma, K; Tanida, I; Shirato, I; Ueno, T; Takahara, H; Nishitani, T; Kominami, E; Tomino, Y				Asanuma, K; Tanida, I; Shirato, I; Ueno, T; Takahara, H; Nishitani, T; Kominami, E; Tomino, Y			MAP-LC3, a promising autophagosomal marker, is processed during the differentiation and recovery of podocytes from PAN nephrosis	FASEB JOURNAL			English	Article						processing; puromycin	PUROMYCIN AMINONUCLEOSIDE; GLOMERULOSCLEROSIS; DISSECTION; APOPTOSIS; PROTEINS; HOMOLOG; KIDNEY; INJURY; ENZYME	Microtubule-associated protein 1 light chain 3 (LC3) is a unique modifier protein. LC3-I, the cytosolic form, is modified to LC3-II, the membrane-bound form, by a mechanism similar to ubiquitylation by E1- and E2-like enzymes, Apg7p and Apg3p, respectively. In the present study, we found that LC3-I is processed to LC3-II during the differentiation and recovery from puromycin aminonucleoside-induced nephrosis of podocytes. LC3 is especially expressed in the podocytes of rat kidney as the membrane-bound form LC3-II. Biochemical analysis using a conditionally immortalized mouse podocyte clone (MPC) revealed that LC3-I is processed to LC3-II during the differentiation of cells into mature podocytes and accumulates in the membrane-rich fraction of the cell lysate. LC3-II-localized vesicles, which differ from lysosomes and endosomes, in differentiated MPC cells are morphologically similar to autophagic vacuoles during starvation-induced autophagy. During starvation-induced autophagy, autophagosomes fuses with lysosome and LC3-II on autophagosomes is finally degraded by lysosomal proteases. However, in differentiated MPC cells, little LC3-II on the vesicles is degraded by lysosomal proteases, suggesting that little LC3-II-localized vesicles in differentiated MPC cells fuse with lysosome. Furthermore, the LC3-II level in differentiated MPC cells increases with recovery from damage caused by experimental puromycin aminonucleoside-induced nephrosis. These results suggest that LC3-II-localized vesicles play an important role in the physiological function of podocytes.	Juntendo Univ, Sch Med, Dept Internal Med, Div Nephrol,Bunkyo Ku, Tokyo 1138421, Japan; Juntendo Univ, Sch Med, Dept Biochem, Tokyo 113, Japan	Juntendo University; Juntendo University	Tomino, Y (corresponding author), Juntendo Univ, Sch Med, Dept Internal Med, Div Nephrol,Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	yasu@med.juntendo.ac.jp	Tanida, Isei/C-8277-2009; Kominami, Eiki/D-3802-2009	Tanida, Isei/0000-0001-8999-3990				AKASAKI K, 1991, J BIOCHEM-TOKYO, V110, P922, DOI 10.1093/oxfordjournals.jbchem.a123690; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P603; BERKENSTAM A, 1983, VIRCHOWS ARCH B, V44, P275, DOI 10.1007/BF02890177; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; CAULFIELD JP, 1976, LAB INVEST, V34, P43; COERS W, 1994, EXP NEPHROL, V2, P40; FRIES JWU, 1989, LAB INVEST, V60, P205; Inokuchi S, 1996, KIDNEY INT, V50, P1278, DOI 10.1038/ki.1996.439; JOHNSON RJ, 1994, KIDNEY INT, V45, P352, DOI 10.1038/ki.1994.45; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; KIHARA I, 1995, PATHOL INT, V45, P625, DOI 10.1111/j.1440-1827.1995.tb03514.x; Kim YH, 2001, KIDNEY INT, V60, P957, DOI 10.1046/j.1523-1755.2001.060003957.x; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kobayashi N, 1998, CELL TISSUE RES, V291, P163, DOI 10.1007/s004410050988; Kriz W, 1998, KIDNEY INT, V54, P687, DOI 10.1046/j.1523-1755.1998.00044.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Legesse-Miller A, 2000, J BIOL CHEM, V275, P32966, DOI 10.1074/jbc.M000917200; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; MANN SS, 1994, J BIOL CHEM, V269, P11492; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; MUNDEL P, 1995, ANAT EMBRYOL, V192, P387; MUNO D, 1993, ARCH BIOCHEM BIOPHYS, V306, P103, DOI 10.1006/abbi.1993.1486; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; NOVIKOFF PM, 1985, J CELL BIOL, V101, P339, DOI 10.1083/jcb.101.2.339; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Reiser J, 2000, KIDNEY INT, V57, P2035, DOI 10.1046/j.1523-1755.2000.00070.x; Schiffer M, 2001, J CLIN INVEST, V108, P807, DOI 10.1172/JCI12367; Shirato I, 2000, J AM SOC NEPHROL, V11, P2381, DOI 10.1681/ASN.V11122381; Smoyer WE, 1998, J MOL MED, V76, P172, DOI 10.1007/s001090050206; Striker G E, 1987, Adv Nephrol Necker Hosp, V16, P169; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; TANIDA I, 2002, IN PRESS J BIOL CHEM; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ueno T, 1999, J BIOL CHEM, V274, P15222, DOI 10.1074/jbc.274.21.15222	35	169	195	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1165	+		10.1096/fj.02-0580fje	http://dx.doi.org/10.1096/fj.02-0580fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709412				2022-12-28	WOS:000182580100030
J	Meggio, F; Pinna, LA				Meggio, F; Pinna, LA			One-thousand-and-one substrates of protein kinase CK2?	FASEB JOURNAL			English	Review						CK2; casein kinase 2; phosphoacceptor sites; phosphoproteome	IN-VITRO PHOSPHORYLATION; VIRUS P-PROTEIN; MANNOSE 6-PHOSPHATE RECEPTOR; CYCLE-REGULATED PHOSPHORYLATION; NUCLEAR-LOCALIZATION SEQUENCE; UBIQUITIN-CONJUGATING ENZYME; ZINC-FINGER PROTEIN; II PHOSPHORYLATION; CASEIN KINASE-2; DNA-BINDING	CK2 (formerly termed "casein kinase 2") is a ubiquitous, highly pleiotropic and constitutively active Ser/Thr protein kinase whose implication in neoplasia, cell survival, and virus infection is supported by an increasing number of arguments. Here an updated inventory of 307 CK2 protein substrates is presented. More than one-third of these are implicated in gene expression and protein synthesis as being either transcriptional factors (60) or effectors of DNA/RNA structure (50) or translational elements. Also numerous are signaling proteins and proteins of viral origin or essential to virus life cycle. In comparison, only a minority of CK2 targets (a dozen or so) are classical metabolic enzymes. An analysis of 308 sites phosphorylated by CK2 highlights the paramount relevance of negatively charged side chains that are (by far) predominant over any other residues at positions n+3 (the most crucial one), n+1, and n+2. Based on this signature, it is predictable that proteins phosphorylated by CK2 are much more numerous than those identified to date, and it is possible that CK2 alone contributes to the generation of the eukaryotic phosphoproteome more so than any other individual protein kinase. The possibility that CK2 phosphosites play some global role, e. g., by destabilizing alpha helices, counteracting caspase cleavage, and generating adhesive motifs, will be discussed.	Univ Padua, Dipartimento Chim Biol, I-35121 Padua, Italy; Univ Padua, Ist Neurosci, CNR, I-35121 Padua, Italy; Venetain Inst Mol Med, Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Veneto Institute Molecular Medicine	Pinna, LA (corresponding author), Univ Padua, Dipartimento Chim Biol, Viale G Colombo 3, I-35121 Padua, Italy.	lorenzo.pinna@unipd.it						Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Angenstein F, 1999, HIPPOCAMPUS, V9, P173, DOI 10.1002/(SICI)1098-1063(1999)9:2<173::AID-HIPO8>3.0.CO;2-K; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; AROOR AR, 1994, BIOCHEMISTRY-US, V33, P3350, DOI 10.1021/bi00177a028; Azuma Y, 1997, BIOCHIMIE, V79, P247, DOI 10.1016/S0300-9084(97)83512-2; BENNETT MK, 1993, J NEUROSCI, V13, P1701; Bergholtz S, 2001, NUCLEIC ACIDS RES, V29, P3546, DOI 10.1093/nar/29.17.3546; Birnbaum MJ, 1997, J CELL BIOCHEM, V66, P175, DOI 10.1002/(SICI)1097-4644(19970801)66:2<175::AID-JCB5>3.0.CO;2-N; Block K, 2001, J BIOL CHEM, V276, P41049, DOI 10.1074/jbc.M106453200; BOSSER R, 1995, MOL CELL BIOL, V15, P661; Briggs LJ, 2001, BIOCHEM J, V353, P69, DOI 10.1042/bj3530069; Bryant HE, 2000, J VIROL, V74, P11322, DOI 10.1128/JVI.74.23.11322-11328.2000; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; BURNETT G, 1954, J BIOL CHEM, V211, P969; Caldwell BD, 1999, J BIOL CHEM, V274, P34646, DOI 10.1074/jbc.274.49.34646; Carbonnet F, 1998, BIOCHEM BIOPH RES CO, V247, P569, DOI 10.1006/bbrc.1998.8743; CARDELLINI E, 1994, BIOL CHEM H-S, V375, P255, DOI 10.1515/bchm3.1994.375.4.255; Chattopadhyay D, 1997, VIROLOGY, V239, P11, DOI 10.1006/viro.1997.8838; Chen JL, 1997, VIROLOGY, V228, P200, DOI 10.1006/viro.1996.8401; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; Cohen P, 2002, NAT CELL BIOL, V4, pE127, DOI 10.1038/ncb0502-e127; Conner J, 1999, J GEN VIROL, V80, P1471, DOI 10.1099/0022-1317-80-6-1471; Coqueret O, 1998, J BIOL CHEM, V273, P2561, DOI 10.1074/jbc.273.5.2561; Cordenonsi M, 1999, EUR J BIOCHEM, V264, P374, DOI 10.1046/j.1432-1327.1999.00616.x; Dahma H, 2001, PEPTIDES, V22, P1491, DOI 10.1016/S0196-9781(01)00471-5; deCarcer G, 1997, PLANTA, V201, P487, DOI 10.1007/s004250050093; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Dobransky T, 2000, BIOCHEM J, V349, P141, DOI 10.1042/0264-6021:3490141; Dokas LA, 1998, BRAIN RES, V781, P320, DOI 10.1016/S0006-8993(97)01257-2; Dubois T, 2002, EUR J BIOCHEM, V269, P909, DOI 10.1046/j.0014-2956.2001.02725.x; Dupuy LC, 1999, J VIROL, V73, P8384, DOI 10.1128/JVI.73.10.8384-8392.1999; Ehrnsperger C, 2001, BIOL CHEM, V382, P1463, DOI 10.1515/BC.2001.180; Eichwald C, 2002, J VIROL, V76, P3461, DOI 10.1128/JVI.76.7.3461-3470.2002; Ekdahl KN, 1997, BIOCHEM J, V328, P625, DOI 10.1042/bj3280625; Engemann H, 2002, NUCLEIC ACIDS RES, V30, P1408, DOI 10.1093/nar/30.6.1408; Escargueil AE, 2000, J BIOL CHEM, V275, P34710, DOI 10.1074/jbc.M005179200; Fadden P, 1998, FEBS LETT, V435, P105, DOI 10.1016/S0014-5793(98)01047-3; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Fienberg AA, 1999, J EXP ZOOL, V285, P76, DOI 10.1002/(SICI)1097-010X(19990415)285:1<76::AID-JEZ9>3.0.CO;2-K; Fischer T, 2000, P NATL ACAD SCI USA, V97, P4040, DOI 10.1073/pnas.97.8.4040; Fish KN, 1998, J VIROL, V72, P6657, DOI 10.1128/JVI.72.8.6657-6664.1998; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Formby B, 1998, MOL CELL BIOCHEM, V187, P23, DOI 10.1023/A:1006865721693; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; Fritz G, 1999, ONCOGENE, V18, P1033, DOI 10.1038/sj.onc.1202394; Ganju RK, 1996, BLOOD, V88, P4159; Ganley IG, 2001, BIOCHEM J, V354, P369, DOI 10.1042/0264-6021:3540369; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gelsthorpe M, 1997, GENE, V186, P189, DOI 10.1016/S0378-1119(96)00701-9; Gerber DA, 2000, J BIOL CHEM, V275, P23919, DOI 10.1074/jbc.M002697200; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; Ghavidel A, 1997, GENE DEV, V11, P2780, DOI 10.1101/gad.11.21.2780; Glavy JS, 1997, J BIOL CHEM, V272, P5909, DOI 10.1074/jbc.272.9.5909; Grein S, 1999, MOL CELL BIOCHEM, V191, P121, DOI 10.1023/A:1006806226764; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Gulli MP, 1997, CHROMOSOMA, V105, P532, DOI 10.1007/s004120050215; Guo CH, 2001, J BIOL CHEM, V276, P5992, DOI 10.1074/jbc.M004862200; Han MH, 2001, J BIOL CHEM, V276, P27698, DOI 10.1074/jbc.M101983200; Hanyaloglu AC, 2001, J BIOL CHEM, V276, P18066, DOI 10.1074/jbc.M009275200; Hardtke CS, 2000, EMBO J, V19, P4997, DOI 10.1093/emboj/19.18.4997; Hatomi M, 2000, BIOL PHARM BULL, V23, P1167, DOI 10.1248/bpb.23.1167; HEMER F, 1993, J BIOL CHEM, V268, P17108; Hinchliffe KA, 1999, CURR BIOL, V9, P983, DOI 10.1016/S0960-9822(99)80429-1; Hjerrild M, 2001, BIOCHEM J, V355, P347, DOI 10.1042/0264-6021:3550347; HOECK WG, 1994, J CELL BIOCHEM, V56, P262, DOI 10.1002/jcb.240560220; Hsieh HL, 2000, BBA-GENE STRUCT EXPR, V1494, P248, DOI 10.1016/S0167-4781(00)00245-1; Jaffe L, 1997, GENE DEV, V11, P1327, DOI 10.1101/gad.11.10.1327; Janson IM, 1997, J BIOCHEM-TOKYO, V121, P112; Jellinek DA, 2000, BIOCHEM J, V350, P453, DOI 10.1042/0264-6021:3500453; Jensen HH, 2001, INT J BIOCHEM CELL B, V33, P577, DOI 10.1016/S1357-2725(01)00039-5; Jones NC, 1999, HUM MOL GENET, V8, P2239, DOI 10.1093/hmg/8.12.2239; JUNGI TW, 1998, CURR TREND IMMUNOL, V1, P1; Kalafatis M, 1998, J BIOL CHEM, V273, P8459, DOI 10.1074/jbc.273.14.8459; Kalive M, 2001, MOL CELL BIOCHEM, V227, P99, DOI 10.1023/A:1013185528298; Kanekatsu M, 1998, BIOCHEM MOL BIOL INT, V46, P99; Karki S, 1997, J BIOL CHEM, V272, P5887, DOI 10.1074/jbc.272.9.5887; Kasahara H, 1999, MOL CELL BIOL, V19, P526; Kayukawa K, 1999, GENE, V234, P139, DOI 10.1016/S0378-1119(99)00164-X; KENNEDY EP, 1992, ANNU REV BIOCHEM, V61, P1; Kim J, 1999, BIOCHEM BIOPH RES CO, V257, P777, DOI 10.1006/bbrc.1999.0460; Kim YM, 2002, J BIOL CHEM, V277, P16837, DOI 10.1074/jbc.M201379200; Klenova EM, 2001, MOL CELL BIOL, V21, P2221, DOI 10.1128/MCB.21.6.2221-2234.2001; KLOCKE B, 1995, MOL CELL BIOCHEM, V142, P49, DOI 10.1007/BF00928913; Kohl A, 1999, VIROLOGY, V263, P517, DOI 10.1006/viro.1999.9978; KOIKE T, 1988, J BIOCHEM-TOKYO, V103, P928, DOI 10.1093/oxfordjournals.jbchem.a122389; Komaba S, 2001, GENE, V275, P141, DOI 10.1016/S0378-1119(01)00626-6; KORNER C, 1994, J BIOL CHEM, V269, P16529; Krantz DE, 1997, J BIOL CHEM, V272, P6752, DOI 10.1074/jbc.272.10.6752; Kumar BRP, 2001, J BIOL CHEM, V276, P16804, DOI 10.1074/jbc.M100934200; Lazaro JB, 2000, BIOCHEM BIOPH RES CO, V275, P26, DOI 10.1006/bbrc.2000.3251; Li MF, 1999, J MOL BIOL, V293, P1067, DOI 10.1006/jmbi.1999.3207; Lickert H, 2000, J BIOL CHEM, V275, P5090, DOI 10.1074/jbc.275.7.5090; Lieberman DN, 1999, NAT NEUROSCI, V2, P125, DOI 10.1038/5680; Lin RT, 1999, MOL CELL BIOCHEM, V191, P169, DOI 10.1023/A:1006850009017; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; Liu Z, 1997, VIROLOGY, V232, P198, DOI 10.1006/viro.1997.8548; Liu ZP, 1997, GENE DEV, V11, P3413, DOI 10.1101/gad.11.24.3413; Longshaw VM, 2000, BIOL CHEM, V381, P1133, DOI 10.1515/BC.2000.139; Lotfering B, 1999, VIROLOGY, V255, P50, DOI 10.1006/viro.1998.9577; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; Macica CM, 2001, J NEUROSCI, V21, P1160; Madrid R, 2001, EMBO J, V20, P7008, DOI 10.1093/emboj/20.24.7008; MAEKAWA T, 2002, BIOL PHARM BULL, V22, P667; Majumdar R, 2002, NUCLEIC ACIDS RES, V30, P1154, DOI 10.1093/nar/30.5.1154; Maldonado E, 1999, FEBS LETT, V443, P256, DOI 10.1016/S0014-5793(98)01734-7; Malikova MA, 2001, BIOCHEMISTRY-MOSCOW+, V66, P205, DOI 10.1023/A:1002899700167; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MARIN O, 1992, FEBS LETT, V301, P111, DOI 10.1016/0014-5793(92)80221-2; Marin O, 2000, FEBS LETT, V481, P63, DOI 10.1016/S0014-5793(00)01971-2; Massimi P, 1996, ONCOGENE, V12, P2325; McShan GD, 2000, J GEN VIROL, V81, P1995, DOI 10.1099/0022-1317-81-8-1995; MEGGIO F, 1979, J BIOCHEM-TOKYO, V86, P261; MEGGIO F, 1984, J BIOL CHEM, V259, P4576; MEIER UT, 1992, CELL, V70, P127; MENDEZ R, 1994, J BIOL CHEM, V269, P6170; Milhon JL, 2000, MOL BIOCHEM PARASIT, V108, P225, DOI 10.1016/S0166-6851(00)00221-8; Minin AA, 1998, BIOCHEMISTRY-MOSCOW+, V63, P1074; Miravet S, 2002, J BIOL CHEM, V277, P1884, DOI 10.1074/jbc.M110248200; Mitchell C, 1997, J BIOL CHEM, V272, P25394, DOI 10.1074/jbc.272.40.25394; Miyata Y, 1997, P NATL ACAD SCI USA, V94, P14500, DOI 10.1073/pnas.94.26.14500; Morrison EE, 1998, J VIROL, V72, P7108, DOI 10.1128/JVI.72.9.7108-7114.1998; Moyers JS, 1998, BIOCHEM J, V333, P609, DOI 10.1042/bj3330609; Murakami N, 1998, BIOCHEMISTRY-US, V37, P1989, DOI 10.1021/bi971959a; Nambirajan S, 2000, J BIOSCIENCE, V25, P33, DOI 10.1007/BF02985179; Negro A, 2000, BIOCHEM BIOPH RES CO, V271, P337, DOI 10.1006/bbrc.2000.2628; Ng TI, 1998, VIROLOGY, V241, P37, DOI 10.1006/viro.1997.8963; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Nuthall HN, 2002, MOL CELL BIOL, V22, P389, DOI 10.1128/MCB.22.2.389-399.2002; O'Brien KA, 1999, BIOCHEM BIOPH RES CO, V260, P658, DOI 10.1006/bbrc.1999.0892; Ohtsuki K, 1998, FEBS LETT, V428, P235, DOI 10.1016/S0014-5793(98)00538-9; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; OReilly D, 1997, EMBO J, V16, P2420, DOI 10.1093/emboj/16.9.2420; OU WJ, 1992, J BIOL CHEM, V267, P23789; Ouyang L, 1998, J BIOL CHEM, V273, P23019, DOI 10.1074/jbc.273.36.23019; Paas Y, 1999, IMMUNOPHARMACOLOGY, V42, P175, DOI 10.1016/S0162-3109(99)00027-2; Padmanabhan S, 2001, J BIOL CHEM, V276, P41566, DOI 10.1074/jbc.M106352200; PAI CY, 1995, J CELL SCI, V108, P1911; Pancetti F, 1999, BIOCHEM BIOPH RES CO, V260, P17, DOI 10.1006/bbrc.1999.0849; Pardo PS, 1998, ARCH BIOCHEM BIOPHYS, V349, P397, DOI 10.1006/abbi.1997.0466; Park HS, 2001, BIOCHEM J, V358, P783, DOI 10.1042/0264-6021:3580783; Parker LE, 1999, INTELL AUTOM SOFT CO, V5, P5; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pflum MKH, 2001, J BIOL CHEM, V276, P47733, DOI 10.1074/jbc.M105590200; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PINNA LA, 1994, CELL MOL BIOL RES, V40, P383; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; PINNA LA, 1995, BIOCH CELL MEMBRANES, P15; PINNA LA, 1985, P 16 FEBS C A, P153; Plafker SM, 1999, J VIROL, V73, P9053, DOI 10.1128/JVI.73.11.9053-9062.1999; Plomann M, 1998, EUR J BIOCHEM, V256, P201, DOI 10.1046/j.1432-1327.1998.2560201.x; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Prieschl EE, 1998, NUCLEIC ACIDS RES, V26, P2291, DOI 10.1093/nar/26.10.2291; Ralet MC, 1999, J PROTEIN CHEM, V18, P315, DOI 10.1023/A:1021091413084; Raman C, 1998, J BIOL CHEM, V273, P19183, DOI 10.1074/jbc.273.30.19183; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Ritter M, 2001, EUR J IMMUNOL, V31, P999, DOI 10.1002/1521-4141(200104)31:4<999::AID-IMMU999>3.0.CO;2-R; RITTSCHOF D, 1982, EUR J BIOCHEM, V123, P333, DOI 10.1111/j.1432-1033.1982.tb19772.x; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Rodriguez P, 2000, J MOL BIOL, V298, P225, DOI 10.1006/jmbi.2000.3674; Rohwer A, 1999, EUR J BIOCHEM, V263, P518, DOI 10.1046/j.1432-1327.1999.00537.x; Romero-Oliva F, 2001, J CELL BIOCHEM, V81, P445, DOI 10.1002/1097-4644(20010601)81:3<445::AID-JCB1058>3.0.CO;2-2; ROSORIUS O, 1993, J BIOL CHEM, V268, P21470; Rossi R, 1999, EMBO J, V18, P5745, DOI 10.1093/emboj/18.20.5745; Russo GL, 2000, BIOCHEM J, V351, P143, DOI 10.1042/0264-6021:3510143; Ruzzene M, 2000, EUR J BIOCHEM, V267, P3065, DOI 10.1046/j.1432-1327.2000.01333.x; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Saeki K, 1999, BIOCHEM J, V338, P49, DOI 10.1042/0264-6021:3380049; Sanz-Ezquerro JJ, 1998, J GEN VIROL, V79, P471, DOI 10.1099/0022-1317-79-3-471; Sapir T, 1999, EUR J BIOCHEM, V265, P181, DOI 10.1046/j.1432-1327.1999.00711.x; Sarno S, 1997, BIOCHEMISTRY-US, V36, P11717, DOI 10.1021/bi9705772; SCHUBERT U, 1994, J MOL BIOL, V236, P16, DOI 10.1006/jmbi.1994.1114; Schuster N, 2001, J CELL BIOCHEM, V81, P172, DOI 10.1002/1097-4644(20010401)81:1<172::AID-JCB1033>3.0.CO;2-O; Schwanbeck R, 2001, J BIOL CHEM, V276, P26012, DOI 10.1074/jbc.M011053200; Schwemmle M, 1997, J BIOL CHEM, V272, P21818, DOI 10.1074/jbc.272.35.21818; Scotto C, 1998, J BIOL CHEM, V273, P3901, DOI 10.1074/jbc.273.7.3901; Seger D, 1998, J BIOL CHEM, V273, P24805, DOI 10.1074/jbc.273.38.24805; Semplici F, 2002, ONCOGENE, V21, P3978, DOI 10.1038/sj.onc.1205574; Shen J, 2001, J IMMUNOL, V167, P4919, DOI 10.4049/jimmunol.167.9.4919; Sheu GT, 1999, MOL CELL BIOCHEM, V191, P181, DOI 10.1023/A:1006802125856; Shimoyama Y, 1996, FEBS LETT, V391, P238, DOI 10.1016/0014-5793(96)00744-2; Son MY, 1999, BIOCHEM BIOPH RES CO, V263, P743, DOI 10.1006/bbrc.1999.1460; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Steinmetz MO, 2001, EMBO REP, V2, P505, DOI 10.1093/embo-reports/kve105; Stemmer C, 2002, J BIOL CHEM, V277, P1092, DOI 10.1074/jbc.M109503200; Steplewski A, 2000, GENE, V246, P169, DOI 10.1016/S0378-1119(00)00077-9; Sugano S, 1999, P NATL ACAD SCI USA, V96, P12362, DOI 10.1073/pnas.96.22.12362; Sugano S, 1998, P NATL ACAD SCI USA, V95, P11020, DOI 10.1073/pnas.95.18.11020; Tawfic S, 2001, HISTOL HISTOPATHOL, V16, P573, DOI 10.14670/HH-16.573; Taylor JA, 1999, J MOL BIOL, V290, P839, DOI 10.1006/jmbi.1999.2912; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Trott RL, 2001, J BIOL CHEM, V276, P2159, DOI 10.1074/jbc.M005996200; Tsutsui H, 1999, BIOCHEM BIOPH RES CO, V262, P198, DOI 10.1006/bbrc.1999.1130; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; Tuteja N, 2001, PLANT J, V25, P9, DOI 10.1046/j.1365-313x.2001.00918.x; Veis A, 1998, EUR J ORAL SCI, V106, P234, DOI 10.1111/j.1600-0722.1998.tb02181.x; Vulsteke V, 1997, J BIOL CHEM, V272, P32972, DOI 10.1074/jbc.272.52.32972; Wada T, 1996, NUCLEIC ACIDS RES, V24, P876, DOI 10.1093/nar/24.5.876; Wadd S, 1999, J BIOL CHEM, V274, P28991, DOI 10.1074/jbc.274.41.28991; Walter J, 2000, J BIOL CHEM, V275, P23523, DOI 10.1074/jbc.M002850200; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang Z, 2000, BIOCHEMISTRY-US, V39, P11114, DOI 10.1021/bi0006767; Westmark CJ, 2002, BIOCHEM J, V362, P375, DOI 10.1042/0264-6021:3620375; Wilson LK, 1997, J BIOL CHEM, V272, P12961, DOI 10.1074/jbc.272.20.12961; Winter B, 1997, BIOL CHEM, V378, P1445, DOI 10.1515/bchm.1997.378.12.1445; Wong EV, 1996, J NEUROCHEM, V66, P779; Wong HN, 1998, J BIOL CHEM, V273, P17227, DOI 10.1074/jbc.273.27.17227; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Yamaguchi Y, 1998, NUCLEIC ACIDS RES, V26, P3854, DOI 10.1093/nar/26.16.3854; Yamauchi S, 2002, J BIOL CHEM, V277, P20583, DOI 10.1074/jbc.M200909200; Yaron Y, 2001, J IMMUNOL, V166, P5058, DOI 10.4049/jimmunol.166.8.5058; Yin XY, 2000, J BIOL CHEM, V275, P6850, DOI 10.1074/jbc.275.10.6850; Zetina CR, 2001, PROTEINS, V44, P479, DOI 10.1002/prot.1113; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001; Zhi Y, 1999, J VIROL, V73, P3246, DOI 10.1128/JVI.73.4.3246-3257.1999; Zhou YY, 2001, MOL CELL BIOCHEM, V220, P1, DOI 10.1023/A:1011087910699	221	1072	1115	0	52	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					349	368		10.1096/fj.02-0473rev	http://dx.doi.org/10.1096/fj.02-0473rev			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12631575				2022-12-28	WOS:000181892600034
J	Weinreb, O; Mandel, S; Youdim, MBH				Weinreb, O; Mandel, S; Youdim, MBH			CDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells	FASEB JOURNAL			English	Article						dopamine; R-apomorphine; melatonin; apoptosis; neurodegenerative diseases	DOPAMINE-INDUCED APOPTOSIS; ACTIVATED PROTEIN-KINASE; ANTI-PARKINSON DRUG; OXIDATIVE STRESS; PC12 CELLS; INDUCED NEUROTOXICITY; NEURONAL CELLS; ASCORBIC-ACID; BCL-2 FAMILY; DNA-DAMAGE	Antioxidants have concentration-dependent neuroprotective and proapoptotic activities in models of Parkinson's disease. The aim of our study was to determine gene-protein pathways of the antioxidants, dopamine (DA), R-apomorphine (R-APO), melatonin, and green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG), in neuroblastoma cells, using a customized cDNA microarray and quantitative reverse transcriptase-polymerase chain reaction gene expression techniques. We demonstrate a concentration-dependent correlation between these compounds and modulation of cell survival/cell death-related gene pathways. High toxic concentration of DA (500 muM), R-APO (50 muM), melatonin (50 muM), and EGCG (50 muM) exhibited a similar profile of proapoptotic gene expression, increasing the level of bax, caspase-6, fas ligand, and the cell-cycle inhibitor gadd45 genes, while decreasing antiapoptotic bcl-2 and bcl-xL. Conversely, the low neuroprotective concentrations (1-10 muM) of these compounds induced an antiapoptotic response. Melatonin displayed an extremely low index of mortality, which may be partially explained by the observation that a high concentration did not significantly affect the expression of mitochondrial Bcl-2 family members, bcl-2 and bax. Protein analysis of Bcl-2, Bax, and activated caspase-3 correlated with the gene expression pattern. Our results provide for the first time new insights into the molecular events involved in the dose-dependent neuroprotective and neurotoxic activities of catechols and indole amine compounds.	Technion Israel Inst Technol, Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Eve Topf & USA Natl Parkinson Fdn, Ctr Excellence Neurodegenerat Dis Res, Fac Med, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Dept Pharmacol, Fac Med, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rappaport Family Res Inst, Fac Med, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Pharmacol, POB 9697, IL-31096 Haifa, Israel.	Youdim@tx.technion.ac.il						Antolin I, 2002, BRAIN RES, V943, P163, DOI 10.1016/S0006-8993(02)02551-9; Baas H, 1998, CLIN NEUROPHARMACOL, V21, P86; Barzilai A, 2001, CELL MOL NEUROBIOL, V21, P215, DOI 10.1023/A:1010991020245; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Choi YT, 2001, LIFE SCI, V70, P603, DOI 10.1016/S0024-3205(01)01438-2; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DAVIES AM, 1995, TRENDS NEUROSCI, V18, P355, DOI 10.1016/0166-2236(95)93928-Q; El-Bacha RD, 2001, BIOCHEM PHARMACOL, V61, P73, DOI 10.1016/S0006-2952(00)00524-4; Fallon J, 1997, EXP NEUROL, V144, P193, DOI 10.1006/exnr.1997.6416; Gassen M, 1996, EUR J PHARMACOL, V308, P219, DOI 10.1016/0014-2999(96)00291-9; Gassen M, 1998, MOVEMENT DISORD, V13, P242, DOI 10.1002/mds.870130208; GASSEN M, 1998, ANTIOXIDANT CYTOPROT; Gerlach M, 1997, MOVEMENT DISORD, V12, P258; Gitto E, 2001, J PHARM PHARMACOL, V53, P1393, DOI 10.1211/0022357011777747; Gotz M E, 1990, J Neural Transm Suppl, V29, P241; GOTZ ME, 1994, PHARMACOL THERAPEUT, V63, P37, DOI 10.1016/0163-7258(94)90055-8; Grunblatt E, 2001, J NEUROCHEM, V77, P146, DOI 10.1046/j.1471-4159.2001.t01-1-00227.x; Grunblatt E, 2001, J NEUROCHEM, V78, P1, DOI 10.1046/j.1471-4159.2001.00397.x; Grunblatt E, 1999, MOVEMENT DISORD, V14, P612, DOI 10.1002/1531-8257(199907)14:4<612::AID-MDS1010>3.0.CO;2-6; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hattori A, 1998, NEUROREPORT, V9, P2569, DOI 10.1097/00001756-199808030-00026; Jin BK, 1998, NEUROSCI LETT, V245, P61, DOI 10.1016/S0304-3940(98)00170-0; Junn E, 2001, J NEUROCHEM, V78, P374, DOI 10.1046/j.1471-4159.2001.00425.x; Kang CD, 1998, NEUROSCI LETT, V256, P37, DOI 10.1016/S0304-3940(98)00751-4; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Levites Y, 2002, BIOCHEM PHARMACOL, V63, P21, DOI 10.1016/S0006-2952(01)00813-9; Levites Y, 2002, J BIOL CHEM, V277, P30574, DOI 10.1074/jbc.M202832200; Levites Y, 2001, J NEUROCHEM, V78, P1073, DOI 10.1046/j.1471-4159.2001.00490.x; Lin JK, 2000, J AGR FOOD CHEM, V48, P2736, DOI 10.1021/jf000066d; Linert W, 1996, BBA-MOL BASIS DIS, V1316, P160, DOI 10.1016/0925-4439(96)00020-8; LOU Y, 1998, J BIOL CHEM, V273, P3756; Maruyama W, 2002, J NEURAL TRANSM, V109, P467, DOI 10.1007/s007020200038; Maruyama W, 2001, J NEUROCHEM, V78, P727, DOI 10.1046/j.1471-4159.2001.00448.x; Mayo JC, 1998, J PINEAL RES, V24, P179, DOI 10.1111/j.1600-079X.1998.tb00531.x; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Olivier G, 2001, J PINEAL RES, V31, P320, DOI 10.1034/j.1600-079X.2001.310406.x; Reiter RJ, 1999, ANN NY ACAD SCI, V890, P471, DOI 10.1111/j.1749-6632.1999.tb08028.x; Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; Sakagami H, 1997, ANTICANCER RES, V17, P221; SANER A, 1971, MOL PHARMACOL, V7, P147; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Schroeter H, 2000, FREE RADICAL BIO MED, V29, P1222, DOI 10.1016/S0891-5849(00)00415-9; Seo JH, 2002, FASEB J, V16, P1826, DOI 10.1096/fj.02-0041fje; Shen YX, 2002, J PINEAL RES, V32, P163, DOI 10.1034/j.1600-079x.2002.1o839.x; Simantov R, 1996, NEUROSCIENCE, V74, P39, DOI 10.1016/0306-4522(96)00102-9; TODD RD, 1992, BIOL PSYCHIAT, V31, P794, DOI 10.1016/0006-3223(92)90311-M; WALKINSHAW G, 1995, J CLIN INVEST, V95, P2458, DOI 10.1172/JCI117946; WALKINSHAW G, 1994, NEUROSCIENCE, V63, P975, DOI 10.1016/0306-4522(94)90566-5; Wolfler A, 2001, FEBS LETT, V502, P127, DOI 10.1016/S0014-5793(01)02680-1; Youdim M B, 1987, Adv Neurol, V45, P127; Youdim MBH, 2000, J NEURAL TRANSM-SUPP, P83; YOUDIM MBH, 2001, DRUGS PREVENT CELL D, V86	56	107	113	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					935	+		10.1096/fj.02-0712fje	http://dx.doi.org/10.1096/fj.02-0712fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626434				2022-12-28	WOS:000181892600028
J	Kunzmann, S; Wohlfahrt, JG; Itoh, S; Asao, H; Komada, M; Akdis, CA; Blaser, K; Schmidt-Weber, CB				Kunzmann, S; Wohlfahrt, JG; Itoh, S; Asao, H; Komada, M; Akdis, CA; Blaser, K; Schmidt-Weber, CB			SARA and Hgs attenuate susceptibility to TGF-beta 1-mediated T cell suppression	FASEB JOURNAL			English	Article						SARA; Hgs; TGF-beta 1; CD4(+) T cells; T cell tolerance; nucleofection	GROWTH-FACTOR-BETA; FYVE DOMAIN PROTEIN; ZINC-FINGER DOMAIN; RECEPTOR ACTIVATION; SMAD ANCHOR; TRANSFORMING GROWTH-FACTOR-BETA-1; FUNCTIONAL-CHARACTERIZATION; EARLY ENDOSOMES; HRS; IDENTIFICATION	Transforming growth factor-beta1 (TGF-beta1) is a pluripotent cytokine that controls peripheral T cell tolerance mainly in mucosal immunity. It is secreted by regulatory T cells (Tr/Th3) but also by other immununologically active cells. Smad anchor for receptor activation (SARA) and hepatic growth factor-regulated tyrosine kinase substrate (Hgs) are involved in TGF-beta1 signaling. Both molecules are known to present Smad2 and Smad3 to the TGF-beta receptor complex. The role of SARA and Hgs in TGF-beta1 susceptibility of human CD4(+) T cells is unclear. We demonstrate here that TGF-beta1 up-regulates SARA mRNA expression in CD4(+) T cells similar to that of Smad7. However, the increase in SARA expression was lower (6.1+/-0.3-fold vs. 25+/-4.1-fold) compared with Smad7 and delayed, with a maximum at 12 h compared with 2 h. Th1 and Th2 cell subsets expressed the same levels of SARA and Hgs. Compared with resting cells, significantly lower levels of the two molecules were found in antigen/allergen- or anti-CD3/CD28-stimulated cells. Down-regulation of SARA and Hgs mRNA in preactivated CD4(+) T cells was accompanied by a twofold increase in a TGF-beta1 responsive reporter gene assay. Overexpression of SARA and Hgs in T cells yielded a dose-dependent decrease in cotransfected reporter gene expression, indicating an inhibitory function of both molecules. Thus, SARA and Hgs are regulators of TGF-beta1 susceptibility in T cells and integrate regulatory signals into the influence of TGF-beta1-mediated suppression of human T cells.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Tohoku Univ, Sch Med, Dept Microbiol & Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 226, Japan	Swiss Institute of Allergy & Asthma Research; Netherlands Cancer Institute; Tohoku University; Tokyo Institute of Technology	Schmidt-Weber, CB (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	csweber@siaf.unizh.ch	Akdis, Cezmi/AAV-4844-2020; Schmidt-Weber, Carsten B./AAU-1621-2021	Akdis, Cezmi/0000-0001-8020-019X; Schmidt-Weber, Carsten B./0000-0002-3203-8084; Itoh, Susumu/0000-0002-7967-0730				Akdis CA, 1999, ALLERGY, V54, P31, DOI 10.1111/j.1398-9995.1999.tb04435.x; Akdis M, 2000, EUR J IMMUNOL, V30, P3533, DOI 10.1002/1521-4141(2000012)30:12<3533::AID-IMMU3533>3.0.CO;2-5; Applied Biosystems, 1997, APPL BIOS US B; Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Cottrez F, 2001, J IMMUNOL, V167, P773, DOI 10.4049/jimmunol.167.2.773; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Goto D, 2001, BIOCHEM BIOPH RES CO, V281, P1100, DOI 10.1006/bbrc.2001.4489; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Itoh F, 2002, GENES CELLS, V7, P321, DOI 10.1046/j.1365-2443.2002.00519.x; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; Joss A, 2000, EUR J IMMUNOL, V30, P1683, DOI 10.1002/1521-4141(200006)30:6<1683::AID-IMMU1683>3.0.CO;2-A; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 2000, J EXP MED, V192, P151, DOI 10.1084/jem.192.2.151; Randall RA, 2002, EMBO J, V21, P145, DOI 10.1093/emboj/21.1.145; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; Song XY, 1998, J CLIN INVEST, V101, P2615, DOI 10.1172/JCI2480; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; Wiedemann C, 1998, NATURE, V394, P426, DOI 10.1038/28752; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649	34	34	34	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					194	202		10.1096/fj.02-0550com	http://dx.doi.org/10.1096/fj.02-0550com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554698				2022-12-28	WOS:000181456900044
J	Caetano, MS; Vieira-De-Abreu, A; Teixeira, LK; Werneck, MBF; Barcinski, MA; Viola, JPB				Caetano, MS; Vieira-De-Abreu, A; Teixeira, LK; Werneck, MBF; Barcinski, MA; Viola, JPB			NFATC2 transcription factor regulates cell cycle progression during lymphocyte activation: evidence of its involvement in the control of cyclin gene expression	FASEB JOURNAL			English	Article						NFAT; T cell; proliferation; apoptosis	HUMAN T-CELLS; SWISS 3T3 FIBROBLASTS; IMMUNE-RESPONSE; DEATH OCCURS; MICE LACKING; CALCINEURIN; APOPTOSIS; PHASE; IL-4; DIFFERENTIATION	Upon antigen stimulation, lymphocytes enter in cell cycle and proliferate, and most of the activated T cells die by apoptosis. Many of the proteins that regulate lymphocyte activation are under the control of transcription factors belonging to the NEAT family. As previously demonstrated, NFATC2-/- mice consistently showed a marked increase in lymphocyte proliferation. Here, we evaluate the role of NFATC2 in regulating lymphocyte proliferation and its involvement in the control of cell cycle progression during lymphocyte activation. NFATC2/- lymphocytes, including CD4(+) T cells and B cells, hyperproliferated upon stimulation when compared with NFATC2+/+ cells. Analysis of cell death demonstrated that NFATC2-/- lymphocytes displayed an increased rate of apoptosis after antigen stimulation in addition to the hyperproliferation. Cell cycle analysis after antigen stimulation showed that NFATC2-/- cultures contained more cycling cells when compared with NFATC2+/+ cultures, which is related to a shortening in time of cell division upon activation. Furthermore, hyperproliferation of NFATC2-/- lymphocytes is correlated to an overexpression of cyclins A2, B1, E, and F. Taken together, our results suggest that the NFATC2 transcription factor plays an important role in the control of cell cycle during lymphocyte activation and may act as an inhibitor of cell proliferation in normal cells.	INCA, Inst Nacl Canc, Div Expt Med, BR-20230130 Rio De Janeiro, Brazil; USP, Dept Parasitol, BR-09500900 Sao Paulo, Brazil	National Cancer Institute (Inca); Universidade de Sao Paulo	Viola, JPB (corresponding author), INCA, Inst Nacl Canc, Div Expt Med, Praca Cruz Vermelha 23-6 andar, BR-20230130 Rio De Janeiro, Brazil.	jpviola@inca.gov.br	Viola, Joao P.B./AAP-4125-2020; Werneck, Miriam B.F./H-5802-2012; Teixeira, Leonardo Karam/S-8773-2016	Viola, Joao P.B./0000-0002-0698-3146; Teixeira, Leonardo Karam/0000-0001-6117-423X; Werneck, Miriam/0000-0003-1287-8526				ANRAKU Y, 1991, BIOCHIM BIOPHYS ACTA, V1093, P169, DOI 10.1016/0167-4889(91)90119-I; Baksh S, 2000, ONCOGENE, V19, P2820, DOI 10.1038/sj.onc.1203585; Ben-Sasson SZ, 2001, J IMMUNOL, V166, P112, DOI 10.4049/jimmunol.166.1.112; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; Blanchard P, 2000, ELECTROCHEM COMMUN, V2, P1, DOI 10.1016/S1388-2481(99)00130-7; BOEHME SA, 1993, EUR J IMMUNOL, V23, P1552, DOI 10.1002/eji.1830230724; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Desdouets C, 1999, BIOCHEM BIOPH RES CO, V261, P118, DOI 10.1006/bbrc.1999.0575; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Fournel S, 1996, J IMMUNOL, V157, P4309; Grogan JL, 2001, IMMUNITY, V14, P205, DOI 10.1016/S1074-7613(01)00103-0; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Karas M, 1999, MOL BIOL CELL, V10, P4441, DOI 10.1091/mbc.10.12.4441; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Kiani A, 1997, IMMUNITY, V7, P849, DOI 10.1016/S1074-7613(00)80403-3; Kramer A, 1998, LEUKEMIA, V12, P893, DOI 10.1038/sj.leu.2401051; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Li QS, 2000, EUR J IMMUNOL, V30, P3329, DOI 10.1002/1521-4141(200011)30:11<3329::AID-IMMU3329>3.0.CO;2-#; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; Liu Z, 1995, WIREL NETW, V1, P1, DOI 10.1007/BF01196254; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rengarajan J, 2002, NAT IMMUNOL, V3, P48, DOI 10.1038/ni744; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; Scuderi R, 1996, BLOOD, V87, P3360, DOI 10.1182/blood.V87.8.3360.bloodjournal8783360; TERADA N, 1991, J IMMUNOL, V147, P698; Tomono M, 1998, ARCH BIOCHEM BIOPHYS, V353, P374, DOI 10.1006/abbi.1998.0667; Tomono M, 1996, BIOCHEM J, V317, P675, DOI 10.1042/bj3170675; Trama J, 2000, J IMMUNOL, V165, P4884, DOI 10.4049/jimmunol.165.9.4884; VINDELOV LL, 1977, VIRCHOWS ARCH B, V24, P227; Viola JPB, 1998, BLOOD, V91, P2223, DOI 10.1182/blood.V91.7.2223.2223_2223_2230; Viola JPB, 1999, J CLIN IMMUNOL, V19, P98, DOI 10.1023/A:1020502516196; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; Yang R, 1999, BLOOD, V93, P2067; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1	44	71	73	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1940	+		10.1096/fj.02-0282fje	http://dx.doi.org/10.1096/fj.02-0282fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368232				2022-12-28	WOS:000179167600023
J	Planaguma, A; Titos, E; Lopez-Parra, M; Gaya, J; Pueyo, G; Arroyo, V; Claria, J				Planaguma, A; Titos, E; Lopez-Parra, M; Gaya, J; Pueyo, G; Arroyo, V; Claria, J			Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor alpha-mediated CINC-1 release in rat liver cells: novel actions of lipoxin A(4) (LXA(4)) and ASA-triggered 15-epi-LXA(4)	FASEB JOURNAL			English	Article						Kupffer cells; hepatocytes; nonsteroidal antiinflammatory drug; arachidonic acid metabolites	SODIUM-SALICYLATE; PPAR-ALPHA; PROTEIN; INFLAMMATION; GAMMA; CYCLOOXYGENASE; INTERLEUKIN-8; LEUKOTRIENES; EICOSANOIDS; EXPRESSION	The mechanism of action of aspirin (ASA) is related to cyclooxygenase (COX) inhibition, but additional actions cannot be excluded for their antiinflammatory properties and antithrombotic activity. In the current investigation, we examined the effects of ASA on COX and 5-lipoxygenase (5-LO) pathways and its impact on peroxisome proliferator-activated receptor alpha (PPARalpha.) and cytokine-induced neutrophil chemoattractant-1 (CINC-1) levels in rat liver cells. In Kupffer cells, the liver resident macrophages, ASA switched eicosanoid biosynthesis from prostaglandin E-2 (PGE(2)) to leukotriene B-4 (LTB4) and 15-epi-lipoxin A(4) (15-epi-LXA(4)) formation. In hepatocytes, ASA significantly inhibited PPARalpha. protein expression and CINC-1 secretion, effects that were also observed in hepatocytes exposed to the selective PPARalpha agonist Wy-14643. In contrast, treatment of hepatocytes with PGE2 in association with LTB4 had no significant effect on PPARalpha. but stimulated CINC-1 release. Interestingly, the endogenous antiinflammatory eicosanoids LXA(4) and ASA-triggered 15-epi-LXA(4), in addition to inhibiting macrophage 5-LO activity to a similar extent as PGE(2), significantly reduced PPARalpha and CINC-1 levels in hepatocytes. Taken together and because arachidonic acid-derived products, PPARalpha levels, and CINC-1 secretion are involved in the extent and duration of an inflammatory response, these findings provide additional molecular mechanisms for the pharmacological properties of ASA.	Univ Barcelona, IDIBAPS, Hosp Clin, DNA Unit, E-08036 Barcelona, Spain; Univ Barcelona, IDIBAPS, Hosp Clin, Hormonal Lab, E-08036 Barcelona, Spain; Univ Barcelona, IDIBAPS, Hosp Clin, Liver Unit, E-08036 Barcelona, Spain; Quim Farmaceut Bayer SA, CC Div, Barcelona 08036, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Bayer AG	Claria, J (corresponding author), Univ Barcelona, IDIBAPS, Hosp Clin, DNA Unit, Villarroel 170, E-08036 Barcelona, Spain.	jclaria@clinic.ub.es	Claria, Joan/M-7772-2019; Arroyo, Vicente/F-9189-2015; Titos, Esther/AAA-5394-2019	Arroyo, Vicente/0000-0002-2728-1848; Titos, Esther/0000-0002-2543-2243; Claria, Joan/0000-0003-4333-7749				BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BOCHNER F, 1988, EUR J CLIN PHARMACOL, V35, P287, DOI 10.1007/BF00558267; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; BREZINSKI DA, 1992, CIRCULATION, V86, P56, DOI 10.1161/01.CIR.86.1.56; Chinetti G, 2000, INFLAMM RES, V49, P497, DOI 10.1007/s000110050622; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Dong ZG, 1997, J BIOL CHEM, V272, P9962; Engstrom K, 2001, PROSTAG LEUKOTR ESS, V64, P291, DOI 10.1054/plef.2001.0275; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Gronert K, 1998, J EXP MED, V187, P1285, DOI 10.1084/jem.187.8.1285; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KIM DH, 1990, BIOCHEM PHARMACOL, V40, P481, DOI 10.1016/0006-2952(90)90546-W; KOOP E, 1994, SCIENCE, V265, P956; Lee H, 2000, CIRC RES, V87, P516; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Pang LH, 1998, J IMMUNOL, V161, P2509; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; PAYAN DG, 1995, BASIC CLIN PHARM, P538; Pillinger MH, 1998, P NATL ACAD SCI USA, V95, P14540, DOI 10.1073/pnas.95.24.14540; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; SERHAN CN, 1995, BIOCHEMISTRY-US, V34, P14609, DOI 10.1021/bi00044a041; Serhan CN, 1997, PROSTAG OTH LIPID M, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; Titos E, 1999, AM J PHYSIOL-CELL PH, V277, pC870, DOI 10.1152/ajpcell.1999.277.5.C870; Titos E, 2000, GASTROENTEROLOGY, V119, P794, DOI 10.1053/gast.2000.17831; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Wang ACC, 2001, AM J RESP CELL MOL, V24, P688, DOI 10.1165/ajrcmb.24.6.4376; WATANABE K, 1989, J BIOL CHEM, V264, P19559; WATANABE K, 1991, EXP MOL PATHOL, V55, P30, DOI 10.1016/0014-4800(91)90016-Q	37	52	53	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1937	+		10.1096/fj.02-0224fje	http://dx.doi.org/10.1096/fj.02-0224fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368230				2022-12-28	WOS:000179167600026
J	Zucchi, R; Ghelardoni, S; Carnicelli, V; Frascarelli, S; Ronca, F; Ronca-Testoni, S				Zucchi, R; Ghelardoni, S; Carnicelli, V; Frascarelli, S; Ronca, F; Ronca-Testoni, S			Ca2+ channel remodeling in perfused heart: effects of mechanical work and interventions affecting Ca2+ cycling on sarcolemmal and sarcoplasmic reticulum Ca2+ channels	FASEB JOURNAL			English	Article						intracellular signaling; plasticity; protein kinases; L-type channel; ryanodine receptor	CARDIAC RYANODINE RECEPTORS; PROTEIN-KINASE-II; SKELETAL-MUSCLE; RAT-HEART; CALCIUM-CHANNELS; RELEASE CHANNELS; CA-2+ CHANNEL; PHOSPHORYLATION; MODULATION; ACTIVATION	We investigated whether changes in cardiac work or in Ca2+ fluxes may affect the expression of sarcolemmal or sarcoplasmic reticulum Ca2+ channels (DHPRs and RyRs, respectively). Isolated rat hearts were perfused at low Ca2+ concentration (0.8 mM instead of 1.5 mM), at low preload (5 cm instead of 20 cm), in the presence of 100 nM nifedipine or with a cardioplegic solution. After 60 min, hypocalcemic perfusion produced significant reduction in [H-3]-PN 200-110 and [H-3]-ryanodine binding, due to approximate to30% reduction in Bmax (P<0.01), with unchanged Kd. Such modifications were reversible. Similar results were obtained in the nifedipine and cardioplegia groups. Low preload perfusion produced similar contractile effects as hypocalcemic perfusion, but it had no effect on radioligand binding. After hypocalcemic perfusion, DHPR and RyR gene expression, evaluated by RT-PCR, were not modified. Chelerythrine (protein kinase C inhibitor) and lavendustin C (Ca2+/calmodulin-dependent protein kinase II inhibitor), but not H-89 (protein kinase A inhibitor), abolished the effects of hypocalcemic perfusion on [H-3]-PN 200-110 and [H-3]-ryanodine binding. We conclude that reduced Ca2+ entry and/or intracellular Ca2+ cycling determines DHPR and RyR remodeling through posttranslational protein modifications. Both protein kinase C and Ca2+/calmodulin-dependent protein kinase II appear to play a role in this phenomenon.	Univ Pisa, Dipartimento Sci Uomo Ambiente, Sez Biochim, I-56100 Pisa, Italy	University of Pisa	Zucchi, R (corresponding author), Univ Pisa, Dipartimento Sci Uomo Ambiente, Sez Biochim, Via Roma 55, I-56100 Pisa, Italy.	r.zucchi@med.unipi.it	Zucchi, Riccardo/AAC-8963-2022	ZUCCHI, RICCARDO/0000-0002-6450-3788				Anger M, 1998, CIRCULATION, V98, P2477, DOI 10.1161/01.CIR.98.22.2477; Bayer KU, 1998, EMBO J, V17, P5598, DOI 10.1093/emboj/17.19.5598; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Dzhura I, 2000, NAT CELL BIOL, V2, P173, DOI 10.1038/35004052; Fukuda N, 2001, CIRCULATION, V104, P1639, DOI 10.1161/hc3901.095898; GULATI J, 1990, J PHYSL, V327, P79; Houser SR, 2000, J MOL CELL CARDIOL, V32, P1595, DOI 10.1006/jmcc.2000.1206; Kamp TJ, 2000, CIRC RES, V87, P1095, DOI 10.1161/01.RES.87.12.1095; Keef KD, 2001, AM J PHYSIOL-CELL PH, V281, pC1743; Lakatta EG, 1986, HEART CARDIOVASCULAR, P819; Li L, 1997, J PHYSIOL-LONDON, V501, P17, DOI 10.1111/j.1469-7793.1997.017bo.x; LOKUTA AJ, 1995, J PHYSIOL-LONDON, V487, P609, DOI 10.1113/jphysiol.1995.sp020904; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; Marks AR, 2001, J MOL CELL CARDIOL, V33, P615, DOI 10.1006/jmcc.2000.1343; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; MURPHY BJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P333, DOI 10.1016/0167-4889(90)90230-B; Nattel S, 1999, CARDIOVASC RES, V42, P298, DOI 10.1016/S0008-6363(99)00022-X; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; SainteBeuve C, 1997, J MOL CELL CARDIOL, V29, P1237; Soderling TR, 2001, J BIOL CHEM, V276, P3719, DOI 10.1074/jbc.R000013200; TAKAHASHI T, 1992, J CLIN INVEST, V90, P927, DOI 10.1172/JCI115969; TAKASAGO T, 1991, J BIOCHEM-TOKYO, V109, P163, DOI 10.1093/oxfordjournals.jbchem.a123339; Tavi P, 1998, CIRC RES, V83, P1165, DOI 10.1161/01.RES.83.11.1165; Temsah RM, 2001, FASEB J, V15, P2515, DOI 10.1096/fj.00-0870fje; Temsah RM, 1999, AM J PHYSIOL-HEART C, V277, pH584, DOI 10.1152/ajpheart.1999.277.2.H584; Tomaselli GF, 1999, CARDIOVASC RES, V42, P270, DOI 10.1016/S0008-6363(99)00017-6; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Vondriska TM, 2001, AM J PHYSIOL-HEART C, V280, pH1434, DOI 10.1152/ajpheart.2001.280.4.H1434; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zucchi R, 1998, CIRC RES, V83, P908; Zucchi R, 1997, PHARMACOL REV, V49, P1; ZUCCHI R, 1994, CIRC RES, V74, P271, DOI 10.1161/01.RES.74.2.271; Zucchi R, 2002, J MOL CELL CARDIOL, V34, pA71, DOI 10.1016/S0022-2828(02)91010-2; Zucchi R, 1995, CARDIOVASC RES, V30, P769; Zucchi R, 2001, CARDIOVASC RES, V50, P56, DOI 10.1016/S0008-6363(00)00318-7; ZUCCHI R, 1995, CIRC RES, V76, P1049, DOI 10.1161/01.RES.76.6.1049	38	10	13	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1976	+		10.1096/fj.02-0402fje	http://dx.doi.org/10.1096/fj.02-0402fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397086				2022-12-28	WOS:000179167600004
J	Vetter, R; Rehfeld, U; Reissfelder, C; Weiss, W; Wagner, KD; Gunther, J; Hammes, A; Tschope, C; Dillmann, W; Paul, M				Vetter, R; Rehfeld, U; Reissfelder, C; Weiss, W; Wagner, KD; Gunther, J; Hammes, A; Tschope, C; Dillmann, W; Paul, M			Transgenic overexpression of the sarcoplasmic reticulum Ca2+ ATPase improves reticular Ca2+ handling in normal and diabetic rat hearts	FASEB JOURNAL			English	Article						calcium regulation; relaxation; papillary muscle; streptozotocin-induced cardiomyopathy	LEFT-VENTRICULAR FUNCTION; CARDIAC CONTRACTILITY; CALCIUM-TRANSPORT; MESSENGER-RNA; GENE-TRANSFER; EXPRESSION; CA2+-ATPASE; DYSFUNCTION; FAILURE; CARDIOMYOCYTES	Slowed relaxation in diabetic cardiomyopathy (CM) is partially related to diminished expression of the sarcoplasmic reticulum (SR) Ca2+-ATPase SERCA2a. To evaluate the impact of SERCA2a overexpression on SR Ca2+ handling in diabetic CM, we 1) generated transgenic rats harboring a human cytomegalovirus enhancer/chicken beta-actin promotor-controlled rat SERCA2 transgene (SERCA2-TGR), 2) characterized their SR phenotype, and 3) examined whether transgene expression may rescue SR Ca2+ transport in streptozotocin-induced diabetes. The transgene was expressed in all heart chambers. Compared to wild-type (WT) rats, a heterozygous line exhibited increased SERCA2 mRNA (1.5-fold), SERCA2 protein (+26%) and SR Ca2+ uptake (+37%). Phospholamban expression was not altered. In SERCA2-TGR, contraction amplitude (+48%) and rates of contraction (+34%) and relaxation (+35%) of isolated papillary muscles (PM) were increased (P<0.05 vs. WT, respectively); the lusitropic and inotropic responses of PM to forskolin were stronger than in WT. In diabetic myocardium with SR dysfunction, Ca2+ uptake and SERCA2 protein of SERCA2-TGR were 1.3-fold higher (P<0.05 vs. diabetic WT). Thus, a SERCA2 overexpression in rat heart improves Ca2+ uptake, accelerates relaxation and compensates, in part, for depressed Ca2+ uptake in diabetic CM. Therefore, SERCA2 expression might constitute an important therapeutic target to rescue cardiac SR Ca2+ handling in diabetes.	Free Univ Berlin, Benjamin Franklin Med Ctr, Inst Clin Pharmacol & Toxicol, Dept Toxicol, D-14195 Berlin, Germany; Free Univ Berlin, Benjamin Franklin Med Ctr, Dept Cardiol & Pulmol, D-14195 Berlin, Germany; Humboldt Univ, Charite, Dept Physiol, D-10117 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of California System; University of California San Diego	Vetter, R (corresponding author), Free Univ Berlin, Benjamin Franklin Med Ctr, Inst Clin Pharmacol & Toxicol, Dept Toxicol, D-14195 Berlin, Germany.	rvetter@zedat.fu-berlin.de	Wagner, Kay-Dietrich/E-6119-2016; Paul, Martin/K-5425-2015	Wagner, Kay-Dietrich/0000-0001-5483-7760; Tschope, Carsten/0000-0001-5243-8985; Hammes-Lewin, Annette/0000-0003-1663-8378				Baker DL, 1998, CIRC RES, V83, P1205, DOI 10.1161/01.RES.83.12.1205; Bers DM, 1997, BASIC RES CARDIOL, V92, P1, DOI 10.1007/BF00794062; Bluhm WF, 1999, CARDIOVASC RES, V43, P382, DOI 10.1016/S0008-6363(99)00109-1; Cernohorsky J, 1998, AM J PHYSIOL-HEART C, V275, pH264, DOI 10.1152/ajpheart.1998.275.1.H264; CHUA BHL, 1983, AM J PHYSIOL, V245, P91; del Monte F, 1999, CIRCULATION, V100, P2308, DOI 10.1161/01.CIR.100.23.2308; Depre C, 2000, J MOL CELL CARDIOL, V32, P985, DOI 10.1006/jmcc.2000.1139; Dhalla NS, 1998, CARDIOVASC RES, V40, P239, DOI 10.1016/S0008-6363(98)00186-2; DILLMANN WH, 1985, AM J PHYSIOL, V248, pE602, DOI 10.1152/ajpendo.1985.248.5.E602; FEIN FS, 1980, CIRC RES, V47, P922, DOI 10.1161/01.RES.47.6.922; Frank K, 2000, ANN MED, V32, P572, DOI 10.3109/07853890008998837; GANGULY PK, 1983, AM J PHYSIOL, V244, pE528, DOI 10.1152/ajpendo.1983.244.6.E528; Greene AL, 2000, J BIOL CHEM, V275, P24722, DOI 10.1074/jbc.M001783200; Han XL, 2000, BIOCHEM J, V352, P79, DOI 10.1042/0264-6021:3520079; Hattori Y, 2000, J PHYSIOL-LONDON, V527, P85, DOI 10.1111/j.1469-7793.2000.00085.x; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; Ishikawa T, 1999, AM J PHYSIOL-HEART C, V277, pH2185, DOI 10.1152/ajpheart.1999.277.6.H2185; Ito K, 2001, CIRC RES, V89, P422, DOI 10.1161/hh1701.095522; JANE LM, 2001, CIRC RES, V89, P160; KANNEL WB, 1974, AM J CARDIOL, V34, P29, DOI 10.1016/0002-9149(74)90089-7; Kotsanas G, 2000, CARDIOVASC RES, V46, P450, DOI 10.1016/S0008-6363(00)00062-6; KOZLOWSKI RZ, 1994, BRIT J PHARMACOL, V111, P250, DOI 10.1111/j.1476-5381.1994.tb14052.x; LagadicGossmann D, 1996, AM J PHYSIOL-HEART C, V270, pH1529, DOI 10.1152/ajpheart.1996.270.5.H1529; LOPASCHUK GD, 1982, P W PHARMACOL SOC, V25, P47; MAHLER F, 1975, AM J CARDIOL, V35, P626, DOI 10.1016/0002-9149(75)90048-X; MAKINO N, 1987, AM J PHYSIOL, V253, P202; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; MULLINS JJ, 1990, J HYPERTENS, V8, pS35; Netticadan T, 2001, DIABETES, V50, P2133, DOI 10.2337/diabetes.50.9.2133; PENPARGKUL S, 1981, J MOL CELL CARDIOL, V13, P303, DOI 10.1016/0022-2828(81)90318-7; Ren J, 1997, AM J PHYSIOL-HEART C, V273, pH2876, DOI 10.1152/ajpheart.1997.273.6.H2876; Richardson P, 1996, CIRCULATION, V93, P841, DOI 10.1161/01.CIR.93.5.841; Rothermund L, 2000, CIRCULATION, V102, P1582, DOI 10.1161/01.CIR.102.13.1582; Rupp H, 2000, BRIT J PHARMACOL, V131, P1748, DOI 10.1038/sj.bjp.0703741; RUSS M, 1991, BIOCHEM BIOPH RES CO, V178, P906, DOI 10.1016/0006-291X(91)90977-F; Sato Y, 2001, J BIOL CHEM, V276, P9392, DOI 10.1074/jbc.M006889200; Sprung J, 1998, ANESTHESIOLOGY, V88, P1202, DOI 10.1097/00000542-199805000-00010; SWANK RT, 1971, ANAL BIOCHEM, V39, P462, DOI 10.1016/0003-2697(71)90436-2; Teshima Y, 2000, J MOL CELL CARDIOL, V32, P655, DOI 10.1006/jmcc.2000.1107; Tschope C, 1999, AM J PHYSIOL-HEART C, V277, pH2333, DOI 10.1152/ajpheart.1999.277.6.H2333; VADLAMUDI R, 1980, P W PHARMACOL SOC, V23, P29; Wagner KD, 1998, J MOL CELL CARDIOL, V30, P2341, DOI 10.1006/jmcc.1998.0794; WANG DW, 1995, AM J PHYSIOL-HEART C, V269, pH1288, DOI 10.1152/ajpheart.1995.269.4.H1288; XU KY, 1995, CIRC RES, V77, P88, DOI 10.1161/01.RES.77.1.88; Yao A, 1998, J MOL CELL CARDIOL, V30, P2711, DOI 10.1006/jmcc.1998.0834; ZARAINHERZBERG A, 1994, BIOCHEM BIOPH RES CO, V203, P113, DOI 10.1006/bbrc.1994.2156; Zhong Y, 2001, AM J PHYSIOL-HEART C, V281, pH1137, DOI 10.1152/ajpheart.2001.281.3.H1137	48	77	81	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10					1657	+		10.1096/fj.01-1019fje	http://dx.doi.org/10.1096/fj.01-1019fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206992				2022-12-28	WOS:000177814000012
J	Estienne, V; Duthoit, C; Reichert, M; Praetor, A; Carayon, P; Hunziker, W; Ruf, J				Estienne, V; Duthoit, C; Reichert, M; Praetor, A; Carayon, P; Hunziker, W; Ruf, J			Androgen-dependent expression of Fc gamma RIIB2 by thyrocytes from patients with autoimmune Graves' disease: a possible molecular clue for sex dependence of autoimmune disease	FASEB JOURNAL			English	Article						autoimmune diseases; IgG Fc receptors; sex dependence	THYROID FOLLICULAR CELLS; FC RECEPTOR; ANTIGEN PRESENTATION; TRANSCYTOSIS; MHC; THYROGLOBULIN; IGG; IMMUNOGLOBULINS; LOCALIZATION; EPITOPES	Thyrocyte expression of HLA class I and class II antigens and related accessory molecules would convert these epithelial cells into functional antigen-presenting cells. Here we show that whereas normal thyrocytes express FcRn, Graves' disease thyrocytes also express FcgammaRIIB2. We further find that expression of FcgammaRIIB2, but not FcRn, is repressed by dihydrotestosterone. By mediating the uptake and transport of autoantibodies, we suggest that these IgG Fc receptors contribute in various ways to the onset and/or progression of autoimmune thyroid diseases. The androgen-mediated decrease of FcgammaRIIB2 expression in Graves' disease thyrocytes also provides a rationale for the predominant susceptibility of women to develop an autoimmune thyroid disease. Our findings open up a new prospect to autoimmunity, linking the role of the target organ to the sex dependence in autoimmune disease.	Fac Med Timone, INSERM, U555, F-13385 Marseille 5, France; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; Inst Mol & Cell Biol, Singapore 117609, Singapore	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Lausanne; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hunziker, W (corresponding author), Fac Med Timone, INSERM, U555, 27 Bd Jean Moulin, F-13385 Marseille 5, France.	Hunziker@imcb.nus.edu.sg; Jean.Ruff@medicine.univ-mrs.fr	Ruf, Jean/E-3963-2016; Hunziker, Walter/B-3140-2010; Hunziker, Walter/GSM-8190-2022	Ruf, Jean/0000-0003-4300-8048; Hunziker, Walter/0000-0002-5265-4933; 				AHMED SA, 1986, J IMMUNOL, V136, P143; Amigorena S, 1998, CURR OPIN IMMUNOL, V10, P88, DOI 10.1016/S0952-7915(98)80037-X; AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; Arvan P, 1997, THYROID, V7, P89, DOI 10.1089/thy.1997.7.89; Catalfamo M, 1999, INT IMMUNOL, V11, P269, DOI 10.1093/intimm/11.2.269; Cianga P, 1999, EUR J IMMUNOL, V29, P2515, DOI 10.1002/(SICI)1521-4141(199908)29:08&lt;2515::AID-IMMU2515&gt;3.0.CO;2-D; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Dai Y, 1999, J IMMUNOL, V162, P6987; Dalal M, 1997, J IMMUNOL, V159, P3; DEMICCO C, 1991, CANCER-AM CANCER SOC, V67, P3036, DOI 10.1002/1097-0142(19910615)67:12<3036::AID-CNCR2820671218>3.0.CO;2-D; Dufour V, 1999, J IMMUNOL METHODS, V229, P49, DOI 10.1016/S0022-1759(99)00105-2; Duthoit C, 2000, ENDOCRINOLOGY, V141, P2518, DOI 10.1210/en.141.7.2518; Duthoit C, 2001, BIOCHEM J, V360, P557, DOI 10.1042/0264-6021:3600557; EIDINGER D, 1972, J EXP MED, V136, P1098, DOI 10.1084/jem.136.5.1098; Ermann J, 2001, NAT IMMUNOL, V2, P759, DOI 10.1038/ni0901-759; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739; Gomez F, 2001, CLIN DIAGN LAB IMMUN, V8, P806, DOI 10.1128/CDLI.8.4.806-810.2001; Gomez F, 2000, CLIN DIAGN LAB IMMUN, V7, P682, DOI 10.1128/CDLI.7.4.682-686.2000; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; Hunziker W, 1998, J MAMMARY GLAND BIOL, V3, P287, DOI 10.1023/A:1018715511178; Kacskovics I, 2000, J IMMUNOL, V164, P1889, DOI 10.4049/jimmunol.164.4.1889; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LANZAVECCHIA A, 1995, J EXP MED, V181, P1945, DOI 10.1084/jem.181.6.1945; LONDEI M, 1984, NATURE, V312, P639, DOI 10.1038/312639a0; Praetor A, 1999, J CELL SCI, V112, P2291; PUJOLBORRELL R, 1983, NATURE, V304, P71, DOI 10.1038/304071a0; Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181; Rasmussen AK, 1996, MOL CELL ENDOCRINOL, V116, P165, DOI 10.1016/0303-7207(95)03711-X; SCHRODER FH, 1993, CANCER, V72, P3810, DOI 10.1002/1097-0142(19931215)72:12+<3810::AID-CNCR2820721710>3.0.CO;2-O; SHERIDAN PJ, 1988, J ENDOCRINOL INVEST, V11, P571, DOI 10.1007/BF03350183; SOSPEDRA M, 1995, J IMMUNOL, V154, P4213; Sospedra M, 1997, CLIN EXP IMMUNOL, V109, P98, DOI 10.1046/j.1365-2249.1997.3811277.x; VivesPi M, 1997, TISSUE ANTIGENS, V50, P153, DOI 10.1111/j.1399-0039.1997.tb02854.x; WEETMAN AP, 1994, ENDOCR REV, V15, P788, DOI 10.1210/er.15.6.788; WEINSTEIN Y, 1984, J IMMUNOL, V132, P656; Whitacre CC, 2001, NAT IMMUNOL, V2, P777, DOI 10.1038/ni0901-777; Zimmer K P, 1997, Curr Top Pathol, V91, P117; Zimmer KP, 1997, HISTOCHEM CELL BIOL, V107, P115, DOI 10.1007/s004180050095	39	28	30	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1087	1092		10.1096/fj.01-0998hyp	http://dx.doi.org/10.1096/fj.01-0998hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087070				2022-12-28	WOS:000177813100040
J	Sarma, T; Voyno-Yasenetskaya, T; Hope, TJ; Rasenick, MM				Sarma, T; Voyno-Yasenetskaya, T; Hope, TJ; Rasenick, MM			Heterotrimeric G-proteins associate with microtubules during differentiation in PC12 pheochromocytoma cells	FASEB JOURNAL			English	Article						tubulin; G-protein; NGF; cytoskeleton; growth cone	NERVE GROWTH-FACTOR; ADRENAL GLOMERULOSA CELLS; BETA-ADRENERGIC RECEPTORS; COUPLED RECEPTORS; KINASE ACTIVATION; ALPHA-SUBUNITS; MAP KINASE; PHOSPHORYLATES TUBULIN; SIGNAL-TRANSDUCTION; REGULATORY SUBUNIT	Tubulin modifies G-protein signaling and heterotrimeric G-proteins regulate microtubule assembly. Here we report an interplay among G-protein-coupled receptor and receptor tyrosine kinase (such as nerve growth factor-NGF) signaling systems in PC12 pheochromocytoma cells that resulted in a translocation of G(alphas),G(alphai1), and G(alphao) from cell bodies to cellular processes where they appear to localize with tubulin-containing structures. This relocation appeared to depend on the integrity of microtubules, as it was blocked and reversed by nocodazole. Latrunculin, which promotes actin filament depolymerization, had no effect. Both deconvolution microscopy and immunoprecipitation showed a significant increase of G(alpha) association with microtubules that was coincident with the extension of "neurites." There were distinctions among the G(alpha) subtypes, with G(alphas) showing the most profound NGF-induced colocalization with tubulin. Translocation of G(alpha) was blocked by agents that inhibit the MAP kinases required for neuronal differentiation, suggesting that G-protein relocation is triggered by the intracellular signals for differentiation. Consistent with this, Galpha in Neuro-2A cells, which spontaneously differentiate, showed a similar translocation coincident with differentiation. Thus, diverse signals that promote neuronal differentiation and changes in cell morphology may use specific G-proteins to evoke cytoskeletal rearrangement.	Univ Illinois, Coll Med, Dept Physiol, Chicago, IL USA; Univ Illinois, Coll Med, Dept Biophys, Chicago, IL USA; Univ Illinois, Coll Med, Dept Psychiat, Chicago, IL USA; Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL USA; Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Rasenick, MM (corresponding author), Univ Illinois, Dept Physiol & Biophys, 835 S Wolcott M-C 901, Chicago, IL 60612 USA.	RAZ@uic.edu	voyno-yasenetskaya, tatyana/A-3171-2008		NIAID NIH HHS [AI 47770-04] Funding Source: Medline; NIA NIH HHS [AG 15482] Funding Source: Medline; NIGMS NIH HHS [GM 56159] Funding Source: Medline; NIMH NIH HHS [MH 39595, MH 57391] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047770, R56AI047770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM056159, R01GM056159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057391, R01MH039595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015482] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Cote M, 1997, ENDOCRINOLOGY, V138, P69, DOI 10.1210/en.138.1.69; Cote M, 1997, ENDOCRINOLOGY, V138, P3299, DOI 10.1210/en.138.8.3299; Cowen DS, 1996, J BIOL CHEM, V271, P22297, DOI 10.1074/jbc.271.37.22297; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Crouch MF, 2000, CELL SIGNAL, V12, P153, DOI 10.1016/S0898-6568(99)00080-7; DEGTYAREV MY, 1994, CELL SIGNAL, V6, P25, DOI 10.1016/0898-6568(94)90058-2; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; Dent EW, 1999, J NEUROSCI, V19, P8894, DOI 10.1523/JNEUROSCI.19-20-08894.1999; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Gallo G, 1999, CURR BIOL, V9, pR490, DOI 10.1016/S0960-9822(99)80304-2; Gao ZH, 1999, J BIOL CHEM, V274, P5972, DOI 10.1074/jbc.274.9.5972; GUNNING PW, 1981, J NEUROSCI, V1, P368; GUNNING PW, 1981, J NEUROSCI, V1, P1085; Haga K, 1998, EUR J BIOCHEM, V255, P363, DOI 10.1046/j.1432-1327.1998.2550363.x; HERMOUET S, 1992, FEBS LETT, V312, P223, DOI 10.1016/0014-5793(92)80940-I; IBARRONDO J, 1995, P NATL ACAD SCI USA, V92, P8413, DOI 10.1073/pnas.92.18.8413; Ip NY, 1995, PROG BRAIN RES, V105, P189; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Murthy KS, 1998, J BIOL CHEM, V273, P4695, DOI 10.1074/jbc.273.8.4695; NIKODIJEVIC B, 1994, CELL MOL NEUROBIOL, V14, P27, DOI 10.1007/BF02088587; Nusse O, 1996, J CELL SCI, V109, P221; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Popova JS, 1997, J BIOL CHEM, V272, P6760, DOI 10.1074/jbc.272.10.6760; RANSNAS LA, 1989, P NATL ACAD SCI USA, V86, P7900, DOI 10.1073/pnas.86.20.7900; RASENICK MM, 1981, NATURE, V294, P560, DOI 10.1038/294560a0; RASENICK MM, 1984, J NEUROCHEM, V43, P1447, DOI 10.1111/j.1471-4159.1984.tb05407.x; ROYCHOWDHURY S, 1993, BIOCHEMISTRY-US, V32, P4955, DOI 10.1021/bi00069a034; Roychowdhury S, 1999, J BIOL CHEM, V274, P13485, DOI 10.1074/jbc.274.19.13485; Roychowdhury S, 1997, J BIOL CHEM, V272, P31576, DOI 10.1074/jbc.272.50.31576; Saunders C, 2000, MOL PHARMACOL, V57, P44; Saunders C, 1997, J BIOL CHEM, V272, P19035, DOI 10.1074/jbc.272.30.19035; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Short SM, 2000, J BIOL CHEM, V275, P12970, DOI 10.1074/jbc.275.17.12970; Slaughter T, 1997, J NEUROSCI, V17, P5807; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; STOWARD PJ, 1991, HISTOCHEMISTRY THEOR, V3, P1; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG N, 1991, BIOCHEMISTRY-US, V30, P10957, DOI 10.1021/bi00109a021; WANG N, 1990, J BIOL CHEM, V265, P1239; WILSON BS, 1994, ENDOCRINOLOGY, V134, P233, DOI 10.1210/en.134.1.233; Witt-Enderby PA, 2000, CELL MOTIL CYTOSKEL, V46, P28, DOI 10.1002/(SICI)1097-0169(200005)46:1<28::AID-CM4>3.0.CO;2-5; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Wu HC, 1998, J CELL BIOCHEM, V70, P553, DOI 10.1002/(SICI)1097-4644(19980915)70:4<553::AID-JCB11>3.0.CO;2-I; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Yan K, 2001, J NEUROCHEM, V76, P182, DOI 10.1046/j.1471-4159.2001.00013.x; Yan K, 1996, J NEUROCHEM, V66, P1489; Yu JZ, 2002, MOL PHARMACOL, V61, P352, DOI 10.1124/mol.61.2.352; Yu WQ, 1996, J CELL BIOL, V133, P151, DOI 10.1083/jcb.133.1.151; Zhong HY, 1999, BIOCHEM J, V344, P889, DOI 10.1042/0264-6021:3440889	59	35	35	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					848	859		10.1096/fj.02-0730com	http://dx.doi.org/10.1096/fj.02-0730com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724344				2022-12-28	WOS:000183165000011
J	Tuo, JS; Jaruga, P; Rodriguez, H; Bohr, VA; Dizdaroglu, M				Tuo, JS; Jaruga, P; Rodriguez, H; Bohr, VA; Dizdaroglu, M			Primary fibroblasts of Cockayne syndrome patients are defective in cellular repair of 8-hydroxyguanine and 8-hydroxyadenine resulting from oxidative stress	FASEB JOURNAL			English	Article						GS; fibroblast cell line; gamma irradiation	TRANSCRIPTION-COUPLED REPAIR; B GENE-PRODUCT; EXCISION-REPAIR; DNA-DAMAGE; XERODERMA-PIGMENTOSUM; MAMMALIAN-CELLS; PREFERENTIAL REPAIR; IONIZING-RADIATION; ESCHERICHIA-COLI; ACTIVE GENES	Cockayne syndrome (CS) is a genetic human disease with clinical symptoms that include neurodegeneration and premature aging. The disease is caused by the disruption of CSA, CSB, or some types of xeroderma pigmentosum genes. It is known that the CSB protein coded by the CS group B gene plays a role in the repair of 8-hydroxyguanine (8-OH-Gua) in transcription-coupled and non-strand discriminating modes. Recently we reported a defect of CSB mutant cells in the repair of another oxidatively modified lesion 8-hydroxyadenine (8-OHAde). We show here that primary fibroblasts from CS patients lack the ability to efficiently repair these particular types of oxidatively induced DNA damages. Primary fibroblasts of 11 CS patients and 6 control individuals were exposed to 2 Gy of ionizing radiation to induce oxidative DNA damage and allowed to repair the damage. DNA from cells was analyzed using liquid chromatography/isotope dilution mass spectrometry to measure the biologically important lesions 8-OH-Gua and 8-OHAde. After irradiation, no significant change in background levels of 8-OH-Gua and 8-OH Ade was observed in control human cells, indicating their complete cellular repair. In contrast, cells from CS patients accumulated significant amounts of these lesions, providing evidence for a lack of DNA repair. This was supported by the observation that incision of 8-OH-Gua- or 8-OHAde-containing oligodeoxynucleotides by whole cell extracts of fibroblasts from CS patients was deficient compared to control individuals. This study suggests that the cells from CS patients accumulate oxidatively induced specific DNA base lesions, especially after oxidative stress. A deficiency in cellular repair of oxidative DNA damage might contribute to developmental defects in CS patients.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; NIST, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institute of Standards & Technology (NIST) - USA	Dizdaroglu, M (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	miral@nist.gov	Jaruga, Pawel/M-4378-2015; Bohr, Vilhelm/AAP-5931-2020	Jaruga, Pawel/0000-0001-9192-6084	NATIONAL INSTITUTE ON AGING [Z01AG000731] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Balajee AS, 2000, GENE, V250, P15, DOI 10.1016/S0378-1119(00)00172-4; BARRETT SF, 1991, MUTAT RES, V255, P281, DOI 10.1016/0921-8777(91)90032-K; Bohr VA, 2002, FREE RADICAL BIO MED, V32, P804, DOI 10.1016/S0891-5849(02)00787-6; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; Cleaver JE, 1999, HUM MUTAT, V14, P9, DOI 10.1002/(SICI)1098-1004(1999)14:1<9::AID-HUMU2>3.3.CO;2-Y; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; DIANOV G, 1991, NUCLEIC ACIDS RES, V19, P3829, DOI 10.1093/nar/19.14.3829; Dizdaroglu M, 2002, FREE RADICAL BIO MED, V32, P1102, DOI 10.1016/S0891-5849(02)00826-2; Dizdaroglu M, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.3.e12; Friedberg EC, 1996, BIOESSAYS, V18, P731, DOI 10.1002/bies.950180908; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P42; GUSCHLBAUER W, 1991, NUCLEIC ACIDS RES, V19, P1753, DOI 10.1093/nar/19.8.1753; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hayashi M, 2001, J NEUROPATH EXP NEUR, V60, P350, DOI 10.1093/jnen/60.4.350; Jaruga P, 1996, NUCLEIC ACIDS RES, V24, P1389, DOI 10.1093/nar/24.8.1389; KAMIYA H, 1995, NUCLEIC ACIDS RES, V23, P2893, DOI 10.1093/nar/23.15.2893; Kipling D, 1997, J CLIN PATHOL-MOL PA, V50, P234; KLEIN JC, 1992, NUCLEIC ACIDS RES, V20, P4437, DOI 10.1093/nar/20.17.4437; KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LEPAGE F, 1995, CARCINOGENESIS, V16, P2779; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; Mallery DL, 1998, AM J HUM GENET, V62, P77, DOI 10.1086/301686; MAYNE LV, 1982, CANCER RES, V42, P1473; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; Rapin I, 2000, NEUROLOGY, V55, P1442, DOI 10.1212/WNL.55.10.1442; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P4615, DOI 10.1021/bi00068a019; SOFFER D, 1979, ANN NEUROL, V6, P340, DOI 10.1002/ana.410060407; Tan XZ, 1999, CARCINOGENESIS, V20, P2287, DOI 10.1093/carcin/20.12.2287; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; Tuo J, 2001, J BIOL CHEM, V276, P45772, DOI 10.1074/jbc.M107888200; Tuo J, 2000, FREE RADICAL BIO MED, V29, P147, DOI 10.1016/S0891-5849(00)00324-5; Tuo JS, 2002, J BIOL CHEM, V277, P30832, DOI 10.1074/jbc.M204814200; Tuo JS, 2002, DNA REPAIR, V1, P913, DOI 10.1016/S1568-7864(02)00116-7; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; Wallace SS, 2002, FREE RADICAL BIO MED, V33, P1, DOI 10.1016/S0891-5849(02)00827-4; Wang D, 1998, MUTAT RES-FUND MOL M, V400, P99, DOI 10.1016/S0027-5107(98)00066-9; WOOD ML, 1992, NUCLEIC ACIDS RES, V20, P6023, DOI 10.1093/nar/20.22.6023; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	47	122	122	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					668	674		10.1096/fj.02-0851com	http://dx.doi.org/10.1096/fj.02-0851com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665480				2022-12-28	WOS:000182580100012
J	Lu, KK; Singer, HA				Lu, KK; Singer, HA			Adhesion dependent CaMKII activation in vascular smooth muscle cells	FASEB JOURNAL			English	Meeting Abstract	Experimental Biology 2003 Meeting	APR 11-15, 2003	SAN DIEGO, CALIFORNIA						Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA	Albany Medical College									0	23	23	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 14	2003	17	4	1	S			A56	A56		10.1096/fj.01-0752fje	http://dx.doi.org/10.1096/fj.01-0752fje			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	658QZ	12424217				2022-12-28	WOS:000181733100273
J	Reinehr, R; Schliess, F; Haussinger, D				Reinehr, R; Schliess, F; Haussinger, D			Hyperosmolarity and CD95L trigger CD95/EGFR association and tyrosine phosphorylation of CD95 as prerequisites for CD95 membrane trafficking and DISC formation	FASEB JOURNAL			English	Article						apoptosis; osmosignaling; oxidative stress; c-Jun-N-terminal kinase; protein kinase C	CELL-VOLUME; GROWTH-FACTOR; RECEPTOR; INHIBITION; ACTIVATION; FAS; SHRINKAGE; PROLIFERATION; INDUCTION; MECHANISM	The mechanisms underlying CD95 ligand (CD95L)- and hyperosmolarity-induced activation of the CD95 system [Reinehr, R., Graf, D., Fischer, R., Schliess, F., and Haussinger, D. (2002) Hepatology 36, 602-614] as initial steps of apoptosis were studied. Hyperosmotic exposure (405 mosmol/l) of rat hepatocytes induced within 1 min oxidative stress and antioxidant-sensitive activation of the epidermal growth factor receptor (EGFR) and c-Jun-N-terminal-kinase (JNK). After 30 min of hyperosmotic exposure EGFR associated with CD95 and CD95 became tyrosine phosphorylated. Inhibition of JNK or protein kinase C (PKC) had no effect on EGFR phosphorylation but abolished CD95/EGFR association, CD95-tyrosine phosphorylation, membrane targeting, and Fas-associated death domain/caspase 8 recruitment to CD95 [death-inducing signaling complex (DISC) formation]. Inhibition of EGFR tyrosine kinase activity prevented CD95 tyrosine phosphorylation and DISC formation but not hyperosmolarity-induced EGFR phosphorylation and EGFR association with CD95. Tyrosine-phosphorylated CD95 was enriched in the plasma membrane. All maneuvers preventing CD95 tyrosine phosphorylation inhibited CD95 membrane trafficking and DISC formation. Stimulation of EGFR by EGF induced EGFR phosphorylation but no association with CD95 or CD95 phosphorylation. Addition of CD95L also induced EGFR and JNK activation, EGFR/CD95 association, CD95 tyrosine phosphorylation, DISC formation, and CD95 membrane targeting with an inhibitor sensitivity profile similar to that of hyperosmotic CD95 activation, except that inhibition of PKC was ineffective. The data suggest that moderate hyperosmolarity or CD95L trigger oxidative stress and EGFR activation followed by a JNK-dependent EGFR/CD95association and CD95 tyrosine phosphorylation, probably through EGFR tyrosine kinase activity. This provides a signal for CD95 membrane trafficking and DISC formation.	Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, D-4000 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Haussinger, D (corresponding author), Univ Klinikum Dusseldorf, Klin Gastroenterol Hepatol & Infektiol, Moorenstr 5, D-40225 Dusseldorf, Germany.	haeussin@uni-duesseldorf.de	Reinehr, Roland/G-6118-2016					Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; BORNER CD, 1996, AM J PHYSIOL-CELL PH, V40, pC950; Budd RC, 2002, J CLIN INVEST, V109, P437, DOI 10.1172/JC1200215077; Dunkelberg JC, 2001, HEPATOLOGY, V33, P1349, DOI 10.1053/jhep.2001.24750; Fumarola C, 2001, CELL DEATH DIFFER, V8, P1004, DOI 10.1038/sj.cdd.4400902; GORG B, 2002, IN PRESS HEPATOLOGY; HALLBRUCKER C, 1993, EUR J BIOCHEM, V211, P449, DOI 10.1111/j.1432-1033.1993.tb17570.x; Haussinger D, 1996, BIOCHEM J, V313, P697; Haussinger D, 1999, BIOCHEM BIOPH RES CO, V255, P551, DOI 10.1006/bbrc.1998.9946; HERNANDEZSOTOMAYOR SMT, 1991, J BIOL CHEM, V266, P21281; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; Kagan VE, 2002, J IMMUNOL, V169, P487, DOI 10.4049/jimmunol.169.1.487; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KOH YH, 2001, FASEB J, DOI DOI 10.1096/FJ.00-572FJE; Kurz AK, 2000, BIOCHEM J, V350, P207, DOI 10.1042/0264-6021:3500207; Kurz AK, 1998, HEPATOLOGY, V28, P774, DOI 10.1002/hep.510280326; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lang F, 1998, PFLUG ARCH EUR J PHY, V436, P377, DOI 10.1007/s004240050646; Lang F, 2000, CELL PHYSIOL BIOCHEM, V10, P417, DOI 10.1159/000016367; Lang F, 2000, PFLUG ARCH EUR J PHY, V440, P902, DOI 10.1007/s004240000358; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Meves A, 2002, ARCH DERMATOL RES, V294, P243, DOI 10.1007/s00403-002-0315-1; Nobel CSI, 2000, APOPTOSIS, V5, P153, DOI 10.1023/A:1009684713784; Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x; Reinehr R, 2002, HEPATOLOGY, V36, P602, DOI 10.1053/jhep.2002.35447; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SAHA N, 1992, EUR J BIOCHEM, V209, P437, DOI 10.1111/j.1432-1033.1992.tb17307.x; SAHA N, 1993, BIOCHEM J, V296, P701, DOI 10.1042/bj2960701; Schlehr F, 1999, ATHLET THER TODAY, V4, P13, DOI 10.1123/att.4.4.13; Schliess F, 2002, BIOL CHEM, V383, P577, DOI 10.1515/BC.2002.059; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Wettstein M, 1997, HEPATOLOGY, V26, P1560; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; Yu SP, 2001, CURR OPIN CELL BIOL, V13, P405, DOI 10.1016/S0955-0674(00)00228-3	37	97	98	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					731	+		10.1096/fj.02-0915fje	http://dx.doi.org/10.1096/fj.02-0915fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586732				2022-12-28	WOS:000181456900035
J	Zhang, Y; Luo, Y; Zhai, QW; Ma, LY; Dorf, ME				Zhang, Y; Luo, Y; Zhai, QW; Ma, LY; Dorf, ME			Negative role of cAMP-dependent protein kinase A in RANTES-mediated transcription of proinflammatory mediators through Raf	FASEB JOURNAL			English	Article						astrocytes; chemokines; inflammation	SIGNAL-REGULATED KINASE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MAP KINASE; REACTIVE ASTROCYTES; ALZHEIMERS-DISEASE; ADENYLYL CYCLASES; MURINE ASTROCYTES; A ACTIVITY; ACTIVATION; EXPRESSION	The chemokine RANTES (regulated on activation normal T cell expressed and secreted) is expressed in several inflammatory diseases of the central nervous system and is a powerful stimulus for astrocyte production of proinflammatory mediators. The mechanism of RANTES-mediated astrocyte activation was investigated. RANTES stimulation decreased both intracellular cyclic AMP (cAMP) levels and cAMP-dependent protein kinase A (PKA) activity in cultures of primary mouse astrocytes. H-89, a potent inhibitor of PKA, mimicked RANTES-mediated chemokine and cytokine transcription. RANTES treatments activated Raf-1 kinase activity, and conversely a dominant negative Raf and a Raf-1 inhibitor blocked RANTES-induced chemokine transcription. Transfection with a constitutively active Raf was sufficient to induce transcription of proinflammatory mediators. The combined data indicate that Raf-1 is required for RANTES-mediated astrocyte activation. Decreases of cAMP and PKA activity contributed to the transcription of proinflammatory mediators by cross-talk with the Raf1/mitogen-activated protein kinase pathway. The results identify an upstream signaling pathway for amplification of proinflammatory mediators in the central nervous system.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Childrens Hosp, Dept Neurol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Dorf, ME (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Armenise Bldg D530,200 Longwood Ave, Boston, MA 02115 USA.	dorf@hms.harvard.edu	Zhang, Ye/D-5015-2011	Zhang, Ye/0000-0002-3494-7206; Zhai, Qiwei/0000-0002-9617-7403				Bakhiet M, 2001, NAT CELL BIOL, V3, P150, DOI 10.1038/35055057; Barnes DA, 1998, J NEUROIMMUNOL, V87, P17, DOI 10.1016/S0165-5728(98)00041-1; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Couty JP, 2001, J BIOL CHEM, V276, P33805, DOI 10.1074/jbc.M104631200; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Dorf ME, 2000, J NEUROIMMUNOL, V111, P109, DOI 10.1016/S0165-5728(00)00371-4; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; Fischer FR, 2000, J NEUROIMMUNOL, V110, P195, DOI 10.1016/S0165-5728(00)00351-9; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Grimaldi M, 1997, BIOCHEM BIOPH RES CO, V235, P242, DOI 10.1006/bbrc.1997.6513; Gutkind JS, 1998, ONCOGENE, V17, P1331, DOI 10.1038/sj.onc.1202186; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Han YL, 2000, GLIA, V30, P1; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; Johnstone M, 1999, J NEUROIMMUNOL, V93, P182, DOI 10.1016/S0165-5728(98)00226-4; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; KREBS EG, 1989, JAMA-J AM MED ASSOC, V262, P1815, DOI 10.1001/jama.262.13.1815; Lee SJ, 2000, J IMMUNOL, V165, P4658, DOI 10.4049/jimmunol.165.8.4658; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu F, 2001, AM J PHYSIOL-LUNG C, V280, pL1309, DOI 10.1152/ajplung.2001.280.6.L1309; Luo Y, 2000, J IMMUNOL, V165, P4015, DOI 10.4049/jimmunol.165.7.4015; Luo Y, 2002, GLIA, V39, P19, DOI 10.1002/glia.10079; Mark MD, 1997, J BIOL CHEM, V272, P17238, DOI 10.1074/jbc.272.27.17238; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mayr BM, 2001, P NATL ACAD SCI USA, V98, P10936, DOI 10.1073/pnas.191152098; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Muniz M, 1997, P NATL ACAD SCI USA, V94, P14461, DOI 10.1073/pnas.94.26.14461; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Ransohoff RM, 1999, J NEUROIMMUNOL, V98, P57, DOI 10.1016/S0165-5728(99)00082-X; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Schwaninger M, 2000, GLIA, V31, P51, DOI 10.1002/(SICI)1098-1136(200007)31:1<51::AID-GLIA50>3.0.CO;2-M; Streit WJ, 2001, NEUROBIOL AGING, V22, P909, DOI 10.1016/S0197-4580(01)00290-1; Sun DM, 1997, J NEUROSCI RES, V48, P192; Tanabe S, 1997, J IMMUNOL, V159, P5671; Tani M, 1996, AM J PATHOL, V148, P889; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; Van der Voorn P, 1999, AM J PATHOL, V154, P45, DOI 10.1016/S0002-9440(10)65249-2; Wagner BL, 2000, J BIOL CHEM, V275, P8263, DOI 10.1074/jbc.275.12.8263; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xia MQ, 2000, J NEUROIMMUNOL, V108, P227, DOI 10.1016/S0165-5728(00)00285-X; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Zhang Y, 2002, J BIOL CHEM, V277, P19042, DOI 10.1074/jbc.M112442200; Zhao J, 1998, J CELL BIOCHEM, V71, P36, DOI 10.1002/(SICI)1097-4644(19981001)71:1<36::AID-JCB4>3.0.CO;2-2	56	11	11	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					734	+		10.1096/fj.02-0962fje	http://dx.doi.org/10.1096/fj.02-0962fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586731				2022-12-28	WOS:000181456900029
J	Rodrigues, S; Van Aken, E; Van Bocxlaer, S; Attoub, S; Nguyen, QD; Bruyneel, E; Westley, BR; May, FEB; Thim, L; Mareel, M; Gespach, C; Emami, S				Rodrigues, S; Van Aken, E; Van Bocxlaer, S; Attoub, S; Nguyen, QD; Bruyneel, E; Westley, BR; May, FEB; Thim, L; Mareel, M; Gespach, C; Emami, S			Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling	FASEB JOURNAL			English	Article							ENDOTHELIAL GROWTH-FACTOR; HUMAN CANCER-CELLS; CELLULAR INVASION; BASEMENT-MEMBRANE; EPITHELIAL-CELLS; GENE-EXPRESSION; UP-REGULATION; PS2 GENE; ANGIOGENESIS; HYPOXIA	We previously established that the trefoil peptides (TFFs) pS2, spasmolytic polypeptide, and intestinal trefoil factor are involved in cellular scattering and invasion in kidney and colonic cancer cells. Using the chorioallantoic membrane (CAM) assay and the formation of tube-like structures by human umbilical vein endothelial cells (HUVEC) plated on the Matrigel matrix substratum, we report here that TFFs are proangiogenic factors. Angiogenic activity of TFFs is comparable to that induced by vascular endothelial growth factor, leptin, and transforming growth factor-alpha. Stimulation of angiogenesis by pS2 in the CAM assay is blocked by pharmacological inhibitors of cyclooxygenase COX-2 (NS-398) and epidermal growth factor receptor (EGF-R) tyrosine kinase (ZD1839), but is independent of KDR/Flk-1 and thromboxane A2 receptors. In contrast, the morphogenic switch induced by pS2 in HUVEC cells could be inhibited by the specific KDR heptapeptide antagonist ATWLPPR and by inhibitors of COX-2 and EGF-R signaling. These results implicate TFFs in the formation of new blood vessels during normal and pathophysiological processes linked to wound healing, inflammation, and cancer progression in the digestive mucosa and other human solid tumors associated with aberrant expression of TFFs.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Newcastle Univ, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; Newcastle University - UK; Novo Nordisk	Emami, S (corresponding author), Hop St Antoine, INSERM, U482, F-75571 Paris 12, France.	emami@st-antoine.inserm.fr	Attoub, Samir/N-6852-2018					Andre T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.3.CO;2-5; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; Binetruy-Tournaire R, 2000, EMBO J, V19, P1525, DOI 10.1093/emboj/19.7.1525; BONKHOFF H, 1995, HUM PATHOL, V26, P824, DOI 10.1016/0046-8177(95)90002-0; Bossenmeyer-Pourie C, 2002, J CELL BIOL, V157, P761, DOI 10.1083/jcb200108056; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Castilla MA, 1999, CIRC RES, V85, P1132; Chadwick MP, 1997, BIOCHEM J, V327, P117, DOI 10.1042/bj3270117; Chua CC, 1998, BBA-MOL CELL RES, V1401, P187, DOI 10.1016/S0167-4889(97)00129-8; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; Ciardiello F, 2001, CLIN CANCER RES, V7, P1459; COCKERILL GW, 1994, LAB INVEST, V71, P497; Colombel M, 1999, J UROLOGY, V162, P927, DOI 10.1097/00005392-199909010-00092; Daniel TO, 1999, CANCER RES, V59, P4574; DUBOIS RN, 1994, AM J PHYSIOL, V266, pG822; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FORGUELAFITTE ME, 1980, FEBS LETT, V114, P243, DOI 10.1016/0014-5793(80)81125-2; FORGUELAFITTE ME, 1984, BIOCHIM BIOPHYS ACTA, V798, P192, DOI 10.1016/0304-4165(84)90303-9; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; Gothie E, 2002, M S-MED SCI, V18, P70, DOI 10.1051/medsci/200218170; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARRISHOOKER SA, 1983, J CELL PHYSIOL, V114, P302, DOI 10.1002/jcp.1041140308; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hoffmann W, 2001, HISTOL HISTOPATHOL, V16, P319, DOI 10.14670/HH-16.319; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Jacoby RF, 1996, CANCER RES, V56, P710; Jones MK, 1999, NAT MED, V5, P1418; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Liekens S, 2001, CANCER RES, V61, P5057; Liu D, 1997, LAB INVEST, V77, P557; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Machado JC, 2000, J PATHOL, V190, P437; MARAGOUDAKIS ME, 1988, TISSUE CELL, V20, P531, DOI 10.1016/0040-8166(88)90055-9; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; Masunaga R, 2000, CLIN CANCER RES, V6, P4064; MENDENHALL W, 1994, INTRO PROBABILITY ST, P91; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; Okada F, 2000, LAB INVEST, V80, P1617, DOI 10.1038/labinvest.3780172; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Pai R, 2001, BIOCHEM BIOPH RES CO, V286, P923, DOI 10.1006/bbrc.2001.5494; PASSANITI A, 1992, LAB INVEST, V67, P519; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; Prest SJ, 2002, FASEB J, V16, P592, DOI 10.1096/fj.01-0498fje; Regnauld K, 2002, ONCOGENE, V21, P4020, DOI 10.1038/sj.onc.1205498; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; Rodrigues S, 2001, CLIN CANCER RES, V7, p3771S; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Taupin D, 1999, J CLIN INVEST, V103, pR31, DOI 10.1172/JCI3304; THIM L, 1993, FEBS LETT, V318, P345, DOI 10.1016/0014-5793(93)80543-4; THIM L, 1995, BIOCHEMISTRY-US, V34, P4757, DOI 10.1021/bi00014a033; Tran CP, 1999, GUT, V44, P636, DOI 10.1136/gut.44.5.636; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Vega-Diaz B, 2001, J INVEST DERMATOL, V116, P525, DOI 10.1046/j.1523-1747.2001.01294.x; Vinals F, 2001, MOL CELL BIOL, V21, P7218, DOI 10.1128/MCB.21.21.7218-7230.2001; Wang DG, 1997, INT J CANCER, V74, P270, DOI 10.1002/(SICI)1097-0215(19970620)74:3<270::AID-IJC6>3.0.CO;2-W; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; WOODBURN JR, 1998, CELL MOL BIOL LETT, V3, P348	76	107	112	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					7	16		10.1096/fj.02-0201com	http://dx.doi.org/10.1096/fj.02-0201com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12522107	Green Published			2022-12-28	WOS:000181453700034
J	Baar, K; Wende, AR; Jones, TE; Marison, M; Nolte, LA; Chen, M; Kelly, DP; Holloszy, JO				Baar, K; Wende, AR; Jones, TE; Marison, M; Nolte, LA; Chen, M; Kelly, DP; Holloszy, JO			Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1	FASEB JOURNAL			English	Article						GLUT4; mitochondrial biogenesis; NRF-1; NRF-2	GLUCOSE-TRANSPORT CAPACITY; NUCLEAR RESPIRATORY FACTORS; MITOCHONDRIAL BIOGENESIS; BIOCHEMICAL ADAPTATIONS; ENDURANCE EXERCISE; ENERGY-METABOLISM; GENE-EXPRESSION; MESSENGER-RNA; ACTIVATION; GLUT-4	Endurance exercise induces increases in mitochondria and the GLUT4 isoform of the glucose transporter in muscle. Although little is known about the mechanisms underlying these adaptations, new information has accumulated regarding how mitochondrial biogenesis and GLUT4 expression are regulated. This includes the findings that the transcriptional coactivator PGC-1 promotes mitochondrial biogenesis and that NRF-1 and NRF-2 act as transcriptional activators of genes encoding mitochondrial enzymes. We tested the hypothesis that increases in PGC-1, NRF-1, and NRF-2 are involved in the initial adaptive response of muscle to exercise. Five daily bouts of swimming induced increases in mitochondrial enzymes and GLUT4 in skeletal muscle in rats. One exercise bout resulted in similar to twofold increases in full-length muscle PGC-1 mRNA and PGC-1 protein, which were evident 18 h after exercise. A smaller form of PGC-1 increased after exercise. The exercise induced increases in muscle NRF-1 and NRF-2 that were evident 12 to 18 h after one exercise bout. These findings suggest that increases in PGC-1, NRF-1, and NRF-2 represent key regulatory components of the stimulation of mitochondrial biogenesis by exercise and that PGC-1 mediates the coordinated increases in GLUT4 and mitochondria.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Holloszy, JO (corresponding author), Washington Univ, Sch Med, Dept Med, Campus Box 8113,4566 Scott Ave, St Louis, MO 63110 USA.	jhollosz@im.wustl.edu	Kelly, Daniel/ABG-2056-2021; Wende, Adam/AFG-8878-2022	Wende, Adam/0000-0002-5536-4675; Baar, Keith/0000-0001-9337-6186	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045416, R01DK045416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG000425, R56AG000425, R01AG000425] Funding Source: NIH RePORTER; NIA NIH HHS [AG00078, AG00425] Funding Source: Medline; NIDDK NIH HHS [DK45416] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNARD RJ, 1970, J APPL PHYSIOL, V28, P762, DOI 10.1152/jappl.1970.28.6.762; Booth F, 1977, Ann N Y Acad Sci, V301, P431, DOI 10.1111/j.1749-6632.1977.tb38219.x; BOOTH FW, 1997, HDB PHYSL 12, P1075; BRAIDOTTI G, 1993, J BIOL CHEM, V268, P1109; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; CASLA A, 1990, BIOCHEM BIOPH RES CO, V171, P182, DOI 10.1016/0006-291X(90)91374-2; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; CHI MMY, 1983, AM J PHYSIOL, V244, pC276, DOI 10.1152/ajpcell.1983.244.3.C276; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; CONSTABLE SH, 1987, AM J PHYSIOL, V253, pC316, DOI 10.1152/ajpcell.1987.253.2.C316; COYLE EF, 1985, J APPL PHYSIOL, V59, P853, DOI 10.1152/jappl.1985.59.3.853; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY GA, 1987, J BIOL CHEM, V262, P9109; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FOSTER DO, 1979, CAN J PHYSIOL PHARM, V57, P257, DOI 10.1139/y79-039; FRIEDMAN JE, 1990, FEBS LETT, V268, P13, DOI 10.1016/0014-5793(90)80960-Q; GOODYEAR LJ, 1992, DIABETES, V41, P1091, DOI 10.2337/diabetes.41.9.1091; Goto M, 2000, BIOCHEM BIOPH RES CO, V274, P350, DOI 10.1006/bbrc.2000.3134; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; HOLLOSZY JO, 1979, AM J PHYSIOL, V236, pR180, DOI 10.1152/ajpregu.1979.236.3.R180; HOLLOSZY JO, 1970, BIOCHEM BIOPH RES CO, V40, P1368, DOI 10.1016/0006-291X(70)90017-3; HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; Holmes BF, 1999, J APPL PHYSIOL, V87, P1990, DOI 10.1152/jappl.1999.87.5.1990; Hood D A, 2000, Exerc Sport Sci Rev, V28, P68; Hood DA, 2001, J APPL PHYSIOL, V90, P1137, DOI 10.1152/jappl.2001.90.3.1137; HOPPELER H, 1973, PFLUG ARCH EUR J PHY, V344, P217, DOI 10.1007/BF00588462; Kakuma T, 2000, ENDOCRINOLOGY, V141, P4576, DOI 10.1210/en.141.12.4576; KERN M, 1990, BIOCHEM J, V270, P397, DOI 10.1042/bj2700397; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Li B, 1999, J BIOL CHEM, V274, P17534, DOI 10.1074/jbc.274.25.17534; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; MOLE PA, 1971, J CLIN INVEST, V50, P2323, DOI 10.1172/JCI106730; MURAKAMI S, 1998, J PLASMA FUSION RES, V1, P122; Ojuka EO, 2000, J APPL PHYSIOL, V88, P1072, DOI 10.1152/jappl.2000.88.3.1072; OSCAI LB, 1971, J BIOL CHEM, V246, P6968; PETTE D, 1992, REV PHYSIOL BIOCH P, V120, P115, DOI 10.1007/BFb0036123; PLOUG T, 1990, AM J PHYSIOL, V259, pE778, DOI 10.1152/ajpendo.1990.259.6.E778; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; REN JM, 1993, AM J PHYSIOL, V264, pC146, DOI 10.1152/ajpcell.1993.264.1.C146; REN JM, 1994, J BIOL CHEM, V269, P14396; Scarpulla RC, 1996, TRENDS CARDIOVAS MED, V6, P39, DOI 10.1016/1050-1738(95)00129-8; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; WATSON JD, 1995, GENE, V158, P275, DOI 10.1016/0378-1119(95)00029-6; WEINSTEIN SP, 1994, DIABETES, V43, P1185, DOI 10.2337/diabetes.43.10.1185; WINDER WW, 1974, EUR J BIOCHEM, V47, P461, DOI 10.1111/j.1432-1033.1974.tb03713.x; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; YAN Z, 1995, AM J PHYSIOL-ENDOC M, V268, pE277, DOI 10.1152/ajpendo.1995.268.2.E277	54	739	770	3	83	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					1879	1886		10.1096/fj.02-0367com	http://dx.doi.org/10.1096/fj.02-0367com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12468452				2022-12-28	WOS:000180574300008
J	Bruton, JD; Lemmens, R; Shi, CL; Persson-Sjogren, S; Westerblad, H; Ahmed, M; Pyne, NJ; Frame, M; Furman, BL; Islam, MS				Bruton, JD; Lemmens, R; Shi, CL; Persson-Sjogren, S; Westerblad, H; Ahmed, M; Pyne, NJ; Frame, M; Furman, BL; Islam, MS			Ryanodine receptors of pancreatic-cells mediate a distinct context-dependent signal for insulin secretion	FASEB JOURNAL			English	Article						calcium signaling; islets of Langerhans; calcium-induced calcium release; diabetes	CA2+-INDUCED CA2+ RELEASE; ADENOSINE 3'-5'-CYCLIC MONOPHOSPHATE; BETA-CELLS; ENDOPLASMIC-RETICULUM; CALCIUM-RELEASE; SARCOPLASMIC-RETICULUM; PHOSPHODIESTERASE ACTIVITY; SMOOTH-MUSCLE; K+ CHANNELS; CAFFEINE	The ryanodine (RY) receptors in beta-cells amplify signals by Ca(2+)-induced Ca(2+) release (CICR). The role of CICR in insulin secretion remains unclear in spite of the fact that caffeine is known to stimulate secretion. This effect of caffeine is attributed solely to the inhibition of cAMP-phosphodiesterases (cAMP-PDEs). We demonstrate that stimulation of insulin secretion by caffeine is due to a sensitization of the RY receptors. The dose-response relationship of caffeine-induced inhibition of cAMP-PDEs was not correlated with the stimulation of insulin secretion. Sensitization of the RY receptors stimulated insulin secretion in a context-dependent manner, that is, only in the presence of a high concentration of glucose. This effect of caffeine depended on an increase in [Ca(2+)](i). Confocal images of beta-cells demonstrated an increase in [Ca(2+)](i) induced by caffeine but not by forskolin. 9-Methyl-7-bromoeudistomin D (MBED), which sensitizes RY receptors, did not inhibit cAMP-PDEs, but it stimulated secretion in a glucose-dependent manner. The stimulation of secretion by caffeine and MBED involved both the first and the second phases of secretion. We conclude that the RY receptors of beta-cells mediate a distinct glucose-dependent signal for insulin secretion and may be a target for developing drugs that will stimulate insulin secretion only in a glucose-dependent manner.	Karolinska Inst, Karolinska Hosp, Dept Mol Med, Dept Endocrinol, S-17176 Stockholm, Sweden; Karolinska Inst, Dept Physiol, S-10401 Stockholm, Sweden; Umea Univ, Dept Integrat Med Biol, Sect Histol & Cell Biol, Umea, Sweden; Univ Strathclyde, Dept Physiol & Pharmacol, Strathclyde Inst Biomed Sci, Glasgow G1 1XW, Lanark, Scotland	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Umea University; University of Strathclyde	Islam, MS (corresponding author), Karolinska Inst, Karolinska Hosp, Dept Mol Med, Dept Endocrinol, L6B-01, S-17176 Stockholm, Sweden.	Shahidul.Islam@molmed.ki.se	Islam, Shahidul/K-3295-2019	Islam, Shahidul/0000-0002-9016-1881; Westerblad, Hakan/0000-0002-8180-3029; Bruton, Joseph/0000-0002-6985-099X; Pyne, Nigel/0000-0002-5657-4578				Ahmad M, 2000, BRIT J PHARMACOL, V129, P1228, DOI 10.1038/sj.bjp.0703165; Alonso MT, 1999, J CELL BIOL, V144, P241, DOI 10.1083/jcb.144.2.241; BEAVO JA, 1970, MOL PHARMACOL, V6, P597; CAPITO K, 1976, BIOCHEM J, V158, P335, DOI 10.1042/bj1580335; Cavallaro RA, 1999, J MED CHEM, V42, P2527, DOI 10.1021/jm980469t; COOPER RH, 1973, BIOCHEM J, V134, P599, DOI 10.1042/bj1340599; DONOSO P, 1994, BRIT J PHARMACOL, V111, P455, DOI 10.1111/j.1476-5381.1994.tb14757.x; Dukes ID, 1998, J BIOL CHEM, V273, P24457, DOI 10.1074/jbc.273.38.24457; Gamberucci A, 1999, FEBS LETT, V446, P309, DOI 10.1016/S0014-5793(99)00220-3; HernandezCruz A, 1997, J GEN PHYSIOL, V109, P147, DOI 10.1085/jgp.109.2.147; HILLAIREBUYS D, 1987, EUR J PHARMACOL, V136, P109, DOI 10.1016/0014-2999(87)90786-2; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; ISLAM MS, 1992, FEBS LETT, V296, P287, DOI 10.1016/0014-5793(92)80306-2; ISLAM MS, 1995, BIOCHEM J, V306, P679, DOI 10.1042/bj3060679; Islam MS, 1998, DIABETOLOGIA, V41, pA37; Islam MS, 2002, DIABETES, V51, P1299, DOI 10.2337/diabetes.51.5.1299; ISLAM MS, 1993, BIOCHEM J, V293, P423, DOI 10.1042/bj2930423; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; Kang GX, 2001, J PHYSIOL-LONDON, V536, P375, DOI 10.1111/j.1469-7793.2001.0375c.xd; Kermode H, 1998, FEBS LETT, V431, P59, DOI 10.1016/S0014-5793(98)00725-X; Koizumi S, 1999, NEURON, V22, P125, DOI 10.1016/S0896-6273(00)80684-4; Lemmens R, 2001, J BIOL CHEM, V276, P9971, DOI 10.1074/jbc.M009463200; Maechler P, 2000, IUBMB LIFE, V50, P27, DOI 10.1080/15216540050176557; MCNULTY TJ, 1993, BIOCHEM J, V291, P799, DOI 10.1042/bj2910799; Mears D, 1999, DIABETES, V48, pA443; Mitchell KJ, 2001, J CELL BIOL, V155, P41, DOI 10.1083/jcb.200103145; MULLER CE, 1993, BIOCHEM PHARMACOL, V46, P1825, DOI 10.1016/0006-2952(93)90589-O; Ohi Y, 2001, JPN J PHARMACOL, V85, P382, DOI 10.1254/jjp.85.382; Porta M, 2002, BIOPHYS J, V82, p82A; Pyne NJ, 1997, BIOCHEM J, V328, P689; Qian WJ, 2001, BIOCHEM BIOPH RES CO, V286, P315, DOI 10.1006/bbrc.2001.5379; ROE MW, 1993, J BIOL CHEM, V268, P9953; ROUSSEAU E, 1988, ARCH BIOCHEM BIOPHYS, V267, P75, DOI 10.1016/0003-9861(88)90010-0; SAMS DJ, 1972, BIOCHEM J, V129, P945, DOI 10.1042/bj1290945; Seino-Umeda A, 1998, EUR J PHARMACOL, V357, P261, DOI 10.1016/S0014-2999(98)00589-5; Shi CL, 1997, CELL TRANSPLANT, V6, P33, DOI 10.1016/S0963-6897(96)00181-9; Takasawa S, 1998, J BIOL CHEM, V273, P2497, DOI 10.1074/jbc.273.5.2497; TANIGUCHI T, 1996, ENDOCRINOL METAB, V3, P135; Tengholm A, 1999, J BIOL CHEM, V274, P36883, DOI 10.1074/jbc.274.52.36883; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Varadi A, 2002, DIABETES, V51, pS190, DOI 10.2337/diabetes.51.2007.S190; Wissing F, 2002, BIOCHEM J, V361, P605, DOI 10.1042/0264-6021:3610605; Yu GY, 2000, BASIC RES CARDIOL, V95, P137, DOI 10.1007/s003950050175; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200	44	48	54	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2002	16	14					301	+		10.1096/fj.02-0481fje	http://dx.doi.org/10.1096/fj.02-0481fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475892				2022-12-28	WOS:000180574300016
J	Gabriel, C; Ali, C; Lesne, S; Fernandez-Monreal, M; Docagne, F; Plawinski, L; MacKenzie, ET; Buisson, A; Vivien, D				Gabriel, C; Ali, C; Lesne, S; Fernandez-Monreal, M; Docagne, F; Plawinski, L; MacKenzie, ET; Buisson, A; Vivien, D			Transforming growth factor alpha-induced expression of type-1 plasminogen activator inhibitor in astrocytes rescues neurons from excitotoxicity	FASEB JOURNAL			English	Article						PAI-1; neuroprotection; ischemia	FOCAL CEREBRAL-ISCHEMIA; METABOTROPIC GLUTAMATE-RECEPTOR; REDUCES INFARCT VOLUME; NEUROTROPHIC FACTOR; RAT-BRAIN; UP-REGULATION; TGF-ALPHA; KINASE; SURVIVAL; INJURY	Although transforming growth factor (TGF)-alpha, a member of the epidermal growth factor (EGF) family, has been shown to protect neurons against excitotoxic and ischemic brain injuries, its mechanism of action remains unknown. In the present study, we used in vitro models of apoptotic or necrotic paradigms demonstrating that TGF-alpha rescues neurons from N-methyl-D-aspartate (NMDA)-induced excitotoxic death, with the obligatory presence of astrocytes. Because neuronal tissue-type plasminogen activator (t-PA) release was shown to potentiate NMDA-induced excitotoxicity, we observed that TGF-alpha treatment reduced NMDA-induced increase of t-PA activity in mixed cultures of neurons and astrocytes. In addition, we showed that although TGF-alpha induces activation of the extracellular signal-regulated kinases (ERKs) in astrocytes, it failed to activate p42/p44 in neurons. Finally, we showed that TGF-alpha, by an ERK-dependent mechanism, stimulates the astrocytic expression of PAI-1, a t-PA inhibitor, which mediates the neuroprotective activity of TGF-alpha against NMDA-mediated excitotoxic neuronal death. Taken together, we indicate that TGF-alpha rescues neurons from NMDA-induced excitotoxicity in mixed cultures through inhibition of t-PA activity, involving PAI-1 overexpression by an ERK-dependent pathway in astrocytes.	Univ Caen, CNRS, UMR 6551, Ctr CYCERON, F-14074 Caen, France	Centre National de la Recherche Scientifique (CNRS); Universite de Caen Normandie	Vivien, D (corresponding author), Univ Caen, CNRS, UMR 6551, Ctr CYCERON, IFR 47,Bd H Becquerel,BP 5229, F-14074 Caen, France.	a.buisson@neuro.unicaen.fr; d.vivien@neuro.unicaen.fr	Docagne, Fabian/S-8308-2018; Mackenzie, Eric Thomson/L-1938-2015; Monreal, Monica Fernandez/P-6685-2019; buisson, alain/AAI-8218-2020; Fernandez-Monreal, Mónica/I-7954-2012	Monreal, Monica Fernandez/0000-0001-7278-448X; buisson, alain/0000-0002-4281-7911; Fernandez-Monreal, Mónica/0000-0001-7278-448X; Lesne, Sylvain/0000-0001-9411-1868; Ali, Carine/0000-0001-8007-7910; Docagne, Fabian/0000-0003-1745-0625; VIVIEN, DENIS/0000-0002-7636-2185; MacKenzie, Eric T/0000-0003-1057-7033; Plawinski, Laurent/0000-0002-5288-4413				ALEXI T, 1993, NEUROSCIENCE, V55, P903, DOI 10.1016/0306-4522(93)90307-2; Alexi T, 1997, NEUROSCIENCE, V78, P73, DOI 10.1016/S0306-4522(97)83046-1; Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; Boillee S, 2001, J NEUROSCI, V21, P7079, DOI 10.1523/JNEUROSCI.21-18-07079.2001; Buisson A, 1998, FASEB J, V12, P1683, DOI 10.1096/fasebj.12.15.1683; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1997, AM J PHYSIOL-HEART C, V273, pH2091, DOI 10.1152/ajpheart.1997.273.5.H2091; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Deb TB, 2001, J BIOL CHEM, V276, P15554, DOI 10.1074/jbc.M100928200; Debrock S, 1997, BBA-PROTEIN STRUCT M, V1337, P257, DOI 10.1016/S0167-4838(96)00173-2; FERRER I, 1995, NEUROSCIENCE, V66, P189, DOI 10.1016/0306-4522(94)00584-R; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; GOMEZPINILLA F, 1988, BRAIN RES, V438, P385, DOI 10.1016/0006-8993(88)91369-8; Hailer NP, 2001, EUR J NEUROSCI, V14, P315, DOI 10.1046/j.0953-816x.2001.01649.x; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hanson MG, 1998, J NEUROSCI, V18, P7361; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Junier MP, 2000, PROG NEUROBIOL, V62, P443, DOI 10.1016/S0301-0082(00)00017-4; Justicia C, 1999, J CEREBR BLOOD F MET, V19, P128, DOI 10.1097/00004647-199902000-00002; Justicia C, 2001, J CEREBR BLOOD F MET, V21, P1097, DOI 10.1097/00004647-200109000-00007; KOH JY, 1992, BRAIN RES, V587, P233, DOI 10.1016/0006-8993(92)91002-V; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Komesli S, 1998, EUR J BIOCHEM, V254, P505, DOI 10.1046/j.1432-1327.1998.2540505.x; Kornblum HI, 1997, J COMP NEUROL, V380, P243, DOI 10.1002/(SICI)1096-9861(19970407)380:2<243::AID-CNE7>3.0.CO;2-3; KUMAR V, 1995, CELL BIOL INT, V19, P373, DOI 10.1006/cbir.1995.1083; LAZAR LM, 1992, J NEUROSCI, V12, P1688; LEE DC, 1995, PHARMACOL REV, V47, P51; LeMagueresseBattistoni B, 1996, ENDOCRINOLOGY, V137, P4243, DOI 10.1210/en.137.10.4243; Liu YM, 2000, NEUROSCI LETT, V282, P137, DOI 10.1016/S0304-3940(00)00860-0; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MILLER S, 1995, J NEUROSCI, V15, P6103; Minoshima T, 1999, J BIOCHEM-TOKYO, V126, P889, DOI 10.1093/oxfordjournals.jbchem.a022531; MORRISON RS, 1987, SCIENCE, V238, P72, DOI 10.1126/science.3498986; Nicole O, 2001, J NEUROSCI, V21, P3024, DOI 10.1523/JNEUROSCI.21-09-03024.2001; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Perez-Navarro E, 2000, J NEUROCHEM, V75, P2190, DOI 10.1046/j.1471-4159.2000.0752190.x; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Rabchevsky AG, 1998, J NEUROSCI, V18, P10541, DOI 10.1523/jneurosci.18-24-10541.1998; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Rose K, 1993, IN VITRO BIOL METHOD, P46; Ruocco A, 1999, J CEREBR BLOOD F MET, V19, P1345, DOI 10.1097/00004647-199912000-00008; Sandberg T, 1997, MOL HUM REPROD, V3, P781, DOI 10.1093/molehr/3.9.781; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Schabitz WR, 2000, STROKE, V31, P2212, DOI 10.1161/01.STR.31.9.2212; SEROOGY KB, 1995, BRAIN RES, V670, P157, DOI 10.1016/0006-8993(94)01300-7; SPORN MB, 1990, CELL REGUL, V1, P875, DOI 10.1091/mbc.1.12.875; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; YAMADA M, 1995, EUR J NEUROSCI, V7, P2130, DOI 10.1111/j.1460-9568.1995.tb00635.x; Zelenaia O, 2000, MOL PHARMACOL, V57, P667, DOI 10.1124/mol.57.4.667; Zhou RX, 2001, BRAIN RES BULL, V56, P37, DOI 10.1016/S0361-9230(01)00591-3	60	42	47	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					277	+		10.1096/fj.02-0403fje	http://dx.doi.org/10.1096/fj.02-0403fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12490542				2022-12-28	WOS:000180574300035
J	Mazzucato, M; Cozzi, MR; Pradella, P; Perissinotto, D; Malmstrom, A; Morgelin, M; Spessotto, P; Colombatti, A; De Marco, L; Perris, R				Mazzucato, M; Cozzi, MR; Pradella, P; Perissinotto, D; Malmstrom, A; Morgelin, M; Spessotto, P; Colombatti, A; De Marco, L; Perris, R			Vascular PG-M/versican variants promote platelet adhesion at low shear rates and cooperate with collagens to induce aggregation	FASEB JOURNAL			English	Article						proteoglycan; hemostasis; shear stress	VON-WILLEBRAND-FACTOR; HUMAN ATHEROSCLEROTIC LESIONS; SMOOTH-MUSCLE CELLS; SULFATE PROTEOGLYCAN; THROMBUS FORMATION; BOVINE AORTA; FLOW CONDITIONS; VI COLLAGEN; I COLLAGEN; FIBRINOGEN	We have identified a novel von Willebrand factor/fibrinogen/selectin-independent, platelet adhesion-promoting function of vascular PG-M/versicans that may be relevant in normal venous thrombosis and critical in atherosclerotic conditions. A purification scheme was devised to obtain vascular versicans, which by biochemical, immunochemical, and ultrastructural means were asserted to be 1) composed primarily of isoforms V1 and V2; 2) free of contaminants; 3) prevalently substituted with chondroitin-4-sulfate and dermatan sulfate (DS) chains; and 4) capable of binding hyaluronan to form link protein-stabilized ternary complexes. Real-time analysis of human platelet perfused under diverse shear forces showed that they largely failed to bind to several vascular and nonvascular proteoglycans (PGs). In contrast, they bound in a dose- and shear rate-dependent manner to vascular versicans, exhibiting a unique attachment-detachment kinetics and establishing a firm substrate tethering characterized with no significant aggregation. Digestion of these PGs with lyases and competition experiments with purified glycosaminoglycans revealed that platelet adhesion to vascular versicans was primarily mediated by their DS chains. Incorporation of the versicans into fibrillar collagen substrates augmented their adhesive activity and strongly promoted platelet aggregation at low and high shear rates. Affinity chromatography of platelet surfaces on DS columns identified a 120-140 kDa polypeptide complex that behaved as a specific vascular versican binding membrane ligand in solid-phase binding assays. These findings indicate that selective versican variants of the subendothelium may serve as ancillary GPIbalpha/integrin/selectin-independent platelet ligands in healthy and diseased vascular beds and may be directly responsible for the platelet accruing after rupture of atherosclerotic plaques., versican variants promote platelet adhesion at low shear rates and cooperate with collagens to induce aggregation.	Univ Parma, Dept Evolutionary & Funct Biol, I-43100 Parma, Italy; IRCCS, CRO, Natl Canc Inst, Div Expt Oncol 2, I-33081 Aviano, PN, Italy; Lund Univ, Dept Cell & Mol Biol, S-22184 Lund, Sweden; Univ Udine, MATI Ctr Excellence, I-35100 Udine, Italy	University of Parma; IRCCS Aviano (CRO); Lund University; University of Udine	De Marco, L (corresponding author), Univ Parma, Dept Evolutionary & Funct Biol, Viale Sci 11-A, I-43100 Parma, Italy.	ldemarco@cro.it; rperris@cro.it	Spessotto, Paola/K-5005-2012; Mazzucato, Mario/ABF-5472-2020; Cozzi, Maria Rita/ABD-7970-2020	Spessotto, Paola/0000-0002-3033-404X; Mazzucato, Mario/0000-0001-8319-053X; Cozzi, Maria Rita/0000-0001-6841-2632; colombatti, alfonso/0000-0002-3676-2379; Malmstrom, Anders/0000-0002-6691-146X				AKIYAMA F, 1987, ARCH BIOCHEM BIOPHYS, V252, P574, DOI 10.1016/0003-9861(87)90065-8; Andre P, 2000, BLOOD, V96, P3322, DOI 10.1182/blood.V96.10.3322.h8003322_3322_3328; Barnes M J, 1998, Curr Opin Hematol, V5, P314, DOI 10.1097/00062752-199809000-00002; Baumann H, 1997, SEMIN THROMB HEMOST, V23, P203, DOI 10.1055/s-2007-996092; Bennett JS, 1997, J BIOL CHEM, V272, P8137, DOI 10.1074/jbc.272.13.8137; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; CADROY Y, 1993, ARTERIOSCLER THROMB, V13, P1213, DOI 10.1161/01.ATV.13.8.1213; Cerletti C, 1999, THROMB HAEMOSTASIS, V82, P787; CHENG F, 1994, GLYCOBIOLOGY, V4, P685, DOI 10.1093/glycob/4.5.685; Clemetson KJ, 1999, CURR BIOL, V9, pR110, DOI 10.1016/S0960-9822(99)80063-3; DALFERES ER, 1987, EXP MOL PATHOL, V47, P363, DOI 10.1016/0014-4800(87)90019-0; DAVIES CA, 2001, OXIDAT STRESS DIS, V7, P17; Eriksen GV, 1999, BIOCHEM J, V340, P613, DOI 10.1042/0264-6021:3400613; Evanko SP, 1998, AM J PATHOL, V152, P533; FABRIS F, 1992, THROMB RES, V66, P409, DOI 10.1016/0049-3848(92)90290-Q; Fay WP, 1999, BLOOD, V93, P1825, DOI 10.1182/blood.V93.6.1825.406k37_1825_1830; FRANSSON LA, 1979, BIOCHIM BIOPHYS ACTA, V586, P179, DOI 10.1016/0304-4165(79)90416-1; Geberhiwot T, 1999, EXP CELL RES, V253, P723, DOI 10.1006/excr.1999.4653; Godyna S, 1996, BLOOD, V88, P2569, DOI 10.1182/blood.V88.7.2569.bloodjournal8872569; Ismail NAE, 1997, INT J EXP PATHOL, V78, P71, DOI 10.1046/j.1365-2613.1997.d01-242.x; ISOGAI Z, 2001, IN PRESS J BIOL CHEM; Johnson HJ, 1997, J BIOL CHEM, V272, P18709, DOI 10.1074/jbc.272.30.18709; KAPOOR R, 1986, BIOCHEM J, V240, P575, DOI 10.1042/bj2400575; Kauhanen P, 2000, ARTERIOSCL THROM VAS, V20, pE113, DOI 10.1161/01.ATV.20.11.e113; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; KEHREL B, 1993, BLOOD, V82, P3364; Kroll MH, 1996, BLOOD, V88, P1525; KUO HJ, 1995, EUR J BIOCHEM, V232, P364, DOI 10.1111/j.1432-1033.1995.364zz.x; LARK MW, 1988, J HISTOCHEM CYTOCHEM, V36, P1211, DOI 10.1177/36.10.3047228; Lemire JM, 1999, ARTERIOSCL THROM VAS, V19, P1630, DOI 10.1161/01.ATV.19.7.1630; Lethias C, 1996, INT ANGIOL, V15, P104; Matsuura R, 1996, J PATHOL, V180, P311, DOI 10.1002/(SICI)1096-9896(199611)180:3<311::AID-PATH657>3.0.CO;2-B; Mazzucato M, 1999, J BIOL CHEM, V274, P3033, DOI 10.1074/jbc.274.5.3033; MCMURTREY J, 1979, J BIOL CHEM, V254, P1621; Merten M, 2000, CIRCULATION, V102, P1931, DOI 10.1161/01.CIR.102.16.1931; Miura S, 2000, J BIOL CHEM, V275, P7539, DOI 10.1074/jbc.275.11.7539; MORGELIN M, 1989, J BIOL CHEM, V264, P12080; Moroi M, 1997, BLOOD, V90, P4413; Nakamura T, 1998, J BIOL CHEM, V273, P4338, DOI 10.1074/jbc.273.8.4338; NAKASHIMA Y, 1992, ARTERY, V19, P256; Ni HY, 2000, J CLIN INVEST, V106, P385, DOI 10.1172/JCI9896; Nugent MA, 2000, P NATL ACAD SCI USA, V97, P6722, DOI 10.1073/pnas.97.12.6722; OEGEMA TR, 1979, J BIOL CHEM, V254, P1312; Perissinotto D, 2000, DEVELOPMENT, V127, P2823; RADHAKRISHNAMURTHY B, 1986, BIOCHIM BIOPHYS ACTA, V882, P85, DOI 10.1016/0304-4165(86)90059-0; RICHARDSON M, 1993, EXP MOL PATHOL, V58, P77, DOI 10.1006/exmp.1993.1007; Ruggeri ZM, 2000, J CLIN INVEST, V105, P699, DOI 10.1172/JCI9604; Ruggeri ZM, 1999, BLOOD, V94, P172, DOI 10.1182/blood.V94.1.172.413k17_172_178; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; SRINIVASAN SR, 1988, ATHEROSCLEROSIS, V72, P1, DOI 10.1016/0021-9150(88)90056-1; TANGELDER GJ, 1988, AM J PHYSIOL, V254, pH1059, DOI 10.1152/ajpheart.1988.254.6.H1059; TSAO CH, 1981, LAB INVEST, V45, P450; Tsuji S, 1999, BLOOD, V94, P968, DOI 10.1182/blood.V94.3.968.415a13_968_975; VANZANTEN GH, 1994, J CLIN INVEST, V93, P615, DOI 10.1172/JCI117014; vanZanten GH, 1996, BLOOD, V88, P3862, DOI 10.1182/blood.V88.10.3862.bloodjournal88103862; Vasudevan S, 2000, J BIOL CHEM, V275, P12763, DOI 10.1074/jbc.275.17.12763; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6; Zaidi TN, 1996, BLOOD, V88, P2967, DOI 10.1182/blood.V88.8.2967.bloodjournal8882967	60	30	32	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					1903	1916		10.1096/fj.02-0382com	http://dx.doi.org/10.1096/fj.02-0382com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12468455				2022-12-28	WOS:000180574300011
J	McMahon, B; Mitchell, D; Shattock, R; Martin, F; Brady, HR; Godson, C				McMahon, B; Mitchell, D; Shattock, R; Martin, F; Brady, HR; Godson, C			Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation	FASEB JOURNAL			English	Article						eicosanoids; GPCR; RTK; transactivation	ACTIVATED PROTEIN-KINASE; GROWTH; A(4); B-4; IDENTIFICATION; NEUTROPHILS; INHIBITION; ROLES; RAS	The lipoxygenase-derived leukotrienes (LTs) are important proinflammatory lipid mediators. Lipoxins (LXs), more recently described lipoxygenase products, modulate many proinflammatory actions of LTs and have impressive proresolution properties. Mesangial cell (MC) proliferation is a central event in the pathogenesis of glomerulonephritis. LTD4-induced proliferation of mesangial cells is modulated by LXA(4). Here, we demonstrate that LXA(4) inhibits PDGF- and LTD4-stimulated proliferation through modulation of platelet-derived growth factor receptor beta (PDGFRbeta) activation. Specifically, we demonstrate that LTD4 transactivates the PDGFRbeta, a process associated with c-src recruitment and ras activation. We demonstrate expression of cysLT(1) and cysLT(2) receptors in MCs. LTD4-induced c-src activation was insensitive to pertussis toxin and the cysLT(1) receptor antagonist Zafirlukast but was blocked by the nonselective antagonist Pobilukast. We show that LXA(4) inhibits LTD4-stimulated activation of the PDGFRbeta and that LXA(4) modulates PDGF-BB-stimulated tyrosine phosphorylation of the PDGFRbeta and subsequent mitogenic events. Furthermore, expression of recombinant LXA(4) receptor (ALXR) in CHOK1 cells was associated with an attenuation of serum-stimulated proliferation. These data demonstrate that LXA(4) receptor (ALXR) activation is accompanied by antimitogenic effects coupled with inactivation of growth factor receptors, highlighting the complex cross-talk between G protein-coupled receptors and receptor tyrosine kinases in an inflammatory milieu. These data elaborate on the profile of cell signaling events that underpin the anti-inflammatory and proresolution bioactions of LX.	Univ Coll Dublin, Dept Med & Therapeut, Dublin 7, Ireland; Mater Misericordiae Univ Hosp, Dept Med & Therapeut, Ctr Mol Inflammat & Vasc Res, Dublin 7, Ireland; Univ Coll Dublin, Dept Pharmacol, Dublin 7, Ireland; Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 7, Ireland; Dublin Mol Med Ctr, Dublin, Ireland	University College Dublin; Mater Misericordiae University Hospital; University College Dublin; University College Dublin; University College Dublin; Trinity College Dublin; University College Dublin	Godson, C (corresponding author), Univ Coll Dublin, Dept Med & Therapeut, 41 Eccles St, Dublin 7, Ireland.	cgodson@mater.ie		Godson, Catherine/0000-0003-0655-1041				BADR KF, 1989, P NATL ACAD SCI USA, V86, P3438, DOI 10.1073/pnas.86.9.3438; BADR KF, 1992, J AM SOC NEPHROL, V3, P907; BADR KF, 1988, J CLIN INVEST, V81, P1702, DOI 10.1172/JCI113509; BARNETT R, 1986, AM J PHYSIOL, V250, pF838, DOI 10.1152/ajprenal.1986.250.5.F838; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Bokemeyer D, 2000, KIDNEY INT, V58, P549, DOI 10.1046/j.1523-1755.2000.t01-1-00201.x; BRADY HR, 1990, AM J PHYSIOL, V259, pF809, DOI 10.1152/ajprenal.1990.259.5.F809; Chiang N, 1999, J CLIN INVEST, V104, P309, DOI 10.1172/JCI7016; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; Gilbert RE, 2001, KIDNEY INT, V59, P1324, DOI 10.1046/j.1523-1755.2001.0590041324.x; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; Grewal JS, 2001, J BIOL CHEM, V276, P27335, DOI 10.1074/jbc.M103578200; Gronert K, 2001, AM J PATHOL, V158, P3, DOI 10.1016/S0002-9440(10)63937-5; Harris RC, 2000, KIDNEY INT, V58, P898, DOI 10.1046/j.1523-1755.2000.00240.x; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; KATOH T, 1993, J CLIN INVEST, V91, P1507, DOI 10.1172/JCI116356; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; LEE TH, 1991, BIOCHEM BIOPH RES CO, V180, P1416, DOI 10.1016/S0006-291X(05)81354-3; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Lynch KR, 1999, NATURE, V399, P789; McMahon B, 2001, TRENDS PHARMACOL SCI, V22, P391, DOI 10.1016/S0165-6147(00)01771-5; McMahon B, 2000, J BIOL CHEM, V275, P27566; Mene P, 2001, J NEPHROL, V14, P198; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601, DOI 10.1124/mol.58.6.1601; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; Panettieri RA, 1998, AM J RESP CELL MOL, V19, P453, DOI 10.1165/ajrcmb.19.3.2999; Papayianni A, 1996, J IMMUNOL, V156, P2264; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; SASAKI S, 1994, EXP NEPHROL, V2, P269; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Serhan CN, 1997, PROSTAG OTH LIPID M, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; WU SH, 1994, IMMUNOPHARMACOLOGY, V28, P125, DOI 10.1016/0162-3109(94)90028-0	38	108	116	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13	1				1817	+		10.1096/fj.02-0416fje	http://dx.doi.org/10.1096/fj.02-0416fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223454				2022-12-28	WOS:000181189100008
J	Sato, K; Kadiiska, MB; Ghio, AJ; Corbett, J; Fann, YC; Holland, SM; Thurman, RG; Mason, RP				Sato, K; Kadiiska, MB; Ghio, AJ; Corbett, J; Fann, YC; Holland, SM; Thurman, RG; Mason, RP			In vivo lipid-derived free radical formation by NADPH oxidase in acute lung injury induced by lipopolysaccharide: a model for ARDS	FASEB JOURNAL			English	Article						spin trapping; knockout mice; GdCl3	GADOLINIUM CHLORIDE; XANTHINE-OXIDASE; SOYBEAN LIPOXYGENASE; ISCHEMIA-REPERFUSION; KUPFFER CELLS; SEPTIC SHOCK; RAT-LIVER; ENDOTOXIN; PEROXIDATION; LEUKOCYTES	Intratracheal instillation of lipopolysaccharide (LPS) activates alveolar macrophages and infiltration of neutrophils, causing lung injury/acute respiratory distress syndrome. Free radicals are a special focus as the final causative molecules in the pathogenesis of lung injury caused by LPS. Although in vitro investigation has demonstrated radical generation after exposure of cells to LPS, in vivo evidence is lacking. Using electron spin resonance (ESR) and the spin trap alpha-(4-pyridyl-1-oxide)-N-tert-butylnitrone (POBN), we investigated in vivo free radical production by rats treated with intratracheal instillation of LPS. ESR spectroscopy of lipid extract from lungs exposed to LPS for 6 h gave a spectrum consistent with that of a POBN/carbon-centered radical adduct (a(N) =14.94+/-0.07 G and a(beta)(H)=2.42+/-0.06 G) tentatively assigned as a product of lipid peroxidation. To further investigate the mechanism of LPS-initiated free radical generation, rats were pretreated with the phagocytic toxicant GdCl3, which significantly decreased the production of radical adducts with a corresponding decrease in neutrophil infiltration. NADPH oxidase knockout mice completely blocked phagocyte-mediated, ESR-detectable radical production in this model of acute lung injury. Rats treated intratracheally with LPS generate lipid-derived free radicals via activation of NADPH oxidase.	NIEHS, Free Rad Metab Sect, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA; US EPA, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; Univ N Carolina, Dept Pharmacol, Hepatobiol & Toxicol Lab, Chapel Hill, NC USA; Univ N Carolina, Curriculum Toxicol, Chapel Hill, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); United States Environmental Protection Agency; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Sato, K (corresponding author), NIEHS, Free Rad Metab Sect, Lab Pharmacol & Chem, NIH, POB 12233,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	sato@niehs.nih.gov	Mason, Ronald P/G-5967-2019; Kadiiska, Maria B./AAC-9981-2019	Mason, Ronald P/0000-0002-1859-9109; 				AIKENS J, 1991, J BIOL CHEM, V266, P15091; BADWEY JA, 1980, ANNU REV BIOCHEM, V49, P695, DOI 10.1146/annurev.bi.49.070180.003403; Blackwell TS, 1999, AM J RESP CRIT CARE, V159, P1644, DOI 10.1164/ajrccm.159.5.9806166; BRIGHAM KL, 1986, AM REV RESPIR DIS, V133, P913; Brown AP, 1997, SHOCK, V7, P186, DOI 10.1097/00024382-199703000-00006; Chabot F, 1998, EUR RESPIR J, V11, P745; DEITCH EA, 1991, CRIT CARE MED, V19, P785, DOI 10.1097/00003246-199106000-00010; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; FAGGIONI R, 1994, J LAB CLIN MED, V123, P394; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; Fujii Y, 1998, AM J RESP CRIT CARE, V157, P1645, DOI 10.1164/ajrccm.157.5.9705040; Garg R, 2000, HYPERTENSION, V36, P430, DOI 10.1161/01.HYP.36.3.430; Ghio AJ, 1998, FREE RADICAL BIO MED, V24, P11, DOI 10.1016/S0891-5849(97)00063-4; Gonzalez PK, 1996, SHOCK, V6, pS23, DOI 10.1097/00024382-199610001-00006; Hassoun PM, 1998, AM J RESP CRIT CARE, V158, P299, DOI 10.1164/ajrccm.158.1.9709116; IWAHASHI H, 1992, FREE RADICAL RES COM, V16, P295, DOI 10.3109/10715769209049182; Iwahashi H, 1996, FREE RADICAL RES, V25, P255, DOI 10.3109/10715769609149051; IWAHASHI H, 1991, ARCH BIOCHEM BIOPHYS, V285, P172, DOI 10.1016/0003-9861(91)90346-K; JACKSON SH, 1995, J EXP MED, V182, P751, DOI 10.1084/jem.182.3.751; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; Kadiiska MB, 1997, CHEM RES TOXICOL, V10, P1104, DOI 10.1021/tx970049r; Kono H, 2000, J CLIN INVEST, V106, P867, DOI 10.1172/JCI9020; Kubo H, 1996, J CLIN INVEST, V97, P2680, DOI 10.1172/JCI118718; Kubo K, 1999, Respirology, V4, P167, DOI 10.1046/j.1440-1843.1999.00169.x; Kukan M, 1997, HEPATOLOGY, V26, P1250; Lavigne MC, 2001, CIRCULATION, V104, P79, DOI 10.1161/01.CIR.104.1.79; Liu KJ, 1999, FREE RADICAL BIO MED, V27, P82, DOI 10.1016/S0891-5849(99)00042-8; LLOYD SS, 1993, FREE RADICAL BIO MED, V14, P233, DOI 10.1016/0891-5849(93)90020-U; Modlin RL, 1999, NEW ENGL J MED, V340, P1834, DOI 10.1056/NEJM199906103402312; Muranaka H, 1997, INFECT IMMUN, V65, P3422, DOI 10.1128/IAI.65.8.3422-3429.1997; MURPHY PG, 1991, FREE RADICAL RES COM, V15, P167, DOI 10.3109/10715769109049137; NODA H, 1994, SHOCK, V1, P291, DOI 10.1097/00024382-199404000-00008; PENDINO KJ, 1995, AM J RESP CELL MOL, V13, P125, DOI 10.1165/ajrcmb.13.2.7542894; Peralta C, 1999, HEPATOLOGY, V30, P1481, DOI 10.1002/hep.510300622; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PRYOR WA, 1982, ANN NY ACAD SCI, V393, P1, DOI 10.1111/j.1749-6632.1982.tb31228.x; RABINOVICI R, 1993, J APPL PHYSIOL, V74, P1791, DOI 10.1152/jappl.1993.74.4.1791; Royall J A, 1995, New Horiz, V3, P113; Sato K, 1998, AM J RESP CRIT CARE, V157, P853, DOI 10.1164/ajrccm.157.3.9703098; TAPPEL AL, 1973, FED PROC, V32, P1870; THOMAS CE, 1985, J BIOL CHEM, V260, P3275; Vega VL, 1999, SHOCK, V11, P403; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; YASUI S, 1995, EUR RESPIR J, V8, P1293, DOI 10.1183/09031936.95.08081293; Zhou MY, 1998, J CLIN INVEST, V101, P2427, DOI 10.1172/JCI407	45	138	148	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2002	16	13					1713	1720		10.1096/fj.02-0331com	http://dx.doi.org/10.1096/fj.02-0331com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12409313				2022-12-28	WOS:000180218500003
J	Thum, T; Borlak, J				Thum, T; Borlak, J			Testosterone, cytochrome P450, and cardiac hypertrophy	FASEB JOURNAL			English	Article						CYP; cytochrome P450 mono-oxygenases; testosterone metabolism; cardiac hypertrophy	SPONTANEOUSLY HYPERTENSIVE RATS; NUCLEAR TRANSCRIPTION FACTORS; ANDROGEN RECEPTORS; GENE-EXPRESSION; HEART-FAILURE; RESPONSE ELEMENT; MESSENGER-RNA; ENZYMES; ACID; CARDIOMYOCYTES	Cytochrome P450 mono-oxygenases (CYP) play an essential role in steroid metabolism, and there is speculation that sex hormones might influence cardiac mass and physiology. As CYP mono-oxygenases activity is frequently altered during disease, we tested our hypothesis that CYP mono-oxygenase expression and testosterone metabolism are altered in cardiac hypertrophy. We investigate major CYP mono-oxygenase isoforms and other steroid-metabolizing enzymes and the androgen receptor in normal, hypertrophic, and assist device-supported human hearts and in spontaneously hypertensive rats (SHR). We show increased and idiosyncratic metabolism of testosterone in hypertrophic heart and link these changes to altered CYP mono-oxygenase expression. We show significant induction of 5-alpha steroid reductase and P450 aromatase gene expression and enhanced production of dihydrotestosterone, which can be inhibited by the 5-alpha reductase inhibitor finasteride. We show increased gene expression of the androgen receptor and increased levels of lipid peroxidation in diseased hearts, the latter being markedly inhibited by CYP mono-oxygenase inactivation. We show alpha-MHC to be significantly repressed in cardiac hypertrophy and restored to normal on testosterone supplementation. We conclude that heart-specific steroid metabolism is of critical importance in cardiac hypertrophy.	Fraunhofer Inst Toxicol & Aerosol Res, Ctr Drug Res & Med Biotechnol, D-30659 Hannover, Germany	Fraunhofer Gesellschaft	Borlak, J (corresponding author), Fraunhofer Inst Toxicol & Aerosol Res, Ctr Drug Res & Med Biotechnol, Nicolai Fuchs Str 1, D-30659 Hannover, Germany.	Borlak@ita.fhg.de		Thum, Thomas/0000-0003-4360-1511				Ahmad SR, 2001, LANCET, V357, P1766, DOI 10.1016/S0140-6736(00)04891-1; ARLOTTO MP, 1991, METHOD ENZYMOL, V206, P454; BASU AK, 1994, HYPERTENSION, V24, P480, DOI 10.1161/01.HYP.24.4.480; Baumer AT, 2000, J MOL CELL CARDIOL, V32, P121, DOI 10.1006/jmcc.1999.1061; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; BOLUYT MO, 1994, CIRC RES, V75, P23, DOI 10.1161/01.RES.75.1.23; BONDY SC, 1994, BIOCHEM PHARMACOL, V48, P155, DOI 10.1016/0006-2952(94)90235-6; Borlak J, 2001, BIOCHEM PHARMACOL, V61, P145, DOI 10.1016/S0006-2952(00)00537-2; Capdevila JH, 2000, J LIPID RES, V41, P163; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; Claessens F, 2001, J STEROID BIOCHEM, V76, P23, DOI 10.1016/S0960-0760(00)00154-0; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Coley KC, 1997, PHARMACOTHERAPY, V17, P379; Csonka C, 2000, FREE RADICAL BIO MED, V29, P612, DOI 10.1016/S0891-5849(00)00365-8; Davydov DR, 2001, TRENDS BIOCHEM SCI, V26, P155, DOI 10.1016/S0968-0004(00)01749-7; de Leeuw PW, 1998, J CARDIOVASC PHARM, V32, pS9, DOI 10.1097/00005344-199800003-00003; Dickerman RD, 1998, CARDIOLOGY, V90, P145, DOI 10.1159/000006834; Dodic M, 2001, CIRC RES, V89, P623, DOI 10.1161/hh1901.097086; FULTON D, 1995, BRIT J PHARMACOL, V114, P99, DOI 10.1111/j.1476-5381.1995.tb14911.x; GEORGE J, 1995, BIOCHEM PHARMACOL, V49, P873, DOI 10.1016/0006-2952(94)00515-N; Gerbal-Chaloin S, 2002, J BIOL CHEM, V277, P209, DOI 10.1074/jbc.M107228200; GILLARDON F, 1991, NEUROSCI LETT, V125, P77, DOI 10.1016/0304-3940(91)90135-G; Guengerich F. P., 1995, CYTOCHROME P, P473; Hayward CS, 2001, LANCET, V357, P1354, DOI 10.1016/S0140-6736(00)04523-2; Hingtgen SD, 2001, ANTIOXID REDOX SIGN, V3, P433, DOI 10.1089/15230860152409077; Izumi Y, 2000, HYPERTENSION, V36, P511, DOI 10.1161/01.HYP.36.4.511; Jurkovicova D, 2001, PHYSIOL RES, V50, P35; KARARA A, 1989, J BIOL CHEM, V264, P19822; Karvonen U, 1997, J BIOL CHEM, V272, P15973, DOI 10.1074/jbc.272.25.15973; Kivisto KT, 1996, BRIT J CLIN PHARMACO, V42, P387, DOI 10.1046/j.1365-2125.1996.42615.x; Kivisto KT, 1996, N-S ARCH PHARMACOL, V353, P207; LIN AL, 1985, ARTERIOSCLEROSIS, V5, P659, DOI 10.1161/01.ATV.5.6.659; LIN AL, 1981, CIRC RES, V49, P1010, DOI 10.1161/01.RES.49.4.1010; LIN MC, 1993, J STEROID BIOCHEM, V45, P333; Marsh JD, 1998, CIRCULATION, V98, P256, DOI 10.1161/01.CIR.98.3.256; MOFFAT MP, 1993, AM J PHYSIOL, V264, pH1154, DOI 10.1152/ajpheart.1993.264.4.H1154; MORANO I, 1990, CIRC RES, V66, P1585, DOI 10.1161/01.RES.66.6.1585; Nakao K, 1997, J CLIN INVEST, V100, P2362, DOI 10.1172/JCI119776; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; Omdahl JL, 2001, STEROIDS, V66, P381, DOI 10.1016/S0039-128X(00)00157-4; Pascussi JM, 2000, MOL PHARMACOL, V58, P1441, DOI 10.1124/mol.58.6.1441; PORTO CS, 1995, J STEROID BIOCHEM, V53, P561, DOI 10.1016/0960-0760(95)00111-C; Reiser PJ, 2001, AM J PHYSIOL-HEART C, V280, pH1814, DOI 10.1152/ajpheart.2001.280.4.H1814; Shorofsky SR, 1999, CIRC RES, V84, P424, DOI 10.1161/01.RES.84.4.424; Simpson AECM, 1997, GEN PHARMACOL-VASC S, V28, P351, DOI 10.1016/S0306-3623(96)00246-7; Skelton R, 1998, ARCH DIS CHILD-FETAL, V78, pF133, DOI 10.1136/fn.78.2.F133; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Snajdrova L, 1998, J BIOL CHEM, V273, P28032, DOI 10.1074/jbc.273.43.28032; STERN JO, 1974, J BIOL CHEM, V249, P7495; Thum T, 2000, BRIT J PHARMACOL, V130, P1745, DOI 10.1038/sj.bjp.0703465; Thum T, 2000, LANCET, V355, P979, DOI 10.1016/S0140-6736(00)99016-0; Thum T, 2000, XENOBIOTICA, V30, P1063, DOI 10.1080/00498250010005196; Thum T, 2000, FASEB J, V14, P740, DOI 10.1096/fasebj.14.5.740; Tilakaratne A, 2002, ARCH ORAL BIOL, V47, P59, DOI 10.1016/S0003-9969(01)00087-5; Walles M, 2001, DRUG METAB DISPOS, V29, P761; WRIGHT JR, 1981, ARCH BIOCHEM BIOPHYS, V206, P296, DOI 10.1016/0003-9861(81)90095-3; Wu S, 1996, J BIOL CHEM, V271, P3460; Xiao YF, 1998, J PHYSIOL-LONDON, V508, P777, DOI 10.1111/j.1469-7793.1998.777bp.x; Yu ZG, 2000, MOL PHARMACOL, V57, P1011; Zafeiridis A, 1998, CIRCULATION, V98, P656, DOI 10.1161/01.CIR.98.7.656	60	111	115	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1537	1549		10.1096/fj.02-0138com	http://dx.doi.org/10.1096/fj.02-0138com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374776				2022-12-28	WOS:000179167600035
J	Ishida, Y; Kondo, T; Ohshima, T; Fujiwara, H; Iwakura, Y; Mukaida, N				Ishida, Y; Kondo, T; Ohshima, T; Fujiwara, H; Iwakura, Y; Mukaida, N			A pivotal involvement of IFN-gamma in the pathogenesis of acetaminophen-induced acute liver injury	FASEB JOURNAL			English	Article						interferon; chemokines; adhesion molecules; nitric oxide synthase	INDUCED HEPATIC-NECROSIS; NITRIC-OXIDE SYNTHASE; INDUCED HEPATOTOXICITY; INTERFERON-GAMMA; FACTOR-ALPHA; IN-VITRO; MICE; PARACETAMOL; PRETREATMENT; HEPATOCYTES	In wild-type BALB/c mice, i.p. administration of acetaminophen (APAP; 750 mg/kg) induced intrahepatic IFN-gamma mRNA expression and a marked increase in serum transaminase levels, leading to acute lethality of similar to45%. Histopathological examination showed centrilobular hepatic necrosis with leukocyte infiltration and a large number of apoptotic hepatocytes 10 and 24 h after APAP challenge. mRNA expression of intercellular adhesion molecule 1, vascular cell adhesion molecule 1, interleukin (IL) 1alpha, IL-1beta, IL-6, tumor necrosis factor alpha, monocyte chemoattractant protein 1, macrophage inflammatory protein (MIP) 1alpha, MIP-2, KC, IP-10, Mig, Fas, and inducible nitric oxide synthase was enhanced in the liver of wild-type mice injected with APAP. To clarify the role of IFN-gamma in this process, IFN-gamma-deficient mice were treated in the same manner. All IFN-gamma-deficient mice survived with reduced serum transaminase elevation and attenuated hepatic necrosis, leukocyte infiltration, and hepatocyte apoptosis. The gene expression of all molecules was significantly attenuated in IFN-gamma-deficient mice. Administration of an anti-IFN-gamma neutralizing antibody even 2 or 8 h after APAP challenge to wild-type mice alleviated APAP-induced liver injury, and all mice survived. Thus, IFN-gamma is responsible for APAP-induced liver injury by mediating leukocyte infiltration, hepatocyte apoptosis, and NO production as well as cytokine and chemokine production. Moreover, immunoneutralization of IFN-gamma may be therapeutically effective for developing APAP-induced liver injury.	Kanazawa Univ, Grad Sch Med Sci, Div Environm Sci Forens & Social Environm Med, Kanazawa, Ishikawa 9208640, Japan; Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Oncol, Osaka, Japan; Univ Tokyo, Inst Med Sci, Lab Anim Res Ctr, Tokyo 108, Japan; Kanazawa Univ, Canc Res Inst, Div Mol Bioregulat, Kanazawa, Ishikawa 920, Japan	Kanazawa University; Osaka University; University of Tokyo; Kanazawa University	Ohshima, T (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Div Environm Sci Forens & Social Environm Med, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan.	ohshimat@med.kanazawa-u.ac.jp	Iwakura, Yoichiro/E-5457-2011; Mukaida, Naofumi/D-7623-2011	Iwakura, Yoichiro/0000-0002-9934-5775; Mukaida, Naofumi/0000-0002-4193-1851; Kondo, Toshikazu/0000-0002-5059-8309				Blazka ME, 1996, TOXICOL PATHOL, V24, P181, DOI 10.1177/019262339602400206; BLAZKA ME, 1995, TOXICOL APPL PHARM, V133, P43, DOI 10.1006/taap.1995.1125; Boess F, 1998, HEPATOLOGY, V27, P1021, DOI 10.1002/hep.510270418; DAHLIN DC, 1984, P NATL ACAD SCI-BIOL, V81, P1327, DOI 10.1073/pnas.81.5.1327; DEGROOTE J, 1995, ACTA GASTRO-ENT BELG, V58, P326; Delanty N, 1996, IRISH MED J, V89, P156; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; Gardner CR, 1998, HEPATOLOGY, V27, P748, DOI 10.1002/hep.510270316; Goldin RD, 1996, J PATHOL, V179, P432; Hajri A, 1998, BRIT J CANCER, V78, P841, DOI 10.1038/bjc.1998.591; Hogaboam CM, 2000, AM J PATHOL, V156, P1245, DOI 10.1016/S0002-9440(10)64995-4; Hogaboam CM, 1999, FASEB J, V13, P1565, DOI 10.1096/fasebj.13.12.1565; Hogaboam CM, 1999, GENE THER, V6, P573, DOI 10.1038/sj.gt.3300858; KELLOKUMPULEHTINEN P, 1989, LANCET, V1, P1143; KUO PC, 1994, J SURG RES, V56, P594, DOI 10.1006/jsre.1994.1094; Luster MI, 2001, TOXICOL LETT, V120, P317, DOI 10.1016/S0378-4274(01)00284-3; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MAEDA H, 1994, J LEUKOCYTE BIOL, V56, P588, DOI 10.1002/jlb.56.5.588; Maeda M, 1998, NEUROSCI LETT, V240, P69, DOI 10.1016/S0304-3940(97)00901-4; Makin AJ, 1997, ADV INTERNAL MED, V42, P453; Michael SL, 1999, HEPATOLOGY, V30, P186, DOI 10.1002/hep.510300104; Mihm S, 1996, MED MICROBIOL IMMUN, V185, P95, DOI 10.1007/s004300050020; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P211; Mizuhara H, 1996, HEPATOLOGY, V23, P1608, DOI 10.1002/hep.510230643; NAKAE D, 1990, AM J PATHOL, V136, P787; Neumann B, 1996, J IMMUNOL, V156, P1587; Ray SD, 1996, J PHARMACOL EXP THER, V279, P1470; Robson RL, 2001, J IMMUNOL, V167, P1028, DOI 10.4049/jimmunol.167.2.1028; Sass G, 2001, J CLIN INVEST, V107, P439, DOI 10.1172/JCI10613; Shen S, 1991, DNA Seq, V2, P111, DOI 10.3109/10425179109039679; Simpson KJ, 2000, J PATHOL, V190, P489; Smith GS, 1998, J SURG RES, V80, P252, DOI 10.1006/jsre.1998.5441; Tagawa Y, 1997, J IMMUNOL, V159, P1418; TAKADA H, 1995, DIGEST DIS SCI, V40, P1831, DOI 10.1007/BF02212709; Taylor BS, 1998, BIOCHEMISTRY-MOSCOW+, V63, P766; Tsuji H, 1999, J IMMUNOL, V162, P1049; WAWRYK SO, 1989, IMMUNOL REV, V108, P135, DOI 10.1111/j.1600-065X.1989.tb00016.x; WHITCOMB DC, 1994, NEW ENGL J MED, V331, P1311	38	169	176	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1227	10.1096/fj.02-0046com	http://dx.doi.org/10.1096/fj.02-0046com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153990				2022-12-28	WOS:000177814000031
J	Yao, ZX; Papadopoulos, V				Yao, ZX; Papadopoulos, V			Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity	FASEB JOURNAL			English	Article						cholesterol-binding protein; high-density lipoproteins; neurotoxicity; Alzheimer's Disease	APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; PEPTIDE; MEMBRANE; RECEPTOR; BINDING; PREVALENCE	Amyloid beta-peptide (Abeta), Abeta precursor protein (APP), apolipoprotein E (apoE), and elevated cholesterol levels have been linked to Alzheimer's disease (AD) pathology. High cholesterol levels increase APP and apoE expression in human NT2 neuron progenitor cells. A cholesterol-rich environment also induces processing of APP, leading to the formation of Abeta and Abeta peptide fragments. Using a novel method, we determined that 1) cholesterol binds to Abeta at alpha-secretase cleavage site; 2) Abeta(17-40) rather than Abeta(1-40) prevents cholesterol from binding to apoE; 3) Abeta(1-40) inhibits cholesterol from binding to low-density lipoprotein (LDL), leading to decrease cholesterol influx and intracellular cholesterol levels; 4) the binding of cholesterol to apoE or LDL was abolished completely in presence of Abeta(1-42). Increased extracellular free cholesterol levels are toxic to neurons; this toxicity is prevented by specific lipoproteins, such as high-density lipoproteins, which maintain their ability to bind cholesterol in the presence of Abeta. We propose that one of the physiological functions of Abeta and APP is to control cholesterol transport. AD is associated with increased Abeta production. High cholesterol levels also lead to overproduction of Abeta. Abeta blocks cholesterol trafficking and changes cholesterol homeostasis leading to neurodegeneration and the onset and/or progression of AD pathology.	Georgetown Univ, Sch Med, Dept Cell Biol, Div Hormone Res, Washington, DC 20057 USA; Georgetown Univ, Sch Med, Dept Pharmacol, Washington, DC 20057 USA; Georgetown Univ, Sch Med, Dept Neurosci, Washington, DC 20057 USA	Georgetown University; Georgetown University; Georgetown University	Papadopoulos, V (corresponding author), Georgetown Univ, Sch Med, Dept Cell Biol, Div Hormone Res, 3900 Reservoir Rd NW, Washington, DC 20057 USA.	papadopv@georgetown.edu	Papadopoulos, Vassilios/AAI-2613-2019	Papadopoulos, Vassilios/0000-0002-1183-8568				Avdulov NA, 1997, J NEUROCHEM, V69, P1746; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Futerman AH, 1996, TRENDS NEUROSCI, V19, P144, DOI 10.1016/S0166-2236(96)80025-7; Galbete JL, 2000, BIOCHEM J, V348, P307, DOI 10.1042/0264-6021:3480307; GINSBERG L, 1993, MOL CHEM NEUROPATHOL, V19, P37, DOI 10.1007/BF03160167; GINSBERG L, 1993, BRAIN RES, V615, P355, DOI 10.1016/0006-8993(93)90050-W; Havel RJ, 1995, METABOLIC MOL BASES, V7th, P1841, DOI [10.1036/ommbid.142, DOI 10.1036/OMMBID.142]; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Johnson W J, 1997, Subcell Biochem, V28, P235; LaDu MJ, 1997, J NEUROSCI RES, V49, P9, DOI 10.1002/(SICI)1097-4547(19970701)49:1<9::AID-JNR2>3.0.CO;2-H; Li H, 2001, P NATL ACAD SCI USA, V98, P1267, DOI 10.1073/pnas.031461598; Liang JS, 1996, BIOCHEM BIOPH RES CO, V219, P962, DOI 10.1006/bbrc.1996.0332; Liu YB, 1998, P NATL ACAD SCI USA, V95, P13266, DOI 10.1073/pnas.95.22.13266; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Michikawa M, 2000, J NEUROCHEM, V74, P1008, DOI 10.1046/j.1471-4159.2000.0741008.x; NASLUND J, 1995, NEURON, V15, P219, DOI 10.1016/0896-6273(95)90079-9; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; SING CF, 1985, AM J HUM GENET, V37, P268; Small DH, 1999, J NEUROCHEM, V73, P443, DOI 10.1046/j.1471-4159.1999.0730443.x; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Tokuda T, 2000, BIOCHEM J, V348, P359, DOI 10.1042/0264-6021:3480359; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yao ZX, 2001, BRAIN RES, V889, P181, DOI 10.1016/S0006-8993(00)03131-0	31	93	95	1	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1677	+		10.1096/fj.02-0285fje	http://dx.doi.org/10.1096/fj.02-0285fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206998				2022-12-28	WOS:000177814000011
J	Garcia, JGN; Wang, PY; Schaphorst, KL; Becker, PM; Borbiev, T; Liu, F; Birukova, A; Jacobs, K; Bogatcheva, N; Verin, AD				Garcia, JGN; Wang, PY; Schaphorst, KL; Becker, PM; Borbiev, T; Liu, F; Birukova, A; Jacobs, K; Bogatcheva, N; Verin, AD			Critical involvement of p38 MAP kinase in pertussis toxin-induced cytoskeletal reorganization and lung permeability	FASEB JOURNAL			English	Article						ADP-ribosyltransferase; beta-oligomer; endothelial cell; transendothelial electrical resistance; HSP 27; caldesmon	ACTIVATED PROTEIN-KINASE; MANGANESE SUPEROXIDE-DISMUTASE; MYELOMONOCYTIC CELL-ADHESION; ENDOTHELIAL BARRIER FUNCTION; LIGHT-CHAIN KINASE; TYROSINE PHOSPHORYLATION; VASCULAR-PERMEABILITY; ALBUMIN PERMEABILITY; MOLECULAR-CLONING; MAMMALIAN-CELLS	Bordetella pertussis is an important cause of infection in humans worldwide, with full expression of the syndrome associated with characteristic increases in lung permeability and airway edema. The exact cellular mechanisms by which pertussis toxin (PTX) exerts pulmonary toxicity remain unknown, but may involve its ability to ADP-ribosylate-specific G-proteins. We determined that PTX directly and reproducibly reduced lung endothelial and epithelial cell barrier function in vitro and in vivo assessed by decreases in transmonolayer electrical resistance (TER) and isolated perfused lung preparations. Alterations in lung permeability began similar to30 min after PTX and were dependent on intrinsic ADP-ribosyltransferase activity, as neither the cell binding beta-oligomer subunit or a genetically engineered PTX mutant (devoid of ADP-ribosyltransferase activity) altered TER. PTX-induced barrier dysfunction was associated with mild increases in F-actin stress fiber formation and causally linked to p38 MAP kinase activities. PTX-mediated p38 MAP kinase activation did not involve either p42/p44 ERK, p60(src), Rho family of GTPases, or phosphatidylinositol-3' kinase pathways. PTX-mediated decreases in TER were temporally linked to phosphorylation of the actin binding proteins Hsp27 and caldesmon, known substrates for the Ser/Thr kinase MAPKAP2, whose activity is regulated by p38 MAP kinase. In addition to defining novel signaling pathways involved in PTX-induced respiratory pathophysiology, these data suggest that the direct cell-activating effects of PTX be carefully considered as a potential limitation to its use as a tool in signal transduction analysis.	Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD USA	Johns Hopkins University	Garcia, JGN (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,4B-77, Baltimore, MD 21224 USA.	drgarcia@jhmi.edu	Garcia, Joe GN/E-8862-2010	Bogatcheva, Natalia/0000-0002-5177-5872	NHLBI NIH HHS [HL 58064, HL 03666, HL 60628] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060628, K08HL003666, P01HL058064] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKER PM, 1992, J APPL PHYSIOL, V73, P2616, DOI 10.1152/jappl.1992.73.6.2616; Borbiev T, 2000, ANAL BIOCHEM, V285, P260, DOI 10.1006/abio.2000.4763; Chen FS, 1998, J NEUROCHEM, V71, P248; CLERCH LB, 1994, J CLIN INVEST, V93, P2482, DOI 10.1172/JCI117257; Daum G, 1998, FEBS LETT, V427, P271, DOI 10.1016/S0014-5793(98)00448-7; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; ERREDE B, 1995, MOL REPROD DEV, V42, P477, DOI 10.1002/mrd.1080420416; Garcia JGN, 2000, J APPL PHYSIOL, V89, P2333, DOI 10.1152/jappl.2000.89.6.2333; GARCIA JGN, 1990, J CELL PHYSIOL, V142, P186, DOI 10.1002/jcp.1041420123; GARCIA JGN, 1992, BLOOD, V79, P2056; Garcia JGN, 2001, AM J PHYSIOL-CELL PH, V280, pC1233, DOI 10.1152/ajpcell.2001.280.5.C1233; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; GARCIA JGN, 1991, AM J RESP CELL MOL, V5, P113, DOI 10.1165/ajrcmb/5.2.113; GARCIA JGN, 1986, J CELL PHYSIOL, V128, P96, DOI 10.1002/jcp.1041280115; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829; GARCIA JGN, 1997, AM J PHYSIOL, V17, pLU72; GIAEVER I, 1993, NATURE, V366, P591, DOI 10.1038/366591a0; GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; Hale KK, 1999, J IMMUNOL, V162, P4246; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; KASLOW HR, 1992, FASEB J, V6, P2684, DOI 10.1096/fasebj.6.9.1612292; KINDT RM, 1995, NEURON, V15, P79, DOI 10.1016/0896-6273(95)90066-7; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; LUM H, 1994, AM J PHYSIOL, V267, pL223, DOI 10.1152/ajplung.1994.267.3.L223; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Morrison DL, 1996, BIOCHEM CELL BIOL, V74, P549, DOI 10.1139/o96-459; MULLERWIELAND D, 1991, BIOCHEM BIOPH RES CO, V181, P1479, DOI 10.1016/0006-291X(91)92106-T; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; PATTERSON CE, 1994, BLOOD COAGUL FIBRIN, V5, P63, DOI 10.1097/00001721-199402000-00010; PATTERSON CE, 1995, AM J PHYSIOL-LUNG C, V268, pL926, DOI 10.1152/ajplung.1995.268.6.L926; PIZZA M, 1989, SCIENCE, V246, P497, DOI 10.1126/science.2683073; SCHAPHORST KL, 1997, AM J RESP CELL MOL B, V17, P441; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SOBUE K, 1991, J BIOL CHEM, V266, P12115; STASEK JE, 1992, J CELL PHYSIOL, V153, P62, DOI 10.1002/jcp.1041530110; STERNAD CF, 1987, FEBS LETT, V225, P16; TAMURA M, 1983, J BIOL CHEM, V258, P6756; THOM RE, 1989, FEBS LETT, V244, P181, DOI 10.1016/0014-5793(89)81188-3; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Tsan MF, 1999, AM J RESP CELL MOL, V20, P465, DOI 10.1165/ajrcmb.20.3.3373; Verin AD, 1998, AM J RESP CELL MOL, V19, P767, DOI 10.1165/ajrcmb.19.5.3126; Verin AD, 2000, AM J PHYSIOL-LUNG C, V279, pL360, DOI 10.1152/ajplung.2000.279.2.L360; Vuong PT, 1998, J CELL PHYSIOL, V175, P379, DOI 10.1002/(SICI)1097-4652(199806)175:3<379::AID-JCP16>3.3.CO;2-T; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wong WSF, 1997, BIOCHEM BIOPH RES CO, V236, P479, DOI 10.1006/bbrc.1997.6986; Wong WSF, 1996, IMMUNOLOGY, V88, P90, DOI 10.1046/j.1365-2567.1996.d01-646.x; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397; ZHAO Z, 1996, J BIOL CHEM, V6, P22251; [No title captured]	53	60	64	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2002	16	9					1064	1076		10.1096/fj.01-0895com	http://dx.doi.org/10.1096/fj.01-0895com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087068				2022-12-28	WOS:000177813100038
J	Hopfer, H; Maron, R; Butzmann, U; Helmchen, U; Weiner, HL; Kalluri, R				Hopfer, H; Maron, R; Butzmann, U; Helmchen, U; Weiner, HL; Kalluri, R			The importance of cell-mediated immunity in the course and severity of autoimmune anti-glomerular basement membrane disease in mice	FASEB JOURNAL			English	Article						glomerulonephritis; Goodpasture syndrome; alpha 3(IV) type IV collagen; autoimmunity	IV COLLAGEN; GOODPASTURES-SYNDROME; T-CELLS; GLOMERULONEPHRITIS; SUSCEPTIBILITY; CHAIN; RAT; AUTOANTIBODIES; AUTOANTIGEN; ANTIBODIES	Anti-glomerular basement membrane (GBM) disease is a rapidly progressive glomerulonephritis (GN) resulting from autoimmunity against the Goodpasture antigen alpha3(IV)NC1. In addition to the well-characterized antibody contribution, a T helper 1 (Th1) response has been suspected as the culprit for glomerular injury. We induced anti-GBM disease in DBA/1, C57BL/6, AKR, and NOD mice with recombinant human alpha3(IV) NC1 to investigate the involvement of humoral and cellular autoimmunity. DBA/1 mice had crescentic GN 11 wk postimmunization with alpha3(IV)NC1. C57BL/6 and AKR mice developed a chronic disease course resulting in comparable kidney injury to DBA/1 mice within 6 months. NOD revealed only minor glomerular changes. The rapid course and the severity of the disease in DBA/1 mice can be explained by our immunological findings in their sera and splenocytes: 1) high antibody titers specific for the putative clinically relevant epitope of alpha3(IV)NC1 with Th1-type isotypes, and 2) a strong proliferative response and high amounts of the inflammatory cytokine IFN-gamma, secreted by splenocytes stimulated in vitro with alpha3(IV)NC1, with only low amounts of the anti-inflammatory cytokine IL-10. Our in vivo and in vitro results provide direct evidence that the balance between Th1 and Th2 responses associates with the outcome of anti-GBM disease in mice.	Beth Israel Deaconess Med Ctr, Dept Med, Program Matrix Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Univ Hamburg, Dept Pathol, D-20246 Hamburg, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Hamburg	Kalluri, R (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Program Matrix Biol, 330 Brookline Ave,Dana 514, Boston, MA 02215 USA.	rkalluri@bidmc.harvard.edu	Weiner, Irving D/G-6333-2016; Hopfer, Helmut/T-5954-2019; Kalluri, Raghu/E-2677-2015	Weiner, Irving D/0000-0002-0046-0600; Hopfer, Helmut/0000-0003-1755-2170; Kalluri, Raghu/0000-0002-2190-547X	NIDDK NIH HHS [DK-51711, DK-55001] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051711] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Abbate M, 1998, KIDNEY INT, V54, P1550, DOI 10.1046/j.1523-1755.1998.00153.x; Abrass Christine K., 1997, P291; Batista FD, 1998, IMMUNITY, V8, P751, DOI 10.1016/S1074-7613(00)80580-4; Bolton WK, 1996, KIDNEY INT, V50, P1753, DOI 10.1038/ki.1996.495; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; David M, 2001, J BIOL CHEM, V276, P6370, DOI 10.1074/jbc.M008956200; Fisher M, 1997, KIDNEY INT, V51, P222, DOI 10.1038/ki.1997.27; Hellmark T, 1999, KIDNEY INT, V55, P936, DOI 10.1046/j.1523-1755.1999.055003936.x; Holdsworth SR, 1999, KIDNEY INT, V55, P1198, DOI 10.1046/j.1523-1755.1999.00369.x; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; Kalluri R, 1997, J CLIN INVEST, V100, P2263, DOI 10.1172/JCI119764; Kalluri R, 2000, J BIOL CHEM, V275, P20027, DOI 10.1074/jbc.M904549199; KOHLFELDT E, 1997, FEBS LETT, V414, P557; Lanzavecchia A, 2000, SCIENCE, V290, P92, DOI 10.1126/science.290.5489.92; LERNER RA, 1967, J EXP MED, V126, P989, DOI 10.1084/jem.126.6.989; Luross JA, 2001, IMMUNOLOGY, V103, P407, DOI 10.1046/j.1365-2567.2001.01267.x; Martin RM, 1998, J IMMUNOL METHODS, V212, P187, DOI 10.1016/S0022-1759(98)00015-5; McDevitt HO, 1998, CURR OPIN IMMUNOL, V10, P677, DOI 10.1016/S0952-7915(98)80088-5; Merkel F, 1996, KIDNEY INT, V49, P1127, DOI 10.1038/ki.1996.163; Meyers Catherine M., 1997, P959; Nakamura A, 2000, J EXP MED, V191, P899, DOI 10.1084/jem.191.5.899; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; NISHIKAWA K, 1993, J EXP MED, V177, P667, DOI 10.1084/jem.177.3.667; NISHIKAWA K, 1994, EUR J IMMUNOL, V24, P249; PETTERSSON E, 1984, CLIN IMMUNOL IMMUNOP, V31, P171, DOI 10.1016/0090-1229(84)90237-X; Randolph DA, 1999, SCIENCE, V286, P2159, DOI 10.1126/science.286.5447.2159; Reynolds J, 1998, NEPHROL DIAL TRANSPL, V13, P44, DOI 10.1093/ndt/13.1.44; Reynolds J, 2000, J CLIN INVEST, V105, P643, DOI 10.1172/JCI6710; Reynolds J, 2001, J AM SOC NEPHROL, V12, P61, DOI 10.1681/ASN.V12161; REYNOLDS J, 2000, J AM SOC NEPHROL, V11, P481; Sado Y, 1998, KIDNEY INT, V54, P311; SADO Y, 1986, J CLIN LAB IMMUNOL, V19, P193; Schweitzer AN, 1997, J IMMUNOL, V158, P2713; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; WEBER M, 1988, NEPHRON, V49, P54, DOI 10.1159/000184986; WIESLANDER J, 1985, J BIOL CHEM, V260, P8564; Wu J, 2001, J IMMUNOL, V167, P2388, DOI 10.4049/jimmunol.167.4.2388	39	58	59	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					860	868		10.1096/fj.02-0746com	http://dx.doi.org/10.1096/fj.02-0746com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724345				2022-12-28	WOS:000183165000012
J	Goetze, JP; Christoffersen, C; Perko, M; Arendrup, H; Rehfeld, JF; Kastrup, J; Nielsen, LB				Goetze, JP; Christoffersen, C; Perko, M; Arendrup, H; Rehfeld, JF; Kastrup, J; Nielsen, LB			Increased cardiac BNP expression associated with myocardial ischemia	FASEB JOURNAL			English	Article						heart failure; proBNP; ventricle	BRAIN NATRIURETIC PEPTIDE; ACUTE CORONARY SYNDROMES; INCREASED PLASMA-LEVELS; HEART-FAILURE; UNSTABLE ANGINA; A-TYPE; INFARCTION; DYSFUNCTION; HORMONES; PROTEIN	Congestive heart failure is accompanied by increased cardiac brain natriuretic peptide (BNP) gene expression with elevated plasma concentrations of BNP and its precursor, proBNP. We investigated if myocardial ischemia in the absence of overt heart failure may be another mechanism for increased myocardial BNP expression. The BNP expression was examined in hypoxic myocardium of patients undergoing coronary bypass grafting surgery, in patients with coronary artery disease and normal left ventricular function undergoing percutaneous transluminal intervention therapy, and in heart failure patients without coronary artery disease. BNP mRNA was quantified by real-time PCR, and plasma BNP and proBNP concentrations were measured with radioimmunoassays. Quantitative analysis of BNP mRNA in atrial and ventricular biopsies from coronary bypass grafting patients revealed close associations of plasma BNP and proBNP concentrations to ventricular, but not atrial, BNP mRNA levels. Plasma BNP and proBNP concentrations were markedly increased in patients with coronary artery disease but without concomitant left ventricular dysfunction. These results are compatible with the notion that myocardial ischemia, even in the absence of left ventricular dysfunction, augments cardiac BNP gene expression and increases plasma BNP and proBNP concentrations. Thus, elevated BNP and proBNP concentrations do not necessarily reflect heart failure but may also result from cardiac ischemia.	Univ Copenhagen, Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Rigshosp, Dept Med B, Cardiac Catheterizat Lab, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Nielsen, LB (corresponding author), Univ Copenhagen, Rigshosp, Dept Clin Biochem, KB 3011,9 Blegdamsvej, DK-2100 Copenhagen, Denmark.	larsbo@rh.dk		Christoffersen, Christina/0000-0003-3751-5203; Goetze, Jens Peter/0000-0001-6356-3829				Boomsma F, 2001, CARDIOVASC RES, V51, P442, DOI 10.1016/S0008-6363(01)00195-X; Christoffersen C, 2002, HYPERTENSION, V40, P54, DOI 10.1161/01.HYP.0000021780.21830.DD; CHUN YS, 2002, BIOCH J; Clerico A, 2002, CLIN CHEM LAB MED, V40, P371, DOI 10.1515/CCLM.2002.060; Cowie MR, 2002, PROG CARDIOVASC DIS, V44, P293, DOI 10.1053/pcad.2002.24599; Cowie MR, 1997, LANCET, V350, P1349, DOI 10.1016/S0140-6736(97)06031-5; de Bold AJ, 2001, CAN J PHYSIOL PHARM, V79, P705, DOI 10.1139/cjpp-79-8-705; de Lemos JA, 2001, NEW ENGL J MED, V345, P1014, DOI 10.1056/NEJMoa011053; Goetze JP, 2002, CLIN CHEM, V48, P1035; Hunt PJ, 1997, CLIN ENDOCRINOL, V47, P287, DOI 10.1046/j.1365-2265.1997.2361058.x; Kikuta K, 1996, AM HEART J, V132, P101, DOI 10.1016/S0002-8703(96)90396-8; Luo YX, 2001, CIRCULATION, V104, P202; Maisel Alan, 2001, Cardiology Clinics, V19, P557, DOI 10.1016/S0733-8651(05)70243-5; McDonagh TA, 1998, LANCET, V351, P9, DOI 10.1016/S0140-6736(97)03034-1; MORITA E, 1993, CIRCULATION, V88, P82, DOI 10.1161/01.CIR.88.1.82; Muders F, 1997, AM HEART J, V134, P442, DOI 10.1016/S0002-8703(97)70079-6; Nagaya N, 1998, AM HEART J, V135, P21, DOI 10.1016/S0002-8703(98)70338-2; Nielsen LB, 2002, ARTERIOSCL THROM VAS, V22, P1489, DOI 10.1161/01.ATV.0000030199.06252.26; Redfield MM, 2002, J AM COLL CARDIOL, V40, P976, DOI 10.1016/S0735-1097(02)02059-4; Richards AM, 1998, CIRCULATION, V97, P1921, DOI 10.1161/01.CIR.97.19.1921; Sabatine MS, 2002, CIRCULATION, V105, P1760, DOI 10.1161/01.CIR.0000015464.18023.0A; Schrier RW, 1999, NEW ENGL J MED, V341, P577, DOI 10.1056/NEJM199908193410806; Talwar S, 2000, HEART, V84, P421, DOI 10.1136/heart.84.4.421; YASUE H, 1994, CIRCULATION, V90, P195, DOI 10.1161/01.CIR.90.1.195	24	289	321	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1105	+		10.1096/fj.02-0796fje	http://dx.doi.org/10.1096/fj.02-0796fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709407				2022-12-28	WOS:000182580100015
J	Aukema, HM; Evans, LI; Ogborn, MR; Nitschmann, E; Bankovic-Calic, N				Aukema, HM; Evans, LI; Ogborn, MR; Nitschmann, E; Bankovic-Calic, N			Dietary conjugated linoleic acid (CLA) alters cytosolic phospholipase A(2) (cPLA(2)) and cyclooxygenase-1 (COX-1) and COX-2 protein expression in normal and diseased rat kidneys	FASEB JOURNAL			English	Meeting Abstract	Experimental Biology 2003 Meeting	APR 11-15, 2003	SAN DIEGO, CALIFORNIA						Univ Manitoba, Winnipeg, MB R3T 2N2, Canada	University of Manitoba				Aukema, Harold/0000-0002-6982-7239					0	14	16	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 17	2003	17	5	2	S			A1121	A1121		10.1096/fj.02-0460fje	http://dx.doi.org/10.1096/fj.02-0460fje			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	659UY	12490538				2022-12-28	WOS:000181796901736
J	Mitev, YA; Wolf, SS; Almeida, OFX; Patchev, VK				Mitev, YA; Wolf, SS; Almeida, OFX; Patchev, VK			Developmental expression profiles and distinct regional estrogen responsiveness suggest a novel role for the steroid receptor coactivator SRC-1 as a discriminative amplifier of estrogen signaling in the rat brain	FASEB JOURNAL			English	Article						ontogeny; regulation; hypothalamus; cortex	ELEMENT-BINDING PROTEIN; CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA; REPRODUCTIVE-BEHAVIOR; ER-BETA; HORMONE; ALPHA; COREGULATORS; PITUITARY; MICE	The regional distribution, developmental profiles, and gonadectomy- and estrogen-induced changes in the density of transcripts encoding the steroid receptor coactivator-1 (SRC-1) were examined in the female rat brain by semiquantitative in situ hybridization. The results demonstrate striking differences in the abundance of SRC-1 mRNA in discrete brain regions throughout ontogeny. Whereas transcript densities gradually decreased with age in the cerebral cortex, they peaked prominently during the peripubertal period in the hypothalamic medial preoptic area (MPOA) and ventromedial nucleus (VMN). Gonadectomy and estrogen substitution influenced SRC-1 mRNA levels in sexually mature animals in a region-specific fashion. Ovariectomy resulted in a down-regulation of SRC-1 mRNA levels in the VMN, a brain region richly endowed with estrogen receptors and playing a major role in neuroendocrine control of reproductive functions. In contrast, SRC-1 transcript levels were significantly upregulated after estradiol treatment. Interestingly, SRC-1 expression in the cortex was refractory to alterations of the estrogen milieu. The obtained SRC-1 mRNA expression profiles during development clearly demonstrate brain region specificity and regulation by estrogen, thus it is proposed that SRC-1 amplifies estrogen receptor-dependent transcription in a temporally and spatially coordinated manner and therefore contributes to the functional specialization of brain areas involved in the regulation of reproduction.	Schering AG Jenapharm, Gender Hlth Care Res, D-07745 Jena, Germany; Max Planck Inst Psychiat, Dept Neuroendocrinol, D-80804 Munich, Germany	Schering AG; Max Planck Society	Patchev, VK (corresponding author), Jenapharm GmbH & Co KG, Otto Schott St 15, D-07745 Jena, Germany.	Vladimir.Patchev@jenapharm.de	Almeida, Osborne F.X. F/E-8402-2010	Almeida, Osborne F.X. F/0000-0001-7331-6928				Apostolakis EM, 2002, MOL ENDOCRINOL, V16, P1511, DOI 10.1210/me.16.7.1511; Auger AP, 2000, P NATL ACAD SCI USA, V97, P7551, DOI 10.1073/pnas.97.13.7551; Auger AP, 2002, ENDOCRINOLOGY, V143, P3009, DOI 10.1210/en.143.8.3009; Bousios S, 2001, J STEROID BIOCHEM, V78, P401, DOI 10.1016/S0960-0760(01)00123-6; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; MADEIRA MD, 1995, PROG NEUROBIOL, V45, P275, DOI 10.1016/0301-0082(94)00052-J; McEwen B, 2002, RECENT PROG HORM RES, V57, P357, DOI 10.1210/rp.57.1.357; Mcewen BS, 1999, ENDOCR REV, V20, P279, DOI 10.1210/er.20.3.279; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Meijer OC, 2000, ENDOCRINOLOGY, V141, P2192, DOI 10.1210/en.141.6.2192; Meijer OC, 2002, J NEUROENDOCRINOL, V14, P499, DOI 10.1046/j.1365-2826.2002.00795.x; Misiti S, 1999, ENDOCRINOLOGY, V140, P1957, DOI 10.1210/en.140.4.1957; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Molenda HA, 2002, ENDOCRINOLOGY, V143, P436, DOI 10.1210/en.143.2.436; Murphy DD, 1997, P NATL ACAD SCI USA, V94, P1482, DOI 10.1073/pnas.94.4.1482; Ojeda SR, 1994, PHYSL REPRODUCTION, V2, P363; ONATE SA, 1995, SCIENCE, V270, P1354; Osterlund MK, 2000, J CLIN ENDOCR METAB, V85, P3840, DOI 10.1210/jc.85.10.3840; PATCHEV VK, 1999, STEROID HORMONE DEPE, P39; PFAFF DW, 1994, PHYSL REPRODUCTION, V2, P107; PILGRIM C, 1994, NEUROSCIENCE, V60, P843, DOI 10.1016/0306-4522(94)90267-4; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; Smith CL, 2002, MOL CELL BIOL, V22, P525, DOI 10.1128/MCB.22.2.525-535.2002; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Swanson L. W, 1998, BRAIN MAPS STRUCTURE; ToranAllerand CD, 1996, DEV NEUROSCI-BASEL, V18, P36, DOI 10.1159/000111393; Weiss RE, 1999, EMBO J, V18, P1900, DOI 10.1093/emboj/18.7.1900; WHITFIELD HJ, 1990, CELL MOL NEUROBIOL, V10, P145, DOI 10.1007/BF00733641; Xu JJ, 1998, ELECTROCHEM SOLID ST, V1, P1, DOI 10.1149/1.1390615	32	51	51	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					518	+		10.1096/fj.02-0513fje	http://dx.doi.org/10.1096/fj.02-0513fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551846				2022-12-28	WOS:000181453700011
J	Szado, T; Kuo, KH; Bernard-Helary, K; Poburko, D; Lee, CH; Seow, C; Ruegg, UT; Van Breemen, C				Szado, T; Kuo, KH; Bernard-Helary, K; Poburko, D; Lee, CH; Seow, C; Ruegg, UT; Van Breemen, C			Agonist-induced mitochondrial Ca2+ transients in smooth muscle	FASEB JOURNAL			English	Article						calcium; mitochondria; sarcoplasmic reticulum; SMC	CYTOSOLIC CA2+; INOSITOL 1,4,5-TRISPHOSPHATE; SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; CALCIUM OSCILLATIONS; AEQUORIN; RELEASE; FLUORESCENCE; INHIBITION; TRANSPORT	We investigated the role of mitochondria (MT) in calcium signaling in a culture of rat aortic smooth muscle cells. We used targeted aequorin to selectively measure [Ca2+] in this organelle. Our results reveal that smooth muscle cell stimulation with agonists causes a large, transient increase in mitochondrial [Ca2+] ([Ca2+](m)). This large transient can be blocked with inhibitors of the sarco-endoplasmic reticulum Ca2+-ATPase, suggesting a close relationship between the sarcoplasmic reticulum (SR) and the mitochondria. FCCP completely abolished the response to agonists, and targeted mitochondrial GFP revealed a vast tubular network of MT in these cells. When added before stimulation with ATP, IP3 inhibitors partially blocked the ATP-induced rise in mitochondrial Ca2+ release. The role of the Na+/Ca2+ exchanger (NCX) was examined by removing extracellular Na+. This procedure prevented the decrease in the [Ca2+](m) transient normally seen on removal of extracellular Ca2+. We propose a functional linkage of MT and SR dependent on a narrow junctional space between the two organelles in which Ca2+ diffusion is restricted. Approximately half of the mitochondria appear to be associated with the superficial SR, which communicates with the extracellular space via NCX.	Univ British Columbia, St Pauls Hosp, iCAPTUR4E Ctr, Vancouver, BC V5Z 1M9, Canada; Childrens & Womens Hlth Ctr British Columbia, Vancouver, BC, Canada; Univ Lausanne, Sch Pharm, Pharmacol Grp, CH-1015 Lausanne, Switzerland	St. Paul's Hospital; University of British Columbia; University of Saskatchewan; BC Women's Hospital & Health Centre; University of Lausanne	Van Breemen, C (corresponding author), BC Res Inst Childrens & Womens Hlth, 2082-950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	breemen@interchange.ubc.ca	Seow, Chun/AAQ-4099-2020	RUEGG, Urs/0000-0001-6078-8280				ALLEN DG, 1978, NATURE, V273, P509, DOI 10.1038/273509a0; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BLINKS JR, 1978, J PHYSIOL-LONDON, V277, P291, DOI 10.1113/jphysiol.1978.sp012273; Boittin FX, 1998, CELL CALCIUM, V23, P303, DOI 10.1016/S0143-4160(98)90026-4; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; CAUVIN C, 1985, CARDIOVASCULAR EFFEC, P259; Challet C, 2001, J BIOL CHEM, V276, P3791, DOI 10.1074/jbc.M006209200; Cho H, 2001, BRIT J PHARMACOL, V134, P1066, DOI 10.1038/sj.bjp.0704347; COBBOLD PH, 1983, J CELL SCI, V61, P123; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; CROMPTON M, 1978, EUR J BIOCHEM, V82, P25, DOI 10.1111/j.1432-1033.1978.tb11993.x; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; Drummond RM, 1996, PFLUG ARCH EUR J PHY, V431, P473, DOI 10.1007/s004240050025; Drummond RM, 1999, J PHYSIOL-LONDON, V516, P139, DOI 10.1111/j.1469-7793.1999.139aa.x; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; EHRLICH BE, 1995, CURR OPIN NEUROBIOL, V5, P304, DOI 10.1016/0959-4388(95)80042-5; Gerencser AA, 2001, CELL CALCIUM, V30, P311, DOI 10.1054/ceca.2001.0238; Greenwood IA, 1997, J PHYSIOL-LONDON, V505, P53, DOI 10.1111/j.1469-7793.1997.053bc.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Gurney AM, 2000, CELL CALCIUM, V27, P339, DOI 10.1054/ceca.2000.0124; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HANSFORD RG, 1985, REV PHYSIOL BIOCH P, V102, P1, DOI 10.1007/BFb0034084; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; KARAKI H, 1981, BLOOD VESSELS, V18, P28; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; KRONER H, 1986, BIOL CHEM H-S, V367, P483, DOI 10.1515/bchm3.1986.367.1.483; LEE CH, 2002, IN PRESS AM J PHYSL; Li PL, 2001, AM J PHYSIOL-HEART C, V280, pH208, DOI 10.1152/ajpheart.2001.280.1.H208; LO RA, 1996, BRIT J PHARMACOL, V118, P885; McCarron JG, 1999, J PHYSIOL-LONDON, V516, P149, DOI 10.1111/j.1469-7793.1999.149aa.x; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; Montero M, 2001, MOL BIOL CELL, V12, P63, DOI 10.1091/mbc.12.1.63; Nassar A, 2000, J BIOL CHEM, V275, P23661, DOI 10.1074/jbc.M000457200; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Pozzan T, 2000, CELL CALCIUM, V28, P279, DOI 10.1054/ceca.2000.0166; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; RIZZUTO R, 1993, CYTOTECHNOLOGY, V11, P44; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Ruegg Urs T., 1999, Trends in Pharmacological Sciences, V20, P351, DOI 10.1016/S0165-6147(99)01377-2; RUTTER GA, 1988, BIOCHEM J, V252, P181, DOI 10.1042/bj2520181; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; VANBREEMEN C, 1995, TRENDS PHARMACOL SCI, V16, P98, DOI 10.1016/S0165-6147(00)88990-7; Yusufi ANK, 2001, AM J PHYSIOL-RENAL, V281, pF91, DOI 10.1152/ajprenal.2001.281.1.F91	48	54	54	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					28	37		10.1096/fj.02-0334com	http://dx.doi.org/10.1096/fj.02-0334com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12522109				2022-12-28	WOS:000181453700036
J	Wilms, H; Rosenstiel, P; Sievers, J; Deuschl, G; Zecca, L; Lucius, R				Wilms, H; Rosenstiel, P; Sievers, J; Deuschl, G; Zecca, L; Lucius, R			Activation of microglia by human neuromelanin is NF-kappa B-dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease	FASEB JOURNAL			English	Article						nitric oxide; interleukin-6; tumor necrosis factor alpha; neurodegeneration	TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE SYNTHASE; BETA-AMYLOID STIMULATION; SUBSTANTIA-NIGRA; TNF-ALPHA; DOPAMINERGIC NEURODEGENERATION; MPTP MODEL; IN-VITRO; BRAIN; MACROPHAGES	It has been suggested that microglial inflammation augments the progression of Parkinson's disease (PD). However, endogenous factors initiating microglial activation are largely unknown. We therefore investigated the effects of human neuromelanin (NM) on the release of neurotoxic mediators and the underlying signaling pathways from rat microglia in vitro. The addition of NM to microglial cultures induced positive chemotactic effects, activated the proinflammatory transcription factor nuclear factor kappaB (NF-kappaB) via phosphorylation and degradation of the inhibitor protein kappaB (IkappaB), and led to an up-regulation of tumor necrosis factor alpha, interleukin-6, and nitric oxide. The impairment of NF-kappaB function by the IkappaB kinase inhibitor sulfasalazine was paralleled by a decline in neurotoxic mediators. NM also activated p38 mitogen-activated protein kinase (MAPK), the inhibition of this pathway by SB203580 diminished phosphorylation of the transactivation domain of the p65 subunit of NF-kappaB. These findings demonstrate a crucial role of NM in the pathogenesis of PD by augmentation of microglial activation, leading to a vicious cycle of neuronal death, exposure of additional neuromelanin, and chronification of inflammation. The antagonization of microglial activation by a pharmacological intervention targeting microglial NF-kappaB or p38 MAPK could point to additional venues in the treatment of PD.	Univ Kiel, Neurol Klin, D-24105 Kiel, Germany; Univ Kiel, Inst Anat, D-24098 Kiel, Germany; CNR, Inst Biomed Technol, I-20090 Milan, Italy	University of Kiel; University of Kiel; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	Wilms, H (corresponding author), Univ Kiel, Neurol Klin, Niemannsweg 147, D-24105 Kiel, Germany.	h.wilms@neurologie.uni-kiel.de	Sievers, Jobst/A-8672-2010; Rosenstiel, Philip/A-5137-2009; Deuschl, Gunther/A-7986-2010; Lucius, Ralph/B-1614-2010; Wilms, Henrik/J-3082-2013	Rosenstiel, Philip/0000-0002-9692-8828; Deuschl, Gunther/0000-0002-4176-9196; 	Telethon [E.0828] Funding Source: Medline	Telethon(Fondazione Telethon)		Aisen P, 1999, CURR OPIN CHEM BIOL, V3, P200, DOI 10.1016/S1367-5931(99)80033-7; Akama KT, 2000, J BIOL CHEM, V275, P7918, DOI 10.1074/jbc.275.11.7918; Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; Bal-Price A, 2001, J NEUROSCI, V21, P6480; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; BOKA G, 1994, NEUROSCI LETT, V172, P151, DOI 10.1016/0304-3940(94)90684-X; CHAO CC, 1993, J IMMUNOL, V151, P1473; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; Combs CK, 2001, J NEUROSCI, V21, P1179; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; GEBICKEHAERTER PJ, 1989, J NEUROSCI, V9, P183; GIBB WRG, 1992, BRAIN RES, V581, P283, DOI 10.1016/0006-8993(92)90719-P; GIULIAN D, 1993, ADV NEUROL, V59, P315; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Ishikawa A, 1998, J NEUROL, V245, pP4, DOI 10.1007/PL00007745; KARIN M, 2000, ANNU REV IMMUNOL, P18621; KASTNER A, 1992, J NEUROCHEM, V59, P1080, DOI 10.1111/j.1471-4159.1992.tb08350.x; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; Liberatore GT, 1999, NAT MED, V5, P1403; LINDQUIST NG, 1988, NEUROSCI LETT, V93, P1, DOI 10.1016/0304-3940(88)90002-X; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Ma TC, 2000, ARZNEIMITTELFORSCH, V50, P512; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; McGeer PL, 2001, ADV NEUROL, V86, P83; Mihm MJ, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-11-j0003.2001; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Pal PK, 1999, NEUROTOXICOLOGY, V20, P227; Rosenstiel P, 2001, MICROSC RES TECHNIQ, V54, P18, DOI 10.1002/jemt.1116; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Shoham S, 2000, CELL MOL BIOL, V46, P743; SIEVERS J, 1994, GLIA, V12, P245, DOI 10.1002/glia.440120402; SOKOLOWSKI AL, 1990, PHARMACOL TOXICOL, V66, P252, DOI 10.1111/j.1600-0773.1990.tb00743.x; Van Deventer SJH, 2001, GASTROENTEROLOGY, V121, P1242; Waetzig GH, 2002, J IMMUNOL, V168, P5342, DOI 10.4049/jimmunol.168.10.5342; Wilms H, 1999, J NEUROIMMUNOL, V98, P89, DOI 10.1016/S0165-5728(99)00066-1; Wilms H, 1997, CELL TISSUE RES, V287, P447, DOI 10.1007/s004410050769; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zecca L, 1996, NEUROSCIENCE, V73, P407, DOI 10.1016/0306-4522(96)00047-4; Zecca L, 2000, J NEUROCHEM, V74, P1758, DOI 10.1046/j.1471-4159.2000.0741758.x; Zecca L, 2001, J NEUROCHEM, V76, P1766, DOI 10.1046/j.1471-4159.2001.00186.x; ZIELASEK J, 1992, CELL IMMUNOL, V141, P111, DOI 10.1016/0008-8749(92)90131-8	46	242	256	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					500	+		10.1096/fj.02-0314fje	http://dx.doi.org/10.1096/fj.02-0314fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12631585				2022-12-28	WOS:000181453700015
J	Robling, AG; Li, JL; Shultz, KL; Beamer, WG; Turner, CH				Robling, AG; Li, JL; Shultz, KL; Beamer, WG; Turner, CH			Evidence for a skeletal mechanosensitivity gene on mouse chromosome 4	FASEB JOURNAL			English	Article						mechanobiology; bone adaptation; bone genetics; mechanosensitivity; osteoporosis	QUANTITATIVE TRAIT LOCI; BONE MASS; PHYSICAL-ACTIVITY; C3H/HEJ MICE; INBRED MICE; EXPRESSION; SEROTONIN; C57BL/6J; DENSITY; DETERMINANTS	Differences in skeletal mechanical adaptation between C3H/HeJ (C3H) and C57BL/6J (B6) mouse strains suggest that these mice can be used to elucidate the genes involved in mechanosensitivity regulation. The C3H and B6 skeletons also differ in bone size, and several quantitative trait loci (QTL) have been mapped for bone size. We hypothesized that genes controlling bone size (external diameter) might exert their effect by influencing mechanosensitivity. The hypothesis was tested by applying mechanical loads to the ulnae of the B6.C3H-4T (4T) congenic mouse strain, which is genetically 98.4% B6 and carries the C3H chromosome 4 (Chr. 4) QTL genomic DNA. Mechanical strain was measured at the midshaft ulna in separate calibration animals. 4T mice were significantly more responsive to mechanical stimulation than B6 control mice, as assessed by changes in bone geometry and fluorochrome-derived bone formation rates. Bone formation rates were also greater in the ulnae and femora of 6-wk-old 4T mice engaged in normal cage activity compared with age-matched B6 mice. Collectively, the results might explain why 4T mice have wider femora and ulnae than do B6 control mice and suggest that mouse Chr. 4 contains a genetic locus that modulates the mechanosensitivity of bone tissue.	Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA; Jackson Lab, Bar Harbor, ME 04609 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Jackson Laboratory	Robling, AG (corresponding author), Indiana Univ, Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS 5045, Indianapolis, IN 46202 USA.	arobling@anatomy.iupui.edu						Akhter MP, 1998, CALCIFIED TISSUE INT, V63, P442, DOI 10.1007/s002239900554; Beamer WG, 1999, MAMM GENOME, V10, P1043, DOI 10.1007/s003359901159; Beamer WG, 2001, J BONE MINER RES, V16, P1195, DOI 10.1359/jbmr.2001.16.7.1195; Bliziotes MM, 2001, BONE, V29, P477, DOI 10.1016/S8756-3282(01)00593-2; Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756-3282(97)00295-0; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Eisman JA, 1999, ENDOCR REV, V20, P788, DOI 10.1210/er.20.6.788; KANNUS P, 1995, ANN INTERN MED, V123, P27, DOI 10.7326/0003-4819-123-1-199507010-00003; KANNUS P, 1996, BONE S1, V18, P1; Kodama Y, 2000, CALCIFIED TISSUE INT, V66, P298, DOI 10.1007/s002230010060; LAUDER JM, 1993, TRENDS NEUROSCI, V16, P233, DOI 10.1016/0166-2236(93)90162-F; Mason DJ, 1997, BONE, V20, P199, DOI 10.1016/S8756-3282(96)00386-9; Moiseiwitsch JRD, 1997, ANAT EMBRYOL, V195, P71; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Parfitt AM, 1983, BONE HISTOMORPHOMETR, P53; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756-3282(98)00061-1; Pedersen EA, 1999, CALCIFIED TISSUE INT, V65, P41, DOI 10.1007/s002239900655; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; REDDI AH, 1993, J BONE MINER RES, V8, P499; ROBLING AG, 2002, BONE; Rosen Vicki, 1996, P661; SHUEY DL, 1993, ANAT EMBRYOL, V187, P75; SLEMENDA CW, 1991, J BONE MINER RES, V6, P561; Takeda S, 2001, J BONE MINER METAB, V19, P195, DOI 10.1007/s007740170042; TORRANCE AG, 1994, CALCIFIED TISSUE INT, V54, P241, DOI 10.1007/BF00301686; Turner CH, 2001, J BONE MINER RES, V16, P206, DOI 10.1359/jbmr.2001.16.2.206; TURNER CH, 2002, IN PRESS CALCIF TISS, V70; TURNER CH, 2002, T ORTHOP RES SOC, V27, P114; TURNER CH, 2002, T ORTHOP RES SOC, V27, P42; Wallace BA, 2000, CALCIFIED TISSUE INT, V67, P10, DOI 10.1007/s00223001089; WILSON G, 2002, J BONE MINER RES S1, V17	32	47	48	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2002	16	14					324	+		10.1096/fj.02-0393fje	http://dx.doi.org/10.1096/fj.02-0393fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12490544				2022-12-28	WOS:000180574300037
J	Issa, R; Zhou, XY; Trim, N; Millward-Sadler, H; Krane, S; Benyon, C; Iredale, J				Issa, R; Zhou, XY; Trim, N; Millward-Sadler, H; Krane, S; Benyon, C; Iredale, J			Mutation in collagen-I that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration	FASEB JOURNAL			English	Article						apoptosis; metalloproteinase (MMP); tissue inhibitor of metalloproteinase (TIMP); hepatic regeneration	TISSUE INHIBITOR; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE-2; LIPOCYTES SYNTHESIZE; GENE-EXPRESSION; RAT; APOPTOSIS; CLEAVAGE; MECHANISMS; MICE	Collagen-I, which predominates in the neomatrix of fibrotic liver, regulates hepatocyte and hepatic stellate cell (HSC) phenotypes. Recovery from liver fibrosis is accompanied by hepatocyte regeneration, matrix degradation, and HSC apoptosis. Using mice bearing a mutated collagen-I gene (r/r mice), which confers resistance to collagenase degradation, we have investigated the hypothesis that collagen-I degradation is critical to HSC apoptosis and hepatocyte regeneration during recovery from liver fibrosis. During a 28-day recovery period after 8 wk of CCl4 treatment, wild-type (WT) livers had significantly (43%) decreased hydroxyproline (OHP) content. In r/r livers, however, OHP content remained elevated at peak fibrosis levels. Expressed markers of activated HSC (alpha-smooth muscle actin, collagen-I), elevated at peak fibrosis, dropped to control levels in WT livers after 28 days but remained raised in the r/r livers. Moreover, relative to WT livers, r/r livers had significantly reduced stellate cell apoptosis and hepatocyte regeneration during the recovery period. Using extracted collagen-I from each genotype as culture substrata, relative to r/r, we show that WT collagen-I promotes hepatocyte proliferation via stimulation of integrin alphavbeta(3). Failure to degrade collagen-I critically impairs HSC apoptosis and may prevent the effective restoration of hepatocyte mass in liver fibrosis.	Univ Southampton, Southampton Gen Hosp, Liver Res Grp, Southampton SO19 6YD, Hants, England; Univ Southampton, Southampton Gen Hosp, Dept Histopathol Infect Inflammat & Repair, Southampton SO19 6YD, Hants, England; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA	University of Southampton; University of Southampton; Harvard University; Harvard Medical School; Massachusetts General Hospital	Iredale, J (corresponding author), Univ Southampton, Southampton Gen Hosp, Mail Point 811,Level D,S Block, Southampton SO19 6YD, Hants, England.	jpi@soton.ac.uk		Iredale, John/0000-0003-2174-5127	Medical Research Council [G9900297] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Alcolado R, 1997, CLIN SCI, V92, P103, DOI 10.1042/cs0920103; ARTHUR MJP, 1989, J CLIN INVEST, V84, P1076, DOI 10.1172/JCI114270; ARTHUR MJP, 1992, BIOCHEM J, V287, P701, DOI 10.1042/bj2870701; Benyon RC, 1996, GASTROENTEROLOGY, V110, P821, DOI 10.1053/gast.1996.v110.pm8608892; Benyon RC, 1999, HEPATOLOGY, V30, P977, DOI 10.1002/hep.510300431; BURT AD, 1993, J PATHOL, V170, P105, DOI 10.1002/path.1711700203; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; HASTY KA, 1993, MATRIX, V13, P181, DOI 10.1016/S0934-8832(11)80001-6; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hovell C. J., 1995, Hepatology, V22, p369A; Iimuro Y, 1999, HEPATOLOGY, V30, p299A; IREDALE JP, 1994, GUT, V35, P729, DOI 10.1136/gut.35.6.729; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Iredale JP, 1996, HEPATOLOGY, V24, P176, DOI 10.1002/hep.510240129; IREDALE JP, 1992, J CLIN INVEST, V90, P282, DOI 10.1172/JCI115850; IREDALE JP, 1995, CLIN SCI, V89, P75, DOI 10.1042/cs0890075; Issa R, 2001, GUT, V48, P548, DOI 10.1136/gut.48.4.548; Iwamoto H, 1999, J LAB CLIN MED, V134, P83, DOI 10.1016/S0022-2143(99)90057-4; Iwamoto H, 1999, DIGEST DIS SCI, V44, P1038, DOI 10.1023/A:1026633302985; Iwamoto H, 1998, J HEPATOL, V29, P752, DOI 10.1016/S0168-8278(98)80256-0; Krane SM, 1996, J BIOL CHEM, V271, P28509, DOI 10.1074/jbc.271.45.28509; Leyland H, 1996, HEPATOLOGY, V24, P1172, DOI 10.1002/hep.510240532; LIU ML, 1994, HEPATOLOGY, V19, P1521; LIU X, 1995, J CELL BIOL, V130, P227, DOI 10.1083/jcb.130.1.227; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; MARS WM, 1995, HEPATOLOGY, V21, P1695, DOI 10.1016/0270-9139(95)90477-8; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Preaux AM, 1999, HEPATOLOGY, V30, P944, DOI 10.1002/hep.510300432; ROCKEY DC, 1992, J SUBMICR CYTOL PATH, V24, P193; Rudolph KL, 2000, SCIENCE, V287, P1253, DOI 10.1126/science.287.5456.1253; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; Thompson KC, 1998, HEPATOLOGY, V28, P1518, DOI 10.1002/hep.510280611; UKEI T, 1999, NAT MED, V5, P226; VYAS SK, 1995, GASTROENTEROLOGY, V109, P889, DOI 10.1016/0016-5085(95)90399-2; WU H, 1990, P NATL ACAD SCI USA, V87, P5888, DOI 10.1073/pnas.87.15.5888; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481; Zhao WG, 2000, J CLIN INVEST, V106, P941, DOI 10.1172/JCI10158; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	45	158	167	2	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					47	+		10.1096/fj.02-0494fje	http://dx.doi.org/10.1096/fj.02-0494fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475903				2022-12-28	WOS:000180218500026
J	Sfondrini, L; Besusso, D; Rumio, C; Rodolfo, M; Menard, S; Balsari, A				Sfondrini, L; Besusso, D; Rumio, C; Rodolfo, M; Menard, S; Balsari, A			Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA	FASEB JOURNAL			English	Article						murine tumors; CpG-oligodeoxynucleotides; danger signal; innate immunity	CPG-CONTAINING OLIGODEOXYNUCLEOTIDES; ANTISENSE C-MYC; BACTERIAL-DNA; TUMOR-DEVELOPMENT; DENDRITIC CELLS; PROTO-NEU; IMMUNOSTIMULATORY DNA; TH1 RESPONSES; IN-VIVO; MURINE	Unmethylated CpG-oligodeoxynucleotides (CpG-ODNs) are recognized as a 'danger signal' and are potent immunostimulators. To test whether tumors might be prevented by maintaining the innate immune system on continuous alert, proto-neutransgenic female mice, which develop spontaneous mammary tumors, were systemically treated with CpG-ODNs at 10-day intervals. Tumor incidence and number of tumors/mouse were significantly lower in treated mice compared with the control group. Moreover, CpG-ODN systemic treatment significantly reduced lung metastases induced by intravenous inoculation of N202.1A cells derived from a spontaneous mammary carcinoma. Growth of established tumors was modestly inhibited after CpG-ODN systemic treatment but strongly on peritumoral application. Our data indicate that systemic repeated injection of CpG-ODN to maintain the innate immune system on continuous alert prevents the onset of genetically determined tumors and confers tumor protection when the tumor load is low.	Ist Nazl Tumori, Dept Expt Oncol, Chair Immunol, Mol Targeting Unit, I-20133 Milan, Italy; Ist Nazl Tumori, Dept Expt Oncol, Melanoma Genet Unit, I-20133 Milan, Italy; Univ Milan, Inst Pathol, I-20133 Milan, Italy; Univ Milan, Dept Human Anat, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan; University of Milan	Balsari, A (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Chair Immunol, Mol Targeting Unit, Via Venezian 1, I-20133 Milan, Italy.	balsari@istitutotumori.mi.it	rodolfo, monica/H-2671-2012; Sfondrini, Lucia/M-5148-2016; balsari, andrea/M-5657-2016; menard, sylvie mm/C-7940-2011	rodolfo, monica/0000-0002-9196-0298; Sfondrini, Lucia/0000-0003-0350-5402; balsari, andrea/0000-0002-3250-2668; Besusso, Dario/0000-0001-9793-9644				Akira S, 2001, ADV IMMUNOL, V78, P1, DOI 10.1016/S0065-2776(01)78001-7; Amici A, 1998, CANCER IMMUNOL IMMUN, V47, P183, DOI 10.1007/s002620050519; Ballas ZK, 1996, J IMMUNOL, V157, P1840; Boggio K, 1998, J EXP MED, V188, P589, DOI 10.1084/jem.188.3.589; Carpentier AF, 1999, CANCER RES, V59, P5429; Di Carlo E, 2001, CLIN CANCER RES, V7, p830S; Elkins KL, 1999, J IMMUNOL, V162, P2291; Esserman LJ, 1999, CANCER IMMUNOL IMMUN, V47, P337, DOI 10.1007/s002620050539; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hafner M, 2001, CANCER RES, V61, P5523; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Jakob T, 1998, J IMMUNOL, V161, P3042; Kawarada Y, 2001, J IMMUNOL, V167, P5247, DOI 10.4049/jimmunol.167.9.5247; Kim JJ, 1998, EUR J IMMUNOL, V28, P1089, DOI 10.1002/(SICI)1521-4141(199803)28:03<1089::AID-IMMU1089>3.0.CO;2-L; Klinman DM, 1999, IMMUNITY, V11, P123, DOI 10.1016/S1074-7613(00)80087-4; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 1998, J IMMUNOL, V161, P2428; Lipford GB, 1997, EUR J IMMUNOL, V27, P3420, DOI 10.1002/eji.1830271242; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Menard S, 2000, CANCER RES, V60, P273; Pupa SM, 2001, GENE THER, V8, P75, DOI 10.1038/sj.gt.3301360; Reilly RT, 2000, CANCER RES, V60, P3569; Sfondrini L, 1998, GENE THER, V5, P247, DOI 10.1038/sj.gt.3300575; Sfondrini L, 2000, CANCER RES, V60, P3777; Sfondrini L, 2002, J IMMUNOL, V169, P151, DOI 10.4049/jimmunol.169.1.151; Smith JB, 1998, J NATL CANCER I, V90, P1146, DOI 10.1093/jnci/90.15.1146; Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8; Sun SQ, 1997, J IMMUNOL, V159, P3119; Wickstrom E, 1997, ANTISENSE NUCLEIC A, V7, P225, DOI 10.1089/oli.1.1997.7.225; YAMAMOTO S, 1992, J IMMUNOL, V148, P4072; Zimmermann S, 1998, J IMMUNOL, V160, P3627	32	29	31	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2002	16	13					1749	1754		10.1096/fj.02-0383com	http://dx.doi.org/10.1096/fj.02-0383com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12409317				2022-12-28	WOS:000180218500007
J	Umemura, M; Nishimura, H; Yajima, T; Wajjwalk, W; Matsuguchi, T; Takahashi, M; Nishiyama, Y; Makino, M; Nagai, Y; Yoshikai, Y				Umemura, M; Nishimura, H; Yajima, T; Wajjwalk, W; Matsuguchi, T; Takahashi, M; Nishiyama, Y; Makino, M; Nagai, Y; Yoshikai, Y			Overexpression of interleukin-15 prevents the development of murine retrovirus-induced acquired immunodeficiency syndrome	FASEB JOURNAL			English	Article						IL-15; transgenic mice; murine AIDS; CD8(+); CTL; NK cells; gene therapy	CYTOTOXIC T-LYMPHOCYTES; RECEPTOR-BETA-CHAIN; NATURAL-KILLER; DELAYED PROGRESSION; IL-15; CELLS; AIDS; CYTOKINE; MICE; EXPRESSION	LP-BM5 murine leukemia virus (MuLV) infection causes murine acquired immunodeficiency syndrome (MAIDS), a disease characterized by varied functional abnormalities of immunocompetent cells. We found that MAIDS progression was severely retarded in IL-15 transgenic (Tg) mice constructed with cDNA encoding secretable IL-15 under the control of an MHC class I promoter. Several immune defects, including impaired natural killer activity, depressed IFN-gamma production by T cells stimulated with anti-T cell receptor cross-linking, and increased susceptibility to Mycobacteium bovis infection, were prevented in IL-15 Tg mice inoculated with LP-BM5 MuLV. Cytotoxic T lymphocyte response to a highly antigenic 10-mer peptide encoded by LP-BM5-defective virus gag p12 gene was detected in the spleen and peritoneal exudate cells from IL-15 Tg mice infected with LP-BM5 MuLV. Intramuscular injection of cDNA encoding secretable IL-15 also prevented the development of MAIDS. These results indicate that IL-15 prevents the progression of MAIDS and may provide insight into an immunotherapeutic approach using the IL-15 gene for controlling retrovirus-induced immunodeficiency.	Kyushu Univ, Med Inst Bioregulat, Div Host Def, Higashi Ku, Fukuoka 8128582, Japan; Nagoya Univ, Grad Sch Med, Dis Mechanism & Control Res Inst, Host Def Lab, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dept Pathol 2, Ctr Excellence, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Dis Mechanism & Control Res Inst, Virol Lab, Nagoya, Aichi 4668550, Japan; Natl Inst Infect Dis, Leprosy Res Ctr, Tokyo 1890002, Japan; Toyama Inst Hlth, Toyama 9390363, Japan	Kyushu University; Nagoya University; Nagoya University; Nagoya University; National Institute of Infectious Diseases (NIID)	Yoshikai, Y (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Host Def, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yoshikai@bioreg.kyushu-u.ac.jp	Matsuguchi, Tetsuya/HGU-0412-2022; Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; 				AOKI Y, 1994, J IMMUNOL, V153, P3611; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; CHATTOPADHYAY SK, 1991, J VIROL, V65, P4232, DOI 10.1128/JVI.65.8.4232-4241.1991; Fehniger TA, 2001, J EXP MED, V193, P219, DOI 10.1084/jem.193.2.219; GAZZINELLI RT, 1994, J EXP MED, V180, P2199, DOI 10.1084/jem.180.6.2199; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; GREEN WR, 1994, J VIROL, V68, P4679, DOI 10.1128/JVI.68.7.4679-4684.1994; GREEN WR, 1994, VIROLOGY, V200, P292, DOI 10.1006/viro.1994.1189; Green WR, 1999, IMMUNOL REV, V168, P271, DOI 10.1111/j.1600-065X.1999.tb01298.x; Hiroi T, 2000, J IMMUNOL, V165, P4329, DOI 10.4049/jimmunol.165.8.4329; Hiromatsu K, 1997, MICROBIOL IMMUNOL, V41, P221, DOI 10.1111/j.1348-0421.1997.tb01194.x; HIROMATSU K, 1994, EUR J IMMUNOL, V24, P2446, DOI 10.1002/eji.1830241028; HITOSHI Y, 1993, J EXP MED, V177, P621, DOI 10.1084/jem.177.3.621; Ishimitsu R, 2001, J IMMUNOL, V166, P1991, DOI 10.4049/jimmunol.166.3.1991; KANAGAWA O, 1995, EUR J IMMUNOL, V25, P2421, DOI 10.1002/eji.1830250902; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Kimura K, 1999, EUR J IMMUNOL, V29, P1532, DOI 10.1002/(SICI)1521-4141(199905)29:05<1532::AID-IMMU1532>3.0.CO;2-Z; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; MAKINO M, 1992, J IMMUNOL, V149, P1702; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; Mayrand SM, 1998, J IMMUNOL, V160, P39; Mizuochi T, 1998, VACCINE, V16, P2026, DOI 10.1016/S0264-410X(98)00082-6; MORSE HC, 1992, AIDS, V6, P607, DOI 10.1097/00002030-199207000-00001; MORSE HC, 1989, J IMMUNOL, V143, P844; MOSIER DE, 1985, J EXP MED, V161, P766, DOI 10.1084/jem.161.4.766; Muralidhar G, 1996, J IMMUNOL, V157, P625; Nishimura H, 2000, J EXP MED, V191, P157, DOI 10.1084/jem.191.1.157; Ohteki T, 1997, J IMMUNOL, V159, P5931; OKADA Y, 1992, J VIROL, V66, P5177, DOI 10.1128/JVI.66.9.5177-5182.1992; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Umemura M, 2001, J LEUKOCYTE BIOL, V69, P138; Umemura M, 2001, J IMMUNOL, V167, P946, DOI 10.4049/jimmunol.167.2.946; Usami J, 1996, J VIROL, V70, P8917, DOI 10.1128/JVI.70.12.8917-8925.1996; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; WANG Y, 1994, IMMUNOLOGY, V83, P384; Xin KQ, 1999, VACCINE, V17, P858, DOI 10.1016/S0264-410X(98)00271-0; Yajima T, 2002, J IMMUNOL, V168, P1198, DOI 10.4049/jimmunol.168.3.1198	40	14	14	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					1755	1763		10.1096/fj.02-0274com	http://dx.doi.org/10.1096/fj.02-0274com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12409318				2022-12-28	WOS:000180218500008
J	Szuba, A; Skobe, M; Karkkainen, MJ; Shin, WS; Beynet, DP; Rockson, NB; Dakhil, N; Spilman, S; Goris, ML; Strauss, HW; Quertermous, T; Alitalo, K; Rockson, SG				Szuba, A; Skobe, M; Karkkainen, MJ; Shin, WS; Beynet, DP; Rockson, NB; Dakhil, N; Spilman, S; Goris, ML; Strauss, HW; Quertermous, T; Alitalo, K; Rockson, SG			Therapeutic lymphangiogenesis with human recombinant VEGF-C	FASEB JOURNAL			English	Article						lymphedema; lymphatics; microcirculation; growth factors; angiogenesis	LYMPHATIC ENDOTHELIUM; TRANSGENIC MICE; GROWTH-FACTORS; BREAST-CANCER; BLOOD-VESSELS; UPPER-LIMB; LYMPHEDEMA; ANGIOGENESIS; RECEPTOR; MODEL	Chronic regional impairments of the lymphatic circulation often lead to striking architectural abnormalities in the lymphedematous tissues. Lymphedema is a common, disabling disease that currently lacks a cure. Vascular endothelial growth factors C and D mediate lymphangiogenesis through the VEGFR-3 receptor on lymphatic endothelia. The purpose of this study was to investigate the therapeutic potential for lymphangiogenesis with VEGF-C. We developed a rabbit ear model to simulate human chronic postsurgical lymphatic insufficiency. Successful, sustained surgical ablation of the ear lymphatics was confirmed by water displacement volumetry. After complete healing, the experimental animals (n=8) received a single, s.c. 100 mug dose of VEGF-C in the operated ear; controls (n=8) received normal saline. Radionuclide lymphoscintigraphy was performed to quantitate lymphatic function. Immunohistochemistry (IHC) was performed 7-8 days following treatment. After VEGF-C, there was a quantifiable amelioration of lymphatic function. IHC confirmed a significant increase in lymphatic vascularity, along with reversal of the intense tissue hypercellularity of untreated lymphedema. This study confirms the capacity of a single dose of VEGF-C to induce therapeutic lymphangiogenesis in acquired lymphedema. In addition to improving lymphatic function and vascularity, VEGF-C can apparently reverse the abnormalities in tissue architecture that accompany chronic lymphatic insufficiency.	Stanford Univ, Sch Med, Div Cardiovasc Med, Falk Cardiovasc Res Ctr, Stanford, CA 94305 USA; Derald H Ruttenberg Canc Ctr, Mt Sinai Sch Med, New York, NY USA; Univ Helsinki, Haartman Inst, Helsinki, Finland	Stanford University; Icahn School of Medicine at Mount Sinai; University of Helsinki	Rockson, NB (corresponding author), Stanford Univ, Sch Med, Div Cardiovasc Med, Falk Cardiovasc Res Ctr, Stanford, CA 94305 USA.	srockson@cvmed.stanford.edu	Szuba, Andrzej/AAY-1162-2020; Alitalo, Kari K/J-5013-2014; Szuba, Andrzej/C-1655-2013	Alitalo, Kari K/0000-0002-7331-0902; rockson, stanley/0000-0003-1253-474X; Szuba, Andrzej/0000-0002-7555-6201; Quertermous, Thomas/0000-0002-7645-9067				Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; Bourgeois P, 1998, CANCER-AM CANCER SOC, V83, P2805; CHEN HC, 1989, PLAST RECONSTR SURG, V83, P1022, DOI 10.1097/00006534-198906000-00016; Daroczy J, 1995, CLIN DERMATOL, V13, P433, DOI 10.1016/0738-081X(95)00086-U; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Erhard H, 1996, J INVEST DERMATOL, V106, P135, DOI 10.1111/1523-1747.ep12329708; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gerber LH, 1998, CANCER, V83, P2803, DOI 10.1002/(SICI)1097-0142(19981215)83:12B+<2803::AID-CNCR29>3.3.CO;2-N; HUANG G-K, 1983, Microsurgery, V4, P236; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P1751; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; KANTER MA, 1990, PLAST RECONSTR SURG, V85, P573, DOI 10.1097/00006534-199004000-00012; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Lee-Donaldson L, 1999, LYMPHOLOGY, V32, P111; Mortimer PS, 1998, CANCER, V83, P2798, DOI 10.1002/(SICI)1097-0142(19981215)83:12B+<2798::AID-CNCR28>3.3.CO;2-5; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Olszewski W, 1970, Pol Med J, V9, P1441; OLSZEWSKI W, 1968, J CARDIOVASC SURG, V9, P178; Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com; PECKING A, 1991, B CANCER, V78, P373; Petrek JA, 1998, CANCER-AM CANCER SOC, V83, P2776, DOI 10.1002/(SICI)1097-0142(19981215)83:12B+<2776::AID-CNCR25>3.0.CO;2-V; PILLER NB, 1980, LYMPHOLOGY, V13, P109; PILLER NB, 1990, ARCH HISTOL CYTOL, V53, P209, DOI 10.1679/aohc.53.Suppl_209; Rivard A, 1998, MOL MED, V4, P429, DOI 10.1007/BF03401749; ROCKSON S, 2000, CURRENT THERAPY VASC; Rockson SG, 1998, CANCER, V83, P2882, DOI 10.1002/(SICI)1097-0142(19981215)83:12B+<2882::AID-CNCR45>3.0.CO;2-0; Rockson SG, 2001, AM J MED, V110, P288, DOI 10.1016/S0002-9343(00)00727-0; Ruiter D J, 1993, Behring Inst Mitt, P258; Ryan TJ, 1995, CLIN DERMATOL, V13, P451, DOI 10.1016/0738-081X(95)00091-S; SAARISTO A, IN PRESS FASEB J; SCHIRGER A, 1962, JAMA-J AM MED ASSOC, V182, P124; SCHLINGEMANN RO, 1985, LAB INVEST, V52, P71; SEGERSTROM K, 1992, SCAND J PLAST RECONS, V26, P223, DOI 10.3109/02844319209016016; Skobe M, 2000, J INVEST DERM SYMP P, V5, P14, DOI 10.1046/j.1087-0024.2000.00001.x; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Sleeman JP, 2001, MICROSC RES TECHNIQ, V55, P61, DOI 10.1002/jemt.1157; SUKUL DMKSK, 1993, J BIOMED ENG, V15, P477, DOI 10.1016/0141-5425(93)90062-4; Szuba A, 1998, Vasc Med, V3, P145, DOI 10.1177/1358836X9800300209; SZUBA A, IN PRESS NUCL MED CO; Veikkola T, 2000, CANCER RES, V60, P203; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223	46	178	194	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1985	+		10.1096/fj.02-0401fje	http://dx.doi.org/10.1096/fj.02-0401fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397087				2022-12-28	WOS:000179167600007
J	Britt, KL; Kerr, J; O'Donnell, L; Jones, MEE; Drummond, AE; Davis, SR; Simpson, ER; Findlay, JK				Britt, KL; Kerr, J; O'Donnell, L; Jones, MEE; Drummond, AE; Davis, SR; Simpson, ER; Findlay, JK			Estrogen regulates development of the somatic cell phenotype in the eutherian ovary	FASEB JOURNAL			English	Article						estrogen deficiency; Sertoli cell; granulosa cell; sex steroids	SEX-DETERMINING REGION; TARGETED DISRUPTION; GERM-CELLS; AROMATASE-ACTIVITY; RECEPTORS ALPHA; MAMMALIAN GONAD; MOUSE; GENE; MICE; REVERSAL	Steroids play a critical role in gonadal differentiation in birds, reptiles, and amphibia whereas gonadal differentiation in mammals is thought to be determined by genetic mechanisms. The gonads of female mice incapable of synthesizing estrogens due to disruption of the aromatase gene (ArKO) provide a unique model to test the role of estrogen in regulating the gonadal phenotype. We have shown that in the absence of estrogen, genetically female mice develop testicular tissue within their ovaries. The ovaries develop cells that possess structural and functional characteristics of testicular interstitial cells and of seminiferous tubule-like structures lined with Sertoli cells. Moreover, the ovaries express mRNA for the testis-specific Sertoli cell transcription factor Sox 9 and espin protein, which is specific for inter-Sertoli cell junctions. The development of the testicular tissue in this model can be reverted/postponed by replacing estrogen. When ArKO female mice were fed a diet containing phytoestrogens, the appearance of Leydig and Sertoli cells was postponed and reduced. Furthermore, administration of estradiol-17beta decreased the number of Sertoli and Leydig cells in the ovaries. These findings constitute definitive evidence that estrogen plays a critical role in maintaining female somatic interstitial and granulosa cells in the eutherian ovary.	Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia; Monash Univ, Dept Anat & Cell Biol, Clayton, Vic 3168, Australia; Jean Hailes Fdn, Clayton, Vic 3168, Australia	Prince Henry's Institute of Medical Research; Monash University; Monash University	Britt, KL (corresponding author), Prince Henrys Inst Med Res, POB 5152, Clayton, Vic 3168, Australia.	kara.britt@med.monash.edu.au	Britt, Kara/B-2437-2013; Davis, Susan D/GZL-2361-2022; Britt, Kara/A-5568-2009; Davis, Susan R/A-3111-2009	Britt, Kara/0000-0001-6069-7856; Davis, Susan R/0000-0002-2955-0415; Jones, Margaret/0000-0002-0678-3187; Drummond, Ann/0000-0002-2183-6013; O'Donnell, Liza/0000-0001-5848-6136	NATIONAL INSTITUTE ON AGING [R37AG008174] Funding Source: NIH RePORTER; NIA NIH HHS [R37AG08174] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; Bishop CE, 2000, NAT GENET, V26, P490, DOI 10.1038/82652; BRITT K, 2001, US END SOC M JUN 18; Britt KL, 2000, ENDOCRINOLOGY, V141, P2614, DOI 10.1210/en.141.7.2614; Burns RK, 1925, J EXP ZOOL, V42, P31, DOI 10.1002/jez.1400420104; Buyse A, 1935, J EXP ZOOL, V70, P1, DOI 10.1002/jez.1400700102; Capel B, 1996, CURR TOP DEV BIOL, V32, P1, DOI 10.1016/S0070-2153(08)60423-8; Chapin CL, 1917, J EXP ZOOL, V23, P453, DOI 10.1002/jez.1400230209; Colvin JS, 2001, CELL, V104, P875, DOI 10.1016/S0092-8674(01)00284-7; Couse JF, 1999, SCIENCE, V286, P2328, DOI 10.1126/science.286.5448.2328; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Coveney D, 2001, BIOL REPROD, V65, P613, DOI 10.1095/biolreprod65.2.613; CRUMEYROLLEARIAS M, 1976, GERONTOLOGY, V22, P185, DOI 10.1159/000212133; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; DESVAGES G, 1992, J STEROID BIOCHEM, V41, P851, DOI 10.1016/0960-0760(92)90437-N; DESVAGES G, 1993, GEN COMP ENDOCR, V92, P54, DOI 10.1006/gcen.1993.1142; Dorizzi M, 1996, DIFFERENTIATION, V60, P193, DOI 10.1046/j.1432-0436.1996.6040193.x; Dupont S, 2000, DEVELOPMENT, V127, P4277; Dym M, 1970, Biology Reprod., V3, P308; ENGLE ET, 1946, CANCER RES, V6, P578; Findlay JK, 2000, MOL CELL ENDOCRINOL, V163, P81, DOI 10.1016/S0303-7207(99)00243-9; Fisher CR, 1998, P NATL ACAD SCI USA, V95, P6965, DOI 10.1073/pnas.95.12.6965; GONDOS B, 1980, J ENDOCRINOL, V87, P265, DOI 10.1677/joe.0.0870265; GREENE R. R., 1942, Biol. Sympos., V9, P105; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HACKER A, 1995, DEVELOPMENT, V121, P1603; HASHIMOTO N, 1990, J EXP ZOOL, V253, P61, DOI 10.1002/jez.1402530109; Jones MEE, 2000, P NATL ACAD SCI USA, V97, P12735, DOI 10.1073/pnas.97.23.12735; Jost A., 1973, Recent Progress Hormone Res, V29, P1; Kent J, 1996, DEVELOPMENT, V122, P2813; Lillie FR, 1917, J EXP ZOOL, V23, P371, DOI 10.1002/jez.1400230208; MACINTYRE MN, 1956, ANAT RECORD, V124, P27, DOI 10.1002/ar.1091240103; MCLAREN A, 1991, BIOESSAYS, V13, P151, DOI 10.1002/bies.950130402; MERCHANT H, 1975, DEV BIOL, V44, P1, DOI 10.1016/0012-1606(75)90372-3; Merchant-Larios H, 1981, Prog Clin Biol Res, V59B, P383; Ng LJ, 1997, DEV BIOL, V183, P108, DOI 10.1006/dbio.1996.8487; O'Donnell L, 2000, BIOL REPROD, V63, P99, DOI 10.1095/biolreprod63.1.99; O'Donnell L, 2001, ENDOCR REV, V22, P289, DOI 10.1210/er.22.3.289; Pailhoux E, 2001, DEV DYNAM, V222, P328, DOI 10.1002/dvdy.1194; PIEAU C, 1994, ENV CONTROL GONADAL; RUSSELL L, 1977, TISSUE CELL, V9, P475, DOI 10.1016/0040-8166(77)90007-6; Scully RE, 1979, ATLAS TUMOR PATHOLOG; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; TAKETO T, 1984, ANN NY ACAD SCI, V438, P671, DOI 10.1111/j.1749-6632.1984.tb38370.x; TAKETOHOSOTANI T, 1985, J EXP ZOOL, V236, P229, DOI 10.1002/jez.1402360213; Toda K, 2001, J ENDOCRINOL, V170, P99, DOI 10.1677/joe.0.1700099; TURNER CD, 1962, AM ZOOL, V2, P565; Vaillant S, 2001, DEV DYNAM, V222, P228, DOI 10.1002/dvdy.1190; Vaillant S, 2001, J EXP ZOOL, V290, P727, DOI 10.1002/jez.1123; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; Vidal VPI, 2001, NAT GENET, V28, P216, DOI 10.1038/90046; VOGL AW, 1989, INT REV CYTOL, V119, P1; Whitworth DJ, 1998, TRENDS ENDOCRIN MET, V9, P2, DOI 10.1016/S1043-2760(98)00002-2; Wilson J D, 1981, Recent Prog Horm Res, V37, P1; WILSON JD, 1981, SCIENCE, V211, P1278, DOI 10.1126/science.7010602; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15	57	81	81	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2002	16	11					1389	1397		10.1096/fj.01-0992com	http://dx.doi.org/10.1096/fj.01-0992com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12205030				2022-12-28	WOS:000178441800013
J	Hajitou, A; Grignet-Debrus, C; Devy, L; Berndt, S; Blacher, S; Deroanne, CF; Bajou, K; Fong, T; Chiang, YW; Foidart, JM; Noel, A				Hajitou, A; Grignet-Debrus, C; Devy, L; Berndt, S; Blacher, S; Deroanne, CF; Bajou, K; Fong, T; Chiang, YW; Foidart, JM; Noel, A			The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells	FASEB JOURNAL			English	Article						angiogenesis; adenoviruses; angiostatic factors; anti-tumoral effects	IN-VIVO; ANGIOGENESIS; CANCER; INHIBITOR; GENE; ACTIVATION; GENERATION; INVASION; THERAPY; SURFACE	Endostatin and angiostatin are known as tumor-derived angiogenesis inhibitors, but their mechanisms of action are not yet completely defined. We report here that endostatin and angiostatin, delivered by adenoviral vectors, reduced in vitro the neovessel formation in the mouse aortic ring assay by 85 and 40%, respectively. We also demonstrated in vivo that both endostatin and angiostatin inhibited local invasion and tumor vascularization of transplanted murine malignant keratinocytes, and reduced by 50 and 90% the development of highly vascularized murine mammary tumors. This inhibition of tumor growth was associated with a reduction of tumor vascularization. Expression analysis of vascular endothelial growth factor (VEGF) carried out in the mouse aortic ring model revealed a 3- to 10-fold down-regulation of VEGF mRNA expression in endostatin-treated rings. A similar down-regulation of VEGF expression at both mRNA and protein levels was also observed in the two in vivo cancer models after treatment with each angiogenesis inhibitor. This suggests that endostatin and angiostatin effects may be mediated, at least in part, by their ability to down-regulate VEGF expression within the tumor. This work provides evidence that endostatin and angiostatin act on tumor cells themselves.	Univ Liege, Inst Pathol B23, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Univ Liege, Lab Connect Tissues Biol, B-4000 Liege, Belgium; Aventis, Dept Oncol, Hayward, CA 94545 USA	University of Liege; University of Liege; Sanofi-Aventis	Noel, A (corresponding author), Univ Liege, Inst Pathol B23, Lab Tumor & Dev Biol, B-4000 Liege, Belgium.	agnes.noel@ulg.ac.be		Bajou, Khalid/0000-0002-5529-9228; Noel, Agnes/0000-0002-7670-6179; Hajitou, Amin/0000-0003-1119-5686				Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Blacher Silvia, 2001, Angiogenesis, V4, P133, DOI 10.1023/A:1012251229631; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen CT, 2000, HUM GENE THER, V11, P1983, DOI 10.1089/10430340050143417; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; Deroanne CF, 1997, CANCER RES, V57, P5590; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; Dhanabal M, 1999, CANCER RES, V59, P189; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187; Gyorffy S, 2001, AM J PATHOL, V159, P1137, DOI 10.1016/S0002-9440(10)61790-7; HAJITOU A, 1995, INT J CANCER, V63, P702, DOI 10.1002/ijc.2910630516; Hajitou A, 2001, CANCER RES, V61, P3450; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kim YM, 2000, CANCER RES, V60, P5410; Kirsch M, 1998, CANCER RES, V58, P4654; Kuo CJ, 2001, P NATL ACAD SCI USA, V98, P4605, DOI 10.1073/pnas.081615298; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Munaut C, 1999, J BIOL CHEM, V274, P5588, DOI 10.1074/jbc.274.9.5588; NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Perletti G, 2000, CANCER RES, V60, P1793; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com; Sim BKL, 1997, CANCER RES, V57, P1329; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; Soff GA, 2000, CANCER METAST REV, V19, P97, DOI 10.1023/A:1026525121027; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; Sun Y, 2001, IEEE J SEL TOP QUANT, V7, P1; Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200; Wen W, 1999, CANCER RES, V59, P6052; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Yokoyama Y, 2000, CANCER RES, V60, P4362	45	141	176	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2002	16	11					1802	+		10.1096/fj.02-0109fje	http://dx.doi.org/10.1096/fj.02-0109fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12354694				2022-12-28	WOS:000178441800003
J	Hu, VW; Black, GE; Torres-Duarte, A; Abramson, FP				Hu, VW; Black, GE; Torres-Duarte, A; Abramson, FP			H-3-thymidine is a defective tool with which to measure rates of DNA synthesis	FASEB JOURNAL			English	Article						radiation damage; stable isotopes; mass spectrometry	CHEMICAL-REACTION INTERFACE; CELL-CYCLE PROGRESSION; MASS-SPECTROMETRY; PROLIFERATION; <H-3>THYMIDINE; RADIOTOXICITY; FRAGMENTATION; APOPTOSIS; TRITIUM; ARREST	Metabolic incorporation of H-3-thymidine into cellular DNA is a widely used protocol to monitor rates of DNA synthesis and cell proliferation. However, this radiochemical has also been reported to induce cell-cycle arrest and apoptosis in addition to DNA damage. Using stable isotope-labeled thymidine, we demonstrate that H-3-thymidine induces dose-dependent inhibition of the rate of DNA synthesis. This inhibition occurred within the first round of replication after addition of the radiolabeled tracer and demonstrates the cytotoxic effects of conventional doses of H-3-thymidine (typically greater than or equal to1 muCi/ml). These results thus show that stable isotope methods are superior to radioisotopes for determining rates of DNA synthesis and cell replication. Because H-3-thymidine perturbs the very process it was employed to study, experiments using H-3-thymidine to monitor DNA synthesis and cell proliferation should be interpreted with caution.	George Washington Univ, Dept Biochem & Mol Biol, Med Ctr, Washington, DC 20037 USA; George Washington Univ, Dept Pharmacol, Med Ctr, Washington, DC 20037 USA	George Washington University; George Washington University	Hu, VW (corresponding author), George Washington Univ, Dept Biochem & Mol Biol, Med Ctr, 2300 Eye St NW, Washington, DC 20037 USA.	bcmvwh@gwumc.edu		Hu, Valerie/0000-0002-3357-0777				ABRAMSON FP, 1994, MASS SPECTROM REV, V13, P341, DOI 10.1002/mas.1280130403; Chen P, 1998, ANAL CHEM, V70, P1664, DOI 10.1021/ac971294i; CLEAVER JE, 1972, SCIENCE, V177, P996, DOI 10.1126/science.177.4053.996; DOVER R, 1994, J CELL SCI, V107, P1181; EHMANN UK, 1975, NATURE, V258, P633, DOI 10.1038/258633a0; HOFER KG, 1971, RADIAT RES, V47, P94, DOI 10.2307/3573291; Hu VW, 2001, FASEB J, V15, P1562, DOI 10.1096/fj.01-0102com; Hu VW, 2000, FASEB J, V14, P448, DOI 10.1096/fasebj.14.3.448; KASSIS AI, 1980, RADIAT RES, V84, P407, DOI 10.2307/3575480; LEMOTTE PK, 1982, P NATL ACAD SCI-BIOL, V79, P7763, DOI 10.1073/pnas.79.24.7763; Macallan DC, 1998, P NATL ACAD SCI USA, V95, P708, DOI 10.1073/pnas.95.2.708; MAURER HR, 1981, CELL TISSUE KINET, V14, P111, DOI 10.1111/j.1365-2184.1981.tb00516.x; Neese RA, 2001, ANAL BIOCHEM, V298, P189, DOI 10.1006/abio.2001.5375; Nias AHW, 1998, INTRO RADIOBIOLOGY; Nissim I, 2000, ANAL BIOCHEM, V278, P198, DOI 10.1006/abio.1999.4427; Olive PL, 1999, INT J RADIAT BIOL, V75, P395, DOI 10.1080/095530099140311; SOLARY E, 1992, EXP CELL RES, V203, P495, DOI 10.1016/0014-4827(92)90027-6; Teffera Y, 1996, ANAL CHEM, V68, P1888, DOI 10.1021/ac951255b; VESTAL ML, 1990, ACS SYM SER, V420, P215; Wang B, 1999, HEALTH PHYS, V77, P16, DOI 10.1097/00004032-199907000-00005; Yanokura M, 2000, INT J RADIAT BIOL, V76, P295, DOI 10.1080/095530000138637; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2	22	38	42	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1456	+		10.1096/fj.02-0142fje	http://dx.doi.org/10.1096/fj.02-0142fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205046				2022-12-28	WOS:000177813100015
J	Patel, HH; Ludwig, LM; Fryer, RM; Hsu, AK; Warltier, DC; Gross, GJ				Patel, HH; Ludwig, LM; Fryer, RM; Hsu, AK; Warltier, DC; Gross, GJ			Delta opioid agonists and volatile anesthetics facilitate cardioprotection via potentiation of K-ATP channel opening	FASEB JOURNAL			English	Article						isoflurane; infarction; ischemia; preconditioning	PROTEIN-KINASE-C; SENSITIVE POTASSIUM CHANNELS; RABBIT VENTRICULAR MYOCYTES; MYOCARDIAL PROTECTION; STUNNED MYOCARDIUM; NITRIC-OXIDE; RAT-HEART; ISOFLURANE; MITOCHONDRIAL; MECHANISM	Opioids and volatile anesthetics produce marked cardioprotective effects against myocardial infarction via the activation of ATP-sensitive potassium (K-ATP) channels, however, the effect of combined treatment with both drugs is unknown. We examined the hypothesis that opioids and volatile anesthetics potentiate cardiac K-ATP channel opening, thereby enhancing cardioprotection. Rats were treated with the delta opioid agonists, TAN-67 or BW373U86, or isoflurane, together or alone with and without diazoxide, a mitochondrial K-ATP channel opener. Glibenclamide, a non-selective K-ATP channel blocker, was used to further characterize the signaling mechanism involved. Myocardial infarct size (IS) was determined by tetrazolium staining and was expressed as a percent of the area at risk (AAR). High doses of TAN-67 (10 mg/kg), diazoxide (10 mg/kg), and isoflurane (1 MAC) produced a significant reduction in IS compared with the control group (30+/-3%, 36+/-5%, and 42+/-2 vs. 58+/-2%, respectively), whereas lower doses of the drugs had no effect except for the low dose of isoflurane (0.5 MAC). The combination of TAN-67 and diazoxide or isoflurane and diazoxide resulted in a marked reduction in IS compared with controls in the presence of high (9+/-3% and 14+/-3%) and low (17+/-7% and 31+/-7%) dose combinations, respectively. The combination of TAN-67 or BW373U86 and isoflurane also caused a striking reduction in IS/AAR (16+/-7% and 7+/-2%, respectively). To date, this is the first demonstration that opioids and volatile anesthetics work in conjunction to confer protection against myocardial infarction through potentiation of cardiac K-ATP channel opening.	Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; Harvard Univ, Inst Med, Ctr Neurol Dis, Boston, MA 02115 USA; Med Coll Wisconsin, Dept Anesthesiol, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Harvard University; Medical College of Wisconsin	Gross, GJ (corresponding author), Med Coll Wisconsin, Dept Pharmacol & Toxicol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	ggross@mcw.edu	Patel, Hemal/C-7325-2019	Patel, Hemal/0000-0001-6722-9625				Benedict PE, 1999, CIRCULATION, V100, P357; Carroll R, 2001, CARDIOVASC RES, V51, P691, DOI 10.1016/S0008-6363(01)00330-3; Forbes RA, 2001, CIRC RES, V88, P802, DOI 10.1161/hh0801.089342; Fryer RM, 2001, AM J PHYSIOL-HEART C, V280, pH1346, DOI 10.1152/ajpheart.2001.280.3.H1346; Fryer RM, 1999, CIRC RES, V84, P846; Fryer RM, 2000, J PHARMACOL EXP THER, V294, P451; Han J, 1996, BIOCHEM BIOPH RES CO, V229, P852, DOI 10.1006/bbrc.1996.1891; Hu KL, 1996, CIRC RES, V78, P492, DOI 10.1161/01.RES.78.3.492; Kashimoto S, 1998, EUR J ANAESTH, V15, P553; Kersten JR, 1996, ANESTH ANALG, V83, P27, DOI 10.1097/00000539-199607000-00006; Kersten JR, 1997, ANESTHESIOLOGY, V86, P1128, DOI 10.1097/00000542-199705000-00017; Kersten JR, 1996, ANESTHESIOLOGY, V85, P794, DOI 10.1097/00000542-199610000-00015; Kersten JR, 1997, ANESTHESIOLOGY, V87, P361, DOI 10.1097/00000542-199708000-00024; Liu YG, 1997, AM J PHYSIOL-HEART C, V273, pH1637, DOI 10.1152/ajpheart.1997.273.4.H1637; Liu YG, 1996, CIRC RES, V78, P443, DOI 10.1161/01.RES.78.3.443; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nakayama M, 1997, ACTA ANAESTH SCAND, V41, P531, DOI 10.1111/j.1399-6576.1997.tb04737.x; Ockaili R, 1999, AM J PHYSIOL-HEART C, V277, pH2425, DOI 10.1152/ajpheart.1999.277.6.H2425; Patel HH, 2001, J MOL CELL CARDIOL, V33, P1455, DOI 10.1006/jmcc.2001.1408; Piriou V, 1997, BRIT J ANAESTH, V79, P68, DOI 10.1093/bja/79.1.68; Piriou V, 2000, ANESTHESIOLOGY, V93, P756, DOI 10.1097/00000542-200009000-00025; SAKAI K, 2000, ACTA ANAESTHESIOL SC, V44; Sasaki N, 2000, CIRCULATION, V101, P439, DOI 10.1161/01.CIR.101.4.439; Sato T, 2000, CIRCULATION, V102, P800, DOI 10.1161/01.CIR.102.7.800; Schultz JE, 1998, CIRCULATION, V97, P1282, DOI 10.1161/01.CIR.97.13.1282; Schultz JEJ, 1998, AM J PHYSIOL-HEART C, V274, pH909, DOI 10.1152/ajpheart.1998.274.3.H909; Schultz JEJ, 1996, CIRC RES, V78, P1100, DOI 10.1161/01.RES.78.6.1100; Toller WG, 1999, ANESTHESIOLOGY, V91, P713, DOI 10.1097/00000542-199909000-00024; Toller WG, 2000, ANESTHESIOLOGY, V92, P1400, DOI 10.1097/00000542-200005000-00031; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; Vanden Hoek TL, 2000, CIRC RES, V86, P541, DOI 10.1161/01.RES.86.5.541	31	48	52	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1468	+		10.1096/fj.02-0170fje	http://dx.doi.org/10.1096/fj.02-0170fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205051				2022-12-28	WOS:000177813100011
J	Straub, RH; Gunzler, C; Miller, LE; Cutolo, M; Scholmerich, J; Schill, S				Straub, RH; Gunzler, C; Miller, LE; Cutolo, M; Scholmerich, J; Schill, S			Anti-inflammatory cooperativity of corticosteroids and norepinephrine in rheumatoid arthritis synovial tissue in vivo and in vitro	FASEB JOURNAL			English	Article						RA; osteoarthritis; cortisol; NE; cytokine	PITUITARY-ADRENAL AXIS; GLUCOCORTICOID-RECEPTOR; ADRENERGIC-RECEPTORS; CYCLIC-NUCLEOTIDES; SMOOTH-MUSCLE; FIBROBLASTS; EXPRESSION; SECRETION; PATHWAY; ALPHA	Corticosteroids (CS) and norepinephrine (NE) support each other's biological effects. Thus, deficiency of cortisol and reduced synovial sympathetic innervation (SSI) may be proinflammatory in rheumatoid arthritis (RA). This study tested the anti-inflammatory cooperativity of CS and NE in human RA synovial tissue. In an in vivo study, 32 patients with RA (with prior CS therapy/without SSI: n=7; without prior CS therapy/with SSI: 6; with prior CS therapy/with SSI: 19) were investigated for synovial inflammation. In an in vitro study with synoviocytes from RA and OA patients, the separate and combined effects of cortisol and NE were studied. In the in vivo study, patients with prior CS therapy/with SSI showed lower secretion of synovial IL-8 than the other groups, lower synovial density of T cells and macrophages, and lower overall inflammation. In the in vitro study, a cooperative suppressive effect of NE (10(-6) M to 10(-8) M) and cortisol (10(-6) M and 10(-7) M) on secretion of IL-8 and TNF from primary early culture mixed RA synoviocytes was observed. This cooperative effect was not observed in OA synoviocytes. In the same RA and OA patients, the cooperative effect was lost in 3rd passage synovial fibroblasts. This study demonstrates the cooperativity of cortisol and NE for inhibition of proinflammatory mediators produced in the synovial tissue of RA patients. These results underscore that coupling of an efficient secretion of systemic cortisol together with local production of NE is important in order to lower synovial inflammation.	Univ Hosp Regensburg, Dept Internal Med 1, Lab Neuroendocrinoimmunol, Div Rheumatol, D-93042 Regensburg, Germany; Univ Genoa, Dept Internal Med, Div Rheumatol, Genoa, Italy; Bavarian Red Cross Hosp, Univ Regensburg, Fac Med, Dept Orthoped Surg, Bad Abbach, Germany	University of Regensburg; University of Genoa; University of Regensburg	Straub, RH (corresponding author), Univ Hosp Regensburg, Dept Internal Med 1, Lab Neuroendocrinoimmunol, Div Rheumatol, D-93042 Regensburg, Germany.	rainer.straub@klinik.uni-r.de		Straub, Rainer H/0000-0003-1165-4555				ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BRION F, 1978, HORM METAB RES, V10, P556, DOI 10.1055/s-0028-1093391; CASE JP, 1990, J IMMUNOL, V145, P3755; Crofford LJ, 1997, J CLIN ENDOCR METAB, V82, P1279, DOI 10.1210/jc.82.4.1279; Cronstein BN, 1996, ARTHRITIS RHEUM-US, V39, P1951, DOI 10.1002/art.1780391203; Cutolo M, 1999, J RHEUMATOL, V26, P282; Demir H, 1999, SCAND J RHEUMATOL, V28, P41; DIBATTISTA JA, 1991, J RHEUMATOL, V18, P102; DIBATTISTA JA, 1994, LAB INVEST, V71, P270; DONG Y, 1989, J BIOL CHEM, V264, P13679; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; GRUOL DJ, 1986, J BIOL CHEM, V261, P4909; Gudbjornsson B, 1996, J RHEUMATOL, V23, P596; Gutierrez MA, 1999, J RHEUMATOL, V26, P277; HALL J, 1994, ARTHRITIS RHEUM, V37, P1132, DOI 10.1002/art.1780370804; JOHNSON JE, 1988, TUMOR DIAGNOSIS ELEC, V2, P1; Kanik KS, 2000, J CLIN ENDOCR METAB, V85, P1461, DOI 10.1210/jc.85.4.1461; Korn SH, 1998, BIOCHEM PHARMACOL, V56, P1561, DOI 10.1016/S0006-2952(98)00179-8; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; Miller LE, 2000, FASEB J, V14, P2097, DOI 10.1096/fj.99-1082com; MOTULSKY HJ, 1982, NEW ENGL J MED, V307, P18, DOI 10.1056/NEJM198207013070104; NAKADA MT, 1987, MOL PHARMACOL, V31, P377; OIKARINEN J, 1984, BIOCHIM BIOPHYS ACTA, V799, P158, DOI 10.1016/0304-4165(84)90290-3; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; RENZ H, 1988, J IMMUNOL, V141, P2388; Schmidt P, 2001, MOL ENDOCRINOL, V15, P553, DOI 10.1210/me.15.4.553; Schramm CM, 2000, J PHARMACOL EXP THER, V292, P280; SCHUBERT D, 1980, BRAIN RES, V190, P67, DOI 10.1016/0006-8993(80)91160-9; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; Straub RH, 2000, J NEUROCHEM, V75, P2464, DOI 10.1046/j.1471-4159.2000.0752464.x; STRAUB RH, 1995, J NEUROIMMUNOL, V61, P53, DOI 10.1016/0165-5728(95)00073-B; Straub RH, 2002, ARTHRITIS RHEUM, V46, P654, DOI 10.1002/art.10177; Templ E, 1996, BRIT J RHEUMATOL, V35, P350; VANDENBRINK HR, 1993, CLIN EXP RHEUMATOL, V11, P649; VERGHESE MW, 1995, J PHARMACOL EXP THER, V272, P1313	35	56	57	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					993	1000		10.1096/fj.02-0085com	http://dx.doi.org/10.1096/fj.02-0085com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087060				2022-12-28	WOS:000177813100030
J	Hribal, ML; Perego, L; Lovari, S; Andreozzi, F; Menghini, R; Perego, C; Finzi, G; Usellini, L; Placidi, C; Capella, C; Guzzi, V; Lauro, D; Bertuzzi, F; Davalli, A; Pozza, G; Pontiroli, A; Federici, M; Lauro, R; Brunetti, A; Folli, F; Sesti, G				Hribal, ML; Perego, L; Lovari, S; Andreozzi, F; Menghini, R; Perego, C; Finzi, G; Usellini, L; Placidi, C; Capella, C; Guzzi, V; Lauro, D; Bertuzzi, F; Davalli, A; Pozza, G; Pontiroli, A; Federici, M; Lauro, R; Brunetti, A; Folli, F; Sesti, G			Chronic hyperglycemia impairs insulin secretion by affecting insulin receptor expression, splicing, and signaling in RIN beta-cell line and human islets of Langerhans	FASEB JOURNAL			English	Article						glucose toxicity; diabetes; pancreatic islets	HUMAN PANCREATIC-ISLETS; P70 S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-TRANSCRIPTION; PROLONGED EXPOSURE; PROTEIN-SYNTHESIS; CAUSES APOPTOSIS; GLUCOSE; PHOSPHORYLATION; DIFFERENTIATION	0Recent evidence suggests that insulin signaling through the insulin receptor A type (Ex11-), regulates insulin gene transcription. Because chronic hyperglycemia negatively affects insulin receptor function and regulates alternative splicing of the insulin receptor, we inquired whether chronic exposure of pancreatic beta-cells to high glucose results in alterations in insulin signaling due to changes in insulin receptor expression and relative abundance of its spliced isoforms. Our results demonstrate that the insulin receptor is localized in insulin secretory vescicles in human pancreatic beta-cells. Furthermore, we find that alterations in insulin expression and secretion caused by chronic exposure to high glucose are paralleled by decreased insulin receptor expression and increased relative abundance of the Ex11+ isoform in both human islets and RIN beta-cells. PDX-1 and HMGI(Y) transcription factors are down-regulated by high glucose. These changes are associated with defects in insulin signaling involving insulin receptor-associated PI 3-kinase/Akt/PHAS-I pathway in RIN beta-cells. Re-expression in RIN beta-cells chronically exposed to high glucose of the Ex11-, but not the Ex11+, isoform restored insulin mRNA expression. These data suggest that changes in early steps of insulin receptor signaling may play a role in determining beta-cell dysfunction caused by chronic hyperglycemia.	Univ Catanzaro Magna Graecia, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy; Univ Roma Tor Vergata, Dept Internal Med, Mol Med Lab, Rome, Italy; HS Raffaele, Dept Med, Unit Endocrinol & Metab Dis, Milan, Italy; Univ Milan, Dept Internal Med, I-20122 Milan, Italy; CNR, Ctr Studio Farmacol Cellulare & Mol, I-20133 Milan, Italy; Univ Insubria, Dept Surg Pathol, Varese, Italy; HS Raffaele, Dept Surg, Milan, Italy; HS Raffaele, Dept Med, Milan, Italy; Univ Vita Salute San Raffaele, Milan, Italy	Magna Graecia University of Catanzaro; University of Rome Tor Vergata; University of Milan; Consiglio Nazionale delle Ricerche (CNR); University of Insubria; Vita-Salute San Raffaele University	Folli, F (corresponding author), Univ Catanzaro Magna Graecia, Dipartimento Med Sperimentale & Clin, Via Campanella 115, I-88100 Catanzaro, Italy.	folli.franco@hsr.it; sesti@unicz.it	Lauro, Davide/K-4683-2018; pontiroli, antonio e/AAI-5575-2020; Federici, Massimo/G-9940-2012; Sesti, Giorgio/B-1509-2012; Brunetti, Antonio/K-7756-2016; menghini, rossella/I-3485-2012; Perego, Carla/L-6147-2015; folli, franco/J-2795-2018; Andreozzi, Francesco/J-4073-2018	Federici, Massimo/0000-0003-4989-5194; menghini, rossella/0000-0001-8397-2355; Perego, Carla/0000-0003-3027-1779; folli, franco/0000-0001-9824-5222; Lovari, Sarah/0000-0003-3065-4227; Andreozzi, Francesco/0000-0001-9375-1513; Lauro, Davide/0000-0002-8597-4415; Sesti, Giorgio/0000-0002-1618-7688; Brunetti, Antonio/0000-0003-1533-8779	Telethon [GGP04245, E.0739, E.1309] Funding Source: Medline	Telethon(Fondazione Telethon)		Boden G, 1996, AM J PHYSIOL-ENDOC M, V270, pE251, DOI 10.1152/ajpendo.1996.270.2.E251; Bogdanovic E, 2001, DIABETES, V50, pA267; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BRUNETTI A, 1989, J CLIN INVEST, V83, P192, DOI 10.1172/JCI113858; Brunetti A, 2001, FASEB J, V15, P492, DOI 10.1096/fj.00-0190com; BRUNETTI A, 1993, J CLIN INVEST, V92, P1288, DOI 10.1172/JCI116702; EIZIRIK DL, 1992, J CLIN INVEST, V90, P1263, DOI 10.1172/JCI115989; Federici M, 2001, FASEB J, V15, P22; Federici M, 2001, DIABETES, V50, P1290, DOI 10.2337/diabetes.50.6.1290; FOLLI F, 1992, J BIOL CHEM, V267, P22171; FORSAYETH JR, 1987, J BIOL CHEM, V262, P4134; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; FREIDENBERG GR, 1987, J CLIN INVEST, V79, P240, DOI 10.1172/JCI112789; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Jackerott M, 2001, DIABETES, V50, pS146, DOI 10.2337/diabetes.50.2007.S146; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; KAN M, 1995, DIABETES, V44, P1081, DOI 10.2337/diabetes.44.9.1081; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kulkarni RN, 1999, J CLIN INVEST, V104, pR69, DOI 10.1172/JCI8339; Kurowski TG, 1999, DIABETES, V48, P658, DOI 10.2337/diabetes.48.3.658; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Ling ZD, 1996, J CLIN INVEST, V98, P2805, DOI 10.1172/JCI119108; Marshak S, 1999, DIABETES, V48, P1230, DOI 10.2337/diabetes.48.6.1230; MCCLAIN DA, 1991, MOL ENDOCRINOL, V5, P734, DOI 10.1210/mend-5-5-734; Moran A, 1997, J CLIN INVEST, V99, P534, DOI 10.1172/JCI119190; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; NORGREN S, 1994, P NATL ACAD SCI USA, V91, P1465, DOI 10.1073/pnas.91.4.1465; NORGREN S, 1994, BIOCHEM BIOPH RES CO, V199, P277, DOI 10.1006/bbrc.1994.1225; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Poitout V, 1996, J CLIN INVEST, V97, P1041, DOI 10.1172/JCI118496; Porzio O, 1999, J CLIN INVEST, V104, P357, DOI 10.1172/JCI5870; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; Senn JJ, 2002, DIABETES, V51, P3391, DOI 10.2337/diabetes.51.12.3391; SESTI G, 1995, DIABETOLOGIA, V38, P445, DOI 10.1007/BF00410282; SESTI G, 1994, ACTA DIABETOL, V31, P59, DOI 10.1007/BF00570536; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; Song XM, 1999, AM J PHYSIOL-REG I, V277, pR1690, DOI 10.1152/ajpregu.1999.277.6.R1690; Takano A, 2001, DIABETES, V50, P1891, DOI 10.2337/diabetes.50.8.1891; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; TOOZE J, 1991, CELL BIOPHYS, V19, P117, DOI 10.1007/BF02989885; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; YAMAGUCHI Y, 1991, ENDOCRINOLOGY, V129, P2058, DOI 10.1210/endo-129-4-2058	50	51	59	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1340	+		10.1096/fj.02-0685fje	http://dx.doi.org/10.1096/fj.02-0685fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738810				2022-12-28	WOS:000183165000040
J	Tezapsidis, N; Merz, PA; Merz, G; Hong, H				Tezapsidis, N; Merz, PA; Merz, G; Hong, H			Microtubular interactions of presenilin direct kinesis of A beta peptide and its precursors	FASEB JOURNAL			English	Article						Alzheimer's disease; amyloid precursor protein; cytoskeleton; trafficking	RECEPTOR-RELATED PROTEIN; ALZHEIMERS-DISEASE; AMYLOID PRECURSOR; GAMMA-SECRETASE; FULL-LENGTH; ENDOCYTIC PATHWAY; APOLIPOPROTEIN-E; CELLS; SURFACE; BINDING	In our previous study we demonstrated that presenilin 1 (PS1) interacts with cytoplasmic linker protein 170/Restin (CLIP-170/Restin). Herein we show that disruption of the interaction of these proteins within neuronal cell-lines (SY5Y and N2a) can be accomplished by the transfection of vectors that drive the expression of peptide fragments corresponding to their binding domains (BDPs). Interestingly, the disruption of the PS1/CLIP-170 complex is associated with both decreased secretion of endogenous Abeta and decreased uptake of exogenous Abeta from the medium. BDP-expressing cells were also more resistant to surges of Abeta secretion induced by thapsigargin and ionomycin (that elevate intracellular calcium concentrations) and mutations in PS1 linked to familial Alzheimer's disease. Uptake of Abeta by SY5Y cells was amplified when preincubated with ApoE and was mediated through lipoprotein receptor-related protein (LRP). BDP-expressing cells or cells treated with PS1 anti-sense oligonucleotides were less capable of taking up Abeta from the medium compared with controls, indicating that the PS1/CLIP-170 interaction is involved and that PS1 cannot be substituted. In this study, we also mapped the minimum binding domains (mBDPs) of PS1 and CLIP-70 to regions corresponding to the N-terminal end of the large cytoplasmic loop of PS1 and the metal binding motif-containing C-terminal end of CLIP-170. Further, our data obtained from experiments involving in vitro taxol-polymerization of tubulin and confocal immmunofluorescence suggest that PS1, via CLIP-170, may serve as an anchor to the microtubules for specific subcellular fractions containing amyloidogenic fragments. Interestingly, Notch is absent from this population of microtubule binding subcellular fractions and its cleavage was unaffected in cells transfected with the PS1-based BDP. This raises the possibility that the interaction of PS1 with CLIP-170 could provide the conceptual basis for anti-amyloidogenic therapeutic strategies with improved specificity. However, this approach may be hampered by a low efficiency, because it may also block Abeta clearance from the interstitial space of the CNS.	Columbia Univ, Coll Phys & Surg, Dept Pathol, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; New York State Inst Basic Res Dev Disabil, Dept Virol, Staten Isl, NY 10314 USA; New York State Inst Basic Res Dev Disabil, Lab Digital Microscopy, Staten Isl, NY 10314 USA	Columbia University; Institute for Basic Research in Developmental Disabilities; Institute for Basic Research in Developmental Disabilities	Tezapsidis, N (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol, Taub Inst Res Alzheimers Dis & Aging Brain, P&S 15-408,630 W 168th St, New York, NY 10032 USA.	nt2024@columbia.edu						Armogida M, 2001, NAT CELL BIOL, V3, P1030, DOI 10.1038/ncb1101-1030; BEELER TJ, 1979, J BIOL CHEM, V254, P6229; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; Dujardin DL, 2002, CURR OPIN CELL BIOL, V14, P44, DOI 10.1016/S0955-0674(01)00292-7; Efthimiopoulos S, 1996, P NATL ACAD SCI USA, V93, P8046, DOI 10.1073/pnas.93.15.8046; Figueiredo-Pereira ME, 1999, J NEUROCHEM, V72, P1417, DOI 10.1046/j.1471-4159.1999.721417.x; FRACKOWIAK J, 1995, BRAIN RES, V676, P225, DOI 10.1016/0006-8993(94)01465-T; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hashimoto Y, 2000, J NEUROSCI, V20, P8401, DOI 10.1523/JNEUROSCI.20-22-08401.2000; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Hoogenraad CC, 2000, J CELL SCI, V113, P2285; Johnsingh AA, 2000, FEBS LETT, V465, P53, DOI 10.1016/S0014-5793(99)01664-6; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kopan R, 2002, NEURON, V33, P321, DOI 10.1016/S0896-6273(02)00585-8; Lah JJ, 2000, MOL CELL NEUROSCI, V16, P111, DOI 10.1006/mcne.2000.0861; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; Pigino G, 2001, J NEUROSCI, V21, P834, DOI 10.1523/JNEUROSCI.21-03-00834.2001; Poirier J, 2000, ANN NY ACAD SCI, V924, P81; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; RICKARD JE, 1991, J BIOL CHEM, V266, P17597; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saura CA, 2000, J BIOL CHEM, V275, P17136, DOI 10.1074/jbc.M909624199; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; Tarsounas M, 2001, DEV BIOL, V236, P400, DOI 10.1006/dbio.2001.0286; Tezapsidis N, 1998, BIOCHEMISTRY-US, V37, P1274, DOI 10.1021/bi9714159; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; VASSILACOPOULOU D, 1995, J NEUROCHEM, V64, P2140; Xia XF, 2002, P NATL ACAD SCI USA, V99, P8760, DOI 10.1073/pnas.132045399; Yamauchi K, 2002, ANN CLIN LAB SCI, V32, P65; Yamazaki T, 1996, J CELL SCI, V109, P999	41	18	20	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1322	+		10.1096/fj.02-0980fje	http://dx.doi.org/10.1096/fj.02-0980fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738804				2022-12-28	WOS:000183165000032
J	Deindl, E; Ziegelhoffer, T; Kanse, SM; Fernandez, B; Neubauer, E; Carmeliet, P; Preissner, KT; Schaper, W				Deindl, E; Ziegelhoffer, T; Kanse, SM; Fernandez, B; Neubauer, E; Carmeliet, P; Preissner, KT; Schaper, W			Receptor-independent role of the urokinase-type plasminogen activator during arteriogenesis	FASEB JOURNAL			English	Article						arteriogenesis; plasminogen system; leukocytes	ANGIOGENESIS; GROWTH; CELLS; MEMBRANE; BINDING; MATRIX; STIMULATION; ENHANCEMENT; PROTEOLYSIS; EXPRESSION	To define the role of the plasminogen activators (PAs) urokinase PA (uPA) and tissue PA (tPA) as well as the uPA receptor (uPAR) in arteriogenesis, we investigated their impact in a rabbit and mouse model of adaptive collateral artery growth. Collateral artery growth was induced by occlusion of the femoral artery in rabbit and wild-type (WT) mice and in mice with targeted inactivation of uPA (uPA(-/-)), tPA (tPA(-/-)), or uPAR (uPAR(-/-)). Northern blot results revealed a significant up-regulation of uPA but not uPAR or tPA in the early phase of arteriogenesis in rabbit and WT mice. This up-regulation on RNA level was followed by an increased protein level and enzymatic activity. Impaired perfusion recovery upon femoral artery ligation was observed by laser Doppler analysis in vivo in uPA-deficient mice but not in uPAR or tPA deficiency compared with WT mice. Immunohistochemical studies revealed an association of leukocyte infiltration with arteriogenesis in WT mice that was strongly reduced in uPA(-/-) but not in uPAR- or tPA-deficient mice. We conclude that arteriogenesis is promoted by an uPA-mediated infiltration of leukocytes that is not dependent on uPAR.	Max Planck Inst Physiol & Clin Res, D-6350 Bad Nauheim, Germany; Univ Giessen, Inst Biochem, Giessen, Germany; Katholieke Univ Leuven, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium; Katholieke Univ Leuven VIB, Louvain, Belgium	Max Planck Society; Justus Liebig University Giessen; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven	Deindl, E (corresponding author), Max Planck Inst, Dept Expt Cardiol, Benekestr 2, D-61231 Bad Nauheim, Germany.	e.deindl@kerckhoff.mpg.de	Carmeliet, Peter/AAQ-5140-2020; Corujo, Francisco Borja Fernández/AAG-8258-2020; Deindl, Elisabeth/A-2511-2013	Carmeliet, Peter/0000-0001-7961-1821; Corujo, Francisco Borja Fernández/0000-0001-9179-910X; Ziegelhoeffer, Tibor/0000-0001-9320-8481; Kanse, Sandip/0000-0003-0782-9957				Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; BEHRENDT N, 1995, BIOL CHEM H-S, V376, P269; BLASI F, 1994, FIBRINOLYSIS, V8, P182, DOI 10.1016/0268-9499(94)90716-1; Cai WJ, 2000, J MOL CELL CARDIOL, V32, P997, DOI 10.1006/jmcc.2000.1137; CAO DR, 1995, J IMMUNOL, V154, P1817; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Carmeliet P, 1997, CIRC RES, V81, P829; CARMELIET P, 1995, TRENDS CARDIOVAS MED, V5, P117, DOI 10.1016/1050-1738(95)00050-J; Carmeliet Peter, 1996, Seminars in Thrombosis and Hemostasis, V22, P525, DOI 10.1055/s-2007-999055; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; COLLEN D, 1991, BLOOD, V78, P3114; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; Deindl E, 2001, BIOTECHNIQUES, V31, P1250, DOI 10.2144/01316bm04; Deindl E, 2001, CIRC RES, V89, P779, DOI 10.1161/hh2101.098613; Dewerchin M, 1996, J CLIN INVEST, V97, P870, DOI 10.1172/JCI118489; DOLLERY CM, 1995, CIRC RES, V77, P863, DOI 10.1161/01.RES.77.5.863; Fibbi G, 1998, LAB INVEST, V78, P1109; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; HARPEL PC, 1990, J BIOL CHEM, V265, P11289; Heil M, 2002, AM J PHYSIOL-HEART C, V283, pH2411, DOI 10.1152/ajpheart.01098.2001; Ito WD, 1997, AM J PHYSIOL-HEART C, V273, pH1255, DOI 10.1152/ajpheart.1997.273.3.H1255; Ito WD, 1997, CIRC RES, V80, P829; Kanse SM, 1997, ARTERIOSCL THROM VAS, V17, P2848, DOI 10.1161/01.ATV.17.11.2848; KIRCHHEIMER JC, 1989, J IMMUNOL, V143, P2634; KNOEPFLER PS, 1995, J MOL CELL CARDIOL, V27, P1317, DOI 10.1016/S0022-2828(05)82394-6; LEE SW, 1992, J BIOL CHEM, V267, P13020; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; LOSKUTOFF DJ, 1995, ANN NY ACAD SCI, V748, P177; MARTINEZ J, 1994, EUR J CELL BIOL, V64, P257; MCGUIRE PG, 1989, J CELL BIOCHEM, V40, P215, DOI 10.1002/jcb.240400210; Min HY, 1996, CANCER RES, V56, P2428; MOSER TL, 1995, BIOCHEM J, V307, P867, DOI 10.1042/bj3070867; OSSOWSKI L, 1996, CURR TOP MICROBIOL I, V213; RAO NK, 1995, J CLIN INVEST, V96, P465, DOI 10.1172/JCI118057; SALONEN EM, 1984, FEBS LETT, V172, P29, DOI 10.1016/0014-5793(84)80866-2; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAPER W, 1971, CIRC RES, V28, P671, DOI 10.1161/01.RES.28.6.671; Scholz D, 2002, J MOL CELL CARDIOL, V34, P775, DOI 10.1006/jmcc.2002.2013; Scholz D, 2000, VIRCHOWS ARCH, V436, P257, DOI 10.1007/s004280050039; SILVERSTEIN RL, 1986, J BIOL CHEM, V261, P9959; Sitrin RG, 1996, J LEUKOCYTE BIOL, V59, P302, DOI 10.1002/jlb.59.2.302; Sitrin RG, 1996, J CLIN INVEST, V97, P1942, DOI 10.1172/JCI118626; STEPHENS RW, 1992, BIOCHEMISTRY-US, V31, P7572, DOI 10.1021/bi00148a019; STEPHENS RW, 1992, EUR J BIOCHEM, V207, P937, DOI 10.1111/j.1432-1033.1992.tb17127.x; Syrovets T, 1997, BLOOD, V89, P4574, DOI 10.1182/blood.V89.12.4574; Syrovets T, 1997, N-S ARCH PHARMACOL, V355, P312; van Royen N, 2001, CARDIOVASC RES, V49, P543, DOI 10.1016/S0008-6363(00)00206-6; vanLeeuwen RTJ, 1996, FIBRINOLYSIS, V10, P59, DOI 10.1016/S0268-9499(96)80081-6; VASSALLI JD, 1994, FIBRINOLYSIS, V8, P172, DOI 10.1016/0268-9499(94)90715-3; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; Wysocki SJ, 1996, CARDIOVASC RES, V31, P28; Yu W, 1997, J CELL BIOL, V137, P767, DOI 10.1083/jcb.137.3.767	54	42	44	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1174	+		10.1096/fj.02-0800fje	http://dx.doi.org/10.1096/fj.02-0800fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692088				2022-12-28	WOS:000182580100040
J	Fischer, L; Szellas, D; Radmark, O; Steinhilber, D; Werz, O				Fischer, L; Szellas, D; Radmark, O; Steinhilber, D; Werz, O			Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors	FASEB JOURNAL			English	Article						leukotriene; polymorphonuclear leukocytes; inflammation; MAPK; calcium	HUMAN POLYMORPHONUCLEAR LEUKOCYTES; HUMAN-NEUTROPHILS; PRODUCT FORMATION; MONO-MAC-6 CELLS; IN-VITRO; LEUKOTRIENES; CALCIUM; TRANSLOCATION; STIMULATION; PEROXIDASE	Nonredox-type 5-lipoxygenase (5-LO) inhibitors such as ZM230487 or L-739.010 potently suppress leukotriene biosynthesis at low cellular peroxide tone. Here, we show that inhibition of 5-LO product formation by nonredox-type 5-LO inhibitors in human isolated polymorphonuclear leukocytes (PMNL) depends on the activation pathway of 5-LO. Thus, compared with 5-LO product synthesis induced by the Ca2+-mobilizing agent ionophore A23187, cell stress-induced 5-LO product formation involving 5-LO kinase pathways required similar to10- to 100-fold higher concentrations of ZM230487 or L-739.010 for comparable 5-LO inhibition. No such differences were observed for the iron ligand-type 5-LO inhibitor BWA4C or the novel-type 5-LO inhibitors hyperforin and 3-O-acetyl-11-keto-boswellic acid. Experiments using purified 5-LO revealed that Ca2+ is no prerequisite for potent enzyme inhibition by ZM230487, and exposure of PMNL to the combination of ionophore and cell stress did not restore potent 5-LO suppression. Intriguingly, a significant difference in the potency of nonredox-type inhibitors (but not of BWA4C) was determined between wild-type 5-LO and the mutant S271A/S663A-5-LO (lacking phosphorylation sites for ERK1/2 and MAPKAPK-2) in HeLa cells. Collectively, our data suggest that compared with Ca2+-mediated 5-LO product formation, enzyme activation involving 5-LO phosphorylation events specifically and strongly alters the susceptibility of 5-LO toward nonredox-type inhibitors in intact cells.	Goethe Univ Frankfurt, Inst Pharmaceut Chem, D-60439 Frankfurt, Germany; Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, S-17177 Stockholm, Sweden	Goethe University Frankfurt; Karolinska Institutet	Werz, O (corresponding author), Goethe Univ Frankfurt, Inst Pharmaceut Chem, Marie Curie Str 9, D-60439 Frankfurt, Germany.	o.werz@pharmchem.uni-frankfurt.de	Steinhilber, Dieter/J-3221-2012					Alanko J, 1998, BIOCHEM PHARMACOL, V55, P101, DOI 10.1016/S0006-2952(97)00398-5; Albert D, 2002, BIOCHEM PHARMACOL, V64, P1767, DOI 10.1016/S0006-2952(02)01387-4; Avis I, 2001, FASEB J, V15, P2007, DOI 10.1096/fj.00-0866fje; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; BRUNGS M, 1995, P NATL ACAD SCI USA, V92, P107, DOI 10.1073/pnas.92.1.107; Burkert E, 2003, J LEUKOCYTE BIOL, V73, P191, DOI 10.1189/jlb.0702354; Burkert E, 2002, J LEUKOCYTE BIOL, V71, P477; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; CHILTON FH, 1982, J BIOL CHEM, V257, P5402; Claesson HE, 1999, J INTERN MED, V245, P205, DOI 10.1046/j.1365-2796.1999.00418.x; CLAESSON HE, 1981, BIOCHEM BIOPH RES CO, V99, P1230, DOI 10.1016/0006-291X(81)90751-8; CLANCY RM, 1983, P NATL ACAD SCI-BIOL, V80, P7200, DOI 10.1073/pnas.80.23.7200; CRAWLEY GC, 1992, J MED CHEM, V35, P2600, DOI 10.1021/jm00092a010; Ding XZ, 1999, BIOCHEM BIOPH RES CO, V261, P218, DOI 10.1006/bbrc.1999.1012; Garcia C, 1996, J BONE MINER RES, V11, P1619; Ghosh J, 1998, P NATL ACAD SCI USA, V95, P13182, DOI 10.1073/pnas.95.22.13182; Gupta S, 2001, CANCER-AM CANCER SOC, V91, P737, DOI 10.1002/1097-0142(20010215)91:4<737::AID-CNCR1059>3.0.CO;2-F; HAMMARBERG T, 1995, EUR J BIOCHEM, V230, P401; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; Junger WG, 1998, J CLIN INVEST, V101, P2768, DOI 10.1172/JCI1354; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; Lepley RA, 1996, ARCH BIOCHEM BIOPHYS, V331, P141, DOI 10.1006/abbi.1996.0292; MCMILLAN RM, 1992, TRENDS PHARMACOL SCI, V13, P323, DOI 10.1016/0165-6147(92)90100-K; Mehrabian M, 2002, CIRC RES, V91, P120, DOI 10.1161/01.RES.0000028008.99774.7F; NASSER SMS, 1994, THORAX, V49, P743, DOI 10.1136/thx.49.8.743; Ohd JF, 2000, GASTROENTEROLOGY, V119, P1007, DOI 10.1053/gast.2000.18141; Peters-Golden M, 2000, AM J RESP CRIT CARE, V161, pS36, DOI 10.1164/ajrccm.161.supplement_1.ltta-8; POUBELLE PE, 1987, BIOCHEM BIOPH RES CO, V149, P649, DOI 10.1016/0006-291X(87)90417-7; Provost P, 1999, P NATL ACAD SCI USA, V96, P1881, DOI 10.1073/pnas.96.5.1881; Radmark OP, 2000, AM J RESP CRIT CARE, V161, pS11, DOI 10.1164/ajrccm.161.supplement_1.ltta-3; Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com; SAFAYHI H, 1992, J PHARMACOL EXP THER, V261, P1143; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SERHAN CN, 1984, PROSTAG OTH LIPID M, V27, P563, DOI 10.1016/0090-6980(84)90092-3; Smith WG, 1995, J PHARMACOL EXP THER, V275, P1332; Steinhilber D, 1999, CURR MED CHEM, V6, P71; Turner CR, 1996, INFLAMM RES, V45, P42, DOI 10.1007/BF02263504; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Werz O, 1997, N-S ARCH PHARMACOL, V356, P441, DOI 10.1007/PL00005074; Werz O, 1996, EUR J BIOCHEM, V242, P90, DOI 10.1111/j.1432-1033.1996.0090r.x; Werz O, 2002, FASEB J, V16, P1441, DOI 10.1096/fj.01-0909fje; Werz O, 2002, J BIOL CHEM, V277, P14793, DOI 10.1074/jbc.M111945200; Werz O, 2001, BLOOD, V97, P2487, DOI 10.1182/blood.V97.8.2487; Werz O, 1998, MOL PHARMACOL, V54, P445, DOI 10.1124/mol.54.2.445	48	114	118	3	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					949	+		10.1096/fj.02-0815fje	http://dx.doi.org/10.1096/fj.02-0815fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670876				2022-12-28	WOS:000181892600011
J	Jenniskens, GJ; Koopman, WJH; Willems, PHGM; Pecker I; Veerkamp, JH; van Kuppevelt, TH				Jenniskens, GJ; Koopman, WJH; Willems, PHGM; Pecker, I; Veerkamp, JH; van Kuppevelt, TH			Phenotypic knockout of heparan sulfates in myotubes impairs excitation-induced calcium spiking	FASEB JOURNAL			English	Article						basal lamina; blocking antibodies; heparan sulfate proteoglycan; heparanase, skeletal muscle	SKELETAL-MUSCLE; INTRACELLULAR IMMUNIZATION; MAMMALIAN HEPARANASE; BASEMENT-MEMBRANES; PROTEOGLYCANS; AGRIN; CA2+; METASTASIS; ANTIBODIES; CHANNELS	Little is known about the physiological functions of heparan sulfates (HSs), which are present in the basal lamina surrounding skeletal muscle fibers. Here, we present a new system in which HS is phenotypically knocked out by endogenous expression of epitope-specific anti-HS antibodies. Single-chain antibodies, containing an immunoglobulin leader peptide, were produced by using various expression systems. Antibodies were detected in the Golgi apparatus, the site of HS biosynthesis. Likewise, the HS-degrading enzyme heparanase was expressed. Endogenous expression of antibodies or heparanase in myoblasts resulted in HS-defective myotubes. Excitability and calcium kinetics of HS-defective myotubes were severely compromised, as determined by analysis of electrically induced calcium spikes via video-speed UV confocal laser scanning microscopy. Phenotypically knocking out of individual HS epitopes resulted in specific effects on excitability and calcium kinetics. These data indicate important roles for HSs in skeletal muscle calcium kinetics.	Univ Nijmegen, Dept Biochem 194, Med Ctr, NCMLS, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Microscop Imaging Ctr, Med Ctr, NL-6500 HB Nijmegen, Netherlands; InSight Ltd, IL-76121 Rehovot, Israel	Radboud University Nijmegen; Radboud University Nijmegen	van Kuppevelt, TH (corresponding author), Univ Nijmegen, Dept Biochem 194, Med Ctr, NCMLS, POB 9101, NL-6500 HB Nijmegen, Netherlands.	A.vankuppevelt@ncmls.kun.nl	Koopman, Werner J.H./D-3592-2009; van Kuppevelt, A.H.M.S.M./L-4463-2015; Koopman, Werner J.H./AAC-9668-2020; Willems, P.H.G.M./L-4759-2015	Koopman, Werner J.H./0000-0002-5340-6747; Koopman, Werner J.H./0000-0002-5340-6747; Willems, P.H.G.M./0000-0002-0915-1599				Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BEZPROZVANNY IB, 1993, MOL BIOL CELL, V4, P347, DOI 10.1091/mbc.4.3.347; BIOCCA S, 1995, TRENDS CELL BIOL, V5, P248, DOI 10.1016/S0962-8924(00)89019-4; BOWDEN DC, 1996, J NEUROCHEM, V66, P2580; BRANDAN E, 1985, J CELL BIOL, V101, P985, DOI 10.1083/jcb.101.3.985; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; Dennissen MABA, 2002, J BIOL CHEM, V277, P10982, DOI 10.1074/jbc.M104852200; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; GORDONSMITH EC, 1989, CLIN HAEMATOL, V2, P1; GOSH TK, 1988, J BIOL CHEM, V263, P11075; HOCH W, 1994, J CELL BIOL, V126, P1, DOI 10.1083/jcb.126.1.1; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; INCE C, 1985, PFLUG ARCH EUR J PHY, V403, P240, DOI 10.1007/BF00583594; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Jenniskens GJ, 2000, J NEUROSCI, V20, P4099; KNAUS HG, 1990, J BIOL CHEM, V265, P11156; KNAUS HG, 1992, P NATL ACAD SCI USA, V89, P3586, DOI 10.1073/pnas.89.8.3586; KOBAYASHI S, 1988, BIOCHEM BIOPH RES CO, V153, P625, DOI 10.1016/S0006-291X(88)81141-0; Koopman WJH, 2001, BIOPHYS J, V81, P57, DOI 10.1016/S0006-3495(01)75679-2; LACINOVA L, 1993, J PHYSIOL-LONDON, V465, P181, DOI 10.1113/jphysiol.1993.sp019672; LAMB GD, 1994, J PHYSIOL-LONDON, V474, P319, DOI 10.1113/jphysiol.1994.sp020024; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; Marasco WA, 1997, GENE THER, V4, P11, DOI 10.1038/sj.gt.3300346; Martinez M, 1996, J MUSCLE RES CELL M, V17, P575, DOI 10.1007/BF00124356; Nicole S, 2000, NAT GENET, V26, P480, DOI 10.1038/82638; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Portier GL, 1999, IN VITRO CELL DEV-AN, V35, P219, DOI 10.1007/s11626-999-0030-8; RAPRAEGER A, 1989, J CELL BIOL, V109, P2509, DOI 10.1083/jcb.109.5.2509; RITOV VB, 1985, FEBS LETT, V188, P77, DOI 10.1016/0014-5793(85)80878-4; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; WALLACE BG, 1990, J NEUROSCI, V10, P3576	41	9	9	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					878	+		10.1096/fj.02-0572fje	http://dx.doi.org/10.1096/fj.02-0572fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626439				2022-12-28	WOS:000181892600031
J	Luciano, F; Herrant, M; Jacquel, A; Ricci, JE; Auberger, P				Luciano, F; Herrant, M; Jacquel, A; Ricci, JE; Auberger, P			The P54-cleaved form of the tyrosine kinase Lyn generated by caspases during BCR-induced cell death in B lymphoma acts as a negative regulator of apoptosis	FASEB JOURNAL			English	Article						BCR-induced apoptosis; c-DNA array; c-Myc	MYC-INDUCED APOPTOSIS; RECEPTOR-INDUCED APOPTOSIS; FAS-MEDIATED APOPTOSIS; ANTIGEN RECEPTOR; C-MYC; SIGNAL-TRANSDUCTION; DOWN-MODULATION; PROTEIN-KINASE; T-LYMPHOCYTES; MITOCHONDRIA	Engagement of the B cell receptor antigen (BCR) triggers apoptosis on immature B cell lines. We report here that BCR triggering leads to caspase activation followed by Lyn cleavage and induction of apoptosis. The cleavage process is mitochondrion-dependent and involves caspases 9 and 7. Stable expression of the cleaved form of Lyn (Lyn-Delta-N) in Ramos B cells impairs BCR-mediated apoptosis as judged by loss of Deltapsim, caspase activation and PARP cleavage. Activation of the main survival pathways upon BCR-triggering was unaltered in both cell variants. However, the PI3-K inhibitor Ly294002 resensitizes Lyn-Delta-N cells to apoptosis. Selected cDNA expression arrays revealed that anti-IgM modulates the expression of similar to20 genes in both cell variants. Among them, only c-Myc was found to be differentially regulated, which suggests a role for c-Myc in the B cell apoptotic response. Interestingly, c-Myc expression decreased more rapidly in Lyn-Delta-N compared with Lyn-WT cells during the first hours of anti-IgM stimulation. Nevertheless, rapid down-regulation of c-Myc following BCR engagement seems to correlate with the resistance of B cells to apoptosis. Thus, the soluble form of Lyn generated by caspases following BCR triggering acts as an inhibitor of B lymphocyte death likely through the modulation of c-Myc expression.	Fac Med, INSERM, U526, Equipe Labellisee Ligue Natl Contre Canc, F-06107 Nice 2, France; La Jolla Inst Allergy & Immunol, San Diego, CA USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; La Jolla Institute for Immunology	Auberger, P (corresponding author), Fac Med, INSERM, U526, Equipe Labellisee Ligue Natl Contre Canc, UFR50,Ave Valombrose, F-06107 Nice 2, France.	auberger@unice.fr	AUBERGER, Patrick/G-1491-2013; RICCI, Jean Ehrland/AAS-4379-2020; luciano, frederic/P-6264-2016; Jacquel, Arnaud/O-1928-2017; Jacquel, Arnaud/AAJ-4760-2021; Ricci, Jean Ehrland/I-7117-2016	AUBERGER, Patrick/0000-0002-2481-8275; RICCI, Jean Ehrland/0000-0003-1585-8117; luciano, frederic/0000-0001-9253-4998; Jacquel, Arnaud/0000-0001-5062-8048; Jacquel, Arnaud/0000-0001-5062-8048; Ricci, Jean Ehrland/0000-0003-1585-8117				Benschop RJ, 1999, CURR OPIN IMMUNOL, V11, P143, DOI 10.1016/S0952-7915(99)80025-9; Berard R, 1999, J IMMUNOL, V163, P4655; Bouchon A, 2000, EUR J IMMUNOL, V30, P69, DOI 10.1002/1521-4141(200001)30:1<69::AID-IMMU69>3.0.CO;2-#; Bras A, 1999, FASEB J, V13, P931, DOI 10.1096/fasebj.13.8.931; Carey GB, 2000, IMMUNOL REV, V176, P105; Dang CV, 1999, MOL CELL BIOL, V19, P1; Doi T, 1999, INT IMMUNOL, V11, P933, DOI 10.1093/intimm/11.6.933; Gauld SB, 2002, J IMMUNOL, V168, P3855, DOI 10.4049/jimmunol.168.8.3855; GERVAIS FG, 1995, MOL CELL BIOL, V15, P2393; Gold MR, 2000, IMMUNOL REV, V176, P47; GRAVES JD, 1998, J EXP MED, V188, P651; Hagiyama H, 1999, ONCOGENE, V18, P4091, DOI 10.1038/sj.onc.1202772; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Herold MJ, 2002, J IMMUNOL, V168, P3902, DOI 10.4049/jimmunol.168.8.3902; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Kasibhatla S, 2000, CURR BIOL, V10, P1205, DOI 10.1016/S0960-9822(00)00727-2; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; King LB, 2000, IMMUNOL REV, V176, P86; Koncz G, 2002, IMMUNOL LETT, V82, P41, DOI 10.1016/S0165-2478(02)00017-2; Luciano F, 2002, LEUKEMIA, V16, P700, DOI 10.1038/sj.leu.2402401; Luciano F, 2001, ONCOGENE, V20, P4935, DOI 10.1038/sj.onc.1204661; Nagata S, 1998, J HUM GENET, V43, P2, DOI 10.1007/s100380050029; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nikiforov MA, 2000, ONCOGENE, V19, P4828, DOI 10.1038/sj.onc.1203880; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Oberg F, 2001, LEUKEMIA, V15, P217, DOI 10.1038/sj.leu.2402025; Ricci JE, 1999, ONCOGENE, V18, P3963, DOI 10.1038/sj.onc.1202782; Ricci JE, 2001, FASEB J, V15, P1777, DOI 10.1096/fj.00-0665fje; Rolink AG, 2001, CURR OPIN IMMUNOL, V13, P202, DOI 10.1016/S0952-7915(00)00205-3; Sandel PC, 1999, IMMUNITY, V10, P289, DOI 10.1016/S1074-7613(00)80029-1; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SEFTON BM, 1994, CURR OPIN IMMUNOL, V6, P372, DOI 10.1016/0952-7915(94)90115-5; Sonenshein GE, 1997, J IMMUNOL, V158, P1994; Sordet O, 2001, BLOOD, V97, P3931, DOI 10.1182/blood.V97.12.3931; Tamir I, 1998, ONCOGENE, V17, P1353, DOI 10.1038/sj.onc.1202187; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tiberio L, 2001, CELL DEATH DIFFER, V8, P967, DOI 10.1038/sj.cdd.4400909; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wu M, 1996, MOL CELL BIOL, V16, P5015; Yang Y, 2001, BLOOD CELL MOL DIS, V27, P1, DOI 10.1006/bcmd.2000.0344; YURCHAK LK, 1995, MOL CELL BIOL, V15, P6914, DOI 10.1128/mcb.15.12.6914	45	18	19	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					711	+		10.1096/fj.02-0716fje	http://dx.doi.org/10.1096/fj.02-0716fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586738				2022-12-28	WOS:000181456900032
J	Planque, S; Zhou, YX; Nishiyama, Y; Sinha, M; O'Connor-McCourt, M; Arnett, FC; Paul, S				Planque, S; Zhou, YX; Nishiyama, Y; Sinha, M; O'Connor-McCourt, M; Arnett, FC; Paul, S			Autoantibodies to the epidermal growth factor receptor in systemic sclerosis, lupus, and autoimmune mice	FASEB JOURNAL			English	Article						Fas defects; EGFR; antibody library	EGF RECEPTOR; MONOCLONAL-ANTIBODY; ANTIGEN RECOGNITION; HEAVY-CHAIN; EXPRESSION; BINDING; PROTEIN; TRAFFICKING; FIBROBLASTS; ACTIVATION	Autoantibodies to the recombinant extracellular domain of epidermal growth factor receptor (exEGFR) were detected by ELISA in the serum of Fas-defective old MRL/MpJ/lpr and C3H/HeJ/gld mice, but not young mice from these strains, or nonautoimmune young and old BALB/c, MRL/MpJ/++, and C3H/HeJ/MMTV mice. Compared with control human subjects without autoimmune disease, the frequency of exEGFR-binding autoantibodies was increased in scleroderma (systemic sclerosis) patients and to a lesser extent in lupus patients. Phage autoantibodies (Fv fragments) isolated from a lupus library by selection on a linear epitope of EGFR (residues 294310) displayed the ability to bind exEGFR. Treatment of EGFR-expressing A431 cells with autoantibodies purified by affinity chromatography on immobilized exEGFR resulted in specific staining of the cells. Short-lived but strong inhibition of cellular DNA synthesis was observed in the presence of the autoantibodies. We concluded that autoantibody responses to EGFR hold the potential of fulfilling a pathogenic role in autoimmune disease.	Univ Texas, Houston Med Sch, Dept Pathol, Chem Immunol & Therapeut Res Ctr, Houston, TX 77030 USA; Univ Texas, Houston Med Sch, Dept Internal Med, Chem Immunol & Therapeut Res Ctr, Houston, TX 77030 USA; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; National Research Council Canada	Paul, S (corresponding author), Univ Texas, Houston Med Sch, Dept Pathol, Chem Immunol & Therapeut Res Ctr, MSB 2-250,6431 Fannin, Houston, TX 77030 USA.	Sudhir.Paul@uth.tmc.edu	Sinha, Meenal/B-7158-2016	Sinha, Meenal/0000-0002-4008-4080	NATIONAL CANCER INSTITUTE [R01CA080312] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI031268, R01AI031268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR044888] Funding Source: NIH RePORTER; NCI NIH HHS [CA-80312] Funding Source: Medline; NHLBI NIH HHS [HL-44126] Funding Source: Medline; NIAID NIH HHS [AI-31268] Funding Source: Medline; NIAMS NIH HHS [P50AR44888] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Baron AT, 1997, HYBRIDOMA, V16, P259, DOI 10.1089/hyb.1997.16.259; BARRY MM, 1993, MOL IMMUNOL, V30, P833, DOI 10.1016/0161-5890(93)90006-W; Bogdan S, 2001, CURR BIOL, V11, pR292, DOI 10.1016/S0960-9822(01)00167-1; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Ellis I, 1997, DEVELOPMENT, V124, P1593; GHERARDI E, 1992, NATURE, V357, P201, DOI 10.1038/357201a0; GILL PJ, 1997, JAVA REP, V2, P16; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; Handford PA, 2000, BBA-MOL CELL RES, V1498, P84, DOI 10.1016/S0167-4889(00)00085-9; HEINER JS, 1994, AM J REPROD IMMUNOL, V32, P152, DOI 10.1111/j.1600-0897.1994.tb01106.x; Jones M. K., 1999, Frontiers in Bioscience, V4, pD303; Jordan KC, 2000, NAT GENET, V24, P429, DOI 10.1038/74294; MODJTAHEDI H, 1993, BRIT J CANCER, V67, P254, DOI 10.1038/bjc.1993.49; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; NAKOPOULOU L, 1994, NEPHROL DIAL TRANSPL, V9, P764; Okada T, 2001, BIOL NEONATE, V79, P46, DOI 10.1159/000047065; Oyama N, 1998, J DERMATOL SCI, V16, P120, DOI 10.1016/S0923-1811(97)00040-6; PAUL S, 1991, J BIOL CHEM, V266, P16128; Paul S, 2001, J BIOL CHEM, V276, P28314, DOI 10.1074/jbc.M102530200; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; ROSENTHAL AK, 1993, ANN RHEUM DIS, V52, P531, DOI 10.1136/ard.52.7.531; Sambrook J, 1989, MOL CLONING LAB MANU, V3; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; Sivinski Connie L., 1999, P347; SOROKIN A, 1995, ONCOGENE, V11, P1531; STYREN SD, 1990, BRAIN RES, V512, P347, DOI 10.1016/0006-8993(90)90647-T; SUN M, 1994, J BIOL CHEM, V269, P734; Sun M, 1997, J MOL BIOL, V271, P374, DOI 10.1006/jmbi.1997.1196; TAMURA M, 1995, HUM REPROD, V10, P1891, DOI 10.1093/oxfordjournals.humrep.a136203; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Tan FK, 2000, ARTHRITIS RHEUM-US, V43, P2464, DOI 10.1002/1529-0131(200011)43:11<2464::AID-ANR13>3.0.CO;2-F; Tebar F, 2002, MOL BIOL CELL, V13, P2057, DOI 10.1091/mbc.01-12-0571; TOKIYAMA K, 1990, J RHEUMATOL, V17, P1463; TOSI E, 1995, INT J CANCER, V62, P643, DOI 10.1002/ijc.2910620525; Walker RA, 1998, J PATHOL, V185, P234, DOI 10.1002/(SICI)1096-9896(199807)185:3<234::AID-PATH128>3.0.CO;2-8; Yang XD, 1999, CANCER RES, V59, P1236; Zhou YX, 2001, FASEB J, V15, pA1199	42	15	19	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					136	143		10.1096/fj.01-0847com	http://dx.doi.org/10.1096/fj.01-0847com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554692				2022-12-28	WOS:000181456900038
J	Veitonmaki, N; Fuxe, J; Hultdin, M; Roos, G; Pattersson, RF; Cao, Y				Veitonmaki, N; Fuxe, J; Hultdin, M; Roos, G; Pattersson, RF; Cao, Y			Immortalization of bovine capillary endothelial cells by hTERT alone involves inactivation of endogenous p16(INK4A)/pRb	FASEB JOURNAL			English	Article						telomere; telomerase; p16(INK4A)	TELOMERASE REVERSE-TRANSCRIPTASE; HUMAN EPITHELIAL-CELLS; HUMAN FIBROBLASTS; LIFE-SPAN; REPLICATIVE SENESCENCE; DNA METHYLATION; IN-VIVO; EXPRESSION; GROWTH; CANCER	Recent studies show that stable expression of the human telomerase catalytic subunit, hTERT, alone can lead several types of normal human somatic cells to bypass replicative senescence and become immortal. The molecular mechanisms by which telomerase immortalizes cells are not fully understood, although a key function of telomerase is to maintain a critical length of telomeres in order to preserve the stability and integrity of the genome. Here we report that stable transfection of hTERT alone was sufficient to allow bovine capillary endothelial (BCE) cells to bypass senescence and acquire immortality. Surprisingly, telomere lengths in these stable transfectants were progressively shortened during an increasing number of population doublings (PDLs), despite high telomerase activity. The expression of the cyclin-dependent kinase inhibitors (CDKIs) p16(INK4A) and p21(CIP1/WAF1) was concomitantly repressed, and the retinoblastoma protein (pRb) was maintained in a hyperphosphorylated state in the telomerase-expressing cells. Re-expression of p16(INK4A) in these cells by either treatment with a demethylating agent or by adenovirus-mediated expression reinduced a senescence-like phenotype, suggesting that the inactivation of p16(INK4A) was due to DNA methylation and was crucial for the immortalization process. In agreement with this finding, the expression levels of the prototypic DNA methyltransferase DNMT1 were elevated in the hTERT-positive cells.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Stockholm Branch, Ludwig Inst Canc Res, S-17177 Stockholm, Sweden; Umea Univ, Dept Med Biosci, S-90187 Umea, Sweden	Karolinska Institutet; Karolinska Institutet; Ludwig Institute for Cancer Research; Umea University	Cao, Y (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.	yihai.cao@mtc.ki.se	Fuxe, Jonas/T-4433-2017	Fuxe, Jonas/0000-0003-4576-9377				Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Andersson AM, 1998, J VIROL, V72, P9585, DOI 10.1128/JVI.72.12.9585-9596.1998; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; BICNELL R, 1996, ENDOTHELIAL CELL CUL; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Candal FJ, 1996, MICROVASC RES, V52, P221, DOI 10.1006/mvre.1996.0060; Cao RH, 2001, P NATL ACAD SCI USA, V98, P6390, DOI 10.1073/pnas.101564798; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Duan JM, 2001, J BIOL CHEM, V276, P48325, DOI 10.1074/jbc.M104814200; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; FOLKMAN J, 1980, T OPHTHAL SOC UK, V100, P346; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P17; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fuxe J, 2000, CELL GROWTH DIFFER, V11, P373; Fuxe J, 2000, ONCOGENE, V19, P1724, DOI 10.1038/sj.onc.1203496; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Hara E, 1996, MOL CELL BIOL, V16, P859; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hooijberg E, 2000, J IMMUNOL, V165, P4239, DOI 10.4049/jimmunol.165.8.4239; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kanai Y, 2001, INT J CANCER, V91, P205, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin K, 2000, P NATL ACAD SCI USA, V97, P9385, DOI 10.1073/pnas.170282597; Loughran O, 1996, ONCOGENE, V13, P561; MacKenzie KL, 2000, EXP CELL RES, V259, P336, DOI 10.1006/excr.2000.4982; MEHLE C, 1994, CANCER RES, V54, P236; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Norrback KF, 1998, BLOOD, V92, P567, DOI 10.1182/blood.V92.2.567.414a18_567_573; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Thomas M, 2000, NAT BIOTECHNOL, V18, P39, DOI 10.1038/71894; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wright WE, 2001, CURR OPIN GENET DEV, V11, P98, DOI 10.1016/S0959-437X(00)00163-5; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	54	37	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					764	+		10.1096/fj.02-0599-fje	http://dx.doi.org/10.1096/fj.02-0599-fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586745				2022-12-28	WOS:000181456900025
J	Kajimura, M; Shimoyama, M; Tsuyama, S; Suzuki, T; Kozaki, S; Takenaka, S; Tsubota, K; Oguchi, Y; Suematsu, M				Kajimura, M; Shimoyama, M; Tsuyama, S; Suzuki, T; Kozaki, S; Takenaka, S; Tsubota, K; Oguchi, Y; Suematsu, M			Visualization of gaseous monoxide reception by soluble guanylate cyclase in the rat retina	FASEB JOURNAL			English	Article						nitric oxide; carbon monoxide; soluble guanylate cyclase; neural transmission	NITRIC-OXIDE SYNTHASE; CARBON-MONOXIDE; HEME OXYGENASE-2; DEPENDENT ACTIVATION; ENDOGENOUS MODULATOR; MONOCLONAL-ANTIBODY; CELLS; LIVER; MICE; TRANSDUCTION	Immunohistochemistry using novel monoclonal antibodies (mAbs) allowed us to uncover tissue activities of soluble guanylate cyclase (sGC) fine tuned by NO and CO. Upon NO and CO applications in vitro, purified sGC increased the affinity to mAb3221 by 100- and 10-fold, respectively, but not to mAb28131. Immunohistochemistry for gas-generating enzymes revealed that NO occurred in amacrine, bipolar, and Muller's glia cells (MGCs), whereas CO was derived mostly from heme oxygenase (HO)-2 in MGCs. Basal sGC immunoreactivities in vivo to mAb3221 but not to mAb28131 were enhanced by injecting L-arginine and attenuated by blocking NO synthases, suggesting the ability of the former mAb to sense NO. Comparison of mAb-assisted immunohistochemistry suggested that sGC activities were enhanced by zinc protoporphyrin-IX, an HO inhibitor, and repressed completely by blocking NO. However, suggested roles of CO played in situ varied among different retinal layers. In inner plexiform and inner nuclear layers located in the proximity of the cellular NO sources, CO serves as a simple inhibitor of local sGC, while playing roles in housekeeping sGC activation in external limiting membrane standing far from them. These results suggest that CO generated in MGCs is a diffusible gas mediator regulating sGC in both autocrine and paracrine manners.	Keio Univ, Sch Med, Dept Biochem & Integrat Med Biol, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan; Tokyo Dent Coll, Dept Ophthalmol, Chiba, Japan; Univ Osaka Prefecture, Dept Mol Biol Life Sci & Vet Sci, Osaka, Japan	Keio University; Keio University; Tokyo Dental College; Osaka Metropolitan University	Suematsu, M (corresponding author), Keio Univ, Sch Med, Dept Biochem & Integrat Med Biol, Tokyo 1608582, Japan.	msuem@sc.itc.keio.ac.jp	Suematsu, Makoto/I-8135-2013; Kajimura, Mayumi/L-1734-2013; Suematsu, Makoto/O-5762-2018	Suematsu, Makoto/0000-0002-7165-6336; Suematsu, Makoto/0000-0002-7165-6336				ANTONINI E, 1971, N HOLLAND RES MONOGR, V12, P13; Burnett AL, 1998, NAT MED, V4, P84, DOI 10.1038/nm0198-084; Cao LX, 2000, VISUAL NEUROSCI, V17, P319, DOI 10.1017/S0952523800173018; Chun MH, 1999, VISUAL NEUROSCI, V16, P379, DOI 10.1017/S0952523899162175; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Dizhoor AM, 2000, CELL SIGNAL, V12, P711, DOI 10.1016/S0898-6568(00)00134-0; Friedman JM, 1998, GENET MED, V1, P54; Goda N, 1998, J CLIN INVEST, V101, P604, DOI 10.1172/JCI1324; Guidry C, 1996, INVEST OPHTH VIS SCI, V37, P740; Hangai M, 1999, INVEST OPHTH VIS SCI, V40, P450; HAUGH LM, 1990, ANN BIOMED ENG, V18, P19, DOI 10.1007/BF02368415; Hobbs AJ, 1997, TRENDS PHARMACOL SCI, V18, P484, DOI 10.1016/S0165-6147(97)01137-1; IGNARRO LJ, 1990, PHARMACOL TOXICOL, V67, P1, DOI 10.1111/j.1600-0773.1990.tb00772.x; Imai T, 2001, CIRC RES, V89, P55, DOI 10.1161/hh1301.092679; Ingi T, 1996, NEURON, V16, P835, DOI 10.1016/S0896-6273(00)80103-8; Job C, 1998, J CELL BIOL, V143, P1661, DOI 10.1083/jcb.143.6.1661; Johansson K, 2000, INVEST OPHTH VIS SCI, V41, P305; Koesling D, 1999, Rev Physiol Biochem Pharmacol, V135, P41, DOI 10.1007/BFb0033669; KUTTY RK, 1995, P NATL ACAD SCI USA, V92, P1177, DOI 10.1073/pnas.92.4.1177; Kyokane T, 2001, GASTROENTEROLOGY, V120, P1227, DOI 10.1053/gast.2001.23249; MILLS SL, 1995, NATURE, V377, P734, DOI 10.1038/377734a0; Ozawa N, 2002, J CLIN INVEST, V109, P457, DOI [10.1172/JCI0213190, 10.1172/JCI200213190]; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POSS KD, 1995, NEURON, V15, P867, DOI 10.1016/0896-6273(95)90177-9; SUEMATSU M, 1993, MICROVASC RES, V46, P28, DOI 10.1006/mvre.1993.1033; SUEMATSU M, 1995, J CLIN INVEST, V96, P2431, DOI 10.1172/JCI118300; Suzuki T, 2001, FEBS LETT, V507, P49, DOI 10.1016/S0014-5793(01)02943-X; Tsuyama S, 1999, FEBS LETT, V455, P291, DOI 10.1016/S0014-5793(99)00884-4; VARDIMON L, 1986, P NATL ACAD SCI USA, V83, P9060, DOI 10.1073/pnas.83.23.9060; Wakabayaski Y, 1999, AM J PHYSIOL-GASTR L, V277, pG1088, DOI 10.1152/ajpgi.1999.277.5.G1088; Wolin MS, 1999, RESP PHYSIOL, V115, P229, DOI 10.1016/S0034-5687(99)00023-7; Yamaguchi T, 1996, BBA-GEN SUBJECTS, V1289, P110, DOI 10.1016/0304-4165(95)00128-X; Zakhary R, 1997, P NATL ACAD SCI USA, V94, P14848, DOI 10.1073/pnas.94.26.14848	33	53	54	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					506	+		10.1096/fj.02-0359fje	http://dx.doi.org/10.1096/fj.02-0359fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551840				2022-12-28	WOS:000181453700008
J	Kosmadaki, MG; Yaar, M; Arble, BL; Gilchrest, BA				Kosmadaki, MG; Yaar, M; Arble, BL; Gilchrest, BA			UV induces VEGF through a TNF-alpha-independent pathway	FASEB JOURNAL			English	Article						skin; cytokines; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; VASCULAR-PERMEABILITY FACTOR; HUMAN KERATINOCYTES; FACTOR EXPRESSION; ULTRAVIOLET-B; FACTOR GENE; CULTURED KERATINOCYTES; FACTOR VPF/VEGF; CANCER CELLS	Vascular endothelial growth factor (VEGF) is a potent keratinocyte-derived angiogenic factor. Prior reports suggest that following UV irradiation VEGF in keratinocytes is induced primarily by tumor necrosis factor (TNF)-alpha, a cytokine synthesized and secreted by keratinocytes after UV irradiation. We investigated whether blocking TNF-alpha binding to its receptors would inhibit UV-induced VEGF expression and secretion in the keratinocyte-derived line SCC-12F. Irradiation with physiologic UV doses (30 mJ/cm(2)) substantially induced VEGF mRNA in this cell line, as expected, and mRNA induction was followed by increased VEGF in medium conditioned by UV-irradiated cells. Also as expected, TNF-alpha induced VEGF expression and secretion in a dose-dependent manner. Addition of a hexapeptide (Ac-KWIIVW-NH2), known to block TNF-alpha binding to its receptors, abrogated this TNF-alpha effect on VEGF mRNA induction. However, addition of the peptide to cells immediately after UV irradiation did not substantially affect VEGF mRNA induction or secretion into the medium. Our results suggest that VEGF induction after UV irradiation is mediated by multiple mechanisms and that blocking a single pathway does not affect the response.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA	Boston University	Gilchrest, BA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St,J-Bldg, Boston, MA 02118 USA.	bgilcre@bu.edu						Abeyama K, 2000, J CLIN INVEST, V105, P1751, DOI 10.1172/JCI9745; ADASHI EY, 1989, J BIOL CHEM, V264, P11591; ANDREANI CL, 1991, J BIOL CHEM, V266, P6761; BALLAUN C, 1995, J INVEST DERMATOL, V104, P7, DOI 10.1111/1523-1747.ep12613450; Blaudschun R, 2000, FEBS LETT, V474, P195, DOI 10.1016/S0014-5793(00)01605-7; Brauchle M, 1996, J BIOL CHEM, V271, P21793, DOI 10.1074/jbc.271.36.21793; BRENNEISEN P, 2002, BIOCH J, V2; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1995, J IMMUNOL, V154, P2801; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clingen PH, 2001, BRIT J DERMATOL, V145, P54, DOI 10.1046/j.1365-2133.2001.04281.x; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; CORSINI E, 1995, PHOTODERMATOL PHOTO, V11, P112, DOI 10.1111/j.1600-0781.1995.tb00149.x; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DETMAR M, 1995, J INVEST DERMATOL, V105, P44, DOI 10.1111/1523-1747.ep12312542; Detmar M, 1997, J INVEST DERMATOL, V108, P263, DOI 10.1111/1523-1747.ep12286453; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; Diaz BV, 2000, J BIOL CHEM, V275, P642, DOI 10.1074/jbc.275.1.642; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GILCHREST BA, 1993, J INVEST DERMATOL, V101, P666, DOI 10.1111/1523-1747.ep12371673; GILL PJ, 1997, JAVA REP, V2, P16; Gille J, 2000, J INVEST DERMATOL, V115, P30, DOI 10.1046/j.1523-1747.2000.00020.x; Huang S, 2000, CANCER RES, V60, P5334; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; JOHNSON B, 1984, PHYSL PATHOPHYSIOLOG, P2414; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; Kozlowska U, 1998, DERMATOLOGY, V196, P89, DOI 10.1159/000017878; Kruszynski M, 1999, CYTOKINE, V11, P37, DOI 10.1006/cyto.1998.0389; Leccia MT, 1998, J INVEST DERMATOL, V110, P691; Leverkus M, 1998, J INVEST DERMATOL, V110, P353, DOI 10.1046/j.1523-1747.1998.00154.x; Longuet-Perret I, 1998, BRIT J DERMATOL, V138, P221; Mildner M, 1999, PHOTOCHEM PHOTOBIOL, V70, P674, DOI 10.1562/0031-8655(1999)070<0674:UAURDR>2.3.CO;2; PALOMBELLA VJ, 1989, J BIOL CHEM, V264, P18128; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Rheinwald J, 1983, HUMAN CARCINOGENESIS; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Weninger W, 1996, LAB INVEST, V75, P647; WERNINGHAUS K, 1991, PHOTODERMATOL PHOTO, V8, P236; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015	47	32	36	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					446	+		10.1096/fj.02-0379fje	http://dx.doi.org/10.1096/fj.02-0379fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551841				2022-12-28	WOS:000181453700003
J	Valable, S; Bellail, A; Lesne, S; Liot, G; MacKenzie, ET; Vivien, D; Bernaudin, M; Petit, E				Valable, S; Bellail, A; Lesne, S; Liot, G; MacKenzie, ET; Vivien, D; Bernaudin, M; Petit, E			Angiopoietin-1-induced phosphatidyl-inositol 3-kinase activation prevents neuronal apoptosis	FASEB JOURNAL			English	Article						ischemia; angiogenesis; Tie-2 receptor; PI3-K; Ang-1	ENDOTHELIAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAY; FOCAL CEREBRAL-ISCHEMIA; BLOOD-BRAIN-BARRIER; CELL-SURVIVAL; PROTEIN-KINASE; SYMPATHETIC NEURONS; HIPPOCAMPAL-NEURONS; NEUROTROPHIC FACTOR; FACTOR EXPRESSION	Although angiopoietin-1 (Ang-1) is recognized as an endothelial growth factor, its presence in brain following an ischemic event suggests a role in the evolution of neuronal damage. Using primary neuronal cultures, we showed that neurons express Ang-1 and possess the functional angiopoietin-receptor Tie-2, which is phosphorylated in the presence of Ang-1. We further investigated in vitro whether Ang-1 could protect neurons against either excitotoxic necrosis or apoptosis induced by serum deprivation (SD). A neuroprotective effect for Ang-1 was detected exclusively in the apoptotic paradigm. Treatment of cells with the phosphatidylinositol 3-kinase (PI3-K) inhibitor, LY294002, inhibited Ang-1-induced phosphorylation of Akt, restored the cleavage of the effector caspase-3, and reduced the protective effect of Ang-1 against SD-induced toxicity. These findings suggest that Ang-1 has a neuroprotective effect against apoptotic stress and that this effect is dependent on the PI3-K/Akt pathway and inhibition of caspase-3 cleavage. This study provides evidence that Ang-1 is not just angiogenic but also neuroprotective. The understanding of neuroprotective mechanisms induced by Ang-1 may promote strategies based on the pleiotropic effects of angiogenic factors. Such approaches could be useful for the treatment of brain diseases in which both neuronal death and angiogenesis are involved.	Univ Caen, CNRS, UMR 6551, IFR 47,Ctr Cyceron, F-14074 Caen, France	Centre National de la Recherche Scientifique (CNRS); Universite de Caen Normandie	Petit, E (corresponding author), Univ Caen, CNRS, UMR 6551, IFR 47,Ctr Cyceron, Bd H Becquerel,BP 5229, F-14074 Caen, France.	e.petit@neuro.unicaen.fr	Mackenzie, Eric Thomson/L-1938-2015; PETIT, Edwige/C-1896-2008; valable, samuel/B-7578-2008; Bernaudin, Myriam/B-7663-2008	valable, samuel/0000-0003-0355-0270; Bernaudin, Myriam/0000-0003-0778-3397; MacKenzie, Eric T/0000-0003-1057-7033; Liot, Geraldine/0000-0002-4784-7693; VIVIEN, DENIS/0000-0002-7636-2185; Lesne, Sylvain/0000-0001-9411-1868; , Anita/0000-0002-6982-5882				Abdulmalek K, 2001, AM J PHYSIOL-LUNG C, V281, pL582, DOI 10.1152/ajplung.2001.281.3.L582; Abumiya T, 1999, J CEREBR BLOOD F MET, V19, P1038, DOI 10.1097/00004647-199909000-00012; Beck H, 2000, AM J PATHOL, V157, P1473, DOI 10.1016/S0002-9440(10)64786-4; Bernaudin M, 1998, EXP NEUROL, V150, P30, DOI 10.1006/exnr.1997.6728; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Cheung WM, 2000, CHINESE J PHYSIOL, V43, P119; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Harfouche R, 2002, MICROVASC RES, V64, P135, DOI 10.1006/mvre.2002.2421; Hayashi T, 1997, STROKE, V28, P2039, DOI 10.1161/01.STR.28.10.2039; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887, DOI 10.1097/00004647-199808000-00009; Jin K, 2001, NEUROSCIENCE, V108, P351, DOI 10.1016/S0306-4522(01)00154-3; Jin KL, 2000, J MOL NEUROSCI, V14, P197, DOI 10.1385/JMN:14:3:197; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kim I, 2000, ONCOGENE, V19, P4549, DOI 10.1038/sj.onc.1203800; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Kovacs Z, 1996, STROKE, V27, P1865, DOI 10.1161/01.STR.27.10.1865; KRUPINSKI J, 1993, LANCET, V342, P742, DOI 10.1016/0140-6736(93)91734-4; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lin TN, 2000, J CEREBR BLOOD F MET, V20, P387, DOI 10.1097/00004647-200002000-00021; Lin WP, 2001, CHINESE J ASTRON AST, V1, P21, DOI 10.1088/1009-9271/1/1/21; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; Matsuzaki H, 2001, FASEB J, V15, P1218, DOI 10.1096/fj.00-0495fje; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; Nicole O, 2001, J NEUROSCI, V21, P3024, DOI 10.1523/JNEUROSCI.21-09-03024.2001; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Orike N, 2001, J CELL BIOL, V154, P995, DOI 10.1083/jcb.200101068; Papadakis CM, 2000, EUR PHYS J E, V1, P275, DOI 10.1007/s101890050029; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Patt S, 1997, J CEREBR BLOOD F MET, V17, P801; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1; Teichert-Kuliszewska K, 2001, CARDIOVASC RES, V49, P659, DOI 10.1016/S0008-6363(00)00231-5; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Wang MM, 2002, EXP NEUROL, V173, P283, DOI 10.1006/exnr.2001.7844; Wang RG, 2002, ACTA PHARMACOL SIN, V23, P405; Yamada M, 2001, J NEUROCHEM, V78, P940, DOI 10.1046/j.1471-4159.2001.00497.x; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002; Zhang ZG, 2002, NEUROSCIENCE, V113, P683, DOI 10.1016/S0306-4522(02)00175-6; Zhang ZG, 2002, TRENDS CARDIOVAS MED, V12, P62, DOI 10.1016/S1050-1738(01)00149-9	56	87	94	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					443	+		10.1096/fj.02-0372fje	http://dx.doi.org/10.1096/fj.02-0372fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12514118				2022-12-28	WOS:000181453700019
J	Karahalil, B; Hogue, BA; De Souza-Pinto, NC; Bohr, VA				Karahalil, B; Hogue, BA; De Souza-Pinto, NC; Bohr, VA			Base excision repair capacity in mitochondria and nuclei: tissue-specific variations	FASEB JOURNAL			English	Article						BER; repair activity; mouse tissues; oxidative stress; nucleus	DNA-REPAIR; EXPRESSION; DAMAGE; ENDONUCLEASE; BRAIN; LIVER; HEART; YOUNG; GENE; MICE	Base excision repair is the main pathway for repair of oxidative base lesions in DNA. Mammalian cells must maintain genomic stability in their nuclear and mitochondrial genomes, which have different degrees of vulnerability to DNA damage. This study quantifies DNA glycosylase activity in mitochondria and nucleus from C57/BL6 mouse tissues including brain, liver, heart, muscle, kidney, and testis. The activities of oxoguanine DNA glycosylase (OGG1), uracil DNA glycosylase, and endonuclease III homologue 1 (NTH1) were measured using oligonucleotide substrates with DNA lesions specific for each glycosylase. Mitochondrial content was normalized to citrate synthase activity and mitochondrial function was assessed by measuring cytochrome c oxidase (COX) activity. In nuclear and mitochondrial extracts, the highest DNA glycosylase activities were in testis. Brain and heart, tissues with the highest oxidative load, did not have higher levels of OGG1 or NTH1 activity than muscle or kidney, which are more glycolytic tissues. In general, mitochondrial extracts have lower DNA glycosylase activity than nuclear extracts. There was no correlation between glycosylase activities in the mitochondrial extracts and COX activity, suggesting that DNA repair enzymes may be regulated by a mechanism different from this mitochondrial enzyme.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Gazi Univ, Fac Pharm, Dept Toxicol, TR-06330 Ankara, Turkey	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Gazi University	Bohr, VA (corresponding author), 5600 Nathan Shock Dr,Box 1, Baltimore, MD 21224 USA.	bohrv@grc.nia.nih.gov	Karahalil, Bensu/AFU-8097-2022; Souza-Pinto, Nadja C./C-3462-2013; Souza-Pinto, Nadja/T-3050-2019; Bohr, Vilhelm/AAP-5931-2020	Souza-Pinto, Nadja C./0000-0003-4206-964X; Souza-Pinto, Nadja/0000-0003-4206-964X; 	NATIONAL INSTITUTE ON AGING [Z01AG000733, ZIAAG000733] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOHR VA, 1995, MUTAT RES-DNAGING G, V338, P25, DOI 10.1016/0921-8734(95)00008-T; Bohr VA, 2002, FREE RADICAL BIO MED, V32, P804, DOI 10.1016/S0891-5849(02)00787-6; CHAN AC, 1976, J CELL BIOL, V70, P685, DOI 10.1083/jcb.70.3.685; CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; Dantzer F, 2002, NUCLEIC ACIDS RES, V30, P2349, DOI 10.1093/nar/30.11.2349; de Souza-Pinto NC, 2001, FREE RADICAL BIO MED, V30, P916, DOI 10.1016/S0891-5849(01)00483-X; Gillardon F, 1997, MOL BRAIN RES, V52, P194, DOI 10.1016/S0169-328X(97)00237-4; Hamilton ML, 2001, NUCLEIC ACIDS RES, V29, P2117, DOI 10.1093/nar/29.10.2117; HANSKI I, 1982, ANN BOT FENN, V19, P1; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; JONES JS, 1991, NUCLEIC ACIDS RES, V19, P893, DOI 10.1093/nar/19.4.893; Kanoh M, 1999, CIRCULATION, V99, P2757, DOI 10.1161/01.CIR.99.21.2757; KOHLER SW, 1991, ENVIRON MOL MUTAGEN, V18, P316, DOI 10.1002/em.2850180421; Korr H, 2001, CHEM-BIOL INTERACT, V134, P217, DOI 10.1016/S0009-2797(01)00154-5; Laposa RR, 2001, P NATL ACAD SCI USA, V98, P12860, DOI 10.1073/pnas.241519498; Li YY, 2001, CIRCULATION, V104, P2492, DOI 10.1161/hc4501.098944; Lin LH, 2000, J NEUROCHEM, V74, P1098; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MarinGarcia J, 1997, BIOCHEM CELL BIOL, V75, P137, DOI 10.1139/bcb-75-2-137; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; NILSEN H, 1997, NUCLEIC ACIDS RES, V21, P2579; PETERSON C, 1985, J NEUROCHEM, V45, P1779, DOI 10.1111/j.1471-4159.1985.tb10534.x; Rasmussen HN, 1997, ANAL BIOCHEM, V252, P153, DOI 10.1006/abio.1997.2304; Richardson LL, 2000, BIOL REPROD, V62, P789, DOI 10.1095/biolreprod62.3.789; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; Schmerold I, 2001, EXP GERONTOL, V36, P1375, DOI 10.1016/S0531-5565(01)00103-6; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; Tan YS, 1996, ACTA MED OKAYAMA, V50, P53; Walter CA, 1998, P NATL ACAD SCI USA, V95, P10015, DOI 10.1073/pnas.95.17.10015; Wilson TM, 1996, MUTAT RES-DNA REPAIR, V362, P237, DOI 10.1016/0921-8777(95)00053-4; Zahn RK, 1996, MECH AGEING DEV, V89, P79, DOI 10.1016/0047-6374(96)01738-1	34	96	103	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					1895	1902		10.1096/fj.02-0463com	http://dx.doi.org/10.1096/fj.02-0463com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12468454				2022-12-28	WOS:000180574300010
J	Takezawa, T; Takenouchi, T; Imai, K; Takahashi, T; Hashizume, K				Takezawa, T; Takenouchi, T; Imai, K; Takahashi, T; Hashizume, K			Cell culture on thin tissue sections commonly prepared for histopathology	FASEB JOURNAL			English	Article						scaffold; tissue engineering; cell behavior; TOSHI-substratum; cellomics	ANGIOGENIC ACTIVITY; BASEMENT-MEMBRANE; NEURITE OUTGROWTH; PLACENTAL TISSUES; GENE-EXPRESSION; MESSENGER-RNA; DIFFERENTIATION; RECONSTRUCTION; SECRETION; GROWTH	Thin tissue sections commonly prepared on a glass slide for histopathology retain many in vivo biochemical attributes related not only to structure but also function. We hypothesized that such tissue sections might serve as novel cell culture substrata that would reflect tissue conditions in vivo. Here we report the applicability of tissue section substrata to tissue reconstruction and serum-free culture. Four different cell types were cultured on section and acellularized section substrata prepared from a bovine placenta. The labyrinth region of the substratum induced cell differentiation to elicit the formation of multicellular spheroids of BeWo cells (human choriocarcinoma cells), a capillary network-like structure for CPAE cells (bovine pulmonary artery endothelial cells), and a neuronal network-like structure for PC-12 cells (rat pheochromocytoma cells). The substratum provided a microenvironment that maintained the viability of PC-12 cells in a serum-free culture. We also succeeded in preparing a multicellular mass of normal human dermal fibroblasts (NHDFs) involving acellularized section-derived components. This technology offers the novel investigation of cell behaviors induced by culturing different cell types on various tissue sections and will be a useful tool for identifying cell characteristics and clarifying the molecular mechanisms that regulate the behavior of each cell type.	Natl Inst Agrobiol Sci, Lab Anim Cell Biol, Kukizaki, Ibaraki 3050901, Japan; Natl Inst Agrobiol Sci, Lab Reprod Biol & Technol, Kukizaki, Ibaraki 3050901, Japan	National Institute of Agrobiological Sciences - Japan; National Institute of Agrobiological Sciences - Japan	Takezawa, T (corresponding author), Natl Inst Agrobiol Sci, Lab Anim Cell Biol, Ikenodai 2, Kukizaki, Ibaraki 3050901, Japan.	t.takezawa@affrc.go.jp		Takezawa, Toshiaki/0000-0002-1825-838X				ALBINI A, 1987, CANCER RES, V47, P3239; Badylak S, 1999, BIOMATERIALS, V20, P2257, DOI 10.1016/S0142-9612(99)00156-8; CARNOW TB, 1985, J NEUROSCI, V5, P1965; Chen CS, 1998, BIOTECHNOL PROGR, V14, P356, DOI 10.1021/bp980031m; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Ferber D, 1999, SCIENCE, V284, P422, DOI 10.1126/science.284.5413.422; GOBIN AS, 2002, FASEB J         0326, DOI DOI 10.1096/F4.01-0759FJE; HOHN HP, 1994, EXP CELL RES, V215, P40, DOI 10.1006/excr.1994.1312; Holmes TC, 2000, P NATL ACAD SCI USA, V97, P6728, DOI 10.1073/pnas.97.12.6728; JOSHI MS, 1991, J EXP ZOOL, V260, P229, DOI 10.1002/jez.1402600212; Kizaki K, 2001, REPRODUCTION, V121, P573, DOI 10.1530/rep.0.1210573; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Lee MJ, 1998, ARCH PHARM RES, V21, P260, DOI 10.1007/BF02975285; LI ML, 1987, P NATL ACAD SCI USA, V84, P136, DOI 10.1073/pnas.84.1.136; LIVESEY SA, 1995, TRANSPLANTATION, V60, P1, DOI 10.1097/00007890-199507150-00001; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Nakano H, 2002, CELL TISSUE RES, V307, P225, DOI 10.1007/s00441-001-0491-x; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; Oberpenning F, 1999, NAT BIOTECHNOL, V17, P149, DOI 10.1038/6146; Persidis A, 1999, NAT BIOTECHNOL, V17, P508, DOI 10.1038/8700; PETTMANN B, 1988, J NEUROSCI, V8, P3624; REYNOLDS LP, 1988, J REPROD FERTIL, V83, P497; REYNOLDS LP, 1987, J REPROD FERTIL, V81, P233, DOI 10.1530/jrf.0.0810233; Rialas CM, 2000, EXP CELL RES, V260, P268, DOI 10.1006/excr.2000.5017; Russo E, 2000, SCIENTIST, V14, P8; Saltzman WM, 1999, NAT BIOTECHNOL, V17, P534, DOI 10.1038/9835; Sarges J, 1998, J VET MED A, V45, P1, DOI 10.1111/j.1439-0442.1998.tb00795.x; SCHUETZ EG, 1988, J CELL PHYSIOL, V134, P309, DOI 10.1002/jcp.1041340302; SENIOR PV, 1988, DEVELOPMENT, V104, P431; Takezawa T, 1997, TISSUE ENG, V3, P329, DOI 10.1089/ten.1997.3.329; Takezawa T, 2000, TISSUE ENG, V6, P641, DOI 10.1089/10763270050199587; TAKEZAWA T, 1992, J CELL SCI, V101, P495; TAKEZAWA T, 1990, BIO-TECHNOL, V8, P854, DOI 10.1038/nbt0990-854; TAKEZAWA T, 1993, EXP CELL RES, V208, P430, DOI 10.1006/excr.1993.1265	35	12	12	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13	1				1847	+		10.1096/fj.02-0405fje	http://dx.doi.org/10.1096/fj.02-0405fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223453				2022-12-28	WOS:000181189100001
J	Febbraio, MA; Pedersen, BK				Febbraio, MA; Pedersen, BK			Muscle-derived interleukin-6: mechanisms for activation and possible biological roles	FASEB JOURNAL			English	Review						cytokines; lipolysis; intracellular signaling; metabolism; calcium; glycogen; metabolic syndrome	TUMOR-NECROSIS-FACTOR; HUMAN SKELETAL-MUSCLE; C-REACTIVE PROTEIN; EXERCISE-INDUCED INCREASE; NITRIC-OXIDE SYNTHASE; TNF-ALPHA; STRENUOUS EXERCISE; GLUCOSE-TRANSPORT; CYTOKINE RESPONSE; CARBOHYDRATE INGESTION	It has recently been demonstrated that the marked increase in the systemic concentration of cytokine interleukin-6 (IL-6) seen with exercise originates from the contracting limb and that skeletal muscle cells per se are the likely source of the production. This review summarizes the possible mechanisms for activation and biological consequences of muscle-derived IL-6. It appears that intramuscular IL-6 is stimulated by complex signaling cascades initiated by both calcium (Ca2+)-dependent and -independent stimuli. It also seems likely that skeletal muscle produces IL-6 to aid in maintaining metabolic homeostasis during periods of altered metabolic demand such as muscular exercise or insulin stimulation. It may do so via local and/or systemic effects. This review also explores the efficacy that IL-6 may be used as a therapeutic drug in treating metabolic disorders such as obesity, type 2 diabetes, and atherosclerosis. for activation and possible biological roles.	Univ Copenhagen, Rigshosp, Copenhagen Muscle Res Ctr, Sect 7652, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Rigshosp, Dept Infect Dis, DK-2200 Copenhagen N, Denmark; Univ Melbourne, Dept Physiol, Parkville, Vic 3052, Australia	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Melbourne	Pedersen, BK (corresponding author), Univ Copenhagen, Rigshosp, Copenhagen Muscle Res Ctr, Sect 7652, Tagensvej 20, DK-2200 Copenhagen N, Denmark.	bkp@rh.dk	Febbraio, Mark/AAE-9632-2019; Pedersen, Bente Klarlund/AGR-3217-2022	Pedersen, Bente Klarlund/0000-0001-6508-6288; Febbraio, Mark/0000-0002-9296-4418				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BARTOCCIONI E, 1994, IMMUNOL LETT, V42, P135, DOI 10.1016/0165-2478(94)90076-0; Bedard S, 1997, BIOCHEM J, V325, P487, DOI 10.1042/bj3250487; BERGERON R, 1999, AM J PHYSIOL, V267, pE938; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Booth J, 1997, J APPL PHYSIOL, V83, P511, DOI 10.1152/jappl.1997.83.2.511; Boppart MD, 2000, J PHYSIOL-LONDON, V526, P663, DOI 10.1111/j.1469-7793.2000.00663.x; BOUREY RE, 1990, J APPL PHYSIOL, V69, P1689, DOI 10.1152/jappl.1990.69.5.1689; Bradley SJ, 1999, DIABETES, V48, P1815, DOI 10.2337/diabetes.48.9.1815; Bruunsgaard H, 2000, CLIN EXP IMMUNOL, V121, P255, DOI 10.1046/j.1365-2249.2000.01281.x; Bruunsgaard H, 1999, J INFECT DIS, V180, P551, DOI 10.1086/314873; Bruunsgaard H, 1997, J PHYSIOL-LONDON, V499, P833, DOI 10.1113/jphysiol.1997.sp021972; BYRD SK, 1989, J APPL PHYSIOL, V66, P1383, DOI 10.1152/jappl.1989.66.3.1383; Castell LM, 1997, EUR J APPL PHYSIOL O, V75, P47; Chae HJ, 2001, PHARMACOL RES, V43, P275, DOI 10.1006/phrs.2000.0778; Chin ER, 1996, J PHYSIOL-LONDON, V491, P813, DOI 10.1113/jphysiol.1996.sp021259; Coggan A R, 1991, Exerc Sport Sci Rev, V19, P1; Coker RH, 2001, AM J PHYSIOL-ENDOC M, V280, pE918, DOI 10.1152/ajpendo.2001.280.6.E918; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Croisier JL, 1999, MUSCLE NERVE, V22, P208, DOI 10.1002/(SICI)1097-4598(199902)22:2<208::AID-MUS8>3.0.CO;2-B; CRYER PE, 1993, AM J PHYSIOL, V264, pE149, DOI 10.1152/ajpendo.1993.264.2.E149; De Rossi M, 2000, INT IMMUNOL, V12, P1329, DOI 10.1093/intimm/12.9.1329; Derave W, 2000, AM J PHYSIOL-ENDOC M, V279, pE947, DOI 10.1152/ajpendo.2000.279.5.E947; DERIJK RH, 1994, PSYCHONEUROENDOCRINO, V19, P155, DOI 10.1016/0306-4530(94)90005-1; DICOSMO BF, 1994, INT IMMUNOL, V6, P1829, DOI 10.1093/intimm/6.12.1829; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dovio A, 2001, JAMA-J AM MED ASSOC, V286, P2233, DOI 10.1001/jama.286.18.2233; DRENTH JPH, 1995, J APPL PHYSIOL, V79, P1497, DOI 10.1152/jappl.1995.79.5.1497; Ershler WB, 2000, ANNU REV MED, V51, P245, DOI 10.1146/annurev.med.51.1.245; FEBBRAIO MA, 2002, J PHYSIOL-LONDON, pP539; Fernandez-Real JM, 2000, DIABETES, V49, P517, DOI 10.2337/diabetes.49.3.517; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Gadient RA, 1999, STEM CELLS, V17, P127, DOI 10.1002/stem.170127; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Gleeson M, 2000, J PHYSIOL-LONDON, V529, P1, DOI 10.1111/j.1469-7793.2000.00001.x; Gleeson M, 2000, IMMUNOL CELL BIOL, V78, P554, DOI 10.1046/j.1440-1711.2000.00953.x; Halse R, 2001, DIABETES, V50, P1102, DOI 10.2337/diabetes.50.5.1102; Hardin J, 2000, GUT, V47, P184, DOI 10.1136/gut.47.2.184; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Hellsten Y, 1997, J PHYSIOL-LONDON, V498, P239, DOI 10.1113/jphysiol.1997.sp021855; Hibi M, 1996, J MOL MED-JMM, V74, P1, DOI 10.1007/BF00202068; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Howlett K, 1999, AM J PHYSIOL-ENDOC M, V276, pE1130, DOI 10.1152/ajpendo.1999.276.6.E1130; Howlett K, 1998, J APPL PHYSIOL, V84, P1413, DOI 10.1152/jappl.1998.84.4.1413; JAMES DE, 1980, NATURE, V338, P83; Jeukendrup AE, 1999, J PHYSIOL-LONDON, V515, P579, DOI 10.1111/j.1469-7793.1999.579ac.x; Jonsdottir IH, 2000, J PHYSIOL-LONDON, V528, P157, DOI 10.1111/j.1469-7793.2000.00157.x; Kanemaki T, 1998, HEPATOLOGY, V27, P1296, DOI 10.1002/hep.510270515; Keller C, 2001, FASEB J, V15, P2748, DOI 10.1096/fj.01-0507fje; KELLER C, 2002, J PHYSL, pP539; KELLY KL, 1992, J BIOL CHEM, V267, P3423; Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, pE745; Kjaer M, 1998, ADV EXP MED BIOL, V441, P117; Klausen T, 1997, EUR J APPL PHYSIOL, V76, P480, DOI 10.1007/s004210050278; Klouche M, 1999, J IMMUNOL, V163, P4583; LANGBERG H, 2002, J PHYSIOL-LONDON, pP539; LEE AD, 1995, AM J PHYSIOL-REG I, V268, pR997, DOI 10.1152/ajpregu.1995.268.4.R997; LIAO JF, 1995, AM J PHYSIOL-REG I, V268, pR896, DOI 10.1152/ajpregu.1995.268.4.R896; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; LYNGSO D, 2002, IN PRESS J PHYSL LON; Malm C, 2000, J PHYSIOL-LONDON, V529, P243, DOI 10.1111/j.1469-7793.2000.00243.x; MATTHYS P, 1995, INFECT IMMUN, V63, P1158, DOI 10.1128/IAI.63.4.1158-1164.1995; Mazzeo RS, 2001, J APPL PHYSIOL, V91, P2143; McCarty MF, 1999, MED HYPOTHESES, V52, P465, DOI 10.1054/mehy.1997.0684; MCCONELL G, 1994, J APPL PHYSIOL, V77, P1537, DOI 10.1152/jappl.1994.77.3.1537; MIZUHARA H, 1994, J EXP MED, V179, P1529, DOI 10.1084/jem.179.5.1529; Mohamed-Ali V, 1999, AM J PHYSIOL-ENDOC M, V277, pE971, DOI 10.1152/ajpendo.1999.277.6.E971; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Moldoveanu AI, 2000, J APPL PHYSIOL, V89, P1499, DOI 10.1152/jappl.2000.89.4.1499; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Nagaraju K, 1998, CLIN EXP IMMUNOL, V113, P407; NehlsenCannarella SL, 1997, J APPL PHYSIOL, V82, P1662, DOI 10.1152/jappl.1997.82.5.1662; Nielsen HB, 1996, AM J PHYSIOL-REG I, V271, pR222, DOI 10.1152/ajpregu.1996.271.1.R222; Nieman DC, 1998, MED SCI SPORT EXER, V30, P671, DOI 10.1097/00005768-199805000-00005; Nieman DC, 1998, J APPL PHYSIOL, V84, P1252, DOI 10.1152/jappl.1998.84.4.1252; NONOGAKI K, 1995, ENDOCRINOLOGY, V136, P2143, DOI 10.1210/en.136.5.2143; NORTHOFF H, 1991, INT J SPORTS MED, V12, pS9, DOI 10.1055/s-2007-1024743; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Orban Z, 1999, J CLIN ENDOCR METAB, V84, P2126, DOI 10.1210/jc.84.6.2126; Ostrowski K, 2000, EUR J APPL PHYSIOL, V83, P512, DOI 10.1007/s004210000312; Ostrowski K, 1999, J PHYSIOL-LONDON, V515, P287, DOI 10.1111/j.1469-7793.1999.287ad.x; Ostrowski K, 1998, J PHYSIOL-LONDON, V508, P949, DOI 10.1111/j.1469-7793.1998.949bp.x; Ostrowski K, 2001, EUR J APPL PHYSIOL, V84, P244, DOI 10.1007/s004210170012; Pedersen BK, 2000, PHYSIOL REV, V80, P1055, DOI 10.1152/physrev.2000.80.3.1055; Pedersen BK, 1997, INT J SPORTS MED, V18, pS2, DOI 10.1055/s-2007-972695; Pedersen BK, 1998, CAN J PHYSIOL PHARM, V76, P505, DOI 10.1139/cjpp-76-5-505; Pedersen BK, 2001, J PHYSIOL-LONDON, V536, P329, DOI 10.1111/j.1469-7793.2001.0329c.xd; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Pue CA, 1996, J IMMUNOL, V156, P1594; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rhind SG, 2001, AM J PHYSIOL-REG I, V281, pR66; Richter EA, 2001, J PHYSIOL-LONDON, V535, P313, DOI 10.1111/j.1469-7793.2001.t01-2-00313.x; Ridker PM, 2000, CIRCULATION, V101, P1767, DOI 10.1161/01.CIR.101.15.1767; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; RITCHIE DG, 1990, AM J PHYSIOL, V258, pE57, DOI 10.1152/ajpendo.1990.258.1.E57; Rohde T, 1997, AM J PHYSIOL-ENDOC M, V273, pE85, DOI 10.1152/ajpendo.1997.273.1.E85; Saghizadeh M, 1996, J CLIN INVEST, V97, P1111, DOI 10.1172/JCI118504; SCHINDLER R, 1990, BLOOD, V75, P40; Sigal RJ, 2000, METABOLISM, V49, P386, DOI 10.1016/S0026-0495(00)90374-3; SIGAL RJ, 1994, J CLIN ENDOCR METAB, V78, P359, DOI 10.1210/jc.78.2.359; SPRENGER H, 1992, CLIN IMMUNOL IMMUNOP, V63, P188, DOI 10.1016/0090-1229(92)90012-D; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Starkie RL, 2001, J PHYSIOL-LONDON, V533, P585, DOI 10.1111/j.1469-7793.2001.0585a.x; Starkie RL, 2000, J PHYSIOL-LONDON, V528, P647, DOI 10.1111/j.1469-7793.2000.t01-1-00647.x; Starkie RL, 2001, AM J PHYSIOL-CELL PH, V280, pC769, DOI 10.1152/ajpcell.2001.280.4.C769; Steensberg A, 2001, J APPL PHYSIOL, V91, P1708, DOI 10.1152/jappl.2001.91.4.1708; Steensberg A, 2001, J PHYSIOL-LONDON, V537, P633, DOI 10.1111/j.1469-7793.2001.00633.x; Steensberg A, 2000, J PHYSIOL-LONDON, V529, P237, DOI 10.1111/j.1469-7793.2000.00237.x; Steensberg A, 2001, EUR J APPL PHYSIOL, V84, P155, DOI 10.1007/s004210000351; Steensberg A, 2001, AM J PHYSIOL-CELL PH, V281, pC1001; Stephenson DG, 1999, J PHYSIOL-LONDON, V519, P177, DOI 10.1111/j.1469-7793.1999.0177o.x; STITH RD, 1994, CIRC SHOCK, V44, P210; STOUTHARD JML, 1995, AM J PHYSIOL-ENDOC M, V268, pE813, DOI 10.1152/ajpendo.1995.268.5.E813; Stouthard JML, 1996, BIOCHEM BIOPH RES CO, V220, P241, DOI 10.1006/bbrc.1996.0389; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Suzuki K, 2000, EUR J APPL PHYSIOL, V81, P281, DOI 10.1007/s004210050044; Tanaka T, 2001, J MOL CELL CARDIOL, V33, P1627, DOI 10.1006/jmcc.2001.1428; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; Toft AD, 2000, J APPL PHYSIOL, V89, P2401, DOI 10.1152/jappl.2000.89.6.2401; TOFT AD, 2002, IN PRESS AM J PHYSL; Tsigos C, 1997, J CLIN ENDOCR METAB, V82, P4167, DOI 10.1210/jc.82.12.4167; Tuyt LML, 1999, J IMMUNOL, V162, P4893; ULLUM H, 1994, J APPL PHYSIOL, V77, P93, DOI 10.1152/jappl.1994.77.1.93; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Vgontzas AN, 2000, J CLIN ENDOCR METAB, V85, P1151, DOI 10.1210/jc.85.3.1151; WAHREN J, 1971, J CLIN INVEST, V50, P2715, DOI 10.1172/JCI106772; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; Youd JM, 2000, DIABETES, V49, P1904, DOI 10.2337/diabetes.49.11.1904; Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3; Zierath JR, 2000, DIABETOLOGIA, V43, P821, DOI 10.1007/s001250051457	137	599	628	0	46	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2002	16	11					1335	1347		10.1096/fj.01-0876rev	http://dx.doi.org/10.1096/fj.01-0876rev			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12205025				2022-12-28	WOS:000178441800008
J	Hoenderop, JGJ; Dardenne, O; Van Abel, M; Van der Kemp, AWCM; Van Os, CH; St-Arnaud, R; Bindels, RJM				Hoenderop, JGJ; Dardenne, O; Van Abel, M; Van der Kemp, AWCM; Van Os, CH; St-Arnaud, R; Bindels, RJM			Modulation of renal Ca2+ transport protein genes by dietary Ca2+ and 1,25-dihydroxyvitamin D-3 in 25-hydroxyvitamin D-3-1 alpha-hydroxylase knockout mice	FASEB JOURNAL			English	Article						ECaC; CaT1; vitamin D; calcium reabsorption	VITAMIN-D-RECEPTOR; EPITHELIAL CALCIUM-CHANNEL; D ENDOCRINE SYSTEM; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; TARGETED ABLATION; BINDING-PROTEIN; RABBIT KIDNEY; ANIMAL-MODEL; IDENTIFICATION; STIMULATION	Pseudovitamin D-deficiency rickets (PDDR) is an autosomal disease characterized by hyperparathyroidism, rickets, and undetectable levels of 1,25-dihydroxyvitaminD(3) (1,25(OH)(2)D-3). Mice in which the 1,25-hydroxyvitamin D-3-1alpha-hydroxylase (1alpha-OHase) gene was inactivated presented the same clinical phenotype as patients with PDDR and were used to study renal expression of the epithelial Ca2+ channel (ECaC1), the calbindins, Na+/Ca2+ exchanger (NCX1), and Ca2+-ATPase (PMCA1b). Serum Ca2+ (1.20+/-0.05 mM) and mRNA/protein expression of ECaC1 (41+/-3%), calbindin-D-28K (31+/-2%), calbindin-D-9K (58+/-7%), NCX1 (10+/-2%), PMCA1b (96+/-4%) were decreased in 1alpha-OHase(-/-) mice compared with 1alpha-OHase(+/-) littermates. Feeding these mice a Ca2+-enriched diet normalized serum Ca2+ levels and expression of Ca2+ proteins except for calbindin-D-9K expression. 1,25(OH)(2)D-3 repletion resulted in increased expression of Ca2+ transport proteins and normalization of serum Ca2+ levels. Localization of Ca2+ transport proteins was clearly polarized in which ECaC1 was localized along the apical membrane, calbindin-D-28K in the cytoplasm, and calbindin-D-9K along the apical and basolateral membranes, resulting in a comprehensive mechanism facilitating renal transcellular Ca2+ transport. This study demonstrated that high dietary Ca2+ intake is an important regulator of the renal Ca2+ transport proteins in 1,25(OH)(2)D-3-deficient status and thus contributes to the normalization of blood Ca2+ levels.	Univ Med Ctr Nijmegen, Dept Cell Physiol, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands; Shriners Hosp Children, Genet Unit, Montreal, PQ, Canada	Radboud University Nijmegen; McGill University	Bindels, RJM (corresponding author), Univ Med Ctr Nijmegen, Dept Cell Physiol, Nijmegen Ctr Mol Life Sci, POB 9101, NL-6500 HB Nijmegen, Netherlands.	r.bindels@ncmls.kun.nl	Bindels, René JM/B-9824-2013; Hoenderop, Joost G.J./H-8047-2014	Bindels, René JM/0000-0003-1167-1339; Hoenderop, Joost G.J./0000-0002-1816-8544				Arnold DB, 1997, P NATL ACAD SCI USA, V94, P8842, DOI 10.1073/pnas.94.16.8842; BARAN DT, 1994, J CELL BIOCHEM, V56, P510, DOI 10.1002/jcb.240560411; Baran DT, 2000, J CELL BIOCHEM, V80, P259; Chirayath MV, 1998, AM J PHYSIOL-GASTR L, V274, pG389, DOI 10.1152/ajpgi.1998.274.2.G389; Dardenne O, 2001, ENDOCRINOLOGY, V142, P3135, DOI 10.1210/en.142.7.3135; de Boland AR, 1998, J CELL BIOCHEM, V69, P470, DOI 10.1002/(SICI)1097-4644(19980615)69:4<470::AID-JCB8>3.0.CO;2-K; GALLIN WJ, 1995, CURR OPIN NEUROBIOL, V5, P367, DOI 10.1016/0959-4388(95)80050-6; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; HOENDEROP JG, 2002, IN PRESS ANN REV PHY, V64; Hoenderop JGJ, 2000, AM J PHYSIOL-RENAL, V278, pF352, DOI 10.1152/ajprenal.2000.278.3.F352; Hoenderop JGJ, 2000, J AM SOC NEPHROL, V11, P1171, DOI 10.1681/ASN.V1171171; Hoenderop JGJ, 1999, P NATL ACAD SCI USA, V96, P6084, DOI 10.1073/pnas.96.11.6084; Hoenderop JGJ, 2001, J AM SOC NEPHROL, V12, P1342, DOI 10.1681/ASN.V1271342; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Kato A, 1998, BIOCHEM BIOPH RES CO, V244, P724, DOI 10.1006/bbrc.1998.8318; Kim YS, 1996, ENDOCRINOLOGY, V137, P3649, DOI 10.1210/en.137.9.3649; KUMAR R, 1994, AM J PHYSIOL, V266, pF477, DOI 10.1152/ajprenal.1994.266.3.F477; LAWSON DEM, 1971, NATURE, V230, P228, DOI 10.1038/230228a0; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Li YC, 2001, AM J PHYSIOL-ENDOC M, V281, pE558, DOI 10.1152/ajpendo.2001.281.3.E558; Loffing J, 2001, AM J PHYSIOL-RENAL, V281, pF1021, DOI 10.1152/ajprenal.0085.2001; Muller D, 2000, BIOCHEM BIOPH RES CO, V275, P47, DOI 10.1006/bbrc.2000.3227; NEMERE I, 1994, J BIOL CHEM, V269, P23750; Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201; NING G, 1993, FEBS LETT, V336, P521, DOI 10.1016/0014-5793(93)80868-U; Norman AW, 2001, STEROIDS, V66, P147, DOI 10.1016/S0039-128X(00)00165-3; NORMAN AW, 1993, J BIOL CHEM, V268, P20022; Panda DK, 2001, P NATL ACAD SCI USA, V98, P7498, DOI 10.1073/pnas.131029498; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; THEOFAN G, 1986, J BIOL CHEM, V261, P7311; Van Cromphaut SJ, 2001, P NATL ACAD SCI USA, V98, P13324, DOI 10.1073/pnas.231474698; VanBaal J, 1996, AM J PHYSIOL-RENAL, V271, pF985, DOI 10.1152/ajprenal.1996.271.5.F985; Vazquez G, 2000, J BIOL CHEM, V275, P16134, DOI 10.1074/jbc.C901008199; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Weber K, 2001, BIOCHEM BIOPH RES CO, V289, P1287, DOI 10.1006/bbrc.2001.6121; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; Zanello LP, 1997, J BIOL CHEM, V272, P22617, DOI 10.1074/jbc.272.36.22617	39	172	182	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2002	16	11					1398	1406		10.1096/fj.02-0225com	http://dx.doi.org/10.1096/fj.02-0225com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12205031				2022-12-28	WOS:000178441800014
J	Adamson, P; Wilbourn, B; Etienne-Manneville, S; Calder, V; Beraud, E; Milligan, G; Couraud, PO; Greenwood, J				Adamson, P; Wilbourn, B; Etienne-Manneville, S; Calder, V; Beraud, E; Milligan, G; Couraud, PO; Greenwood, J			Lymphocyte trafficking through the blood-brain barrier is dependent on endothelial cell heterotrimeric G-protein signaling	FASEB JOURNAL			English	Article						endothelium; lymphocyte migration; EC	CENTRAL-NERVOUS-SYSTEM; TRANSENDOTHELIAL MIGRATION; IN-VITRO; T-LYMPHOCYTES; RETINAL BARRIER; BASIC-PROTEIN; ALPHA-SUBUNIT; ICAM-1; ACTIVATION; ADHESION	We have previously shown that the engagement of ICAM-1 on brain endothelial cells (EC) results in the propagation of EC signaling pathways that are necessary for efficient lymphocyte migration across the tight vascular barriers of the brain. Signaling via this receptor alone, however, is unlikely to explain the differential recruitment of leukocytes at different vascular beds. In this study, we investigated the role of EC heterotrimeric G-protein-mediated signaling in supporting transendothelial migration of T lymphocytes. Treatment of brain EC monolayers with pertussis toxin (PTX) resulted in ADP-ribosylation of G-protein alpha subunits and inhibition (>80%) of lymphocyte migration without affecting lymphocyte adhesion. Aortic and high endothelial venule EC treated identically resulted in only partial inhibition of lymphocyte migration (<40%). Expression of ribosylation-resistant (PTX-insensitive) G-protein alpha subunits in brain EC restored their ability to support lymphocyte migration after pretreatment with PTX. Treatment of brain EC with PTX did not inhibit ICAM-1-stimulated tyrosine phosphorylation of focal adhesion kinase, suggesting the effects of PTX in inhibiting EC facilitation of lymphocyte migration are distinct from activation of EC through ICAM-1. We conclude that a heterotrimeric G-protein-mediated signaling pathway in brain EC is essential for efficient transendothelial migration of T lymphocytes into the brain.	UCL, Inst Ophthalmol, Div Cell Biol, Endothelial & Epithelial Cell Biol Res Unit, London EC1V 9EL, England; Inst Cochin Genet Mol, Dept Biol Cellulaire, CNRS, UMR8104,INSERM567, F-75014 Paris, France; Univ Aix Marseille 2, Fac Med, Immunol Lab, Marseille, France; Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of London; University College London; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Aix-Marseille Universite; University of Glasgow	Greenwood, J (corresponding author), UCL, Inst Ophthalmol, Div Cell Biol, Endothelial & Epithelial Cell Biol Res Unit, Bath St, London EC1V 9EL, England.	J.Greenwood@ucl.ac.uk	Etienne-Manneville, Sandrine/C-5879-2015; Calder, Virginia/AAG-8278-2020; Milligan, Graeme/F-9426-2011	Etienne-Manneville, Sandrine/0000-0001-6651-3675; Calder, Virginia/0000-0003-1422-2926; Milligan, Graeme/0000-0002-6946-3519; Greenwood, John/0000-0003-4496-2984				ABBOTT NJ, 1992, J CELL SCI, V103, P23; Adamson P, 1999, J IMMUNOL, V162, P2964; AGER A, 1987, J CELL SCI, V87, P133; AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; Andjelkovic AV, 1999, J CELL BIOL, V145, P403, DOI 10.1083/jcb.145.2.403; Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; BERAUD E, 1986, J IMMUNOL, V136, P511; BERAUD E, 1993, J NEUROIMMUNOL, V47, P41, DOI 10.1016/0165-5728(93)90283-5; BOURDOULOUS S, 1995, EUR J IMMUNOL, V25, P1176, DOI 10.1002/eji.1830250507; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; Devine L, 1996, IMMUNOLOGY, V88, P456, DOI 10.1046/j.1365-2567.1996.d01-666.x; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; Etienne S, 1998, J IMMUNOL, V161, P5755; Etienne-Manneville S, 2000, J IMMUNOL, V165, P3375, DOI 10.4049/jimmunol.165.6.3375; Fabian G, 1998, NEUROCHEM INT, V33, P179, DOI 10.1016/S0197-0186(98)00008-4; Greenwood J, 1996, J NEUROIMMUNOL, V71, P51, DOI 10.1016/S0165-5728(96)00130-0; GREENWOOD J, 1995, IMMUNOLOGY, V86, P408; GREENWOOD J, 1992, J NEUROIMMUNOL, V39, P123, DOI 10.1016/0165-5728(92)90181-J; GREENWOOD J, 1993, IMMUNOLOGY, V80, P401; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; HUGHES CCW, 1988, IMMUNOLOGY, V64, P677; KOBAYASHI I, 1989, FEBS LETT, V257, P177, DOI 10.1016/0014-5793(89)81815-0; MALE D, 1994, IMMUNOLOGY, V81, P366; MALE D, 1990, CELL IMMUNOL, V127, P1, DOI 10.1016/0008-8749(90)90109-5; MCGUIRE PG, 1987, LAB INVEST, V57, P94; NURNBERG B, 1994, BIOCHEM J, V300, P387; OPPENHEIMERMARKS N, 1991, J IMMUNOL, V147, P2913; Phillips R, 2002, EUR J IMMUNOL, V32, P837, DOI 10.1002/1521-4141(200203)32:3<837::AID-IMMU837>3.0.CO;2-Q; PIZZA M, 1989, SCIENCE, V246, P497, DOI 10.1126/science.2683073; Pryce G, 1997, J NEUROIMMUNOL, V75, P84, DOI 10.1016/S0165-5728(97)00006-4; Reiss Y, 1998, EUR J IMMUNOL, V28, P3086, DOI 10.1002/(SICI)1521-4141(199810)28:10<3086::AID-IMMU3086>3.3.CO;2-Q; ROUX F, 1994, J CELL PHYSIOL, V159, P101, DOI 10.1002/jcp.1041590114; ROZDZINSKI E, 1993, J EXP MED, V178, P917, DOI 10.1084/jem.178.3.917; Saha C, 1998, J BIOL CHEM, V273, P21629, DOI 10.1074/jbc.273.34.21629; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Walters CE, 2002, J IMMUNOL, V168, P4087, DOI 10.4049/jimmunol.168.8.4087; WANG YF, 1993, J NEUROIMMUNOL, V48, P161, DOI 10.1016/0165-5728(93)90188-5; WILCOX MD, 1995, J BIOL CHEM, V270, P4189, DOI 10.1074/jbc.270.9.4189	38	28	29	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1185	10.1096/fj.02-0035com	http://dx.doi.org/10.1096/fj.02-0035com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153986				2022-12-28	WOS:000177814000027
J	Teunis, MAT; Kavelaars, A; Voest, E; Bakker, JM; Ellenbroek, BA; Cools, AR; Heijnen, CJ				Teunis, MAT; Kavelaars, A; Voest, E; Bakker, JM; Ellenbroek, BA; Cools, AR; Heijnen, CJ			Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system	FASEB JOURNAL			English	Article						dopamine; cancer progression; MADB106; VEGF	SCHIZOPHRENIC-PATIENTS; WISTAR RATS; LUNG-CANCER; MICE; SUSCEPTIBILITY; APOMORPHINE; TUMORIGENESIS; INTERLEUKIN-4; NEUROBIOLOGY; PROGRESSION	Outgrowth of solid tumors requires blood supply to the tumor. Tumor angiogenesis is dependent on the interplay between tumor-derived angiogenic factors and stromal cells. Recently, it has been shown that the neurotransmitter dopamine is a potent inhibitor of VEGF-induced angiogenesis. Moreover, there is evidence that patients with schizophrenia have a hyperreactive dopaminergic system and are relatively protected from cancer. We hypothesized that hyperreactivity of the dopaminergic system is related to reduced angiogenesis and tumor development. Therefore, we investigated tumor growth and angiogenesis in two lines of Wistar rats with high (APO-SUS) or low (APO-UNSUS) dopaminergic reactivity. Subcutaneous implants of mammary adenocarcinoma cells (MADB106) in matrigel remained 35% smaller in APO-SUS rats than in APO-UNSUS rats (P<0.01). Moreover, APO-SUS rats developed less lung metastases after i.v. administration of MADB106 tumor cells. Furthermore, hemoglobin content (APO-SUS: 40.6+/-7.6; APO-UNSUS: 76.9+/-13 mg/dl, P<0.05) and expression of the endothelial determinant PECAM-1 in tumors from APO-SUS rats were reduced (APO-SUS: 37+/-18; APO-UNSUS 69+/-25 units, P<0.01), indicating that reduced angiogenesis is responsible for reduced tumor development in APO-SUS rats. These results suggest a novel link between dopaminergic reactivity, angiogenesis, and tumor development and may explain part of the individual differences in cancer progression.	UMC Utrecht, Lab Psychoneuroimmunol, NL-3584 EA Utrecht, Netherlands; UMC Utrecht, Dept Med Oncol, NL-3584 EA Utrecht, Netherlands; Univ Nijmegen, Dept Psychoneuropharmacol, Nijmegen Inst Neurosci, Nijmegen, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen	Heijnen, CJ (corresponding author), UMC Utrecht, Lab Psychoneuroimmunol, Room KC 03-068-0,Lundlaan 6, NL-3584 EA Utrecht, Netherlands.	c.heijnen@wkz.azu.nl	Ellenbroek, Bart/C-4570-2012	Ellenbroek, Bart/0000-0003-1996-4873				BARUCH I, 1988, J NERV MENT DIS, V176, P598, DOI 10.1097/00005053-198810000-00004; BASU S, 1995, J NEUROIMMUNOL, V60, P1, DOI 10.1016/0165-5728(95)00044-3; Basu S, 2001, NAT MED, V7, P569, DOI 10.1038/87895; Ben-Eliyahu S, 1999, INT J CANCER, V80, P880; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; BRAFF D, 1978, PSYCHOPHYSIOLOGY, V15, P339, DOI 10.1111/j.1469-8986.1978.tb01390.x; Breivik T, 2000, BEHAV GENET, V30, P123, DOI 10.1023/A:1001903221046; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Compagni A, 2000, BRIT J CANCER, V83, P1; COOLS AR, 1990, BRAIN RES BULL, V24, P49, DOI 10.1016/0361-9230(90)90288-B; COOLS AR, 2002, PHARM BIOCH BEHAV, V60, P151; DASGUPTA PS, 1987, J CANCER RES CLIN, V113, P363, DOI 10.1007/BF00397720; DeClerck YA, 2000, EUR J CANCER, V36, P1258, DOI 10.1016/S0959-8049(00)00094-0; Egan MF, 1997, CURR OPIN NEUROBIOL, V7, P701, DOI 10.1016/S0959-4388(97)80092-X; ELLENBROEK BA, 1995, J NEUROSCI, V15, P7604; Fukushi J, 2000, J IMMUNOL, V165, P2818, DOI 10.4049/jimmunol.165.5.2818; GULBINAT W, 1992, BRIT J PSYCHIAT, V161, P75, DOI 10.1192/S0007125000297080; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HARRIS AE, 1988, SCHIZOPHRENIA BULL, V14, P85, DOI 10.1093/schbul/14.1.85; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; ISHIBASHI M, 1994, CANCER RES, V54, P3442; Kavelaars A, 1997, J NEUROSCI, V17, P2580; Kim SS, 2001, KOREAN J RADIOL, V2, P68, DOI 10.3348/kjr.2001.2.2.68; Lammers CH, 1995, BIOL PSYCHIAT, V38, P803, DOI 10.1016/0006-3223(95)00065-8; Laruelle M, 2000, BRAIN RES REV, V31, P371, DOI 10.1016/S0165-0173(99)00054-5; Lewis DA, 2000, NEURON, V28, P325, DOI 10.1016/S0896-6273(00)00111-2; LIEBERMAN JA, 1987, PSYCHOPHARMACOLOGY, V91, P415, DOI 10.1007/BF00216006; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Los M, 2001, SEMIN ONCOL, V28, P93, DOI 10.1016/S0093-7754(01)90047-8; Matar P, 1997, J EXP CLIN CANC RES, V16, P249; Matsuyama W, 2000, CHEST, V118, P948, DOI 10.1378/chest.118.4.948; Moon HS, 2000, INT J GYNECOL CANCER, V10, P151, DOI 10.1046/j.1525-1438.2000.00013.x; MORTENSEN PB, 1994, SCHIZOPHR RES, V12, P185, DOI 10.1016/0920-9964(94)90028-0; Muller-Spahn F, 1998, J PSYCHIATR RES, V32, P265, DOI 10.1016/S0022-3956(98)00005-3; Overmier JB, 1997, PHYSIOL BEHAV, V61, P555, DOI 10.1016/S0031-9384(96)00502-1; PASSANITI A, 1992, LAB INVEST, V67, P519; Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871; Rots NY, 1996, ENDOCRINOLOGY, V137, P1678, DOI 10.1210/en.137.5.1678; Rots NY, 1996, BRAIN RES, V710, P189, DOI 10.1016/0006-8993(95)01379-2; Saleh M, 1999, J NATL CANCER I, V91, P438, DOI 10.1093/jnci/91.5.438; SEEMAN P, 1987, SYNAPSE, V1, P133, DOI 10.1002/syn.890010203; SWERDLOW NR, 2002, SCHIZOPHR B, V24, P285; Toru M, 1998, PSYCHIAT CLIN NEUROS, V52, pS170, DOI 10.1111/j.1440-1819.1998.tb03213.x; Volpert OV, 1998, J EXP MED, V188, P1039, DOI 10.1084/jem.188.6.1039; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497	48	56	59	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1465	+		10.1096/fj.02-0145fje	http://dx.doi.org/10.1096/fj.02-0145fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205050				2022-12-28	WOS:000177813100012
J	Xu, B; Chibber, R; Ruggerio, D; Kohner, E; Ritter, J; Ferro, A				Xu, B; Chibber, R; Ruggerio, D; Kohner, E; Ritter, J; Ferro, A			Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products	FASEB JOURNAL			English	Article						diabetes mellitus; vasodilation; endothelial function; AGE proteins	OXIDATIVE STRESS; CELL BIOLOGY; IN-VITRO; RECEPTOR; GLYCOSYLATION; PROTEINS; N-EPSILON-(CARBOXYMETHYL)LYSINE; DYSFUNCTION; VASODILATATION; GLYCOXIDATION	Endothelial damage is believed to play a key role in the development of both micro- and macrovascular disease in diabetes, and advanced glycation end products (AGEs) may contribute importantly to this. To determine whether glucose-derived AGEs can cause endothelial dysfunction, we examined the effects of albumin AGE-modified by glucose (AGE-Glu) both in vivo, after injection into rabbit femoral artery, and in vitro on rabbit aortic rings and cultured human umbilical vein endothelial cells (HUVEC). Exposure of blood vessels to AGE-Glu, in vivo and in vitro, inhibited endothelium-dependent vasorelaxation, whereas unmodified albumin did not. In isolated rabbit aorta, this effect was reversible after AGE-Glu washout, and the response to the endothelium-independent vasodilator sodium nitroprusside was unaffected by AGE-Glu. In HUVEC, AGE-Glu inhibited endothelial nitric oxide synthase activity, and this was associated with a decrease in serine phosphorylation of this enzyme. Longer term (72 h) incubation decreased HUVEC viability. Use of specific antibodies demonstrated that these effects were mediated by N-epsilon-(carboxymethyl)lysine (CML), an important AGE found in vivo, and by the AGE-R1 receptor. Furthermore, these effects all occurred at CML concentrations similar to those found in the plasma of diabetic patients. These results suggest an important role of AGE in the pathogenesis of diabetic vasculopathy.	Kings Coll London, Dept Clin Pharmacol, Div Cardiovasc, GKT Sch Med,Ctr Cardiovasc Biol & Med, London SE1 7EH, England; Diabet Microangiopathy Res Unit, Villeurbanne, France	University of London; King's College London	Ferro, A (corresponding author), Kings Coll London, Dept Clin Pharmacol, Div Cardiovasc, GKT Sch Med,Ctr Cardiovasc Biol & Med, St Thomas Hosp Campus,Lambeth Palace Rd, London SE1 7EH, England.	albert.ferro@kcl.ac.uk		Ferro, Albert/0000-0002-5486-9145				AGGARWAL M, 1992, CLIN RES, V40, pA179; AMEZCUA JL, 1988, BRIT J PHARMACOL, V95, P830, DOI 10.1111/j.1476-5381.1988.tb11711.x; ARAKI N, 1995, EUR J BIOCHEM, V230, P408, DOI 10.1111/j.1432-1033.1995.0408h.x; Baynes JW, 2000, FREE RADICAL BIO MED, V28, P1708, DOI 10.1016/S0891-5849(00)00228-8; Berg TJ, 1998, DIABETES CARE, V21, P1997, DOI 10.2337/diacare.21.11.1997; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; BUCALA R, 1991, J CLIN INVEST, V87, P432, DOI 10.1172/JCI115014; Busse R, 1998, J VASC RES, V35, P73, DOI 10.1159/000025568; CALVER A, 1992, J CLIN INVEST, V90, P2548, DOI 10.1172/JCI116149; CAYATTE AJ, 1994, ARTERIOSCLER THROMB, V14, P753, DOI 10.1161/01.ATV.14.5.753; Chakravarthy U, 1998, DIABETES, V47, P945, DOI 10.2337/diabetes.47.6.945; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Chibber R, 1997, DIABETOLOGIA, V40, P156, DOI 10.1007/s001250050657; COHEN RA, 1993, CIRCULATION, V87, P67; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; ELLIOTT TG, 1993, CLIN SCI, V85, P687, DOI 10.1042/cs0850687; FAULKNER KM, 1994, J BIOL CHEM, V269, P23471; FERRO A, 1999, BRIT J PHARMACOL, V126, P1842; Fontana L, 1999, BRIT J PHARMACOL, V126, P730, DOI 10.1038/sj.bjp.0702331; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; Gardner PR, 1996, ARCH BIOCHEM BIOPHYS, V325, P20, DOI 10.1006/abbi.1996.0003; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; Guo Zhijian, 2002, Zhonghua Yi Xue Za Zhi, V82, P1328; Horie K, 1997, J CLIN INVEST, V100, P2995, DOI 10.1172/JCI119853; IGNARRO LJ, 1988, J PHARMACOL EXP THER, V246, P218; Jensen J S, 1997, J Cardiovasc Risk, V4, P121; Kilhovd BK, 1999, DIABETES CARE, V22, P1543, DOI 10.2337/diacare.22.9.1543; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MCVEIGH GE, 1992, DIABETOLOGIA, V35, P771; Miura J, 2003, J DIABETES COMPLICAT, V17, P16, DOI 10.1016/S1056-8727(02)00183-6; Nishikawa T, 2000, KIDNEY INT, V58, pS26, DOI 10.1046/j.1523-1755.2000.07705.x; Ohgami N, 2001, J BIOL CHEM, V276, P13348, DOI 10.1074/jbc.M011613200; Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200; Onorato JM, 1998, ANN NY ACAD SCI, V854, P277, DOI 10.1111/j.1749-6632.1998.tb09909.x; POSTON L, 1995, CLIN SCI, V88, P245, DOI 10.1042/cs0880245; Pricci F, 2000, KIDNEY INT, V58, pS31, DOI 10.1046/j.1523-1755.2000.07706.x; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; Sakata N, 1999, ATHEROSCLEROSIS, V142, P67, DOI 10.1016/S0021-9150(98)00192-0; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SESSA WC, 1994, CIRC RES, V74, P349, DOI 10.1161/01.RES.74.2.349; SHUKLA SD, 1992, THROMB RES, V66, P239, DOI 10.1016/0049-3848(92)90194-F; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; Sobrevia L, 1997, EXP PHYSIOL, V82, P423, DOI 10.1113/expphysiol.1997.sp004038; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Stitt AW, 1999, BIOCHEM BIOPH RES CO, V256, P549, DOI 10.1006/bbrc.1999.0291; THORNALLEY PJ, 1995, CONTRIB NEPHROL, V112, P24; Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013; TSAO PS, 1994, ARTERIOSCLER THROMB, V14, P1529, DOI 10.1161/01.ATV.14.10.1529; Wautier J L, 1998, Vasc Med, V3, P131, DOI 10.1191/135886398672565440; XU B, 1993, ACTA PHARM SINIC, V14, P229; Yamagishi S, 1996, FEBS LETT, V384, P103, DOI 10.1016/0014-5793(96)00279-7	62	156	172	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1289	+		10.1096/fj.02-0490fje	http://dx.doi.org/10.1096/fj.02-0490fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738813				2022-12-28	WOS:000183165000034
J	Bussolati, B; Deambrosis, I; Russo, S; Deregibus, MC; Camussi, G				Bussolati, B; Deambrosis, I; Russo, S; Deregibus, MC; Camussi, G			Altered angiogenesis and survival in human tumor-derived endothelial cells	FASEB JOURNAL			English	Article						VEGF-D; angiopoietin-1; apoptosis; Akt; PTEN	GROWTH-FACTOR RECEPTOR-3; IN-VITRO; BCL-2 EXPRESSION; KAPOSIS-SARCOMA; UP-REGULATION; SOLID TUMORS; VEGF-C; CANCER; MICROENVIRONMENT; ANGIOPOIETIN-1	Knowledge on the functional properties of tumor-derived endothelial cells (TEC) can be relevant for the development of antiangiogenic therapeutic strategies. In the present study, we obtained and characterized endothelial cell lines from human renal carcinomas. TEC did not undergo senescence and showed constant expression of markers of endothelial activation and angiogenesis. In vitro, TEC, in contrast to normal endothelial cells, were resistant to apoptosis, proadhesive for renal carcinoma cells, and able to grow and organize in the absence of serum in persistent capillary-like structures. In vivo, TEC were able to grow in immunodeficient mice and to form vascular structures connected with the circulation. At a molecular level, gene array analysis showed an increased expression of genes involved in survival and cell adhesion compared with expression in normal microvascular endothelial cells. Moreover, expression of angiopoietin-1 and vascular endothelial growth factor (VEGF)-D and the Akt survival pathway were up-regulated. Inhibition of interaction of VEGFR-2 or VEGFR-3 with VEGF-D but not of Tie-2-angiopoietin-1 interaction with soluble receptors abrogated Akt activation and survival of TEC. These results indicate that at least some of the TEC within a tumor display abnormal characteristics in terms of survival and angiogenic properties and also indicate the presence of a functional autocrine pathway related to VEGF-D.	Univ Turin, Dipartimento Med Interna, Turin, Italy; Univ Turin, Dipartimento Sci Clin & Biol, Turin, Italy; Osped San Giovanni Battista Torino, Ctr Ric Med Sperimentale, I-10126 Turin, Italy	University of Turin; University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette	Camussi, G (corresponding author), Osped San Giovanni Battista Torino, Dipartimento Med Interna, Cattedra Nefrol, Corso Dogliotti 14, I-10126 Turin, Italy.	giovanni.camussi@unito.it	Camussi, Giovanni/J-7624-2016; Bussolati, Benedetta/AAA-9058-2022	Camussi, Giovanni/0000-0003-2795-232X; Bussolati, Benedetta/0000-0002-3663-5134				Achen MG, 2002, GROWTH FACTORS, V20, P99, DOI 10.1080/08977190290031969; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Bussolati B, 2000, AM J PATHOL, V157, P1713, DOI 10.1016/S0002-9440(10)64808-0; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Deregibus MC, 2002, J BIOL CHEM, V277, P25195, DOI 10.1074/jbc.M200921200; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; DVORAK HF, 1988, AM J PATHOL, V133, P95; Dye JF, 2001, MICROVASC RES, V62, P94, DOI 10.1006/mvre.2001.2333; Dye JF, 2001, PLACENTA, V22, P32, DOI 10.1053/plac.2000.0579; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Huang HY, 2001, LAB INVEST, V81, P1729, DOI 10.1038/labinvest.3780386; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; Ibrahim EC, 2001, CANCER RES, V61, P6838; Ilan N, 1998, J CELL SCI, V111, P3621; Iwahana M, 1998, ANTICANCER RES, V18, P2977; Jain RK, 1996, CANCER METAST REV, V15, P195, DOI 10.1007/BF00437472; Jung YD, 2000, CANCER METAST REV, V19, P147, DOI 10.1023/A:1026510130114; Kerbel RS, 2001, CANCER METAST REV, V20, P79, DOI 10.1023/A:1013172910858; Kerbel RS, 2001, J CLIN ONCOL, V19, p45S; Kubo H, 2000, BLOOD, V96, P546; Kumar S, 1999, CANCER RES, V59, P856; Kurose K, 2001, HUM MOL GENET, V10, P1907, DOI 10.1093/hmg/10.18.1907; Le Bouteiller P, 1999, IMMUNOL REV, V167, P233; Liu W, 2000, APOPTOSIS, V5, P323, DOI 10.1023/A:1009679307513; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; McDonald DM, 2000, CANCER METAST REV, V19, P109, DOI 10.1023/A:1026529222845; Melder RJ, 2002, NEOPLASIA, V4, P3, DOI 10.1038/sj.neo.7900209; Nor JE, 2001, LAB INVEST, V81, P453, DOI 10.1038/labinvest.3780253; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Partanen TA, 1999, CANCER-AM CANCER SOC, V86, P2406, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.3.CO;2-5; Podgrabinska S, 2002, P NATL ACAD SCI USA, V99, P16069, DOI 10.1073/pnas.242401399; Ruoslahti E, 2000, ANNU REV IMMUNOL, V18, P813, DOI 10.1146/annurev.immunol.18.1.813; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Skobe M, 1999, J INVEST DERMATOL, V113, P1047, DOI 10.1046/j.1523-1747.1999.00798.x; St Croix B, 2000, SCIENCE, V289, P1197; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stratmann A, 2001, INT J CANCER, V91, P273, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1054>3.0.CO;2-Q; Wang JH, 2002, CANCER-AM CANCER SOC, V94, P2745, DOI 10.1002/cncr.10520	46	223	232	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1159	+		10.1096/fj.02-0557fje	http://dx.doi.org/10.1096/fj.02-0557fje			32	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709414				2022-12-28	WOS:000182580100032
J	Seibold, S; Rudroff, C; Weber, M; Galle, J; Wanner, C; Marx, M				Seibold, S; Rudroff, C; Weber, M; Galle, J; Wanner, C; Marx, M			Identification of a new tumor suppressor gene located at chromosome 8p21.3-22	FASEB JOURNAL			English	Article						MTSG1; cancer; tumor progression; D8S254; 3D culture	IN-VITRO ANGIOGENESIS; URINARY-BLADDER CANCER; BREAST CARCINOMAS; COLORECTAL-CANCER; ENDOTHELIAL-CELLS; LEUCINE-ZIPPER; TUBE FORMATION; SHORT ARM; GROWTH; LOCALIZATION	Transformation of normal cells into malignant tumor cells, a process termed carcinogenesis, depends on progressive acquisition of genetic alterations. These result in activation of protooncogenes or inactivation of tumor suppressor genes responsible for the loss of proliferative control in tumor cells and the failure to undergo cellular differentiation. The aim of our study was the identification of molecular regulators of carcinogenesis by studying gene expression during induction of cellular differentiation and quiescence in a three-dimensional (3D) cell culture model. Here, we report the discovery of a tumor suppressor gene located at chromosome 8p21.3-22 near marker D8S254. It is ubiquitously expressed in normal tissue and transiently upregulated during initiation of cellular differentiation and quiescence in 3D cell culture. In contrast, mRNA expression was not detectable in tissue from pancreatic tumor and the pancreatic tumor cell line MIA PaCa-2. Recombinant expression in the tumor cell line MIA PaCa-2 inhibited proliferation, as shown by a 30% reduction of BrdU uptake after recombinant expression. Immunocytochemistry and Western blot analysis of subcellular fractions demonstrated a mitochondrial localization for the mature protein. In conclusion, we identified a tumor suppressor gene at chromosome 8p21.3-22, encoding a mitochondrial protein, controlling cellular proliferation.	Univ Med Ctr, Dept Med, D-97080 Wurzburg, Germany; Univ Cologne, Fac Med, Merheim Med Ctr,Cologne Gen Hosp, Dept Internal Med 1, Cologne, Germany; Univ Witten Herdecke, Dept Surg, Wuppertal, Germany	University of Wurzburg; University of Cologne; Witten Herdecke University	Seibold, S (corresponding author), Univ Med Ctr, Dept Med, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	seibold_s@medizin.uni-wuerzburg.de						Bannai H, 2002, BIOINFORMATICS, V18, P298, DOI 10.1093/bioinformatics/18.2.298; BARDI G, 1993, BRIT J CANCER, V67, P1106, DOI 10.1038/bjc.1993.203; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Chan KL, 2002, CANCER, V94, P3179, DOI 10.1002/cncr.10612; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUAQUI RF, 1995, CANCER RES, V55, P4995; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; El-Naggar AK, 1998, ONCOGENE, V16, P2983, DOI 10.1038/sj.onc.1201808; El-Naggar AK, 2001, J MOL DIAGN, V3, P164, DOI 10.1016/S1525-1578(10)60668-X; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; FUJIWARA Y, 1993, CANCER RES, V53, P1172; Gruber H E, 2000, BMC Musculoskelet Disord, V1, P1, DOI 10.1186/1471-2474-1-1; Gustafson CE, 1996, CANCER RES, V56, P5238; Hussain SP, 1999, MUTAT RES-FUND MOL M, V428, P23, DOI 10.1016/S1383-5742(99)00028-9; ICHIKAWA T, 1994, CANCER RES, V54, P2299; Ilan N, 1998, J CELL SCI, V111, P3621; Ishii H, 1999, P NATL ACAD SCI USA, V96, P3928, DOI 10.1073/pnas.96.7.3928; Itahana K, 2002, J BIOL CHEM, V277, P18206, DOI 10.1074/jbc.M201028200; Kerangueven F, 1997, CANCER RES, V57, P5469; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MADRI JA, 1983, J CELL BIOL, V97, P153, DOI 10.1083/jcb.97.1.153; MARX M, 1994, J CLIN INVEST, V93, P131, DOI 10.1172/JCI116936; Marx M, 1997, KIDNEY INT, V51, P110, DOI 10.1038/ki.1997.14; MERWIN JR, 1990, J CELL PHYSIOL, V142, P117, DOI 10.1002/jcp.1041420115; Nagase T, 1999, DNA Res, V6, P337, DOI 10.1093/dnares/6.5.337; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Ohgaki K, 1999, GENE CHROMOSOME CANC, V25, P1, DOI 10.1002/(SICI)1098-2264(199905)25:1<1::AID-GCC1>3.0.CO;2-3; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; POWIS G, 1995, PHARMACOL THERAPEUT, V68, P149, DOI 10.1016/0163-7258(95)02004-7; Prols F, 2001, EXP CELL RES, V269, P42, DOI 10.1006/excr.2001.5294; Rudroff C, 2002, CLIN EXP METASTAS, V19, P181, DOI 10.1023/A:1014598904644; Sasiadek M, 2001, INT J ONCOL, V19, P401; SUZUKI H, 1995, GENE CHROMOSOME CANC, V13, P168, DOI 10.1002/gcc.2870130306; Tsai MH, 2002, HEPATO-GASTROENTEROL, V49, P672; Vocke CD, 1996, CANCER RES, V56, P2411; Wagner U, 1997, AM J PATHOL, V151, P753; Wistuba II, 1999, CANCER RES, V59, P1973; YAREMKO ML, 1995, GENE CHROMOSOME CANC, V13, P186, DOI 10.1002/gcc.2870130308; Yokota T, 1999, CANCER-AM CANCER SOC, V85, P447	43	84	88	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1180	+		10.1096/fj.02-0934fje	http://dx.doi.org/10.1096/fj.02-0934fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692079				2022-12-28	WOS:000182580100044
J	Stadler, MB; Stadler, BM				Stadler, MB; Stadler, BM			Allergenicity prediction by protein sequence	FASEB JOURNAL			English	Article						genetically modified food; allergen database; allergenicity prediction; bioinformatics; sequence motifs	TIGR GENE INDEXES; POTENTIAL ALLERGENICITY; DATABASE; FOODS; FAMILIES	Potential allergenicity of transgenic proteins for consumption must be investigated before their introduction into the food chain. A prerequisite is sequence analysis. We have critically reviewed the performance of the current guidelines proposed by the Food and Agriculture Organization (FAO) and the World Health Organization (WHO) for allergenicity prediction based on protein sequence and show that its precision is very low. To improve prediction, we propose a new strategy based on sequence motifs identified from a new allergen database. If tested on random test sequences and known allergens, both methods are apparently very sensitive. However, the precision of our motif-based prediction (95.5%) is superior to the current method (36.6%). We conclude that the proposed motif-based prediction is a superior alternative to the current method for use in the decision-tree approach for allergenicity assessment.	Univ Bern, Inselspital, Inst Immunol, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern	Stadler, MB (corresponding author), Univ Bern, Inselspital, Inst Immunol, Sahlihaus 2, CH-3010 Bern, Switzerland.	michael.stadler@insel.ch						Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Astwood JD, 1996, MONOGR ALLERGY, V32, P105; Bailey T L, 1994, Proc Int Conf Intell Syst Mol Biol, V2, P28; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P21, DOI 10.1093/nar/24.1.21; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BENTON D, 1990, NUCLEIC ACIDS RES, V18, P1517, DOI 10.1093/nar/18.6.1517; Bredehorst R, 2001, J CHROMATOGR B, V756, P33, DOI 10.1016/S0378-4347(01)00069-X; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; BUCHER P, 1994, ISMB, V2, P53; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Gendel SM, 1998, ADV FOOD NUTR RES, V42, P45, DOI 10.1016/S1043-4526(08)60092-3; Gendel SM, 1998, ADV FOOD NUTR RES, V42, P63, DOI 10.1016/S1043-4526(08)60093-5; Gendel SM, 2002, ANN NY ACAD SCI, V964, P87; George DG, 1996, NUCLEIC ACIDS RES, V24, P17, DOI 10.1093/nar/24.1.17; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Hileman RE, 2002, INT ARCH ALLERGY IMM, V128, P280, DOI 10.1159/000063861; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; Metcalfe DD, 1996, CRIT REV FOOD SCI, V36, pS165, DOI 10.1080/10408399609527763; METZGER H, 1991, CLIN EXP ALLERGY, V21, P269, DOI 10.1111/j.1365-2222.1991.tb01658.x; Nadler M J, 2000, Adv Immunol, V76, P325; Pagni M, 2001, NUCLEIC ACIDS RES, V29, P148, DOI 10.1093/nar/29.1.148; Pearson W R, 2000, Methods Mol Biol, V132, P185; Quackenbush J, 2000, NUCLEIC ACIDS RES, V28, P141, DOI 10.1093/nar/28.1.141; Quackenbush J, 2001, NUCLEIC ACIDS RES, V29, P159, DOI 10.1093/nar/29.1.159; Taylor SL, 2001, J ALLERGY CLIN IMMUN, V107, P765, DOI 10.1067/mai.2001.114241; Wootton JC, 1996, METHOD ENZYMOL, V266, P554	29	157	165	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1141	+		10.1096/fj.02-1052fje	http://dx.doi.org/10.1096/fj.02-1052fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709401				2022-12-28	WOS:000182580100016
J	Allen, DA; Harwood, SM; Varagunam, M; Raftery, MJ; Yaqoob, MM				Allen, DA; Harwood, SM; Varagunam, M; Raftery, MJ; Yaqoob, MM			High glucose-induced oxidative stress causes apoptosis in proximal tubular epithelial cells and is mediated by multiple caspases	FASEB JOURNAL			English	Article						diabetic nephropathy; peroxynitrite; cell death; ebselen	HUMAN ENDOTHELIAL-CELLS; PEROXYNITRITE-INDUCED APOPTOSIS; NITRIC-OXIDE; DIABETES-MELLITUS; NITROTYROSINE FORMATION; TGF-BETA; ACTIVATION; PROTEIN; HYPERGLYCEMIA; PROLIFERATION	Diabetic nephropathy is the leading cause of end-stage renal disease in the Western world. Poor glycemic control contributes to the development of diabetic nephropathy, but the mechanisms underlying high glucose-induced tissue injury are not fully understood. In the present study, the effect of high glucose on a proximal tubular epithelial cell (PTEC) line was investigated. Reactive oxygen species (ROS) were detected using the fluorescent probes dichlorofluorescein diacetate, dihydrorhodamine 123, and 2,3-diaminonapthalene. Peroxynitrite (ONOO-) generation and nitrite concentrations were increased after 24 h of high glucose treatment (P<0.05). LLC-PK1 cells exposed to high D-glucose (25 mM) for up to 48 h had increased DNA fragmentation (P<0.01), caspase-3 activity (P<0.001), and annexin-V staining (P<0.05) as well as decreased expression of XIAP when compared with controls (5 mM D-glucose). The ONOO- scavenger ebselen reduced DNA fragmentation and caspase-3 activity as well as the high glucose-induced nitrite production and DCF fluorescence. High glucose-induced DNA fragmentation was completely prevented by an inhibitor of caspase-3 (P<0.01) and a pan-caspase inhibitor (P<0.001). Caspase inhibition did not affect ROS generation. This study, in a PTEC line, demonstrates that high glucose causes the generation of ONOO-, leading to caspase-mediated apoptosis. Ebselen and a caspase-3 inhibitor provided significant protection against high glucose-mediated apoptosis, implicating ONOO- as a proapoptotic ROS in early diabetic nephropathy.	Univ London, Dept Expt Med & Nephrol, William Harvey Res Inst, St Bartholomews & Royal London Sch Med & Dent, London EC1A 7BE, England	University of London; Queen Mary University London	Allen, DA (corresponding author), Univ London, Dept Expt Med & Nephrol, William Harvey Res Inst, St Bartholomews & Royal London Sch Med & Dent, Suite 22,Domin House,59 Bartholomews Close, London EC1A 7BE, England.	d.a.allen@qmul.ac.uk						Adrie C, 2000, AM J PHYSIOL-CELL PH, V279, pC452, DOI 10.1152/ajpcell.2000.279.2.C452; Arteel GE, 1999, FEBS LETT, V445, P226, DOI 10.1016/S0014-5793(99)00073-3; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Bestwick CS, 2001, BBA-GEN SUBJECTS, V1528, P49, DOI 10.1016/S0304-4165(01)00167-2; Bian K, 1999, AM J PHYSIOL-RENAL, V277, pF33, DOI 10.1152/ajprenal.1999.277.1.F33; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; CATALANO C, 1992, NEPHROL DIAL TRANSPL, V7, P181, DOI 10.1093/oxfordjournals.ndt.a092103; CATALANO C, 1993, CLIN SCI, V84, P461, DOI 10.1042/cs0840461; Ceriello A, 2001, DIABETOLOGIA, V44, P834; Ceriello A, 1996, DIABETES, V45, P471, DOI 10.2337/diabetes.45.4.471; Ceriello A, 2002, DIABETES, V51, P1076, DOI 10.2337/diabetes.51.4.1076; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; DECKERT T, 1981, ACTA ENDOCRINOL-COP, V97, P14; Du XL, 1999, FREE RADICAL BIO MED, V27, P752, DOI 10.1016/S0891-5849(99)00079-9; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; Ha H, 1999, DIABETES RES CLIN PR, V45, P147, DOI 10.1016/S0168-8227(99)00044-3; Ha HJ, 2000, KIDNEY INT, V58, pS19, DOI 10.1046/j.1523-1755.2000.07704.x; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Ho FM, 2000, CIRCULATION, V101, P2618, DOI 10.1161/01.CIR.101.22.2618; HUNT JV, 1988, BIOCHEM J, V256, P205, DOI 10.1042/bj2560205; Iglesias-de la Cruz MC, 2001, KIDNEY INT, V59, P87, DOI 10.1046/j.1523-1755.2001.00469.x; IKENAGA H, 1993, CLIN SCI, V84, P469, DOI 10.1042/cs0840469; Ishii N, 2001, J AM SOC NEPHROL, V12, P1630, DOI 10.1681/ASN.V1281630; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; Jones SC, 1999, DIABETIC MED, V16, P932, DOI 10.1046/j.1464-5491.1999.00174.x; Kikkawa R, 1997, KIDNEY INT, V52, pS39; Kim MS, 2001, BIOCHEM PHARMACOL, V61, P779, DOI 10.1016/S0006-2952(01)00541-X; Montero A, 2000, KIDNEY INT, V58, P1963, DOI 10.1111/j.1523-1755.2000.00368.x; MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7; Noiri E, 2001, AM J PHYSIOL-RENAL, V281, pF948, DOI 10.1152/ajprenal.0071.2001; Park SH, 2001, KIDNEY INT, V59, P1695, DOI 10.1046/j.1523-1755.2001.0590051695.x; Posthuma N, 2001, PERITON DIALYSIS INT, V21, P43; Powell LA, 2001, FREE RADICAL BIO MED, V31, P1149, DOI 10.1016/S0891-5849(01)00648-7; Prabhakar SS, 2001, AM J PHYSIOL-RENAL, V281, pF179, DOI 10.1152/ajprenal.2001.281.1.F179; Priyadarsini KI, 2001, CHEM RES TOXICOL, V14, P567, DOI 10.1021/tx000239t; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Smith SC, 1999, PLACENTA, V20, P309, DOI 10.1053/plac.1998.0383; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; Suarez-Pinzon WL, 2001, J AUTOIMMUN, V16, P449, DOI 10.1006/jaut.2001.0507; SuarezPinzon WL, 1997, DIABETES, V46, P907, DOI 10.2337/diabetes.46.5.907; Supinski G, 1999, J APPL PHYSIOL, V87, P783, DOI 10.1152/jappl.1999.87.2.783; Szabo E, 2001, J INVEST DERMATOL, V117, P74, DOI 10.1046/j.0022-202x.2001.01388.x; Tannous M, 1999, DIABETOLOGIA, V42, P539, DOI 10.1007/s001250051192; Thuraisingham RC, 2000, KIDNEY INT, V57, P1968, DOI 10.1046/j.1523-1755.2000.00046.x; Tilton RG, 1997, J CLIN INVEST, V99, P2192, DOI 10.1172/JCI119392; Uemura S, 2001, CIRC RES, V88, P1291, DOI 10.1161/hh1201.092042; Varghese J, 2001, EUR J IMMUNOL, V31, P2035, DOI 10.1002/1521-4141(200107)31:7<2035::AID-IMMU2035>3.0.CO;2-Y; Virag L, 1998, FREE RADICAL BIO MED, V25, P1075, DOI 10.1016/S0891-5849(98)00139-7; Virag L, 1998, IMMUNOLOGY, V94, P345, DOI 10.1046/j.1365-2567.1998.00534.x; Zanetti M, 2001, ARTERIOSCL THROM VAS, V21, P195, DOI 10.1161/01.ATV.21.2.195; Zhuang SG, 2000, AM J PHYSIOL-CELL PH, V279, pC341, DOI 10.1152/ajpcell.2000.279.2.C341	55	193	201	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					908	+		10.1096/fj.02-0130fje	http://dx.doi.org/10.1096/fj.02-0130fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670885				2022-12-28	WOS:000181892600006
J	Bachschmid, M; Thurau, S; Zou, MH; Ullrich, V				Bachschmid, M; Thurau, S; Zou, MH; Ullrich, V			Endothelial cell activation by endotoxin involves superoxide/NO-mediated nitration of prostacyclin synthase and thromboxane receptor stimulation	FASEB JOURNAL			English	Article						nitric oxide; 6-ketoprostaglandin F1-alpha; peroxynitrous acid; lipopolysaccharides; prostaglandin endoperoxides	SMOOTH-MUSCLE CELLS; BOVINE CORONARY-ARTERIES; NITRIC-OXIDE RELEASE; TYROSINE NITRATION; PROSTAGLANDIN-I2 SYNTHASE; SIMULTANEOUS GENERATION; VASCULAR ENDOTHELIUM; XANTHINE-OXIDASE; NAD(P)H OXIDASE; IN-VIVO	In bovine coronary artery segments, peroxynitrite inhibits prostacyclin (PGI(2)) synthase by tyrosine nitration. Using this pharmacological model, we show that a 1 h exposure of bovine coronary artery segments to endotoxin (lipopolysaccharide [LPS]) inhibits the relaxation phase following angiotensin II (Ang II) stimulation and causes a vasospasm that can be suppressed by a thromboxane A(2) (TxA(2)) receptor blocker. In parallel, PGI(2) synthesis decreases in favor of prostaglandin E-2 formation. Immunoprecipitation and costaining with an anti-nitrotyrosine antibody identified PGI(2) synthase as the main nitrated protein in the endothelium. All effects of LPS could be prevented in the presence of the nitric oxide (NO) synthase inhibitor N-omega-monomethyl-L-arginine and polyethylene-glycolated Cu/Zn- superoxide dismutase. Thus, the early phase of endothelial cell activation in bovine coronary arteries by inflammatory agents proceeds by a protein synthesis-independent priming process for a source of superoxide that we tentatively attribute to xanthine oxidase. Upon receptor activation, Ang II stimulates NO and superoxide production, resulting in a peroxynitrite-mediated nitration and inhibition of PGI(2) synthase. The remaining 15-hydroxy-prostaglandin 9,11-endoperoxide (PGH(2)) first activates the TxA(2)/PGH(2) receptor and then is converted to prostaglandin E-2 (PGE(2)) by smooth muscle cells. PGE(2) together with a lack of NO and PGI(2) is known to promote the adhesion of white blood cells and their immigration to the inflammatory locus.	Univ Konstanz, Fak Biol, D-78457 Constance, Germany	University of Konstanz	Ullrich, V (corresponding author), Univ Konstanz, Fak Biol, Fach X910, D-78457 Constance, Germany.	volker.ullrich@uni-konstanz.de		Bachschmid, Markus Michael/0000-0002-0748-5528				BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; Bhagat K, 1996, CARDIOVASC RES, V32, P822; Bhagat K, 1997, CIRCULATION, V96, P3042, DOI 10.1161/01.CIR.96.9.3042; Brandes RP, 1999, HYPERTENSION, V33, P1243, DOI 10.1161/01.HYP.33.5.1243; Chen JY, 1999, ELECTROCHEM COMMUN, V1, P274, DOI 10.1016/S1388-2481(99)00056-9; Cines DB, 1998, BLOOD, V91, P3527; Cosentino F, 1998, J CLIN INVEST, V101, P1530, DOI 10.1172/JCI650; Daiber A, 2002, J BIOL CHEM, V277, P11882, DOI 10.1074/jbc.M111988200; DARLEYUSMAR VM, 1992, FREE RADICAL RES COM, V17, P9, DOI 10.3109/10715769209061085; DEWITT DL, 1983, J CLIN INVEST, V72, P1882, DOI 10.1172/JCI111151; Dogne JM, 2000, CURR MED CHEM, V7, P609, DOI 10.2174/0929867003374868; Goligorsky MS, 2000, ACTA PHYSIOL SCAND, V168, P33; Griendling KK, 1999, CIRC RES, V85, P562, DOI 10.1161/01.RES.85.6.562; Hailer NP, 2000, TRANSPLANTATION, V70, P236; HAROLD JG, 1985, PROSTAGLANDINS, V29, P19, DOI 10.1016/0090-6980(85)90147-9; Harrison R, 1997, BIOCHEM SOC T, V25, P786, DOI 10.1042/bst0250786; Houston M, 1999, J BIOL CHEM, V274, P4985, DOI 10.1074/jbc.274.8.4985; Hunt BJ, 1997, LANCET, V350, P293, DOI 10.1016/S0140-6736(05)62261-1; Klein T, 1998, MOL PHARMACOL, V53, P385, DOI 10.1124/mol.53.3.385; Kromer BM, 1999, BRIT J PHARMACOL, V126, P1171, DOI 10.1038/sj.bjp.0702433; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; Minetti M, 2000, BIOCHEMISTRY-US, V39, P6689, DOI 10.1021/bi9927991; Pfeiffer S, 2001, FASEB J, V15, P2355, DOI 10.1096/fj.01-0295com; POBER JS, 1988, AM J PATHOL, V133, P426; Prescott SM, 2001, J INVEST MED, V49, P104, DOI 10.2310/6650.2001.34106; Pueyo ME, 1998, AM J PHYSIOL-CELL PH, V274, pC214, DOI 10.1152/ajpcell.1998.274.1.C214; RAND MJ, 1993, CLIN EXP PHARMACOL P, V20, P141, DOI 10.1111/j.1440-1681.1993.tb01661.x; RHODEN KJ, 1989, BRIT J PHARMACOL, V98, P325, DOI 10.1111/j.1476-5381.1989.tb16898.x; Ryan Matthew G., 1997, Biochemical Society Transactions, V25, p530S; SAUSSY DL, 1986, J BIOL CHEM, V261, P3025; SCHMIDT P, IN PRESS J BIOL CHEM; Scott GS, 2001, MED HYPOTHESES, V56, P95, DOI 10.1054/mehy.2000.1118; SHIMIZU S, 1994, RES COMMUN CHEM PATH, V84, P301; SMITH WL, 1983, J BIOL CHEM, V258, P5922; Sohn HY, 2000, BRIT J PHARMACOL, V131, P667, DOI 10.1038/sj.bjp.0703566; Soler M, 2000, CIRC RES, V87, P504; Spisni E, 2001, EXP CELL RES, V266, P31, DOI 10.1006/excr.2001.5198; Stevens T, 2000, AM J PHYSIOL-LUNG C, V279, pL419, DOI 10.1152/ajplung.2000.279.3.L419; Thorup C, 1998, PFLUG ARCH EUR J PHY, V435, P432, DOI 10.1007/s004240050535; Ullrich V, 2000, BIOCHEM BIOPH RES CO, V278, P1, DOI 10.1006/bbrc.2000.3733; VANE JR, 1990, NEW ENGL J MED, V323, P27; Vanhoutte PM, 2002, EUR HEART J SUPPL, V4, pA8, DOI 10.1016/S1520-765X(02)90068-4; Yura T, 1999, KIDNEY INT, V56, P471, DOI 10.1046/j.1523-1755.1999.00596.x; Zhang H, 1999, CARDIOVASC RES, V44, P215, DOI 10.1016/S0008-6363(99)00183-2; Zou MH, 1999, J EXP MED, V190, P135, DOI 10.1084/jem.190.1.135; Zou MH, 1999, BRIT J PHARMACOL, V126, P1283, DOI 10.1038/sj.bjp.0702434; Zou MH, 1996, FEBS LETT, V382, P101, DOI 10.1016/0014-5793(96)00160-3; Zou MH, 2000, ARCH BIOCHEM BIOPHYS, V376, P149, DOI 10.1006/abbi.2000.1699; Zou MH, 1997, BIOL CHEM, V378, P707, DOI 10.1515/bchm.1997.378.7.707	52	76	81	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					914	+		10.1096/fj.02-0530fje	http://dx.doi.org/10.1096/fj.02-0530fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670882				2022-12-28	WOS:000181892600012
J	Muller, I; Klocke, A; Alex, M; Kotzsch, M; Luther, T; Morgenstern, E; Zieseniss, S; Zahler, S; Preissner, K; Engelmann, B				Muller, I; Klocke, A; Alex, M; Kotzsch, M; Luther, T; Morgenstern, E; Zieseniss, S; Zahler, S; Preissner, K; Engelmann, B			Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets	FASEB JOURNAL			English	Article						lipopolysaccharide; platelet rich plasma; superoxide dismutase; catalase; microparticles	ATHEROSCLEROTIC PLAQUES; FACTOR EXPRESSION; BLOOD; MICROPARTICLES; LEUKOCYTES; DYSFUNCTION; ACTIVATION; MONOCYTES	Although tissue factor (TF), the principial initiator of physiological coagulation and pathological thrombosis, has recently been proposed to be present in human blood, the functional significance and location of the intravascular TF is unknown. In the plasma portion of blood, we found TF to be mainly associated with circulating microvesicles. By cell sorting with the specific marker CD42b, platelet-derived microvesicles were identified as a major location of the plasma TF. This was confirmed by the presence of full-length TF in microvesicles acutely shedded from the activated platelets. TF was observed to be stored in the alpha-granules and the open canalicular system of resting platelets and to be exposed on the cell surface after platelet activation. Functional competence of the blood-based TF was enabled when the microvesicles and platelets adhered to neutrophils, as mediated by P-selectin and neutrophil counterreceptor (PSGL-1, CD18 integrins) interactions. Moreover, neutrophil-secreted oxygen radical species supported the intravascular TF activity. The pools of platelet and microvesicle TF contributed additively and to a comparable extent to the overall blood TF activity, indicating a substantial participation of the microvesicle TF. Our results introduce a new concept of TF-mediated coagulation crucially dependent on TF associated with microvesicles and activated platelets, which principally enables the entire coagulation system to proceed on a restricted cell surface.	Univ Munich, Inst Physiol, D-81377 Munich, Germany; Univ Munich, Inst Klin Chem, D-81377 Munich, Germany; Tech Univ Dresden, Inst Pathol, D-01307 Dresden, Germany; Univ Saarland, D-66421 Homburg, Germany; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany	University of Munich; University of Munich; Technische Universitat Dresden; Saarland University; Justus Liebig University Giessen	Engelmann, B (corresponding author), Univ Munich Klinikum, Inst Klin Chem Vaskulare Biol & Hamostase, Marchioninistr 15, D-81377 Munich, Germany.	Bernd.Engelmann@klch.med.uni-muenchen.de		Zahler, Stefan/0000-0002-5140-7287				ALBRECHT S, 1992, BLOOD COAGUL FIBRIN, V3, P263, DOI 10.1097/00001721-199206000-00005; Angelillo-Scherrer A, 2001, NAT MED, V7, P215, DOI 10.1038/84667; Bouchard BA, 2001, CURR OPIN HEMATOL, V8, P263, DOI 10.1097/00062752-200109000-00001; Camire RM, 1998, BLOOD, V92, P3035, DOI 10.1182/blood.V92.9.3035.421k54_3035_3041; Dahlback B, 2000, LANCET, V355, P1627, DOI 10.1016/S0140-6736(00)02225-X; EVANGELISTA V, 1991, BLOOD, V77, P2379; Hughes M, 2000, BLOOD, V96, P188, DOI 10.1182/blood.V96.1.188.013k12_188_194; Joop K, 2001, THROMB HAEMOSTASIS, V85, P810; Kaikita K, 1997, ARTERIOSCL THROM VAS, V17, P2232, DOI 10.1161/01.ATV.17.10.2232; Lawson CA, 1997, J CLIN INVEST, V99, P1729, DOI 10.1172/JCI119337; Line BR, 2001, SEMIN NUCL MED, V31, P90, DOI 10.1053/snuc.2001.21406; Mallat Z, 2000, CIRCULATION, V101, P841, DOI 10.1161/01.CIR.101.8.841; May AE, 1999, THROMB HAEMOSTASIS, V82, P962, DOI 10.1055/s-0037-1615939; Misumi K, 1998, AM J CARDIOL, V81, P22, DOI 10.1016/S0002-9149(97)00801-1; NAGAI M, 1993, SOLID STATE IONICS, V62, P151, DOI 10.1016/0167-2738(93)90263-3; Nemerson Y, 2000, THROMB HAEMOSTASIS, V83, P802; Nieswandt B, 2001, J EXP MED, V193, P459, DOI 10.1084/jem.193.4.459; Nieuwland R, 2000, BLOOD, V95, P930, DOI 10.1182/blood.V95.3.930.003k46_930_935; Nieuwland R, 1997, CIRCULATION, V96, P3534; Osterud B, 1998, BLOOD COAGUL FIBRIN, V9, pS9; Ozcan M, 2001, THROMB HAEMOSTASIS, V85, P250, DOI 10.1055/s-0037-1615705; Penn MS, 1999, CIRCULATION, V99, P1753, DOI 10.1161/01.CIR.99.13.1753; Randolph GJ, 1998, BLOOD, V92, P4167, DOI 10.1182/blood.V92.11.4167.423k35_4167_4177; Rauch U, 2000, BLOOD, V96, P170, DOI 10.1182/blood.V96.1.170.013k42_170_175; Rauch U, 2001, ANN INTERN MED, V134, P224, DOI 10.7326/0003-4819-134-3-200102060-00014; Soejima H, 1999, CIRCULATION, V99, P2908, DOI 10.1161/01.CIR.99.22.2908; Suefuji H, 1997, AM HEART J, V134, P253, DOI 10.1016/S0002-8703(97)70132-7; Thiruvikraman SV, 1996, LAB INVEST, V75, P451; Toschi V, 1997, CIRCULATION, V95, P594, DOI 10.1161/01.CIR.95.3.594; Zillmann A, 2001, BIOCHEM BIOPH RES CO, V281, P603, DOI 10.1006/bbrc.2001.4399	30	319	335	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					476	+		10.1096/fj.02-0574fje	http://dx.doi.org/10.1096/fj.02-0574fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12514112	Green Submitted			2022-12-28	WOS:000181453700024
J	White, RA; Kannan, MS; Walseth, TF				White, RA; Kannan, MS; Walseth, TF			Intracellular calcium signaling through the cADPR pathway is agonist specific in porcine airway smooth muscle	FASEB JOURNAL			English	Article						CD38; cADPR; airway smooth muscle; calcium signaling	CYCLIC-ADP-RIBOSE; CA2+-INDUCED CA2+ RELEASE; RAT CARDIAC MYOCYTES; ENDOTHELIN RECEPTORS; HUMAN CD38; CELLS; HYDROLYSIS; CYCLASE; ACETYLCHOLINE; OSCILLATIONS	Cyclic ADP-ribose (cADPR) induces intracellular Ca(2+) ([Ca(2+)](i)) release in airway smooth muscle, and the cADPR antagonist, 8-amino-cADPR, abolishes [Ca(2+)](i) oscillations elicited by acetylcholine (ACh), suggesting that cADPR is involved during muscarinic receptor activation. Whether the cADPR signaling pathway is common to agonists acting through different G protein-coupled receptors is not known. Using digital video imaging of Fura2-AM loaded porcine airway smooth muscle cells, we examined the effects of the membrane-permeant cADPR antagonist, 8-bromo-cADPR (8Br-cADPR), on the [Ca(2+)](i) responses to ACh, histamine and endothelin-1 (ET-1). In cells preincubated with 100 muM 8Br-cADPR, the [Ca(2+)](i) responses to ACh and ET-1 were significantly attenuated, whereas responses to histamine were not, suggesting agonist specificity of cADPR signaling. The effects of 8Br-cADPR were concentration dependent. We further examined whether muscarinic receptor subtypes specifically couple to this pathway, because in porcine airway smooth muscle cells, ACh activates both M(2) and M(3) muscarinic receptors coupled to G(alphai) and G(alphaq), respectively. Methoctramine, an M(2)-selective antagonist, attenuated the [Ca(2+)](i) responses to Ach, and there was no further attenuation by 8Br-cADPR. In airway smooth muscle, the CD38/cADPR signaling pathway is involved in [Ca(2+)](i) responses to contractile agonists in an agonist-specific manner.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ Minnesota, Coll Vet Med, Dept Vet Pathobiol, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Walseth, TF (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA.	walseth@mail.ahc.umn.edu	Walseth, Timothy F/F-9518-2010	Walseth, Timothy F/0000-0003-2558-7859	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL057498] Funding Source: Medline; NIDA NIH HHS [P50 DA011806] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BARON CB, 1984, P NATL ACAD SCI-BIOL, V81, P6899, DOI 10.1073/pnas.81.21.6899; Barone F, 2002, FASEB J, V16, DOI 10.1096/fj.01-0749com; Cancela JM, 2001, ANNU REV PHYSIOL, V63, P99, DOI 10.1146/annurev.physiol.63.1.99; Chini EN, 1997, P NATL ACAD SCI USA, V94, P5872, DOI 10.1073/pnas.94.11.5872; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Esguerra M, 2002, GLIA, V39, P314, DOI 10.1002/glia.10115; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Hall IP, 2000, EUR RESPIR J, V15, P1120, DOI 10.1034/j.1399-3003.2000.01523.x; Han MK, 2000, J BIOL CHEM, V275, P20799, DOI 10.1074/jbc.M001189200; Hay DWP, 1999, N-S ARCH PHARMACOL, V359, P404, DOI 10.1007/PL00005368; Higashida H, 1997, J BIOL CHEM, V272, P31272, DOI 10.1074/jbc.272.50.31272; Higashida H, 1999, J BIOL CHEM, V274, P33348, DOI 10.1074/jbc.274.47.33348; Higashida H, 2000, BIOCHEM J, V352, P197, DOI 10.1042/0264-6021:3520197; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Kannan MS, 1997, AM J PHYSIOL-LUNG C, V272, pL659, DOI 10.1152/ajplung.1997.272.4.L659; Kotlikoff MI, 1998, AM J RESP CRIT CARE, V158, pS109, DOI 10.1164/ajrccm.158.supplement_2.13tac600; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1995, BIOCHIMIE, V77, P345, DOI 10.1016/0300-9084(96)88145-4; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 1997, ADV EXP MED BIOL, V419, P411; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; LUCCHESI PA, 1990, AM J PHYSIOL, V258, pC730, DOI 10.1152/ajpcell.1990.258.4.C730; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Morel JL, 1997, BRIT J PHARMACOL, V121, P451, DOI 10.1038/sj.bjp.0701157; Morita K, 1997, J BIOL CHEM, V272, P21002, DOI 10.1074/jbc.272.34.21002; MURRAY RK, 1993, AM J PHYSIOL, V264, pC485, DOI 10.1152/ajpcell.1993.264.2.C485; Okamoto H, 1997, METHOD ENZYMOL, V280, P306; Podesta M, 2000, FASEB J, V14, P680, DOI 10.1096/fasebj.14.5.680; Prakash YS, 1998, AM J PHYSIOL-CELL PH, V274, pC1653, DOI 10.1152/ajpcell.1998.274.6.C1653; Prakash YS, 1997, AM J PHYSIOL-CELL PH, V272, pC966, DOI 10.1152/ajpcell.1997.272.3.C966; Roux E, 1997, BRIT J PHARMACOL, V120, P1294, DOI 10.1038/sj.bjp.0701061; Sethi JK, 1997, J BIOL CHEM, V272, P16358, DOI 10.1074/jbc.272.26.16358; SHIEH CC, 1991, J PHARMACOL EXP THER, V256, P141; Shieh Char-Chang, 1995, Journal of Biomedical Science, V2, P272, DOI 10.1007/BF02253388; Sims SM, 1996, AM J PHYSIOL-LUNG C, V271, pL300, DOI 10.1152/ajplung.1996.271.2.L300; TAKIGAWA M, 1995, EUR J BIOCHEM, V228, P102, DOI 10.1111/j.1432-1033.1995.0102o.x; Verderio C, 2001, J NEUROCHEM, V78, P646, DOI 10.1046/j.1471-4159.2001.00455.x; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; White TA, 2000, BBA-MOL CELL RES, V1498, P64, DOI 10.1016/S0167-4889(00)00077-X; Yu JZ, 2000, AM J PHYSIOL-HEART C, V279, pH873, DOI 10.1152/ajpheart.2000.279.3.H873; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017	43	71	72	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					482	+		10.1096/fj.02-0622fje	http://dx.doi.org/10.1096/fj.02-0622fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551848				2022-12-28	WOS:000181453700005
J	Thiriet, N; Ladenheim, B; McCoy, MT; Cadet, JL				Thiriet, N; Ladenheim, B; McCoy, MT; Cadet, JL			Analysis of ecstasy (MDMA)-induced transcriptional responses in the rat cortex	FASEB JOURNAL			English	Article						MDMA; cortex; gene expression; cDNA arrays; SYBR green PCR	SEROTONIN-DOPAMINE INTERACTIONS; ACTIVATED PROTEIN-KINASES; C-FOS EXPRESSION; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; METHYLENEDIOXYMETHAMPHETAMINE MDMA; SUPEROXIDE-DISMUTASE; TRANSGENIC MICE; GENE-EXPRESSION; 5-HT3 RECEPTORS; OXIDATIVE STRESS	3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a popular drug of abuse. MDMA is pharmacologically classified as an entactogen because of its affinities to classical hallucinogens and stimulants. Oral ingestion of a single dose of the drug is associated with euphoria, elevated self-confidence, and heightened sensory awareness in humans. Evidence for neurotoxicity in the human serotonin (5-HT) system has been provided. In rats, a single injection of MDMA induces hyperthermia and formation of reactive oxygen species. These effects may cause MDMA-associated, long-term 5-HT depletion, with the cortex being quite sensitive to the biochemical effects of MDMA. It has been suggested that these MDMA effects may be associated with molecular changes in this brain region. To test these ideas, we have made use of the cDNA array analysis, which can provide a more global view of the molecular changes secondary to MDMA injections. Our results show that the genes regulated by MDMA encode proteins that belong to signaling pathways, transcription regulators, or xenobiotic metabolism. Our observations indicate that cortical cells respond to the acute administration of MDMA by modulating transcription of several genes that might lead to long-term changes in the brain.	NIDA, Mol Neuropsychiat Sect, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Cadet, JL (corresponding author), NIDA, Mol Neuropsychiat Sect, NIH, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.	jcadet@intra.nida.nih.gov		THIRIET, Nathalie/0000-0002-0076-4946	NATIONAL INSTITUTE ON DRUG ABUSE [Z01DA000153] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Aguirre N, 1997, J NEUROCHEM, V68, P1099; Aguirre N, 1999, NEUROREPORT, V10, P3675, DOI 10.1097/00001756-199911260-00039; Bai FJ, 2001, CHEM RES TOXICOL, V14, P863, DOI 10.1021/tx010011l; Bai FJ, 1999, CHEM RES TOXICOL, V12, P1150, DOI 10.1021/tx990084t; Bankson MG, 2001, J PHARMACOL EXP THER, V297, P846; Beckmann AM, 1997, NEUROCHEM INT, V31, P477, DOI 10.1016/S0197-0186(96)00136-2; Berry MD, 2000, J NEUROSCI RES, V60, P150, DOI 10.1002/(SICI)1097-4547(20000415)60:2<150::AID-JNR3>3.0.CO;2-4; CADET JL, 1995, SYNAPSE, V21, P169, DOI 10.1002/syn.890210210; CADET JL, 1994, BRAIN RES, V655, P259, DOI 10.1016/0006-8993(94)91624-1; Cadet JL, 2002, SYNAPSE, V44, P211, DOI 10.1002/syn.10074; Colado MI, 1997, BRIT J PHARMACOL, V121, P889, DOI 10.1038/sj.bjp.0701213; COLADO MJ, 1994, BRIT J PHARMACOL, V111, P131, DOI 10.1111/j.1476-5381.1994.tb14034.x; DAFTERS RI, 1994, PSYCHOPHARMACOLOGY, V114, P505, DOI 10.1007/BF02249342; Davies KJA, 2000, IUBMB LIFE, V50, P279, DOI 10.1080/15216540051081010; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Granoff MI, 1998, NEUROPSYCHOBIOLOGY, V37, P36, DOI 10.1159/000026474; Gudelsky GA, 1996, J NEURAL TRANSM, V103, P1397, DOI 10.1007/BF01271253; Gudelsky GA, 1996, J NEUROCHEM, V66, P243; Gurd JW, 1997, NEUROCHEM INT, V31, P635, DOI 10.1016/S0197-0186(97)00022-3; Hegadoren KM, 1999, NEUROSCI BIOBEHAV R, V23, P539, DOI 10.1016/S0149-7634(98)00046-3; Herrera DG, 1996, PROG NEUROBIOL, V50, P83, DOI 10.1016/S0301-0082(96)00021-4; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HIRAMATSU M, 1990, J PHARMACOL EXP THER, V254, P521; Hoyer D, 1997, NEUROPHARMACOLOGY, V36, P419, DOI 10.1016/S0028-3908(97)00036-1; Iwakura Y, 2001, J BIOL CHEM, V276, P40025, DOI 10.1074/jbc.M103125200; Jayanthi S, 1999, NEUROSCIENCE, V91, P1379, DOI 10.1016/S0306-4522(98)00698-8; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KUMAGAI Y, 1991, CHEM RES TOXICOL, V4, P330, DOI 10.1021/tx00021a012; Lee SA, 2000, MOL BRAIN RES, V75, P16, DOI 10.1016/S0169-328X(99)00280-6; LEONARDI ETK, 1994, NEUROPSYCHOPHARMACOL, V10, P231, DOI 10.1038/npp.1994.26; Liechti ME, 2000, NEUROPSYCHOPHARMACOL, V22, P513, DOI 10.1016/S0893-133X(99)00148-7; Marcotte ER, 2001, TRENDS PHARMACOL SCI, V22, P426, DOI 10.1016/S0165-6147(00)01741-7; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Massa SM, 1996, CEREBROVAS BRAIN MET, V8, P95; Mates JM, 2000, TOXICOLOGY, V153, P83, DOI 10.1016/S0300-483X(00)00306-1; MATTHEWS RT, 1989, PHARMACOL BIOCHEM BE, V33, P741, DOI 10.1016/0091-3057(89)90464-4; MCKENNA DJ, 1990, J NEUROCHEM, V54, P14, DOI 10.1111/j.1471-4159.1990.tb13277.x; MILLER FD, 1987, J CELL BIOL, V105, P3065, DOI 10.1083/jcb.105.6.3065; Morales M, 1996, BRAIN RES, V731, P199, DOI 10.1016/S0006-8993(96)00557-4; MORATALLA R, 1992, J NEUROSCI, V12, P2609; Morgan MJ, 2000, PSYCHOPHARMACOLOGY, V152, P230, DOI 10.1007/s002130000545; Paillart C, 1996, J CELL BIOL, V134, P499, DOI 10.1083/jcb.134.2.499; PATTERSON PH, 1995, CURR OPIN NEUROBIOL, V5, P642, DOI 10.1016/0959-4388(95)80070-0; Portas CM, 2000, PROG NEUROBIOL, V60, P13, DOI 10.1016/S0301-0082(98)00097-5; Reeves DC, 2002, MOL MEMBR BIOL, V19, P11, DOI 10.1080/09687680110110048; Ricaurte GA, 2000, NEUROPSYCHOBIOLOGY, V42, P5, DOI 10.1159/000026664; ROBINSON TE, 1982, BRAIN RES, V253, P231, DOI 10.1016/0006-8993(82)90690-4; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHEFFEL U, 1992, NEUROPHARMACOLOGY, V31, P881, DOI 10.1016/0028-3908(92)90126-A; SCHMIDT CJ, 1990, ANN NY ACAD SCI, V600, P665, DOI 10.1111/j.1749-6632.1990.tb16917.x; SCHMIDT CJ, 1987, J PHARMACOL EXP THER, V240, P1; Shankaran H, 1999, EUR J PHARMACOL, V385, P103, DOI 10.1016/S0014-2999(99)00728-1; Shirayama Y, 2000, EUR J PHARMACOL, V402, P215, DOI 10.1016/S0014-2999(00)00521-5; Simantov R, 1997, FASEB J, V11, P141, DOI 10.1096/fasebj.11.2.9039956; Stephenson CP, 1999, NEUROSCIENCE, V92, P1011, DOI 10.1016/S0306-4522(99)00049-4; STONE DM, 1987, NEUROPHARMACOLOGY, V26, P1677, DOI 10.1016/0028-3908(87)90117-1; Stumm G, 1999, FASEB J, V13, P1065, DOI 10.1096/fasebj.13.9.1065; SUGITA S, 1992, NEURON, V8, P199, DOI 10.1016/0896-6273(92)90121-S; Urade Y, 1996, J LIPID MEDIAT CELL, V14, P71, DOI 10.1016/0929-7855(96)01511-8; VACCARINO FM, 1993, MOL BRAIN RES, V19, P76, DOI 10.1016/0169-328X(93)90151-E; van Hooft JA, 2000, TRENDS NEUROSCI, V23, P605, DOI 10.1016/S0166-2236(00)01662-3; White SR, 1996, PROG NEUROBIOL, V49, P455, DOI 10.1016/0301-0082(96)00027-5; Wildering WC, 2002, J NEUROSCI, V22, P2419, DOI 10.1523/JNEUROSCI.22-07-02419.2002; YAKEL JL, 1988, NEURON, V1, P615, DOI 10.1016/0896-6273(88)90111-0; Yau JLW, 1997, NEUROSCIENCE, V78, P111, DOI 10.1016/S0306-4522(96)00497-6; Yeh SY, 1997, PHARMACOL BIOCHEM BE, V58, P701, DOI 10.1016/S0091-3057(97)90010-1	68	27	28	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					1887	1894		10.1096/fj.02-0502com	http://dx.doi.org/10.1096/fj.02-0502com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12468453				2022-12-28	WOS:000180574300009
J	del Prete, MJ; Robles, MS; Guio, A; Martinez, C; Izquierdo, M; Garcia-Sanz, JA				del Prete, MJ; Robles, MS; Guio, A; Martinez, C; Izquierdo, M; Garcia-Sanz, JA			Degradation of cellular mRNA is a general early apoptosis-induced event	FASEB JOURNAL			English	Article						RNA metabolism; caspase inhibitors; signaling pathways; in vivo apoptosis	ACTIVATION-INDUCED APOPTOSIS; 28S RIBOSOMAL-RNA; LYMPHOPROLIFERATIVE SYNDROME; MONOCLONAL-ANTIBODY; T-CELLS; DEATH; LYMPHOCYTE; RECEPTOR; CASPASE; FAS	The fate of cellular mRNAs was analyzed in several cell lines of lymphoid origin, after induction of apoptosis by different mechanisms. Cytoplasmic mRNAs are specifically degraded as part of the early apoptotic response. This degradation is not species restricted and is independent of the cell line, the apoptotic stimulus, the intrinsic half-life of the mRNAs, and the transcriptional status of the gene (constitutive or inducible). mRNA degradation precedes DNA fragmentation and correlates with the appearance of phosphatidylserine in the outer cell membrane. In addition, apoptosis-induced mRNA degradation is an active process that can be dissected from other apoptotic hallmarks (degradation of annexin V, DNA, and poly(ADP-ribose) polymerase [PARP]), which suggests that apoptosis-induced mRNA degradation is controlled by a distinct signaling pathway. Furthermore, mRNA degradation also occurs in vivo, specifically during thymocyte apoptosis. Taken together, these data support the notion that degradation of mRNA is a general early apoptotic event that may become a new apoptotic hallmark.	CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Univ Valladolid, Fac Med, CSIC, Inst Mol Biol & Genet, E-47005 Valladolid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid	Garcia-Sanz, JA (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Cantoblanco UAM, E-28049 Madrid, Spain.	jasanz@cnb.uam.es	Robles, Maria S/D-6307-2015; Garcia-Sanz, Jose A./AAA-2956-2019; Robles, Maria/ABH-1497-2020; Izquierdo, Manuel/D-2971-2017; Izquierdo, Manuel/I-4812-2013; Garcia-Sanz, Jose A/E-7684-2011; Izquierdo, Manuel/I-4812-2013	Robles, Maria S/0000-0001-9149-8761; Garcia-Sanz, Jose A./0000-0002-1153-6025; Robles, Maria/0000-0001-9149-8761; Izquierdo, Manuel/0000-0002-7701-1002; Izquierdo, Manuel/0000-0002-7701-1002; Garcia-Sanz, Jose A/0000-0002-1153-6025; Izquierdo, Manuel/0000-0002-7261-404X; Guio-Carrion, Ana/0000-0002-8963-4389				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Affar EB, 2001, J BIOL CHEM, V276, P2935, DOI 10.1074/jbc.M007269200; Arch RH, 1999, ANNU REV CELL DEV BI, V15, P113, DOI 10.1146/annurev.cellbio.15.1.113; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CIDLOWSKI JA, 1982, ENDOCRINOLOGY, V111, P184, DOI 10.1210/endo-111-1-184; Clemens MJ, 1998, ONCOGENE, V17, P2921, DOI 10.1038/sj.onc.1202227; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Crawford DR, 1997, FREE RADICAL BIO MED, V22, P1295, DOI 10.1016/S0891-5849(96)00544-8; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Evan G, 1997, INT J CANCER, V71, P709, DOI 10.1002/(SICI)1097-0215(19970529)71:5<709::AID-IJC2>3.0.CO;2-V; GARCIASANZ JA, 1993, EUR J IMMUNOL, V23, P1877, DOI 10.1002/eji.1830230822; Gerner C, 2000, J BIOL CHEM, V275, P39018, DOI 10.1074/jbc.M006495200; GILLIS S, 1978, J IMMUNOL, V120, P2027; GOLDSMITH MA, 1989, J BIOL CHEM, V264, P17190; Gonalons E, 1998, J IMMUNOL, V161, P1837; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hieronymus T, 2000, CELL DEATH DIFFER, V7, P538, DOI 10.1038/sj.cdd.4400684; HOUGE G, 1995, MOL CELL BIOL, V15, P2051; Izquierdo M, 1996, J IMMUNOL, V157, P21; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; King KL, 2000, CELL DEATH DIFFER, V7, P994, DOI 10.1038/sj.cdd.4400731; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LANIER LL, 1981, J IMMUNOL, V127, P1691; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; MAMALAKI C, 1993, INT IMMUNOL, V5, P1285, DOI 10.1093/intimm/5.10.1285; MAMALAKI C, 1992, P NATL ACAD SCI USA, V89, P11342, DOI 10.1073/pnas.89.23.11342; Marissen WE, 2000, CELL DEATH DIFFER, V7, P1234, DOI 10.1038/sj.cdd.4400750; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MULLNER EW, 1997, MANUAL IMMUNOLOGICAL, V1, P389; MULLNER EW, 1997, IMMUNOLOGY METHODS M, V1, P407; Nadano D, 2000, J BIOL CHEM, V275, P13967, DOI 10.1074/jbc.275.18.13967; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PING L, 1992, J IMMUNOL, V148, P3354; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; RUSSELL JH, 1995, CURR OPIN IMMUNOL, V7, P382, DOI 10.1016/0952-7915(95)80114-6; Rutjes SK, 1999, J BIOL CHEM, V274, P24799, DOI 10.1074/jbc.274.35.24799; Samali A, 1997, CELL DEATH DIFFER, V4, P289, DOI 10.1038/sj.cdd.4400246; SANTIS AG, 1995, EUR J IMMUNOL, V25, P2142, DOI 10.1002/eji.1830250804; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; Shortman K, 1990, Semin Immunol, V2, P3; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SULVERMAN RH, 1997, RIBONUCLEASES STRUCT, P515; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Sytwu HK, 1996, IMMUNITY, V5, P17, DOI 10.1016/S1074-7613(00)80306-4; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	65	49	54	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					2003	+		10.1096/fj.02-0392fje	http://dx.doi.org/10.1096/fj.02-0392fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397088	Green Submitted			2022-12-28	WOS:000179167600015
J	Faehling, M; Kroll, J; Fohr, KJ; Fellbrich, G; Mayr, U; Trischler, G; Waltenberger, J				Faehling, M; Kroll, J; Fohr, KJ; Fellbrich, G; Mayr, U; Trischler, G; Waltenberger, J			Essential role of calcium in vascular endothelial growth factor A-induced signaling: mechanism of the antiangiogenic effect of carboxyamidotriazole	FASEB JOURNAL			English	Article						angiogenesis; endothelial cells; signal transduction; angiogenesis inhibitors; nitric oxide	FACTOR RECEPTOR KDR; PHASE-I TRIAL; NITRIC-OXIDE; TYROSINE PHOSPHORYLATION; TRANSDUCTION PATHWAYS; TRANSCRIPTION FACTORS; NUCLEAR FACTOR; ION CHANNELS; SOLID TUMORS; PLC-GAMMA	Vascular endothelial growth factor-A (VEGF-A) plays a major role in tumor angiogenesis and raises the concentration of intracellular free calcium ([Ca2+](i)). Carboxyamidotriazole (CAI), an inhibitor of calcium influx and of angiogenesis, is under investigation as a tumoristatic agent. We studied the effect of CAI and the role of [Ca2+](i) in VEGF-A signaling in human endothelial cells. VEGF-A induced a biphasic [Ca2+](i) signal. VEGF-A increased the level of intracellular inositol 1,4,5-trisphosphate (IP3), which suggests that VEGF-A releases Ca2+ from IP3-sensitive stores and induces store-operated calcium influx. Reduction of either extracellular or intracellular free Ca2+ inhibited VEGF-A-induced proliferation. CAI inhibited IP3 formation, both phases of the calcium signal, nitric oxide (NO) release, and proliferation induced by VEGF-A. CAI prevented neither activation of VEGF receptor-2 (VEGFR-2) (KDR/Flk-1), phospholipase C-gamma, or mitogen-activated protein kinase (MAP kinase) nor translocation of nuclear factor of activated T cells (NFAT). We conclude that calcium signaling is necessary for VEGF-A-induced proliferation. MAP kinase activation occurs independently of [Ca2+](i) but is not sufficient to induce proliferation in the absence of calcium signaling. Inhibition of the VEGF-A-induced [Ca2+](i) signal and proliferation by CAI can be explained by inhibition of IP3 formation and may contribute to the antiangiogenic action of CAI. Calcium-dependent NO formation may represent a link between calcium signaling and proliferation.	Univ Ulm, Dept Internal Med 2, D-89081 Ulm, Germany; Univ Ulm, Dept Anesthesiol, D-89081 Ulm, Germany	Ulm University; Ulm University	Waltenberger, J (corresponding author), Univ Ulm, Dept Internal Med 2, Robert Koch Str 8, D-89081 Ulm, Germany.	johannes.waltenberger@medizin.uni-ulm.de	Waltenberger, Johannes/I-1813-2013	Waltenberger, Johannes/0000-0002-2417-9880				ADAMS DJ, 1989, FASEB J, V3, P2389, DOI 10.1096/fasebj.3.12.2477294; Armesilla AL, 1999, MOL CELL BIOL, V19, P2032; Bates DO, 1997, AM J PHYSIOL-HEART C, V273, pH687, DOI 10.1152/ajpheart.1997.273.2.H687; Bauer KS, 1999, CLIN CANCER RES, V5, P2324; Bauer KS, 2000, J PHARMACOL EXP THER, V292, P31; BENZAQUEN LR, 1995, NAT MED, V1, P534, DOI 10.1038/nm0695-534; Berlin J, 1997, J CLIN ONCOL, V15, P781, DOI 10.1200/JCO.1997.15.2.781; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; BROCK TA, 1991, AM J PATHOL, V138, P213; CRISCUOLO GR, 1989, J NEUROSURG, V71, P884, DOI 10.3171/jns.1989.71.6.0884; Cunningham SA, 1999, AM J PHYSIOL-CELL PH, V276, pC176, DOI 10.1152/ajpcell.1999.276.1.C176; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; FLEMING I, 1995, CIRC RES, V76, P522, DOI 10.1161/01.RES.76.4.522; FOHR KJ, 1993, METHOD ENZYMOL, V221, P149, DOI 10.1016/0076-6879(93)21014-Y; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garnier-Raveaud S, 2001, GROWTH FACTORS, V19, P35, DOI 10.3109/08977190109001074; Ge SG, 2000, CLIN CANCER RES, V6, P1248; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; HOOD HF, 1998, AM J PHYSIOL, V274, pH1054; HUPE DJ, 1990, J CELL PHYSIOL, V144, P457, DOI 10.1002/jcp.1041440313; HUPE DJ, 1991, J BIOL CHEM, V266, P10136; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kohn EC, 1996, CANCER RES, V56, P569; KOHN EC, 1992, CANCER RES, V52, P3208; Kohn EC, 2002, NEW ANGIOTHERAPY, P527; KOHN EC, 1995, P NATL ACAD SCI USA, V92, P1307, DOI 10.1073/pnas.92.5.1307; KOHN EC, 1990, J NATL CANCER I, V82, P54, DOI 10.1093/jnci/82.1.54; Kohn EC, 1997, J CLIN ONCOL, V15, P1985, DOI 10.1200/JCO.1997.15.5.1985; Kohn EC, 2001, CLIN CANCER RES, V7, P1600; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kroll J, 1999, BIOCHEM BIOPH RES CO, V265, P636, DOI 10.1006/bbrc.1999.1729; Kroll J, 1998, BIOCHEM BIOPH RES CO, V252, P743, DOI 10.1006/bbrc.1998.9719; McLaughlin AP, 2001, AM J PHYSIOL-CELL PH, V281, pC1448, DOI 10.1152/ajpcell.2001.281.5.C1448; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Santella L, 1998, BIOCHEM BIOPH RES CO, V244, P317, DOI 10.1006/bbrc.1998.8086; Seymour LW, 1996, LAB INVEST, V75, P427; Smits A, 1989, GROWTH FACTORS, V2, P1, DOI 10.3109/08977198909069076; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; SOLTOFF SP, 1988, ANNU REV PHYSIOL, V50, P207; Takahashi H, 1998, JPN J CANCER RES, V89, P445, DOI 10.1111/j.1349-7006.1998.tb00583.x; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TEICHER BA, 1994, CANCER CHEMOTH PHARM, V34, P515, DOI 10.1007/BF00685664; Waltenberger J, 1997, CIRCULATION, V96, P4083; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	64	96	102	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2002	16	11					1805	+		10.1096/fj.01-0938fje	http://dx.doi.org/10.1096/fj.01-0938fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12354692				2022-12-28	WOS:000178441800004
J	Thunnissen, MMGM; Andersson, B; Samuelsson, B; Wong, CH; Haeggstrom, JZ				Thunnissen, MMGM; Andersson, B; Samuelsson, B; Wong, CH; Haeggstrom, JZ			Crystal structures of leukotriene A(4) hydrolase in complex with captopril and two competitive tight-binding inhibitors	FASEB JOURNAL			English	Article						inflammation; metallopeptidase; ACE	BIFUNCTIONAL ENZYME; ACTIVE-SITE; B-4; AMINOPEPTIDASE; MECHANISM; MUTATION; RESIDUE; 5-LIPOXYGENASE; INACTIVATION; CONVERSION	Leukotriene (LT) A(4) hydrolase/aminopeptidase is a bifunctional zinc enzyme that catalyzes the final step in the biosynthesis of LTB4, a potent chemoattractant and immune modulating lipid mediator. Here, we report a high-resolution crystal structure of LTA(4) hydrolase in complex with captopril, a classical inhibitor of the zinc peptidase angiotensin-converting enzyme. Captopril makes few interactions with the protein, but its free thiol group is bound to the zinc, apparently accounting for most of its inhibitory action on LTA(4) hydrolase. In addition, we have determined the structures of LTA(4) hydrolase in complex with two selective tight-binding inhibitors, a thioamine and a hydroxamic acid. Their common benzyloxyphenyl tail, designed to mimic the carbon backbone of LTA(4), binds into a narrow hydrophobic cavity in the protein. The free hydroxyl group of the hydroxamic acid makes a suboptimal, monodentate complex with the zinc, and strategies for improved inhibitor design can be deduced from the structure. Taken together, the three crystal structures provide the molecular basis for the divergent pharmacological profiles of LTA(4) hydrolase inhibitors. Moreover, they help define the binding pocket for the fatty acid-derived epoxide LTA(4) as well as the subsites for a tripeptide substrate, which in turn have important implications for the molecular mechanisms of enzyme catalyses.	Karolinska Inst, Div Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Univ Stockholm, Arrhenius Lab, Dept Biochem, S-10691 Stockholm, Sweden; Scripps Res Inst, Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Karolinska Institutet; Stockholm University; Scripps Research Institute	Haeggstrom, JZ (corresponding author), Karolinska Inst, Div Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	jesper.haeggstrom@mbb.ki.se	Thunnissen, Marjolein MGM/B-9366-2011					Agha AM, 2000, TOXICOL APPL PHARM, V168, P123, DOI 10.1006/taap.2000.8985; Andberg MB, 1997, J BIOL CHEM, V272, P23057, DOI 10.1074/jbc.272.37.23057; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bailie MB, 1996, J IMMUNOL, V157, P5221; BARRET AJ, 1998, HDB PROTEOLYTIC ENZY, P994; BARRETT AJ, 1998, HDB PROTEOLYTIC ENZY, P992; BLOMSTER M, 1995, EUR J BIOCHEM, V231, P528, DOI 10.1111/j.1432-1033.1995.tb20728.x; Byrum RS, 1999, J IMMUNOL, V163, P6810; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Griffiths RJ, 1997, J EXP MED, V185, P1123, DOI 10.1084/jem.185.6.1123; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haeggstrom JZ, 2000, AM J RESP CRIT CARE, V161, pS25, DOI 10.1164/ajrccm.161.supplement_1.ltta-6; HOGG JH, 1995, BIOORGAN MED CHEM, V3, P1405, DOI 10.1016/0968-0896(95)00128-4; Hogg JH, 1998, CHEM-EUR J, V4, P1698, DOI 10.1002/(SICI)1521-3765(19980904)4:9<1698::AID-CHEM1698>3.3.CO;2-A; HOLMES MA, 1981, BIOCHEMISTRY-US, V20, P6912, DOI 10.1021/bi00527a026; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LARAGH JH, 1990, AM J HYPERTENS, V3, pS257, DOI 10.1093/ajh/3.11S.257S; LAWTON G, 1992, ADV DRUG DESIGN RES, P161; Luciani N, 1998, BIOCHEMISTRY-US, V37, P686, DOI 10.1021/bi971705p; Mancuso P, 2001, INFECT IMMUN, V69, P2011, DOI 10.1128/IAI.69.4.2011-2016.2001; MARTIN MFR, 1984, LANCET, V1, P1325; MAYCOCK AL, 1982, J BIOL CHEM, V257, P3911; MEDINA JF, 1991, P NATL ACAD SCI USA, V88, P7620, DOI 10.1073/pnas.88.17.7620; Menard A, 1996, BIOCHEM J, V320, P687, DOI 10.1042/bj3200687; MUELLER MJ, 1995, P NATL ACAD SCI USA, V92, P8383, DOI 10.1073/pnas.92.18.8383; Mueller MJ, 1996, P NATL ACAD SCI USA, V93, P5931, DOI 10.1073/pnas.93.12.5931; OHISHI N, 1987, J BIOL CHEM, V262, P10200; ORNING L, 1991, J BIOL CHEM, V266, P16507; ORNING L, 1994, J BIOL CHEM, V269, P11269; ORNING L, 1991, J BIOL CHEM, V266, P1375; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; Penning TD, 2001, CURR PHARM DESIGN, V7, P163, DOI 10.2174/1381612013398248; Rudberg PC, 2002, J BIOL CHEM, V277, P1398, DOI 10.1074/jbc.M106577200; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHINDO K, 1994, J IMMUNOL, V153, P5750; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; Thunnissen MMGM, 2001, NAT STRUCT BIOL, V8, P131, DOI 10.1038/84117; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; Vazeux G, 1998, BIOCHEM J, V334, P407, DOI 10.1042/bj3340407; WEI YA, 1993, J MED CHEM, V36, P211, DOI 10.1021/jm00054a004; WETTERHOLM A, 1991, BIOCHIM BIOPHYS ACTA, V1080, P96, DOI 10.1016/0167-4838(91)90134-L; WETTERHOLM A, 1995, J PHARMACOL EXP THER, V275, P31; WETTERHOLM A, 1992, P NATL ACAD SCI USA, V89, P9141, DOI 10.1073/pnas.89.19.9141; WILLIAMS TA, 1994, J BIOL CHEM, V269, P29430; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; YUAN W, 1992, J AM CHEM SOC, V114, P6552, DOI 10.1021/ja00042a041	50	60	65	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1648	+		10.1096/fj.01-1017fje	http://dx.doi.org/10.1096/fj.01-1017fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207002				2022-12-28	WOS:000177814000015
J	Ying, WZ; Sanders, PW				Ying, WZ; Sanders, PW			Dietary salt intake activates MAP kinases in the rat kidney	FASEB JOURNAL			English	Article						p42 MAP kinase; p44 MAP kinase; p38 MAP kinase; shear; transforming growth factor beta; nitric oxide; flavones; imidazoles	NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR-BETA; SIGNAL-REGULATED KINASE; SHEAR-STRESS; PROTEIN-KINASE; SENSITIVE HYPERTENSION; GENE-EXPRESSION; CELL; TYROSINE; SMAD	This study explored the hypothesis that dietary salt promoted changes in renal expression of TGF-beta1 and NOS3 by modulating the mitogen-activated protein kinase (MAPK) pathways. Sprague-Dawley rats were maintained for four days on formulated diets that contained 0.3, 1.0, 3.0, or 8.0% NaCl. An increase in salt intake to greater than or equal to3.0% NaCl increased kinase activities of p38 MAPK and p42/44 MAPK, but not p46/54 JNK/SAPK, in the cortex and outer and inner medulla. Associated with this increased activity was a relative increase in the phosphorylated forms of the transcription factors ATF-2 and Elk-1. Compared with rats on 0.3% NaCl diet, glomerular preparations from rats on 8.0% NaCl diet contained more NOS3 and produced greater amounts of total and active TGF-beta1 and NOx. PD-098059, a MEK1 inhibitor, and SB-203580, an inhibitor of p38 MAPKalpha-gamma, diminished NOS3 expression and production of TGF-beta1 and NOx. TEA, administered intravenously 5 min before harvesting kidneys of rats on the 8.0% NaCl diet, decreased activities of both p38 MAPK and p42/44 MAPK, compared with vehicle-treated animals. Thus, an increase in dietary salt activated through a TEA-sensitive pathway the p38 MAPK and p42/44 MAPK signaling cascades, which promoted the increase in glomerular TGF-beta1 and NOS3 expression.	Univ Alabama Birmingham, Dept Med, Div Nephrol, Cell Adhes & Matrix Res Ctr, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Nephrol Res & Training, Birmingham, AL USA; Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Dept Vet Affairs Med Ctr, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Sanders, PW (corresponding author), Univ Alabama Birmingham, Dept Med, Div Nephrol, Cell Adhes & Matrix Res Ctr, 642 Lyons Harrison Res Bldg,1530 3rd Ave S, Birmingham, AL 35294 USA.	psanders@uab.edu		Sanders, Paul/0000-0002-2915-5714				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Azuma N, 2001, AM J PHYSIOL-HEART C, V280, pH189, DOI 10.1152/ajpheart.2001.280.1.H189; Bech JN, 1998, AM J PHYSIOL-RENAL, V274, pF914, DOI 10.1152/ajprenal.1998.274.5.F914; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; CHEN PY, 1991, J CLIN INVEST, V88, P1559, DOI 10.1172/JCI115467; Chen PY, 1998, HYPERTENSION, V31, P918, DOI 10.1161/01.HYP.31.4.918; CHEN PY, 1993, HYPERTENSION, V22, P812, DOI 10.1161/01.HYP.22.6.812; CHEN PY, 1993, LAB INVEST, V68, P174; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; DENG AH, 1993, AM J PHYSIOL, V264, pF212, DOI 10.1152/ajprenal.1993.264.2.F212; DENG XL, 1994, KIDNEY INT, V46, P639, DOI 10.1038/ki.1994.316; Go YM, 1998, AM J PHYSIOL-HEART C, V275, pH1898, DOI 10.1152/ajpheart.1998.275.5.H1898; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; Hamaguchi A, 1999, HYPERTENSION, V34, P126, DOI 10.1161/01.HYP.34.1.126; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Li YS, 1996, MOL CELL BIOL, V16, P5947; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Maulik N, 1998, AM J PHYSIOL-HEART C, V275, pH1857, DOI 10.1152/ajpheart.1998.275.5.H1857; OHNO M, 1995, J CLIN INVEST, V95, P1363, DOI 10.1172/JCI117787; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; PATEL A, 1993, HYPERTENSION, V22, P863, DOI 10.1161/01.HYP.22.6.863; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RELMAN AS, 1949, P SOC EXP BIOL MED, V70, P11; SAKAI T, 1987, ANAT EMBRYOL, V176, P373; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; SHULTZ PJ, 1993, J CLIN INVEST, V91, P642, DOI 10.1172/JCI116244; SHYY JYJ, 1995, P NATL ACAD SCI USA, V92, P8069, DOI 10.1073/pnas.92.17.8069; TOLINS JP, 1990, AM J PHYSIOL, V258, pH655, DOI 10.1152/ajpheart.1990.258.3.H655; TOLINS JP, 1994, KIDNEY INT, V46, P230, DOI 10.1038/ki.1994.264; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Ying WZ, 1999, AM J PHYSIOL-HEART C, V277, pH1293, DOI 10.1152/ajpheart.1999.277.4.H1293; Ying WZ, 1998, KIDNEY INT, V54, P1150, DOI 10.1046/j.1523-1755.1998.00117.x; Ying WZ, 1998, AM J PHYSIOL-RENAL, V275, pF18, DOI 10.1152/ajprenal.1998.275.1.F18; Ying WZ, 1998, AM J PHYSIOL-RENAL, V274, pF635, DOI 10.1152/ajprenal.1998.274.4.F635; Zhang ZJ, 1998, RNA, V4, P394	46	23	24	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1683	+		10.1096/fj.02-0982fje	http://dx.doi.org/10.1096/fj.02-0982fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206991				2022-12-28	WOS:000177814000008
J	Kampa, M; Papakonstanti, EA; Hatzoglou, A; Stathopoulos, EN; Stournaras, C; Castanas, E				Kampa, M; Papakonstanti, EA; Hatzoglou, A; Stathopoulos, EN; Stournaras, C; Castanas, E			The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors, which increase PSA secretion and modify actin cytoskeleton	FASEB JOURNAL			English	Article						testosterone receptor; membrane receptor; cancer cells (LNCaP)	HORMONE-BINDING GLOBULIN; HUMAN ENDOMETRIAL CELLS; FOCAL ADHESION KINASE; PITUITARY-TUMOR CELLS; ANDROGEN RECEPTOR; PLASMA-MEMBRANES; STEROID-HORMONES; TYROSINE PHOSPHORYLATION; CALCIUM-CONCENTRATION; CHANNEL ACTIVATION	Recent findings have shown that, in addition to the genomic action of steroids, through intracellular receptors, short-time effects could be mediated through binding to membrane sites. In the present study of prostate cancer LNCaP cells, we report that dihydrotestosterone and the non-internalizable analog testosterone-BSA increase rapidly the release of prostate-specific antigen (PSA) in the culture medium. Membrane testosterone binding sites were identified through ligand binding on membrane preparations, flow cytometry, and confocal laser microscopy of the non-internalizable fluorescent analog testosterone-BSA-FITC, on whole cells. Binding on these sites is time- and concentration-dependent and specific for testosterone, presenting a K-D of 10.9 nM and a number of 144 sites/mg protein (similar to13000 sites/cell). Membrane sites differ immunologically for intracellular androgen receptors. The secretion of PSA after membrane testosterone receptor stimulation was inhibited after pretreatment with the actin cytoskeleton disrupting agent cytochalasin B. In addition, membrane testosterone binding modifies the intracellular dynamic equilibrium of monomeric to filamentous actin and remodels profoundly the actin cytoskeleton organization. These results are discussed in the context of a possible involvement of these sites in cancer chemotherapy.	Univ Crete, Sch Med, Lab Expt Endocrinol, GR-71110 Iraklion, Greece; Univ Crete, Sch Med, Biochem Lab, GR-71110 Iraklion, Greece; Univ Crete, Sch Med, Pathol Lab, GR-71110 Iraklion, Greece	University of Crete; University of Crete; University of Crete	Castanas, E (corresponding author), Univ Crete, Sch Med, Lab Expt Endocrinol, POB 1393, GR-71110 Iraklion, Greece.	castanas@med.uoc.gr	Castanas, Elias/E-7007-2010	Castanas, Elias/0000-0002-8370-1835; Papakonstanti, Evangelia/0000-0002-7119-6026				Armen TA, 2000, J CELL BIOCHEM, V79, P620, DOI 10.1002/1097-4644(20001215)79:4<620::AID-JCB110>3.3.CO;2-8; Benten WPM, 1997, FEBS LETT, V407, P211, DOI 10.1016/S0014-5793(97)00346-3; Benten WPM, 1999, FASEB J, V13, P123, DOI 10.1096/fasebj.13.1.123; Benten WPM, 1999, MOL BIOL CELL, V10, P3113, DOI 10.1091/mbc.10.10.3113; BILHARTZ DL, 1991, UROLOGY, V38, P95, DOI 10.1016/S0090-4295(05)80066-4; Borski RJ, 2000, TRENDS ENDOCRIN MET, V11, P427, DOI 10.1016/S1043-2760(00)00325-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANN DW, 1995, J STEROID BIOCHEM, V52, P113, DOI 10.1016/0960-0760(94)00160-N; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; CANTIELLO HF, 1993, J BIOL CHEM, V268, P4596; Dermitzaki E, 2001, ENDOCRINOLOGY, V142, P2022, DOI 10.1210/en.142.5.2022; DIEZ A, 1984, HORM METAB RES, V16, P475, DOI 10.1055/s-2007-1014823; Ding AQ, 2001, J APPL PHYSIOL, V91, P2742, DOI 10.1152/jappl.2001.91.6.2742; Ding VDH, 1998, ENDOCRINOLOGY, V139, P213, DOI 10.1210/en.139.1.213; Falkenstein E, 2001, MOL CELL BIOCHEM, V218, P71, DOI 10.1023/A:1007269507856; FELDEN F, 1992, J STEROID BIOCHEM, V42, P279, DOI 10.1016/0960-0760(92)90130-B; FORTUNATI N, 1992, J STEROID BIOCHEM, V42, P185, DOI 10.1016/0960-0760(92)90027-G; FRAIRIA R, 1991, J STEROID BIOCHEM, V40, P805, DOI 10.1016/0960-0760(91)90306-P; FULLER CM, 1994, AM J PHYSIOL, V266, pC661, DOI 10.1152/ajpcell.1994.266.3.C661; GOLENHOFEN N, 1995, KIDNEY INT, V48, P1837, DOI 10.1038/ki.1995.482; GORCZYNSKA E, 1995, ENDOCRINOLOGY, V136, P2052, DOI 10.1210/en.136.5.2052; Grazzini E, 1998, NATURE, V392, P509, DOI 10.1038/33176; GUEANT JL, 1991, J MOL ENDOCRINOL, V7, P113, DOI 10.1677/jme.0.0070113; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; HRYB DJ, 1990, J BIOL CHEM, V265, P6048; JENSEN EV, 1996, ANN NY ACAD SCI, V748, P1; KILEY SC, 1992, MOL ENDOCRINOL, V6, P120, DOI 10.1210/me.6.1.120; KONOPLYA EF, 1992, INT J BIOCHEM, V24, P1979, DOI 10.1016/0020-711X(92)90294-B; Koukouritaki SB, 1997, J CELL BIOCHEM, V65, P492, DOI 10.1002/(SICI)1097-4644(19970615)65:4<492::AID-JCB5>3.0.CO;2-J; Koukouritaki SB, 1996, J CELL BIOCHEM, V62, P251, DOI 10.1002/(SICI)1097-4644(199608)62:2<251::AID-JCB13>3.0.CO;2-O; Koukouritaki SB, 1999, MOL MED, V5, P382, DOI 10.1007/BF03402127; Koukouritaki SB, 1999, MOL MED, V5, P731, DOI 10.1007/BF03402097; KRUPENKO SA, 1994, J STEROID BIOCHEM, V51, P115, DOI 10.1016/0960-0760(94)90122-8; Kumar MV, 1998, PROG NUCLEIC ACID RE, V59, P289; Leung GPH, 2001, AM J PHYSIOL-CELL PH, V280, pC1160, DOI 10.1152/ajpcell.2001.280.5.C1160; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; Lyng FM, 2000, BIOL REPROD, V63, P736, DOI 10.1095/biolreprod63.3.736; MCEWEN BS, 1991, TRENDS PHARMACOL SCI, V12, P141, DOI 10.1016/0165-6147(91)90531-V; Mosmann T., 1973, J IMMUNOL METHODS, V65, P53; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nadal A, 1998, FASEB J, V12, P1341, DOI 10.1096/fasebj.12.13.1341; Nakhla AM, 1996, ENDOCRINOLOGY, V137, P4126, DOI 10.1210/en.137.10.4126; Nemere I, 1998, BIOCHEM BIOPH RES CO, V248, P443, DOI 10.1006/bbrc.1998.8492; OESTERLING JE, 1997, CANC PRINCIPLES PRAC, V1, P1322; Panagiotou S, 1999, J CELL BIOCHEM, V73, P204, DOI 10.1002/(SICI)1097-4644(19990501)73:2<204::AID-JCB6>3.0.CO;2-V; Papakonstanti EA, 1998, J CELL BIOCHEM, V70, P60, DOI 10.1002/(SICI)1097-4644(19980701)70:1<60::AID-JCB7>3.0.CO;2-1; Papakonstanti EA, 2000, MOL MED, V6, P303, DOI 10.1007/BF03401939; PORTO CS, 1995, J STEROID BIOCHEM, V53, P561, DOI 10.1016/0960-0760(95)00111-C; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; THEODOROPOULOS PA, 1992, FEBS LETT, V311, P241, DOI 10.1016/0014-5793(92)81111-X; Watson CS, 1999, EXP PHYSIOL, V84, P1013, DOI 10.1111/j.1469-445X.1999.01903.x; Watson CS, 1999, STEROIDS, V64, P5, DOI 10.1016/S0039-128X(98)00107-X; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; YOUNG CYF, 1991, CANCER RES, V51, P3748; ZHOU ZX, 1994, RECENT PROG HORM RES, V49, P249	55	135	138	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1429	+		10.1096/fj.02-0131fje	http://dx.doi.org/10.1096/fj.02-0131fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205037	Bronze			2022-12-28	WOS:000177813100009
J	Sriram, K; Matheson, JM; Benkovic, SA; Miller, DB; Luster, MI; O'Callaghan, JP				Sriram, K; Matheson, JM; Benkovic, SA; Miller, DB; Luster, MI; O'Callaghan, JP			Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease	FASEB JOURNAL			English	Article						brain; neurodegeneration; neuroprotection; MPTP	TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA PRODUCTION; ALZHEIMERS-DISEASE; SUBSTANTIA-NIGRA; GLIAL-CELLS; RAT-BRAIN; COMPLEX-I; QUANTITATIVE ASPECTS; CEREBROSPINAL-FLUID; MULTIPLE-SCLEROSIS	The pathogenic mechanisms underlying idiopathic Parkinson's disease (PD) remain enigmatic. Recent findings suggest that inflammatory processes are associated with several neurodegenerative disorders, including PD. Enhanced expression of the proinflammatory cytokine, tumor necrosis factor (TNF)-alpha, has been found in association with glial cells in the substantia nigra of patients with PD. To determine the potential role for TNF-alpha in PD, we examined the effects of the 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP), a dopaminergic neurotoxin that mimics some of the key features associated with PD, using transgenic mice lacking TNF receptors. Administration of MPTP to wild-type (+/+) mice resulted in a time-dependent expression of TNF-alpha in striatum, which preceded the loss of dopaminergic markers and reactive gliosis. In contrast, transgenic mice carrying homozygous mutant alleles for both the TNF receptors (TNFR-DKO), but not the individual receptors, were completely protected against the dopaminergic neurotoxicity of MPTP. The data indicate that the proinflammatory cytokine TNF-alpha is an obligatory component of dopaminergic neurodegeneration. Moreover, because TNF-alpha is synthesized predominantly by microglia and astrocytes, our findings implicate the participation of glial cells in MPTP-induced neurotoxicity. Similar mechanisms may underlie the etiopathogenesis of PD.	NIOSH, CDC, TMBB, HELD, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	O'Callaghan, JP (corresponding author), NIOSH, CDC, TMBB, HELD, Mailstop L-3014,1095 Willowdale Rd, Morgantown, WV 26505 USA.	jdo5@cdc.gov	Sriram, Krishnan/F-1039-2014; O'Callaghan, James/O-2958-2013	Sriram, Krishnan/0000-0001-7005-1872				Aloe L, 1997, NEUROSCI LETT, V238, P65, DOI 10.1016/S0304-3940(97)00850-1; BALABAN CD, 1988, NEUROSCIENCE, V26, P337, DOI 10.1016/0306-4522(88)90150-9; BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; BIGDA J, 1994, J EXP MED, V180, P445, DOI 10.1084/jem.180.2.445; BOKA G, 1994, NEUROSCI LETT, V172, P151, DOI 10.1016/0304-3940(94)90684-X; Botchkina GI, 1997, MOL MED, V3, P765, DOI 10.1007/BF03401714; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG IY, 1990, J IMMUNOL, V144, P2999; Cleeter MWJ, 2001, FEBS LETT, V504, P50, DOI 10.1016/S0014-5793(01)02763-6; Dabbeni-Sala F, 2001, FASEB J, V15, P1786, DOI 10.1096/fj.00-0427fje; deBock F, 1996, NEUROREPORT, V7, P1125, DOI 10.1097/00001756-199604260-00004; Declercq W, 1998, J IMMUNOL, V161, P390; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; FILLIT H, 1991, NEUROSCI LETT, V129, P318, DOI 10.1016/0304-3940(91)90490-K; FRANCIS JW, 1995, NEUROTOXICOL TERATOL, V17, P7, DOI 10.1016/0892-0362(94)00048-I; Galasso JM, 2000, NEUROREPORT, V11, P231, DOI 10.1097/00001756-200002070-00002; GIASSON BI, 2000, NEURODEGENERATIVE DE, P219; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Goossens V, 1999, ANTIOXID REDOX SIGN, V1, P285, DOI 10.1089/ars.1999.1.3-285; GRAMSBERGEN JBP, 1994, BRAIN RES, V667, P216, DOI 10.1016/0006-8993(94)91499-0; HETIER E, 1991, EXP BRAIN RES, V86, P407; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; Hunot S, 1999, J NEUROSCI, V19, P3440; Hunot S, 2001, CLIN NEUROSCI RES, V1, P434, DOI 10.1016/S1566-2772(01)00022-6; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LEE SC, 1993, J IMMUNOL, V150, P2659; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; Lippa CF, 1995, NEURODEGENERATION, V4, P425, DOI 10.1006/neur.1995.0051; LITTLE AR, 2002, CEL MOL MEC TOX ACT, V3, P233; Masliah E., 2000, NEURODEGENERATIVE DE, P131; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; Miller DB, 1998, ANN NY ACAD SCI, V844, P153, DOI 10.1111/j.1749-6632.1998.tb08230.x; MIZUNO Y, 1995, BBA-MOL BASIS DIS, V1271, P265, DOI 10.1016/0925-4439(95)00038-6; MIZUNO Y, 1987, J NEUROCHEM, V48, P1787, DOI 10.1111/j.1471-4159.1987.tb05737.x; MIZUNO Y, 1993, ADV NEUROL, V60, P282; Mogi M, 1996, NEUROSCI LETT, V211, P13, DOI 10.1016/0304-3940(96)12706-3; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Mogi M, 1999, NEUROSCI LETT, V268, P101, DOI 10.1016/S0304-3940(99)00388-2; MOGI M, 1995, J NEURAL TRANSM-PARK, V9, P87, DOI 10.1007/BF02252965; Nagatsu T, 2000, ADV RES NEURODEGENER, V8, P277; NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8; Nishimura M, 2001, NEUROSCI LETT, V311, P1, DOI 10.1016/S0304-3940(01)02111-5; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; O'Callaghan JP, 1999, ANAL BIOCHEM, V274, P18, DOI 10.1006/abio.1999.4260; O'Callaghan JP, 1998, ANN NY ACAD SCI, V844, P40; OCALLAGHAN JP, 1990, BRAIN RES, V521, P73, DOI 10.1016/0006-8993(90)91526-M; OCALLAGHAN JP, 1994, J PHARMACOL EXP THER, V270, P741; OCALLAGHAN JP, 1995, NEUROCHEM INT, V26, P115, DOI 10.1016/0197-0186(94)00106-5; OCALLAGHAN JP, 1993, ANN NY ACAD SCI, V679, P195, DOI 10.1111/j.1749-6632.1993.tb18299.x; OCALLAGHAN JP, 2002, CURRENT PROTOCOLS TO; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; Pearce RKB, 1997, J NEURAL TRANSM, V104, P661, DOI 10.1007/BF01291884; Raivich Gennadij, 1996, Keio Journal of Medicine, V45, P239; Ransohoff Richard M., 1996, Cytokine and Growth Factor Reviews, V7, P35, DOI 10.1016/1359-6101(96)00003-2; Ren LQ, 1999, MOL BRAIN RES, V65, P198, DOI 10.1016/S0169-328X(99)00016-9; RODNITZKY RL, 1995, NEUROSCIENCE MED, P427; Sairanen T, 2001, STROKE, V32, P1750, DOI 10.1161/01.STR.32.8.1750; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOFIC E, 1992, NEUROSCI LETT, V142, P128, DOI 10.1016/0304-3940(92)90355-B; Sriram K, 1998, J NEUROSCI, V18, P10287; Sriram K, 1997, BRAIN RES, V749, P44, DOI 10.1016/S0006-8993(96)01271-1; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TCHELINGERIAN JL, 1993, NEURON, V10, P213, DOI 10.1016/0896-6273(93)90312-F; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Unger JW, 1998, MICROSC RES TECHNIQ, V43, P24, DOI 10.1002/(SICI)1097-0029(19981001)43:1<24::AID-JEMT4>3.0.CO;2-P; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200	80	292	302	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1474	+		10.1096/fj.02-0216fje	http://dx.doi.org/10.1096/fj.02-0216fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205053	Green Submitted			2022-12-28	WOS:000177813100001
J	Siems, W; Sommerburg, O; Schild, L; Augustin, W; Langhans, CD; Wiswedel, I				Siems, W; Sommerburg, O; Schild, L; Augustin, W; Langhans, CD; Wiswedel, I			beta-Carotene cleavage products induce oxidative stress in vitro by impairing mitochondrial respiration	FASEB JOURNAL			English	Article						carotenoid cleavage products; oxidative phosphorylation; glutathione; rat liver mitochondria	NA+-K+-ATPASE; VITAMIN-A; LUNG-CANCER; ANTIOXIDANT REACTIONS; LIPID-PEROXIDATION; ALPHA-TOCOPHEROL; IDENTIFICATION; SUPPLEMENTATION; DEGRADATION; PREVENTION	Carotenoids are widely used as important micronutrients in food. Furthermore, carotenoid supplementation has been used in the treatment of diseases associated with oxidative stress. However, in some clinical studies harmful effects have been observed, for example, a higher incidence of lung cancer in individuals exposed to extraordinary oxidative stress. The causal mechanisms are still unclear. Carotenoid cleavage products (CCPs), including highly reactive aldehydes and epoxides, are formed during oxidative attacks in the course of antioxidative action. Here, we tested the hypothesis that CCPs may increase oxidative stress by impairing mitochondrial function. We found that CCPs strongly inhibit state 3 respiration of isolated rat liver mitochondria even at concentrations between 0.5 and 20 muM. This was true for retinal, beta-ionone, and mixtures of cleavage products, which were generated in the presence of hypochlorite to mimic their formation in inflammatory regions. The inhibition of mitochondrial respiration was accompanied by a reduction in protein sulfhydryl content, decreasing glutathione levels and redox state, and elevated accumulation of malondialdehyde. Changes in mitochondrial membrane potential favor functional deterioration of the adenine nucleotide translocator. The findings may reflect a basic mechanism of increasing the risk of cancer induced by CCPs.	Univ Magdeburg, Fac Med, Inst Clin Chem & Pathol Biochem, Dept Pathol Biochem, D-39120 Magdeburg, Germany; Herzog Julius Hosp Rheumatol & Orthoped, Bad Harzburg, Germany; Univ Heidelberg, Childrens Hosp, D-6900 Heidelberg, Germany; Univ Ulm, Childrens Hosp, D-89069 Ulm, Germany	Otto von Guericke University; Ruprecht Karls University Heidelberg; Ulm University	Wiswedel, I (corresponding author), Univ Magdeburg, Fac Med, Inst Clin Chem & Pathol Biochem, Dept Pathol Biochem, Leipziger Str 44, D-39120 Magdeburg, Germany.	ingrid.wiswedel@medizin.uni-magdeburg.de						Albanes D, 1996, J NATL CANCER I, V88, P1560, DOI 10.1093/jnci/88.21.1560; BAKER MA, 1990, ANAL BIOCHEM, V190, P360, DOI 10.1016/0003-2697(90)90208-Q; Bianchi-Santamaria A, 1999, INT J VITAM NUTR RES, V69, P3, DOI 10.1024/0300-9831.69.1.3; Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834; Buege J A, 1978, Methods Enzymol, V52, P302; BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CHEN JJ, 1995, FREE RADICAL BIO MED, V19, P583, DOI 10.1016/0891-5849(95)00066-7; Chen YQ, 1999, CANCER RES, V59, P3985; CHIRICO S, 1994, METHOD ENZYMOL, V233, P314; DAVIES JMS, 1993, FREE RADICAL BIO MED, V15, P637, DOI 10.1016/0891-5849(93)90167-S; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GOODMAN DS, 1966, J BIOL CHEM, V241, P1929; HANDELMAN GJ, 1991, FREE RADICAL BIO MED, V10, P427, DOI 10.1016/0891-5849(91)90051-4; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; HOMNICK DN, 1993, J PEDIATR-US, V122, P703, DOI 10.1016/S0022-3476(06)80008-9; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; KENNEDY TA, 1992, J BIOL CHEM, V267, P4658; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Krinsky NI, 1998, ANN NY ACAD SCI, V854, P443, DOI 10.1111/j.1749-6632.1998.tb09923.x; LIEBLER DC, 1993, ANN NY ACAD SCI, V691, P20, DOI 10.1111/j.1749-6632.1993.tb26154.x; Liebler DC, 1996, CHEM RES TOXICOL, V9, P8, DOI 10.1021/tx950151t; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADER I, 1964, SCIENCE, V144, P533, DOI 10.1126/science.144.3618.533; Mayne ST, 1996, FASEB J, V10, P690, DOI 10.1096/fasebj.10.7.8635686; Mayne ST, 1996, J NATL CANCER I, V88, P1513; MORDI RC, 1993, TETRAHEDRON, V49, P911, DOI 10.1016/S0040-4020(01)80333-1; Murata M, 2000, J BIOL CHEM, V275, P2003, DOI 10.1074/jbc.275.3.2003; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; OLSON JA, 1993, ANN NY ACAD SCI, V691, P156, DOI 10.1111/j.1749-6632.1993.tb26167.x; Olson JA, 1995, FASEB J, V9, P1547, DOI 10.1096/fasebj.9.15.8529833; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PACKER L, 1993, ANN NY ACAD SCI, V691, P48, DOI 10.1111/j.1749-6632.1993.tb26156.x; Pappalardo G, 1997, EUR J CLIN NUTR, V51, P661, DOI 10.1038/sj.ejcn.1600457; Parker RS, 1996, FASEB J, V10, P542, DOI 10.1096/fasebj.10.5.8621054; PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0; Quiles JL, 1999, INT J VITAM NUTR RES, V69, P243, DOI 10.1024/0300-9831.69.4.243; RIBAYAMERCADO JD, 1995, J NUTR, V125, P1854, DOI 10.1093/jn/125.7.1854; Schild L, 2001, FASEB J, V15, P565; SCHMITZ HH, 1991, J NUTR, V121, P1613, DOI 10.1093/jn/121.10.1613; SHRAGO E, 1995, PROSTAG LEUKOTR ESS, V52, P163, DOI 10.1016/0952-3278(95)90016-0; Siems WG, 2000, FREE RADICAL RES, V33, P427, DOI 10.1080/10715760000300961; Siems WG, 1996, FREE RADICAL BIO MED, V20, P215, DOI 10.1016/0891-5849(95)02041-1; SIES H, 1992, ANN NY ACAD SCI, V669, P7, DOI 10.1111/j.1749-6632.1992.tb17085.x; SLAGA TJ, 1995, ADV EXP MED BIOL, V369, P167; Sommerburg O, 2000, EUR J PEDIATR, V159, P86, DOI 10.1007/PL00013811; SOMMERBURG O, COMMUNICATION; STEINBRECHT I, 1970, ACTA BIOL MED GER, V25, P731; STRATTON SP, 1993, CHEM RES TOXICOL, V6, P542, DOI 10.1021/tx00034a024; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; von Lintig J, 2001, ARCH BIOCHEM BIOPHYS, V385, P47, DOI 10.1006/abbi.2000.2096; Wang XD, 1999, NUTR REV, V57, P263; Wiswedel I, 2002, FREE RADICAL RES, V36, P1, DOI 10.1080/10715760210170; Wyss A, 2000, BIOCHEM BIOPH RES CO, V271, P334, DOI 10.1006/bbrc.2000.2619; Young AJ, 2001, ARCH BIOCHEM BIOPHYS, V385, P20, DOI 10.1006/abbi.2000.2149; Ziegler RG, 1996, CANCER CAUSE CONTROL, V7, P157, DOI 10.1007/BF00115646	58	92	93	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1289	+		10.1096/fj.01-0765fje	http://dx.doi.org/10.1096/fj.01-0765fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154001				2022-12-28	WOS:000176683900029
J	Ramjeesingh, R; Leung, R; Siu, CH				Ramjeesingh, R; Leung, R; Siu, CH			Interleukin-8 secreted by endothelial cells induces chemotaxis of melanoma cells through the chemokine receptor CXCR1	FASEB JOURNAL			English	Article						chemokines; under-agarose assay; transendothelial migration; antibody inhibition	TRANSENDOTHELIAL MIGRATION; CANCER-CELLS; IN-VITRO; MALIGNANT-MELANOMA; AMINO-ACID; EXPRESSION; IL-8; METASTASIS; GROWTH; MATRIX	There is increasing evidence that both cell adhesion molecules and soluble factors are involved in tumor metastasis. We have found that endothelial cells secrete chemoattractants that can induce melanoma cell chemotaxis. Protein separation on an ion-exchange column shows the association of IL-8 with fractions that contain the chemoattractant activity. This activity is completely lost from the conditioned medium after immunoprecipitation with anti-IL-8 antibodies, indicating that IL-8 is the major melanoma chemoattractant secreted by endothelial cells. IL-8(77), the predominant endothelial IL-8 isoform that contains 77 amino acids, is found to be twice as potent as the more common 72-amino acid isoform IL-8(72). Antibody inhibition studies indicate that the chemotactic response of melanoma cells is mediated by the CXC-chemokine receptor CXCR1 and not by the more promiscuous CXCR2. When stimulated by tumor necrosis factor alpha, the nonresponsive WM35 melanoma cells synthesize a higher level of CXCR1 and become chemotactic toward interleukin (IL)-8. Pretreatment of cells with pertussis toxin nullifies their chemotactic response, suggesting the involvement of G proteins. Antibodies against either IL-8 or CXCR1 inhibit melanoma transendothelial migration in a coculture assay by 30%. These results are consistent with a role for IL-8-induced chemotaxis in the transendothelial migration of melanoma cells.	Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto	Siu, CH (corresponding author), Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	chi.hung.siu@utoronto.ca	Ramjeesingh, Ravi/AAB-3374-2022	Ramjeesingh, Ravi/0000-0001-5584-3505				ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; AlonsoVarona A, 1996, B CANCER, V83, P27; AUERBACH R, 1985, MICROVASC RES, V29, P401, DOI 10.1016/0026-2862(85)90028-7; AYALON O, 1994, J CELL BIOL, V126, P247, DOI 10.1083/jcb.126.1.247; AZNAVOORIAN S, 1990, J CELL BIOL, V110, P1427, DOI 10.1083/jcb.110.4.1427; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Baggiolini M, 2001, J INTERN MED, V250, P91, DOI 10.1046/j.1365-2796.2001.00867.x; Belien ATJ, 1999, J CELL BIOL, V144, P373, DOI 10.1083/jcb.144.2.373; BERENS ME, 1994, CLIN EXP METASTAS, V12, P405, DOI 10.1007/BF01755884; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; Damaj BB, 1996, J BIOL CHEM, V271, P12783, DOI 10.1074/jbc.271.22.12783; De Larco JE, 2001, CANCER RES, V61, P2857; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; GESSER B, 1995, BIOCHEM BIOPH RES CO, V210, P660, DOI 10.1006/bbrc.1995.1711; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; HAMMOND MEW, 1995, J IMMUNOL, V155, P1428; HERLYN M, 1985, CANCER RES, V45, P5670; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; Inoue K, 2000, CANCER RES, V60, P2290; Kim SJ, 2001, NEOPLASIA, V3, P33, DOI 10.1038/sj.neo.7900124; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; LEE J, 1992, J BIOL CHEM, V267, P16283; Lewalle JM, 1997, EXP CELL RES, V237, P347, DOI 10.1006/excr.1997.3799; Liotta L A, 1986, Prog Clin Biol Res, V212, P17; Luca M, 1997, AM J PATHOL, V151, P1105; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2002, CANCER RES, V62, P7328; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NELSON RD, 1975, J IMMUNOL, V115, P1650; NICOLSON GL, 1982, J HISTOCHEM CYTOCHEM, V30, P214, DOI 10.1177/30.3.7061823; NOURSHARGH S, 1992, J IMMUNOL, V148, P106; OPAS M, 1985, EXP CELL BIOL, V53, P241; Orr FW, 2000, J PATHOL, V190, P310, DOI 10.1002/(SICI)1096-9896(200002)190:3<310::AID-PATH525>3.0.CO;2-P; PAULI BU, 1990, CANCER METAST REV, V9, P175, DOI 10.1007/BF00046359; REPESH LA, 1989, INVAS METAST, V9, P192; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Rofstad EK, 2000, CANCER RES, V60, P4932; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; RUSCIANO D, 1992, BIOESSAYS, V14, P185, DOI 10.1002/bies.950140309; SAMANTA AK, 1990, J BIOL CHEM, V265, P183; Sandig M, 1997, CELL MOTIL CYTOSKEL, V38, P351, DOI 10.1002/(SICI)1097-0169(1997)38:4<351::AID-CM5>3.3.CO;2-Z; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; Scherbarth S, 1997, CANCER RES, V57, P4105; Schraufstatter IU, 2001, AM J PHYSIOL-LUNG C, V280, pL1094, DOI 10.1152/ajplung.2001.280.6.L1094; Singh RK, 2000, HISTOL HISTOPATHOL, V15, P843, DOI 10.14670/HH-15.843; SINGH RK, 1994, CANCER RES, V54, P3242; STRACKE ML, 1988, BIOCHEM BIOPH RES CO, V153, P1076, DOI 10.1016/S0006-291X(88)81338-X; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; Voura EB, 1998, MICROSC RES TECHNIQ, V43, P265, DOI 10.1002/(SICI)1097-0029(19981101)43:3<265::AID-JEMT9>3.0.CO;2-Z; Voura EB, 2001, MOL BIOL CELL, V12, P2699, DOI 10.1091/mbc.12.9.2699; Voura EB, 2001, CLIN EXP METASTAS, V18, P527, DOI 10.1023/A:1011884807746; Voura EB, 1998, CELL TISSUE RES, V293, P375, DOI 10.1007/s004410051129; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; WANG JM, 1990, BIOCHEM BIOPH RES CO, V169, P165, DOI 10.1016/0006-291X(90)91449-3; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; Wu LJ, 1996, J BIOL CHEM, V271, P31202, DOI 10.1074/jbc.271.49.31202; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D	63	64	67	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1292	+		10.1096/fj.02-0560fje	http://dx.doi.org/10.1096/fj.02-0560fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738812				2022-12-28	WOS:000183165000029
J	Casas, F; Daury, L; Grandemange, S; Busson, M; Seyer, P; Hatier, R; Carazo, A; Cabello, G; Wrutniak-Cabello, C				Casas, F; Daury, L; Grandemange, S; Busson, M; Seyer, P; Hatier, R; Carazo, A; Cabello, G; Wrutniak-Cabello, C			Endocrine regulation of mitochondrial activity: involvement of truncated RXR alpha and c-Erb A alpha 1 proteins	FASEB JOURNAL			English	Article						mitochondrial import; mitochondrial transcription; mt-DNA; triiodothyronine; 9-cis-retinoic acid	THYROID-HORMONE ACTION; RETINOID-X-RECEPTOR; RAT-LIVER; RNA-SYNTHESIS; PEROXISOME PROLIFERATORS; MYOBLAST DIFFERENTIATION; GENE-EXPRESSION; CELL-DEATH; VITAMIN-A; ACID	The importance of mitochondrial activity has recently been extended to the regulation of developmental processes. Numerous pathologies associated with organelle's dysfunctions emphasize their physiological importance. However, regulation of mitochondrial genome transcription, a key element for organelle's function, remains poorly understood. After characterization in the organelle of a truncated form of the triiodothyronine nuclear receptor (p43), a T3-dependent transcription factor of the mitochondrial genome, our purpose was to search for other mitochondrial receptors involved in the regulation of organelle transcription. We show that a 44 kDa protein related to RXRalpha (mt-RXR), another nuclear receptor, is located in the mitochondrial matrix. We found that mt-RXR is produced after cytosolic or intramitochondrial enzymatic cleavage of the RXRalpha nuclear receptor. After mitochondrial import and binding to specific sequences of the organelle genome, mt-RXR induces a ligand-dependent increase in mitochondrial RNA levels. mt-RXR physically interacts with p43 and acts alone or through a heterodimerical complex activated by 9-cis-retinoic acid and T3 to increase RNA levels. These data indicate that hormonal regulation of mitochondrial transcription occurs through pathways similar to those that take place in the nucleus and open a new way to better understand hormone and vitamin action at the cellular level.	INRA, UMR Differenciat Cellulaire & Croissance 866, Unite Endocrinol Cellulaire, INRA UMII ENSAM, F-34060 Montpellier 1, France; Fac Med Vandoeuvre Nancy, EMI 0014, INSERM, Electron Microscope Unit, F-54505 Vandoeuvre Les Nancy, France	INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine	Cabello, G (corresponding author), INRA, UMR Differenciat Cellulaire & Croissance 866, Unite Endocrinol Cellulaire, INRA UMII ENSAM, 2 Pl Viala, F-34060 Montpellier 1, France.	cabello@ensam.inra.fr	Grandemange, Stéphanie/G-7928-2015	Francois, Casas/0000-0002-5535-8195; Daury, Laetitia/0000-0002-1296-7150				BEER DG, 1982, BIOCHEM BIOPH RES CO, V109, P1276, DOI 10.1016/0006-291X(82)91915-5; Berdanier CD, 2001, DIABETES RES CLIN PR, V54, pS11, DOI 10.1016/S0168-8227(01)00331-X; Cai Y, 1996, ARCH BIOCHEM BIOPHYS, V325, P107, DOI 10.1006/abbi.1996.0013; Casas F, 1999, MOL CELL BIOL, V19, P7913; Casas F, 2000, FEBS LETT, V478, P4, DOI 10.1016/S0014-5793(00)01814-7; CHOU SY, 1995, ENDOCRINOLOGY, V136, P5520, DOI 10.1210/en.136.12.5520; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Enriquez JA, 1999, MOL CELL BIOL, V19, P657; Estornell E, 2000, BRIT J NUTR, V84, P927; Fleischer S, 1974, Methods Enzymol, V31, P6; Gaemers IC, 1998, MOL REPROD DEV, V50, P1, DOI 10.1002/(SICI)1098-2795(199805)50:1&lt;1::AID-MRD1&gt;3.0.CO;2-P; Gao G, 2000, J CELL BIOCHEM, V80, P53; Greenawalt J W, 1974, Methods Enzymol, V31, P310; Hamai N, 1997, CELL STRUCT FUNCT, V22, P421, DOI 10.1247/csf.22.421; HERTZ R, 1991, BIOCHEM J, V274, P745, DOI 10.1042/bj2740745; Imai T, 2001, P NATL ACAD SCI USA, V98, P224, DOI 10.1073/pnas.011528898; KANEKO T, 1988, MOL CELL BIOL, V8, P3311, DOI 10.1128/MCB.8.8.3311; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; LI G, 1994, INT J ONCOL, V5, P301; LIEBERHERR M, 1987, J BIOL CHEM, V262, P13168; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARTINO G, 1986, MOL BIOL REP, V11, P205, DOI 10.1007/BF00419598; MatsushimaNishiwaki R, 1996, BIOCHEM BIOPH RES CO, V225, P946, DOI 10.1006/bbrc.1996.1276; Nagaya T, 1998, J BIOL CHEM, V273, P33166, DOI 10.1074/jbc.273.50.33166; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Noguchi M, 1997, P NATL ACAD SCI USA, V94, P11534, DOI 10.1073/pnas.94.21.11534; Ostronoff LK, 1996, BIOCHEM J, V316, P183, DOI 10.1042/bj3160183; Prufer K, 2002, MOL ENDOCRINOL, V16, P961, DOI 10.1210/me.16.5.961; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; Rochard P, 2000, J BIOL CHEM, V275, P2733, DOI 10.1074/jbc.275.4.2733; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; Ruiz-Lozano P, 1998, DEVELOPMENT, V125, P533; SANYAL A, 1995, J BIOL CHEM, V270, P11970, DOI 10.1074/jbc.270.20.11970; VANDENBOGERT C, 1992, J CELL PHYSIOL, V152, P632, DOI 10.1002/jcp.1041520323; VANITALLIE CM, 1988, MOL ENDOCRINOL, V2, P332, DOI 10.1210/mend-2-4-332; VANITALLIE CM, 1992, ENDOCRINOLOGY, V130, P567, DOI 10.1210/en.130.2.567; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Wrutniak C, 1998, ANN NY ACAD SCI, V839, P93, DOI 10.1111/j.1749-6632.1998.tb10738.x; WRUTNIAK C, 1995, J BIOL CHEM, V270, P16347, DOI 10.1074/jbc.270.27.16347; Wrutniak-Cabello C, 2001, J MOL ENDOCRINOL, V26, P67, DOI 10.1677/jme.0.0260067	41	78	85	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					426	436		10.1096/fj.02-0732com	http://dx.doi.org/10.1096/fj.02-0732com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12631582				2022-12-28	WOS:000181892600041
J	Cooper, S				Cooper, S			Reappraisal of serum starvation, the restriction point, G0, and G1 phase arrest points	FASEB JOURNAL			English	Review						G0; G1 arrest; G1 phase; restriction point; cell cycle; quiescence	MAMMALIAN-CELL CYCLE; C-MYC; RETINOBLASTOMA PROTEIN; SYNCHRONIZATION; PROLIFERATION; GENE; PHOSPHORYLATION; EXPRESSION; G1-PHASE; EVENTS	The restriction point in the G1 phase of the mammalian cell cycle is the oldest, best-known, and widely accepted control point regulating division cycle in mammalian cells. Origins of the restriction point and its subsequent history are reanalyzed here. The initial proposal of the restriction point has an alternative explanation, which is that cells arrested with a G1 phase amount of DNA can arise from the inhibition of a process or processes occurring throughout the cell cycle and are not restricted to any particular phase of the cell cycle or specifically related to any event in the G1 phase of the cell cycle. The initial evidence and subsequent analyses require reexamination. It is proposed that the arrest of cells with a particular DNA content equivalent to that in cells in the G1 phase of the division cycle does not mean there is any particular G1 phase control point.	Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Cooper, S (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.	cooper@umich.edu						Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Coleman ML, 2001, NAT CELL BIOL, V3, pE250, DOI 10.1038/ncb1101-e250; COOPER S, 1979, NATURE, V280, P17, DOI 10.1038/280017a0; Cooper S, 2002, CELL BIOL INT, V26, P715, DOI 10.1006/cbir.2002.0925; COOPER S, 1971, J BACTERIOL, V106, P709, DOI 10.1128/JB.106.2.709-711.1971; COOPER S, 1974, J THEOR BIOL, V46, P117, DOI 10.1016/0022-5193(74)90143-X; Cooper S, 1999, IUBMB LIFE, V48, P225, DOI 10.1080/152165499307279; Cooper S, 2001, J THEOR BIOL, V208, P399, DOI 10.1006/jtbi.2000.2228; Cooper S, 1997, Microb Comp Genomics, V2, P269, DOI 10.1089/omi.1.1997.2.269; Cooper S, 1998, EXP CELL RES, V238, P110, DOI 10.1006/excr.1997.3807; COOPER S, 1987, BIOESSAYS, V7, P220, DOI 10.1002/bies.950070507; Cooper S, 1998, FASEB J, V12, P367, DOI 10.1096/fasebj.12.3.367; COOPER S, 1988, J THEOR BIOL, V135, P393, DOI 10.1016/S0022-5193(88)80253-4; Cooper S, 2001, CELL MOL LIFE SCI, V58, P580, DOI 10.1007/PL00000883; Cooper S, 2000, Prog Cell Cycle Res, V4, P27; Cooper S, 1998, CELL PROLIFERAT, V31, P9, DOI 10.1046/j.1365-2184.1998.00110.x; Cooper S, 2000, ASM NEWS, V66, P71; COOPER S, 1981, CELL GROWTH DIFFER, P315; COOPER S, 1991, BACTERIAL GROWTH DIV; DIMATTEO G, 1995, CELL GROWTH DIFFER, V6, P1213; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KELLY K, 1984, CURR TOP MICROBIOL, V113, P117; Kim TY, 2001, MOL BIOL CELL, V12, P2207, DOI 10.1091/mbc.12.7.2207; LAJTHA LG, 1963, J CELL COMP PHYSL, V60, P143; LARK KG, 1969, J MOL BIOL, V42, P221, DOI 10.1016/0022-2836(69)90039-4; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Shedden K, 2002, P NATL ACAD SCI USA, V99, P4379, DOI 10.1073/pnas.062569899; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365	33	118	125	2	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					333	340		10.1096/fj.02-0352rev	http://dx.doi.org/10.1096/fj.02-0352rev			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12631573	Green Submitted			2022-12-28	WOS:000181892600032
J	Sun, L; Iqbal, J; Dolgilevich, S; Yuen, T; Wu, XB; Moonga, BS; Adebanjo, OA; Bevis, PJR; Lund, F; Huang, CLH; Blair, HC; Abe, E; Zaidi, M				Sun, L; Iqbal, J; Dolgilevich, S; Yuen, T; Wu, XB; Moonga, BS; Adebanjo, OA; Bevis, PJR; Lund, F; Huang, CLH; Blair, HC; Abe, E; Zaidi, M			Disordered osteoclast formation and function in a CD38 (ADP-ribosyl cyclase)-deficient mouse establishes an essential role for CD38 in bone resorption	FASEB JOURNAL			English	Article						Ca2+ channel; osteoclast; ryanodine receptor; bone resorption; osteoporosis	CYCLIC ADP-RIBOSE; PANCREATIC BETA-CELLS; CD38/ADP-RIBOSYL CYCLASE; INTRACELLULAR CALCIUM; INSULIN-SECRETION; EXTRACELLULAR CALCIUM; HUMAN ERYTHROCYTES; SIGNALING PATHWAY; RAT OSTEOCLASTS; OUTER SURFACE	We have evaluated the role of the ADP-ribosyl cyclase, CD38, in bone remodeling, a process by which the skeleton is being renewed constantly through the coordinated activity of osteoclasts and osteoblasts. CD38 catalyzes the cyclization of its substrate, NAD(+),to the Ca2+-releasing second messenger, cyclic ADP-ribose (cADPr). We have shown previously that CD38 is expressed both in osteoblasts and osteoclasts. Its activation in the osteoclast triggers Ca2+ release through ryanodine receptors (RyRs), stimulation of interleukin-6 (IL-6), and an inhibition of bone resorption. Here, we have examined the consequences of deleting the CD38 gene in mice on skeletal remodeling. We report that CD38(-/-) mice displayed a markedly reduced bone mineral density (BMD) at the femur, tibia, and lumbar spine at 3 months and at the lumbar spine at 4 months, with full normalization of the BMD at all sites at 5 months. The osteoporosis at 3 months was accompanied by a reduction in primary spongiosa and increased osteoclast surfaces on histomorphometric analysis. Hematopoetic stem cells isolated ex vivo from CD38(-/-) mice showed a dramatic similar tofourfold increase in osteoclast formation in response to incubation for 6 days with RANK-L and M-CSF. The osteoclasts so formed in these cultures showed a similar to2.5-fold increase in resorptive activity compared with wild-type cells. However, when adherent bone marrow stromal cells were allowed to mature into alkaline phosphatase-positive colony-forming units (CFU-Fs), those derived from CD38(-/-) mice showed a significant reduction in differentiation compared with wild-type cells. Real-time RTPCR on mRNA isolated from osteoclasts at day 6 showed a significant reduction in IL-6 and IL-6 receptor mRNA, together with significant decreases in the expression of all calcineurin A isoforms, alpha, beta, and gamma. These findings establish a critical role for CD38 in osteoclast formation and bone resorption. We speculate that CD38 functions as a cellular NAD(+) "sensor," particularly during periods of active motility and secretion.	Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY USA; Mt Sinai Sch Med, Dept Med & Geriatr, New York, NY USA; Vet Affairs Med Ctr, Div Endocrinol, New York, NY USA; Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, New York, NY USA; Trudeau Inst Inc, Lake Placid, NY USA; Univ Cambridge, Physiol Lab, Cambridge CB2 3EG, England; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Trudeau Institute; University of Cambridge; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zaidi, M (corresponding author), Mt Sinai Sch Med, Div Endocrinol, Box 1055,1 Gustave Levy Pl, New York, NY 10029 USA.	mone.zaidi@mssm.edu	Huang, Christopher LH/A-6248-2008	Zaidi, Mone/0000-0001-5911-9522	NIA NIH HHS [R01 AG14197-07] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abe E, 2000, J BONE MINER RES, V15, P663, DOI 10.1359/jbmr.2000.15.4.663; Adebanjo OA, 1998, J CELL BIOL, V142, P1347, DOI 10.1083/jcb.142.5.1347; Adebanjo OA, 2000, BIOCHEM BIOPH RES CO, V273, P884, DOI 10.1006/bbrc.2000.3041; Adebanjo OA, 1999, NAT CELL BIOL, V1, P409, DOI 10.1038/15640; Adebanjo OA, 2000, AM J PHYSIOL-RENAL, V278, pF784, DOI 10.1152/ajprenal.2000.278.5.F784; Adebanjo OA, 1996, AM J PHYSIOL-RENAL, V270, pF469, DOI 10.1152/ajprenal.1996.270.3.F469; Antonelli A, 2001, DIABETES, V50, P985, DOI 10.2337/diabetes.50.5.985; Cockayne DA, 1998, BLOOD, V92, P1324, DOI 10.1182/blood.V92.4.1324.416k26_1324_1333; De Flora Antonio, 1998, Cell Biochemistry and Biophysics, V28, P45; Deaglio S, 2001, FASEB J, V15, P580; DeFlora A, 1996, BIOCHEM J, V320, P665, DOI 10.1042/bj3200665; Fernandez JE, 1998, J BIOL REG HOMEOS AG, V12, P81; Ferrero E, 1999, IMMUNOGENETICS, V49, P597, DOI 10.1007/s002510050654; Franco L, 1998, FASEB J, V12, P1507; Fukushi Y, 2001, J BIOL CHEM, V276, P649, DOI 10.1074/jbc.M004469200; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; Kato I, 1999, J BIOL CHEM, V274, P1869, DOI 10.1074/jbc.274.4.1869; Khoo KM, 2000, J BIOL CHEM, V275, P24807, DOI 10.1074/jbc.M908231199; LEE CL, 2000, HUMAN CD38 RELATED M, P39; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1993, BIOCHEM BIOPH RES CO, V191, P639, DOI 10.1006/bbrc.1993.1265; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; MALGAROLI A, 1989, J BIOL CHEM, V264, P14342; Moonga BS, 2002, J ENDOCRINOL, V173, DOI 10.1677/joe.0.1730395; MOONGA BS, 1990, J PHYSIOL-LONDON, V429, P29, DOI 10.1113/jphysiol.1990.sp018242; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Podesta M, 2000, FASEB J, V14, P680, DOI 10.1096/fasebj.14.5.680; Romanello M, 2001, BIOCHEM BIOPH RES CO, V285, P1226, DOI 10.1006/bbrc.2001.5325; Shubinsky G, 1997, IMMUNITY, V7, P315, DOI 10.1016/S1074-7613(00)80353-2; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; Sun L, 1999, J CELL BIOL, V146, P1161, DOI 10.1083/jcb.146.5.1161; Sun L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0705com; SUN L, 2002, IN PRESS AM J PHYSL; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; Verderio C, 2001, J NEUROCHEM, V78, P646, DOI 10.1046/j.1471-4159.2001.00455.x; Zaidi M, 1999, J BONE MINER RES, V14, P669, DOI 10.1359/jbmr.1999.14.5.669; ZAIDI M, 1995, J CLIN INVEST, V96, P1582, DOI 10.1172/JCI118197; ZAIDI M, 1989, BIOCHEM BIOPH RES CO, V163, P1461, DOI 10.1016/0006-291X(89)91143-1; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416	42	53	55	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					369	375		10.1096/fj.02-0205com	http://dx.doi.org/10.1096/fj.02-0205com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12631576				2022-12-28	WOS:000181892600035
J	Tureci, O; Ding, JY; Hilton, H; Bian, HJ; Ohkawa, H; Braxenthaler, M; Seitz, G; Raddrizzani, L; Friess, H; Buchler, M; Sahin, U; Hammer, J				Tureci, O; Ding, JY; Hilton, H; Bian, HJ; Ohkawa, H; Braxenthaler, M; Seitz, G; Raddrizzani, L; Friess, H; Buchler, M; Sahin, U; Hammer, J			Computational dissection of tissue contamination for identification of colon cancer-specific expression profiles	FASEB JOURNAL			English	Article						expression signature; colorectal cancer; profile	GENE-EXPRESSION; MESSENGER-RNA; MATRIX METALLOPROTEINASE-1; EPITHELIAL-CELLS; MARKER; DIFFERENTIATION; ADENOMAS; PATTERNS; PROTEIN; TARGET	Microarray profiles of bulk tumor tissues reflect gene expression corresponding to malignant cells as well as to many different types of contaminating normal cells. In this report, we assess the feasibility of querying baseline multitissue transcriptome databases to dissect disease-specific genes. Using colon cancer as a model tumor, we show that the application of Boolean operators (AND, OR, BUTNOT) for database searches leads to genes with expression patterns of interest. The BUTNOT operator for example allows the assignment of "expression signatures" to normal tissue specimens. These expression signatures were then used to computationally identify contaminating cells within conventionally dissected tissue specimens. The combination of several logic operators together with an expression database based on multiple human tissue specimens can resolve the problem of tissue contamination, revealing novel cancer-specific gene expression. Several markers, previously not known to be colon cancer associated, are provided.	Johannes Gutenberg Univ Mainz, Med Klin 3, Med Klin & Poliklin 3, D-55131 Mainz, Germany; Hoffmann La Roche Inc, Roche Genom & Informat Sci, Nutley, NJ 07110 USA; Klinikum Bamberg, Inst Pathol, D-96049 Bamberg, Germany; Heidelberg Univ, Dept Surg, D-69120 Heidelberg, Germany	Johannes Gutenberg University of Mainz; Roche Holding; Ruprecht Karls University Heidelberg	Tureci, O (corresponding author), Johannes Gutenberg Univ Mainz, Med Klin 3, Med Klin & Poliklin 3, Obere Zahlbacher Str 63, D-55131 Mainz, Germany.	Tureci@mail.uni-mainz.de	Sahin, Ugur/L-4818-2017	Sahin, Ugur/0000-0003-0363-1564				Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Bekku S, 1998, RES EXP MED, V198, P175, DOI 10.1007/s004330050101; Boller K, 1997, J VIROL, V71, P4581, DOI 10.1128/JVI.71.6.4581-4588.1997; BROITMAN SA, 1993, PROG FOOD NUTR SCI, V17, P1; Cohen MB, 1998, LAB INVEST, V78, P101; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Fleming RE, 1995, J CLIN INVEST, V96, P2907, DOI 10.1172/JCI118362; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hanamura N, 1997, INT J CANCER, V73, P10, DOI 10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO;2-4; Hanski C, 1997, LAB INVEST, V77, P685; Herrero J, 2001, BIOINFORMATICS, V17, P126, DOI 10.1093/bioinformatics/17.2.126; Khan J, 1998, CANCER RES, V58, P5009; Kinugasa T, 1998, INT J CANCER, V76, P148, DOI 10.1002/(SICI)1097-0215(19980330)76:1<148::AID-IJC23>3.3.CO;2-J; Liu XL, 1996, CANCER RES, V56, P3371; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Melis R, 1999, ELECTROPHORESIS, V20, P1055, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<1055::AID-ELPS1055>3.0.CO;2-O; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; MULDER TPJ, 1990, FREE RADICAL BIO MED, V9, P501, DOI 10.1016/0891-5849(90)90128-6; Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461; Notterman DA, 2001, CANCER RES, V61, P3124; Rechreche H, 1997, EUR J BIOCHEM, V248, P225, DOI 10.1111/j.1432-1033.1997.00225.x; RETTIG WJ, 1994, INT J CANCER, V58, P385, DOI 10.1002/ijc.2910580314; Riethmuller G, 1998, J CLIN ONCOL, V16, P1788, DOI 10.1200/JCO.1998.16.5.1788; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHWEINFEST CW, 1993, P NATL ACAD SCI USA, V90, P4166, DOI 10.1073/pnas.90.9.4166; Shankavaram UT, 1997, J CELL PHYSIOL, V173, P327, DOI 10.1002/(SICI)1097-4652(199712)173:3<327::AID-JCP4>3.3.CO;2-R; Shiozawa J, 2000, MODERN PATHOL, V13, P925, DOI 10.1038/modpathol.3880169; St Croix B, 2000, SCIENCE, V289, P1197; Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555, DOI 10.1038/9858; Takahashi KI, 1998, ANTICANCER RES, V18, P3381; Tschmelitsch J, 1997, CANCER RES, V57, P2181; Wellmann A, 2000, BLOOD, V96, P398; WELT S, 1994, J CLIN ONCOL, V12, P1193, DOI 10.1200/JCO.1994.12.6.1193; Werner T, 2001, PHARMACOGENOMICS, V2, P25, DOI 10.1517/14622416.2.1.25; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962; Zutter MM, 1998, JNCI-J NATL CANCER I, V90, P642, DOI 10.1093/jnci/90.9.642	37	35	37	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					376	385		10.1096/fj.02-0478com	http://dx.doi.org/10.1096/fj.02-0478com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12631577				2022-12-28	WOS:000181892600036
J	Teixeira, CE; Ifa, DR; Corso, G; Santagada, V; Caliendo, G; Antunes, E; De Nucci, G				Teixeira, CE; Ifa, DR; Corso, G; Santagada, V; Caliendo, G; Antunes, E; De Nucci, G			Sequence and structure-activity relationship of a scorpion venom toxin with nitrergic activity in rabbit corpus cavernosum	FASEB JOURNAL			English	Article						nitric oxide; Tityus serrulatus; sodium channels; erectile tissue	AMINO-ACID-SEQUENCE; TITYUS-SERRULATUS; ERECTILE DYSFUNCTION; SODIUM-CHANNELS; NITRIC-OXIDE; RELAXATION; THIONINS; PEPTIDES; KARSCH	An alpha-toxin responsible for nitric oxide (NO) release in rabbit corpus cavernosum (RbCC) was isolated from Tityus serrulatus venom (TSV). The isolated peptide (molecular mass of 7427.66+/-0.15 Da) was identified as Ts3 after determination of Cys residues, N-terminal amino acid analysis, and proteolytic peptide mapping. Ts3 (30 nM) markedly relaxed the RbCC; this response was blocked by the NO synthesis inhibitor N-omega-nitro-L-arginine methyl ester (100 muM) and the Na+ channel blocker tetrodotoxin (100 nM). Synthetic peptides based on either Ts3 (P1-16, P17-32, P33-48, P49-64, P9-24, P25-40, P41-56, YGLPDKVPTKT) or Bukatoxin (isolated from Buthus martensi Karsch scorpion venom) sequence (Buka11, Buka11-B, PDKVP, PDSEP) were assayed. These peptides slightly relaxed the RbCC, and such an effect was independent of Na+ channel activation or NO release. Our results indicate that Ts3 exerts nitrergic actions and contributes to the relaxing activity of TSV in RbCC, thus providing a valuable tool to investigate the mechanisms underlying nerve activation in erectile tissues, because NO released from nitrergic fibers plays a key role in the erectile process. Our findings revealed the key importance of the Ts3 structure three-dimensional conformation maintenance for biological activity, because linear peptide sequences neither presented substantial relaxations nor was this effect related to nitrergic activity.	Univ Estadual Campinas, Fac Med Sci, Dept Pharmacol, BR-13081970 Campinas, SP, Brazil; Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, BR-05508900 Sao Paulo, Brazil; Univ Naples Federico II, Dept Toxicol & Pharmaceut Chem, Naples, Italy	Universidade Estadual de Campinas; Universidade de Sao Paulo; University of Naples Federico II	Teixeira, CE (corresponding author), Univ Estadual Campinas, Fac Med Sci, Dept Pharmacol, POB 6111, BR-13081970 Campinas, SP, Brazil.	cleber.teixeira@directnet.com.br	Corso, Gaetano/H-9450-2013; ANTUNES, EDSON/F-6731-2012; Ifa, Demian/D-3978-2012; De Nucci, Gilberto/ABB-7380-2021; De Nucci, Gilberto/J-5990-2012	Corso, Gaetano/0000-0003-4720-1320; ANTUNES, EDSON/0000-0003-2201-8247; De Nucci, Gilberto/0000-0002-4346-7941; De Nucci, Gilberto/0000-0002-4346-7941; Caliendo, Giuseppe/0000-0002-5098-6045				AMITAI Y, 1985, CLIN PEDIATR, V24, P136, DOI 10.1177/000992288502400303; Andersson KE, 2001, PHARMACOL REV, V53, P417; BAWASKAR HS, 1982, LANCET, V1, P552; Bivalacque TJ, 2000, TRENDS PHARMACOL SCI, V21, P484, DOI 10.1016/S0165-6147(00)01587-X; Corona M, 1996, TOXICON, V34, P251, DOI 10.1016/0041-0101(95)00129-8; COURAUD F, 1984, HDB NATURAL TOXINS, V2, P659; FREIREMAIA L, 1995, J TOXICOL-TOXIN REV, V14, P423, DOI 10.3109/15569549509019472; FURCHGOTT R F, 1988, P401; Gordon D, 1998, J TOXICOL-TOXIN REV, V17, P131, DOI 10.3109/15569549809009247; HERSHKOVICH Y, 1985, TOXICON, V23, P845, DOI 10.1016/0041-0101(85)90015-7; IGNARRO LJ, 1990, BIOCHEM BIOPH RES CO, V170, P843, DOI 10.1016/0006-291X(90)92168-Y; ISMAIL M, 1995, TOXICON, V33, P825, DOI 10.1016/0041-0101(95)00005-7; JOVER E, 1980, BIOCHEM BIOPH RES CO, V95, P1607, DOI 10.1016/S0006-291X(80)80082-9; KIRSCH GE, 1989, J GEN PHYSIOL, V93, P67, DOI 10.1085/jgp.93.1.67; LEBRETON F, 1994, BIOCHEMISTRY-US, V33, P11135, DOI 10.1021/bi00203a010; Lue TF, 2000, NEW ENGL J MED, V342, P1802, DOI 10.1056/NEJM200006153422407; Martin-Eauclaire M. F., 1995, Handbook of neurotoxicology., P683; MARTINEAUCLAIRE MF, 1994, FEBS LETT, V342, P181, DOI 10.1016/0014-5793(94)80496-6; NITTI G, 1995, EUR J BIOCHEM, V228, P250, DOI 10.1111/j.1432-1033.1995.tb20257.x; Oren DA, 1998, STRUCTURE, V6, P1095, DOI 10.1016/S0969-2126(98)00111-7; Orru S, 1997, BIOL CHEM, V378, P989; POSSANI LD, 1982, TOXICON, V20, P75; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; POSSANI LD, 1991, J BIOL CHEM, V266, P3178; Possani LD, 2000, BIOCHIMIE, V82, P861, DOI 10.1016/S0300-9084(00)01167-6; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; Simard J.M., 1990, P414; Srinivasan KN, 2001, FEBS LETT, V494, P145, DOI 10.1016/S0014-5793(01)02342-0; Teixeira CE, 2001, UROLOGY, V57, P816, DOI 10.1016/S0090-4295(00)01047-5; Teixeira CE, 1998, BRIT J PHARMACOL, V123, P435, DOI 10.1038/sj.bjp.0701623; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X; WHEELER KP, 1983, PFLUG ARCH EUR J PHY, V397, P164, DOI 10.1007/BF00582058	32	18	21	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					485	+		10.1096/fj.02-0635fje	http://dx.doi.org/10.1096/fj.02-0635fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551849				2022-12-28	WOS:000181453700006
J	Himly, M; Jahn-Schmid, B; Dedic, A; Kelemen, P; Wopfner, N; Altmann, F; van Ree, R; Briza, P; Richter, K; Ebner, C; Ferreira, F				Himly, M; Jahn-Schmid, B; Dedic, A; Kelemen, P; Wopfner, N; Altmann, F; van Ree, R; Briza, P; Richter, K; Ebner, C; Ferreira, F			Art v 1, the major allergen of mugwort pollen, is a modular glycoprotein with a defensin-like and a hydroxyproline-rich domain	FASEB JOURNAL			English	Article						IgE; type I allergy; O-glycan; epitope; T cell	3-DIMENSIONAL SOLUTION STRUCTURE; PLANT DEFENSINS; RECOMBINANT ALLERGENS; STRUCTURAL MOTIF; IGE; PROTEINS; IDENTIFICATION; EXPRESSION; DIAGNOSIS; PEPTIDES	In late summer, pollen grains originating from Compositae weeds (e.g., mugwort, ragweed) are a major source of allergens worldwide. Here, we report the isolation of a cDNA clone coding for Art v 1, the major allergen of mugwort pollen. Sequence analysis showed that Art v 1 is a secreted allergen with an N-terminal cysteine-rich domain homologous to plant defensins and a C-terminal proline-rich region containing several (Ser/Ala)(Pro)(2-4) repeats. Structural analysis showed that some of the proline residues in the C-terminal domain of Art v 1 are posttranslationally modified by hydroxylation and O-glycosylation. The O-glycans are composed of 3 galactoses and 9-16 arabinoses linked to a hydroxyproline and represent a new type of plant O-glycan. A 3-D structural model of Art v 1 was generated showing a characteristic "head and tail" structure. Evaluation of the antibody binding properties of natural and recombinant Art v 1 produced in Escherichia coli revealed the involvement of the defensin fold and posttranslational modifications in the formation of epitopes recognized by IgE antibodies from allergic patients. However, posttranslational modifications did not influence T-cell recognition. Thus, recombinant nonglycosylated Art v 1 is a good starting template for engineering hypoallergenic vaccines for weed-pollen therapy.	Salzburg Univ, Inst Genet & Gen Biol, A-5020 Salzburg, Austria; Univ Vienna, Inst Pathophysiol, A-1090 Vienna, Austria; Univ Agr Vienna, Inst Chem, A-1190 Vienna, Austria; Sanquin Res CLB, Dept Immunopathol, NL-1066 CX Amsterdam, Netherlands	Salzburg University; University of Vienna; University of Natural Resources & Life Sciences, Vienna	Ferreira, F (corresponding author), Salzburg Univ, Inst F Genet U Allg Biol, Hellbrunnerstr 34, A-5020 Salzburg, Austria.	fatima.ferreira@mh.sbg.ac.at	Ferreira, Fatima/E-4889-2011; Briza, Peter/D-7309-2012; Ferreira, Fatima/AAB-4321-2019; Himly, Martin/D-1568-2015	Ferreira, Fatima/0000-0003-0989-2335; Briza, Peter/0000-0002-4941-6782; Ferreira, Fatima/0000-0003-0989-2335; Altmann, Friedrich/0000-0002-0112-7877; Himly, Martin/0000-0001-5416-085X				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Akdis CA, 1998, EUR J IMMUNOL, V28, P914, DOI 10.1002/(SICI)1521-4141(199803)28:03<914::AID-IMMU914>3.0.CO;2-C; ALLEN AK, 1978, BIOCHEM J, V171, P665, DOI 10.1042/bj1710665; Almeida MS, 2002, J MOL BIOL, V315, P749, DOI 10.1006/jmbi.2001.5252; ALTMANN F, 1991, INSECT BIOCHEM, V21, P467, DOI 10.1016/0020-1790(91)90099-Z; Altmann F, 2000, J GEN VIROL, V81, P1111, DOI 10.1099/0022-1317-81-4-1111; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bacic A, 1996, Essays Biochem, V31, P91; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI 10.1016/j.chiabu.2021.105188; BRUIX M, 1993, BIOCHEMISTRY-US, V32, P715, DOI 10.1021/bi00053a041; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409, DOI 10.1067/mai.2000.109832; Charpin J., 1974, ATLAS EUROPEAN ALLER; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; DELAHOZ F, 1990, MOL IMMUNOL, V27, P651, DOI 10.1016/0161-5890(90)90008-N; Diaz-Perales A, 2000, CLIN EXP ALLERGY, V30, P1403, DOI 10.1046/j.1365-2222.2000.00909.x; DOMON C, 1990, PLANT MOL BIOL, V15, P643, DOI 10.1007/BF00017838; EBNER C, 1995, INT ARCH ALLERGY IMM, V107, P183, DOI 10.1159/000236971; Fant F, 1999, PROTEINS, V37, P388, DOI 10.1002/(SICI)1097-0134(19991115)37:3<388::AID-PROT7>3.0.CO;2-F; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; FLOCKNER H, 1995, PROTEINS, V23, P376, DOI 10.1002/prot.340230311; FU DT, 1995, ANAL BIOCHEM, V227, P377, DOI 10.1006/abio.1995.1294; Gao AG, 2000, NAT BIOTECHNOL, V18, P1307, DOI 10.1038/82436; Gupta N, 1996, J ALLERGY CLIN IMMUN, V98, P903, DOI 10.1016/S0091-6749(96)80006-6; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Hanfrey C, 1996, PLANT MOL BIOL, V30, P597, DOI 10.1007/BF00049334; Hirschwehr R, 1998, J ALLERGY CLIN IMMUN, V101, P196, DOI 10.1016/S0091-6749(98)70384-7; KIELISZEWSKI MJ, 1994, PLANT J, V5, P157, DOI 10.1046/j.1365-313X.1994.05020157.x; KING TP, 1995, ALLERGY, V50, P765, DOI 10.1111/j.1398-9995.1995.tb01222.x; KOBAYASHI Y, 1991, BIOPOLYMERS, V31, P1213, DOI 10.1002/bip.360311009; Kolarich D, 2000, ANAL BIOCHEM, V285, P64, DOI 10.1006/abio.2000.4737; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kraft D, 1999, INT ARCH ALLERGY IMM, V118, P171, DOI 10.1159/000024058; KREZEL AM, 1995, PROTEIN SCI, V4, P1478, DOI 10.1002/pro.5560040805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPORT DTA, 1969, BIOCHEMISTRY-US, V8, P1155, DOI 10.1021/bi00831a049; Li HM, 1996, J MOL BIOL, V261, P415, DOI 10.1006/jmbi.1996.0473; MAURER D, 1995, J IMMUNOL, V154, P6285; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NILSEN BM, 1991, J BIOL CHEM, V266, P2660; NILSEN BM, 1990, MOL IMMUNOL, V27, P1047, DOI 10.1016/0161-5890(90)90128-M; OSBORN RW, 1995, FEBS LETT, V368, P257, DOI 10.1016/0014-5793(95)00666-W; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schuurman J, 1997, J ALLERGY CLIN IMMUN, V99, P545, DOI 10.1016/S0091-6749(97)70083-6; SPIEKSMA FTM, 1980, CLIN ALLERGY, V10, P319, DOI 10.1111/j.1365-2222.1980.tb02114.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287, DOI 10.1159/000236135; Valenta R, 2002, CL ALLER IM, V16, P495; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; WINZLER R J, 1955, Methods Biochem Anal, V2, P279, DOI 10.1002/9780470110188.ch10	55	110	124	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					106	+		10.1096/fj.02-0472fje	http://dx.doi.org/10.1096/fj.02-0472fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475905				2022-12-28	WOS:000180218500023
J	Hoeflich, A; Weber, MM; Fisch, T; Nedbal, S; Fottner, C; Elmlinger, MW; Wanke, D; Wolf, E				Hoeflich, A; Weber, MM; Fisch, T; Nedbal, S; Fottner, C; Elmlinger, MW; Wanke, D; Wolf, E			Insulin-like growth factor binding protein 2 (IGFBP-2) separates hypertrophic and hyperplastic effects of growth hormone (GH)/IGF-I excess on adrenocortical cells in vivo	FASEB JOURNAL			English	Article						adrenal gland; hypertrophy; hyperplasia; growth hormone; IGF binding protein 2; transgenic mouse; corticosterone	I IGF-I; MESSENGER-RIBONUCLEIC-ACID; BOVINE ADRENAL-CELLS; TRANSGENIC MICE; CORTICOSTERONE LEVELS; RECEPTOR-BINDING; ANGIOTENSIN-II; SIZE CONTROL; BODY-WEIGHT; OVEREXPRESSION	GH and IGF-I are capable of inducing cellular hypertrophy and/or hyperplasia. Chronic overexpression of GH in transgenic mice results in systemically and locally increased IGF-I levels and in disproportionate overgrowth, including adrenocortical enlargement and corticosterone hypersecretion. Using PEPCK-bovine GH transgenic (G) mice, we demonstrate that adrenal enlargement involves both hypertrophy (44%) and hyperplasia (50%) of zona fasciculata cells. To clarify whether IGFBP-2 affected cell volume and number, we crossed hemizygous G mice with hemizygous CMV-IGFBP-2 transgenic (B) mice, generating G mice, B mice, GB double transgenic mice, and nontransgenic controls (C). The absolute weight of the adrenal glands was significantly increased in 5-wk- and 4-month-old G mice vs. C and B mice. IGFBP-2 overexpression in GB mice reduced this effect of GH excess by 26% and 37% in 5-wk- and 4-month-old animals, respectively. GH-induced hypertrophy of zona fasciculata cells was completely abolished by IGFBP-2 overexpression in GB mice whereas hyperplasia was not affected. Basal and ACTH-induced plasma corticosterone levels of 4-month-old G mice, but not of GB mice, were two- to threefold increased compared with C mice. Plasma ACTH levels were similar in all groups. Our data show that IGFBP-2 potently separates hypertrophic and hyperplastic effects of GH/IGF-I excess on adrenocortical cells.	Univ Munich, Inst Mol Anim Breeding, Gene Ctr, D-81377 Munich, Germany; Univ Munich, Inst Vet Pathol, D-81377 Munich, Germany; Univ Cologne, Med Dept Koln Merheim 2, Lab Endocrine Res, D-5000 Cologne, Germany; Univ Tubingen, Childrens Hosp, Lab Endocrine Res, Tubingen, Germany	University of Munich; University of Munich; University of Cologne; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL	Wolf, E (corresponding author), Univ Munich, Inst Mol Anim Breeding, Gene Ctr, Feodoe Kynen Str 25, D-81377 Munich, Germany.	ewolf@lmb.uni-muenchen.de		Wolf, Eckhard/0000-0002-0430-9510; Wanke, Rudiger/0000-0002-0153-224X; Hoeflich, Andreas/0000-0003-2018-2836				Balducci R, 1998, HORM RES, V49, P210, DOI 10.1159/000023173; Boulle N, 1998, J CLIN ENDOCR METAB, V83, P1713, DOI 10.1210/jc.83.5.1713; Boulle N, 2001, EUR J ENDOCRINOL, V144, P29, DOI 10.1530/eje.0.1440029; CECIM M, 1991, NEUROENDOCRINOLOGY, V53, P313, DOI 10.1159/000125734; Cecim M, 1996, TRANSGENIC RES, V5, P187, DOI 10.1007/BF01969708; Colao A, 2000, J CLIN ENDOCR METAB, V85, P3754, DOI 10.1210/jc.85.10.3754; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; CONLON MA, 1995, J ENDOCRINOL, V146, P247, DOI 10.1677/joe.0.1460247; Coulter CL, 1996, ENDOCRINOLOGY, V137, P4487, DOI 10.1210/en.137.10.4487; DEACON CF, 1986, GEN COMP ENDOCR, V61, P87, DOI 10.1016/0016-6480(86)90253-4; DERCOLE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P935, DOI 10.1073/pnas.81.3.935; DUNN TB, 1970, JNCI-J NATL CANCER I, V44, P1323; ERHARD MH, 1994, J IMMUNOASSAY, V15, P1, DOI 10.1080/15321819408009568; Fottner C, 2001, J ENDOCRINOL, V168, P465, DOI 10.1677/joe.0.1680465; Fottner C, 1998, J ENDOCRINOL, V158, P409, DOI 10.1677/joe.0.1580409; Fottner C, 1999, HORM METAB RES, V31, P203, DOI 10.1055/s-2007-978720; FRITH CH, 1983, MONOGRAPHS PATHOLOGY, P8; Gooch JL, 2001, J BIOL CHEM, V276, P42492, DOI 10.1074/jbc.M102994200; HAN VKM, 1992, ENDOCRINOLOGY, V131, P3100, DOI 10.1210/en.131.6.3100; HENKEL HM, 1995, THESIS U MUNICH; Hoeflich A, 2001, ENDOCRINOLOGY, V142, P1889, DOI 10.1210/en.142.5.1889; Hoeflich A, 1999, ENDOCRINOLOGY, V140, P5488, DOI 10.1210/en.140.12.5488; Hoeflich A, 1998, GROWTH HORM IGF RES, V8, P113, DOI 10.1016/S1096-6374(98)80101-9; Hoeflich A, 2000, CANCER RES, V60, P834; Hoeflich A, 2001, CANCER RES, V61, P8601; Hoflich A, 1998, FEBS LETT, V434, P329, DOI 10.1016/S0014-5793(98)01011-4; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; ILVESMAKI V, 1993, MOL CELL ENDOCRINOL, V97, P71, DOI 10.1016/0303-7207(93)90212-3; Khosravi J, 2001, J CLIN ENDOCR METAB, V86, P694, DOI 10.1210/jc.86.2.694; l'Allemand D, 1998, MOL CELL ENDOCRINOL, V140, P169, DOI 10.1016/S0303-7207(98)00046-X; LAllemand D, 1996, J CLIN ENDOCR METAB, V81, P3892, DOI 10.1210/jc.81.11.3892; Le Roy C, 2000, ENDOCRINOLOGY, V141, P1599, DOI 10.1210/en.141.5.1599; LEWINSKI A, 1986, EXP CLIN ENDOCRINOL, V87, P176, DOI 10.1055/s-0029-1210540; Logie A, 2000, ENDOCRINOLOGY, V141, P3165, DOI 10.1210/en.141.9.3165; MARCUSSEN N, 1992, J MICROSC-OXFORD, V165, P417, DOI 10.1111/j.1365-2818.1992.tb01496.x; MCGRANE MM, 1988, J BIOL CHEM, V263, P11443; MESIANO S, 1993, J CLIN ENDOCR METAB, V76, P968, DOI 10.1210/jc.76.4.968; Mesiano S, 1997, J CLIN ENDOCR METAB, V82, P1390, DOI 10.1210/jc.82.5.1390; Michl P, 1999, ENDOCR RES, V25, P281, DOI 10.1080/07435809909066148; MURPHY LJ, 1987, ENDOCRINOLOGY, V121, P684, DOI 10.1210/endo-121-2-684; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Ng ST, 1997, NAT MED, V3, P1141, DOI 10.1038/nm1097-1141; OTTENWELLER JE, 1979, ACTA ENDOCRINOL-COP, V91, P150, DOI 10.1530/acta.0.0910150; PENHOAT A, 1991, J MOL ENDOCRINOL, V7, P223, DOI 10.1677/jme.0.0070223; Potter CJ, 2001, CURR OPIN GENET DEV, V11, P279, DOI 10.1016/S0959-437X(00)00191-X; Prelle K, 2001, ENDOCRINOLOGY, V142, P1309, DOI 10.1210/en.142.3.1309; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; SLOOTWEG MC, 1995, ENDOCRINOLOGY, V136, P4210, DOI 10.1210/en.136.10.4210; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Swinyard CA, 1939, ANAT REC, V74, P71, DOI 10.1002/ar.1090740108; WANKE R, 1992, HORM RES, V37, P74, DOI 10.1159/000182406; Weber MM, 1997, EUR J ENDOCRINOL, V136, P296, DOI 10.1530/eje.0.1360296; Weber MM, 1999, ENDOCRINOLOGY, V140, P1537, DOI 10.1210/en.140.4.1537; WEBER MM, 1994, EUR J ENDOCRINOL, V130, P265, DOI 10.1530/eje.0.1300265; WEBER MM, 1995, ENDOCRINOLOGY, V136, P3714, DOI 10.1210/en.136.9.3714; WEIDENFELD J, 1993, NEUROENDOCRINOLOGY, V58, P49, DOI 10.1159/000126511; WOLF E, 1993, MECH AGEING DEV, V68, P71, DOI 10.1016/0047-6374(93)90141-D; Wolf E, 1997, ENDOCRINOLOGY, V138, P307, DOI 10.1210/en.138.1.307; Wolf E, 2000, PEDIATR NEPHROL, V14, P572, DOI 10.1007/s004670000362	61	43	43	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2002	16	13					1721	1731		10.1096/fj.02-0349com	http://dx.doi.org/10.1096/fj.02-0349com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12409314				2022-12-28	WOS:000180218500004
J	Iljin, K; Petrova, TV; Veikkola, T; Kumar, V; Poutanen, M; Alitalo, K				Iljin, K; Petrova, TV; Veikkola, T; Kumar, V; Poutanen, M; Alitalo, K			A fluorescent Tie1 reporter allows monitoring of vascular development and endothelial cell isolation from transgenic mouse embryos	FASEB JOURNAL			English	Article						receptor tyrosine kinase; promoter; angiogenesis	RECEPTOR TYROSINE KINASE; GROWTH-FACTOR RECEPTOR-3; ENHANCED EXPRESSION; GENE-EXPRESSION; PROTEIN; MICE; LYMPHANGIOGENESIS; SUFFICIENT; INTEGRITY; SURVIVAL	Tie1 is an endothelial receptor tyrosine kinase essential for development and maintenance of the vascular system. Here we report generation of transgenic mice expressing enhanced green fluorescent protein (EGFP) or a chimeric protein consisting of a Zeosin resistance marker and EGFP under the control of mouse Tie1 promoter. Intravital monitoring of fluorescence showed that the EGFP reporter recapitulates the Tie1 expression pattern in the developing vasculature, and flow cytometry using EGFP allowed the isolation of essentially pure Tie1-expressing endothelial cells from transgenic mouse embryos. However, EGFP and LacZ transgenic markers were strongly down-regulated in the adult vasculature; unlike the Tie1-LacZ knock-in locus, the promoter was not reactivated during tumor neovascularization, indicating the presence of additional regulatory elements in the Tie1 locus. Starting at midgestation, Tie1 promoter activity became stronger in the arterial than in the venous endothelium; in adult mice, promoter activity was observed in arterioles, capillaries, and lymphatic vessels, indicating a significant degree of specificity in different types of endothelial cells. Our results establish Tie1-Z/EGFP transgenic mice as a useful model to study embryonic vascular development and a convenient source for the isolation of primary endothelial cells.	Univ Helsinki, Mol Canc Biol Lab, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; Biomedicum Helsinki, Ludwig Inst Canc Res, FIN-00014 Helsinki, Finland; Univ Turku, Inst Biomed, Dept Physiol, FIN-20520 Turku, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Ludwig Institute for Cancer Research; University of Turku	Alitalo, K (corresponding author), Univ Helsinki, Mol Canc Biol Lab, Haartman Inst, POB 63 Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	Kari.Alitalo@Helsinki.Fi	Alitalo, Kari K/J-5013-2014; Poutanen, Matti/I-1700-2018	Alitalo, Kari K/0000-0002-7331-0902; Poutanen, Matti/0000-0002-8953-1734; Iljin, Kristiina/0000-0002-5161-0584				Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Brown LF, 2000, AM J PATHOL, V156, P2179, DOI 10.1016/S0002-9440(10)65088-2; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599; Felts K, 2000, STRATEGIES NEWSLETTE, V13, P85; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GALE NW, 2002, IN PRESS ANGIOPOIETI; Gubin AN, 1997, BIOCHEM BIOPH RES CO, V236, P347, DOI 10.1006/bbrc.1997.6963; Hanazono Y, 1997, HUM GENE THER, V8, P1313, DOI 10.1089/hum.1997.8.11-1313; Hatva E, 1996, AM J PATHOL, V148, P763; HATVA E, 1995, AM J PATHOL, V146, P368; Hatva E, 1996, J NEUROPATH EXP NEUR, V55, P1124, DOI 10.1097/00005072-199611000-00003; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; KAIPAINEN A, 1994, CANCER RES, V54, P6571; Kappel A, 1999, BLOOD, V93, P4284, DOI 10.1182/blood.V93.12.4284.412k25_4284_4292; KORHONEN J, 1994, ONCOGENE, V9, P395; KORHONEN J, 1992, BLOOD, V80, P2548; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; Kubo H, 2000, BLOOD, V96, P546; Lin WC, 1999, CLIN CANCER RES, V5, P1745; Liu HS, 1999, BIOCHEM BIOPH RES CO, V260, P712, DOI 10.1006/bbrc.1999.0954; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Marelli-Berg FM, 2000, J IMMUNOL METHODS, V244, P205, DOI 10.1016/S0022-1759(00)00258-1; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Marron MB, 2000, J BIOL CHEM, V275, P39741, DOI 10.1074/jbc.M007189200; McCarthy MJ, 1999, LAB INVEST, V79, P889; Motoike T, 2000, GENESIS, V28, P75, DOI 10.1002/1526-968X(200010)28:2<75::AID-GENE50>3.0.CO;2-S; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Partanen J, 1996, DEVELOPMENT, V122, P3013; Puri MC, 1999, DEVELOPMENT, V126, P4569; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Salven P, 1996, BRIT J CANCER, V74, P69, DOI 10.1038/bjc.1996.317; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Urness LD, 2000, NAT GENET, V26, P328, DOI 10.1038/81634; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WILLIAMS RL, 1988, CELL, V52, P121; Yabkowitz R, 1999, BLOOD, V93, P1969, DOI 10.1182/blood.V93.6.1969.406k14_1969_1979; Yabkowitz R, 1997, BLOOD, V90, P706, DOI 10.1182/blood.V90.2.706.706_706_715; Zhuo L, 1997, DEV BIOL, V187, P36, DOI 10.1006/dbio.1997.8601	49	42	42	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					1764	1774		10.1096/fj.01-1043com	http://dx.doi.org/10.1096/fj.01-1043com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12409319				2022-12-28	WOS:000180218500009
J	Kreuzer, J; Viedt, C; Brandes, RP; Seeger, F; Rosenkranz, AS; Sauer, H; Babich, A; Nurnberg, B; Kather, H; Krieger-Brauer, HI				Kreuzer, J; Viedt, C; Brandes, RP; Seeger, F; Rosenkranz, AS; Sauer, H; Babich, A; Nurnberg, B; Kather, H; Krieger-Brauer, HI			Platelet-derived growth factor activates production of reactive oxygen species by NAD(P)H-oxidase in smooth muscle cells through Gi1,2	FASEB JOURNAL			English	Article						G proteins; p22phox; PDGF alpha receptor; tyrosine kinase	DEPENDENT H2O2 GENERATION; BETA-GAMMA-SUBUNITS; PROTEIN-KINASE; PERTUSSIS-TOXIN; ANGIOTENSIN-II; NADPH OXIDASE; G(BETA-GAMMA) SUBUNITS; SIGNALING PATHWAYS; CRITICAL COMPONENT; INSULIN-RECEPTOR	Recent findings indicate that platelet-derived growth factor (PDGF) plays a role in the generation of reactive oxygen species (ROS) as second messengers in smooth muscle cells (SMC). To identify the source and signal transduction pathway of ROS formation in SMC, we investigated PDGF-induced ROS formation. Stimulation of SMC with PDGF resulted in a rapid increase of ROS production. Using an inactivating antibody, we identified the increase to be dependent on p22phox, a NAD(P)H-oxidase subunit. ROS release was completely inhibited by the Gi protein inhibitor PTX as well as an antibody against Galphai1,2, however, not by antibodies against Galphai3/0, Galphas, and Gbeta1beta2. The effect of PDGF on ROS production in SMC membranes could likewise be mimicked by the use of a recombinant Galphai2 subunit but not by Galphai3, Galphai0, Galphas, and Gbetagamma subunits. Immunoaffinity chromatography demonstrated coupling of Galphai1,2 to the PDGF alpha-receptor, which, after preincubation of the SMC membranes with PDGF, was increased in the absence of GTPgammaS but decreased in the presence of GTPgammaS and prevented by PTX tretament. These data define a novel G protein-dependent mechanism by which PDGF signaling is transduced through direct coupling of the Galphai1,2 subunit of the trimeric G proteins to the PDGF tyrosine kinase receptor.	Heidelberg Univ, D-69115 Heidelberg, Germany; Goethe Univ Frankfurt, Inst Kardiovask Physiol, D-6000 Frankfurt, Germany; Free Univ Berlin, Inst Pharmakol, D-1000 Berlin, Germany; Univ Cologne, Innere Med Klin 3, D-5000 Cologne 41, Germany; Univ Cologne, Inst Neurophysiol, D-5000 Cologne 41, Germany; Univ Dusseldorf, Inst Physiol Chem 2, D-4000 Dusseldorf, Germany	Ruprecht Karls University Heidelberg; Free University of Berlin; University of Cologne; University of Cologne; Heinrich Heine University Dusseldorf	Krieger-Brauer, HI (corresponding author), Heidelberg Univ, Bergheimer Str 58, D-69115 Heidelberg, Germany.	joerg_kreuzer@med.uni-heidelberg.de	Brandes, Ralf P/L-3058-2017	Brandes, Ralf P/0000-0002-8035-0048; Nurnberg, Bernd/0000-0002-5995-6555				Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BASS DA, 1983, J IMMUNOL, V130, P1910; Brar SS, 1999, J BIOL CHEM, V274, P20017, DOI 10.1074/jbc.274.28.20017; Chaika OV, 1997, J BIOL CHEM, V272, P11968, DOI 10.1074/jbc.272.18.11968; Chidiac P, 1998, BIOCHEM PHARMACOL, V55, P549, DOI 10.1016/S0006-2952(97)00361-4; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Degtiar VE, 1997, J PHYSIOL-LONDON, V502, P321, DOI 10.1111/j.1469-7793.1997.321bk.x; Djellas Y, 1999, J BIOL CHEM, V274, P14325, DOI 10.1074/jbc.274.20.14325; Fedorov YV, 1998, MOL CELL BIOL, V18, P5780, DOI 10.1128/MCB.18.10.5780; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; HALENDA SP, 1986, FEBS LETT, V204, P341, DOI 10.1016/0014-5793(86)80840-7; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; Hannken T, 1998, KIDNEY INT, V54, P1923, DOI 10.1046/j.1523-1755.1998.00212.x; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; IKEZU T, 1995, J BIOL CHEM, V270, P29224, DOI 10.1074/jbc.270.49.29224; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; Kanzaki M, 1997, J BIOL CHEM, V272, P14733, DOI 10.1074/jbc.272.23.14733; KARIYA K, 1987, ATHEROSCLEROSIS, V63, P251, DOI 10.1016/0021-9150(87)90128-6; KNEZEVIC I, 1993, J BIOL CHEM, V268, P26011; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Krieger-Brauer HI, 2000, J BIOL CHEM, V275, P35920, DOI 10.1074/jbc.M002490200; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIANG MN, J BIOL CHEM, V266, P13342; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; Marumo T, 1997, CIRCULATION, V96, P2361; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MUNSHI R, 1989, J BIOL CHEM, V264, P14853; Neptune ER, 1999, J BIOL CHEM, V274, P2824, DOI 10.1074/jbc.274.5.2824; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; Peppel K, 2000, CIRCULATION, V102, P793, DOI 10.1161/01.CIR.102.7.793; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROTHENBERG PL, 1988, J BIOL CHEM, V263, P15546; Segal AW, 1997, ANN NY ACAD SCI, V832, P215, DOI 10.1111/j.1749-6632.1997.tb46249.x; SENOGLES SE, 1987, J BIOL CHEM, V262, P4860; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; THANNICKAL VJ, 1993, AM J PHYSIOL, V265, pL622, DOI 10.1152/ajplung.1993.265.6.L622; Uehara T, 1999, EUR J BIOCHEM, V259, P801, DOI 10.1046/j.1432-1327.1999.00100.x; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Viedt C, 2000, ARTERIOSCL THROM VAS, V20, P940, DOI 10.1161/01.ATV.20.4.940; WANG JF, 1991, BIOCHEM J, V279, P311, DOI 10.1042/bj2790311; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026; Wu GY, 1998, J BIOL CHEM, V273, P7197, DOI 10.1074/jbc.273.13.7197; Yau L, 1999, EUR J BIOCHEM, V266, P1147, DOI 10.1046/j.1432-1327.1999.00968.x; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488; ZIDEK W, 1983, RES EXP MED, V183, P129, DOI 10.1007/BF01851778	54	69	70	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					38	+		10.1096/fj.01-1036fje	http://dx.doi.org/10.1096/fj.01-1036fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12424219				2022-12-28	WOS:000180218500037
J	Savaskan, NE; Brauer, AU; Kuhbacher, M; Eyupoglu, IY; Kyriakopoulos, A; Ninnemann, O; Behne, D; Nitsch, R				Savaskan, NE; Brauer, AU; Kuhbacher, M; Eyupoglu, IY; Kyriakopoulos, A; Ninnemann, O; Behne, D; Nitsch, R			Selenium deficiency increases susceptibility to glutamate-induced excitotoxicity	FASEB JOURNAL			English	Article						seizure; oxidative glutamate toxicity; neuronal cell death; hippocampus; NF-kappa B	METABOLISM; TOXICITY; NEUROPROTECTION; IDENTIFICATION; NEUROTOXICITY; INHIBITION; EXPRESSION; APOPTOSIS; NEURONS; PATHWAY	Excitotoxic brain lesions, such as stroke and epilepsy, lead to increasing destruction of neurons hours after the insult. The deadly cascade of events involves detrimental actions by free radicals and the activation of proapoptotic transcription factors, which finally result in neuronal destruction. Here, we provide direct evidence that the nutritionally essential trace element selenium has a pivotal role in neuronal susceptibility to excitotoxic lesions. First, we observed in neuronal cell cultures that addition of selenium in the form of selenite within the physiological range protects against excitotoxic insults and even attenuates primary damage. The neuroprotective effect of selenium is not directly mediated via antioxidative effects of selenite but requires de novo protein synthesis. Gel shift analysis demonstrates that this effect is connected to the inhibition of glutamate-induced NF-kappaB and AP-1 activation. Furthermore, we provide evidence that selenium deficiency in vivo results in a massive increase in susceptibility to kainate-induced seizures and cell loss. These findings indicate the importance of selenium for prevention and therapy of excitotoxic brain damage.	Humboldt Univ, Sch Med, Charite, Inst Anat,Dept Cell & Neurobiol, D-10115 Berlin, Germany; Humboldt Univ, Sch Med, Charite, Dept Neurol, D-10115 Berlin, Germany; Hahn Meitner Inst Berlin GmbH, Dept Mol Trace Element Res Life Sci, D-14109 Berlin, Germany; Univ Erlangen Nurnberg, Dept Neurosurg, D-91054 Erlangen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Helmholtz-Zentrum fuer Materialien und Energie GmbH (HZB); University of Erlangen Nuremberg	Savaskan, NE (corresponding author), Humboldt Univ, Sch Med, Charite, Inst Anat,Dept Cell & Neurobiol, D-10098 Berlin, Germany.	nicolai.savaskan@charite.de	Nitsch, Robert/AAI-9129-2021; Bräuer, Anja/N-3692-2019; Braeuer, Anja/K-8339-2013; Savaskan, Nicolai/D-2923-2018	Eyupoglu, Ilker/0000-0002-8185-7764; Savaskan, Nicolai/0000-0003-1348-094X				Beck MA, 2001, FASEB J, V15, P1481, DOI 10.1096/fj.00-0721fje; Behne D, 2001, ANNU REV NUTR, V21, P453, DOI 10.1146/annurev.nutr.21.1.453; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; Behne D, 1996, J REPROD FERTIL, V106, P291, DOI 10.1530/jrf.0.1060291; BEHNE D, 1994, BIOL TRACE ELEM RES, V43-5, P287, DOI 10.1007/BF02917327; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; Ganther HE, 2001, ADV EXP MED BIOL, V492, P119; Gu J, 1997, J NEUROSCI RES, V47, P626, DOI 10.1002/(SICI)1097-4547(19970315)47:6<626::AID-JNR8>3.0.CO;2-F; Hawkes WC, 1996, BIOL PSYCHIAT, V39, P121, DOI 10.1016/0006-3223(95)00085-2; Kim YH, 1999, SCIENCE, V284, P647, DOI 10.1126/science.284.5414.647; KOPF A, 1990, ANAESTHESIST, V39, P633; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Maher P, 1996, J NEUROSCI, V16, P6394; MASON AC, 1986, J NUTR, V116, P1883, DOI 10.1093/jn/116.10.1883; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; MULLER A, 1984, BIOCHEM PHARMACOL, V33, P3235, DOI 10.1016/0006-2952(84)90083-2; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; Neve J, 1996, J Cardiovasc Risk, V3, P42; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Post A, 1998, J NEUROSCI, V18, P8236; RAMAEKERS VT, 1994, NEUROPEDIATRICS, V25, P217, DOI 10.1055/s-2008-1073025; RATAN RR, 1994, J NEUROSCI, V14, P4385; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; Schubert D, 2001, J NEUROSCI, V21, P7455, DOI 10.1523/JNEUROSCI.21-19-07455.2001; Shen HM, 2001, FREE RADICAL BIO MED, V30, P9, DOI 10.1016/S0891-5849(00)00421-4; SPALLHOLZ JE, 1990, ANN NY ACAD SCI, V587, P123, DOI 10.1111/j.1749-6632.1990.tb00140.x; Sundaram N, 2000, J NEURO-ONCOL, V46, P125, DOI 10.1023/A:1006436326003; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; WEBER GF, 1991, LANCET, V337, P1443, DOI 10.1016/0140-6736(91)93130-2; Weber GF, 1999, NEUROSCI BIOBEHAV R, V23, P1079, DOI 10.1016/S0149-7634(99)00041-X; Yan J, 1998, J NEUROSCI, V18, P8682; Zhang XA, 1997, EUR J NEUROSCI, V9, P760, DOI 10.1111/j.1460-9568.1997.tb01424.x	32	116	122	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					112	+		10.1096/fj.02-0067fje	http://dx.doi.org/10.1096/fj.02-0067fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12424220				2022-12-28	WOS:000180218500033
J	Zippin, JH; Chen, YQ; Nahirney, P; Kamenetsky, M; Wuttke, MS; Fischman, DA; Levin, LR; Buck, J				Zippin, JH; Chen, YQ; Nahirney, P; Kamenetsky, M; Wuttke, MS; Fischman, DA; Levin, LR; Buck, J			Compartmentalization of bicarbonate-sensitive adenylyl cyclase in distinct signaling microdomains	FASEB JOURNAL			English	Article						G-protein; cAMP; transmembrane spanning domains	DEPENDENT PROTEIN-KINASE; C-OXIDASE ACTIVITY; REGULATORY SUBUNIT; ANCHOR PROTEIN; CAMP; CENTROSOME; PHOSPHORYLATION; LOCALIZATION; MITOCHONDRIA; EXPRESSION	Intracellular targets of the ubiquitous second messenger cAMP are located at great distances from the most widely studied source of cAMP, the G protein responsive transmembrane adenylyl cyclases. We previously identified an alternative source of cAMP in mammalian cells lacking transmembrane spanning domains, the "soluble" adenylyl cyclase (sAC). We now demonstrate that sAC is distributed in specific subcellular compartments: mitochondria, centrioles, mitotic spindles, mid-bodies, and nuclei, all of which contain cAMP targets. Distribution at these intracellular sites proves that adenylyl cyclases are in close proximity to all cAMP effectors, suggesting a model in which local concentrations of cAMP are regulated by individual adenylyl cyclases targeted to specific microdomains throughout the cell.	Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Tri Inst MD PhD Program, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Cell Biol, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Levin, LR (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pharmacol, 1300 York Ave, New York, NY 10021 USA.	llevin@med.cornell.edu		Levin, Lonny/0000-0002-5204-6356				BEAVO JA, 1994, MOL PHARMACOL, V46, P399; Bender E, 2000, FEBS LETT, V466, P130, DOI 10.1016/S0014-5793(99)01773-1; BEVENSEE MO, 2000, KIDNEY, V1; BRAUN T, 1975, P NATL ACAD SCI USA, V72, P1097, DOI 10.1073/pnas.72.3.1097; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Constantinescu A, 1999, J BIOL CHEM, V274, P26985, DOI 10.1074/jbc.274.38.26985; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; Diviani D, 2000, CURR BIOL, V10, P417, DOI 10.1016/S0960-9822(00)00422-X; Diviani D, 2001, J CELL SCI, V114, P1431; Feliciello A, 1998, J BIOL CHEM, V273, P23361, DOI 10.1074/jbc.273.36.23361; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; JAISWAL BS, 2001, J BIOL CHEM, V21, P21; JUNGMANN RA, 1988, METHOD ENZYMOL, V159, P225; KERYER G, 1993, EXP CELL RES, V204, P230, DOI 10.1006/excr.1993.1029; KUETTEL MR, 1985, J CELL BIOL, V101, P965, DOI 10.1083/jcb.101.3.965; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; Lutz W, 2001, J BIOL CHEM, V276, P20774, DOI 10.1074/jbc.M101324200; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; QIAO J, 2002, IN PRESS J BIOL CHEM, V8; Rich TC, 2000, J GEN PHYSIOL, V116, P147, DOI 10.1085/jgp.116.2.147; Rich TC, 2001, P NATL ACAD SCI USA, V98, P13049, DOI 10.1073/pnas.221381398; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; Schwencke C, 1999, MOL ENDOCRINOL, V13, P1061, DOI 10.1210/me.13.7.1061; SHMYREV II, 1990, MOL CELL BIOCHEM, V93, P47; Sinclair ML, 2000, MOL REPROD DEV, V56, P6, DOI 10.1002/(SICI)1098-2795(200005)56:1&lt;6::AID-MRD2&gt;3.0.CO;2-M; SLY WS, 1995, ANNU REV BIOCHEM, V64, P375, DOI 10.1146/annurev.bi.64.070195.002111; SQUINTO SP, 1989, BIOCHEM J, V260, P673, DOI 10.1042/bj2600673; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858; Wuttke M S, 2001, JOP, V2, P154; Yang WL, 1998, BIOCHEMISTRY-US, V37, P14175, DOI 10.1021/bi981402a; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982; Zippin JH, 2001, TRENDS ENDOCRIN MET, V12, P366, DOI 10.1016/S1043-2760(01)00454-4	40	218	231	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					82	+		10.1096/fj.02-0598fje	http://dx.doi.org/10.1096/fj.02-0598fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475901				2022-12-28	WOS:000180218500020
J	Shin, SY; Ko, JS; Chang, JS; Min, DS; Choi, C; Bae, SS; Kim, MJ; Hyun, DS; Kim, JH; Han, MY; Kim, YH; Kim, YS; Na, DS; Suh, PG; Lee, YH				Shin, SY; Ko, JS; Chang, JS; Min, DS; Choi, C; Bae, SS; Kim, MJ; Hyun, DS; Kim, JH; Han, MY; Kim, YH; Kim, YS; Na, DS; Suh, PG; Lee, YH			Negative regulatory role of overexpression of PLC gamma 1 in the expression of early growth response 1 gene in rat 3Y1 fibroblasts	FASEB JOURNAL			English	Article						Egr-1; tumor suppressor; PLG gamma 1 overexpression	TRANSCRIPTION FACTOR EGR-1; TERNARY COMPLEX FACTORS; PROTEIN-SYNTHESIS INHIBITORS; FIBROSARCOMA HT1080 CELLS; COLONY-STIMULATING FACTOR; PHOSPHOLIPASE C-GAMMA-1; C-FOS; TRANSFORMING GROWTH-FACTOR-BETA-1; DIFFERENTIAL REGULATION; ELEVATED CONTENT	The early growth response 1 (Egr-1) gene product is a transcription factor that functions as an oikis factor. Loss of Egr-1 expression is closely associated with tumor formation. Phospholipase Cgammal (PLCgamma1) is overexpressed in some tumors, and its overexpression causes anchorage-independent growth. Here we report that overexpression of PLCgammal and SH2-SH3 domain of PLCgamma1 decreased induction of Egr-1 and the Egr-1-regulated genes TSP-1 and PAI-1. Results from the nuclear run-on assay and transfection experiment with the proximal 455 base pair region of the Egr-1 promoter (-454 to +1) showed that Egr-1 transcriptional activity was suppressed in PLCgamma1-3Y1 cells whereas decay of Egr-1 mRNA was similar in both cell lines. Serum response element- and ternary complex factor Elk-l-mediated transcriptional activation of the reporter gene in response to EGF were also inhibited in PLCgamma1-3Y1 cells. Pretreatment with the protein synthesis inhibitor cycloheximide (CHX) partially abrogated the serum-induced suppression of Egr-1 transcription in PLCgammal-3Y1 cells, suggesting that a CHX-sensitive factor(s) is involved in the suppression of Egr-1 transcription in PLCgamma1-3Y1 cells. Our results demonstrated that overexpression of PLCgamma1 functions as a negative modulator of the tumor suppressor Egr-1 gene expression, possibly through inhibition of Elk-l-dependent transcriptional activity.	Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, Nam Gu 705717, Daegu, South Korea; Kyungpook Natl Univ, Dept Microbiol, Taegu 702701, South Korea; Univ Ulsan, Coll Med, Asan Inst Life Sci, Seoul 138736, South Korea; Daejin Univ, Dept Biol, Pochon Gun 487800, Kyeonggido, South Korea; Catholic Univ Korea, Coll Med, Dept Physiol, Seoul 137701, South Korea; Chonnam Natl Univ, Res Inst Med Sci, Kwangju 501746, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea; Green Cross Inst Med Genet, Seoul 135260, South Korea; Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Clin Res Inst,Dept Psychiat, Seoul 151742, South Korea; Univ Ulsan, Coll Med, Dept Biochem, Seoul 138736, South Korea	Yeungnam University; Kyungpook National University; University of Ulsan; Daejin University; Catholic University of Korea; Chonnam National University; Pohang University of Science & Technology (POSTECH); Seoul National University (SNU); Seoul National University Hospital; University of Ulsan	Lee, YH (corresponding author), Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, 317-1 Daemyung Dong, Nam Gu 705717, Daegu, South Korea.	younglee@med.yu.ac.kr	Suh, Pann-Ghill/F-3610-2010					ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; CAO XM, 1992, J BIOL CHEM, V267, P1345; Chang JS, 1997, CANCER RES, V57, P5465; Chen CY, 1996, MOL CELL BIOL, V16, P6582; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Clarkson RWE, 1999, MOL ENDOCRINOL, V13, P619, DOI 10.1210/me.13.4.619; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HUANG KJ, 1995, CHINESE J CHEM ENG, V3, P1; HUANG RP, 1994, ONCOGENE, V9, P1367; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HUANG RP, 1995, CANCER RES, V55, P5054; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEVIN WJ, 1995, ONCOGENE, V11, P1261; Liao HJ, 2001, J BIOL CHEM, V276, P8627, DOI 10.1074/jbc.C100030200; LIM RW, 1987, ONCOGENE, V1, P263; Liu CT, 1996, CRIT REV ONCOGENESIS, V7, P101, DOI 10.1615/CritRevOncog.v7.i1-2.70; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORELLO D, 1990, ONCOGENE, V5, P1511; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NANNEY LB, 1992, CELL GROWTH DIFFER, V3, P233; NOH DY, 1994, CANCER, V73, P36, DOI 10.1002/1097-0142(19940101)73:1<36::AID-CNCR2820730108>3.0.CO;2-5; PARK JG, 1994, CANCER RES, V54, P2240; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RIM M, 1992, ONCOGENE, V7, P2065; RUPPRECHT HD, 1993, AM J PHYSIOL, V265, pF351, DOI 10.1152/ajprenal.1993.265.3.F351; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; Shin SY, 2001, J BIOL CHEM, V276, P7797, DOI 10.1074/jbc.M009465200; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; Smith MR, 1998, CARCINOGENESIS, V19, P177, DOI 10.1093/carcin/19.1.177; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; Smith MR, 1996, BIOCHEM BIOPH RES CO, V222, P186, DOI 10.1006/bbrc.1996.0719; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Tsai JC, 2000, AM J PHYSIOL-CELL PH, V279, pC1414, DOI 10.1152/ajpcell.2000.279.5.C1414; Watanabe S, 1997, BLOOD, V89, P1197, DOI 10.1182/blood.V89.4.1197; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YEATMAN TJ, 1994, BIOCHEM BIOPH RES CO, V201, P1043, DOI 10.1006/bbrc.1994.1807; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	47	13	13	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1504	1514		10.1096/fj.02-0022com	http://dx.doi.org/10.1096/fj.02-0022com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374773				2022-12-28	WOS:000179167600032
J	Mayr, M; Hu, YH; Hainaut, P; Xu, QB				Mayr, M; Hu, YH; Hainaut, P; Xu, QB			Mechanical stress-induced DNA damage and rac-p38MAPK signal pathways mediate p53-dependent apoptosis in vascular smooth muscle cells	FASEB JOURNAL			English	Article						signaling; cyclic strain stress; cell death; oxidative stress; arteriosclerosis	ACTIVATED PROTEIN-KINASES; ATHEROSCLEROTIC PLAQUES; P53-MEDIATED APOPTOSIS; SUPEROXIDE-PRODUCTION; HUMAN CYTOMEGALOVIRUS; OXIDATIVE STRESS; NAD(P)H OXIDASE; GENE-EXPRESSION; P53 PROTEIN; VEIN GRAFTS	Recently, we demonstrated that biomechanical stress induces apoptosis of vascular smooth muscle cells (SMCs) (Mayr et al., FASEB J. 2000; 15:261-270). In this article we investigated the molecular mechanisms of mechanical stress-induced apoptosis. When SMCs were subjected to cyclic strain, tumor-suppressor p53 was activated as evidenced by gel mobility shift assays and Western blot analyses. p53 activation was largely attenuated if SMCs were pretreated with SB202190, a specific p38MAPK inhibitor, or were stably transfected with dominant negative rac, an upstream signal transducer of p38MAPK pathways. Kinase assays provided direct evidence that p38MAPKs phosphorylated p53 within 30 min of cyclic strain. Additionally, mechanical stress resulted in oxidative DNA damage as detected by the presence of 8-oxoguanine. Treatment with the antioxidant U-74389G abrogated p53 activation. p53 activation was followed by expression and mitochondrial translocation of the proapoptotic protein Bax. Likewise, mechanical stress resulted in up-regulation of anti-apoptotic Bcl-2 proteins, including Bcl-2 and Bcl-xL. However, a marked loss of mitochondrial membrane potential occurred in wild-type, but not in p53-/-, SMCs. The latter lost their ability to express Bax and showed no apoptosis in response to cyclic strain. Taken together, our data provide the first evidence that SMC apoptosis induced by mechanical stress is p53-dependent.	St George Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England; Univ Innsbruck, Inst Pathophysiol, A-6020 Innsbruck, Austria; Austrian Acad Sci, Inst Biomed Aging Res, Innsbruck, Austria; Int Agcy Res Canc, F-69372 Lyon, France	St Georges University London; University of Innsbruck; Austrian Academy of Sciences; World Health Organization; International Agency for Research on Cancer (IARC)	Xu, QB (corresponding author), St George Hosp, Sch Med, Dept Cardiol Sci, Cranmer Terrace, London SW17 0RE, England.	q.xu@sghms.ac.uk	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610; Mayr, Manuel/0000-0002-0597-829X				BENES AJ, 1985, J CELL SCI, V75, P35; Bennett MR, 1998, CIRC RES, V82, P704, DOI 10.1161/01.RES.82.6.704; Bennett MR, 1997, CIRC RES, V81, P591, DOI 10.1161/01.RES.81.4.591; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cook SA, 1999, CIRC RES, V85, P940; Frangos SG, 1999, ARCH SURG-CHICAGO, V134, P1142, DOI 10.1001/archsurg.134.10.1142; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Goldschmidt ME, 2001, CIRC RES, V88, P674, DOI 10.1161/hh0701.089749; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; HENGARTNER MO, 2000, NATURE, V407, P775; Hishikawa K, 1997, CIRC RES, V81, P797; Hu YH, 1999, CIRCULATION, V100, P861, DOI 10.1161/01.CIR.100.8.861; Hu YH, 1998, FASEB J, V12, P1135, DOI 10.1096/fasebj.12.12.1135; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Ihling C, 1997, ARTERIOSCL THROM VAS, V17, P2218, DOI 10.1161/01.ATV.17.10.2218; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; KASAI H, 1997, MUTAT RES, V87, P147; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lehoux S, 1998, HYPERTENSION, V32, P338, DOI 10.1161/01.HYP.32.2.338; Li, 2000, Arterioscler Thromb Vasc Biol, V20, pE1; Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Malins DC, 2000, P NATL ACAD SCI USA, V97, P12442, DOI 10.1073/pnas.230438797; Mallat Z, 2001, CIRC RES, V88, P998, DOI 10.1161/hh1001.090571; MARINET W, 2001, CIRC RES, V88, P648; Matsushita H, 2000, CIRCULATION, V101, P1447, DOI 10.1161/01.CIR.101.12.1447; Mayr M, 2000, FASEB J, V14, P261, DOI 10.1096/fasebj.14.2.261; Mayr M, 2001, EXP GERONTOL, V36, P969, DOI 10.1016/S0531-5565(01)00090-0; Mayr U, 2002, CIRC RES, V90, P197, DOI 10.1161/hh0202.103715; Metzler B, 2000, AM J PATHOL, V156, P1875, DOI 10.1016/S0002-9440(10)65061-4; MIYASHITA T, 1995, CELL, V80, P293; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Perlman H, 1997, CIRCULATION, V95, P981; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; SINGH B, 1992, DNA CELL BIOL, V11, P489, DOI 10.1089/dna.1992.11.489; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Tanaka K, 1999, CIRCULATION, V99, P1656, DOI 10.1161/01.CIR.99.13.1656; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walsh K, 2000, CIRC RES, V87, P184, DOI 10.1161/01.RES.87.3.184; West NEJ, 2001, ARTERIOSCL THROM VAS, V21, P189, DOI 10.1161/01.ATV.21.2.189; Xu QB, 2000, TRENDS CARDIOVAS MED, V10, P35, DOI 10.1016/S1050-1738(00)00042-6; Xu QB, 1997, J CLIN INVEST, V100, P1089, DOI 10.1172/JCI119619; XU QB, 1995, CIRCULATION, V92, P1223, DOI 10.1161/01.CIR.92.5.1223; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517	47	119	127	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1423	+		10.1096/fj.02-0042fje	http://dx.doi.org/10.1096/fj.02-0042fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205035	Green Submitted			2022-12-28	WOS:000177813100020
J	Ghyczy, M; Torday, C; Boros, M				Ghyczy, M; Torday, C; Boros, M			Simultaneous generation of methane, carbon dioxide, and carbon monoxide from choline and ascorbic acid - a defensive mechanism against reductive stress?	FASEB JOURNAL			English	Article						redox balance; mitochondria; electrophilic methyl groups; hydrogen peroxide; iron; oxygen radicals	HYDROGEN-PEROXIDE; PROTECTION	Indirect evidence suggests that an abnormal increase in reducing power (reductive stress) may be associated with abnormal clinical states. We have recently proposed that under such conditions biomolecules with electrophilic methyl groups (EMGs) bound to positively charged nitrogen or sulfur moieties may act as electron acceptors and that this poising mechanism may entail the generation of methane gas. Here we report for the first time the generation of methane by rat liver mitochondria. We also report the formation of methane from choline in the presence of hydrogen peroxide, catalytic iron, and ascorbic acid. In this system, carbon monoxide and carbon dioxide are formed from the ascorbate molecule in parallel with methane generation. In view of these findings, we try to explain the essential role of biomolecules with EMG moiety. We hypothesize that this concerted reaction may be a defensive response to reductive stress and may provide the protection needed against redox imbalance in living systems.	Univ Szeged, Inst Surg Res, H-6701 Szeged, Hungary; Phospholipid GmbH, Cologne, Germany	Szeged University	Boros, M (corresponding author), Univ Szeged, Inst Surg Res, POB 464, H-6701 Szeged, Hungary.	boros@expsur.szote.u-szeged.hu	Boros, Mihály/B-5195-2008					Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; Boros M, 1999, SHOCK, V12, P56, DOI 10.1097/00024382-199911001-00174; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHANCE B, 1957, FED PROC, V16, P671; Davies M./ B., 1991, VITAMIN C ITS CHEM B; DORMANDY TL, 1966, LANCET, V1, P755; DUAN J, 1990, J CARDIOVASC PHARM, V15, P163, DOI 10.1097/00005344-199001000-00026; DUAN JM, 1990, N-S ARCH PHARMACOL, V342, P342; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Ghyczy M, 2001, BRIT J NUTR, V85, P409, DOI 10.1079/BJN2000274; Gutteridge JMC, 1999, REDOX REP, V4, P129, DOI 10.1179/135100099101534819; Halliwell B, 2000, FEBS LETT, V486, P10, DOI 10.1016/S0014-5793(00)02197-9; Ido Y, 1997, DIABETOLOGIA, V40, pS115, DOI 10.1007/s001250051422; Ido Y, 2001, FASEB J, V15, P1419, DOI 10.1096/fj.00-0652fje; Kristal BS, 1998, FREE RADICAL BIO MED, V24, P1269, DOI 10.1016/S0891-5849(97)00444-9; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Liochev SI, 2002, REDOX REP, V7, P55, DOI 10.1179/135100002125000190; Lipinski B, 2002, BRIT J NUTR, V87, P93, DOI 10.1079/BJN2001435; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORITA S, 1985, ANESTH ANALG, V64, P343; NIKNAHAD H, 1995, CHEM-BIOL INTERACT, V98, P27, DOI 10.1016/0009-2797(95)03631-U; Nulton-Persson AC, 2001, J BIOL CHEM, V276, P23357, DOI 10.1074/jbc.M100320200; Parinandi NL, 1999, ANTIOXID REDOX SIGN, V1, P193, DOI 10.1089/ars.1999.1.2-193; SOHAL RS, 1990, MECH AGEING DEV, V53, P209, DOI 10.1016/0047-6374(90)90039-I; Staubli A, 1998, AM J PHYSIOL-GASTR L, V274, pG1031, DOI 10.1152/ajpgi.1998.274.6.G1031; STORM G, 1989, CANCER CHEMOTH PHARM, V24, P341, DOI 10.1007/BF00257439; SWARM RA, 1987, AM J SURG, V153, P48, DOI 10.1016/0002-9610(87)90200-5; Thauer RK, 1998, MICROBIOL-UK, V144, P2377, DOI 10.1099/00221287-144-9-2377; THOMAS C E, 1985, Journal of Free Radicals in Biology and Medicine, V1, P293; Williamson JR, 1999, DIABETES RES CLIN PR, V45, P81; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061	31	51	54	1	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1124	+		10.1096/fj.02-0918fje	http://dx.doi.org/10.1096/fj.02-0918fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692080				2022-12-28	WOS:000182580100034
J	Cedrola, S; Guzzi, G; Ferrari, D; Gritti, A; Vescovi, AL; Pendergrass, JC; La Porta, CAM				Cedrola, S; Guzzi, G; Ferrari, D; Gritti, A; Vescovi, AL; Pendergrass, JC; La Porta, CAM			Inorganic mercury changes the fate of murine CNS stem cells	FASEB JOURNAL			English	Article						neuronal stem cell; inorganic mercury; HSP-70	AMYOTROPHIC-LATERAL-SCLEROSIS; ADULT MAMMALIAN BRAIN; DENTAL AMALGAM FILLINGS; CENTRAL-NERVOUS-SYSTEM; APAF-1 APOPTOSOME; CHLORIDE HGCL2; GRANULE CELLS; BETA-TUBULIN; MOUSE BRAIN; HUMAN FETAL	Stem cells isolated from the central nervous system of both embryonic and adult mice can generate neurons and glia through the activation of different patterns of differentiation in dependence of exposure to appropriate epigenetic signals. On the other hand, environmental conditions might affect the proliferation, migration, and differentiation of these cells. We report here, for the first time, that inorganic mercury affects the proliferative and differentiative capacity of adult neuronal stem cells (ANSCs). Actually, inorganic mercury increases apoptosis in ASNC. Furthermore, in stem cell-derived astrocytes, high levels of the 70 kDa heat shock protein (HSP-70) occur, while the levels of GTP-beta-tubulin activity dramatically decrease. Interestingly, when induced to differentiate, inorganic mercury modifies morphological proprieties of astrocytes, while the neuron population is reduced. These results demonstrate that inorganic mercury produces toxicity in the ANSC-derived neuronal population and affects the biological properties of the glial-derived population.	Dept Gen Physiol & Biochem, Sect Gen Pathol, I-20133 Milan, Italy; Italian Assoc Met & Biocompatibil Res, Milan, Italy; San Raffaele Hosp, Inst Stem Cell Res, Dept Biotechnol, Milan, Italy; Tox Exposure Study Trust Fdn ALT, Lexington, KY USA	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	La Porta, CAM (corresponding author), Dept Gen Physiol & Biochem, Sect Gen Pathol, Celoria 26, I-20133 Milan, Italy.	Caterina.LaPorta@unimi.it	Gritti, Angela/K-2729-2016; Vescovi, Angelo Luigi/A-4919-2015; Ferrari, Daniela/AHE-7647-2022; la porta, caterina/K-7345-2013	Gritti, Angela/0000-0002-9845-0370; Vescovi, Angelo Luigi/0000-0002-1742-4112; Ferrari, Daniela/0000-0001-7251-9854; Guzzi, Gianpaolo/0000-0002-7171-4460; la porta, caterina/0000-0002-3010-8966				ADAMS CR, 1983, JAMA-J AM MED ASSOC, V250, P642; ALBERS JW, 1982, NEUROLOGY, V32, P1168, DOI 10.1212/WNL.32.10.1168; ALBERS JW, 1988, ANN NEUROL, V24, P651, DOI 10.1002/ana.410240510; ALTMAN J, 1966, J COMP NEUROL, V126, P337, DOI 10.1002/cne.901260302; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ALTMAN J, 1990, J COMP NEUROL, V301, P365, DOI 10.1002/cne.903010304; ALTMAN J, 1990, J COMP NEUROL, V301, P325, DOI 10.1002/cne.903010302; Alvarez-Buylla A, 2002, BRAIN RES BULL, V57, P751, DOI 10.1016/S0361-9230(01)00770-5; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; ARMSTRONG R D, 1963, Am Ind Hyg Assoc J, V24, P366, DOI 10.1080/00028896309343231; ARVIDSON B, 1992, MUSCLE NERVE, V15, P1089, DOI 10.1002/mus.880151006; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; BHATTACHARYYA T, 1995, J BIOL CHEM, V270, P1705, DOI 10.1074/jbc.270.4.1705; Bucio L, 1999, MUTAT RES-FUND MOL M, V423, P65, DOI 10.1016/S0027-5107(98)00226-7; CHAPMAN LJ, 1990, BRIT J IND MED, V47, P838; Clarkson TW, 2002, ENVIRON HEALTH PERSP, V110, P11, DOI 10.1289/ehp.02110s111; CLARKSON TW, 1988, BIOL MONITORING TOXI, P199; COROTTO FS, 1993, NEUROSCI LETT, V149, P111, DOI 10.1016/0304-3940(93)90748-A; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 1997, J NEUROSCI, V17, P5046; Dougherty CA, 2001, BIOCHEMISTRY-US, V40, P15725, DOI 10.1021/bi010070y; DRASCH G, 1994, EUR J PEDIATR, V153, P607, DOI 10.1007/s004310050200; DUHR EF, 1993, TOXICOL APPL PHARM, V122, P273, DOI 10.1006/taap.1993.1196; Fonfria E, 2001, NEUROPHARMACOLOGY, V41, P819, DOI 10.1016/S0028-3908(01)00130-7; GOERING PL, 1992, FUND APPL TOXICOL, V19, P319, DOI 10.1016/0272-0590(92)90169-I; Gritti A, 2002, J NEUROSCI, V22, P437, DOI 10.1523/JNEUROSCI.22-02-00437.2002; Gritti A, 1999, J NEUROSCI, V19, P3287; Gritti A, 1996, J NEUROSCI, V16, P1091; Gritti A, 2002, J PHYSIOL-PARIS, V96, P81, DOI 10.1016/S0928-4257(01)00083-3; GUENEAU G, 1982, DEV NEUROSCI-BASEL, V5, P345, DOI 10.1159/000112694; JULIAN FT, 1991, SPECTROMETRY ACTA RE, V14, P169; KAPLAN MS, 1981, J COMP NEUROL, V195, P323, DOI 10.1002/cne.901950211; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; KISHI R, 1978, TOXICOL APPL PHARM, V46, P555, DOI 10.1016/0041-008X(78)90303-4; KOSTA L, 1975, NATURE, V254, P238, DOI 10.1038/254238a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leong CCW, 2001, NEUROREPORT, V12, P733, DOI 10.1097/00001756-200103260-00024; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LORSCHEIDER FL, 1995, TOXICOLOGY, V97, P19, DOI 10.1016/0300-483X(94)02964-V; LORSCHEIDER FL, 1990, LANCET, V336, P1578, DOI 10.1016/0140-6736(90)93353-Q; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACEY RI, 1984, AM J PHYSIOL, V246, P195; MITCHELL JD, 1987, NEUROL CLIN, V5, P43, DOI 10.1016/S0733-8619(18)30934-4; MOLLERMADSEN B, 1986, ENVIRON RES, V41, P29, DOI 10.1016/S0013-9351(86)80165-7; MOLLERMADSEN B, 1990, TOXICOL APPL PHARM, V103, P303, DOI 10.1016/0041-008X(90)90232-J; MORIWAKA F, 1993, J NEUROL SCI, V118, P38, DOI 10.1016/0022-510X(93)90243-R; NYLANDER M, 1987, SWED DENT J, V11, P179; Pamphlett R, 1996, J NEUROL SCI, V135, P63, DOI 10.1016/0022-510X(95)00258-4; Pendergrass AC, 1997, NEUROTOXICOLOGY, V18, P315; Ratcliffe HE, 1996, J TOXICOL ENV HEALTH, V49, P221, DOI 10.1080/009841096160817; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Sallsten G, 1996, J DENT RES, V75, P594, DOI 10.1177/00220345960750011301; SCHIONNING JD, 1993, TOXICOL APPL PHARM, V121, P43, DOI 10.1006/taap.1993.1127; SHAPIRO IM, 1982, LANCET, V1, P1147; Shenker BJ, 2000, ENVIRON RES, V84, P89, DOI 10.1006/enrs.2000.4078; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; Tiffany-Castiglioni E, 2001, NEUROTOXICOLOGY, V22, P577, DOI 10.1016/S0161-813X(01)00050-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; Yenari MA, 1999, MOL MED TODAY, V5, P525, DOI 10.1016/S1357-4310(99)01599-3	62	19	20	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					869	+		10.1096/fj.02-0491fje	http://dx.doi.org/10.1096/fj.02-0491fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670884				2022-12-28	WOS:000181892600009
J	Muthuchamy, M; Gashev, A; Boswell, N; Dawson, N; Zawieja, D				Muthuchamy, M; Gashev, A; Boswell, N; Dawson, N; Zawieja, D			Molecular and functional analyses of the contractile apparatus in lymphatic muscle	FASEB JOURNAL			English	Article						lymph; lymph pump; contractile proteins	HEAVY-CHAIN ISOFORMS; EMBRYONIC STEM-CELLS; SMOOTH-MUSCLE; NUCLEOTIDE-BINDING; MYOSIN; ACTIN; EXPRESSION; DIFFERENTIATION; CDNA; IDENTIFICATION	Lymphatics are necessary for the generation and regulation of lymph flow. Lymphatics use phasic contractions and extrinsic compressions to generate flow; tonic contractions alter resistance. Lymphatic muscle exhibits important differences from typical vascular smooth muscle. In this study, the thoracic duct exhibited significant functional differences from mesenteric lymphatics. To understand the molecular basis for these differences, we examined the profiles of contractile proteins and their messages in mesenteric lymphatics, thoracic duct, and arterioles. Results demonstrated that mesenteric lymphatics express only SMB smooth muscle myosin heavy chain (SM-MHC), whereas thoracic duct and arterioles expressed both SMA and SMB isoforms. Both SM1 and SM2 isoforms of SM-MHC were detected in arterioles and mesenteric and thoracic lymphatics. In addition, the fetal cardiac/skeletal slow-twitch muscle-specific beta-MHC message was detected only in mesenteric lymphatics. All four actin messages, cardiac alpha-actin, vascular alpha-actin, enteric gamma-actin, and skeletal alpha-actin, were present in both mesenteric lymphatics and arterioles. However, in thoracic duct, predominantly cardiac alpha-actin and vascular alpha-actin were found. Western blot and immunohistochemical analyses corroborated the mRNA studies. However, in arterioles only vascular alpha-actin protein was detected. These data indicate that lymphatics display genotypic and phenotypic characteristics of vascular, cardiac, and visceral myocytes, which are needed to fulfill the unique roles of the lymphatic system.	Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Physiol, Cardiovasc Res Inst,Coll Med, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Zawieja, D (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Physiol, Cardiovasc Res Inst,Coll Med, College Stn, TX 77843 USA.	dcz@tamu.edu		Zawieja, David/0000-0002-2644-6524	NHLBI NIH HHS [R01 HL075199, R01 HL070308, R01 HL070308-01A1, R01 HL075199-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070308, R01HL075199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; Babu GJ, 2000, MICROSC RES TECHNIQ, V50, P532, DOI 10.1002/1097-0029(20000915)50:6<532::AID-JEMT10>3.0.CO;2-E; Babu GJ, 2001, NAT CELL BIOL, V3, P1025, DOI 10.1038/ncb1101-1025; BENOIT JN, 1989, AM J PHYSIOL, V257, pH2059, DOI 10.1152/ajpheart.1989.257.6.H2059; Eddinger TJ, 1998, COMP BIOCHEM PHYS B, V119, P425, DOI 10.1016/S0305-0491(98)00003-0; GASHEV A A, 1990, Fiziologicheskii Zhurnal SSSR Imeni I M Sechenova, V76, P1489; GNEPP DR, 1984, EDEMA, P263; HANLEY CA, 1992, MICROVASC RES, V43, P134, DOI 10.1016/0026-2862(92)90012-E; HANSENSMITH F, 1991, HYPERTENSION, V17, P902, DOI 10.1161/01.HYP.17.6.902; Hein TW, 2001, J MOL CELL CARDIOL, V33, P271, DOI 10.1006/jmcc.2000.1298; Herman IM, 1993, CURR OPIN CELL BIOL, V5, P48, DOI 10.1016/S0955-0674(05)80007-9; HUGHES SM, 1992, CELL, V68, P659, DOI 10.1016/0092-8674(92)90142-Y; Khromov AS, 1996, J PHYSIOL-LONDON, V492, P669, DOI 10.1113/jphysiol.1996.sp021336; Kumar A, 1997, P NATL ACAD SCI USA, V94, P4406, DOI 10.1073/pnas.94.9.4406; Lauzon AM, 1998, J MUSCLE RES CELL M, V19, P825, DOI 10.1023/A:1005489501357; LESSARD JL, 1988, CELL MOTIL CYTOSKEL, V10, P349, DOI 10.1002/cm.970100302; MALMQVIST U, 1990, CIRC RES, V66, P832, DOI 10.1161/01.RES.66.3.832; MCHALE NG, 1992, J PHYSIOL-LONDON, V450, P503, DOI 10.1113/jphysiol.1992.sp019139; MCHALE NG, 1983, J PHYSIOL-LONDON, V338, P527, DOI 10.1113/jphysiol.1983.sp014687; MCHUGH KM, 1988, MOL CELL BIOL, V8, P5224, DOI 10.1128/MCB.8.12.5224; MISLIN H, 1966, EXPERIENTIA S, V14, P87; MUTHUCHAMY M, 1993, MOL CELL BIOL, V13, P3311, DOI 10.1128/MCB.13.6.3311; MUTHUCHAMY M, 1992, J BIOL CHEM, V267, P18728; NAGAI R, 1989, J BIOL CHEM, V264, P9734; NAGAI R, 1988, P NATL ACAD SCI USA, V85, P1047, DOI 10.1073/pnas.85.4.1047; Ng WA, 1997, PEDIATR RES, V41, P285, DOI 10.1203/00006450-199702000-00021; OWENS GK, 1995, PHYSIOL REV, V75, P487; PERIASAMY M, 1984, J BIOL CHEM, V259, P3573; ROBBINS J, 1990, J BIOL CHEM, V265, P11905; ROVNER AS, 1986, AM J PHYSIOL, V250, pC861, DOI 10.1152/ajpcell.1986.250.6.C861; RUBENSTEIN PA, 1990, BIOESSAYS, V12, P309, DOI 10.1002/bies.950120702; Schildmeyer LA, 2000, FASEB J, V14, P2213, DOI 10.1096/fj.99-0927com; SKALLI O, 1988, AM J PATHOL, V130, P515; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; SOMLYO AP, 1976, FED PROC, V35, P1288; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; THIEVENT A, 1995, CELL TISSUE RES, V279, P199, DOI 10.1007/BF00300704; VANHELDEN DF, 1993, J PHYSIOL-LONDON, V471, P465, DOI 10.1113/jphysiol.1993.sp019910; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; White SL, 1998, AM J PHYSIOL-CELL PH, V275, pC581, DOI 10.1152/ajpcell.1998.275.2.C581; ZAWIEJA DC, 1993, AM J PHYSIOL, V264, pH1283, DOI 10.1152/ajpheart.1993.264.4.H1283; Zawieja DC, 1999, PROGR APPL MICR, V23, P33; ZWEIFACH BW, 1985, EXPT BIOL LYMPHATIC, V9, P45	43	115	118	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					920	+		10.1096/fj.02-0626fje	http://dx.doi.org/10.1096/fj.02-0626fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670880				2022-12-28	WOS:000181892600014
J	Yin, YJ; Salah, Z; Maoz, M; Ram, SCE; Ochayon, S; Neufeld, G; Katzav, S; Bar-Shavit, R				Yin, YJ; Salah, Z; Maoz, M; Ram, SCE; Ochayon, S; Neufeld, G; Katzav, S; Bar-Shavit, R			Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation	FASEB JOURNAL			English	Article						thrombin receptor; vascular endothelial growth factor; invasion; metastasis	ENDOTHELIAL GROWTH-FACTOR; COUPLED THROMBIN RECEPTOR; PROTEIN-KINASE-C; SIGNALING PATHWAYS; TYROSINE KINASE; FACTOR VEGF; PROTHROMBIN DEFICIENCY; EXTRACELLULAR-MATRIX; EMBRYONIC LETHALITY; BLOOD-COAGULATION	The formation of new blood vessels is a critical determinant of tumor progression. We find that Par1 gene expression plays a central role in blood vessel recruitment in animal models. By in vivo injection of either Matrigel plugs containing Par1-expressing cells or of rat prostatic carcinoma cells transfected with tetracycline-inducible Par1 expression vectors, we show that Par1 significantly enhances both angiogenesis and tumor growth. Several vascular endothelial growth factor (VEGF) splice forms are induced in cells expressing Par1. Activation of PAR1 markedly augments the expression of VEGF mRNAs and of functional VEGFs as determined by in vitro assays for endothelial tube alignment and bovine aortic endothelial cell proliferation. Because neutralizing anti-VEGF antibodies potently inhibited Par1-induced endothelial cell proliferation, we conclude that Par1-induced angiogenesis requires VEGF. Specific inhibitors of protein kinase C (PKC), Src, and phosphatidylinositol 3-kinase (PI3K) inhibit Par1-induced VEGF expression, suggesting the participation of these kinases in the process. We also show that oncogenic transformation by genes known to be part of PAR1 signaling machinery is sufficient to increase VEGF expression in NIH 3T3 cells. These data support the novel notion that initiation of cell signaling either by activating PAR1 or by the activated forms of oncogenes is sufficient to induce VEGF and hence angiogenesis.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Oncol, IL-91010 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91010 Jerusalem, Israel; Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Technion Israel Institute of Technology	Bar-Shavit, R (corresponding author), Hadassah Univ Hosp, Dept Oncol, POB 12000, IL-91120 Jerusalem, Israel.	barshav@md.huji.ac.il	Neufeld, Gera/F-1524-2019					Bar-Shavit R, 2002, IMMUNOLOGY, V105, P35, DOI 10.1046/j.0019-2805.2001.01351.x; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P6258, DOI 10.1073/pnas.93.13.6258; Carmeliet P, 2001, SCIENCE, V293, P1602, DOI 10.1126/science.1064981; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CHEN YH, 1994, J BIOL CHEM, V269, P27372; Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; Cui JS, 1996, NATURE, V384, P66, DOI 10.1038/384066a0; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Fiedler W, 1997, BLOOD, V89, P1870, DOI 10.1182/blood.V89.6.1870; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Griffin CT, 2001, SCIENCE, V293, P1666, DOI 10.1126/science.1061259; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Huang YQ, 2001, THROMB HAEMOSTASIS, V86, P1094; Hynes RO, 1999, BRAZ J MED BIOL RES, V32, P501, DOI 10.1590/S0100-879X1999000500002; Itoh T, 1998, CANCER RES, V58, P1048; KATZAV S, 1995, ONCOGENE, V11, P1079; KATZAV S, 1993, ONCOGENE, V8, P1757; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Landau E, 2000, J BIOL CHEM, V275, P2281, DOI 10.1074/jbc.275.4.2281; LEACH KL, 1992, J BIOL CHEM, V267, P21816; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; Maulon L, 2001, ONCOGENE, V20, P1964, DOI 10.1038/sj.onc.1204266; Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PASSANITI A, 1992, LAB INVEST, V67, P519; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Preissner KT, 2000, J PATHOL, V190, P360; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; Richard DE, 2001, ONCOGENE, V20, P1556, DOI 10.1038/sj.onc.1204193; Ricketts WA, 1999, MOL ENDOCRINOL, V13, P1988, DOI 10.1210/me.13.12.1988; RICKLES FR, 1983, BLOOD, V62, P14; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shock DD, 1997, BIOCHEM J, V321, P525, DOI 10.1042/bj3210525; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SLOANE BF, 1986, P NATL ACAD SCI USA, V83, P2483, DOI 10.1073/pnas.83.8.2483; Sun WY, 1998, P NATL ACAD SCI USA, V95, P7597, DOI 10.1073/pnas.95.13.7597; TERMAN BI, 1991, ONCOGENE, V6, P1677; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; Toomey JR, 1996, BLOOD, V88, P1583; Trousseau A., 1872, LECT CLIN MED DELIVE, P281; Tsopanoglou NE, 1999, J BIOL CHEM, V274, P23969, DOI 10.1074/jbc.274.34.23969; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Xue JC, 1998, P NATL ACAD SCI USA, V95, P7603, DOI 10.1073/pnas.95.13.7603; ZACHARSKI LR, 1995, THROMB HAEMOSTASIS, V73, P793	66	100	108	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					163	174		10.1096/fj.02-0316com	http://dx.doi.org/10.1096/fj.02-0316com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554695				2022-12-28	WOS:000181456900041
J	Savarino, A; Bensi, T; Chiocchetti, A; Bottarel, F; Mesturini, R; Ferrero, E; Calosso, L; Deaglio, S; Ortolan, E; Butto, S; Cafaro, A; Katada, T; Ensoli, B; Malavasi, F; Dianzani, U				Savarino, A; Bensi, T; Chiocchetti, A; Bottarel, F; Mesturini, R; Ferrero, E; Calosso, L; Deaglio, S; Ortolan, E; Butto, S; Cafaro, A; Katada, T; Ensoli, B; Malavasi, F; Dianzani, U			Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120.	FASEB JOURNAL			English	Article						CD4; leukocyte surface antigens; lentiviruses; lymphocytes; antiviral molecules	HUMAN-IMMUNODEFICIENCY-VIRUS; LYMPHOCYTE SURFACE MOLECULES; T-CELL ACTIVATION; ANTIRETROVIRAL THERAPY; HIV-1-INFECTED CHILDREN; TYPE-1 INFECTION; LIPID RAFTS; CD4; RECEPTOR; BINDING	CD38 is a progression marker in HIV-1 infection, it displays lateral association with CD4, and down-modulates gp120/CD4 binding. The aim of this study was to elucidate the mechanism behind the interplay between CD4, CD38, and HIV-1. We used mouse cell transfectants expressing human CD4 and either CD38 or other CD4-associated molecules to show that CD38 specifically inhibits gp120/CD4 binding. Human cell transfectants expressing truncated forms of CD38 and bioinformatic analysis were used to map the anti-HIV activity and show that it is concentrated in the membrane-proximal region. This region displayed significant sequence-similarity with the V3 loop of the HIV-1 gp120 glycoprotein. In line with this similarity, synthetic soluble peptides derived from this region reproduced the anti-HIV effects of full-length CD38 and inhibited HIV-1 and HIV-2 primary isolates from different subtypes and with different coreceptor use. A multiple-branched peptide construct presenting part of the sequence of the V3-like region potently and selectively inhibited HIV-1 replication in the nanomolar range. Conversely, a deletion in the V3-like region abrogated the anti-HIV-1 activity of CD38 and its lateral association with CD4. These findings may provide new insights into the early events of HIV-1 fusion and strategies to intervene.	A Avogadro Univ Eastern Piedmont, Dept Med Sci, Immunol Lab, Interdisciplinary Res Ctr Autoimmune Dis, I-28100 Novara, Italy; Univ Turin, Dept Genet Biol & Biochem, Turin, Italy; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Tokyo, Japan; Ist Super Sanita, Virol Lab, Div Retrovirol, I-00161 Rome, Italy	University of Eastern Piedmont Amedeo Avogadro; University of Turin; University of Tokyo; Istituto Superiore di Sanita (ISS)	Savarino, A (corresponding author), A Avogadro Univ Eastern Piedmont, Dept Med Sci, Immunol Lab, Interdisciplinary Res Ctr Autoimmune Dis, Via Solaroli 17, I-28100 Novara, Italy.	asavarino@medscape.com	Cafaro, Aurelio/K-5314-2016; Dianzani, Umberto/K-1952-2016; Ensoli, Barbara/J-9169-2016; Buttò, Stefano/J-9324-2018	Ensoli, Barbara/0000-0002-0545-8737; Cafaro, Aurelio/0000-0001-9675-6344; Chiocchetti, Annalisa/0000-0002-4349-1087; Butto, Stefano/0000-0002-3289-2686; Savarino, Andrea/0000-0003-0983-3693; MALAVASI, Fabio/0000-0002-1844-174X; ORTOLAN, Erika/0000-0003-2287-9020				Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; BENJOUAD A, 1995, VIROLOGY, V206, P457, DOI 10.1016/S0042-6822(95)80061-1; Bragardo M, 1997, J IMMUNOL, V159, P1619; Carbone J, 2000, AIDS, V14, P2823, DOI 10.1097/00002030-200012220-00003; Cesano A, 1998, J IMMUNOL, V160, P1106; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; CHOE H, 1996, CELL, V85, P135; Denisova G, 1997, J IMMUNOL, V158, P1157; Dettin M, 1997, BIOCHEM BIOPH RES CO, V241, P584, DOI 10.1006/bbrc.1997.7857; DIANZANI U, 1995, EUR J IMMUNOL, V25, P1306, DOI 10.1002/eji.1830250526; DIANZANI U, 1994, J IMMUNOL, V153, P952; Feito MJ, 1997, INT IMMUNOL, V9, P1141, DOI 10.1093/intimm/9.8.1141; Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660; Hammache D, 1998, J BIOL CHEM, V273, P7967, DOI 10.1074/jbc.273.14.7967; HaraYokoyama M, 1996, J BIOL CHEM, V271, P12951, DOI 10.1074/jbc.271.22.12951; Hoffman NG, 2002, J VIROL, V76, P3852, DOI 10.1128/JVI.76.8.3852-3864.2002; Hoshino S, 1997, J IMMUNOL, V158, P741; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Kaufmann GR, 2000, AIDS, V14, P2643, DOI 10.1097/00002030-200012010-00003; Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Levy JA, 2001, TRENDS IMMUNOL, V22, P312, DOI 10.1016/S1471-4906(01)01925-1; Lichtenthaler Hartmut K., METHODS ENZYMOLOGY, P350, DOI [10.1016/0076-6879(87)48036-1, DOI 10.1016/0076-6879(90)84256-G, DOI 10.1016/0076-6879(87)48036-1]; MALAVASI F, 1984, HUM IMMUNOL, V9, P9, DOI 10.1016/0198-8859(84)90003-X; Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Moir S, 1996, J VIROL, V70, P8019, DOI 10.1128/JVI.70.11.8019-8028.1996; Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211; Munshi CB, 1997, METHOD ENZYMOL, V280, P318; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; Nardese V, 2001, NAT STRUCT BIOL, V8, P611, DOI 10.1038/89653; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; Rabehi L, 1998, AIDS RES HUM RETROV, V14, P1605, DOI 10.1089/aid.1998.14.1605; Resino S, 2001, CLIN EXP IMMUNOL, V125, P266, DOI 10.1046/j.1365-2249.2001.01612.x; Roussanov BV, 2000, AIDS, V14, P2715, DOI 10.1097/00002030-200012010-00011; Savarino A, 1999, FASEB J, V13, P2265, DOI 10.1096/fasebj.13.15.2265; Savarino A, 1999, CELL BIOCHEM FUNCT, V17, P47, DOI 10.1002/(SICI)1099-0844(199903)17:1<47::AID-CBF810>3.0.CO;2-V; Savarino A, 2000, AIDS, V14, P1079, DOI 10.1097/00002030-200006160-00004; Savarino A, 2001, AIDS, V15, P2221, DOI 10.1097/00002030-200111230-00002; Spina CA, 1997, J CLIN INVEST, V99, P1774, DOI 10.1172/JCI119342; Su J, 2000, AIDS RES HUM RETROV, V16, P37, DOI 10.1089/088922200309584; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Tilling R, 2002, AIDS, V16, P589, DOI 10.1097/00002030-200203080-00010; TRUNEH A, 1991, J BIOL CHEM, V266, P5942; Vigano A, 1998, LANCET, V352, P1905, DOI 10.1016/S0140-6736(05)60396-0; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; YAHI N, 1995, P NATL ACAD SCI USA, V92, P4867, DOI 10.1073/pnas.92.11.4867; ZANOTTO C, 1995, VIROLOGY, V206, P807, DOI 10.1006/viro.1995.1003; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353; Zubiaur M, 2002, J BIOL CHEM, V277, P13, DOI 10.1074/jbc.M107474200; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	53	26	28	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					461	+		10.1096/fj.02-0512fje	http://dx.doi.org/10.1096/fj.02-0512fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551845				2022-12-28	WOS:000181453700001
J	Leheste, JR; Melsen, F; Wellner, M; Jansen, P; Schlichting, U; Renner-Muller, I; Andreassen, TT; Wolf, E; Bachmann, S; Nykjaer, A; Willnow, TE				Leheste, JR; Melsen, F; Wellner, M; Jansen, P; Schlichting, U; Renner-Muller, I; Andreassen, TT; Wolf, E; Bachmann, S; Nykjaer, A; Willnow, TE			Hypocalcemia and osteopathy in mice with kidney-specific megalin gene defect	FASEB JOURNAL			English	Article						Cre recombinase; endocytosis; LDL receptor gene family; osteomalacia; vitamin D	D-BINDING PROTEIN; VITAMIN-D; CYTOSOLIC ADAPTER; PROXIMAL TUBULE; RECEPTOR; GP330; CLONING; FAMILY; CELLS; MODEL	Megalin is an endocytic receptor highly expressed in the proximal tubules of the kidney. Recently, we demonstrated that this receptor is essential for the renal uptake and conversion of 25-OH vitamin D(3) to 1,25-(OH)(2) vitamin D(3), a central step in vitamin D and bone metabolism. Unfortunately, the perinatal lethality of the conventional megalin knockout mouse model precluded the detailed analysis of the significance of megalin for calcium homeostasis and bone turnover in vivo. Here, we have generated a new mouse model with conditional inactivation of the megalin gene in the kidney by using Cre recombinase. Animals with a renal-specific receptor gene defect were viable and fertile. However, lack of receptor expression in the kidney results in plasma vitamin D deficiency, in hypocalcemia and in severe bone disease, characterized by a decrease in bone mineral content, an increase in osteoid surfaces, and a lack of mineralizing activity. These features are consistent with osteomalacia (softening of the bones) as a consequence of hypovitaminosis D and demonstrate the crucial importance of the megalin pathway for systemic calcium homeostasis and bone metabolism.	Free Univ Berlin, Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Free Univ Berlin, Fac Med, D-1000 Berlin, Germany; Humboldt Univ, Franz Volhard Clin, Berlin, Germany; Univ Munich, Gene Ctr, Munich, Germany; Aarhus Univ, Dept Biochem Med, Aarhus, Denmark; Aarhus Univ, Inst Anat, Dept Connect Tissue Biol, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Dept Pathol, DK-8000 Aarhus, Denmark	Free University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Franz-Volhard Clinical Research Center; Humboldt University of Berlin; University of Munich; Aarhus University; Aarhus University; Aarhus University	Willnow, TE (corresponding author), Free Univ Berlin, Max Delbruck Ctr Mol Med, Robert Roessle Str 10, D-13125 Berlin, Germany.	willnow@mdc-berlin.de		Willnow, Thomas/0000-0001-9515-7921; Wolf, Eckhard/0000-0002-0430-9510; Nykjaer, Anders/0000-0001-6422-6736				Biemesderfer D, 1999, J BIOL CHEM, V274, P17518, DOI 10.1074/jbc.274.25.17518; Birn H, 2002, AM J PHYSIOL-RENAL, V282, pF408, DOI 10.1152/ajprenal.00206.2000; Bland R, 2001, KIDNEY INT, V60, P1277, DOI 10.1046/j.1523-1755.2001.00966.x; Christensen EI, 1999, J AM SOC NEPHROL, V10, P685; Christensen EI, 1999, J AM SOC NEPHROL, V10, P2224; DELUCA HF, 1976, CLIN ENDOCRINOL, V5, pS97, DOI 10.1111/j.1365-2265.1976.tb03819.x; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HADDAD JG, 1995, J STEROID BIOCHEM, V53, P1; HILPERT J, 2002, IN PRESS KIDNEY INT; Hjalm G, 1996, EUR J BIOCHEM, V239, P132, DOI 10.1111/j.1432-1033.1996.0132u.x; Holick MF, 2000, CLIN LAB MED, V20, P569; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; Leheste JR, 1999, AM J PATHOL, V155, P1361, DOI 10.1016/S0002-9440(10)65238-8; MENDEL CM, 1989, ENDOCR REV, V10, P232, DOI 10.1210/edrv-10-3-232; MOESTRUP SK, 1995, J CLIN INVEST, V96, P1404, DOI 10.1172/JCI118176; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; Nykjaer A, 2001, P NATL ACAD SCI USA, V98, P13895, DOI 10.1073/pnas.241516998; Oleinikov AV, 2000, BIOCHEM J, V347, P613, DOI 10.1042/0264-6021:3470613; Patrie KM, 2001, J AM SOC NEPHROL, V12, P667, DOI 10.1681/ASN.V124667; Rader K, 2000, J AM SOC NEPHROL, V11, P2167, DOI 10.1681/ASN.V11122167; Safadi FF, 1999, J CLIN INVEST, V103, P239, DOI 10.1172/JCI5244; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; Schmitz C, 2002, J BIOL CHEM, V277, P618, DOI 10.1074/jbc.M109959200; Theilig F, 2001, J AM SOC NEPHROL, V12, P2209, DOI 10.1681/ASN.V12112209; White P, 2000, TRENDS ENDOCRIN MET, V11, P320, DOI 10.1016/S1043-2760(00)00317-9; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Willnow TE, 2002, CURR OPIN LIPIDOL, V13, P255, DOI 10.1097/00041433-200206000-00004; Zehnder D, 2001, J CLIN ENDOCR METAB, V86, P888, DOI 10.1210/jc.86.2.888	30	127	138	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2002	16	14					247	+		10.1096/fj.02-0578fje	http://dx.doi.org/10.1096/fj.02-0578fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475886				2022-12-28	WOS:000180574300013
J	Mariani, TJ; Budhraja, V; Mecham, BH; Gu, CC; Watson, MA; Sadovsky, Y				Mariani, TJ; Budhraja, V; Mecham, BH; Gu, CC; Watson, MA; Sadovsky, Y			A variable fold-change threshold determines significance for expression microarrays	FASEB JOURNAL			English	Article						noise; GeneChip; signal intensity; trophoblasts	ACTIVATED RECEPTOR-GAMMA; GENE-EXPRESSION; PPAR-GAMMA; DIFFERENTIATION; TROPHOBLAST	The use of expression microarrays to determine bona fide changes in gene expression between experimental paradigms is confounded by noise due to variability in measurement. To assess the variability associated with transcript hybridization to commercial oligonucleotide-based microarrays, we generated a data set consisting of five replicate hybridizations of a single labeled cRNA target from three distinct experimental paradigms, using the Affymetrix human U95 GeneChip set. We found that the variability of expression level in our data set is intensity-specific. We quantified the observed variability in our data set in order to determine significant changes in gene expression. LOESS fitting to a plot of the standard deviation of replicates assigned a variability associated with a specific intensity. This allowed for the calculation of a "variable fold-change" threshold for any absolute intensity at any level of statistical confidence. Testing of this method indicates that it removes intensity-specific bias and results in a 5- to 10-fold reduction in the number of false-positive changes. We suggest that this approach can be widely used to improve prediction of significant changes in gene expression for oligonucleotide-based microarray experiments and reduce false leads, even in the absence of replicates.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Mariani, TJ (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Med, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.	tmariani@rics.bwh.harvard.edu	Gu, C. Charles/A-7934-2010	Gu, C. Charles/0000-0002-8527-8145				Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Butte A J, 2001, Pac Symp Biocomput, P6; CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282; DeRisi J, 1996, NAT GENET, V14, P457; Ideker T, 2000, J COMPUT BIOL, V7, P805, DOI 10.1089/10665270050514945; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Long AD, 2001, J BIOL CHEM, V276, P19937, DOI 10.1074/jbc.M010192200; Nelson DM, 1999, AM J OBSTET GYNECOL, V180, P896, DOI 10.1016/S0002-9378(99)70661-7; Schaiff WT, 2000, J CLIN ENDOCR METAB, V85, P3874, DOI 10.1210/jc.85.10.3874; Tsien C L, 2001, Pac Symp Biocomput, P496; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Waite LL, 2000, J CLIN ENDOCR METAB, V85, P3808, DOI 10.1210/jc.85.10.3808; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	15	70	73	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2002	16	14					321	+		10.1096/fj.02-0351fje	http://dx.doi.org/10.1096/fj.02-0351fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475896				2022-12-28	WOS:000180574300022
J	Ritter, O; Schuh, K; Brede, M; Rothlein, N; Burkard, N; Hein, L; Neyses, L				Ritter, O; Schuh, K; Brede, M; Rothlein, N; Burkard, N; Hein, L; Neyses, L			AT(2)-Receptor activation regulates myocardial eNOS expression via the calcineurin-NF-AT pathway	FASEB JOURNAL			English	Article						angiotensin; nitric oxide synthase; hypertrophy	II TYPE-2 RECEPTOR; NITRIC-OXIDE; ANGIOTENSIN RECEPTOR; MICE LACKING; PROTEIN; HYPERTROPHY; KINASE; GENE; TRANSCRIPTION; MODULATION	Stimulation of rat cardiomyocytes with angiotensin II (AngII) increased eNOS protein expression 3.3-fold. This was blocked by Cyclosporin A (CsA). Inhibition of the AT(1)-receptor did not reduce AngII-mediated eNOS protein expression, whereas AT(2) stimulation increased it 2.4-fold and AT(2) inhibition suppressed it. The modulatory effects of the AT(2)-receptor on eNOS expression was confirmed in mice with a genetic deletion of the AT(2)-receptor (AT(2)-KO). In gel shift assays two putative NF-AT sites in a 1.6 kb eNOS promoter fragment showed NF-AT binding and a supershift by NF-AT2(-c1)-specific antibodies. Stimulation of transfected cells with AngII or specific AT(2)-receptor agonists resulted in a significant increase in eNOS promoter activity, which was blocked by CsA, MCIP1, and mutation of an upstream NF-AT site. Conclusion: 1) AngII-stimulation of the myocardium, both in vivo and in vitro, is accompanied by increased expression of eNOS. 2) This effect is mediated by the calcineurin pathway and is induced by the AT(2)-receptor. 3) These results define a calcineurin/NF-AT/eNOS pathway as downstream effector of AT(2)-receptor activation in the myocardium.	Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester Heart Ctr, Manchester M13 9WL, Lancs, England; Univ Wurzburg, Dept Med, Wurzburg, Germany; Univ Wurzburg, Dept Pharmacol & Toxicol, Wurzburg, Germany	University of Manchester; University of Wurzburg; University of Wurzburg	Neyses, L (corresponding author), Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester Heart Ctr, Oxford Rd, Manchester M13 9WL, Lancs, England.	ludwig.neyses@mhc.cmht.nwest.nhs.uk	Neyses, Ludwig/AGY-7446-2022					Akishita M, 2000, CIRCULATION, V102, P1684, DOI 10.1161/01.CIR.102.14.1684; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brede M, 2001, CIRCULATION, V104, P2602, DOI 10.1161/hc4601.099401; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; FIELDER B, 2002, P NATL ACAD SCI USA, V99, P11363; Gohlke P, 1998, HYPERTENSION, V31, P349, DOI 10.1161/01.HYP.31.1.349; Hammes A, 1998, CIRC RES, V83, P877; Hansen JL, 2000, CIRC RES, V87, P753, DOI 10.1161/01.RES.87.9.753; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; Horiuchi M, 1999, HYPERTENSION, V33, P613, DOI 10.1161/01.HYP.33.2.613; Ichihara S, 2001, CIRCULATION, V104, P346, DOI 10.1161/01.CIR.104.3.346; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; Kim YM, 1999, CIRC RES, V84, P253, DOI 10.1161/01.RES.84.3.253; Lee HT, 2001, J AM SOC NEPHROL, V12, P233, DOI 10.1681/ASN.V122233; Lu HK, 1996, AM J PHYSIOL-CELL PH, V271, pC1340, DOI 10.1152/ajpcell.1996.271.4.C1340; Matsubara H, 2001, CIRC RES, V88, P861, DOI 10.1161/hh0901.091204; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Mollnau H, 2002, CIRC RES, V90, pE58, DOI 10.1161/01.RES.0000012569.55432.02; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; Navarro-Antolin J, 2000, J BIOL CHEM, V275, P3075, DOI 10.1074/jbc.275.5.3075; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Neylon CB, 1998, CELL CALCIUM, V23, P281, DOI 10.1016/S0143-4160(98)90024-0; Ritter O, 2002, CIRCULATION, V105, P2265, DOI 10.1161/01.CIR.0000016044.19527.96; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; Schneider MD, 2001, CIRCULATION, V104, P247, DOI 10.1161/01.CIR.104.3.247; Senbonmatsu T, 2000, J CLIN INVEST, V106, pR25, DOI 10.1172/JCI10037; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; Serneri GGN, 2001, CIRC RES, V88, P961, DOI 10.1161/hh0901.089882; SEYEDI N, 1995, HYPERTENSION, V26, P164, DOI 10.1161/01.HYP.26.1.164; Sugden PH, 1999, CIRC RES, V84, P633, DOI 10.1161/01.RES.84.6.633; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; Wollert KC, 2002, HYPERTENSION, V39, P87, DOI 10.1161/hy1201.097292; Xie YW, 1996, CIRC RES, V79, P381, DOI 10.1161/01.RES.79.3.381; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320	39	54	60	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					283	+		10.1096/fj.02-0321fje	http://dx.doi.org/10.1096/fj.02-0321fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12490546				2022-12-28	WOS:000180574300031
J	Shadidi, M; Sioud, M				Shadidi, M; Sioud, M			Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells	FASEB JOURNAL			English	Article						phage display; targeting peptides; antisense; ribozyme; cellular internalization	TARGETED DRUG-DELIVERY; GENE DELIVERY; TRANSFERRIN RECEPTOR; PHAGE LIBRARIES; THERAPY; LIGANDS; SELECTION; ANTIBODY; VECTORS; INTEGRINS	Cancer therapy is currently limited by the difficulty of achieving efficient delivery into target cells. To investigate whether therapeutics can be delivered specifically to cancer cells, we have explored the possibility of selecting small peptides that bind specifically, or preferentially, to breast cancer cell lines. By using random peptide phage libraries and an experimental approach that allows the selection of internalized peptides, cell-specific binding peptides have been identified. The peptides define a major core motif (LTVXPWY) that was not found in negative phages. Phage displaying LTVSPWY peptide sequence exhibited a specific binding to breast cancer cells. None of the selected peptides bound to human primary cells from different tissue origin (e.g., epithelial, endothelial, hematopoetic). The potential of the selected peptides to mediate cellular internalization in the context of phages and recombinant GFP-peptide fusions was demonstrated. By linking the LTVSPWY peptide to an antisense phosphorothioate oligonucleotide against the ErbB2 receptor, specific delivery to cancer cells was achieved. In contrast to free antisense, the peptide-antisense conjugates inhibited ErbB2 gene expression. Thus, efficient delivery of antisense oligonucleotides can be achieved by coupling them to cancer cell-specific peptides, identified by a method that did not require any knowledge about their corresponding receptors.	Norwegian Radium Hosp, Dept Immunol, Mol Med Grp, Inst Canc Res, N-0310 Oslo, Norway	University of Oslo	Sioud, M (corresponding author), Norwegian Radium Hosp, Dept Immunol, Mol Med Grp, Inst Canc Res, N-0310 Oslo, Norway.	mosioud@ulrik.uio.no						Adams GP, 1999, J IMMUNOL METHODS, V231, P249, DOI 10.1016/S0022-1759(99)00161-1; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Avrameas A, 1999, BIOCONJUGATE CHEM, V10, P87, DOI 10.1021/bc980081c; Barry MA, 1996, NAT MED, V2, P299, DOI 10.1038/nm0396-299; Bonnycastle LLC, 1996, J MOL BIOL, V258, P747, DOI 10.1006/jmbi.1996.0284; Carter BJ, 2000, CONTRIB MICROBIOL, V4, P85; Crooke ST, 2000, METHOD ENZYMOL, V313, P3; Cunningham CC, 2001, CANCER, V92, P1265, DOI 10.1002/1097-0142(20010901)92:5<1265::AID-CNCR1447>3.0.CO;2-5; Dachs GU, 1997, ONCOL RES, V9, P313; Gewirtz AM, 1998, BLOOD, V92, P712, DOI 10.1182/blood.V92.3.712.415a32_712_736; Hong FD, 2000, CANCER RES, V60, P6551; HURFORD RK, 1995, NAT GENET, V10, P430, DOI 10.1038/ng0895-430; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Johnsson K, 1999, CURR TOP MICROBIOL, V243, P87; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; Kirpotin D, 1997, BIOCHEMISTRY-US, V36, P66, DOI 10.1021/bi962148u; Klapper LN, 2000, ADV CANCER RES, V77, P25; Koivunen E, 1999, J NUCL MED, V40, P883; Kolonin M, 2001, CURR OPIN CHEM BIOL, V5, P308, DOI 10.1016/S1367-5931(00)00207-6; Lee JH, 2001, EUR J BIOCHEM, V268, P2004, DOI 10.1046/j.1432-1327.2001.02073.x; Lee RJ, 1997, CRIT REV THER DRUG, V14, P173; Mahato RI, 1999, J DRUG TARGET, V7, P249, DOI 10.3109/10611869909085509; Mazzucchelli L, 1999, BLOOD, V93, P1738, DOI 10.1182/blood.V93.5.1738.405a18_1738_1748; Midoux P, 1999, BIOCONJUGATE CHEM, V10, P406, DOI 10.1021/bc9801070; Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2; Morris MC, 1999, NUCLEIC ACIDS RES, V27, P3510, DOI 10.1093/nar/27.17.3510; Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; PIETERSZ GA, 1992, IMMUNOL REV, V129, P57, DOI 10.1111/j.1600-065X.1992.tb01419.x; Ponka P, 1999, INT J BIOCHEM CELL B, V31, P1111, DOI 10.1016/S1357-2725(99)00070-9; Poul MA, 2000, J MOL BIOL, V301, P1149, DOI 10.1006/jmbi.2000.4026; Robbins PD, 1998, TRENDS BIOTECHNOL, V16, P35, DOI 10.1016/S0167-7799(97)01137-2; SAMBROOK J, 1989, LAB MANUAL, pE3; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Sioud M, 1996, CLIN IMMUNOL IMMUNOP, V79, P105, DOI 10.1006/clin.1996.0057; Stein CA, 2001, J CLIN INVEST, V108, P641, DOI 10.1172/JCI13885; TRAIL PA, 1993, SCIENCE, V261, P212, DOI 10.1126/science.8327892; VAUGHN JP, 1995, P NATL ACAD SCI USA, V92, P8338, DOI 10.1073/pnas.92.18.8338; Zwick MB, 1998, CURR OPIN BIOTECH, V9, P427, DOI 10.1016/S0958-1669(98)80017-7	39	117	138	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2002	16	14					256	+		10.1096/fj.02-0280fje	http://dx.doi.org/10.1096/fj.02-0280fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12490548				2022-12-28	WOS:000180574300036
J	Muller, FU; Lewin, G; Matus, M; Neumann, J; Riemann, B; Wistuba, J; Schutz, G; Schmitz, W				Muller, FU; Lewin, G; Matus, M; Neumann, J; Riemann, B; Wistuba, J; Schutz, G; Schmitz, W			Impaired cardiac contraction and relaxation and decreased expression of sarcoplasmic Ca2+-ATPase in mice lacking the CREM gene	FASEB JOURNAL			English	Article						transcription factor; cAMP response element modulator (CREM) knockout ventricular function; SERCA beta-adrenoreceptor	CONGESTIVE-HEART-FAILURE; TRANSCRIPTIONAL REGULATION; DILATED CARDIOMYOPATHY; BETA-ADRENOCEPTORS; TRANSGENIC MICE; CAMP; PROTEINS; BETA-2-ADRENOCEPTORS; ISOFORM; BETA-1-ADRENOCEPTORS	Congestive heart failure is the common endpoint of various cardiac diseases representing a leading cause of cardiovascular mortality in Western countries. Characteristic functional alterations of the failing heart are explained by expressional changes of myocardial regulatory proteins; however, little is known about underlying mechanisms regulating cardiac gene expression in the failing heart. Here, we address the specific role of transcription factor CREM for cardiac function in CREM mutant mice with complete inactivation of the CREM gene. We show that CREM mutant mice display distinct alterations of cardiac function resembling characteristic functional defects of the failing heart. Left ventricular hemodynamic assessment of CREM mutant mice revealed impairment of both cardiac contraction and relaxation in basal state, as well as a decreased responsiveness to beta-adrenergic stimulation. The diminished cardiac contractile performance was associated with a selective down-regulation of beta(1)-adrenergic receptors and a decreased ventricular expression of SERCA, the Ca2+-ATPase of the sarcoplasmic reticulum. The cardiac phenotype of CREM mutant mice provides the first evidence that CREM represents an important key regulator of cardiac gene expression, which is essential for normal left ventricular contractile performance and response to beta-adrenoreceptor stimulation.	Univ Munster, Inst Pharmacol & Toxicol, D-48149 Munster, Germany; Univ Munster, Dept Nucl Med, D-48149 Munster, Germany; Univ Munster, Inst Reprod Med, D-48149 Munster, Germany; German Canc Res Ctr, Mol Biol Cell Div 1, D-6900 Heidelberg, Germany	University of Munster; University of Munster; University of Munster; Helmholtz Association; German Cancer Research Center (DKFZ)	Muller, FU (corresponding author), Univ Munster, Inst Pharmacol & Toxicol, Domagkstr 12, D-48149 Munster, Germany.	mullerf@uni-muenster.de						[Anonymous], 1990, Lancet, V336, P1; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; BRODDE OE, 1991, PHARMACOL REV, V43, P203; Cho MC, 1999, J BIOL CHEM, V274, P22251, DOI 10.1074/jbc.274.32.22251; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; Cohn JN, 1996, NEW ENGL J MED, V335, P490, DOI 10.1056/NEJM199608153350707; Colucci WS., 1997, HEART DIS TXB CARDIO, P394; DOOLEY DJ, 1986, EUR J PHARMACOL, V130, P137, DOI 10.1016/0014-2999(86)90193-7; ENGEL G, 1981, N-S ARCH PHARMACOL, V317, P277, DOI 10.1007/BF00501307; ESCHENHAGEN T, 1992, MOL PHARMACOL, V42, P773; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; Hjalmarson A, 2000, JAMA-J AM MED ASSOC, V283, P1295, DOI 10.1001/jama.283.10.1295; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luss I, 1999, J MOL CELL CARDIOL, V31, P1299, DOI 10.1006/jmcc.1999.0962; Mehrhof FB, 2001, CIRCULATION, V104, P2088, DOI 10.1161/hc4201.097133; Mittmann C, 1998, CARDIOVASC RES, V39, P267, DOI 10.1016/S0008-6363(98)00139-4; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Moriscot AS, 1997, ENDOCRINOLOGY, V138, P26, DOI 10.1210/en.138.1.26; MOTOMURA S, 1990, BRIT J PHARMACOL, V101, P363, DOI 10.1111/j.1476-5381.1990.tb12715.x; MULLER FU, 1995, CIRCULATION, V92, P2041, DOI 10.1161/01.CIR.92.8.2041; Muller FU, 2000, MOL CELL BIOCHEM, V212, P11, DOI 10.1023/A:1007176030884; Muller FU, 1998, FASEB J, V12, P1191; MULLER FU, 1993, CIRC RES, V72, P696, DOI 10.1161/01.RES.72.3.696; Muller FU, 2001, CARDIOVASC RES, V52, P95, DOI 10.1016/S0008-6363(01)00361-3; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHIMOMURA H, 1990, NUCLEIC ACIDS RES, V18, P4591, DOI 10.1093/nar/18.15.4591; Sigmund M, 1996, EUR J CLIN PHARMACOL, V51, P127, DOI 10.1007/s002280050172; STEINFATH M, 1992, J MOL CELL CARDIOL, V24, P1189, DOI 10.1016/0022-2828(92)93182-J; Zhang L, 2001, J MOL CELL CARDIOL, V33, P233, DOI 10.1006/jmcc.2000.1295	36	35	35	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					103	+		10.1096/fj.02-0486fje	http://dx.doi.org/10.1096/fj.02-0486fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475904				2022-12-28	WOS:000180218500013
J	Copani, A; Sortino, MA; Caricasole, A; Chiechio, S; Chisari, M; Battaglia, G; Giuffrida-Stella, AM; Vancheri, C; Nicoletti, F				Copani, A; Sortino, MA; Caricasole, A; Chiechio, S; Chisari, M; Battaglia, G; Giuffrida-Stella, AM; Vancheri, C; Nicoletti, F			Erratic expression of DNA polymerases by beta-amyloid causes neuronal death	FASEB JOURNAL			English	Article						Alzheimer's; cell cycle; DNA replication; apoptosis	CYCLIN-DEPENDENT KINASES; BASE EXCISION-REPAIR; REPLICATION; INVOLVEMENT; OVEREXPRESSION; REQUIREMENT; INSTABILITY; ACTIVATION; APOPTOSIS; PROTEINS	An ectopic reentrance into the cell cycle with ensuing DNA replication is required for neuronal apoptosis induced by beta-amyloid. Here, we investigate the repertoire of DNA polymerases expressed in beta-amyloid-treated neurons, and their specific role in DNA synthesis and apoptosis. We show that exposure of cultured cortical neurons to beta-amyloid induces the expression of DNA polymerase-beta, proliferating cell nuclear antigen, and the p49 and p58 subunits of DNA primase. Induction requires the activity of cyclin-dependent kinases. The knockdown of the p49 primase subunit prevents beta-amyloid-induced neuronal DNA synthesis and apoptosis. Similar effects are observed by knocking down DNA polymerase-beta or by using dideoxycytidine, a preferential inhibitor of this enzyme. Thus, the reparative enzyme DNA polymerase-beta unexpectedly mediates a large component of de novo DNA synthesis and apoptotic death in neurons exposed to beta-amyloid. These data indicate that DNA polymerases become death signals when erratically expressed by differentiated neurons.	Univ Catania, Dept Pharmaceut Sci, I-95125 Catania, Italy; Univ Catania, Dept Expt & Clin Pharmacol, I-95125 Catania, Italy; Univ Catania, Dept Chem Sci, I-95125 Catania, Italy; Univ Catania, Inst Resp Dis, I-95125 Catania, Italy; Univ Roma La Sapienza, Dept Human Physiol & Pharmacol, I-00185 Rome, Italy; INM Neuromed, I-86077 Pozzilli, Italy	University of Catania; University of Catania; University of Catania; University of Catania; Sapienza University Rome; IRCCS Neuromed	Copani, A (corresponding author), Univ Catania, Dept Pharmaceut Sci, Viale A Doria 6, I-95125 Catania, Italy.	acopani@katamail.com	Chiechio, Santina/E-2212-2018; Nicoletti, Ferdinando/T-4898-2019; Nicoletti, Ferdinando/K-4410-2016; Battaglia, Giuseppe/A-7709-2010; VANCHERI, Carlo/K-9417-2016; Nicoletti, Ferdinando/A-2446-2010	Chiechio, Santina/0000-0003-4648-391X; Battaglia, Giuseppe/0000-0001-7571-3417; NICOLETTI, Ferdinando/0000-0003-3366-7269; Sortino, Maria Angela/0000-0002-2734-1521; VANCHERI, Carlo/0000-0002-5120-9926; Nicoletti, Ferdinando/0000-0003-0917-443X				Blasko I, 2000, FEBS LETT, V470, P221, DOI 10.1016/S0014-5793(00)01323-5; Canitrot Y, 1999, FASEB J, V13, P1107, DOI 10.1096/fasebj.13.9.1107; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; Canitrot Y, 2000, FASEB J, V14, P1765, DOI 10.1096/fj.99-1063com; Caricasole A, 2000, BBA-GENE STRUCT EXPR, V1517, P63, DOI 10.1016/S0167-4781(00)00260-8; Copani A, 1999, FASEB J, V13, P2225, DOI 10.1096/fasebj.13.15.2225; Copani A, 2001, TRENDS NEUROSCI, V24, P25, DOI 10.1016/S0166-2236(00)01663-5; Frechet M, 2002, ONCOGENE, V21, P2320, DOI 10.1038/sj.onc.1205295; Frechet M, 2001, FEBS LETT, V505, P229, DOI 10.1016/S0014-5793(01)02834-4; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Giovanni A, 1999, J BIOL CHEM, V274, P19011, DOI 10.1074/jbc.274.27.19011; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Husseman JW, 2000, NEUROBIOL AGING, V21, P815, DOI 10.1016/S0197-4580(00)00221-9; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; LEE MYWT, 1985, NUCLEIC ACIDS RES, V13, P8623, DOI 10.1093/nar/13.23.8623; Matsuo K, 2000, FASEB J, V14, P1318, DOI 10.1096/fj.14.10.1318; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Rao KS, 2001, ANN NY ACAD SCI, V928, P113; ROELEN BAJ, 1994, DEV BIOL, V166, P716, DOI 10.1006/dbio.1994.1350; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; Servant L, 2002, J MOL BIOL, V315, P1039, DOI 10.1006/jmbi.2001.5307; SIEGEL RL, 1982, J BIOL CHEM, V257, P1785; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; Sugo N, 2000, EMBO J, V19, P1397, DOI 10.1093/emboj/19.6.1397; Sutton MD, 2001, P NATL ACAD SCI USA, V98, P8342, DOI 10.1073/pnas.111036998; SWEASY JB, 1992, J BIOL CHEM, V267, P1407; Yang Y, 2001, J NEUROSCI, V21, P2661, DOI 10.1523/JNEUROSCI.21-08-02661.2001; ZMUDZKA BZ, 1988, NUCLEIC ACIDS RES, V16, P9587, DOI 10.1093/nar/16.20.9587	34	51	52	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					2006	+		10.1096/fj.02-0422fje	http://dx.doi.org/10.1096/fj.02-0422fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397084				2022-12-28	WOS:000179167600002
J	Garrido, JL; Godoy, J; Alvarez, A; Bronfman, M; Inestrosa, NC				Garrido, JL; Godoy, J; Alvarez, A; Bronfman, M; Inestrosa, NC			Protein kinase C inhibits amyloid beta-peptide neurotoxicity by acting on members of the Wnt pathway	FASEB JOURNAL			English	Article						A beta neurotoxicity; PKC; Wnt signaling	GLYCOGEN-SYNTHASE KINASE-3-BETA; ALZHEIMERS-DISEASE; HIPPOCAMPAL-NEURONS; SIGNALING PATHWAY; PRECURSOR PROTEIN; CATENIN; PHOSPHORYLATION; ACTIVATION; APOPTOSIS; CELLS	Current evidence supports the notion that the amyloid beta-peptide (Abeta) plays a major role in the neurotoxicity observed in the brain in Alzheimer's disease. However, the signal transduction mechanisms involved still remain unknown. In the present work, we analyzed the effect of protein kinase C (PKC) on some members of the Writ signaling pathway and its implications for Abeta neurotoxicity. Activation of PKC by phorbol 12-myristate 13-acetate protected rat hippocampal neurons from A(3 toxicity. This effect was accomplished by inhibition of glycogen synthase kinase-3beta (GSK-3beta) activity, which led to the accumulation of cytoplasmic beta-catenin and transcriptional activation via beta-catenin/T-cell factor/lymphoid enhancer factor-1 (TCF/LEF-1) of Writ target genes, which in the present study were engrailed-1 (en-1) and cyclin D1 (cycD1). In contrast, inhibition of Ca2+-dependent PKC isoforms activated GSK-3beta and offered no protection from Abeta neurotoxicity. Wnt-3a and lithium salts, classical activators of the Writ pathway, mimicked PKC activation. Our results suggest that regulation of members of the Writ signaling pathway by Ca2+-dependent PKC isoforms may be important in controlling the neurotoxic process induced by Abeta.	Pontificia Univ Catolica Chile, Mol Neurobiol Unit, Ctr Regulac Celular & Patol, MIFAB,Fac Ciencias Biol, Santiago, Chile	Pontificia Universidad Catolica de Chile	Inestrosa, NC (corresponding author), Pontificia Univ Catolica Chile, Mol Neurobiol Unit, Ctr Regulac Celular & Patol, MIFAB,Fac Ciencias Biol, Alameda 340, Santiago, Chile.	ninestr@genes.bio.puc.cl	Godoy, Juan A/F-5398-2018	Godoy, Juan A/0000-0001-9920-6698; Alvarez Rojas, Alejandra/0000-0002-8129-9280				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alvarez A, 1998, J NEUROSCI, V18, P3213; Behrens MM, 1999, NEUROSCIENCE, V94, P917, DOI 10.1016/S0306-4522(99)00212-2; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; BRUEL A, 1991, NEUROSCI LETT, V133, P89, DOI 10.1016/0304-3940(91)90064-Z; CACERES A, 1984, DEV BRAIN RES, V13, P314, DOI 10.1016/0165-3806(84)90167-6; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Calderon FH, 1998, MOL PSYCHIATR, V3, P247, DOI 10.1038/sj.mp.4000383; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; De Ferrari GV, 2000, BRAIN RES REV, V33, P1, DOI 10.1016/S0165-0173(00)00021-7; DEFERRARI GV, 2002, IN PRESS MOL PSYCHIA; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Favit A, 1998, P NATL ACAD SCI USA, V95, P5562, DOI 10.1073/pnas.95.10.5562; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Galceran J, 2000, DEVELOPMENT, V127, P469; Garcia-Huidobro T, 1999, EUR J BIOCHEM, V266, P855, DOI 10.1046/j.1432-1327.1999.00923.x; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; GOODE N, 1992, J BIOL CHEM, V267, P16878; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Kang DE, 1999, J NEUROSCI, V19, P4229; Lee SMK, 2000, DEVELOPMENT, V127, P457; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Ma WY, 2001, EUR J NEUROSCI, V13, P1125, DOI 10.1046/j.1460-9568.2001.01475.x; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shibamoto S, 1998, GENES CELLS, V3, P659; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; Takashima A, 1998, NEUROSCI RES, V31, P317, DOI 10.1016/S0168-0102(98)00061-3; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; Xie J, 2000, MOL BRAIN RES, V82, P107, DOI 10.1016/S0169-328X(00)00187-X; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	43	137	145	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1982	+		10.1096/fj.02-0327fje	http://dx.doi.org/10.1096/fj.02-0327fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397090				2022-12-28	WOS:000179167600001
J	Mascolo, N; Izzo, AA; Ligresti, A; Costagliola, A; Pinto, L; Cascio, MG; Maffia, P; Cecio, A; Capasso, F; Di Marzo, V				Mascolo, N; Izzo, AA; Ligresti, A; Costagliola, A; Pinto, L; Cascio, MG; Maffia, P; Cecio, A; Capasso, F; Di Marzo, V			The endocannabinoid system and the molecular basis of paralytic ileus in mice	FASEB JOURNAL			English	Article						anandamide transport; cannabinoid receptors; intestine; myenteric plexus	GUINEA-PIG ILEUM; IRRITATION-INDUCED ILEUS; GASTROINTESTINAL TRANSIT; PERITONEAL-IRRITATION; POSTOPERATIVE ILEUS; CANNABINOID RECEPTORS; LONGITUDINAL MUSCLE; CHOLINERGIC NEURONS; CIRCULAR MUSCLE; SMALL-INTESTINE	The endocannabinoid system (i.e., the cannabinoid receptors and their endogenous ligands) plays an important role in the physiological control of intestinal motility. However, its participation in intestinal pathological states is still poorly understood. In the present study, we investigated the possible role of the endocannabinoid system in the pathogenesis of paralytic ileus, a pathological state consisting of decreased intestinal motility following peritonitis, surgery, or other noxious situations. Ileus was induced by i.p. administration of acetic acid, and gastrointestinal propulsion was assessed by the charcoal method. Endocannabinoid levels were measured by isotope-dilution gas chromatography-mass spectrometry, whereas cannabinoid CB1 receptors were identified by immunohistochemistry. Acetic acid administration inhibited gastrointestinal transit (ileus), and this effect was accompanied by increased levels of the endocannabinoid anandamide compared with control mice and by overexpression of CB1 receptors in myenteric nerves. Furthermore, acetic acid-induced ileus was alleviated by the CB1 receptor antagonist SR141716A and worsened by VDM11, a selective inhibitor of anandamide cellular uptake (and hence inactivation). From these findings, it can be concluded that the intestinal hypomotility typical of paralytic ileus is due, at least in part, to the enhancement of anandamide levels and CB1 expression during this condition, and that selective, nonpsychotropic CB1 receptor antagonists could represent new drugs to treat this disorder.	Univ Naples Federico II, Dept Expt Pharmacol, I-80131 Naples, Italy; CNR, Inst Biomol Chem, I-80078 Pozzuoli, NA, Italy; Univ Naples Federico II, Dept Biol Struct Funct & Technol, I-80137 Naples, Italy; Dept Pharmaceut Sci, I-84084 Fisciano, SA, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Izzo, AA (corresponding author), Univ Naples Federico II, Dept Expt Pharmacol, Via D Montesano 49, I-80131 Naples, Italy.	aaizzo@unina.it; vdimarzo@icmib.na.cnr.it	Ligresti, Alessia/B-7564-2015; Di Marzo, Vincenzo/AAD-7742-2019	Ligresti, Alessia/0000-0003-1787-3900; Di Marzo, Vincenzo/0000-0002-1490-3070; Izzo, Angelo/0000-0002-8557-2133				Baker D, 2001, FASEB J, V15, P300, DOI 10.1096/fj.00-0399fje; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; Bisogno T, 1999, BIOCHEM BIOPH RES CO, V256, P377, DOI 10.1006/bbrc.1999.0254; Brown DR, 2001, ADV EXP MED BIOL, V493, P197; Bueno L, 1978, DIGEST DIS SCI, V23, P690; Calignano A, 1997, EUR J PHARMACOL, V340, pR7; Capasso R, 2001, BRIT J PHARMACOL, V134, P945, DOI 10.1038/sj.bjp.0704339; COUSINS HM, 1995, NEUROSCIENCE, V65, P193, DOI 10.1016/0306-4522(94)00466-I; Coutts AA, 2002, J COMP NEUROL, V448, P410, DOI 10.1002/cne.10270; Coutts AA, 1997, BRIT J PHARMACOL, V121, P1557, DOI 10.1038/sj.bjp.0701301; De Petrocellis L, 2000, FEBS LETT, V483, P52, DOI 10.1016/S0014-5793(00)02082-2; DeWinter BY, 1997, BRIT J PHARMACOL, V120, P464, DOI 10.1038/sj.bjp.0700913; Di Marzo V, 2000, CURR PHARM DESIGN, V6, P1361; FONTAINE J, 1984, BRIT J PHARMACOL, V81, P231, DOI 10.1111/j.1476-5381.1984.tb10070.x; FRIDE E, 1995, BRAIN RES, V697, P83, DOI 10.1016/0006-8993(95)00790-W; Friese N, 1997, LIFE SCI, V60, P625, DOI 10.1016/S0024-3205(96)00647-9; FURNESS JB, 1974, MED BIOL, V52, P82; GALLIGAN JJ, 1986, J PHARMACOL EXP THER, V238, P594; GRISPOON L, 1997, MARIHUANA FORBIDDEN; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; Hanus L, 1999, P NATL ACAD SCI USA, V96, P14228, DOI 10.1073/pnas.96.25.14228; Heinemann A, 1999, NEUROPHARMACOLOGY, V38, P1289, DOI 10.1016/S0028-3908(99)00056-8; HOLZER P, 1986, GASTROENTEROLOGY, V91, P360, DOI 10.1016/0016-5085(86)90569-X; HOLZER P, 1984, BRIT J PHARMACOL, V82, P259, DOI 10.1111/j.1476-5381.1984.tb16466.x; Izzo AA, 2001, BRIT J PHARMACOL, V132, P1411, DOI 10.1038/sj.bjp.0703975; Izzo AA, 2000, BRIT J PHARMACOL, V129, P1627, DOI 10.1038/sj.bjp.0703265; Izzo AA, 1998, BRIT J PHARMACOL, V124, P1363, DOI 10.1038/sj.bjp.0701964; Izzo AA, 2001, BRIT J PHARMACOL, V134, P563, DOI 10.1038/sj.bjp.0704293; Izzo Angelo A., 2001, Current Opinion in Pharmacology, V1, P597, DOI 10.1016/S1471-4892(01)00102-3; Kalff JC, 1999, GASTROENTEROLOGY, V117, P378, DOI 10.1053/gast.1999.0029900378; Kalff JC, 2000, GASTROENTEROLOGY, V118, P316, DOI 10.1016/S0016-5085(00)70214-9; Kulkarni-Narla A, 2000, CELL TISSUE RES, V302, P73, DOI 10.1007/s004410000261; LIVINGSTON EH, 1990, DIGEST DIS SCI, V35, P121, DOI 10.1007/BF01537233; MAGGI CA, 1994, N-S ARCH PHARMACOL, V350, P529; Mang CF, 2001, BRIT J PHARMACOL, V134, P161, DOI 10.1038/sj.bjp.0704220; MILLER MS, 1981, J PHARMACOL METHOD, V6, P211, DOI 10.1016/0160-5402(81)90110-8; OKASORA T, 1986, GASTROENTEROLOGY, V90, P1964, DOI 10.1016/0016-5085(86)90268-4; PAIRET M, 1989, J PHARM PHARMACOL, V41, P757, DOI 10.1111/j.2042-7158.1989.tb06360.x; Pertwee RG, 1996, BRIT J PHARMACOL, V118, P2199, DOI 10.1111/j.1476-5381.1996.tb15663.x; Pertwee RG, 2001, GUT, V48, P859, DOI 10.1136/gut.48.6.859; Pinto L, 2002, GASTROENTEROLOGY, V123, P227, DOI 10.1053/gast.2002.34242; RINALDICARMONA M, 1995, LIFE SCI, V56, P1941, DOI 10.1016/0024-3205(95)00174-5; RIVIERE PJM, 1993, GASTROENTEROLOGY, V104, P724, DOI 10.1016/0016-5085(93)91007-5; RIVIERE PJM, 1994, J PHARMACOL EXP THER, V270, P846; Sang Q, 1998, ANAT REC, V251, P185; Schwarz NT, 2001, GASTROENTEROLOGY, V121, P1354, DOI 10.1053/gast.2001.29605; SIMS SM, 1986, TRENDS PHARMACOL SCI, V11, P1; Tache Y., 1991, J GASTROINTEST MOTIL, V3, P19; Tallarida RJ, 1986, MANUAL PHARM CALCULA; UNEKWE PC, 1991, PHARMACOL RES, V23, P389, DOI 10.1016/1043-6618(91)90053-Z; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Van Sickle MD, 2001, GASTROENTEROLOGY, V121, P767, DOI 10.1053/gast.2001.28466; WARD SM, 1994, J PHYSIOL-LONDON, V480, P91, DOI 10.1113/jphysiol.1994.sp020343	53	76	79	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1973	+		10.1096/fj.02-0338fje	http://dx.doi.org/10.1096/fj.02-0338fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397089				2022-12-28	WOS:000179167600008
J	Magnaghi, V; Veber, D; Morabito, A; Buccellato, FR; Melcangi, RC; Scalabrino, G				Magnaghi, V; Veber, D; Morabito, A; Buccellato, FR; Melcangi, RC; Scalabrino, G			Decreased GFAP-mRNA expression in spinal cord of cobalamin-deficient rats	FASEB JOURNAL			English	Article						CNS; hypothalamus; subacute combined degeneration; vitamin B12	FIBRILLARY ACIDIC PROTEIN; SUBACUTE COMBINED DEGENERATION; TOTALLY GASTRECTOMIZED RATS; EPIDERMAL GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; MYELIN BASIC-PROTEIN; GENE-EXPRESSION; GLIAL-CELLS; ORNITHINE DECARBOXYLASE; VITAMIN-B-12 COBALAMIN	We have demonstrated previously that chronic vitamin B-12 [cobalamin (Cbl)] deficiency preferentially affects glial cells in the rat central nervous system (CNS) and severely affects peripheral glial cells independently of and concomitantly with the central neuropathy. In this study, we determined the mRNA levels for myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in different CNS areas of rats made Cbl-deficient by total gastrectomy, as well as the mRNA levels for glycoprotein P-o and peripheral myelin protein (PMP)(22) in the sciatic nerve. GFAP-mRNA levels were significantly decreased in the spinal cord (SC) and hypothalamus, but not in the cortex, hippocampus, or striatum of totally gastrectomized (TGX) rats. No differences in GFAP protein levels were found in the SC and hypothalamus of the TGX rats treated or not with Cbl. MBP-mRNA levels were significantly decreased only in the hypothalamus, and the levels of mRNA for both glial markers returned to normal with Cbl replacement therapy. The levels of mRNA for the various myelin proteins in the sciatic nerve were not modified by Cbl deficiency. These results demonstrate that: a) the neurotrophic action of Cbl in rat CNS occurs in a zonal manner; and b) Cbl deficiency does not affect myelin synthesis (with the sole exception of the hypothalamus).	Univ Milan, Inst Gen Pathol, I-20133 Milan, Italy; Univ Milan, Dept Endocrinol, I-20133 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy; Univ Milan, Inst Biometr & Med Stat, I-20133 Milan, Italy	University of Milan; University of Milan; University of Milan; University of Milan	Scalabrino, G (corresponding author), Univ Milan, Inst Gen Pathol, Via Mangiagalli 31, I-20133 Milan, Italy.	giuseppe.scalabrino@unimi.it	Melcangi, Roberto Cosimo/AAA-6534-2022	MELCANGI, COSIMO ROBERTO/0000-0003-0861-8967				Armitage P, 1994, STAT METHODS MED RES, P312; AVOLA R, 1988, J NEUROSCI RES, V19, P230, DOI 10.1002/jnr.490190208; Bartlett MS, 1937, PROC R SOC LON SER-A, V160, P0268, DOI 10.1098/rspa.1937.0109; Beck W S, 1991, Adv Intern Med, V36, P33; Buccellato FR, 1999, FASEB J, V13, P297, DOI 10.1096/fasebj.13.2.297; Campagnoni A, 2001, BRAIN PATHOL, V11, P74; Carenini S, 1999, GLIA, V27, P203, DOI 10.1002/(SICI)1098-1136(199909)27:3<203::AID-GLIA2>3.3.CO;2-Z; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHL D, 1981, EUR J CELL BIOL, V24, P191; DEACON R, 1986, J NEUROL SCI, V72, P113, DOI 10.1016/0022-510X(86)90040-7; Dyer CA, 2000, J NEUROSCI RES, V60, P412, DOI 10.1002/(SICI)1097-4547(20000501)60:3<412::AID-JNR16>3.3.CO;2-5; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; LAPING NJ, 1994, BRAIN PATHOL, V1, P259; Lemke G., 1992, INTRO MOL NEUROBIOLO, P281; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; Martini R, 1997, GLIA, V19, P298; MCQUEEN JK, 1994, J ENDOCRINOL, V143, P411, DOI 10.1677/joe.0.1430411; Melcangi R C, 2001, Prog Brain Res, V132, P31; Melcangi RC, 1997, J NEUROENDOCRINOL, V9, P729, DOI 10.1046/j.1365-2826.1997.00621.x; Melcangi RC, 1999, J NEUROBIOL, V40, P471, DOI 10.1002/(SICI)1097-4695(19990915)40:4<471::AID-NEU5>3.0.CO;2-P; Melcangi RC, 1999, J NEUROSCI RES, V56, P349, DOI 10.1002/(SICI)1097-4547(19990515)56:4<349::AID-JNR3>3.3.CO;2-8; Melcangi RC, 1996, BRAIN RES, V711, P10, DOI 10.1016/0006-8993(95)01302-4; Morell Pierre, 1999, P69; MORRISON RS, 1985, J NEUROSCI RES, V14, P167, DOI 10.1002/jnr.490140202; Newman Sammye, 1995, P535; PANT SS, 1968, ACTA NEUROL SCAN S35, V44, P8; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; Powers J, 1996, MOL CHEM NEUROPATHOL, V27, P31, DOI 10.1007/BF02815031; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; SAVAGE DG, 1995, BAILLIERE CLIN HAEM, V8, P657, DOI 10.1016/S0950-3536(05)80225-2; Scalabrino G, 1999, FASEB J, V13, P2083, DOI 10.1096/fasebj.13.14.2083; SCALABRINO G, 1995, LAB INVEST, V72, P114; Scalabrino G, 2000, J NEUROPATH EXP NEUR, V59, P808, DOI 10.1093/jnen/59.9.808; SCALABRINO G, 1990, LAB INVEST, V62, P297; Shibuki K, 1996, NEURON, V16, P587, DOI 10.1016/S0896-6273(00)80078-1; Staugaitis SM, 1996, BIOESSAYS, V18, P13, DOI 10.1002/bies.950180106; TAKAHASHI Y, 1992, PROG NEUROBIOL, V38, P523, DOI 10.1016/0301-0082(92)90041-C; Tredici G, 1998, J SUBMICR CYTOL PATH, V30, P165; Tredici G, 1998, J NEUROL SCI, V156, P18, DOI 10.1016/S0022-510X(98)00005-7; Walz W, 2000, GLIA, V31, P95, DOI 10.1002/1098-1136(200008)31:2<95::AID-GLIA10>3.0.CO;2-6; Wu VW, 1998, J NEUROSCI RES, V51, P675, DOI 10.1002/(SICI)1097-4547(19980315)51:6<675::AID-JNR2>3.3.CO;2-N	45	16	16	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2002	16	11					1820	+		10.1096/fj.02-0231fje	http://dx.doi.org/10.1096/fj.02-0231fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12354698				2022-12-28	WOS:000178441800001
J	Corbi, N; Di Padova, M; De Angelis, R; Bruno, T; Libri, V; Iezzi, S; Floridi, A; Fanciulli, M; Passananti, C				Corbi, N; Di Padova, M; De Angelis, R; Bruno, T; Libri, V; Iezzi, S; Floridi, A; Fanciulli, M; Passananti, C			The alpha-like RNA polymerase II core subunit 3 (RPB3) is involved in tissue-specific transcription and muscle differentiation via interaction with the myogenic factor myogenin	FASEB JOURNAL			English	Article						pol II subunits; doxorubicin; yeast two hybrid	YEAST; DOXORUBICIN; MYOD; INTERFERENCE; ADRIAMYCIN; PROTEINS; MUTATION; FAMILY	RNA polymerase II core subunit 3 (RPB3) is an alpha-like core subunit of RNA polymerase II (pol II). It is selectively down-regulated upon treatment with doxorubicin (dox). Due to the failure of skeletal muscle cells to differentiate when exposed to dox, we hypothesized that RPB3 is involved in muscle differentiation. To this end, we have isolated human muscle RPB3-interacting proteins by using yeast two-hybrid screening. It is of interest that an interaction between RPB3 and the myogenic transcription factor myogenin was identified. This interaction involves a specific region of RPB3 protein that is not homologous to the prokaryotic alpha subunit. Although RPB3 contacts the basic helix-loop-helix (HLH) region of myogenin, it does not bind other HLH myogenic factors such as MyoD, Myf5, and MRF4. Coimmunoprecipitation experiments indicate that myogenin contacts the pol II complex and that the RPB3 subunit is responsible for this interaction. We show that RPB3 expression is regulated during muscle differentiation. Exogenous expression of RPB3 slightly promotes myogenin transactivation activity and muscle differentiation, whereas the region of RPB3 that contacts myogenin, when used as a dominant negative molecule (Sud), counteracts these effects. These results indicate for the first time that the RPB3 pol II subunit is involved in the regulation of tissue-specific transcription.	CNR, Ist Tecnol Biomed, I-00137 Rome, Italy; Regina Elena Inst Canc Res, Cell Metab & Pharmacokinet Lab, I-00158 Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of L'Aquila	Passananti, C (corresponding author), CNR, Ist Tecnol Biomed, Viale Marx 43, I-00137 Rome, Italy.	passananti@itbm.rm.cnr.it	Iezzi, Simona/AAA-3275-2021; Corbi, Nicoletta/AAW-8835-2020; Corbi, Nicoletta/K-2313-2014; bruno, tiziana/AAC-4913-2022; Passananti, Claudio/K-9593-2016; fanciulli, maurizio/ABH-6745-2020	Iezzi, Simona/0000-0002-7484-5861; bruno, tiziana/0000-0003-0352-4523; DI PADOVA, Monica/0000-0003-3808-7159; PASSANANTI, CLAUDIO/0000-0002-9288-5736; CORBI, NICOLETTA/0000-0002-4505-1632; Libri, Valentina/0000-0002-2080-1089	Telethon [A.160] Funding Source: Medline	Telethon(Fondazione Telethon)		AZUMA Y, 1993, NUCLEIC ACIDS RES, V21, P3749, DOI 10.1093/nar/21.16.3749; Bergstrom DA, 2001, MOL CELL BIOL, V21, P2404, DOI 10.1128/MCB.21.7.2404-2412.2001; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Biesiada E, 1999, MOL CELL BIOL, V19, P2577; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DOROSHOW JH, 1983, CANCER RES, V43, P4543; Fanciulli M, 1998, FEBS LETT, V427, P236, DOI 10.1016/S0014-5793(98)00431-1; Fanciulli M, 1996, FEBS LETT, V384, P48, DOI 10.1016/0014-5793(96)00277-3; FORNARI FA, 1994, MOL PHARMACOL, V45, P649; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Groisman R, 1996, J BIOL CHEM, V271, P5258; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Ishihama A, 1981, Adv Biophys, V14, P1; Kimura M, 1997, J BIOL CHEM, V272, P25851, DOI 10.1074/jbc.272.41.25851; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KOLODZIEJ PA, 1991, MOL CELL BIOL, V11, P4669, DOI 10.1128/MCB.11.9.4669; Korobko IV, 1997, GENE, V185, P1, DOI 10.1016/S0378-1119(96)00626-9; KURABAYASHI M, 1993, J BIOL CHEM, V268, P5524; KURABAYASHI M, 1994, J BIOL CHEM, V269, P6031; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; Larkin RM, 1997, J BIOL CHEM, V272, P12824, DOI 10.1074/jbc.272.19.12824; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MAIONE R, 1997, BIOCHIM BIOPHYS ACTA, V1332, P19; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MOLTENKIN JD, 1995, CELL, V83, P1125; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OLSON E, 1992, SYM SOC EXP BIOL, V46, P331; PATI UK, 1994, GENE, V145, P289, DOI 10.1016/0378-1119(94)90022-1; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Rawls A, 1998, DEVELOPMENT, V125, P2349; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Schneider S, 1996, BIOTECHNIQUES, V20, P960; SIEGFRIED JA, 1983, J BIOL CHEM, V258, P339; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; Tan Q, 2000, GENE DEV, V14, P339; TREICH I, 1991, J BIOL CHEM, V266, P21971; Ulmasov T, 1996, J BIOL CHEM, V271, P5085, DOI 10.1074/jbc.271.9.5085; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; Woychik Nancy A., 1993, Gene Expression, V3, P77; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; Yasui K, 1998, BIOCHEMISTRY-US, V37, P5542, DOI 10.1021/bi972939b; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; YU YJ, 1994, MUTAT RES LETT, V325, P91, DOI 10.1016/0165-7992(94)90007-8; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	50	21	21	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1639	+		10.1096/fj.02-0123fje	http://dx.doi.org/10.1096/fj.02-0123fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207009				2022-12-28	WOS:000177814000018
J	Harteneck, C; Kuchta, SN; Huber, A; Paulsen, R; Schultz, G				Harteneck, C; Kuchta, SN; Huber, A; Paulsen, R; Schultz, G			The PDZ-scaffold protein INAD abolishes apparent store-dependent regulation of the light-activated cation channel TRP	FASEB JOURNAL			English	Article						photoreceptors; TRP channels; PDZ proteins	DROSOPHILA TRP; SIGNALING COMPLEXES; DOMAIN PROTEIN; CA2+ CHANNEL; VISUAL TRANSDUCTION; INSP(3) RECEPTOR; KINASE-C; PHOTORECEPTORS; BINDING; GENE	In fly photoreceptor cells, light initiates a G protein-coupled phospholipase Cbeta-dependent signaling cascade that results in the depolarization of the cell membrane, which is mediated by the cation channels TRP and TRPL. Together with phospholipase Cbeta and an eye-specific protein kinase C, TRP is tethered to the scaffolding protein INAD, which forms a multimolecular signaling complex. Divergent data from expressed TRP and studies from photoreceptor cells have brought up a controversy whether or not a capacitative calcium entry (CCE) mechanism is involved in the Drosophila phototransduction pathway. Our initial characterization of TRP from photoreceptors of Calliphora vicina supported the hypothesis of a CCE mechanism, as heterologously expressed TRP was stimulated after application of thapsigargin. The situation changed when the PDZ domain protein INAD was coexpressed with TRP. In cells coexpressing TRP and INAD, no calcium entry was detectable on application of store depletion protocols. Suppression of CCE by INAD was not observed when the described interaction was disrupted by mutations in TRP and INAD. Our data show that apparent activation of TRP by CCE is abolished by INAD. Within the complex, the proteins necessary for phototransduction mutually influence their activities. The results support the hypothesis of a store-independent activation of TRP.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany; Univ Karlsruhe, Inst Zool, Abt Zellbiol & Neurobiol, D-76131 Karlsruhe, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Karlsruhe Institute of Technology	Harteneck, C (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Germany.	hartenek@zedat.fu-berlin.de		Huber, Armin/0000-0003-3977-089X				Acharya JK, 1997, NEURON, V18, P881, DOI 10.1016/S0896-6273(00)80328-1; Adamski FM, 1998, J BIOL CHEM, V273, P17713, DOI 10.1074/jbc.273.28.17713; Bahner M, 2002, NEURON, V34, P83, DOI 10.1016/S0896-6273(02)00630-X; Bahner M, 2000, J BIOL CHEM, V275, P2901, DOI 10.1074/jbc.275.4.2901; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; Cook B, 1999, CELL CALCIUM, V25, P161, DOI 10.1054/ceca.1998.0018; COSENS DJ, 1969, NATURE, V224, P285, DOI 10.1038/224285a0; Gillo B, 1996, J PHOTOCH PHOTOBIO B, V35, P77, DOI 10.1016/1011-1344(96)07303-4; Gillo B, 1996, P NATL ACAD SCI USA, V93, P14146, DOI 10.1073/pnas.93.24.14146; Hardie RC, 1996, CELL CALCIUM, V20, P315, DOI 10.1016/S0143-4160(96)90037-8; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Hardie RC, 2001, NATURE, V413, P186, DOI 10.1038/35093002; HARTENECK C, 1995, FEBS LETT, V358, P297, DOI 10.1016/0014-5793(94)01455-A; Huber A, 1996, J BIOL CHEM, V271, P11710, DOI 10.1074/jbc.271.20.11710; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; Huber A, 2001, EUR J NEUROSCI, V14, P769, DOI 10.1046/j.0953-816x.2001.01704.x; Kumar R, 2001, J BIOL CHEM, V276, P24971, DOI 10.1074/jbc.M103570200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li HS, 2000, J CELL BIOL, V150, P1411, DOI 10.1083/jcb.150.6.1411; Minke B, 1996, MOL NEUROBIOL, V12, P163, DOI 10.1007/BF02740652; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; PAK WL, 1995, INVEST OPHTH VIS SCI, V36, P2340; PAK WL, 1970, NATURE, V227, P518, DOI 10.1038/227518b0; Paulsen R, 2000, PFLUG ARCH EUR J PHY, V439, pR181, DOI 10.1007/s004240000138; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; Raghu P, 2000, MOL CELL NEUROSCI, V15, P429, DOI 10.1006/mcne.2000.0846; RANGANATHAN R, 1994, NEURON, V13, P837, DOI 10.1016/0896-6273(94)90250-X; SHIEH BH, 1995, NEURON, V14, P201, DOI 10.1016/0896-6273(95)90255-4; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Sinkins WG, 1996, J BIOL CHEM, V271, P2955, DOI 10.1074/jbc.271.6.2955; Tsunoda S, 1999, CELL CALCIUM, V26, P165, DOI 10.1054/ceca.1999.0070; Tsunoda S, 2001, J NEUROSCI, V21, P150, DOI 10.1523/JNEUROSCI.21-01-00150.2001; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; Wes PD, 1999, NAT NEUROSCI, V2, P447, DOI 10.1038/8116; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Xu XZS, 2000, NEURON, V26, P647, DOI 10.1016/S0896-6273(00)81201-5; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	45	8	9	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1668	+		10.1096/fj.02-0192fje	http://dx.doi.org/10.1096/fj.02-0192fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206995	Bronze			2022-12-28	WOS:000177814000007
J	Kaminski, JM; Huber, MR; Summers, JB; Ward, MB				Kaminski, JM; Huber, MR; Summers, JB; Ward, MB			Design of a nonviral vector for site-selective, efficient integration into the human genome	FASEB JOURNAL			English	Article						gene therapy; transposon; recombination	IMMUNODEFICIENCY-VIRUS TYPE-1; DROSOPHILA ELEMENT MARINER; DIRECT GENE-TRANSFER; IN-VIVO; TRANSPOSABLE ELEMENT; HOMOLOGOUS RECOMBINATION; GERMLINE TRANSFORMATION; RETROVIRAL INTEGRASE; MAMMALIAN-CELLS; SLEEPING-BEAUTY	Gene therapy in eukaryotes has met many obstacles. Research into the design of suitable nonviral vectors has been slow. To our knowledge, no nonviral vector has been proposed that allows for the possibility of highly efficient, site-selective integration into the genome of mammalian cells. On the basis of prior studies investigating the components necessary for transposon, retrovirus-like retrotransposon, and retroviral integration, we propose a nonviral system that would potentially allow for site-selective, efficient integration into the mammalian genome. Transposons have been developed that can transform a variety of cell lines. For example, the Sleeping Beauty transposon (SB) can transform a wide range of vertebrate cells from fish to human, and it mediates stable integration and long-term transgene expression in mice. However, the efficiency of transposition varies significantly among cell lines, suggesting the possible involvement of host factors in SB transposition. Here, we propose the use of a chimeric transposase (i.e., transposase-host DNA binding domain) to bypass the potential requirement of a host DNA-directing factor (or factors) for efficient, site-selective integration. We also discuss another potential method of docking the transposon-based vector adjacent to the host DNA, utilizing repetitive sequences for homologous recombination to promote efficient site-selective integration, as well as other site-selective nonviral approaches.	Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA; Mayo Clin, Dept Internal Med, Rochester, MN 55905 USA; Univ S Alabama Hosp, Dept Internal Med, Mobile, AL 36617 USA; Univ Chicago Hosp, Dept Radiol, Chicago, IL 60637 USA	Fox Chase Cancer Center; Mayo Clinic; University of South Alabama; University of Chicago; University of Illinois System	Kaminski, JM (corresponding author), Fox Chase Canc Ctr, Dept Radiat Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	JM_Kaminski@fccc.edu	Kaminski, Joseph/AAB-6493-2020; Wilson, Matthew H/K-3193-2013	Kaminski, Joseph/0000-0002-7518-4962				Albuquerque-Silva J, 2001, NAT BIOTECHNOL, V19, P1011, DOI 10.1038/nbt1101-1011a; Boulikas T, 1997, ANTICANCER RES, V17, P1471; BUSHMAN F, 1995, SCIENCE, V267, P1443, DOI 10.1126/science.7878462; BUSHMAN FD, 1994, P NATL ACAD SCI USA, V91, P9233, DOI 10.1073/pnas.91.20.9233; Bushman FD, 1997, J VIROL, V71, P458, DOI 10.1128/JVI.71.1.458-464.1997; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; CHESNOKOV IN, 1995, J BIOL CHEM, V270, P18539, DOI 10.1074/jbc.270.31.18539; Chiang YP, 1996, MOL CELL BIOCHEM, V155, P131; CHOWDHURY NR, 1993, J BIOL CHEM, V268, P11265; Coates CJ, 1998, P NATL ACAD SCI USA, V95, P3748, DOI 10.1073/pnas.95.7.3748; Coates CJ, 1997, MOL GEN GENET, V253, P728, DOI 10.1007/s004380050377; COTTEN M, 1993, J VIROL, V67, P3777, DOI 10.1128/JVI.67.7.3777-3785.1993; COX GS, 1998, BIOCHIM BIOPHYS ACTA, V1493, P302; CURIEL DT, 1994, ANN NY ACAD SCI, V716, P36, DOI 10.1111/j.1749-6632.1994.tb21702.x; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; Diaz V, 1999, J BIOL CHEM, V274, P6634, DOI 10.1074/jbc.274.10.6634; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; Engelman A, 1999, ADV VIRUS RES, V52, P411, DOI 10.1016/S0065-3527(08)60309-7; Fadool JM, 1998, P NATL ACAD SCI USA, V95, P5182, DOI 10.1073/pnas.95.9.5182; FARHOOD H, 1994, ANN NY ACAD SCI, V716, P23, DOI 10.1111/j.1749-6632.1994.tb21701.x; Fischer SEJ, 2001, P NATL ACAD SCI USA, V98, P6759, DOI 10.1073/pnas.121569298; FLINT SJ, 2000, PRINCIPLES VIROLOGY, P199; Goldhaber-Gordon I, 2002, J BIOL CHEM, V277, P7694, DOI 10.1074/jbc.M110341200; GOTTSCHALK S, 1994, GENE THER, V1, P185; Groth AC, 2000, P NATL ACAD SCI USA, V97, P5995, DOI 10.1073/pnas.090527097; Gueiros FJ, 1997, SCIENCE, V276, P1716, DOI 10.1126/science.276.5319.1716; Hernandez YJ, 1999, J VIROL, V73, P8549, DOI 10.1128/JVI.73.10.8549-8558.1999; Holmes-Son M L, 2001, Adv Genet, V43, P33, DOI 10.1016/S0065-2660(01)43003-3; Holmes-Son ML, 2000, J VIROL, V74, P11548, DOI 10.1128/JVI.74.24.11548-11556.2000; Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5; Izsvak Z, 2000, J MOL BIOL, V302, P93, DOI 10.1006/jmbi.2000.4047; JURKA J, 1992, J MOL EVOL, V35, P286, DOI 10.1007/BF00161166; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KAMINSKI JM, IN PRESS CANC TREAT; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; Kang YK, 1999, J BIOL CHEM, V274, P36585, DOI 10.1074/jbc.274.51.36585; Katz RA, 1996, VIROLOGY, V217, P178, DOI 10.1006/viro.1996.0105; Kay MA, 1997, P NATL ACAD SCI USA, V94, P4686, DOI 10.1073/pnas.94.9.4686; KIRCHNER J, 1995, SCIENCE, V267, P1488, DOI 10.1126/science.7878467; Koduri RK, 2001, GENE, V280, P87, DOI 10.1016/S0378-1119(01)00772-7; Kren BT, 1998, NAT MED, V4, P285, DOI 10.1038/nm0398-285; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; Lampe DJ, 1996, EMBO J, V15, P5470, DOI 10.1002/j.1460-2075.1996.tb00930.x; Lee SE, 2000, ANTICANCER RES, V20, P417; Lestini BJ, 2002, J CONTROL RELEASE, V78, P235, DOI 10.1016/S0168-3659(01)00505-3; Li XG, 2001, CANCER GENE THER, V8, P555, DOI 10.1038/sj.cgt.7700337; LIDHOLM DA, 1993, GENETICS, V134, P859; LOGIE C, 1995, P NATL ACAD SCI USA, V92, P5940, DOI 10.1073/pnas.92.13.5940; Lohe AR, 1996, GENETICS, V143, P365; LOUKERIS TG, 1995, P NATL ACAD SCI USA, V92, P9485, DOI 10.1073/pnas.92.21.9485; LOUKERIS TG, 1995, SCIENCE, V270, P2002, DOI 10.1126/science.270.5244.2002; Luo GB, 1998, P NATL ACAD SCI USA, V95, P10769, DOI 10.1073/pnas.95.18.10769; Moreira JN, 2001, BBA-BIOMEMBRANES, V1515, P167, DOI 10.1016/S0005-2736(01)00411-4; NABEL EG, 1994, HUM GENE THER, V5, P1089, DOI 10.1089/hum.1994.5.9-1089; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; Park JW, 2001, J CONTROL RELEASE, V74, P95, DOI 10.1016/S0168-3659(01)00315-7; Raz E, 1998, CURR BIOL, V8, P82, DOI 10.1016/S0960-9822(98)70038-7; Rubin EJ, 1999, P NATL ACAD SCI USA, V96, P1645, DOI 10.1073/pnas.96.4.1645; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; Sauer Brian, 1994, Current Opinion in Biotechnology, V5, P521, DOI 10.1016/0958-1669(94)90068-X; Schagen FHE, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.23.e104; Schouten GJ, 1998, NUCLEIC ACIDS RES, V26, P3013, DOI 10.1093/nar/26.12.3013; Shaik MS, 2001, J CONTROL RELEASE, V76, P285, DOI 10.1016/S0168-3659(01)00450-3; Sherman A, 1998, NAT BIOTECHNOL, V16, P1050, DOI 10.1038/3497; SKALKA AM, 1993, GENE, V135, P175, DOI 10.1016/0378-1119(93)90063-9; Stevens SW, 1996, J VIROL, V70, P6459, DOI 10.1128/JVI.70.9.6459-6462.1996; STEVENS SW, 1994, P NATL ACAD SCI USA, V91, P5557, DOI 10.1073/pnas.91.12.5557; Strauss M, 1998, NAT MED, V4, P274, DOI 10.1038/nm0398-274; Thyagarajan B, 2001, MOL CELL BIOL, V21, P3926, DOI 10.1128/MCB.21.12.3926-3934.2001; van der Steege G, 2001, NAT BIOTECHNOL, V19, P305, DOI 10.1038/86664; VEGA MA, 1991, HUM GENET, V87, P245; Vos JC, 1996, GENE DEV, V10, P755, DOI 10.1101/gad.10.6.755; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; WU GY, 1994, J BIOL CHEM, V269, P11542; Xu L, 2001, MOL MED, V7, P723, DOI 10.1007/BF03401962; Yant SR, 2000, NAT GENET, V25, P35, DOI 10.1038/75568; Zhang L, 2001, NUCLEIC ACIDS RES, V29, P3566, DOI 10.1093/nar/29.17.3566; Zhang LN, 1998, NUCLEIC ACIDS RES, V26, P3687, DOI 10.1093/nar/26.16.3687	80	33	41	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1242	10.1096/fj.02-0127hyp	http://dx.doi.org/10.1096/fj.02-0127hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153992				2022-12-28	WOS:000177814000033
J	Romerio, F; Zella, D				Romerio, F; Zella, D			MEK and ERK inhibitors enhance the antiproliferative effect of interferon-alpha 2b	FASEB JOURNAL			English	Article						signal transduction; cancer; T lymphocytes	ACTIVATED PROTEIN-KINASE; T-CELL PROLIFERATION; DEPENDENT KINASE; GROWTH-FACTOR; PHOTODYNAMIC THERAPY; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; IN-VITRO; ALPHA; ARREST	Interferon (IFN)-alpha, initially characterized as an antiviral cytokine, affects several cellular functions. It is used in clinical practice for the treatment of several tumors, including hematopoietic malignancies, due to its antiproliferative effects. To better characterize the molecular mechanism(s) underlying this property, we conducted our studies in purified primary CD4+ T cells stimulated with anti-CD3 and interleukin (IL)-2. Upon treatment with IFN-alpha, the cells were blocked in the G0/G1 phase of the cell cycle and exhibited impaired entry into S phase and reduced proliferation. Moreover, we detected short- and long-term inhibition of extracellular signal-regulated kinase (ERK) and mitogen-activated ERK-regulating kinase (MEK) function, known to control cellular proliferation. The activity of the upstream regulators, Ras and Raf-1, was not affected. Analysis of downstream events controlled by the MEK/ERK pathway showed reduced activity of cyclin-dependent kinase (Cdk)-2 and -4, high levels of the mitotic inhibitors, p21(Waf1) and p27(Kip1), and decreased cyclin D and E expression. When IFN-alpha was used in combination with MEK and ERK inhibitors, we observed a dose-dependent additive effect in reducing cellular proliferation. Our data demonstrate that IFN-alpha may be associated with other molecules to inhibit cellular growth by targeting the MEK/ERK pathway. This may eventually lead to new clinical strategies to strengthen its anticancer effect.	Univ Maryland, Inst Biotechnol, Inst Human Virol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Zella, D (corresponding author), Univ Maryland, Inst Biotechnol, Inst Human Virol, 725 W Lombard St, Baltimore, MD 21201 USA.	zella@umbi.umd.edu	ZELLA, DAVIDE/AAC-7630-2020	ZELLA, DAVIDE/0000-0001-5576-5770				AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; Alecu M, 1998, ANTICANCER RES, V18, P4651; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arora T, 1999, J IMMUNOL, V162, P3289; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Baumgarth N, 1997, J IMMUNOL, V159, P1182; BORDEN EC, 1997, CANC MED, P1199; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; BRUNET A, 1994, ONCOGENE, V9, P3379; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; Chen B, 2000, CANCER LETT, V150, P111, DOI 10.1016/S0304-3835(99)00381-X; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DeSilva DR, 1996, J EXP MED, V183, P2017, DOI 10.1084/jem.183.5.2017; DeSilva DR, 1998, J IMMUNOL, V160, P4175; Erickson S, 1999, CELL GROWTH DIFFER, V10, P575; Essayan DM, 1999, J ALLERGY CLIN IMMUN, V103, P451, DOI 10.1016/S0091-6749(99)70470-7; Fiddes RJ, 1998, ONCOGENE, V16, P2803, DOI 10.1038/sj.onc.1201815; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Herberman Ronald B., 1997, Seminars in Oncology, V24, P78; Hulleman E, 1999, J CELL PHYSIOL, V180, P325, DOI 10.1002/(SICI)1097-4652(199909)180:3<325::AID-JCP3>3.0.CO;2-R; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; KLIMPEL GR, 1990, CELL IMMUNOL, V128, P603, DOI 10.1016/0008-8749(90)90052-S; Krishnaswamy G, 1996, J INTERF CYTOK RES, V16, P819, DOI 10.1089/jir.1996.16.819; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; Lund TC, 1999, CELL IMMUNOL, V192, P133, DOI 10.1006/cimm.1999.1466; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; OKAZAKI K, 1995, ONCOGENE, V10, P1149; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Petricoin EF, 1997, NATURE, V390, P629, DOI 10.1038/37648; Pfeffer LM, 1998, CANCER RES, V58, P2489; Porras A, 1998, MOL ENDOCRINOL, V12, P825, DOI 10.1210/me.12.6.825; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; Romerio F, 2000, BRIT J CANCER, V83, P532, DOI 10.1054/bjoc.2000.1263; RUBINSTEIN S, 1981, J VIROL, V37, P755, DOI 10.1128/JVI.37.2.755-758.1981; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; Sangfelt O, 1999, ONCOGENE, V18, P2798, DOI 10.1038/sj.onc.1202609; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; Subramaniam PS, 1998, ONCOGENE, V16, P1885, DOI 10.1038/sj.onc.1201712; Subramaniam PS, 1997, J INTERF CYTOK RES, V17, P11, DOI 10.1089/jir.1997.17.11; Tachibana K, 1997, EMBO J, V16, P4333, DOI 10.1093/emboj/16.14.4333; TAKAHASHI I, 1989, J ANTIBIOT, V42, P153; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; Zagury D, 1998, P NATL ACAD SCI USA, V95, P3851, DOI 10.1073/pnas.95.7.3851; Zella D, 1999, J IMMUNOL, V163, P3169; Zella D, 2000, J IMMUNOL, V164, P2296, DOI 10.4049/jimmunol.164.5.2296; Zhang W, 1996, NEUROSURGERY, V38, P587, DOI 10.1097/00006123-199603000-00035; ZHANG Y, 1999, CRYST ENG, V2, P1	64	53	61	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1680	+		10.1096/fj.02-0120fje	http://dx.doi.org/10.1096/fj.02-0120fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206994				2022-12-28	WOS:000177814000003
J	Warren, GL; Hulderman, T; Jensen, N; McKinstry, M; Mishra, M; Luster, MI; Simeonova, PP				Warren, GL; Hulderman, T; Jensen, N; McKinstry, M; Mishra, M; Luster, MI; Simeonova, PP			Physiological role of tumor necrosis factor alpha in traumatic muscle injury	FASEB JOURNAL			English	Article						muscle function; inflammation; inflammatory cytokines	CONTRACTION-INDUCED INJURY; MURINE SKELETAL-MUSCLE; TNF-ALPHA; KAPPA-B; ECCENTRIC CONTRACTIONS; INDUCED HEPATOTOXICITY; CONTUSION INJURY; SATELLITE CELLS; BALB/C MICE; DIFFERENTIATION	The degenerative and regenerative roles of tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory cytokine with pleiotropic functions, were investigated by using TNF receptor 1 and 2 double knockout (TNFR-DKO) and TNF-alpha antibody neutralized mice following traumatic freeze injury to the tibialis anterior muscle. In wild-type control mice, TNF-alpha mRNA transcripts and protein increased following injury and gradually returned to control (uninjured) levels by 13 days. A reduction in MyoD mRNA expression occurred in TNF-alpha-deficient mice, although there were no visible differences in MyoD immunostaining or histological characteristics in regenerating muscles. At 5 days post-injury, the reductions in isometric strength in TNFR-DKO and TNF-alpha-depleted mice did not differ from that of wild-type mice but by 13 days after injury, the TNFR-DKO and TNF-alpha depleted mice exhibited strength deficits twice that of wild-type mice (i.e., 27-31% vs 13%). Muscle injury was also accompanied by increased expression of interleukin-6 (IL-6), but IL-6-deficient mice demonstrated MyoD expression and recovery of isometric strength similar to that of wild-type mice. These data indicate that TNF-alpha is involved in the recovery of muscle function after traumatic muscle injury, and this effect might be associated with modulation of muscle regulatory genes, including MyoD.	NIOSH, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA; Georgia State Univ, Dept Phys Therapy, Atlanta, GA 30303 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); University System of Georgia; Georgia State University	Simeonova, PP (corresponding author), NIOSH, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, 1095 Willowdale Rd, Morgantown, WV 26505 USA.	phs9@cdc.gov	Warren, Gordon/A-9794-2008	Warren, Gordon/0000-0002-7073-8524				AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; Alloatti G, 2000, AM J PHYSIOL-REG I, V279, pR2156, DOI 10.1152/ajpregu.2000.279.6.R2156; ANDERSON JE, 1995, EXP CELL RES, V216, P325, DOI 10.1006/excr.1995.1041; Beiner JM, 1999, AM J SPORT MED, V27, P2, DOI 10.1177/03635465990270011101; Bruccoleri A, 1997, HEPATOLOGY, V25, P133, DOI 10.1002/hep.510250125; CANTINI M, 1994, BIOCHEM BIOPH RES CO, V202, P1688, DOI 10.1006/bbrc.1994.2129; CANTINI M, 1995, J NEUROPATH EXP NEUR, V54, P121, DOI 10.1097/00005072-199501000-00014; Collins RA, 2001, J HISTOCHEM CYTOCHEM, V49, P989, DOI 10.1177/002215540104900807; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRISCO JJ, 1994, AM J SPORT MED, V22, P702, DOI 10.1177/036354659402200521; Gallucci RM, 2000, FASEB J, V14, P2525, DOI 10.1096/fj.00-0073com; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; KAYAMA F, 1995, TOXICOL APPL PHARM, V131, P224, DOI 10.1006/taap.1995.1065; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; Li YP, 2001, FASEB J, V15, P1413, DOI 10.1096/fj.00-0632fje; Li YP, 2001, CURR OPIN RHEUMATOL, V13, P483, DOI 10.1097/00002281-200111000-00005; LOWE DA, 1995, J APPL PHYSIOL, V79, P1260, DOI 10.1152/jappl.1995.79.4.1260; Luster MI, 1999, CRIT REV TOXICOL, V29, P491, DOI 10.1080/10408449991349258; Massimino ML, 1997, BIOCHEM BIOPH RES CO, V235, P754, DOI 10.1006/bbrc.1997.6823; Merly F, 1999, MUSCLE NERVE, V22, P724, DOI 10.1002/(SICI)1097-4598(199906)22:6<724::AID-MUS9>3.0.CO;2-O; MITCHELL CA, 1992, CELL TISSUE RES, V269, P159, DOI 10.1007/BF00384736; Pavlath GK, 1998, DEV DYNAM, V212, P495, DOI 10.1002/(SICI)1097-0177(199808)212:4<495::AID-AJA3>3.3.CO;2-I; RALPH P, 1983, J IMMUNOL, V130, P108; ROBERTSON TA, 1992, J ANAT, V181, P265; Spencer MJ, 2000, NEUROMUSCULAR DISORD, V10, P612, DOI 10.1016/S0960-8966(00)00160-7; Szalay K, 1997, EUR J CELL BIOL, V74, P391; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Warren G L, 2001, Exerc Sport Sci Rev, V29, P82; Warren GL, 1998, J APPL PHYSIOL, V84, P2171, DOI 10.1152/jappl.1998.84.6.2171; Warren GL, 1999, SPORTS MED, V27, P43, DOI 10.2165/00007256-199927010-00004; Warren GL, 1999, J PHYSIOL-LONDON, V515, P609, DOI 10.1111/j.1469-7793.1999.609ac.x; Warren GL, 2000, MED SCI SPORT EXER, V32, P820, DOI 10.1097/00005768-200004000-00015; WILCOX PG, 1994, AM J RESP CRIT CARE, V150, P1368, DOI 10.1164/ajrccm.150.5.7952566; Zador E, 2001, MUSCLE NERVE, V24, P1058, DOI 10.1002/mus.1110; Zhang Minghuang, 1998, P517	38	175	191	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1630	+		10.1096/fj.02-0187fje	http://dx.doi.org/10.1096/fj.02-0187fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207010				2022-12-28	WOS:000177814000014
J	Dodic, M; Hantzis, V; Duncan, J; Rees, S; Koukoulas, I; Johnson, K; Wintour, EM; Moritz, K				Dodic, M; Hantzis, V; Duncan, J; Rees, S; Koukoulas, I; Johnson, K; Wintour, EM; Moritz, K			Programming effects of short prenatal exposure to cortisol	FASEB JOURNAL			English	Article						renin-angiotensin system; glucocorticoid; sheep; mineralocorticoid	LOW-BIRTH-WEIGHT; ELEVATED BLOOD-PRESSURE; PITUITARY-ADRENAL AXIS; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; MATERNAL UNDERNUTRITION; GLUCOCORTICOID RECEPTORS; GENE-EXPRESSION; FETAL KIDNEY; DUTCH FAMINE; ADULT SHEEP	Recent studies have linked fetal exposure to a suboptimal intrauterine environment with adult hypertension. The aims of this study were twofold: 1) to see whether cortisol treatment administered to the ewe for 2 days at 27 days of gestation (term similar to150 days) resulted in high blood pressure in offspring; 2) to study the effect of the same treatment on gene expression in the brain at 130 days of gestation and in lambs at 2 months of age. Mean arterial pressure was significantly higher in the adult female and male offspring of sheep treated with cortisol than in the control group (females: 89+/-2 mmHg vs. 81+/-2; P<0.05 and males: 102 +/- 4 mmHg vs. 91 +/- 3; P<0.05). Prenatal cortisol treatment led to up-regulation of angiotensinogen, AT(1), MR, and GR mRNA in the hippocampus in fetuses at 130 days of gestation but not in the animals at 2 months of age. This is the first evidence that short prenatal exposure to cortisol programmed high blood pressure in the adult female and male offspring of sheep. Altered gene expression in the hippocampus could have a significant effect on the development of the hippocampus, and on postnatal behavior.	Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic 3010, Australia	Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Melbourne	Dodic, M (corresponding author), Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3052, Australia.	m.dodic@hfi.unimelb.edu.au	Moritz, Karen/G-2508-2015	Moritz, Karen/0000-0002-8085-0034				ALLEN AM, 2000, ANGIOTENSIN 2 RECEPT, P129; ARMANINI D, 1983, CLIN ENDOCRINOL, V19, P609, DOI 10.1111/j.1365-2265.1983.tb00038.x; Barker DJP, 1998, CLIN SCI, V95, P115, DOI 10.1042/CS19980019; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark PM, 1996, CLIN ENDOCRINOL, V45, P721, DOI 10.1046/j.1365-2265.1996.8560864.x; DENNY JB, 1991, BRAIN RES, V567, P321, DOI 10.1016/0006-8993(91)90812-A; Dodic M, 1999, CLIN SCI, V97, P103, DOI 10.1042/CS19980356; Dodic M, 2002, AM J PHYSIOL-REG I, V282, pR343, DOI 10.1152/ajpregu.00222.2001; Dodic M, 2001, CLIN EXP PHARMACOL P, V28, P952, DOI 10.1046/j.1440-1681.2001.03556.x; Dodic M, 2001, CIRC RES, V89, P623, DOI 10.1161/hh1901.097086; Dodic M, 1998, CLIN SCI, V94, P149, DOI 10.1042/cs0940149; Gass P, 2000, EMBO REP, V1, P447, DOI 10.1093/embo-reports/kvd088; Gatford KL, 2000, CLIN SCI, V98, P553, DOI 10.1042/cs0980553; Gomez-Sanchez EP, 1999, HYPERTENSION, V33, P1369, DOI 10.1161/01.HYP.33.6.1369; Hantzis V, 2002, KIDNEY INT, V61, P405, DOI 10.1046/j.1523-1755.2002.00157.x; Hawkins P, 1999, J ENDOCRINOL, V163, P553, DOI 10.1677/joe.0.1630553; HENRY C, 1994, J NEUROENDOCRINOL, V6, P341, DOI 10.1111/j.1365-2826.1994.tb00591.x; Hoet JJ, 1999, J PHYSIOL-LONDON, V514, P617, DOI 10.1111/j.1469-7793.1999.617ad.x; Huxley RR, 2000, J HYPERTENS, V18, P815, DOI 10.1097/00004872-200018070-00002; Johren O, 1996, AM J PHYSIOL-ENDOC M, V271, pE104, DOI 10.1152/ajpendo.1996.271.1.E104; Kakinuma Y, 1997, NEUROSCI LETT, V232, P167, DOI 10.1016/S0304-3940(97)00605-8; KINGDOM JCP, 1993, BRIT J OBSTET GYNAEC, V100, P476, DOI 10.1111/j.1471-0528.1993.tb15276.x; Kingdom JCP, 1999, KIDNEY INT, V55, P424, DOI 10.1046/j.1523-1755.1999.00295.x; Konje JC, 1996, CLIN SCI, V91, P169, DOI 10.1042/cs0910169; Kwong WY, 2000, DEVELOPMENT, V127, P4195; LangleyEvans SC, 1997, J HYPERTENS, V15, P537, DOI 10.1097/00004872-199715050-00010; LangleyEvans SC, 1996, CLIN SCI, V91, P607, DOI 10.1042/cs0910607; Law CM, 1996, J HYPERTENS, V14, P935; Levitt NS, 1996, NEUROENDOCRINOLOGY, V64, P412, DOI 10.1159/000127146; Levitt NS, 2000, J CLIN ENDOCR METAB, V85, P4611, DOI 10.1210/jc.85.12.4611; Lindsay RS, 1996, HYPERTENSION, V27, P1200, DOI 10.1161/01.HYP.27.6.1200; Meaney MJ, 2001, ANNU REV NEUROSCI, V24, P1161, DOI 10.1146/annurev.neuro.24.1.1161; Peers A, 2001, KIDNEY INT, V59, P425, DOI 10.1046/j.1523-1755.2001.059002425.x; Phillips DIW, 2000, HYPERTENSION, V35, P1301, DOI 10.1161/01.HYP.35.6.1301; Ravelli ACJ, 1999, AM J CLIN NUTR, V70, P811; REYNOLDS ML, 1985, ANAT EMBRYOL, V171, P41, DOI 10.1007/BF00319053; Reynolds RM, 2001, J CLIN ENDOCR METAB, V86, P245, DOI 10.1210/jc.86.1.245; Roseboom TJ, 2000, HEART, V84, P595, DOI 10.1136/heart.84.6.595; Roseboom TJ, 2000, AM J CLIN NUTR, V72, P1101; Seckl JR, 1997, FRONT NEUROENDOCRIN, V18, P49, DOI 10.1006/frne.1996.0143; Seckl JR, 2000, KIDNEY INT, V57, P1412, DOI 10.1046/j.1523-1755.2000.00984.x; Sherman RC, 2000, CLIN SCI, V98, P269, DOI 10.1042/CS19990275; Takahashi LK, 1998, INT J DEV NEUROSCI, V16, P199, DOI 10.1016/S0736-5748(98)00020-3; TAKAHASHI LK, 1990, PHYSIOL BEHAV, V47, P357, DOI 10.1016/0031-9384(90)90154-V; TANGALAKIS K, 1992, J STEROID BIOCHEM, V42, P527, DOI 10.1016/0960-0760(92)90266-L; TILLET Y, 1987, ANAT EMBRYOL, V177, P173, DOI 10.1007/BF00572542; Ullian ME, 1996, HYPERTENSION, V27, P1346, DOI 10.1161/01.HYP.27.6.1346; WALKER BR, 1994, J HYPERTENS, V12, P33; WAYNER MJ, 1995, PEPTIDES, V16, P1079, DOI 10.1016/0196-9781(95)00089-3; WEINSTOCK M, 1988, PROG BRAIN RES, V73, P319; Welberg LAM, 2000, EUR J NEUROSCI, V12, P1047, DOI 10.1046/j.1460-9568.2000.00958.x; Welberg LAM, 2001, NEUROSCIENCE, V104, P71, DOI 10.1016/S0306-4522(01)00065-3; Welberg LAM, 2001, J NEUROENDOCRINOL, V13, P113, DOI 10.1046/j.1365-2826.2001.00601.x; Whorwood CB, 2001, ENDOCRINOLOGY, V142, P2854, DOI 10.1210/en.142.7.2854; Woodall SM, 1996, PEDIATR RES, V40, P438, DOI 10.1203/00006450-199609000-00012; WRIGHT JW, 1994, NEUROSCI BIOBEHAV R, V18, P21, DOI 10.1016/0149-7634(94)90034-5; YANG K, 1992, J MOL ENDOCRINOL, V8, P173, DOI 10.1677/jme.0.0080173	58	152	154	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1017	1026		10.1096/fj.01-1045com	http://dx.doi.org/10.1096/fj.01-1045com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087063	Green Submitted			2022-12-28	WOS:000177813100033
J	Habib, GM; Shi, ZZ; Cuevas, AA; Lieberman, MW				Habib, GM; Shi, ZZ; Cuevas, AA; Lieberman, MW			Identification of two additional members of the membrane-bound dipeptidase family	FASEB JOURNAL			English	Article						MBD gene family; leukotriene D4; glutathione; asthma	GAMMA-GLUTAMYL-TRANSPEPTIDASE; RENAL DIPEPTIDASE; LEUKOTRIENE D-4; PHOSPHOLIPASE-C; METABOLISM; GENE; PURIFICATION; INHIBITORS; ENZYMES; ASTHMA	We have cloned two mouse cDNAs encoding previously unidentified membrane-bound dipeptidases [membrane-bound dipeptidase-2 (MBD-2) and membrane-bound dipeptidase-3 (MBD-3)] from membrane-bound dipeptidase-1 (MBD-1) deficient mice (Habib, G.M., Shi, ZZ., Cuevas, A.A., Guo, Q., Matzuk, M.M., and Lieberman, M.W. (1998) Proc. Natl. Acad. Sci. USA 95, 4859-4863). These enzymes are closely related to MBD-1 (EC 3.4.13.19), which is known to cleave leukotriene D-4 (LTD4) and cystinyl-bis-glycine. MBD-2 cDNA is 56% identical to MBD-1 with a predicted amino acid identity of 33%. The MBD-3 and MBD-1 cDNAs share a 55% nucleotide identity and a 39% predicted amino acid sequence identity. All three genes are tightly linked on the same chromosome. Expression of MBD-2 and MBD-3 in Cos cells indicated that both are membrane-bound through a glycosylphosphatidyl-inositol linkage. MBD-2 cleaves leukotriene D-4 (LTD4) but not cystinyl-bis-glycine, while MBD-3 cleaves cystinyl-bisglycine but not LTD4. MBD-1 is expressed at highest levels in kidney, lung, and heart and is absent in spleen, while MBD-2 is expressed at highest levels in lung, heart, and testis and at somewhat lower levels in spleen. Of the tissues examined, MBD-3 expression was detected only in testis. Our identification of a second enzyme capable of cleaving LTD4 raises the possibility that clearance of LTD4 during asthma and in related inflammatory conditions may be mediated by more than one enzyme.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Lieberman, MW (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.	mikel@bcm.tmc.edu						CAMPBELL BJ, 1984, J BIOL CHEM, V259, P4586; Carter BZ, 1998, J BIOL CHEM, V273, P28277, DOI 10.1074/jbc.273.43.28277; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENZLINGER C, 1986, J BIOL CHEM, V261, P5601; Devillier P, 1999, PHARMACOL RES, V40, P3, DOI 10.1006/phrs.1998.0458; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; Habib GM, 1996, J BIOL CHEM, V271, P16273, DOI 10.1074/jbc.271.27.16273; Habib GM, 1999, ADV EXP MED BIOL, V469, P295; Habib GM, 1998, P NATL ACAD SCI USA, V95, P4859, DOI 10.1073/pnas.95.9.4859; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; HOOPER NM, 1987, BIOCHEM J, V244, P465, DOI 10.1042/bj2440465; Horwitz RJ, 1998, AM J RESP CRIT CARE, V157, P1363, DOI 10.1164/ajrccm.157.5.9706059; HUBER M, 1987, EUR J BIOCHEM, V167, P73, DOI 10.1111/j.1432-1033.1987.tb13305.x; KENNY AJ, 1987, MAMMALIAN ECTOENZYME, P329; KOZAK EM, 1982, J BIOL CHEM, V257, P6322; KROPP H, 1982, ANTIMICROB AGENTS CH, V22, P62, DOI 10.1128/AAC.22.1.62; LIEBERMAN MW, 1995, AM J PATHOL, V147, P1175; LITTLEWOOD GM, 1989, BIOCHEM J, V257, P361, DOI 10.1042/bj2570361; Meister A., 1995, METABOLIC BASIS INHE, P1461; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH S, 1993, BIOCHIM BIOPHYS ACTA, V1163, P234, DOI 10.1016/0167-4838(93)90157-M	21	40	44	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1313	+		10.1096/fj.02-0899fje	http://dx.doi.org/10.1096/fj.02-0899fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738806				2022-12-28	WOS:000183165000033
J	Wu, B; Iwakiri, R; Ootani, A; Fujise, T; Tsunada, S; Fujimoto, K				Wu, B; Iwakiri, R; Ootani, A; Fujise, T; Tsunada, S; Fujimoto, K			Platelet activating factor promotes mucosal apoptosis via FasL mediating caspase-9 active pathway in rat small intestine after ischemia-reperfusion	FASEB JOURNAL			English	Article						platelet activating factor acetylhydrolase; platelet endothelial cell adhesion; molecule-1; interleukin-6; Bid; cytochrome c	ENDOTHELIAL CELL-INTERACTIONS; INDUCED LEUKOCYTE ADHERENCE; EPITHELIAL-CELLS; FACTOR RECEPTOR; CYTOCHROME-C; P-SELECTIN; INJURY; PECAM-1; INTERLEUKIN-10; PAF	Platelet activating factor (PAF) is a proinflammatory lipid mediator for inflammatory response. It is unclear whether PAF is involved in the very complex process of ischemia-reperfusion (I/R) induced mucosal apoptosis in small intestine. Intestinal I/R was induced in rats intestine by 60 min occlusion of the superior mesenteric artery, followed by a 60 min reperfusion. I/R induced mucosal apoptosis and PAF activity but inhibited PAF-acetylhydrolase activity. Increases in interleukin-6 (IL-6) and decreases in IL-10 were observed. Western blot analysis showed that I/R induced expressions of platelet endothelial cell adhesion molecule-1 (PECAM-1) and Fas and Fas ligand (FasL) proteins, cleaved Bid, and enhanced the release of cytochrome c from mitochondria to activate caspase-9. Pretreatment of PAF antagonist BN-52021 attenuated these changes, except the increase in Fas. The results showed that I/R-inhibited mucosal PAF-acetylhydrolase activity resulted in an increase of activated PAF. The activated PAF increased the mucosal IL-6 and PECAM-1, enhanced the expression of FasL but not Fas, and led to the cleavage of Bid and the release of cytochrome c from mitochondria to activate caspase-9. This finding suggests that PAF promotes mucosal apoptosis after I/R in the rat small intestine partly through FasL mediating caspase-9 active pathway.	Saga Med Sch, Dept Internal Med & Gastrointestinal Endoscopy, Div Gastroenterol, Saga 8498501, Japan	Saga University	Fujimoto, K (corresponding author), Saga Med Sch, Dept Internal Med & Gastrointestinal Endoscopy, Div Gastroenterol, 5-1-1 Nabeshima, Saga 8498501, Japan.	fujimoto@post.saga-med.ac.jp						Arai H, 2002, J BIOCHEM, V131, P635, DOI 10.1093/oxfordjournals.jbchem.a003145; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Berdyshev EV, 2001, FASEB J, V15, P2171, DOI 10.1096/fj.01-0181com; Berman ME, 1996, J IMMUNOL, V156, P1515; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; Evans PC, 2001, TRANSPLANTATION, V71, P457, DOI 10.1097/00007890-200102150-00020; FERRARIS L, 1993, GUT, V34, P665, DOI 10.1136/gut.34.5.665; Honda Z, 2002, J BIOCHEM, V131, P773, DOI 10.1093/oxfordjournals.jbchem.a003164; Ilan N, 2001, FASEB J, V15, P362, DOI 10.1096/fj.00-0372com; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Kogaki S, 1999, CARDIOVASC RES, V43, P968, DOI 10.1016/S0008-6363(99)00140-6; KUBES P, 1990, AM J PHYSIOL, V259, pG300, DOI 10.1152/ajpgi.1990.259.2.G300; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Massberg S, 1998, BLOOD, V92, P507, DOI 10.1182/blood.V92.2.507; Murohisa G, 2002, LIVER, V22, P394, DOI 10.1034/j.1600-0676.2002.01552.x; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Newman PJ, 1999, J CLIN INVEST, V103, P5, DOI 10.1172/JCI5928; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; NISHIYAMA R, 1993, TRANSPLANTATION, V55, P1261, DOI 10.1097/00007890-199306000-00010; Noda T, 1998, AM J PHYSIOL-GASTR L, V274, pG270, DOI 10.1152/ajpgi.1998.274.2.G270; Panes J, 1999, HEPATOLOGY, V30, P445, DOI 10.1002/hep.510300214; Panes J, 1998, GASTROENTEROLOGY, V114, P1066, DOI 10.1016/S0016-5085(98)70328-2; Parker MA, 2002, J NEUROSCI RES, V69, P39, DOI 10.1002/jnr.10235; Pender SLF, 1998, GASTROENTEROLOGY, V115, P573, DOI 10.1016/S0016-5085(98)70136-2; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Salter JW, 2001, AM J PHYSIOL-GASTR L, V281, pG1432, DOI 10.1152/ajpgi.2001.281.6.G1432; Sandoval D, 1996, GASTROENTEROLOGY, V111, P1081, DOI 10.1016/S0016-5085(96)70077-X; Singbartl K, 2001, FASEB J, V15, P2337, DOI 10.1096/fj.01-0199com; Steidler L, 2000, SCIENCE, V289, P1352, DOI 10.1126/science.289.5483.1352; STEWART AG, 1990, P NATL ACAD SCI USA, V87, P3215, DOI 10.1073/pnas.87.8.3215; Stordeur P, 1998, Int Rev Immunol, V16, P501, DOI 10.3109/08830189809043006; SUEMATSU M, 1993, AM J PHYSIOL, V264, pH881, DOI 10.1152/ajpheart.1993.264.3.H881; Sun Z, 2001, SCAND J GASTROENTERO, V36, P55, DOI 10.1080/00365520150218066; Takahashi H, 2001, NAT MED, V7, P26, DOI 10.1038/83306; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; THOMPSON CB, 1995, SCIENCE, V267, P1455; Turegun M, 1999, PLAST RECONSTR SURG, V104, P1033; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Walterscheid JP, 2002, J EXP MED, V195, P171, DOI 10.1084/jem.20011450; Werner AB, 2002, J BIOL CHEM, V277, P40760, DOI 10.1074/jbc.M204351200; Wu B, 2002, FREE RADICAL BIO MED, V33, P649, DOI 10.1016/S0891-5849(02)00917-6; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZIMMERMAN BJ, 1994, AM J PHYSIOL, V266, pH847, DOI 10.1152/ajpheart.1994.266.3.H847; Zingarelli B, 2001, GUT, V48, P610, DOI 10.1136/gut.48.5.610	47	35	36	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1156	+		10.1096/fj.02-0499fje	http://dx.doi.org/10.1096/fj.02-0499fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709415				2022-12-28	WOS:000182580100022
J	Bode, JG; Ludwig, S; Ehrhardt, C; Erhardt, A; Albrecht, U; Schaper, F; Heinrich, PC; Haussinger, D				Bode, JG; Ludwig, S; Ehrhardt, C; Erhardt, A; Albrecht, U; Schaper, F; Heinrich, PC; Haussinger, D			IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3	FASEB JOURNAL			English	Article						cross-talk; viral resistance; interferon therapy; viral hepatitis	VIRUS; EXPRESSION; INTERLEUKIN-6; COUNTERACTS; INHIBITION; RECEPTOR; PATHWAY; BINDING; DOMAIN; STAT1	Eighty percent of patients newly infected with the hepatitis C virus (HCV) develop chronic infection, suggesting that HCV can develop effective strategies to escape the unspecific and specific immune response of the host. Because SOCS molecules have been recognized to be powerful inhibitors of cytokine signaling via the Jak/STAT pathway, virus-induced expression of these molecules should be an efficient instrument to counteract the cellular response toward interferons (IFNs), an essential part of first line antiviral immune response. This study shows that overexpression of HCV core protein inhibits IFN-alpha-induced tyrosine phosphorylation and activation of STAT1 in hepatic cells. With the use of a STAT1-YFP fusion protein, further evidence is given that HCV core is capable to inhibit nuclear translocation of STAT1. Inhibition of STAT1-tyrosine phosphorylation was accompanied by the induction of SOCS3-mRNA expression, suggesting that the HCV core protein impairs IFN-alpha-induced signal transduction via induction of SOCS3 expression. HCV core protein was competent to partially rescue growth of a genetically engineered influenza A virus lacking its own IFN antagonist. These IFN-antagonistic properties of the HCV core protein may be part of the molecular basis of IFN-alpha unresponsiveness in about one-half of chronically infected HCV-patients.	Univ Dusseldorf, Med Klin, Klin Gastroenterol Hepatol & Infektiol, D-40225 Dusseldorf, Germany; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Rhein Westfal TH Aachen Klinikum, Inst Biochem, D-52074 Aachen, Germany	Heinrich Heine University Dusseldorf; University of Wurzburg; RWTH Aachen University; RWTH Aachen University Hospital	Bode, JG (corresponding author), Univ Dusseldorf, Med Klin, Klin Gastroenterol Hepatol & Infektiol, Moorenstr 05, D-40225 Dusseldorf, Germany.	Johannes.Bode@t-online.de	Schaper, Fred/F-1403-2013	Schaper, Fred/0000-0002-8899-5414; Ludwig, Stephan/0000-0003-4490-3052				Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297; Basu A, 2001, VIROLOGY, V288, P379, DOI 10.1006/viro.2001.1100; BERG T, 2001, HEPATITIS C, P229; Bergmann M, 2000, J VIROL, V74, P6203, DOI 10.1128/JVI.74.13.6203-6206.2000; Bouloy M, 2001, J VIROL, V75, P1371, DOI 10.1128/JVI.75.3.1371-1377.2001; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Didcock L, 1999, J VIROL, V73, P9928, DOI 10.1128/JVI.73.12.9928-9933.1999; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Foster GR, 1997, SEMIN LIVER DIS, V17, P287, DOI 10.1055/s-2007-1007205; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; Garcia-Sastre A, 2001, VIROLOGY, V279, P375, DOI 10.1006/viro.2000.0756; Garcin D, 1999, J VIROL, V73, P6559, DOI 10.1128/JVI.73.8.6559-6565.1999; Heim MH, 1999, J VIROL, V73, P8469, DOI 10.1128/JVI.73.10.8469-8475.1999; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; KURACHI S, 1998, BIOCHEMICA, V3, P43; Manns M P, 2001, Indian J Gastroenterol, V20 Suppl 1, pC47; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Shen XN, 2000, FEBS LETT, V480, P132, DOI 10.1016/S0014-5793(00)01905-0; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tan SL, 2001, VIROLOGY, V284, P1, DOI 10.1006/viro.2001.0885; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; *WHO, 2000, HEP C FACT SHEEP	30	239	252	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					488	+		10.1096/fj.02-0664fje	http://dx.doi.org/10.1096/fj.02-0664fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551851				2022-12-28	WOS:000181453700007
J	Daniels, CB; Lewis, BC; Tsopelas, C; Munns, SL; Orgeig, S; Baldwin, ME; Stacker, SA; Achen, MG; Chatterton, BE; Cooter, RD				Daniels, CB; Lewis, BC; Tsopelas, C; Munns, SL; Orgeig, S; Baldwin, ME; Stacker, SA; Achen, MG; Chatterton, BE; Cooter, RD			Regenerating lizard tails: A new model for investigating lymphangiogenesis	FASEB JOURNAL			English	Article						tail autotomy; tissue regeneration; vascular endothelial growth factor; lymphoedema; lymphoscintigraphy	ENDOTHELIAL GROWTH-FACTOR; AMPHIBIAN LIMB REGENERATION; VEGF-C; TYROSINE KINASES; TRANSGENIC MICE; RECEPTOR-3; LYMPHEDEMA; LIGAND; FLT4	Impaired lymphatic drainage in human limbs causes the debilitating swelling termed lymphoedema. In mammals, known growth factors involved in the control of lymphangiogenesis (growth of new lymph vessels) are vascular endothelial growth factors-C and -D (VEGF-C/D). Here we characterize a model of lymphangiogenesis in which the tail of lizards is regenerated without becoming oedematous. Three weeks after the tail is shed (autotomy), there are a small number of large diameter lymphatic vessels in the regenerated tail. Thereafter, the number increases and the diameter decreases. A functional lymphatic network, as determined by lymphoscintigraphy, is established 6 wk after autotomy. The new network differs morphologically and functionally from that in original tails. This lymphatic regeneration is associated with an up-regulation of a reptilian homologue of the VEGF-C/D protein family (rVEGF-C/D), as determined by Western blot analysis using a human reactive VEGF-C polyclonal antibody. Regenerating lizard tails are potentially useful models for studying the molecular basis of lymphangiogenesis with a view to developing possible treatments for human lymphoedema.	Univ Adelaide, Dept Environm Biol, Adelaide, SA 5005, Australia; Royal Adelaide Hosp, Dept Nucl Med, Adelaide, SA 5000, Australia; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic, Australia; Royal Adelaide Hosp, Dept Plast & Reconstruct Surg, Adelaide, SA 5005, Australia	University of Adelaide; Royal Adelaide Hospital; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Adelaide Hospital	Daniels, CB (corresponding author), Univ Adelaide, Dept Environm Biol, Adelaide, SA 5005, Australia.	chris.daniels@adelaide.edu.au	Munns, Suzy/B-8276-2013; Stacker, Steven A/J-2205-2012; Daniels, Christopher B/F-8886-2010; Orgeig, Sandra/B-8476-2009	Munns, Suzy/0000-0002-5688-4680; Stacker, Steven A/0000-0003-4096-9273; Orgeig, Sandra/0000-0003-0849-2209; Daniels, Christopher/0000-0001-8288-6068; Achen, Marc/0000-0002-3791-803X				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Bellairs A.D., 1985, Biology of Reptilia, V15, P301; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brockes JP, 1997, SCIENCE, V276, P81, DOI 10.1126/science.276.5309.81; COX PG, 1968, J EXP ZOOL, V171, P127; COX PG, 1968, J EXP ZOOL, V171, P151; DANIELS CB, 1985, COPEIA, P468, DOI 10.2307/1444860; DANIELS CB, 1984, HERPETOLOGICA, V40, P337; Geraudie J, 1998, INT REV CYTOL, V180, P1; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; Khazanchi RK, 1996, BRIT J PLAST SURG, V49, P123, DOI 10.1016/S0007-1226(96)90087-9; Latil A, 2000, INT J CANCER, V89, P167, DOI 10.1002/(SICI)1097-0215(20000320)89:2<167::AID-IJC11>3.0.CO;2-9; Mescher AL, 1996, INT J DEV BIOL, V40, P785; Mortimer PS, 1997, ANGIOLOGY, V48, P87, DOI 10.1177/000331979704800114; OTTAVIANI G., 1977, BIOL REPTILIA, V6, P315; SAVAGE RC, 1984, SURG GYNECOL OBSTET, V159, P501; Sheppard L., 1972, British J Herpet, V4, P276; Slavin SA, 1997, PLAST RECONSTR SURG, V99, P730, DOI 10.1097/00006534-199703000-00020; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Tsopelas C, 2002, HELL J NUCL MED, V1, P42; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; Veronesi U, 1999, JNCI-J NATL CANCER I, V91, P368, DOI 10.1093/jnci/91.4.368	24	23	23	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					479	+		10.1096/fj.02-0579fje	http://dx.doi.org/10.1096/fj.02-0579fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12514111				2022-12-28	WOS:000181453700025
J	Jurd, R; Arras, M; Lambert, S; Drexler, B; Siegwart, R; Crestani, F; Zaugg, M; Vogt, KE; Ledermann, B; Antkowiak, B; Rudolph, U				Jurd, R; Arras, M; Lambert, S; Drexler, B; Siegwart, R; Crestani, F; Zaugg, M; Vogt, KE; Ledermann, B; Antkowiak, B; Rudolph, U			General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta 3 subunit	FASEB JOURNAL			English	Article						anesthesia; animal model; knock-in; gene targeting	AMINOBUTYRIC ACID(A) RECEPTOR; SUBUNIT MESSENGER-RNAS; RAT SPINAL-CORD; A RECEPTOR; INTRAVENOUS ANESTHETICS; SYNAPTIC TRANSMISSION; BETA(3) SUBUNIT; MICE LACKING; ETOMIDATE; BINDING	General anesthetics are widely used in clinical practice. On the molecular level, these compounds have been shown to modulate the activity of various neuronal ion channels. However, the functional relevance of identified sites in mediating essential components of the general anesthetic state, such as immobility and hypnosis, is still unknown. Using gene-targeting technology, we generated mice harboring a subtle point mutation (N265M) in the second transmembrane region of the beta3 subunit of the GABA(A) receptor. In these mice, the suppression of noxious-evoked movements in response to the intravenous anesthetics etomidate and propofol is completely abolished, while only slightly decreased with the volatile anesthetics enflurane and halothane. 3(N265M) mice also display a profound reduction in the loss of righting reflex duration in response to intravenous but not volatile anesthetics. In addition, electrophysiological recordings revealed that anesthetic agents were significantly less effective in enhancing GABA(A) receptor-mediated currents, and in decreasing spontaneous action potential firing in cortical brain slices derived from mutant mice. Taken together, our results demonstrate that a single molecular target, and indeed a specific residue (N265) located within the GABA(A) receptor beta3 subunit, is a major determinant of behavioral responses evoked by the intravenous anesthetics etomidate and propofol, whereas volatile anesthetics appear to act via a broader spectrum of molecular targets.	Univ Zurich, Inst Pharmacol & Toxicol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Lab Anim Sci, CH-8057 Zurich, Switzerland; Univ Tubingen, Dept Anesthesiol, D-72076 Tubingen, Germany	University of Zurich; University of Zurich; Eberhard Karls University of Tubingen	Rudolph, U (corresponding author), Univ Zurich, Inst Pharmacol & Toxicol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	rudolph@pharma.unizh.ch	Zaugg, Michael/G-4287-2016; Drexler, Berthold/AAF-8358-2020; Siegwart, Roland/A-4495-2008	Vogt, Kaspar/0000-0002-0859-876X; Zaugg, Michael/0000-0002-2016-8973; Siegwart, Roland/0000-0002-2760-7983; Drexler, Berthold/0000-0001-7202-1511; Arras, Margarete/0000-0003-3864-9879				Antkowiak B, 1998, ANESTHESIOLOGY, V88, P1592, DOI 10.1097/00000542-199806000-00024; Antognini JF, 2001, SLEEP, V24, P26, DOI 10.1093/sleep/24.1.26; ARRAS M, 2001, COMPARATIVE MED, V51, P436; Barnard EA, 1998, PHARMACOL REV, V50, P291; Belelli D, 1997, P NATL ACAD SCI USA, V94, P11031, DOI 10.1073/pnas.94.20.11031; Benke D, 1997, J NEUROCHEM, V69, P806; BENKE D, 1994, J BIOL CHEM, V269, P27100; Benson JA, 1998, FEBS LETT, V431, P400, DOI 10.1016/S0014-5793(98)00803-5; Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; Carlson BX, 2000, MOL PHARMACOL, V57, P474, DOI 10.1124/mol.57.3.474; Cheng G, 2000, ANESTHESIOLOGY, V93, P1075, DOI 10.1097/00000542-200010000-00032; Collinson N, 2002, J NEUROSCI, V22, P5572; DildyMayfield JE, 1996, J PHARMACOL EXP THER, V276, P1058; Eckenhoff RG, 1998, MOL PHARMACOL, V54, P610; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Friederich P, 1999, ANESTHESIOLOGY, V91, P1853, DOI 10.1097/00000542-199912000-00040; Fritschy JM, 1998, J COMP NEUROL, V390, P194; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; Guertin PA, 1999, NEUROSCIENCE, V88, P353, DOI 10.1016/S0306-4522(98)00371-6; GUNTHER U, 1995, P NATL ACAD SCI USA, V92, P7749, DOI 10.1073/pnas.92.17.7749; Homanics GE, 1997, MOL PHARMACOL, V51, P588, DOI 10.1124/mol.51.4.588; Homanics GE, 1997, P NATL ACAD SCI USA, V94, P4143, DOI 10.1073/pnas.94.8.4143; Jenkins A, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-06-j0002.2001; Jones A, 1997, J NEUROSCI, V17, P1350; Krasowski MD, 1999, CELL MOL LIFE SCI, V55, P1278, DOI 10.1007/s000180050371; Krasowski MD, 1998, MOL PHARMACOL, V53, P530, DOI 10.1124/mol.53.3.530; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Lingamaneni R, 2001, ANESTHESIOLOGY, V95, P1460, DOI 10.1097/00000542-200112000-00027; Low K, 2000, SCIENCE, V290, P131, DOI 10.1126/science.290.5489.131; MA W, 1993, J COMP NEUROL, V338, P337, DOI 10.1002/cne.903380303; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; McKernan RM, 2000, NAT NEUROSCI, V3, P587, DOI 10.1038/75761; Mihalek RM, 1999, P NATL ACAD SCI USA, V96, P12905, DOI 10.1073/pnas.96.22.12905; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Miralles CP, 1999, J COMP NEUROL, V413, P535; MOHLER H, 2001, HANDB EXP PHARM, V150, P101; Moody EJ, 1997, J NEUROCHEM, V69, P1310; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; PERSOHN E, 1991, NEUROSCIENCE, V42, P497, DOI 10.1016/0306-4522(91)90392-2; Pistis M, 1999, J PHYSIOL-LONDON, V515, P3, DOI 10.1111/j.1469-7793.1999.003ad.x; Quinlan JJ, 1998, ANESTHESIOLOGY, V88, P775, DOI 10.1097/00000542-199803000-00030; RAMPIL IJ, 1994, ANESTHESIOLOGY, V80, P606, DOI 10.1097/00000542-199403000-00017; Rudolph U, 1999, NATURE, V401, P796, DOI 10.1038/44579; Sanna E, 1997, MOL PHARMACOL, V51, P484; Siegwart R, 2002, J NEUROCHEM, V80, P140, DOI 10.1046/j.0022-3042.2001.00682.x; Sur C, 2001, J NEUROSCI, V21, P3409, DOI 10.1523/JNEUROSCI.21-10-03409.2001; Tomlin SL, 1998, ANESTHESIOLOGY, V88, P708, DOI 10.1097/00000542-199803000-00022; Ugarte SD, 2000, NEUROSCIENCE, V95, P795; Vicini S, 2001, J NEUROSCI, V21, P3009, DOI 10.1523/JNEUROSCI.21-09-03009.2001; Vogt KE, 2001, J NEUROSCI, V21, P75, DOI 10.1523/JNEUROSCI.21-01-00075.2001; WAUD DR, 1972, J PHARMACOL EXP THER, V183, P577; WONG SM, ANESTHESIOLOGY, V95, P154; Yamakura T, 2001, ANNU REV PHARMACOL, V41, P23, DOI 10.1146/annurev.pharmtox.41.1.23; Zhang L, 1997, BRIT J PHARMACOL, V120, P353, DOI 10.1038/sj.bjp.0700934	54	451	465	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					250	+		10.1096/fj.02-0611fje	http://dx.doi.org/10.1096/fj.02-0611fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475885				2022-12-28	WOS:000180574300019
J	Filomeni, G; Rotilio, G; Ciriolo, MR				Filomeni, G; Rotilio, G; Ciriolo, MR			Glutathione disulfide induces apoptosis in U937 cells by a redox-mediated p38 mitogen-activated protein kinase pathway	FASEB JOURNAL			English	Article						redox signaling; thioredoxin; MAPK; GSH redox state; mixed disulfide	OXIDATIVE STRESS; MAMMALIAN THIOREDOXIN; REDUCED GLUTATHIONE; DEATH RECEPTORS; BCL-2; INHIBITION; CANCER; GSH; TRANSDUCTION; DEPLETION	Changes in the intracellular reduced/oxidized glutathione ratio (GSH/GSSG) are crucial reduction-oxidation (redox) events that trigger downstream proliferation or death responses. We investigated the molecular mechanisms underlying redox-mediated cell signaling upon an oxidative insult by treating U937 cells with exogenous nonpermeable GSSG. This treatment results in a significant decrease of exofacial cell membrane thiol groups and intracellular decrement of GSH content, owing to its engagement in the formation of mixed disulfides. Changes in thioredoxin redox state were also observed, and they may be related to the activation of upstream ASK1 and selective induction of downstream p38 mitogen-activated protein kinase (MAPK) pathway, detectable by phosphorylation of MKK3/6 and p38 MAPK. Moreover, an increase in reactive oxygen species production was detected, and cells were committed to apoptosis along the mitochondrial pathway, evidenced by Bcl-2 down-regulation, cytochome c release from mitochondria, caspase-9 cleavage, and caspase-3 activation. GSH ethyl ester, a precursor of GSH, by counteracting intracellular mixed disulfide formation, canceled both p38 MAPK activation and GSSG-mediated apoptosis via inhibition of thioredoxin oxidation and stabilization of thioredoxin/ASK1 complex, whereas, blockage of p38 MAPK by specific inhibitor SB 203580 allowed apoptosis at a very reduced extent. Results suggest that kinase cascade may serve as a primary transducer of cytoplasmic oxidative signals to the nucleus before apoptosis-inducing signals are activated.	Univ G dAnnunzio, Dept Biomed Sci, Chieti, Italy; Univ Roma Tor Vergata, Dept Biol, Rome, Italy	G d'Annunzio University of Chieti-Pescara; University of Rome Tor Vergata	Ciriolo, MR (corresponding author), Univ G dAnnunzio, Dept Biomed Sci, Via Vestini 66013, Chieti, Italy.	ciriolo@bio.uniroma2.it	Ciriolo, Maria Rosa/K-6572-2016	Ciriolo, Maria Rosa/0000-0002-7863-9029; Filomeni, Giuseppe/0000-0002-2719-1412				Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; Bonavida B, 1999, INT J ONCOL, V15, P793; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; Ciriolo MR, 2000, J BIOL CHEM, V275, P5065, DOI 10.1074/jbc.275.7.5065; Ciriolo MR, 1997, J BIOL CHEM, V272, P2700, DOI 10.1074/jbc.272.5.2700; CIRIOLO MR, 1993, EUR J BIOCHEM, V215, P711, DOI 10.1111/j.1432-1033.1993.tb18083.x; Cleveland JL, 2000, NATURE, V407, P309, DOI 10.1038/35030277; Coffey RNT, 2000, CANCER-AM CANCER SOC, V88, P2092, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2092::AID-CNCR15>3.0.CO;2-9; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; ESTRELA JM, 1995, NAT MED, V1, P84, DOI 10.1038/nm0195-84; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; HALLIWELL B, 1988, HUM TOXICOL, V7, P7, DOI 10.1177/096032718800700102; Hehner SP, 2000, J IMMUNOL, V165, P4319, DOI 10.4049/jimmunol.165.8.4319; Herrlich P, 2000, BIOCHEM PHARMACOL, V59, P35, DOI 10.1016/S0006-2952(99)00298-1; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; JORDAN J, 1987, BRIT J CANCER, V55, P627, DOI 10.1038/bjc.1987.127; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Kurata S, 2000, J BIOL CHEM, V275, P23413, DOI 10.1074/jbc.C000308200; Lizard G, 1998, FASEB J, V12, P1651, DOI 10.1096/fasebj.12.15.1651; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; MARTENSSON J, 1993, P NATL ACAD SCI USA, V90, P317, DOI 10.1073/pnas.90.1.317; MAXWELL SRJ, 1995, DRUGS, V49, P345, DOI 10.2165/00003495-199549030-00003; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Nishiyama A, 2001, IUBMB LIFE, V52, P29, DOI 10.1080/15216540252774739; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Rahman I, 2000, FREE RADICAL BIO MED, V28, P1405, DOI 10.1016/S0891-5849(00)00215-X; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; REGLINSKI J, 1988, J BIOL CHEM, V263, P12360; Rincon M, 2000, FREE RADICAL BIO MED, V28, P1328, DOI 10.1016/S0891-5849(00)00219-7; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0; Solary E, 2000, LEUKEMIA, V14, P1833, DOI 10.1038/sj.leu.2401902; STEINMAN HM, 1995, J BIOL CHEM, V270, P3487; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Trevillyan JM, 1999, ARCH BIOCHEM BIOPHYS, V364, P19, DOI 10.1006/abbi.1999.1099; VAHMEIJER AL, 2000, BIOCHEM PHARMACOL, V59, P1557; van der Kolk DM, 1999, ADV EXP MED BIOL, V457, P187; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Voehringer DW, 2000, ANTIOXID REDOX SIGN, V2, P537, DOI 10.1089/15230860050192314; Voehringer DW, 1999, FREE RADICAL BIO MED, V27, P945, DOI 10.1016/S0891-5849(99)00174-4	61	112	118	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					64	+		10.1096/fj.02-0105fje	http://dx.doi.org/10.1096/fj.02-0105fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12424221	Green Submitted			2022-12-28	WOS:000180218500041
J	Gouni-Berthold, I; Sachinidis, A				Gouni-Berthold, I; Sachinidis, A			Does the coronary risk factor low density lipoprotein alter growth and signaling in vascular smooth muscle cells?	FASEB JOURNAL			English	Review						LDL; atherosclerosis; hypertension; signal transduction; MAP kinases; sphingosine-1 phosphate	ACTIVATED PROTEIN-KINASE; INTIMA-MEDIA THICKNESS; NECROSIS-FACTOR-ALPHA; C-FOS EXPRESSION; OXIDIZED LDL; SPHINGOSINE 1-PHOSPHATE; ENDOTHELIAL-CELLS; LYSOPHOSPHATIDIC ACID; HEART-DISEASE; COUPLED RECEPTORS	There is increasing evidence that hypertension promotes low density lipoprotein (LDL) transportation into the subendothelial space of the vascular wall. Vascular smooth muscle cell (VSMC) proliferation plays an important role in the development and progression of cardiovascular diseases. Recently, several studies have demonstrated that LDL acts as a classic growth factor promoting VSMC growth via mitogenic signals normally elicited by classic growth factors. The present work summarizes current nontraditional concepts regarding possible cellular mechanisms through which hypertension and LDL may promote the development of atherosclerosis. Especially addressed are the possible effects of an elevated blood pressure in combination with LDL on VSMC growth. The new research concept concerning LDL as a growth factor and carrier for biological active phospholipids such as sphingosine-1-phosphate and sphingosylphosphorylcholine may contribute to an understanding of the pathogenesis of atherosclerosis by elevated high blood pressure.	Univ Cologne, Ctr Physiol & Pathophysiol, D-50931 Cologne, Germany; Univ Cologne, Med Clin 2, D-50931 Cologne, Germany	University of Cologne; University of Cologne	Sachinidis, A (corresponding author), Univ Cologne, Ctr Physiol & Pathophysiol, Robert Koch Str 39, D-50931 Cologne, Germany.	A.Sachinidis@uni-koeln.de	Sachinidis, Agapios/AAD-4178-2020; Sachinidis, Agapios/AAM-7988-2020					Abdellatif M, 1998, MOL CELL BIOL, V18, P6729, DOI 10.1128/MCB.18.11.6729; Anber V, 1996, ATHEROSCLEROSIS, V124, P261, DOI 10.1016/0021-9150(96)05842-X; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; Auge N, 1999, J BIOL CHEM, V274, P21533, DOI 10.1074/jbc.274.31.21533; AUGE N, 1995, BIOCHEM J, V309, P1015, DOI 10.1042/bj3091015; AUTIO I, 1990, FEBS LETT, V277, P247, DOI 10.1016/0014-5793(90)80857-F; Balagopalakrishna C, 1997, MOL CELL BIOCHEM, V170, P85, DOI 10.1023/A:1006840927835; Bhunia AK, 1997, J BIOL CHEM, V272, P15642, DOI 10.1074/jbc.272.25.15642; Bhunia AK, 1996, J BIOL CHEM, V271, P10660, DOI 10.1074/jbc.271.18.10660; BIHARIVARGA M, 1988, ARTERIOSCLEROSIS, V8, P851, DOI 10.1161/01.ATV.8.6.851; Bjorkerud B, 1996, ARTERIOSCL THROM VAS, V16, P416, DOI 10.1161/01.ATV.16.3.416; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Bonnefont-Rousselot D, 1999, CLIN CHEM LAB MED, V37, P939, DOI 10.1515/CCLM.1999.139; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; Bots ML, 1999, J INTERN MED, V245, P269, DOI 10.1046/j.1365-2796.1999.0442f.x; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Carlson SA, 1996, J BIOL CHEM, V271, P23146, DOI 10.1074/jbc.271.38.23146; CASTELLI WP, 1984, AM J MED, V76, P4, DOI 10.1016/0002-9343(84)90952-5; Chai YC, 1996, J BIOL CHEM, V271, P17791, DOI 10.1074/jbc.271.30.17791; Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chatterjee S, 1996, GLYCOBIOLOGY, V6, P303, DOI 10.1093/glycob/6.3.303; Chatterjee S, 1998, ARTERIOSCL THROM VAS, V18, P1523, DOI 10.1161/01.ATV.18.10.1523; Chatterjee S, 1997, INDIAN J BIOCHEM BIO, V34, P56; Chatterjee S, 1997, GLYCOBIOLOGY, V7, P703, DOI 10.1093/glycob/7.5.703; CHATTERJEE S, 1992, MOL CELL BIOCHEM, V111, P143; CHEN JK, 1991, J CELL PHYSIOL, V146, P110, DOI 10.1002/jcp.1041460115; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN SY, 1994, ONCOGENE, V9, P2691; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Crouse JR, 1996, STROKE, V27, P69, DOI 10.1161/01.STR.27.1.69; Cucina A, 1998, EUR J VASC ENDOVASC, V16, P197, DOI 10.1016/S1078-5884(98)80220-7; CURMI PA, 1990, CIRC RES, V66, P1692, DOI 10.1161/01.RES.66.6.1692; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DALY MM, 1972, CIRC RES, V31, P410, DOI 10.1161/01.RES.31.3.410; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Deigner HP, 1996, FEBS LETT, V385, P149, DOI 10.1016/0014-5793(96)00371-7; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Frank PG, 2001, AM J PHYSIOL-CELL PH, V280, pC1204, DOI 10.1152/ajpcell.2001.280.5.C1204; FRY DL, 1987, ARTERIOSCLEROSIS, V7, P88, DOI 10.1161/01.ATV.7.1.88; GENEST J, 1992, J AM COLL CARDIOL, V19, P792, DOI 10.1016/0735-1097(92)90520-W; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; Gouni-Berthold I, 2001, EXP CLIN ENDOCR DIAB, V109, P203, DOI 10.1055/s-2001-15107; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HOLVOET P, 1994, FASEB J, V8, P1279, DOI 10.1096/fasebj.8.15.8001740; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Hu YH, 2000, ARTERIOSCL THROM VAS, V20, P18, DOI 10.1161/01.ATV.20.1.18; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; JEANNETON O, 1993, J PHARMACOL EXP THER, V267, P31; Jing Q, 1999, CIRC RES, V84, P831; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; KIM MY, 1991, J BIOL CHEM, V266, P484; Kimura T, 2001, J BIOL CHEM, V276, P31780, DOI 10.1074/jbc.M104353200; Klouche M, 1999, J IMMUNOL, V163, P4583; Klouche M, 2000, CIRCULATION, V101, P1799, DOI 10.1161/01.CIR.101.15.1799; Kluk MJ, 2001, CIRC RES, V89, P496, DOI 10.1161/hh1801.096338; KO Y, 1995, EUR J CELL BIOL, V68, P306; Koba S, 2000, PROSTAG LEUKOTR ESS, V63, P329, DOI 10.1054/plef.2000.0223; Koba S, 1999, J AM COLL CARDIOL, V34, P1644, DOI 10.1016/S0735-1097(99)00349-6; Kohno M, 1998, CIRCULATION, V98, P353, DOI 10.1161/01.CIR.98.4.353; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; LIBBY P, 1985, J CELL PHYSIOL, V124, P1, DOI 10.1002/jcp.1041240102; Lin MT, 1999, J BIOMED SCI, V6, P260; LOCHER R, 1991, SCAND J CLIN LAB INV, V51, P541, DOI 10.3109/00365519109104563; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Luo Y, 1996, J IMMUNOL, V157, P2143; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; Marathe GK, 2001, TRENDS CARDIOVAS MED, V11, P139, DOI 10.1016/S1050-1738(01)00100-1; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; MARTIN MJ, 1986, LANCET, V2, P933; Mertens A, 2001, FASEB J, V15, P2073, DOI 10.1096/fj.01-0273rev; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MOREL DW, 1983, J LIPID RES, V24, P1070; MULVANY MJ, 1990, J HYPERTENS, V8, pS225; Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042/0264-6021:3520809; NATARAJAN V, 1995, J LIPID RES, V36, P2005; Nickenig G, 1997, CIRCULATION, V95, P473; NILSSON J, 1985, P NATL ACAD SCI USA, V82, P4418, DOI 10.1073/pnas.82.13.4418; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Nofer JR, 2001, J BIOL CHEM, V276, P34480, DOI 10.1074/jbc.M103782200; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Oinuma T, 1997, J Atheroscler Thromb, V4, P79; Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PARHAMI F, 1995, ARTERIOSCL THROM VAS, V15, P2019, DOI 10.1161/01.ATV.15.11.2019; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; Pyne S, 1996, EUR J BIOCHEM, V237, P819, DOI 10.1111/j.1432-1033.1996.0819p.x; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; Rao GN, 1996, J BIOL CHEM, V271, P27760, DOI 10.1074/jbc.271.44.27760; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RESINK TJ, 1992, ARTERIOSCLER THROMB, V12, P278, DOI 10.1161/01.ATV.12.3.278; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUBIN K, 1988, LANCET, V1, P1353; Sachinidis A, 1999, ARTERIOSCL THROM VAS, V19, P2412, DOI 10.1161/01.ATV.19.10.2412; Sachinidis A, 1997, MOL PHARMACOL, V52, P389, DOI 10.1124/mol.52.3.389; SACHINIDIS A, 1993, BIOCHEM BIOPH RES CO, V192, P794, DOI 10.1006/bbrc.1993.1484; SACHINIDIS A, 1995, HYPERTENSION, V26, P771, DOI 10.1161/01.HYP.26.5.771; Sachinidis A, 1997, HYPERTENSION, V29, P326, DOI 10.1161/01.HYP.29.1.326; SACHINIDIS A, 1990, HYPERTENSION, V15, P704, DOI 10.1161/01.HYP.15.6.704; SALONEN R, 1991, J INTERN MED, V229, P225, DOI 10.1111/j.1365-2796.1991.tb00336.x; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCOTTBURDEN T, 1989, BIOCHEM BIOPH RES CO, V159, P624, DOI 10.1016/0006-291X(89)90040-5; Seewald S, 1997, CARDIOVASC RES, V36, P92, DOI 10.1016/S0008-6363(97)00139-9; Seewald S, 1997, ATHEROSCLEROSIS, V130, P121, DOI 10.1016/S0021-9150(96)06055-8; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; SMITH EB, 1972, LANCET, V1, P463; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; SPIEGELK S, 2002, IN PRESS J BIOL CHEM; Stein O, 1999, ATHEROSCLEROSIS, V144, P285, DOI 10.1016/S0021-9150(99)00065-9; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STIKORAHM A, 1992, ARTERIOSCLER THROMB, V12, P1099, DOI 10.1161/01.ATV.12.9.1099; Suc I, 1998, FASEB J, V12, P665, DOI 10.1096/fasebj.12.9.665; Sugano M, 2000, BIOCHEM BIOPH RES CO, V272, P872, DOI 10.1006/bbrc.2000.2877; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Sun P, 2000, ARTERIOSCL THROM VAS, V20, P2005, DOI 10.1161/01.ATV.20.8.2005; Tamama K, 2001, BIOCHEM J, V353, P139, DOI 10.1042/bj3530139; TENSEN CP, 1994, P NATL ACAD SCI USA, V91, P4816, DOI 10.1073/pnas.91.11.4816; Theilmeier G, 2000, FASEB J, V14, P2032, DOI 10.1096/fj.99-1029com; Tigyi G, 2001, MOL PHARMACOL, V60, P1161, DOI 10.1124/mol.60.6.1161; TKACHUK VA, 1994, MOL PHARMACOL, V46, P1129; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; Underwood PA, 2000, CARDIOVASC RES, V47, P749, DOI 10.1016/S0008-6363(00)00129-2; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VASILE E, 1983, J CELL BIOL, V96, P1677, DOI 10.1083/jcb.96.6.1677; Watanabe T, 2001, CIRCULATION, V103, P1440, DOI 10.1161/01.CIR.103.10.1440; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551; Yamakawa T, 1998, HYPERTENSION, V31, P248, DOI 10.1161/01.HYP.31.1.248; Yamazaki R, 2000, EUR J PHARMACOL, V404, P375, DOI 10.1016/S0014-2999(00)00620-8; Yang CM, 2001, BRIT J PHARMACOL, V132, P1531, DOI 10.1038/sj.bjp.0703976; Yang CM, 2000, CELL SIGNAL, V12, P205, DOI 10.1016/S0898-6568(99)00087-X; Yatomi Y, 1997, J BIOL CHEM, V272, P5291, DOI 10.1074/jbc.272.8.5291; ZWIJSEN RML, 1992, BIOCHEM BIOPH RES CO, V186, P1410, DOI 10.1016/S0006-291X(05)81563-3	158	21	22	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1477	1487		10.1096/fj.02-0260rev	http://dx.doi.org/10.1096/fj.02-0260rev			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374770				2022-12-28	WOS:000179167600029
J	Venturini, G; Colasanti, M; Persichini, T; Fioravanti, E; Ascenzi, P; Palomba, L; Cantoni, O; Musci, G				Venturini, G; Colasanti, M; Persichini, T; Fioravanti, E; Ascenzi, P; Palomba, L; Cantoni, O; Musci, G			beta-Amyloid inhibits NOS activity by subtracting NADPH availability	FASEB JOURNAL			English	Article						Alzheimer's disease; nitric oxide; constitutive NOS inhibition	NITRIC-OXIDE SYNTHASE; ENZYME COMPLEX RECEPTOR; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; IN-VITRO; PEPTIDE; ACCUMULATION; MODULATION; GENERATION; ASTROCYTES	The amyloid peptides Abeta1-42 and Abeta25-35 strongly inhibited the activity of constitutive neuronal and endothelial nitric oxide synthases (i.e., NOS-I and NOS-III, respectively) in cell-free assays. The molecular mechanism of NOS inhibition by Abeta fragments was studied in detail with Abeta25-35. The inhibitory ability was mostly NADPH-dependent and specific for the soluble form of Abeta25-35. Optical, fluorescence, and NMR spectroscopy showed that the soluble, but not aggregated, Abeta25-35 interacted with NADPH, thus suggesting that a direct recruitment of NADPH may result in diminished availability of the redox cofactor for NOS functioning. To assess the physiological relevance of our findings, rat neuronal-like PC12 and glioma C6 cell lines were used as cellular models. After Abeta25-35 internalization into cells was verified, the activity of constitutive NOS was measured using the DAF-2DA detection system and found to be severely impaired upon Abeta25-35 uptake. Consistent with previous results on the molecular cross-talk between NOS isoforms, repression of constitutive NOS by Abeta25-35 resulted in enhanced expression of inducible NOS (NOS-II) mRNA in C6 cells. Our results represent the first evidence that amyloid fragments impair constitutive NOS activity in cell-free and cellular systems, providing a possible molecular mechanism for the onset and/or maintenance of Alzheimer's disease.	Univ Messina, Dept Microbiol Genet & Mol Sci, I-98166 Messina, Italy; Univ Urbino, Inst Pharmacol & Pharmacognosy, I-61029 Urbino, Italy; Univ Roma Tre, Dept Biol, Rome, Italy	University of Messina; University of Urbino; Roma Tre University	Musci, G (corresponding author), Univ Messina, Dept Microbiol Genet & Mol Sci, Salita Sperone 31, I-98166 Messina, Italy.	musci@unime.it	Musci, Giovanni/H-2862-2012; COLASANTI, MARCO/A-5616-2010	Musci, Giovanni/0000-0002-5196-709X; COLASANTI, MARCO/0000-0002-5752-4943; PERSICHINI, TIZIANA/0000-0001-8291-6706				Akama KT, 2000, J BIOL CHEM, V275, P7918, DOI 10.1074/jbc.275.11.7918; Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; Almeida A, 2001, J NEUROCHEM, V77, P676, DOI 10.1046/j.1471-4159.2001.00276.x; Boland K, 1996, J BIOL CHEM, V271, P18032, DOI 10.1074/jbc.271.30.18032; BOLAND K, 1995, J BIOL CHEM, V270, P28022; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Colasanti M, 2000, TRENDS PHARMACOL SCI, V21, P249, DOI 10.1016/S0165-6147(00)01499-1; Colasanti M, 1998, BIOCHEM BIOPH RES CO, V246, P453, DOI 10.1006/bbrc.1998.8642; Colasanti M, 2000, BRAIN RES BULL, V52, P155, DOI 10.1016/S0361-9230(00)00262-8; COLASANTI M, 1995, J BIOL CHEM, V270, P26731, DOI 10.1074/jbc.270.45.26731; Colasanti M, 2000, BIOCHEM BIOPH RES CO, V275, P776, DOI 10.1006/bbrc.2000.3396; de la Torre JC, 2000, BRAIN RES REV, V34, P119, DOI 10.1016/S0165-0173(00)00043-6; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; Glabe C, 2001, J MOL NEUROSCI, V17, P137, DOI 10.1385/JMN:17:2:137; Gouras GK, 1998, J NEUROCHEM, V71, P1920; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; HAASS C, 1991, J NEUROSCI, V11, P3783; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; He XY, 1998, J BIOL CHEM, V273, P10741, DOI 10.1074/jbc.273.17.10741; Huang AN, 2001, AM J PHYSIOL-CELL PH, V281, pC719, DOI 10.1152/ajpcell.2001.281.2.C719; Hudetz AG, 1998, AM J PHYSIOL-HEART C, V274, pH982, DOI 10.1152/ajpheart.1998.274.3.H982; Hudetz AG, 1999, J APPL PHYSIOL, V87, P505, DOI 10.1152/jappl.1999.87.2.505; IVERSEN LL, 1995, BIOCHEM J, V311, P1; Law A, 2001, BRAIN RES REV, V35, P73, DOI 10.1016/S0165-0173(00)00051-5; LEONI S, 1986, CELL MOL BIOL, V32, P247; Lopez-Figueroa MO, 2000, BRAIN RES, V852, P239, DOI 10.1016/S0006-8993(99)02241-6; McCarty MF, 1999, MED HYPOTHESES, V53, P369, DOI 10.1054/mehy.1998.0783; Petit PX, 2001, BIOCHEM J, V353, P357, DOI 10.1042/0264-6021:3530357; PIACENTINI M, 1983, BIOCHIM BIOPHYS ACTA, V731, P151, DOI 10.1016/0005-2736(83)90004-4; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; Price JM, 2001, NEUROL RES, V23, P506, DOI 10.1179/016164101101198758; Qu XW, 2001, FASEB J, V15, P439, DOI 10.1096/fj.99-0343com; Rossi F, 1996, BIOCHEM BIOPH RES CO, V225, P474, DOI 10.1006/bbrc.1996.1197; Sanz MJ, 2001, BRIT J PHARMACOL, V134, P305, DOI 10.1038/sj.bjp.0704234; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; Stefano GB, 2000, PROG NEUROBIOL, V60, P513, DOI 10.1016/S0301-0082(99)00038-6; STUEHR DJ, 1992, ADV ENZYMOL RAMB, V65, P287; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; Taylor BS, 1997, ARCH SURG-CHICAGO, V132, P1177; TERZI E, 1994, BIOCHEMISTRY-US, V33, P1345, DOI 10.1021/bi00172a009; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Togashi H, 1997, P NATL ACAD SCI USA, V94, P2676, DOI 10.1073/pnas.94.6.2676; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; Venturini G, 2000, BIOCHEM PHARMACOL, V60, P539, DOI 10.1016/S0006-2952(00)00352-X; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Yan SD, 1997, NATURE, V389, P689; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0; Young MJ, 1999, BRAIN RES BULL, V50, P27, DOI 10.1016/S0361-9230(99)00084-2; ZHAO B, 1995, J NEUROSCI RES, V40, P261, DOI 10.1002/jnr.490400215	53	35	38	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1970	+		10.1096/fj.02-0186fje	http://dx.doi.org/10.1096/fj.02-0186fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397094				2022-12-28	WOS:000179167600006
J	Stroh, C; Cassens, U; Samraj, AK; Sibrowski, W; Schulze-Osthoff, K; Los, M				Stroh, C; Cassens, U; Samraj, AK; Sibrowski, W; Schulze-Osthoff, K; Los, M			The role of caspases in cryoinjury: caspase inhibition strongly improves the recovery of cryopreserved hematopoietic and other cells	FASEB JOURNAL			English	Article						apoptosis; cryopreservation; stem cells; cathepsins; calpains	INDUCED APOPTOSIS; PRESERVATION INJURY; ENDOTHELIAL-CELLS; DEATH; ACTIVATION; MECHANISMS; HEPATOCYTES; HYPOTHERMIA; RECEPTORS; SURVIVAL	Cryopreserved cells and tissues are increasingly used for stem cell transplantation and tissue engineering. However, their freezing, storage, and thawing is associated with severe damage, suggesting the need for better cryopreservation methods. Here, we show that activation of caspase-3 is induced during the freeze-thaw process. Moreover, we demonstrate that prevention of caspase activation by the caspase inhibitor zVAD-fmk strongly improves the recovery and survival of several cryopreserved cell types and hematopoietic progenitor cells. A short preincubation with the caspase inhibitor after thawing also enhances the colony-forming activity of hematopoietic progenitor cells up to threefold. Furthermore, overexpression of Bcl-2, but not the blockade of the death receptor signaling, confers protection, indicating that cryoinjury-associated cell death is mediated by a Bcl-2-controlled mitochondrial pathway. Thus, our data suggest the use of zVAD-fmk as an efficient cryoprotective agent. The addition of caspase inhibitors may be an important tool for the cryopreservation of living cells and advantageous in cell transplantation, tissue engineering, and other genetic technologies.	Univ Munster, Inst Expt Dermatol, D-48149 Munster, Germany; Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Univ Munster, Inst Transfus Med, D-48149 Munster, Germany	University of Munster; Heinrich Heine University Dusseldorf; University of Munster	Los, M (corresponding author), Univ Munster, Inst Expt Dermatol, Rontgenstr 21, D-48149 Munster, Germany.	los@uni-muenster.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Los, Marek/0000-0001-9518-1411				Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bilzer M, 2000, J HEPATOL, V32, P508, DOI 10.1016/S0168-8278(00)80404-3; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Burek C, 2001, ONCOGENE, V20, P6493, DOI 10.1038/sj.onc.1204841; Cassens U, 2001, BONE MARROW TRANSPL, V28, P13, DOI 10.1038/sj.bmt.1703082; COUNDOURIS JA, 1993, XENOBIOTICA, V23, P1399, DOI 10.3109/00498259309059449; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; EAVES CJ, 1978, BLOOD, V52, P1196; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Eroglu A, 2000, NAT BIOTECHNOL, V18, P163, DOI 10.1038/72608; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fowke KR, 2000, J IMMUNOL METHODS, V244, P139, DOI 10.1016/S0022-1759(00)00263-5; Fu T, 2001, CELL TRANSPLANT, V10, P59; Gao D, 2000, ILAR J, V41, P187; HANSEN TN, 1994, CRYOBIOLOGY, V31, P101, DOI 10.1006/cryo.1994.1013; Hollister WR, 1998, MOL UROL, V2, P13; Hubel A, 2001, TRANSFUSION, V41, P579, DOI 10.1046/j.1537-2995.2001.41050579.x; Jaeschke H, 1996, J HEPATOL, V25, P774, DOI 10.1016/S0168-8278(96)80253-4; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kato S, 2000, BONE MARROW TRANSPL, V26, P1281, DOI 10.1038/sj.bmt.1702707; KRUUV J, 1983, J CELL PHYSIOL, V115, P179, DOI 10.1002/jcp.1041150212; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; Los M, 1998, J IMMUNOL, V161, P3050; Los M, 2001, TRENDS IMMUNOL, V22, P31, DOI 10.1016/S1471-4906(00)01814-7; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MAZUR P, 1984, AM J PHYSIOL, V247, pC125, DOI 10.1152/ajpcell.1984.247.3.C125; Peters SMA, 1998, TRANSPLANTATION, V65, P625, DOI 10.1097/00007890-199803150-00005; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Rauen U, 1999, FASEB J, V13, P155, DOI 10.1096/fasebj.13.1.155; Renz A, 2001, BLOOD, V98, P1542, DOI 10.1182/blood.V98.5.1542; Rowley S D, 1992, J Hematother, V1, P233, DOI 10.1089/scd.1.1992.1.233; Rudner J, 2001, J CELL SCI, V114, P4161; Sadowski-Debbing K, 2002, ARCH IMMUNOL THER EX, V50, P19; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596	42	85	99	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1651	+		10.1096/fj.02-0034fje	http://dx.doi.org/10.1096/fj.02-0034fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207004	Green Submitted			2022-12-28	WOS:000177814000020
J	Crosbie, RH; Dovico, SA; Flanagan, JD; Chamberlain, JS; Ownby, CL; Campbell, KP				Crosbie, RH; Dovico, SA; Flanagan, JD; Chamberlain, JS; Ownby, CL; Campbell, KP			Characterization of aquaporin-4 in muscle and muscular dystrophy	FASEB JOURNAL			English	Article						aquaporin; water channel; dystrophin; sarcoglycans; DMD	INSENSITIVE WATER CHANNEL; TRANSGENIC MDX MICE; GLYCOPROTEIN-COMPLEX; SKELETAL-MUSCLE; SARCOGLYCAN COMPLEX; CARDIOMYOPATHIC HAMSTER; NEUROMUSCULAR-JUNCTIONS; ALPHA-DYSTROGLYCAN; DELTA-SARCOGLYCAN; DEFICIENT MICE	Aquaporins are a growing family of transmembrane proteins that transport water and, in some cases, glycerol and urea across cellular membranes. Aquaporin-4 (AQP4) is enriched at the sarcolemma of skeletal muscle and may play a role in accommodating the rapid changes in cell volume and hydrostatic forces that occur during contraction in order to prevent damage to the sarcolemma. Recent evidence has shown that AQP4 is absent in dystrophin-deficient mdx mice, suggesting that AQP4 associates with dystrophin and has a role in the dystrophic process. To examine the relationship between aquaporins and muscle disease, and between aquaporins and dystrophin, we have investigated aquaporin expression in various mouse models of muscular dystrophy and cardiomyopathy before and after the onset of pathology. We find that AQP4 is expressed in prenecrotic mdx muscle despite the absence of dystrophin and that AQP4 is lost after the onset of muscle degeneration. Analysis of various dystrophin transgenic mice reveals that AQP4 is lost even when the dystrophin-glycoprotein complex is present, suggesting that loss of AQP4 is not directly resulting from loss of the DGC. AQP4 was also lost in muscular dystrophies caused by primary mutations in the sarcoglycan genes. Taken together, our data demonstrate that AQP4 loss in skeletal muscle correlates with muscular dystrophy and is a common feature of pathogenesis.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Neurol, Iowa City, IA 52242 USA; Univ Washington, Sch Med, Dept Neurol, Hlth Sci Ctr K24B, Seattle, WA USA; Oklahoma State Univ, Dept Physiol Sci, Stillwater, OK 74078 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa; University of Washington; University of Washington Seattle; Oklahoma State University System; Oklahoma State University - Stillwater	Campbell, KP (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, 400 Eckstein Med Res Bldg, Iowa City, IA 52242 USA.	kevin-campbell@uiowa.edu		Chamberlain, Jeffrey/0000-0001-5299-0059; Campbell, Kevin/0000-0003-2066-5889	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044533, R01AR048179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NIAID NIH HHS [5R01AI26923] Funding Source: Medline; NIAMS NIH HHS [AR44533, R01 AR048179] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Corrado K, 1996, J CELL BIOL, V134, P873, DOI 10.1083/jcb.134.4.873; COX GA, 1994, NAT GENET, V8, P333, DOI 10.1038/ng1294-333; Crosbie RH, 2000, HUM MOL GENET, V9, P2019, DOI 10.1093/hmg/9.13.2019; Crosbie RH, 1999, J CELL BIOL, V145, P153, DOI 10.1083/jcb.145.1.153; Crosbie RH, 1997, J BIOL CHEM, V272, P31221, DOI 10.1074/jbc.272.50.31221; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Durbeej M, 2000, MOL CELL, V5, P141, DOI 10.1016/S1097-2765(00)80410-4; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; Frigeri A, 1998, J CLIN INVEST, V102, P695, DOI 10.1172/JCI2545; Frigeri A, 2001, FASEB J, V15, P90, DOI 10.1096/fj.00-0260com; Frigeri A, 2001, FASEB J, V15, P1282, DOI 10.1096/fj.00-0525fje; GREENBERG DS, 1994, NAT GENET, V8, P340, DOI 10.1038/ng1294-340; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; Holt KH, 1998, J BIOL CHEM, V273, P34667, DOI 10.1074/jbc.273.52.34667; Holt KH, 1998, MOL CELL, V1, P841, DOI 10.1016/S1097-2765(00)80083-0; IWATA Y, 1993, FEBS LETT, V329, P227, DOI 10.1016/0014-5793(93)80227-L; Jimi T, 2000, NEUROSCI LETT, V291, P93, DOI 10.1016/S0304-3940(00)01382-3; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; Kameya S, 1999, J BIOL CHEM, V274, P2193, DOI 10.1074/jbc.274.4.2193; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; KOWALCHUK JM, 1988, J APPL PHYSIOL, V65, P2080, DOI 10.1152/jappl.1988.65.5.2080; Lim LE, 1998, CURR OPIN NEUROL, V11, P443, DOI 10.1097/00019052-199810000-00006; LINDINGER MI, 1994, AM J PHYSIOL, V266, pR1896, DOI 10.1152/ajpregu.1994.266.6.R1896; Liu JW, 1999, J NEUROL SCI, V164, P24, DOI 10.1016/S0022-510X(99)00051-9; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MCARDLE A, 1994, MUSCLE NERVE, V17, P1378, DOI 10.1002/mus.880171206; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; MIZUNO Y, 1995, AM J PATHOL, V146, P530; Montanaro F, 1999, J CELL BIOL, V145, P1325, DOI 10.1083/jcb.145.6.1325; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; Nguyen T M, 1991, J Cell Biol, V115, P1695, DOI 10.1083/jcb.115.6.1695; Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PHELPS SF, 1995, HUM MOL GENET, V4, P1251, DOI 10.1093/hmg/4.8.1251; PONS F, 1991, FEBS LETT, V282, P161, DOI 10.1016/0014-5793(91)80468-I; RAFAEL JA, 1994, HUM MOL GENET, V3, P1725, DOI 10.1093/hmg/3.10.1725; Rafael JA, 1996, J CELL BIOL, V134, P93, DOI 10.1083/jcb.134.1.93; ROBERDS SL, 1993, J BIOL CHEM, V268, P11496; Sakamoto A, 1997, P NATL ACAD SCI USA, V94, P13873, DOI 10.1073/pnas.94.25.13873; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; VANBEAUMONT W, 1973, J APPL PHYSIOL, V34, P102, DOI 10.1152/jappl.1973.34.1.102; WAKAYAMA Y, 1989, J NEUROL SCI, V91, P191, DOI 10.1016/0022-510X(89)90087-7; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8; YANG B, 1994, J BIOL CHEM, V269, P6040; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; Yang BX, 2000, AM J PHYSIOL-CELL PH, V278, pC1108, DOI 10.1152/ajpcell.2000.278.6.C1108; Yokota T, 2000, P JPN ACAD B-PHYS, V76, P22, DOI 10.2183/pjab.76.22; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	60	39	41	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2002	16	9					943	949		10.1096/fj.01-0327com	http://dx.doi.org/10.1096/fj.01-0327com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087055				2022-12-28	WOS:000177813100025
J	Liu, F; Schaphorst, KL; Verin, AD; Jacobs, K; Birukova, A; Day, RM; Bogatcheva, N; Bottaro, DP; Garcia, JGN				Liu, F; Schaphorst, KL; Verin, AD; Jacobs, K; Birukova, A; Day, RM; Bogatcheva, N; Bottaro, DP; Garcia, JGN			Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3 beta	FASEB JOURNAL			English	Article						beta-catenin; MAP kinases; endothelial permeability; cytoskeleton; transendothelial electrical resistance	C-MET RECEPTOR; PROTEIN-KINASE-C; SCATTER FACTOR; VASCULAR-PERMEABILITY; TYROSINE PHOSPHORYLATION; INTERCELLULAR-JUNCTIONS; DIFFERENTIAL REGULATION; BIOLOGICAL RESPONSES; EPITHELIAL-CELLS; HGF/SF RECEPTOR	The stabilization of endothelial cell (EC) barrier function within newly formed capillaries is a critical feature of angiogenesis. We examined human lung EC barrier regulation elicited by hepatocyte growth factor (HGF), a recognized angiogenic factor and EC chemoattractant. HGF rapidly and dose-dependently elevated transendothelial electrical resistance (TER) of EC monolayers (>50% increase at 100 ng/ml), with immunofluorescence microscopic evidence of both cytoplasmic actin stress fiber dissolution and strong augmentation of the cortical actin ring. HGF rapidly stimulated phosphatidylinositol 3'-kinase, ERK, p38 mitogen-activated protein kinase, and protein kinase C activities. Pharmacological inhibitor studies demonstrated each pathway to be intimately involved in HGF-induced increases in TER, cortical actin thickening, and phosphorylation of the Ser/Thr glycogen synthase kinase-3beta (GSK-3beta), a potential target for the HGF barrier-promoting response. GSK-3beta phosphorylation was strongly correlated with reductions in both HGF-induced TER and enhanced beta-catenin immunoreactivity observed at cell-cell junctions. Our data suggest a model in which HGF-mediated EC cytoskeletal rearrangement and barrier enhancement depend critically on the activation of a complex kinase cascade that converges at GSK-3beta to increase the availability of beta-catenin, thereby enhancing endothelial junctional integrity and vascular barrier function.	Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA; Tufts Univ, New England Med Ctr, Boston, MA 02111 USA; NCI, Bethesda, MD 20892 USA	Johns Hopkins University; Tufts Medical Center; Tufts University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Liu, F (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA.		Garcia, Joe GN/E-8862-2010; Bottaro, Donald P/F-8550-2010; Bottaro, Donald P/AAF-3853-2020	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334; Bogatcheva, Natalia/0000-0002-5177-5872	NHLBI NIH HHS [HL 50533, HL 69340, HL 58064, HL 03666] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003666, R01HL069340, R01HL050533, P01HL058064] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Becker PM, 2001, AM J PHYSIOL-LUNG C, V281, pL1500, DOI 10.1152/ajplung.2001.281.6.L1500; Borbiev T, 2001, AM J PHYSIOL-LUNG C, V280, pL983, DOI 10.1152/ajplung.2001.280.5.L983; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Davies G, 2001, INT J MOL MED, V7, P385; Day RM, 1999, ONCOGENE, V18, P3399, DOI 10.1038/sj.onc.1202683; Dejana E, 1997, ANN NY ACAD SCI, V811, P36, DOI 10.1111/j.1749-6632.1997.tb51986.x; Dirks WG, 1999, IN VITRO CELL DEV-AN, V35, P558; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Elefteriou F, 1999, EUR J BIOCHEM, V263, P840, DOI 10.1046/j.1432-1327.1999.00563.x; FIXMAN ED, 1995, ONCOGENE, V10, P237; Garcia JGN, 2000, J APPL PHYSIOL, V89, P2333, DOI 10.1152/jappl.2000.89.6.2333; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GIAIVER I, 1993, NATURE, V366, P591; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Guerin C, 2000, BIOCHEM BIOPH RES CO, V273, P287, DOI 10.1006/bbrc.2000.2935; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; Hiscox S, 1999, BIOCHEM BIOPH RES CO, V261, P406, DOI 10.1006/bbrc.1999.1002; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Hollande F, 2001, AM J PHYSIOL-GASTR L, V280, pG910, DOI 10.1152/ajpgi.2001.280.5.G910; Isagawa T, 2000, BIOCHEM BIOPH RES CO, V273, P209, DOI 10.1006/bbrc.2000.2926; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Jiang WG, 1999, J CELL PHYSIOL, V181, P319, DOI 10.1002/(SICI)1097-4652(199911)181:2<319::AID-JCP14>3.0.CO;2-S; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Liang CC, 2001, J BIOL CHEM, V276, P21146, DOI 10.1074/jbc.M010669200; Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Machover W, 1998, PIANO KEYBOARD, V1, P71; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Matsumoto K, 1998, J BIOL CHEM, V273, P22913, DOI 10.1074/jbc.273.36.22913; Merenmies J, 1997, CELL GROWTH DIFFER, V8, P3; Nagahori T, 1999, AM J RESP CELL MOL, V21, P490, DOI 10.1165/ajrcmb.21.4.3614; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; Papkoff J, 1997, J BIOL CHEM, V272, P4536; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; PELICCI G, 1995, ONCOGENE, V10, P1631; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rosen EM, 1995, ADV CANCER RES, V67, P257, DOI 10.1016/S0065-230X(08)60715-0; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SCHAPHORST KL, 1997, AM J RESP CELL MOL B, V17, P441; Shen BQ, 1997, AM J PHYSIOL-LUNG C, V272, pL1115, DOI 10.1152/ajplung.1997.272.6.L1115; Stahl SJ, 1997, BIOCHEM J, V326, P763, DOI 10.1042/bj3260763; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Verin AD, 2000, AM J PHYSIOL-LUNG C, V279, pL360, DOI 10.1152/ajplung.2000.279.2.L360; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; YANAGITA K, 1993, J BIOL CHEM, V268, P21212; Zhang LL, 2000, J NEUROSCI RES, V59, P489, DOI 10.1002/(SICI)1097-4547(20000215)59:4<489::AID-JNR3>3.0.CO;2-9; ZHU H, 1994, J BIOL CHEM, V269, P29943	65	135	138	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2002	16	9					950	962		10.1096/fj.01-0870com	http://dx.doi.org/10.1096/fj.01-0870com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087056				2022-12-28	WOS:000177813100026
J	Cantarella, G; Lempereur, L; Presta, M; Ribatti, D; Lombardo, G; Lazarovici, P; Zappala, G; Pafumi, C; Bernardini, R				Cantarella, G; Lempereur, L; Presta, M; Ribatti, D; Lombardo, G; Lazarovici, P; Zappala, G; Pafumi, C; Bernardini, R			Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo	FASEB JOURNAL			English	Article						growth factors; endothelium; trkA(NGFR); proliferation; blood vessels	EMBRYO CHORIOALLANTOIC MEMBRANE; FACTOR-LIKE PROTEIN; FACTOR RECEPTOR; PC12 CELLS; HUMAN PROSTATE; EXPRESSION; AFFINITY; TRK; ADENOCARCINOMA; PROLIFERATION	Nerve growth factor (NGF) has important functions during embryonic development and on various tissues and organs under normal and pathological conditions during the extrauterine life. RT-PCR analysis and immunological methods demonstrate that human umbilical vein endothelial cells (HUVECs) express the NGF receptors trkA(NGFR) and p75(NTR). NGF treatment caused a rapid phosphorylation of trkA(NGFR) in HUVECs, determining a parallel increase of phosphorylated ERK1/2. Accordingly, NGF induced a significant increase in HUVEC proliferation that was abolished by the trkA(NGFR) inhibitor K252a. Also, HUVECs express significant levels of NGF under standard culture conditions that were up-regulated during serum starvation. Endogenous NGF was responsible for the basal levels of trkA(NGFR) and ERK1/2 phosphorylation observed in untreated HUVEC cultures. Finally, NGF exerted a potent, direct, angiogenic activity in vivo when delivered onto the chorioallantoic membrane of the chicken embryo. The data indicate that NGF may play an important role in blood vessel formation in the nervous system and in several pathological processes, including tumors and inflammatory diseases. Unraveling mechanisms of NGF-dependent angiogenesis could provide valuable tools for novel therapeutic approaches in antiangiogenic therapy.	Univ Catania, Sch Med, Dept Expt & Clin Pharmacol, I-95125 Catania, Italy; Univ Bari, Sch Med, Dept Human Anat & Histol, Bari, Italy; Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Brescia, Italy; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol & Expt Therapeut, IL-91120 Jerusalem, Israel	University of Catania; Universita degli Studi di Bari Aldo Moro; University of Brescia; Hebrew University of Jerusalem	Bernardini, R (corresponding author), Univ Catania, Sch Med, Dept Expt & Clin Pharmacol, Cittadella Univ,Ed 12,3P,Viale Andrea Doria, I-95125 Catania, Italy.	bernardi@unict.it	Presta, Marco/B-4345-2010; Bernardini, Renato/AAF-6680-2021; Cantarella, Giuseppina/AHD-9609-2022	bernardini, renato/0000-0002-4765-0663; PRESTA, Marco/0000-0002-4398-8376; pafumi, carlo/0000-0001-9253-4592				Aloe L, 1999, MICROSC RES TECHNIQ, V45, P285, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<285::AID-JEMT12>3.0.CO;2-3; Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; Boss V, 2001, J NEUROSCI, V21, P18, DOI 10.1523/JNEUROSCI.21-01-00018.2001; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Calza L, 2001, P NATL ACAD SCI USA, V98, P4160, DOI 10.1073/pnas.051626998; Chiarenza A, 2001, CANCER RES, V61, P3002; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Descamps S, 1998, J BIOL CHEM, V273, P16659, DOI 10.1074/jbc.273.27.16659; DJAKIEW D, 1991, CANCER RES, V51, P3304; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P10984, DOI 10.1073/pnas.90.23.10984; Faller DV, 1999, CLIN EXP PHARMACOL P, V26, P74, DOI 10.1046/j.1440-1681.1999.02992.x; Goldbrunner RH, 2000, J NEURO-ONCOL, V50, P53, DOI 10.1023/A:1006462504447; GRAHAM CW, 1992, J UROLOGY, V147, P1444, DOI 10.1016/S0022-5347(17)37590-0; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jiang H, 1997, J CELL BIOCHEM, V66, P229, DOI 10.1002/(SICI)1097-4644(19970801)66:2<229::AID-JCB10>3.0.CO;2-C; KOIZUMI S, 1988, J NEUROSCI, V8, P715; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MARCHETTI D, 1993, INT J CANCER, V55, P692, DOI 10.1002/ijc.2910550430; Nakagawara A, 1997, EUR J CANCER, V33, P2050, DOI 10.1016/S0959-8049(97)00280-3; PFLUG BR, 1992, CANCER RES, V52, P5403; Pincelli C, 2000, EUR J DERMATOL, V10, P85; Raychaudhuri SK, 2001, ARCH DERMATOL RES, V293, P291, DOI 10.1007/s004030100224; RIBATTI D, 1995, DEV BIOL, V170, P39, DOI 10.1006/dbio.1995.1193; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Ribatti D, 2001, INT J MOL MED, V8, P265; Sortino MA, 2000, MOL ENDOCRINOL, V14, P124, DOI 10.1210/me.14.1.124; Tagliabue E, 2000, J BIOL CHEM, V275, P5388, DOI 10.1074/jbc.275.8.5388; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; Yano H, 2000, Pharm Acta Helv, V74, P253, DOI 10.1016/S0031-6865(99)00036-9	33	194	205	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1307	+		10.1096/fj.01-1000fje	http://dx.doi.org/10.1096/fj.01-1000fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154004				2022-12-28	WOS:000176683900020
J	Li, JH; Huang, XR; Zhu, HJ; Oldfield, M; Cooper, M; Truong, LD; Johnson, RJ; Lan, HY				Li, JH; Huang, XR; Zhu, HJ; Oldfield, M; Cooper, M; Truong, LD; Johnson, RJ; Lan, HY			Advanced glycation end products activate Smad signaling via TGF-beta-dependent and -independent mechanisms: implications for diabetic renal and vascular disease	FASEB JOURNAL			English	Article						TGF-beta/Smad signaling; Smad7; AGEs and RAGE; diabetic nephropathy and vasculopathy	GROWTH-FACTOR-BETA; MATRIX GENE-EXPRESSION; EMBRYONIC LUNG MORPHOGENESIS; RECEPTOR COMPLEX; EPITHELIAL-CELLS; MESANGIAL CELLS; OXIDANT STRESS; CROSS-TALK; IN-VIVO; KAPPA-B	While it is thought that advanced glycation end products (AGEs) act by stimulating transforming growth factor (TGF)-beta to mediate diabetic injury, we report that AGEs can activate TGF-beta signaling, Smads, and mediate diabetic scarring directly and independently of TGF-beta. AGEs activate Smad2/3 in renal and vascular cells at 5 min, peaking over 15.30 min before TGF-beta synthesis at 24 h and occurs in TGF-beta receptor I and II mutant cells. This is mediated by RAGE and ERK/p38 mitogen-activated protein kinases (MAPKs). In addition, AGEs also activate Smads at 24 h via the classic TGF-beta-dependent pathway. A substantial inhibition of AGE-induced Smad activation and collagen synthesis by ERK/p38 MAPK inhibitors, but not by TGF-beta blockade, suggests that the MAPK-Smad signaling crosstalk pathway is a key mechanism in diabetic scarring. Prevention of AGE-induced Smad activation and collagen synthesis by overexpression of Smad7 indicates that Smad signaling may play a critical role in diabetic complications. This is further supported by the findings that activation of Smad2/3 in human diabetic nephropathy and vasculopathy is associated with local deposition of AGEs and upregulation of RAGE. Thus, AGEs act by activating Smad signaling to mediate diabetic complications via both TGF-beta-dependent and -independent pathways, shedding new light on the pathogenesis of diabetic organ injury.	Baylor Coll Med, Dept Med Nephrol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic, Australia; Univ Melbourne, Austin & Repatriat Med Ctr, Dept Med, Melbourne, Vic, Australia	Baylor College of Medicine; Baylor College of Medicine; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Lan, HY (corresponding author), Baylor Coll Med, Dept Med Nephrol, 1 Baylor Plaza,Alkek N520, Houston, TX 77030 USA.	hlan@bcm.tmc.edu	Li, Jinhua/I-2741-2014; Lan, Hui Yao/C-9734-2015	Lan, Hui Yao/0000-0003-4283-9755; Li, Jinhua/0000-0003-4039-5759; Zhu, Hong-Jian/0000-0002-1478-995X	Juvenile Diabetes Research Foundation (JDRF) [1-2001-596, 4-1999-821]; Texas Advanced Technology Program [004949-0005-2001]; National Health & Medical Research Council [164812]	Juvenile Diabetes Research Foundation (JDRF)(Juvenile Diabetes Research Foundation); Texas Advanced Technology Program; National Health & Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	This work is supported by grants from the Juvenile Diabetes Research Foundation (JDRF 1-2001-596 and 4-1999-821), Texas Advanced Technology Program (004949-0005-2001), and from the National Health & Medical Research Council (164812).	Bierhaus A, 1997, DIABETES, V46, P1481, DOI 10.2337/diabetes.46.9.1481; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; Border WA, 1996, DIABETES METAB REV, V12, P309; Bucala R, 1995, AM J KIDNEY DIS, V26, P875, DOI 10.1016/0272-6386(95)90051-9; Chen RH, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134887; Cooper ME, 2001, AM J HYPERTENS, V14, P475, DOI 10.1016/S0895-7061(00)01323-6; Forbes JM, 2001, DIABETOLOGIA, V44, P108, DOI 10.1007/s001250051587; Han DC, 2000, AM J PHYSIOL-RENAL, V278, pF628, DOI 10.1152/ajprenal.2000.278.4.F628; Hill-Kapturczak N, 2000, J BIOL CHEM, V275, P40904, DOI 10.1074/jbc.M006621200; Hong SW, 2001, AM J PATHOL, V158, P1653; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kelly DJ, 2001, J AM SOC NEPHROL, V12, P2098, DOI 10.1681/ASN.V12102098; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; LAN HY, 1995, J HISTOCHEM CYTOCHEM, V43, P97, DOI 10.1177/43.1.7822770; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li JH, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000014252.37680.E4; Massague J, 2000, GENE DEV, V14, P627; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1999, J CLIN INVEST, V104, P5, DOI 10.1172/JCI6094; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Oldfield MD, 2001, J CLIN INVEST, V108, P1853; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Reeves WB, 2000, P NATL ACAD SCI USA, V97, P7667, DOI 10.1073/pnas.97.14.7667; Rumble JR, 1997, J CLIN INVEST, V99, P1016, DOI 10.1172/JCI119229; Schmidt AM, 2000, TRENDS ENDOCRIN MET, V11, P368, DOI 10.1016/S1043-2760(00)00311-8; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI200114002; Sharma K, 1996, DIABETES, V45, P522, DOI 10.2337/diabetes.45.4.522; Striker LJ, 1996, NEPHROL DIAL TRANSPL, V11, P62; THROCKMORTON DC, 1995, KIDNEY INT, V48, P111, DOI 10.1038/ki.1995.274; Vasan S, 1996, NATURE, V382, P275, DOI 10.1038/382275a0; VLASSARA H, 1995, MOL MED, V1, P634, DOI 10.1007/BF03401604; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI11771; YANG CW, 1994, P NATL ACAD SCI USA, V91, P9436, DOI 10.1073/pnas.91.20.9436; YANG Z, 1991, J EXP MED, V174, P515, DOI 10.1084/jem.174.3.515; Yeh CH, 2001, DIABETES, V50, P1495, DOI 10.2337/diabetes.50.6.1495; Zhao JS, 2000, J BIOL CHEM, V275, P23992, DOI 10.1074/jbc.M002433200; Zhao JS, 2000, MECH DEVELOP, V93, P71, DOI 10.1016/S0925-4773(00)00281-1; Zhu HJ, 1999, J BIOL CHEM, V274, P32258, DOI 10.1074/jbc.274.45.32258; Zimmerman CM, 2000, GENE, V249, P17, DOI 10.1016/S0378-1119(00)00162-1; Ziyadeh FN, 2000, P NATL ACAD SCI USA, V97, P8015, DOI 10.1073/pnas.120055097	43	210	231	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					176	178		10.1096/fj.02-1117fje	http://dx.doi.org/10.1096/fj.02-1117fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	12709399				2022-12-28	WOS:000188829300055
J	Muller, YL; Yueh, YG; Yaworsky, PJ; Salbaum, JM; Kappen, C				Muller, YL; Yueh, YG; Yaworsky, PJ; Salbaum, JM; Kappen, C			Caudal dysgenesis in islet-1 transgenic mice	FASEB JOURNAL			English	Article						maternal diabetes; pancreas; embryopathy	INSULIN GENE-TRANSCRIPTION; DOMINANT SACRAL AGENESIS; HOMEOBOX GENE; DIABETIC EMBRYOPATHY; SONIC-HEDGEHOG; NEURAL-TUBE; BIRTH-WEIGHT; PAX-3 GENE; PAIRED BOX; EXPRESSION	Maternal diabetes during pregnancy is responsible for the occurrence of diabetic embryopathy, a spectrum of birth defects that includes heart abnormalities, neural tube defects, and caudal dysgenesis syndromes. Here, we report that mice transgenic for the homeodomain transcription factor Isl-1 develop profound caudal growth defects that resemble human sacral/caudal agenesis. Isl-1 is normally expressed in the pancreas and is required for pancreas development and endocrine cell differentiation. Aberrant regulation of this pancreatic transcription factor causes increased mesodermal cell death, and the severity of defects is dependent on transgene dosage. Together with the finding that mutation of the pancreatic transcription factor HLXB9 causes sacral agenesis, our results implicate pancreatic transcription factors in the pathogenesis of birth defects associated with diabetes.	Mayo Clin Scottsdale, Samuel C Johnson Med Res Ctr, Scottsdale, AZ USA; Neurosci Inst, San Diego, CA USA	Mayo Clinic; Mayo Clinic Phoenix	Kappen, C (corresponding author), Univ Nebraska, Med Ctr, Munroe Meyer Inst, Ctr Human Mol Genet, 600 S 42nd St, Omaha, NE 68198 USA.	ckappen@unmc.edu	Yueh, Yir Gloria/U-1699-2019		NCRR NIH HHS [P20 RR018788] Funding Source: Medline; NICHD NIH HHS [R01 HD037804] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037804] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018788] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Alles A J, 1993, Birth Defects Orig Artic Ser, V29, P83; Arber S, 1999, NEURON, V23, P659, DOI 10.1016/S0896-6273(01)80026-X; BAKER L, 1993, J DIABETES COMPLICAT, V7, P204, DOI 10.1016/1056-8727(93)90046-2; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BIEBERICH CJ, 1990, P NATL ACAD SCI USA, V87, P8462, DOI 10.1073/pnas.87.21.8462; Bohring A, 1999, AM J MED GENET, V87, P99, DOI 10.1002/(SICI)1096-8628(19991119)87:2<99::AID-AJMG1>3.0.CO;2-Q; Briscoe J, 1999, SEMIN CELL DEV BIOL, V10, P353, DOI 10.1006/scdb.1999.0295; BUCHANAN TA, 1994, ANNU REV MED, V45, P245; Casson IF, 1997, BRIT MED J, V315, P275, DOI 10.1136/bmj.315.7103.275; Cederberg J, 2001, PEDIATR RES, V49, P755, DOI 10.1203/00006450-200106000-00007; Chang TI, 1999, SEMIN REPROD ENDOCR, V17, P153, DOI 10.1055/s-2007-1016222; Dabelea D, 2001, J PEDIATR ENDOCR MET, V14, P1085; Dias MS, 1998, PEDIATR NEUROSURG, V28, P223, DOI 10.1159/000028655; DUHAMEL B, 1961, ARCH DIS CHILD, V36, P152, DOI 10.1136/adc.36.186.152; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Edlund H, 2001, DIABETES, V50, pS5, DOI 10.2337/diabetes.50.2007.S5; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FREINKEL N, 1988, HORM METAB RES, V20, P463, DOI 10.1055/s-2007-1010861; Gardner DP, 1996, TRANSGENIC RES, V5, P37, DOI 10.1007/BF01979920; GAUSE A, 1987, EUR J IMMUNOL, V17, P981, DOI 10.1002/eji.1830170714; Goto Motoko P., 1994, Current Opinion in Pediatrics, V6, P486, DOI 10.1097/00008480-199408000-00023; GOULDING M, 1993, GENOMICS, V17, P355, DOI 10.1006/geno.1993.1332; Greene MF, 2001, TERATOLOGY, V63, P116, DOI 10.1002/tera.1021; Habener JF, 1998, P ASSOC AM PHYSICIAN, V110, P12; Hagan DM, 2000, AM J HUM GENET, V66, P1504, DOI 10.1086/302899; Harrison KA, 1999, NAT GENET, V23, P71, DOI 10.1038/12674; Hattersley AT, 1999, LANCET, V353, P1789, DOI 10.1016/S0140-6736(98)07546-1; HOTH CF, 1993, AM J HUM GENET, V52, P455; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; KAPPEN C, 1999, GENETIC MANIPULATION, P69; KUCERA J, 1971, J REPROD MED, V7, P73; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Li H, 1999, NAT GENET, V23, P67; Lynch SA, 2000, J MED GENET, V37, P561, DOI 10.1136/jmg.37.8.561; LYNCH SA, 1995, NAT GENET, V11, P93, DOI 10.1038/ng0995-93; Lyons Jones K., 1988, SMITHS RECOGNIZABLE; MANSOURI A, 1994, J CELL SCI, P35; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; MARTINEZFRIAS ML, 1994, AM J MED GENET, V51, P108, DOI 10.1002/ajmg.1320510206; Meigs JB, 2000, DIABETES, V49, P2201, DOI 10.2337/diabetes.49.12.2201; MILLS JL, 1982, TERATOLOGY, V25, P385, DOI 10.1002/tera.1420250316; *NAT DIAB DAT GROU, 1995, NIH PUBL; Olson LK, 1998, MOL ENDOCRINOL, V12, P207, DOI 10.1210/me.12.2.207; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; Phelan SA, 1997, DIABETES, V46, P1189, DOI 10.2337/diabetes.46.7.1189; Roduit R, 2000, J BIOL CHEM, V275, P35799, DOI 10.1074/jbc.M006001200; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Ross AJ, 1998, NAT GENET, V20, P358, DOI 10.1038/3828; Rundle CH, 1998, BBA-GENE STRUCT EXPR, V1398, P164, DOI 10.1016/S0167-4781(98)00046-3; Salbaum JM, 1998, MECH DEVELOP, V71, P201, DOI 10.1016/S0925-4773(98)00005-7; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1127, DOI 10.1210/me.9.9.1127; Shashikant CS, 1995, DEVELOPMENT, V121, P4339; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; TASSABEHJI M, 1993, NAT GENET, V3, P26, DOI 10.1038/ng0193-26; Terauchi Y, 2000, DIABETES, V49, P82, DOI 10.2337/diabetes.49.1.82; Thaler J, 1999, NEURON, V23, P675, DOI 10.1016/S0896-6273(01)80027-1; Van Assche EA, 1998, J PERINAT MED, V26, P337; Weir GC, 1997, ACTA DIABETOL, V34, P177, DOI 10.1007/s005920050071; Yaworsky PJ, 1997, J BIOL CHEM, V272, P25112, DOI 10.1074/jbc.272.40.25112; Yueh YG, 1998, P NATL ACAD SCI USA, V95, P9956, DOI 10.1073/pnas.95.17.9956	66	10	11	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1349	+		10.1096/fj.02-0856fje	http://dx.doi.org/10.1096/fj.02-0856fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738808	Green Accepted			2022-12-28	WOS:000183165000028
J	Hedborg, F; Ulleras, E; Grimelius, L; Wassberg, E; Maxwell, PH; Hero, B; Berthold, F; Schilling, F; Harms, D; Sandstedt, B; Franklin, G				Hedborg, F; Ulleras, E; Grimelius, L; Wassberg, E; Maxwell, PH; Hero, B; Berthold, F; Schilling, F; Harms, D; Sandstedt, B; Franklin, G			Evidence for hypoxia-induced neuronal-to-chromaffin metaplasia in neuroblastoma	FASEB JOURNAL			English	Article						angiogenesis; differentiation; sympathetic nervous system; insulin-like growth factor; vascular-endothelial growth factor	GROWTH-FACTOR-II; INDUCIBLE FACTOR 1-ALPHA; GENE-EXPRESSION; O-2 HOMEOSTASIS; NERVOUS-SYSTEM; TUMORS; CELLS; CANCER; DIFFERENTIATION; TRANSCRIPTION	We present evidence that in neuroblastoma, a pediatric malignancy of embryonal sympathetic origin, hypoxia, underlies a phenotypic switch from a primitive neuronal to a chromaffin cell type. This conclusion is based on morphological and molecular data on 116 clinical tumors and is supported by data on the phenotypic effects of hypoxia on neuroblastoma cell lines when studied in monolayer culture and as tumor xenografts. In the clinical material, extensive chromaffin features were seen in regions of chronic tumor hypoxia. This was the exclusive form of intratumoral maturation of stroma-poor tumors and was also seen in stroma-rich tumors, either exclusively or in combination with ganglion-like cells. In neuroblastoma cell lines, hypoxia induced changes in gene expression associated with the chromaffin features observed in vivo. We therefore propose tumor hypoxia as a major cue determining phenotype in sympathetic tumors of neuroblastic origin. Because it appears to be reversible upon reoxygenation in monolayer culture, we suggest the term metaplasia for the phenomenon.	Rudbeck Lab, Dept Genet, SE-75185 Uppsala, Sweden; Rudbeck Lab, Dept Pathol, SE-75185 Uppsala, Sweden; Univ Hosp, Dept Women & Child Hlth, SE-75185 Uppsala, Sweden; Univ Uppsala, Evolutionary Biol Ctr, SE-75185 Uppsala, Sweden; Univ Uppsala, Biomed Ctr, SE-75185 Uppsala, Sweden; Univ London Imperial Coll Sci Technol & Med, Renal Sect, London, England; Univ Cologne, Dept Pediat, D-50924 Cologne, Germany; Olga Hosp, Dept Pediat Hematol & Oncol, D-70176 Stuttgart, Germany; Univ Kiel, Dept Pediat Pathol, D-24042 Kiel, Germany; Karolinska Inst, Childhood Canc Res Unit, SE-17176 Stockholm, Sweden; Biacore AB, SE-75450 Uppsala, Sweden	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University; Imperial College London; University of Cologne; General Hospital of N. Ionia Agia Olga; Klinikum Stuttgart; University of Kiel; Karolinska Institutet	Hedborg, F (corresponding author), Rudbeck Lab, Dept Genet, SE-75185 Uppsala, Sweden.	fredrik.hedborg@genpat.uu.se	Maxwell, Patrick H/C-5557-2008	Maxwell, Patrick H/0000-0002-0338-2679				Ambros PF, 2000, NEUROBLASTOMA, P21; Bae SK, 1999, CANCER RES, V59, P5989; BARSON AJ, 1978, ARCH DIS CHILD, V53, P436; BERTHOLD F, 1990, NEUROBLASTOMA TUMOR, P1; Brizel DM, 1996, CANCER RES, V56, P941; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brown JM, 1999, CANCER RES, V59, P5863; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; COOPER MJ, 1990, CELL GROWTH DIFFER, V1, P149; Coupland RE., 1965, NATURAL HIST CHROMAF; ELBADRY OM, 1989, J CLIN INVEST, V84, P829, DOI 10.1172/JCI114243; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; Feldser D, 1999, CANCER RES, V59, P3915; Gestblom C, 1997, AM J PATHOL, V150, P107; GRIMELIUS L, 1980, INVEST CELL PATHOL, V3, P3; HARMS D, 1989, EUR J PEDIATR, V148, P720, DOI 10.1007/BF00443094; Hartmann O, 2000, NEUROBLASTOMA, P437; HEDBORG F, 1995, AM J PATHOL, V146, P833; HEDBORG F, 1995, EUR J CANCER, V4, P435; Hockel M, 1996, CANCER RES, V56, P4509; HODGKISS RJ, 1991, BRIT J CANCER, V63, P119, DOI 10.1038/bjc.1991.24; Hodgkiss RJ, 1997, ADV EXP MED BIOL, V428, P61; Hoehner JC, 1998, LAB INVEST, V78, P29; Hoehner JC, 1996, LAB INVEST, V75, P659; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; JACKSON A, 1995, J NEUROBIOL, V26, P485, DOI 10.1002/neu.480260403; Kietzmann T, 1997, CELL BIOL TOXICOL, V13, P243, DOI 10.1023/A:1007427206391; Kim KW, 1998, CANCER RES, V58, P348; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Langley K, 1999, CELL TISSUE RES, V298, P185, DOI 10.1007/PL00008810; Matthay KK, 2000, NEUROBLASTOMA, P417; Morrison SJ, 2000, J NEUROSCI, V20, P7370; Mugishima H, 2000, NEUROBLASTOMA, P293; OHLSSON R, 1989, EMBO J, V8, P1993, DOI 10.1002/j.1460-2075.1989.tb03606.x; Olshan AF, 2000, NEUROBLASTOMA, P33; Pahlman S, 2000, NEUROBLASTOMA, P9; Rijken PFJW, 2000, INT J RADIAT ONCOL, V48, P571, DOI 10.1016/S0360-3016(00)00686-6; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Shen YP, 2002, J NEUROSCI, V22, P239, DOI 10.1523/JNEUROSCI.22-01-00239.2002; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Siemann DW, 1998, INT J RADIAT ONCOL, V42, P697, DOI 10.1016/S0360-3016(98)00336-8; Slack JMW, 2001, CURR OPIN GENET DEV, V11, P581, DOI 10.1016/S0959-437X(00)00236-7; Soulier V, 1997, COMP BIOCHEM PHYS A, V118, P1, DOI 10.1016/S0300-9629(96)00369-6; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; Tsuchida Y, 2000, NEUROBLASTOMA, P453; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030	48	15	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					598	609		10.1096/fj.02-0390com	http://dx.doi.org/10.1096/fj.02-0390com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665472				2022-12-28	WOS:000182580100004
J	Kosaka, H; Yoneyama, H; Zhang, L; Fujii, S; Yamamoto, A; Igarashi, J				Kosaka, H; Yoneyama, H; Zhang, L; Fujii, S; Yamamoto, A; Igarashi, J			Induction of LOX-1 and iNOS expressions by ischemia-reperfusion of rat kidney and the opposing effect of L-arginine	FASEB JOURNAL			English	Article						NO end product; ox-LDL; renal cortex	NITRIC-OXIDE SYNTHASE; LOW-DENSITY-LIPOPROTEIN; MYOCARDIAL ISCHEMIA/REPERFUSION INJURY; HERITABLE HYPERLIPIDEMIC RABBITS; SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; ATHEROSCLEROTIC LESIONS; KNOCKOUT MICE; RECEPTOR; ACTIVATION	Lectin-like oxidized low-density lipoprotein receptor (LOX-1) is a newly identified endothelial cell surface major receptor for oxidatively modified low-density lipoprotein. Progression of arthrosclerosis in the donor organ after organ transplantation is a major problem. We hypothesized that ischemia-reperfusion induces LOX-1. After 1 h ischemia of bilateral kidneys plus 3, 6, or 12 h reperfusion, we first revealed that LOX-1 mRNA expression was increased in renal cortex and medulla at 6 h after reperfusion, which was decreased by L-arginine supplement. Plasma nitric oxide (NO) end-product nitrite plus nitrate and inducible nitric oxide synthase (NOS) expression were increased after reperfusion of 6 h. However, NOS substrate L-arginine did not augment but markedly decreased plasma NO end product, because L-arginine supplement suppressed inducible NOS expression in kidney. We hypothesized that available L-arginine is depleted by ischemia-reperfusion, leading to inducible NOS induction. Ischemia decreased L-arginine levels in kidney and L-arginine supplement increased NO end products in renal cortex in the earliest phase of reperfusion. These results disclosed for the first time that a deficiency in L-arginine by ischemia reperfusion causes uncoupling of constitutive NOS, which induces inducible NOS and LOX-1, implying why L-arginine is effective for stroke or transplantation in preventing atherosclerotic progress.	Kagawa Med Univ, Dept Physiol 2, Miki, Kagawa 7610793, Japan	Kagawa University	Kosaka, H (corresponding author), Kagawa Med Univ, Dept Physiol 2, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	hkosaka@kms.ac.jp						BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; Blair A, 1999, J BIOL CHEM, V274, P32512, DOI 10.1074/jbc.274.45.32512; CANADA A T, 1986, Journal of Free Radicals in Biology and Medicine, V2, P327, DOI 10.1016/S0748-5514(86)80032-0; Chatterjee PK, 2002, KIDNEY INT, V61, P862, DOI 10.1046/j.1523-1755.2002.00234.x; Chen MY, 2000, ARTERIOSCL THROM VAS, V20, P1107, DOI 10.1161/01.ATV.20.4.1107; Chen MY, 2001, BIOCHEM BIOPH RES CO, V282, P153, DOI 10.1006/bbrc.2001.4516; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; Hoffmeyer MR, 2000, CIRC RES, V87, P812, DOI 10.1161/01.RES.87.9.812; Kakoki M, 2000, J AM SOC NEPHROL, V11, P301, DOI 10.1681/ASN.V112301; Kakutani M, 2001, BIOCHEM BIOPH RES CO, V282, P180, DOI 10.1006/bbrc.2001.4508; Kanno S, 2000, CIRCULATION, V101, P2742, DOI 10.1161/01.CIR.101.23.2742; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOSAKA H, 1989, CARCINOGENESIS, V10, P563, DOI 10.1093/carcin/10.3.563; Kume N, 1998, CIRC RES, V83, P322, DOI 10.1161/01.RES.83.3.322; Kumura E, 1996, AM J PHYSIOL-CELL PH, V270, pC748, DOI 10.1152/ajpcell.1996.270.3.C748; Li DY, 1999, CIRC RES, V84, P1043, DOI 10.1161/01.RES.84.9.1043; Ling H, 1999, AM J PHYSIOL-RENAL, V277, pF383; Luoma JS, 1998, ARTERIOSCL THROM VAS, V18, P157, DOI 10.1161/01.ATV.18.2.157; McDonald KK, 1997, J BIOL CHEM, V272, P31213, DOI 10.1074/jbc.272.50.31213; Mizoguchi K, 2002, TRANSPLANTATION, V73, P1185, DOI 10.1097/00007890-200204270-00002; Nagase M, 1997, BIOCHEM BIOPH RES CO, V237, P496, DOI 10.1006/bbrc.1997.7176; Nagase M, 2000, J AM SOC NEPHROL, V11, P1826, DOI 10.1681/ASN.V11101826; Node K, 1997, FASEB J, V11, P793, DOI 10.1096/fasebj.11.10.9271364; Okada K, 1998, CIRCULATION, V97, P2346, DOI 10.1161/01.CIR.97.23.2346; POU S, 1992, J BIOL CHEM, V267, P24173; Ravalli S, 1998, CIRCULATION, V97, P2338, DOI 10.1161/01.CIR.97.23.2338; Rosen GM, 2002, J BIOL CHEM, V277, P40275, DOI 10.1074/jbc.M200853200; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Rueckschloss U, 2001, CIRCULATION, V104, P1767, DOI 10.1161/hc4001.097056; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; Tanaka S, 1996, AM J PHYSIOL-GASTR L, V271, pG405, DOI 10.1152/ajpgi.1996.271.3.G405; Uittenbogaard A, 2000, J BIOL CHEM, V275, P11278, DOI 10.1074/jbc.275.15.11278; Vallon V, 2001, J AM SOC NEPHROL, V12, P1599, DOI 10.1681/ASN.V1281599; Yoneyama H, 2001, BIOCHEM J, V360, P247, DOI 10.1042/0264-6021:3600247; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986; Zhou MS, 2001, J HYPERTENS, V19, P421, DOI 10.1097/00004872-200103000-00010; Zingarelli B, 2002, FASEB J, V16, DOI 10.1096/fj.01-0533com	38	44	52	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					636	643		10.1096/fj.02-0585com	http://dx.doi.org/10.1096/fj.02-0585com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665476				2022-12-28	WOS:000182580100008
J	Kumar, A; Boriek, AM				Kumar, A; Boriek, AM			Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy	FASEB JOURNAL			English	Article						mechanical loading; TNF-alpha; IL-1 beta; free radicals	TUMOR-NECROSIS-FACTOR; B KINASE IKK; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; PROTEIN LOSS; FACTOR-ALPHA; MDX MOUSE; TNF-ALPHA; EXPRESSION; TRANSCRIPTION	The ex vivo effects of passive mechanical stretch on the activation of nuclear factor-kappaB (NF-kappaB) pathways in skeletal muscles from normal and mdx mouse, a model of Duchenne muscular dystrophy (DMD), were investigated. The NF-kappaB/DNA binding activity of the diaphragm muscle was increased by the application of axial mechanical stretch in a time-dependent manner. The increased activation of NF-kappaB was associated with a concomitant increase in I-kappaB (IkappaB) kinase activity and the degradation of IkappaBalpha protein. Pretreatment of the muscles with nifedipine (a Ca2+ channel blocker) and gadolinium(III) chloride (a stretch-activated channel blocker) did not alter the level of activation of NF-kappaB, ruling out involvement of Ca2+ influx through these channels. Furthermore, N-acetyl cysteine, a free radical inhibitor, blocked the mechanical stretch-induced NF-kappaB activation, suggesting the involvement of free radicals. Compared with normal diaphragm, the basal level of NF-kappaB activity was higher in muscles from mdx mice, and it was further enhanced in mechanically stretched muscles. Furthermore, activation of NF-kappaB and increased expression of inflammatory cytokines IL-1beta and tumor necrosis factor alpha in the mdx mouse precede the onset of muscular dystrophy. Our results show that mechanical stretch activates the classical NF-kappaB pathway and this pathway could be predominately active in DMD.	Baylor Coll Med, Dept Med, Div Pulm, Houston, TX 77030 USA	Baylor College of Medicine	Boriek, AM (corresponding author), Baylor Coll Med, Dept Med, Div Pulm, Suite 520B,1 Baylor Plaza, Houston, TX 77030 USA.	boriek@bcm.tmc.edu		Kumar, Ashok/0000-0002-2444-9529; Kumar, Ashok/0000-0001-8571-2848	PHS HHS [63134] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anker SD, 1997, LANCET, V349, P1050, DOI 10.1016/S0140-6736(96)07015-8; Argiles JM, 1999, MED RES REV, V19, P223, DOI 10.1002/(SICI)1098-1128(199905)19:3<223::AID-MED3>3.0.CO;2-N; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Boriek AM, 2001, AM J PHYSIOL-CELL PH, V280, pC46, DOI 10.1152/ajpcell.2001.280.1.C46; Danialou G, 2001, FASEB J, V15, P1655, DOI 10.1096/fj.01-0030fje; Emery AEH, 2002, LANCET, V359, P687, DOI 10.1016/S0140-6736(02)07815-7; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; GarciaMartinez C, 1995, BIOCHEM BIOPH RES CO, V217, P839, DOI 10.1006/bbrc.1995.2848; GLOGAUER M, 1995, AM J PHYSIOL-CELL PH, V269, pC1093, DOI 10.1152/ajpcell.1995.269.5.C1093; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Grady RM, 1999, NAT CELL BIOL, V1, P215, DOI 10.1038/12034; GUTTRIDGE DC, 2000, SCIENCE, V289, P2363, DOI [10.1126/sci-ence.289.5488.2363, DOI 10.1126/SCI-ENCE.289.5488.2363, DOI 10.1126/science.289.5488.2363, DOI 10.1126/SCIENCE.289.5488.2363]; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Hu MCT, 1999, ONCOGENE, V18, P5514, DOI 10.1038/sj.onc.1202740; Hunter RB, 2002, FASEB J, V16, P529, DOI 10.1096/fj.01-0866com; Inoh H, 2002, FASEB J, V16, P405, DOI 10.1096/fj.01-0354fje; Kamogawa Y, 2001, CARDIOVASC RES, V50, P509, DOI 10.1016/S0008-6363(01)00205-X; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kherif S, 1999, DEV BIOL, V205, P158, DOI 10.1006/dbio.1998.9107; Kolodziejczyk SM, 2001, CURR BIOL, V11, P1278, DOI 10.1016/S0960-9822(01)00397-9; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; Kumar A, 1998, ONCOGENE, V17, P913, DOI 10.1038/sj.onc.1201998; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Layne MD, 1999, EXP CELL RES, V249, P177, DOI 10.1006/excr.1999.4465; Lew AM, 1999, BIOCHEM J, V341, P647, DOI 10.1042/0264-6021:3410647; Li YP, 1999, ANTIOXID REDOX SIGN, V1, P97, DOI 10.1089/ars.1999.1.1-97; Li YP, 2000, AM J PHYSIOL-REG I, V279, pR1165, DOI 10.1152/ajpregu.2000.279.4.R1165; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; Llovera M, 1997, BIOCHEM BIOPH RES CO, V230, P238, DOI 10.1006/bbrc.1996.5827; Lundberg I, 1995, J NEUROIMMUNOL, V63, P9, DOI 10.1016/0165-5728(95)00122-0; MILLER SC, 1988, MOL CELL BIOL, V8, P2295, DOI 10.1128/MCB.8.6.2295; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Nakashima J, 1998, CLIN CANCER RES, V4, P1743; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Porreca E, 1999, THROMB HAEMOSTASIS, V81, P543; Reid MB, 2001, RESP RES, V2, P269, DOI 10.1186/rr67; Roy R R, 1991, Exerc Sport Sci Rev, V19, P269; Ruwhof C, 2000, CARDIOVASC RES, V47, P23, DOI 10.1016/S0008-6363(00)00076-6; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Spencer MJ, 1997, J CLIN INVEST, V99, P2745, DOI 10.1172/JCI119464; SPENCER MJ, 1995, J BIOL CHEM, V270, P10909, DOI 10.1074/jbc.270.18.10909; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; TIDBALL JG, 1995, J CELL SCI, V108, P2197; VANDENBURGH HH, 1982, J BIOL CHEM, V257, P13448; Vandenburgh HH, 1996, AM J PHYSIOL-CELL PH, V270, pC1284, DOI 10.1152/ajpcell.1996.270.5.C1284; Watanabe N, 2001, Rinsho Byori, V49, P829; Yamazaki T, 1998, CIRC RES, V82, P430, DOI 10.1161/01.RES.82.4.430; Zhao SP, 1997, INT J CARDIOL, V58, P257, DOI 10.1016/S0167-5273(96)02873-2; Zhou LZH, 2001, FREE RADICAL BIO MED, V31, P1405, DOI 10.1016/S0891-5849(01)00719-5	54	211	218	1	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					386	396		10.1096/fj.02-0542com	http://dx.doi.org/10.1096/fj.02-0542com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12631578				2022-12-28	WOS:000181892600037
J	Forster, MJ; Morris, P; Sohal, RS				Forster, MJ; Morris, P; Sohal, RS			Genotype and age influence the effect of caloric intake on mortality in mice	FASEB JOURNAL			English	Article						caloric restriction; aging; C57BL/6; DBA/2; B6D2F(1)	FOOD RESTRICTION; SURVIVAL	Long-term caloric restriction (CR) has been repeatedly shown to increase life span and delay the onset of age-associated pathologies in laboratory mice and rats. The purpose of the current study was to determine whether the CR-associated increase in life span occurs in all strains of mice or only in some genotypes and whether the effects of CR and ad libitum (AL) feeding on mortality accrue gradually or are rapidly inducible and reversible. In one experiment, groups of male C57BL/6, DBA/2, and B6D2F(1) mice were fed AL or CR (60% of AL) diets beginning at 4 months of age until death. In the companion study, separate groups of mice were maintained chronically on AL or CR regimens until 7, 17, or 22-24 months of age, after which, half of each AL and CR group was switched to the opposite regimen for 11 wk. This procedure yielded four experimental groups for each genotype, namely AL-->AL, AL-->CR, CR-->CR, and CR-->AL, designated according to long-term and short-term caloric regimen, respectively. Long-term CR resulted in increased median and maximum life span in C57BL/6 and B6D2F(1) mice but failed to affect either parameter in the DBA/2 mice. The shift from AL-->CR increased mortality in 17- and 24-month-old mice, whereas the shift from CR-->AL did not significantly affect mortality of any age group. Such increased risk of mortality following implementation of CR at older ages was evident in all three strains but was most dramatic in DBA/2 mice. Results of this study indicate that CR does not have beneficial effects in all strains of mice, and it increases rather than decreases mortality if initiated in advanced age.	Univ N Texas, Hlth Sci Ctr Ft Worth, Dept Pharmacol & Neurosci, Inst Aging & Alzheimers Dis Res, Ft Worth, TX 76107 USA; Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA	University of North Texas System; University of North Texas Health Science Center; University of Southern California	Forster, MJ (corresponding author), Univ N Texas, Hlth Sci Ctr Ft Worth, Dept Pharmacol & Neurosci, Inst Aging & Alzheimers Dis Res, Ft Worth, TX 76107 USA.	forsterm@hsc.unt.edu			NIA NIH HHS [R01 AG013563-13, R01 AG013563] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013563] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BRONSON RT, 1991, GROWTH DEVELOP AGING, V55, P169; FERNANDES G, 1976, P NATL ACAD SCI USA, V73, P1279, DOI 10.1073/pnas.73.4.1279; Fishbein L., 1991, BIOL EFFECTS DIETARY; FORSTER M J, 1991, Biomedical and Environmental Sciences, V4, P144; Forster MJ, 1999, NEUROBIOL AGING, V20, P167, DOI 10.1016/S0197-4580(99)00041-X; GOODRICK CL, 1990, MECH AGEING DEV, V55, P69, DOI 10.1016/0047-6374(90)90107-Q; HARRISON DE, 1987, J NUTR, V117, P376, DOI 10.1093/jn/117.2.376; Ingram D K, 1987, Basic Life Sci, V42, P247; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Masoro EJ, 1998, EXP GERONTOL, V33, P61, DOI 10.1016/S0531-5565(97)00071-5; MCCARTER RJM, 1995, CLIN GERIATR MED, V11, P553, DOI 10.1016/S0749-0690(18)30256-8; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492; Weindruch R, 1996, TOXICOL PATHOL, V24, P742, DOI 10.1177/019262339602400618; Weindruch R., 1988, RETARDATION AGING DI	15	172	175	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					690	+		10.1096/fj.02-0533fje	http://dx.doi.org/10.1096/fj.02-0533fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586746	Green Accepted			2022-12-28	WOS:000181456900022
J	Linden, T; Katschinski, DM; Eckhardt, K; Scheid, A; Pagel, H; Wenger, RH				Linden, T; Katschinski, DM; Eckhardt, K; Scheid, A; Pagel, H; Wenger, RH			The antimycotic ciclopirox olamine induces HIF-1 alpha stability, VEGF expression, and angiogenesis	FASEB JOURNAL			English	Article						erythropoietin; hypoxia; iron; oxygen sensor; vascular endothelial growth factor	INDUCIBLE FACTOR-I; ENDOTHELIAL GROWTH-FACTOR; GENE-EXPRESSION; IRON CHELATORS; NUCLEAR TRANSLOCATION; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; CHELATABLE IRON; DNA-BINDING; HIF-ALPHA	The heterodimeric hypoxia-inducible factor (HIF)-1 is a master regulator of oxygen homeostasis. Protein stability and transactivation function of the subunit are controlled by iron- and oxygen-dependent hydroxylation of proline and asparagine residues. The anti-mycotic ciclopirox olamine (CPX) is a lipophilic bidentate iron chelator that stabilizes HIF-1alpha under normoxic conditions at lower concentrations than other iron chelators, probably by inhibiting HIF-1alpha hydroxylation. As shown by the inhibition of iron-dependent quenching of FITC-labeled deferoxamine (DFX) fluorescence, CPX appears to have an even higher affinity for iron than DFX. Initial observations that treatment with 1% CPX, but not with placebo, occasionally caused reddening of wound margins in a mouse skin wound model prompted us to investigate the capability of CPX to induce angiogenesis. CPX-induced HIF-1-mediated reporter gene activity and endogenous HIF-1 target gene expression, including elevation of transcription, mRNA, and protein levels of the vascular endothelial growth factor (VEGF). In the chick chorioallantoic membrane assay, inert polymer disks containing CPX but not the solvent alone induced angiogenesis. In summary, these results suggest that CPX induces angiogenesis in vivo via HIF-1 and VEGF induction. Therefore, CPX might serve as an alternative to recombinant VEGF treatment or to VEGF gene therapy for therapeutic angiogenesis.	Univ Leipzig, Carl Ludwig Inst Physiol, D-04103 Leipzig, Germany; Med Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany; Univ Zurich Irchel, Inst Physiol, CH-8000 Zurich, Switzerland; Univ Childrens Hosp Zurich, Dept Surg, CH-8000 Zurich, Switzerland	Leipzig University; University of Lubeck; University of Zurich; University Children's Hospital Zurich	Wenger, RH (corresponding author), Univ Leipzig, Carl Ludwig Inst Physiol, Liebigstr 27, D-04103 Leipzig, Germany.	wenr@medizin.uni-leipzig.de	Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839				ALPERMANN HG, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1328; Ash JD, 2000, DEV BIOL, V223, P383, DOI 10.1006/dbio.2000.9755; Bohn M, 2000, J AM ACAD DERMATOL, V43, pS57, DOI 10.1067/mjd.2000.109072; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breuer W, 2001, BLOOD, V97, P792, DOI 10.1182/blood.V97.3.792; Chilov D, 1999, J CELL SCI, V112, P1203; COPPI G, 1992, FARMACO, V47, P779; Corral CJ, 1999, ARCH SURG-CHICAGO, V134, P200, DOI 10.1001/archsurg.134.2.200; Deodato B, 2002, GENE THER, V9, P777, DOI 10.1038/sj.gt.3301697; Di Peppe SR, 2002, GENE THER, V9, P1271, DOI 10.1038/sj.gt.3301798; DITTMAR W, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1317; Dor Y, 2002, EMBO J, V21, P1939, DOI 10.1093/emboj/21.8.1939; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Farinelli SE, 1996, J NEUROSCI, V16, P1150, DOI 10.1523/jneurosci.16-03-01150.1996; Gao J, 2001, BLOOD, V98, P842, DOI 10.1182/blood.V98.3.842; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Hanel H, 1991, Mycoses, V34 Suppl 1, P91; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HOCKEL M, 1993, ARCH SURG-CHICAGO, V128, P423; Hofer T, 2001, FASEB J, V15, P2715, DOI 10.1096/fj.01-0546fje; HOFFMAN BD, 1991, CYTOMETRY, V12, P26, DOI 10.1002/cyto.990120105; HOYES KP, 1992, CANCER RES, V52, P4591; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Isner JM, 2002, NATURE, V415, P234, DOI 10.1038/415234a; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; IWATA K, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1323; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jones MK, 2001, GASTROENTEROLOGY, V121, P1040, DOI 10.1053/gast.2001.29308; JUE SG, 1985, DRUGS, V29, P330, DOI 10.2165/00003495-198529040-00002; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; KEBERLE H, 1964, ANN NY ACAD SCI, V119, P758; KELLNER HM, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1337; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; LANGER R, 1976, NATURE, V263, P797, DOI 10.1038/263797a0; Le NTV, 2002, BBA-REV CANCER, V1603, P31, DOI 10.1016/S0304-419X(02)00068-9; LEDERMAN HM, 1984, BLOOD, V64, P748; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Morishita R, 2001, PHARMACOL THERAPEUT, V91, P105, DOI 10.1016/S0163-7258(01)00150-4; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OLIVO M, 1992, ANAT RECORD, V234, P105, DOI 10.1002/ar.1092340112; PAGEL H, 1991, ENDOCRINOLOGY, V128, P2633, DOI 10.1210/endo-128-5-2633; PAGEL H, 1998, J ONCOL PHARM PRACT, V4, P218; Rauen U, 2000, FASEB J, V14, P1953, DOI 10.1096/fj.00-0071com; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Rosen T, 1997, INT J DERMATOL, V36, P788, DOI 10.1046/j.1365-4362.1997.00309.x; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Supp DM, 2000, J INVEST DERMATOL, V114, P5, DOI 10.1046/j.1523-1747.2000.00824.x; Szabo S, 2001, J PHYSIOL-PARIS, V95, P325, DOI 10.1016/S0928-4257(01)00045-6; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wanner RM, 2000, BLOOD, V96, P1558, DOI 10.1182/blood.V96.4.1558.h8001558_1558_1565; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wenk J, 2001, J INVEST DERMATOL, V116, P833, DOI 10.1046/j.1523-1747.2001.01345.x; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zaman K, 1999, J NEUROSCI, V19, P9821	60	85	95	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					761	+		10.1096/fj.02-0586fje	http://dx.doi.org/10.1096/fj.02-0586fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594177				2022-12-28	WOS:000181456900017
J	Wang, ET; Yin, YL; Zhao, M; Forrester, JV; McCaig, CD				Wang, ET; Yin, YL; Zhao, M; Forrester, JV; McCaig, CD			Physiological electric fields control the G(1)/S phase cell cycle checkpoint to inhibit endothelial cell proliferation	FASEB JOURNAL			English	Article						bioelectricity; cell growth; cyclin; apoptosis	ANGIOGENESIS; NEOVASCULARIZATION; STIMULATION; MECHANISMS; CANCER; ROOTS	Vascular endothelial cell (VEC) proliferation is a key event in angiogenesis and is tightly regulated. Electric potential differences exist around the vascular endothelium and give rise to endogenous electric fields (EFs), whether these EFs influence VEC proliferation is unclear. We exposed cultured VECs to applied EFs of physiological strengths for up to 72 h. EF at 50 or 100 mV/mm did not influence cell proliferation, but at 200 mV/mm, cell density, cell growth rate, and mitosis index decreased significantly. EF-induced reduction in VEC proliferation was not due to increased apoptosis, because caspase apoptosis inhibitor Z-VAD-FMK (20 muM), had no effect on this response. Rather, EF responses were mediated via decreased entry of cells into S phase from G(1) phase, as shown by flow cytometry. Western blot showed that EFs decreased G(1)-specific cyclin E expression and increased cyclin/cyclin-dependent kinase complex inhibitor p27(kip1) expression. Thus EFs controlled VEC proliferation through induction of cell cycle arrest at G(1) by down-regulation of cyclin E expression and up-regulation of p27(kip1) expression, rather than by promoting apoptosis. If control of the cell cycle by endogenous EFs extends beyond VECs, this would be of widespread biological significance in vivo.	Univ Aberdeen, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland; Univ Aberdeen, Sch Med, Dept Ophthalmol, Aberdeen AB25 2ZD, Scotland	University of Aberdeen; University of Aberdeen	McCaig, CD (corresponding author), Univ Aberdeen, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland.	c.mccaig@abdn.ac.uk	McCaig, Colin/B-1774-2010					Atkinson EA, 1998, J BIOL CHEM, V273, P21261, DOI 10.1074/jbc.273.33.21261; AZADNIV M, 1993, RADIAT ENVIRON BIOPH, V32, P73, DOI 10.1007/BF01213133; BRAYMAN AA, 1986, RADIAT ENVIRON BIOPH, V25, P141, DOI 10.1007/BF01211738; Buckley CD, 1997, BRIT MED J, V315, P236, DOI 10.1136/bmj.315.7102.236; Buschmann I, 1999, NEWS PHYSIOL SCI, V14, P121; Cherrington JM, 2000, ADV CANCER RES, V79, P1, DOI 10.1016/S0065-230X(00)79001-4; CHU ZW, 1991, ACTA PHARM SINIC, V12, P285; CORONEL R, 1991, CIRC RES, V68, P1241, DOI 10.1161/01.RES.68.5.1241; Cuzick J, 1998, LANCET, V352, P359, DOI 10.1016/S0140-6736(97)10002-2; FITZSIMMONS RJ, 1992, J CELL PHYSIOL, V150, P84, DOI 10.1002/jcp.1041500112; Goldman R, 1996, BIOELECTROMAGNETICS, V17, P450, DOI 10.1002/(SICI)1521-186X(1996)17:6<450::AID-BEM4>3.0.CO;2-2; HIRATA S, 1989, ARTHRITIS RHEUM, V32, P1065, DOI 10.1002/anr.1780320903; Hoshi T, 1998, ANTICANCER RES, V18, P4347; INOUE M, 1985, BIOELECTROMAGNETICS, V6, P293, DOI 10.1002/bem.2250060309; Kanno S, 1999, CIRCULATION, V99, P2682, DOI 10.1161/01.CIR.99.20.2682; Koch AE, 1998, ARTHRITIS RHEUM-US, V41, P951, DOI 10.1002/1529-0131(199806)41:6<951::AID-ART2>3.0.CO;2-D; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; MATSUBARA T, 1989, J CLIN INVEST, V83, P158, DOI 10.1172/JCI113853; McCaig CD, 1997, BIOESSAYS, V19, P819, DOI 10.1002/bies.950190912; McCaig CD, 2002, TRENDS NEUROSCI, V25, P354, DOI 10.1016/S0166-2236(02)02174-4; NAEGELE RJ, 1991, CANCER BIOCHEM BIOPH, V12, P95; NORDENSTROM BEW, 1994, EUR J SURG, P7; Nuccitelli R., 1988, ADV CELL BIOL, V2, P213, DOI DOI 10.1016/S1569-2558(08)60435-X; Patterson C, 1999, CIRCULATION, V99, P2614, DOI 10.1161/01.CIR.99.20.2614; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROBERTSON D, 1981, BIOELECTROMAGNETICS, V2, P329, DOI 10.1002/bem.2250020405; ROBINSON KR, 1985, J CELL BIOL, V101, P2023, DOI 10.1083/jcb.101.6.2023; RYABY JT, 1998, CLIN ORTHOP S, V355, P205; SAWYER PN, 1966, BIOPHYS J, V6, P641, DOI 10.1016/S0006-3495(66)86683-3; SAWYER PN, 1953, AM J PHYSIOL, V175, P103, DOI 10.1152/ajplegacy.1953.175.1.103; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Spranger J, 2000, DIABETOLOGIA, V43, P1404, DOI 10.1007/s001250051546; Stupack DG, 1999, BRAZ J MED BIOL RES, V32, P573, DOI 10.1590/S0100-879X1999000500011; Szekanecz Z, 1998, J INVEST MED, V46, P27; WRIGHT HP, 1972, ATHEROSCLEROSIS, V15, P93; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O; Zhao M, 1996, J CELL SCI, V109, P1405; Zhao M, 1999, P NATL ACAD SCI USA, V96, P4942, DOI 10.1073/pnas.96.9.4942	39	50	60	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					458	+		10.1096/fj.02-0510fje	http://dx.doi.org/10.1096/fj.02-0510fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551844				2022-12-28	WOS:000181453700002
J	Galman, C; Ostlund-Lindqvist, AM; Bjorquist, A; Schreyer, S; Svensson, L; Angelin, B; Rudling, M				Galman, C; Ostlund-Lindqvist, AM; Bjorquist, A; Schreyer, S; Svensson, L; Angelin, B; Rudling, M			Pharmacological interference with intestinal bile acid transport reduces plasma cholesterol in LDL receptor/apoE deficiency	FASEB JOURNAL			English	Article						lipoproteins; hyperlipidemia; cholesterol 7 alpha-hydroxylase; statins; resins	DENSITY-LIPOPROTEIN RECEPTOR; SERUM-CHOLESTEROL; GROWTH-HORMONE; MICE LACKING; 7-ALPHA-HYDROXY-4-CHOLESTEN-3-ONE; ABSORPTION; PROTEINS; S-8921; ASSAY; RATS	Reduction of plasma cholesterol by statins is fundamental to prevent coronary heart disease. Such therapy is often sub-optimal, however, particularly in patients with reduced LDL receptors (familial hypercholesterolemia), and novel or adjuvant therapies are therefore warranted. Cholesterol elimination is profoundly influenced by the rate of its conversion to bile acids (BA), regulated by the enzyme Cyp7a1. Induced fecal loss of BA by resin treatment reduces plasma cholesterol, presumably through induction of hepatic LDL receptors (LDLR). We here describe the effect of PR835, a drug belonging to a new class of lipid-lowering agents that inhibit the Slc10a2 protein, the intestinal transporter responsible for active uptake of BA. Treatment reduced plasma cholesterol by 40% in mice devoid of both the LDLR and its ligand, apoE, while triglycerides and HDL cholesterol were unchanged. Cyp7a1 enzyme activity and mRNA were induced several-fold, and hepatic HMG CoA reductase mRNA increased, mirroring an induced synthesis of BA and cholesterol. The addition of a statin potentiated the effect, leading to reductions of plasma total and LDL cholesterol by 64% and 70%, respectively. These effects could not be attributed to induction of other known hepatic lipoprotein receptors and indicate the presence of new points of targeting in lipid-lowering therapy.	Huddinge Univ Hosp, Karolinska Inst, CME, Dept Med,Metab Unit, S-14186 Stockholm, Sweden; Huddinge Univ Hosp, Karolinska Inst, Novum, Ctr Nutr & Toxicol,Mol Nutr Unit, Stockholm, Sweden; Astra Zeneca R&D, Mol Biol Cell Biol & Biochem, Molndal, Sweden	Karolinska Institutet; Karolinska Institutet; AstraZeneca	Rudling, M (corresponding author), Huddinge Univ Hosp, Karolinska Inst, CME, Dept Med,Metab Unit, M63, S-14186 Stockholm, Sweden.	mats.rudling@cnt.ki.se						Angelin B, 1999, CURR OPIN LIPIDOL, V10, P269, DOI 10.1097/00041433-199906000-00009; AXELSON M, 1988, FEBS LETT, V239, P324, DOI 10.1016/0014-5793(88)80944-X; Bonge H, 2000, ANAL BIOCHEM, V282, P94, DOI 10.1006/abio.2000.4600; Dietschy JM, 2002, J BIOL CHEM, V277, P3801, DOI 10.1074/jbc.R100057200; Edwards PA, 2002, J LIPID RES, V43, P2; EINARSSON K, 1986, J LIPID RES, V27, P82; Grundy SM, 1998, CIRCULATION, V97, P1436; Higaki J, 1998, ARTERIOSCL THROM VAS, V18, P1304, DOI 10.1161/01.ATV.18.8.1304; Ichihashi T, 1998, J PHARMACOL EXP THER, V284, P43; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; LEWIS MC, 1995, J LIPID RES, V36, P1098; Love MW, 1998, CURR OPIN LIPIDOL, V9, P225, DOI 10.1097/00041433-199806000-00007; PETTERSSON L, 1994, J CHROMATOGR B, V657, P31, DOI 10.1016/0378-4347(94)80066-9; Rader DJ, 2001, NAT MED, V7, P1282, DOI 10.1038/nm1201-1282; Root C, 2002, J LIPID RES, V43, P1320, DOI 10.1194/jlr.M200121-JLR200; Rudling M, 2001, FASEB J, V15, P1350, DOI 10.1096/fj.00-0715com; Rudling M, 1998, AM J PATHOL, V153, P1923, DOI 10.1016/S0002-9440(10)65706-9; RUDLING M, 1992, P NATL ACAD SCI USA, V89, P6983, DOI 10.1073/pnas.89.15.6983; RUDLING MJ, 1990, P NATL ACAD SCI USA, V87, P3469, DOI 10.1073/pnas.87.9.3469; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Sartipy P, 1999, J BIOL CHEM, V274, P25913, DOI 10.1074/jbc.274.36.25913; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Spady DK, 1998, J BIOL CHEM, V273, P126, DOI 10.1074/jbc.273.1.126; Willnow TE, 1999, NAT CELL BIOL, V1, pE157, DOI 10.1038/14109	25	20	20	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2002	16	14					265	+		10.1096/fj.0341fje	http://dx.doi.org/10.1096/fj.0341fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475897				2022-12-28	WOS:000180574300018
J	Podesta, M; Pitto, A; Figari, O; Bacigalupo, A; Bruzzone, S; Guida, L; Franco, L; De Flora, A; Zocchi, E				Podesta, M; Pitto, A; Figari, O; Bacigalupo, A; Bruzzone, S; Guida, L; Franco, L; De Flora, A; Zocchi, E			Cyclic ADP-ribose generation by CD38 improves human hemopoietic stem cell engraftment into NOD/SCID mice	FASEB JOURNAL			English	Article						bone marrow; hemopoietic progenitors; mononuclear cells	INTRACELLULAR CALCIUM; PERIPHERAL-BLOOD; BONE-MARROW; EXPRESSION; MOLECULE; NAD+	Cyclic ADP-ribose (cADPR) is a potent and universal intracellular calcium mobilizer, recently shown to behave as a new hemopoietic cytokine stimulating the in vitro proliferation of both committed and uncommitted human hemopoietic progenitors (HP). Here, we investigated the effects of cADPR on engraftment of hemopoietic stem cells (HSC) into irradiated NOD/SCID mice. Two different protocols were used: i) a 24 h in vitro priming of cord blood-derived mononuclear cells (MNC) with micromolar cADPR, followed by their infusion into irradiated mice (both primary and secondary transplants); and ii) co-infusion of MNC with CD38-transfected, cADPR-generating, irradiated murine 3T3 fibroblasts. We demonstrated a dual effect of cADPR on human HP in vivo: i) enhanced proliferation of committed progenitors, responsible for improvement of short-term engraftment; ii) expansion of HSC, with increased long-term human engraftment into secondary recipients and a significantly higher expansion factor of CD34(+) progenitors in mice co-infused with MNC and CD38(+) 3T3 fibroblasts. These results hold promise for the possible therapeutic use of cADPR, and of cADPR-producing stroma, to achieve long-term expansion of human HSC, that is, those HP capable of self-renewal and responsible for repopulation of the bone marrow.	San Martino Hosp, Dept Hematol, Div 2, Genoa, Italy; Univ Genoa, Dept Expt Med, Biochem Sect, I-16126 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16126 Genoa, Italy; G Gaslini Inst Children, Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini	Podesta, M (corresponding author), San Martino Hosp, Dept Hematol, Div 2, Genoa, Italy.	marina.podesta@hsanmartino.liguria.it	Podestà, Marina/K-3875-2016; Bruzzone, Santina/A-4264-2015	Podestà, Marina/0000-0002-6755-613X; Bruzzone, Santina/0000-0003-2034-3716				Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bhatia M, 1998, NAT MED, V4, P1038, DOI 10.1038/2023; Bruzzone S, 2001, J BIOL CHEM, V276, P48300, DOI 10.1074/jbc.M107308200; Bruzzone S, 2001, FASEB J, V15, P10; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; Cashman J, 1997, BRIT J HAEMATOL, V98, P1026, DOI 10.1046/j.1365-2141.1997.3233140.x; Childs R, 1999, BLOOD, V94, P3234, DOI 10.1182/blood.V94.9.3234.421k16_3234_3241; CLINE MJ, 1979, NATURE, V277, P177, DOI 10.1038/277177a0; Franco L, 2001, J BIOL CHEM, V276, P21642, DOI 10.1074/jbc.M010536200; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1999, BLOOD, V94, P2545, DOI 10.1182/blood.V94.8.2545.420k45_2545_2547; Guida L, 2002, J BIOL CHEM, V277, P47097, DOI 10.1074/jbc.M207793200; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KAISHO T, 1994, P NATL ACAD SCI USA, V91, P5325, DOI 10.1073/pnas.91.12.5325; KRAUSE DS, 1994, BLOOD, V84, P691; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; METCALF R. L., 1971, Pesticides in the environment. Volume 1, Part I., V1, P1; Podesta M, 2000, FASEB J, V14, P680, DOI 10.1096/fasebj.14.5.680; Rice AM, 2000, TRANSPLANTATION, V69, P927; Sirard C, 1996, BLOOD, V87, P1539, DOI 10.1182/blood.V87.4.1539.bloodjournal8741539; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; SUTHERLAND HJ, 1989, BLOOD, V74, P1563; van Hennik PB, 1999, BLOOD, V94, P3055, DOI 10.1182/blood.V94.9.3055.421k05_3055_3061; Wong L, 1999, BBA-GEN SUBJECTS, V1472, P555, DOI 10.1016/S0304-4165(99)00161-0; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017; Zocchi E, 2001, FASEB J, V15, P1610, DOI 10.1096/fj.00-0803fje	29	20	25	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					310	+		10.1096/fj.02-0520fje	http://dx.doi.org/10.1096/fj.02-0520fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475890				2022-12-28	WOS:000180574300021
J	Quaschning, T; Ruschitzka, F; Stallmach, T; Shaw, S; Morawietz, H; Goettsch, W; Hermann, M; Slowinski, T; Theuring, F; Hocher, B; Luscher, TF; Gassmann, M				Quaschning, T; Ruschitzka, F; Stallmach, T; Shaw, S; Morawietz, H; Goettsch, W; Hermann, M; Slowinski, T; Theuring, F; Hocher, B; Luscher, TF; Gassmann, M			Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice	FASEB JOURNAL			English	Article						endothelium; hematocrit; nitric oxide; blood pressure	NITRIC-OXIDE; DEPENDENT RELAXATION; NERVOUS-SYSTEM; SMOOTH-MUSCLE; SHEAR-STRESS; C-KIT; CELLS; RELEASE; GENE; DYSFUNCTION	The endothelium controls blood flow and pressure by releasing several vasoactive factors, among them the vasodilator nitric oxide (NO) and the potent vasoconstrictor endothelin-1 (ET-1). Although increased NO levels have been found in excessive erythrocytosis, little is known concerning ET-1 expression in this condition. Thus, we examined the endothelin system in transgenic mice that due to constitutive overexpression of erythropoietin (Epo) reached hematocrit levels of similar to80%. Surprisingly, despite generalized vasodilatation, polycythemic mice exhibited a two- to fivefold elevation in ET-1 mRNA levels in aorta, liver, heart, and kidney. In line with this, increased expression of ET-1 protein was detected in the pulmonary artery by immunohistochemical analysis. Compared with their wild-type littermates, aortic rings of Epo transgenic animals exhibited a marked reduction in vascular reactivity to ET-1 and big ET-1, but this effect was abrogated upon preincubation with the NO synthase inhibitor N-nitro-L-arginine methyl ester (L-NAME). Pretreatment of polycythemic mice with the ETA receptor antagonist darusentan for 3 wk significantly prolonged their survival upon acute exposure to L-NAME. Taken together, these results demonstrate for the first time that excessive erythrocytosis induces a marked activation of the tissue endothelin system that results in increased mortality upon blockade of NO-mediated vasodilatation. Because ETA antagonism prolonged survival after acute blockade of NO synthesis, endothelin may be regarded as a contributor to the adverse cardiovascular effects of erythrocytosis and may thus represent a new target in the treatment of cardiovascular disease associated with erythrocytosis.	Univ Zurich, Inst Vet Physiol, CH-8057 Zurich, Switzerland; Univ Zurich, Cardiol & Cardiovasc Res & Inst Physiol, CH-8006 Zurich, Switzerland; Univ Hosp Wurzburg, Dept Med, Wurzburg, Germany; Univ Zurich Hosp, Inst Pathol, CH-8091 Zurich, Switzerland; Univ Bern, Inselspital, CH-3010 Bern, Switzerland; Univ Halle Wittenberg, Inst Pathophysiol, Halle An Der Saale, Germany; Humboldt Univ, Univ Hosp Charite, Dept Nephrol, Berlin, Germany; Free Univ Berlin, D-1000 Berlin, Germany; Humboldt Univ, Univ Hosp Charite, Inst Pharmacol & Toxicol, Berlin, Germany	University of Zurich; University of Zurich; University of Wurzburg; University of Zurich; University Zurich Hospital; University of Bern; Martin Luther University Halle Wittenberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Gassmann, M (corresponding author), Univ Zurich, Inst Vet Physiol, Winterthurerstr 260, CH-8057 Zurich, Switzerland.	maxg@access.unizh.ch	Goettsch, Winfried/S-5733-2016; Hocher, Berthold/AAC-3510-2020	Goettsch, Winfried/0000-0003-1015-0726; Hocher, Berthold/0000-0001-8143-0579; Hermann, Matthias/0000-0002-0694-7719; Gassmann, Max/0000-0003-2750-8878				Barton M, 1998, HYPERTENSION, V31, P499, DOI 10.1161/01.HYP.31.1.499; Bertinieri G, 1998, HYPERTENSION, V31, P848, DOI 10.1161/01.HYP.31.3.848; Bichet S, 1999, FASEB J, V13, P285, DOI 10.1096/fasebj.13.2.285; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; Camenisch G, 2001, PFLUG ARCH EUR J PHY, V443, P240, DOI 10.1007/s004240100679; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; dUscio LV, 1997, HYPERTENSION, V29, P435, DOI 10.1161/01.HYP.29.1.435; FUKURODA T, 1994, BIOCHEM BIOPH RES CO, V199, P1461, DOI 10.1006/bbrc.1994.1395; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; HAHN AWA, 1990, CELL REGUL, V1, P649, DOI 10.1091/mbc.1.9.649; HART RG, 1990, STROKE, V21, P1111, DOI 10.1161/01.STR.21.8.1111; HAYNES WG, 1994, LANCET, V344, P852, DOI 10.1016/S0140-6736(94)92827-4; HERGERSBERG M, 1995, HUM MOL GENET, V4, P359, DOI 10.1093/hmg/4.3.359; HIRATA Y, 1993, J CLIN INVEST, V91, P1367, DOI 10.1172/JCI116338; Hocher B, 1997, J CLIN INVEST, V99, P1380, DOI 10.1172/JCI119297; Hofer T, 2002, PFLUG ARCH EUR J PHY, V443, P503, DOI 10.1007/s00424-001-0759-8; Hu J, 1998, BIOCHEM BIOPH RES CO, V245, P894, DOI 10.1006/bbrc.1998.8543; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Jefferson JA, 2002, LANCET, V359, P407, DOI 10.1016/S0140-6736(02)07594-3; LEMOLI RM, 1994, EXP HEMATOL, V22, P919; LUSCHER TF, 1988, NEW ENGL J MED, V319, P462, DOI 10.1056/NEJM198808253190802; LUSCHER TF, 1990, ENDOTHELIUM MODULATO; MACARTHUR H, 1994, BIOCHEM BIOPH RES CO, V200, P395, DOI 10.1006/bbrc.1994.1462; Malek AM, 1999, J MOL CELL CARDIOL, V31, P387, DOI 10.1006/jmcc.1998.0873; Maurer MH, 2002, NEUROSCI LETT, V327, P181, DOI 10.1016/S0304-3940(02)00425-1; Morawietz H, 2000, J PHYSIOL-LONDON, V525, P761, DOI 10.1111/j.1469-7793.2000.00761.x; Noll G, 1996, CIRCULATION, V93, P866, DOI 10.1161/01.CIR.93.5.866; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; POHL U, 1986, HYPERTENSION, V8, P37, DOI 10.1161/01.HYP.8.1.37; Quaschning T, 2001, HYPERTENSION, V37, P1108, DOI 10.1161/01.HYP.37.4.1108; RAKUGI H, 1990, BIOCHEM BIOPH RES CO, V169, P973, DOI 10.1016/0006-291X(90)91989-6; RAPOPORT RM, 1983, NATURE, V306, P174, DOI 10.1038/306174a0; Ruschitzka FT, 2000, P NATL ACAD SCI USA, V97, P11609, DOI 10.1073/pnas.97.21.11609; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; VALLANCE P, 1989, LANCET, V2, P997; Wagner KF, 2001, BLOOD, V97, P536, DOI 10.1182/blood.V97.2.536; Waskow C, 2002, IMMUNITY, V17, P277, DOI 10.1016/S1074-7613(02)00386-2; WEBB RC, 1987, HYPERTENSION, V9, P268, DOI 10.1161/01.HYP.9.3.268; WELLINGS RP, 1994, BRIT J PHARMACOL, V111, P515, DOI 10.1111/j.1476-5381.1994.tb14767.x; Wiessner C, 2001, J CEREBR BLOOD F MET, V21, P857, DOI 10.1097/00004647-200107000-00011; YANAGISAWA M, 1988, J HYPERTENS, V6, pS188, DOI 10.1097/00004872-198812040-00056	41	62	65	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					259	+		10.1096/fj.02-0296fje	http://dx.doi.org/10.1096/fj.02-0296fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12490547				2022-12-28	WOS:000180574300039
J	Crosbie, RH; Barresi, R; Campbell, KP				Crosbie, RH; Barresi, R; Campbell, KP			Loss of sarcolemma nNOS in sarcoglycan-deficient muscle	FASEB JOURNAL			English	Article						nitric oxide synthase; muscular dystrophy; dystrophin; syntrophin	NITRIC-OXIDE SYNTHASE; GIRDLE MUSCULAR-DYSTROPHY; VASCULAR SMOOTH-MUSCLE; GLYCOPROTEIN COMPLEX; SKELETAL-MUSCLE; BETA-SARCOGLYCAN; ALPHA-SARCOGLYCAN; GAMMA-SARCOGLYCAN; DELTA-SARCOGLYCAN; MDX MICE	nNOS, anchored to the sarcolemma through its interactions with the dystrophin-glycoprotein complex, is dramatically reduced in dystrophin-deficient mdx mice and Duchenne muscular dystrophy patients. Recent evidence suggests that loss of nNOS in dystrophin-deficient muscle may contribute significantly to the progression of muscle pathology through a variety of mechanisms. To investigate whether nNOS plays a role in other forms of muscular dystrophy, we analyzed protein expression of nNOS in several sarcoglycan-deficient animal models of muscular dystrophy as well as patients with primary mutations in the sarcoglycan genes. Primary mutations in alpha-, beta-, delta-, and gamma-sarcoglycan result in autosomal recessive limb girdle muscular dystrophy (AR-LGMD). We report that loss of the sarcoglycan-sarcospan complex in muscle causes a dramatic reduction in the levels of nNOS expression at the membrane, even in the presence of normal dystrophin and syntrophin expression. Furthermore, we show that expression of three out of four sarcoglycans is not sufficient to maintain nNOS at the sarcolemma. Our data suggest that loss of nNOS may contribute to muscle pathology in AR-LGMD with primary mutations in the sarcoglycans.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA; Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa; University of California System; University of California Los Angeles	Campbell, KP (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, 400 Eckstein Med Res Bldg, Iowa City, IA 52242 USA.	kevin-campbell@uiowa.edu	Barresi, Rita/AAB-9569-2022	Barresi, Rita/0000-0001-7351-959X; Campbell, Kevin/0000-0003-2066-5889	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR048179] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allamand V, 2000, HUM MOL GENET, V9, P2459, DOI 10.1093/hmg/9.16.2459; Araishi K, 1999, HUM MOL GENET, V8, P1589, DOI 10.1093/hmg/8.9.1589; BENOTHMANE K, 1992, NAT GENET, V2, P315, DOI 10.1038/ng1292-315; Blake DJ, 1996, J BIOL CHEM, V271, P7802, DOI 10.1074/jbc.271.13.7802; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; Chang WJ, 1996, P NATL ACAD SCI USA, V93, P9142, DOI 10.1073/pnas.93.17.9142; Chao DS, 1996, J EXP MED, V184, P609, DOI 10.1084/jem.184.2.609; Cohn RD, 2001, J CLIN INVEST, V107, pR1, DOI 10.1172/JCI11642; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Crosbie RH, 2000, HUM MOL GENET, V9, P2019, DOI 10.1093/hmg/9.13.2019; Crosbie RH, 1998, HUM MOL GENET, V7, P823, DOI 10.1093/hmg/7.5.823; Crosbie RH, 1999, J CELL BIOL, V145, P153, DOI 10.1083/jcb.145.1.153; Crosbie RH, 1997, J BIOL CHEM, V272, P31221, DOI 10.1074/jbc.272.50.31221; Crosbie RH, 2001, NAT MED, V7, P27, DOI 10.1038/83309; Crosbie RH, 1998, FEBS LETT, V427, P279, DOI 10.1016/S0014-5793(98)00442-6; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Durbeej M, 2000, MOL CELL, V5, P141, DOI 10.1016/S1097-2765(00)80410-4; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Ettinger AJ, 1997, J BIOL CHEM, V272, P32534, DOI 10.1074/jbc.272.51.32534; Gee SH, 1998, J NEUROSCI, V18, P128; Gossrau R, 1996, ACTA HISTOCHEM, V98, P345, DOI 10.1016/S0065-1281(96)80027-4; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; Holt KH, 1998, MOL CELL, V1, P841, DOI 10.1016/S1097-2765(00)80083-0; HOMBURGER F, 1962, MED EXP, V6, P339; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; LEE KH, 1994, J BIOL CHEM, V269, P14371; Lim LE, 1998, CURR OPIN NEUROL, V11, P443, DOI 10.1097/00019052-199810000-00006; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; LJUNGGREN A, 1995, ANN NEUROL, V38, P367, DOI 10.1002/ana.410380305; McNally EM, 1998, FEBS LETT, V422, P27, DOI 10.1016/S0014-5793(97)01593-7; Miyagoe-Suzuki Y, 2001, MICROSC RES TECHNIQ, V55, P164, DOI 10.1002/jemt.1167; MIZUNO Y, 1995, AM J PATHOL, V146, P530; Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; Okazaki Y, 1996, NAT GENET, V13, P87, DOI 10.1038/ng0596-87; PassosBueno MR, 1996, HUM MOL GENET, V5, P815, DOI 10.1093/hmg/5.6.815; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Piccolo F, 1996, HUM MOL GENET, V5, P2019, DOI 10.1093/hmg/5.12.2019; PICCOLO F, 1995, NAT GENET, V5, P1963; Rando TA, 1998, NEUROMUSCULAR DISORD, V8, P14, DOI 10.1016/S0960-8966(97)00124-7; ROBERDS SL, 1993, J BIOL CHEM, V268, P11496; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; Roberts CK, 1997, AM J PHYSIOL-ENDOC M, V273, pE220, DOI 10.1152/ajpendo.1997.273.1.E220; SadouletPuccio HM, 1996, HUM MOL GENET, V5, P489, DOI 10.1093/hmg/5.4.489; Sakamoto A, 1997, P NATL ACAD SCI USA, V94, P13873, DOI 10.1073/pnas.94.25.13873; Sander M, 2000, P NATL ACAD SCI USA, V97, P13818, DOI 10.1073/pnas.250379497; Sanders DB, 2000, PERFUSION-UK, V15, P97, DOI 10.1177/026765910001500203; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Sotgia F, 2000, J BIOL CHEM, V275, P38048, DOI 10.1074/jbc.M005321200; Sunada Y, 2001, HUM MOL GENET, V10, P173, DOI 10.1093/hmg/10.3.173; Thomas GD, 1998, J PHYSIOL-LONDON, V506, P817, DOI 10.1111/j.1469-7793.1998.817bv.x; Thomas GD, 1998, P NATL ACAD SCI USA, V95, P15090, DOI 10.1073/pnas.95.25.15090; WANG T, 1995, NATURE, V374, P262, DOI 10.1038/374262a0; Wehling M, 2001, J CELL BIOL, V155, P123, DOI 10.1083/jcb.200105110; Wehling M, 1998, NEUROMUSCULAR DISORD, V8, P22, DOI 10.1016/S0960-8966(97)00136-3; WELLER B, 1990, J NEUROL SCI, V100, P9, DOI 10.1016/0022-510X(90)90005-8; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	67	66	70	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2002	16	13					1786	1791		10.1096/fj.02-0519com	http://dx.doi.org/10.1096/fj.02-0519com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12409321				2022-12-28	WOS:000180218500011
J	Qiu, W; Campbell, RL; Gangloff, A; Dupuis, P; Boivin, RP; Tremblay, MR; Poirier, D; Lin, SX				Qiu, W; Campbell, RL; Gangloff, A; Dupuis, P; Boivin, RP; Tremblay, MR; Poirier, D; Lin, SX			A concerted, rational design of type 1 17 beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity	FASEB JOURNAL			English	Article						hybrid inhibitor; inhibition kinetics; protein crystallography; molecular modeling; drug design	STEROID-BINDING-SITE; HUMAN-PLACENTA; ESTROGENIC 17-BETA-HYDROXYSTEROID-DEHYDROGENASE; 20-ALPHA-HYDROXYSTEROID DEHYDROGENASE; CHEMICAL-SYNTHESIS; METHYL-ETHER; ACTIVE-SITE; 17-BETA-DEHYDROGENASE; ESTRONE; INACTIVATION	Human estrogenic 17beta-hydroxysteroid dehydrogenase (17beta-HSD type 1) catalyzes the final step in the synthesis of active estrogens that stimulate the proliferation of breast cancer cells. Based on the initial premise to make use of the binding energies of both the substrate and cofactor sites, and molecular modeling starting from the enzyme structure, several estradiol-adenosine hybrids were designed and synthesized. Among these hybrids, EM-1745 with a linker of 8-CH2 groups is proved to be the best competitive inhibitor with a K-i of 3.0 +/- 0.8 nM. The crystal structure of the EM-1745 enzyme complex at 1.6 Angstrom provides evidence at atomic resolution of strong interactions between both the steroid and cofactor moieties and the enzyme molecule, as illustrated by a sigma(A)-weighted 2F(o)-F-c electron density map contoured at 3.0 sigma. The substrate entry loop is further stabilized in this complex compared with previous complexes of the enzyme. These results confirm our initial strategy of combining studies of structural biology and enzyme mechanism in the inhibitor design, which may be applied to other steroidogenic enzymes involved in human diseases.	Univ Laval, CHUL, Oncol & Mol Endocrinol Res Ctr, Med Ctr, Quebec City, PQ G1V 4G2, Canada	Laval University	Poirier, D (corresponding author), Univ Laval, CHUL, Oncol & Mol Endocrinol Res Ctr, Med Ctr, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	sxlin@crchul.ulaval.ca		Dupuis, Philippe/0000-0002-5970-6716; Campbell, Robert/0000-0002-5473-5876; Gangloff, Anne/0000-0002-6848-6559; Lin, Sheng-Xiang/0000-0001-9149-375X				ADAMS J, 1981, CANCER RES, V41, P4720; ADAMS JB, 1985, MOL CELL ENDOCRINOL, V41, P1, DOI 10.1016/0303-7207(85)90138-8; American Cancer Society, 2002, CANC FACTS FIG 2002; AUCHUS RJ, 1986, BIOCHEMISTRY-US, V25, P7295, DOI 10.1021/bi00371a008; Azzi A, 1996, NAT STRUCT BIOL, V3, P665, DOI 10.1038/nsb0896-665; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BHATNAGAR YM, 1978, J BIOL CHEM, V253, P811; BIELLMANN JF, 1976, EUR J BIOCHEM, V63, P477, DOI 10.1111/j.1432-1033.1976.tb10250.x; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; Bull HG, 1996, J AM CHEM SOC, V118, P2359, DOI 10.1021/ja953069t; CHIN CC, 1980, J BIOL CHEM, V255, P3660; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; GHOSH D, 1995, STRUCTURE, V3, P503, DOI 10.1016/S0969-2126(01)00183-6; INANO H, 1985, J STEROID BIOCHEM, V22, P681; INANO H, 1980, J BIOL CHEM, V255, P7694; INANO H, 1983, EUR J BIOCHEM, V129, P691; Jin YW, 1999, J VAC SCI TECHNOL B, V17, P489, DOI 10.1116/1.590582; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LABRIE C, 1992, CANCER RES, V52, P610; Labrie F, 1985, Important Adv Oncol, P193; Labrie F, 1997, STEROIDS, V62, P148, DOI 10.1016/S0039-128X(96)00174-2; Le Bail JC, 1998, CANCER LETT, V133, P101, DOI 10.1016/S0304-3835(98)00211-0; Le Bail JC, 2001, LIFE SCI, V68, P751, DOI 10.1016/S0024-3205(00)00974-7; LIN SX, 1983, BIOCHEMISTRY-US, V22, P681, DOI 10.1021/bi00272a024; LIN SX, 1984, U SCI VIE TERRE, P173; MAKELA S, 1995, P SOC EXP BIOL MED, V208, P51; McPherson A, 1982, PREPARATION ANAL PRO; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miyoshi Y, 2001, INT J CANCER, V94, P685, DOI 10.1002/ijc.1525; MURDOCK GL, 1988, BIOCHEMISTRY-US, V27, P4452, DOI 10.1021/bi00412a036; *NAT CANC I CAN, 2001, CAN CANC STAT 2001; OTWINOWSKI Z, 1996, METHODS ENZYMOLOGY, V76; Parang K, 2001, NAT STRUCT BIOL, V8, P37; Pelletier JD, 1996, BIOORGAN MED CHEM, V4, P1617, DOI 10.1016/0968-0896(96)00154-X; Peltoketo H, 1999, J MOL ENDOCRINOL, V23, P1, DOI 10.1677/jme.0.0230001; Penning TM, 1996, ENDOCR-RELAT CANCER, V3, P41, DOI 10.1677/erc.0.0030041; PHILIPPSEN A, 2001, DINO VISUALIZING STR; Poirier D, 1998, J STEROID BIOCHEM, V64, P83, DOI 10.1016/S0960-0760(97)00136-2; *POV TEAM, 1999, PERS VIS RAY TRAC V; Qiu W, 1999, J STEROID BIOCHEM, V68, P239, DOI 10.1016/S0960-0760(99)00036-9; Sam K M, 1998, Drug Des Discov, V15, P157; SANTNER SJ, 1993, J STEROID BIOCHEM, V45, P383, DOI 10.1016/0960-0760(93)90007-J; Sawicki MW, 1999, P NATL ACAD SCI USA, V96, P840, DOI 10.1073/pnas.96.3.840; Segel I. H, 1976, BIOCH CALCULATION, V2nd; SIMARD J, 1987, J STEROID BIOCHEM, V26, P539, DOI 10.1016/0022-4731(87)90005-7; SWEET F, 1991, BIOCHEM BIOPH RES CO, V180, P1057, DOI 10.1016/S0006-291X(05)81173-8; THOMAS DB, 1984, CANCER-AM CANCER SOC, V53, P595, DOI 10.1002/1097-0142(19840201)53:3+<595::AID-CNCR2820531304>3.0.CO;2-Y; THOMAS JL, 1986, J STEROID BIOCHEM, V25, P103, DOI 10.1016/0022-4731(86)90287-6; THOMAS JL, 1983, J BIOL CHEM, V258, P1500; TOBIAS B, 1982, J BIOL CHEM, V257, P2783; Tremblay MR, 2001, STEROIDS, V66, P821, DOI 10.1016/S0039-128X(01)00116-7; Tremblay MR, 1998, J STEROID BIOCHEM, V66, P179, DOI 10.1016/S0960-0760(98)00043-0; VIHKO R, 1989, CRIT REV ONCOL HEMAT, V9, P1, DOI 10.1016/S1040-8428(89)80012-5; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wolf E, 2002, J MOL BIOL, V317, P215, DOI 10.1006/jmbi.2001.5371; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222; Zhorov BS, 2000, PROTEINS, V38, P414, DOI 10.1002/(SICI)1097-0134(20000301)38:4<414::AID-PROT7>3.0.CO;2-X; ZHU DW, 1993, J MOL BIOL, V234, P242, DOI 10.1006/jmbi.1993.1578	60	83	87	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13	1				1829	+		10.1096/fj.02-0026fje	http://dx.doi.org/10.1096/fj.02-0026fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223444				2022-12-28	WOS:000181189100006
J	Wyatt, AW; Steinert, JR; Wheeler-Jones, CPD; Morgan, AJ; Sugden, D; Pearson, JD; Sobrevia, L; Mann, GE				Wyatt, AW; Steinert, JR; Wheeler-Jones, CPD; Morgan, AJ; Sugden, D; Pearson, JD; Sobrevia, L; Mann, GE			Early activation of the p42/p44(MAPK) pathway mediates adenosine-induced nitric oxide production in human endothelial cells: a novel calcium-insensitive mechanism	FASEB JOURNAL			English	Article						mitogen-activated protein kinases; NO; L-arginine; A(2a) purinoceptors	L-ARGININE TRANSPORT; PROTEIN-KINASE; CYCLIC-AMP; A(2B) RECEPTORS; CULTURED HUMAN; SYSTEM Y(+); SYNTHASE; RELAXATION; CHANNELS; RELEASE	Adenosine is released from the myocardium, endothelial cells, and skeletal muscle in ischemia and is an important regulator of coronary blood flow. We have already shown that acute (2 min) activation of A(2a) purinoceptors stimulates NO production in human fetal umbilical vein endothelial cells (1) and now report a key role for p42/p44 mitogen-activated protein kinases (p42/p44(MAPK)) in the regulation of the L-arginine-nitric oxide (NO) signaling pathway. Expression of mRNA for the A(2a)-, A(2b)-, and A(3) -adenosine receptor subtypes was abundant whereas A(1)-adenosine receptor mRNA levels were negligible. Activation of A(2a) purinoceptors by adenosine (10 muM) or the A(2a) receptor agonist CGS21680 (100 nM) resulted in an increase in L-arginine transport and NO release that was not mediated by changes in intracellular Ca2+, pH, or cAMP. Stimulation of endothelial cells with adenosine was associated with a membrane hyperpolarization and phosphorylation of p42/p44(MAPK). L-NAME abolished the adenosine-induced hyperpolarization and stimulation of L-arginine transport whereas sodium nitroprusside activated an outward potassium current. Genistein (10 muM) and PD98059 (10 muM), an inhibitor of MAPK kinase 1/2 (MEK1/2), inhibited adenosine-stimulated L-arginine transport, NO production, and phosphorylation of p42/p44(MAPK). We found no evidence for activation of eNOS via the serine/threonine kinase Akt/ PKB (protein kinase B) in adenosine-stimulated cells. Our results provide the first evidence that adenosine stimulates the endothelial cell L-arginine-NO pathway in a Ca2+-insensitive manner involving p42/p44(MAPK), with release of NO leading to a membrane hyperpolarization and activation of L-arginine transport.	Kings Coll London, GKT Sch Biomed Sci, Ctr Cardiovasc Biol & Med, London SE1 1UL, England; Univ London Royal Vet Coll, Dept Vet Basic Sci, London NW1 0UT, England; Kings Coll London, GKT Sch Biomed Sci, Endocrinol & Reprod Res Grp, London SE1 1UL, England; Univ Concepcion, Fac Biol Sci, Cellular & Mol Physiol Lab, Concepcion, Chile	University of London; King's College London; University of London; University of London Royal Veterinary College; University of London; King's College London; Universidad de Concepcion	Mann, GE (corresponding author), Kings Coll London, GKT Sch Biomed Sci, Ctr Cardiovasc Biol & Med, Guys Campus, London SE1 1UL, England.	giovanni.mann@kcl.ac.uk	Sobrevia, Luis/H-9608-2016; Wenger, Roland H./B-7953-2009; Steinert, Joern/A-6678-2008; Steinert, Joern/ABB-4561-2020; Steinert, Joern R/AAI-2742-2020; Stroka, Deborah M/F-1806-2013	Wenger, Roland H./0000-0001-7592-4839; Steinert, Joern/0000-0003-1640-0845; Steinert, Joern R/0000-0003-1640-0845; Sobrevia, Luis/0000-0001-5802-2243; Mann, Giovanni/0000-0001-7311-2044				ABEBE W, 1995, AM J PHYSIOL-HEART C, V269, pH1672, DOI 10.1152/ajpheart.1995.269.5.H1672; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; Bogle RG, 1996, J PHYSIOL-LONDON, V490, P229, DOI 10.1113/jphysiol.1996.sp021138; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; BUSSOLATI O, 1993, AM J PHYSIOL, V265, pC1006, DOI 10.1152/ajpcell.1993.265.4.C1006; CaulinGlaser T, 1997, CIRC RES, V81, P885; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Duszyk R, 2000, FREE RADICAL RES, V33, P449, DOI 10.1080/10715760000300991; ETHIER MF, 1993, AM J PHYSIOL, V265, pH131, DOI 10.1152/ajpheart.1993.265.1.H131; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Feoktistov I, 2002, CIRC RES, V90, P531, DOI 10.1161/01.RES.0000012203.21416.14; Ferro A, 1999, BRIT J PHARMACOL, V126, P1872, DOI 10.1038/sj.bjp.0702512; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; FLEMING I, 1994, CIRC RES, V74, P1220, DOI 10.1161/01.RES.74.6.1220; Fukao M, 1999, J BIOL CHEM, V274, P10927, DOI 10.1074/jbc.274.16.10927; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gao ZH, 1999, J BIOL CHEM, V274, P5972, DOI 10.1074/jbc.274.9.5972; GRAIER WF, 1993, BIOCHEM J, V291, P263, DOI 10.1042/bj2910263; GRAIER WF, 1992, BIOCHEM J, V288, P345, DOI 10.1042/bj2880345; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Hein T, 1998, FASEB J, V12, pA13; Hisamoto K, 2001, J BIOL CHEM, V276, P47642, DOI 10.1074/jbc.M103853200; JACOB R, 1991, CELL CALCIUM, V12, P127, DOI 10.1016/0143-4160(91)90014-6; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KAVANAUGH MP, 1993, BIOCHEMISTRY-US, V32, P5781, DOI 10.1021/bi00073a009; Li JM, 1998, J SURG RES, V80, P357, DOI 10.1006/jsre.1998.5439; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; MARTIN PL, 1994, J PHARMACOL EXP THER, V270, P893; MAY MJ, 1998, AM J PHYSIOL, V43, pC789; Ogonowski AA, 2000, AM J PHYSIOL-CELL PH, V278, pC136; Olanrewaju HA, 2000, GEN PHARMACOL-VASC S, V35, P171, DOI 10.1016/S0306-3623(01)00107-0; Olanrewaju HA, 2000, AM J PHYSIOL-HEART C, V279, pH650, DOI 10.1152/ajpheart.2000.279.2.H650; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PARRATT JR, 1994, CARDIOVASC RES, V28, P783, DOI 10.1093/cvr/28.6.783; Prentice DJ, 2000, N-S ARCH PHARMACOL, V362, P427, DOI 10.1007/s002100000292; Richard LF, 1998, AM J PHYSIOL-HEART C, V274, pH35, DOI 10.1152/ajpheart.1998.274.1.H35; Rolleston S, 2000, J PHYSIOL-LONDON, V523, p151P; Ruehlmann DO, 1998, FASEB J, V12, P613, DOI 10.1096/fasebj.12.7.613; Sala R, 2002, AM J PHYSIOL-CELL PH, V282, pC134, DOI 10.1152/ajpcell.2002.282.1.C134; Sexl V, 1997, J BIOL CHEM, V272, P5792, DOI 10.1074/jbc.272.9.5792; SEXL V, 1995, BRIT J PHARMACOL, V114, P1577, DOI 10.1111/j.1476-5381.1995.tb14942.x; Skinner MR, 1996, J PHYSIOL-LONDON, V495, P553, DOI 10.1113/jphysiol.1996.sp021615; SMITS P, 1995, CIRCULATION, V92, P2135, DOI 10.1161/01.CIR.92.8.2135; SOBREVIA L, 1994, AM J PHYSIOL, V267, pC39, DOI 10.1152/ajpcell.1994.267.1.C39; Sobrevia L, 1997, J PHYSIOL-LONDON, V499, P135, DOI 10.1113/jphysiol.1997.sp021916; SOBREVIA L, 1995, J PHYSIOL-LONDON, V489, P183, DOI 10.1113/jphysiol.1995.sp021040; STEINHORN RH, 1994, J PHYSIOL-LONDON, V266, P2001; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; VIALS A, 1993, BRIT J PHARMACOL, V109, P424, DOI 10.1111/j.1476-5381.1993.tb13586.x; Wheeler-Jones C, 1997, FEBS LETT, V420, P28, DOI 10.1016/S0014-5793(97)01481-6; WheelerJones CPD, 1996, FEBS LETT, V388, P180, DOI 10.1016/0014-5793(96)00547-9; Wyatt AW, 1998, J PHYSIOL-LONDON, V506P, p32P	58	109	111	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1584	1594		10.1096/fasebj.16.12.1584	http://dx.doi.org/10.1096/fasebj.16.12.1584			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374781	Green Published			2022-12-28	WOS:000179167600040
J	Iervolino, A; Trisciuoglio, D; Ribatti, D; Candiloro, A; Biroccio, A; Zupi, G; Del Bufalo, D				Iervolino, A; Trisciuoglio, D; Ribatti, D; Candiloro, A; Biroccio, A; Zupi, G; Del Bufalo, D			Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity	FASEB JOURNAL			English	Article						endothelial cells; cancer line; angiogenic factor; vascularization	ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1; MESSENGER-RNA STABILITY; KAPPA-B ACTIVITY; FACTOR EXPRESSION; CARCINOMA-CELLS; SYNERGISTICALLY ACT; HUMAN GLIOBLASTOMA; CANCER CELLS; FACTOR GENE	The aim of this paper was to study the molecular mechanisms by which bcl-2 increases hypoxia-induced vascular endothelial growth factor (VEGF) expression. We demonstrated that bcl-2 overexpression in M14 human melanoma cell line enhances hypoxia-induced VEGF mRNA stability and promoter activation. In particular, the half-life of the message was longer in bcl-2 transfectants (approximately 330 min) than in control cells (approximately 180 min). In addition, bcl-2 overexpression increased VEGF promoter activity through the hypoxia-inducible factor-1 (HIF-1) transcription factor. Increased HIF-1 protein expression and DNA binding activity were detected in bcl-2 overexpressing cells compared with control cells. An enhanced functional activity of secreted VEGF was found both in in vitro and in vivo angiogenic assays, and the use of VEGF specific antibodies validated the role of VEGF on bcl-2-induced angiogenesis. Taken together our results indicate that bcl-2 plays an important role in melanoma angiogenesis, and that VEGF mRNA stabilization and HIF-1-mediated transcriptional activity are two important control points in bcl-2/hypoxia-induced VEGF expression.	Regina Elena Inst Canc Res, Dept Expt Chemotherapy, I-00158 Rome, Italy; Univ Bari, Sch Med, Dept Human Anat & Histol, I-70121 Bari, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universita degli Studi di Bari Aldo Moro	Del Bufalo, D (corresponding author), Regina Elena Inst Canc Res, Dept Expt Chemotherapy, Via Messi Oro 156, I-00158 Rome, Italy.	delbufalo@ifo.it	Biroccio, Annamaria/B-2861-2018; Del Bufalo, Donatella/AAC-1594-2021; Del Bufalo, Donatella/K-8673-2016; trisciuoglio, Daniela/H-2131-2016; trisciuoglio, daniela/AAL-4002-2021	Biroccio, Annamaria/0000-0003-3198-3532; Del Bufalo, Donatella/0000-0002-3148-6096; Del Bufalo, Donatella/0000-0002-3148-6096; trisciuoglio, Daniela/0000-0002-7007-7914; 				Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Biroccio A, 2000, FASEB J, V14, P652, DOI 10.1096/fasebj.14.5.652; Biroccio A, 1999, INT J CANCER, V82, P125, DOI 10.1002/(SICI)1097-0215(19990702)82:1<125::AID-IJC21>3.0.CO;2-Q; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; Desbaillets I, 1999, ONCOGENE, V18, P1447, DOI 10.1038/sj.onc.1202424; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Fernandez A, 2001, J NATL CANCER I, V93, P208, DOI 10.1093/jnci/93.3.208; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Grover R, 1996, EUR J SURG ONCOL, V22, P342, DOI 10.1016/S0748-7983(96)90154-7; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harmey JH, 1998, ANN SURG ONCOL, V5, P271, DOI 10.1007/BF02303785; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Huang ZW, 2000, ONCOGENE, V19, P6627, DOI 10.1038/sj.onc.1204087; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; KIESER A, 1994, ONCOGENE, V9, P963; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Levy AP, 1998, TRENDS CARDIOVAS MED, V8, P246, DOI 10.1016/S1050-1738(98)00020-6; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LEVY AP, 1995, CIRC RES, V76, P758, DOI 10.1161/01.RES.76.5.758; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Mazure NM, 1996, CANCER RES, V56, P3436; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nabors LB, 2001, CANCER RES, V61, P2154; Rak J, 2000, J INVEST DERM SYMP P, V5, P24, DOI 10.1046/j.1087-0024.2000.00012.x; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Ribatti D, 1999, J CELL SCI, V112, P4213; Ricca A, 2000, INT J CANCER, V86, P188, DOI 10.1002/(SICI)1097-0215(20000415)86:2<188::AID-IJC7>3.3.CO;2-N; Richard DE, 1999, BIOCHEM BIOPH RES CO, V266, P718, DOI 10.1006/bbrc.1999.1889; Rivard A, 2000, J BIOL CHEM, V275, P29643, DOI 10.1074/jbc.M001029200; SCOTLANDI K, 1994, INT J CANCER, V58, P95, DOI 10.1002/ijc.2910580116; Selzer E, 1998, MELANOMA RES, V8, P197, DOI 10.1097/00008390-199806000-00001; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Straume O, 2001, AM J PATHOL, V159, P223, DOI 10.1016/S0002-9440(10)61688-4; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; White FC, 1997, GROWTH FACTORS, V14, P199, DOI 10.3109/08977199709021520; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	49	96	106	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1453	+		10.1096/fj.02-0122fje	http://dx.doi.org/10.1096/fj.02-0122fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205045				2022-12-28	WOS:000177813100016
J	Lohn, M; Dubrovska, G; Lauterbach, B; Luft, FC; Gollasch, M; Sharma, AM				Lohn, M; Dubrovska, G; Lauterbach, B; Luft, FC; Gollasch, M; Sharma, AM			Periadventitial fat releases a vascular relaxing factor	FASEB JOURNAL			English	Article						fat; adventitium; ion channels; tyrosine phosphorylation	SENSITIVE POTASSIUM CHANNELS; SMOOTH-MUSCLE CELLS; ADIPOSE-TISSUE; REACTIVE HYPEREMIA; CORONARY-ARTERIES; ATP; AUTOREGULATION; TONE	Virtually all blood vessels are surrounded by adventitial fat. Adipocytes produce a host of vasoactive substances that may influence vascular contraction. We tested whether or not perivascular adipose tissue modulates contraction of aortic ring preparations. We studied aortic rings surrounded by periadventitial adipose tissue from adult Sprague-Dawley rats. At a maximum concentration of 300 nM angiotensin II, 6.5 muM serotonin, and 5 muM phenylephrine, the contractile response of intact rings was 95%, 80%, and 30% lower than that of vessels without periadventitial fat. The anticontractile effect of periadventitial fat was reduced by inhibition of ATP-dependent K+ channels with glibenclamide (3 muM) and by the tyrosine kinase inhibitor genistein (10 muM). Blocking NOS, cyclo-oxygenase, cytochrome P450, or adenosine receptors did not restore the vascular response in intact vessels. The anticontractile effect of perivascular fat was present in Zucker fa/fa rats, suggesting that leptin receptors were not responsible. Transferring the bath solution from intact vessels, isolated periadventitial tissue, and cultured rat adipocytes to precontracted vessels lacking periadventitial fat resulted in a rapid relaxation. We suggest that perivascular adventitial adipose tissue releases a transferable adventitium-derived relaxing factor that acts by tyrosine kinase-dependent activation of K+ channels in vascular smooth muscle cells.	HELIOS Klinikum Berlin, Franz Volhard Clin, D-13125 Berlin, Germany; Humboldt Univ, Fac Med Charite, Max Delbruck Ctr Mol Med, Berlin, Germany	Franz-Volhard Clinical Research Center; Helios Kliniken; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Sharma, AM (corresponding author), HELIOS Klinikum Berlin, Franz Volhard Clin, Wiltbergstr 50, D-13125 Berlin, Germany.	gollasch@fvk-berlin.de; sharma@fvk-berlin.de		Luft, Friedrich/0000-0002-8635-1199				CLAYTON FC, 1992, PHARMACOLOGY, V44, P92, DOI 10.1159/000138877; Crandall DL, 1997, MICROCIRCULATION-LON, V4, P211, DOI 10.3109/10739689709146786; DAUT J, 1990, SCIENCE, V247, P1341, DOI 10.1126/science.2107575; Engeli S, 2000, HORM METAB RES, V32, P485, DOI 10.1055/s-2007-978675; GOLLASCH M, 1995, J PHARMACOL EXP THER, V275, P681; Gollasch M, 1996, CIRC RES, V78, P676, DOI 10.1161/01.RES.78.4.676; Harvey J, 1997, J PHYSIOL-LONDON, V504, P527, DOI 10.1111/j.1469-7793.1997.527bd.x; HONG KW, 1994, AM J PHYSIOL, V266, pH11, DOI 10.1152/ajpheart.1994.266.1.H11; Hu SL, 1999, J PHARMACOL EXP THER, V291, P1372; Matsushita Y, 2000, EUR J PHARMACOL, V389, P51, DOI 10.1016/S0014-2999(99)00872-9; NARISHIGE T, 1993, CIRC RES, V73, P771, DOI 10.1161/01.RES.73.4.771; NELSON MT, 1995, AM J PHYSIOL, V268, P799; Quilley J, 2000, TRENDS PHARMACOL SCI, V21, P121, DOI 10.1016/S0165-6147(00)01445-0; SAMAHA FF, 1992, AM J PHYSIOL, V262, pC1220, DOI 10.1152/ajpcell.1992.262.5.C1220; SOLTIS EE, 1991, CLIN EXP HYPERTENS A, V13, P277, DOI 10.3109/10641969109042063; Spanswick D, 1997, NATURE, V390, P521, DOI 10.1038/37379; VANELLI G, 1994, AM J PHYSIOL, V266, pH43, DOI 10.1152/ajpheart.1994.266.1.H43	17	368	390	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2002	16	9					1057	1063		10.1096/fj.02-0024com	http://dx.doi.org/10.1096/fj.02-0024com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087067				2022-12-28	WOS:000177813100037
J	Williamson, AL; Brindley, PJ; Abbenante, G; Prociv, P; Berry, C; Girdwood, K; Pritchard, DI; Fairlie, DP; Hotez, PJ; Dalton, JP; Loukas, A				Williamson, AL; Brindley, PJ; Abbenante, G; Prociv, P; Berry, C; Girdwood, K; Pritchard, DI; Fairlie, DP; Hotez, PJ; Dalton, JP; Loukas, A			Cleavage of hemoglobin by hookworm cathepsin D aspartic proteases and its potential contribution to host specificity	FASEB JOURNAL			English	Article						parasite; Ancylostoma caninum; Necator americanus; nematode	HUMAN EOSINOPHILIC ENTERITIS; ADULT HAEMONCHUS-CONTORTUS; BLOOD-FEEDING PARASITES; ANCYLOSTOMA-CANINUM; PLASMODIUM-FALCIPARUM; CAENORHABDITIS-ELEGANS; IN-VIVO; DEGRADATION; INFECTION; IDENTIFICATION	Hookworms routinely reach the gut of nonpermissive hosts but fail to successfully feed, develop, and reproduce. To investigate the effects of host-parasite coevolution on the ability of hookworms to feed in nonpermissive hosts, we cloned and expressed aspartic proteases from canine and human hookworms. We show here that a cathepsin D-like protease from the canine hookworm Ancylosotoma caninum (Ac-APR-1) and the orthologous protease from the human hookworm Necator americanus (Na-APR-1) are expressed in the gut and probably exert their proteolytic activity extracellularly. Both proteases were detected immunologically and enzymatically in somatic extracts of adult worms. The two proteases were expressed in baculovirus, and both cleaved human and dog hemoglobin (Hb) in vitro. Each protease digested Hb from its permissive host between twofold (whole molecule) and sixfold (synthetic peptides) more efficiently than Hb from the nonpermissive host, despite the two proteases' having identical residues lining their active site clefts. Furthermore, both proteases cleaved Hb at numerous distinct sites and showed different substrate preferences. The findings suggest that the paradigm of matching the molecular structure of the food source within a host to the molecular structure of the catabolic proteases of the parasite is an important contributing factor for host-parasite compatibility and host species range.	Queensland Inst Med Res, Div Infect Dis & Immunol, Brisbane, Qld 4006, Australia; Univ Queensland, Dept Microbiol & Parasitol, Brisbane, Qld, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia; Tulane Univ, Dept Trop Med, New Orleans, LA 70118 USA; Cardiff Univ, Sch Biosci, Cardiff, S Glam, Wales; Univ Nottingham, Boots Sci Inst, Nottingham NG7 2RD, England; George Washington Univ, Ctr Med, Dept Microbiol & Trop Med, Washington, DC 20037 USA; Dublin City Univ, Fac Hlth & Sci, Sch Biotechnol, Dublin 9, Ireland	QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland; Tulane University; Cardiff University; University of Nottingham; George Washington University; Dublin City University	Loukas, A (corresponding author), George Washington Univ, Ctr Med, Dept Microbiol & Trop Med, Ross Hall,Room 727,2300 Eye St NW, Washington, DC 20037 USA.	mtmacl@gwumc.edu	Loukas, Alex/B-7355-2014; Fairlie, David P/F-8865-2014; Berry, Colin/A-4338-2010; Dalton, John/K-4457-2014	Loukas, Alex/0000-0002-0896-8441; Fairlie, David P/0000-0002-7856-8566; Berry, Colin/0000-0002-9943-548X; Plummer, Beverley/0000-0002-6559-7237; Hotez, Peter/0000-0001-8770-1042; Brindley, Paul J./0000-0003-1765-0002				BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY, P919; Beyer BM, 1996, J BIOL CHEM, V271, P15590, DOI 10.1074/jbc.271.26.15590; Bielefeldt-Ohmann H, 1998, VIRUS RES, V57, P63, DOI 10.1016/S0168-1702(98)00087-2; Brindley PJ, 1997, MOL BIOCHEM PARASIT, V89, P1, DOI 10.1016/S0166-6851(97)00098-4; Brindley PJ, 2001, MOL BIOCHEM PARASIT, V112, P103, DOI 10.1016/S0166-6851(00)00351-0; Brinkworth RI, 2001, J BIOL CHEM, V276, P38844, DOI 10.1074/jbc.M101934200; Brinkworth RI, 2000, INT J PARASITOL, V30, P785, DOI 10.1016/S0020-7519(00)00045-X; Chen Ming Gang, 1993, P237; Coombs GH, 2001, TRENDS PARASITOL, V17, P532, DOI 10.1016/S1471-4922(01)02037-2; CROESE J, 1994, ANN INTERN MED, V120, P369, DOI 10.7326/0003-4819-120-5-199403010-00003; Crompton DWT, 1999, J PARASITOL, V85, P397, DOI 10.2307/3285768; Daub J, 2000, PARASITOLOGY, V120, P171, DOI 10.1017/S0031182099005375; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Fruitier I, 1998, BIOCHEM BIOPH RES CO, V246, P719, DOI 10.1006/bbrc.1998.8614; Geier G, 1999, EUR J BIOCHEM, V264, P872, DOI 10.1046/j.1432-1327.1999.00679.x; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; Harrop SA, 1996, BIOCHEM BIOPH RES CO, V227, P294, DOI 10.1006/bbrc.1996.1503; HOTEZ PJ, 1995, SCI AM, V272, P68, DOI 10.1038/scientificamerican0695-68; Humason G. L., 1979, ANIMAL TISSUE TECHNI; Jolodar A, 1998, BBA-PROTEIN STRUCT M, V1382, P13, DOI 10.1016/S0167-4838(97)00141-6; Jones BF, 2002, MOL BIOCHEM PARASIT, V119, P107, DOI 10.1016/S0166-6851(01)00409-1; KNOX DP, 1993, PARASITOLOGY, V106, P395, DOI 10.1017/S0031182000067147; Longbottom D, 1997, MOL BIOCHEM PARASIT, V88, P63, DOI 10.1016/S0166-6851(97)00074-1; LOUKAS A, 1992, T ROY SOC TROP MED H, V86, P650, DOI 10.1016/0035-9203(92)90175-C; Loukas A, 1998, PARASITOL TODAY, V14, P54, DOI 10.1016/S0169-4758(97)01188-5; Loukas A, 2001, CLIN MICROBIOL REV, V14, P689, DOI 10.1128/CMR.14.4.689-703.2001; Prociv P, 1997, CHEM IMMUNOL, V66, P62; Prociv P, 1998, PARASITOL TODAY, V14, P51, DOI 10.1016/S0169-4758(97)01187-3; PROCIV P, 1990, LANCET, V335, P1299, DOI 10.1016/0140-6736(90)91186-E; SAWANGJAROEN N, 1995, PARASITE IMMUNOL, V17, P29, DOI 10.1111/j.1365-3024.1995.tb00963.x; SWOFFORD DL, 1998, PAUP ASTERISQUE PHYL; Tcherepanova I, 2000, J BIOL CHEM, V275, P26359, DOI 10.1074/jbc.M000956200; Wasilewski MM, 1996, MOL BIOCHEM PARASIT, V81, P179, DOI 10.1016/0166-6851(96)02703-X; Yoshida Y., 1960, Japanese Journal of Parasitology, V9, P735	36	98	101	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1458	+		10.1096/fj.02-0181fje	http://dx.doi.org/10.1096/fj.02-0181fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205047				2022-12-28	WOS:000177813100003
J	Murphy, MP; Das, P; Nyborg, AC; Rochette, MJ; Dodson, MW; Loosbrock, NM; Souder, TM; McLendon, C; Merit, SL; Piper, SC; Jansen, KR; Golde, TE				Murphy, MP; Das, P; Nyborg, AC; Rochette, MJ; Dodson, MW; Loosbrock, NM; Souder, TM; McLendon, C; Merit, SL; Piper, SC; Jansen, KR; Golde, TE			Overexpression of nicastrin increases A beta production	FASEB JOURNAL			English	Article						amyloid beta-peptide; presenilin; gamma-secretase	GAMMA-SECRETASE CLEAVAGE; AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; TRANSMEMBRANE DOMAIN; PRESENILIN; NOTCH; MUTATIONS; DROSOPHILA; COMPLEX	gamma-Secretase cleavage is the final proteolytic step that releases the amyloid beta-peptide (Abeta) from the amyloid beta-protein precursor (APP). Significant evidence indicates that the presenilins (PS) are catalytic components of a high molecular weight gamma-secretase complex. The glycoprotein nicastrin was recently identified as a functional unit of this complex based on 1) binding to PS and 2) the ability to modulate Abeta production following mutation of a conserved DYIGS region. In contrast to the initial report, we find that overexpression of wild-type (WT) nicastrin increases Abeta production, whereas DYIGS mutations (MT) have little or no effect. The increase in Abeta production is associated with an increase in gamma-secretase activity but not with a detectable increase in PS1 levels. Subcellular fractionation studies show that WT but not MT nicastrin matures into buoyant membrane fractions enriched in gamma-secretase activity. These data support the hypothesis that nicastrin is an essential component of the gamma-secretase complex. The finding that WT nicastrin overexpression can increase gamma-secretase activity without altering levels of the presumed catalytic component (PS) of the enzyme may point to a role for nicastrin in facilitating cleavage by regulating substrate interactions with the gamma-secretase complex.	Mayo Clin Jacksonville, Dept Neurosci, Mol Neurobiol Lab, Jacksonville, FL 32224 USA	Mayo Clinic	Golde, TE (corresponding author), Mayo Clin Jacksonville, Dept Neurosci, Mol Neurobiol Lab, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	tgolde@mayo.edu						Arawaka S, 2002, J NEUROCHEM, V83, P1065, DOI 10.1046/j.1471-4159.2002.01207.x; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; Cruts M, 1998, HUM MOL GENET, V7, P43, DOI 10.1093/hmg/7.1.43; De Jonghe C, 1998, NEUROBIOL DIS, V5, P281, DOI 10.1006/nbdi.1998.0202; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Dermaut B, 2002, AM J HUM GENET, V70, P1568, DOI 10.1086/340732; Desforges M, 2002, VIROLOGY, V295, P63, DOI 10.1006/viro.2001.1329; DeTure M, 2002, AM J PATHOL, V161, P1711, DOI 10.1016/S0002-9440(10)64448-3; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Goutte C, 2000, DEVELOPMENT, V127, P2481; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Kinoshita A, 2002, J BIOL CHEM, V277, P28530, DOI 10.1074/jbc.M203372200; Kopan R, 2002, NEURON, V33, P321, DOI 10.1016/S0896-6273(02)00585-8; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; Levitan D, 2001, DEV BIOL, V240, P654, DOI 10.1006/dbio.2001.0486; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Lopez-Schier H, 2002, DEV CELL, V2, P79, DOI 10.1016/S1534-5807(01)00109-5; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; McLendon C, 2000, FASEB J, V14, P2383; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Murphy MP, 2002, BBA-MOL BASIS DIS, V1586, P199, DOI 10.1016/S0925-4439(01)00098-9; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 2002, FEBS LETT, V520, P117, DOI 10.1016/S0014-5793(02)02802-8; Wahrle S, 2002, NEUROBIOL DIS, V9, P11, DOI 10.1006/nbdi.2001.0470; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	53	31	35	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1138	+		10.1096/fj.02-1050fje	http://dx.doi.org/10.1096/fj.02-1050fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692078				2022-12-28	WOS:000182580100036
J	Silva, AP; Pinheiro, PS; Carvalho, AP; Carvalho, CM; Jakobsen, B; Zimmer, J; Malva, JO				Silva, AP; Pinheiro, PS; Carvalho, AP; Carvalho, CM; Jakobsen, B; Zimmer, J; Malva, JO			Activation of neuropeptide Y receptors is neuroprotective against excitotoxicity in organotypic hippocampal slice cultures	FASEB JOURNAL			English	Article						NPY; AMPA; kainate; neuroprotection; neurodegeneration	SUPPRESSES EPILEPTIFORM ACTIVITY; RAT HIPPOCAMPUS; DENTATE GYRUS; IN-VITRO; KAINATE RECEPTORS; GLUTAMATE RELEASE; AMPA RECEPTORS; CELL-DEATH; NEURONS; EXPRESSION	Glutamate and NPY have been implicated in hippocampal neuropathology in temporal lobe epilepsy. Thus, we investigated the involvement of NPY receptors in mediating neuroprotection against excitotoxic insults in organotypic cultures of rat hippocampal slices. Exposure of hippocampal slice cultures to 2 muM AMPA (alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionate) induced neuronal degeneration, monitored by propidium iodide uptake, of granule cells and CA1 pyramidal cells. For dentate granule cells, selective activation of Y1, Y2, or Y5 receptors with 1 muM [Leu(31), Pro(34)]NPY, 300 nM NPY13-36 or 1 muM 500 nM NPY(19-23)-(Gly(1), Ser(3), Gln(4), Thr(6), Ala(31), Aib(32), Gln(34))-PP, respectively, had a neuroprotective effect against AMPA, whereas only the activation of Y2 receptors was effective for CA1 pyramidal cells. When the slice cultures were exposed to 6 muM kainate, the CA3 pyramidal cells displayed significant degeneration, and in this case the activation of Y1, Y2, and Y5 receptors was neuroprotective. For the kainic acid-induced degeneration of CA1 pyramidal cells, it was again found that only the Y2 receptor activation was effective. Based on the present findings, it was concluded that Y1, Y2, and Y5 receptors effectively can modify glutamate receptor-mediated neurodegeneration in the hippocampus.	Univ Coimbra, Fac Med, Inst Biochem, P-3004504 Coimbra, Portugal; Univ Coimbra, Dept Zool, Ctr Neurosci Coimbra, P-3004517 Coimbra, Portugal; Univ So Denmark, Dept Anat & Neurobiol, DK-5000 Odense, Denmark	Universidade de Coimbra; Universidade de Coimbra; University of Southern Denmark	Malva, JO (corresponding author), Univ Coimbra, Fac Med, Inst Biochem, P-3004504 Coimbra, Portugal.	jomalva@cnc.cj.uc.pt	Pinheiro, Paulo/O-8765-2017; Silva, Ana Paula/L-4184-2014; Malva, Joao/L-3557-2014	Pinheiro, Paulo/0000-0002-9024-1021; Silva, Ana Paula/0000-0002-7802-8690; Malva, Joao/0000-0002-5438-4447				Ambrosio AF, 2000, EUR J NEUROSCI, V12, P2021, DOI 10.1046/j.1460-9568.2000.00091.x; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Bacci A, 2002, P NATL ACAD SCI USA, V99, P17125, DOI 10.1073/pnas.012481899; Balasubramaniam A, 1997, PEPTIDES, V18, P445, DOI 10.1016/S0196-9781(96)00347-6; Baraban SC, 1997, J NEUROSCI, V17, P8927, DOI 10.1523/jneurosci.17-23-08927.1997; Bijak M, 1999, NEUROSCI LETT, V268, P115, DOI 10.1016/S0304-3940(99)00381-X; BONNEFIL PC, 1993, NEUROSCI LETT, V154, P5; Cabrele C, 2000, J BIOL CHEM, V275, P36043, DOI 10.1074/jbc.M000626200; Chittajallu R, 1999, TRENDS PHARMACOL SCI, V20, P26, DOI 10.1016/S0165-6147(98)01286-3; Doods H, 1999, EUR J PHARMACOL, V384, pR3, DOI 10.1016/S0014-2999(99)00650-0; Dumont Y, 1998, J NEUROSCI, V18, P5565; Fujikawa DG, 2000, NEUROSCIENCE, V98, P41, DOI 10.1016/S0306-4522(00)00085-3; Furtinger S, 2001, J NEUROSCI, V21, P5804, DOI 10.1523/JNEUROSCI.21-15-05804.2001; Grove KL, 2000, NEUROSCIENCE, V100, P731, DOI 10.1016/S0306-4522(00)00308-0; Ho MWY, 2000, J NEUROPHYSIOL, V83, P723, DOI 10.1152/jn.2000.83.2.723; HSU SSF, 1994, NEUROSCI LETT, V178, P189, DOI 10.1016/0304-3940(94)90756-0; JACQUES D, 1997, NEUROSCIENCE, V79, P5804; Kanatani A, 2000, BIOCHEM BIOPH RES CO, V272, P169, DOI 10.1006/bbrc.2000.2696; Klapstein GJ, 1997, J NEUROPHYSIOL, V78, P1651, DOI 10.1152/jn.1997.78.3.1651; Kristensen BW, 1999, BRAIN RES, V841, P143, DOI 10.1016/S0006-8993(99)01833-8; Kristensen BW, 2001, BRAIN RES, V917, P21, DOI 10.1016/S0006-8993(01)02900-6; Larm JA, 1997, J NEUROCHEM, V69, P617; Lee CC, 1998, REGUL PEPTIDES, V75-6, P71, DOI 10.1016/S0167-0115(98)00054-8; LEES GJ, 1993, BRAIN RES, V628, P1, DOI 10.1016/0006-8993(93)90930-L; Malva JO, 1998, NEUROCHEM INT, V32, P1, DOI 10.1016/S0197-0186(97)00046-6; Marsh DJ, 1999, P NATL ACAD SCI USA, V96, P13518, DOI 10.1073/pnas.96.23.13518; McCullough LA, 1998, REGUL PEPTIDES, V75-6, P101, DOI 10.1016/S0167-0115(98)00058-5; McQuiston AR, 1996, J NEUROPHYSIOL, V76, P3159, DOI 10.1152/jn.1996.76.5.3159; Michel MC, 1998, PHARMACOL REV, V50, P143; MILLER LDP, 1994, NEUROSCIENCE, V63, P471, DOI 10.1016/0306-4522(94)90544-4; Noraberg J, 1999, BRAIN RES PROTOC, V3, P278, DOI 10.1016/S1385-299X(98)00050-6; Parker RMC, 1999, EUR J NEUROSCI, V11, P1431, DOI 10.1046/j.1460-9568.1999.00553.x; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; Patrylo PR, 1999, J NEUROPHYSIOL, V82, P478, DOI 10.1152/jn.1999.82.1.478; Pringle AK, 1997, BRAIN RES, V755, P36, DOI 10.1016/S0006-8993(97)00089-9; Schwarzer C, 1996, BRAIN RES REV, V22, P27; Silva AP, 2001, J NEUROCHEM, V79, P286, DOI 10.1046/j.1471-4159.2001.00560.x; Silva AP, 2001, J NEUROSCI RES, V65, P378, DOI 10.1002/jnr.1164; Statnick MA, 1998, BRAIN RES, V810, P16, DOI 10.1016/S0006-8993(98)00855-5; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Takahashi Y, 2000, NEUROSCI LETT, V287, P105, DOI 10.1016/S0304-3940(00)01133-2; vandenPol AN, 1996, J NEUROSCI, V16, P5883; Vezzani A, 1999, TRENDS NEUROSCI, V22, P25, DOI 10.1016/S0166-2236(98)01284-3; VITALE M, 1993, HISTOCHEMISTRY, V100, P223, DOI 10.1007/BF00269095; WAN CP, 1995, LIFE SCI, V56, P1055, DOI 10.1016/0024-3205(95)00041-4; WETTSTEIN JG, 1995, PHARMACOL THERAPEUT, V65, P397, DOI 10.1016/0163-7258(95)98598-K; Whittaker E, 1999, BRAIN RES, V827, P229, DOI 10.1016/S0006-8993(99)01302-5; WIELAND HA, 1995, PEPTIDES, V16, P1389, DOI 10.1016/0196-9781(95)02028-4; Woldbye DPD, 1997, NAT MED, V3, P761, DOI 10.1038/nm0797-761	49	76	79	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1118	+		10.1096/fj.02-0885fje	http://dx.doi.org/10.1096/fj.02-0885fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692082	Green Submitted			2022-12-28	WOS:000182580100045
J	Takamiya, R; Takahashi, M; Myint, T; Park, YS; Miyazawa, N; Endo, T; Fujiwara, N; Sakiyama, H; Misonou, Y; Miyamoto, Y; Fujii, J; Taniguchi, N				Takamiya, R; Takahashi, M; Myint, T; Park, YS; Miyazawa, N; Endo, T; Fujiwara, N; Sakiyama, H; Misonou, Y; Miyamoto, Y; Fujii, J; Taniguchi, N			Glycation proceeds faster in mutated Cu, Zn-superoxide dismutases related to familial amyotrophic lateral sclerosis	FASEB JOURNAL			English	Article						ROS; hydrogen peroxide; copper; posttranslational modification	MUTANT CU,ZN-SUPEROXIDE DISMUTASES; END-PRODUCTS; NEURODEGENERATIVE DISEASES; IMMUNOLOGICAL DETECTION; WILD-TYPE; IN-VITRO; MUTATIONS; AGGREGATION; SOD1; GENE	Amyotrophic lateral sclerosis (ALS) involves the progressive degeneration of motor neurons in the spinal cord and motor cortex. It has been shown that 15-20% of patients with familial ALS (FALS) have defects in the Sod1 gene that encodes Cu, Zn-superoxide dismutase (SOD). To elucidate the pathological role of mutated Cu, Zn-SODs in FALS, the susceptibility of mutants to glycation was examined. Mutated Cu, Zn-SODs (G37R, G93A, and I113T) related to FALS and wild type were produced in a baculovirus/insect cell expression system. Glycated and nonglycated proteins were separated on a boronate column, and the nonglycated fraction was then incubated with glucose. The mutated Cu, Zn-SODs were found to be highly susceptible to glycation compared with the wild-type enzyme as estimated by Western blot analysis using an anti-hexitol lysine antibody. The mutated Cu, Zn-SOD incubated with glucose generated higher levels of hydrogen peroxide than the wild-type enzyme. Mutated Cu, Zn-SODs were also shown to be highly susceptible to fructation, and the fructated mutant also produced higher levels of hydrogen peroxide than the wild type. These results suggest that high susceptibility of mutated Cu, Zn-SODs to glycation could be the origin of the oxidative stress associated with neuronal dysfunction in FALS.	Osaka Univ, Sch Med, Dept Biochem, Osaka 5650871, Japan; Yamagata Univ, Sch Med, Dept Biochem, Yamagata 9909585, Japan	Osaka University; Yamagata University	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Dept Biochem, 2-2 Yamadaoka, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp	Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014; Park, Yong Seek/ABG-6398-2021; Takahashi, Motoko/I-3154-2013	Taniguchi, Naoyuki/0000-0001-5889-5968; Park, Yong Seek/0000-0002-9260-3102; Takahashi, Motoko/0000-0002-2112-6142				ANDERSEN PM, 1999, AMYOTROPH LATERAL SC, P223; ARAI K, 1987, J BIOL CHEM, V262, P16969; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Cleveland DW, 2000, NAT MED, V6, P1320, DOI 10.1038/82122; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Eum WS, 1999, MOL CELLS, V9, P110; FUJII J, 1995, J NEUROCHEM, V64, P1456; Fujii J, 1996, NEPHROL DIAL TRANSPL, V11, P34; JAING ZY, 1990, FEBS LETT, V268, P69; Kato H, 1999, GENES IMMUN, V1, P97, DOI 10.1038/sj.gene.6363638; Kato S, 2000, ACTA NEUROPATHOL, V100, P490, DOI 10.1007/s004010000226; Kawasaki Y, 1998, FEBS LETT, V441, P116, DOI 10.1016/S0014-5793(98)01529-4; Miyazawa N, 1998, BIOCHEM J, V336, P101, DOI 10.1042/bj3360101; MYINT T, 1995, BBA-MOL BASIS DIS, V1272, P73, DOI 10.1016/0925-4439(95)00067-E; NIWA J, 2002, J BIOL CHEM; Okado-Matsumoto A, 2000, FREE RADICAL RES, V33, P65, DOI 10.1080/10715760000300621; OOKAWARA T, 1992, J BIOL CHEM, V267, P18505; PAULTON KR, 1993, FUNC NEUROL, V8, P33; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SAKURAI T, 1998, FEBS LETT, P406; Sasaki N, 1998, AM J PATHOL, V153, P1149, DOI 10.1016/S0002-9440(10)65659-3; Shibata N, 1999, ACTA NEUROPATHOL, V97, P240, DOI 10.1007/s004010050980; Shibata N, 2001, BRAIN RES, V917, P97, DOI 10.1016/S0006-8993(01)02926-2; Shibata N, 2002, ACTA NEUROPATHOL, V104, P171, DOI 10.1007/s00401-002-0537-5; Shibata N, 2000, ACTA NEUROPATHOL, V100, P275, DOI 10.1007/s004019900173; Shinpo K, 2000, BRAIN RES, V861, P151, DOI 10.1016/S0006-8993(00)02047-3; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; Wong PC, 2002, NAT NEUROSCI, V5, P633, DOI 10.1038/nn0702-633	31	28	28	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					938	+		10.1096/fj.02-0768fje	http://dx.doi.org/10.1096/fj.02-0768fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626432				2022-12-28	WOS:000181892600023
J	Amon, M; Menger, MD; Vollmar, B				Amon, M; Menger, MD; Vollmar, B			Heme oxygenase and nitric oxide synthase mediate cooling-associated protection against TNF-alpha-induced microcirculatory dysfunction and apoptotic cell death	FASEB JOURNAL			English	Article						cooling; inflammation; apoptosis; TNF-alpha; nitric oxide; carbon monoxide; mice; microcirculation; leukocyte-endothelial cell interaction	LEUKOCYTE ADHESION; CARBON-MONOXIDE; ENDOTHELIAL-CELLS; RELAXING FACTOR; HYPOTHERMIA; EXPRESSION; INDUCTION; ISCHEMIA; INFLAMMATION; NEUTROPHILS	Local cooling protects against TNF-alpha-induced injury by attenuating inflammation-associated microcirculatory dysfunction and leukocytic response. Mechanisms of protection, however, are not fully understood. We studied whether the metabolites of the HO and NOS pathway, exerting potent vasodilatory, antioxidant, and anti-apoptotic properties, are involved in tissue cryoprotection. In animals pretreated with L-NAME or SnPP-IX, cooling-associated abrogation of TNF-alpha-induced microcirculatory dysfunction was abolished. Combined L-NAME/SnPP-IX pretreatment did not cause greater blunting than seen when each mediator system was inhibited separately. In SnPP-IX- but not L-NAME-pretreated animals, transient hypothermia failed to reduce TNF-alpha-mediated leukocyte adherence. Vice versa, treatment of TNF-alpha-exposed animals with either the NO donor L-arginine or the HO-1 inductor hemin mimicked cooling-associated tissue protection except for failure of L-arginine to abrogate the inflammatory leukocyte response. The efficiency of cooling to inhibit TNF-alpha-induced apoptotic cell death was blunted in SnPP-IX-, L-NAME-, and SnPP-IX/L-NAME-pre-treated animals. Coadministration of Trolox in SnPPIX-treated animals partly attenuated leukocyte adherence and cell apoptosis, implying that the HO pathway metabolite biliverdin contributes to the salutary effects of cooling. Thus, our study provides evidence that metabolites of the HO and the NOS pathway mediate the cooling-associated protection of inflamed tissue. Biliverdin rather than CO and NO mediates the anti-inflammatory action, whereas a coordinated function of the gaseous monoxides prevents microcirculatory dysfunction and apoptotic cell death.	Univ Saarland, Inst Clin & Expt Surg, D-66421 Homburg, Germany	Saarland University	Vollmar, B (corresponding author), Univ Rostock, Dept Expt Surg, D-18055 Rostock, Germany.	brigitte.vollmar@med.uni-rostock.de						BREASTED JH, 1930, E SMITH SURG PAPYRUS, V1; Ceneviva GD, 1998, AM J PHYSIOL-LUNG C, V275, pL717, DOI 10.1152/ajplung.1998.275.4.L717; Clancy RM, 1998, ARTHRITIS RHEUM-US, V41, P1141, DOI 10.1002/1529-0131(199807)41:7<1141::AID-ART2>3.0.CO;2-S; CLANCY RM, 1995, P SOC EXP BIOL MED, V210, P93; COHN BT, 1989, AM J SPORT MED, V17, P344, DOI 10.1177/036354658901700306; Cullen KE, 1997, J BIOL CHEM, V272, P1742, DOI 10.1074/jbc.272.3.1742; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Durante W, 1997, CIRC RES, V80, P557, DOI 10.1161/01.RES.80.4.557; Edwards AD, 1995, BIOCHEM BIOPH RES CO, V217, P1193, DOI 10.1006/bbrc.1995.2895; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEHSEL K, 1995, J IMMUNOL, V155, P2858; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; GRASER T, 1990, BIOMED BIOCHIM ACTA, V49, P293; Haddix TL, 1996, J SURG RES, V64, P176, DOI 10.1006/jsre.1996.0325; Hayashi S, 1999, CIRC RES, V85, P663, DOI 10.1161/01.RES.85.8.663; Hickey MJ, 1997, J IMMUNOL, V158, P3391; HIRASAWA M, 1994, BRIT J CANCER, V70, P466, DOI 10.1038/bjc.1994.329; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; Kubes P, 2000, AM J MED, V109, P150, DOI 10.1016/S0002-9343(00)00480-0; Kunkel EJ, 2000, J IMMUNOL, V164, P3301, DOI 10.4049/jimmunol.164.6.3301; LAING DR, 1973, NEW ZEAL MED J, V78, P155; LEHR HA, 1993, AM J PATHOL, V143, P1055; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; LUO DS, 1994, EUR J PHARM-MOLEC PH, V267, P263, DOI 10.1016/0922-4106(94)90149-X; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Matz JM, 1996, PHYSIOL BEHAV, V60, P1369, DOI 10.1016/S0031-9384(96)00220-X; MEININGER GA, 1992, AM J PHYSIOL, V263, pH647, DOI 10.1152/ajpheart.1992.263.3.H647; Menger MD, 2000, MICROCIRCULATION, V7, P291, DOI 10.1038/sj.mn.7300117; MONCADA S, 1991, PHARMACOL REV, V43, P109; Morisaki H, 2001, ANESTHESIOLOGY, V95, P192, DOI 10.1097/00000542-200107000-00030; Motoyoshi N, 2001, J THORAC CARDIOV SUR, V122, P351, DOI 10.1067/mtc.2001.113935; Motterlini R, 1996, AM J PHYSIOL-HEART C, V270, pH107, DOI 10.1152/ajpheart.1996.270.1.H107; Nash GB, 2001, PFLUG ARCH EUR J PHY, V442, P762, DOI 10.1007/s004240100598; OLEARY DS, 1994, AM J PHYSIOL, V266, pR1213, DOI 10.1152/ajpregu.1994.266.4.R1213; Petrache I, 2000, AM J PHYSIOL-LUNG C, V278, pL312, DOI 10.1152/ajplung.2000.278.2.L312; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SWAN H, 1973, SURGERY, V73, P736; Thom SR, 2000, P NATL ACAD SCI USA, V97, P1305, DOI 10.1073/pnas.97.3.1305; Thorlacius H, 1998, J TRAUMA, V45, P715, DOI 10.1097/00005373-199810000-00016; Vollmar B, 2000, AM J PHYSIOL-HEART C, V279, pH1591, DOI 10.1152/ajpheart.2000.279.4.H1591; WARD ME, 1993, J APPL PHYSIOL, V74, P1606, DOI 10.1152/jappl.1993.74.4.1606; Westermann S, 1999, SURGERY, V126, P881, DOI 10.1067/msy.2099.100474; Wyllie A H, 1992, Semin Immunol, V4, P389; Xu XP, 1995, CARDIOVASC RES, V30, P841, DOI 10.1016/S0008-6363(95)00117-4; Yamauchi J, 1999, DIGEST SURG, V16, P400, DOI 10.1159/000018755; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795	48	54	56	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					175	185		10.1096/fj.02-0368com	http://dx.doi.org/10.1096/fj.02-0368com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554696				2022-12-28	WOS:000181456900042
J	Pompl, PN; Ho, L; Bianchi, M; McManus, T; Qin, W; Pasinetti, GM				Pompl, PN; Ho, L; Bianchi, M; McManus, T; Qin, W; Pasinetti, GM			A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis	FASEB JOURNAL			English	Article						inflammation; COX-2; ALS; nimesulide	SPINAL-CORD; MICE; ALS; EXCITOTOXICITY; DISEASE; DEATH	Recent studies indicate that the proinflammatory enzyme cyclooxygenase (COX)-2, an enzyme involved in inflammatory cascades but also normal neuronal activities, is elevated in the brain and spinal cord of amyotrophic lateral sclerosis (ALS) patients and ALS mouse model systems. On the basis of this evidence, we explored the impact of COX-2 inhibition on the onset and progression of ALS-like disease in the G93A human superoxide dismutase (SOD)1 mouse model of ALS. We found that prophylactic administration of nimesulide, a preferential COX-2 inhibitor, in the feed resulted in a significant delay in the onset of ALS type motor impairment. This delay of ALS symptomatology temporally overlapped with the inhibition of prostaglandin E-2 elevation in the spinal cord of SOD1-G93A transgenic mice relative to untreated SOD1-G93A controls. This study strongly supports a role for COX-2 in the pathophysiology of ALS and provides the first experimental evidence that prophylactic treatment with COX-2 inhibitors can significantly delay the onset of motor dysfunction in the SOD1-G93A transgenic mouse model of ALS.	CUNY Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Pasinetti, GM (corresponding author), CUNY Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA.	giulio.pasinetti@mssm.edu		Pasinetti, Giulio/0000-0002-1524-5196				Aisen PS, 2002, NEUROLOGY, V58, P1050, DOI 10.1212/WNL.58.7.1050; Almer G, 2001, ANN NEUROL, V49, P176, DOI 10.1002/1531-8249(20010201)49:2<176::AID-ANA37>3.0.CO;2-X; Barneoud P, 1999, EXP NEUROL, V155, P243, DOI 10.1006/exnr.1998.6984; Bennett A, 2000, Expert Opin Pharmacother, V1, P277, DOI 10.1517/14656566.1.2.277; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Drachman DB, 2000, ANN NEUROL, V48, P792, DOI 10.1002/1531-8249(200011)48:5<792::AID-ANA14>3.3.CO;2-X; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hewett SJ, 2000, J PHARMACOL EXP THER, V293, P417; Kelley KA, 1999, AM J PATHOL, V155, P995, DOI 10.1016/S0002-9440(10)65199-1; KIMURA H, 1985, BRAIN RES, V330, P235, DOI 10.1016/0006-8993(85)90682-1; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Miller RG, 1996, NEUROLOGY, V47, pS86, DOI 10.1212/WNL.47.4_Suppl_2.86S; Mirjany M, 2002, J PHARMACOL EXP THER, V301, P494, DOI 10.1124/jpet.301.2.494; Olsen MK, 2001, ANN NEUROL, V50, P730, DOI 10.1002/ana.1252; Pentland AP, 1999, CARCINOGENESIS, V20, P1939, DOI 10.1093/carcin/20.10.1939; Vane J. R., 1998, AM J MED, V104, p2S, DOI [DOI 10.1016/S0002-9343(97)00203-9, 10.1016/S0002-9343(97)00203-9]; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Yasojima K, 2001, NEUROLOGY, V57, P952, DOI 10.1212/WNL.57.6.952	19	113	119	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					725	+		10.1096/fj.02-0876fje	http://dx.doi.org/10.1096/fj.02-0876fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586733				2022-12-28	WOS:000181456900003
J	Weiss, JN; Qu, ZL; Garfinkel, A				Weiss, JN; Qu, ZL; Garfinkel, A			Understanding biological complexity: lessons from the past	FASEB JOURNAL			English	Review						modeling; computational biology; pattern formation; emergent properties; nonlinear dynamics	VENTRICULAR-FIBRILLATION; DYNAMICAL TRANSITIONS; EXCITABLE MEDIA; SPIRAL WAVES; RESTITUTION; MECHANISM; PHOSPHORYLATION; PROPAGATION; EVOLUTION; PATTERNS	Advances in molecular biology now permit complex biological systems to be tracked at an exquisite level of detail. The information flow is so great, however, that using intuition alone to draw connections is unrealistic. Thus, the need to integrate mathematical biology with experimental biology is greater than ever. To achieve this integration, obstacles that have traditionally prevented effective communication between theoreticians and experimentalists must be overcome, so that experimentalists learn the language of mathematics and dynamical modeling and theorists learn the language of biology. Fifty years ago Alan Hodgkin and Andrew Huxley published their quantitative model of the nerve action potential; in the same year, Alan Turing published his work on pattern formation in activator-inhibitor systems. These classic studies illustrate two ends of the spectrum in mathematical biology: the detailed model approach and the minimal model approach. When combined, they are highly synergistic in analyzing the mechanisms underlying the behavior of complex biological systems. Their effective integration will be essential for unraveling the physical basis of the mysteries of life.	Univ Calif Los Angeles, Sch Med, Cardiovasc Res Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med Cardiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol Sci, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Weiss, JN (corresponding author), Univ Calif Los Angeles, Sch Med, Cardiovasc Res Lab, 3645 MRL Bldg, Los Angeles, CA 90095 USA.	jweiss@mednet.ucla.edu			NHLBI NIH HHS [P50 HL52319] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052319] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLESSIE MA, 1973, CIRC RES, V33, P54, DOI 10.1161/01.RES.33.1.54; Ball P., 1999, SELF MADE TAPESTRY P; COURTEMANCHE M, 1993, PHYS REV LETT, V70, P2182, DOI 10.1103/PhysRevLett.70.2182; DAVIDENKO JM, 1992, NATURE, V355, P349, DOI 10.1038/355349a0; FRAME LH, 1988, CIRCULATION, V78, P1277, DOI 10.1161/01.CIR.78.5.1277; Garfinkel A, 2000, P NATL ACAD SCI USA, V97, P6061, DOI 10.1073/pnas.090492697; GRAY RA, 1995, SCIENCE, V270, P1222, DOI 10.1126/science.270.5239.1222; GULKO FB, 1972, BIOFIZIKA+, V17, P261; Harper JW, 2002, TRENDS CELL BIOL, V12, P104, DOI 10.1016/S0962-8924(01)02238-3; HODGES A, 2000, A TURING ENIGMA; HODGKIN AL, 1952, J PHYSIOL-LONDON, V116, P497, DOI 10.1113/jphysiol.1952.sp004719; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HODGKIN AL, 1952, J PHYSIOL-LONDON, V116, P449, DOI 10.1113/jphysiol.1952.sp004717; HODGKIN AL, 1952, J PHYSIOL-LONDON, V116, P473, DOI 10.1113/jphysiol.1952.sp004718; Holter NS, 2000, P NATL ACAD SCI USA, V97, P8409, DOI 10.1073/pnas.150242097; Karma A, 1994, CHAOS, V4, P461, DOI 10.1063/1.166024; KRINSKII VI, 1966, BIOPHYS-USSR, V11, P776; Meinhardt H., 1982, MODELS BIOL PATTERN; MOE GK, 1964, AM HEART J, V67, P200, DOI 10.1016/0002-8703(64)90371-0; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; NOLASCO JB, 1968, J APPL PHYSIOL, V25, P191, DOI 10.1152/jappl.1968.25.2.191; Qu ZL, 1999, AM J PHYSIOL-HEART C, V276, pH269, DOI 10.1152/ajpheart.1999.276.1.H269; Qu ZL, 1997, PHYS REV LETT, V78, P1387, DOI 10.1103/PhysRevLett.78.1387; Riccio ML, 1999, CIRC RES, V84, P955; Salazar-Ciudad I, 2001, EVOL DEV, V3, P95, DOI 10.1046/j.1525-142x.2001.003002095.x; Salazar-Ciudad I, 2001, EVOL DEV, V3, P84, DOI 10.1046/j.1525-142x.2001.003002084.x; STARMER CF, 1997, WORLD WIDE WEB; Szathmary E, 2001, NATURE, V411, P143, DOI 10.1038/35075686; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; Vincent S, 2001, NATURE, V411, P533, DOI 10.1038/35079214; Weiss JN, 2000, CIRC RES, V87, P1103, DOI 10.1161/01.RES.87.12.1103; WINFREE AT, 1972, SCIENCE, V175, P634, DOI 10.1126/science.175.4022.634; WINFREE AT, 1987, TIME BREAKS DOWN; Xie FG, 2002, AM J PHYSIOL-HEART C, V283, pH448, DOI 10.1152/ajpheart.00898.2001; ZAIKIN AN, 1970, NATURE, V225, P535, DOI 10.1038/225535b0	35	27	27	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					1	6		10.1096/fj.02-0408rev	http://dx.doi.org/10.1096/fj.02-0408rev			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12522106				2022-12-28	WOS:000181453700033
J	Ohkubo, N; Lee, YD; Morishima, A; Terashima, T; Kikkawa, S; Tohyama, M; Sakanaka, M; Tanaka, J; Maeda, N; Vitek, MP; Mitsuda, N				Ohkubo, N; Lee, YD; Morishima, A; Terashima, T; Kikkawa, S; Tohyama, M; Sakanaka, M; Tanaka, J; Maeda, N; Vitek, MP; Mitsuda, N			Apolipoprotein E and Reelin ligands modulate tau phosphorylation through an Apolipoprotein E receptor/disabled-1/glycogen synthase kinase-3 beta cascade	FASEB JOURNAL			English	Article						Alzheimer's disease; neurofibrillary tangles; signal transduction cascades; reeler mice; yotari mice	PAIRED HELICAL FILAMENTS; TRANSGENIC MICE; ALZHEIMERS-DISEASE; PROTEIN-KINASE; NEUROFIBRILLARY TANGLES; SIGNALING PATHWAY; MOUSE; GENE; BRAIN; RECEPTORS	Neurofibrillary tangles comprised of highly phosphorylated tau proteins are a key component of Alzheimer's disease pathology. Mice lacking Reelin (Reln), double-knockouts lacking the VLDL receptor (VLDLR) and ApoE receptor2 (ApoER2), and mice lacking disabled-1 (Dab1) display increased levels of phosphorylated tau. Because Reln binds to recombinant ApoE receptors, assembly of a Reln/ApoE-receptor/Dab1 (RAD) complex may initiate a signal transduction cascade that controls tau phosphorylation. Conversely, disruption of this RAD complex may increase tau phosphorylation and lead to neurodegeneration. To substantiate this concept, we mated Reln-deficient mice to ApoE-deficient mice and found that in the absence of Reln, tau phosphorylation increased as the amount of ApoE decreased. Paralleling the change in tau phosphorylation levels, we found that GSK-3beta activity increased in Reln-deficient mice and further increased in mice lacking both Reln and ApoE. CDK-5 activity was similar in mice lacking Reln, ApoE, or both. GSK-3beta and CDK-5 activity increased in Dab1-deficient mice, independent of ApoE levels. Further supporting the idea that increased tau phosphorylation results primarily from increased kinase activity, the activity of two phosphatases was similar in all conditions tested. These data support a novel, ligand-mediated signal transduction cascade-initiated by the assembly of a RAD complex that suppresses kinase activity and controls tau phosphorylation.	Ehime Univ, Sch Med, Dept Physiol, Shigenobu, Ehime 7910295, Japan; Ehime Univ, Sch Med, Dept Anat, Shigenobu, Ehime 7910295, Japan; Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Osaka 5650871, Japan; Ajou Univ, Sch Med, Dept Anat, Suwon 442749, South Korea; Kobe Univ, Sch Med, Dept Anat, Kobe, Hyogo 6500017, Japan; Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA	Ehime University; Ehime University; Osaka University; Ajou University; Kobe University; Duke University	Mitsuda, N (corresponding author), Ehime Univ, Sch Med, Dept Physiol, Shigenobu, Ehime 7910295, Japan.	mitsuda@m.ehime-u.ac.jp	Tanaka, Junya/Y-1033-2019	Tanaka, Junya/0000-0003-1056-5948; Vitek, Michael/0000-0001-8140-8048				Ahlijanian MK, 2000, P NATL ACAD SCI USA, V97, P2910, DOI 10.1073/pnas.040577797; Anderson R, 1998, NEUROSCIENCE, V85, P93, DOI 10.1016/S0306-4522(97)00598-8; Bar I, 2000, EUR J MORPHOL, V38, P321, DOI 10.1076/ejom.38.5.321.7361; BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DArcangelo G, 1996, MOL BRAIN RES, V39, P234, DOI 10.1016/0169-328X(96)00046-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DREWES G, 1993, FEBS LETT, V336, P425, DOI 10.1016/0014-5793(93)80850-T; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777; GENIS I, 1995, NEUROSCI LETT, V199, P5, DOI 10.1016/0304-3940(95)12007-Q; GONG CX, 1994, NEUROSCIENCE, V61, P765, DOI 10.1016/0306-4522(94)90400-6; GONG CX, 1994, J NEUROCHEM, V62, P803; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; Hall GF, 1997, P NATL ACAD SCI USA, V94, P4733, DOI 10.1073/pnas.94.9.4733; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell GED, 2001, J ARTHROPLASTY, V16, P121, DOI 10.1054/arth.2001.19158; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; IQBAL K, 1986, LANCET, V15, P1174; ISHIGURO K, 1993, FEBS LETT, V325, P167, DOI 10.1016/0014-5793(93)81066-9; Jackson GR, 2002, NEURON, V34, P509, DOI 10.1016/S0896-6273(02)00706-7; Kojima T, 2000, MOL BRAIN RES, V75, P121, DOI 10.1016/S0169-328X(99)00313-7; Lazaro JB, 1997, J CELL SCI, V110, P1251; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; MIAO GG, 1994, P NATL ACAD SCI USA, V91, P11050, DOI 10.1073/pnas.91.23.11050; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; Rice DS, 1998, DEVELOPMENT, V125, P3719; ROBERTSON J, 1993, DEMENTIA, V4, P256, DOI 10.1159/000107331; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Spittaels K, 1999, AM J PATHOL, V155, P2153, DOI 10.1016/S0002-9440(10)65533-2; Spittaels K, 2000, J BIOL CHEM, V275, P41340, DOI 10.1074/jbc.M006219200; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Sun W, 2002, J BIOL CHEM, V277, P11933, DOI 10.1074/jbc.M107182200; TAKAHASHI M, 1991, FEBS LETT, V289, P37, DOI 10.1016/0014-5793(91)80903-G; Tamatani M, 2001, NAT MED, V7, P317, DOI 10.1038/85463; Tesseur I, 2000, AM J PATHOL, V156, P951, DOI 10.1016/S0002-9440(10)64963-2; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Tseng HC, 2002, FEBS LETT, V523, P58, DOI 10.1016/S0014-5793(02)02934-4; Tueting P, 1999, NEUROREPORT, V10, P1329, DOI 10.1097/00001756-199904260-00032; Wang XS, 1998, J NEUROSCI RES, V51, P658, DOI 10.1002/(SICI)1097-4547(19980301)51:5<658::AID-JNR13>3.0.CO;2-Z; Wirths O, 2001, NEUROSCI LETT, V316, P145, DOI 10.1016/S0304-3940(01)02399-0; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382	48	81	87	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2002	16	14					295	+		10.1096/fj.02-0434fje	http://dx.doi.org/10.1096/fj.02-0434fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12490540				2022-12-28	WOS:000180574300041
J	Jagoe, RT; Lecker, SH; Gomes, M; Goldberg, AL				Jagoe, RT; Lecker, SH; Gomes, M; Goldberg, AL			Patterns of gene expression in atrophying skeletal muscles: response to food deprivation	FASEB JOURNAL			English	Article						cDNA microarray; ubiquitin; proteasome; cachexia	UBIQUITIN-PROTEASOME PATHWAY; PYRUVATE-DEHYDROGENASE KINASE; END RULE PATHWAY; MUSCULAR-DYSTROPHY; PROTEIN-SYNTHESIS; MESSENGER-RNA; MYOFIBRILLAR PROTEINS; PROLONGED STARVATION; DENERVATION ATROPHY; CANCER CACHEXIA	During fasting and many systemic diseases, muscle undergoes rapid loss of protein and functional capacity. To define the transcriptional changes triggering muscle atrophy and energy conservation in fasting, we used cDNA microarrays to compare mRNAs from muscles of control and food-deprived mice. Expression of >94% of genes did not change, but interesting patterns emerged among genes that were differentially expressed: 1) mRNAs encoding polyubiquitin, ubiquitin extension proteins, and many (but not all) proteasome subunits increased, which presumably contributes to accelerated protein breakdown; 2) a dramatic increase in mRNA for the ubiquitin ligase, atrogin-1, but not most E3s; 3) a significant suppression of mRNA for myosin binding protein H (but not other myofibrillar proteins) and IGF binding protein 5, which may favor cell protein loss; 4) decreases in mRNAs for several glycolytic enzymes and phosphorylase kinase subunits, and dramatic increases in mRNAs for pyruvate dehydrogenase kinase 4 and glutamine synthase, which should promote glucose sparing and gluconeogenesis. During fasting, metallothionein mRNA increased dramatically, mRNAs for extracellular matrix components fell, and mRNAs that may favor cap-independent mRNA translation rose. Significant changes occurred in mRNAs for many growth-related proteins and transcriptional regulators. These transcriptional changes indicate a complex adaptive program that should favor protein degradation and suppress glucose oxidation in muscle. Similar analysis of muscles atrophying for other causes is allowing us to identify a set of atrophy-specific changes in gene expression.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Renal Unit, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	alfred_goldberg@hms.harvard.edu	Gomes, Marcelo/AAC-6041-2021	Jagoe, R. Thomas/0000-0001-7069-0519	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002707] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02707] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam M, 2001, MOL CELL BIOL, V21, P6270, DOI 10.1128/MCB.21.18.6270-6279.2001; Ahern C A, 2001, BMC Physiol, V1, P8, DOI 10.1186/1472-6793-1-8; Attaix D, 1997, MOL BIOL REP, V24, P95, DOI 10.1023/A:1006806103675; Bailey JL, 1996, J CLIN INVEST, V97, P1447, DOI 10.1172/JCI118566; Bayol S, 2000, BIOCHEM BIOPH RES CO, V273, P282, DOI 10.1006/bbrc.2000.2667; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; BODINE SC, 2001, SCIENCE, V25, P25; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; Brushia Robert J., 1999, Frontiers in Bioscience, V4, pd618, DOI 10.2741/Brushia; Busquets S, 2000, BBA-GEN SUBJECTS, V1475, P5, DOI 10.1016/S0304-4165(00)00050-7; CALDER PC, 1989, INT J BIOCHEM, V21, P561, DOI 10.1016/0020-711X(89)90138-9; CHEREL Y, 1991, CLIN SCI, V81, P611, DOI 10.1042/cs0810611; CLEMMONS DR, 1999, HDB PHYSL 7, V5, P573; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; CRIE JS, 1983, BIOCHEM J, V210, P63, DOI 10.1042/bj2100063; Cros N, 2001, J CELL BIOCHEM, V83, P508, DOI 10.1002/jcb.1248; Dalla Libera L, 1999, AM J PHYSIOL-CELL PH, V277, pC982, DOI 10.1152/ajpcell.1999.277.5.C982; Deval C, 2001, BIOCHEM J, V360, P143, DOI 10.1042/0264-6021:3600143; Di Giovanni S, 2000, NEUROLOGY, V55, P854, DOI 10.1212/WNL.55.6.854; DIFFEE GM, 1991, AM J PHYSIOL, V261, pC1099, DOI 10.1152/ajpcell.1991.261.6.C1099; DODGSON SJ, 1991, CARBONIC ANHYDRASES; Dulhunty AF, 1996, ACTA PHYSIOL SCAND, V156, P375, DOI 10.1046/j.1365-201X.1996.193000.x; Esser K, 1999, J BIOL CHEM, V274, P12095, DOI 10.1074/jbc.274.17.12095; Estivariz CF, 1997, ENDOCRINE, V7, P65, DOI 10.1007/BF02778066; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; Fischer D, 2000, BIOCHEM BIOPH RES CO, V267, P504, DOI 10.1006/bbrc.1999.1987; FONG YM, 1989, J SURG RES, V46, P457, DOI 10.1016/0022-4804(89)90160-1; Freise D, 2000, J BIOL CHEM, V275, P14476, DOI 10.1074/jbc.275.19.14476; Garlick PJ, 1998, J NUTR, V128, p356S, DOI 10.1093/jn/128.2.356S; GEDDES R, 1994, CARBOHYD RES, V256, P139, DOI 10.1016/0008-6215(94)84233-7; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; GOLDBERG AL, 1972, AM J PHYSIOL, V223, P1384, DOI 10.1152/ajplegacy.1972.223.6.1384; GOLDBERG AL, 1978, FED PROC, V37, P2301; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; GOODMAN MN, 1984, AM J PHYSIOL, V246, pE383, DOI 10.1152/ajpendo.1984.246.5.E383; Gregg RG, 1996, P NATL ACAD SCI USA, V93, P13961, DOI 10.1073/pnas.93.24.13961; HARMON CS, 1984, BIOCHEM J, V223, P687, DOI 10.1042/bj2230687; Hasselgren P O, 1999, Curr Opin Clin Nutr Metab Care, V2, P201, DOI 10.1097/00075197-199905000-00002; Hildebrandt AL, 2000, AM J PHYSIOL-ENDOC M, V278, pE1078, DOI 10.1152/ajpendo.2000.278.6.E1078; Hill DA, 2001, BIOCHEM CELL BIOL, V79, P317, DOI 10.1139/bcb-79-3-317; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; HOLNESS MJ, 1990, BIOCHEM J, V270, P245, DOI 10.1042/bj2700245; *INC PHARM INC, 1999, GEMTM MICR REPR STUD; Jacob ST, 1999, GENE EXPRESSION, V7, P301; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; Kahn BB, 1996, DIABETES, V45, P1644, DOI 10.2337/diabetes.45.11.1644; Kelly EJ, 1997, P NATL ACAD SCI USA, V94, P10045, DOI 10.1073/pnas.94.19.10045; KETTELHUT IC, 1994, BRAZ J MED BIOL RES, V27, P981; KING PA, 1983, BIOCHEM J, V216, P523, DOI 10.1042/bj2160523; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; KRUSZYNSKA YT, 2001, HDB PHYSL 7, V2, P579; Kwon YT, 2001, MOL CELL BIOL, V21, P8007, DOI 10.1128/MCB.21.23.8007-8021.2001; LADU MJ, 1991, AM J PHYSIOL, V260, pR953, DOI 10.1152/ajpregu.1991.260.5.R953; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; Lecker SH, 1999, J CLIN INVEST, V104, P1411, DOI 10.1172/JCI7300; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; LI JB, 1976, AM J PHYSIOL, V231, P441, DOI 10.1152/ajplegacy.1976.231.2.441; LI JB, 1984, AM J PHYSIOL, V246, pE32, DOI 10.1152/ajpendo.1984.246.1.E32; Liang QR, 2002, DIABETES, V51, P174, DOI 10.2337/diabetes.51.1.174; Llovera M, 1998, MOL CELL ENDOCRINOL, V142, P183, DOI 10.1016/S0303-7207(98)00105-1; LOWELL BB, 1986, METABOLISM, V35, P1121, DOI 10.1016/0026-0495(86)90025-9; LOWELL BB, 1986, BIOCHEM J, V234, P237, DOI 10.1042/bj2340237; Maret W, 2001, CHEM-BIOL INTERACT, V130, P891, DOI 10.1016/S0009-2797(00)00243-X; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; MEDINA R, 1991, BIOMED BIOCHIM ACTA, V50, P347; MEDINA R, 1995, BIOCHEM J, V307, P631, DOI 10.1042/bj3070631; MILLWARD DJ, 1973, NATURE, V241, P204, DOI 10.1038/241204a0; Mitch WE, 1999, AM J PHYSIOL-CELL PH, V276, pC1132, DOI 10.1152/ajpcell.1999.276.5.C1132; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Mitch WE, 1999, MINER ELECTROL METAB, V25, P216, DOI 10.1159/000057450; MORTIMORE GE, 1987, ANNU REV NUTR, V7, P539, DOI 10.1146/annurev.nu.07.070187.002543; NAIR KS, 1987, AM J CLIN NUTR, V46, P557, DOI 10.1093/ajcn/46.4.557; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; OWEN OE, 2001, HDB PHYSL 7, V2, P1199; Price SR, 1996, J CLIN INVEST, V98, P1703, DOI 10.1172/JCI118968; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Richard I, 2000, J CELL BIOL, V151, P1583, DOI 10.1083/jcb.151.7.1583; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Sacksteder KA, 1999, J BIOL CHEM, V274, P24461, DOI 10.1074/jbc.274.35.24461; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Solomon V, 1998, J BIOL CHEM, V273, P25216, DOI 10.1074/jbc.273.39.25216; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Stockholm D, 2001, AM J PHYSIOL-CELL PH, V280, pC1561, DOI 10.1152/ajpcell.2001.280.6.C1561; Sugden MC, 2000, BIOCHEM J, V346, P651, DOI 10.1042/0264-6021:3460651; TAKAHASHI H, 1993, AM REV RESPIR DIS, V147, P1562, DOI 10.1164/ajrccm/147.6_Pt_1.1562; Tawa NE, 1997, J CLIN INVEST, V100, P197, DOI 10.1172/JCI119513; Taylor GA, 2000, J BIOL CHEM, V275, P4215, DOI 10.1074/jbc.275.6.4215; Titorenko VI, 2001, NAT REV MOL CELL BIO, V2, P357, DOI 10.1038/35073063; Tkatchenko AV, 2001, NEUROMUSCULAR DISORD, V11, P269, DOI 10.1016/S0960-8966(00)00198-X; Vescovo G, 2000, HEART, V84, P431, DOI 10.1136/heart.84.4.431; Williams AB, 1999, FASEB J, V13, P1435, DOI 10.1096/fasebj.13.11.1435; WING SS, 1994, AM J PHYSIOL, V267, pE39, DOI 10.1152/ajpendo.1994.267.1.E39; WING SS, 1993, AM J PHYSIOL, V264, pE668, DOI 10.1152/ajpendo.1993.264.4.E668; Wittwer M, 2002, FASEB J, V16, P884, DOI 10.1096/fj.01-0792fje; Wu PF, 2000, ARCH BIOCHEM BIOPHYS, V381, P1, DOI 10.1006/abbi.2000.1946; Wu PF, 1999, DIABETES, V48, P1593, DOI 10.2337/diabetes.48.8.1593; Wu PF, 1998, BIOCHEM J, V329, P197, DOI 10.1042/bj3290197; YOKOTA S, 1990, HISTOCHEMISTRY, V93, P287	98	255	263	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					1697	1712		10.1096/fj.02-0312com	http://dx.doi.org/10.1096/fj.02-0312com			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12409312				2022-12-28	WOS:000180218500002
J	Stephanou, A; Scarabelli, TM; Townsend, PA; Bell, R; Yellon, D; Knight, RA; Latchman, DS				Stephanou, A; Scarabelli, TM; Townsend, PA; Bell, R; Yellon, D; Knight, RA; Latchman, DS			RETRACTED: The C-terminal activation domain of the STAT-1 transcription enhances ischemia/reperfusion-induced apoptosis in cardiac myocytes (Retracted article. See vol. 32, pg. 2315, 2018)	FASEB JOURNAL			English	Article; Retracted Publication						co-activator; ischemia	TARGETED DISRUPTION; REPERFUSION INJURY; GENE-EXPRESSION; ISCHEMIA; PATHWAY; SPECIFICITY; INDUCTION; CASPASE; COMPLEX; CELLS	We have demonstrated previously that the STAT-1 transcription factor plays a key role in ischemia/reperfusion (I/R)-induced apoptosis in cardiac myocytes. In the present study we assessed which region of the STAT-1 molecule mediates apoptosis in cardiac myocytes. A STAT-1 construct (amino acid 350-750) lacking the N-terminus could enhance I/R-induced apoptosis in cardiac myocytes. However, a STAT-1 construct, which lacks 60 amino acids at the C-terminus (amino acid 691-750), was ineffective in promoting I/R-induced apoptosis in cardiac myocytes. Furthermore, overexpression of a C-terminal STAT-1 construct (amino acid 691-750) containing the transcriptional activation domain, but not the DNA binding domain, strongly enhanced I/R-induced apoptotic cell death. Cardiac myocytes isolated from mice expressing a truncated C-terminal STAT-1 were more sensitive to I/R-induced cell death. Finally, isolated hearts from these animals exposed to I/R injury had larger infarct size and greater number of TUNEL-positive myocytes than control hearts. These studies demonstrate that the C-terminal transactivation domain of STAT-1 is necessary and sufficient for I/R injury-induced apoptosis in cardiac myocytes.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England; UCL, Hatter Inst, London, England; Royal Brompton Hosp, Natl Heart & Lung Inst, London SW3 6LY, England	University of London; University College London; University of London; University College London; Imperial College London; Royal Brompton Hospital	Stephanou, A (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.	a.stephanou@ich.ucl.ac.uk	Yellon, Derek M/ABD-5110-2021; Townsend, Paul/AAF-8234-2020	Townsend, Paul/0000-0001-8956-9508; Yellon, Derek/0000-0001-7791-9320				Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Chatterjee-Kishore M, 2000, TRENDS CELL BIOL, V10, P106, DOI 10.1016/S0962-8924(99)01709-2; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Moissac D, 2000, J MOL CELL CARDIOL, V32, P53, DOI 10.1006/jmcc.1999.1057; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Kim JW, 2000, ONCOGENE, V19, P4491, DOI 10.1038/sj.onc.1203796; King P, 1998, J BIOL CHEM, V273, P8699, DOI 10.1074/jbc.273.15.8699; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; RAMMA CV, 2001, P NATL ACAD SCI USA, V98, P6674; Scarabelli T, 2001, CIRCULATION, V104, P253, DOI 10.1161/01.CIR.104.3.253; Scarabelli TM, 1999, J IMMUNOL METHODS, V228, P23, DOI 10.1016/S0022-1759(99)00090-3; Stephanou A, 1998, J MOL CELL CARDIOL, V30, P849, DOI 10.1006/jmcc.1998.0651; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Stephanou A, 2001, CELL DEATH DIFFER, V8, P434, DOI 10.1038/sj.cdd.4400846; Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002; Sumeray MS, 1998, MOL CELL BIOCHEM, V186, P61, DOI 10.1023/A:1006859011722; Xuan YT, 2001, P NATL ACAD SCI USA, V98, P9050, DOI 10.1073/pnas.161283798; Yamauchi-Takihara K, 2000, TRENDS CARDIOVAS MED, V10, P298, DOI 10.1016/S1050-1738(01)00066-4; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963	28	47	51	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13	1				1841	+		10.1096/fj.02-0150fje	http://dx.doi.org/10.1096/fj.02-0150fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223448				2022-12-28	WOS:000181189100003
J	Arispe, N; Doh, M				Arispe, N; Doh, M			Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease A beta P (1-40) and (1-42) peptides	FASEB JOURNAL			English	Article						amyloid-beta-peptide; A beta P ion channels; calcium; phosphatidylserine; membrane interaction	AMYLOID PRECURSOR PROTEIN; RAPID CELLULAR DEGENERATION; CULTURED CORTICAL-NEURONS; BILAYER-MEMBRANES; ZN2+-SENSITIVE CHANNEL; CALCIUM CHANNELS; ION CHANNELS; PC12 CELLS; CONGO RED; BRAIN	Cell degeneration in Alzheimer's disease is mediated by a toxic mechanism that involves interaction of the AbetaP peptide with the plasma membrane of the target cell. We report here that PC12 cells become resistant to the cytotoxic action of AbetaP when incubated in a medium that enriches cholesterol levels of the surface membrane. On the other hand, making cholesterol-deficient membranes by either cholesterol extraction with cyclodextrin or by inhibiting de novo synthesis of cholesterol makes PC12 cells more vulnerable to the action of AbetaP. Increasing cholesterol content of PS liposomes also suppresses AbetaP-dependent liposome aggregation. We suggest that by modifying the fluidity of the neuronal membranes, cholesterol modulates the incorporation and pore formation of AbetaP into cell membranes. This idea is supported by our finding that the enhanced cytotoxicity generated by lowering the membrane cholesterol content can be reversed by AbetaP calcium channel blockers Zn2+ and tromethamine.	USUHS, Uniformed Serv Univ Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; USUHS, Uniformed Serv Univ Sch Med, Inst Mol Med, Bethesda, MD 20814 USA		Arispe, N (corresponding author), USUHS, Uniformed Serv Univ Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	narispe@usuhs.mil						ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; ARISPE N, 1994, MOL CELL BIOCHEM, V140, P119, DOI 10.1007/BF00926750; Arispe N, 1996, P NATL ACAD SCI USA, V93, P1710, DOI 10.1073/pnas.93.4.1710; Arispe NJ, 2002, BIOPHYS J, V82, p17A; Arispe NJ, 2001, BIOPHYS J, V80, p135A; ARISPE NJ, 2001, SOC NEUR ABSTR, V27; Avdulov NA, 1997, J NEUROCHEM, V69, P1746; Bhatia R, 2000, FASEB J, V14, P1233, DOI 10.1096/fasebj.14.9.1233; BI X, 2001, SOC NEUR ABSTR, V27; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Chochina SV, 2001, J LIPID RES, V42, P1292; DEA D, 2001, SOC NEUR ABSTR, V27; DURELL SR, 1994, BIOPHYS J, V67, P2137, DOI 10.1016/S0006-3495(94)80717-9; Eckert GP, 2001, NEUROREPORT, V12, P883, DOI 10.1097/00001756-200104170-00003; ENDO A, 1992, J LIPID RES, V33, P1569; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; FURUKAWA K, 1994, NEUROREPORT, V5, P2016, DOI 10.1097/00001756-199410270-00006; GALDZICKI Z, 1994, BRAIN RES, V646, P332, DOI 10.1016/0006-8993(94)90101-5; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; Hirakura Y, 2000, AMYLOID, V7, P194, DOI 10.3109/13506120009146834; Hirakura Y, 1999, J NEUROSCI RES, V57, P458, DOI 10.1002/(SICI)1097-4547(19990815)57:4<458::AID-JNR5>3.0.CO;2-4; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; Kawahara M, 2000, J BIOL CHEM, V275, P14077, DOI 10.1074/jbc.275.19.14077; Kawahara M, 2001, CELL MOL NEUROBIOL, V21, P1, DOI 10.1023/A:1007168910582; Kawahara M, 1997, BIOPHYS J, V73, P67, DOI 10.1016/S0006-3495(97)78048-2; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Kourie JI, 2001, CELL MOL NEUROBIOL, V21, P173, DOI 10.1023/A:1010932603406; Kourie JI, 2000, AM J PHYSIOL-CELL PH, V278, pC1063, DOI 10.1152/ajpcell.2000.278.6.C1063; LEE G, 2002, IN PRESS PEPTIDES; Lee KYC, 2001, BIOPHYS J, V80, p23A; Lin H, 1999, BIOCHEMISTRY-US, V38, P11189, DOI 10.1021/bi982997c; Lin H, 2001, FASEB J, V15, P2433, DOI 10.1096/fj.01-0377com; LIN MC, 2002, IN PRESS PEPTIDES; Lundbaek JA, 1996, BIOCHEMISTRY-US, V35, P3825, DOI 10.1021/bi952250b; Lutjohann D, 2000, J LIPID RES, V41, P195; MacManus A, 2000, J BIOL CHEM, V275, P4713, DOI 10.1074/jbc.275.7.4713; MASON RP, 1992, NEUROBIOL AGING, V13, P413, DOI 10.1016/0197-4580(92)90116-F; Mason RP, 1996, BIOCHEM BIOPH RES CO, V222, P78, DOI 10.1006/bbrc.1996.0699; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MIRZABEKOV T, 1994, BIOCHEM BIOPH RES CO, V202, P1142, DOI 10.1006/bbrc.1994.2047; Mirzabekov TA, 1996, J BIOL CHEM, V271, P1988, DOI 10.1074/jbc.271.4.1988; Muller WE, 2001, BIOCHEM SOC T, V29, P617, DOI 10.1042/BST0290617; Muller WE, 1998, AMYLOID, V5, P10, DOI 10.3109/13506129809007284; MULLER WE, 1995, BRAIN RES, V674, P133, DOI 10.1016/0006-8993(94)01463-R; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Pang L, 1999, BIOCHEMISTRY-US, V38, P12003, DOI 10.1021/bi990227a; Racchi M, 1997, BIOCHEM J, V322, P893, DOI 10.1042/bj3220893; Rhee SK, 1998, J BIOL CHEM, V273, P13379, DOI 10.1074/jbc.273.22.13379; SELKOE JD, 2000, JAMA-J AM MED ASSOC, V238, P1615; SIMMONS MA, 1993, NEUROSCI LETT, V150, P133, DOI 10.1016/0304-3940(93)90519-Q; Simons M, 2001, NEUROLOGY, V57, P1089, DOI 10.1212/WNL.57.6.1089; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Vargas J, 2000, BIOPHYS J, V79, P934, DOI 10.1016/S0006-3495(00)76348-X; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Zhou Y, 1996, NEUROREPORT, V7, P2487; Zhu YJ, 2000, FASEB J, V14, P1244, DOI 10.1096/fasebj.14.9.1244	63	169	174	0	26	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1526	1536		10.1096/fj.02-0829com	http://dx.doi.org/10.1096/fj.02-0829com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374775				2022-12-28	WOS:000179167600034
J	Buresi, MC; Buret, AG; Hollenberg, MD; MacNaughton, WK				Buresi, MC; Buret, AG; Hollenberg, MD; MacNaughton, WK			Activation of proteinase-activated receptor 1 stimulates epithelial chloride secretion through a unique MAP kinase- and cyclo-oxygenase-dependent pathway	FASEB JOURNAL			English	Article						epidermal growth factor; PAR-1; inflammatory bowel disease; PCR	EPIDERMAL GROWTH-FACTOR; INFLAMMATORY BOWEL-DISEASE; CYTOSOLIC PHOSPHOLIPASE A(2); SMOOTH-MUSCLE CELLS; EGF RECEPTOR; COUPLED RECEPTORS; IN-VITRO; ION-TRANSPORT; T-84 CELLS; THROMBIN	Proteinase-activated receptor 1 (PAR-1) is activated by thrombin and induces chloride secretion by intestinal epithelial cells. To elucidate further the mechanisms whereby PAR -1 stimulates secretion, monolayers of SCBN intestinal epithelial cells were studied in modified Ussing chambers. Short circuit current responses were determined after basolateral application of thrombin and the PAR-1 -activating peptide, Ala-parafluoro-Phe-Arg-cyclohexyl-Ala-Citrulline-Tyr (Cit-NH2) in the presence or absence of a variety of signal transduction and cyclo-oxygenase (COX) pathway inhibitors. Increased kinase activity was monitored by immunoprecipitation and Western blot analysis of target phosphoproteins. The PAR 1-induced chloride secretory response was significantly attenuated by inhibitors of the EGF receptor tyrosine kinase, Src-kinase, MEK1/2, as well as by inhibitors of cytosolic phospholipase (cPL) A(2), COX-1 and COX-2. PAR-1-induced activation of cPLA(2), as shown by Western blot of phosphoserine residues, was blocked in cells treated with the MEK inhibitor U0126, indicating that the MEK-ERK1/2 MAP kinase pathway mediated PAR-1-induced cPLA2 phosphorylation. Our data show that PAR 1-induced chloride secretion in SCBN cells involves Src, EGF receptor trans-activation, activation of a MAPK pathway, phosphorylation of cPLA2, COX activity, but not PGF(2alpha) or PGE(2). These findings may be of clinical importance in inflammatory diseases of the intestine where secretory dysfunction is evident and thrombin levels are elevated.	Univ Calgary, Mucosal Inflammat Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary	MacNaughton, WK (corresponding author), Univ Calgary, Mucosal Inflammat Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	wmacnaug@ucalgary.ca	Hollenberg, Morley/AFV-6966-2022					AUTHI KS, 1985, FEBS LETT, V180, P95, DOI 10.1016/0014-5793(85)80239-8; Barrett KE, 2000, ANNU REV PHYSIOL, V62, P535, DOI 10.1146/annurev.physiol.62.1.535; Beubler E, 2001, J PHARMACOL EXP THER, V297, P940; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bos M, 1997, CLIN CANCER RES, V3, P2099; Buresi MC, 2001, AM J PHYSIOL-GASTR L, V281, pG323, DOI 10.1152/ajpgi.2001.281.2.G323; Chamouard P, 1995, EUR J GASTROEN HEPAT, V7, P1183; Cirino G, 1996, J EXP MED, V183, P821, DOI 10.1084/jem.183.3.821; Dary O, 1999, BIOCHEM SOC T, V27, P246, DOI 10.1042/bst0270246; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEJONG E, 1989, GUT, V30, P188, DOI 10.1136/gut.30.2.188; Derian CK, 1997, EXP CELL RES, V232, P1, DOI 10.1006/excr.1997.3483; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GHOSH S, 1983, ACTA HAEMATOL-BASEL, V70, P50, DOI 10.1159/000206688; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Haas M, 2000, J BIOL CHEM, V275, P27832; Halushka P V, 1988, Eicosanoids, V1, P41; Handlogten ME, 2001, J BIOL CHEM, V276, P13941, DOI 10.1074/jbc.M007306200; Hazan-Halevy I, 2000, J BIOL CHEM, V275, P12416, DOI 10.1074/jbc.275.17.12416; HINTERLEITNER TA, 1991, P SOC EXP BIOL MED, V197, P249; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Kanda Y, 2001, BRIT J PHARMACOL, V132, P1657, DOI 10.1038/sj.bjp.0703952; Kawabata A, 1999, J PHARMACOL EXP THER, V288, P358; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; KOCHINTORN U, 1993, AM J PHYSIOL, V264, pC671; KOVALENKO M, 1994, CANCER RES, V54, P6106; Lan RS, 2001, BRIT J PHARMACOL, V132, P93, DOI 10.1038/sj.bjp.0703776; Lepple-Wienhues A, 2001, FASEB J, V15, P927, DOI 10.1096/fj.00-0264com; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; MacNaughton WK, 2000, J PHARMACOL EXP THER, V293, P539; OKAZAKI T, 1981, J BIOL CHEM, V256, P7316; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Pang G, 1996, GASTROENTEROLOGY, V111, P8, DOI 10.1053/gast.1996.v111.pm8698229; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC183, DOI 10.1152/ajpcell.1999.277.2.C183; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rao RK, 1996, J PHARMACOL EXP THER, V278, P193; Ricketts WA, 1999, MOL ENDOCRINOL, V13, P1988, DOI 10.1210/me.13.12.1988; Samokhin GP, 1999, EUR J PHARMACOL, V386, P297, DOI 10.1016/S0014-2999(99)00737-2; Seymour ML, 2001, FASEB J, V15, pA830; Singer II, 1998, GASTROENTEROLOGY, V115, P297, DOI 10.1016/S0016-5085(98)70196-9; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Stadnicki A, 1997, DIGEST DIS SCI, V42, P2356, DOI 10.1023/A:1018891323205; Teoh DA, 2000, J PARASITOL, V86, P800; Tognetto M, 2000, BRIT J PHARMACOL, V131, P689, DOI 10.1038/sj.bjp.0703618; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Uribe JM, 1996, J BIOL CHEM, V271, P26588, DOI 10.1074/jbc.271.43.26588; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; Waltenberger J, 1999, CIRC RES, V85, P12; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Wong PYD, 1999, J PHYSIOL-LONDON, V514, P809, DOI 10.1111/j.1469-7793.1999.809ad.x; WOOD JD, 1993, PHARMACOLOGY, V47, P7; WU W, 2002, IN PRESS J BIOL CHEM; Zheng XL, 1998, J PHARMACOL EXP THER, V285, P325	60	45	46	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1515	1525		10.1096/fj.02-0039com	http://dx.doi.org/10.1096/fj.02-0039com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374774				2022-12-28	WOS:000179167600033
J	Parman, T; Wells, PG				Parman, T; Wells, PG			Embryonic prostaglandin H synthase-2 (PHS-2) expression and benzo[a]pyrene teratogenicity in PHS-2 knockout mice	FASEB JOURNAL			English	Article						cyclooxygenase-2; free radicals; reactive oxygen species; developmental biology; toxicology	SYNTHASE-CATALYZED BIOACTIVATION; ENDOPEROXIDE-H SYNTHASE-1; PHENYTOIN; CYCLOOXYGENASE-2; OXIDATION; PURIFICATION; CARCINOGENS; METABOLISM; MOUSE; COX-2	The developmental role of prostaglandin H synthase-2 (PHS-2), which converts xenobiotics such as benzo[a] pyrene (B[ a] P) to toxic free radical intermediates, is poorly understood. In this study, we determined the embryonic expression and teratological relevance of PHS-2 in pregnant CD-1 and B6/129S7 PHS-2 knockout mice. Wild-type (+/+) B6/129S7 dams given B[ a] P on gestational day (GD)10 had three times more fetal malformations than did +/- PHS-2-eficient dams (P<0.05). GD 10-13 CD-1 embryos had high PHS-2 protein expression, and both +/+ and +/- GD 19 B6/129S7 fetuses had more B[a]P-initiated malformations and postpartum lethality than did -/- littermates (P<0.05). Thus, embryonic PHS-2 is expressed constitutively during organogenesis and contributes substantially to B[a] P teratogenicity.	Univ Toronto, Fac Pharm, Toronto, ON M5S 2S2, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 2S2, Canada	University of Toronto; University of Toronto	Wells, PG (corresponding author), Univ Toronto, Fac Pharm, 19 Russell St, Toronto, ON M5S 2S2, Canada.							BOROUJERDI M, 1981, CANCER RES, V41, P951; Brake PB, 1999, ENDOCRINOLOGY, V140, P1672, DOI 10.1210/en.140.4.1672; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dipple A., 1984, ACS MONOGR SER, V182, P41, DOI DOI 10.1074/JBC.M409155200; FRENKEL K, 1989, ENVIRON HEALTH PERSP, V81, P45, DOI 10.2307/3430803; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; IDE ML, 1983, PROTECTIVE AGENTS CA, P125; Johnson JL, 1995, ARCH BIOCHEM BIOPHYS, V324, P26, DOI 10.1006/abbi.1995.9934; JONES KL, 1975, TERATOLOGY, V12, P1, DOI 10.1002/tera.1420120102; Juchau MR, 1998, DRUG METAB REV, V30, P541, DOI 10.3109/03602539808996324; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Kelley DJ, 1997, CARCINOGENESIS, V18, P795, DOI 10.1093/carcin/18.4.795; Kim PM, 1996, CANCER RES, V56, P1526; Kim PM, 1996, MOL PHARMACOL, V49, P172; Langenbach R, 1999, BIOCHEM PHARMACOL, V58, P1237, DOI 10.1016/S0006-2952(99)00158-6; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; MARNETT LJ, 1990, ENVIRON HEALTH PERSP, V88, P5, DOI 10.1289/ehp.90885; MARSHBURN PB, 1990, MOL REPROD DEV, V25, P309, DOI 10.1002/mrd.1080250402; Maslinska D, 1999, FOLIA NEUROPATHOL, V37, P287; McKanna JA, 1998, AM J PHYSIOL-REG I, V275, pR227, DOI 10.1152/ajpregu.1998.275.1.R227; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; NAMKUNG MJ, 1985, J STEROID BIOCHEM, V22, P563, DOI 10.1016/0022-4731(85)90179-7; Nicol CJ, 2000, FASEB J, V14, P111, DOI 10.1096/fasebj.14.1.111; NICOL CJ, 1995, NAT GENET, V11, P104, DOI 10.1038/ng0995-104b; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; OSBORNE MR, 1987, BENZOPYRENES, P198; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Park JM, 1997, AM J PHYSIOL-RENAL, V273, pF538, DOI 10.1152/ajprenal.1997.273.4.F538; Parman T, 1998, J BIOL CHEM, V273, P25079, DOI 10.1074/jbc.273.39.25079; Parman T, 1999, NAT MED, V5, P582, DOI 10.1038/8466; PERCIVAL MD, 1994, ARCH BIOCHEM BIOPHYS, V315, P111, DOI 10.1006/abbi.1994.1478; POTTENGER LH, 1990, CARCINOGENESIS, V11, P321, DOI 10.1093/carcin/11.2.321; SCOLNIK D, 1994, JAMA-J AM MED ASSOC, V271, P1745; SCOLNIK D, 1994, JAMA-J AM MED ASSOC, V271, P767, DOI 10.1001/jama.271.10.767; SHUM S, 1979, TERATOLOGY, V20, P365, DOI 10.1002/tera.1420200307; SMITH WL, 1995, SEMIN NEPHROL, V15, P179; STRICKLER SM, 1985, LANCET, V2, P746; Wells PG, 1996, CRIT REV BIOCHEM MOL, V31, P1, DOI 10.3109/10409239609110574; WELLS PG, 1997, HDB EXPT PHARM, P453; WELLS PG, 1997, COMPREHENSIVE TOXICO, P489; Wiese FW, 2001, CARCINOGENESIS, V22, P5, DOI 10.1093/carcin/22.1.5; Winn LM, 1997, FREE RADICAL BIO MED, V22, P607, DOI 10.1016/S0891-5849(96)00340-1; Winn LM, 1999, FREE RADICAL BIO MED, V26, P266, DOI 10.1016/S0891-5849(98)00193-2; Winn LM, 1995, EUR J NEUROL, V2, P5	47	36	38	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1001	1009		10.1096/fj.01-0140com	http://dx.doi.org/10.1096/fj.01-0140com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087061				2022-12-28	WOS:000177813100031
J	Salven, P; Hattori, K; Heissig, B; Rafii, S				Salven, P; Hattori, K; Heissig, B; Rafii, S			Interleukin-1 alpha (IL-1 alpha) promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion	FASEB JOURNAL			English	Article						inflammation; leukocyte; mononuclear; endothelium	ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; VASCULAR DEVELOPMENT; FACTOR RECEPTOR-1; TYROSINE KINASE; FLT-1; EXPRESSION; ATHEROSCLEROSIS; DISEASE; CANCER	During inflammation, functional changes occur in the vasculature, including extensive endothelial cell mitotic activity and remodeling of capillaries. Interleukin-1alpha (IL-1alpha) is a prototypical proinflammatory cytokine. Vascular endothelial growth factor (VEGF) is a strong endothelial cell-specific mitogen that exerts a pivotal role in angiogenesis under physiological and pathological conditions. We show that IL-1alpha stimulates VEGF secretion by human peripheral blood mononuclear cells (PBMNCs) in a dose-dependent manner. This represents induction of de novo VEGF synthesis, as an induction of VEGF mRNA was observed. Also, the release of VEGF was blocked by cycloheximide. Reverse transcription-polymerase chain reaction (RT-PCR) detected four VEGF splice variants in unstimulated and in IL-1alpha-stimulated PBMNCs. In vivo in mice, subcutaneously administered IL-1alpha caused a strong local angiogenic response, which was accompanied by an infiltrate of VEGF-expressing inflammatory cells. The angiogenic effect of IL-1alpha was blocked when the mice were treated with VEGF receptor 2 (VEGFR-2) neutralizing antibodies. VEGFR-1 blocking antibodies had a marginal inhibitory effect on IL-1alpha-induced angiogenesis. These observations indicate that IL-1alpha induces angiogenesis by activating the VEGF-VEGFR-2 signaling pathway between inflammatory cells and blood vessel endothelial cells. This novel mechanism of IL-1alpha-action may enhance the shift to angiogenic phenotype in various conditions designated by excessive angiogenesis.	Cornell Univ, Weill Med Coll, Div Hematol Oncol, New York, NY 10021 USA	Cornell University	Salven, P (corresponding author), Cornell Univ, Weill Med Coll, Div Hematol Oncol, 1300 York Ave,Room C-606, New York, NY 10021 USA.	pjs2004@med.cornell.edu	Heissig, Beate/AAF-6771-2021	Heissig, Beate/0000-0002-0348-5934				Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; BENEZRA D, 1990, ARCH OPHTHALMOL-CHIC, V108, P573, DOI 10.1001/archopht.1990.01070060121061; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; Brown LF, 1997, LAB INVEST, V76, P245; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Couper LL, 1997, CIRC RES, V81, P932; Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FREEMAN MR, 1995, CANCER RES, V55, P4140; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hiratsuka S, 2001, CANCER RES, V61, P1207; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Lu D, 2000, J BIOL CHEM, V275, P14321, DOI 10.1074/jbc.275.19.14321; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; MAHADEVAN V, 1989, CANCER RES, V49, P415; MCKANE WR, 1994, J BONE MINER RES, V9, P1313; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; NICOSIA RF, 1994, AM J PATHOL, V145, P1023; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Salven P, 2001, FASEB J, V15, P1318, DOI 10.1096/fj.00-0627fje; Siemeister G, 1996, BIOCHEM BIOPH RES CO, V222, P249, DOI 10.1006/bbrc.1996.0730; Sullivan GW, 2000, J LEUKOCYTE BIOL, V67, P591, DOI 10.1002/jlb.67.5.591; Suzuma K, 2000, J BIOL CHEM, V275, P40725, DOI 10.1074/jbc.M006509200; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832	39	112	117	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1471	+		10.1096/fj.02-0134fje	http://dx.doi.org/10.1096/fj.02-0134fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205052				2022-12-28	WOS:000177813100002
J	Schwerin, M; Dorroch, U; Beyer, M; Swalve, H; Metges, CC; Junghans, P				Schwerin, M; Dorroch, U; Beyer, M; Swalve, H; Metges, CC; Junghans, P			Dietary protein modifies hepatic gene expression associated with oxidative stress responsiveness in growing pigs	FASEB JOURNAL			English	Article						protein diets; soy protein	HIGH-DENSITY-LIPOPROTEINS; MESSENGER-RNA; SOY PROTEIN; DIFFERENTIAL DISPLAY; METHIONINE RESIDUES; SIGNALING PATHWAYS; APOLIPOPROTEINS AI; CASEIN PROTEIN; BREAST-CANCER; AMINO-ACIDS	Understanding the basis for differences in nutrient requirements and for nutrient effects on health and performance requires an appreciation of the links between nutrition and gene expression. We developed and applied molecular probes to characterize diet-associated postabsorptive hepatic gene expression in growing pigs chronically fed protein-restricted diets based on either casein (CAS) or soy protein isolate (SPI). Eighty-eight expressed sequence tags (ESTs) were identified on the basis of diet-related changes in expression, by using an mRNA differential display method. Expression profiling based on transcription analysis by real-time reverse transcriptase-polymerase chain reaction showed that the SPI diet significantly changed the pattern of gene expression as compared with the CAS diet and allowed identification of coregulated genes. The expression of six genes involved in the metabolism of stress response (glutathione S-transferase, peptide methionine sulfoxide reductase, apolipoprotein A-I, organic anion transport polypeptide 2, calnexin, heat shock transcription factor 1) exhibited significant changes in the transcription level and indicated an increased oxidative stress response in pigs fed the SPI diet. Hierarchical clustering of gene expression data of all 33 ESTs analyzed across 14 pigs fed the two different diets resulted in clustering of genes related to the oxidative stress response with genes related to the regulation of gene expression and neuronal signaling.	Res Inst Biol Farm Anim, Res Unit Mol Biol, D-18196 Dummerstorf, Germany; Res Inst Biol Farm Anim, Res Unit Nutr Physiol Oskar Kellner, D-18196 Dummerstorf, Germany; Res Inst Biol Farm Anim, Res Unit Genet & Biometr, D-18196 Dummerstorf, Germany	Forschungsinstitut fur Nutztierbiologie (FBN); Forschungsinstitut fur Nutztierbiologie (FBN); Forschungsinstitut fur Nutztierbiologie (FBN)	Schwerin, M (corresponding author), Res Inst Biol Farm Anim, Res Unit Mol Biol, Wilhelm Stahl Alee 2, D-18196 Dummerstorf, Germany.	schwerin@fbn-dummerstorf.de	Swalve, Hermann/ABB-4625-2020	Swalve, Hermann/0000-0002-8398-3115; Junghans, Peter/0000-0002-4061-2517				AIELLO LP, 1994, P NATL ACAD SCI USA, V91, P6231, DOI 10.1073/pnas.91.13.6231; Allred CD, 2001, CARCINOGENESIS, V22, P1667, DOI 10.1093/carcin/22.10.1667; Anthony JC, 2001, J NUTR, V131, p856S, DOI 10.1093/jn/131.3.856S; Appelt LC, 1997, NUTR CANCER, V28, P270, DOI 10.1080/01635589709514587; Aubel C, 2001, CELL SIGNAL, V13, P417, DOI 10.1016/S0898-6568(01)00159-0; Backlund M, 1997, J BIOL CHEM, V272, P31755, DOI 10.1074/jbc.272.50.31755; Desai M, 1997, AM J PHYSIOL-GASTR L, V273, pG899, DOI 10.1152/ajpgi.1997.273.4.G899; Deutz NEP, 1998, J NUTR, V128, P2435, DOI 10.1093/jn/128.12.2435; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Gardner CD, 2001, AM J CLIN NUTR, V73, P728; Garner B, 1998, J BIOL CHEM, V273, P6080, DOI 10.1074/jbc.273.11.6080; Garner B, 1998, J BIOL CHEM, V273, P6088, DOI 10.1074/jbc.273.11.6088; Greaves KA, 2000, J NUTR, V130, P820, DOI 10.1093/jn/130.4.820; Harman H. H., 1976, MODERN FACTOR ANAL; Hesketh JE, 1998, BRIT J NUTR, V80, P307, DOI 10.1079/096582198388265; Hsiang BN, 1999, J BIOL CHEM, V274, P37161, DOI 10.1074/jbc.274.52.37161; Iritani N, 1996, J NUTR, V126, P380, DOI 10.1093/jn/126.2.380; Jousse C, 2000, J NUTR, V130, P1555, DOI 10.1093/jn/130.6.1555; JOUSSE C, 1998, BIOCHEM J, V15, P147; Khan N, 2001, PHARMACOL TOXICOL, V88, P294, DOI 10.1034/j.1600-0773.2001.d01-120.x; Koletzko B, 1998, BRIT J NUTR, V80, pS5, DOI 10.1079/BJN19980104; Lamartiniere CA, 2000, AM J CLIN NUTR, V71, p1705S, DOI 10.1093/ajcn/71.6.1705S; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; Levine RL, 2000, IUBMB LIFE, V50, P301, DOI 10.1080/15216540051081056; LI FS, 1994, NUCLEIC ACIDS RES, V22, P1764, DOI 10.1093/nar/22.9.1764; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Lohrke B, 2001, BRIT J NUTR, V85, P447, DOI 10.1079/BJN2000291; Lovati MR, 2000, J NUTR, V130, P2543, DOI 10.1093/jn/130.10.2543; Lu SC, 2001, P NATL ACAD SCI USA, V98, P5560, DOI 10.1073/pnas.091016398; Lyons J, 2000, P NATL ACAD SCI USA, V97, P5071, DOI 10.1073/pnas.090083297; MESSINA M, 1991, JNCI-J NATL CANCER I, V83, P541, DOI 10.1093/jnci/83.8.541; Metges CC, 2000, AM J PHYSIOL-ENDOC M, V278, pE868, DOI 10.1152/ajpendo.2000.278.5.E868; Morita T, 1997, J NUTR, V127, P470, DOI 10.1093/jn/127.3.470; MOUNDRAS C, 1995, METABOLISM, V44, P1146, DOI 10.1016/0026-0495(95)90007-1; NISHIO Y, 1994, FASEB J, V8, P103, DOI 10.1096/fasebj.8.1.8299882; Panzenbock U, 2000, J BIOL CHEM, V275, P19536, DOI 10.1074/jbc.M000458200; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Saggau E, 2000, J ANIM PHYSIOL AN N, V84, P29, DOI 10.1046/j.1439-0396.2000.00278.x; SAS Institute, 1999, SAS STAT US GUID VER; SCHMITZ M, 1991, J NUTR, V121, P1575, DOI 10.1093/jn/121.10.1575; Schwerin M, 1999, J ANIM PHYSIOL AN N, V81, P113, DOI 10.1046/j.1439-0396.1999.813177.x; Seneviratne CK, 1999, AM J PHYSIOL-HEART C, V277, pH2124, DOI 10.1152/ajpheart.1999.277.6.H2124; Taniguchi M, 2000, BRIT J NUTR, V84, P211; Tovar-Palacio C, 1998, J NUTR, V128, P839, DOI 10.1093/jn/128.5.839; Varadarajan S, 2001, J AM CHEM SOC, V123, P5625, DOI 10.1021/ja010452r; Vasquez OL, 2001, J NEUROCHEM, V76, P1593, DOI 10.1046/j.1471-4159.2001.00223.x; Wang ST, 1997, J NUTR, V127, P2135, DOI 10.1093/jn/127.11.2135	48	27	27	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1322	+		10.1096/fj.01-0734fje	http://dx.doi.org/10.1096/fj.01-0734fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154008				2022-12-28	WOS:000176683900019
J	Tinhofer, I; Anether, G; Senfter, M; Pfaller, K; Bernhard, D; Hara, M; Greil, R				Tinhofer, I; Anether, G; Senfter, M; Pfaller, K; Bernhard, D; Hara, M; Greil, R			Stressful death of T-ALL tumor cells following treatment with the antitumor agent Tetrocarcin-A	FASEB JOURNAL			English	Article						ER-stress; heat shock protein; apoptosis	DRUG-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; CHRONIC LYMPHOCYTIC-LEUKEMIA; BCL-2 GENE-EXPRESSION; HEAT-SHOCK PROTEINS; ENDOPLASMIC-RETICULUM; CHILDHOOD NEUROBLASTOMAS; CASPASE ACTIVATION; OCCURS DOWNSTREAM; CANCER-CELLS	The T-ALL cell lines CCRF-CEM and Jurkat were studied for their sensitivity toward apoptosis induced by tetrocarcin-A (TC-A), an antibacterial and antitumor agent isolated from the actinomycete Micromonospora. This substance promoted cell death via a mitochondrial signaling pathway, that is, by activation of Bid and Bax, loss of the mitochondrial transmembrane potential, release of cytochrome c, and activation of effector caspases, even under conditions of Bcl-2 overexpression. Furthermore, sensitivity to TC-A was not dependent on expression of wild-type caspase-8. In contrast, this apoptotic pathway was inhibited markedly by pretreatment of cells with cycloheximide, an inhibitor of de novo protein synthesis. cDNA microarray chip analysis revealed that TC-A induced a significant up-regulation of members of the heat shock protein family known to be involved in the endoplasmic reticulum (ER)-stress-induced apoptotic program. The activation of caspase-12, the central inducer caspase involved in ER-stress by TC-A treatment, is in concordance with this result. These results show that, in TALL cells, TC-A induces an apoptotic machinery via mitochondrial and ER signaling, which is not inhibited by aberrant expression/function of important regulators of death receptor- and drug-induced apoptosis.	Univ Innsbruck, Dept Hematol & Oncol, Lab Mol Cytol, A-6020 Innsbruck, Austria; Univ Innsbruck, Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Anat & Histol, A-6020 Innsbruck, Austria; Kyowa Hakko Kogyo Co Ltd, Pharmaceut Res Inst, Nagaizumi, Shizuoka 411, Japan	University of Innsbruck; University of Innsbruck; University of Innsbruck; Kyowa Kirin Ltd	Tinhofer, I (corresponding author), Univ Innsbruck, Dept Hematol & Oncol, Lab Mol Cytol, A-6020 Innsbruck, Austria.	Inge.Tinhofer@uibk.ac.at	Greil, Richard F/C-7673-2017	Greil, Richard F/0000-0002-4462-3694; Tinhofer, Ingeborg/0000-0002-0512-549X; Bernhard, David/0000-0002-2383-6607				Basu S, 2000, CELL STRESS CHAPERON, V5, P443, DOI 10.1379/1466-1268(2000)005<0443:HSPTFO>2.0.CO;2; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cotter Finbarr E., 1999, Seminars in Hematology, V36, P9; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Ferreira CG, 2000, CLIN CANCER RES, V6, P203; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Gao G, 2000, J CELL BIOCHEM, V80, P53; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hartmann BL, 1999, ONCOGENE, V18, P713, DOI 10.1038/sj.onc.1202339; Houghton Janet A., 1999, Current Opinion in Oncology, V11, P475, DOI 10.1097/00001622-199911000-00008; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KITADA S, 1994, ANTISENSE RES DEV, V4, P71, DOI 10.1089/ard.1994.4.71; Klasa RJ, 2000, CLIN CANCER RES, V6, P2492; Konopleva M, 2000, BLOOD, V95, P3929; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Leung S, 2001, INT J CANCER, V91, P846, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1131>3.0.CO;2-Y; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Makin G, 2000, CELL TISSUE RES, V301, P143, DOI 10.1007/s004419900160; Mano Y, 1999, EUR J CANCER, V35, P1214, DOI 10.1016/S0959-8049(99)00124-0; Marschitz I, 2000, AM J CLIN PATHOL, V113, P219, DOI 10.1309/491W-L1TN-UFQX-T61B; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORIMOTO M, 1982, J ANTIBIOT, V35, P1033, DOI 10.7164/antibiotics.35.1033; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakashima T, 2000, CANCER RES, V60, P1229; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nylandsted J, 2000, ANN NY ACAD SCI, V926, P122; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Pepper C, 1999, LEUKEMIA RES, V23, P1007, DOI 10.1016/S0145-2126(99)00122-8; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; REED JC, 1989, ONCOGENE RES, V4, P271; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Teitz T, 2001, J MOL MED, V79, P428, DOI 10.1007/s001090100233; Thomas A, 1996, ONCOGENE, V12, P1055; Tomiuk S, 2001, Brief Bioinform, V2, P329, DOI 10.1093/bib/2.4.329; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Villunger A, 1997, CANCER RES, V57, P3331; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Wu GS, 1996, CLIN CANCER RES, V2, P623; Zangemeister-Wittke U, 1998, BRIT J CANCER, V78, P1035, DOI 10.1038/bjc.1998.624	57	44	44	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1295	+		10.1096/fj.02-0020fje	http://dx.doi.org/10.1096/fj.02-0020fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12060673				2022-12-28	WOS:000176683900035
J	Ejima, K; Layne, MD; Carvajal, IM; Kritek, PA; Baron, RM; Chen, YH; vom Saal, J; Levy, BD; Yet, SF; Perrella, MA				Ejima, K; Layne, MD; Carvajal, IM; Kritek, PA; Baron, RM; Chen, YH; vom Saal, J; Levy, BD; Yet, SF; Perrella, MA			Cyclooxygenase-2 deficient mice are resistant to endotoxin-induced inflammation and death	FASEB JOURNAL			English	Article						sepsis; nitric oxide synthase-2; heme oxygenase-1; NF-kappa B; AP-1	NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE-CELLS; HEME OXYGENASE-1; INDUCED MORTALITY; PROTECTS MICE; INTERLEUKIN-10; SEPSIS; INDUCTION	Sepsis is a systemic inflammatory response to a blood-borne infection that is associated with an extremely high rate of morbidity and mortality. The present study investigates the role of cyclooxygenase (COX)-2 in host responses to bacterial endotoxemia. After administration of Escherichia coli lipopolysaccharide, 50% of wild-type mice die within 96 h. COX-2 deficient mice displayed a dramatic improvement in survival with reduced leukocyte infiltration into critical organs (kidneys and lungs) and a blunted and delayed induction of the cytokine inducible genes nitric oxide synthase 2 and heme oxygenase-1. Translocation and activation of transcription factors important for signaling events during an inflammatory response, such as nuclear factor (NF)-kappaB, were also markedly reduced. While the absence of COX-2 did not alter the induction of several pro-inflammatory cytokines in tissue macrophages, induction of the anti-inflammatory cytokine IL-10 was exaggerated. Administration of IL-10 to wild-type mice reduced NF-kappaB activation. Taken together, our data suggest that COX-2 deficient mice are resistant to many of the detrimental consequences of endotoxemia. These beneficial effects occur, in part, by a compensatory increase in IL-10 that counterbalances the pro-inflammatory host response to endotoxemia.	Brigham & Womens Hosp, Dept Internal Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Kaohsiung Med Univ, Dept Internal Med, Div Infect Dis, Kaohsiung, Taiwan	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Kaohsiung Medical University	Perrella, MA (corresponding author), Brigham & Womens Hosp, Dept Internal Med, 75 Francis St, Boston, MA 02115 USA.	mperrella@rics.bwh.harvard.edu	Yet, Shaw-Fang/B-1067-2010	Chen, Yen-hsu/0000-0002-8667-4844; Yet, Shaw-Fang/0000-0001-9097-3962; Layne, Matthew/0000-0003-0007-4870				Alcaraz MJ, 2001, BBA-GEN SUBJECTS, V1526, P13, DOI 10.1016/S0304-4165(01)00112-X; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; Bone RC, 1997, CHEST, V112, P235, DOI 10.1378/chest.112.1.235; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FINK MP, 1989, J APPL PHYSIOL, V67, P1950, DOI 10.1152/jappl.1989.67.5.1950; Fink MP, 2001, AM J PHYSIOL-LUNG C, V281, pL534, DOI 10.1152/ajplung.2001.281.3.L534; FLETCHER JR, 1993, ANN SURG, V217, P668, DOI 10.1097/00000658-199306000-00008; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GERARD C, 1993, J EXP MED, V177, P547, DOI 10.1084/jem.177.2.547; Hamilton LC, 1998, BRIT J PHARMACOL, V125, P335, DOI 10.1038/sj.bjp.0702077; HOWARD M, 1993, J EXP MED, V177, P1205, DOI 10.1084/jem.177.4.1205; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Langenbach R, 1999, ANN NY ACAD SCI, V889, P52, DOI 10.1111/j.1749-6632.1999.tb08723.x; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MONCADA S, 1992, J LAB CLIN MED, V120, P187; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; NORTHOVER BJ, 1962, J PATHOL BACTERIOL, V83, P463, DOI 10.1002/path.1700830217; Parrillo J E, 1993, N Engl J Med, V328, P1471; Pellacani A, 1998, CIRC RES, V83, P396, DOI 10.1161/01.RES.83.4.396; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; Perrella MA, 1996, P NATL ACAD SCI USA, V93, P2054, DOI 10.1073/pnas.93.5.2054; Perrow C., 1994, TECHNOLOGY STUDIES, V1, P1; Pinsky MR, 2001, CONTRIB NEPHROL, V132, P354; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; Reddy RC, 2001, AM J PHYSIOL-LUNG C, V281, pL537, DOI 10.1152/ajplung.2001.281.3.L537; Santucci L, 1996, GASTROENTEROLOGY, V111, P736, DOI 10.1053/gast.1996.v111.pm8780580; SCHREIBER BM, 1988, ATHEROSCLEROSIS, V69, P69, DOI 10.1016/0021-9150(88)90290-0; Song GY, 1999, SURGERY, V126, P378, DOI 10.1016/S0039-6060(99)70180-7; STONE R, 1994, SCIENCE, V264, P365, DOI 10.1126/science.8153620; Tabary O, 2003, AM J PATHOL, V162, P293, DOI 10.1016/S0002-9440(10)63820-5; VANDERPOLL T, 1995, J IMMUNOL, V155, P5397; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; Wiesel P, 2000, CIRCULATION, V102, P3015, DOI 10.1161/01.cir.102.24.3015; Wiesel P, 2000, J BIOL CHEM, V275, P24840, DOI 10.1074/jbc.M000835200; Yamano S, 2001, J GENE MED, V3, P450, DOI 10.1002/jgm.213; Yet SF, 2002, METHOD ENZYMOL, V353, P163; Yet SF, 2001, CIRC RES, V89, P168, DOI 10.1161/hh1401.093314; Yet SF, 1997, J BIOL CHEM, V272, P4295, DOI 10.1074/jbc.272.7.4295	47	102	104	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1325	+		10.1096/fj.02-1078fje	http://dx.doi.org/10.1096/fj.02-1078fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738799				2022-12-28	WOS:000183165000038
J	Meilhac, O; Ho-Tin-Noe, B; Houard, X; Philippe, M; Michel, JB; Angles-Cano, E				Meilhac, O; Ho-Tin-Noe, B; Houard, X; Philippe, M; Michel, JB; Angles-Cano, E			Pericellular plasmin induces smooth muscle cell anoikis	FASEB JOURNAL			English	Article						plasminogen activators; extracellular matrix; metalloproteinases; fibronectin	ACTIVATOR INHIBITOR TYPE-1; VARICOSE-VEINS; UROKINASE; BINDING; DEGRADATION; MECHANISM; APOPTOSIS; FIBRIN; FIBRONECTIN; CLEAVAGE	Smooth muscle cell (SMC) rarefaction is involved in the development of several vascular pathologies. We suggest that the plasminogen activation system is a potential extracellular signal that can induce pericellular proteolysis and apoptosis of vascular SMCs. Using primary cultures of arterial SMCs, we show that plasmin generated from plasminogen on the cell surface induces cell retraction and fibronectin fragmentation, leading to detachment and morphological/biochemical changes characteristic of apoptosis (also called anoikis). The generation of cell-bound plasmin mediated by tissue-type plasminogen activator (t-PA), constitutively expressed by VSMCs, requires binding of plasminogen to the cell surface and is inhibited by epsilon-aminocaproic acid (IC50=0.9+/-0.2 mM), a competitor of plasminogen binding to membrane glycoproteins. Conversely, addition of alpha(2)-antiplasmin, which blocks free plasmin in the cell supernatant, could not fully prevent anoikis. Finally, an MMP inhibitor failed to prevent VSMC anoikis, arguing for a direct involvement of plasmin in this phenomenon. Indeed, similar changes are induced by plasmin directly added to VSMCs or to arterial rings, ex-vivo. We show for the first time that pathological anoikis can be triggered by a process that requires functional assembly of the plasminogen activation system on the surface of VSMCs.	CHU Bichat Claude Bernard, INSERM, U460, F-75877 Paris 18, France; Coll France, INSERM, U36, F-75231 Paris 05, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Meilhac, O (corresponding author), CHU Bichat Claude Bernard, INSERM, U460, Bat 13,46 Rue Henri Huchard, F-75877 Paris 18, France.	u460@bichat.inserm.fr	Ho-Tin-Noé, Benoit/U-8059-2018; Michel, Jean-Baptiste/AAH-9336-2020; Meilhac, Olivier/N-4385-2017; ANGLES-CANO, Eduardo/ABA-1739-2020; ANGLES-CANO, Eduardo/G-2311-2012	Ho-Tin-Noé, Benoit/0000-0002-7428-1760; ANGLES-CANO, Eduardo/0000-0001-7891-3975; ANGLES-CANO, Eduardo/0000-0001-7891-3975; Meilhac, Olivier/0000-0002-3740-7539				ANGLESCANO E, 1987, THROMB HAEMOSTASIS, V58, P843; ANGLESCANO E, 1992, BIOCHIM BIOPHYS ACTA, V1156, P34, DOI 10.1016/0304-4165(92)90092-9; ANGLESCANO E, 1994, CHEM PHYS LIPIDS, V67-8, P353, DOI 10.1016/0009-3084(94)90157-0; ANIDJAR S, 1990, CIRCULATION, V82, P973, DOI 10.1161/01.CIR.82.3.973; Badier-Commander C, 2000, J PATHOL, V192, P105, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH670>3.0.CO;2-1; Badier-Commander C, 2001, J PATHOL, V193, P398, DOI 10.1002/path.819; BARICOS WH, 1995, KIDNEY INT, V47, P1039, DOI 10.1038/ki.1995.150; BATTLE T, 1994, TISSUE CELL, V26, P943, DOI 10.1016/0040-8166(94)90043-4; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; CHAIN D, 1991, FEBS LETT, V285, P251, DOI 10.1016/0014-5793(91)80810-P; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; Davis GE, 2001, J CELL SCI, V114, P917; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Di Matola T, 2000, J CLIN ENDOCR METAB, V85, P1188, DOI 10.1210/jc.85.3.1188; EHRLICH MI, 1981, J LAB CLIN MED, V98, P263; Ellis V, 1997, BLOOD, V90, P2312, DOI 10.1182/blood.V90.6.2312.2312_2312_2322; FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035; FLEURY V, 1993, J BIOL CHEM, V268, P18554; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; GAUSSEM P, 1993, J BIOL CHEM, V268, P12150; Gonzalez W, 2000, HYPERTENSION, V36, P103, DOI 10.1161/01.HYP.36.1.103; HERRON GS, 1991, ARTERIOSCLER THROMB, V11, P1667, DOI 10.1161/01.ATV.11.6.1667; HOLDERBAUM D, 1986, J CELL PHYSIOL, V126, P216, DOI 10.1002/jcp.1041260210; Ikari Y, 2001, J BIOL CHEM, V276, P11798, DOI 10.1074/jbc.M008503200; Isik FF, 1998, J CELL PHYSIOL, V175, P149, DOI 10.1002/(SICI)1097-4652(199805)175:2<149::AID-JCP4>3.0.CO;2-O; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kapila YL, 1999, J BIOL CHEM, V274, P30906, DOI 10.1074/jbc.274.43.30906; Kockx MM, 2000, J PATHOL, V190, P267, DOI 10.1002/(SICI)1096-9896(200002)190:3<267::AID-PATH523>3.0.CO;2-A; Lau HKF, 1999, CARDIOVASC RES, V43, P1049, DOI 10.1016/S0008-6363(99)00136-4; Lijnen HR, 2001, FRONT BIOSCI, V6, pD239, DOI 10.2741/Lijnen; LIOTTA LA, 1981, THROMB RES, V21, P663, DOI 10.1016/0049-3848(81)90268-1; LopezCandales A, 1997, AM J PATHOL, V150, P993; LUPU F, 1995, ARTERIOSCL THROM VAS, V15, P1444, DOI 10.1161/01.ATV.15.9.1444; Luttun A, 2002, ARTERIOSCL THROM VAS, V22, P499, DOI 10.1161/hq0302.104529; Madden HL, 2000, AM J RESP CRIT CARE, V162, P1553, DOI 10.1164/ajrccm.162.4.2001015; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Michel JB, 2001, ARTERIOSCL THROM VAS, V21, P1389; Montes R, 1996, BRIT J HAEMATOL, V92, P979, DOI 10.1046/j.1365-2141.1996.416951.x; Nayeem N, 1999, J CELL SCI, V112, P4739; Ryniers F, 2002, BIOL CHEM, V383, P159, DOI 10.1515/BC.2002.016; Salame MY, 2000, ATHEROSCLEROSIS, V152, P19, DOI 10.1016/S0021-9150(99)00441-4; Shireman PK, 1996, J VASC SURG, V24, P719, DOI 10.1016/S0741-5214(96)70003-4; Sinniger V, 1999, J BIOL CHEM, V274, P12414, DOI 10.1074/jbc.274.18.12414; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; Takeda K, 2001, ARTERIOSCL THROM VAS, V21, P868, DOI 10.1161/01.ATV.21.5.868; Ugwu F, 2001, THROMB RES, V102, P61, DOI 10.1016/S0049-3848(01)00218-3; VANLEEUWEN RTJ, 1994, CIRCULATION, V90, P362, DOI 10.1161/01.CIR.90.1.362; Walsh K, 2000, CIRC RES, V87, P184, DOI 10.1161/01.RES.87.3.184; WEISS RE, 1981, BIOCHEM J, V197, P529, DOI 10.1042/bj1970529; WIMAN B, 1973, EUR J BIOCHEM, V36, P25, DOI 10.1111/j.1432-1033.1973.tb02880.x	53	84	88	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1301	+		10.1096/fj.02-0687fje	http://dx.doi.org/10.1096/fj.02-0687fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738809				2022-12-28	WOS:000183165000035
J	Gauss, KA; Bunger, PL; Young, CJ; Siemsen, DW; Larson, T; Quinn, MT				Gauss, KA; Bunger, PL; Young, CJ; Siemsen, DW; Larson, T; Quinn, MT			Identification of a TNF alpha-responsive element within the p67(phax) promoter	FASEB JOURNAL			English	Meeting Abstract	90th Annual Meeting of the American-Association-for-Immunologists	MAY 06-10, 2003	DENVER, COLORADO	American Assoc Immunologists					Montana State Univ, Marsh Lab, Bozeman, MT 59717 USA	Montana State University System; Montana State University Bozeman			Bunger, Lutz/A-8751-2014; Bunger, Lutz/T-5647-2019	Bunger, Lutz/0000-0003-4457-8288; Bunger, Lutz/0000-0003-4457-8288					0	17	18	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR 14	2003	17	7		S			C97	C97						1	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	669TR	12424222				2022-12-28	WOS:000182367000451
J	Gotte, M				Gotte, M			Syndecans in inflammation	FASEB JOURNAL			English	Review						cell surface heparan sulfate; leukocyte endothelial interaction; growth factor; chemokine; cytokine	HEPARAN-SULFATE PROTEOGLYCANS; FIBROBLAST-GROWTH-FACTOR; HUMAN NEUTROPHIL MIGRATION; INTEGRIN MAC-1 CD11B/CD18; NECROSIS-FACTOR-ALPHA; ENDOTHELIAL-CELLS; EXTRACELLULAR-MATRIX; LEUKOCYTE ADHESION; P-SELECTIN; IN-VITRO	Cell surface heparan sulfate (HS) influences a multitude of molecules, cell types, and processes relevant to inflammation. HS binds to cell surface and matrix proteins, cytokines, and chemokines. These interactions modulate inflammatory cell maturation and activation, leukocyte rolling, and tight adhesion to endothelium, as well as extravasation and chemotaxis. The syndecan family of transmembrane proteoglycans is the major source of cell surface HS on all cell types. Recent in vitro and in vivo data suggest the involvement of syndecans in the modulation of leukocyte-endothelial interactions and extravasation, the formation of chemokine and kininogen gradients, participation in chemokine and growth factor signaling, as well as repair processes. Thus, the complex role of HS in inflammation is reflected by multiple functions of its physiological carriers, the syndecans. Individual and common functions of the four mammalian syndecan family members can be distinguished. Recently generated transgenic and knockout mouse models will facilitate analysis of the individual processes that each syndecan is involved in.	Protogeneia Inc, Protogenia Res Labs, D-48149 Munster, Germany		Gotte, M (corresponding author), Protogeneia Inc, Protogenia Res Labs, Mendelstr 11, D-48149 Munster, Germany.	protogenia@technologiehof-ms.de	Gotte, M/Z-5878-2019; Götte, Martin/G-2254-2018	Gotte, M/0000-0003-2360-2496; Götte, Martin/0000-0003-2360-2496	NCI NIH HHS [R01-CA-28735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Ali S, 2001, BIOCHEM J, V358, P737, DOI 10.1042/0264-6021:3580737; Alon R, 2002, SEMIN IMMUNOL, V14, P93, DOI 10.1006/smim.2001.0346; AlvarezSilva M, 1996, J LEUKOCYTE BIOL, V59, P435, DOI 10.1002/jlb.59.3.435; Andre P, 2000, BLOOD, V96, P3322, DOI 10.1182/blood.V96.10.3322.h8003322_3322_3328; Baciu PC, 2000, J CELL SCI, V113, P315; Bame KJ, 2001, GLYCOBIOLOGY, V11, p91R, DOI 10.1093/glycob/11.6.91R; BARTLETT MR, 1995, J LEUKOCYTE BIOL, V57, P207, DOI 10.1002/jlb.57.2.207; Bayer-Garner IB, 2001, MODERN PATHOL, V14, P877, DOI 10.1038/modpathol.3880405; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BESNER G, 1990, CELL REGUL, V1, P811, DOI 10.1091/mbc.1.11.811; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Borghesi LA, 1999, BLOOD, V93, P140, DOI 10.1182/blood.V93.1.140.401k40_140_148; Borgquist JD, 2002, J LEUKOCYTE BIOL, V71, P764; Borset M, 2000, BLOOD, V96, P2528; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CALROS TM, 1994, BLOOD, V84, P2068; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; Chowers Y, 2001, GASTROENTEROLOGY, V120, P449, DOI 10.1053/gast.2001.21202; Cinamon G, 2001, NAT IMMUNOL, V2, P515, DOI 10.1038/88710; CINAMON G, 2002, DIRECTIONS SCI, V1, P65; Clark R. A. F, 1996, MOL CELLULAR BIOL WO; Clasper S, 1999, J BIOL CHEM, V274, P24113, DOI 10.1074/jbc.274.34.24113; Clemetson KJ, 2000, BLOOD, V96, P4046; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Colgan Sean P, 2002, ScientificWorldJournal, V2, P76; Conrad H. E., 1998, HEPARIN BINDING PROT; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; COOMBE DR, 1994, BLOOD, V84, P739; Dawson TC, 2000, BLOOD, V96, P1681, DOI 10.1182/blood.V96.5.1681.h8001681a_1681_1684; Day R, 1999, LANCET, V354, P62, DOI 10.1016/S0140-6736(98)09267-8; Day R, 1999, DIGEST DIS SCI, V44, P2508, DOI 10.1023/A:1026647308089; DECAT B, 2000, BIOCHIM BIOPHYS ACTA, V1488, P59; DELLO SP, 2002, BIOL CHEM, V383, P69; Dempsey LA, 2000, GLYCOBIOLOGY, V10, P467, DOI 10.1093/glycob/10.5.467; Denis CV, 2001, P NATL ACAD SCI USA, V98, P4072, DOI 10.1073/pnas.061307098; Derksen PWB, 2002, BLOOD, V99, P1405, DOI 10.1182/blood.V99.4.1405; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; Douglas MS, 1997, CLIN EXP IMMUNOL, V107, P578, DOI 10.1046/j.1365-2249.1997.3141206.x; Dunzendorfer S, 2001, BLOOD, V97, P1079, DOI 10.1182/blood.V97.4.1079; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Ethell IM, 2000, J CELL BIOL, V151, P53, DOI 10.1083/jcb.151.1.53; Etzioni A, 1999, BLOOD, V94, P3281, DOI 10.1182/blood.V94.10.3281.422k37_3281_3288; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; FRENETTE PS, 1995, P NATL ACAD SCI USA, V92, P7450, DOI 10.1073/pnas.92.16.7450; Fuki IV, 2000, BIOCHEM J, V351, P607, DOI 10.1042/0264-6021:3510607; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; Furuta GT, 2000, J LEUKOCYTE BIOL, V68, P251; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; Gambero A, 2002, BIOCHEM PHARMACOL, V63, P65, DOI 10.1016/S0006-2952(01)00841-3; Gao YH, 2000, J CELL PHYSIOL, V184, P373, DOI 10.1002/1097-4652(200009)184:3<373::AID-JCP12>3.0.CO;2-I; Gautam N, 2001, NAT MED, V7, P1123, DOI 10.1038/nm1001-1123; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Ghosh S, 2001, INVEST OPHTH VIS SCI, V42, pS888; Giuffre L, 1997, J CELL BIOL, V136, P945, DOI 10.1083/jcb.136.4.945; Godiska R, 1997, J LEUKOCYTE BIOL, V61, P353, DOI 10.1002/jlb.61.3.353; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; GOLDSHMIDT G, 2002, DIRECTIONS SCI, V1, P73; Gotte M, 2002, INVEST OPHTH VIS SCI, V43, P1135; GOTTE M, 1995, EUR J CELL BIOL, V66, P226; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Gupta P, 2000, BLOOD, V95, P147; Hadley TJ, 1997, BLOOD, V89, P3077, DOI 10.1182/blood.V89.9.3077; HAUSSER H, 1994, FEBS LETT, V353, P243, DOI 10.1016/0014-5793(94)01044-7; Heinzelmann M, 1999, J IMMUNOL, V162, P4240; Herren B, 2002, NEWS PHYSIOL SCI, V17, P73, DOI 10.1152/nips.01373.2001; Hoffmann JN, 2000, AM J PHYSIOL-CELL PH, V279, pC98, DOI 10.1152/ajpcell.2000.279.1.C98; Holen I, 2001, BRIT J HAEMATOL, V114, P414, DOI 10.1046/j.1365-2141.2001.02963.x; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Horowitz A, 2002, J CELL BIOL, V157, P715, DOI 10.1083/jcb.200112145; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Ihrcke NS, 1996, J CELL PHYSIOL, V168, P625, DOI 10.1002/(SICI)1097-4652(199609)168:3<625::AID-JCP15>3.3.CO;2-A; IHRCKE NS, 1993, IMMUNOL TODAY, V14, P500, DOI 10.1016/0167-5699(93)90265-M; Ihrcke NS, 1998, J CELL PHYSIOL, V175, P255, DOI 10.1002/(SICI)1097-4652(199806)175:3<255::AID-JCP3>3.0.CO;2-N; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; Ishiguro K, 2000, DEV DYNAM, V219, P539, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1081>3.0.CO;2-K; Ishiguro K, 2000, J BIOL CHEM, V275, P5249, DOI 10.1074/jbc.275.8.5249; Ishiguro K, 2001, J BIOL CHEM, V276, P47483, DOI 10.1074/jbc.M106268200; Jaakkola P, 2000, PROG NUCLEIC ACID RE, V63, P109; Jacobs W, 1998, CELL TISSUE RES, V292, P101, DOI 10.1007/s004410051039; Johnson Aaron N., 2002, TheScientificWorldJOURNAL, V2, P892; Johnson P, 2000, BIOCHEM PHARMACOL, V59, P455, DOI 10.1016/S0006-2952(99)00266-X; Johnston B, 2002, SEMIN IMMUNOL, V14, P83, DOI 10.1006/smim.2001.0345; Jouan V, 1999, BLOOD, V94, P984, DOI 10.1182/blood.V94.3.984.415k31_984_993; Kainulainen V, 1996, J BIOL CHEM, V271, P18759, DOI 10.1074/jbc.271.31.18759; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; KAINULAINEN V, 1998, ANN U TURKUENSIS; Kaneider NC, 2002, J CELL SCI, V115, P227; Kaneider NC, 2001, BIOCHEM BIOPH RES CO, V287, P42, DOI 10.1006/bbrc.2001.5534; Kato M, 1998, NAT MED, V4, P691, DOI 10.1038/nm0698-691; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kheradmand F, 2002, BIOESSAYS, V24, P8, DOI 10.1002/bies.10037; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Kinnunen T, 1998, J BIOL CHEM, V273, P10702, DOI 10.1074/jbc.273.17.10702; Kitamura N, 1996, EUR SURG RES, V28, P428, DOI 10.1159/000129487; Kitayama J, 2000, CELL IMMUNOL, V203, P39, DOI 10.1006/cimm.2000.1671; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kodaira Y, 2000, J IMMUNOL, V165, P1599, DOI 10.4049/jimmunol.165.3.1599; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Kosher RA, 1998, MICROSC RES TECHNIQ, V43, P123, DOI 10.1002/(SICI)1097-0029(19981015)43:2<123::AID-JEMT5>3.0.CO;2-G; Lacy HM, 2001, BLOOD, V98, P2160, DOI 10.1182/blood.V98.7.2160; Lauri SE, 1999, J NEUROSCI, V19, P1226; Lebakken CS, 2000, EXP CELL RES, V259, P315, DOI 10.1006/excr.2000.4981; Lee TD, 2002, AM J PATHOL, V160, P841, DOI 10.1016/S0002-9440(10)64907-3; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Ley K, 1998, CIRC RES, V83, P287, DOI 10.1161/01.RES.83.3.287; Li JA, 1997, CIRC RES, V81, P785; LIDER O, 1990, EUR J IMMUNOL, V20, P493, DOI 10.1002/eji.1830200306; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Lipscombe RJ, 1998, J LEUKOCYTE BIOL, V63, P342, DOI 10.1002/jlb.63.3.342; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; Lortat-Jacob H, 2002, P NATL ACAD SCI USA, V99, P1229, DOI 10.1073/pnas.032497699; Lundqvist K, 2001, BRIT J DERMATOL, V144, P254, DOI 10.1046/j.1365-2133.2001.04009.x; Luo JY, 2001, J CELL BIOCHEM, V80, P522, DOI 10.1002/1097-4644(20010315)80:4<522::AID-JCB1006>3.0.CO;2-H; Luster AD, 1998, P ASSOC AM PHYSICIAN, V110, P183; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Lyon M, 1998, MATRIX BIOL, V17, P485, DOI 10.1016/S0945-053X(98)90096-8; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; Manakil JF, 2001, J DENT RES, V80, P1704, DOI 10.1177/00220345010800080501; Marshall D, 2002, SEMIN IMMUNOL, V14, P133, DOI 10.1006/smim.2001.0350; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; McCafferty DM, 2002, J IMMUNOL, V168, P4930, DOI 10.4049/jimmunol.168.10.4930; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; Miller SJ, 1998, THROMB HAEMOSTASIS, V80, P481; Modrowski D, 2000, J BIOL CHEM, V275, P9178, DOI 10.1074/jbc.275.13.9178; Moromizato Y, 2000, AM J PATHOL, V157, P1277, DOI 10.1016/S0002-9440(10)64643-3; Murakami M, 2002, J BIOL CHEM, V277, P19145, DOI 10.1074/jbc.M112385200; Nelson RM, 1995, ANNU REV CELL DEV BI, V11, P601, DOI 10.1146/annurev.cellbio.11.1.601; Oksala O, 1997, J DENT RES, V76, P1250, DOI 10.1177/00220345970760060401; Olofsson AM, 1999, J CLIN INVEST, V104, P885, DOI 10.1172/JCI6671; Ottonello L, 1998, INFLAMM RES, V47, P345, DOI 10.1007/s000110050340; Parish CR, 1998, IMMUNOL CELL BIOL, V76, P104, DOI 10.1046/j.1440-1711.1998.00722.x; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Patel DD, 2001, CLIN IMMUNOL, V99, P43, DOI 10.1006/clim.2000.4997; Patel KD, 2002, SEMIN IMMUNOL, V14, P73, DOI 10.1006/smim.2001.0344; PEREIRA HA, 1990, J CLIN INVEST, V85, P1468, DOI 10.1172/JCI114593; Perollet C, 1998, BLOOD, V91, P3289, DOI 10.1182/blood.V91.9.3289.3289_3289_3299; Peter K, 1999, CIRCULATION, V100, P1533, DOI 10.1161/01.CIR.100.14.1533; Pillarisetti S, 2000, TRENDS CARDIOVAS MED, V10, P60, DOI 10.1016/S1050-1738(00)00048-7; Pillarisetti S, 1995, J BIOL CHEM, V270, P29760; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; Reizes O, 2001, CELL, V106, P105, DOI 10.1016/S0092-8674(01)00415-9; Renne T, 2000, J BIOL CHEM, V275, P33688, DOI 10.1074/jbc.M000313200; RIBATTI D, 1991, ACTA ANAT, V142, P334; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; Robinson MJ, 2002, J BIOL CHEM, V277, P3658, DOI 10.1074/jbc.M102950200; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; Salek-Ardakani S, 2000, BLOOD, V96, P1879, DOI 10.1182/blood.V96.5.1879.h8001879_1879_1888; SALMIVIRTA M, 1991, J BIOL CHEM, V266, P7733; Sanderson RD, 2002, ANN HEMATOL, V81, P125, DOI 10.1007/s00277-002-0437-8; SANDERSON RD, 1989, CELL REGUL, V1, P27, DOI 10.1091/mbc.1.1.27; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Saphire ACS, 2001, J VIROL, V75, P9187, DOI 10.1128/JVI.75.19.9187-9200.2001; Schofield KP, 1999, BIOCHEM J, V343, P663, DOI 10.1042/0264-6021:3430663; Schonherr E, 2000, Dev Immunol, V7, P89, DOI 10.1155/2000/31748; Sebestyen A, 2000, CYTOKINE, V12, P1557, DOI 10.1006/cyto.2000.0754; Seidel C, 2000, BLOOD, V96, P3139, DOI 10.1182/blood.V96.9.3139.h8003139_3139_3146; Simons M, 2001, CELL SIGNAL, V13, P855, DOI 10.1016/S0898-6568(01)00190-5; SNEED TB, 1994, CELL IMMUNOL, V153, P456, DOI 10.1006/cimm.1994.1042; Splettstoesser WD, 2002, MICROSC RES TECHNIQ, V57, P441, DOI 10.1002/jemt.10098; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Stepp MA, 2002, J CELL SCI, V115, P4517, DOI 10.1242/jcs.00128; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Swain SD, 2002, ANTIOXID REDOX SIGN, V4, P69, DOI 10.1089/152308602753625870; Tanabe H, 1999, J PATHOL, V187, P338, DOI 10.1002/(SICI)1096-9896(199902)187:3<338::AID-PATH229>3.0.CO;2-#; Tanaka Y, 1996, J EXP MED, V184, P1987, DOI 10.1084/jem.184.5.1987; Uchiba M, 1996, AM J PHYSIOL-LUNG C, V270, pL921, DOI 10.1152/ajplung.1996.270.6.L921; Ueno M, 2001, J BIOL CHEM, V276, P29134, DOI 10.1074/jbc.M102089200; Vaday GG, 2001, J LEUKOCYTE BIOL, V69, P885; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Viklund L, 2002, BIOCHEM BIOPH RES CO, V290, P146, DOI 10.1006/bbrc.2001.6187; Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129; Wan MX, 2001, INFLAMM RES, V50, P581, DOI 10.1007/PL00000237; Watchorn TM, 2002, AM J PHYSIOL-ENDOC M, V282, pE763, DOI 10.1152/ajpendo.00408.2001; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; WEINSTATSASLOW D, 1994, FASEB J, V8, P401, DOI 10.1096/fasebj.8.6.7513289; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; Worapamorn W, 2001, J CELL PHYSIOL, V186, P448, DOI 10.1002/1097-4652(2001)9999:9999<000::AID-JCP1047>3.0.CO;2-V; Wrenshall LE, 1999, J LEUKOCYTE BIOL, V66, P391, DOI 10.1002/jlb.66.3.391; WRENSHALL LE, 1993, HUM IMMUNOL, V38, P165, DOI 10.1016/0198-8859(93)90535-9; WRENSHALL LE, 1995, J IMMUNOL, V154, P871; Wrenshall LE, 1999, J IMMUNOL, V163, P3793; WRENSHALL LE, 1994, TRANSPLANTATION, V57, P1087, DOI 10.1097/00007890-199404150-00018; Xie X, 2000, J BIOL CHEM, V275, P34818, DOI 10.1074/jbc.M001257200; Yamashita Y, 1999, J IMMUNOL, V162, P5940; YEAMAN C, 1993, J CELL PHYSIOL, V157, P413, DOI 10.1002/jcp.1041570226; YEAMAN C, 1993, J CELL BIOL, V122, P941, DOI 10.1083/jcb.122.4.941; Zhang YF, 1999, J BIOL CHEM, V274, P14786, DOI 10.1074/jbc.274.21.14786	204	288	296	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					575	591		10.1096/fj.02-0739rev	http://dx.doi.org/10.1096/fj.02-0739rev			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665470				2022-12-28	WOS:000182580100002
J	Rosenkranz, AA; Lunin, VG; Gulak, PV; Sergienko, OV; Shumiantseva, MA; Voronina, OL; Gilyazova, DG; John, AP; Kofner, AA; Mironov, AF; Jans, DA; Sobolev, AS				Rosenkranz, AA; Lunin, VG; Gulak, PV; Sergienko, OV; Shumiantseva, MA; Voronina, OL; Gilyazova, DG; John, AP; Kofner, AA; Mironov, AF; Jans, DA; Sobolev, AS			Recombinant modular transporters for cell-specific nuclear delivery of locally acting drugs enhance photosensitizer activity	FASEB JOURNAL			English	Article						targeted drug delivery; intracellular transport; nucleo-cytoplasmic transport; cancer; melanoma	TARGETED INTRACELLULAR DELIVERY; VIVO PROTEIN TRANSDUCTION; GENE-TRANSFER; PHOTODYNAMIC ACTIVITY; IN-VITRO; RECEPTOR; HORMONE; FUSION; TOXIN; PEPTIDES	The search for new pharmaceuticals that are specific for diseased rather than normal cells in the case of cancer and viral disease has raised interest in locally acting drugs that act over short distances within the cell and for which different cell compartments have distinct sensitivities. Thus, photo sensitizers (PSs) used in anti-cancer therapy should ideally be transported to the most sensitive subcellular compartments in order for their action to be most pronounced. Here we describe the design, production, and characterization of the effects of bacterially expressed modular recombinant transporters for PSs comprising 1) a-melanocyte-stimulating hormone as an internalizable, cell-specific ligand; 2) an optimized nuclear localization sequence of the SV40 large T-antigen; 3) an Escherichia coli hemoglobin-like protein as a carrier; and 4) an endosomolytic amphipathic polypeptide, the translocation domain of diphtheria toxin. These modular transporters delivered PSs into the nuclei, the most vulnerable sites for the action of PSs, of murine melanoma cells, but not non-MSH receptor-overexpressing cells, to result in cytotoxic effects several orders of magnitude greater than those of nonmodified PSs. The modular fusion proteins described here for the first time, capable of cell-specific targeting to particular subcellular compartments to increase drug efficacy, represent new pharmaceuticals with general application.	Russian Acad Sci, Inst Gene Biol, Dept Mol Genet Intracellular Transport, Moscow 119334, Russia; Moscow MV Lomonosov State Univ, Fac Biol, Dept Biophys, Moscow 119899, Russia; Russian Acad Agr Sci, All Russia Inst Agr Biotechnol, Lab Mol Diagnost & Gene Engn Constructs, Moscow 127550, Russia; Russian Acad Sci, Bach Inst Biochem, Lab Enzyme Syst, Moscow 119071, Russia; Australian Natl Univ, John Curtin Sch Med Res, Nucl Signaling Lab, Canberra, ACT 2601, Australia; Moscow Acad Fine Chem Technol, Dept Chem & Technol Fine Organ Chem, Moscow 117571, Russia; Monash Univ, Dept Biochem & Mol Biol, Nucl Signaling Lab, Clayton, Vic 3168, Australia	Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Lomonosov Moscow State University; All-Russia Research Institute of Agricultural Biotechnology; Research Center of Biotechnology RAS; Russian Academy of Sciences; Australian National University; John Curtin School of Medical Research; Monash University	Sobolev, AS (corresponding author), Russian Acad Sci, Inst Gene Biol, Dept Mol Genet Intracellular Transport, 34-5 Vavilov St, Moscow 119334, Russia.	asobol@l.biophys.bio.msu.ru	Voronina, Olga L/F-4959-2018; Mironov, Andrey/ABB-3245-2021; Sobolev, Alexander S./P-6302-2015; Rosenkranz, Andrey A/J-3514-2015	Voronina, Olga L/0000-0001-7206-3594; Sobolev, Alexander S./0000-0001-8315-7764; Rosenkranz, Andrey A/0000-0001-9941-6118; Jans, David/0000-0001-5115-4745; Mironov, Andrey F./0000-0001-8353-1904				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; AKHLYNINA TV, 1995, CANCER RES, V55, P1014; AKHLYNINA TV, 1990, B EXP BIOL MED+, V109, P183, DOI 10.1007/BF00841665; Akhlynina TV, 1997, J BIOL CHEM, V272, P20328, DOI 10.1074/jbc.272.33.20328; AKHLYNINA TV, 1993, PHOTOCHEM PHOTOBIOL, V58, P45, DOI 10.1111/j.1751-1097.1993.tb04901.x; Akhlynina TV, 1999, INT J CANCER, V81, P734, DOI 10.1002/(SICI)1097-0215(19990531)81:5<734::AID-IJC12>3.3.CO;2-A; Atkins JH, 2002, NAT REV DRUG DISCOV, V1, P491, DOI 10.1038/nrd842; Barati S, 2002, EXP NEUROL, V177, P75, DOI 10.1006/exnr.2002.7999; Bisland SK, 1999, BIOCONJUGATE CHEM, V10, P982, DOI 10.1021/bc990020u; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Chan CK, 2001, GENE THER, V8, P166, DOI 10.1038/sj.gt.3301366; Chenal A, 2002, PROTEIN ENG, V15, P383, DOI 10.1093/protein/15.5.383; de Jong M, 2002, SEMIN NUCL MED, V32, P133, DOI 10.1053/snuc.2002.31027; FINLAY GJ, 1984, ANAL BIOCHEM, V139, P272, DOI 10.1016/0003-2697(84)90002-2; Frankel AE, 2002, CLIN CANCER RES, V8, P1004; Gibbs JB, 2000, J CLIN INVEST, V105, P9, DOI 10.1172/JCI9084; Hamblin MR, 2000, PHOTOCHEM PHOTOBIOL, V72, P533, DOI 10.1562/0031-8655(2000)072<0533:SRTPT>2.0.CO;2; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jiang J, 1996, Exp Dermatol, V5, P325, DOI 10.1111/j.1600-0625.1996.tb00136.x; Kwekkeboom DJ, 2002, SEMIN NUCL MED, V32, P84, DOI 10.1053/snuc.2002.31022; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langer R, 2001, SCIENCE, V293, P58, DOI 10.1126/science.1063273; Liang H, 2000, LASER MED SCI, V15, P109, DOI 10.1007/s101030050056; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Mironov A. F., 1992, P SOC PHOTO-OPT INS, V1922, P204; Nir S, 2000, PROG LIPID RES, V39, P181, DOI 10.1016/S0163-7827(00)00004-7; O'Hare KB, 1993, J DRUG TARGET, V1, P217, DOI 10.3109/10611869308996079; PLANK C, 1994, J BIOL CHEM, V269, P12918; Poul MA, 2000, J MOL BIOL, V301, P1149, DOI 10.1006/jmbi.2000.4026; *QIAGEN, 2001, QIAEXPR; Ramage JG, 2003, LEUKEMIA RES, V27, P79, DOI 10.1016/S0145-2126(02)00077-2; Rosenkranz AA, 1997, BIOCHEM BIOPH RES CO, V236, P750, DOI 10.1006/bbrc.1997.7040; Rosenkranz AA, 2000, IMMUNOL CELL BIOL, V78, P452, DOI 10.1046/j.1440-1711.2000.00925.x; SAHM UG, 1994, PEPTIDES, V15, P441, DOI 10.1016/0196-9781(94)90202-X; Salazar-Onfray F, 2002, BRIT J CANCER, V87, P414, DOI 10.1038/sj.bjc.6600441; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; SIEGRIST W, 1986, ANAL BIOCHEM, V159, P191, DOI 10.1016/0003-2697(86)90327-1; Silver RB, 1998, METHOD CELL BIOL, V56, P237, DOI 10.1016/S0091-679X(08)60429-X; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Sobolev AS, 2000, PROG BIOPHYS MOL BIO, V73, P51, DOI 10.1016/S0079-6107(00)00002-X; Trail PA, 1999, CURR OPIN IMMUNOL, V11, P584, DOI 10.1016/S0952-7915(99)00012-6; Uherek C, 1998, J BIOL CHEM, V273, P8835, DOI 10.1074/jbc.273.15.8835; WEN ZL, 1991, J BIOL CHEM, V266, P12289; Wikberg JES, 2000, PHARMACOL RES, V42, P393, DOI 10.1006/phrs.2000.0725; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Wong WS, 1996, INT J BIOCHEM CELL B, V28, P1223, DOI 10.1016/S1357-2725(96)00074-X	48	50	58	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1121	+		10.1096/fj.02-0888fje	http://dx.doi.org/10.1096/fj.02-0888fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692081				2022-12-28	WOS:000182580100041
J	Kamphuis, PJGH; Gardoni, F; Kamal, A; Croiset, G; Bakker, JM; Cattabeni, F; Gispen, WH; van Bel, F; Di Luca, M; Wiegant, VM				Kamphuis, PJGH; Gardoni, F; Kamal, A; Croiset, G; Bakker, JM; Cattabeni, F; Gispen, WH; van Bel, F; Di Luca, M; Wiegant, VM			Long-lasting effects of neonatal dexamethasone treatment on spatial learning and hippocampal synaptic plasticity. Involvement of the NMDA receptor complex	FASEB JOURNAL			English	Article						glucocorticoid; rat; LTP; alpha CaMKII; NR2B	D-ASPARTATE RECEPTOR; PROTEIN-KINASE-II; MESSENGER-RNA LEVELS; TERM POTENTIATION; POSTSYNAPTIC DENSITIES; GLUTAMATE RECEPTORS; PRETERM INFANTS; NR2B SUBUNIT; ADULT RATS; GLUCOCORTICOIDS	The effects of neonatal dexamethasone (DEX) treatment on spatial learning and hippocampal synaptic plasticity were investigated in adult rats. Spatial learning in reference and working memory versions of the Morris maze was impaired in DEX-treated rats. In hippocampal slices of DEX rats, long-term depression was facilitated and potentiation was impaired. Paired-pulse facilitation was normal, suggesting a postsynaptic defect as cause of the learning and plasticity deficits. Western blot analysis of hippocampal postsynaptic densities (PSD) revealed a reduction in NR2B subunit protein, whereas the abundance of the other major N-methyl-D-aspartate (NMDA) receptor subunits (NR1, NR2A), AMPA receptor subunits (GluR2/3), scaffolding proteins, and Ca2+/calmodulin-dependent protein kinase II (alphaCaMKII) were unaltered. This selective reduction in NR2B likely resulted from altered receptor assembly rather than subunit expression, because the abundance of NR2B in the homogenate and crude synaptosomal fractions was unaltered. In addition, the activity of alphaCaMKII, an NMDA receptor complex associated protein kinase, was increased in PSD of DEX rats. The results indicate that neonatal treatment with DEX causes alterations in composition and function of the hippocampal NMDA receptor complex that persist into adulthood. These alterations likely explain the deficits in hippocampal synaptic plasticity and spatial learning induced by neonatal DEX treatment.	Univ Utrecht, Dept Pharmaccol & Anat, Rudolf Magnus Inst Neurosci, Med Ctr, NL-3508 AB Utrecht, Netherlands; Univ Utrecht, Dept Neonatol, Wilhelmina Childrens Hosp, Med Ctr, Utrecht, Netherlands; Univ Milan, Dept Pharmacol Sci, Milan, Italy	Utrecht University; Utrecht University Medical Center; Utrecht University; Wilhelmina Kinderziekenhuis; University of Milan	Wiegant, VM (corresponding author), Univ Utrecht, Dept Pharmaccol & Anat, Rudolf Magnus Inst Neurosci, Med Ctr, POB 85060, NL-3508 AB Utrecht, Netherlands.	V.M.Wiegant@med.uu.nl	Croiset, Gerda/J-5650-2014; Gardoni, Fabrizio/A-3135-2009; DiLuca, Monica/A-7632-2012	Gardoni, Fabrizio/0000-0003-4598-5563; DiLuca, Monica/0000-0003-2298-615X; Kamal, Amer/0000-0002-0545-0815				Bakker JM, 2000, J IMMUNOL, V165, P5932, DOI 10.4049/jimmunol.165.10.5932; BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6; Barrington K J, 2001, BMC Pediatr, V1, P1, DOI 10.1186/1471-2431-1-1; BENESOVA O, 1989, NEUROPHARMACOLOGY, V28, P89, DOI 10.1016/0028-3908(89)90073-7; Biessels GJ, 1996, DIABETES, V45, P1259, DOI 10.2337/diabetes.45.9.1259; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bolt RJ, 2001, PEDIATR PULM, V32, P76, DOI 10.1002/ppul.1092; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Clayton DA, 2002, J NEUROSCI, V22, P3628; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; CUMMINGS JJ, 1989, NEW ENGL J MED, V320, P1505, DOI 10.1056/NEJM198906083202301; Das S, 1998, NATURE, V393, P377, DOI 10.1038/30748; DEKLOET ER, 1988, PROG BRAIN RES, V73, P101; Di Luca M, 2001, NEUROREPORT, V12, P1301, DOI 10.1097/00001756-200105080-00049; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; Doyle LW, 2000, J PAEDIATR CHILD H, V36, P256; Dunah AW, 2000, MOL PHARMACOL, V57, P342; ELLIOTT EM, 1993, BRAIN RES, V602, P84, DOI 10.1016/0006-8993(93)90245-I; Ferguson SA, 2001, NEUROTOXICOL TERATOL, V23, P57, DOI 10.1016/S0892-0362(00)00115-X; Finer NN, 2000, J PEDIATR-US, V137, P9, DOI 10.1067/mpd.2000.107799; Gardoni F, 1998, J NEUROCHEM, V71, P1733; Gardoni F, 2001, J BIOL CHEM, V276, P7609, DOI 10.1074/jbc.M009922200; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUMDON A, 2002, ANNU REV BIOCHEM, V71, P473; Kamphuis PJGH, 2002, NEUROENDOCRINOLOGY, V76, P158, DOI 10.1159/000064526; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; KERR DS, 1989, SCIENCE, V245, P1505, DOI 10.1126/science.2781293; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Liu J, 1999, J NEUROSCI, V19, P8292; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; Matthews SG, 2000, PEDIATR RES, V47, P291, DOI 10.1203/00006450-200003000-00003; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MCEWEN BS, 1995, CURR OPIN NEUROBIOL, V5, P205, DOI 10.1016/0959-4388(95)80028-X; McGowan JE, 2000, J NEUROSCI, V20, P7424; MCNAMARA RK, 1993, BRAIN RES REV, V18, P33, DOI 10.1016/0165-0173(93)90006-L; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Nair SM, 1998, J NEUROSCI, V18, P2685; Santin LJ, 1999, BEHAV BRAIN RES, V102, P137, DOI 10.1016/S0166-4328(99)00011-X; SAPOLSKY RM, 1986, BRAIN RES REV, V11, P65, DOI 10.1016/0165-0173(86)90010-X; SCHEETZ AJ, 1994, FASEB J, V8, P745, DOI 10.1096/fasebj.8.10.8050674; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Steele RJ, 1999, HIPPOCAMPUS, V9, P118, DOI 10.1002/(SICI)1098-1063(1999)9:2<118::AID-HIPO4>3.0.CO;2-8; STEINBEHRENS BA, 1994, J NEUROCHEM, V63, P596; Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; Tarnow-Mordi W, 1999, BRIT MED J, V319, P1385, DOI 10.1136/bmj.319.7222.1385; Venero C, 1999, EUR J NEUROSCI, V11, P2465, DOI 10.1046/j.1460-9568.1999.00668.x; VICEDOMINI JP, 1986, PHYSIOL BEHAV, V36, P145, DOI 10.1016/0031-9384(86)90088-0; Weiland NG, 1997, NEUROSCIENCE, V78, P653, DOI 10.1016/S0306-4522(96)00619-7; Yamakura T, 1999, PROG NEUROBIOL, V59, P279, DOI 10.1016/S0301-0082(99)00007-6; Yeh TF, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.5.e7; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	61	60	61	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					911	+		10.1096/fj.02-0333fje	http://dx.doi.org/10.1096/fj.02-0333fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626441				2022-12-28	WOS:000181892600018
J	Petrache, I; Birukov, K; Zaiman, AL; Crow, MT; Deng, HT; Wadgaonkar, R; Romer, LH; Garcia, JGN				Petrache, I; Birukov, K; Zaiman, AL; Crow, MT; Deng, HT; Wadgaonkar, R; Romer, LH; Garcia, JGN			Caspase-dependent cleavage of myosin light chain kinase (MLCK) is involved in TNF-alpha-mediated bovine pulmonary endothelial cell apoptosis	FASEB JOURNAL			English	Article						cytoskeleton; stress fibers; Rho kinase; blebbing; autoinhibitory domain	TUMOR-NECROSIS-FACTOR; PHOSPHORYLATION; PROTEINS; ISOFORMS; SITE; FORM	Cytoskeletal proteins are key participants in the cellular progression to apoptosis. Our previous work demonstrated the critical dependence of actomyosin rearrangement and MLC phosphorylation in TNF-alpha-induced endothelial cell apoptosis. As these events reflect the activation of the multifunctional endothelial cell (EC) MLCK isoform, we assessed the direct role of EC MLCK in the regulation of TNF-alpha-induced apoptosis. Bovine pulmonary artery endothelial cells expressing either an adenovirus encoding antisense MLCK cDNA (Ad. GFP-AS MLCK) or a dominant/ negative EC MLCK construct (EC MLCK-ATPdel) resulted in marked reductions in MLCK activity and TNF-alpha-mediated apoptosis. In contrast, a constitutively active EC MLCK lacking the carboxyl-terminal autoinhibitory domains (EC MLCK-1745) markedly enhanced the apoptotic response to TNF-alpha. Immunostaining in GFP-EC MLCK-expressing cells revealed colocalization of caspase 8 and EC MLCK along actin stress fibers after TNF-alpha. TNF-alpha induced the caspase-dependent cleavage of EC MLCK-1745 in transfected endothelial cells, which was confirmed by mass spectroscopy with in vitro cleavage by caspase 3 at LKKD (D-1703). The resulting MLCK fragments displayed significant calmodulin-independent kinase activity. These studies convincingly demonstrate that novel interactions between the apoptotic machinery and EC MLCK exist that regulate the endothelial contractile apparatus in TNF-alpha- induced apoptosis.	Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Albert Einstein Coll Med, Dept Med, New York, NY USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Yeshiva University	Garcia, JGN (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,Room 4B-77, Baltimore, MD 21224 USA.	drgarcia@jhmi.edu	Birukov, Konstantin/FJB-5755-2022; Garcia, Joe GN/E-8862-2010		NHLBI NIH HHS [K08 HL004396, HL 04396, HL 50533, HL 58064] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL058064, R01HL050533, K08HL004396] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELSTEIN RS, 1983, J CLIN INVEST, V72, P1863, DOI 10.1172/JCI111148; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Birukov KG, 2001, J BIOL CHEM, V276, P8567, DOI 10.1074/jbc.M005270200; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Garcia JGN, 1998, J APPL PHYSIOL, V84, P1817, DOI 10.1152/jappl.1998.84.5.1817; Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HERRING BP, 1990, J BIOL CHEM, V265, P16588; HOCKING DC, 1990, CIRC RES, V67, P68, DOI 10.1161/01.RES.67.1.68; ITO M, 1991, BIOCHEMISTRY-US, V30, P3498, DOI 10.1021/bi00228a021; Jin YJ, 2001, J BIOL CHEM, V276, P30342, DOI 10.1074/jbc.M102404200; Jin YJ, 2001, J BIOL CHEM, V276, P39667, DOI 10.1074/jbc.M101886200; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Lazar V, 1999, GENOMICS, V57, P256, DOI 10.1006/geno.1999.5774; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Petrache I, 2001, AM J PHYSIOL-LUNG C, V280, pL1168, DOI 10.1152/ajplung.2001.280.6.L1168; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Verin AD, 1998, AM J RESP CELL MOL, V19, P758, DOI 10.1165/ajrcmb.19.5.3125; Verin AD, 1998, AM J RESP CELL MOL, V19, P767, DOI 10.1165/ajrcmb.19.5.3126; WRIGHT SC, 1993, J CELL BIOCHEM, V53, P222, DOI 10.1002/jcb.240530307	25	82	86	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					407	416		10.1096/fj.02-0672com	http://dx.doi.org/10.1096/fj.02-0672com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12631580				2022-12-28	WOS:000181892600039
J	Starkie, R; Ostrowski, SR; Jauffred, S; Febbraio, M; Pedersen, BK				Starkie, R; Ostrowski, SR; Jauffred, S; Febbraio, M; Pedersen, BK			Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans	FASEB JOURNAL			English	Article						cytokines; interleukins; inflammation; physical activity	TUMOR-NECROSIS-FACTOR; MUSCLE-DERIVED INTERLEUKIN-6; HUMAN SKELETAL-MUSCLE; PLASMA INTERLEUKIN-6; CYTOKINE RELEASE; ACTIVATION; MONOCYTES	During "nondamaging" exercise, skeletal muscle markedly releases interleukin (IL)-6, and it has been suggested that one biological role of this phenomenon is to inhibit the production of tumor necrosis factor (TNF)-alpha, which is known to cause pathogenesis such as insulin resistance and atherosclerosis. To test this hypothesis, we performed three experiments in which eight healthy males either rested (CON), rode a bicycle for 3 h (EX), or were infused with recombinant human IL-6 (rhIL-6) for 3 h while they rested. After 2.5 h, the volunteers received a bolus of Escherichia coli lipopolysaccharide endotoxin (0.06 ng/kg) i.v. to induce low-grade inflammation. In CON, plasma TNF-alpha increased significantly in response to endotoxin. In contrast, during EX, which resulted in elevated IL-6, and rhIL-6, the endotoxin-induced increase in TNF-alpha was totally attenuated. In conclusion, physical exercise and rhIL-6 infusion at physiological concentrations inhibit endotoxin-induced TNF-alpha production in humans. Hence, these data provide the first experimental evidence that physical activity mediates antiinflammatory activity and suggest that the mechanism include IL-6, which is produced by and released from exercising muscles.	Univ Copenhagen, Rigshosp 7641, Dept Infect Dis, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Rigshosp 7641, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Pedersen, BK (corresponding author), Univ Copenhagen, Rigshosp 7641, Dept Infect Dis, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	bkp@rh.dk	Ostrowski, Sisse R/E-7423-2011; Pedersen, Bente Klarlund/AGR-3217-2022; Febbraio, Mark/AAE-9632-2019	Ostrowski, Sisse R/0000-0001-5288-3851; Pedersen, Bente Klarlund/0000-0001-6508-6288; 				Blair SN, 1999, MED SCI SPORT EXER, V31, pS646, DOI 10.1097/00005768-199911001-00025; Bruunsgaard H, 1999, J GERONTOL A-BIOL, V54, pM357, DOI 10.1093/gerona/54.7.M357; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; Keller C, 2001, FASEB J, V15, P2748, DOI 10.1096/fj.01-0507fje; Krabbe KS, 2001, CLIN DIAGN LAB IMMUN, V8, P333, DOI 10.1128/CDLI.8.2.333-338.2001; MATTHYS P, 1995, INFECT IMMUN, V63, P1158, DOI 10.1128/IAI.63.4.1158-1164.1995; Mishima Y, 2001, DIABETES RES CLIN PR, V52, P119, DOI 10.1016/S0168-8227(00)00247-3; MIZUHARA H, 1994, J EXP MED, V179, P1529, DOI 10.1084/jem.179.5.1529; Ostrowski K, 1998, J PHYSIOL-LONDON, V508, P949, DOI 10.1111/j.1469-7793.1998.949bp.x; Pedersen BK, 2000, PHYSIOL REV, V80, P1055, DOI 10.1152/physrev.2000.80.3.1055; Pedersen BK, 2001, J PHYSIOL-LONDON, V536, P329, DOI 10.1111/j.1469-7793.2001.0329c.xd; Pickup JC, 2000, LIFE SCI, V67, P291, DOI 10.1016/S0024-3205(00)00622-6; Ridker PM, 2000, CIRCULATION, V101, P1767, DOI 10.1161/01.CIR.101.15.1767; Starkie RL, 2001, AM J PHYSIOL-CELL PH, V280, pC769, DOI 10.1152/ajpcell.2001.280.4.C769; Steensberg A, 2001, J PHYSIOL-LONDON, V537, P633, DOI 10.1111/j.1469-7793.2001.00633.x; Steensberg A, 2001, AM J PHYSIOL-CELL PH, V281, pC1001; Steppich B, 2000, AM J PHYSIOL-CELL PH, V279, pC578, DOI 10.1152/ajpcell.2000.279.3.C578; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; vanderPoll T, 1996, J CLIN INVEST, V97, P713, DOI 10.1172/JCI118469; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; Vozarova B, 2001, OBES RES, V9, P414, DOI 10.1038/oby.2001.54; Wallenius V, 2002, NAT MED, V8, P75, DOI 10.1038/nm0102-75	23	537	558	1	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					884	+		10.1096/fj.02-0670fje	http://dx.doi.org/10.1096/fj.02-0670fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626436				2022-12-28	WOS:000181892600016
J	Batetta, B; Mulas, MF; Sanna, F; Putzolu, M; Bonatesta, RR; Gasperi-Campani, A; Roncuzzi, L; Baiocchi, D; Dessi, S				Batetta, B; Mulas, MF; Sanna, F; Putzolu, M; Bonatesta, RR; Gasperi-Campani, A; Roncuzzi, L; Baiocchi, D; Dessi, S			Role of cholesterol ester pathway in the control of cell cycle in human aortic smooth muscle cells	FASEB JOURNAL			English	Article						acyl-CoA : cholesterol acyltransferase multidrug resistance-1; caveolin-1; cyclin D1; mitogen-activated protein kinase; extracellular related kinase 1/2	DENSITY-LIPOPROTEIN CHOLESTEROL; RESISTANCE P-GLYCOPROTEINS; GENE-EXPRESSION; MDR1; ESTERIFICATION; ACYLTRANSFERASE; METABOLISM; CAVEOLIN; GROWTH; PROLIFERATION	Cholesterol esterification by acyl-CoA:cholesterol acyltransferase (ACAT) and proliferation of vascular smooth muscle cells (VSMC) are key events in vascular proliferative diseases. Here we performed experiments to ascertain the role of cholesterol ester pathway in the control of human aortic VSMC cycle progression. Results showed that serum-induced VSMC proliferation was preceded by an increased ability of the cells to esterify cholesterol as well as by an increased expression of ACAT and multidrug resistance (MDR1) mRNAs and extracellular related kinases 1/2 (ERK1/2), whereas caveolin-1 levels were markedly decreased. Cell cycle analyses performed in the presence of two inhibitors of cholesterol esterification, directly inhibiting ACAT (Sandoz 58-035) or the transport of cholesterol substrate from plasma membrane to endoplasmic reticulum (progesterone), indicate that each inhibitor suppressed the serum-induced DNA synthesis by accumulation of VSMCs in the G(1) phase. The effect was associated with a rapid inhibition of ERK1/2 mitogenic signaling pathway; a down-regulation of cyclin D1, ACAT, and MDR1 mRNA; and an up-regulation of caveolin-1. These data provide a plausible link between cholesterol esterification and control of cell cycle G(1)/S transition, supporting the hypothesis that cholesterol esterification may accelerate the progression of human vascular proliferative diseases by modulating the rate of the VSMC proliferation.	Univ Cagliari, Dept Biomed Sci & Biotechnol, I-09124 Cagliari, Italy; Univ Bologna, Interdepartmental Ctr Res Canc, Bologna, Italy; Univ Bologna, Dept Expt Pathol, Natl Inst Canc Res, Genova Biotechnol Unit, I-40126 Bologna, Italy	University of Cagliari; University of Bologna; University of Bologna; University of Genoa; IRCCS AOU San Martino IST	Dessi, S (corresponding author), Univ Cagliari, Dept Biomed Sci & Biotechnol, Italy Via Porcell 4, I-09124 Cagliari, Italy.	sdessi@vaxca1.unica.it	Roncuzzi, laura/C-7449-2019	Roncuzzi, laura/0000-0002-5437-6543; Batetta, Barbara/0000-0001-6932-778X				Batetta B, 1999, CELL PROLIFERAT, V32, P49, DOI 10.1046/j.1365-2184.1999.00132.x; Batetta B, 2001, CELL MOL LIFE SCI, V58, P1113, DOI 10.1007/PL00000925; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Debry P, 1997, J BIOL CHEM, V272, P1026, DOI 10.1074/jbc.272.2.1026; DESSI S, 1984, CHEM-BIOL INTERACT, V48, P271, DOI 10.1016/0009-2797(84)90140-6; DESSI S, 1992, ONCOLOGY, V49, P436; Dessi S, 1997, BIOCHEM J, V321, P603, DOI 10.1042/bj3210603; DESSI S, 1994, CANCER, V73, P253, DOI 10.1002/1097-0142(19940115)73:2<253::AID-CNCR2820730204>3.0.CO;2-F; DESSI S, 1991, INT J HEMATOL, V54, P483; DESSI S, 1992, BRIT J CANCER, V66, P787, DOI 10.1038/bjc.1992.361; DESSI S, 1995, CLIN SCI, V89, P505, DOI 10.1042/cs0890505; DESSI S, 1989, EXP MOL PATHOL, V51, P97, DOI 10.1016/0014-4800(89)90010-5; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Field FJ, 1998, J LIPID RES, V39, P1938; Fielding CJ, 1999, BIOCHEMISTRY-US, V38, P2506, DOI 10.1021/bi981012o; Fielding CJ, 2001, CURR OPIN LIPIDOL, V12, P281, DOI 10.1097/00041433-200106000-00007; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Incardona JP, 2000, CURR OPIN CELL BIOL, V12, P193, DOI 10.1016/S0955-0674(99)00076-9; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Lange Y, 1997, J BIOL CHEM, V272, P17018, DOI 10.1074/jbc.272.27.17018; LANGE Y, 1994, J BIOL CHEM, V269, P29371; Lee WS, 1997, NAT MED, V3, P1005, DOI 10.1038/nm0997-1005; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luker GD, 1999, J BIOL CHEM, V274, P6979, DOI 10.1074/jbc.274.11.6979; MATSUDA K, 1994, MED RES REV, V14, P271, DOI 10.1002/med.2610140302; Metherall JE, 1996, J BIOL CHEM, V271, P2634, DOI 10.1074/jbc.271.5.2634; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; Pani A, 2000, CELL MOL LIFE SCI, V57, P1094, DOI 10.1007/PL00000745; PAPE ME, 1995, J LIPID RES, V36, P823; RAO KN, 1986, BRIT J CANCER, V54, P305, DOI 10.1038/bjc.1986.177; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Rodriguez A, 1999, ARTERIOSCL THROM VAS, V19, P2199, DOI 10.1161/01.ATV.19.9.2199; Rosano GMC, 2001, INT J FERTIL WOMEN M, V46, P248; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPYRIDOPOULOS I, 1998, FRONT BIOSCI, V3, P269; Takano Y, 2000, AM J PATHOL, V156, P585, DOI 10.1016/S0002-9440(10)64763-3; Ward MR, 1998, ATHEROSCLEROSIS, V137, P267, DOI 10.1016/S0021-9150(97)00275-X; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; Yao PM, 2001, J BIOL CHEM, V276, P42468, DOI 10.1074/jbc.M101419200	45	28	34	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					746	+		10.1096/fj.02-0396fje	http://dx.doi.org/10.1096/fj.02-0396fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594184				2022-12-28	WOS:000181456900007
J	Hosogane, N; Shinki, T; Kasuga, H; Taketomi, S; Toyama, Y; Suda, T				Hosogane, N; Shinki, T; Kasuga, H; Taketomi, S; Toyama, Y; Suda, T			Mechanisms for the reduction of 24,25-dihydroxyvitamin D-3 levels and bone mass in 24-hydroxylase transgenic rats	FASEB JOURNAL			English	Article						CYP24; megalin; vitamin D binding protein; renal osteodystrophy; albuminuria	D-BINDING-PROTEIN; RENAL OSTEODYSTROPHY; NEPHROTIC SYNDROME; ESCHERICHIA-COLI; EPITHELIAL-CELLS; MESSENGER-RNA; COMPLEMENT C3; VITAMIN; EXPRESSION; IDENTIFICATION	24-Hydroxylase (CYP24) is an enzyme distributed in the target tissues of 1alpha,25-dihydroxyvitamin D-3 [1alpha,25(OH)(2)D-3]. Two functions for this enzyme have been reported: One is production of 24,25-dihydroxyvitamin D-3 [24,25(OH)(2)D-3] and the other is inactivation of 1alpha,25(OH)(2)D-3. To elucidate other physiologic roles of CYP24 in vivo, we previously generated rats that constitutively express the CYP24 gene. These transgenic (Tg) rats developed unexpected phenotypes, such as low plasma levels of 24,25(OH)(2)D-3, lipidemia, and albuminuria. In this study, we elucidated the mechanisms for inducing low plasma 24,25(OH)(2)D-3 levels and bone loss. Tg rats excreted massive amounts of vitamin D binding protein (DBP), which coincided with the loss of albumin. In Tg rats, the renal expression pattern of megalin, which serves as an endocytotic receptor responsible for the reuptake of urinary proteins such as DBP and albumin, was identical to that of the wild-type rats. Excreted albumin appeared to compete for the binding and reabsorption of the DBP-25-hydroxyvitamin D-3 [25(OH)D-3] complex with megalin, resulting in a loss of 25(OH)D-3 into the urine and subsequent reduction of plasma 24,25(OH)(2)D-3. In this prominent rat model of nephritis, supplementation of 25(OH)D-3 was effective in preventing bone loss in an early stage of renal insufficiency.	Keio Univ, Sch Med, Dept Orthopaed Surg, Shinjuku Ku, Tokyo 1608582, Japan; Showa Univ, Sch Dent, Dept Biochem, Shinagawa Ku, Tokyo 1428555, Japan; Takeda Chem Ind Ltd, Div Pharmaceut Res, Yodogawa Ku, Osaka 532, Japan; Saitama Med Sch, Res Ctr Genom Med, Div Pathophysiol, Hidaka, Saitama, Japan	Keio University; Showa University; Takeda Chemical Industries; Saitama Medical University	Hosogane, N (corresponding author), Keio Univ, Sch Med, Dept Orthopaed Surg, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	shinki@dent.showa-u.ac.jp	Toyama, Yoshiaki/K-5743-2013					Abe K, 1998, KIDNEY INT, V54, P120, DOI 10.1046/j.1523-1755.1998.00961.x; AKIYOSHISHIBATA M, 1994, EUR J BIOCHEM, V224, P335, DOI 10.1111/j.1432-1033.1994.00335.x; BERL T, 1978, ANN INTERN MED, V88, P774, DOI 10.7326/0003-4819-88-6-774; Birn H, 2000, J CLIN INVEST, V105, P1353, DOI 10.1172/JCI8862; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boyan BD, 2001, STEROIDS, V66, P363, DOI 10.1016/S0039-128X(00)00162-8; BRICKMAN AS, 1974, ARCH INTERN MED, V134, P883; CHRISTENSEN EI, 1992, J HISTOCHEM CYTOCHEM, V40, P1481, DOI 10.1177/40.10.1382088; CHRISTENSEN EI, 1995, EUR J CELL BIOL, V66, P349; Christensen EI, 1999, J AM SOC NEPHROL, V10, P2224; Coburn J W, 1998, J Am Soc Nephrol, V9, pS71; COOKE NE, 1989, ENDOCR REV, V10, P294, DOI 10.1210/edrv-10-3-294; Cui SY, 1996, AM J PHYSIOL-RENAL, V271, pF900, DOI 10.1152/ajprenal.1996.271.4.F900; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; Ghazali A, 1999, KIDNEY INT, V55, P2169, DOI 10.1046/j.1523-1755.1999.00480.x; HADDAD JG, 1981, J CLIN INVEST, V67, P1550, DOI 10.1172/JCI110186; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HOLICK MF, 1971, BIOCHEMISTRY-US, V10, P2799; HRUSKA KA, 1995, NEW ENGL J MED, V333, P166, DOI 10.1056/NEJM199507203330307; Kasuga H, 2002, BIOCHEM BIOPH RES CO, V297, P1332, DOI 10.1016/S0006-291X(02)02254-4; LAWSON DEM, 1971, NATURE, V230, P228, DOI 10.1038/230228a0; Leheste JR, 1999, AM J PATHOL, V155, P1361, DOI 10.1016/S0002-9440(10)65238-8; MALLUCHE HH, 1979, J CLIN INVEST, V63, P494, DOI 10.1172/JCI109327; MASSRY SG, 1980, KIDNEY INT, V18, P409, DOI 10.1038/ki.1980.154; MENDEL CM, 1989, ENDOCR REV, V10, P232, DOI 10.1210/edrv-10-3-232; Mittal SK, 1999, KIDNEY INT, V55, P1912, DOI 10.1046/j.1523-1755.1999.00413.x; Morita Y, 1997, J AM SOC NEPHROL, V8, P1363; MOUTABARRIK A, 1995, NEPHRON, V70, P55, DOI 10.1159/000188544; NAKAMURA T, 1992, CALCIFIED TISSUE INT, V50, P221, DOI 10.1007/BF00296286; NAKAMURA T, 1988, CALCIFIED TISSUE INT, V43, P235, DOI 10.1007/BF02555140; NAKAMURA T, 1992, BONE, V13, P229, DOI 10.1016/8756-3282(92)90202-8; NORMAN AW, 1971, SCIENCE, V173, P51, DOI 10.1126/science.173.3991.51; Nykjaer A, 1999, CELL, V96, P507, DOI 10.1016/S0092-8674(00)80655-8; OHYAMA Y, 1994, J BIOL CHEM, V269, P10545; Oren R, 1995, IMMUNOLOGY, V86, P575; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; Safadi FF, 1999, J CLIN INVEST, V103, P239, DOI 10.1172/JCI5244; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; Sakaki T, 1999, EUR J BIOCHEM, V262, P43, DOI 10.1046/j.1432-1327.1999.00375.x; Shinki T, 1997, P NATL ACAD SCI USA, V94, P12920, DOI 10.1073/pnas.94.24.12920; St-Arnaud R, 2000, ENDOCRINOLOGY, V141, P2658, DOI 10.1210/en.141.7.2658; Suda T, 1994, Curr Opin Nephrol Hypertens, V3, P59, DOI 10.1097/00041552-199401000-00008; Tang S, 1999, J AM SOC NEPHROL, V10, P69; WELCH TR, 1993, J CLIN INVEST, V92, P1451, DOI 10.1172/JCI116722; Welch TR, 2000, PEDIATR RES, V48, P200, DOI 10.1203/00006450-200008000-00013; YAMATO H, 1989, ENDOCRINOLOGY, V124, P511, DOI 10.1210/endo-124-1-511	46	12	12	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					737	+		10.1096/fj.02-0965fje	http://dx.doi.org/10.1096/fj.02-0965fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594170				2022-12-28	WOS:000181456900008
J	Isoda, T; Paolocci, N; Haghighi, K; Wang, CR; Wang, YB; Georgakopoulos, D; Servillo, G; Della Fazia, MA; Kranias, GF; DePaoli-Roach, AA; Sassone-Corsi, P; Kass, DA				Isoda, T; Paolocci, N; Haghighi, K; Wang, CR; Wang, YB; Georgakopoulos, D; Servillo, G; Della Fazia, MA; Kranias, GF; DePaoli-Roach, AA; Sassone-Corsi, P; Kass, DA			Novel regulation of cardiac force-frequency relation by CREM (cAMP response element modulator)	FASEB JOURNAL			English	Article						CRE-responsive transcription factor; mouse; phosphatase; phospholamban; sarcoplasmic reticulum; cardiac function	TRANSCRIPTION FACTOR CREM; ADENOVIRAL GENE-TRANSFER; HEART-FAILURE; BINDING PROTEIN; SER(16) PHOSPHORYLATION; DILATED CARDIOMYOPATHY; MICE LACKING; PHOSPHOLAMBAN; EXPRESSION; SPERMATOGENESIS	The cAMP response element modulator (CREM) plays pivotal roles in the hypothalamic-pituitary-gonadal axis. CREM mRNA is robustly expressed in human myocardium, and identified isoforms may suppress cAMP response element-mediated transcription. However, little is known about the physiological importance of CREM in intact hearts remains unknown. We studied CREM-null mice and age-matched control littermates by in vivo pressure-volume loops to analyze basal and reserve cardiac function. Basal systolic and diastolic function, echocardiographic morphology, and myocardial histology were normal in CREM-null animals. However functional reserve with increasing heart rate was markedly depressed, with less contractile augmentation (+22+/-9% CREM-/- vs. +62+/-11% controls, P<0.05) and relaxation shortening (5+/-5% CREM-/- vs. -18+/-3% controls; P<0.05) at faster rates. In contrast, isoproterenol dose-responses were similar, suggesting normal beta-adrenergic receptor-coupled signaling. Gene expression of calcium handling proteins (SERCA, phospholamban) and stress-response genes (e. g., alpha-skeletal actin, beta-myosin heavy chain, natriuretic peptides) were similar between groups. However, total and serine-phosphorylated phospholamban protein declined -38 and -64% respectively, and protein phosphatase-1 (PP1) activity increased 44% without increased protein levels (all P<0.01) in CREM-/- vs. controls. These results demonstrate novel involvement of CREM in regulation of PP1 activity and of PLB, likely resulting in a potent frequency-dependent influence on cardiac function.	Johns Hopkins Med Inst, Div Cardiol, Dept Med, Baltimore, MD 21287 USA; Univ Maryland, Dept Physiol, Baltimore, MD 21201 USA; Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN USA; ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, Strasbourg, France	Johns Hopkins University; Johns Hopkins Medicine; University System of Maryland; University of Maryland Baltimore; University System of Ohio; University of Cincinnati; Indiana University System; Indiana University-Purdue University Indianapolis; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Kass, DA (corresponding author), Johns Hopkins Med Inst, Div Cardiol, Dept Med, Halsted 500,600 N Wolfe St, Baltimore, MD 21287 USA.	dkass@jhmi.edu	paolocci, nazareno/A-7124-2009; Sassone-Corsi, Paolo/H-6182-2011	Servillo, Giuseppe/0000-0001-7960-7689; Della Fazia, Maria Agnese/0000-0002-5373-8477; Wang, Yibin/0000-0003-0852-0767; Paolocci, Nazareno/0000-0001-7011-997X	NHLBI NIH HHS [HL-64018, P01 HL 59408, HL-52318, HL-26057, P50 HL 52307] Funding Source: Medline; NIDDK NIH HHS [DK36569] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026057, P01HL059408, R37HL026057, R01HL064018, P50HL052318, P50HL052307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036569] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; Allen PB, 2000, J NEUROSCI, V20, P3537, DOI 10.1523/JNEUROSCI.20-10-03537.2000; Behr R, 2001, INT J ANDROL, V24, P126, DOI 10.1046/j.1365-2605.2001.00277.x; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; Boknik P, 2001, AM J PHYSIOL-HEART C, V280, pH786, DOI 10.1152/ajpheart.2001.280.2.H786; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; Brittsan AG, 2000, J BIOL CHEM, V275, P12129, DOI 10.1074/jbc.275.16.12129; Carr AN, 2002, MOL CELL BIOL, V22, P4124, DOI 10.1128/MCB.22.12.4124-4135.2002; Chu GX, 2000, J BIOL CHEM, V275, P38938, DOI 10.1074/jbc.M004079200; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; De Cesare D, 2000, J ENDOCRINOL INVEST, V23, P592, DOI 10.1007/BF03343781; DRAKEHOLLAND AJ, 1992, CARDIOVASC RES, V26, P496, DOI 10.1093/cvr/26.5.496; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; Fimia GM, 2001, MOL CELL ENDOCRINOL, V179, P17, DOI 10.1016/S0303-7207(01)00463-4; Foulkes NS, 1996, P NATL ACAD SCI USA, V93, P14140, DOI 10.1073/pnas.93.24.14140; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Georgakopoulos D, 2000, AM J PHYSIOL-HEART C, V279, pH443, DOI 10.1152/ajpheart.2000.279.1.H443; Georgakopoulos D, 2001, J PHYSIOL-LONDON, V534, P535, DOI 10.1111/j.1469-7793.2001.00535.x; Georgakopoulos D, 1998, AM J PHYSIOL-HEART C, V274, pH1416, DOI 10.1152/ajpheart.1998.274.4.H1416; GOLDSPINK PH, 1994, CIRC RES, V74, P1042, DOI 10.1161/01.RES.74.6.1042; Hagemann D, 2000, J BIOL CHEM, V275, P22532, DOI 10.1074/jbc.C000253200; Hajjar RJ, 1998, J MOL MED-JMM, V76, P747, DOI 10.1007/s001090050276; Hajjar RJ, 1997, CIRC RES, V81, P145, DOI 10.1161/01.RES.81.2.145; Hoshijima M, 2002, NAT MED, V8, P864, DOI 10.1038/nm739; Huang BY, 1999, CIRC RES, V85, P848, DOI 10.1161/01.RES.85.9.848; Maldonado R, 1999, P NATL ACAD SCI USA, V96, P14094, DOI 10.1073/pnas.96.24.14094; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Meyer M, 1999, AM J PHYSIOL-HEART C, V276, pH779, DOI 10.1152/ajpheart.1999.276.3.H779; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MULLER FU, 1995, CIRCULATION, V92, P2041, DOI 10.1161/01.CIR.92.8.2041; Muller FU, 1998, FASEB J, V12, P1191; Muller FU, 2002, FASEB J, V16, P103, DOI 10.1096/fj.02-0486fje; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; Netticadan T, 2000, CIRC RES, V86, P596, DOI 10.1161/01.RES.86.5.596; Neumann J, 1997, J MOL CELL CARDIOL, V29, P265, DOI 10.1006/jmcc.1996.0271; Pfeffer M, 1998, EUR J NEUROSCI, V10, P2896, DOI 10.1111/j.1460-9568.1998.00309.x; Ross J, 1998, BASIC RES CARDIOL, V93, P95; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Sande JB, 2002, CARDIOVASC RES, V53, P382, DOI 10.1016/S0008-6363(01)00489-8; SCHWMIDT U, 1999, AM J PHYSIOL, V277, pH474; SEED WA, 1984, CIRCULATION, V70, P799, DOI 10.1161/01.CIR.70.5.799; Servillo G, 1998, GENE DEV, V12, P3639, DOI 10.1101/gad.12.23.3639; SHARIR T, 1994, CIRCULATION, V89, P2045, DOI 10.1161/01.CIR.89.5.2045	47	18	18	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					144	151		10.1096/fj.01-0981com	http://dx.doi.org/10.1096/fj.01-0981com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554693				2022-12-28	WOS:000181456900039
J	Pei, W; Liou, AKF; Chen, J				Pei, W; Liou, AKF; Chen, J			Two caspase-mediated apoptotic pathways induced by rotenone toxicity in cortical neuronal cells	FASEB JOURNAL			English	Article						cortical neurons; MPT; caspase; apoptosis	MITOCHONDRIAL PERMEABILITY TRANSITION; CYTOCHROME-C RELEASE; OXIDATIVE STRESS; DNA FRAGMENTATION; RESPIRATORY-CHAIN; INDUCTION; EXCITOTOXICITY; SUPEROXIDE; INVOLVEMENT; ACTIVATION	Our results presented here suggest that cortical neurons degenerate via two caspase-mediated apoptotic pathways when challenged with 0.5 muM rotenone. Although these two pathways can be attributed to the loss of mitochondrial integrity, the triggers for these pathways are likely due to two separate subsequent events (the release of cytochrome c and the emergence of mitochondrial permeability transition [MPT]). Despite some reports suggesting that the release of cytochrome c is a consequence of MPT, the results of our time course experiments suggest otherwise. In fact, we observed that the release of cytochrome c occurred much earlier than MPT; hence, the former is unlikely to be a consequence of the latter. In addition, we observed that the presence of an MPT inhibitor did not attenuate the activation of caspase-3, and that caspase-1-mediated cell death did not exhibit nuclear condensation and DNA fragmentation. Taken together, these results suggest that there are two routes by which cortical neurons degenerate during ischemic injury or in neurodegenerative diseases.	Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15217 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Chen, J (corresponding author), Univ Pittsburgh, Sch Med S526, Dept Neurol, Biomed Sci Tower 3500,Terrace St, Pittsburgh, PA 15261 USA.	Jun@med.pitt.edu		Chen, Jun/0000-0002-8077-3403				Anjum R, 2001, CELL DEATH DIFFER, V8, P1038, DOI 10.1038/sj.cdd.4400915; Anup R, 1999, INDIAN J BIOCHEM BIO, V36, P266; Asumendi A, 2002, BRIT J CANCER, V86, P1951, DOI 10.1038/sj.bjc.6600356; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Campbell VA, 2001, NEUROPHARMACOLOGY, V40, P702, DOI 10.1016/S0028-3908(00)00210-0; Cao GD, 2002, J CEREBR BLOOD F MET, V22, P534, DOI 10.1097/00004647-200205000-00005; Cao GD, 2001, J NEUROSCI, V21, P4678, DOI 10.1523/JNEUROSCI.21-13-04678.2001; Cao GD, 2002, J NEUROSCI, V22, P5423; Cardoso SM, 2002, BRAIN RES, V931, P117, DOI 10.1016/S0006-8993(02)02256-4; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; CHAUDHRY A, 1988, MOL PHARMACOL, V34, P543; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; COSSON P, 1993, RACHIS, V5, P5; Esposti MD, 1998, BBA-BIOENERGETICS, V1364, P222, DOI 10.1016/S0005-2728(98)00029-2; Fasanmade AA, 2001, ARCH PHARM RES, V24, P126, DOI 10.1007/BF02976480; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; HART J, 1994, MICROCONTAMINATION, V12, P63; Hirsch T, 1997, BIOSCIENCE REP, V17, P67, DOI 10.1023/A:1027339418683; ISEKI S, 1986, EXP CELL RES, V167, P311, DOI 10.1016/0014-4827(86)90172-2; Isenberg JS, 2000, TOXICOL SCI, V53, P340, DOI 10.1093/toxsci/53.2.340; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; Kantrow SP, 2000, FREE RADICAL BIO MED, V28, P251, DOI 10.1016/S0891-5849(99)00238-5; Kim GW, 2002, J CEREBR BLOOD F MET, V22, P798, DOI 10.1097/00004647-200207000-00005; Kim GW, 2000, J CEREBR BLOOD F MET, V20, P119, DOI 10.1097/00004647-200001000-00016; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lim MLR, 2001, FEBS LETT, V503, P69, DOI 10.1016/S0014-5793(01)02693-X; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; LUSTIG HS, 1992, J NEUROCHEM, V59, P2193; Pasinelli P, 1998, P NATL ACAD SCI USA, V95, P15763, DOI 10.1073/pnas.95.26.15763; Schulz JB, 1996, NEUROCHEM INT, V29, P167, DOI 10.1016/0197-0186(95)00122-0; Simbula G, 1997, AM J PHYSIOL-CELL PH, V273, pC479, DOI 10.1152/ajpcell.1997.273.2.C479; TAKAYANAGI R, 1980, BIOCHEM J, V192, P853, DOI 10.1042/bj1920853; Takeyama N, 2002, EXP CELL RES, V274, P16, DOI 10.1006/excr.2001.5447; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; White MJ, 1996, J NEUROSCI METH, V70, P195, DOI 10.1016/S0165-0270(96)00118-5; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; YAGI T, 1991, J BIOENERG BIOMEMBR, V23, P211, DOI 10.1007/BF00762218; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5	44	48	48	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					520	+		10.1096/fj.02-0653fje	http://dx.doi.org/10.1096/fj.02-0653fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551850				2022-12-28	WOS:000181453700012
J	Okamoto, T; Yamagishi, S; Inagaki, Y; Amano, S; Koga, K; Abe, R; Takeuchi, M; Ohno, S; Yoshimura, A; Makita, T				Okamoto, T; Yamagishi, S; Inagaki, Y; Amano, S; Koga, K; Abe, R; Takeuchi, M; Ohno, S; Yoshimura, A; Makita, T			Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin	FASEB JOURNAL			English	Article						vascular endothelial growth factor; receptor for AGE; reactive oxygen species	ENDOTHELIAL GROWTH-FACTOR; PROSTACYCLIN-PRODUCING ABILITY; ANGIOTENSIN-II; TIE2 RECEPTOR; PROTEIN; HYPOXIA; CELLS; ANGIOPOIETIN-2; PROLIFERATION; PENTOSIDINE	We previously have found that advanced glycation end products (AGE), senescent macroproteins formed at an accelerated rate in diabetes, arise in vivo not only from glucose but also from reducing sugars. Furthermore, we recently have shown that glyceraldehyde- and glycolaldehyde-derived AGE (glycer- and glycol-AGE) are mainly involved in loss of pericytes, the earliest histopathological hallmark of diabetic retinopathy. However, the effects of these AGE proteins on angiogenesis, another vascular derangement in diabetic retinopathy, remain to be elucidated. In this study, we investigated whether these AGE proteins elicit changes in cultured endothelial cells that are associated with angiogenesis. When human skin microvascular endothelial cells (EC) were cultured with glycer-AGE or glycol-AGE, growth and tube formation of EC, the key steps of angiogenesis, were significantly stimulated. The AGE-induced growth stimulation was significantly enhanced in AGE receptor (RAGE) -overexpressed EC. Furthermore, AGE increased transcriptional activity of nuclear factor-kappaB (NF-kappaB) and activator protein-1 (AP-1) and then up-regulated mRNA levels of vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) in EC. Cerivastatin, a hydroxymethylglutaryl CoA reductase inhibitor; pyrrolidinedithiocarbamate; or curcumin was found to completely prevent the AGE-induced increase in NF-kappaB and AP-1 activity, VEGF mRNA up-regulation, and the resultant increase in DNA synthesis in microvascular EC. These results suggest that the AGE-RAGE interaction elicited angiogenesis through the transcriptional activation of the VEGF gene via NF-kappaB and AP-1 factors. By blocking AGE-RAGE signaling pathways, cerivastatin might be a promising remedy for treating patients with proliferative diabetic retinopathy.	Kurume Univ, Dept Med, Div Endocrinol & Metab, Sch Med, Kurume, Fukuoka 8300011, Japan; Hokkaido Univ, Sch Med, Dept Dermatol, Sapporo, Hokkaido 0608638, Japan; Hokuriku Univ, Dept Biochem, Kanazawa, Ishikawa 9201181, Japan; Hokkaido Univ, Sch Med, Dept Ophthalmol, Sapporo, Hokkaido 0608638, Japan; Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Fukuoka 8128582, Japan	Kurume University; Hokkaido University; Hokuriku University; Hokkaido University; Kyushu University	Yamagishi, S (corresponding author), Kurume Univ, Dept Med, Div Endocrinol & Metab, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	shoichi@med.kurume-u.ac.jp	Abe, Riichiro/A-5450-2012; Yoshimura, Akihiko/K-5515-2013					Bancroft CC, 2001, CLIN CANCER RES, V7, P435; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; BUCALA R, 1994, P NATL ACAD SCI USA, V91, P9441, DOI 10.1073/pnas.91.20.9441; Chua CC, 1998, BBA-MOL CELL RES, V1401, P187, DOI 10.1016/S0167-4889(97)00129-8; COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Duyndam MCA, 2001, J BIOL CHEM, V276, P48066, DOI 10.1074/jbc.M106282200; DYER DG, 1991, J BIOL CHEM, V266, P11654; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; Ichiki T, 2001, ARTERIOSCL THROM VAS, V21, P1896, DOI 10.1161/hq1201.099430; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; KAWAHARA A, 1995, P NATL ACAD SCI USA, V92, P8724, DOI 10.1073/pnas.92.19.8724; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MAKITA Z, 1991, NEW ENGL J MED, V325, P836, DOI 10.1056/NEJM199109193251202; MAKITA Z, 1992, SCIENCE, V258, P651, DOI 10.1126/science.1411574; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; NOMURA M, 1995, J BIOL CHEM, V270, P28316; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; Saaristo A, 2000, ONCOGENE, V19, P6122, DOI 10.1038/sj.onc.1203969; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takeuchi M, 1999, MOL MED, V5, P393, DOI 10.1007/BF03402128; Takeuchi M, 2000, MOL MED, V6, P114, DOI 10.1007/BF03401779; Vincent L, 2001, FEBS LETT, V495, P159, DOI 10.1016/S0014-5793(01)02337-7; Yamagishi S, 1999, LAB INVEST, V79, P501; Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723; Yamagishi S, 1998, DIABETOLOGIA, V41, P1435, DOI 10.1007/s001250051089; Yamagishi S, 1996, FEBS LETT, V384, P103, DOI 10.1016/0014-5793(96)00279-7; Yamagishi S, 1999, MICROVASC RES, V57, P329, DOI 10.1006/mvre.1999.2145; YAMAGISHI S, 1993, BIOCHEM BIOPH RES CO, V191, P840, DOI 10.1006/bbrc.1993.1293; Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V290, P973, DOI 10.1006/bbrc.2001.6312; Yamagishi S, 1999, BIOCHEM BIOPH RES CO, V258, P353, DOI 10.1006/bbrc.1999.0625; YAMAGISHI S, 1993, BIOCHEM BIOPH RES CO, V190, P418, DOI 10.1006/bbrc.1993.1064; YAMAGISHI SI, 1995, BIOCHEM BIOPH RES CO, V213, P681, DOI 10.1006/bbrc.1995.2185; Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI11771; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; ZIEGLER SF, 1993, ONCOGENE, V8, P663	44	230	245	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1928	+		10.1096/fj.02-0030fje	http://dx.doi.org/10.1096/fj.02-0030fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368225				2022-12-28	WOS:000179167600017
J	Sugawara, T; Lewen, A; Gasche, Y; Yu, FS; Chan, PH				Sugawara, T; Lewen, A; Gasche, Y; Yu, FS; Chan, PH			Overexpression of SOD1 protects vulnerable motor neurons after spinal cord injury by attenuating mitochondrial cytochrome c release	FASEB JOURNAL			English	Article						superoxide dismutase; superoxide; reactive oxygen species; caspase-9	AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; CASPASE-3 APOPTOTIC CASCADE; CUZN-SUPEROXIDE-DISMUTASE; NECROSIS-FACTOR-ALPHA; OXIDATIVE STRESS; GLIAL APOPTOSIS; UP-REGULATION; MOUSE MODEL	Defective Cu,Zn-superoxide dismutase (SOD1) is responsible for some types of amyotrophic lateral sclerosis, and ventral horn motor neurons (VMN) have been shown to die through a mitochondria-dependent apoptotic pathway after chronic exposure to high levels of reactive oxygen species (ROS). VMN are also selectively vulnerable to mild spinal cord injury (SCI); however, the involvement of SOD1, ROS, and apoptosis in their death has not been clarified. Mild compression SCI was induced in SOD1-overexpressing transgenic rats and wild-type littermates. Superoxide production, mitochondrial release of cytochrome c, and activation of caspase-9 were examined, and apoptotic DNA injury was also characterized. In the wild-type animals, increased superoxide production, mitochondrial release of cytochrome c, and cleaved caspase-9 were observed exclusively in VMN after SCI. Subsequently, a majority of VMN (75%) selectively underwent delayed apoptotic cell death. Transgenic animals showed less superoxide production, mitochondrial cytochrome c release, and caspase-9 activation, resulting in death of only 45% of the VMN. These results suggest that the ROS-initiated mitochondrial signaling pathway possibly plays a pivotal role in apoptotic VMN death after SCI and that increased levels of SOD1 in VMN reduce oxidative stress, thereby attenuating the activation of the pathway and delayed cell death.	Stanford Univ, Neurosurg Labs, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Neurol & Neurol Sci, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Program Neurosci, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Chan, PH (corresponding author), Stanford Univ, Neurosurg Labs, Dept Neurosurg, Sch Med, 1201 Welch Rd,MSLS P314, Stanford, CA 94305 USA.	phchan@leland.stanford.edu	Lewén, Anders/A-5156-2013	Lewén, Anders/0000-0003-4925-1348; Yu, Fengshan/0000-0001-8620-3084				Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Buki A, 2000, J NEUROSCI, V20, P2825; Carriedo SG, 2000, J NEUROSCI, V20, P240, DOI 10.1523/JNEUROSCI.20-01-00240.2000; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Chan PH, 1996, ADV NEUROL, V71, P271; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Clark RSB, 1997, J NEUROSCI, V17, P9172; Copin JC, 2001, FASEB J, V15, P525, DOI 10.1096/fj.00-0330com; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Enari M, 1998, NATURE, V393, P396, DOI 10.1038/30782; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Fujimura M, 1999, J NEUROSCI, V19, P3414; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Guegn C, 2001, J NEUROSCI, V21, P6569, DOI 10.1523/JNEUROSCI.21-17-06569.2001; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Kim GW, 2000, J CEREBR BLOOD F MET, V20, P1690, DOI 10.1097/00004647-200012000-00008; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Launey T, 1998, BRAIN RES, V781, P148, DOI 10.1016/S0006-8993(97)01225-0; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lewen A, 2001, NEUROBIOL DIS, V8, P380, DOI 10.1006/nbdi.2001.0396; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; Liu RG, 1998, ANN NEUROL, V44, P763, DOI 10.1002/ana.410440510; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XZ, 1997, J NEUROSCI, V17, P5395; Murakami K, 1998, J NEUROSCI, V18, P205; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pan WH, 1999, J NEUROSCI, V19, P3649; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; RINK A, 1995, AM J PATHOL, V147, P1575; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROSS IB, 1993, NEUROSURGERY, V33, P470; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Springer JE, 2000, J NEUROSCI, V20, P7246; SUGAWARA T, 2002, IN PRESS J NEUROSCI; Terro F, 1998, BRAIN RES, V809, P319, DOI 10.1016/S0006-8993(98)00883-X; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; vonEuler M, 1997, EXP NEUROL, V145, P502, DOI 10.1006/exnr.1997.6481; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	53	104	105	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1997	+		10.1096/fj.02-0251fje	http://dx.doi.org/10.1096/fj.02-0251fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368231				2022-12-28	WOS:000179167600024
J	van der Schaft, DWJ; Dings, RPM; de Lussanet, QG; van Eijk, LI; Nap, AW; Beets-Tan, RGH; Steege, JCABT; Wagstaff, J; Mayo, KH; Griffioen, AW				van der Schaft, DWJ; Dings, RPM; de Lussanet, QG; van Eijk, LI; Nap, AW; Beets-Tan, RGH; Steege, JCABT; Wagstaff, J; Mayo, KH; Griffioen, AW			The designer antiangiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models	FASEB JOURNAL			English	Article						apoptosis; melanoma; migration; ovarian carcinoma	ANGIOGENESIS INHIBITOR; MICROVESSEL DENSITY; PLATELET FACTOR-4; APOPTOSIS; ANGIOSTATIN; ENDOSTATIN; CARCINOMA; SURFACE; CANCER; PROLIFERATION	The de novo designed angiogenesis inhibitor anginex was tested in vitro and in vivo for its mechanism of action and antitumor activity. The data presented here demonstrate that anginex is a powerful antiangiogenic agent with significant antitumor activity. The mechanism of action of anginex was found to be the induction of anoikis leading to apoptosis in angiogenically activated endothelial cells, resulting in an up to 90% inhibition of migration in the wound assay. Anginex inhibited angiogenesis as demonstrated in the in vitro mouse aortic ring assay. In addition, tumor-induced angiogenesis in the chick chorioallantoic membrane was markedly inhibited. Anginex showed profound antitumor activity in the syngeneic mouse B16F10 melanoma model and in a xenograft human tumor model. Microvessel density determination as well as magnetic resonance imaging showed that the antitumor activity in these tumor models resulted from the antiangiogenic activity of anginex. A complete absence of toxicity was observed in these models. The data presented here demonstrate that anginex is a promising agent for further clinical development.	Univ Maastricht, Angiogenesis Lab, Dept Internal Med, GROW, Maastricht, Netherlands; Univ Maastricht, Dept Radiol, Maastricht, Netherlands; Univ Maastricht, Dept Obstet & Gynecol, Maastricht, Netherlands; Univ Maastricht, Dept Pathol, Maastricht, Netherlands; Univ Minnesota, Ctr Hlth Sci, Dept Biochem, Minneapolis, MN USA	Maastricht University; Maastricht University; Maastricht University; Maastricht University; University of Minnesota System; University of Minnesota Twin Cities	Griffioen, AW (corresponding author), Univ Hosp Maastricht, Angiogenesis Lab, Dept Pathol, P Debyelaan 25, NL-6202 AZ Maastricht, Netherlands.	a.griffioen@intmed.unimaas.nl	Beets-Tan, Regina/AAZ-9119-2020; Dings, Ruud/C-6188-2008	Wagstaff, John/0000-0002-1140-5981; Dings, Ruud/0000-0001-7686-1331				BOUMATERSTEEGE JCA, 2002, CRIT REV EUKAR GENE, V11, P41; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Fujita E, 1996, BIOCHEM BIOPH RES CO, V224, P74, DOI 10.1006/bbrc.1996.0986; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Griffioen AW, 1996, CANCER RES, V56, P1111; Griffioen AW, 1997, BLOOD, V90, P1150, DOI 10.1182/blood.V90.3.1150.1150_1150_1159; GRIFFIOEN AW, 2001, BIOCHEM J, P233; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; HARDER R, 1991, EXP CELL RES, V197, P259, DOI 10.1016/0014-4827(91)90431-S; Hillen HFP, 1997, INT J CANCER, V74, P81; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Mayo KH, 1996, PROTEIN SCI, V5, P1301, DOI 10.1002/pro.5560050709; Molema G, 1998, IMMUNOL TODAY, V19, P392, DOI 10.1016/S0167-5699(98)01314-0; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; van der Schaft DWJ, 2000, BLOOD, V96, P176, DOI 10.1182/blood.V96.1.176.013k32_176_181; van der Schaft DWJ, 2002, ANN MED, V34, P19; vanDijke CF, 1996, RADIOLOGY, V198, P813, DOI 10.1148/radiology.198.3.8628876; Wild R, 2000, MICROVASC RES, V59, P368, DOI 10.1006/mvre.1999.2233; YAMAOKA M, 1993, CANCER RES, V53, P4262; YAMAOKA M, 1993, CANCER RES, V53, P5233; Yokoyama Y, 2000, CANCER RES, V60, P2190	34	91	99	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1991	+		10.1096/fj.02-0509fje	http://dx.doi.org/10.1096/fj.02-0509fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397082				2022-12-28	WOS:000179167600013
J	Georget, M; Mateo, P; Vandecasteele, G; Jurevicius, J; Lipskaia, L; Defer, N; Hanoune, J; Hoerter, J; Fischmeister, R				Georget, M; Mateo, P; Vandecasteele, G; Jurevicius, J; Lipskaia, L; Defer, N; Hanoune, J; Hoerter, J; Fischmeister, R			Augmentation of cardiac contractility with no change in L-type Ca2+ current in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8)	FASEB JOURNAL			English	Article						cAMP; isolated heart; calcium transient; cell shortening; compartmentation	BETA(2)-ADRENERGIC RECEPTOR OVEREXPRESSION; GENETICALLY-ENGINEERED MICE; LEFT-VENTRICULAR FUNCTION; HEART-FAILURE; MYOCARDIAL-CONTRACTILITY; RYANODINE RECEPTORS; TROPONIN-I; PHOSPHORYLATION; PHOSPHOLAMBAN; MOUSE	The beta-adrenergic cascade is severely impaired in heart failure(HF), in part because of a reduction in the activity of the two dominant cardiac adenylyl cyclase (AC) isoforms, AC5 and AC6. Hence, cardiac-directed AC overexpression is a conceivable therapeutic strategy in HF. In this study, we explored the consequences at the cellular and organ level of a cardiac-directed expression of the human AC8 in the transgenic mouse line AC8TG. Unlike AC5 and AC6, which are inhibited by intracellular Ca2+, AC8 is stimulated by Ca2+-calmodulin. Langendorff perfused hearts from AC8TG mice had a twofold higher left ventricular systolic pressure, a 40% faster heart rate, a 37% faster relaxation, and a 30% higher sensitivity to external Ca2+ than nontransgenic control mice (NTG). Cell shortening measured in isolated ventricular myocytes developed 22% faster and relaxed 43% faster in AC8TG than in NTG mice. Likewise, Ca2+ transients measured in fluo-3 AM-loaded myocytes were 30% higher and relaxed 24% faster in AC8TG compared with NTG mice. In spite of the large increase in Ca2+ transients and contraction, expression of AC8 had no effect on the whole-cell L-type Ca2+ current (I-Ca,I-L) amplitude. Moreover, I-Ca,I-L was unchanged even when AC8 was activated by raising intracellular Ca2+. Thus, cardiac expression of AC8 leads to an increase in cAMP that activates specifically Ca2+ uptake into the sarcoplasmic reticulum but not Ca2+ influx at the sarcolemma, suggesting a strong compartmentation of the cAMP signal.	Univ Paris Sud, Fac Pharm, INSERM, U446,Lab Cardiol Cellulaire & Mol, F-92296 Chatenay Malabry, France; Hop Henri Mondor, INSERM, U99, Lab Regulat Genes & Signalisat Cellulaire, F-94010 Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Fischmeister, R (corresponding author), Univ Paris Sud, Fac Pharm, INSERM, U446,Lab Cardiol Cellulaire & Mol, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.	Fisch@vjf.inserm.fr	Lipskaia, Larissa/AAK-9322-2020; Fischmeister, Rodolphe/L-6061-2018; Vandecasteele, Gregoire/M-2922-2018	Fischmeister, Rodolphe/0000-0003-2086-9865; Vandecasteele, Gregoire/0000-0002-4046-4171				Bittner HB, 1997, J MOL CELL CARDIOL, V29, P961, DOI 10.1006/jmcc.1996.0339; CALI JJ, 1994, J BIOL CHEM, V269, P12190; Cross HR, 1999, CIRC RES, V85, P1077; DEFER N, 1994, FEBS LETT, V351, P109, DOI 10.1016/0014-5793(94)00836-1; Defer N, 2000, AM J PHYSIOL-RENAL, V279, pF400, DOI 10.1152/ajprenal.2000.279.3.F400; Du XJ, 2000, CARDIOVASC RES, V48, P448, DOI 10.1016/S0008-6363(00)00187-5; Du XJ, 2000, CIRCULATION, V101, P71, DOI 10.1161/01.CIR.101.1.71; Du XJ, 2001, CARDIOVASC RES, V50, P443, DOI 10.1016/S0008-6363(01)00244-9; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; Espinasse I, 1999, CARDIOVASC RES, V42, P87, DOI 10.1016/S0008-6363(98)00283-1; Gao MH, 1999, CIRCULATION, V99, P1618, DOI 10.1161/01.CIR.99.12.1618; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; HOIT BD, 1995, CIRC RES, V77, P632, DOI 10.1161/01.RES.77.3.632; ISHIKAWA Y, 1994, J CLIN INVEST, V93, P2224, DOI 10.1172/JCI117219; Iwase M, 1997, AM J PHYSIOL-HEART C, V272, pH585, DOI 10.1152/ajpheart.1997.272.1.H585; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; Lai NC, 2000, CIRCULATION, V102, P2396, DOI 10.1161/01.CIR.102.19.2396; Li L, 2000, AM J PHYSIOL-HEART C, V278, pH769, DOI 10.1152/ajpheart.2000.278.3.H769; Li L, 1998, AM J PHYSIOL-HEART C, V274, pH1335, DOI 10.1152/ajpheart.1998.274.4.H1335; Liggett SB, 2000, CIRCULATION, V101, P1707; Lipskaia L, 2000, CIRC RES, V86, P795, DOI 10.1161/01.RES.86.7.795; LORENZ JN, 1997, AM J PHYSIOL-HEART C, V273, pH2826; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; Rapundalo ST, 1998, CARDIOVASC RES, V38, P559, DOI 10.1016/S0008-6363(98)00063-7; Reithmann C, 1997, EUR J PHARMACOL, V330, P79, DOI 10.1016/S0014-2999(97)10131-5; Rockman HA, 1997, AM J PHYSIOL-HEART C, V272, pH1553, DOI 10.1152/ajpheart.1997.272.4.H1553; Rockman HA, 1996, J CLIN INVEST, V97, P1618, DOI 10.1172/JCI118587; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; Tepe NM, 1999, BIOCHEMISTRY-US, V38, P16706, DOI 10.1021/bi991619k; Tepe NM, 1999, FEBS LETT, V458, P236, DOI 10.1016/S0014-5793(99)01147-3; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Wang X, 2000, MOL CELL BIOCHEM, V214, P131, DOI 10.1023/A:1007131925048; Wolska BM, 1996, AM J PHYSIOL-HEART C, V271, pH1250, DOI 10.1152/ajpheart.1996.271.3.H1250; YOSHIDA A, 1992, J BIOCHEM-TOKYO, V111, P186, DOI 10.1093/oxfordjournals.jbchem.a123735; ZHANG R, 1995, CIRC RES, V76, P1028, DOI 10.1161/01.RES.76.6.1028; Zhang R, 1995, J BIOL CHEM, V270, P30773, DOI 10.1074/jbc.270.51.30773; Zhou YY, 1999, MOL PHARMACOL, V56, P485, DOI 10.1124/mol.56.3.485; Zhou YY, 1999, J PHYSIOL-LONDON, V521, P351, DOI 10.1111/j.1469-7793.1999.00351.x; Zhou YY, 1997, AM J PHYSIOL-HEART C, V273, pH1611, DOI 10.1152/ajpheart.1997.273.3.H1611	43	30	30	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1636	+		10.1096/fj.02-0292fje	http://dx.doi.org/10.1096/fj.02-0292fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206999				2022-12-28	WOS:000177814000009
J	Mitsunaga, Y; Ciric, B; Van Keulen V; Warrington, AE; Soldan, MMP; Bieber, AJ; Rodriguez, M; Pease, LR				Mitsunaga, Y; Ciric, B; Van Keulen, V; Warrington, AE; Soldan, MMP; Bieber, AJ; Rodriguez, M; Pease, LR			Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease	FASEB JOURNAL			English	Article						recombinant IgM expression vector; Theiler's virus-induced demyelination; remyelination; dhfr	MONOCLONAL-ANTIBODY; MULTIPLE-SCLEROSIS; NATURAL AUTOANTIBODY; REMYELINATION; OLIGODENDROCYTES	Certain human sera from patients with monoclonal gammopathies contain factors that induce myelin repair in animals with demyelinating disease. We hypothesize that antibodies functionally distinguish the serum of one patient from another. However, pooled normal polyclonal human IgM antibodies also induce remyelination. Definitive proof that specific antibodies are the biologically active components of serum is missing because unquestionably pure preparations of antibody molecules cannot be generated by fractionation. To demonstrate definitively that antibody is the biologically active component of patient serum, recombinant antibody was generated for evaluation in bioassays. The induction of remyelination in vivo requires milligram quantities of antibody. Consequently, an expression system was engineered to express high-titer, recombinant human IgM antibodies in vitro. A resulting recombinant antibody (rHIgM22) was evaluated for its ability to induce remyelination in the Theiler's virus mouse model of chronic-progressive demyelinating disease. We demonstrate that a single recombinant monoclonal antibody recapitulates the key characteristics of patient serum, including binding specificity, the induction of calcium signals in oligodendrocytes in vitro, and the induction of myelin repair within demyelinated plaques in vivo. The rHIgM22 antibody provides a new venue for the analysis of mechanisms governing remyelination and may prove useful in the treatment of demyelinating diseases.	Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Immunol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Pease, LR (corresponding author), Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.	pease.larry@mayo.edu		Paz Soldan, M. Mateo/0000-0003-0521-7789; Rodriguez, Moses/0000-0001-6328-6497				Asakura K, 1997, J NEUROCHEM, V68, P2281; Ciric B, 2001, BLOOD, V97, P321, DOI 10.1182/blood.V97.1.321; KISHIMOTO T, 1989, NUCLEIC ACIDS RES, V17, P4385, DOI 10.1093/nar/17.11.4385; LINNINGTON C, 1984, J NEUROIMMUNOL, V6, P387, DOI 10.1016/0165-5728(84)90064-X; Losman MJ, 1997, CANCER-AM CANCER SOC, V80, P2660, DOI 10.1002/(SICI)1097-0142(19971215)80:12+<2660::AID-CNCR43>3.3.CO;2-I; Miller DJ, 1997, J NEUROIMMUNOL, V75, P204, DOI 10.1016/S0165-5728(97)00027-1; MILLER DJ, 1995, J IMMUNOL, V154, P2460; MILLER DJ, 1994, J NEUROSCI, V14, P6230; Niedbala WG, 1998, HYBRIDOMA, V17, P299, DOI 10.1089/hyb.1998.17.299; Pavelko KD, 1998, J NEUROSCI, V18, P2498; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; TSUJIMOTO Y, 1984, NUCLEIC ACIDS RES, V12, P8407, DOI 10.1093/nar/12.22.8407; WARRINGTON AE, 1992, J NEUROSCI RES, V33, P338, DOI 10.1002/jnr.490330218; Warrington AE, 2000, P NATL ACAD SCI USA, V97, P6820, DOI 10.1073/pnas.97.12.6820	14	65	69	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1325	+		10.1096/fj.01-0994fje	http://dx.doi.org/10.1096/fj.01-0994fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154009				2022-12-28	WOS:000176683900023
J	Pecheur, I; Peyruchaud, O; Serre, CM; Guglielmi, J; Voland, C; Bourre, F; Margue, C; Cohen-Solal, M; Buffet, A; Kieffer, N; Clezardin, P				Pecheur, I; Peyruchaud, O; Serre, CM; Guglielmi, J; Voland, C; Bourre, F; Margue, C; Cohen-Solal, M; Buffet, A; Kieffer, N; Clezardin, P			Integrin alpha v beta 3 expression confers on tumor cells a greater propensity to metastasize to bone	FASEB JOURNAL			English	Article						metastasis; breast cancer; bone tropism; vitronectin receptor	BREAST-CANCER CELLS; N-TERMINAL DOMAIN; BISPHOSPHONATE IBANDRONATE; ADHESION; ALPHA(V)BETA(3); RECEPTORS; INVOLVEMENT; ACTIVATION; PROSTATE; BINDING	The reasons why tumor cells metastasize to bone remain obscure. There is some evidence to support the theory that integrins (acting as cell surface adhesion receptors) play a role in mediating metastasis in certain organs. Here, we report that overexpression of a functionally active integrin alphavbeta3 in Chinese hamster ovary (CHO) tumor cells drastically increased the incidence, number, and area of bone metastases in nude mice compared with those observed in mock-transfected CHO cells (CHO dhfr(+)) or in CHO cells expressing a functionally inactive integrin alphavbeta3 (CHO 3 744). Moreover, a breast cancer cell line (B02) established from bone metastases caused by MDA-MB-231 cells constitutively overexpressed integrin alphavbeta3, whereas the cell surface expression level of other integrins remained unchanged. In vivo, the extent of bone metastases in B02-bearing mice was significantly increased compared with that of MDAMB-231-bearing mice. In vitro, B02 cells and CHO cells expressing a functionally active integrin alphavbeta3 exhibited substantially increased invasion of and adhesion to mineralized bone, bone sialoprotein, and collagen compared with those found with MDA-MB-231, CHO dhfr(+), and CHO 3 744 cells, respectively. Overall, our findings suggest that integrin alphavbeta3 expression in tumor cells accelerates the development of osteolytic lesions, presumably through increased invasion of and adhesion to bone.	Fac Med Laennec, INSERM, Res Unit 403, F-69372 Lyon 08, France; CNRS, UMR 5533, Pessac, France; CRP Sante, CNRS, Lab Franco Luxembourgeois Rech Biomed, Luxembourg, Luxembourg; Lariboisiere Hosp, INSERM, Res Unit 349, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Luxembourg Institute of Health; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Clezardin, P (corresponding author), Fac Med Laennec, INSERM, Res Unit 403, Rue Guillaume Paradin, F-69372 Lyon 08, France.	clezardin@lyon151.inserm.fr	Clezardin, Philippe/M-8071-2014	Clezardin, Philippe/0000-0003-0149-4463; Peyruchaud, Olivier/0000-0002-5393-4945				Abdel-Ghany M, 2001, J BIOL CHEM, V276, P25438, DOI 10.1074/jbc.M100478200; Boissier S, 1997, CANCER RES, V57, P3890; Brakebusch C, 2002, J CLIN INVEST, V109, P999, DOI 10.1172/JCI200215468; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Byzova TV, 2000, EXP CELL RES, V254, P299, DOI 10.1006/excr.1999.4765; Cheresh D.A., 1993, ADV MOL CELL BIOL, V6, P225; CLEZARDIN P, 1993, CANCER RES, V53, P1421; Clezardin P, 1997, BIOCHEM J, V321, P819, DOI 10.1042/bj3210819; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; FISHER L, 1999, EXTRACELLULAR MATRIX, P368; Gauthier K, 1999, EMBO J, V18, P623, DOI 10.1093/emboj/18.3.623; Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18; Hiraga T, 2001, CANCER RES, V61, P4418; KOUKOULIS GK, 1991, AM J PATHOL, V139, P787; Liapis H, 1996, DIAGN MOL PATHOL, V5, P127, DOI 10.1097/00019606-199606000-00008; Magnetto S, 1999, INT J CANCER, V83, P263, DOI 10.1002/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T; MasellisSmith A, 1997, CANCER RES, V57, P930; MATSUSHIMA T, 1996, TRENDS CHEM PHYS, V4, P1; MIETTINEN M, 1993, AM J PATHOL, V142, P1009; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; NAGLE RB, 1995, AM J PATHOL, V146, P1498; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Peyruchaud O, 1998, BLOOD, V92, P4178, DOI 10.1182/blood.V92.11.4178.423k08_4178_4187; Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Schaffner-Reckinger E, 1998, J BIOL CHEM, V273, P12623, DOI 10.1074/jbc.273.20.12623; Silletti S, 2001, P NATL ACAD SCI USA, V98, P119, DOI 10.1073/pnas.011343298; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Sung V, 1998, J CELL PHYSIOL, V176, P482, DOI 10.1002/(SICI)1097-4652(199809)176:3<482::AID-JCP5>3.0.CO;2-K; Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200; van der Pluijm G, 1997, LAB INVEST, V77, P665; Voland C, 2000, J BONE MINER RES, V15, P361, DOI 10.1359/jbmr.2000.15.2.361; Waltregny D, 2000, J BONE MINER RES, V15, P834, DOI 10.1359/jbmr.2000.15.5.834; Yoneda T, 1997, J CLIN INVEST, V99, P2509, DOI 10.1172/JCI119435	36	194	204	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1266	+		10.1096/fj.01-0911fje	http://dx.doi.org/10.1096/fj.01-0911fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12153995				2022-12-28	WOS:000176683900022
J	Coltella, N; Manara, MC; Cerisano, V; Trusolino, L; Di Renzo, MF; Scotlandi, K; Ferracini, R				Coltella, N; Manara, MC; Cerisano, V; Trusolino, L; Di Renzo, MF; Scotlandi, K; Ferracini, R			Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma	FASEB JOURNAL			English	Article						signal transduction; MAPK; PKB/AKT; invasion; tumor growth	HEPATOCYTE GROWTH-FACTOR; FACTOR SIGNAL-TRANSDUCTION; FACTOR SCATTER FACTOR; TYROSINE KINASE; MET PROTOONCOGENE; MUSCULOSKELETAL TUMORS; OSTEO-SARCOMA; MAP KINASE; NEUROTROPHIN RECEPTORS; PLASMINOGEN-ACTIVATOR	Signal transduction downstream HGF receptor (MET) activation involves multiple pathways that account for mitogenesis, motility and morphogenesis in a cell type-dependent fashion. MET receptor is aberrantly expressed in almost 100% of human osteosarcomas. We analyzed the effect of the MET receptor activation in five human osteosarcoma cell lines evaluating the levels of HGF-dependent activation of MAPK and PKB/AKT as biochemical readouts of mitogenic and invasive responses, respectively. All the cell lines tested expressed high levels of the MET proto-oncogene. Four cell lines showed activation of the MAPK cascade upon HGF stimulation, suggesting that this growth factor serves a common proliferative function in osteosarcomas. Two lines showed activation of PKB/AKT, that is known to be involved in migration mediated by HGF receptor. Accordingly, cell lines where MAPK cascade was activated responded to HGF with increased proliferation, while induction and inhibition of PKB/AKT activity corresponded to acquisition or block of the invasive-motile response to HGF, respectively. Both the HGF dependent responses were reverted by the specific MET inhibitor K252a. These data show that HGF activates both the mitogen and motogen machinery in osteosarcoma cells and suggest that HGF might promote their malignant behavior by concomitant activation of different pathways and biological functions.	Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Lab Canc Genet,Div Mol Oncol, I-10060 Candiolo, To, Italy; Ist Ortoped Rizzoli, Oncol Res Lab, Bologna, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IRCCS Istituto Ortopedico Rizzoli	Coltella, N (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment IRCC, Lab Canc Genet,Div Mol Oncol, Strada Prov 141,Km 3-95, I-10060 Candiolo, To, Italy.	nadia.coltella@ircc.it	Ferracini, Riccardo/AAL-4622-2020; Manara, Maria Cristina/K-3366-2018; Coltella, Nadia/AAO-3671-2020; Trusolino, Livio/A-3896-2011; Scotlandi, Katia/J-9009-2016; DI RENZO, Maria Flavia/B-6091-2012	Manara, Maria Cristina/0000-0001-5686-720X; Scotlandi, Katia/0000-0001-6114-9499; DI RENZO, Maria Flavia/0000-0002-5093-3373; Trusolino, Livio/0000-0002-6379-3365				AHN NG, 1991, J BIOL CHEM, V266, P4220; Albini A, 1998, Pathol Oncol Res, V4, P230; BACCI G, 1988, TUMORI J, V74, P421, DOI 10.1177/030089168807400408; Bacci G, 2001, CLIN ORTHOP RELAT R, P186; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; BOROS P, 1995, LANCET, V345, P293, DOI 10.1016/S0140-6736(95)90279-1; Chin LS, 1997, CLIN CANCER RES, V3, P771; Comoglio PM, 2001, NAT CELL BIOL, V3, pE161, DOI 10.1038/35083116; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DAHLIN DC, 1967, J BONE JOINT SURG AM, VA 49, P101, DOI 10.2106/00004623-196749010-00008; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; FERRACINI R, 1995, ONCOGENE, V10, P739; Ferracini R, 1996, ONCOGENE, V12, P1697; Ferracini R, 2000, J CELL PHYSIOL, V184, P191, DOI 10.1002/1097-4652(200008)184:2<191::AID-JCP6>3.0.CO;2-B; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GOORIN AM, 1981, SURG CLIN N AM, V61, P1379; HALABAN R, 1992, ONCOGENE, V7, P2195; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KOBAYASHI H, 1992, CANCER RES, V52, P3610; MALAWER MM, 1983, J SURG ONCOL, V22, P236, DOI 10.1002/jso.2930220406; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NYE SH, 1992, MOL BIOL CELL, V3, P677, DOI 10.1091/mbc.3.6.677; Oda Y, 2000, HUM PATHOL, V31, P709, DOI 10.1053/hupa.2000.8230; Oda Yoshinao, 1995, General and Diagnostic Pathology, V141, P97; Olivero M, 1999, INT J CANCER, V82, P640, DOI 10.1002/(SICI)1097-0215(19990827)82:5<640::AID-IJC4>3.0.CO;2-6; PARK M, 1986, COLD SPRING HARB SYM, V51, P967, DOI 10.1101/SQB.1986.051.01.110; Pavalko FM, 2003, J CELL PHYSIOL, V194, P194, DOI 10.1002/jcp.10221; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Porte H, 1998, CLIN CANCER RES, V4, P1375; Ried S, 1999, J BIOL CHEM, V274, P16377, DOI 10.1074/jbc.274.23.16377; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1995, CANCER RES, V55, P1963; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; Ruggeri BA, 1999, CURR MED CHEM, V6, P845; SANTOS OFP, 1994, DEV BIOL, V163, P525, DOI 10.1006/dbio.1994.1169; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Scotlandi K, 1996, AM J PATHOL, V149, P1209; SCOTLANDI K, 1992, ANN ONCOL, V3, pS29, DOI 10.1093/annonc/3.suppl_2.S29; SERRA M, 1993, ANTICANCER RES, V13, P323; SERRA M, 1992, HUM PATHOL, V23, P1326, DOI 10.1016/0046-8177(92)90050-D; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; Stefanou DG, 1998, ANTICANCER RES, V18, P4673; TAPLEY P, 1992, ONCOGENE, V7, P371; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wallenius V, 2000, AM J PATHOL, V156, P821, DOI 10.1016/S0002-9440(10)64950-4; WUISMAN P, 1990, J BONE JOINT SURG AM, V72A, P60, DOI 10.2106/00004623-199072010-00010; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	59	68	79	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1162	+		10.1096/fj.02-0576fje	http://dx.doi.org/10.1096/fj.02-0576fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709413				2022-12-28	WOS:000182580100023
J	Fiorucci, S; Distrutti, E; de Lima, OM; Romano, M; Mencarelli, A; Barbanti, M; Palazzini, E; Morelli, A; Wallace, JL				Fiorucci, S; Distrutti, E; de Lima, OM; Romano, M; Mencarelli, A; Barbanti, M; Palazzini, E; Morelli, A; Wallace, JL			Relative contribution of acetylated cyclooxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin	FASEB JOURNAL			English	Article						gastric adaptation; cyclooxygenase 1; ATL; aspirin-triggered lipoxin; licofelone	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRIGGERED 15-EPI-LIPOXIN A(4); STABLE ANALOGS; RAT STOMACH; INHIBITION; DAMAGE; 5-LIPOXYGENASE; INFLAMMATION; LEUKOTRIENES; EXPRESSION	In addition to inhibiting formation of prothrombotic eicosanoids, aspirin causes the acetylation of cyclooxygenase (COX)-2. The acetylated COX-2 remains active, and upon cell activation, initiates the generation of 15R-HETE, a lipid substrate for 5-lipoxygenase (LOX) leading to the formation of 15-epi-LXA(4) (also termed "aspirin-triggered lipoxin," or ATL). Because ATL potently inhibits polymorphonuclear cell (PMN) function, we assessed the relative contribution of this lipid mediator in conjunction with another 5-LOX product, the leukotriene (LT)B-4, to the pathogenesis of acute damage and gastric adaptation to aspirin. Data presented herein indicate that acute injury and gastric adaptation to aspirin is associated with ATL generation. Administration of COX inhibitors (celecoxib, indomethacin, ketoprofen) to aspirin-treated rats exacerbated acute injury and abolished adaptation to aspirin. Moreover, it inhibited ATL formation and caused a four- to fivefold increase in LTB4 synthesis. In contrast, licofelone, a COX/5-LOX inhibitor, did not exacerbate acute gastric injury nor did it interfere with gastric adaptation to aspirin. Although licofelone blocked ATL and LTB4 formation in aspirin-treated rats, it attenuated aspirin-induced gastric PMN margination. These findings indicate that the balance between the production of LTB4 and ATL modulates PMN recruitment/function and gastric mucosal responses to aspirin.	Univ Perugia, Dipartimento Med Clin & Sperimentale, Clin Gastroenterol & Epatol, I-06100 Perugia, Italy; Univ Calgary, Dept Pharmacol, Calgary, AB, Canada; Univ G DAnnunzio, Dipartimento Sci Biomediche, Chieti, Italy; Alfa Wassermann, Bologna, Italy	University of Perugia; University of Calgary; G d'Annunzio University of Chieti-Pescara	Fiorucci, S (corresponding author), Digest Policlin, Clin Gastroenterol & Endoscopia, I-06100 Perugia, Italy.	fiorucci@unipg.it	Wallace, John/AAL-3763-2021; Fiorucci, Stefano/I-1251-2012; Romano, Mario/I-7986-2012	Romano, Mario/0000-0001-8512-1458				ANDREWS FJ, 1994, AM J PHYSIOL, V266, pG657, DOI 10.1152/ajpgi.1994.266.4.G657; Chiang N, 1998, J PHARMACOL EXP THER, V287, P779; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Davies NM, 1997, ALIMENT PHARM THERAP, V11, P1101, DOI 10.1046/j.1365-2036.1997.00247.x; Ferraz JGP, 1997, GASTROENTEROLOGY, V113, P195, DOI 10.1016/S0016-5085(97)70095-7; Fiorucci S, 2000, J IMMUNOL, V165, P5245, DOI 10.4049/jimmunol.165.9.5245; Fiorucci S, 1999, GASTROENTEROLOGY, V116, P1089, DOI 10.1016/S0016-5085(99)70012-0; FIORUCCI S, IN PRESS GASTROENTER; Gronert K, 1998, J EXP MED, V187, P1285, DOI 10.1084/jem.187.8.1285; Gyomber E, 1996, J GASTROEN HEPATOL, V11, P922; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LAUFER SA, 1994, J MED CHEM, V37, P1894, DOI 10.1021/jm00038a021; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; LEE M, 1992, DIGEST DIS SCI, V37, P1282, DOI 10.1007/BF01296573; Mancini JA, 1997, MOL PHARMACOL, V51, P52, DOI 10.1124/mol.51.1.52; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; PATRIGNANI P, 1994, J PHARMACOL EXP THER, V271, P1705; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; ROMANO M, 1992, BIOCHEMISTRY-US, V31, P8269, DOI 10.1021/bi00150a021; ROMANO M, IN PRESS LAB INVEST; Scalia R, 1997, P NATL ACAD SCI USA, V94, P9967, DOI 10.1073/pnas.94.18.9967; Serhan CN, 1997, PROSTAG OTH LIPID M, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; Serhan CN, 2001, J CLIN INVEST, V107, P1481, DOI 10.1172/JCI13375; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Takano T, 1998, J CLIN INVEST, V101, P819, DOI 10.1172/JCI1578; Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264; WALLACE JL, 1990, GASTROENTEROLOGY, V98, P1178, DOI 10.1016/0016-5085(90)90331-T; Wallace JL, 2000, GASTROENTEROLOGY, V119, P706, DOI 10.1053/gast.2000.16510; WALLACE JL, J LIPID MEDIAT, V7, P183; Wenzel SE, 1996, ANN PHARMACOTHER, V30, P858, DOI 10.1177/106002809603000725	32	58	65	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1171	+		10.1096/fj.02-0777fje	http://dx.doi.org/10.1096/fj.02-0777fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709408				2022-12-28	WOS:000182580100019
J	Eller, MS; Li, GZ; Firoozabadi, R; Puri, N; Gilchrest, BA				Eller, MS; Li, GZ; Firoozabadi, R; Puri, N; Gilchrest, BA			Induction of a p95/Nbs1-mediated S phase checkpoint by telomere 3 ' overhang specific DNA	FASEB JOURNAL			English	Article						DNA damage responses; senescence; ATM; p53 phosphorylation	NIJMEGEN BREAKAGE SYNDROME; CELL-CYCLE ARREST; LARGE-T-ANTIGEN; ATAXIA-TELANGIECTASIA; CATALYTIC SUBUNIT; FISSION YEAST; P53; DAMAGE; REPAIR; PHOSPHORYLATION	Telomere shortening induces a nonproliferative senescent phenotype, believed to reduce cancer risk, and telomeres are involved in a poorly understood manner in responses to DNA damage. Although telomere disruption induces p53 and triggers apoptosis or cell cycle arrest, the features of the disrupted telomere that trigger this response and the precise mechanism involved are poorly understood. Using human cells, we show that DNA oligonucleotides homologous to the telomere 3' overhang sequence specifically induce and activate p53 and activate an S phase checkpoint by modifying the Nijmegen breakage syndrome protein, known to mediate the S phase checkpoint after DNA damage. These responses are mediated, at least in part, by the ATM kinase and are not attributable to disruption of cellular telomeres. Based on these and earlier data, we propose that these oligonucleotides mimic a physiological signal, exposure of the telomere 3' overhang due to opening of the normal telomere loop structure, and hence evoke these protective anti-proliferative responses in the absence of DNA damage or telomere disruption.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA	Boston University	Gilchrest, BA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St,J Bldg, Boston, MA 02118 USA.			Li, Guangmu/0000-0001-7115-0928				Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chamankhah M, 1999, NUCLEIC ACIDS RES, V27, P2072, DOI 10.1093/nar/27.10.2072; Chan SWL, 2002, ONCOGENE, V21, P553, DOI 10.1038/sj.onc.1205082; Cruz PD, 2000, J INVEST DERMATOL, V114, P253, DOI 10.1046/j.1523-1747.2000.00866.x; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Eller MS, 2002, EXP CELL RES, V276, P185, DOI 10.1006/excr.2002.5531; ELLER MS, 1994, NATURE, V372, P413, DOI 10.1038/372413a0; Eller MS, 1996, P NATL ACAD SCI USA, V93, P1087, DOI 10.1073/pnas.93.3.1087; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; Eller MS, 2000, PIGM CELL RES, V13, P94, DOI 10.1034/j.1600-0749.13.s8.17.x; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Funk WD, 2000, EXP CELL RES, V258, P270, DOI 10.1006/excr.2000.4945; Gilchrest BA, 1999, J INVEST DERM SYMP P, V4, P35, DOI 10.1038/sj.jidsp.5640178; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Goukassian DA, 1999, J INVEST DERMATOL, V112, P25, DOI 10.1046/j.1523-1747.1999.00468.x; Goukassian DA, 2002, FASEB J, V16, P754, DOI 10.1096/fj.01-0829fje; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hadshiew IM, 2001, J DERMATOL SCI, V25, P127, DOI 10.1016/S0923-1811(00)00125-0; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 2002, ONCOGENE, V21, P592, DOI 10.1038/sj.onc.1205084; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; KASAI H, 1991, OXIDATIVE STRESS OXI, P99; Khlgatian MK, 2002, J INVEST DERMATOL, V118, P126, DOI 10.1046/j.0022-202x.2001.01667.x; Kobayashi N, 2001, PIGM CELL RES, V14, P94, DOI 10.1034/j.1600-0749.2001.140204.x; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lin WC, 2001, GENE DEV, V15, P1833; Maeda T, 1999, MUTAT RES-DNA REPAIR, V433, P137, DOI 10.1016/S0921-8777(98)00071-8; Marusic L, 1997, MOL CELL BIOL, V17, P6394, DOI 10.1128/MCB.17.11.6394; Milyavsky M, 2001, NUCLEIC ACIDS RES, V29, P5207, DOI 10.1093/nar/29.24.5207; Naka K, 1999, BIOCHEM BIOPH RES CO, V255, P753, DOI 10.1006/bbrc.1998.9938; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Pedeux R, 1998, J INVEST DERMATOL, V111, P472, DOI 10.1046/j.1523-1747.1998.00324.x; RHEINWALD JG, 1983, HUMAN CARCINOGENESIS, P86; Ritchie KB, 2000, GENETICS, V155, P475; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Saretzki G, 1999, ONCOGENE, V18, P5148, DOI 10.1038/sj.onc.1202898; SETLOW RB, 1966, J MOL BIOL, V17, P237, DOI 10.1016/S0022-2836(66)80105-5; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; Von Zglinicki T, 2000, ANN NY ACAD SCI, V908, P99, DOI 10.1111/j.1749-6632.2000.tb06639.x; Wang LH, 1998, ANTICANCER RES, V18, P321; WOLF DA, 1995, ONCOGENE, V10, P2067; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; XUDONG Z, 2000, NAT GENET, V25, P347; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	76	53	55	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					152	162		10.1096/fj.02-0197com	http://dx.doi.org/10.1096/fj.02-0197com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554694				2022-12-28	WOS:000181456900040
J	Blazquez, C; Casanova, ML; Planas, A; del Pulgar, TG; Villanueva, C; Fernandez-Acenero, MJ; Aragones, J; Huffman, JW; Jorcano, JL; Guzman, M				Blazquez, C; Casanova, ML; Planas, A; del Pulgar, TG; Villanueva, C; Fernandez-Acenero, MJ; Aragones, J; Huffman, JW; Jorcano, JL; Guzman, M			Inhibition of tumor angiogenesis by cannabinoids	FASEB JOURNAL			English	Article						cancer; vascular endothelium; angiogenic factor; apoptosis; experimental therapeutics	MATRIX METALLOPROTEINASE-2; GROWTH-FACTORS; GLIOMA GROWTH; RAT-BRAIN; ACTIVATION; EXPRESSION; RECEPTOR; SYSTEM; CERAMIDE; CB1	Cannabinoids, the active components of marijuana and their derivatives, induce tumor regression in rodents (8). However, the mechanism of cannabinoid antitumoral action in vivo is as yet unknown. Here we show that local administration of a nonpsychoactive cannabinoid to mice inhibits angiogenesis of malignant gliomas as determined by immunohistochemical analyses and vascular permeability assays. In vitro and in vivo experiments show that at least two mechanisms may be involved in this cannabinoid action: the direct inhibition of vascular endothelial cell migration and survival as well as the decrease of the expression of proangiogenic factors (vascular endothelial growth factor and angiopoietin-2) and matrix metalloproteinase-2 in the tumors. Inhibition of tumor angiogenesis may allow new strategies for the design of cannabinoid-based antitumoral therapies.	Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain; CIEMAT, Dept Cellular & Mol Biol & Gene Therapy, E-28040 Madrid, Spain; IDIBAPS, CSIC, IIBB, Dept Pharmacol & Toxicol, Barcelona, Spain; Hosp Gen Mostoles, Dept Pathol, Madrid, Spain; Hosp Princesa, Dept Immunol, Madrid, Spain; Clemson Univ, Dept Chem, Clemson, SC 29634 USA	Complutense University of Madrid; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Hospital de La Princesa; Clemson University	Guzman, M (corresponding author), Univ Complutense, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain.	mgp@bbm1.ucm.es	Planas, Anna M/J-5991-2014; Aceñero, M Jesús Fernández/ABC-5904-2020; Gomez del Pulgar, Teresa/GXV-5256-2022	Planas, Anna M/0000-0002-6147-1880; Aceñero, M Jesús Fernández/0000-0002-2439-3553; Casanova, M. Llanos/0000-0001-7742-8265; Guzman, Manuel/0000-0001-7475-118X				Avgeropoulos N G, 1999, Oncologist, V4, P209; Baker D, 2000, NATURE, V404, P84, DOI 10.1038/35003583; Batkai S, 2001, NAT MED, V7, P827, DOI 10.1038/89953; Bifulco M, 2002, NAT MED, V8, P547, DOI 10.1038/nm0602-547; Bifulco M, 2001, FASEB J, V15, P2745, DOI 10.1096/fj.01-0320fje; Blazquez C, 2000, FASEB J, V14, P2315, DOI 10.1096/fj.00-0122com; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Casanova ML, 2002, CANCER RES, V62, P3402; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Guzman M, 2001, TRENDS PHARMACOL SCI, V22, P19, DOI 10.1016/S0165-6147(00)01586-8; Guzman M, 2001, J MOL MED-JMM, V78, P613, DOI 10.1007/s001090000177; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Huffman JW, 1999, BIOORGAN MED CHEM, V7, P2905, DOI 10.1016/S0968-0896(99)00219-9; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; Kleihues P, 1993, HISTOLOGICAL TYPING; Kodera T, 2000, J NEURO-ONCOL, V46, P105, DOI 10.1023/A:1006387600909; Liu J, 2000, BIOCHEM J, V346, P835, DOI 10.1042/0264-6021:3460835; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Malan TP, 2001, PAIN, V93, P239, DOI 10.1016/S0304-3959(01)00321-9; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Munoz C, 1996, J IMMUNOL, V157, P3587; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; MUNSON AE, 1975, J NATL CANCER I, V55, P597, DOI 10.1093/jnci/55.3.597; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Pertwee RG, 2000, EXPERT OPIN INV DRUG, V9, P1553, DOI 10.1517/13543784.9.7.1553; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; Planas AM, 2001, NEUROBIOL DIS, V8, P834, DOI 10.1006/nbdi.2001.0435; Porter AC, 2001, PHARMACOL THERAPEUT, V90, P45, DOI 10.1016/S0163-7258(01)00130-9; Ros J, 2002, GASTROENTEROLOGY, V122, P85, DOI 10.1053/gast.2002.30305; Sanchez C, 2001, CANCER RES, V61, P5784; Vince GH, 1999, INT J DEV NEUROSCI, V17, P437, DOI 10.1016/S0736-5748(99)00018-0; Wagner JA, 1997, NATURE, V390, P518, DOI 10.1038/37371; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Zagzag D, 2000, LAB INVEST, V80, P837, DOI 10.1038/labinvest.3780088	44	219	230	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					529	+		10.1096/fj.02-0795fje	http://dx.doi.org/10.1096/fj.02-0795fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12514108				2022-12-28	WOS:000181453700032
J	Deshpande, DA; Walseth, TF; Panettieri, RA; Kannan, MS				Deshpande, DA; Walseth, TF; Panettieri, RA; Kannan, MS			CD38-cyclic ADP-ribose-mediated Ca2+ signaling contributes to airway smooth muscle hyperresponsiveness	FASEB JOURNAL			English	Article						cADPR; cytokines; inflammation	NECROSIS-FACTOR-ALPHA; RECEPTOR GENE-EXPRESSION; INTERFERON-GAMMA; CD38 GENE; IN-VITRO; HYDROLASE ACTIVITIES; INSULIN-SECRETION; CALCIUM-RELEASE; UP-REGULATION; B-CELLS	We previously demonstrated that cyclic ADP-ribose (cADPR) elicits Ca2+ release in airway smooth muscle (ASM) cells through ryanodine receptor channels. CD38 is a cell surface protein that catalyzes the synthesis and degradation of cADPR. In inflammatory diseases such as asthma, augmented Ca2+ responses and Ca2+ sensitivity contribute to increased ASM contractility in response to agonists. In this study, we investigated the regulation of CD38 expression and the role of cADPR-mediated Ca2+ release in airway inflammation. Human ASM cells in culture between the second and fifth passages were exposed to tumor necrosis factor alpha (TNF-alpha), interleukin 1beta, or interferon gamma, or bovine serum albumin (controls). CD38 expression was measured by reverse transcriptase-polymerase chain reaction (RT-PCR), real-time PCR, and Western blot analysis, and ADP-ribosyl cyclase activity was assayed with nicotinamide guanine dinucleotide as the substrate. Ca2+ responses to acetylcholine, bradykinin, and thrombin were measured in fura-2AM-loaded cells by fluorescence microscopy. Cytokines caused significant augmentation of CD38 expression, ADP-ribosyl cyclase activity, and Ca2+ responses to the agonists, compared with the control. TNF-alpha effects were greater than those of the other two cytokines. The cADPR antagonist 8-bromo-cADPR attenuated the Ca2+ responses to the agonists in control and cytokine-treated cells, with the magnitude of inhibition correlating with the level of CD38. This study provides the first demonstration of a role for CD38-cADPR signaling in a model of inflammatory airway disease.	Univ Minnesota, Coll Vet Med, Dept Vet Pathobiol, St Paul, MN 55108 USA; Univ Minnesota, Dept Pharmacol, St Paul, MN 55108 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Pennsylvania	Kannan, MS (corresponding author), Univ Minnesota, Coll Vet Med, Dept Vet Pathobiol, 1971 Commonwealth Ave, St Paul, MN 55108 USA.	kanna001@tc.umn.edu	Walseth, Timothy F/F-9518-2010; panettieri, reynold/AAG-9485-2019	Walseth, Timothy F/0000-0003-2558-7859; 	NHLBI NIH HHS [R01 HL057498] Funding Source: Medline; NIDA NIH HHS [P50 DA011806] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ammit AJ, 2000, AM J RESP CELL MOL, V23, P794, DOI 10.1165/ajrcmb.23.6.4184; Amrani Y, 2001, AM J RESP CRIT CARE, V164, P2098, DOI 10.1164/ajrccm.164.11.2108005; AMRANI Y, 1993, CR ACAD SCI III-VIE, V316, P1489; Amrani Y, 2000, Respir Res, V1, P49, DOI 10.1186/rr12; Amrani Y, 2001, MOL PHARMACOL, V60, P646; Amrani Y, 1998, THORAX, V53, P713, DOI 10.1136/thx.53.8.713; Amrani Y, 1999, J IMMUNOL, V163, P2128; AMRANI Y, 1995, BRIT J PHARMACOL, V114, P4, DOI 10.1111/j.1476-5381.1995.tb14896.x; Amrani Y, 1997, AM J PHYSIOL-LUNG C, V273, pL1020, DOI 10.1152/ajplung.1997.273.5.L1020; Amrani Y, 2000, MOL PHARMACOL, V58, P237, DOI 10.1124/mol.58.1.237; Amrani Y, 2002, CURR OPIN ALLERGY CL, V2, P39, DOI 10.1097/00130832-200202000-00007; BAI TR, 1995, AM J PHYSIOL-LUNG C, V269, pL309, DOI 10.1152/ajplung.1995.269.3.L309; Barchasz E, 1999, EUR J PHARMACOL, V379, P87, DOI 10.1016/S0014-2999(99)00484-7; Bauvois B, 1999, J INTERF CYTOK RES, V19, P1059, DOI 10.1089/107999099313299; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; CHEN H, 1994, EUR RESPIR J, V7, P74, DOI 10.1183/09031936.94.07010074; CHEN Z, 1994, ALGEBRA C, V1, P1; Cockayne DA, 1998, BLOOD, V92, P1324, DOI 10.1182/blood.V92.4.1324.416k26_1324_1333; Coirault C, 2000, REV MAL RESPIR, V17, P549; Dipp M, 2001, CIRC RES, V89, P77, DOI 10.1161/hh1301.093616; Dogan S, 2002, BIOL REPROD, V66, P596, DOI 10.1095/biolreprod66.3.596; Ferrero E, 2000, CHEM IMMUNOL, V75, P1; Guo DQ, 1998, J IMMUNOL, V160, P2742; Hakonarson H, 2001, AM J RESP CELL MOL, V25, P761, DOI 10.1165/ajrcmb.25.6.4628; Hauck RW, 1999, AM J PHYSIOL-LUNG C, V277, pL22, DOI 10.1152/ajplung.1999.277.1.L22; Higashida H, 1997, J BIOL CHEM, V272, P31272, DOI 10.1074/jbc.272.50.31272; Higashida H, 1997, FEBS LETT, V418, P355, DOI 10.1016/S0014-5793(97)01410-5; Hirshman CA, 1999, LIFE SCI, V64, P443, DOI 10.1016/S0024-3205(98)00586-4; Hirst SJ, 2000, CLIN EXP ALLERGY, V30, P54, DOI 10.1046/j.1365-2222.30.s1.1.x; Hotta K, 1999, AM J PHYSIOL-LUNG C, V276, pL405, DOI 10.1152/ajplung.1999.276.3.L405; Hotta K, 2000, AM J PHYSIOL-LUNG C, V279, pL319, DOI 10.1152/ajplung.2000.279.2.L319; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; Kannan MS, 1997, AM J PHYSIOL-LUNG C, V272, pL659, DOI 10.1152/ajplung.1997.272.4.L659; Kannan MS, 1996, AM J PHYSIOL-HEART C, V270, pH801, DOI 10.1152/ajpheart.1996.270.2.H801; Kato I, 1999, J BIOL CHEM, V274, P1869, DOI 10.1074/jbc.274.4.1869; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; Laporte JD, 2000, AM J PHYSIOL-LUNG C, V279, pL932, DOI 10.1152/ajplung.2000.279.5.L932; Laporte JD, 1999, AM J PHYSIOL-LUNG C, V277, pL943, DOI 10.1152/ajplung.1999.277.5.L943; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; Lee HC, 1997, ADV EXP MED BIOL, V419, P411; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; LYNN S, 1995, FEBS LETT, V367, P23, DOI 10.1016/0014-5793(95)00499-Y; Martin JG, 2000, EUR RESPIR J, V16, P349, DOI 10.1034/j.1399-3003.2000.16b25.x; Mehta K, 2000, CHEM IMMUNOL, V75, P20; Miscia S, 2002, CELL GROWTH DIFFER, V13, P13; Nata K, 1997, GENE, V186, P285, DOI 10.1016/S0378-1119(96)00723-8; Obase Y, 2001, ANN ALLERG ASTHMA IM, V86, P304, DOI 10.1016/S1081-1206(10)63303-0; Okamoto H, 2000, CHEM IMMUNOL, V75, P121; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Pennings HJ, 1998, EUR RESPIR J, V12, P45, DOI 10.1183/09031936.98.12010045; Prakash YS, 1998, AM J PHYSIOL-CELL PH, V274, pC1653, DOI 10.1152/ajpcell.1998.274.6.C1653; Reynolds A M, 2000, Respirology, V5, P153, DOI 10.1046/j.1440-1843.2000.00240.x; Riffo-Vasquez Y, 2000, INT J BIOCHEM CELL B, V32, P833, DOI 10.1016/S1357-2725(00)00029-7; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SALARI H, 1992, J ALLERGY CLIN IMMUN, V90, P918, DOI 10.1016/0091-6749(92)90464-D; Schmidlin F, 1998, MOL PHARMACOL, V53, P1009; Shalita-Chesner M, 2001, MOL CELL ENDOCRINOL, V176, P1, DOI 10.1016/S0303-7207(01)00484-1; Sherman GG, 2002, PEDIATR RES, V51, P740, DOI [10.1203/00006450-200206000-00013, 10.1203/01.PDR.0000017478.64723.79]; Simon AR, 2002, AM J PHYSIOL-LUNG C, V282, pL1296, DOI 10.1152/ajplung.00315.2001; Sukkar M B, 2001, Respirology, V6, P199, DOI 10.1046/j.1440-1843.2001.00334.x; Walseth TF, 1997, METHOD ENZYMOL, V280, P294; White TA, 2000, BBA-MOL CELL RES, V1498, P64, DOI 10.1016/S0167-4889(00)00077-X; Yagui K, 1998, DIABETOLOGIA, V41, P1024, DOI 10.1007/s001250051026; Yang CM, 2001, BIOCHEM J, V354, P439, DOI 10.1042/0264-6021:3540439	65	132	135	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					452	+		10.1096/fj.02-0450fje	http://dx.doi.org/10.1096/fj.02-0450fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12514117				2022-12-28	WOS:000181453700018
J	Dickinson, DA; Iles, KE; Zhang, HQ; Blank, V; Forman, HJ				Dickinson, DA; Iles, KE; Zhang, HQ; Blank, V; Forman, HJ			Curcumin alters EpRE and AP-1 binding complexes and elevates glutamate-cysteine ligase gene expression	FASEB JOURNAL			English	Article						GCS; GSH; immunodepletion; MafG; MafK	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; ANTIOXIDANT RESPONSE ELEMENT; NAPHTHOFLAVONE-INDUCED EXPRESSION; REGULATORY SUBUNIT GENE; TRANSCRIPTION FACTORS; MEDIATED EXPRESSION; TUMOR PROMOTION; KAPPA-B; ACTIVATION; INDUCTION	Dietary use of curcumin, the active component of tumeric, one of the most widely used spices, is linked to several beneficial health effects, although the underlying molecular mechanisms remain largely unknown. Correlations have been established between curcumin exposure and increases in enzymes for glutathione synthesis, particularly glutamate-cysteine ligase (GCL), and metabolism as well as glutathione content, suggesting the eliciting of an adaptive response to stress. In this study, using HBE1 cells, we found that the mechanism of curcumin-induced GCL elevation occurred via transcription of the two Gcl genes. Gcl transcription has been shown in several systems to be mediated through binding of transcription factor complexes to TRE and EpRE elements. Studies herein showed that curcumin caused modest but sustained increases in binding of proteins to DNA sequences for both cis elements but, more importantly, altered the compositions and nuclear content of proteins in these complexes. Curcumin exposure increased JunD and c-Jun content in AP-1 complexes and increased JunD while decreasing MafG/MafK in EpRE complexes. Thus, the beneficial effects elicited by curcumin appear to be due to changes in the pool of transcription factors that compose EpRE and AP-1 complexes, affecting gene expression of GCL and other phase II enzymes.	Univ Alabama Birmingham, Sch Publ Hlth, Dept Environm Hlth Sci, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA; McGill Univ, Dept Med, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Lady Davis Institute; McGill University	Forman, HJ (corresponding author), Univ Alabama Birmingham, Sch Publ Hlth, Dept Environm Hlth Sci, 1665 Univ Blvd,Ryals 534, Birmingham, AL 35294 USA.	hforman@uab.edu		Forman, Henry Jay/0000-0001-5838-2791				Araujo CAC, 2001, MEM I OSWALDO CRUZ, V96, P723, DOI 10.1590/S0074-02762001000500026; Araujo CAC, 1999, MEM I OSWALDO CRUZ, V94, P791, DOI 10.1590/S0074-02761999000600015; Awasthi S, 1996, AM J CLIN NUTR, V64, P761, DOI 10.1093/ajcn/64.5.761; BENEDETTI A, 1980, BIOCHIM BIOPHYS ACTA, V620, P281, DOI 10.1016/0005-2760(80)90209-X; Bierhaus A, 1997, THROMB HAEMOSTASIS, V77, P772; BLANCHARD O, 1997, BROOKINGS PAPERS EC, V2, P89; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Dickinson DA, 2002, FREE RADICAL BIO MED, V33, P974, DOI 10.1016/S0891-5849(02)00991-7; Dickinson DA, 2002, BIOCHEM PHARMACOL, V64, P1019, DOI 10.1016/S0006-2952(02)01172-3; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hamilton RF, 1996, AM J RESP CELL MOL, V15, P275, DOI 10.1165/ajrcmb.15.2.8703485; Hill-Kapturczak N, 2001, AM J PHYSIOL-RENAL, V281, pF851, DOI 10.1152/ajprenal.0140.2001; HUANG MT, 1988, CANCER RES, V48, P5941; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Iles KE, 2002, FREE RADICAL BIO MED, V32, P1304, DOI 10.1016/S0891-5849(02)00840-7; ILES KE, 1995, HEPATOLOGY, V21, P1154, DOI 10.1016/0270-9139(95)90268-6; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Iwanaga M, 1998, FREE RADICAL BIO MED, V24, P1256, DOI 10.1016/S0891-5849(97)00443-7; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kwong M, 1999, J BIOL CHEM, V274, P37491, DOI 10.1074/jbc.274.52.37491; Lee JM, 2001, BIOCHEM BIOPH RES CO, V280, P286, DOI 10.1006/bbrc.2000.4106; LIU JY, 1993, CARCINOGENESIS, V14, P857, DOI 10.1093/carcin/14.5.857; Liu RM, 1996, AM J RESP CELL MOL, V14, P192, DOI 10.1165/ajrcmb.14.2.8630270; Liu RM, 1998, AM J PHYSIOL-LUNG C, V275, pL861, DOI 10.1152/ajplung.1998.275.5.L861; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; MUKHOPADHYAY A, 1982, AGENTS ACTIONS, V12, P508, DOI 10.1007/BF01965935; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Myhrstad MCW, 2001, BBA-GENE STRUCT EXPR, V1517, P212, DOI 10.1016/S0167-4781(00)00276-1; Pendurthi UR, 1997, ARTERIOSCL THROM VAS, V17, P3406, DOI 10.1161/01.ATV.17.12.3406; Piper JT, 1998, INT J BIOCHEM CELL B, V30, P445, DOI 10.1016/S1357-2725(98)00015-6; Punithavathi D, 2000, BRIT J PHARMACOL, V131, P169, DOI 10.1038/sj.bjp.0703578; REDDY ACP, 1994, FOOD CHEM TOXICOL, V32, P279, DOI 10.1016/0278-6915(94)90201-1; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; ROBISON TW, 1995, BBA-LIPID LIPID MET, V1256, P334, DOI 10.1016/0005-2760(95)00041-A; RUBY AJ, 1995, CANCER LETT, V94, P79, DOI 10.1016/0304-3835(95)03827-J; SEKURA R, 1977, J BIOL CHEM, V252, P2599; Seol DW, 2000, ONCOGENE, V19, P1132, DOI 10.1038/sj.onc.1203404; Shih SC, 2001, GROWTH FACTORS, V19, P19, DOI 10.3109/08977190109001073; Shin M, 2002, BBA-MOL CELL RES, V1589, P311, DOI 10.1016/S0167-4889(02)00195-7; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Singhal SS, 1999, TOXICOL LETT, V109, P87, DOI 10.1016/S0378-4274(99)00124-1; Soltaninassab SR, 2000, J CELL PHYSIOL, V182, P163, DOI 10.1002/(SICI)1097-4652(200002)182:2<163::AID-JCP4>3.0.CO;2-1; SRIMAL RC, 1973, J PHARM PHARMACOL, V25, P447, DOI 10.1111/j.2042-7158.1973.tb09131.x; Sun WM, 1996, BIOCHEM J, V320, P321, DOI 10.1042/bj3200321; Tsuchiya K, 1995, GENOMICS, V30, P630, DOI 10.1006/geno.1995.1293; Tyulmenkov VV, 2000, STEROIDS, V65, P505, DOI 10.1016/S0039-128X(00)00109-4; Varadkar Prajakta, 2001, Journal of Radiological Protection, V21, P361, DOI 10.1088/0952-4746/21/4/304; Venkatesan N, 1999, LIFE SCI, V66, pPL21, DOI 10.1016/S0024-3205(99)00576-7; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wild AC, 2000, FREE RADICAL RES, V32, P281, DOI 10.1080/10715760000300291; Wild AC, 1998, BIOCHEM J, V332, P373, DOI 10.1042/bj3320373; YANKASKAS JR, 1993, AM J PHYSIOL, V264, pC1219, DOI 10.1152/ajpcell.1993.264.5.C1219	62	137	145	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					473	+		10.1096/fj.02-0566fje	http://dx.doi.org/10.1096/fj.02-0566fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12514113				2022-12-28	WOS:000181453700023
J	Schwahn, BC; Chen, ZT; Laryea, MD; Wendel, U; Lussier-Cacan, S; Genest, J; Mar, MH; Zeisel, SH; Castro, C; Garrow, T; Rozen, R				Schwahn, BC; Chen, ZT; Laryea, MD; Wendel, U; Lussier-Cacan, S; Genest, J; Mar, MH; Zeisel, SH; Castro, C; Garrow, T; Rozen, R			Homocysteine-betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency	FASEB JOURNAL			English	Article						homocystinuria; hyperhomocysteinemia; folate; methyl donors; choline metabolism	CORONARY-ARTERY DISEASE; PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE; METHIONINE METABOLISM; PLASMA HOMOCYSTEINE; DIETARY METHIONINE; FOLATE-DEFICIENCY; RAT HEPATOCYTES; FOLIC-ACID; METHYLATION; CHOLINE	Hyperhomocysteinemia, a proposed risk factor for cardiovascular disease, is also observed in other common disorders. The most frequent genetic cause of hyperhomocysteinemia is a mutated methylenetetrahydrofolate reductase (MTHFR), predominantly when folate status is impaired. MTHFR synthesizes a major methyl donor for homocysteine remethylation to methionine. We administered the alternate choline-derived methyl donor, betaine, to wild-type mice and to littermates with mild or severe hyperhomocysteinemia due to hetero- or homozygosity for a disruption of the Mthfr gene. On control diets, plasma homocysteine and liver choline metabolite levels were strongly dependent on the Mthfr genotype. Betaine supplementation decreased homocysteine in all three genotypes, restored liver betaine and phosphocholine pools, and prevented severe steatosis in Mthfr-deficient mice. Increasing betaine intake did not further decrease homocysteine. In humans with cardiovascular disease, we found a significant negative correlation between plasma betaine and homocysteine concentrations. Our results emphasize the strong interrelationship between homocysteine, folate, and choline metabolism. Hyperhomocysteinemic Mthfr-compromised mice appear to be much more sensitive to changes of choline/betaine intake than do wild-type animals. Hyperhomocysteinemia, in the range of that associated with folate deficiency or with homozygosity for the 677T MTHFR variant, may be associated with disturbed choline metabolism.	McGill Univ, Montreal Childrens Hosp, Dept Pediat, Montreal, PQ H3H 1P3, Canada; McGill Univ, Montreal Childrens Hosp, Dept Human Genet, Montreal, PQ H3H 1P3, Canada; McGill Univ, Montreal Childrens Hosp, Dept Biol, Montreal, PQ H3H 1P3, Canada; Univ Childrens Hosp, Metab Unit, Dusseldorf, Germany; Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada; McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ, Canada; Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Nutr, Chapel Hill, NC USA; Univ Illinois, Dept Food Sci & Human Nutr, Urbana, IL 61801 USA	McGill University; McGill University; McGill University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Illinois System; University of Illinois Urbana-Champaign	Rozen, R (corresponding author), FCCMG Montreal Childrens Hosp, 4060 Ste Catherine W,Room 200, Montreal, PQ H3Z 2Z3, Canada.	rima.rozen@mcgill.ca	Carmen, Castro/C-7813-2009	Carmen, Castro/0000-0002-6802-0572				Abdelmalek MF, 2001, AM J GASTROENTEROL, V96, P2711; ALLEN RH, 1993, METABOLISM, V42, P1448, DOI 10.1016/0026-0495(93)90198-W; BAKER DH, 1985, J NUTR, V115, P1291, DOI 10.1093/jn/115.10.1291; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bostom AG, 1999, J AM SOC NEPHROL, V10, P891; Bottiglieri T, 2000, J NEUROL NEUROSUR PS, V69, P228, DOI 10.1136/jnnp.69.2.228; Burns SP, 1998, BBA-MOL BASIS DIS, V1406, P274, DOI 10.1016/S0925-4439(98)00015-5; Chen ZT, 2001, HUM MOL GENET, V10, P433, DOI 10.1093/hmg/10.5.433; Christensen B, 1997, ARTERIOSCL THROM VAS, V17, P569, DOI 10.1161/01.ATV.17.3.569; DALERY K, 1995, AM J CARDIOL, V75, P1107, DOI 10.1016/S0002-9149(99)80739-5; DUCE AM, 1988, HEPATOLOGY, V8, P65, DOI 10.1002/hep.1840080113; Durand P, 1996, CLIN CHIM ACTA, V252, P83, DOI 10.1016/0009-8981(96)06325-5; Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008; FINKELSTEIN JD, 1974, METABOLISM, V23, P387, DOI 10.1016/0026-0495(74)90057-2; FINKELSTEIN JD, 1971, ARCH BIOCHEM BIOPHYS, V146, P84, DOI 10.1016/S0003-9861(71)80044-9; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; Garrow TA, 1996, J BIOL CHEM, V271, P22831, DOI 10.1074/jbc.271.37.22831; HOFFMAN DR, 1981, LIPIDS, V16, P561, DOI 10.1007/BF02534900; HOLME E, 1989, ARCH DIS CHILD, V64, P1061, DOI 10.1136/adc.64.7.1061; KIM YI, 1994, J NUTR, V124, P2197, DOI 10.1093/jn/124.11.2197; KOC HH, ANAL BIOCH; Laryea MD, 1998, CLIN CHEM, V44, P1937; Lepage N, 1997, CLIN CHEM, V43, P2397; LEVER M, 1994, BBA-GEN SUBJECTS, V1200, P259, DOI 10.1016/0304-4165(94)90165-1; LIEBER CS, 1994, ALCOHOL CLIN EXP RES, V18, P592, DOI 10.1111/j.1530-0277.1994.tb00915.x; McGregor DO, 2001, KIDNEY INT, V59, P2267, DOI 10.1046/j.1523-1755.2001.00743.x; MCKEEVER MP, 1991, CLIN SCI, V81, P551, DOI 10.1042/cs0810551; Millian NS, 1998, ARCH BIOCHEM BIOPHYS, V356, P93, DOI 10.1006/abbi.1998.0757; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; Mudd S.H., 1995, METABOLIC MOL BASES, V1, P1279; MUDD SH, 1975, METABOLISM, V24, P721, DOI 10.1016/0026-0495(75)90040-2; NishimakiMogami T, 1996, BBA-LIPID LIPID MET, V1304, P21, DOI 10.1016/S0005-2760(96)00100-2; Park EI, 1999, J BIOL CHEM, V274, P7816, DOI 10.1074/jbc.274.12.7816; Park EI, 1997, J NUTR BIOCHEM, V8, P541, DOI 10.1016/S0955-2863(97)00101-0; PASCALE R, 1982, FEBS LETT, V145, P293, DOI 10.1016/0014-5793(82)80186-5; Ray JG, 1999, PLACENTA, V20, P519, DOI 10.1053/plac.1999.0417; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; REGLAND B, 1995, J NEURAL TRANSM-GEN, V100, P165, DOI 10.1007/BF01271539; Rosenblatt DS., 1995, METABOLIC MOL BASES, P3111; SAUNDERSON CL, 1990, BRIT J NUTR, V63, P339, DOI 10.1079/BJN19900120; SCHWAHN B, 2001, CLIN CONSEQUENCES AM, V1, P189; SCHWAHN B, 2002, IN PRESS BR J CLIN P; SELHUB J, 1992, AM J CLIN NUTR, V55, P131, DOI 10.1093/ajcn/55.1.131; STEENGE GR, 2001, 3 INT C HOM MET SORR; STORCH KJ, 1991, AM J CLIN NUTR, V54, P386, DOI 10.1093/ajcn/54.2.386; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; VARELAMOREIRAS G, 1992, J NUTR BIOCHEM, V3, P519, DOI 10.1016/0955-2863(92)90073-R; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; WENDEL U, 1984, EUR J PEDIATR, V142, P147, DOI 10.1007/BF00445602; WILCKEN DEL, 1983, NEW ENGL J MED, V309, P448, DOI 10.1056/NEJM198308253090802; YAO ZM, 1988, J BIOL CHEM, V263, P2998; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413	52	130	130	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					512	+		10.1096/fj.02-0456fje	http://dx.doi.org/10.1096/fj.02-0456fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551843	Green Submitted			2022-12-28	WOS:000181453700010
J	Goebel, MU; Trebst, AE; Steiner, J; Xie, YF; Exton, MS; Frede, S; Canbay, AE; Michel, MC; Heemann, U; Schedlowski, M				Goebel, MU; Trebst, AE; Steiner, J; Xie, YF; Exton, MS; Frede, S; Canbay, AE; Michel, MC; Heemann, U; Schedlowski, M			Behavioral conditioning of immunosuppression is possible in humans	FASEB JOURNAL			English	Article						conditioned reaction; interleukin-2; cyclosporin; behavioral conditioning; cyclosporin A	SPLENIC INNERVATION; IMMUNE-SYSTEM; CATECHOLAMINES; DEXAMETHASONE; ENHANCEMENT; SUPPRESSION; MESSENGER; BRAIN	Behavioral conditioned immunosuppression has been described in rodents as the most impressive demonstration of brain-to-immune system interaction. To analyze whether behavioral conditioned immunosuppression is possible in humans, healthy subjects in this double-blind, placebo-controlled study were conditioned in four sessions over 3 consecutive days, receiving the immunosuppressive drug cyclosporin A as an unconditioned stimulus paired with a distinctively flavored drink (conditioned stimulus) each 12 h. In the next week, re-exposure to the conditioned stimulus (drink), but now paired with placebo capsules, induced a suppression of immune functions as analyzed by the IL-2 and IFN-gamma mRNA expression, intracellular production, and in vitro release of IL-2 and IFN-gamma, as well as lymphocyte proliferation. These data demonstrate for the first time that immunosuppression can be behaviorally conditioned in humans.	Univ Essen Gesamthsch, Dept Med Psychol, D-45122 Essen, Germany; Univ Essen Gesamthsch, Dept Physiol, Essen, Germany; Univ Essen Gesamthsch, Dept Med, D-4300 Essen, Germany	University of Duisburg Essen; University of Duisburg Essen; University of Duisburg Essen	Schedlowski, M (corresponding author), Univ Essen Gesamthsch, Dept Med Psychol, Hufelandstr 55, D-45122 Essen, Germany.	manfred.schedlowski@uni-essen.de	Canbay, Ali/AAL-9620-2020	Canbay, Ali/0000-0001-6069-7899				ADER R, 1993, BRAIN BEHAV IMMUN, V7, P334, DOI 10.1006/brbi.1993.1033; ADER R, 1975, PSYCHOSOM MED, V37, P333, DOI 10.1097/00006842-197507000-00007; ADER R, 1982, SCIENCE, V215, P1534, DOI 10.1126/science.7063864; ADER R, 2000, PSYCHONEUROIMMUNOLOG; ADER R, 2000, PSYCHONEUROIMMUNOLOG, V2, P3; BOVBJERG D, 1982, P NATL ACAD SCI-BIOL, V79, P583, DOI 10.1073/pnas.79.2.583; BUNJES D, 1981, EUR J IMMUNOL, V11, P657, DOI 10.1002/eji.1830110812; Elenkov IJ, 2000, PHARMACOL REV, V52, P595; Exton MS, 2000, NEUROIMMUNOMODULAT, V7, P106, DOI 10.1159/000026428; Exton MS, 2000, BEHAV BRAIN RES, V110, P129, DOI 10.1016/S0166-4328(99)00191-6; Exton MS, 1998, J NEUROIMMUNOL, V88, P182, DOI 10.1016/S0165-5728(98)00122-2; Exton MS, 1999, AM J PHYSIOL-REG I, V276, pR1710, DOI 10.1152/ajpregu.1999.276.6.R1710; Exton MS, 2000, AM J PHYSIOL-REG I, V279, pR1310, DOI 10.1152/ajpregu.2000.279.4.R1310; EXTON MS, IN PRESS IMMUNOL REV; Hsueh Chi-Mei, 1994, Neuroimmunomodulation, V1, P370, DOI 10.1159/000097190; Hsueh CM, 1999, J NEUROIMMUNOL, V94, P172, DOI 10.1016/S0165-5728(98)00250-1; KLOSTERHALFEN W, 1983, BEHAV NEUROSCI, V97, P663, DOI 10.1037/0735-7044.97.4.663; Kohm AP, 2000, IMMUNOL TODAY, V21, P539, DOI 10.1016/S0167-5699(00)01747-3; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; Sabbioni MEE, 1997, FASEB J, V11, P1291, DOI 10.1096/fasebj.11.14.9409548; Schedlowski M, 1996, J IMMUNOL, V156, P93	21	165	171	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2002	16	14					1869	1873		10.1096/fj.02-0389com	http://dx.doi.org/10.1096/fj.02-0389com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12468450				2022-12-28	WOS:000180574300006
J	Seo, JH; Rah, JC; Choi, SH; Shin, JK; Min, K; Kim, HS; Park, CH; Kim, S; Kim, EM; Lee, SH; Lee, S; Suh, SW; Suh, YH				Seo, JH; Rah, JC; Choi, SH; Shin, JK; Min, K; Kim, HS; Park, CH; Kim, S; Kim, EM; Lee, SH; Lee, S; Suh, SW; Suh, YH			alpha-Synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway	FASEB JOURNAL			English	Article						cytotoxicity; protection	NERVE-CELL INCLUSIONS; PHOSPHATIDYLINOSITOL 3-KINASE; NACP/ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; PROTEIN-KINASE; CYTOCHROME-C; MICE; COMPONENT; RELEASE; DISPLAY	alpha-Synuclein (alpha-SN) is a ubiquitous protein that is especially abundant in the brain and has been postulated to play a central role in the pathogenesis of Parkinson's disease, Alzheimer's disease, and other neurodegenerative disorders. However, little is known about the neuronal functions of alpha-SN and the molecular and cellular mechanisms underlying neuronal loss. Here, we show that alpha-SN plays dual roles of neuroprotection and neurotoxicity depending on its concentration or level of expression. At nanomolar concentrations, alpha-SN protected neurons against serum deprivation, oxidative stress, and excitotoxicity through the PI3/Akt signaling pathway, and its protective effect was increased by Bcl-2 overexpression. Conversely, at both low micromolar and overexpressed levels in the cell, alpha-SN resulted in cytotoxicity. This might be related to decreased Bcl-xL expression and increased bax expression, which is subsequently followed by cytochrome c release and caspase activation and also by microglia-mediated inflammatory responses via the NFkappaB and mitogen-activated protein kinase pathways.	Seoul Natl Univ, Coll Med, Natl Creat Res Initiat Ctr Alzheimers Dementia, Dept Pharmacol, Seoul 110799, South Korea; Seoul Natl Univ, MRC, Neurosci Res Inst, Seoul 110799, South Korea; Seoul Natl Univ, Boramae Hosp, Coll Med, Dept Neurosurg, Seoul 156707, South Korea; Seoul Natl Univ, Sch Chem & Mol Engn, Lab Struct Proteom, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Seoul National University (SNU)	Suh, YH (corresponding author), Seoul Natl Univ, Coll Med, Natl Creat Res Initiat Ctr Alzheimers Dementia, Dept Pharmacol, Seoul 110799, South Korea.	yhsuh@plaza.snu.ac.kr	Suh, Yoo-Hun/J-2761-2012; Kim, Hye Sun/J-2752-2012; Suh, Won/H-8306-2013	Suh, Won/0000-0002-1768-4635; Rah, Jong-Cheol/0000-0003-3780-0522				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Borghi R, 2000, NEUROSCI LETT, V287, P65, DOI 10.1016/S0304-3940(00)01153-8; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Goedert M, 1998, MOL PSYCHIATR, V3, P462, DOI 10.1038/sj.mp.4000458; Goedert M, 1999, PHILOS T ROY SOC B, V354, P1101, DOI 10.1098/rstb.1999.0466; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Goedert M, 1998, BIOCHEM SOC T, V26, P463, DOI 10.1042/bst0260463; Golbe LI, 1999, MOVEMENT DISORD, V14, P6, DOI 10.1002/1531-8257(199901)14:1<6::AID-MDS1004>3.0.CO;2-L; Hsu LJ, 2000, AM J PATHOL, V157, P401, DOI 10.1016/S0002-9440(10)64553-1; Iwai A, 2000, BBA-MOL BASIS DIS, V1502, P95, DOI 10.1016/S0925-4439(00)00036-3; Kakimura J, 2001, EUR J PHARMACOL, V417, P59, DOI 10.1016/S0014-2999(01)00902-5; Kholodilov NG, 1999, J NEUROCHEM, V73, P2586, DOI 10.1046/j.1471-4159.1999.0732586.x; Lavedan C, 1998, GENOME RES, V8, P871, DOI 10.1101/gr.8.9.871; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Lucking CB, 2000, CELL MOL LIFE SCI, V57, P1894, DOI 10.1007/PL00000671; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; Mizuno Y, 1998, ANN NEUROL, V44, pS99, DOI 10.1002/ana.410440715; Nunez G, 1998, CURR OPIN NEUROBIOL, V8, P613, DOI 10.1016/S0959-4388(98)80089-5; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Przedborski S, 2001, J NEUROCHEM, V76, P637, DOI 10.1046/j.1471-4159.2001.00174.x; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; Stefanis L, 2001, J NEUROCHEM, V76, P1165, DOI 10.1046/j.1471-4159.2001.00114.x; Tabrizi SJ, 2000, HUM MOL GENET, V9, P2683, DOI 10.1093/hmg/9.18.2683; Takeda A, 1998, LAB INVEST, V78, P1169; Takeda A, 1998, AM J PATHOL, V152, P367; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Yang FS, 2000, BRAIN RES, V853, P381, DOI 10.1016/S0006-8993(99)02207-6; Zhou WB, 2000, BRAIN RES, V866, P33, DOI 10.1016/S0006-8993(00)02215-0	40	183	194	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13	1				1826	+		10.1096/fj.02-0041fje	http://dx.doi.org/10.1096/fj.02-0041fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223445				2022-12-28	WOS:000181189100007
J	Gysin, R; Azzi, A; Visarius, T				Gysin, R; Azzi, A; Visarius, T			gamma-Tocopherol inhibits human cancer cell cycle progression and cell proliferation by down-regulation of cyclins	FASEB JOURNAL			English	Article						vitamin E; G(1)-S transition; cyclin D1; cyclin E	ALPHA-TOCOPHEROL; VITAMIN-E; PROSTATE-CANCER; PROTEIN; PLASMA; EXPRESSION; SUPPLEMENTATION; METABOLISM; MORTALITY; RECEPTOR	Effects of gamma-tocopherol on the cell cycle and proliferation were examined in human prostate carcinoma, colorectal adenocarcinoma, and osteosarcoma cells. Many epidemiological studies have suggested an anticancer activity of vitamin E, yet mechanistic studies are sparse to date. Vitamin E consists of four tocopherols (alpha-, beta-, gamma-, delta-) and the corresponding tocotrienols. Because gamma-tocopherol is the predominant form of tocopherol found in the U.S. diet, while a,tocopherol is the form of vitamin E most readily found in dietary supplements, we compared physiologically relevant concentrations of these tocopherols and found a more significant growth inhibition effect for gamma- than for alpha-tocopherol. Flow cytometry analysis of gamma-tocopherol treated prostate carcinoma DU-145 cells showed decreased progression into the S-phase. This effect was associated with reduced DNA synthesis as measured by 5-bromo-2'-deoxy-uridine incorporation. Furthermore, Western-blot analysis of gamma-tocopherol treated cells showed decreased levels of cyclin D1 and cyclin E. Taken together, the results indicate that gamma-tocopherol inhibits cell cycle progression via reduction of cyclin D1 and cyclin E levels. Because gamma-tocopherol has a weaker antioxidant capacity than alpha-tocopherol and gamma-tocopherol more significantly inhibited cell proliferation as well as DNA synthesis than alpha-tocopherol, we suggest a non-antioxidant mechanism to be at the basis of this effect.	Univ Bern, Inst Biochem & Mol Biol, CH-3012 Bern, Switzerland	University of Bern	Visarius, T (corresponding author), Univ Bern, Inst Biochem & Mol Biol, Buhlstr 28, CH-3012 Bern, Switzerland.	theresa.visarius@mci.unibe.ch						BAKER H, 1986, AM J CLIN NUTR, V43, P382, DOI 10.1093/ajcn/43.3.382; Bauernfeind J., 1980, Vitamin E, P99; BIERI JG, 1974, AM J CLIN NUTR, V27, P980, DOI 10.1093/ajcn/27.8.980; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOSCOBOINIK D, 1991, J BIOL CHEM, V266, P6188; Burton GW, 1998, AM J CLIN NUTR, V67, P669, DOI 10.1093/ajcn/67.4.669; CHATELAIN E, 1993, BIOCHIM BIOPHYS ACTA, V1176, P83, DOI 10.1016/0167-4889(93)90181-N; COONEY RV, 1993, P NATL ACAD SCI USA, V90, P1771, DOI 10.1073/pnas.90.5.1771; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downes CP, 2001, BIOCHEM SOC T, V29, P846, DOI 10.1042/BST0290846; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eichholzer M, 1996, INT J CANCER, V66, P145, DOI 10.1002/(SICI)1097-0215(19960410)66:2&lt;145::AID-IJC1&gt;3.0.CO;2-2; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Freedman JE, 1996, CIRCULATION, V94, P2434, DOI 10.1161/01.CIR.94.10.2434; Galli F, 2002, FREE RADICAL BIO MED, V32, P333, DOI 10.1016/S0891-5849(01)00800-0; Gann PH, 1999, CANCER RES, V59, P1225; HANDELMAN GJ, 1985, J NUTR, V115, P807, DOI 10.1093/jn/115.6.807; Heinonen OP, 1998, J NATL CANCER I, V90, P440, DOI 10.1093/jnci/90.6.440; Helzlsouer KJ, 2000, J NATL CANCER I, V92, P2018, DOI 10.1093/jnci/92.24.2018; HENDRICKSE CW, 1994, BRIT J SURG, V81, P1219, DOI 10.1002/bjs.1800810849; Jiang Q, 2001, AM J CLIN NUTR, V74, P714; Jiang Q, 2000, P NATL ACAD SCI USA, V97, P11494, DOI 10.1073/pnas.200357097; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin JQ, 1999, CANCER RES, V59, P2891; MCLAUGHLIN PJ, 1979, J AM DIET ASSOC, V75, P647; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Parker RS, 2000, BIOCHEM BIOPH RES CO, V277, P531, DOI 10.1006/bbrc.2000.3706; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PRASAD KN, 1992, J AM COLL NUTR, V11, P487; PRYOR WA, 1993, J ORG CHEM, V58, P3521, DOI 10.1021/jo00065a013; QIAO L, 1995, BBA-LIPID LIPID MET, V1258, P215, DOI 10.1016/0005-2760(95)00100-Q; Ricciarelli R, 1998, ARCH BIOCHEM BIOPHYS, V355, P197, DOI 10.1006/abbi.1998.0732; Ricciarelli R, 2000, CIRCULATION, V102, P82, DOI 10.1161/01.CIR.102.1.82; Ricciarelli R, 2001, FASEB J, V15, P2314, DOI 10.1096/fj.01-0258rev; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Stocker A, 1999, IUBMB LIFE, V48, P49, DOI 10.1080/152165499307413; Stone WL, 1997, JNCI-J NATL CANCER I, V89, P1006, DOI 10.1093/jnci/89.14.1006; Tasinato A, 1995, P NATL ACAD SCI USA, V92, P12190, DOI 10.1073/pnas.92.26.12190; TRABER MG, 1985, J CLIN INVEST, V75, P1729, DOI 10.1172/JCI111883; Zha S, 2001, CANCER RES, V61, P8617; Zimmer S, 2000, J BIOL CHEM, V275, P25672, DOI 10.1074/jbc.M000851200	41	152	157	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1952	+		10.1096/fj.02-0362fje	http://dx.doi.org/10.1096/fj.02-0362fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368234				2022-12-28	WOS:000179167600022
J	Harper, ME; Antoniou, A; Villalobos-Menuey, E; Russo, A; Trauger, R; Vendemelio, M; George, A; Bartholomew, R; Carlo, D; Shaikh, A; Kupperman, J; Newell, EW; Bespalov, IA; Wallace, SS; Liu, Y; Rogers, JR; Gibbs, GL; Leahy, JL; Camley, RE; Melamede, R; Newell, MK				Harper, ME; Antoniou, A; Villalobos-Menuey, E; Russo, A; Trauger, R; Vendemelio, M; George, A; Bartholomew, R; Carlo, D; Shaikh, A; Kupperman, J; Newell, EW; Bespalov, IA; Wallace, SS; Liu, Y; Rogers, JR; Gibbs, GL; Leahy, JL; Camley, RE; Melamede, R; Newell, MK			Characterization of a novel metabolic strategy used by drug-resistant tumor cells	FASEB JOURNAL			English	Article						cancer; mitochondria; uncoupling proteins; membrane potential; oxygen consumption	UNCOUPLING PROTEIN-2; PROTON LEAK; MITOCHONDRIA; PHOSPHORYLATION; GENE; SENSITIVITY; GLUTATHIONE; APOPTOSIS	Acquired or inherent drug resistance is the major problem in achieving successful cancer treatment. However, the mechanism(s) of pleiotropic drug resistance remains obscure. We have identified and characterized a cellular metabolic strategy that differentiates drug-resistant cells from drug-sensitive cells. This strategy may serve to protect drug-resistant cells from damage caused by chemotherapeutic agents and radiation. We show that drug-resistant cells have low mitochondrial membrane potential, use nonglucose carbon sources (fatty acids) for mitochondrial oxygen consumption when glucose becomes limited, and are protected from exogenous stress such as radiation. In addition, drug-resistant cells express high levels of mitochondrial uncoupling protein 2 (UCP2). The discovery of this metabolic strategy potentially facilitates the design of novel therapeutic approaches to drug resistance.	Univ Colorado, Dept Biol, Colorado Springs, CO 80918 USA; Univ Colorado, Dept Phys, Colorado Springs, CO 80918 USA; Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; Univ Vermont, Coll Med, Dept Med, Div Endocrinol, Burlington, VT 05405 USA; Univ Vermont, Coll Med, Div Immunobiol, Burlington, VT 05405 USA; Immune Response Corp, San Diego, CA USA; Univ Toronto, Toronto Western Res Inst, Toronto, ON, Canada; Univ Toronto, Dept Physiol, Toronto, ON, Canada; Univ Vermont, Markey Ctr Mol Genet, Dept Microbiol & Mol Genet, Burlington, VT USA; Colorado Associates Med Phys, Colorado Springs, CO USA	University of Colorado System; University of Colorado at Colorado Springs; University of Colorado System; University of Colorado at Colorado Springs; University of Ottawa; University of Vermont; University of Vermont; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Vermont	Newell, MK (corresponding author), Univ Colorado, Dept Biol, 134 Sci Bldg,1420 Austin Bluffs Pkwy, Colorado Springs, CO 80918 USA.	mnewell@mail.uccs.edu	Newell, Evan W/F-9711-2012	Newell, Evan W/0000-0002-2889-243X; Wallace, Susan S./0000-0002-3906-0321; Harper, Mary-Ellen/0000-0003-3864-5886; Shaikh, Allison/0000-0002-2548-4166	NHLBI NIH HHS [R01 HL61346] Funding Source: Medline; NIDDK NIH HHS [DK 56818] Funding Source: Medline; NIGMS NIH HHS [R01 GM62562] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061346] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056818, R56DK056818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062562] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arceci R J, 1995, Curr Opin Hematol, V2, P268; Bhushan A, 1998, IMMUNOL CELL BIOL, V76, P350, DOI 10.1046/j.1440-1711.1998.00758.x; Bhushan A, 1996, BIOCHEM PHARMACOL, V51, P477, DOI 10.1016/0006-2952(96)84208-0; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; BRAND MD, 1993, BIOCHEM J, V291, P739, DOI 10.1042/bj2910739; BRAND MD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P128, DOI 10.1016/0005-2728(90)90232-S; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; HALICKA HD, 1995, CANCER RES, V55, P444; HARPER ME, 1993, J BIOL CHEM, V268, P14850; HIMMSHAGEN J, 1990, BROWN ADIPOSE TISSUE; Landowski TH, 1997, BLOOD, V89, P1854, DOI 10.1182/blood.V89.6.1854; MACFARLANE DE, 1986, J BIOL CHEM, V261, P6947; Medvedev AV, 2001, J BIOL CHEM, V276, P10817, DOI 10.1074/jbc.M010587200; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; NOBES CD, 1990, J BIOL CHEM, V265, P12903; REINHART PH, 1982, BIOCHEM J, V204, P731, DOI 10.1042/bj2040731; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; Skulachev VP, 1996, FEBS LETT, V397, P7, DOI 10.1016/0014-5793(96)00989-1; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; WALLACE S, 1997, OXIDATIVE STRESS MOL; Yu DS, 1997, J UROLOGY, V157, P727, DOI 10.1016/S0022-5347(01)65259-5	25	145	153	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1550	1557		10.1096/fj.02-0541com	http://dx.doi.org/10.1096/fj.02-0541com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374777				2022-12-28	WOS:000179167600036
J	Montero, M; Lobaton, CD; Moreno, A; Alvarez, J				Montero, M; Lobaton, CD; Moreno, A; Alvarez, J			A novel regulatory mechanism of the mitochondrial Ca2+ uniporter revealed by the p38 mitogen-activated protein kinase inhibitor sb202190	FASEB JOURNAL			English	Article						calcium; mitochondria; aequorin; MAP kinase	ADRENAL CHROMAFFIN CELLS; SIGNAL-TRANSDUCTION; MAP KINASE; ENDOPLASMIC-RETICULUM; CALCIUM-TRANSPORT; INTACT-CELLS; TRANSLOCATION; PERMEABILITY; MICRODOMAINS; TRANSIENTS	It is widely acknowledged that mitochondrial Ca2+ uptake modulates the cytosolic [Ca2+] ([Ca2+](c)) acting as a transient Ca2+ buffer. In addition, mitochondrial [Ca2+] ([Ca2+](M)) regulates the rate of respiration and may trigger opening of the permeability transition pore and start apoptosis. However, no mechanism for the physiological regulation of mitochondrial Ca2+ uptake has been described. We show here that SB202190, an inhibitor of p38 mitogen-activated protein (MAP) kinase, strongly stimulates ruthenium red-sensitive mitochondrial Ca2+ uptake, both in intact and in permeabilized HeLa cells. The [Ca2+](M) peak induced by agonists was increased about fourfold in the presence of the inhibitor, with a concomitant reduction in the [Ca2+](c), peak. The stimulation occurred fast and was rapidly reversible. In addition, experiments in permeabilized cells perfused with controlled [Ca2+] showed that SB202190 stimulated mitochondrial Ca2+ uptake by more than 10-fold, but only in the physiological [Ca2+](c), range (1-4 muM). Other structurally related p38 MAP kinase inhibitors (SB203580, PD169316, or SB220025) produced little or no effect. Our data suggest that in HeLa cells, a protein kinase sensitive to SB202190 tonically inhibits the mitochondrial Ca2+ uniporter. This novel regulatory mechanism may be of paramount importance to modulate mitochondrial Ca2+ uptake under different physiopathological conditions.	Univ Valladolid, Fac Med, Dept Bioquim & Biol Mol & Fisiol, IBGM, E-47005 Valladolid, Spain; CSIC, E-47005 Valladolid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid; Consejo Superior de Investigaciones Cientificas (CSIC)	Alvarez, J (corresponding author), Univ Valladolid, Fac Med, Dept Bioquim & Biol Mol & Fisiol, IBGM, Ramon & Cajal 7, E-47005 Valladolid, Spain.	jalvarez@ibgm.uva.es	Montero, Mayte/K-8212-2014; Alvarez, Javier/K-8210-2014; Lobaton, Carmen D/A-9134-2015	Montero, Mayte/0000-0001-7702-6653; Alvarez, Javier/0000-0003-0636-5521; Lobaton, Carmen D/0000-0001-9574-3082; Moreno, Alfredo/0000-0002-7444-5198				ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; Arnaudeau S, 2001, J BIOL CHEM, V276, P29430, DOI 10.1074/jbc.M103274200; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Behr TM, 2001, CIRCULATION, V104, P1292, DOI 10.1161/hc3601.094275; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Collins TJ, 2001, J BIOL CHEM, V276, P26411, DOI 10.1074/jbc.M101101200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Feranchak AP, 2001, J CLIN INVEST, V108, P1495, DOI 10.1172/JCI200112190; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Giovannucci DR, 1999, J NEUROSCI, V19, P9261; Gunter TE, 1998, BBA-BIOENERGETICS, V1366, P5, DOI 10.1016/S0005-2728(98)00117-0; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; Huang FY, 2000, INT J ENG SCI, V38, P275, DOI 10.1016/S0020-7225(99)00041-5; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kusuhara M, 1998, CIRC RES, V83, P824, DOI 10.1161/01.RES.83.8.824; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Lee SH, 2000, J NEUROSCI RES, V60, P623, DOI 10.1002/(SICI)1097-4547(20000601)60:5<623::AID-JNR7>3.0.CO;2-4; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Montero M, 1997, FASEB J, V11, P881, DOI 10.1096/fasebj.11.11.9285486; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Park YB, 1996, J PHYSIOL-LONDON, V492, P329, DOI 10.1113/jphysiol.1996.sp021312; Pausawasdi N, 2000, AM J PHYSIOL-GASTR L, V278, pG24, DOI 10.1152/ajpgi.2000.278.1.G24; Pozzan T, 2000, EUR J BIOCHEM, V267, P5269, DOI 10.1046/j.1432-1327.2000.01567.x; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Rustenbeck I, 1998, BIOCHEM PHARMACOL, V56, P977, DOI 10.1016/S0006-2952(98)00232-9; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Villalobos C, 2002, FASEB J, V16, DOI 10.1096/fj.01-0630com; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WHITE HS, 1997, EPILEPSIES, V2, P1; Wilk-Blaszczak MA, 1998, J NEUROSCI, V18, P112	38	67	71	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1955	+		10.1096/fj.02-0553fje	http://dx.doi.org/10.1096/fj.02-0553fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368236				2022-12-28	WOS:000179167600027
J	Hicks, AER; Leppanen, A; Cummings, RD; McEver, RP; Hellewell, PG; Norman, KE				Hicks, AER; Leppanen, A; Cummings, RD; McEver, RP; Hellewell, PG; Norman, KE			Glycosulfopeptides modeled on P-selectin glycoprotein ligand-1 inhibit P-selectin-dependent leukocyte rolling in vivo	FASEB JOURNAL			English	Article						intravital microscopy; inflammation; adhesion molecules; microcirculation; venules	IN-VIVO; SIALYL LEWIS(X); ADHESION MOLECULE-1; CARBOHYDRATE LIGAND; CELL-ADHESION; BINDING; PSGL-1; OLIGOSACCHARIDE; VENULES; ELAM-1	Leukocytic inflammation can be limited by inhibiting selectin-dependent leukocyte rolling. In spite of intensive efforts to develop small molecule selectin inhibitors with defined structure-activity profiles, inhibition of P-selectin-dependent leukocyte rolling in vivo by such a compound has yet to be described. We recently reported that glycosulfopeptides (GSP), modeled on the high affinity selectin ligand PSGL-1, inhibit leukocyte binding to P-selectin in vitro. Here, we have used intravital microscopy to investigate whether GSP can inhibit P-selectin-dependent leukocyte rolling in vivo. Surgical preparation of the mouse cremaster muscle for intravital microscopy induced P-selectin-dependent leukocyte rolling. Baseline rolling was recorded for 1 min followed by i.v. injection of GSP. 2-GSP-6 and 4-GSP-6 substantially reversed P-selectin-dependent leukocyte rolling, whereas control GSP, which are not fully glycosylated, did not. Inhibition of leukocyte rolling by 2- and 4-GSP-6 lasted 2-4 min. Clearance studies with I-125-labeled 4-GSP-6 demonstrated rapid reduction in its circulating levels concurrent with accumulation in urine. These data represent the first demonstration that a precisely defined structure based on a natural P-selectin ligand can inhibit P-selectin-dependent leukocyte rolling in vivo.	Univ Sheffield, Div Clin Sci N, Cardiovasc Res Grp, Sheffield, S Yorkshire, England; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA	University of Sheffield; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation	Norman, KE (corresponding author), No Gen Hosp, Ctr Clin Sci, Cardiovasc Res Grp, Sheffield S5 7AU, S Yorkshire, England.	k.norman@shef.ac.uk						Baran KW, 2001, CIRCULATION, V104, P2778, DOI 10.1161/hc4801.100236; BERG EL, 1991, J BIOL CHEM, V266, P14869; Borges E, 1997, BLOOD, V90, P1934, DOI 10.1182/blood.V90.5.1934; CUMMINGS RD, 1999, ESSENTIALS GLYCOBIOL, P391; Eguchi H, 1999, CIRC RES, V84, P525, DOI 10.1161/01.RES.84.5.525; Eriksson EE, 2001, FASEB J, V15, P1149, DOI 10.1096/fj.00-0537com; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Goetz DJ, 1997, J CELL BIOL, V137, P509, DOI 10.1083/jcb.137.2.509; GRANERT C, 1994, J CLIN INVEST, V93, P929, DOI 10.1172/JCI117098; Hartwell DM, 1998, J CELL BIOL, V143, P1129, DOI 10.1083/jcb.143.4.1129; Hicks AE, 2001, FASEB J, V15, pA1183; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; Johnson RC, 1997, J CLIN INVEST, V99, P1037, DOI 10.1172/JCI119231; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KANWAR S, 1995, CIRC RES, V77, P879, DOI 10.1161/01.RES.77.5.879; Khor SP, 2000, J PHARMACOL EXP THER, V293, P618; Kim MK, 1998, AM J RESP CELL MOL, V19, P836, DOI 10.1165/ajrcmb.19.5.3032; Kunkel EJ, 1996, J EXP MED, V183, P57, DOI 10.1084/jem.183.1.57; Lefer DJ, 2000, ANNU REV PHARMACOL, V40, P283, DOI 10.1146/annurev.pharmtox.40.1.283; LEFER DJ, 1994, CIRCULATION, V90, P2390, DOI 10.1161/01.CIR.90.5.2390; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; LEY K, 1993, BLOOD, V81, P177; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; LEY K, 1991, J PHYSL, V260, pH1667; LINDBOM L, 1992, ACTA PHYSIOL SCAND, V146, P415, DOI 10.1111/j.1748-1716.1992.tb09442.x; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; Murohara T, 1995, CARDIOVASC RES, V30, P965, DOI 10.1016/S0008-6363(95)00157-3; NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275; Norman KE, 1998, BLOOD, V91, P475, DOI 10.1182/blood.V91.2.475.475_475_483; Norman KE, 2000, BLOOD, V96, P3585; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; Salmela K, 1999, TRANSPLANTATION, V67, P729, DOI 10.1097/00007890-199903150-00015; Sherman DG, 2001, NEUROLOGY, V57, P1428, DOI 10.1212/wnl.57.8.1428; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Sperandio M, 2001, BLOOD, V97, P3812, DOI 10.1182/blood.V97.12.3812; Yang J, 1999, THROMB HAEMOSTASIS, V81, P1; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557; Zimmerman GA, 2001, P NATL ACAD SCI USA, V98, P10023, DOI 10.1073/pnas.191367898	47	18	22	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1461	+		10.1096/fj.02-0075fje	http://dx.doi.org/10.1096/fj.02-0075fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205048				2022-12-28	WOS:000177813100014
J	Lim, D; Lange, K; Santella, L				Lim, D; Lange, K; Santella, L			Activation of oocytes by latrunculin A	FASEB JOURNAL			English	Article						intracellular calcium; fertilization; actin depolymerization; starfish oocytes	CYCLIC-ADP-RIBOSE; SEA-URCHIN EGGS; CA2+-INDUCED CA2+ RELEASE; REPETITIVE CALCIUM WAVES; INOSITOL TRISPHOSPHATE; STARFISH OOCYTES; XENOPUS OOCYTES; SPERM EXTRACT; FERTILIZATION; LOCALIZATION	Actin depolymerization by latrunculin A (LAT-A) in mature starfish oocytes induces a massive calcium mobilization that results in the discharge of the cortical granules and in the elevation of the fertilization envelope. The Ca2+ liberation starts as a circumscribed subplasma membrane hotspot, which is followed by a flash of Ca2+ increase restricted to the cortical layer. Ca2+ propagates rapidly from these peripheral regions to the center of the oocyte, initiating calcium oscillations. Blockade of the inositol 1,4,5-trisphosphate receptors with heparin does not affect the liberation of Ca2+ at the initial hotspot or the cortical flash, but abolishes the centripetal spreading of the wave and the Ca2+ oscillations. In Ca2+-free medium, LAT-A also initiates Ca2+ release at a discrete cortical point, but then propagates throughout the cell without first forming the uniform cortical flash. The latter is thus linked to the influx of external Ca2+, somehow promoted by the depolymerization of cortical (microvillar) actin. The Ca2+ response to spermatozoa (i.e., peripheral hotspot, cortical flash, globalization of the signal) closely mimics that promoted by LAT-A. Thus, the initial cortical release of Ca2+ promoted by the sperm may be due to the depolymerization of actin.	Staz Zool Anton Dohrn, Cell Biol Lab, I-80121 Naples, Italy	Stazione Zoologica Anton Dohrn di Napoli	Santella, L (corresponding author), Staz Zool Anton Dohrn, Cell Biol Lab, Villa Comunale, I-80121 Naples, Italy.	santella@alpha.szn.it	Lim, Dmitry/H-9101-2012; Santella, Luigia/AAM-3524-2020	Santella, Luigia/0000-0001-7159-0499				Abbott AL, 2001, FRONT BIOSCI, V6, pD792, DOI 10.2741/Abbott; Callamaras N, 1999, J GEN PHYSIOL, V113, P199, DOI 10.1085/jgp.113.2.199; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; Carroll DJ, 1997, J CELL BIOL, V138, P1303, DOI 10.1083/jcb.138.6.1303; EDDY EM, 1976, J CELL BIOL, V71, P35, DOI 10.1083/jcb.71.1.35; Galione A, 2000, BIOL CELL, V92, P197, DOI 10.1016/S0248-4900(00)01070-4; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; HIRAI H, 1979, B MAR BIOL STA ASAMU, V16, P161; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; KANATANI H, 1969, NATURE, V221, P273, DOI 10.1038/221273a0; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; Kuroda R, 2001, DEVELOPMENT, V128, P4405; Kyozuka K, 1998, DEVELOPMENT, V125, P4099; Lange J, 1997, EXP CELL RES, V234, P486, DOI 10.1006/excr.1997.3652; Lange K, 1996, FEBS LETT, V395, P137, DOI 10.1016/0014-5793(96)01025-3; Lange K, 1999, J CELL PHYSIOL, V180, P19, DOI 10.1002/(SICI)1097-4652(199907)180:1<19::AID-JCP3>3.0.CO;2-K; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; LEE HC, 1994, MOL CELL BIOCHEM, V138, P229, DOI 10.1007/BF00928466; Lim D, 2001, FASEB J, V15, P2257, DOI 10.1096/fj.01-0157com; Marchant J, 1999, EMBO J, V18, P5285, DOI 10.1093/emboj/18.19.5285; MCCULLOH DH, 1992, J GEN PHYSIOL, V99, P137, DOI 10.1085/jgp.99.2.137; McDougall Alex, 1993, Zygote, V1, P35; McGuinness OM, 1996, DEVELOPMENT, V122, P2199; Mehlmann LM, 1996, DEV BIOL, V180, P489, DOI 10.1006/dbio.1996.0322; MIYAZAKI S, 1992, FEBS LETT, V309, P180, DOI 10.1016/0014-5793(92)81090-9; Mohri T, 2001, CELL CALCIUM, V29, P311, DOI 10.1054/ceca.2000.0196; Santella L, 2000, J BIOL CHEM, V275, P8301, DOI 10.1074/jbc.275.12.8301; SCHROEDER TE, 1983, DEV BIOL, V98, P373, DOI 10.1016/0012-1606(83)90366-4; SPEKSNIJDER JE, 1992, DEV BIOL, V153, P259, DOI 10.1016/0012-1606(92)90111-S; Stricker SA, 1996, DEV BIOL, V176, P243, DOI 10.1006/dbio.1996.0131; SWANN K, 1986, J CELL BIOL, V103, P2333, DOI 10.1083/jcb.103.6.2333; Taylor CW, 2001, CURR BIOL, V11, pR352, DOI 10.1016/S0960-9822(01)00192-0; Tovey SC, 2001, J CELL SCI, V114, P3979; VANHAELST C, 1988, J IMMUNOL, V140, P1256; Wakatsuki T, 2001, J CELL SCI, V114, P1025; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y	39	41	41	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2002	16	9					1050	1056		10.1096/fj.02-0021com	http://dx.doi.org/10.1096/fj.02-0021com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087066				2022-12-28	WOS:000177813100036
J	Stacker, SA; Baldwin, ME; Achen, MG				Stacker, SA; Baldwin, ME; Achen, MG			The role of tumor lymphangiogenesis in metastatic spread	FASEB JOURNAL			English	Review						metastasis; VEGF-C; VEGF-D; VEGF receptors	ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; FACTOR-C EXPRESSION; LYMPH-NODE METASTASIS; VEGF-C; KAPOSIS-SARCOMA; FACTOR FAMILY; MEMBRANE ANTIBODIES; PROX1 FUNCTION; BLOOD-VESSELS	The high mortality rates associated with cancer can be attributed to the metastatic spread of tumor cells from the site of their origin. Tumor cells invade either the blood or lymphatic vessels to access the general circulation and then establish themselves in other tissues. Clinicopathological data suggest that the lymphatics are an initial route for the spread of solid tumors. Detection of sentinel lymph nodes by biopsy provides significant information for staging and designing therapeutic regimens. The role of angiogenesis in facilitating the growth of solid tumors has been well established, but the presence of lymphatic vessels and the relevance of lymphangiogenesis to tumor spread are less clear. Recently, the molecular pathway that signals for lymphangiogenesis and relatively specific markers for lymphatic endothelium have been described allowing analyses of tumor lymphangiogenesis to be performed in animal models. These studies demonstrate that tumor lymphangiogenesis is a major component of the metastatic process and implicate members of the VEGF family of growth factors as key mediators of lymphangiogenesis in both normal biology and tumors.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Stacker, SA (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, POB 2008, Melbourne, Vic 3050, Australia.	steven.stacker@ludwig.edu.au		Achen, Marc/0000-0002-3791-803X; Stacker, Steven/0000-0003-4096-9273				Achen MG, 2000, EUR J BIOCHEM, V267, P2505, DOI 10.1046/j.1432-1327.2000.01257.x; Achen MG, 1998, INT J EXP PATHOL, V79, P255, DOI 10.1046/j.1365-2613.1998.700404.x; Achen MG, 2001, J PATHOL, V193, P147, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH757>3.0.CO;2-G; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Akagi K, 2000, BRIT J CANCER, V83, P887, DOI 10.1054/bjoc.2000.1396; Albertini JJ, 1996, ANN SURG, V223, P217, DOI 10.1097/00000658-199602000-00016; Albertini JJ, 1996, JAMA-J AM MED ASSOC, V276, P1818, DOI 10.1001/jama.276.22.1818; ALGIRE GH, 1945, J NATL CANCER I, V6, P73, DOI 10.1093/jnci/6.1.73; APRELIKOVA O, 1992, CANCER RES, V52, P746; Baldwin ME, 2001, J BIOL CHEM, V276, P19166, DOI 10.1074/jbc.M100097200; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BARSKY SH, 1983, AM J SURG PATHOL, V7, P667, DOI 10.1097/00000478-198310000-00007; Birck A, 1999, MELANOMA RES, V9, P375, DOI 10.1097/00008390-199908000-00006; Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6; BreitenederGeleff S, 1997, AM J PATHOL, V151, P1141; Bunone G, 1999, AM J PATHOL, V155, P1967, DOI 10.1016/S0002-9440(10)65515-0; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Carreira CM, 2001, CANCER RES, V61, P8079; CASLEYSMITH JR, 1961, Q J EXP PHYSL, V46, P1010; Clarijs R, 2001, J PATHOL, V193, P143, DOI 10.1002/path.808; Debinski W, 2001, MOL MED, V7, P598, DOI 10.1007/BF03401866; Dukes CE, 1932, J PATHOL BACTERIOL, V35, P323, DOI 10.1002/path.1700350303; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Ebata N, 2001, MICROVASC RES, V61, P40, DOI 10.1006/mvre.2000.2280; EHRMANN RL, 1968, J NATL CANCER I, V41, P1329; Enholm B, 2001, CIRC RES, V88, P623, DOI 10.1161/01.RES.88.6.623; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; FIDLER IJ, 2001, CANC PRINCIPLES PRAC, P135; FISHER B, 1983, CANCER-AM CANCER SOC, V52, P1551, DOI 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folpe AL, 2000, MODERN PATHOL, V13, P180, DOI 10.1038/modpathol.3880033; Fong TAT, 1999, CANCER RES, V59, P99; Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166; George ML, 2001, NEOPLASIA, V3, P420, DOI 10.1038/sj.neo.7900186; Goldmann E, 1907, LANCET, V2, P1236; GREENBLATT M, 1968, JNCI-J NATL CANCER I, V41, P111; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hamada K, 2000, BLOOD, V96, P3793, DOI 10.1182/blood.V96.12.3793.h8003793_3793_3800; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hashimoto I, 2001, BRIT J CANCER, V85, P93, DOI 10.1054/bjoc.2001.1846; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Ichikura T, 2001, J SURG ONCOL, V78, P132, DOI 10.1002/jso.1133; IDE A. GORDON, 1939, AMER JOUR ROENTGENOL AND RADIUM THERAP, V42, P891; Irrthum A, 2000, AM J HUM GENET, V67, P295, DOI 10.1086/303019; Jackson DG, 2001, TRENDS IMMUNOL, V22, P317, DOI 10.1016/S1471-4906(01)01936-6; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Jenkins NA, 1997, CHROMOSOME RES, V5, P502; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; Joukov V, 1996, EMBO J, V15, P290; Jussila L, 1998, CANCER RES, V58, P1599; Kabashima A, 2001, ONCOLOGY-BASEL, V60, P146, DOI 10.1159/000055312; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kajita T, 2001, BRIT J CANCER, V85, P255, DOI 10.1054/bjoc.2001.1882; Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Karpanen T, 2001, J EXP MED, V194, pF37, DOI 10.1084/jem.194.6.F37; Karpanen T, 2001, CANCER RES, V61, P1786; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Kinoshita J, 2001, BREAST CANCER RES TR, V66, P159, DOI 10.1023/A:1010692132669; Kitadai Y, 2001, INT J CANCER, V93, P662, DOI 10.1002/ijc.1379; Kubo H, 2000, BLOOD, V96, P546; Kukk E, 1996, DEVELOPMENT, V122, P3829; LEAK L V, 1970, Microvascular Research, V2, P361, DOI 10.1016/0026-2862(70)90031-2; LEAK LV, 1966, AM J ANAT, V118, P785, DOI 10.1002/aja.1001180308; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Leu AJ, 2000, CANCER RES, V60, P4324; Lymboussaki A, 1998, AM J PATHOL, V153, P395, DOI 10.1016/S0002-9440(10)65583-6; Lymboussaki A, 2000, CURR TOP MICROBIOL, V251, P75; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Marchio S, 1999, J BIOL CHEM, V274, P27617, DOI 10.1074/jbc.274.39.27617; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; MCCARROLL DR, 1985, J CLIN INVEST, V75, P1089, DOI 10.1172/JCI111802; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Moore KL, 1985, CLIN ORIENTATED ANAT; NERLICH AG, 1991, HISTOCHEMISTRY, V96, P449, DOI 10.1007/BF00316003; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Niki T, 2000, CLIN CANCER RES, V6, P2431; O-charoenrat P, 2001, CANCER-AM CANCER SOC, V92, P556, DOI 10.1002/1097-0142(20010801)92:3<556::AID-CNCR1355>3.0.CO;2-Q; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Ohta Y, 1999, BRIT J CANCER, V81, P54, DOI 10.1038/sj.bjc.6690650; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Orlandini M, 2001, J BIOL CHEM, V276, P6576, DOI 10.1074/jbc.M009573200; OTSUKI Y, 1990, ARCH HISTOL CYTOL, V53, P95, DOI 10.1679/aohc.53.Suppl_95; Paavonen K, 2000, AM J PATHOL, V156, P1499, DOI 10.1016/S0002-9440(10)65021-3; Paavonen K, 2002, J RHEUMATOL, V29, P39; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PAJUSOLA K, 1993, CANCER RES, V53, P3845; Papoutsi M, 2001, MICROSC RES TECHNIQ, V55, P100, DOI 10.1002/jemt.1161; Partanen TA, 1999, CANCER-AM CANCER SOC, V86, P2406, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.3.CO;2-5; Pepper MS, 2001, CLIN CANCER RES, V7, P462; Pepper MS, 2000, LYMPHOLOGY, V33, P144; Prevo R, 2001, J BIOL CHEM, V276, P19420, DOI 10.1074/jbc.M011004200; Pullinger BD, 1935, BRIT J EXP PATHOL, V16, P49; Reichert FL, 1926, ARCH SURG-CHICAGO, V13, P871, DOI 10.1001/archsurg.1926.01130120095004; REMKO P, 2001, J BIOL CHEM, V276, P19420; Rennie J, 1996, SCI AM, V275, P56, DOI 10.1038/scientificamerican0996-56; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ristimaki A, 1998, J BIOL CHEM, V273, P8413, DOI 10.1074/jbc.273.14.8413; Rodriguez-Niedenfuhr M, 2001, ANAT EMBRYOL, V204, P399, DOI 10.1007/s00429-001-0214-9; Roitt I., 1998, IMMUNOLOGY; Ruoslahti E, 1996, SCI AM, V275, P72, DOI 10.1038/scientificamerican0996-72; RYAN TJ, 1989, J INVEST DERMATOL, V93, pS18, DOI 10.1111/1523-1747.ep12580899; Salven P, 1997, BRIT J CANCER, V76, P930, DOI 10.1038/bjc.1997.486; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; Sauter B, 1998, J HISTOCHEM CYTOCHEM, V46, P165, DOI 10.1177/002215549804600205; Schittny JC, 1989, CURR OPIN CELL BIOL, V1, P983, DOI 10.1016/0955-0674(89)90069-0; SCHLINGEMANN RO, 1985, LAB INVEST, V52, P71; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Sinzelle E, 2000, HISTOPATHOLOGY, V37, P93; Skobe M, 1999, J INVEST DERMATOL, V113, P1047, DOI 10.1046/j.1523-1747.1999.00798.x; Skobe M, 2000, J INVEST DERM SYMP P, V5, P14, DOI 10.1046/j.1087-0024.2000.00001.x; Skobe M, 2001, AM J PATHOL, V159, P893, DOI 10.1016/S0002-9440(10)61765-8; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Sleeman JP, 2001, MICROSC RES TECHNIQ, V55, P61, DOI 10.1002/jemt.1157; Sosa-Pineda B, 2000, NAT GENET, V25, P254, DOI 10.1038/76996; Stacker SA, 1999, GROWTH FACTORS, V17, P1, DOI 10.3109/08977199909001058; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Stanton A W, 1996, Vasc Med, V1, P213; Swartz MA, 2001, MICROSC RES TECHNIQ, V55, P92, DOI 10.1002/jemt.1160; Szuba A, 1997, Vasc Med, V2, P321; Taipale J, 1999, CURR TOP MICROBIOL, V237, P85; TIERNEY LM, 1995, CURRENT MED DIAGNOSI; Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Wells KE, 1997, PLAST RECONSTR SURG, V100, P591, DOI 10.1097/00006534-199709000-00006; Weninger W, 1999, LAB INVEST, V79, P243; WERNER JA, 1989, ACTA HISTOCHEM, V85, P15, DOI 10.1016/S0065-1281(89)80090-X; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Witmer AN, 2001, J PATHOL, V195, P490, DOI 10.1002/path.969; Witte M H, 1997, EXS, V79, P65; Witte MH, 2001, MICROSC RES TECHNIQ, V55, P122, DOI 10.1002/jemt.1163; Wood JM, 2000, CANCER RES, V60, P2178; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; Yanai Y, 2001, J EXP CLIN CANC RES, V20, P419; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823; Yonemura Y, 2001, EUR J CANCER, V37, P918, DOI 10.1016/S0959-8049(01)00015-6; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	150	237	270	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					922	934		10.1096/fj.01-0945rev	http://dx.doi.org/10.1096/fj.01-0945rev			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087053				2022-12-28	WOS:000177813100023
J	Stoletov, KV; Ratcliffe, KE; Terman, BI				Stoletov, KV; Ratcliffe, KE; Terman, BI			Fibroblast growth factor receptor substrate 2 participates in vascular endothelial growth factor-induced signaling	FASEB JOURNAL			English	Article						VEGF; KDR; angiogenesis; FRS2; endothelial cells	ACTIVATED PROTEIN-KINASE; TYROSINE KINASE; DOCKING-PROTEIN; PERMEABILITY FACTOR; CELL PROLIFERATION; FOCAL ADHESIONS; ADAPTER PROTEIN; TUMOR-GROWTH; KDR; IDENTIFICATION	Vascular endothelial growth factor (VEGF) activates endothelial cells, in part, by interacting with the kinase insert domain-containing receptor (KDR) receptor tyrosine kinase. Although progress has been made in the identification of cell-signaling proteins that participate in the VEGF-induced response, questions remain concerning the molecular interactions that allow coupling of receptor activation with an increased cellular response. Evidence is provided in this manuscript that indicates a role for the fibroblast growth factor receptor substrate 2 (FRS2) in VEGF-induced signal transduction. VEGF treatment of human umbilical vein endothelial cells (HUVECs) and KDR-transfected porcine aortic endothelial cells leads to the rapid tyrosine phosphorylation of FRS2. FRS2 is associated constitutively with KDR, and VEGF treatment has no effect on this interaction. VEGF treatment of KDR-expressing cells leads to the recruitment of Nck, p21-activated kinase, Crk, Grb2, and protein kinase C to FRS2. The ability of FRS2 to recruit cell-signaling proteins to the cell is significant because it provides a mechanism for enhancing the repertoire of VEGF-induced signaling pathways.	Albert Einstein Coll Med, Dept Med, Div Cardiol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Terman, BI (corresponding author), Albert Einstein Coll Med, Dept Med, Div Cardiol, Forchheimer 715,1300 Morris Pk Ave, Bronx, NY 10461 USA.	Terman@aecom.yu.edu		Stoletov, Konstantin/0000-0002-7384-2917				Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Bouton AH, 2001, ONCOGENE, V20, P6448, DOI 10.1038/sj.onc.1204785; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Delahaye L, 2000, ENDOCRINOLOGY, V141, P621, DOI 10.1210/en.141.2.621; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dhalluin C, 2000, MOL CELL, V6, P921, DOI 10.1016/S1097-2765(00)00089-7; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; DOUGHERVERMAZEN M, 1994, BIOCHEM BIOPH RES CO, V205, P728, DOI 10.1006/bbrc.1994.2726; Duh E, 1999, DIABETES, V48, P1899, DOI 10.2337/diabetes.48.10.1899; FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Lai KMV, 2000, GENE DEV, V14, P1132; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lim YP, 1999, J BIOL CHEM, V274, P19025, DOI 10.1074/jbc.274.27.19025; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PEER J, 1995, LAB INVEST, V72, P638; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Saaristo A, 2000, ONCOGENE, V19, P6122, DOI 10.1038/sj.onc.1203969; SHIBUYA M, 1990, ONCOGENE, V14, P2079; Stoletov KV, 2001, J BIOL CHEM, V276, P22748, DOI 10.1074/jbc.M009720200; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tao Q, 2001, J BIOL CHEM, V276, P21916, DOI 10.1074/jbc.M100763200; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang JK, 1996, ONCOGENE, V13, P721; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	46	21	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1283	+		10.1096/fj.01-0835fje	http://dx.doi.org/10.1096/fj.01-0835fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154000				2022-12-28	WOS:000176683900016
J	Streller, T; Huckstorf, C; Pfeiffer, C; Acker, H				Streller, T; Huckstorf, C; Pfeiffer, C; Acker, H			Unusual cytochrome a(592) with low PO2 affinity correlates as putative oxygen sensor with rat carotid body chemoreceptor discharge	FASEB JOURNAL			English	Article						cytochrome c oxidase; light absorption photometry; electrophysiology	MITOCHONDRIAL RESPIRATORY-CHAIN; C-OXIDASE; NADPH OXIDASE; CELLS; PROTEIN	Light-absorption spectra and afferent chemoreceptor discharge were simultaneously recorded on superfused rat carotid bodies (CBs) under the influence of cytochrome a3-Cu-B ligands (O-2, CN-, CO) in order to identify the primary mitochondrial cytochrome c oxidase (CCO) oxygen sensor. Spectra could be described on the basis of weighted light-absorption spectra of cytochrome b(558) of the NAD(P)H oxidase and mitochondrial cytochromes b and c, CCO, cytochrome a3, and an unusual cytochrome a peaking at 592 nm. Discharge signals were deconvoluted into phasic and tonic activity for comparing different CB responses. The spectral weight of cytochrome a(592) decreased significantly starting at high PO2 (100 mm Hg) and low sodium cyanide (CN-, 10 muM) accompanied by increasing phasic peak discharge. Combined CO-hypoxia or CO-CN- application inhibited photolysis of CO-stimulated chemoreceptor discharge, revealing photometrically cytochrome a(592) as central in oxygen sensing. Control spectra in tissue from sympathetic and nodose ganglia did not show any cytochrome a(592) contribution. According to these results, cytochrome a(592) is assumed as a unique component of CB CCO, revealing in contrast to other cytochromes an apparent low PO2 and high CN- affinity, probably due to a shortcut of electron flow within CCO between Cu-A and cytochrome a3-Cu-B.	Univ Rostock, Inst Physiol, D-18057 Rostock, Germany; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	University of Rostock; Max Planck Society	Streller, T (corresponding author), Univ Rostock, Inst Physiol, Gertrudenstr 9, D-18057 Rostock, Germany.	tino.streller@medizin.uni-rostock.de	Acker, Helmut Anton Josef/AAS-6841-2020; Acker, Helmut/AAJ-8332-2020	Acker, Helmut Anton Josef/0000-0001-5589-5508; 				Buckler KJ, 2000, J PHYSIOL-LONDON, V525, P135, DOI 10.1111/j.1469-7793.2000.00135.x; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Burke PV, 1998, J EXP BIOL, V201, P1163; Carr A B, 1993, J Prosthodont, V2, P2, DOI 10.1111/j.1532-849X.1993.tb00373.x; Das TK, 2000, BIOPOLYMERS, V57, P316, DOI 10.1002/1097-0282(2000)57:5<316::AID-BIP80>3.0.CO;2-3; DELPIANO M, 1980, BRAIN RES, V195, P85, DOI 10.1016/0006-8993(80)90868-9; DUCHEN MR, 1992, J PHYSIOL-LONDON, V450, P33, DOI 10.1113/jphysiol.1992.sp019115; Ehleben W, 1998, RESP PHYSIOL, V114, P25, DOI 10.1016/S0034-5687(98)00078-4; Fu XW, 2000, P NATL ACAD SCI USA, V97, P4374, DOI 10.1073/pnas.97.8.4374; HILL BC, 1993, FEBS LETT, V354, P284; Kannt A, 1999, J BIOL CHEM, V274, P37974, DOI 10.1074/jbc.274.53.37974; Lahiri S, 1999, RESP PHYSIOL, V115, P169, DOI 10.1016/S0034-5687(99)00014-6; Lahiri S, 1999, P NATL ACAD SCI USA, V96, P9427, DOI 10.1073/pnas.96.16.9427; Liao GL, 1996, BBA-BIOENERGETICS, V1274, P109, DOI 10.1016/0005-2728(96)00014-X; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; Michel H, 1998, ANNU REV BIOPH BIOM, V27, P329, DOI 10.1146/annurev.biophys.27.1.329; NAIR PK, 1986, AM J PHYSIOL, V250, P202; O'Kelly I, 2001, BIOCHEM BIOPH RES CO, V283, P1131, DOI 10.1006/bbrc.2001.4919; Porwol T, 2001, RESP PHYSIOL, V128, P331, DOI 10.1016/S0034-5687(01)00310-3; Prabhakar NR, 2000, J APPL PHYSIOL, V88, P2287, DOI 10.1152/jappl.2000.88.6.2287; Strohmaier AR, 1997, J HISTOCHEM CYTOCHEM, V45, P975, DOI 10.1177/002215549704500707; Yoshikawa S, 2000, J INORG BIOCHEM, V82, P1, DOI 10.1016/S0162-0134(00)00137-9	27	32	34	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1277	+		10.1096/fj.02-0166fje	http://dx.doi.org/10.1096/fj.02-0166fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12153998				2022-12-28	WOS:000176683900014
J	Ure, DR; Rodriguez, M				Ure, DR; Rodriguez, M			Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease	FASEB JOURNAL			English	Article						multiple sclerosis autoantibodies; central nervous system disease	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HISTOCOMPATIBILITY COMPLEX-MOLECULES; LYSOLECITHIN-INDUCED DEMYELINATION; T-CELL LINES; MULTIPLE-SCLEROSIS; BASIC-PROTEIN; SYNTHETIC COPOLYMER-1; PROMISCUOUS BINDING; CNS REMYELINATION	Using a murine model of demyelinating disease, we demonstrate that remyelination of spinal cord axons is promoted by antibodies to glatiramer acetate (GA, Copolymer-1, Copaxone(R)), a therapeutic agent for multiple sclerosis (MS). Glatiramer acetate is a mixture of randomly synthesized peptides that induces both T cell activation and antibody production in all treated individuals. These observations prompted us to compare the independent effects of adoptively transferred GA-reactive T cells and antibodies in mice with chronic inflammatory demyelination induced by Theiler's virus. Transferred T cells had no effect on lesion load or the extent of remyelination. Purified polyclonal GA antibodies also did not alter lesion load, which suggests that neither GA T cells or antibodies were pathogenic. On the contrary, GA antibodies enhanced the normally low level of remyelination in chronic lesions. The antibodies, which were primarily immunoglobulin (Ig) G1 and IgG2, cross-reacted with oligodendrocytes, perivascular infiltrating cells, astrocytes, and neurons in spinal cord sections. In glial cultures they bound subsets of early lineage oligodendrocytes and microglia. Thus, several mechanisms may have contributed to the promotion of remyelination. These results support the hypothesis that the antibody response in GA-treated patients is beneficial by facilitating repair of demyelinated lesions.	Mayo Clin & Mayo Fdn, Mayo Med & Grad Sch, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med & Grad Sch, Dept Neurol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Rodriguez, M (corresponding author), Mayo Clin & Mayo Fdn, Mayo Med & Grad Sch, Dept Immunol, 428 Guggenheim Bldg,200 1st St SW, Rochester, MN 55905 USA.	ure.daren@mayo.edu; rodriguez.moses@mayo.edu		Rodriguez, Moses/0000-0001-6328-6497				Aharoni R, 1999, P NATL ACAD SCI USA, V96, P634, DOI 10.1073/pnas.96.2.634; AHARONI R, 1993, EUR J IMMUNOL, V23, P17, DOI 10.1002/eji.1830230105; Aharoni R, 1998, J NEUROIMMUNOL, V91, P135, DOI 10.1016/S0165-5728(98)00166-0; Aharoni R, 1997, P NATL ACAD SCI USA, V94, P10821, DOI 10.1073/pnas.94.20.10821; Aharoni R, 2001, TRANSPLANTATION, V72, P598, DOI 10.1097/00007890-200108270-00007; Ballow M, 1997, J ALLERGY CLIN IMMUN, V100, P151, DOI 10.1016/S0091-6749(97)70217-3; Bartnik BL, 2000, MULT SCLER, V6, P37, DOI 10.1191/135245800678827400; BenNun A, 1996, J NEUROL, V243, pS14, DOI 10.1007/BF00873697; Brenner T, 2001, J NEUROIMMUNOL, V115, P152, DOI 10.1016/S0165-5728(01)00250-8; Comi G, 2001, ANN NEUROL, V49, P290, DOI 10.1002/ana.64.abs; Deisenhammer F, 2001, J INTERF CYTOK RES, V21, P167, DOI 10.1089/107999001750133195; Duda PW, 2000, J CLIN INVEST, V105, P967, DOI 10.1172/JCI8970; Farina C, 2001, BRAIN, V124, P705, DOI 10.1093/brain/124.4.705; Filippi M, 2001, NEUROLOGY, V57, P731, DOI 10.1212/WNL.57.4.731; Fridkis-Hareli M, 1998, J IMMUNOL, V160, P4386; Fridkis-Hareli M, 1998, P NATL ACAD SCI USA, V95, P12528, DOI 10.1073/pnas.95.21.12528; FRIDKISHARELI M, 1994, P NATL ACAD SCI USA, V91, P4872, DOI 10.1073/pnas.91.11.4872; Gran B, 2000, NEUROLOGY, V55, P1704, DOI 10.1212/WNL.55.11.1704; Hussien Y, 2001, J NEUROIMMUNOL, V121, P102, DOI 10.1016/S0165-5728(01)00432-5; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; Johnson N, 2000, ORAL DIS, V6, P1; Kipnis J, 2000, P NATL ACAD SCI USA, V97, P7446, DOI 10.1073/pnas.97.13.7446; Koh CS, 2000, J NEUROIMMUNOL, V108, P22, DOI 10.1016/S0165-5728(00)00282-4; Kotter MR, 2001, GLIA, V35, P204, DOI 10.1002/glia.1085; LIPTON HL, 1976, J NEUROL SCI, V30, P201, DOI 10.1016/0022-510X(76)90267-7; LISAK RP, 1983, J NEUROL SCI, V62, P281, DOI 10.1016/0022-510X(83)90205-8; Loughlin AJ, 1997, J NEUROSCI RES, V47, P384; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; McGavern DB, 1999, J NEUROSCI RES, V58, P492, DOI 10.1002/(SICI)1097-4547(19991115)58:4<492::AID-JNR3>3.0.CO;2-P; Miller A, 1998, J NEUROIMMUNOL, V92, P113, DOI 10.1016/S0165-5728(98)00191-X; MILLER DJ, 1995, J IMMUNOL, V154, P2460; MILLER DJ, 1994, J NEUROSCI, V14, P6230; Neuhaus O, 2000, P NATL ACAD SCI USA, V97, P7452, DOI 10.1073/pnas.97.13.7452; Pavelko KD, 1998, J NEUROSCI, V18, P2498; RACKE MK, 1992, J NEUROIMMUNOL, V37, P75, DOI 10.1016/0165-5728(92)90157-G; Rice G, 2001, ARCH NEUROL-CHICAGO, V58, P1297, DOI 10.1001/archneur.58.8.1297; Rodriguez M, 1996, NEUROLOGY, V46, P538, DOI 10.1212/WNL.46.2.538; RODRIGUEZ M, 1988, VIROLOGY, V166, P463, DOI 10.1016/0042-6822(88)90517-X; Schlegel PG, 1996, P NATL ACAD SCI USA, V93, P5061, DOI 10.1073/pnas.93.10.5061; Stangel M, 1998, J NEUROL SCI, V153, P203, DOI 10.1016/S0022-510X(97)00292-X; Teitelbaum D, 1996, J NEUROIMMUNOL, V64, P209, DOI 10.1016/0165-5728(95)00180-8; Teitelbaum D, 1999, P NATL ACAD SCI USA, V96, P3842, DOI 10.1073/pnas.96.7.3842; TEITELBAUM D, 1973, EUR J IMMUNOL, V3, P273, DOI 10.1002/eji.1830030505; TEITELBAUM D, 1971, European Journal of Immunology, V1, P242, DOI 10.1002/eji.1830010406; Warrington AE, 2000, P NATL ACAD SCI USA, V97, P6820, DOI 10.1073/pnas.97.12.6820; Zhang MF, 2000, J NEUROIMMUNOL, V103, P189, DOI 10.1016/S0165-5728(99)00239-8	46	46	53	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1260	+		10.1096/fj.01-1023fje	http://dx.doi.org/10.1096/fj.01-1023fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12060672				2022-12-28	WOS:000176683900032
J	de Cavanagh, EMV; Piotrkowski, B; Basso, N; Stella, I; Inserra, F; Ferder, L; Fraga, CG				de Cavanagh, EMV; Piotrkowski, B; Basso, N; Stella, I; Inserra, F; Ferder, L; Fraga, CG			Enalapril and losartan attenuate mitochondrial dysfunction in aged rats	FASEB JOURNAL			English	Article						renin-angiotensin system; aging; nitric oxide; glutathione; oxidant damage	NITRIC-OXIDE; ANGIOTENSIN; INHIBITION; OXYGEN; SUPEROXIDE; KIDNEY	Renin-angiotensin system (RAS) inhibition can attenuate the effects of aging on renal function and structure; however, its effect on mitochondrial aging is unknown. To investigate whether an angiotensin-converting enzyme inhibitor (enalapril) or an angiotensin II receptor blocker (losartan) could mitigate age-associated changes in kidney mitochondria, male Wistar rats (14 mo old) received during 8 mo water containing either enalapril (10 mg/kg/day) (Enal), or losartan (30 mg/kg/day) (Los), or no additions (Old). Four-month-old untreated rats (Young) were also studied. In Old rats mitochondrial respiratory control, ADP/O, nitric oxide synthase activity, and uncoupling protein 2 levels were lower (46, 42, 27, and 76%, respectively), and Mn-SOD activity was higher (70%) than in Young, Enal, and Los rats. In Old rats mitochondrial hydrogen peroxide production was higher than in both Young (197%) and Enal or Los (40%) rats. In Old rats, kidney GSH/GSSG was lower than in both Young (80%) and Enal (57%) or Los (68%) rats. In Old rats electron microscopy showed effacement of microvilli in tubular epithelial cells, ill-defined mitochondrial cristae, lower mitochondrial numbers, and enhanced number of osmiophilic bodies relative to Young, Enal, or Los rats. In conclusion, enalapril and losartan can protect against both age-related mitochondrial dysfunction and ultrastructural alterations, underscoring the role of RAS in the aging process. An association with oxidative stress modulation is suggested.	Univ Buenos Aires, Sch Pharm & Biochem, Phys Chem PRALIB, Buenos Aires, DF, Argentina; Inst Cardiovasc Res ININCA, Buenos Aires, DF, Argentina	University of Buenos Aires	Fraga, CG (corresponding author), Junin 956, RA-1113 Buenos Aires, DF, Argentina.	cfraga@huemul.ffyb.uba.ar	Fraga, Cesar/Q-8161-2019					AEBI H, 1984, METHOD ENZYMOL, V105, P121; Arnaiz SL, 1999, NITRIC OXIDE-BIOL CH, V3, P235, DOI 10.1006/niox.1999.0229; Baylis C, 1998, J AM SOC NEPHROL, V9, P699; Bosc LVG, 2001, J HYPERTENS, V19, P1403, DOI 10.1097/00004872-200108000-00008; BOVERIS A, 1999, OXIDAT STRESS DIS, V2, P1; BOVERIS A, 2000, NITRIC OXIDE BIOL PA, P355; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brookes PS, 2002, FREE RADICAL BIO MED, V33, P755, DOI 10.1016/S0891-5849(02)00901-2; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CARLBERG I, 1997, METHOD ENZYMOL, V133, P485; CAVANAGH EM, 1997, AM J PHYSIOL, V272, pR514; De Cavanagh EMV, 2000, AM J PHYSIOL-REG I, V278, pR572, DOI 10.1152/ajpregu.2000.278.3.R572; DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567; Dzau VJ, 2001, HYPERTENSION, V37, P1047, DOI 10.1161/01.HYP.37.4.1047; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; FERDER L, 1994, J AM SOC NEPHROL, V5, P1147; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; GUNZLER WA, 1974, Z KLIN CHEM KLIN BIO, V12, P444; HEUDES D, 1994, AM J PHYSIOL, V266, pR1038, DOI 10.1152/ajpregu.1994.266.3.R1038; Inoue K, 2000, J Renin Angiotensin Aldosterone Syst, V1, P180, DOI 10.3317/jraas.2000.023; JONES OTG, 1994, METHOD ENZYMOL, V233, P222; Knowles RG, 1998, METH MOL B, V100, P67; LANDAHL S, 1986, HYPERTENSION, V8, P1044, DOI 10.1161/01.HYP.8.11.1044; Ma LJ, 2000, KIDNEY INT, V58, P2425, DOI 10.1046/j.1523-1755.2000.00426.x; Meister A., 1995, BIOTHIOLS HLTH DIS, P165; MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Poderoso JJ, 1999, J BIOL CHEM, V274, P37709, DOI 10.1074/jbc.274.53.37709; Rubbo H, 1996, CHEM RES TOXICOL, V9, P809, DOI 10.1021/tx960037q; Sarkela TM, 2001, J BIOL CHEM, V276, P6945, DOI 10.1074/jbc.M007625200; Sastre J, 1998, FREE RADICAL BIO MED, V24, P298, DOI 10.1016/S0891-5849(97)00228-1; SIES H, 1984, METHOD ENZYMOL, V105, P445; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; Yusuf S, 2000, NEW ENGL J MED, V342, P145	34	144	150	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1096	+		10.1096/fj.02-0063fje	http://dx.doi.org/10.1096/fj.02-0063fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709417				2022-12-28	WOS:000182580100027
J	Doherty, TM; Shah, PK; Rajavashisth, TB				Doherty, TM; Shah, PK; Rajavashisth, TB			Cellular origins of atherosclerosis: towards ontogenetic endgame?	FASEB JOURNAL			English	Article							ENDOTHELIAL PROGENITOR CELLS; SMOOTH-MUSCLE-CELLS; BONE-MARROW-CELLS; STEM-CELLS; IN-VIVO; ADULT-RAT; MESENCHYMAL CELLS; GENE-TRANSFER; DIFFERENTIATION; HEPATOCYTES		Cedars Sinai Med Ctr, Dept Med, Div Cardiol, Atherosclerosis Res Ctr, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Burns & Allen Res Inst, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Rajavashisth, TB (corresponding author), Cedars Sinai Med Ctr, Dept Med, Div Cardiol, Atherosclerosis Res Ctr, Davis Res Bldg,Room 1062,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	rajavashisth@cshs.org	Rajavashisth, Tripathi/ABB-6379-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051980, R01HL058555, R01HL051980] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58555, HL51980] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JY, 2002, NAT MED, V8, P891, DOI 10.1038/nm743; Andreassi MG, 2000, ENVIRON MOL MUTAGEN, V35, P265, DOI 10.1002/1098-2280(2000)35:4<265::AID-EM1>3.0.CO;2-M; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; BASHIR R, 2002, KIDNEY INT S1, V61, P110; BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753; Bittner RE, 1999, ANAT EMBRYOL, V199, P391, DOI 10.1007/s004290050237; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Botto N, 2001, MUTAT RES-GEN TOX EN, V493, P23, DOI 10.1016/S1383-5718(01)00162-0; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Campbell JH, 2001, ANN NY ACAD SCI, V947, P18; Chung IM, 1998, AM J PATHOL, V152, P913; Dabeva MD, 1997, P NATL ACAD SCI USA, V94, P7356, DOI 10.1073/pnas.94.14.7356; Davies MJ, 2001, AM J CARDIOL, V88, p2F; DeRuiter MC, 1997, CIRC RES, V80, P444, DOI 10.1161/01.RES.80.4.444; DILLEY RJ, 1992, CELL TISSUE RES, V269, P281, DOI 10.1007/BF00319619; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; HACKNEY JA, 2002, IN PRESS P NATL ACAD; Hillebrands JL, 2002, NAT MED, V8, P194, DOI 10.1038/nm0302-194; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Houston P, 2001, FEBS LETT, V492, P73, DOI 10.1016/S0014-5793(01)02191-3; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Hu YH, 2002, CIRCULATION, V106, P1834, DOI 10.1161/01.CIR.0000031333.86845.DD; Iwaguro H, 2002, CIRCULATION, V105, P732, DOI 10.1161/hc0602.103673; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kaushal S, 2001, NAT MED, V7, P1035, DOI 10.1038/nm0901-1035; Krakowski ML, 1999, AM J PATHOL, V154, P683, DOI 10.1016/S0002-9440(10)65315-1; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Li J, 2001, AM J PATHOL, V158, P1943, DOI 10.1016/S0002-9440(10)64663-9; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; Llevadot J, 2001, J CLIN INVEST, V108, P399, DOI 10.1172/JCI200113131; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; McKay R, 2000, NATURE, V406, P361, DOI 10.1038/35019186; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Moore MAS, 2002, J CLIN INVEST, V109, P313, DOI 10.1172/JCI200214940; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murry CE, 1997, AM J PATHOL, V151, P697; Nabel EG, 2002, CIRCULATION, V105, P672, DOI 10.1161/circ.105.6.672; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; OWENS GK, 1995, PHYSIOL REV, V75, P487; Pang WX, 2000, BLOOD, V95, P1106, DOI 10.1182/blood.V95.3.1106; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; PENN A, 1990, MUTAT RES, V239, P149, DOI 10.1016/0165-1110(90)90003-T; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Rabbani R, 1999, CARDIOVASC RES, V41, P402, DOI 10.1016/S0008-6363(98)00279-X; RAO MS, 1995, SEMIN CELL BIOL, V6, P151; RAO MS, 1990, CELL DIFFER DEV, V29, P155, DOI 10.1016/0922-3371(90)90118-G; RAO MS, 1989, AM J PATHOL, V134, P1069; RAO MS, 1986, J HISTOCHEM CYTOCHEM, V34, P197, DOI 10.1177/34.2.2418098; RAO MS, 1988, BIOCHEM BIOPH RES CO, V156, P131, DOI 10.1016/S0006-291X(88)80814-3; REDDY JK, 1991, DIGEST DIS SCI, V36, P502, DOI 10.1007/BF01298883; Rosenfeld ME, 2002, ARTERIOSCL THROM VAS, V22, P361, DOI 10.1161/hq0302.104847; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; Seshiah PN, 2002, CIRCULATION, V105, P174, DOI 10.1161/hc0202.102248; Shah PK, 2001, CIRCULATION, V104, P1878, DOI 10.1161/circ.104.16.1878; Shen CN, 2000, NAT CELL BIOL, V2, P879, DOI 10.1038/35046522; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Suzuki K, 2001, CIRCULATION, V104, pI207; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Thayer JM, 1995, CELL MOL BIOL RES, V41, P251; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; World Health Organization, 1999, WORLD HLTH REP MAK D	74	18	18	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					592	597		10.1096/fj.02-0913hyp	http://dx.doi.org/10.1096/fj.02-0913hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665471				2022-12-28	WOS:000182580100003
J	Porter, JD; Merriam, AP; Khanna, S; Andrade, FH; Richmonds, CR; Leahy, P; Cheng, G; Karathanasis, P; Zhou, XH; Kusner, LL; Adams, ME; Willem, M; Mayer, U; Kaminski, HJ				Porter, JD; Merriam, AP; Khanna, S; Andrade, FH; Richmonds, CR; Leahy, P; Cheng, G; Karathanasis, P; Zhou, XH; Kusner, LL; Adams, ME; Willem, M; Mayer, U; Kaminski, HJ			Constitutive properties, not molecular adaptations, mediate extraocular muscle sparing in dystrophic mdx mice	FASEB JOURNAL			English	Article						muscular dystrophy; dystrophin-glycoprotein complex; DNA microarray; gene profiling	DUCHENNE MUSCULAR-DYSTROPHY; DEFICIENT SKELETAL-MUSCLE; GENE-EXPRESSION; NITRIC-OXIDE; ACETYLCHOLINE-RECEPTOR; ALPHA-7-BETA-1 INTEGRIN; CALCIUM HOMEOSTASIS; MOUSE DYSTROPHY; CARDIAC-MUSCLE; ANIMAL-MODELS	Extraocular muscle (EOM) is spared in Duchenne muscular dystrophy. Here, we tested putative EOM sparing mechanisms predicted from existing dystrophinopathy models. Data show that mdx mouse EOM contains dystrophin-glycoprotein complex (DGC)-competent and DGC-deficient myofibers distributed in a fiber type-specific pattern. Up-regulation of a dystrophin homologue, utrophin, mediates selective DGC retention. Counter to the DGC mechanical hypothesis, an intact DGC is not a precondition for EOM sarcolemmal integrity, and active adaptation at the level of calcium homeostasis is not mechanistic in protection. A partial, fiber type-specific retention of antiischemic nitric oxide to vascular smooth muscle signaling is not a factor in EOM sparing, because mice deficient in dystrophin and alpha-syntrophin, which localizes neuronal nitric oxide synthase to the sarcolemma, have normal EOMs. Moreover, an alternative transmembrane protein, alpha7beta1 integrin, does not appear to substitute for the DGC in EOM. Finally, genomewide expression profiling showed that EOM does not actively adapt to dystrophinopathy but identified candidate genes for the constitutive protection of mdx EOM. Taken together, data emphasize the conditional nature of dystrophinopathy and the potential importance of nonmechanical DGC roles and support the hypothesis that broad, constitutive structural cell signaling, and/or biochemical differences between EOM and other skeletal muscles are determinants of differential disease responsiveness.	Univ Hosp Cleveland, Dept Ophthalmol, Res Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Univ Kentucky, Dept Toxicol, Lexington, KY 40536 USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Wellcome Trust Ctr Cell Matrix Res, Sch Biol Sci, Manchester, Lancs, England	University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University of Kentucky; University of Washington; University of Washington Seattle; Max Planck Society; University of Manchester	Porter, JD (corresponding author), Univ Hosp Cleveland, Dept Ophthalmol, Res Inst, 11100 Euclid Ave, Cleveland, OH 44106 USA.	jdp7@po.cwru.edu	Andrade, Francisco H/F-1258-2011	Andrade, Francisco H/0000-0002-2460-5798; Kaminski, Henry/0000-0002-8195-0141; Kusner, Linda/0000-0002-5530-2140; Mayer, Ulrike/0000-0003-2328-0052				Adams ME, 2001, J CELL BIOL, V155, P113, DOI 10.1083/jcb.200106158; Andrade FH, 2000, MICROSC RES TECHNIQ, V48, P192, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<192::AID-JEMT7>3.0.CO;2-J; Apostolova MD, 2000, BIOCHEM CELL BIOL, V78, P27, DOI 10.1139/bcb-78-1-27; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Bowe MA, 2000, J CELL BIOL, V148, P801, DOI 10.1083/jcb.148.4.801; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BRIGGS MM, 1988, J MUSCLE RES CELL M, V9, P241, DOI 10.1007/BF01773894; Burkin DJ, 2001, J CELL BIOL, V152, P1207, DOI 10.1083/jcb.152.6.1207; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Campbell WG, 2001, AM J PHYSIOL-CELL PH, V280, pC763, DOI 10.1152/ajpcell.2001.280.4.C763; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Cheng G, 2002, INVEST OPHTH VIS SCI, V43, P1048; Cohn RD, 1999, J NEUROL SCI, V163, P140, DOI 10.1016/S0022-510X(99)00012-X; Dowling P, 2002, NATURWISSENSCHAFTEN, V89, P75, DOI 10.1007/s00114-001-0289-4; DUNN JF, 1991, J NEUROL SCI, V103, P226, DOI 10.1016/0022-510X(91)90168-7; Fischer MD, 2002, PHYSIOL GENOMICS, V9, P71, DOI 10.1152/physiolgenomics.00115.2001; Gramolini AO, 2001, AM J PHYSIOL-CELL PH, V281, pC1300, DOI 10.1152/ajpcell.2001.281.4.C1300; Hayashi YK, 1998, NAT GENET, V19, P94, DOI 10.1038/ng0598-94; HELLIWELL TR, 1992, NEUROMUSCULAR DISORD, V2, P177, DOI 10.1016/0960-8966(92)90004-P; Hodges BL, 1997, J CELL SCI, V110, P2873; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Infante JP, 1999, MOL CELL BIOCHEM, V195, P155, DOI 10.1023/A:1006972315739; JACOBY J, 1990, J MUSCLE RES CELL M, V11, P25, DOI 10.1007/BF01833323; JORGENSEN AO, 1988, CELL MOTIL CYTOSKEL, V9, P164, DOI 10.1002/cm.970090208; Kaminski HJ, 1996, INVEST OPHTH VIS SCI, V37, P345; KAMINSKI HJ, 1992, ANN NEUROL, V32, P586, DOI 10.1002/ana.410320418; KARPATI G, 1986, AM J MED GENET, V25, P653, DOI 10.1002/ajmg.1320250407; KARPATI G, 1990, J NEUROPATH EXP NEUR, V49, P96, DOI 10.1097/00005072-199003000-00002; KARPATI G, 1988, MUSCLE NERVE, V11, P795, DOI 10.1002/mus.880110802; KHURANA TS, 1995, J EXP MED, V182, P467, DOI 10.1084/jem.182.2.467; Lin S, 1998, J NEUROPATH EXP NEUR, V57, P780, DOI 10.1097/00005072-199808000-00007; Lin S, 2000, DEV BRAIN RES, V119, P289, DOI 10.1016/S0165-3806(99)00165-0; MAIER A, 1994, INVEST OPHTH VIS SCI, V35, P3103; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; McLoon LK, 2002, MUSCLE NERVE, V25, P348, DOI 10.1002/mus.10056; Missias AC, 1996, DEV BIOL, V179, P223, DOI 10.1006/dbio.1996.0253; MOVSESIAN MA, 1994, CIRCULATION, V90, P653, DOI 10.1161/01.CIR.90.2.653; ODA K, 1986, J NEUROL SCI, V74, P125, DOI 10.1016/0022-510X(86)90099-7; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PARTRIDGE T, 1991, NEUROPATH APPL NEURO, V17, P353, DOI 10.1111/j.1365-2990.1991.tb00735.x; Peters MF, 1997, J CELL BIOL, V138, P81, DOI 10.1083/jcb.138.1.81; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; PONS F, 1994, J NEUROL SCI, V122, P162, DOI 10.1016/0022-510X(94)90295-X; Porter JD, 1998, CELL TISSUE RES, V292, P495, DOI 10.1007/s004410051078; Porter JD, 1999, BIOCHEM BIOPH RES CO, V257, P678, DOI 10.1006/bbrc.1999.0536; Porter JD, 2001, NEUROMUSCULAR DISORD, V11, P197, DOI 10.1016/S0960-8966(00)00171-1; Porter JD, 2001, P NATL ACAD SCI USA, V98, P12062, DOI 10.1073/pnas.211257298; Porter JD, 1998, NEUROMUSCULAR DISORD, V8, P198, DOI 10.1016/S0960-8966(98)00015-7; Porter JD, 1998, J CELL SCI, V111, P1801; PORTER JD, 1988, INVEST OPHTH VIS SCI, V29, P163; PORTER JD, 1995, SURV OPHTHALMOL, V39, P451, DOI 10.1016/S0039-6257(05)80055-4; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; Porter JD, 1996, NEUROLOGY, V46, P30, DOI 10.1212/WNL.46.1.30; Rafael JA, 2000, HUM MOL GENET, V9, P1357, DOI 10.1093/hmg/9.9.1357; Rafael JA, 2000, MICROSC RES TECHNIQ, V48, P155, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<155::AID-JEMT4>3.0.CO;2-0; Rafael JA, 1998, NAT GENET, V19, P79, DOI 10.1038/ng0598-79; Ragusa RJ, 1996, J NEUROL SCI, V139, P180; Ragusa RJ, 1997, NEUROMUSCULAR DISORD, V7, P379, DOI 10.1016/S0960-8966(97)00096-5; Rando TA, 2001, MUSCLE NERVE, V24, P1575, DOI 10.1002/mus.1192; Rando TA, 2001, MICROSC RES TECHNIQ, V55, P223, DOI 10.1002/jemt.1172; Reeve JL, 1997, MUSCLE NERVE, V20, P357, DOI 10.1002/(SICI)1097-4598(199703)20:3<357::AID-MUS14>3.0.CO;2-Y; Rubinstein NA, 2000, INVEST OPHTH VIS SCI, V41, P3391; Sander M, 2000, P NATL ACAD SCI USA, V97, P13818, DOI 10.1073/pnas.250379497; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Thomas GD, 1998, P NATL ACAD SCI USA, V95, P15090, DOI 10.1073/pnas.95.25.15090; TURNER PR, 1988, NATURE, V335, P735, DOI 10.1038/335735a0; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; Vachon PH, 1997, J CLIN INVEST, V100, P1870, DOI 10.1172/JCI119716	70	58	59	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					893	+		10.1096/fj.02-0810fje	http://dx.doi.org/10.1096/fj.02-0810fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670877				2022-12-28	WOS:000181892600015
J	Kenchappa, RS; Ravindranath, V				Kenchappa, RS; Ravindranath, V			Glutaredoxin is essential for maintenance of brain mitochondrial complex I: studies with MPTP	FASEB JOURNAL			English	Article						brain; mitochondria; thioltransferase; oxidative stress; thiol oxidation	ELECTRON-TRANSPORT CHAIN; OXIDATIVE STRESS; PARKINSONS-DISEASE; THIOLTRANSFERASE GLUTAREDOXIN; GLUTATHIONE DEPLETION; SITU HYBRIDIZATION; MIXED DISULFIDES; S-THIOLATION; RAT-BRAIN; EXPRESSION	Mitochondrial complex I dysfunction is implicated in the pathogenesis of neurodegenerative disorders such as Parkinson's disease. Identification of factors involved in maintenance and restoration of complex I function could potentially help to develop prophylactic and therapeutic strategies for treatment of this class of disorders. Down-regulation of glutaredoxin (thioltransferase, a thiol disulfide oxido-reductase) using antisense oligonucleotides results in the loss of mitochondrial complex I activity in mouse brain. 1-Methyl-4-phenyl-1,2,3,6,tetrahydropyridine (MPTP), the neurotoxin that causes Parkinson's disease-like symptoms in primates and dopaminergic cell loss in mice, acts through the inhibition of complex I. Regeneration of complex I activity in the striatum occurs concurrently with increase in glutaredoxin activity, 4 h after the neurotoxic insult, and is mediated through activation of activating protein-1. Downregulation of glutaredoxin using anti-sense oligonucleotides prevents recovery of complex I in the striatum after MPTP treatment, providing support for the critical role for glutaredoxin in recovery of mitochondrial function in brain. Maintenance and restoration of protein thiol homeostasis by glutaredoxin may be important factors in preventing complex I dysfunction.	Natl Brain Res Ctr, Gurgaon 122001, India; Natl Inst Mental Hlth & Neurosci, Dept Neurochem, Bangalore 560029, Karnataka, India	Department of Biotechnology (DBT) India; National Brain Research Centre (NBRC); National Institute of Mental Health & Neurosciences - India	Ravindranath, V (corresponding author), Natl Brain Res Ctr, SCO 5,6&7,Sector 15 2, Gurgaon 122001, India.	vijir@nbrc.ac.in						Annepu J, 2000, NEUROSCI LETT, V289, P209, DOI 10.1016/S0304-3940(00)01300-8; Balijepalli S, 2000, MOL BRAIN RES, V85, P123, DOI 10.1016/S0169-328X(00)00206-0; Balijepalli S, 1999, J NEUROCHEM, V72, P1170, DOI 10.1046/j.1471-4159.1999.0721170.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; CHRESTENSEN CA, 1995, FEBS LETT, V374, P25, DOI 10.1016/0014-5793(95)01066-N; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; DUPUIS A, 1991, BIOCHEM J, V227, P11; GAN ZR, 1986, J BIOL CHEM, V261, P996; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Jha N, 2000, J BIOL CHEM, V275, P26096, DOI 10.1074/jbc.M000120200; KORNER M, 1989, NEURON, V3, P563, DOI 10.1016/0896-6273(89)90266-3; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; MANNERVIK B, 1975, BIOCHEM J, V149, P785, DOI 10.1042/bj1490785; Mayfield RD, 2002, J NEUROCHEM, V81, P802, DOI 10.1046/j.1471-4159.2002.00860.x; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002; MIEYAL JJ, 1995, GLUTATHIONYL SPECIFI, P305; MIZUNO Y, 1995, BBA-MOL BASIS DIS, V1271, P265, DOI 10.1016/0925-4439(95)00038-6; Park JB, 1997, GENE, V197, P189, DOI 10.1016/S0378-1119(97)00262-X; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; RAMSAY RR, 1986, BIOCHEM BIOPH RES CO, V135, P269, DOI 10.1016/0006-291X(86)90972-1; RAVINDRANATH V, 1990, BIOCHEM BIOPH RES CO, V169, P1075, DOI 10.1016/0006-291X(90)92004-J; ROKUTAN K, 1994, AM J PHYSIOL, V266, pG247, DOI 10.1152/ajpgi.1994.266.2.G247; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; SHIVAKUMAR BR, 1992, BRAIN RES, V595, P256, DOI 10.1016/0006-8993(92)91058-M; SHIVAKUMAR BR, 1995, J PHARMACOL EXP THER, V274, P1167; Sriram K, 1997, BRAIN RES, V749, P44, DOI 10.1016/S0006-8993(96)01271-1; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; TIPTON KF, 1993, J NEUROCHEM, V61, P1191, DOI 10.1111/j.1471-4159.1993.tb13610.x; VAZQUEZ EJ, 2001, J INVEST MED, V49, pA285; Wells W W, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P149; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	37	65	66	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					717	+		10.1096/fj.02-0771fje	http://dx.doi.org/10.1096/fj.02-0771fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594173				2022-12-28	WOS:000181456900005
J	Kupatt, C; Hinkel, R; Vachenauer, R; Horstkotte, J; Raake, P; Sandner, T; Kreuzpointner, R; Muller, F; Dimmeler, S; Feron, O; Boekstegers, P				Kupatt, C; Hinkel, R; Vachenauer, R; Horstkotte, J; Raake, P; Sandner, T; Kreuzpointner, R; Muller, F; Dimmeler, S; Feron, O; Boekstegers, P			VEGF(165) transfection decreases postischemic NF-kappa B-dependent myocardial reperfusion injury in vivo: role of eNOS phosphorylation	FASEB JOURNAL			English	Article						nitric oxide; VEGF; PMN; myocardial infarction	NITRIC-OXIDE SYNTHASE; PRESSURE-REGULATED RETROINFUSION; ADHESION MOLECULE-1 ICAM-1; GROWTH-FACTOR EXPRESSION; VEGF GENE-TRANSFER; ENDOTHELIAL-CELLS; ISCHEMIA-REPERFUSION; TNF-ALPHA; TUMOR ANGIOGENESIS; LEUKOCYTE ADHESION	Endothelial nitric oxide synthase (eNOS) phosphorylation increases nitric oxide formation, for example, after VEGF stimulation. We investigated whether nitric oxide formed after overexpression of VEGF or of phosphomimetic eNOS (S1177D) affects PMN-induced myocardial detriment after ischemia and reperfusion. Pigs (n=8 per group) were subjected to percutaneous liposome-based gene transfer by retroinfusion of the anterior interventricular vein 48 h before LAD occlusion (60 min) and reperfusion (24 h). Thereafter, regional myocardial function was assessed as subendocardial segment shortening (SES), and infarct size was determined. Tissue from the infarct region, the noninfarcted area at risk, and a control region was analyzed for NF-kappaB activation (EMSA), tumor necrosis factor (TNF)-alpha, and E-selectin mRNA and infiltration of polymorphonuclear neutrophils (PMN). L-NAME was applied in one group of VEGF-transfected animals. NF-kappaB activition, PMN infiltration in the infarct region, and AAR were reduced after transfection of VEGF or eNOS S1177D, but not after VEGF+L-NAME coapplication. Infarct size decreased, whereas SES improved after either VEGF or eNOS S1177D transfection, an effect inhibited by L-NAME coapplication. Retroinfusion of liposomal VEGF cDNA reduces NF-kappaB-dependent postischemic inflammation and subsequent myocardial reperfusion injury, an effect mediated at least in part by enhanced eNOS phosphorylation.	Univ Munich, Klinikum Grosshadern, D-81377 Munich, Germany; Goethe Univ Frankfurt, Dept Med 4, D-6000 Frankfurt, Germany; Univ Louvain, Sch Med, Pharmacol & Therapeut Unit, Brussels, Belgium	University of Munich; Goethe University Frankfurt; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Kupatt, C (corresponding author), Univ Munich, Klinikum Grosshadern, Marchioninistr 15, D-81377 Munich, Germany.	c.kupatt@lrz.uni-muenchen.de	FERON, Olivier/AAM-6395-2020; Hinkel, Rabea/I-9165-2014	FERON, Olivier/0000-0001-5360-0286; Hinkel, Rabea/0000-0002-2936-0400; Dimmeler, Stefanie/0000-0002-1045-2436; Kupatt, Christian/0000-0002-3611-1218				Barua M, 2001, J IMMUNOL, V167, P2275, DOI 10.4049/jimmunol.167.4.2275; BOEKSTEGERS P, 1994, J AM COLL CARDIOL, V23, P459, DOI 10.1016/0735-1097(94)90434-0; Boekstegers P, 2000, GENE THER, V7, P232, DOI 10.1038/sj.gt.3301079; Brouet A, 2001, J BIOL CHEM, V276, P32663, DOI 10.1074/jbc.M101371200; BUERKE M, 1995, P NATL ACAD SCI USA, V92, P8031, DOI 10.1073/pnas.92.17.8031; Chen YX, 1999, ARTERIOSCL THROM VAS, V19, P131, DOI 10.1161/01.ATV.19.1.131; DE CR, 1995, J CLIN INVEST, V96, P60; Di Napoli P, 2001, CARDIOVASC RES, V51, P283, DOI 10.1016/S0008-6363(01)00306-6; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Duilio C, 2001, AM J PHYSIOL-HEART C, V280, pH2649, DOI 10.1152/ajpheart.2001.280.6.H2649; Flogel U, 1999, J MOL CELL CARDIOL, V31, P827, DOI 10.1006/jmcc.1998.0921; Frangogiannis NG, 1998, J MOL CELL CARDIOL, V30, P2567, DOI 10.1006/jmcc.1998.0829; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gao F, 2002, CIRCULATION, V105, P1497, DOI 10.1161/01.CIR.0000012529.00367.0F; Griffioen AW, 1996, BLOOD, V88, P667, DOI 10.1182/blood.V88.2.667.bloodjournal882667; Hafezi-Moghadam A, 2002, NAT MED, V8, P473, DOI 10.1038/nm0502-473; Hashimoto Etsuo, 1994, American Journal of Physiology, V267, pH1948; Heil M, 2000, EUR J CELL BIOL, V79, P850, DOI 10.1078/0171-9335-00113; Ichikawa H, 1997, CIRC RES, V81, P922; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; Iwata A, 2001, CIRCULATION, V103, P2753; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; JOHNSON G, 1991, CRIT CARE MED, V19, P244, DOI 10.1097/00003246-199102000-00021; Jones SP, 1999, AM J PHYSIOL-HEART C, V276, pH1567, DOI 10.1152/ajpheart.1999.276.5.H1567; Kalka C, 2000, ANN THORAC SURG, V70, P829, DOI 10.1016/S0003-4975(00)01633-7; Kalra D, 2000, CIRCULATION, V102, P1302, DOI 10.1161/01.CIR.102.11.1302; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Kinugawa K, 1997, CIRC RES, V81, P911; Kupatt C, 1997, CARDIOVASC RES, V36, P386, DOI 10.1016/S0008-6363(97)00191-0; Kupatt C, 1999, CIRC RES, V84, P392, DOI 10.1161/01.RES.84.4.392; Kupatt C, 2002, GENE THER, V9, P518, DOI 10.1038/sj.gt.3301673; Kupatt C, 1997, J MOL CELL CARDIOL, V29, P2599, DOI 10.1006/jmcc.1997.0439; LEY K, 1991, CIRC RES, V69, P1034, DOI 10.1161/01.RES.69.4.1034; Ma XL, 2000, J PHARMACOL EXP THER, V292, P912; Matata BM, 2002, J BIOL CHEM, V277, P2330, DOI 10.1074/jbc.M106393200; Mehta JL, 2002, CIRCULATION, V105, P2206, DOI 10.1161/01.CIR.0000015602.94990.3D; NAKANISHI K, 1992, AM J PHYSIOL, V263, pH1650, DOI 10.1152/ajpheart.1992.263.6.H1650; Nossuli TO, 2001, AM J PHYSIOL-HEART C, V281, pH2549, DOI 10.1152/ajpheart.2001.281.6.H2549; Pabla R, 1996, CIRC RES, V78, P65, DOI 10.1161/01.RES.78.1.65; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468; Sato K, 2001, J AM COLL CARDIOL, V37, P616, DOI 10.1016/S0735-1097(00)01144-X; Scalia R, 1999, FASEB J, V13, P1039, DOI 10.1096/fasebj.13.9.1039; Schluter KD, 2000, CIRC RES, V86, P946, DOI 10.1161/01.RES.86.9.946; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Shimpo M, 2002, CARDIOVASC RES, V53, P993, DOI 10.1016/S0008-6363(01)00546-6; SIEGFRIED MR, 1992, AM J PHYSIOL, V263, pH771, DOI 10.1152/ajpheart.1992.263.3.H771; Torry RJ, 2001, J MOL CELL CARDIOL, V33, P175, DOI 10.1006/jmcc.2000.1292; Tromp SC, 2000, INT IMMUNOL, V12, P671, DOI 10.1093/intimm/12.5.671; Tsao PS, 1997, CIRCULATION, V96, P934; vonDegenfeld G, 1997, CARDIOVASC RES, V35, P233, DOI 10.1016/S0008-6363(97)00126-0; Wang WJ, 2002, CARDIOVASC RES, V53, P165, DOI 10.1016/S0008-6363(01)00445-X; Zahler S, 1997, J MOL CELL CARDIOL, V29, P2953, DOI 10.1006/jmcc.1997.0530; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451; Zingarelli B, 2002, FASEB J, V16, DOI 10.1096/fj.01-0533com	55	43	44	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					705	+		10.1096/fj.02-0673fje	http://dx.doi.org/10.1096/fj.02-0673fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586740	Green Submitted			2022-12-28	WOS:000181456900030
J	Nahmod, KA; Vermeulen, ME; Radien, S; Salamone, G; Gamberale, R; Fernandez-Calotti, P; Alvarez, A; Nahmod, V; Giordano, M; Geffner, JR				Nahmod, KA; Vermeulen, ME; Radien, S; Salamone, G; Gamberale, R; Fernandez-Calotti, P; Alvarez, A; Nahmod, V; Giordano, M; Geffner, JR			Control of dendritic cell differentiation by angiotensin II	FASEB JOURNAL			English	Article						monocytes	MESSENGER-RNA EXPRESSION; RECEPTOR ANTAGONISTS; ANTIGEN PRESENTATION; MANNOSE RECEPTOR; SYSTEM; MONOCYTES; MATURATION; GENERATION; PREVENTS	Here we analyze the role of the angiotensinergic system in the differentiation of dendritic cells (DC). We found that human monocytes produce angiotensin II (AII) and express AT1 and AT2 receptors for AII. DC differentiated from human monocytes in the presence of AT1 receptor antagonists losartan or candesartan show very low levels of CD1a expression and poor endocytic and allostimulatory activities. By contrast, DC differentiation in the presence of either the AT2 receptor antagonist PD 123319 or exogenous AII results in the development of nonadherent cells with CD1a expression and endocytic and allostimulatory activities higher than control DC. Similar contrasting effects were observed in mouse DC obtained from bone marrow cultures supplemented with granulocyte-monocyte colony-stimulating factor. DC differentiated in the presence of the AT1 receptor antagonist losartan express lower levels of CD11c, CD40, and Ia and display a lower ability to endocyte horseradish peroxidase (HRP) and to induce antibody responses in vivo, compared with controls. By contrast, DC differentiation in the presence of either the AT2 receptor antagonist PD 123319 or exogenous AII results in cells with high levels of CD11c, CD40, and Ia, as well as high ability to endocyte HRP and to induce antibody responses in vivo. Our results support the notion that the differentiation of DC is regulated by AII.	Acad Nacl Med Buenos Aires, IIHEMA, Immunol Lab, Inst Hematol Res, RA-1425 Buenos Aires, DF, Argentina; Univ Buenos Aires, Sch Med, Dept Microbiol, Immunogenet Lab, Buenos Aires, DF, Argentina	Buenos Aires National Academy of Medicine; IIHEMA - Instituto de Investigaciones Hematologicas; University of Buenos Aires	Geffner, JR (corresponding author), Acad Nacl Med Buenos Aires, IIHEMA, Immunol Lab, Inst Hematol Res, Pacheco de Melo 3081, RA-1425 Buenos Aires, DF, Argentina.	geffnerj@fibertel.com.ar						Allavena P, 1998, EUR J IMMUNOL, V28, P359, DOI 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO;2-4; Ardaillou R, 1999, J AM SOC NEPHROL, V10, pS30; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Buelens C, 1997, EUR J IMMUNOL, V27, P756, DOI 10.1002/eji.1830270326; Chomarat P, 2000, NAT IMMUNOL, V1, P510, DOI 10.1038/82763; CHULUYAN HE, 1993, J CLIN INVEST, V92, P2768, DOI 10.1172/JCI116895; Chung O, 1999, J HUM HYPERTENS, V13, pS11, DOI 10.1038/sj.jhh.1000744; Chung O, 1998, KIDNEY INT, V54, pS95, DOI 10.1046/j.1523-1755.1998.06719.x; Dinh DT, 2001, CLIN SCI, V100, P481, DOI 10.1042/CS20000263; FINOCCHIARO LME, 1990, J ENDOCRINOL, V126, P59, DOI 10.1677/joe.0.1260059; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; JOHNSTON CI, 1995, LANCET, V346, P1403, DOI 10.1016/S0140-6736(95)92411-6; Kim JA, 1996, BIOCHEM BIOPH RES CO, V226, P862, DOI 10.1006/bbrc.1996.1441; Kintscher U, 2001, HYPERTENSION, V37, P587, DOI 10.1161/01.HYP.37.2.587; KITAZONO T, 1995, CIRCULATION, V91, P1129, DOI 10.1161/01.CIR.91.4.1129; Kranzhofer R, 1999, BIOCHEM BIOPH RES CO, V257, P826, DOI 10.1006/bbrc.1999.0543; Lanzavecchia A, 2001, CELL, V106, P263, DOI 10.1016/S0092-8674(01)00455-X; Lapteva N, 2002, BIOCHEM BIOPH RES CO, V296, P194, DOI 10.1016/S0006-291X(02)00855-0; Lapteva N, 2001, BIOCHEM BIOPH RES CO, V285, P1059, DOI 10.1006/bbrc.2001.5215; Lorell BH, 1999, AM J CARDIOL, V83, p48H; McRae BL, 2000, BLOOD, V96, P210, DOI 10.1182/blood.V96.1.210.013k52_210_217; Menetrier-Caux C, 1998, BLOOD, V92, P4778, DOI 10.1182/blood.V92.12.4778; NAHMOD VE, 1992, 5 WORLD C CLIN PHARM; Napoleone E, 2000, CIRC RES, V86, P139, DOI 10.1161/01.RES.86.2.139; Nicholls MG, 2000, J HUM HYPERTENS, V14, P649, DOI 10.1038/sj.jhh.1001056; Okamura A, 1999, J HYPERTENS, V17, P537, DOI 10.1097/00004872-199917040-00012; Rodgers K, 2000, CLIN DIAGN LAB IMMUN, V7, P635, DOI 10.1128/CDLI.7.4.635-640.2000; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schena M, 1999, AM J HYPERTENS, V12, P388; STAHL PD, 1992, CURR OPIN IMMUNOL, V4, P49, DOI 10.1016/0952-7915(92)90123-V; Stoll M, 2001, REGUL PEPTIDES, V99, P175, DOI 10.1016/S0167-0115(01)00246-4; SUZUKI H, 1995, ENDOCR J, V42, P15, DOI 10.1507/endocrj.42.15; Thery C, 2001, CURR OPIN IMMUNOL, V13, P45, DOI 10.1016/S0952-7915(00)00180-1; Timmermans PBMWM, 1999, HYPERTENS RES-CLIN E, V22, P147, DOI 10.1291/hypres.22.147; Unger T, 2002, AM J CARDIOL, V89, p3A; WIDDOP RE, 1993, AM J PHYSIOL, V264, pH117, DOI 10.1152/ajpheart.1993.264.1.H117; Yanagitani Y, 1999, HYPERTENSION, V33, P335, DOI 10.1161/01.HYP.33.1.335	41	103	113	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					491	+		10.1096/fj.02-0755fje	http://dx.doi.org/10.1096/fj.02-0755fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12514109				2022-12-28	WOS:000181453700026
J	Shelke, RRJ; Leeuwenburgh, C				Shelke, RRJ; Leeuwenburgh, C			Life-long calorie restriction (CR) increases expression of apoptosis repressor with a caspase recruitment domain (ARC) in the brain	FASEB JOURNAL			English	Article						oxidative stress; Bcl-2 family; cytochrome c; mitochondria.	HUMAN SUBSTANTIA-NIGRA; DIETARY RESTRICTION; SKELETAL-MUSCLE; CYTOCHROME-C; OXIDATIVE-STRESS; MITOCHONDRIA; RELEASE; NEURONS; HEART; ACTIVATION	Aging may increase apoptotic events and the susceptibility of the central nervous system to apoptosis. Calorie restriction has been shown to have neuroprotective effects, but the mechanisms in vivo are unknown. We investigated apoptosis and apoptotic regulatory proteins in the brain frontal cortex of 12-month-old ad libitum fed, 26-month-old ad libitum fed, and 26-month-old calorie-restricted (CR) male Fischer 344 rats (CR = 40% restricted compared to ad libitum). We found that specific DNA fragmentation indicative of apoptosis was increased with age (+124%) in the cortices of the brain and that calorie restriction attenuated this increase significantly (-36%). We determined levels of ARC (apoptosis repressor with a caspase recruitment domain), which inhibits caspase-2 activity and also attenuates cytochrome c release from the mitochondria. We found a significant age-associated decline in ARC level, which was attenuated in the brains of the CR rats. In accordance with the changes in ARC expression observed, calorie restriction attenuated the increases in cytosolic cytochrome c and caspase-2 activity with age and suppressed the age-associated rise in cleaved caspase-9 and cleaved caspase-3. However, neither age nor calorie restriction had any effect on caspase-3 and caspase-9 activities. This data provides evidence for an increased incidence of apoptosis in rat brain with age and evidence that calorie restriction has the ability to attenuate this. Furthermore, our data suggest that calorie restriction provides neuroprotection through ARC by suppressing cytochrome c release and caspase-2 activity.	Univ Florida, Coll Hlth & Human Performance, Biochem Aging Lab, FLG 25, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Leeuwenburgh, C (corresponding author), Univ Florida, Coll Hlth & Human Performance, Biochem Aging Lab, FLG 25, Stadium Rd,POB 118206, Gainesville, FL 32611 USA.	cleeuwen@ufl.edu		Leeuwenburgh, Christiaan/0000-0003-0826-4257				Adams SM, 2001, BIOMARKERS, V6, P1, DOI 10.1080/135475001452724; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P603; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLEMAN PD, 1987, NEUROBIOL AGING, V8, P521, DOI 10.1016/0197-4580(87)90127-8; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Dirks A, 2002, AM J PHYSIOL-REG I, V282, pR519, DOI 10.1152/ajpregu.00458.2001; Drew B, 2002, ANN NY ACAD SCI, V959, P66, DOI 10.1111/j.1749-6632.2002.tb02084.x; Ekhterae D, 1999, CIRC RES, V85, pE70; Engidawork E, 2001, BIOCHEM BIOPH RES CO, V281, P84, DOI 10.1006/bbrc.2001.4306; Floyd RA, 2000, ADV RES NEURODEGENER, V8, P387; Floyd RA, 2000, ANN NY ACAD SCI, V899, P222; GADALETA MN, 1992, MUTAT RES, V275, P181, DOI 10.1016/0921-8734(92)90022-H; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gulesserian T, 2001, J NEURAL TRANSM-SUPP, P163; INGRAM DK, 1987, J GERONTOL, V42, P78, DOI 10.1093/geronj/42.1.78; Ingram DK, 2001, ANN NY ACAD SCI, V928, P316; Itoh K, 1996, NEUROBIOL AGING, V17, P843, DOI 10.1016/S0197-4580(96)00168-6; Kajstura J, 1996, AM J PHYSIOL-HEART C, V271, pH1215, DOI 10.1152/ajpheart.1996.271.3.H1215; Kaufmann JA, 2001, J NEUROCHEM, V76, P1099, DOI 10.1046/j.1471-4159.2001.00118.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Kottke TJ, 2002, J BIOL CHEM, V277, P804, DOI 10.1074/jbc.M108419200; Kretsch MJ, 1997, INT J OBESITY, V21, P14, DOI 10.1038/sj.ijo.0800353; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Lee BJ, 2001, MATER RES INNOV, V4, P97, DOI 10.1007/PL00010786; Lee J, 2000, J MOL NEUROSCI, V15, P99, DOI 10.1385/JMN:15:2:99; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mattson MP, 2002, PHYSIOL REV, V82, P637, DOI 10.1152/physrev.00004.2002; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Mattson MP, 2002, AGEING RES REV, V1, P155, DOI 10.1016/S1568-1637(01)00003-4; Mayhew M, 1998, BIOCHEM BIOPH RES CO, V251, P95, DOI 10.1006/bbrc.1998.9438; MEANS LW, 1993, PHYSIOL BEHAV, V54, P503, DOI 10.1016/0031-9384(93)90243-9; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Numata T, 2002, BIOCHEM BIOPH RES CO, V297, P517, DOI 10.1016/S0006-291X(02)02155-1; Pahlavani MA, 2000, P SOC EXP BIOL MED, V223, P163, DOI 10.1046/j.1525-1373.2000.22322.x; Pollack M, 2002, ANN NY ACAD SCI, V959, P93, DOI 10.1111/j.1749-6632.2002.tb02086.x; Pollack M, 2001, J GERONTOL A-BIOL, V56, pB475, DOI 10.1093/gerona/56.11.B475; Pollack M, 1999, HDB OXIDANTS ANTIOXI, P881; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Renganathan M, 1998, FEBS LETT, V434, P346, DOI 10.1016/S0014-5793(98)01009-6; Sayre LM, 2001, CURR MED CHEM, V8, P721, DOI 10.2174/0929867013372922; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; SOHAL RS, 1992, MUTAT RES, V275, P295, DOI 10.1016/0921-8734(92)90033-L; SOHAL RS, 1995, MECH AGEING DEV, V81, P15, DOI 10.1016/0047-6374(94)01578-A; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Spaulding CC, 1997, MECH AGEING DEV, V93, P87, DOI 10.1016/S0047-6374(96)01824-6; Strasser H, 2000, J UROLOGY, V164, P1781, DOI 10.1016/S0022-5347(05)67106-6; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Suzuki Y, 2000, EXP NEUROL, V165, P35, DOI 10.1006/exnr.2000.7465; Viel JJ, 2001, J NEUROSCI RES, V64, P454, DOI 10.1002/jnr.1097; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; Weindruch R., 1988, RETARDATION AGING DI; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	55	48	49	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					494	+		10.1096/fj.02-0803fje	http://dx.doi.org/10.1096/fj.02-0803fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12514107				2022-12-28	WOS:000181453700027
J	Mundt, B; Kuhnel, F; Zender, L; Paul, Y; Tillmann, H; Trautwein, C; Manns, MP; Kubicka, S				Mundt, B; Kuhnel, F; Zender, L; Paul, Y; Tillmann, H; Trautwein, C; Manns, MP; Kubicka, S			Involvement of TRAIL and its receptors in viral hepatitis	FASEB JOURNAL			English	Article						Fas (CD95); apoptosis; hepatitis B; hepatitis C; acute liver failure	NF-KAPPA-B; TUMORICIDAL ACTIVITY; MEDIATED APOPTOSIS; ANTITUMOR-ACTIVITY; FAS LIGAND; LIVER; EXPRESSION; FAMILY; MEMBER; GENE	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is able to kill a broad spectrum of tumor cells but appears to be nontoxic to most normal cells. Because there are conflicting data about the hepatotoxicity of TRAIL, we investigated the physiological function of TRAIL and its receptors in the liver. Hepatocytes are sensitive for FasL- and TRAIL-mediated apoptosis in vitro, but TRAIL induces no apoptosis in healthy livers in vivo. Using mouse models of adenoviral hepatitis and livers of patients with hepatitis infection, we could demonstrate that apoptosis in virally infected hepatocytes is mediated by TRAIL receptor DR5 and TRAIL. In contrast to FasL, TRAIL-mediated apoptosis of hepatocytes in vivo is triggered through viral infection. The TRAIL receptor/ligand system enables the organisms to specifically kill virus-infected hepatocytes, whereas normal uninfected hepatocytes in vivo are resistant to TRAIL-mediated apoptosis. Overexpression of TRAIL in the liver after viral infection is not dependent on lymphocytes, natural killer, or Kupffer cells, which indicates that the TRAIL receptor/ligand system is a paracrine mechanism of hepatocytes against virally infected cells. Our results suggest that TRAIL might be used not only for cancer therapy but also for therapy of patients with viral hepatitis to selectively eliminate infected hepatocytes and limit viral replication.	Hannover Med Sch, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany	Hannover Medical School	Kubicka, S (corresponding author), Hannover Med Sch, Dept Gastroenterol & Hepatol, Carl Neubergstr 1, D-30625 Hannover, Germany.	Kubicka.stefan@mh-hannover.de						Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Chirmule N, 1999, HUM GENE THER, V10, P259, DOI 10.1089/10430349950019048; Clarke P, 2000, J VIROL, V74, P8135, DOI 10.1128/JVI.74.17.8135-8139.2000; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Dejosez M, 2000, CELL DEATH DIFFER, V7, P1127, DOI 10.1038/sj.cdd.4400746; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Gallop JR, 1995, CERN REPORT, V95, P1; Gliniak B, 1999, CANCER RES, V59, P6153; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; HARDONK MJ, 1992, J LEUKOCYTE BIOL, V52, P296, DOI 10.1002/jlb.52.3.296; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kamiya A, 1999, EMBO J, V18, P2127, DOI 10.1093/emboj/18.8.2127; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Kubicka S, 1999, J BIOL CHEM, V274, P32137, DOI 10.1074/jbc.274.45.32137; Kuhnel F, 2000, J BIOL CHEM, V275, P6421, DOI 10.1074/jbc.275.9.6421; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Lieber A, 1997, J VIROL, V71, P8798, DOI 10.1128/JVI.71.11.8798-8807.1997; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OGASAWARA J, 1993, NATURE, V365, P568, DOI 10.1038/365568a0; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Sedger LM, 1999, J IMMUNOL, V163, P920; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Strand S, 1998, NAT MED, V4, P588, DOI 10.1038/nm0598-588; Strater J, 2002, GASTROENTEROLOGY, V122, P659, DOI 10.1053/gast.2002.31889; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zamai L, 1998, J EXP MED, V188, P2375, DOI 10.1084/jem.188.12.2375	43	126	135	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					94	+		10.1096/fj.02-0537fje	http://dx.doi.org/10.1096/fj.02-0537fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475902				2022-12-28	WOS:000180218500019
J	Forlow, SB; Foley, PL; Ley, K				Forlow, SB; Foley, PL; Ley, K			Severely reduced neutrophil adhesion and impaired host defense against fecal and commensal bacteria in CD18-/- P-selectin-/- double null mice	FASEB JOURNAL			English	Article						integrins; knockout; intravital microscopy; inflammation; adhesion molecules	DOUBLE-MUTANT MICE; LUNG INJURY; GLYCOPROTEIN LIGAND; MONOCLONAL-ANTIBODY; CD18-INDEPENDENT MECHANISMS; INFLAMMATORY REACTIONS; LEUKOCYTE RECRUITMENT; ENDOTHELIAL-CELLS; INDUCED PNEUMONIA; GENE-EXPRESSION	Leukocyte recruitment to sites of inflammation requires the functions of selectors and integrins. P-selector null (CD62P- /-) mice show a mild and CD18 null (CD18 /-) mice a more severe neutrophil recruitment defect in some inflammatory models. To investigate the possible cooperative interactions between CD18 integrins and P-selector in mediating neutrophil recruitment, we generated CD18 - /- CD62P - /- double null mice. CD18 /- CD62P /- mice were apparently normal at weaning and fertile but later failed to gain weight, showed increased susceptibility to infection by fecal and commensal bacteria, and survived only 5-6 months. Some CD18-/-CD62P-/- mice showed severe spontaneous skin lesions; most showed neutrophil infiltration in the lungs and liver, and positive bacterial cultures from internal organs. The number and velocity of rolling leukocytes in tumor necrosis factor a treated venules of CD18-/-CD62P-/- mice was similar to those in wild-type mice, but neutrophil adhesion was severely reduced. Only 25% of adhered leukocytes were neutrophils in CD18-/-CD62P-/mice vs. >90% in wild-type, CD62P-/-, and CD18-/- single mutants. Our data show that removing both P-selectin and CD18 integrins from mice leads to severe neutrophil recruitment defects and spontaneous pathology.	Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22908 USA; Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Comparat Med, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Ley, K (corresponding author), Univ Virginia, Dept Biomed Engn, Hlth Sci Ctr Box 800759, Charlottesville, VA 22908 USA.	klausley@virginia.edu		Foley, Patricia/0000-0001-5735-9485	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054136, F32HL010447] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL10447, HL54136] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; Bullard DC, 1996, J EXP MED, V183, P2329, DOI 10.1084/jem.183.5.2329; Bunting M, 2002, CURR OPIN HEMATOL, V9, P30, DOI 10.1097/00062752-200201000-00006; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; DOERSCHUK CM, 1990, J IMMUNOL, V144, P2327; Doerschuk CM, 2000, AM J RESP CELL MOL, V23, P133, DOI 10.1165/ajrcmb.23.2.f193; Essani NA, 1998, J LEUKOCYTE BIOL, V63, P288, DOI 10.1002/jlb.63.3.288; Forlow SB, 2000, J CLIN INVEST, V106, P1457, DOI 10.1172/JCI10555; Gopalan PK, 1997, J IMMUNOL, V158, P367; Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863; HELLMAN P, 1994, AIDS RES HUM RETROV, V10, P391, DOI 10.1089/aid.1994.10.391; Hidari KIPJ, 1997, J BIOL CHEM, V272, P28750, DOI 10.1074/jbc.272.45.28750; ISSEKUTZ AC, 1993, CLIN IMMUNOL IMMUNOP, V67, P257, DOI 10.1006/clin.1993.1073; ISSEKUTZ AC, 1992, IMMUNOLOGY, V76, P655; Jaeschke H, 1996, SHOCK, V6, P351, DOI 10.1097/00024382-199611000-00009; Jung U, 1998, J CLIN INVEST, V102, P1526, DOI 10.1172/JCI119893; Jung U, 1999, J IMMUNOL, V162, P6755; Kamochi M, 1999, AM J PHYSIOL-LUNG C, V277, pL310, DOI 10.1152/ajplung.1999.277.2.L310; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KEENEY SE, 1994, AM J RESP CRIT CARE, V149, P311, DOI 10.1164/ajrccm.149.2.7905767; Kunkel EJ, 2000, J IMMUNOL, V164, P3301, DOI 10.4049/jimmunol.164.6.3301; Lawson JA, 2000, TOXICOL SCI, V54, P509, DOI 10.1093/toxsci/54.2.509; Ley K, 2001, IMMUNOL RES, V24, P87, DOI 10.1385/IR:24:1:87; Mahoney TS, 2001, P NATL ACAD SCI USA, V98, P10284, DOI 10.1073/pnas.181201398; Mizgerd JP, 1997, J EXP MED, V186, P1357, DOI 10.1084/jem.186.8.1357; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; Motosugi H, 1998, AM J RESP CRIT CARE, V157, P192, DOI 10.1164/ajrccm.157.1.9602095; MULLIGAN MS, 1993, J IMMUNOL, V150, P2407; MULLIGAN MS, 1993, J IMMUNOL, V151, P6410; Norman KE, 2001, MICROCIRCULATION, V8, P243, DOI 10.1080/713774036; NORTON CR, 1993, BIOCHEM BIOPH RES CO, V195, P250, DOI 10.1006/bbrc.1993.2037; NOURSHARGH S, 1989, J IMMUNOL, V142, P3193; Pan JL, 1998, J BIOL CHEM, V273, P10068, DOI 10.1074/jbc.273.16.10068; Pan JL, 1998, J BIOL CHEM, V273, P10058, DOI 10.1074/jbc.273.16.10058; PRICE TH, 1987, J IMMUNOL, V139, P4174; PRIES AR, 1988, INT J MICROCIRC, V7, P327; Qin L, 1996, J IMMUNOL, V157, P5016; Ramamoorthy C, 1997, J LEUKOCYTE BIOL, V61, P167, DOI 10.1002/jlb.61.2.167; Robinson SD, 1999, P NATL ACAD SCI USA, V96, P11452, DOI 10.1073/pnas.96.20.11452; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Scharffetter-Kochanek K, 1998, J EXP MED, V188, P119, DOI 10.1084/jem.188.1.119; Sharar SR, 1996, J IMMUNOL, V157, P2555; SHERMAN MP, 1992, J INFECT DIS, V166, P818, DOI 10.1093/infdis/166.4.818; Shi JL, 1998, BLOOD, V92, P520, DOI 10.1182/blood.V92.2.520.414k17_520_528; Smolen JE, 2000, J BIOL CHEM, V275, P15876, DOI 10.1074/jbc.M906232199; Steeber DA, 1997, J IMMUNOL, V159, P952; VEDDER NB, 1990, P NATL ACAD SCI USA, V87, P2643, DOI 10.1073/pnas.87.7.2643; Wickel DJ, 1998, SHOCK, V10, P265, DOI 10.1097/00024382-199810000-00006; WINN RK, 1993, J CLIN INVEST, V92, P1168, DOI 10.1172/JCI116686; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769	50	14	14	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1488	1496		10.1096/fj.02-0230com	http://dx.doi.org/10.1096/fj.02-0230com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374771				2022-12-28	WOS:000179167600030
J	Grune, T; Reinheckel, T; North, JA; Li, R; Bescos, PB; Shringarpure, R; Davies, KJA				Grune, T; Reinheckel, T; North, JA; Li, R; Bescos, PB; Shringarpure, R; Davies, KJA			Ezrin turnover and cell shape changes catalyzed by proteasome in oxidatively stressed cells	FASEB JOURNAL			English	Article						radixin; hydrogen peroxide; ezrin degradation; lactacystin; free radicals; proteolysis	MIXED-FUNCTION OXIDATION; MULTICATALYTIC PROTEINASE COMPLEX; HUMAN BJ FIBROBLASTS; RED BLOOD-CELLS; GLUTAMINE-SYNTHETASE; OXIDIZED PROTEINS; EPITHELIAL-CELLS; SELECTIVE DEGRADATION; MODIFIED HEMOGLOBIN; OXYGEN RADICALS	We find that ezrin, a cytoskeletal protein involved in anchoring actin to the cell membrane, is preferentially degraded and resynthesized after oxidative stress. Ezrin was identified using 2-dimensional gels and amino-terminal microsequencing as one of a select few [S-35]methionine prelabeled proteins degraded in clone 9 rat liver cells exposed to hydrogen peroxide (H2O2). Metabolic labeling of cellular proteins with [S-35]methionine after oxidative stress showed that resynthesis of ezrin rose dramatically but carboxyl terminus anti-ezrin monoclonal antibodies revealed constant intracellular ezrin levels; in other words, degradation and resynthesis were exactly matched. Ezrin degradation was blocked by selective inhibitors of the proteasome (lactacystin, NLVS, and epoxomycin) and by an antisense oligonucleotide directed against the proteasome C2 subunit. H2O2 also caused major changes in cell shape, including significant increases in cell diameter, which must require substantial cytoskeletal rearrangement. Peroxide-induced increases in cell diameter were, however, blocked by the selective proteasome inhibitor lactacystin. The degradation and resynthesis of ezrin may therefore be an underlying mechanism for overall cell shape changes observed during oxidative stress. Oxidative stress induces extensive protein oxidation and degradation and significant increases in cell blebbing, rounding-up, and overall size. Our results indicate that all these oxidant-induced changes may actually be catalyzed by the proteasome.	Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Div Mol & Computat Biol, Los Angeles, CA 90089 USA; Humboldt Univ, Fac Med Charite, Clin Phys Med & Rehabil, Berlin, Germany; Univ Magdeburg, Inst Clin Chem, D-39106 Magdeburg, Germany; Univ Magdeburg, Ctr Surg, D-39106 Magdeburg, Germany	University of Southern California; University of Southern California; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Otto von Guericke University; Otto von Guericke University	Davies, KJA (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock Ave,Room 306, Los Angeles, CA 90089 USA.	kelvin@usc.edu	Bermejo, Paloma/B-7139-2011; Bermejo-Bescós, Paloma/ABE-5782-2021; Reinheckel, Thomas/AAL-9761-2021	Bermejo, Paloma/0000-0003-3881-7852; Bermejo-Bescós, Paloma/0000-0003-3881-7852; Reinheckel, Thomas/0000-0001-9866-9105; Grune, Tilman/0000-0003-4775-9973; Davies, Kelvin/0000-0001-7790-3003	NIEHS NIH HHS [ES-03598] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R56ES003598, R01ES003598, R23ES003598] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARILA D, 1995, BBA-GENE STRUCT EXPR, V1263, P133, DOI 10.1016/0167-4781(95)00090-4; BAUW G, 1990, ELECTROPHORESIS, V11, P528, DOI 10.1002/elps.1150110703; BELLOMO G, 1982, P NATL ACAD SCI-BIOL, V79, P6842, DOI 10.1073/pnas.79.22.6842; BERGSON C, 1993, MOL CELL NEUROSCI, V4, P64, DOI 10.1006/mcne.1993.1008; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BIRGBAUER E, 1991, J NEUROSCI RES, V30, P232; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CERVERA J, 1988, FASEB J, V2, P2591, DOI 10.1096/fasebj.2.10.2898411; Chao CC, 1997, P NATL ACAD SCI USA, V94, P2969, DOI 10.1073/pnas.94.7.2969; CHEN J, 1994, AM J PHYSIOL, V267, pC784, DOI 10.1152/ajpcell.1994.267.3.C784; COWELL GM, 1984, FEBS LETT, V172, P309, DOI 10.1016/0014-5793(84)81147-3; DAVIES K J A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P155, DOI 10.1016/S0748-5514(86)80066-6; Davies KJA, 1995, BIOCHEM SOC SYMP, P1, DOI 10.1042/bss0610001; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; DAVIES KJA, 1993, BIOCHEM SOC T, V21, P346, DOI 10.1042/bst0210346; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; DAVIES KJA, 2000, IUBMB LIFE, V50, P35; DEAN RT, 1986, BIOCHEM J, V240, P489, DOI 10.1042/bj2400489; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GEIGER B, 1984, J CELL BIOL, V99, pS83, DOI 10.1083/jcb.99.1.83s; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; GIULIVI C, 1993, J BIOL CHEM, V268, P8752; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; Grune T, 2002, ARCH BIOCHEM BIOPHYS, V397, P407, DOI 10.1006/abbi.2001.2719; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; Helander TS, 1996, NATURE, V382, P265, DOI 10.1038/382265a0; HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3; JOOSS KU, 1995, ONCOGENE, V10, P603; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LANKES WT, 1993, BIOCHIM BIOPHYS ACTA, V1216, P479, DOI 10.1016/0167-4781(93)90018-9; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; MURAKAMI K, 1990, FREE RADICAL BIO MED, V8, P217, DOI 10.1016/0891-5849(90)90066-R; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLIVER CN, 1987, ARCH BIOCHEM BIOPHYS, V253, P62, DOI 10.1016/0003-9861(87)90637-0; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; OLIVER CN, 1987, J AM GERIATR SOC, V35, P947, DOI 10.1111/j.1532-5415.1987.tb02297.x; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; PAKKANEN R, 1988, EUR J CELL BIOL, V46, P435; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; SALO DC, 1990, J BIOL CHEM, V265, P11919; SATO N, 1992, J CELL SCI, V103, P131; Shuster CB, 1996, CELL MOTIL CYTOSKEL, V35, P175; Sitte N, 2000, FASEB J, V14, P1490, DOI 10.1096/fj.14.11.1490; Sitte N, 2000, FASEB J, V14, P2503, DOI 10.1096/fj.00-0210com; Sitte N, 2000, FASEB J, V14, P2495, DOI 10.1096/fj.00-0209com; STADTMAN ER, 1986, TRENDS BIOCHEM SCI, V11, P11, DOI 10.1016/0968-0004(86)90221-5; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; STIDWILL RP, 1984, J CELL BIOL, V98, P641, DOI 10.1083/jcb.98.2.641; SZWEDA LI, 1992, J BIOL CHEM, V267, P3096; TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TSUKITA S, 1977, TRENDS BIOCHEM SCI, V22, P53; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; Ullrich O, 1999, P NATL ACAD SCI USA, V96, P6223, DOI 10.1073/pnas.96.11.6223; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6; WANG L, AF004811 GENBANK; WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225; WILGENBUS KK, 1993, GENOMICS, V16, P199, DOI 10.1006/geno.1993.1159; WOLFF SP, 1986, TRENDS BIOCHEM SCI, V11, P27, DOI 10.1016/0968-0004(86)90228-8; YAK X, 1996, J BIOL CHEM, V271, P7224	75	36	36	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1602	1610		10.1096/fj.02-0015com	http://dx.doi.org/10.1096/fj.02-0015com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374783				2022-12-28	WOS:000179167600042
J	Stratton, R; Rajkumar, V; Ponticos, M; Nichols, B; Xu, SW; Black, CM; Abraham, DJ; Leask, A				Stratton, R; Rajkumar, V; Ponticos, M; Nichols, B; Xu, SW; Black, CM; Abraham, DJ; Leask, A			Prostacyclin derivatives prevent the fibrotic response to TGF beta 2 by inhibiting the Ras/MEK/ERK pathway	FASEB JOURNAL			English	Article						MAP kinase; SMAD; CTGF; iloprost	GROWTH-FACTOR-BETA; GENE-EXPRESSION; SCLERODERMA FIBROBLASTS; SYSTEMIC-SCLEROSIS; EPITHELIAL-CELLS; PROTEIN-KINASES; RAF-1 KINASE; ACTIVATION; SMAD; CAMP	The SMAD-mediated induction of connective tissue growth factor (CTGF), a fibroproliferative cytokine, by transforming growth factor (TGF)beta is required for the development of sustained fibrosis in humans. Here, we show that in fibroblasts, activation of the Ras/MEK/ERK pathway is required for the SMAD-mediated induction of CTGF by TGFbeta2. We then show that activation of protein kinase A (PKA) in fibroblasts is able to block Ras/MEK/ERK signaling and abolish the fibrotic response. Previously, we found that prostacyclin agonists were able to prevent the induction of CTGF in fibroblasts, and in patients with the fibrotic disease scleroderma. Here, we confirm the in vitro and in vivo antifibrotic effects of prostacyclin derivatives and show that these effects are due to PKA-dependent inhibition of the Ras/MEK/ERK pathway. Ras/MEK/ERK does not directly affect SMAD signaling. The coordinate and varied biological responses to TGFbeta are in part due to the interactions of signaling pathways within target cells. Specific inhibition of fibroblast Ras/MEK/ERK signaling might prevent fibrosis while leaving other physiological effects of TGFbeta unaltered.	FibroGen Inc, San Francisco, CA 94080 USA; Univ Coll, Sch Med, London NW3 2PF, England; Royal Free Hosp, Ctr Rheumatol, London NW3 2PF, England	FibroGen; University of London; University College London; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Leask, A (corresponding author), FibroGen Inc, 225 Gateway Blvd, San Francisco, CA 94080 USA.	aleask@fibrogen.com	Leask, Andy/ABH-9433-2020; Leask, Andrew/G-5217-2015	Ponticos, Markella/0000-0001-5957-5851				Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Bettoni L, 2002, CLIN RHEUMATOL, V21, P244, DOI 10.1007/PL00011223; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; BOSSEMEYER D, 1995, FEBS LETT, V369, P57, DOI 10.1016/0014-5793(95)00580-3; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; CHEN Y, 2002, IN PRESS KIDNEY INT; Chen YJ, 2001, EXP CELL RES, V271, P109, DOI 10.1006/excr.2001.5364; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Flanders KC, 2002, AM J PATHOL, V160, P1057, DOI 10.1016/S0002-9440(10)64926-7; Frey RS, 1997, CANCER LETT, V117, P41, DOI 10.1016/S0304-3835(97)00211-5; GARVEY W, 1984, STAIN TECHNOL, V59, P213, DOI 10.3109/10520298409113858; GJERTSEN BT, 1995, J BIOL CHEM, V270, P20599, DOI 10.1074/jbc.270.35.20599; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Kutz SM, 2001, J CELL SCI, V114, P3905; Leask A, 2001, J CLIN PATHOL-MOL PA, V54, P180, DOI 10.1136/mp.54.3.180; Leask Andrew, 2002, Curr Rheumatol Rep, V4, P136, DOI 10.1007/s11926-002-0009-x; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; MAQUART FX, 1993, J CLIN INVEST, V92, P2368, DOI 10.1172/JCI116842; McCartney-Francis N L, 1998, Int Rev Immunol, V16, P553, DOI 10.3109/08830189809043009; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Shi-Wen X, 2000, EXP CELL RES, V259, P213, DOI 10.1006/excr.2000.4972; SPRUGEL KH, 1987, AM J PATHOL, V129, P601; Stratton R, 2001, J CLIN INVEST, V108, P241, DOI 10.1172/JCI12020; TAYLOR SS, 1988, COLD SPRING HARB SYM, V53, P121, DOI 10.1101/SQB.1988.053.01.018; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; Wotton D, 2001, CELL GROWTH DIFFER, V12, P457; Wotton D, 2001, CURR TOP MICROBIOL, V254, P145; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 2000, SCI STKE, V23, pRE1; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019	46	131	141	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1949	+		10.1096/fj.02-0204fje	http://dx.doi.org/10.1096/fj.02-0204fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368229				2022-12-28	WOS:000179167600021
J	Palinski, W; Napoli, C				Palinski, W; Napoli, C			The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis	FASEB JOURNAL			English	Review						fetal lesion; maternal cholesterol level; vitamin E; postnatal gene expression	LOW-DENSITY-LIPOPROTEIN; FATTY STREAK FORMATION; CARDIOVASCULAR RISK-FACTORS; GENE-EXPRESSION PATTERNS; HEART-DISEASE; NITRIC-OXIDE; OXIDIZED LDL; OXIDATIVE MODIFICATION; MYOCARDIAL-INFARCTION; AMERICAN-COLLEGE	It has long been postulated that pathogenic events during fetal development influence atherosclerosis-related diseases later in life, but the mechanisms involved are unknown. This review focuses on the evidence indicating that maternal hypercholesterolemia during pregnancy is responsible for one cascade of pathogenic events. Maternal hypercholesterolemia is associated with greatly increased fatty streak formation in human fetal arteries and accelerated progression of atherosclerosis during childhood. Recent experiments in genetically more homogeneous rabbits established that temporary diet-induced maternal hypercholesterolemia is sufficient to enhance fetal lesion formation. More important, maternal hypercholesterolemia or ensuing pathogenic events in the fetus increase postnatal atherogenesis in response to hypercholesterolemia. Maternal treatment with cholesterol-lowering agents or antioxidants greatly reduces fetal and postnatal atherogenesis, indicating a pathogenic role of lipid peroxidation and a potential involvement of oxidation-sensitive signaling pathways. Experiments in a murine model showed that differences in arterial gene expression between offspring of normo- and hypercholesterolemic mothers persist long after birth, supporting the assumption that fetal lesion formation is associated with genetic programming, which may in turn affect postnatal atherogenesis. A better understanding of pathogenic programming events in utero may lead to the identification of genes determining the susceptibility to atherosclerosis and define novel preventive approaches.	Univ Calif San Diego, Dept Med 0682, MTF 110, La Jolla, CA 92093 USA; Univ Naples Federico II, Dept Med, I-80131 Naples, Italy	University of California System; University of California San Diego; University of Naples Federico II	Napoli, C (corresponding author), Univ Calif San Diego, Dept Med 0682, MTF 110, 9500 Gilman Dr, La Jolla, CA 92093 USA.	cnapoli@ucsd.edu	Palinski, Wulf/AAW-8032-2021	Napoli, Claudio/0000-0002-5455-555X; Palinski, Wulf/0000-0002-5113-0169	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056989] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-56989] Funding Source: Medline; PHS HHS [5825/2000] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adair LS, 2001, CIRCULATION, V104, P1034, DOI 10.1161/hc3401.095037; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BARKER DJP, 1989, LANCET, V2, P577; Barker DJP, 2000, J HYPERTENS, V18, P843, DOI 10.1097/00004872-200018070-00004; BELKNAP WM, 1988, J CLIN INVEST, V82, P2077, DOI 10.1172/JCI113829; Bendich A, 2001, NUTRITION, V17, P858, DOI 10.1016/S0899-9007(01)00649-9; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; BERENSON GS, 1992, AM J CARDIOL, V70, P851, DOI 10.1016/0002-9149(92)90726-F; Boaz M, 2000, LANCET, V356, P1213, DOI 10.1016/S0140-6736(00)02783-5; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Boren J, 1998, J CLIN INVEST, V101, P2658, DOI 10.1172/JCI2265; BOYD HC, 1989, AM J PATHOL, V135, P815; BUJA LM, 1983, ARTERIOSCLEROSIS, V3, P87, DOI 10.1161/01.ATV.3.1.87; CHAIT A, 1993, AM J MED, V94, P350, DOI 10.1016/0002-9343(93)90144-E; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373; CONIHAY JA, 2001, J LIPID RES, V42, P1111; D'Armiento FP, 2001, STROKE, V32, P2472, DOI 10.1161/hs1101.098520; DARMIENTO FP, 1993, ACTA PAEDIATR, V82, P823, DOI 10.1111/j.1651-2227.1993.tb17620.x; de Nigris F, 2000, CIRCULATION, V102, P2111, DOI 10.1161/01.CIR.102.17.2111; de Nigris F, 2001, BIOCHEM BIOPH RES CO, V281, P945, DOI 10.1006/bbrc.2001.4431; ELPHICK MC, 1977, J PHYSIOL-LONDON, V264, P751, DOI 10.1113/jphysiol.1977.sp011692; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gruszczynska Magdalena, 1993, Cytobios, V74, P167; Haley KJ, 2000, CIRCULATION, V102, P2185; HENDRICKSE W, 1985, BRIT J OBSTET GYNAEC, V92, P945, DOI 10.1111/j.1471-0528.1985.tb03075.x; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; Ignarro LJ, 2002, CIRC RES, V90, P21, DOI 10.1161/hh0102.102330; Ikari Y, 1999, ARTERIOSCL THROM VAS, V19, P2036, DOI 10.1161/01.ATV.19.9.2036; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Kramer MS, 1996, LANCET, V348, P1254, DOI 10.1016/S0140-6736(05)65750-9; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; LI JR, 1980, J CLIN INVEST, V65, P1060, DOI 10.1172/JCI109758; LIAO F, 1994, J CLIN INVEST, V94, P877, DOI 10.1172/JCI117409; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; Martin U, 1999, CLIN SCI, V96, P421, DOI 10.1042/CS19980326; Martinet W, 2001, CIRC RES, V88, P733, DOI 10.1161/hh0701.088684; Martyn CN, 1998, LANCET, V352, P173, DOI 10.1016/S0140-6736(97)10404-4; MCMURRY MP, 1981, METABOLISM, V30, P869, DOI 10.1016/0026-0495(81)90065-2; Mindlen F, 1996, CAN J CARDIOL, V12, P127; Montoudis A, 1999, LIFE SCI, V64, P2439, DOI 10.1016/S0024-3205(99)00201-5; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Napoli C, 2000, FASEB J, V14, P1996, DOI 10.1096/fj.99-0986com; Napoli C, 1997, AM HEART J, V133, P585, DOI 10.1016/S0002-8703(97)70155-8; Napoli C, 1999, CIRCULATION, V99, P2003, DOI 10.1161/01.CIR.99.15.2003; Napoli C, 1997, J CLIN INVEST, V100, P2680, DOI 10.1172/JCI119813; Napoli C, 2002, CIRCULATION, V105, P1360, DOI 10.1161/01.CIR.0000013090.96919.FA; Napoli C, 1999, LANCET, V354, P1234, DOI 10.1016/S0140-6736(99)02131-5; Napoli C, 2001, NITRIC OXIDE-BIOL CH, V5, P88, DOI 10.1006/niox.2001.0337; Napoli C, 2001, EUR HEART J, V22, P4, DOI 10.1053/euhj.2000.2147; Napoli C, 2001, J CELL BIOCHEM, V82, P674, DOI 10.1002/jcb.1198; Napoli C, 2000, CIRC RES, V87, P946, DOI 10.1161/01.RES.87.10.946; *NAT CHOL ED PROGR, 1992, PEDIATRICS, V89, P525; Palinski W, 2000, J INTERN MED, V247, P371, DOI 10.1046/j.1365-2796.2000.00656.x; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; PALINSKI W, 1995, P NATL ACAD SCI USA, V92, P821, DOI 10.1073/pnas.92.3.821; Palinski W, 2001, CONTEMP CARDIOL, P149; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; Palinski W, 2001, CIRC RES, V89, P991, DOI 10.1161/hh2301.099646; Palinski W, 1999, TRENDS CARDIOVAS MED, V9, P205, DOI 10.1016/S1050-1738(00)00022-0; PEDERSEN TR, 1994, LANCET, V344, P1383; Poulter NR, 2001, LANCET, V357, P1990, DOI 10.1016/S0140-6736(00)05131-X; Pryor WA, 2000, FREE RADICAL BIO MED, V28, P141, DOI 10.1016/S0891-5849(99)00224-5; Radunovic N, 2000, J CLIN ENDOCR METAB, V85, P85, DOI 10.1210/jc.85.1.85; Reilly MP, 1998, CIRCULATION, V98, P2822, DOI 10.1161/01.CIR.98.25.2822; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Saiura A, 2001, TRANSPLANTATION, V72, P320, DOI 10.1097/00007890-200107270-00027; Sata M, 1998, J CLIN INVEST, V102, P1682, DOI 10.1172/JCI3531; Scholl T. O., 2001, Preventive nutrition: the comprehensive guide for health professionals, P387; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Smith GCS, 2001, LANCET, V357, P2002, DOI 10.1016/S0140-6736(00)05112-6; Smith SC, 2001, CIRCULATION, V104, P1577, DOI 10.1161/hc3801.097475; Spinler SA, 2001, ANN PHARMACOTHER, V35, P589; Stanton LW, 2000, CIRC RES, V86, P939, DOI 10.1161/01.RES.86.9.939; STARY H, 1989, ARTERIOSCLEROSIS, V9, P1; Stary HC, 2000, AM J CLIN NUTR, V72, p1297S, DOI 10.1093/ajcn/72.5.1297s; Steinberg D., 1999, MOL BASIS CARDIOVASC, P458; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Stuart RO, 2001, P NATL ACAD SCI USA, V98, P5649, DOI 10.1073/pnas.091110798; SUBBIAH MTR, 1983, J CLIN INVEST, V71, P1509, DOI 10.1172/JCI110906; Susser M, 1999, BMJ-BRIT MED J, V318, P885, DOI 10.1136/bmj.318.7188.885; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; VILLAR AJ, 1994, NAT GENET, V8, P373, DOI 10.1038/ng1294-373; WISSLER RW, 1993, ARTERIOSCLER THROMB, V13, P1291; Woollett LA, 2001, CURR OPIN LIPIDOL, V12, P305, DOI 10.1097/00041433-200106000-00010; Yang JC, 2000, CIRCULATION, V102, P3046; Yla-Herttuala S, 1999, ANN NY ACAD SCI, V874, P134, DOI 10.1111/j.1749-6632.1999.tb09231.x	90	192	203	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2002	16	11					1348	1360		10.1096/fj.02-0226rev	http://dx.doi.org/10.1096/fj.02-0226rev			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12205026	Green Published			2022-12-28	WOS:000178441800009
J	Bonvillian, WB				Bonvillian, WB			Science at a crossroads (Reprinted from Technology in Society, vol 24, 2002)	FASEB JOURNAL			English	Reprint						R&D; physical sciences; research funding		Science is entering an alliance with the economy that will speed the effect of innovation through society. Despite the slowdown of the 'new economy', a cascade paradigm of innovation appears key to increasing the rate of economic growth. Yet for science to continue to thrive and make this contribution to innovation, it must traverse at least three key crossroads. First, while life sciences have built a strong advocacy model to secure growing federal research funding, the physical sciences (including mathematics and engineering) have not and must now do so to thrive. Second, the drop in the numbers of physical scientists and engineers must be reversed if we are to have the talent to maintain a strong trend of scientific advance. Third, although science advances are increasingly interdisciplinary and occurring in the space between the historic science stovepipes, the organization of federal science support is largely unchanged since the beginning of the cold war. While a decentralized model has value, we must also consider new approaches that encourage deeper cooperation across science sectors and agencies.	Off Senator Lieberman, Washington, DC USA		Bonvillian, WB (corresponding author), Off Senator Lieberman, Hart Senate Off Bldg, Washington, DC USA.	bill_bonvillian@lieberman.senate.gov						*AAAS, 2000, TRENDS FED RES DISC; BONVILLIAN WR, 2002, TECHNOLOGY SURG, V24; BUSH V, 1967, SCI IS NOT ENOUGH, P27; Cox M.C., 1999, MYTHS RICH POOR WHY; FRIDMAN S, 2000, NEWSBYTES       0327; GOLDEN WT, 1995, IMPACTS EARLY COLD W; HENKE RR, 1997, AM TEACH PROF PROF; HOPPER G, 1987, COMMUNICATION   0517; Jones C., 1998, INTRO EC GROWTH; Klein S., 1986, POSITIVE SUM STRATEG; Kline RR, 2000, IEEE TECHNOL SOC MAG, V19, P19, DOI 10.1109/44.868938; Lieberman JI, 2001, ISSUES SCI TECHNOL, V17, P37; MANDEL MJ, 2001, BUS WEEK        0326, P117; Merrill SA, 1999, SCIENCE, V285, P1679, DOI 10.1126/science.285.5434.1679; *NAT SCI BOARD, SCI ENG IND 2000; PORTER ME, 2001, US COMPETITIVENESS 2; *RECR NEW TEACH IN, 2000, URB TEACH CHALL DEM; ROMER PM, 2000, 7723 NAT BUR EC; Rycroft RW, 1999, ISSUES SCI TECHNOL, V16, P73; *US DEP ED, 2000, INT ED IND TIM SER P; ZUMETA W, 2000, BEST BRIGHTEST 2; 2000, BUSINESS WEEK   0410, P242	22	9	9	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2002	16	9					915	921		10.1096/fj.02-0119lsf	http://dx.doi.org/10.1096/fj.02-0119lsf			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087052				2022-12-28	WOS:000177813100022
J	Sugano, M; Koyanagi, M; Tsuchida, K; Hata, T; Makino, N				Sugano, M; Koyanagi, M; Tsuchida, K; Hata, T; Makino, N			In vivo gene transfer of soluble TNF-alpha receptor 1 alleviates myocardial infarction	FASEB JOURNAL			English	Article						acute myocardial infarction; soluble TNF-alpha receptor 1; apoptosis; gene therapy	TUMOR-NECROSIS-FACTOR; FACTOR-BINDING PROTEIN; ISCHEMIA/REPERFUSION INJURY; APOPTOSIS; EXPRESSION; REPERFUSION; CARDIOMYOCYTES; ISCHEMIA; RATS; ATTENUATION	Apoptosis is the major independent form of cardiomyocyte cell death in acute myocardial infarction (AMI). TNF-alpha release early in the course of AMI contributes to myocardial injury, and TNF-alpha induces apoptosis in cardiomyocytes. Soluble TNF-alpha receptor 1 (sTNFR1) is an antagonist to TNF-alpha. However, the effect of sTNFR1 on AMI remains unclear. Here we report that direct injection of an sTNFR1 expression plasmid DNA to the myocardium reduces infarct size in experimental rat AMI. Treatment with sTNFR1 expression plasmid DNA reduced the TNF-alpha bioactivity in the myocardium and the apoptosis of cardiomyocytes. These findings suggest that the anti-TNF-alpha therapy by sTNFR1 can be a new strategy for treatment of AMI.	Kyushu Univ, Dept Mol & Cellular Biol, Div Mol & Clin Gerontol, Med Inst Bioregulat, Beppu, Oita 8740838, Japan	Kyushu University	Sugano, M (corresponding author), Kyushu Univ, Dept Mol & Cellular Biol, Div Mol & Clin Gerontol, Med Inst Bioregulat, 4546 Tsurumihara, Beppu, Oita 8740838, Japan.	massy@tsurumi.beppu.kyushu-u.ac.jp						Belosjorow S, 1999, AM J PHYSIOL-HEART C, V277, pH2470, DOI 10.1152/ajpheart.1999.277.6.H2470; Bryant D, 1998, CIRCULATION, V97, P1375, DOI 10.1161/01.CIR.97.14.1375; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; ENTMAN ML, 1994, CARDIOVASC RES, V28, P1301, DOI 10.1093/cvr/28.9.1301; Gaines GC, 1999, J VASC SURG, V29, P370, DOI 10.1016/S0741-5214(99)70390-3; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Gurevitch J, 1997, J AM COLL CARDIOL, V30, P1554, DOI 10.1016/S0735-1097(97)00328-8; HIMMLER A, 1990, DNA CELL BIOL, V9, P705, DOI 10.1089/dna.1990.9.705; Irwin MW, 1999, CIRCULATION, V99, P1492, DOI 10.1161/01.CIR.99.11.1492; Kajstura J, 1996, LAB INVEST, V74, P86; Li DY, 1999, AM HEART J, V137, P1145, DOI 10.1016/S0002-8703(99)70375-3; Makino N, 1996, J MOL CELL CARDIOL, V28, P507, DOI 10.1006/jmcc.1996.0047; Oskarsson HJ, 2000, CARDIOVASC RES, V45, P679, DOI 10.1016/S0008-6363(99)00400-9; SECKINGER P, 1989, J BIOL CHEM, V264, P11966; Selinsky CL, 1998, IMMUNOLOGY, V94, P88; Song W, 2000, CARDIOVASC RES, V45, P595, DOI 10.1016/S0008-6363(99)00395-8; Su X, 1998, ARTHRITIS RHEUM-US, V41, P139, DOI 10.1002/1529-0131(199801)41:1<139::AID-ART17>3.3.CO;2-K; Sugano M, 2000, BIOCHEM BIOPH RES CO, V272, P872, DOI 10.1006/bbrc.2000.2877; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; YAMAZAKI T, 1993, AM J PATHOL, V143, P410; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Yoshida H, 2000, HYPERTENSION, V35, P25, DOI 10.1161/01.HYP.35.1.25	22	24	26	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1421	+		10.1096/fj.01-0894fje	http://dx.doi.org/10.1096/fj.01-0894fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205034				2022-12-28	WOS:000177813100021
J	Iijima, Y; Nagai, T; Mizukami, M; Matsuura, K; Ogura, T; Wada, H; Toko, H; Akazawa, H; Takano, H; Nakaya, H; Komuro, I				Iijima, Y; Nagai, T; Mizukami, M; Matsuura, K; Ogura, T; Wada, H; Toko, H; Akazawa, H; Takano, H; Nakaya, H; Komuro, I			Beating is necessary for transdifferentiation of skeletal muscle-derived cells into cardiomyocytes	FASEB JOURNAL			English	Article						stem cells; mechanical stress; transdifferentiation	NATRIURETIC-FACTOR GENE; CARDIAC TROPONIN-T; STEM-CELLS; PERFORMANCE; EXPRESSION; MYOCYTES; TRANSPLANTATION; IDENTIFICATION; TRANSCRIPTION; DYSTROPHIN	Cell transplantation could be a potential therapy for heart damage. Skeletal myoblasts have been expected to be a good cell source for autologous transplantation; however, the safety and efficacy of their transplantation are still controversial. Recent studies have revealed that skeletal muscle possesses the stem cell population that is distinct from myoblasts. To elucidate whether skeletal muscle stem cells can transdifferentiate into cardiomyocytes, we cocultured skeletal muscle cells isolated from transgenic mice expressing green fluorescent protein with cardiomyocytes of neonatal rats. Skeletal muscle-derived cells expressed cardiac-specific proteins such as cardiac troponin T and atrial natriuretic peptide as well as cardiac-enriched transcription factors such as Nkx2E (formerly called Csx/Nkx2.5) and GATA4 by coculture with cardiomyocytes. Skeletal muscle-derived cells also expressed cadherin and connexin 43 at the junctions with neighboring cardiomyocytes. Cardiomyocyte-like action potentials were recorded from beating skeletal muscle-derived cells. Treatment of nifedipine or culture in Ca2+-free media suppressed contraction of cardiomyocytes and inhibited skeletal muscle cells to express cardiac-specific proteins. Cyclic stretch completely restored this inhibitory effect. These results suggest that some part of skeletal muscle cells can transdifferentiate into cardiomyocytes and that direct cell-to-cell contact and contraction of neighboring cardiomyocytes are important for the transdifferentiation.	Chiba Univ, Grad Sch Med, Dept Pharmacol, Chiba, Japan; Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chiba, Japan	Chiba University; Chiba University	Komuro, I (corresponding author), Chiba Univ, Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	komuro-tky@umin.ac.jp		Akazawa, Hiroshi/0000-0002-3574-9607				Aikawa R, 2002, HYPERTENSION, V39, P233, DOI 10.1161/hy0202.102699; Altman GH, 2001, FASEB J, V15, P270, DOI 10.1096/fj.01-0656fje; ARGENTIN S, 1994, MOL CELL BIOL, V14, P777, DOI 10.1128/MCB.14.1.777; Atkins BZ, 1999, J HEART LUNG TRANSPL, V18, P1173, DOI 10.1016/S1053-2498(99)00096-0; Carlson F.D., 1974, MUSCLE PHYSL, VVolume 53; EVANS SM, 1994, MOL CELL BIOL, V14, P4269, DOI 10.1128/MCB.14.6.4269; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hutcheson KA, 2000, CELL TRANSPLANT, V9, P359, DOI 10.1177/096368970000900307; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jain M, 2001, CIRCULATION, V103, P1920; Kawada H, 2001, BLOOD, V98, P2008, DOI 10.1182/blood.V98.7.2008; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; McKinney-Freeman SL, 2002, P NATL ACAD SCI USA, V99, P1341, DOI 10.1073/pnas.032438799; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Pouzet B, 2001, CIRCULATION, V104, pI223; Qu-Petersen ZQ, 2002, J CELL BIOL, V157, P851, DOI 10.1083/jcb.200108150; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Reinecke H, 2000, J CELL BIOL, V149, P731, DOI 10.1083/jcb.149.3.731; Reinecke H, 2002, J MOL CELL CARDIOL, V34, P241, DOI 10.1006/jmcc.2001.1507; SAGGIN L, 1990, DEVELOPMENT, V110, P547; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; SIMPSON P, 1982, CIRC RES, V50, P101, DOI 10.1161/01.RES.50.1.101; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; Tatsumi R, 2001, EXP CELL RES, V267, P107, DOI 10.1006/excr.2001.5252; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Torrente Y, 2001, J CELL BIOL, V152, P335, DOI 10.1083/jcb.152.2.335; Wang Q, 2000, CIRC RES, V86, P478, DOI 10.1161/01.RES.86.4.478; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693; Zou YZ, 2002, ENDOCR J, V49, P1, DOI 10.1507/endocrj.49.1	36	64	73	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1361	+		10.1096/fj.02-1048fje	http://dx.doi.org/10.1096/fj.02-1048fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738802				2022-12-28	WOS:000183165000026
J	Mundle, SD; Saberwal, G				Mundle, SD; Saberwal, G			Evolving intricacies and implications of E2F1 regulation	FASEB JOURNAL			English	Review						E2F; post-translational modifications; pocket proteins	CELL-CYCLE REGULATION; TRANSCRIPTION FACTORS; GENE-EXPRESSION; S-PHASE; PRB; INDUCTION; BINDING; PROTEIN; PHOSPHORYLATION; INHIBITION	E2F transcription factors may play a pivotal role in the transcriptional regulation of several cellular processes far beyond the originally described cell cycle and proliferation. Among the six E2F family members, only E2F1 is noted for its role in apoptosis. The pocket protein family members Rb, p107, and p130 act as the main regulators of E2F activity. Nonetheless, in recent years other protein-protein interactions have been described for E2Fs. The post-translational modifications resulting from such protein interactions may have significant implications in the stability, half-life, and functional activity of E2Fs. In human diseases the significance of E2Fs is still under appreciated and is primarily recognized only as a consequence of the impairment in retinoblastoma gene product (Rb). However, with increasing knowledge of other protein interactions, the derailment of E2F activity could be anticipated to stem from an abnormality of any node in the complex network governing their availability and activity. The present review is intended to provide a perspective on the diversity of biochemical mechanisms underlying abnormal E2F expression and activity, understanding of which may have significant clinical implications.	Rush Univ, Dept Med, Inst Sect Myeloid Dis, Chicago, IL 60612 USA; Rush Univ, Rush Presbyterian St Lukes Med Ctr, MDS Ctr, Chicago, IL 60612 USA	Rush University; Rush University	Mundle, SD (corresponding author), Rush Univ, Dept Med, Inst Sect Myeloid Dis, 2242 W Harrison St,Suite 108, Chicago, IL 60612 USA.	suneelmundle@hotmail.com						BATES S, 1993, NATURE, V395, P124; Bi BY, 2001, IMMUNOLOGY, V104, P37, DOI 10.1046/j.1365-2567.2001.01277.x; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Chiang SY, 1998, BIOCHEMISTRY-US, V37, P3109, DOI 10.1021/bi9721142; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eymin B, 2001, ONCOGENE, V20, P1678, DOI 10.1038/sj.onc.1204242; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Garcia I, 2000, CELL GROWTH DIFFER, V11, P91; Goukassian D, 2001, BRIT J PHARMACOL, V132, P1597, DOI 10.1038/sj.bjp.0703945; Guida P, 1999, BIOCHEM BIOPH RES CO, V258, P596, DOI 10.1006/bbrc.1999.0656; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Humbert PO, 2000, GENE DEV, V14, P690; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Johnston A, 2000, STAND, V2, P27; Jordan-Sciutto KL, 2000, AM J PATHOL, V157, P497, DOI 10.1016/S0002-9440(10)64561-0; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; Koziczak M, 2000, MOL CELL BIOL, V20, P2014, DOI 10.1128/MCB.20.6.2014-2022.2000; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lin WC, 2001, GENE DEV, V15, P1833; Luciakova K, 2000, BIOCHEM J, V351, P251, DOI 10.1042/0264-6021:3510251; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MacManus JP, 1999, NEUROREPORT, V10, P2711, DOI 10.1097/00001756-199909090-00004; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Motonaga K, 2001, BRAIN RES, V905, P250, DOI 10.1016/S0006-8993(01)02535-5; Muller H, 1997, MOL CELL BIOL, V17, P5508; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Mundle SD, 2000, BRIT J HAEMATOL, V109, P376, DOI 10.1046/j.1365-2141.2000.01937.x; Panigone S, 2000, ONCOGENE, V19, P4035, DOI 10.1038/sj.onc.1203743; PEEPER DS, 1995, ONCOGENE, V10, P39; Pierce AM, 1998, MOL CARCINOGEN, V22, P190, DOI 10.1002/(SICI)1098-2744(199807)22:3<190::AID-MC7>3.0.CO;2-P; Raza A, 2000, BLOOD, V95, P1580, DOI 10.1182/blood.V95.5.1580.005k45_1580_1587; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ross JF, 2001, GENE DEV, V15, P392, DOI 10.1101/gad.858501; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Saberwal G, 2002, BLOOD, V100, p337B; Saberwal G, 2002, BLOOD, V100, p375A; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shelat HS, 2001, CIRCULATION, V103, P407; Soni R, 2000, BIOCHEM BIOPH RES CO, V275, P877, DOI 10.1006/bbrc.2000.3349; Takahashi Y, 2000, GENE DEV, V14, P804; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	61	66	69	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					569	574		10.1096/fj.02-0431rev	http://dx.doi.org/10.1096/fj.02-0431rev			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665469				2022-12-28	WOS:000182580100001
J	Shimokawa, I; Higami, Y; Tsuchiya, T; Otani, H; Komatsu, T; Chiba, T; Yamaza, H				Shimokawa, I; Higami, Y; Tsuchiya, T; Otani, H; Komatsu, T; Chiba, T; Yamaza, H			Lifespan extension by reduction of the growth hormone-insulin-like growth factor-1 axis: relation to caloric restriction	FASEB JOURNAL			English	Article						longevity; transgenic rat; dwarf; pathology	DIETARY RESTRICTION; GENE-EXPRESSION; SPAN EXTENSION; DWARF MICE; LONGEVITY; RATS	A reduced growth hormone (GH)-insulin-like growth factor (IGF)-1 axis is associated with an extension of lifespan in laboratory rodents. Several phenotypes of such animal models resemble those induced by caloric restriction (CR). Using a transgenic male Wistar rat model whose GH-IGF-1 axis was moderately suppressed by overexpression of the antisense GH transgene (tg), we elucidated a relationship between the effects of a reduced GH-IGF-1 axis and CR for some biomarkers of aging, lifespan, and pathologies. Heterozygous (tg/-) rats fed ad libitum (AL) had a dwarf phenotype similar to that of control nontransgenic (-/-) rats subjected to 30% CR from 6 wk of age. Both the reduced GH-IGF-1 axis and CR extended lifespan to a similar extent, although the effect of CR seemed to be greater. There was an additive effect of CR to lifespan extension when tg/- rats were subjected to CR. Pathologic analyses indicated that the preventive effect of CR on selected diseases was greater than that of the reduced GH-IGF-1 axis. The present study suggests that CR affects aging and longevity by mechanisms other than suppression of the GH-IGF-1 axis, although CR might exhibit its effects partly through the reduced GH-IGF-1 axis.	Nagasaki Univ, Grad Sch Biomed Sci, Dept Pathol & Gerontol, Nagasaki 8528523, Japan	Nagasaki University	Shimokawa, I (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Pathol & Gerontol, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.	shimo@net.nagasaki-u.ac.jp	Yamaza, Haruyoshi/AAD-4011-2019	Yamaza, Haruyoshi/0000-0003-1138-3943; Higami, Yoshikazu/0000-0003-1381-0777; Tsuchiya, Tomoshi/0000-0002-8419-1478				Bartke A, 2001, NATURE, V414, P412, DOI 10.1038/35106646; BIELSCHOWSKY F, 1961, BRIT J CANCER, V15, P257, DOI 10.1038/bjc.1961.32; BREESE CR, 1991, J GERONTOL, V46, pB180, DOI 10.1093/geronj/46.5.B180; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; CHEN HW, 1972, JNCI-J NATL CANCER I, V49, P1145; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Coschigano KT, 2000, ENDOCRINOLOGY, V141, P2608, DOI 10.1210/en.141.7.2608; Dominici FP, 2000, J ENDOCRINOL, V166, P579, DOI 10.1677/joe.0.1660579; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; Hsieh CC, 2002, MECH AGEING DEV, V123, P1229, DOI 10.1016/S0047-6374(02)00036-2; MAEDA H, 1985, J GERONTOL, V40, P671, DOI 10.1093/geronj/40.6.671; MASORO EJ, 1992, J GERONTOL, V47, pB202, DOI 10.1093/geronj/47.6.B202; MATSUMOTO K, 1993, MOL REPROD DEV, V36, P53, DOI 10.1002/mrd.1080360109; Mattison JA, 2000, J AM AGING ASSOC, V23, P9, DOI 10.1007/s11357-000-0002-0; OOKA H, 1983, MECH AGEING DEV, V22, P113, DOI 10.1016/0047-6374(83)90104-5; RENNELS EG, 1965, TEX REP BIOL MED, V23, P776; Shimokawa I, 2002, AM J PATHOL, V160, P2259, DOI 10.1016/S0002-9440(10)61173-X; Sornson MW, 1996, NATURE, V384, P327, DOI 10.1038/384327a0; WEINDRUCH R, 1988, RETARDATION AGING DI	20	94	99	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1108	+		10.1096/fj.02-0819fje	http://dx.doi.org/10.1096/fj.02-0819fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692087				2022-12-28	WOS:000182580100033
J	Tadokoro, T; Kobayashi, N; Zmudzka, BZ; Ito, S; Wakamatsu, K; Yamaguchi, Y; Korossy, KS; Miller, SA; Beer, JZ; Hearing, VJ				Tadokoro, T; Kobayashi, N; Zmudzka, BZ; Ito, S; Wakamatsu, K; Yamaguchi, Y; Korossy, KS; Miller, SA; Beer, JZ; Hearing, VJ			UV-induced DNA damage and melanin content in human skin differing in racial/ethnic origin	FASEB JOURNAL			English	Article						melanocytes; skin color; photocarcinogenesis; cyclobutane pyrimidine dimers	CYCLOBUTANE PYRIMIDINE DIMERS; HUMAN MELANOCYTES; 6-4 PHOTOPRODUCTS; ULTRAVIOLET-B; P53 GENE; INDUCTION; CANCER; REPAIR; RADIATION; RESPONSES	DNA damage induced by UV radiation is a critical event in skin photocarcinogenesis. However, the role of racial/ethnic origin in determining individual UV sensitivity remains unclear. In this study, we examined the relationships between melanin content and DNA damage induced by UV exposure in situ in normal human skin of different racial/ethnic groups, phototypes, and UV sensitivities. The minimal erythema dose (MED) was established for each subject exposed to UVA/UVB radiation, and skin was biopsied before as well as 7 min, 1 day, and 1 wk after UV exposure. There was great variation among individuals in the amount of DNA damage incurred and rates of its removal. The results show that after exposure to 1 MED of UV, the skin of subjects from all groups suffered significant DNA damage, and that increasing content of constitutive melanin inversely correlated with the amount of DNA damage. It is clear from these results that measured erythemal UV sensitivity of the skin (MED) is a more useful predictor of DNA photodamage than is racial/ethnic origin or skin phototype and that rates of DNA damage removal following UV radiation may be the critical determinant of the UV sensitivity (including predisposition to cancer) of the skin.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Devices & Radiol Hlth, Rockville, MD 20852 USA; Fujita Hlth Univ, Sch Hlth Sci, Dept Chem, Aichi 4701192, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); Fujita Health University	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Room 1B25, Bethesda, MD 20892 USA.	hearingv@nih.gov	Yamaguchi, Yuji/X-6681-2019; Wakamatsu, Kazumasa/AAZ-5877-2020; Yamaguchi, Yuji/B-9312-2008	Wakamatsu, Kazumasa/0000-0003-1748-9001; Ito, Shosuke/0000-0001-9182-5144; Yamaguchi, Yuji/0000-0003-4338-2662	DIVISION OF BASIC SCIENCES - NCI [Z01BC009100] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Malek Z, 2000, PIGM CELL RES, V13, P156, DOI 10.1034/j.1600-0749.13.s8.28.x; Bancroft J.D., 1996, THEORY PRACTICE HIST, VVolume 6; BARKER D, 1995, CANCER RES, V55, P4041; Black HS, 1997, J PHOTOCH PHOTOBIO B, V40, P29, DOI 10.1016/S1011-1344(97)00021-3; Bykov VJ, 2000, J INVEST DERMATOL, V114, P40, DOI 10.1046/j.1523-1747.2000.00821.x; Bykov VJ, 1999, J INVEST DERMATOL, V112, P326, DOI 10.1046/j.1523-1747.1999.00523.x; CARSBERG CJ, 1994, J CELL SCI, V107, P2591; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; De Leeuw SM, 2001, J PHOTOCH PHOTOBIO B, V61, P106, DOI 10.1016/S1011-1344(01)00168-3; DUMAZ N, 1993, P NATL ACAD SCI USA, V90, P10529, DOI 10.1073/pnas.90.22.10529; Duval C, 2001, PIGM CELL RES, V14, P348, DOI 10.1034/j.1600-0749.2001.140506.x; FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869; Funasaka Y, 1998, BRIT J DERMATOL, V139, P216; Gentil A, 1996, NUCLEIC ACIDS RES, V24, P1837, DOI 10.1093/nar/24.10.1837; HALABAN R, 1993, MELANOTROPIC PEPTIDE, P290; HALDER RM, 1995, CANCER, V75, P667, DOI 10.1002/1097-0142(19950115)75:2+<667::AID-CNCR2820751409>3.0.CO;2-I; Hearing VJ, 2000, PIGM CELL RES, V13, P23, DOI 10.1034/j.1600-0749.13.s8.7.x; Hemminki K, 2002, CARCINOGENESIS, V23, P605, DOI 10.1093/carcin/23.4.605; ITO S, 1985, ANAL BIOCHEM, V144, P527, DOI 10.1016/0003-2697(85)90150-2; Jemal A, 2000, JNCI-J NATL CANCER I, V92, P811, DOI 10.1093/jnci/92.10.811; KOBAYASHI N, 1993, J INVEST DERMATOL, V101, P685, DOI 10.1111/1523-1747.ep12371676; Kobayashi N, 1998, J INVEST DERMATOL, V110, P806, DOI 10.1046/j.1523-1747.1998.00178.x; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; KRICKER A, 1994, CANCER CAUSE CONTROL, V5, P367, DOI 10.1007/BF01804988; Langley RGB, 1997, CANCER INVEST, V15, P561, DOI 10.3109/07357909709047598; LAWRENCE CW, 1993, MUTAT RES, V299, P157, DOI 10.1016/0165-1218(93)90093-S; MARKS R, 1995, CANCER-AM CANCER SOC, V75, P607, DOI 10.1002/1097-0142(19950115)75:2+<607::AID-CNCR2820751402>3.0.CO;2-8; Miller SA, 2002, BIOLOGIC EFFECTS OF LIGHT 2001, P113; MONTAGNA W, 1972, PIGMENTATION ITS GEN, P1; MURAMATSU T, 1992, ARCH DERMATOL RES, V284, P232, DOI 10.1007/BF00375800; Nordlund J.J., 1998, PIGMENTARY SYSTEM PH, V1st; PATHAK MA, 1971, BIOL NORMAL ABNORMAL, P149; PRESTON DS, 1992, NEW ENGL J MED, V327, P1649, DOI 10.1056/NEJM199212033272307; Prota G, 1997, PIGM CELL RES, V10, P5, DOI 10.1111/j.1600-0749.1997.tb00460.x; Rozanowska M, 1999, FREE RADICAL BIO MED, V26, P518, DOI 10.1016/S0891-5849(98)00234-2; SETLOW RB, 1978, NATURE, V271, P713, DOI 10.1038/271713a0; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; Smit NPM, 2001, PHOTOCHEM PHOTOBIOL, V74, P424, DOI 10.1562/0031-8655(2001)074<0424:MOPAIO>2.0.CO;2; STRICKLAND PT, 1988, PHOTODERMATOLOGY, V5, P166; Tada A, 1998, CELL GROWTH DIFFER, V9, P575; TADOKORO T, 2002, UV INDUCED MELANOGEN, P67; Virador VM, 2001, FASEB J, V15, P105, DOI 10.1096/fj.01-0518fje; VITASA BC, 1990, CANCER, V65, P2811, DOI 10.1002/1097-0142(19900615)65:12<2811::AID-CNCR2820651234>3.0.CO;2-U; Wakamatsu K, 2002, PIGM CELL RES, V15, P174, DOI 10.1034/j.1600-0749.2002.02017.x; Wakamatsu K, 2002, PIGM CELL RES, V15, P225, DOI 10.1034/j.1600-0749.2002.02009.x; YOUNG AR, 1991, J INVEST DERMATOL, V97, P942, DOI 10.1111/1523-1747.ep12491807; Zeise L, 1995, MELANIN: ITS ROLE IN HUMAN PHOTOPROTECTION, P65; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	48	237	248	1	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1177	+		10.1096/fj.02-0865fje	http://dx.doi.org/10.1096/fj.02-0865fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692083				2022-12-28	WOS:000182580100042
J	Delgado, M; Ganea, D				Delgado, M; Ganea, D			Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation	FASEB JOURNAL			English	Article						neurodegeneration; microglia; inflammation; MPTP neurotoxicity	NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; DOPAMINERGIC NEURODEGENERATION; INDUCED NEUROTOXICITY; ALPHA-SYNUCLEIN; TRANSGENIC MICE; MESSENGER-RNA; GLIAL-CELLS; RAT-BRAIN	Parkinson's disease (PD) is a common neurodegenerative disorder with no effective protective treatment, characterized by a massive degeneration of dopaminergic neurons in the substantia nigra (SNpc) and the subsequent loss of their projecting nerve fibers in the striatum. To elucidate PD pathogenic factors, and thus to develop therapeutic strategies, a murine PD model based on the administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been used extensively. It has been demonstrated that activated microglia cells actively participate in the pathogenesis of MPTP-induced PD through the release of cytotoxic factors. Because current treatments for PD are not effective, considerable research focused lately on a number of regulatory molecules termed microglia-deactivating factors. Vasoactive intestinal peptide (VIP), a neuropeptide with a potent anti-inflammatory effect, has been found to be protective in several inflammatory disorders. This study investigates the putative protective effect of VIP in the MPTP model for PD. VIP treatment significantly decreases MPTP-induced dopaminergic neuronal loss in SNpc and nigrostriatal nerve-fiber loss. VIP prevents MPTP-induced activation of microglia in SNpc and striatum and the expression of the cytotoxic mediators, iNOS, interleukin 1beta, and numor necrosis factor alpha. VIP emerges as a potential valuable neuroprotective agent for the treatment of pathologic conditions in the central nervous system, such as PD, where inflammation-induced neurodegeneration occurs.	Univ Complutense, Dept Cell Biol, Sch Biol, Fac Biol, E-28040 Madrid, Spain; Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA; CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada 18001, Spain	Complutense University of Madrid; Rutgers State University Newark; Rutgers State University New Brunswick; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Delgado, M (corresponding author), Univ Complutense, Dept Cell Biol, Sch Biol, Fac Biol, E-28040 Madrid, Spain.	mariodm@bio.ucm.es	Delgado, Mario/P-1524-2016	Delgado, Mario/0000-0003-1893-5982				Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; BEAL MF, 1990, NEUROSCI LETT, V108, P36; BLOEM BR, 1990, J NEUROL SCI, V97, P273, DOI 10.1016/0022-510X(90)90225-C; de Yebenes EG, 1999, J NEUROCHEM, V73, P812, DOI 10.1046/j.1471-4159.1999.0730812.x; Dehmer T, 2000, J NEUROCHEM, V74, P2213, DOI 10.1046/j.1471-4159.2000.0742213.x; Delgado M, 2003, J LEUKOCYTE BIOL, V73, P155, DOI 10.1189/jlb.0702372; Delgado M, 1999, J IMMUNOL, V162, P1200; Delgado M, 2002, J MOL MED, V80, P16, DOI 10.1007/s00109-001-0291-5; Delgado M, 2002, GLIA, V39, P148, DOI 10.1002/glia.10098; Delgado M, 2001, NAT MED, V7, P563, DOI 10.1038/87887; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Gomariz RP, 2001, CURR PHARM DESIGN, V7, P89, DOI 10.2174/1381612013398374; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Grunblatt E, 2001, J NEUROCHEM, V78, P1, DOI 10.1046/j.1471-4159.2001.00397.x; Grunblatt E, 2000, J NEUROL, V247, P95; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Hulley P, 1995, EUR J NEUROSCI, V7, P2431, DOI 10.1111/j.1460-9568.1995.tb01041.x; Hunot S, 1999, J NEUROSCI, V19, P3440; JAVITCH JA, 1983, EUR J PHARMACOL, V90, P461, DOI 10.1016/0014-2999(83)90574-5; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; KINDT MV, 1987, J PHARMACOL EXP THER, V242, P858; Klevenyi P, 1999, NEUROREPORT, V10, P635, DOI 10.1097/00001756-199902250-00035; Kohutnicka M, 1998, IMMUNOPHARMACOLOGY, V39, P167, DOI 10.1016/S0162-3109(98)00022-8; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KRIEGLSTEIN K, 1995, EMBO J, V14, P736, DOI 10.1002/j.1460-2075.1995.tb07052.x; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Liberatore GT, 1999, NAT MED, V5, P1403; LIPTON JM, 1993, NEUROBIOLOGY CYTOK B, P61; McGeer PL, 2001, ADV NEUROL, V86, P83; MIZUNO Y, 1995, BBA-MOL BASIS DIS, V1271, P265, DOI 10.1016/0925-4439(95)00038-6; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; Pennathur S, 1999, J BIOL CHEM, V274, P34621, DOI 10.1074/jbc.274.49.34621; Pozo D, 2000, IMMUNOL TODAY, V21, P7, DOI 10.1016/S0167-5699(99)01525-X; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Przedborski S, 2001, J NEUROCHEM, V76, P637, DOI 10.1046/j.1471-4159.2001.00174.x; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; PRZEDBORSKI S, 1998, MOV DISORD S, V13, P135; PRZEDBORSKI S, 2000, OXIDAT STRESS DIS, V5, P273; Quan N, 1998, NEUROSCIENCE, V83, P281, DOI 10.1016/S0306-4522(97)00350-3; Rajora N, 1997, J NEUROSCI, V17, P2181; RODNITZKY RL, 1995, NEUROSCIENCE MED, P417; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SCHULZ JB, 1995, J NEUROCHEM, V64, P936, DOI 10.1046/j.1471-4159.1995.64020936.x; SRIRAM K, 2002, FASEB J; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; WHITFIELD HJ, 1990, CELL MOL NEUROBIOL, V10, P145, DOI 10.1007/BF00733641; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629	52	139	154	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					944	+		10.1096/fj.02-0799fje	http://dx.doi.org/10.1096/fj.02-0799fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626429				2022-12-28	WOS:000181892600029
J	Zhang, JH; Li, W; Sanders, MA; Sumpio, BE; Panja, A; Basson, MD				Zhang, JH; Li, W; Sanders, MA; Sumpio, BE; Panja, A; Basson, MD			Regulation of the intestinal epithelial response to cyclic strain by extracellular matrix proteins	FASEB JOURNAL			English	Article						deformation; enterocyte; fibronectin; FAK; integrin; MAPK	EPIDERMAL-GROWTH-FACTOR; FOCAL ADHESION KINASE; SMOOTH-MUSCLE-CELLS; MECHANICAL STRAIN; SMALL-BOWEL; ENDOTHELIAL-CELLS; BRUSH-BORDER; DNA-SYNTHESIS; FIBRONECTIN; INTEGRIN	Repetitive mechanical deformation may stimulate intestinal epithelial proliferation. Because the extracellular matrix modulates static intestinal epithelial biology, we examined whether matrix proteins influence intestinal epithelial responses to deformation. Human Caco-2(BBE) cells and nontransformed human enterocytes (HIPEC) were subjected to 10% average cyclic strain at 10 cycles/min on flexible membranes precoated with matrix proteins without or with plasma fibronectin or functional anti-integrin antibodies in the medium. Strain stimulated proliferation, focal adhesion kinase, extracellular signal-regulated protein kinase (ERK), p38, and Jun N-terminal kinase similarly on collagen I or IV, and more weakly on laminin, but had no effect on fibronectin. MEK blockade (PD98059) prevented strain-stimulated proliferation on collagen but did not affect proliferation on fibronectin. Adding tissue fibronectin to a collagen substrate or plasma fibronectin to the media suppressed strain's mitogenic and signal effects, but not those of epidermal growth factor. Functional antibodies to the alpha5 or alphav integrin subunit blocked strain's effects on Caco-2 proliferation and ERK activation, although ligation of the alpha2 or alpha6 subunit did not. Repetitive strain also stimulated, and fibronectin inhibited, human intestinal primary epithelial cell proliferation. Repetitive deformation stimulates transformed and nontransformed human intestinal epithelial proliferation in a matrix-dependent manner. Tissue or plasma fibronectin may regulate the intestinal epithelial response to strain via integrins containing alpha5 or alphav.	John D Dingell VA Med Ctr, Dept Surg, Detroit, MI 48201 USA; Wayne State Univ, Dept Surg, Detroit, MI 48202 USA; Yale Univ, New Haven, CT 06520 USA; Tianjin Med Univ, Canc Hosp, Tianjin, Peoples R China; W Haven VA Hosp, West Haven, CT USA; SUNY Albany, Dept Med, Albany, NY 12246 USA	Wayne State University; Yale University; Tianjin Medical University; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Basson, MD (corresponding author), John D Dingell VA Med Ctr, Dept Surg, 4646 John R St, Detroit, MI 48201 USA.	Marc.Basson@med.va.gov						Basson MD, 1996, J CELL PHYSIOL, V168, P476, DOI 10.1002/(SICI)1097-4652(199608)168:2<476::AID-JCP26>3.0.CO;2-#; Basson MD, 1996, EXP CELL RES, V225, P301, DOI 10.1006/excr.1996.0180; Basson MD, 2002, METABOLISM, V51, P1525, DOI 10.1053/meta.2002.36303; BASSON MD, 1992, J CLIN INVEST, V90, P15, DOI 10.1172/JCI115828; Basson MD, 2000, CELL PHYSIOL BIOCHEM, V10, P27, DOI 10.1159/000016332; BASSON MD, 2000, J GI SURG, V4, P435; Beaulieu JF, 1997, PROG HISTOCHEM CYTOC, V31, P1; DEVRIES JE, 1986, INT J CANCER, V38, P465, DOI 10.1002/ijc.2910380403; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; EMENAKER NJ, 1998, SURG FORUM, V49, P612; FALLINGBORG J, 1985, SCAND J GASTROENTERO, V20, P1062, DOI 10.3109/00365528509088872; FELDMAN EJ, 1976, GASTROENTEROLOGY, V70, P712; FRIEDMAN HI, 1977, ANAT RECORD, V188, P77, DOI 10.1002/ar.1091880109; Gahtan V, 1999, J VASC SURG, V29, P1031, DOI 10.1016/S0741-5214(99)70244-2; Gong JG, 1998, J BIOL CHEM, V273, P1662, DOI 10.1074/jbc.273.3.1662; HALLDEN G, 1994, AM J PHYSIOL-GASTR L, V267, pG730, DOI 10.1152/ajpgi.1994.267.4.G730; Han OH, 1998, AM J PHYSIOL-GASTR L, V275, pG534, DOI 10.1152/ajpgi.1998.275.3.G534; Hipper A, 2000, PFLUG ARCH EUR J PHY, V440, P19, DOI 10.1007/s004240000246; Ikeda M, 1999, AM J PHYSIOL-HEART C, V276, pH614; INOUE Y, 1993, JPEN-PARENTER ENTER, V17, P165, DOI 10.1177/0148607193017002165; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; Kosmehl H, 1996, VIRCHOWS ARCH, V429, P311; KOUKOULIS GK, 1993, VIRCHOWS ARCH B, V63, P373, DOI 10.1007/BF02899286; Kozlova NI, 2001, ONCOGENE, V20, P4710, DOI 10.1038/sj.onc.1204619; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Li W, 2001, AM J PHYSIOL-GASTR L, V280, pG75, DOI 10.1152/ajpgi.2001.280.1.G75; Liang FQ, 2000, J BIOL CHEM, V275, P20355, DOI 10.1074/jbc.M001660200; Liang H, 2000, MED BIOL ENG COMPUT, V38, P35, DOI 10.1007/BF02344686; LICHTENBERGER LM, 1979, AM J PHYSIOL, V237, pE98, DOI 10.1152/ajpendo.1979.237.1.E98; LOUVARD D, 1992, ANNU REV CELL BIOL, V8, P157, DOI 10.1146/annurev.cb.08.110192.001105; Lussier C, 2000, MICROSC RES TECHNIQ, V51, P169; Malik A K, 1992, Indian J Pathol Microbiol, V35, P88; Matsuda N, 1998, BIOCHEM BIOPH RES CO, V249, P350, DOI 10.1006/bbrc.1998.9151; MATSUDA T, 1983, JPN J CLIN ONCOL, V13, P327; MAYHEW TM, 1990, J ELECTRON MICR TECH, V16, P45, DOI 10.1002/jemt.1060160107; MCNEIL PL, 1989, GASTROENTEROLOGY, V96, P1238, DOI 10.1016/S0016-5085(89)80010-1; MIFTAKHOV RN, 1994, MED ENG PHYS, V16, P406, DOI 10.1016/1350-4533(90)90007-U; OTTERSON MF, 1993, SURG CLIN N AM, V73, P1173; Panja A, 2000, LAB INVEST, V80, P1473, DOI 10.1038/labinvest.3780154; PETERSON MD, 1992, J CELL SCI, V102, P581; Pillai RB, 1999, DIGEST DIS SCI, V44, P1565, DOI 10.1023/A:1026654725101; POLIN RA, 1990, REV INFECT DIS, V12, pS428; Rebres RA, 1996, AM J PHYSIOL-LUNG C, V271, pL409, DOI 10.1152/ajplung.1996.271.3.L409; Reusch HP, 1997, BIOCHEM BIOPH RES CO, V237, P239, DOI 10.1006/bbrc.1997.7121; Reusch P, 1996, CIRC RES, V79, P1046, DOI 10.1161/01.RES.79.5.1046; Sanders MA, 2000, J BIOL CHEM, V275, P38040, DOI 10.1074/jbc.M003871200; SCHWARZBAUER JE, 1991, BIOESSAYS, V13, P527, DOI 10.1002/bies.950131006; Seko Y, 1999, BIOCHEM BIOPH RES CO, V259, P8, DOI 10.1006/bbrc.1999.0720; SHIRAKAMI A, 1986, HORM METAB RES, V18, P345, DOI 10.1055/s-2007-1012311; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; TASMANJONES C, 1982, DIGEST DIS SCI, V27, P519, DOI 10.1007/BF01296731; TUCKER RP, 1994, PERSPECT DEV NEUROBI, V2, P1; TUTTON PJM, 1976, VIRCHOWS ARCH B, V20, P139; Wang DS, 2001, ENDOTHELIUM-NEW YORK, V8, P283, DOI 10.3109/10623320109090806; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WILLIAMSON RCN, 1978, NEW ENGL J MED, V298, P1393, DOI 10.1056/NEJM197806222982505; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; WOMACK WA, 1987, AM J PHYSIOL, V252, pG250, DOI 10.1152/ajpgi.1987.252.2.G250; Wozniak M, 2000, J BONE MINER RES, V15, P1731, DOI 10.1359/jbmr.2000.15.9.1731; Xu RJ, 1996, REPROD FERT DEVELOP, V8, P35, DOI 10.1071/RD9960035; Yano Y, 1996, AM J PHYSIOL-CELL PH, V271, pC635, DOI 10.1152/ajpcell.1996.271.2.C635; Yokosaki Y, 1996, J BIOL CHEM, V271, P24144, DOI 10.1074/jbc.271.39.24144; Yu CF, 2000, AM J PHYSIOL-GASTR L, V278, pG952, DOI 10.1152/ajpgi.2000.278.6.G952; Yun JK, 1999, TISSUE ENG, V5, P67, DOI 10.1089/ten.1999.5.67	65	58	60	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					926	+		10.1096/fj.02-0663fje	http://dx.doi.org/10.1096/fj.02-0663fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626437				2022-12-28	WOS:000181892600026
J	El-Kholy, W; MacDonald, PE; Lin, JH; Wang, J; Fox, JM; Light, PE; Wang, QH; Tsushima, RG; Wheeler, MB				El-Kholy, W; MacDonald, PE; Lin, JH; Wang, J; Fox, JM; Light, PE; Wang, QH; Tsushima, RG; Wheeler, MB			The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks Kv currents via a direct mechanism	FASEB JOURNAL			English	Article						insulin secretion; beta cells; Kv channels; whole-cell and excised patch configuration; sustained and peak currents; activation and inactivation time constants	PANCREATIC BETA-CELLS; INSULIN-SECRETION; K+ CHANNELS; PHOSPHOINOSITIDE 3-KINASE; DNA-SYNTHESIS; ATP CHANNELS; GLUCOSE; WORTMANNIN; KINASE; SENSITIVITY	Voltage-dependent K+ (Kv) channels negatively regulate Ca2+ entry into pancreatic beta-cells by repolarizing glucose-stimulated action potentials. A role for phosphatidylinositol 3-kinase (PI3K) modulation of Kv channel function was investigated using the PI3K inhibitors wortmannin and LY294002, and LY303511, a negative control compound with respect to PI3K activity. In MIN6 insulinoma cells, wortmannin (100 nM) had no effect on whole-cell outward K+ currents, but LY294002 and LY303511 reversibly blocked currents in a dose-dependent manner (IC50=9.0+/-0.7 muM and 64.6+/-9.1 muM, respectively). Western blotting confirmed the specific inhibitory effects of LY294002 and wortmannin on insulin-stimulated PI3K activity. Kv currents in rat beta-cells at near physiological temperatures were inhibited 92% by 25 muM LY294002. Kv2.1 and Kv1.4 are highly expressed in beta-cells, and in Kv2.1-transfected tsA201 cells, 50 muM LY294002 and 100 muM LY303511 reversibly inhibited currents by 99% and 41%, respectively. In Kv1.4-transfected tsA201 cells, 50 muM LY294002 reduced the inactivation time constant from 73 to 18 ms. The insulinotropic properties of LY294002 and its effects in other excitable cells may be caused by inhibition of Kv currents rather than PI3K antagonism. Furthermore, LY294002 may represent a novel structure from which future Kv channel blockers may be developed.	Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Physiol, Toronto, ON, Canada; Univ Alberta, Dept Pharmacol, Edmonton, AB, Canada; St Michaels Hosp, Div Endocrinol & Metab, Toronto, ON M5B 1W8, Canada	University of Toronto; University of Toronto; University of Alberta; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Wheeler, MB (corresponding author), Univ Toronto, Dept Physiol 1, Kings Coll Circle,RM 3352, Toronto, ON M5S 1A8, Canada.	michael.wheeler@utoronto.ca	MacDonald, Patrick/A-4154-2008	MacDonald, Patrick/0000-0002-5439-6288; Wheeler, Michael B./0000-0002-7480-7267				Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; DA S, 2000, J BIOL CHEM, V275, P36269; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dickson LM, 2001, J BIOL CHEM, V276, P21110, DOI 10.1074/jbc.M101257200; Dukes ID, 1996, DIABETES, V45, P845, DOI 10.2337/diabetes.45.7.845; Ethier MF, 2002, CELL CALCIUM, V32, P31, DOI 10.1016/S0143-4160(02)00111-2; Eto K, 2002, DIABETES, V51, P87, DOI 10.2337/diabetes.51.1.87; Gopel SO, 2000, J PHYSIOL-LONDON, V528, P497, DOI 10.1111/j.1469-7793.2000.00497.x; HAGIWARA S, 1995, BIOCHEM BIOPH RES CO, V214, P51, DOI 10.1006/bbrc.1995.2255; Harvey JA, 2000, J HIGH ENERGY PHYS; Henquin J C, 1980, Horm Metab Res Suppl, VSuppl 10, P66; HENQUIN JC, 1977, BIOCHEM BIOPH RES CO, V77, P551, DOI 10.1016/S0006-291X(77)80014-4; HERCHUELZ A, 1980, J PHARMACOL EXP THER, V215, P213; Khan FA, 2001, DIABETES, V50, P2192, DOI 10.2337/diabetes.50.10.2192; LIGHT PE, MOL ENDOCRINOL, V169, P2135; MacDonald PE, 2002, J BIOL CHEM, V277, P44938, DOI 10.1074/jbc.M205532200; MacDonald PE, 2001, MOL ENDOCRINOL, V15, P1423, DOI 10.1210/me.15.8.1423; Macica CM, 2001, J NEUROSCI, V21, P1160; POWIS G, 1994, CANCER RES, V54, P2419; Roper MG, 2002, DIABETES, V51, pS43, DOI 10.2337/diabetes.51.2007.S43; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; ROUZAIREDUBOIS B, 1993, PFLUG ARCH EUR J PHY, V423, P202, DOI 10.1007/BF00374395; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wu RL, 1998, J NEUROSCI, V18, P6261; Wymann MP, 1996, MOL CELL BIOL, V16, P1722	30	65	68	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					720	+		10.1096/fj.02-0802fje	http://dx.doi.org/10.1096/fj.02-0802fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586735				2022-12-28	WOS:000181456900024
J	Kieffer, AE; Goumon, Y; Ruh, O; Chasserot-Golaz, S; Nullans, G; Gasnier, C; Aunis, D; Metz-Boutigue, MH				Kieffer, AE; Goumon, Y; Ruh, O; Chasserot-Golaz, S; Nullans, G; Gasnier, C; Aunis, D; Metz-Boutigue, MH			The N- and C-terminal fragments of ubiquitin are important for the antimicrobial activities	FASEB JOURNAL			English	Article						chromaffin cells; calmodulin; calcineurin activity	MEDULLARY CHROMAFFIN GRANULES; FLIGHT MASS-SPECTROMETRY; BOVINE ADRENAL-MEDULLA; CHROMOGRANIN-A; INNATE IMMUNITY; ANTIBACTERIAL ACTIVITY; PROTEIN-DEGRADATION; NEUROSPORA-CRASSA; SUBSTRATE-SPECIFICITY; POSSIBLE INVOLVEMENT	Secretory granules of chromaffin cells contain catecholamines and several antimicrobial peptides derived from chromogranins and proenkephalin-A. These peptides are secreted in the extracellular medium following exocytosis. Here, we show that ubiquitin is stored in secretory chromaffin granules and released into the circulation upon stimulation of chromaffin cells. We also show that the C-terminal fragment (residues 65-76) of ubiquitin displays, at the micromolar range, a lytic antifungal activity. Using confocal laser scan microscopy and rhodamine-labeled synthetic peptides, we could demonstrate that the C-terminal peptide (residues 65-76) is able to cross the cell wall and the plasma membrane of fungi and to accumulate in fungi, whereas the N-terminal peptide (residues 1-34) is stopped at the fungal wall level. Furthermore, these two peptides act synergistically to kill filamentous fungi. Because of the interaction of the C-terminal sequence of ubiquitin with calmodulin, the synthetic peptide (residues 65-76) was tested in vitro against calmodulin-dependent calcineurin, an enzyme crucial for fungal growth. This peptide was found to inhibit the phosphatase activity of calcineurin. Our data show a new property of ubiquitin C-terminal-derived peptide (65-76) that could be used with N-terminal peptide (1-34) as a new potent antifungal agent.	INSERM, U575, IFR 37, F-67084 Strasbourg, France; CNRS, UPR 2356, IFR 37, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Metz-Boutigue, MH (corresponding author), INSERM, U575, IFR 37, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	metz@neurochem.u-strasbg.fr	Chasserot-Golaz, Sylvette/K-7625-2017; Dominique, Aunis/W-1419-2019	Goumon, Yannick/0000-0003-4336-3437; Chasserot-Golaz, Sylvette/0000-0002-7437-2558				AGELL N, 1988, BIOCHEM J, V250, P883, DOI 10.1042/bj2500883; Ali MF, 2001, BBA-PROTEIN STRUCT M, V1550, P81, DOI 10.1016/S0167-4838(01)00272-2; ALIZADEHKHIAVI K, 1992, VIRCHOWS ARCH A, V420, P139, DOI 10.1007/BF02358805; ASKANAS V, 1991, NEUROSCI LETT, V130, P73, DOI 10.1016/0304-3940(91)90230-Q; ASSEMAN C, 1994, J IMMUNOL METHODS, V173, P93, DOI 10.1016/0022-1759(94)90286-0; Aunis D, 1998, INT REV CYTOL, V181, P213, DOI 10.1016/S0074-7696(08)60419-2; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOND U, 1988, J BIOL CHEM, V263, P2384; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI 10.1016/j.chiabu.2021.105188; BULET P, 1993, J BIOL CHEM, V268, P14893; CARLSON N, 1987, J CELL BIOL, V104, P547, DOI 10.1083/jcb.104.3.547; COX MJ, 1986, ANAL BIOCHEM, V154, P345, DOI 10.1016/0003-2697(86)90535-X; Daino H, 1996, BIOCHEM BIOPH RES CO, V223, P226, DOI 10.1006/bbrc.1996.0875; de Lucca AJ, 1999, ANTIMICROB AGENTS CH, V43, P1, DOI 10.1093/jac/43.1.1; Doskeland AP, 2002, EUR J BIOCHEM, V269, P1561, DOI 10.1046/j.1432-1033.2002.02808.x; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Fox DS, 2001, MOL MICROBIOL, V39, P835, DOI 10.1046/j.1365-2958.2001.02295.x; GALINDO E, 1991, J NEUROENDOCRINOL, V3, P669, DOI 10.1111/j.1365-2826.1991.tb00332.x; Glick BS, 2000, CURR OPIN CELL BIOL, V12, P450, DOI 10.1016/S0955-0674(00)00116-2; Goumon Y, 2000, J BIOL CHEM, V275, P38355, DOI 10.1074/jbc.M007557200; Goumon Y, 1996, EUR J BIOCHEM, V235, P516, DOI 10.1111/j.1432-1033.1996.t01-1-00516.x; Goumon Y, 1998, J BIOL CHEM, V273, P29847, DOI 10.1074/jbc.273.45.29847; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; Harvey KF, 2002, J BIOL CHEM, V277, P9307, DOI 10.1074/jbc.M110443200; HAYASHI T, 1993, BRAIN RES, V620, P171, DOI 10.1016/0006-8993(93)90288-X; HELLE KB, 1971, BIOCHIM BIOPHYS ACTA, V245, P80, DOI 10.1016/0005-2728(71)90010-7; HENSOLD JO, 1988, BLOOD, V71, P1153; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoffmann JA, 1996, CURR OPIN IMMUNOL, V8, P8, DOI 10.1016/S0952-7915(96)80098-7; HORTNAGL H, 1974, J NEUROCHEM, V22, P197, DOI 10.1111/j.1471-4159.1974.tb12201.x; ISHIBASHI Y, 1991, BRIT J CANCER, V63, P320, DOI 10.1038/bjc.1991.75; JAHNGEN JH, 1990, ARCH BIOCHEM BIOPHYS, V276, P32, DOI 10.1016/0003-9861(90)90006-K; Javadpour MM, 1996, J MED CHEM, V39, P3107, DOI 10.1021/jm9509410; JENNISSEN HP, 1992, FEBS LETT, V296, P51, DOI 10.1016/0014-5793(92)80401-2; Kano R, 1999, CURR MICROBIOL, V39, P302, DOI 10.1007/s002849900463; Kawakami T, 1999, J BIOCHEM, V126, P612, DOI 10.1093/oxfordjournals.jbchem.a022493; KELNER KL, 1985, J NEUROSCI, V5, P2161; KENT C, 1989, J ANAT, V166, P213; KUDO T, 1994, BRAIN RES, V639, P1, DOI 10.1016/0006-8993(94)91757-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laub M, 1998, EUR J BIOCHEM, V255, P422, DOI 10.1046/j.1432-1327.1998.2550422.x; LOWE J, 1993, BRAIN PATHOL, V3, P55, DOI 10.1111/j.1750-3639.1993.tb00726.x; Lugardon K, 2000, J BIOL CHEM, V275, P10745, DOI 10.1074/jbc.275.15.10745; Lugardon K, 2001, J BIOL CHEM, V276, P35875, DOI 10.1074/jbc.M104670200; MANAKA H, 1992, NEUROSCI LETT, V139, P47, DOI 10.1016/0304-3940(92)90854-Z; MARTIN B, 1985, J BIOL CHEM, V260, P4932; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Metz-Boutigue MH, 1998, CELL MOL NEUROBIOL, V18, P249, DOI 10.1023/A:1022573004910; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; MOR A, 1994, J BIOL CHEM, V269, P31635; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; Nabika T, 1999, BBA-MOL CELL RES, V1450, P25, DOI 10.1016/S0167-4889(99)00024-5; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; OKADA M, 1993, CLIN CHIM ACTA, V220, P135, DOI 10.1016/0009-8981(93)90042-3; PARAG HA, 1987, EMBO J, V6, P55, DOI 10.1002/j.1460-2075.1987.tb04718.x; Prokisch H, 1997, MOL GEN GENET, V256, P104, DOI 10.1007/s004380050551; Reggiori F, 2002, NAT CELL BIOL, V4, P117, DOI 10.1038/ncb743; SCHLESINGER DH, 1975, BIOCHEMISTRY-US, V14, P2214, DOI 10.1021/bi00681a026; SCHLESINGER DH, 1975, NATURE, V255, P42304; Sepulveda P, 1996, J MED VET MYCOL, V34, P315; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; SMITH AD, 1967, BIOCHEM J, V103, P483, DOI 10.1042/bj1030483; Strub JM, 1996, J BIOL CHEM, V271, P28533, DOI 10.1074/jbc.271.45.28533; STRUB JM, 1995, EUR J BIOCHEM, V229, P356, DOI 10.1111/j.1432-1033.1995.0356k.x; Suresh K, 1997, FEMS MICROBIOL LETT, V150, P95, DOI 10.1016/S0378-1097(97)00103-1; TACCIOLI GE, 1989, NUCLEIC ACIDS RES, V17, P6153, DOI 10.1093/nar/17.15.6153; Takada K, 1997, CLIN CHEM, V43, P1188; Towbin H, 1992, Biotechnology, V24, P145; VIJAYKUMAR S, 1985, P NATL ACAD SCI USA, V82, P3582, DOI 10.1073/pnas.82.11.3582; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; VORM O, 1994, J AM SOC MASS SPECTR, V5, P955, DOI 10.1016/1044-0305(94)80013-8; Wang B, 1993, Hua Xi Yi Ke Da Xue Xue Bao, V24, P127; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu MH, 1999, J BIOL CHEM, V274, P29, DOI 10.1074/jbc.274.1.29; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; ZASLOFF M, 1992, CURR OPIN IMMUNOL, V4, P3, DOI 10.1016/0952-7915(92)90115-U; ZIEGENHAGEN R, 1990, FEBS LETT, V273, P253, DOI 10.1016/0014-5793(90)81097-8	81	78	78	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					776	+		10.1096/fj.02-0699fje	http://dx.doi.org/10.1096/fj.02-0699fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594174				2022-12-28	WOS:000181456900010
J	Micchelli, CA; Esler, WP; Kimberly, WT; Jack, C; Berezovska, O; Kornilova, A; Hyman, BT; Perrimon, N; Wolfe, MS				Micchelli, CA; Esler, WP; Kimberly, WT; Jack, C; Berezovska, O; Kornilova, A; Hyman, BT; Perrimon, N; Wolfe, MS			gamma-secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila	FASEB JOURNAL			English	Article						protease; developmental biology; drug screening	SECRETASE INHIBITORS; TRANSMEMBRANE ASPARTATES; THYMOCYTE DEVELOPMENT; INTRACELLULAR DOMAIN; WINGLESS EXPRESSION; PRESENILIN-1; GENE; PROTEASE; SIGNAL; INTEGRATION	Signaling from the Notch (N) receptor is essential for proper cell-fate determinations and tissue patterning in all metazoans. N signaling requires a presenilin (PS)-dependent transmembrane-cleaving activity that is closely related or identical to the gamma-secretase proteolysis of the amyloid-beta precursor protein (APP) involved in Alzheimer's disease pathogenesis. Here, we show that N-[N-(3,5-difluorophenacetyl)-L-alanyl]-(S)-phenylglycine t-butyl ester, a potent gamma-secretase inhibitor reported to reduce amyloid-beta levels in transgenic mice, prevents N processing, translocation, and signaling in cell culture. This compound also induces developmental defects in Drosophila remarkably similar to those caused by genetic reduction of N. The appearance of this phenocopy depends on the timing and dose of compound exposure, and effects on N-dependent signaling molecules established its biochemical mechanism of action in vivo. Other gamma-secretase inhibitors caused similar effects. Thus, the three-dimensional structure of the drug-binding site(s) in Drosophila gamma-secretase is remarkably conserved vis-a-vis the same site(s) in the mammalian enzyme. These results show that genetics and developmental biology can help elucidate the in vivo site of action of pharmacological agents and suggest that organisms such as Drosophila may be used as simple models for in vivo prescreening of drug candidates.	Harvard Univ, Ctr Neurol Dis, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Dept Genet, Howard Hughes Med Inst, Sch Med, Boston, MA 02115 USA; Harvard Univ, Dept Neurol, Massachusetts Gen Hosp, Alzheimers Dis Res Lab,Sch Med, Charlestown, MA 02129 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital	Wolfe, MS (corresponding author), Harvard Univ, Ctr Neurol Dis, Brigham & Womens Hosp, Sch Med, 77 Ave Louis Pasteur,HIM 626, Boston, MA 02115 USA.	mwolfe@rics.bwh.harvard.edu	Jack, Clifford R/F-2508-2010	Jack, Clifford R/0000-0001-7916-622X; Perrimon, Norbert/0000-0001-7542-472X				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 2001, CURR OPIN HEMATOL, V8, P237, DOI 10.1097/00062752-200107000-00010; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Berezovska O, 2000, J NEUROCHEM, V75, P583, DOI 10.1046/j.1471-4159.2000.0750583.x; Blair SS, 2000, DROSOPHILA PROTOCOLS, P159; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DECELIS JF, 1994, MECH DEVELOP, V46, P109, DOI 10.1016/0925-4773(94)90080-9; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; GETMAN DP, 1993, J MED CHEM, V36, P288, DOI 10.1021/jm00054a014; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; KAUFFMANN RC, 1995, P NATL ACAD SCI USA, V92, P10919, DOI 10.1073/pnas.92.24.10919; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Klein T, 1998, DEVELOPMENT, V125, P2951; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; Presente A, 2001, NEUROREPORT, V12, P3321, DOI 10.1097/00001756-200110290-00035; Rubin GM, 2000, SCIENCE, V287, P2216, DOI 10.1126/science.287.5461.2216; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; WILLIAMS JA, 1994, NATURE, V368, P299, DOI 10.1038/368299a0; Wolfe MS, 2001, J MED CHEM, V44, P2039, DOI 10.1021/jm0004897; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096	44	126	131	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					79	+		10.1096/fj.02-0394fje	http://dx.doi.org/10.1096/fj.02-0394fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12424225				2022-12-28	WOS:000180218500042
J	Rosenkranz, S; Knirel, D; Dietrich, H; Flesch, M; Erdmann, E; Bohm, M				Rosenkranz, S; Knirel, D; Dietrich, H; Flesch, M; Erdmann, E; Bohm, M			Inhibition of the PDGF receptor by red wine flavonoids provides a molecular explanation for the "French paradox"	FASEB JOURNAL			English	Article						catechin; atherosclerosis; vascular smooth muscle cells	CORONARY HEART-DISEASE; E-DEFICIENT MICE; SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; BETA-RECEPTOR; NEOINTIMAL FORMATION; IN-VIVO; HUMAN PLASMA; ALCOHOL; ATHEROSCLEROSIS	The mortality rate from coronary artery disease (CAD) in France is similar to50% compared to other European countries and the United States ("French paradox"). Epidemiological studies indicate an inverse relationship between moderate wine consumption and CAD mortality. Here, we demonstrate that preincubation of vascular smooth muscle cells (VSMCs) with red wine, but not white wine, inhibits ligand binding and the subsequent tyrosine phosphorylation of the platelet-derived growth factor beta receptor (betaPDGFR), which plays a critical role in the pathogenesis of atherosclerosis. As a consequence, red wine abrogates the ligand-induced recruitment of betaPDGFR-associated signaling molecules (RasGAP, SHP-2, PI3K, PLCgamma), PDGF-dependent downstream events such as Erk activation and induction of immediate early genes, and VSMC proliferation and migration. Wine analysis revealed flavonoids of the catechin family as major constituents of red wine, and these were identified as potent inhibitors of betaPDGFR signaling. Importantly, the concentrations of red wine/catechins shown to inhibit the PDGFR in vitro correlate with the serum levels after red wine consumption in humans. We conclude that nonalcoholic constituents of red wine, which accumulate during the "mash fermentation," inhibit betaPDGFR activation and PDGF-dependent cellular responses in VSMCs. Therefore, catechin-mediated inhibition of betaPDGFR signaling offers a molecular explanation for the "French paradox."	Univ Cologne, Innere Med Klin 3, D-50924 Cologne, Germany; Univ Saarlandes Kliniken, Homburg, Germany	University of Cologne; Universitatsklinikum des Saarlandes	Rosenkranz, S (corresponding author), Univ Cologne, Innere Med Klin 3, Joseph Stelzmann Str 9, D-50924 Cologne, Germany.	Stephan.Rosenkranz@medizin.uni-koeln.de	Böhm, Michael/C-3638-2011					Abe J, 1998, HEART, V79, P400, DOI 10.1136/hrt.79.4.400; Ahn HY, 1999, MOL BIOL CELL, V10, P1093, DOI 10.1091/mbc.10.4.1093; American Heart Association, 2000, 2001 HEART STROK STA; Arts ICW, 2001, AM J CLIN NUTR, V74, P227; Banai S, 1998, CIRCULATION, V97, P1960, DOI 10.1161/01.CIR.97.19.1960; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Bell JRC, 2000, AM J CLIN NUTR, V71, P103; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Bilder G, 1999, CIRCULATION, V99, P3292, DOI 10.1161/01.CIR.99.25.3292; CHAMLEY JH, 1979, PHYSIOL REV, V39, P1; CRIQUI MH, 1994, LANCET, V344, P1719, DOI 10.1016/S0140-6736(94)92883-5; Davies MG, 2000, CIRC RES, V86, P779, DOI 10.1161/01.RES.86.7.779; Donovan JL, 1999, J NUTR, V129, P1662, DOI 10.1093/jn/129.9.1662; Feng AN, 1999, CIRCULATION, V100, P2254, DOI 10.1161/01.CIR.100.22.2254; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Fishbein I, 2000, ARTERIOSCL THROM VAS, V20, P667, DOI 10.1161/01.ATV.20.3.667; Flesch M, 1998, AM J PHYSIOL-HEART C, V275, pH1183, DOI 10.1152/ajpheart.1998.275.4.H1183; Flesch M, 2001, BASIC RES CARDIOL, V96, P128, DOI 10.1007/s003950170062; Goldberg IJ, 2001, CIRCULATION, V103, P472; Gronbaek M, 2000, ANN INTERN MED, V133, P411, DOI 10.7326/0003-4819-133-6-200009190-00008; GRONBAEK M, 1995, BRIT MED J, V310, P1165, DOI 10.1136/bmj.310.6988.1165; Hart CE, 1999, CIRCULATION, V99, P564, DOI 10.1161/01.CIR.99.4.564; HART CE, 1990, BIOCHEMISTRY-US, V29, P166, DOI 10.1021/bi00453a022; Hayek T, 1997, ARTERIOSCL THROM VAS, V17, P2744, DOI 10.1161/01.ATV.17.11.2744; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Iijima K, 2000, CIRCULATION, V101, P805, DOI 10.1161/01.CIR.101.7.805; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; Klatsky AL, 1997, AM J CARDIOL, V80, P416, DOI 10.1016/S0002-9149(97)00388-3; Klinghoffer RA, 2001, MOL CELL, V7, P343, DOI 10.1016/S1097-2765(01)00182-4; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; LINDNER V, 1995, AM J PATHOL, V146, P1488; Miura Y, 2001, J NUTR, V131, P27, DOI 10.1093/jn/131.1.27; Rechner A, 1998, DEUT LEBENSM-RUNDSCH, V94, P363; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; Rosenkranz S, 1999, J BIOL CHEM, V274, P28335, DOI 10.1074/jbc.274.40.28335; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Ruidavets JB, 2000, ATHEROSCLEROSIS, V153, P107, DOI 10.1016/S0021-9150(00)00377-4; Sano H, 2001, CIRCULATION, V103, P2955, DOI 10.1161/01.CIR.103.24.2955; Schwartz SM, 1997, J CLIN INVEST, V99, P2814, DOI 10.1172/JCI119472; Tanizawa S, 1996, HEART, V75, P549, DOI 10.1136/hrt.75.6.549; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VASSBOTN FS, 1992, J BIOL CHEM, V267, P15635	45	95	103	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1958	+		10.1096/fj.02-0207fje	http://dx.doi.org/10.1096/fj.02-0207fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397093				2022-12-28	WOS:000179167600011
J	Guo, L; Wu, CY				Guo, L; Wu, CY			Regulation of fibronectin matrix deposition and cell proliferation by the PINCH-ILK-CH-ILKBP complex	FASEB JOURNAL			English	Article						integrin-linked kinase; PINCH; CH-ILKBP; fibronectin	INTEGRIN-LINKED KINASE; FOCAL ADHESION PROTEIN; GLYCOGEN-SYNTHASE KINASE; EXTRACELLULAR-MATRIX; DIABETIC-NEPHROPATHY; CYTOPLASMIC DOMAIN; BINDING PROTEIN; GROWTH-FACTOR; LOCALIZATION; SITES	Alteration in renal glomerular mesangial cell growth and fibronectin matrix deposition is a hallmark of glomerulosclerosis, which ultimately leads to end-stage renal failure. We have previously shown that the expression of integrin-linked kinase (ILK), a cytoplasmic component of the cell-extracellular matrix contacts, is increased in mesangial cells in human patients with diabetic nephropathy. We show here that ILK forms a complex with PINCH and CH-ILKBP in primary mesangial cells, which are co-clustered at fibrillar adhesions, sites that are involved in fibronectin matrix deposition. To investigate functional significance of the PINCH-ILK-CH-ILKBP complex formation, we expressed the PINCH-binding N-terminal fragment and the CH-ILKBP-binding C-terminal fragment of ILK, respectively, in mesangial cells by using an adenoviral expression system. Overexpression of either the N-terminal fragment or the C-terminal fragment of ILK effectively inhibited the PINCH-ILK-CH-ILKBP complex formation. Inhibition of the PINCH-ILK-CH-ILKBP complex formation significantly reduced fibronectin matrix deposition and inhibited cell proliferation. These results indicate that the PINCH-ILK-CH-ILKBP complex is critically involved in the regulation of mesangial fibronectin matrix deposition and cell proliferation, and suggest that it may potentially serve as a useful target in the therapeutic control of progressive renal failure and other pathological processes involving abnormal cell proliferation and fibronectin matrix deposition.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wu, CY (corresponding author), Univ Pittsburgh, Dept Pathol, 707B Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	carywu@imap.pitt.edu						ABBOUD HE, 1995, ANNU REV PHYSIOL, V57, P297; ABRASS CK, 1995, WESTERN J MED, V162, P318; Adler S, 1997, KIDNEY INT, pS42; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Christopher RA, 1997, J CELL SCI, V110, P569; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Clark RAF, 1997, J CELL PHYSIOL, V170, P69; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; GETTNER SN, 1995, J CELL BIOL, V129, P1127, DOI 10.1083/jcb.129.4.1127; Guo LD, 2001, AM J PATHOL, V159, P1735, DOI 10.1016/S0002-9440(10)63020-9; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hobert O, 1999, J CELL BIOL, V144, P45, DOI 10.1083/jcb.144.1.45; Huang Y, 2000, J CELL BIOL, V150, P861, DOI 10.1083/jcb.150.4.861; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kagami S, 2001, EXP CELL RES, V268, P274, DOI 10.1006/excr.2001.5279; Kagami S, 2000, KIDNEY INT, V58, P1088, DOI 10.1046/j.1523-1755.2000.00266.x; Katz BZ, 2000, MOL BIOL CELL, V11, P1047, DOI 10.1091/mbc.11.3.1047; KERJASCHKI D, 1994, KIDNEY INT, V45, P300, DOI 10.1038/ki.1994.39; KREISBERG JI, 1993, KIDNEY INT, V43, P109, DOI 10.1038/ki.1993.18; Kretzler M, 2001, FASEB J, V15, P1843, DOI 10.1096/fj.00-0832fje; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LaFlamme SE, 1996, SEMIN CANCER BIOL, V7, P111, DOI 10.1006/scbi.1996.0016; Li FG, 1999, J CELL SCI, V112, P4589; Mercurius KO, 1998, CIRC RES, V82, P548, DOI 10.1161/01.RES.82.5.548; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; Mulrooney J, 2000, EXP CELL RES, V258, P332, DOI 10.1006/excr.2000.4964; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Olski TM, 2001, J CELL SCI, V114, P525; Pankov R, 2000, J CELL BIOL, V148, P1075, DOI 10.1083/jcb.148.5.1075; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; PETERS DMP, 1987, J CELL BIOL, V104, P121, DOI 10.1083/jcb.104.1.121; Phillips AO, 1999, KIDNEY BLOOD PRESS R, V22, P81, DOI 10.1159/000025912; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 2001, J CELL SCI, V114, P2553; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sechler JL, 1998, J BIOL CHEM, V273, P25533, DOI 10.1074/jbc.273.40.25533; Sottile J, 1998, J CELL SCI, V111, P2933; STERZEL RB, 1993, KIDNEY INT, V43, pS26; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; VIRCHOW R, 1958, DISEASE LIFE MAN, P71; WILLIAMS BD, 1994, J CELL BIOL, V124, P475, DOI 10.1083/jcb.124.4.475; Wolf G, 2000, KIDNEY INT, V58, pS59, DOI 10.1046/j.1523-1755.2000.07710.x; Wu C, 1997, HISTOL HISTOPATHOL, V12, P233; Wu CY, 1996, CELL ADHES COMMUN, V4, P149, DOI 10.3109/15419069609014219; WU CY, 1995, J CELL SCI, V108, P2511; WU CY, 1993, J BIOL CHEM, V268, P21883; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Wu CY, 2001, J CELL SCI, V114, P2549; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zamir E, 1999, J CELL SCI, V112, P1655; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhan Y, 2002, J BIOL CHEM, V277, P4512, DOI 10.1074/jbc.M109520200	66	66	71	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1298	+		10.1096/fj.02-0089fje	http://dx.doi.org/10.1096/fj.02-0089fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12060675				2022-12-28	WOS:000176683900037
J	Hutchings, H; Ortega, N; Plouet, J				Hutchings, H; Ortega, N; Plouet, J			Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation	FASEB JOURNAL			English	Article						angiogenesis; VEGF; tumstatin	ALPHA(V)BETA(3) INTEGRIN; TYROSINE KINASE; FACTOR VEGF; RECEPTOR; ACTIVATION; ISOFORM; IDENTIFICATION; ANGIOGENESIS; MECHANISM; SEQUENCE	Vascular endothelial growth factor (VEGF), a major factor mediating endothelial cell survival, migration, and proliferation during angiogenesis, is expressed as five splice variants (121, 145, 165, 189, and 206 aminoacids) encoded by a single gene. Although the three shorter isoforms are mainly diffusible, the two longer ones are sequestered in cell membranes after secretion. However, their potential role as true components of the extracellular matrix has not been investigated. We determined that endothelial cells could adhere and spread on VEGF(189) and VEGF(165), but not on VEGF(121). Adhesion was mediated by the alpha3beta1 and alphavbeta3 integrins and other alphav integrins but not by the cognate VEGF receptors. Cells migrated on VEGF(165) and VEGF(189) and displayed a stellate morphology with numerous lamellopodia and FAK staining but no actin stress fibers. Tumstatin, an antiangiogenic peptide that interacts with the alphavbeta3 integrin, could inhibit adhesion on VEGF, and this effect was potentiated by anti-alphavbeta3 blocking antibody. Immobilized VEGF almost totally abolished endothelial cell apoptosis through interactions with integrins. The inhibition of alphavbeta3 engagement with immobilized VEGF by tumstatin inhibited most of its survival activity. We have thus determined a new VEGF receptor-independent role for immobilized VEGF in supporting cell adhesion and survival through interactions with integrins.	CNRS, Inst Pharmacol & Biol Struct, UMR 5089, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Plouet, J (corresponding author), CNRS, Inst Pharmacol & Biol Struct, UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.	jean.plouet@ipbs.fr	Ortega, Nathalie/C-3382-2019					Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BENSAID M, 1989, EXP EYE RES, V48, P801, DOI 10.1016/0014-4835(89)90065-1; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Carlson TR, 2001, J BIOL CHEM, V276, P26516, DOI 10.1074/jbc.M100282200; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Dallabrida SM, 2000, BLOOD, V95, P2586, DOI 10.1182/blood.V95.8.2586.008k04_2586_2592; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P29922; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Jonca F, 1997, J BIOL CHEM, V272, P24203, DOI 10.1074/jbc.272.39.24203; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Krutzsch HC, 1999, J BIOL CHEM, V274, P24080, DOI 10.1074/jbc.274.34.24080; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Maeshima Y, 2001, J BIOL CHEM, V276, P31959, DOI 10.1074/jbc.M103024200; Moore A, 1998, METHOD CELL BIOL, V57, P265; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627; Okamoto K, 1999, ONCOL REP, V6, P1201; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Pufe T, 2001, ARTHRITIS RHEUM, V44, P1082, DOI 10.1002/1529-0131(200105)44:5<1082::AID-ANR188>3.0.CO;2-X; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Rusnati M, 1997, MOL BIOL CELL, V8, P2449, DOI 10.1091/mbc.8.12.2449; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Yuan A, 2001, J CLIN ONCOL, V19, P432, DOI 10.1200/JCO.2001.19.2.432	40	169	180	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1520	+		10.1096/fj.02-0691fje	http://dx.doi.org/10.1096/fj.02-0691fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709411				2022-12-28	WOS:000182580100024
J	Levites, Y; Amit, T; Mandel, S; Youdim, MBH				Levites, Y; Amit, T; Mandel, S; Youdim, MBH			Neuroprotection and neurorescue against A beta toxicity and PKC-dependent release of non-amyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate	FASEB JOURNAL			English	Article						neurodegeneration; Alzheimer's disease; protein kinase C; antioxidant	ALPHA-SECRETASE CLEAVAGE; NECROSIS-FACTOR-ALPHA; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; CONVERTING-ENZYME; NERVE-CELLS; ACTIVATION; DISINTEGRIN; ANTIOXIDANT; MELATONIN	Green tea extract and its main polyphenol constituent (-)-epigallocatechin-3-gallate (EGCG) possess potent neuroprotective activity in cell culture and mice model of Parkinson's disease. The central hypothesis guiding this study is that EGCG may play an important role in amyloid precursor protein (APP) secretion and protection against toxicity induced by beta-amyloid (Abeta). The present study shows that EGCG enhances (similar to6-fold) the release of the non-amyloidogenic soluble form of the amyloid precursor protein (sAPPalpha) into the conditioned media of human SH-SY5Y neuroblastoma and rat pheochromocytoma PC12 cells. sAPP release was blocked by the hydroxamic acid-based metalloprotease inhibitor Ro31-9790, which indicated mediation via secretase activity. Inhibition of protein kinase C (PKC) with the inhibitor GF109203X, or by down-regulation of PKC, blocked the EGCG-induced sAPPalpha secretion, suggesting the involvement of PKC. Indeed, EGCG induced the phosphorylation of PKC, thus identifying a novel PKC-dependent mechanism of EGCG action by activation of the non-amyloidogenic pathway. EGCG is not only able to protect, but it can rescue PC12 cells against the beta-amyloid (Abeta) toxicity in a dose-dependent manner. In addition, administration of EGCG (2 mg/kg) to mice for 7 or 14 days significantly decreased membrane-bound holoprotein APP levels, with a concomitant increase in sAPPalpha levels in the hippocampus. Consistently, EGCG markedly increased PKCalpha and PKCepsilon in the membrane and the cytosolic fractions of mice hippocampus. Thus, EGCG has protective effects against Abeta-induced neurotoxicity and regulates secretory processing of non-amyloidogenic APP via PKC pathway.	Technion Israel Inst Technol, Fac Med,Dept Pharmacol, Ctr Excellence Neurodegenerat Dis Res, Eve Topf & USA Natl Parkinson Fdn, IL-31096 Haifa, Israel; Intradept Unit Biotechnol, Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med,Dept Pharmacol, Ctr Excellence Neurodegenerat Dis Res, Eve Topf & USA Natl Parkinson Fdn, POB 9697, IL-31096 Haifa, Israel.	Youdim@Tx.Technion.ac.il						ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Avramovich Y, 2002, J BIOL CHEM, V277, P31466, DOI 10.1074/jbc.M201308200; Bachurin S, 1999, ANN NY ACAD SCI, V890, P155, DOI 10.1111/j.1749-6632.1999.tb07990.x; Bastianetto S, 2000, EUR J NEUROSCI, V12, P1882, DOI 10.1046/j.1460-9568.2000.00069.x; Bastianetto S, 2000, BRIT J PHARMACOL, V131, P711, DOI 10.1038/sj.bjp.0703626; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; Benussi L, 1998, NEUROSCI LETT, V240, P97, DOI 10.1016/S0304-3940(97)00894-X; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Chen C, 2000, ARCH PHARM RES, V23, P605, DOI 10.1007/BF02975249; Choi YT, 2001, LIFE SCI, V70, P603, DOI 10.1016/S0024-3205(01)01438-2; Chyan YJ, 1999, J BIOL CHEM, V274, P21937, DOI 10.1074/jbc.274.31.21937; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Daniels WMU, 1998, J PINEAL RES, V24, P78, DOI 10.1111/j.1600-079X.1998.tb00370.x; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; Gassen M, 1998, MOVEMENT DISORD, V13, P242, DOI 10.1002/mds.870130208; Guo QN, 1996, BBA-LIPID LIPID MET, V1304, P210, DOI 10.1016/S0005-2760(96)00122-1; Haqqi TM, 1999, P NATL ACAD SCI USA, V96, P4524, DOI 10.1073/pnas.96.8.4524; HUNG AY, 1993, J BIOL CHEM, V268, P22959; JACOBSEN JS, 1994, J BIOL CHEM, V269, P8376; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Katiyar SK, 1999, PHOTOCHEM PHOTOBIOL, V69, P148, DOI 10.1111/j.1751-1097.1999.tb03267.x; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KINOUCHI T, 1995, FEBS LETT, V364, P203, DOI 10.1016/0014-5793(95)00392-M; Koike H, 1999, BIOCHEM J, V343, P371, DOI 10.1042/0264-6021:3430371; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lee SR, 2000, NEUROSCI LETT, V287, P191, DOI 10.1016/S0304-3940(00)01159-9; Levites Y, 2002, BIOCHEM PHARMACOL, V63, P21, DOI 10.1016/S0006-2952(01)00813-9; Levites Y, 2002, J BIOL CHEM, V277, P30574, DOI 10.1074/jbc.M202832200; Levites Y, 2001, J NEUROCHEM, V78, P1073, DOI 10.1046/j.1471-4159.2001.00490.x; Lin AMY, 1998, CHINESE J PHYSIOL, V41, P189; Liu ST, 1999, BIOCHEMISTRY-US, V38, P9373, DOI 10.1021/bi990205o; Longo VD, 2000, J NEUROCHEM, V75, P1977, DOI 10.1046/j.1471-4159.2000.0751977.x; Matsushima H, 1996, J NEUROCHEM, V67, P317; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Miranda S, 2000, PROG NEUROBIOL, V62, P633, DOI 10.1016/S0301-0082(00)00015-0; MOREL I, 1993, BIOCHEM PHARMACOL, V45, P13, DOI 10.1016/0006-2952(93)90371-3; Morimoto T, 1998, J NEUROSCI RES, V51, P185, DOI 10.1002/(SICI)1097-4547(19980115)51:2<185::AID-JNR7>3.0.CO;2-9; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nanjo F, 1996, FREE RADICAL BIO MED, V21, P895, DOI 10.1016/0891-5849(96)00237-7; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Pan MH, 2000, BIOCHEM PHARMACOL, V59, P357, DOI 10.1016/S0006-2952(99)00335-4; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; Pike CJ, 1997, J NEUROCHEM, V69, P1601; Racchi M, 1999, ALZHEIMER'S DISEASE AND RELATED DISORDERS, P679; Racchi M, 1999, J NEUROCHEM, V72, P2464, DOI 10.1046/j.1471-4159.1999.0722464.x; Rottkamp CA, 2001, FREE RADICAL BIO MED, V30, P447, DOI 10.1016/S0891-5849(00)00494-9; SALAH N, 1995, ARCH BIOCHEM BIOPHYS, V322, P339, DOI 10.1006/abbi.1995.1473; Savage MJ, 1998, J NEUROSCI, V18, P1743; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schroeter H, 2001, BIOCHEM J, V358, P547, DOI 10.1042/0264-6021:3580547; SCHUBERT D, 1993, BRAIN RES, V629, P275, DOI 10.1016/0006-8993(93)91331-L; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SLACK BE, 1993, J BIOL CHEM, V268, P21097; SMALL DH, 1994, J NEUROSCI, V14, P2117; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Xu X, 1999, P NATL ACAD SCI USA, V96, P7547, DOI 10.1073/pnas.96.13.7547; Yeon SW, 2001, BIOCHEM BIOPH RES CO, V280, P782, DOI 10.1006/bbrc.2000.4181	67	294	318	0	49	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					952	+		10.1096/fj.02-0881fje	http://dx.doi.org/10.1096/fj.02-0881fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670874	Bronze			2022-12-28	WOS:000181892600013
J	Zahalka, MA; Barak, V; Traub, L; Moroz, C				Zahalka, MA; Barak, V; Traub, L; Moroz, C			PLIF induces IL-10 production in monocytes: a calmodulin-p38 mitogen-activated protein kinase-dependent pathway	FASEB JOURNAL			English	Article						immunomodulator; cytokines; fetal-maternal interface	HEAVY-CHAIN FERRITIN; HUMAN MACROPHAGES; HUMAN PLACENTA; CYTOTROPHOBLASTS; INTERLEUKIN-10; EXPRESSION	Recently, we reported the cloning and preliminary characterization of a novel human immunomodulator named PLIF (placenta immunomodulatory ferritin). PLIF has a unique molecular structure, which is composed of a ferritin heavy chain-like domain and a novel cytokine-like domain called C48. Both intact molecule and C48 inhibit T cell proliferation following allogeneic or anti-CD3 stimuli. PLIF is localized at the fetal-maternal interface of human placenta and might play a role in down-modulating the maternal immune reaction toward the embryo. The inhibitory effect of PLIF on T cell activation can be direct, indirect through cytokine mediators, or both. In the present study we investigated the possible indirect effects of PLIF by using its bioactive domain C48. Measurement of various cytokines revealed that C48, predominantly, induce pronounced and rapid IL-10 production in monocytes, which is immune activation-independent. Further, we discovered that C48-induced IL-10 production is mediated through a calcium/calmodulin-p38 mitogen-activated protein (MAP) kinase signaling pathway. However, extracellular signal-related kinases1,2 (ERK1,2), also activated by C48 stimulation, exhibited a limiting effect on IL-10 production.	Tel Aviv Univ, Lab Mol Immunol, Felsenstein Med Res Ctr, Sackler Sch Med,Rabin Med Ctr, IL-49100 Petah Tiqwa, Israel; Hadassah Med Ctr, Immunol Oncol Lab, IL-91120 Jerusalem, Israel	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Hadassah University Medical Center	Moroz, C (corresponding author), Tel Aviv Univ, Lab Mol Immunol, Felsenstein Med Res Ctr, Sackler Sch Med,Rabin Med Ctr, IL-49100 Petah Tiqwa, Israel.	hmoroz@post.tau.ac.il						Akdis CA, 2001, IMMUNOLOGY, V103, P131, DOI 10.1046/j.1365-2567.2001.01235.x; BOHN H, 1971, ARCH GYNAKOL, V210, P440, DOI 10.1007/BF01628222; CHAOUAT G, 1995, J IMMUNOL, V154, P4261; DEWAALMALEFYT R, 1991, J EXP MED, V174, P1209; DEWAALMALEFYT R, 1991, J EXP MED, V174, P915; Gray CP, 2002, BLOOD, V99, P3326, DOI 10.1182/blood.V99.9.3326; Gray CP, 2001, INT J CANCER, V92, P843, DOI 10.1002/ijc.1269; Hanna N, 2000, J IMMUNOL, V164, P5721, DOI 10.4049/jimmunol.164.11.5721; Hennessy A, 1999, J IMMUNOL, V163, P3491; LEE CK, 1990, MOL IMMUNOL, V27, P1137; Lee GW, 2001, EUR J IMMUNOL, V31, P687, DOI 10.1002/1521-4141(200103)31:3<687::AID-IMMU687>3.0.CO;2-I; LIN TM, 1974, J CLIN INVEST, V54, P576, DOI 10.1172/JCI107794; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; MANDAL M, 1995, AM J REPROD IMMUNOL, V33, P60, DOI 10.1111/j.1600-0897.1995.tb01139.x; Matsuoka T, 2001, J IMMUNOL, V166, P2202, DOI 10.4049/jimmunol.166.4.2202; MATZNER Y, 1979, BRIT J HAEMATOL, V42, P345, DOI 10.1111/j.1365-2141.1979.tb01142.x; Moroz C, 2002, J BIOL CHEM, V277, P12901, DOI 10.1074/jbc.M200956200; Reiling N, 2001, J IMMUNOL, V167, P3339, DOI 10.4049/jimmunol.167.6.3339; Roth I, 1996, J EXP MED, V184, P539, DOI 10.1084/jem.184.2.539; Wessells J, 2000, EUR J IMMUNOL, V30, P1830, DOI 10.1002/1521-4141(200007)30:7&lt;1830::AID-IMMU1830&gt;3.0.CO;2-M; YASSEL H, 1992, J IMMUNOL, V149, P2378	21	11	11	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					955	+		10.1096/fj.02-0960fje	http://dx.doi.org/10.1096/fj.02-0960fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670872				2022-12-28	WOS:000181892600001
J	Petrosillo, G; Ruggiero, FM; Di Venosa, N; Paradies, G				Petrosillo, G; Ruggiero, FM; Di Venosa, N; Paradies, G			Decreased complex III activity in mitochondria isolated from rat heart subjected to ischemia and reperfusion: role of reactive oxygen species and cardiolipin	FASEB JOURNAL			English	Article						ROS; mitochondrion; heart ischemia-reperfusion	C-OXIDASE ACTIVITY; CYTOCHROME-OXIDASE; MYOCARDIAL-ISCHEMIA; DEPENDENT DECREASE; LIPID-PEROXIDATION; RADICAL GENERATION; METABOLISM; CHAIN; DEHYDROGENASE; PROTEIN	Reactive oxygen species (ROS) are considered an important factor in ischemia-reperfusion injury to cardiac myocites. We have examined the effects of ischemia (30 min) and ischemia followed by reperfusion (15 min) of rat hearts on the activity of complex III and on the cardiolipin content in isolated mitochondria. Mitochondrial production of H2O2 and lipid peroxidation was also measured. The capacity of mitochondria to produce both H2O2 and lipid peroxidation increased upon reperfusion. The activity of complex III was 22% and 46% lower in ischemic and reperfused rat heart mitochondria, respectively, than that of controls. These changes in complex III activity were associated to parallel changes in state 3 respiration. The mitochondrial content of cardiolipin, which is required for optimal activity of complex III, decreased by 28% and by 50% as a function of ischemia and reperfusion, respectively. The lower complex III activity in mitochondria from reperfused rat hearts could be completely restored to the level of normal hearts by exogenously added cardiolipin. It is proposed that the loss of complex III activity in reperfused rat hearts can be mainly ascribed to a loss of cardiolipin content, due to oxidative attack by oxygen free radicals.	Univ Bari, Dept Biochem & Mol Biol, I-70126 Bari, Italy; Univ Bari, CNR, Unit Study Mitochondria & Bioenerget, I-70126 Bari, Italy; Univ Bari, Dept Emergency & Transplantat, I-70126 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR); Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Paradies, G (corresponding author), Univ Bari, Dept Biochem & Mol Biol, Via E Orabona 4, I-70126 Bari, Italy.	g.paradies@biologia.uniba.it						AMBROSIO G, 1991, J MOL CELL CARDIOL, V23, P1359, DOI 10.1016/0022-2828(91)90183-M; Bailey SM, 1999, FREE RADICAL BIO MED, V27, P891, DOI 10.1016/S0891-5849(99)00138-0; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; BLACK MJ, 1974, ANAL BIOCHEM, V58, P246, DOI 10.1016/0003-2697(74)90464-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLLI R, 1991, CARDIOVASC DRUG THER, V82, P723; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; Buege J A, 1978, Methods Enzymol, V52, P302; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Gomez B, 1999, BIOCHEMISTRY-US, V38, P9031, DOI 10.1021/bi990603r; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; HACKENBROCK CR, 1986, METHOD ENZYMOL, V125, P35; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; Hatch GM, 1996, MOL CELL BIOCHEM, V159, P139, DOI 10.1007/BF00420916; HESS ML, 1984, J MOL CELL CARDIOL, V16, P969, DOI 10.1016/S0022-2828(84)80011-5; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; Lesnefsky EJ, 2001, AM J PHYSIOL-HEART C, V280, pH2770; Lucas DT, 1998, P NATL ACAD SCI USA, V95, P510, DOI 10.1073/pnas.95.2.510; MCCORD JM, 1988, FREE RADICAL BIO MED, V4, P9, DOI 10.1016/0891-5849(88)90005-6; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; NOHL H, 1978, EUR J BIOCHEM, V82, P563, DOI 10.1111/j.1432-1033.1978.tb12051.x; PARADIES G, 1993, ARCH GERONTOL GERIAT, V16, P263, DOI 10.1016/0167-4943(93)90037-I; Paradies G, 2001, MITOCHONDRION, V1, P151, DOI 10.1016/S1567-7249(01)00011-3; PARADIES G, 1984, BIOCHIM BIOPHYS ACTA, V766, P446, DOI 10.1016/0005-2728(84)90260-3; Paradies G, 1999, FREE RADICAL BIO MED, V27, P42, DOI 10.1016/S0891-5849(99)00032-5; Paradies G, 1997, FEBS LETT, V406, P136, DOI 10.1016/S0014-5793(97)00264-0; Paradies G, 1998, FEBS LETT, V424, P155, DOI 10.1016/S0014-5793(98)00161-6; PARADIES G, 1994, FEBS LETT, V350, P213, DOI 10.1016/0014-5793(94)00763-2; Paradies G, 2000, FEBS LETT, V466, P323, DOI 10.1016/S0014-5793(00)01082-6; PARADIES G, 1994, BBA-MOL BASIS DIS, V1225, P165, DOI 10.1016/0925-4439(94)90074-4; Paradies G, 1997, BBA-BIOENERGETICS, V1319, P5, DOI 10.1016/S0005-2728(97)00012-1; PETIT JM, 1992, EUR J BIOCHEM, V209, P267, DOI 10.1111/j.1432-1033.1992.tb17285.x; ROBINSON NC, 1993, J BIOENERG BIOMEMBR, V25, P153, DOI 10.1007/BF00762857; RUGGIERO FM, 1984, LIPIDS, V19, P171, DOI 10.1007/BF02534794; Schlame M, 1997, BBA-LIPID LIPID MET, V1348, P207, DOI 10.1016/S0005-2760(97)00119-7; Skulachev VP, 1997, BIOSCIENCE REP, V17, P347, DOI 10.1023/A:1027344914565; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; YU CA, 1980, BIOCHEMISTRY-US, V19, P3579, DOI 10.1021/bi00556a025; ZWEIER JL, 1987, P NATL ACAD SCI USA, V84, P1404, DOI 10.1073/pnas.84.5.1404	48	9	15	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					714	+		10.1096/fj.02-0729fje	http://dx.doi.org/10.1096/fj.02-0729fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586737				2022-12-28	WOS:000181456900020
J	Raymond, MA; Mollica, L; Vigneault, N; Desormeaux, A; Chan, JSD; Filep, JG; Hebert, MJ				Raymond, MA; Mollica, L; Vigneault, N; Desormeaux, A; Chan, JSD; Filep, JG; Hebert, MJ			Blockade of the apoptotic machinery by cyclosporin A redirects cell death toward necrosis in arterial endothelial cells: regulation by reactive oxygen species and cathepsin D	FASEB JOURNAL			English	Article						programmed cell death; endothelium; oxidative stress; lysosome	CYTOCHROME-C; FAS RECEPTOR; INDUCTION; RELEASE; MITOCHONDRIA; PEROXYNITRITE; ACTIVATION; TACROLIMUS; EXPRESSION; INITIATION	Blockade of the mitochondrial permeability transition pore (mPTP) by cyclosporin A (CsA) inhibits apoptosis in various cell types. However, use of CsA in humans is associated with damage to the arterial endothelium. We evaluated whether inhibition of the apoptotic machinery by CsA promotes other forms of cell death in arterial endothelial cells (EC). Exposure of human umbilical artery EC (HUAEC) to clinically relevant concentrations of CsA for up to 24 h was associated with a significant increase in necrotic features. We detected inhibition of apoptosis and a significant increase in necrosis in HUAEC exposed concomitantly to CsA and mitomycin C, a proapoptotic DNA damaging agent. We found that CsA-induced cell death is independent of caspase activation, p53 induction, and calcineurin inhibition. However, bongkrekic acid, another mPTP blocker, also increased necrosis in HUAEC. Dihydroethidium and acridine orange staining revealed increased intracellular production of reactive oxygen species (ROS) followed by lysosomal damage in HUAEC exposed to CsA. Hydroxyl radical and superoxide scavengers and inhibition of cathepsin D activity significantly attenuated CsA-induced EC death. These results suggest that inhibition of the apoptotic machinery by CsA in arterial EC favors development of a necrotic form of cell death regulated by ROS and secondary lysosomal damage.	Univ Montreal, CHUM, Res Ctr, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Maisonneuve Rosemont Hosp, Guy Bernier Res Ctr, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; Universite de Montreal	Hebert, MJ (corresponding author), Univ Montreal, CHUM, Res Ctr, Labo Y-3624,1560 Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.	marie-josee.hebert.chum@ssss.gouv.qc.ca						Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549; Armstrong VW, 2001, CLIN BIOCHEM, V34, P9, DOI 10.1016/S0009-9120(00)00175-2; Boise LH, 2001, TRENDS MICROBIOL, V9, P64, DOI 10.1016/S0966-842X(00)01937-5; Chautan M, 1999, CURR BIOL, V9, P967, DOI 10.1016/S0960-9822(99)80425-4; Dare E, 2001, FREE RADICAL BIO MED, V30, P1347, DOI 10.1016/S0891-5849(01)00526-3; de Mattos AM, 2000, AM J KIDNEY DIS, V35, P333, DOI 10.1016/S0272-6386(00)70348-9; Esposito C, 2000, KIDNEY INT, V58, P123, DOI 10.1046/j.1523-1755.2000.00147.x; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Filep JG, 1998, J IMMUNOL, V161, P5656; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Hebert MJ, 1998, AM J PATHOL, V152, P523; Hebert MJ, 1996, J IMMUNOL, V157, P3105; Holland GN, 2000, OCUL IMMUNOL INFLAMM, V8, P1, DOI 10.1076/0927-3948(200003)8:1;1-S;FT001; Kagedal K, 2001, FASEB J, V15, P1592, DOI 10.1096/fj.00-0708fje; Kagedal K, 2001, BIOCHEM J, V359, P335, DOI 10.1042/0264-6021:3590335; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kochi S, 2000, LIFE SCI, V66, P2255, DOI 10.1016/S0024-3205(00)00554-3; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kung L, 2000, TRANSPLANTATION, V70, P327, DOI 10.1097/00007890-200007270-00017; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Leist M, 2001, CELL DEATH DIFFER, V8, P324, DOI 10.1038/sj.cdd.4400859; Longoni B, 2001, FASEB J, V15, P731, DOI 10.1096/fj.00-0163com; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Mahalati K, 2001, J AM SOC NEPHROL, V12, P828, DOI 10.1681/ASN.V124828; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Raymond MA, 2002, BIOCHEM BIOPH RES CO, V291, P261, DOI 10.1006/bbrc.2002.6449; Rottenberg H, 1997, BIOCHEM BIOPH RES CO, V240, P68, DOI 10.1006/bbrc.1997.7605; Santos BC, 1998, AM J PHYSIOL-RENAL, V274, pF1167, DOI 10.1152/ajprenal.1998.274.6.F1167; Tafani M, 2002, J BIOL CHEM, V277, P10073, DOI 10.1074/jbc.M111350200; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Walter DH, 1998, CIRCULATION, V98, P1153, DOI 10.1161/01.CIR.98.12.1153; Wang XD, 2001, GENE DEV, V15, P2922; Wyllie AH, 2001, P NATL ACAD SCI USA, V98, P11, DOI 10.1073/pnas.98.1.11	38	39	41	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					515	+		10.1096/fj.02-0500fje	http://dx.doi.org/10.1096/fj.02-0500fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12514115				2022-12-28	WOS:000181453700030
J	Beale, EG; Hammer, RE; Antoine, B; Forest, C				Beale, EG; Hammer, RE; Antoine, B; Forest, C			Glyceroneogenesis comes of age	FASEB JOURNAL			English	Review						phosphoenolpyruvate carboxykinase; lipid homeostasis; obesity; diabetes	PHOSPHOENOLPYRUVATE CARBOXYKINASE; GLYCERIDE-GLYCEROL; ADIPOSE-TISSUE; PYRUVATE	Glyceroneogenesis is a generally ignored metabolic pathway that occurs in adipose tissues and liver of mammalian species. This short review highlights a series of recent discoveries showing that glyceroneogenesis is important in lipid homeostasis.	Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA; Ctr Univ UFR Biomed, F-75006 Paris, France; Univ Paris 05, INSERM, U530, Unite Mixte, F-75270 Paris 06, France; Univ Texas, SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75235 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Beale, EG (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Stop 6540, Lubbock, TX 79430 USA.	elmus.beale@ttuhsc.edu	Beale, Elmus/GNM-8181-2022	Beale, Elmus/0000-0002-7758-0600; Hammer, Robert E./0000-0001-5487-7551; Forest, Claude/0000-0003-3401-8148				BALLARD FJ, 1967, J BIOL CHEM, V242, P2746; Botion LM, 1998, METABOLISM, V47, P1217, DOI 10.1016/S0026-0495(98)90326-2; Devine JH, 1999, J BIOL CHEM, V274, P13604, DOI 10.1074/jbc.274.19.13604; Franckhauser S, 2002, DIABETES, V51, P624, DOI 10.2337/diabetes.51.3.624; Glorian M, 2001, BIOCHIMIE, V83, P933, DOI 10.1016/S0300-9084(01)01343-8; GORIN E, 1969, EUR J BIOCHEM, V8, P370, DOI 10.1111/j.1432-1033.1969.tb00537.x; Kalhan SC, 2001, J BIOL CHEM, V276, P12928, DOI 10.1074/jbc.M006186200; Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201; Olswang Y, 2002, P NATL ACAD SCI USA, V99, P625, DOI 10.1073/pnas.022616299; RESHEF L, 1969, J BIOL CHEM, V244, P1994; RESHEFF L, 1970, J BIOL CHEM, V245, P5979; She P, 2000, MOL CELL BIOL, V20, P6508, DOI 10.1128/MCB.20.17.6508-6517.2000	12	51	51	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					1695	1696		10.1096/fj.02-0407rev	http://dx.doi.org/10.1096/fj.02-0407rev			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12409311				2022-12-28	WOS:000180218500001
J	Condorelli, G; Morisco, C; Latronico, MVG; Claudio, PP; Dent, P; Tsichlis, P; Condorelli, G; Frati, G; Drusco, A; Croce, CM; Napoli, C				Condorelli, G; Morisco, C; Latronico, MVG; Claudio, PP; Dent, P; Tsichlis, P; Condorelli, G; Frati, G; Drusco, A; Croce, CM; Napoli, C			TNF-alpha signal transduction in rat neonatal cardiac myocytes: definition of pathways generating from the TNF-alpha receptor	FASEB JOURNAL			English	Article						cardiomyocyte apoptosis; hypertrophy; AKT; heart failure; tumor necrosis factor alpha	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; HEART-FAILURE; ACTIVATION; AKT; TRANSCRIPTION; KINASE; STIMULATION; APOPTOSIS; SURVIVAL	Cardiomyocyte hypertrophy and apoptosis have been implicated in the loss of contractile function during heart failure (HF). Moreover, patients with HF have been shown to exhibit increased levels of tumor necrosis factor alpha (TNF-alpha) in the myocardium. However, the multiple signal transduction pathways generating from the TNF-alpha receptor in cardiomyocytes and leading preferentially to apoptosis or hypertrophy are still unknown. Here we demonstrate in neonatal rat cardiomyocytes that 1) TNF-alpha induces phosphorylation of AKT, activation of NF-kappaB, and the phosphorylation of JUN kinase; 2) blocking AKT activity prevents NF-kappaB activation, suggesting a role for AKT in regulating NF-kappaB function; 3) AKT and JUN are both critical for the hypertrophic effects of TNF-alpha, since dominant-negative mutants of these genes are capable of inhibiting TNF-alpha-induced ANF-promoter up-regulation and increase in cardiomyocyte cell size, and 4) blocking NF-kappaB, AKT, or JUN alone or in combination does not sensitize cardiomyocytes to the proapoptotic effects of TNF-alpha, in contrast to other cell types, suggesting a cardiac-specific pathway regulating the anti-apoptotic events induced by TNF-alpha. Altogether, the data presented evidence the role of AKT and JUN in TNF-alpha-induced cardiomyocyte hypertrophy and apoptosis.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Roma La Sapienza, Fac Med 2, I-00161 Rome, Italy; IRCCS Neuromed, Pozzilli, IS, Italy; Univ Naples, Dept Med, I-80131 Naples, Italy; Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Dept Radiat Oncol, Richmond, VA 23298 USA; CNR, Ctr Endocrinol & Endocrinol Sperimentale, I-80131 Naples, Italy; Temple Univ, Sbarro Inst Canc Res, Coll Sci & Technol, Dept Biotechnol, Philadelphia, PA 19122 USA	Jefferson University; Sapienza University Rome; IRCCS Neuromed; University of Naples Federico II; Virginia Commonwealth University; Consiglio Nazionale delle Ricerche (CNR); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Condorelli, G (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,Rm 1006, Philadelphia, PA 19107 USA.	gianluigi.condorelli@mail.tju.edu	Condorelli, Gerolama/AAC-3472-2022; Young, Richard A/F-6495-2012; Latronico, Michael/AAB-3691-2019; Frati, Giacomo/ABI-7410-2020; Claudio, Pier Paolo/AAW-7282-2021; Condorelli, Gianluigi/Q-6736-2017	Condorelli, Gerolama/0000-0003-0177-8829; Young, Richard A/0000-0001-8855-8647; Claudio, Pier Paolo/0000-0001-7790-1622; MORISCO, Carmine/0000-0002-2158-6317; Napoli, Claudio/0000-0002-5455-555X; Frati, Giacomo/0000-0003-2703-3761; Condorelli, Gianluigi/0000-0003-0481-6843; Latronico, Michele/0000-0003-4017-5764	NIDDK NIH HHS [R01-DK52825] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Claudio PP, 1999, CIRC RES, V85, P1032; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; Deswal A, 1999, CIRCULATION, V99, P3224, DOI 10.1161/01.CIR.99.25.3224; Gill C, 2002, FASEB J, V16, P135, DOI 10.1096/fj.01-0629com; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; KURRELMEYER KM, 2000, P NATL ACAD SCI US; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Nakamura K, 1998, CIRCULATION, V98, P794, DOI 10.1161/01.CIR.98.8.794; Napoli C, 2000, FASEB J, V14, P1996, DOI 10.1096/fj.99-0986com; Ozes ON, 1999, NATURE, V401, P82; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang NP, 1999, CIRC RES, V85, P387, DOI 10.1161/01.RES.85.5.387; Yokoyama T, 1997, CIRCULATION, V95, P1247; Zen K, 1999, J BIOL CHEM, V274, P28808, DOI 10.1074/jbc.274.40.28808	22	67	70	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2002	16	13					1732	1737		10.1096/fj.02-0419com	http://dx.doi.org/10.1096/fj.02-0419com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12409315	Green Submitted			2022-12-28	WOS:000180218500005
J	Costa, C; Brokaw, JL; Wang, Y; Fodor, WL				Costa, C; Brokaw, JL; Wang, Y; Fodor, WL			Delayed rejection of porcine cartilage is averted by transgenic expression of alpha 1,2-fucosyltransferase	FASEB JOURNAL			English	Article						Gal alpha 1,3-Gal antigen; H-transferase; xenoantibody response; xenotransplantation; tissue engineering	ALPHA-GAL EPITOPES; CYNOMOLGUS MONKEY; DOWN-REGULATION; TRANSPLANTS; PIG; XENOGRAFTS; CELLS; MICE; ALPHA(1,2)-FUCOSYL-TRANSFERASE; ALLOGRAFTS	The use of xenogeneic cells or tissues for tissue engineering applications may lead to advances in biomedical research. Hyperacute and delayed rejection are immunologic hurdles that must be addressed to achieve xenograft survival in the pig-to-primate setting. Expression of human alpha1,2-fucosyltransferase (HT) in the donor cell or tissue protects from hyperacute rejection (HAR) by reducing expression of Galalpha1,3-Gal epitope, the major xenoantigen recognized by human natural antibodies. We hypothesized that Gal 1,3-Gal antigen contributes to delayed tissue rejection. To test this hypothesis, we transplanted control or HT-transgenic engineered porcine cartilage s.c. into alpha1,3-galactosyltransferase knockout (Gal KO) mice. Control porcine cartilage grafted in Gal KO mice was not susceptible to HAR but was rejected in several wk by a prominent cellular immune infiltrate and elevated antibody titers. In contrast, Gal KO mice receiving the HT engineered cartilage showed a markedly reduced anti-pig antibody response and no anti-Galalpha1,3-Gal-elicited antibody response. The HT implants had a mild cellular infiltrate that was confined to the graft periphery. Our study demonstrates that a marked reduction of Galalpha1,3-Gal antigen in HT-transgenic porcine cartilage confers resistance to a process of delayed rejection. Further development of tissue engineering applications that use genetically modified porcine tissues is encouraged.	Alexion Pharmaceut Inc, Dept Mol Sci, Cheshire, CT 06410 USA; Alexion Pharmaceut Inc, Dept Cellular Sci, Cheshire, CT 06410 USA		Costa, C (corresponding author), Alexion Pharmaceut Inc, Dept Mol Sci, 352 Knotter Dr, Cheshire, CT 06410 USA.	costac@alxn.com	Costa, Cristina/AAP-4005-2020	Costa, Cristina/0000-0002-1837-4268	NICHD NIH HHS [R44 HD095784] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alwayn IPJ, 1999, XENOTRANSPLANTATION, V6, P157, DOI 10.1034/j.1399-3089.1999.00030.x; Auchincloss H, 1998, ANNU REV IMMUNOL, V16, P433, DOI 10.1146/annurev.immunol.16.1.433; AYDELOTTE MB, 1988, CONNECT TISSUE RES, V18, P205, DOI 10.3109/03008208809016808; Bondioli K, 2001, MOL REPROD DEV, V60, P189, DOI 10.1002/mrd.1076; Bracy JL, 1998, SCIENCE, V281, P1845, DOI 10.1126/science.281.5384.1845; BRITTBERG M, 1994, NEW ENGL J MED, V331, P889, DOI 10.1056/NEJM199410063311401; Chen, 1996, Mol Diagn, V1, P65, DOI 10.1016/S1084-8592(96)70023-1; Chen CG, 1996, XENOTRANSPLANTATION, V3, P69, DOI 10.1111/j.1399-3089.1996.tb00121.x; Cohney S, 1997, TRANSPLANTATION, V64, P495, DOI 10.1097/00007890-199708150-00020; Costa C, 1999, XENOTRANSPLANTATION, V6, P6, DOI 10.1034/j.1399-3089.1999.00004.x; Costa C, 2002, J IMMUNOL, V168, P3808, DOI 10.4049/jimmunol.168.8.3808; Cozzi E., 1997, XENOTRANSPLANTATION, P665; DALMASSO AP, 1992, AM J PATHOL, V140, P1157; Edge ASB, 1998, CELL TRANSPLANT, V7, P525, DOI 10.1016/S0963-6897(98)00043-8; FODOR WL, 1994, P NATL ACAD SCI USA, V91, P11153, DOI 10.1073/pnas.91.23.11153; Galili U, 1997, XENOTRANSPLANTATION, V4, P127, DOI 10.1111/j.1399-3089.1997.tb00175.x; GALILI U, 1993, SPRINGER SEMIN IMMUN, V15, P155; GOODMAN DJ, 1997, XENOTRANSPLANTATION, P95; HAYES CE, 1974, J BIOL CHEM, V249, P1904; Inverardi L, 1997, TRANSPLANTATION, V63, P1318, DOI 10.1097/00007890-199705150-00021; KANDEL RA, 1995, ARTIF CELL BLOOD SUB, V23, P565, DOI 10.3109/10731199509117971; Kobayashi T, 1997, TRANSPLANTATION, V64, P1255, DOI 10.1097/00007890-199711150-00005; Koike C, 1996, XENOTRANSPLANTATION, V3, P81, DOI 10.1111/j.1399-3089.1996.tb00123.x; Kozlowski T, 1999, TRANSPLANTATION, V67, P18, DOI 10.1097/00007890-199901150-00004; Kwiatkowski P, 1999, TRANSPLANTATION, V67, P219, DOI 10.1097/00007890-199901270-00006; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; Lambrigts D, 1998, TRANSPLANTATION, V66, P547, DOI 10.1097/00007890-199809150-00001; Larsson LC, 1999, TRANSPLANTATION, V68, P1153, DOI 10.1097/00007890-199910270-00016; LaTemple DC, 1998, XENOTRANSPLANTATION, V5, P191, DOI 10.1111/j.1399-3089.1998.tb00027.x; Lin SS, 2000, TRANSPLANTATION, V70, P1667, DOI 10.1097/00007890-200012270-00002; Marchetti P, 1996, TRANSPLANTATION, V61, P1100, DOI 10.1097/00007890-199604150-00019; MATSUMOT.I, 1969, BIOCHIM BIOPHYS ACTA, V194, P180, DOI 10.1016/0005-2795(69)90193-7; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; McKenzie IFC, 2000, TRANSPLANTATION, V70, P1205, DOI 10.1097/00007890-200010270-00014; Naziruddin B, 2001, XENOTRANSPLANTATION, V8, P26; Ohdan H, 2000, J IMMUNOL, V165, P5518, DOI 10.4049/jimmunol.165.10.5518; PIERSON RN, 1989, J EXP MED, V170, P991, DOI 10.1084/jem.170.3.991; Platt JL, 1998, XENOTRANSPLANTATION, V5, P169, DOI 10.1111/j.1399-3089.1998.tb00024.x; Platt JL, 1998, NATURE, V392, P11; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; Sharma A, 1996, P NATL ACAD SCI USA, V93, P7190, DOI 10.1073/pnas.93.14.7190; Sirlin CB, 2001, RADIOLOGY, V219, P35, DOI 10.1148/radiology.219.1.r01ap0435; Stock UA, 2001, ANNU REV MED, V52, P443, DOI 10.1146/annurev.med.52.1.443; Stone KR, 1998, TRANSPLANTATION, V65, P1577, DOI 10.1097/00007890-199806270-00007; Stone KR, 1997, TRANSPLANTATION, V63, P640, DOI 10.1097/00007890-199703150-00005; Tanemura M, 2000, J CLIN INVEST, V105, P301, DOI 10.1172/JCI7358; Uchida T, 1999, TRANSPLANTATION, V68, P1721, DOI 10.1097/00007890-199912150-00016; VOLKOV MV, 1976, CLIN ORTHOP RELAT R, V114, P192; Wang H, 2000, NAT MED, V6, P549, DOI 10.1038/75029; WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955; Yang YG, 1998, J EXP MED, V187, P1335, DOI 10.1084/jem.187.8.1335; Zhong R, 2001, XENOTRANSPLANTATION, V8, P25	52	24	25	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					109	+		10.1096/fj.02-0630fje	http://dx.doi.org/10.1096/fj.02-0630fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475900				2022-12-28	WOS:000180218500025
J	Kontush, A; Chancharme, L; Escargueil-Blanc, I; Therond, P; Salvayre, R; Negre-Salvayre, A; Chapman, MJ				Kontush, A; Chancharme, L; Escargueil-Blanc, I; Therond, P; Salvayre, R; Negre-Salvayre, A; Chapman, MJ			Mildly oxidized LDL particle subspecies are distinct in their capacity to induce apoptosis in endothelial cells: role of lipid hydroperoxides	FASEB JOURNAL			English	Article						atherosclerosis; dense LDL; light LDL; LOOH; cytotoxicity	LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; SHED MEMBRANE MICROPARTICLES; ATHEROSCLEROTIC LESIONS; DNA FRAGMENTATION; PLASMA; BLOOD; DEATH; HETEROGENEITY; ACCUMULATION	The risk of atherosclerosis is intimately related to the heterogeneity of low-density lipoprotein (LDL) particles. The potential relationship between oxidative modification of distinct LDL subspecies and induction of apoptosis in arterial wall cells is indeterminate. The capacity of light LDL3 versus dense LDL5 to induce cytotoxicity in endothelial cells as a function of the degree of copper-mediated oxidation was compared. Mildly oxidized LDL3 (oxLDL3) exerted potent cytotoxicity, which was intimately related to both the degree of oxidation and the oxLDL3 concentration based on either cholesterol content or particle number. In contrast, dense LDL5 particles exerted a minor effect on cell viability. Cells incubated with oxLDL3 exhibited apoptotic features, with cytoplasmic condensation, cell or nuclear fragmentation, and accumulation of DNA fragments. OxLDL3-induced apoptosis involved cytoplasmic release of cytochrome c, with a concomitant increase in caspase-3-like protease activity. OxLDL3 particles were uniquely distinct from oxLDL5 particles in their elevated content of lipid hydroperoxides. Hydroperoxide removal by NaBH4 markedly reduced oxLDL3-induced cytotoxicity, leading to an increase in cell viability. Lipid hydroperoxide content of oxidatively modified LDL subclasses is therefore a major determinant of the induction of apoptosis in endothelial cells. These data are highly relevant to atherogenic hypercholesterolemia, in which the LDL phenotype is dominated by elevated concentrations of light LDL3.	Hop La Pitie Salpetriere, INSERM, U551, F-75651 Paris 13, France; CHU Rangueil, INSERM, U466, F-34054 Toulouse, France; CHU Kremlin Bicetre, INSERM, U347, F-94276 Le Kremlin Bicetre, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Chapman, MJ (corresponding author), Hop La Pitie Salpetriere, INSERM, U551, Pavillon Benjamin Delessert, F-75651 Paris 13, France.	chapman@infobiogen.fr	Kontush, Anatol/J-2198-2016; chapman, john/Y-2742-2019	Negre-Salvayre, Anne/0000-0003-2136-5706				Alcouffe J, 1999, J LIPID RES, V40, P1200; Anber V, 1996, ATHEROSCLEROSIS, V124, P261, DOI 10.1016/0021-9150(96)05842-X; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Bjorkerud B, 1996, ARTERIOSCL THROM VAS, V16, P416, DOI 10.1161/01.ATV.16.3.416; Bjorkerud S, 1996, AM J PATHOL, V149, P367; BOOBIS AR, 1989, TRENDS PHARMACOL SCI, V10, P275, DOI 10.1016/0165-6147(89)90027-8; CAMPOS H, 1995, ARTERIOSCL THROM VAS, V15, P1043, DOI 10.1161/01.ATV.15.8.1043; Chancharme L, 1999, ARTERIOSCL THROM VAS, V19, P810, DOI 10.1161/01.ATV.19.3.810; Chancharme L, 2002, J LIPID RES, V43, P453; Chapman M. J., 1999, ADV VASC BIOL, P69; CHAPMAN MJ, 1988, J LIPID RES, V29, P442; CHAPMAN MJ, 1981, J LIPID RES, V22, P339; Claise C, 1999, ATHEROSCLEROSIS, V147, P95, DOI 10.1016/S0021-9150(99)00170-7; Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394; Dimmeler S, 1997, CIRCULATION, V95, P1760; EscargueilBlanc I, 1997, ARTERIOSCL THROM VAS, V17, P331, DOI 10.1161/01.ATV.17.2.331; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; FREI B, 1988, ANAL BIOCHEM, V175, P120, DOI 10.1016/0003-2697(88)90369-7; GENG YJ, 1995, AM J PATHOL, V147, P251; Girotti AW, 1998, J LIPID RES, V39, P1529; HAN DKM, 1995, AM J PATHOL, V147, P267; HESSLER JR, 1979, ATHEROSCLEROSIS, V32, P213, DOI 10.1016/0021-9150(79)90166-7; Hsieh CC, 2000, ATHEROSCLEROSIS, V151, P481, DOI 10.1016/S0021-9150(00)00453-6; Jovinge S, 1997, ARTERIOSCL THROM VAS, V17, P2225, DOI 10.1161/01.ATV.17.10.2225; Karten B, 1997, CHEM PHYS LIPIDS, V88, P83, DOI 10.1016/S0009-3084(97)00038-8; Kotamraju S, 2001, J BIOL CHEM, V276, P17316, DOI 10.1074/jbc.M011731200; Krauss Ronald M., 1994, Current Opinion in Lipidology, V5, P339, DOI 10.1097/00041433-199410000-00005; Lamarche B, 1997, CIRCULATION, V95, P69, DOI 10.1161/01.CIR.95.1.69; LIAO F, 1991, J CLIN INVEST, V87, P2253, DOI 10.1172/JCI115261; LUC G, 1988, ATHEROSCLEROSIS, V71, P143, DOI 10.1016/0021-9150(88)90138-4; Lund-Katz S, 1998, BIOCHEMISTRY-US, V37, P12867, DOI 10.1021/bi980828m; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; Mallat Z, 2000, CIRCULATION, V101, P841, DOI 10.1161/01.CIR.101.8.841; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; Meilhac O, 1999, FASEB J, V13, P485, DOI 10.1096/fasebj.13.3.485; Napoli C, 2000, FASEB J, V14, P1996, DOI 10.1096/fj.99-0986com; NEGRESALVAYRE A, 1990, BIOCHIM BIOPHYS ACTA, V1045, P224, DOI 10.1016/0005-2760(90)90124-G; NIGON F, 1991, J LIPID RES, V32, P1741; Nishio E, 1996, BIOCHEM BIOPH RES CO, V223, P413, DOI 10.1006/bbrc.1996.0907; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PRICE P, 1990, CANCER RES, V50, P1392; Roland A, 2001, ARTERIOSCL THROM VAS, V21, P594, DOI 10.1161/01.ATV.21.4.594; Sata M, 1998, J CLIN INVEST, V102, P1682, DOI 10.1172/JCI3531; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; Siow RCM, 1999, ARTERIOSCL THROM VAS, V19, P2387, DOI 10.1161/01.ATV.19.10.2387; Smalley DM, 1997, ARTERIOSCL THROM VAS, V17, P3469, DOI 10.1161/01.ATV.17.12.3469; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; Suc I, 1997, ARTERIOSCL THROM VAS, V17, P2158, DOI 10.1161/01.ATV.17.10.2158; THEROND P, 1993, LIPIDS, V28, P245, DOI 10.1007/BF02536647; Tricot O, 2000, CIRCULATION, V101, P2450, DOI 10.1161/01.CIR.101.21.2450; Vieira O, 2000, FASEB J, V14, P532, DOI 10.1096/fasebj.14.3.532; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5; Yla-Herttuala S, 1998, CURR OPIN LIPIDOL, V9, P337	53	20	21	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					88	+		10.1096/fj.02-0293fje	http://dx.doi.org/10.1096/fj.02-0293fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475909				2022-12-28	WOS:000180218500018
J	Pall, ML				Pall, ML			NMDA sensitization and stimulation by peroxynitrite, nitric oxide, and organic solvents as the mechanism of chemical sensitivity in multiple chemical sensitivity	FASEB JOURNAL			English	Review						neural sensitization; vicious cycle; reactive nitrogen species; chemical intolerance	LONG-TERM POTENTIATION; CHRONIC-FATIGUE-SYNDROME; BLOOD-BRAIN-BARRIER; POSTTRAUMATIC-STRESS-DISORDER; CENTRAL-NERVOUS-SYSTEM; EMISSION COMPUTED-TOMOGRAPHY; NEUROLOGIC SYMPTOM COMPLEXES; INFLAMMATORY CELL INVASION; CALCIUM-CHANNEL BLOCKERS; D-ASPARTATE RECEPTOR	Multiple chemical sensitivity (MCS) is a condition where previous exposure to hydrophobic organic solvents or pesticides appears to render people hypersensitive to a wide range of chemicals, including organic solvents. The hypersensitivity is often exquisite, with MCS individuals showing sensitivity that appears to be at least two orders of magnitude greater than that of normal individuals. This paper presents a plausible set of interacting mechanisms to explain such heightened sensitivity. It is based on two earlier theories of MCS: the elevated nitric oxide/peroxynitrite theory and the neural sensitization theory. It is also based on evidence implicating excessive NMDA activity in MCS. Four sensitization mechanisms are proposed to act synergistically, each based on known physiological mechanisms: Nitric oxide-mediated stimulation of neurotransmitter (glutamate) release; peroxynitrite-mediated ATP depletion and consequent hypersensitivity of NMDA receptors; peroxynitrite-mediated increased permeability of the blood-brain barrier, producing increased accessibility of organic chemicals to the central nervous system; and nitric oxide inhibition of cytochrome P450 metabolism. Evidence for each of these mechanisms, which may also be involved in Parkinson's disease, is reviewed. These interacting mechanisms provide explanations for diverse aspects of MCS and a framework for hypothesis-driven MCS research.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA	Washington State University	Pall, ML (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.	martin_pall@wsu.edu						Abou-Donia MB, 2001, J TOXICOL ENV HEAL A, V62, P523, DOI 10.1080/152873901300007824; ADAMEC R, 1994, TOXICOL IND HEALTH, V10, P391; Adamec R, 1997, NEUROSCI BIOBEHAV R, V21, P755, DOI 10.1016/S0149-7634(96)00055-3; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; ANTELMAN SM, 1994, TOXICOL IND HEALTH, V10, P335; Arnetz BB, 1999, SCAND J WORK ENV HEA, V25, P569, DOI 10.5271/sjweh.482; Ashford N., 1998, CHEM EXPOSURES LOW L; Baker DG, 1997, ARCH INTERN MED, V157, P2076, DOI 10.1001/archinte.157.18.2076; Baranano DE, 2001, TRENDS NEUROSCI, V24, P99, DOI 10.1016/S0166-2236(00)01716-1; Bascom R, 1997, ENVIRON HEALTH PERSP, V105, P531, DOI 10.2307/3433365; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; Bell I, 1998, AM J MED, V105, p74S 82S; Bell IR, 1999, TOXICOL IND HEALTH, V15, P295, DOI 10.1191/074823399678846826; BELL IR, 1992, BIOL PSYCHIAT, V32, P218, DOI 10.1016/0006-3223(92)90105-9; Bell IR, 2001, INT J NEUROSCI, V108, P31, DOI 10.3109/00207450108986503; Bell IR, 1998, J WOMENS HEALTH, V7, P1135, DOI 10.1089/jwh.1998.7.1135; Bell IR, 1999, INT J NEUROSCI, V97, P41, DOI 10.3109/00207459908994302; Bennett MR, 2000, PROG NEUROBIOL, V60, P109, DOI 10.1016/S0301-0082(99)00006-4; Bested AC, 2001, MED HYPOTHESES, V57, P231, DOI 10.1054/mehy.2001.1306; Binkley K, 2001, J ALLERGY CLIN IMMUN, V107, P887, DOI 10.1067/mai.2001.114798; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blobner M, 1999, ANESTHESIOLOGY, V91, P999, DOI 10.1097/00000542-199910000-00020; BONUCCELLI U, 1992, LANCET, V340, P53, DOI 10.1016/0140-6736(92)92466-S; Broberger C, 1998, AMINO ACIDS, V14, P25, DOI 10.1007/BF01345238; BRONSTEIN AC, 1995, J TOXICOL-CLIN TOXIC, V33, P93, DOI 10.3109/15563659509000455; BUCHWALD D, 1994, ARCH INTERN MED, V154, P2049, DOI 10.1001/archinte.154.18.2049; Calingasan NY, 1998, AM J PATHOL, V153, P599, DOI 10.1016/S0002-9440(10)65602-7; CARESS SM, 2002, IN PRESS AM J PUB HL; Chase TN, 2000, J NEUROL, V247, P36, DOI 10.1007/PL00007759; Clauw DJ, 1997, NEUROIMMUNOMODULAT, V4, P134, DOI 10.1159/000097332; CODERRE TJ, 1992, J NEUROSCI, V12, P3671; COTMAN CW, 1988, ANNU REV NEUROSCI, V11, P61, DOI 10.1146/annurev.neuro.11.1.61; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; CULLEN MR, 1987, OCCUP MED, V2, P655; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; Dekundy A, 2001, ARCH TOXICOL, V74, P702, DOI 10.1007/s002040000189; Del Dotto P, 2001, MOVEMENT DISORD, V16, P515, DOI 10.1002/mds.1112; Diaz A, 1997, PAIN, V69, P93, DOI 10.1016/S0304-3959(96)03271-X; Dineley KT, 2001, J NEUROCHEM, V77, P961, DOI 10.1046/j.1471-4159.2001.00321.x; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Donnay A., 1999, J CHRONIC FATIGUE SY, V5, P71, DOI [10.1300/J092v05n03_06, DOI 10.1300/J092V05N03_06]; DONNAY A, 2000, CARBON MONOXIDE TOXI, P31; Donnay AH, 1999, INT J TOXICOL, V18, P383, DOI 10.1080/109158199225099; Dudley DL, 1998, DEFINING MULTIPLE CHEMICAL SENSITIVITY, P9; ELLIOTT KJ, 1995, PAIN, V61, P401, DOI 10.1016/0304-3959(94)00214-Y; Fan JS, 1998, J BIOL CHEM, V273, P33472, DOI 10.1074/jbc.273.50.33472; Fernandez M, 1999, TOXICOL IND HEALTH, V15, P305, DOI 10.1191/074823399678846835; Fiedler N, 2001, ANN NY ACAD SCI, V933, P24; Fiedler N, 1996, PSYCHOSOM MED, V58, P38, DOI 10.1097/00006842-199601000-00007; FRIEDMAN MJ, 1994, TOXICOL IND HEALTH, V10, P449; Furlong CE, 2000, GENOME RES, V10, P153, DOI 10.1101/gr.10.2.153; Garbe TR, 2001, Z NATURFORSCH C, V56, P483; Gilbert ME, 2001, ANN NY ACAD SCI, V933, P68; Gots RE, 1996, REGUL TOXICOL PHARM, V24, pS8, DOI 10.1006/rtph.1996.0071; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; GURDAL H, 1992, PHARMACOLOGY, V44, P290, DOI 10.1159/000138932; Hageman G, 1999, J NEUROL, V246, P198, DOI 10.1007/s004150050334; HALEY JE, 1990, BRAIN RES, V518, P218, DOI 10.1016/0006-8993(90)90975-H; Haley RW, 1999, TOXICOL APPL PHARM, V157, P227, DOI 10.1006/taap.1999.8703; Hawkins RD, 1998, PROG BRAIN RES, V118, P155; Heresco-Levy U, 1998, EUR NEUROPSYCHOPHARM, V8, P141, DOI 10.1016/S0924-977X(97)00050-3; Heuser G, 2001, ANN NY ACAD SCI, V933, P319; HEUSER G, 1994, TOXICOL IND HEALTH, V10, P561; Hodgson MJ, 1999, J OCCUP ENVIRON MED, V41, P443, DOI 10.1097/00043764-199906000-00010; Hooper DC, 2000, FASEB J, V14, P691, DOI 10.1096/fasebj.14.5.691; Hooper DC, 2001, J IMMUNOL, V167, P3470, DOI 10.4049/jimmunol.167.6.3470; *IA PERS GULF STUD, 1997, JAMA-J AM MED ASSOC, V227, P238; Ikeda K, 1997, ACT NEUR S, V70, P4; Imaizumi S, 1996, NEUROCHEM INT, V29, P205, DOI 10.1016/0197-0186(95)00120-4; Itzhak Y, 1996, NEUROPHARMACOLOGY, V35, P1065, DOI 10.1016/S0028-3908(96)00037-8; Itzhak Y, 2000, NEUROPHARMACOLOGY, V39, P32, DOI 10.1016/S0028-3908(99)00073-8; ITZHAK Y, 1995, MOL NEUROBIOL, V11, P217, DOI 10.1007/BF02740696; IZHAK Y, 1998, PSYCHOPHARMACOLOGY B, V140, P378; JOHNSON A, 2000, CASUALTIES PROGR; Kastenbauer S, 1999, J INFECT DIS, V180, P1164, DOI 10.1086/315048; Kean RB, 2000, J IMMUNOL, V165, P6511, DOI 10.4049/jimmunol.165.11.6511; Kennedy M, 1998, GASTROENTEROLOGY, V114, P510, DOI 10.1016/S0016-5085(98)70534-7; KHATSENKO OG, 1993, P NATL ACAD SCI USA, V90, P11147, DOI 10.1073/pnas.90.23.11147; Kipen HM, 1999, ARCH ENVIRON HEALTH, V54, P313, DOI 10.1080/00039899909602493; Kissin I, 2000, ANESTH ANALG, V91, P110, DOI 10.1097/00000539-200007000-00021; Kreutzer R, 1999, AM J EPIDEMIOL, V150, P1; KURIYAMA K, 1995, JPN J PHARMACOL, V34, P347; LAFONCAZAL M, 1993, NEUROPHARMACOLOGY, V32, P1259, DOI 10.1016/0028-3908(93)90020-4; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Lallement G, 1999, NEUROTOXICOLOGY, V20, P675; Lallement G, 1998, J PHYSIOLOGY-PARIS, V92, P369, DOI 10.1016/S0928-4257(99)80007-2; Lam HHD, 1996, NEUROSCI LETT, V210, P201, DOI 10.1016/0304-3940(96)12702-6; Li L, 2001, TOXICOL APPL PHARM, V177, P17, DOI 10.1006/taap.2001.9283; Liang J, 1999, NAT STRUCT BIOL, V6, P735; LIPTON SA, 1994, MOL NEUROBIOL, V8, P181, DOI 10.1007/BF02780669; Liu JSH, 2001, AM J PATHOL, V158, P2057, DOI 10.1016/S0002-9440(10)64677-9; Loopuijt LD, 1998, AMINO ACIDS, V14, P17, DOI 10.1007/BF01345237; Mao JR, 2001, ANN NY ACAD SCI, V933, P175; MATTIA CJ, 1993, MOL CHEM NEUROPATHOL, V18, P313, DOI 10.1007/BF03160122; Mayhan WG, 2000, BRAIN RES, V866, P101, DOI 10.1016/S0006-8993(00)02254-X; McMahon S B, 1993, Curr Opin Neurobiol, V3, P602, DOI 10.1016/0959-4388(93)90062-4; Meggs WJ, 1997, ENVIRON HEALTH PERSP, V105, P473, DOI 10.2307/3433355; MICKIEWICZ W, 1988, BIOCHEM PHARMACOL, V37, P4439, DOI 10.1016/0006-2952(88)90658-2; MILLER CS, 1995, ARCH ENVIRON HEALTH, V50, P119, DOI 10.1080/00039896.1995.9940889; Miller CS, 1999, TOXICOL IND HEALTH, V15, P284, DOI 10.1191/074823399678846871; Montastruc JL, 1997, NEUROSCI BIOBEHAV R, V21, P477, DOI 10.1016/S0149-7634(96)00035-8; Muller CM, 1996, ANESTHESIOLOGY, V84, P1435, DOI 10.1097/00000542-199606000-00020; MURRAY CW, 1991, PAIN, V44, P179, DOI 10.1016/0304-3959(91)90135-K; Muttray A, 1995, Int J Occup Med Environ Health, V8, P131; Nag S, 2001, LAB INVEST, V81, P41, DOI 10.1038/labinvest.3780210; Nash JE, 2000, J NEUROSCI, V20, P7782; Nicolson G L, 1998, Med Confl Surviv, V14, P156, DOI 10.1080/13623699808409384; Nohl H, 1996, FREE RADICAL BIO MED, V20, P207, DOI 10.1016/0891-5849(95)02038-1; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OHLSON CG, 1981, SCAND J WORK ENV HEA, V7, P252, DOI 10.5271/sjweh.2549; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Pall ML, 2001, ANN NY ACAD SCI, V933, P323; Pall ML, 2001, MED HYPOTHESES, V57, P139, DOI 10.1054/mehy.2001.1325; Pall ML, 2000, MED HYPOTHESES, V54, P115, DOI 10.1054/mehy.1998.0825; Pall ML, 2001, J CHRONIC FATIGUE SY, V8, P39; Pall ML, 2000, J CHRONIC FATIGUE SY, V7, P45, DOI [10.1300/J092v07n04_05, DOI 10.1300/J092V07N04_05]; PALL ML, 2002, IN PRESS J CHRONIC F; Palmer GC, 2000, AMINO ACIDS, V19, P151, DOI 10.1007/s007260070043; Parales RE, 2000, APPL ENVIRON MICROB, V66, P4098, DOI 10.1128/AEM.66.9.4098-4104.2000; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; Pezzoli G, 2000, NEUROLOGY, V55, P667, DOI 10.1212/WNL.55.5.667; PIETROBON D, 1987, BIOCHEMISTRY-US, V26, P7339, DOI 10.1021/bi00397a022; Platenik J, 2000, LIFE SCI, V67, P335, DOI 10.1016/S0024-3205(00)00632-9; Prast H, 2001, PROG NEUROBIOL, V64, P51, DOI 10.1016/S0301-0082(00)00044-7; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; REA WJ, 1992, CHEM SENSITIVITY, V1; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; Riederer P, 2000, J NEUROL, V247, P8; ROMERO G, 1994, LIFE SCI, V55, P981, DOI 10.1016/0024-3205(94)00632-6; Ross GH, 1999, TOXICOL IND HEALTH, V15, P415, DOI 10.1191/074823399678846853; Rossi J, 1996, TOXICOLOGY, V111, P87, DOI 10.1016/0300-483X(96)03394-X; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; Schultz JB, 1997, MOL CELL BIOCHEM, V174, P171; Sharom FJ, 2001, SEMIN CELL DEV BIOL, V12, P257, DOI 10.1006/scdb.2000.0251; SIMON TR, 1994, TOXICOL IND HEALTH, V10, P573; Singh J., 1995, Indian Journal of Physiology and Pharmacology, V39, P275; Smargiassi A, 1998, NEUROTOXICOLOGY, V19, P709; Snyder S H, 1992, Curr Opin Neurobiol, V2, P323, DOI 10.1016/0959-4388(92)90123-3; Sorg BA, 1997, ENVIRON HEALTH PERSP, V105, P467, DOI 10.2307/3433354; Sorg BA, 2001, ANN NY ACAD SCI, V933, P57; Sorg BA, 1999, CRIT REV NEUROBIOL, V13, P283, DOI 10.1615/CritRevNeurobiol.v13.i3.30; Spitsin SV, 2000, NEUROSCI LETT, V292, P137, DOI 10.1016/S0304-3940(00)01446-4; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Takemura S, 1999, J HEPATOL, V30, P1035, DOI 10.1016/S0168-8278(99)80257-8; TANNER CM, 1992, OCCUP MED, V7, P503; Tochio H, 1998, NAT STRUCT BIOL, V5, P965, DOI 10.1038/2940; TURSKI L, 1993, EXPERIENTIA, V49, P1064, DOI 10.1007/BF01929915; UITTI RJ, 1994, ANN NEUROL, V35, P616, DOI 10.1002/ana.410350516; Wang H, 1999, J NEUROSCI RES, V57, P824, DOI 10.1002/(SICI)1097-4547(19990915)57:6<824::AID-JNR7>3.0.CO;2-V; WIERTELAK EP, 1994, BRAIN RES, V649, P19, DOI 10.1016/0006-8993(94)91044-8; Williams JH, 1996, J LIPID MEDIAT CELL, V14, P331, DOI 10.1016/0929-7855(96)00542-1; Willis WD, 2001, ANN NY ACAD SCI, V933, P142; Winkler F, 2001, J INFECT DIS, V183, P1749, DOI 10.1086/320730; Yunus MB, 2000, J INDIAN RHEUM ASS, V8, P27; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213; ZIEM G, 1995, ARCH INTERN MED, V155, P1913, DOI 10.1001/archinte.155.17.1913; Ziem G, 1997, ENVIRON HEALTH PERSP, V105, P417, DOI 10.2307/3433348	162	47	48	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2002	16	11					1407	1417		10.1096/fj.01-0861hyp	http://dx.doi.org/10.1096/fj.01-0861hyp			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12205032				2022-12-28	WOS:000178441800015
J	Mori, R; Kondo, T; Ohshima, T; Ishida, Y; Mukaida, N				Mori, R; Kondo, T; Ohshima, T; Ishida, Y; Mukaida, N			Accelerated wound healing in tumor necrosis factor receptor p55-deficient mice with reduced leukocyte infiltration	FASEB JOURNAL			English	Article						TNF-Rp55; angiogenesis; collagen production	GROWTH-FACTOR-BETA; GRANULATION-TISSUE MYOFIBROBLASTS; MUSCLE ACTIN EXPRESSION; FACTOR-ALPHA TRANSGENE; GENE-EXPRESSION; INFLAMMATORY CYTOKINES; CULTURED FIBROBLASTS; PULMONARY FIBROSIS; COLLAGEN-SYNTHESIS; ENDOTHELIAL-CELLS	To clarify biological roles of tumor necrosis factor receptor p55 (TNF-Rp55)-mediated signals in wound healing, skin excisions were prepared in BALB/c (WT) and TNF-Rp55-deficient (KO) mice. In WT mice, the wound area was reduced to 50% of the original area 6 days after injury, with angiogenesis and collagen accumulation. Histopathologically, reepithelialization rate was similar to80% 6 days. Myeloperoxidase activity and macrophage recruitment were the most evident 1 and 6 days after injury, respectively. Gene expression of adhesion molecules, interleukin 1alpha (IL-1alpha), IL-1beta, monocyte chemoattractant protein 1, macrophage inflammatory protein 1alpha (MIP-1alpha), MIP-2, transforming growth factor beta1 (TGF-beta1) connective tissue growth factor (CTGF), vascular endothelial growth factor (VEGF), Flt-1, and Flk-1 was enhanced at the wound site. In KO mice, an enhancement in angiogenesis, collagen content, and reepithelialization was accelerated with the increased gene expression of TGF-beta1, CTGF, VEGF, Flt-1, and Flk-1 at the wound sites, resulting in accelerated wound healing compared with WT mice. In contrast, leukocyte infiltration, mRNA expression of adhesion molecules, and cytokines were significantly reduced in KO mice. These observations suggest that TNF-Rp55-mediated signals have some role in promoting leukocyte infiltration at the wound site and negatively affect wound healing, probably by reducing angiogenesis and collagen accumulation.	Kanazawa Univ, Grad Sch Med Sci, Div Environm Sci Forens & Social Environm Med, Kanazawa, Ishikawa 9208640, Japan; Kanazawa Univ, Canc Res Inst, Div Mol Bioregulat, Kanazawa, Ishikawa 920, Japan	Kanazawa University; Kanazawa University	Ohshima, T (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Div Environm Sci Forens & Social Environm Med, 13-1 Takaramachi, Kanazawa, Ishikawa 9208640, Japan.	ohshimat@med.kanazawa-u.ac.jp	Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851; Kondo, Toshikazu/0000-0002-5059-8309; Mori, Ryoichi/0000-0002-7596-9620				Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; ARMENDARIZBORUNDA J, 1992, J BIOL CHEM, V267, P14316; Ashcroft GS, 2000, NAT MED, V6, P1147, DOI 10.1038/80489; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; BECK LS, 1993, J CLIN INVEST, V92, P2841, DOI 10.1172/JCI116904; BETTINGER DA, 1994, J TRAUMA, V36, P810, DOI 10.1097/00005373-199406000-00010; Bryant D, 1998, CIRCULATION, V97, P1375, DOI 10.1161/01.CIR.97.14.1375; Buck M, 1996, AM J PATHOL, V149, P195; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHENG J, 1992, GENE DEV, V6, P1444, DOI 10.1101/gad.6.8.1444; DANON D, 1989, P NATL ACAD SCI USA, V86, P2018, DOI 10.1073/pnas.86.6.2018; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; DESMOULIERE A, 1992, LAB INVEST, V67, P716; DINARELLO CA, 1986, J EXP MED, V163, P1433, DOI 10.1084/jem.163.6.1433; DIPIETRO LA, 1995, AM J PATHOL, V146, P868; DiPietro LA, 1998, J CLIN INVEST, V101, P1693, DOI 10.1172/JCI1020; Fahey T J 3rd, 1990, Cytokine, V2, P92, DOI 10.1016/1043-4666(90)90002-B; FAJARDO LF, 1992, AM J PATHOL, V140, P539; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; HEBDA PA, 1988, J INVEST DERMATOL, V91, P440, DOI 10.1111/1523-1747.ep12476480; HIGUCHI Y, 1992, J EXP MED, V176, P1719, DOI 10.1084/jem.176.6.1719; HOUCK JC, 1961, J INVEST DERMATOL, V36, P451, DOI 10.1038/jid.1961.69; IWAI M, 1995, J CLIN ENDOCR METAB, V80, P450, DOI 10.1210/jc.80.2.450; Jensen JM, 1999, J CLIN INVEST, V104, P1761, DOI 10.1172/JCI5307; Kondo T, 1996, INT J LEGAL MED, V108, P231, DOI 10.1007/BF01369816; LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; MAGNATTI P, 1996, MOL CELLULAR BIOL WO, P427; MAHADEVAN V, 1989, CANCER RES, V49, P415; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MIYAZAKI Y, 1995, J CLIN INVEST, V96, P250, DOI 10.1172/JCI118029; MOONEY DP, 1990, ANN SURG, V211, P124, DOI 10.1097/00000658-199002000-00002; MUSTOE TA, 1987, SCIENCE, V237, P1333, DOI 10.1126/science.2442813; Nagaoka T, 2000, AM J PATHOL, V157, P237, DOI 10.1016/S0002-9440(10)64534-8; NAKAYAMA H, 1992, NUCLEIC ACIDS RES, V20, P4939, DOI 10.1093/nar/20.18.4939; Neumann B, 1996, J IMMUNOL, V156, P1587; Ozawa K, 2001, J CLIN INVEST, V108, P41, DOI 10.1172/JCI11772; Patterson C, 1996, J CLIN INVEST, V98, P490, DOI 10.1172/JCI118816; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PIGUET PF, 1989, J EXP MED, V170, P655, DOI 10.1084/jem.170.3.655; PIGUET PF, 1990, NATURE, V344, P245, DOI 10.1038/344245a0; QUAGLINO D, 1991, J INVEST DERMATOL, V97, P34; RAPALA K, 1991, EUR SURG RES, V23, P261, DOI 10.1159/000129163; REGAN MC, 1993, SURGERY, V113, P173; ROESEL JF, 1995, J SURG RES, V58, P449, DOI 10.1006/jsre.1995.1071; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SALOMON GD, 1991, ANN SURG, V214, P175, DOI 10.1097/00000658-199108000-00012; Sato Y, 2000, INT J LEGAL MED, V113, P140, DOI 10.1007/s004140050285; SCHALL TJ, 1994, CYTOKINE HDB, P419; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; SPORN MB, 1993, J CLIN INVEST, V92, P2565, DOI 10.1172/JCI116868; Subramaniam M, 1997, AM J PATHOL, V150, P1701; Swift ME, 1999, LAB INVEST, V79, P1479; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TRACEY KJ, 1994, CYTOKINE HDB, P289; Tsuji H, 1997, INFECT IMMUN, V65, P1892, DOI 10.1128/IAI.65.5.1892-1898.1997; YOKOI H, 1993, BIOCHEM BIOPH RES CO, V195, P769, DOI 10.1006/bbrc.1993.2112; Yokoi K, 1997, LAB INVEST, V76, P375	62	208	217	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					963	974		10.1096/fj.01-0776com	http://dx.doi.org/10.1096/fj.01-0776com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087057				2022-12-28	WOS:000177813100027
J	Hazan, U; Romero, IA; Cancello, R; Valente, S; Perrin, V; Mariot, V; Dumonceaux, J; Gerhardt, CC; Strosberg, AD; Couraud, PO; Pietri-Rouxel, F				Hazan, U; Romero, IA; Cancello, R; Valente, S; Perrin, V; Mariot, V; Dumonceaux, J; Gerhardt, CC; Strosberg, AD; Couraud, PO; Pietri-Rouxel, F			Human adipose cells express CD4, CXCR4, and CCR5 receptors: a new target cell type for the immunodeficiency virus-1?	FASEB JOURNAL			English	Article						expression of CD4; coreceptors; HIV entry; adipocytes	CHEMOKINE RECEPTORS; TNF-ALPHA; DC-SIGN; INFECTION; HIV-1; ENTRY; SECRETION; TISSUE; MACROPHAGES; CORECEPTORS	The concept that adipocytes belong to an essential endocrine system with some characteristics of immune cells has recently emerged. The aim of this paper is to present evidence of the expression of CD4, CXCR4, and CCR5 receptors by human adipocytes and to test whether adipose cells support HIV entry. Primary human preadipocytes were cultured and differentiated in vitro. Expression of the three receptors on preadipocytes and adipocytes was demonstrated by reverse transcriptase-polymerase chain reaction, immunocytochemical, and immunohistochemical analysis. Infection of adipose cells to HIV-1 was then investigated. The measurement of the viral p24 antigen in preadipocyte culture medium showed an increase of p24 levels between 24 and 72 h postexposure and then a progressive decrease to reach a low level at 10-15 days. Ten days after the infection test, supernatant of preadipocytes contained infectious particles able to infect the susceptible T-CD4 CEM cell line. The expression of viral proteins by adipocytes was confirmed using a fusion test. The presence of viral DNA was exhibited by gag-specific polymerase chain reaction, supporting the hypothesis of HIV-1 X4- and R5-virus entry in preadipocytes. Adipose cells represent the first cell type that does not belong to the immune system expressing all specific HIV receptors and may represent new HIV-1 target cells.	Inst Cochin Genet Mol, CNRS, UPR 0415, F-75014 Paris, France; Inst Cochin Genet Mol, INSERM, U380, F-75014 Paris, France; Univ Paris 07, F-75251 Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Pietri-Rouxel, F (corresponding author), Inst Cochin Genet Mol, CNRS, UPR 0415, 22 Rue Mechain, F-75014 Paris, France.	pietri-rouxel@cochin.inserm.fr	Dumonceaux, Julie/H-3621-2013; Romero, Ignacio/A-7381-2008	Pietri-Rouxel, France/0000-0002-6258-7594; Romero, Ignacio/0000-0002-0322-9180				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Ailhaud G, 2000, INT J OBESITY, V24, pS1, DOI 10.1038/sj.ijo.0801267; Bailer RT, 2000, EUR J IMMUNOL, V30, P1340, DOI 10.1002/(SICI)1521-4141(200005)30:5<1340::AID-IMMU1340>3.0.CO;2-L; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bornstein SR, 2000, DIABETES, V49, P532, DOI 10.2337/diabetes.49.4.532; Clapham PR, 1999, MOL MEMBR BIOL, V16, P49, DOI 10.1080/096876899294751; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; Cousin B, 1999, FASEB J, V13, P305, DOI 10.1096/fasebj.13.2.305; Dumonceaux J, 1998, J VIROL, V72, P512, DOI 10.1128/JVI.72.1.512-519.1998; ELLRODT A, 1984, LANCET, V1, P1383; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Gerhardt CC, 2001, MOL CELL ENDOCRINOL, V175, P81, DOI 10.1016/S0303-7207(01)00394-X; Ghorpade A, 1998, J VIROL, V72, P3351, DOI 10.1128/JVI.72.4.3351-3361.1998; Gottschling-Zeller H, 2000, METABOLISM, V49, P666, DOI 10.1016/S0026-0495(00)80046-3; Hornung F, 2000, J IMMUNOL, V164, P6180, DOI 10.4049/jimmunol.164.12.6180; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Hung CS, 1999, VIROLOGY, V264, P278, DOI 10.1006/viro.1999.0013; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Naif HM, 1998, J VIROL, V72, P830, DOI 10.1128/JVI.72.1.830-836.1998; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Pohlmann S, 2001, J VIROL, V75, P4664, DOI 10.1128/JVI.75.10.4664-4672.2001; Sethi JK, 1999, SEMIN CELL DEV BIOL, V10, P19, DOI 10.1006/scdb.1998.0273; Zilberfarb V, 1997, J CELL SCI, V110, P801	24	57	57	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1254	+		10.1096/fj.01-0947fje	http://dx.doi.org/10.1096/fj.01-0947fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12153994				2022-12-28	WOS:000176683900015
J	Judex, S; Donahue, LR; Rubin, C				Judex, S; Donahue, LR; Rubin, C			Genetic predisposition to low bone mass is paralleled by an enhanced sensitivity to signals anabolic to the skeleton	FASEB JOURNAL			English	Article						trabecular bone; mechanical intervention; high-frequency mechanical stimuli; genetic variation; bone formation; osteoporosis	MINERAL DENSITY; ESTROGEN-RECEPTOR; LOW-MAGNITUDE; STRAIN; POLYMORPHISM; EXERCISE; HISTOMORPHOMETRY; SUSCEPTIBILITY; OSTEOPOROSIS; ARCHITECTURE	The structure of the adult skeleton is determined, in large part, by its genome. Whether genetic variations may influence the effectiveness of interventions to combat skeletal diseases remains unknown. The differential response of trabecular bone to an anabolic (low-level mechanical vibration) and a catabolic (disuse) mechanical stimulus were evaluated in three strains of adult mice. In low bone-mineral-density C57BL/6J mice, the low-level mechanical signal caused significantly larger bone formation rates (BFR) in the proximal tibia, but the removal of functional weight bearing did not significantly alter BFR. In mid-density BALB/cByJ mice, mechanical stimulation also increased BFR, whereas disuse significantly decreased BFR. In contrast, neither anabolic nor catabolic mechanical signals influenced any index of bone formation in high-density C3H/HeJ mice. Together, data from this study indicate that the sensitivity of trabecular tissue to both anabolic and catabolic stimuli is influenced by the genome. Extrapolated to humans, these results may explain in part why prophylaxes for low bone mass are not universally effective, yet also indicate that there may be a genotypic indication of people who are at reduced risk of suffering from bone loss.	SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA; Jackson Lab, Bar Harbor, ME 04609 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Jackson Laboratory	Judex, S (corresponding author), SUNY Stony Brook, Dept Biomed Engn, Psychol A Bldg,3rd Floor, Stony Brook, NY 11794 USA.	stefan.judex@sunysb.edu						Akhter MP, 1998, CALCIFIED TISSUE INT, V63, P442, DOI 10.1007/s002239900554; Aloia JF, 1999, CALCIFIED TISSUE INT, V65, P29, DOI 10.1007/s002239900653; ANDERSON JJB, 1994, ADV NUTR RES, V9, P129; [Anonymous], 2000, NIH Consens Statement, V17, P1; Beamer WG, 1996, BONE, V18, P397, DOI 10.1016/8756-3282(96)00047-6; Bohannon AD, 1999, J WOMEN HEALTH GEN-B, V8, P609, DOI 10.1089/jwh.1.1999.8.609; Brown MA, 2001, J BONE MINER RES, V16, P758, DOI 10.1359/jbmr.2001.16.4.758; CHAMBERS TJ, 1993, BONE MINER, V20, P167, DOI 10.1016/S0169-6009(08)80025-6; Eisman JA, 1999, ENDOCR REV, V20, P788, DOI 10.1210/er.20.6.788; Ensrud KE, 1997, ARCH INTERN MED, V157, P2617, DOI 10.1001/archinte.157.22.2617; Erben RG, 1997, J HISTOCHEM CYTOCHEM, V45, P307, DOI 10.1177/002215549704500215; Fritton JC, 1997, ANN BIOMED ENG, V25, P831, DOI 10.1007/BF02684167; Hanley DA, 2000, J CLIN DENSITOM, V3, P79, DOI 10.1385/JCD:3:1:079; HEANEY RP, 1995, J CLIN ENDOCR METAB, V80, P2289, DOI 10.1210/jc.80.8.2289; HOUDE JP, 1995, CLIN ORTHOP RELAT R, P199; Judex S, 1997, J BONE MINER RES, V12, P1737, DOI 10.1359/jbmr.1997.12.10.1737; Jurada S, 2001, J STEROID BIOCHEM, V78, P15, DOI 10.1016/S0960-0760(01)00069-3; KANIS JA, 1993, OSTEOPOROSIS INT, V3, pS10; Karpf DB, 1997, JAMA-J AM MED ASSOC, V277, P1159; Kodama Y, 2000, CALCIFIED TISSUE INT, V66, P298, DOI 10.1007/s002230010060; Kodama Y, 1999, BONE, V25, P183, DOI 10.1016/S8756-3282(99)00155-6; Koller DL, 2000, J CLIN ENDOCR METAB, V85, P3116, DOI 10.1210/jc.85.9.3116; LeBlanc A., 1999, 1 BIENN SPAC BIOM IN, V1, P17; Lorentzon M, 2001, J BONE MINER METAB, V19, P302, DOI 10.1007/s007740170014; Morey E R, 1979, Physiologist, V22, pS23; Mosley JR, 1997, BONE, V20, P191, DOI 10.1016/S8756-3282(96)00385-7; Obermayer-Pietsch BM, 2000, J BONE MINER RES, V15, P1950, DOI 10.1359/jbmr.2000.15.10.1950; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; PEAD MJ, 1988, J BONE MINER RES, V3, P647; Qin YX, 1998, J ORTHOPAED RES, V16, P482, DOI 10.1002/jor.1100160414; Rubin C, 2000, J BONE MINER RES, V15, pS557; Rubin C, 2002, J BONE MINER RES, V17, P349, DOI 10.1359/jbmr.2002.17.2.349; Rubin C, 2001, FASEB J, V15, P2225, DOI 10.1096/fj.01-0166com; Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122; RUBIN CT, 1985, CALCIFIED TISSUE INT, V37, P411, DOI 10.1007/BF02553711; RUBIN CT, 1984, CALCIFIED TISSUE INT, V36, pS11, DOI 10.1007/BF02406128; Rubin CT, 2001, DRUG DISCOV TODAY, V6, P848, DOI 10.1016/S1359-6446(01)01872-4; Snow CM, 2000, J GERONTOL A-BIOL, V55, pM489, DOI 10.1093/gerona/55.9.M489; Yamada Y, 1998, J BONE MINER RES, V13, P1569, DOI 10.1359/jbmr.1998.13.10.1569	39	120	126	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1280	+		10.1096/fj.01-0913fje	http://dx.doi.org/10.1096/fj.01-0913fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12153999				2022-12-28	WOS:000176683900027
J	Grossin, L; Cournil-Henrionnet, C; Mir, LM; Liagre, B; Dumas, D; Etienne, S; Guingamp, C; Netter, P; Gillet, P				Grossin, L; Cournil-Henrionnet, C; Mir, LM; Liagre, B; Dumas, D; Etienne, S; Guingamp, C; Netter, P; Gillet, P			Direct gene transfer into rat articular cartilage by in vivo electroporation	FASEB JOURNAL			English	Article						electropermeabilization; in vivo gene transfer; electro gene therapy; GFP; patellar cartilage	VIRAL VECTORS; THERAPY	To establish a system for efficient direct in vivo gene targeting into rat joint, we have evaluated a strategy of gene transfer by means of the delivery of external electric pulses (EP) to the knee after intra-articular injection of a reporter gene (GFP). Rats were killed at various times after the electro gene-therapy to analyze GFP gene expression by immunohistochemistry. GFP staining was detected in the superficial, middle, and deep zones of the patellar cartilage at days 2 and 9, and thereafter only in the deep zone (months 1 and 2). The average percentage of GFP-positive cells was estimated at 30% both one and 2 months after the gene transfer. Moreover, no pathologic change caused by the EP was detected in the cartilage. The level and stability of the long-term GFP expression found in this study demonstrate the feasibility of a treatment of joint disorders (inflammatory or degenerative, focal or diffuse) using electric gene transfer.	Univ Nancy 1, Fac Med, CNRS, UMR 7561, F-54505 Vandoeuvre Les Nancy, France; Univ Nancy 1, Fac Med, CNRS, UMR Mecan & Ingn Cellulaire & Tissulaire 7563, F-54505 Vandoeuvre Les Nancy, France; Inst Gustave Roussy, CNRS, UMR Vectorol & Transfert Genes 8121, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Netter, P (corresponding author), Univ Nancy 1, Fac Med, CNRS, UMR 7561, Ave Foret Haye,BP184, F-54505 Vandoeuvre Les Nancy, France.	Patrick.Netter@medecine.uhp-nancy.fr	Dumas, Dominique DD/A-5633-2012; MIR, Lluis M/AAJ-9110-2020	GROSSIN, Laurent/0000-0001-6761-0936; Liagre, Bertrand/0000-0003-4148-2598; GILLET, Pierre/0000-0002-0598-7508; Christel, HENRIONNET/0000-0001-7484-0377; Cournil, Christel/0000-0002-4827-4276				Banga AK, 1998, TRENDS BIOTECHNOL, V16, P408, DOI 10.1016/S0167-7799(98)01238-4; Baragi VM, 1997, OSTEOARTHR CARTILAGE, V5, P275, DOI 10.1016/S1063-4584(97)80023-4; Dumas D, 2000, BIORHEOLOGY, V37, P165; Evans CH, 1999, ARTHRITIS RHEUM-US, V42, P1, DOI 10.1002/1529-0131(199901)42:1<1::AID-ANR1>3.0.CO;2-4; Gao JZ, 2001, TISSUE ENG, V7, P363, DOI 10.1089/10763270152436427; Goater J, 2000, J RHEUMATOL, V27, P983; Goomer RS, 2001, OSTEOARTHR CARTILAGE, V9, P248, DOI 10.1053/joca.2000.0382; Guingamp C, 1997, ARTHRITIS RHEUM, V40, P1670, DOI 10.1002/art.1780400917; Hong K, 2001, BIOMOL ENG, V18, P185, DOI 10.1016/S1389-0344(01)00100-9; Inoue T, 2001, NAT NEUROSCI, V4, P1156, DOI 10.1038/nn1101-1156; LIND L, 1989, DIABETES RES CLIN EX, V11, P141; Madry H, 2001, GENE THER, V8, P1443, DOI 10.1038/sj.gt.3301535; Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262; MIR LM, 1998, CR ACAD SCI III-VIE, V1, P893; Muramatsu T, 1998, INT J MOL MED, V1, P55; Noth U, 2002, TISSUE ENG, V8, P131, DOI 10.1089/107632702753503126; Ohashi S, 2002, BIOCHEM BIOPH RES CO, V293, P1530, DOI 10.1016/S0006-291X(02)00386-8; Pelletier JP, 1999, OSTEOARTHR CARTILAGE, V7, P374, DOI 10.1053/joca.1998.0215; Robbins PD, 1998, PHARMACOL THERAPEUT, V80, P35, DOI 10.1016/S0163-7258(98)00020-5; Rols MP, 1998, NAT BIOTECHNOL, V16, P168, DOI 10.1038/nbt0298-168; Satkauskas S, 2002, MOL THER, V5, P133, DOI 10.1006/mthe.2002.0526; Spack EG, 2001, DRUG DISCOV TODAY, V6, P186, DOI 10.1016/S1359-6446(00)01633-0; Tomita T, 1997, ARTHRITIS RHEUM, V40, P901, DOI 10.1002/art.1780400518; VANDENBERG WB, 1982, RHEUMATOL INT, V1, P165, DOI 10.1007/BF00541171; Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410; Vervoordeldonk MJBM, 2001, BEST PRACT RES CL RH, V15, P771, DOI 10.1053/berh.2001.0193; Vicat JM, 2000, HUM GENE THER, V11, P909, DOI 10.1089/10430340050015518; Watrin A, 2001, RADIOLOGY, V219, P395, DOI 10.1148/radiology.219.2.r01ma32395; WOLF H, 1994, BIOPHYS J, V66, P524, DOI 10.1016/S0006-3495(94)80805-7	29	36	37	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					829	835		10.1096/fj.02-0518com	http://dx.doi.org/10.1096/fj.02-0518com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724342				2022-12-28	WOS:000183165000009
J	Hansel, TT; Kharitonov, SA; Donnelly, LE; Erin, EM; Currie, MG; Moore, WM; Manning, PT; Recker, DP; Barnes, PJ				Hansel, TT; Kharitonov, SA; Donnelly, LE; Erin, EM; Currie, MG; Moore, WM; Manning, PT; Recker, DP; Barnes, PJ			A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics	FASEB JOURNAL			English	Article						respiratory; pharmacology; tolerability	OBSTRUCTIVE PULMONARY-DISEASE; INOS INHIBITOR; AIRWAYS; LUNG; MICE; AIR; BRONCHODILATOR; NITROTYROSINE; PEROXYNITRITE; INFLAMMATION	The inducible isoenzyme of nitric oxide synthase (iNOS) generates nitric oxide (NO) in inflammatory diseases such as asthma. The prodrug L-N-6-(1-iminoethyl)lysine 5-tetrazole amide (SC-51) is rapidly converted in vivo to the active metabolite L-N-6-(1-iminoethyl)lysine (L-NIL). Initially, we performed in vitro experiments in human primary airway epithelial cells to demonstrate that L-NIL causes inhibition of iNOS. In a randomized double-blind placebo-controlled crossover trial, SC-51 was administered as a single oral dose (20 or 200 mg) in separate cohorts of healthy volunteers (two groups of n=12) and mild asthmatic patients (two groups of n=12). SC-51 (200 mg) reduced exhaled breath NO levels to <2 ppb in both healthy volunteers (P<0.001) and mild asthmatics (P<0.001) within 15 min, representing >90% inhibition of baseline levels of NO in asthmatic patients, with the effects lasting at least 72 h. There were no significant effects on blood pressure, pulse rate, or respiratory function (FEV1). This study demonstrates that an inhibitor of iNOS produces marked inhibition of exhaled breath NO in normal and asthmatic subjects without producing the side effects observed following the systemic administration of non-selective NOS inhibitors, and thus provides support for the potential use of iNOS inhibitors to treat a range of inflammatory clinical disorders.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Clin Studies Unit, London, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London, England; Pharmacia Corp, Skokie, IL USA; Pharmacia Corp, St Louis, MO USA	Imperial College London; Imperial College London; Pfizer; Pfizer	Hansel, TT (corresponding author), Royal Brompton Hosp, NHLI Clin Studies Unit, London SW3 6HP, England.	t.hansel@imperial.ac.uk		Barnes, Peter/0000-0002-5122-4018; Donnelly, Louise/0000-0002-0753-5425				Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; ALVING K, 1993, EUR RESPIR J, V6, P1368; Amin Ashok R., 1999, Current Opinion in Rheumatology, V11, P202, DOI 10.1097/00002281-199905000-00009; Ashina M, 1999, LANCET, V353, P287, DOI 10.1016/S0140-6736(98)01079-4; Ashutosh K, 2000, THORAX, V55, P109, DOI 10.1136/thorax.55.2.109; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; BRYNE J, 2001, BR J CARDIOL, V8, P570; Clini E, 1998, THORAX, V53, P881, DOI 10.1136/thx.53.10.881; CONNOR JR, 1995, EUR J PHARMACOL, V273, P15, DOI 10.1016/0014-2999(94)00672-T; Corradi M, 1999, THORAX, V54, P572, DOI 10.1136/thx.54.7.572; Donnelly LE, 2001, AM J RESP CELL MOL, V24, P295, DOI 10.1165/ajrcmb.24.3.4001; Dworski R, 2000, THORAX, V55, pS51, DOI 10.1136/thorax.55.suppl_2.S51; Gomez FP, 1998, EUR RESPIR J, V12, P865, DOI 10.1183/09031936.98.12040865; Hallinan EA, 2002, J MED CHEM, V45, P1686, DOI 10.1021/jm010420e; Hanazawa T, 2000, AM J RESP CRIT CARE, V162, P1273, DOI 10.1164/ajrccm.162.4.9912064; Hart CM, 1999, CHEST, V115, P1407, DOI 10.1378/chest.115.5.1407; Hickey MJ, 2001, CLIN SCI, V100, P1, DOI 10.1042/CS20000135; Hobbs AJ, 1999, ANNU REV PHARMACOL, V39, P191, DOI 10.1146/annurev.pharmtox.39.1.191; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Ichinose M, 2000, AM J RESP CRIT CARE, V162, P701, DOI 10.1164/ajrccm.162.2.9908132; Kaminsky DA, 1999, J ALLERGY CLIN IMMUN, V104, P747, DOI 10.1016/S0091-6749(99)70283-6; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693, DOI 10.1164/ajrccm.163.7.2009041; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Koarai A, 2000, PULM PHARMACOL THER, V13, P267, DOI 10.1006/pupt.2000.0254; KUO HP, 1992, EUR J PHARMACOL, V221, P385; Leckie MJ, 2000, EXPERT OPIN INV DRUG, V9, P3, DOI 10.1517/13543784.9.1.3; Lipton AJ, 2001, NATURE, V413, P171, DOI 10.1038/35093117; Lopez-Jaramillo P, 1998, LANCET, V351, P1176, DOI 10.1016/S0140-6736(05)79119-4; Maziak W, 1998, AM J RESP CRIT CARE, V157, P998, DOI 10.1164/ajrccm.157.3.97-05009; MISKO TP, 1993, ANAL BIOCHEM, V214, P1; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; Moncada S, 1999, J ROY SOC MED, V92, P164, DOI 10.1177/014107689909200402; Moore WM, 1996, J MED CHEM, V39, P669, DOI 10.1021/jm950766n; Perner A, 1999, ALIMENT PHARM THERAP, V13, P135; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9; RITTER J, 2001, BR J CARDIOL, V8, P564; Rutgers SR, 1999, THORAX, V54, P576, DOI 10.1136/thx.54.7.576; Sadeghi-Hashjin G, 1998, CLIN EXP ALLERGY, V28, P1464; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829, DOI 10.1111/j.1476-5381.1996.tb15475.x; SALVEMINI D, 1995, J CLIN INVEST, V96, P301, DOI 10.1172/JCI118035; Shah AM, 2000, PHARMACOL THERAPEUT, V86, P49, DOI 10.1016/S0163-7258(99)00072-8; Singh S, 1997, EUR RESPIR J, V10, P699; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Stirling RG, 1998, THORAX, V53, P1030, DOI 10.1136/thx.53.12.1030; Szabo C, 1999, SHOCK, V12, P1, DOI 10.1097/00024382-199907000-00001; Taylor DA, 1998, AM J RESP CRIT CARE, V158, P99, DOI 10.1164/ajrccm.158.1.9709091; Thomsen LL, 1998, CLIN NEUROSCI, V5, P28; Torreilles J, 2001, FRONT BIOSCI-LANDMRK, V6, pD1161, DOI 10.2741/Torreill; Trifilieff A, 2000, J IMMUNOL, V165, P1526, DOI 10.4049/jimmunol.165.3.1526; Tulic MK, 2000, EUR RESPIR J, V15, P870, DOI 10.1183/09031936.00.15587000; VALLANCE P, 1989, LANCET, V2, P997; WARD JK, 1995, AM J RESP CELL MOL, V13, P175, DOI 10.1165/ajrcmb.13.2.7542897; Weinberger B, 1999, PHARMACOL THERAPEUT, V84, P401, DOI 10.1016/S0163-7258(99)00044-3; Xiong YL, 1999, J IMMUNOL, V162, P445; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892, DOI 10.1164/ajrccm.152.3.7663801; Yates DH, 1996, AM J RESP CRIT CARE, V154, P247, DOI 10.1164/ajrccm.154.1.8680689	59	151	161	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1298	+		10.1096/fj.02-0633fje	http://dx.doi.org/10.1096/fj.02-0633fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738811				2022-12-28	WOS:000183165000030
J	Flamant, M; Tharaux, PL; Placier, S; Henrion, D; Coffman, T; Chatziantoniou, C; Dussaule, JC				Flamant, M; Tharaux, PL; Placier, S; Henrion, D; Coffman, T; Chatziantoniou, C; Dussaule, JC			Epidermal growth factor receptor transactivation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice	FASEB JOURNAL			English	Article						EGF receptor; MAP kinase; fibrosis; vasoconstriction	ACTIVATED PROTEIN-KINASE; ANGIOTENSIN-II; EGF RECEPTOR; HYPERTENSIVE-RATS; COLLAGEN GENE; MITOGEN; INHIBITION; EXPRESSION; HYPERTROPHY; ANTAGONIST	Vascular remodeling and rearrangement of the extracellular matrix formation are among the major adaptive mechanisms in response to a chronic blood pressure increase. Vasoactive peptides, such as endothelin, participate in hypertension-associated vascular fibrosis by stimulating collagen I formation and increasing contractility of arterial wall. In the present study, we tested the hypothesis that activation of the epidermal growth factor (EGF) receptor pathway mediates these events. Experiments were performed in transgenic mice harboring the luciferase gene under the control of the collagen I-alpha2 chain promoter. Endothelin induced a rapid phosphorylation of the mitogen-activated protein kinase (MAPK)/ERK and increased collagen I gene activity in freshly isolated aortas. This effect of endothelin was totally inhibited by an endothelin receptor antagonist, an EGF receptor phosphorylation inhibitor, and a blocker of the MAPK/ERK cascade. In parallel experiments, inhibition of EGF receptor phosphorylation decreased the endothelin-induced pressor effect in isolated aortic rings and in anesthetized animals in vivo. In addition, the endothelin-induced increase of blood pressure was blunted in the waved-2 mice, a strain expressing functionally impaired EGF receptors. Our results provide the first evidence that the EGF receptor mediates at least two of the major actions of endothelin in the vascular tissue: contractility and fibrogenesis.	Hop Tenon, INSERM, U489, F-75020 Paris, France; Hop Lariboisiere, INSERM, U541, F-75010 Paris, France; VA Med Ctr, Div Nephrol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Nephrol, Durham, NC 27710 USA; CHU St Antoine, Serv Physiol, AP HP, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Duke University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Dussaule, JC (corresponding author), INSERM, U489, F-75020 Paris, France.	jean-claude.dussaule@sat.ap-hop-paris.fr	Henrion, Daniel/J-8141-2015; Tharaux, Pierre-Louis/A-9155-2009; Chatziantoniou, Christos/L-2501-2016; Henrion, Daniel/AAK-1995-2021; Henrion, Daniel/N-7023-2015	Henrion, Daniel/0000-0003-1094-0285; Tharaux, Pierre-Louis/0000-0002-6062-5905; Henrion, Daniel/0000-0003-1094-0285; Henrion, Daniel/0000-0003-1094-0285				Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; BERK BC, 1985, J CLIN INVEST, V75, P1083, DOI 10.1172/JCI111772; Boffa JJ, 1999, CIRCULATION, V100, P1901, DOI 10.1161/01.CIR.100.18.1901; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; Bouriquet N, 1996, HYPERTENSION, V27, P382, DOI 10.1161/01.HYP.27.3.382; Brilla CG, 2000, CIRCULATION, V102, P1388, DOI 10.1161/01.CIR.102.12.1388; Buist A, 1998, BIOCHEM BIOPH RES CO, V251, P6, DOI 10.1006/bbrc.1998.9405; Chatziantoniou C, 1998, J CLIN INVEST, V101, P2780, DOI 10.1172/JCI2132; CHUA BHL, 1992, AM J PHYSIOL, V262, pE412, DOI 10.1152/ajpendo.1992.262.4.E412; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dussaule JC, 2000, J AM SOC NEPHROL, V11, pS124; Fakhouri F, 2001, J AM SOC NEPHROL, V12, P2701, DOI 10.1681/ASN.V12122701; Florian JA, 2001, AM J PHYSIOL-REG I, V281, pR878, DOI 10.1152/ajpregu.2001.281.3.R878; Florian JA, 1999, AM J PHYSIOL-HEART C, V276, pH976, DOI 10.1152/ajpheart.1999.276.3.H976; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; Guo X, 1996, Hypertens Res, V19, P23, DOI 10.1291/hypres.19.23; HIRATA Y, 1989, ATHEROSCLEROSIS, V78, P225, DOI 10.1016/0021-9150(89)90227-X; Hocher B, 1997, J CLIN INVEST, V99, P1380, DOI 10.1172/JCI119297; Iwasaki H, 1999, ENDOCRINOLOGY, V140, P4659, DOI 10.1210/en.140.10.4659; IWASAKI H, J CARDIOVASC PHAR S1, V31, pS182; Kodama H, 2002, J MOL CELL CARDIOL, V34, P139, DOI 10.1006/jmcc.2001.1496; Kubo T, 1998, EUR J PHARMACOL, V347, P337, DOI 10.1016/S0014-2999(98)00111-3; LI JS, 1994, HYPERTENSION, V24, P183, DOI 10.1161/01.HYP.24.2.183; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Moreau P, 1997, CIRCULATION, V96, P1593, DOI 10.1161/01.CIR.96.5.1593; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; NAKAMURA T, 1995, KIDNEY INT, V47, P481, DOI 10.1038/ki.1995.61; Northcott C, 2001, HYPERTENSION, V38, P1337, DOI 10.1161/hy1201.096815; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RIPPETOE PE, 1989, AM REV RESPIR DIS, V140, P821, DOI 10.1164/ajrccm/140.3.821; RIVZI M, 1997, J MOL CELL CARDIOL, V29, P1779; Saito Y, 2001, J MOL CELL CARDIOL, V33, P3, DOI 10.1006/jmcc.2000.1272; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; Takemoto M, 1997, HYPERTENSION, V30, P1621, DOI 10.1161/01.HYP.30.6.1621; Tharaux PL, 2000, HYPERTENSION, V36, P330, DOI 10.1161/01.HYP.36.3.330; WANG Y, 1992, BIOCHEM J, V15, P587; WEBER KT, 1989, J AM COLL CARDIOL, V13, P1637, DOI 10.1016/0735-1097(89)90360-4	37	73	77	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					327	+		10.1096/fj.02-0115fje	http://dx.doi.org/10.1096/fj.02-0115fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475899				2022-12-28	WOS:000180574300026
J	Drobna, Z; Jaspers, I; Thomas, DJ; Styblo, M				Drobna, Z; Jaspers, I; Thomas, DJ; Styblo, M			Differential activation of AP-1 in human bladder epithelial cells by inorganic and methylated arsenicals	FASEB JOURNAL			English	Article						arsenic; methylation; ERK; JNK; cancer	SIGNAL-REGULATED KINASE; GROWTH-FACTOR RECEPTOR; MONOMETHYLARSONOUS ACID MMA(III); DNA-BINDING; IN-VITRO; C-JUN; PROTEIN EXPRESSION; GENE-EXPRESSION; TRIVALENT; PHOSPHORYLATION	Chronic exposures to inorganic arsenic (iAs) have been linked to increased incidences of various cancers, including cancer of the urinary bladder. Mechanisms by which iAs promotes cancer may include stimulation of activator protein-1 (AP-1) DNA binding through increased expression and/or phosphorylation of the AP-1 constituents. However, the role of methylated metabolites of iAs in AP-1 activation has not been thoroughly examined. In this study, we show that short-time exposures to 0.1-5 muM arsenite (iAs(III)) or the methylated trivalent arsenicals methylarsine oxide ((MAsO)-O-III), or iododimethylarsine ((DMAsI)-I-III) induce phosphorylation of c-Jun and increase AP-1 DNA binding activity in human bladder epithelial cells. (DMAsI)-I-III and especially (MAsO)-O-III are considerably more potent than iAs(III) as inducers of c-Jun phosphorylation and AP-1 activation. Phosphorylated c-Jun, JunB, JunD, and Fra-1, but not c-Fos, FosB, or ATF-2, are detected in the AP-1-DNA binding complex in cells exposed to trivalent arsenicals. In cells transiently transfected with an AP-1-dependent promoter-reporter construct, (MAsO)-O-III was more potent than iAs(III) in inducing the AP-1-dependent gene transcription. Exposures to trivalent arsenicals induce phosphorylation of extracellular signal-regulated kinase (ERK), but not c-Jun N-terminal kinases or p38 kinases. These results indicate that an ERK-dependent signal transduction pathway is at least partially responsible for c-Jun phosphorylation and AP-1 activation in UROtsa cells exposed to inorganic or methylated trivalent arsenicals.	Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Environm Med & Lung Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Nutr, Chapel Hill, NC 27599 USA; US EPA, Pharmacokinet Branch, Expt Toxicol Div, Natl Hlth & Environm Effects Res Lan,Off Res & De, Res Triangle Pk, NC 27711 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; United States Environmental Protection Agency	Styblo, M (corresponding author), Univ N Carolina, Dept Pediat, CB 7220,535 Burnett Womack Clin Sci Bldg, Chapel Hill, NC 27599 USA.	styblo@med.unc.edu	Jaspers, Ilona/AAZ-5035-2020					ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; [Anonymous], 1987, IARC MON EV CARC S7, V1-42, P100; Aposhian HV, 2000, CHEM RES TOXICOL, V13, P693, DOI 10.1021/tx000114o; Aposhian HV, 1997, ANNU REV PHARMACOL, V37, P397, DOI 10.1146/annurev.pharmtox.37.1.397; Barchowsky A, 1996, FREE RADICAL BIO MED, V21, P783, DOI 10.1016/0891-5849(96)00174-8; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; BATES MN, 1992, AM J EPIDEMIOL, V135, P462, DOI 10.1093/oxfordjournals.aje.a116313; Burleson FG, 1996, RES COMMUN MOL PATH, V93, P131; CARMICHAEL J, 1987, CANCER RES, V47, P936; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Chung YW, 2002, BIOCHEM BIOPH RES CO, V293, P1248; Cullen W.R., 1989, APPL ORGANOMET CHEM, V3, P71; CULLEN WR, 1984, J INORG BIOCHEM, V21, P179, DOI 10.1016/0162-0134(84)83002-0; Del Razo LM, 2001, TOXICOL APPL PHARM, V174, P282, DOI 10.1006/taap.2001.9226; *ENV PROT AG, 1988, RISK ASS FOR SPEC RE; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GRUDA MC, 1994, ONCOGENE, V9, P2537; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Irgolic Kurt J., 1994, P51; Jaspers I, 1999, J BIOL CHEM, V274, P31025, DOI 10.1074/jbc.274.43.31025; Kaltreider RC, 1999, MOL CARCINOGEN, V25, P219; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kitchin KT, 2001, TOXICOL APPL PHARM, V172, P249, DOI 10.1006/taap.2001.9157; Le XC, 2000, ANAL CHEM, V72, P5172, DOI 10.1021/ac000527u; Le XC, 2000, ENVIRON HEALTH PERSP, V108, P1015, DOI 10.2307/3434951; Lin S, 1999, CHEM RES TOXICOL, V12, P924, DOI 10.1021/tx9900775; Lin S, 2002, J BIOL CHEM, V277, P10795, DOI 10.1074/jbc.M110246200; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Mandal BK, 2001, CHEM RES TOXICOL, V14, P371, DOI 10.1021/tx000246h; Mass MJ, 2001, CHEM RES TOXICOL, V14, P355, DOI 10.1021/tx000251l; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Petrick JS, 2000, TOXICOL APPL PHARM, V163, P203, DOI 10.1006/taap.1999.8872; Petrick JS, 2001, CHEM RES TOXICOL, V14, P651, DOI 10.1021/tx000264z; PETZOLDT JL, 1994, UROL RES, V22, P67, DOI 10.1007/BF00310994; Petzoldt JL, 1995, UROL RES, V23, P377, DOI 10.1007/BF00698738; Porter AC, 1999, ONCOGENE, V18, P7794, DOI 10.1038/sj.onc.1203214; REAY PF, 1977, ANAL BIOCHEM, V78, P557, DOI 10.1016/0003-2697(77)90117-8; Salazar AM, 1997, MUTAT RES-FUND MOL M, V381, P259, DOI 10.1016/S0027-5107(97)00207-8; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Simeonova Petia P., 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P281; Simeonova PP, 2002, J BIOL CHEM, V277, P2945, DOI 10.1074/jbc.M109136200; Simeonova PP, 2001, TOXICOL SCI, V60, P279, DOI 10.1093/toxsci/60.2.279; Simeonova PP, 2000, CANCER RES, V60, P3445; Styblo M, 1995, TOXICOL APPL PHARM, V135, P172, DOI 10.1006/taap.1995.1220; Styblo M, 1997, CHEM RES TOXICOL, V10, P27, DOI 10.1021/tx960139g; Styblo M, 2000, ARCH TOXICOL, V74, P289, DOI 10.1007/s002040000134; Styblo M, 1999, ARSENIC EXPOSURE AND HEALTH EFFECTS, P311, DOI 10.1016/B978-008043648-7/50035-2; Thomas DJ, 2001, TOXICOL APPL PHARM, V176, P127, DOI 10.1006/taap.2001.9258; Trouba KJ, 2000, TOXICOL APPL PHARM, V164, P161, DOI 10.1006/taap.1999.8873; VAHTER M, 1994, APPL ORGANOMET CHEM, V8, P175, DOI 10.1002/aoc.590080304; Vahter Marie, 1999, Science Progress, V82, P69; Vega L, 2001, TOXICOL APPL PHARM, V172, P225, DOI 10.1006/taap.2001.9152; Vogt BL, 2001, MUTAT RES-FUND MOL M, V478, P159, DOI 10.1016/S0027-5107(01)00137-3; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wiencke JK, 1997, MUTAT RES-REV MUTAT, V386, P335, DOI 10.1016/S1383-5742(97)00016-1; Wijeweera JB, 2001, TOXICOL SCI, V61, P283, DOI 10.1093/toxsci/61.2.283; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002	59	69	71	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					67	+		10.1096/fj.02-0287fje	http://dx.doi.org/10.1096/fj.02-0287fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475910				2022-12-28	WOS:000180218500015
J	Rissanen, TT; Markkanen, JE; Arve, K; Rutanen, J; Kettunen, MI; Vajanto, I; Jauhiainen, S; Cashion, L; Gruchala, M; Narvanen, O; Taipale, P; Kauppinen, RA; Rubanyi, GM; Yla-Herttuala, S				Rissanen, TT; Markkanen, JE; Arve, K; Rutanen, J; Kettunen, MI; Vajanto, I; Jauhiainen, S; Cashion, L; Gruchala, M; Narvanen, O; Taipale, P; Kauppinen, RA; Rubanyi, GM; Yla-Herttuala, S			Fibroblast growth factor-4 induces vascular permeability, angiogenesis, and arteriogenesis in a rabbit hind limb ischemia model	FASEB JOURNAL			English	Article						vascular endothelial growth factor; therapeutic angiogenesis; collateral growth; adenovirus; gene transfer	GENE-TRANSFER; BIOLOGICAL-PROPERTIES; COLLATERAL GROWTH; SKELETAL-MUSCLE; BLOOD-FLOW; EXPRESSION; PROLIFERATION; CELLS; FGF-4; VEGF	Previous studies have shown that fibroblast growth factor (FGF)-1, FGF-2, and FGF-5 induce therapeutic angiogenesis. Here, we investigated the potential of FGF-4 for therapeutic neovascularization in comparison to vascular endothelial growth factor (VEGF), using adenoviral gene transfer in a novel rabbit hind limb ischemia model, with ischemia restricted to the calf. Magnetic resonance imaging and a modified Miles assay showed that both AdFGF-4 and AdVEGF given intramuscularly (i.m.) resulted in increases in vascular permeability and edema in transduced muscles 6 days after the gene transfer. In contrast, recombinant FGF-4 protein injected in the rabbit skin did not induce acute vascular permeability. Injections (i.m.) of AdFGF-4 and AdVEGF, but not intra-arterially administered AdVEGF, increased collateral growth, popliteal blood flow, and muscle perfusion compared with controls. The angiogenesis response consisted mainly of the enlargement of pre-existing vessels rather than an increase in capillary density. Adenoviral FGF-4 overexpression up-regulated endogenous VEGF, which may explain many of the effects thought to be specific for VEGF such as the increase in vascular permeability. This study demonstrates for the first time that FGF-4 induces vascular permeability, therapeutic angiogenesis, and arteriogenesis comparable to that of VEGF and could be useful for the treatment of peripheral vascular disease.	Univ Kuopio, AI Virtanen Inst, Dept Mol Med, FIN-70211 Kuopio, Finland; Univ Kuopio, AI Virtanen Inst, Dept Biomed NMR, FIN-70211 Kuopio, Finland; Univ Kuopio, AI Virtanen Inst, Natl Bio NMR Facil, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, Dept Thorac & Cardiovasc Surg, SF-70210 Kuopio, Finland; Berlex Biosci, Dept Gene Therapy, Richmond, CA USA; Kuopio Univ Hosp, Dept Obstet & Gynecol, SF-70210 Kuopio, Finland; Kuopio Univ Hosp, Gene Therapy Unit, SF-70210 Kuopio, Finland; Univ Kuopio, Dept Med, FIN-70211 Kuopio, Finland	Finland National Institute for Health & Welfare; University of Eastern Finland; University of Eastern Finland; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; University of Eastern Finland	Yla-Herttuala, S (corresponding author), Univ Kuopio, AI Virtanen Inst, Dept Mol Med, POB 1627, FIN-70211 Kuopio, Finland.	Seppo.Ylaherttuala@uku.fi	Kettunen, Mikko I/K-2299-2012; Gruchala, Marcin/S-8407-2018	Kettunen, Mikko I/0000-0002-2004-660X; Yla-Herttuala, Seppo/0000-0001-7593-2708; Rissanen, Tuomas/0000-0002-1914-2282; Jauhiainen, Suvi/0000-0002-0630-8175; Gruchala, Marcin/0000-0003-4901-2291				Aviezer D, 1999, BIOCHEM BIOPH RES CO, V263, P621, DOI 10.1006/bbrc.1999.1434; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Carmeliet P, 2001, SCIENCE, V293, P1602, DOI 10.1126/science.1064981; Dell'Era P, 2001, ONCOGENE, V20, P2655, DOI 10.1038/sj.onc.1204368; DELLIBOVI P, 1988, MOL CELL BIOL, V8, P2933, DOI 10.1128/MCB.8.7.2933; Deroanne CF, 1997, CANCER RES, V57, P5590; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; Giordano FJ, 1996, NAT MED, V2, P534, DOI 10.1038/nm0596-534; Gowdak LHW, 2000, CIRCULATION, V102, P565; Grosskreutz CL, 1999, MICROVASC RES, V58, P128, DOI 10.1006/mvre.1999.2171; Hiltunen MO, 2000, CIRCULATION, V102, P2262; Ito WD, 1997, AM J PHYSIOL-HEART C, V273, pH1255, DOI 10.1152/ajpheart.1997.273.3.H1255; KLINT P, 1999, FRONT BIOSCI, V4, P165; KONISHI H, 1995, J CLIN INVEST, V96, P1125, DOI 10.1172/JCI118099; Matsunaga T, 2000, CIRCULATION, V102, P3098; MUHLHAUSER J, 1995, HUM GENE THER, V6, P1457, DOI 10.1089/hum.1995.6.11-1457; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; Rissanen TT, 2002, AM J PATHOL, V160, P1393, DOI 10.1016/S0002-9440(10)62566-7; Rissanen TT, 2001, EUR J CLIN INVEST, V31, P651, DOI 10.1046/j.1365-2362.2001.00864.x; Rubanyi Gabor M., 2001, Molecular Aspects of Medicine, V22, P113, DOI 10.1016/S0098-2997(01)00004-8; Schaper W, 1996, CIRC RES, V79, P911, DOI 10.1161/01.RES.79.5.911; Sho E, 2001, ARTERIOSCL THROM VAS, V21, P1139, DOI 10.1161/hq0701.092118; Sundberg C, 2001, AM J PATHOL, V158, P1145, DOI 10.1016/S0002-9440(10)64062-X; TAKESHITA S, 1994, CIRCULATION, V90, P228; Tsurumi Y, 1996, CIRCULATION, V94, P3281, DOI 10.1161/01.CIR.94.12.3281; Ueno H, 1997, ARTERIOSCL THROM VAS, V17, P2453, DOI 10.1161/01.ATV.17.11.2453; Ueno H, 1996, GERONTOLOGY, V42, P25; Urbich C, 2000, CIRC RES, V87, P683, DOI 10.1161/01.RES.87.8.683; Vajanto I, 2002, J GENE MED, V4, P371, DOI 10.1002/jgm.287; Yamamoto H, 2000, ONCOGENE, V19, P3805, DOI 10.1038/sj.onc.1203752; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305	36	113	116	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					100	+		10.1096/fj.02-0377fje	http://dx.doi.org/10.1096/fj.02-0377fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475908				2022-12-28	WOS:000180218500014
J	Rader, C; Popkov, M; Neves, JA; Barbas, CF				Rader, C; Popkov, M; Neves, JA; Barbas, CF			Integrin alpha v beta 3-targeted therapy for Kaposi's sarcoma with an in vitro-evolved antibody	FASEB JOURNAL			English	Article						cancer; HIV; antibody engineering	IMMUNODEFICIENCY-VIRUS TYPE-1; FIBROBLAST-GROWTH-FACTOR; PHAGE DISPLAY APPROACH; TAT PROTEIN; MONOCLONAL-ANTIBODY; AFFINITY MATURATION; TRANSGENIC MICE; FC-RECEPTORS; CELL; ALPHA(V)BETA(3)	Here, we define integrin alphavbeta3 as a molecular target for antibody therapy for Kaposi's sarcoma (KS). We previously reported, using a new phage display strategy based on designed combinatorial V gene libraries, the humanization of mouse monoclonal antibody LM609 directed to human integrin alphavbeta3. In the present study, we describe the in vitro affinity maturation of humanized LM609 by using a phage display strategy for the sequential and parallel optimization of three complementarity determining regions of the antibody molecule. The evolved Fab had an affinity of 150 pM and was converted into IgG1 by use of a new mammalian expression vector. The resulting whole antibody, designated JC-7U IgG1, was found to selectively target human KS in a nude mouse model and inhibit tumor growth at a therapeutically relevant dose. Because of its high affinity and its high degree of humanization, JC-7U IgG1 is an excellent drug candidate for therapeutic applications that involve integrin alphavbeta3 as the molecular target. Of particular interest is therapy for KS, breast cancer, melanoma, and other cancers in which integrin alphavbeta3 is expressed on both angiogenic endothelial cells and tumor cells, which would allow a dual antiangiogenic and antitumor strike with a single drug.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Rader, C (corresponding author), Scripps Res Inst, Dept Mol Biol, BCC-526,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	crader@scripps.edu; carlos@scripps.edu		Rader, Christoph/0000-0001-9955-3454				Barbas C.F., 2001, PHAGE DISPLAY LAB MA; Barbas CF, 1996, TRENDS BIOTECHNOL, V14, P230, DOI 10.1016/0167-7799(96)10029-9; BARBAS CF, 1994, P NATL ACAD SCI USA, V91, P3809, DOI 10.1073/pnas.91.9.3809; Barillari G, 1999, BLOOD, V94, P663; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; Barillari G, 1999, J IMMUNOL, V163, P1929; BATOR JM, 1989, J IMMUNOL METHODS, V125, P167, DOI 10.1016/0022-1759(89)90090-2; Beiboer SHW, 2000, J MOL BIOL, V296, P833, DOI 10.1006/jmbi.2000.3512; Boshoff C, 1998, ADV CANCER RES, V75, P57, DOI 10.1016/S0065-230X(08)60739-3; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Dezube BJ, 2000, CURR OPIN ONCOL, V12, P445, DOI 10.1097/00001622-200009000-00010; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; Ensoli B, 2001, EUR J CANCER, V37, P1251, DOI 10.1016/S0959-8049(01)00121-6; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gallo RC, 1998, SCIENCE, V282, P1837, DOI 10.1126/science.282.5395.1837; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; HERNDIER BG, 1994, AIDS, V8, P575, DOI 10.1097/00002030-199405000-00002; JESPERS LS, 1994, BIO-TECHNOL, V12, P899, DOI 10.1038/nbt0994-899; Kaaya EE, 1996, HISTOPATHOLOGY, V29, P337, DOI 10.1111/j.1365-2559.1996.tb01417.x; Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525; Marcinkiewicz C, 1996, BIOCHEM J, V317, P817, DOI 10.1042/bj3170817; Natali PG, 1997, CANCER RES, V57, P1554; Nor JE, 2001, CANCER RES, V61, P2183; Park JW, 2001, ADV PROTEIN CHEM, V56, P369; Prakash O, 2000, JNCI-J NATL CANCER I, V92, P721, DOI 10.1093/jnci/92.9.721; Rader C, 1998, P NATL ACAD SCI USA, V95, P8910, DOI 10.1073/pnas.95.15.8910; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; SIEGAL B, 1990, CANCER, V65, P492, DOI 10.1002/1097-0142(19900201)65:3<492::AID-CNCR2820650320>3.0.CO;2-C; Steinberger P, 2000, J BIOL CHEM, V275, P36073, DOI 10.1074/jbc.M002765200; Tanaka F, 2000, J AM CHEM SOC, V122, P4835, DOI 10.1021/ja0005441; UCCINI S, 1994, J PATHOL, V173, P23, DOI 10.1002/path.1711730105; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; Wu HR, 1998, P NATL ACAD SCI USA, V95, P6037, DOI 10.1073/pnas.95.11.6037; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626	44	41	46	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					2000	+		10.1096/fj.02-0281fje	http://dx.doi.org/10.1096/fj.02-0281fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397091				2022-12-28	WOS:000179167600012
J	Fanning, AS; Ma, TY; Anderson, JM				Fanning, AS; Ma, TY; Anderson, JM			Isolation and functional characterization of the actin-binding region in the tight junction protein ZO-1	FASEB JOURNAL			English	Article						MAGUK; cytoskeleton; assembly	CELL-CELL ADHESION; EPITHELIAL-CELLS; ALPHA-CATENIN; CDNA CLONING; MAGUK FAMILY; MDCK CELLS; OCCLUDIN; RHO; EXPRESSION; STRANDS	Zonula occludens (ZO)-1 is a member of the MAGUK (membrane-associated guanylate kinase homologs) family of membrane-associated signaling molecules that binds directly to both cytosolic and transmembrane components of the tight junction and is believed to organize these proteins within the apical junctional complex. It also binds directly to F-actin, although the functional relevance of this interaction is unknown. To address this issue, we have used VSVG-tagged transgenes to dissect ZO-1 and have identified a 220 amino acid region of ZO-1 that is necessary for its association with F-actin in MDCK cell pull-down assays. A GST fusion expressing this region can bind directly to F-actin in vitro, whereas a GFP fusion expressing this domain decorates actin stress fibers when expressed in MDCK cells. These results indicate that this actin-binding region (ABR) is both necessary and sufficient for binding to F-actin in vitro and in vivo. VSVG-tagged transgenes that lack the ABR still accumulate at both early and late cell-cell contacts in MDCK cells, suggesting that the ABR is not required for tight junction localization. However, accumulation of constructs lacking the ABR is markedly reduced at tight junctions in confluent cells, suggesting that the ABR does play an important role in the localization of ZO-1 at junctions. Furthermore, the ABR is required for localization to a novel actin-rich pool of ZO-1 that accumulates in puncta at the free edge of cells before initiation of cell-cell contact. We conclude that direct interactions between ZO-1 and F-actin play a role in several different steps of junction assembly.	Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; Univ New Mexico, Sch Med, Dept Med, Albuquerque, NM 87131 USA	University of North Carolina; University of North Carolina Chapel Hill; University of New Mexico	Fanning, AS (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, CB 7545,Med Sci Res Bldg, Chapel Hill, NC 27599 USA.	alan_fanning@med.unc.edu		Anderson, James/0000-0003-2765-7996	NIDDK NIH HHS [R01 DK061397] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061397] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; ANDERSON JM, 1989, J CELL BIOL, V109, P1047, DOI 10.1083/jcb.109.3.1047; AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; BACALLAO R, 1994, J CELL SCI, V107, P3301; Blum MS, 1997, AM J PHYSIOL-HEART C, V273, pH286, DOI 10.1152/ajpheart.1997.273.1.H286; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; CITI S, 2001, TIGHT JUNCTIONS, P231; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FANNING AS, 2001, TIGHT JUNCTIONS, P265; FLEMING TP, 1989, J CELL BIOL, V108, P1407, DOI 10.1083/jcb.108.4.1407; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; HECHT G, 1992, GASTROENTEROLOGY, V102, P416, DOI 10.1016/0016-5085(92)90085-D; HIROKAWA N, 1982, J CELL BIOL, V95, P249, DOI 10.1083/jcb.95.1.249; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; MADARA JL, 1987, AM J PHYSIOL, V253, P171; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Mattagajasingh SN, 2000, J BIOL CHEM, V275, P30573, DOI 10.1074/jbc.M004578200; McCarthy KM, 2000, J CELL SCI, V113, P3387; MEZA I, 1980, J CELL BIOL, V87, P746, DOI 10.1083/jcb.87.3.746; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; MULLIN JM, 1986, AM J PHYSIOL, V251, pC597, DOI 10.1152/ajpcell.1986.251.4.C597; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131; Sears CL, 2000, AM J PHYSIOL-GASTR L, V279, pG1129, DOI 10.1152/ajpgi.2000.279.6.G1129; SILICIANO JD, 1988, J CELL BIOL, V107, P2389, DOI 10.1083/jcb.107.6.2389; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Turner JR, 1997, AM J PHYSIOL-CELL PH, V273, pC1378, DOI 10.1152/ajpcell.1997.273.4.C1378; Turner JR, 2000, SEMIN CELL DEV BIOL, V11, P301, DOI 10.1006/scdb.2000.0180; Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Walsh SV, 2001, GASTROENTEROLOGY, V121, P566, DOI 10.1053/gast.2001.27060; Wittchen ES, 2000, J CELL BIOL, V151, P825, DOI 10.1083/jcb.151.4.825; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; YONEMURA S, 1995, J CELL SCI, V108, P127	47	216	229	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2002	16	11					1835	+		10.1096/fj.02-0121fje	http://dx.doi.org/10.1096/fj.02-0121fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12354695				2022-12-28	WOS:000178441800006
J	Fiorucci, S; Mencarelli, A; Mannucci, R; Distrutti, E; Morelli, A; del Soldato, P; Moncada, S				Fiorucci, S; Mencarelli, A; Mannucci, R; Distrutti, E; Morelli, A; del Soldato, P; Moncada, S			NCX-4016, a nitric oxide-releasing aspirin, protects endothelial cells against apoptosis by modulating mitochondrial function	FASEB JOURNAL			English	Article						caspase-8; caspase-9; cytochrome c; cell respiration	CYTOCHROME-C RELEASE; CONVERTING-ENZYME; S-NITROSYLATION; INHIBITION; RESPIRATION; NO; MECHANISM; DEATH; SUPPRESSION; ACTIVATION	We investigated the effect of a nitric oxide (NO)-releasing derivative of aspirin (NCX-4016) on a mitochondria-dependent model of apoptosis in human umbilical endothelial cells (HUVEC). Exposure of HUVEC to staurosporine caused a progressive fall in mitochondrial membrane potential (Deltapsi(m)) and apoptosis. Exposure to an NO donor, (z)-1-[2-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NO), caused an early (1-3h) hyperpolarization of Deltapsi(m) and reduction of apoptosis that was followed (at 4-8 h) by an accelerated collapse of Deltapsi(m) and cell death. In contrast, treatment with NCX-4016, but not with aspirin or a non-NO-releasing analogue of NCX-4016, protected HUVEC against the apoptotic actions of staurosporine for up to 8 h. Confocal microscopy demonstrated that although NCX-4016 released NO in subcellular compartments, DETA-NO caused a generalized increase in cytosolic fluorescence. Exposure to DETA-NO resulted in a rapid and profound inhibition of cell respiration (78.3 +/- 6.4%), whereas NCX-4016 caused a less pronounced reduction in oxygen consumption (43.5 +/- 5.3%). Staurosporine caused a time-dependent activation of proapoptotic caspases. NCX-4016 prevented this activation, whereas DETA-NO failed to inhibit caspase activity. In contrast to DETA-NO, NCX-4016 did not increase mitochondrial oxidative stress. These data demonstrated that NCX-4016 conveys NO directly inside endothelial cells and modulates mitochondrial function.	Monteluce Policlin, Clin Gastroenterol & Epatol, Dipartimento Med Clin & Sperimentale, I-06122 Perugia, Italy; NicOx SA, F-06906 Sophia Antipolis, France; UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	University of London; University College London	Fiorucci, S (corresponding author), Monteluce Policlin, Clin Gastroenterol & Epatol, Dipartimento Med Clin & Sperimentale, Via E dal Pozzo, I-06122 Perugia, Italy.	fiorucci@unipg.it	Fiorucci, Stefano/I-1251-2012					Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; Budd SL, 2000, P NATL ACAD SCI USA, V97, P6161, DOI 10.1073/pnas.100121097; Cines DB, 1998, BLOOD, V91, P3527; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Clementi E, 1999, P NATL ACAD SCI USA, V96, P1559, DOI 10.1073/pnas.96.4.1559; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; ELLIOTT SN, 1995, GASTROENTEROLOGY, V109, P524, DOI 10.1016/0016-5085(95)90341-0; Eu JP, 2000, BIOCHEMISTRY-US, V39, P1040, DOI 10.1021/bi992046e; Fiorucci S, 2000, J IMMUNOL, V165, P5245, DOI 10.4049/jimmunol.165.9.5245; Fiorucci S, 2000, GASTROENTEROLOGY, V118, P404, DOI 10.1016/S0016-5085(00)70223-X; Fiorucci S, 2001, AM J PHYSIOL-GASTR L, V281, pG654, DOI 10.1152/ajpgi.2001.281.3.G654; Fiorucci S, 2001, TRENDS IMMUNOL, V22, P232, DOI 10.1016/S1471-4906(01)01904-4; Fiorucci S, 1999, GASTROENTEROLOGY, V116, P1089, DOI 10.1016/S0016-5085(99)70012-0; Fulton D, 2002, J BIOL CHEM, V277, P4277, DOI 10.1074/jbc.M106302200; *GRAPHP SOFTW, 2000, PRISM 3; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 2000, J BIOL CHEM, V275, P10954, DOI 10.1074/jbc.275.15.10954; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Liu LM, 1999, CELL DEATH DIFFER, V6, P937, DOI 10.1038/sj.cdd.4400578; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Messmer UK, 1998, EUR J PHARMACOL, V349, P333, DOI 10.1016/S0014-2999(98)00189-7; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Paxinou E, 2001, P NATL ACAD SCI USA, V98, P11575, DOI 10.1073/pnas.201293198; Poderoso JJ, 1999, J BIOL CHEM, V274, P37709, DOI 10.1074/jbc.274.53.37709; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; Vanin AF, 1997, NITRIC OXIDE-BIOL CH, V1, P191, DOI 10.1006/niox.1997.0122; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Zimmermann KC, 2000, NEOPLASIA, V2, P505, DOI 10.1038/sj.neo.7900120	35	38	41	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10					1645	+		10.1096/fj.02-0297fje	http://dx.doi.org/10.1096/fj.02-0297fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207011				2022-12-28	WOS:000177814000017
J	Parker, KK; Brock, AL; Brangwynne, C; Mannix, RJ; Wang, N; Ostuni, E; Geisse, NA; Adams, JC; Whitesides, GM; Ingber, DE				Parker, KK; Brock, AL; Brangwynne, C; Mannix, RJ; Wang, N; Ostuni, E; Geisse, NA; Adams, JC; Whitesides, GM; Ingber, DE			Directional control of lamellipodia extension by constraining cell shape and orienting cell tractional forces	FASEB JOURNAL			English	Article						migration; motility; focal adhesion; cell tension; microspike; microcontact printing	SMOOTH-MUSCLE-CELLS; FOCAL ADHESIONS; RHO FAMILY; MECHANICAL TENSION; GEOMETRIC CONTROL; CARCINOMA-CELLS; LIVING CELLS; RAC; MIGRATION; CYTOSKELETON	Directed cell migration is critical for tissue morphogenesis and wound healing, but the mechanism of directional control is poorly understood. Here we show that the direction in which cells extend their leading edge can be controlled by constraining cell shape using micrometer-sized extracellular matrix (ECM) islands. When cultured on square ECM islands in the presence of motility factors, cells preferentially extended lamellipodia, filopodia, and microspikes from their corners. Square cells reoriented their stress fibers and focal adhesions so that tractional forces were concentrated in these corner regions. When cell tension was dissipated, lamellipodia extension ceased. Mechanical interactions between cells and ECM that modulate cytoskeletal tension may therefore play a key role in the control of directional cell motility.	Harvard Univ, Sch Med, Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Physiol Program, Boston, MA 02115 USA; Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Boston Univ, Dept Phys, Boston, MA 02215 USA; MRC, Mol Cell Biol Lab, London, England; UCL, Dept Biochem & Mol Biol, London, England	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Boston University; University of London; University College London	Ingber, DE (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Dept Surg, Enders 1007,300 Longwood Ave, Boston, MA 02115 USA.	donald.ingber@tch.harvard.edu	Ingber, Donald E/AAC-5894-2019; Adams, Josephine C/B-1121-2009; Wang, Ning/B-6966-2008; Brock, Amy/S-9947-2019	Adams, Josephine C/0000-0002-2225-4947; Geisse, Nicholas/0000-0002-0901-0307	NCI NIH HHS [CA-45548] Funding Source: Medline; NIGMS NIH HHS [GM30367] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030367, R01GM030367] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERCROMBIE M, 1970, EXP CELL RES, V59, P393, DOI 10.1016/0014-4827(70)90646-4; Adams JC, 2000, J CELL BIOL, V150, P807, DOI 10.1083/jcb.150.4.807; Adams JC, 1997, MOL BIOL CELL, V8, P2345, DOI 10.1091/mbc.8.11.2345; Bailly M, 1998, EXP CELL RES, V241, P285, DOI 10.1006/excr.1998.4031; Banyard J, 1998, CANCER METAST REV, V17, P449, DOI 10.1023/A:1006150007710; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; BLANCHARD EM, 1990, PFLUG ARCH EUR J PHY, V416, P219, DOI 10.1007/BF00370248; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Chen CS, 2000, METH MOL B, V139, P209; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Chicurel ME, 1998, NATURE, V392, P730, DOI 10.1038/33719; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Dembo M, 1999, BIOPHYS J, V76, P2307, DOI 10.1016/S0006-3495(99)77386-8; Dike LE, 1999, IN VITRO CELL DEV-AN, V35, P441; DIMILLA PA, 1991, BIOPHYS J, V60, P15, DOI 10.1016/S0006-3495(91)82027-6; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; GIRARD PR, 1995, J CELL PHYSIOL, V163, P179, DOI 10.1002/jcp.1041630121; Goldmann WH, 1996, EXP CELL RES, V226, P234, DOI 10.1006/excr.1996.0223; Goldmann WH, 2002, BIOCHEM BIOPH RES CO, V290, P749, DOI 10.1006/bbrc.2001.6243; GROTENDORST GR, 1984, CELL, V36, P279, DOI 10.1016/0092-8674(84)90221-6; HALLIDAY NL, 1995, EXP CELL RES, V217, P109, DOI 10.1006/excr.1995.1069; Holly SP, 2000, EXP CELL RES, V261, P69, DOI 10.1006/excr.2000.5040; INGBER DE, 1993, J CELL SCI, V104, P613; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kishi H, 2000, J BIOCHEM, V128, P719, DOI 10.1093/oxfordjournals.jbchem.a022806; Knight B, 2000, CURR BIOL, V10, P576, DOI 10.1016/S0960-9822(00)00486-3; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; Meyer CJ, 2000, NAT CELL BIOL, V2, P666, DOI 10.1038/35023621; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; NAKATSUJI N, 1984, NATURE, V307, P453, DOI 10.1038/307453a0; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; OSTER GF, 1983, J EMBRYOL EXP MORPH, V78, P83; Ostuni E, 2000, LANGMUIR, V16, P7811, DOI 10.1021/la000382m; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Pelham RJ, 1999, MOL BIOL CELL, V10, P935, DOI 10.1091/mbc.10.4.935; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; Smith PG, 1997, EXP CELL RES, V232, P127, DOI 10.1006/excr.1997.3492; Verkhovsky AB, 1999, CURR BIOL, V9, P11, DOI 10.1016/S0960-9822(99)80042-6; Wang N, 2001, P NATL ACAD SCI USA, V98, P7765, DOI 10.1073/pnas.141199598; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WANG N, 2002, IN PRESS CELL MOTIL; WANG YL, 1984, J CELL BIOL, V99, P1478, DOI 10.1083/jcb.99.4.1478; Yu JH, 2001, BIOCHEM BIOPH RES CO, V282, P697, DOI 10.1006/bbrc.2001.4622	55	365	379	1	63	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1195	10.1096/fj.02-0038com	http://dx.doi.org/10.1096/fj.02-0038com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153987				2022-12-28	WOS:000177814000028
J	Lentsch, AB				Lentsch, AB			The Duffy antigen/receptor for chemokines (DARC) and prostate cancer. A role as clear as black and white?	FASEB JOURNAL			English	Article						angiogenesis; tumor; neovascularization	BLOOD-GROUP ANTIGEN; ENDOTHELIAL-CELLS; PLASMODIUM-VIVAX; CXC CHEMOKINES; RECEPTOR; EXPRESSION; TUMORIGENICITY; ANGIOGENESIS; MALARIA	Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer-related death among men in the United States. African American men have a 60% greater incidence of prostate cancer and a twofold higher mortality rate than Caucasian men. The Duffy antigen/receptor for chemokines (DARC) is a receptor expressed on erythrocytes and vascular endothelial cells that binds to and clears angiogenic chemokines. The DARC also functions as the erythrocyte receptor for invasion by malarial parasites. Approximately 70% of African Americans lack erythrocyte expression of the DARC as a genetic mechanism of protection against malaria infection. Given the importance of angiogenic chemokines in the development of tumor vascular networks and the chemokine binding properties of the DARC, the possibility that a lack of DARC expression on erythrocytes may represent an epigenetic factor that predisposes African American men to a greater incidence and mortality of prostate cancer should be considered.	Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Lentsch, AB (corresponding author), Univ Cincinnati, Coll Med, Dept Surg, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	alex.lentsch@uc.edu						Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Dawson TC, 2000, BLOOD, V96, P1681, DOI 10.1182/blood.V96.5.1681.h8001681a_1681_1684; Du JG, 2002, J LEUKOCYTE BIOL, V71, P141; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; Hadley TJ, 1997, BLOOD, V89, P3077, DOI 10.1182/blood.V89.9.3077; HADLEY TJ, 1994, J CLIN INVEST, V94, P985, DOI 10.1172/JCI117465; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; Inoue K, 2000, CLIN CANCER RES, V6, P2104; MILLER LH, 1975, SCIENCE, V189, P561, DOI 10.1126/science.1145213; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; Moore BB, 1999, AM J PATHOL, V154, P1503, DOI 10.1016/S0002-9440(10)65404-1; Murdoch C, 1999, CYTOKINE, V11, P704, DOI 10.1006/cyto.1998.0465; Murphy PM, 2000, PHARMACOL REV, V52, P145; NEOTE K, 1994, BLOOD, V84, P44; NEOTE K, 1993, J BIOL CHEM, V268, P12247; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Romagnani P, 2001, J CLIN INVEST, V107, P53, DOI 10.1172/JCI9775; Salcedo R, 2000, FASEB J, V14, P2055, DOI 10.1096/fj.99-0963com; Stanford JL, 1999, NIH PUB, V99-4543; SZABO MC, 1995, J BIOL CHEM, V270, P25348, DOI 10.1074/jbc.270.43.25348; Veltri RW, 1999, UROLOGY, V53, P139, DOI 10.1016/S0090-4295(98)00455-5	23	50	62	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2002	16	9					1093	1095		10.1096/fj.02-0066hyp	http://dx.doi.org/10.1096/fj.02-0066hyp			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087071				2022-12-28	WOS:000177813100041
J	Majumder, B; Wahle, KWJ; Moir, S; Schofield, A; Choe, SN; Farquharson, A; Grant, I; Heys, SD				Majumder, B; Wahle, KWJ; Moir, S; Schofield, A; Choe, SN; Farquharson, A; Grant, I; Heys, SD			Conjugated linoleic acids (CLAs) regulate the expression of key apoptotic genes in human breast cancer cells	FASEB JOURNAL			English	Article						mammary cancer; apoptotic gene expression; antiapoptotic gene expression	MAMMARY EPITHELIAL-CELLS; EICOSAPENTAENOIC ACID; POOR RESPONSE; BCL-2; RISK; CHEMOTHERAPY; PROTEIN; DIET; CONSUMPTION; PREVENTION	Conjugated linoleic acid (CLA) reduces mammary tumorigenesis in rodent models, induces apoptosis in rodent mammary tumor cell lines, and decreases expression of antiapoptotic bcl-2 in rat mammary tissue. This investigation focused on the cell mechanisms underlying the antitumor effects of CLA. Changes (mRNA, protein) in expression of major proapoptotic p53, p21WAF1/CIP1, bax, bcl-Xs genes, and the antiapoptotic bcl-2 gene were observed in malignant MCF-7 and MDA-MB-231 cells and in benign MCF-10a human mammary tumor cells in culture. CLA, but not linoleic acid (LA), inhibited proliferation in all cells; CLA mix was most effective. CLA increased DNA damage (apoptosis). CLA increased mRNA expression of p53 and p21WAF1/CIP1 (three- to fivefold and twofold, respectively) but either decreased bcl-2 by 20-30% or had no effect in MCF-7 and MCF-10a cells, respectively; protein expression reflected mRNA values. In MDA-MBA-231 (mutant p53) cells, mRNA for p53 was not changed, but p21WAF1/CIP1 and bcl-2 mRNA was increased. Protein expression largely reflected mRNA changes but, surprisingly, CLA completely suppressed mutant p53 protein in MDA-MB-231 cells. Apparent antiapoptotic effects of increased bcl-2 expression in MDA-MBA-231 cells were countered by increased proapoptotic p21WAF1/CIP1, Bax, and Bcl-Xs proteins. Findings indicate that CLA elicits mainly proapoptotic effects in human breast tumor cells through both p53-dependent and p53-independent pathways, according to cell type.	Rowett Res Inst, Lipid & Cell Biol Unit, Cell Integr Grp, Bucksburn AB21 9SB, Aberdeen, Scotland; Univ Aberdeen, Sch Med, Unit Surg Oncol, Aberdeen AB25 9ZD, Scotland; Kunsan Natl Univ, Kunsan, South Korea	University of Aberdeen; University of Aberdeen; Kunsan National University	Wahle, KWJ (corresponding author), Rowett Res Inst, Lipid & Cell Biol Unit, Cell Integr Grp, Greenburn Rd, Bucksburn AB21 9SB, Aberdeen, Scotland.	kwjw@rri.sari.ac.uk						BANG HO, 1976, ACTA MED SCAND, V200, P69; Banni S, 1999, CARCINOGENESIS, V20, P1019, DOI 10.1093/carcin/20.6.1019; BOYD NF, 1993, BRIT J CANCER, V68, P627, DOI 10.1038/bjc.1993.398; CAMPOS L, 1993, BLOOD, V81, P3091; CARROLL KK, 1991, AM J CLIN NUTR, V53, pS1064, DOI 10.1093/ajcn/53.4.1064S; Choucroun P, 2001, MUTAT RES-FUND MOL M, V478, P89, DOI 10.1016/S0027-5107(01)00123-3; Connolly JM, 1996, NUTR CANCER, V25, P231, DOI 10.1080/01635589609514447; Durgam VR, 1997, CANCER LETT, V116, P121, DOI 10.1016/S0304-3835(97)00192-4; FITE A, 2001, EUR J SURG ONCOL, V27, P798; FITE A, 2002, IN PRESS CANC RES; Griinari JM, 2000, J NUTR, V130, P2285, DOI 10.1093/jn/130.9.2285; HA YL, 1987, CARCINOGENESIS, V8, P1881, DOI 10.1093/carcin/8.12.1881; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; Ip C, 2000, CANCER EPIDEM BIOMAR, V9, P689; IP C, 1995, NUTR CANCER, V24, P241, DOI 10.1080/01635589509514413; Ip C, 1996, CARCINOGENESIS, V17, P1045, DOI 10.1093/carcin/17.5.1045; IP C, 1991, CANCER RES, V51, P6118; Ip MM, 1999, EXP CELL RES, V250, P22, DOI 10.1006/excr.1999.4499; KAIZER L, 1989, NUTR CANCER, V12, P61, DOI 10.1080/01635588909514002; Kang KH, 1999, EXP CELL RES, V253, P403, DOI 10.1006/excr.1999.4644; KARMILOFFSMITH A, 1984, ADV DEV PSYCHOL, V3, P33; Kikuyama S, 2001, ANTICANCER RES, V21, P2149; Kohlmeier L, 1997, P NUTR SOC, V56, P369, DOI 10.1079/PNS19970039; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LU PJ, 1995, J CELL BIOL, V129, P1363, DOI 10.1083/jcb.129.5.1363; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; NOBMANN ED, 1992, AM J CLIN NUTR, V55, P1024, DOI 10.1093/ajcn/55.5.1024; Noguchi M, 1997, BRIT J CANCER, V75, P348, DOI 10.1038/bjc.1997.57; OCHOA JJH, 2002, INT SOC STUD FATT AC; OCHOA JJH, 2002, IN PRESS BIOCH BIOPH; PARIZA MW, 1983, CANCER RES, V43, P2444; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rose DP, 1999, PHARMACOL THERAPEUT, V83, P217, DOI 10.1016/S0163-7258(99)00026-1; SCHULTZ T, 1992, ANTICANCER RES, V12, P21; Simonsen N, 1998, AM J EPIDEMIOL, V147, P342; Tannenbaum A, 1942, CANCER RES, V12, P468; TRICHOPOULOU A, 1995, JNCI-J NATL CANCER I, V87, P110, DOI 10.1093/jnci/87.2.110; Whitehouse AS, 2001, CANCER RES, V61, P3604; Wigmore SJ, 2000, NUTR CANCER, V36, P177, DOI 10.1207/S15327914NC3602_6; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC	42	80	92	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1447	+		10.1096/fj.01-0720fje	http://dx.doi.org/10.1096/fj.01-0720fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205043				2022-12-28	WOS:000177813100005
J	Mostyn, A; Bispham, J; Pearce, S; Evens, Y; Raver, N; Keisler, DH; Webb, R; Stephenson, T; Symonds, ME				Mostyn, A; Bispham, J; Pearce, S; Evens, Y; Raver, N; Keisler, DH; Webb, R; Stephenson, T; Symonds, ME			Differential effects of leptin on thermoregulation and uncoupling protein abundance in the neonatal lamb	FASEB JOURNAL			English	Article						adipose tissue; development; mitochondria	BROWN ADIPOSE-TISSUE; BODY-WEIGHT; MESSENGER-RNA; CORD-BLOOD; OBESE GENE; TEMPERATURE; EXPRESSION; HUMANS; SERUM; FETAL	As the role of leptin in energy balance in neonate is unknown, we investigated the effect of acute (2 h) and chronic (7 days) administration of leptin (100 mug/day) on thermoregulation and mitochondrial protein abundance in adipose tissue. The concentration of uncoupling protein (UCP)1 and voltage-dependent anion channel (VDAC) located on the inner and outer mitochondrial membranes, respectively, were measured. Administration of leptin prevented the normal decline in colonic temperature over the first few hours and days after birth. It subsequently accelerated the loss of both mRNA and protein for UCP1 but had no effect on VDAC abundance. At seven days of age, colonic temperature was correlated strongly with both mRNA abundance and thermogenic potential of UCP1 in leptin-treated but not control lambs, indicating more effective use of UCP1 for heat production following leptin administration. Leptin had no effect on weight gain or adipose tissue deposition; at one day of age only, leptin mRNA was correlated positively with adipose tissue weight. In conclusion, leptin administration to neonatal lambs improves thermoregulation and promotes the loss of UCP1 in brown adipose tissue.	Univ Hosp, Queens Med Ctr, Sch Human Dev, Acad Div Child Hlth, Nottingham NG7 2UH, England; Univ Nottingham, Sch Biosci, Div Agr Sci, Loughborough, Leics, England; Univ Missouri, Dept Anim Sci, Columbia, MO USA; Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel	Nottingham University Hospital NHS Trust; University of Nottingham; University of Nottingham; University of Missouri System; University of Missouri Columbia; Hebrew University of Jerusalem	Symonds, ME (corresponding author), Univ Hosp, Queens Med Ctr, Sch Human Dev, Acad Div Child Hlth, Nottingham NG7 2UH, England.	michael.symonds@nottingham.ac.uk	Keisler, Duane H/C-2746-2011; Mostyn, Alison/B-9126-2008; Mostyn, Alison/H-1018-2011	Keisler, Duane H/0000-0002-8792-7030; Stephenson, Terence/0000-0001-8871-7847; Symonds, Michael/0000-0001-9649-8963				Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; BALL KT, 1992, ENDOCRINOLOGY, V131, P337, DOI 10.1210/en.131.1.337; BISPHAM J, 2002, IN PRESS PEDIAT RES; Cancello R, 1998, ENDOCRINOLOGY, V139, P4747, DOI 10.1210/en.139.11.4747; CASTEILLA L, 1994, BIOCHEM J, V297, P93, DOI 10.1042/bj2970093; CASTEILLA L, 1989, BIOCHEM J, V257, P665, DOI 10.1042/bj2570665; Clarke L, 1997, AM J PHYSIOL-REG I, V272, pR1931, DOI 10.1152/ajpregu.1997.272.6.R1931; Clarke L, 1997, EXP PHYSIOL, V82, P1015, DOI 10.1017/S095806709701645X; Clarke L, 1997, BRIT J NUTR, V77, P871, DOI 10.1079/BJN19970086; Clarke L, 1996, PEDIATR RES, V40, P330, DOI 10.1203/00006450-199608000-00023; CLRKE L, 1994, J APPL PHYSIOL, P1481; Collins S, 1996, NATURE, V380, P677, DOI 10.1038/380677a0; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Delavaud C, 2000, J ENDOCRINOL, V165, P519, DOI 10.1677/joe.0.1650519; ELIOT RJ, 1981, ENDOCRINOLOGY, V108, P1678, DOI 10.1210/endo-108-5-1678; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gertler A, 1998, FEBS LETT, V422, P137, DOI 10.1016/S0014-5793(97)01613-X; Hytinantti T, 1999, PEDIATR RES, V45, P197, DOI 10.1203/00006450-199902000-00007; Koistinen HA, 1997, J CLIN ENDOCR METAB, V82, P3328, DOI 10.1210/jc.82.10.3328; LEAN MEJ, 1989, P NUTR SOC, V48, P243, DOI 10.1079/PNS19890036; Li H, 1997, AM J PHYSIOL-ENDOC M, V272, pE1031, DOI 10.1152/ajpendo.1997.272.6.E1031; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luheshi GN, 1999, P NATL ACAD SCI USA, V96, P7047, DOI 10.1073/pnas.96.12.7047; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Masuzaki H, 1997, NAT MED, V3, P1029, DOI 10.1038/nm0997-1029; Matsuda J, 1999, PEDIATR RES, V45, P71, DOI 10.1203/00006450-199901000-00012; Mistry AM, 1999, AM J PHYSIOL-REG I, V277, pR742, DOI 10.1152/ajpregu.1999.277.3.R742; Mostyn A, 2001, P NUTR SOC, V60, P187, DOI 10.1079/PNS200086; Nedergaard J, 2001, BBA-BIOENERGETICS, V1504, P82, DOI 10.1016/S0005-2728(00)00247-4; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Qian H, 1998, ENDOCRINOLOGY, V139, P791, DOI 10.1210/en.139.2.791; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Scarpace PJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE259, DOI 10.1152/ajpendo.1998.275.2.E259; Schermer SJ, 1996, REPROD FERT DEVELOP, V8, P995, DOI 10.1071/RD9960995; Schubring C, 1997, J CLIN ENDOCR METAB, V82, P1480, DOI 10.1210/jc.82.5.1480; Shek EW, 1998, HYPERTENSION, V31, P409, DOI 10.1161/01.HYP.31.1.409; Sivitz WI, 1999, ENDOCRINOLOGY, V140, P1511, DOI 10.1210/en.140.4.1511; SYMONDS ME, 1995, EXP PHYSIOL, V80, P907, DOI 10.1113/expphysiol.1995.sp003905; Symonds ME, 1996, P NUTR SOC, V55, P561, DOI 10.1079/PNS19960048; SYMONDS ME, 1992, J PHYSIOL-LONDON, V455, P487, DOI 10.1113/jphysiol.1992.sp019313; SYMONDS ME, 1989, J DEV PHYSIOL, V11, P289; TRAYHURN P, 1993, AM J PHYSIOL, V265, pR676, DOI 10.1152/ajpregu.1993.265.3.R676; Yuan CS, 2000, PEDIATR RES, V48, P380, DOI 10.1203/00006450-200009000-00021; Yuen BSJ, 1999, J ENDOCRINOL, V163, pR1, DOI 10.1677/joe.0.163R001; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	45	40	42	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1438	+		10.1096/fj.02-0077fje	http://dx.doi.org/10.1096/fj.02-0077fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205040				2022-12-28	WOS:000177813100006
J	Smith, CG; Vane, JR				Smith, CG; Vane, JR			The discovery of captopril	FASEB JOURNAL			English	Editorial Material																		[Anonymous], PUBLIC PRIVATE SECTO	1	96	102	1	26	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					788	789		10.1096/fj.03-0093life	http://dx.doi.org/10.1096/fj.03-0093life			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724335				2022-12-28	WOS:000183165000002
J	Bangale, Y; Karle, S; Planque, S; Zhou, YX; Taguchi, H; Nishiyama, Y; Li, L; Kalaga, R; Paul, S				Bangale, Y; Karle, S; Planque, S; Zhou, YX; Taguchi, H; Nishiyama, Y; Li, L; Kalaga, R; Paul, S			VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease	FASEB JOURNAL			English	Article						SLE; neuroimmune regulation; catalytic antibodies	VASOACTIVE-INTESTINAL-PEPTIDE; CATALYTIC ANTIBODIES; FACTOR-VIII; CLEAVAGE; EXPRESSION; INHIBITORS; RECEPTOR; AMIDASE	The immunoregulatory neuropeptide vasoactive intestinal peptide (VIP) was cleaved by purified IgG from Fas-defective C3H/gld mice, lupus patients, and autoimmune thyroiditis patients. No VIPase activity was detected in IgG from control mice and humans. Kinetic analyses of VIPase IgG preparations suggested low-affinity recognition of VIP. Yet the VIPase activity was VIP selective, judged by lack of correlation with other protease activities expressed by the IgG and by noninterference of unrelated peptides in the activity. Recombinant Fv constructs selected from a human lupus phage show library displayed VIPase activity, confirming that the active site is located in the V domains. Inhibition of the VIPase activity by di-isopropylfluorophosphate suggested a serine protease-like mechanism of catalysis. Irreversible binding of a biotinyated phosphonate diester by the IgG and Fv preparations was observed, consistent with the presence of activated nucleophiles similar to those in enzymes capable of covalent catalysis. These observations show that VIP is a target for specific catalytic autoantibodies in autoimmune disease.	Univ Texas, Sch Med, Dept Pathol, Chem Immunol Res Ctr, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Med, Chem Immunol Res Ctr, Houston, TX 77030 USA	University of Texas System; University of Texas System	Paul, S (corresponding author), Univ Texas, Sch Med, Dept Pathol, Chem Immunol Res Ctr, 6431 Fannin, Houston, TX 77030 USA.	Sudhir.Paul@uth.tmc.edu			NIAID NIH HHS [AI 31268, AI 46029] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046029, R01AI031268, R21AI031268] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berisha HI, 2002, PULM PHARMACOL THER, V15, P121, DOI 10.1006/pupt.2001.0337; Bracci-Laudiero L, 1998, NEUROSCI LETT, V248, P97, DOI 10.1016/S0304-3940(98)00342-5; CHAKDER S, 1993, J PHARMACOL EXP THER, V266, P392; Delgado M, 2001, NAT MED, V7, P563, DOI 10.1038/87887; Delgado M, 2001, J IMMUNOL, V166, P1028, DOI 10.4049/jimmunol.166.2.1028; Dorsam G, 2000, ANN NY ACAD SCI, V921, P79; Feher E, 1997, NEUROIMMUNOMODULAT, V4, P250, DOI 10.1159/000097344; Fersht A., 1985, ENZYME STRUCTURE MEC; Ganea D, 1996, ADV NEUROIMMUNOL, V6, P61, DOI 10.1016/S0960-5428(96)00007-1; GAO QS, 1994, J BIOL CHEM, V269, P32389; GHERARDI E, 1992, NATURE, V357, P201, DOI 10.1038/357201a0; Goetzl EJ, 2001, P NATL ACAD SCI USA, V98, P13854, DOI 10.1073/pnas.241503798; Gololobov G, 1999, MOL IMMUNOL, V36, P1215, DOI 10.1016/S0161-5890(99)00141-8; Gomariz RP, 2001, CURR PHARM DESIGN, V7, P89, DOI 10.2174/1381612013398374; Jackson DS, 1998, J MED CHEM, V41, P2289, DOI 10.1021/jm970543s; Kolesnikov AV, 2000, P NATL ACAD SCI USA, V97, P13526, DOI 10.1073/pnas.200360497; Lacroix-Desmazes S, 2002, NEW ENGL J MED, V346, P662, DOI 10.1056/NEJMoa011979; Lacroix-Desmazes S, 1999, NAT MED, V5, P1044, DOI 10.1038/12483; MATSUURA K, 1994, BIOCHEM BIOPH RES CO, V204, P57, DOI 10.1006/bbrc.1994.2425; Matsuura K, 2000, APPL BIOCHEM BIOTECH, V83, P107, DOI 10.1385/ABAB:83:1-3:107; Matsuura K, 1996, BIOL CHEM, V377, P587, DOI 10.1515/bchm3.1996.377.9.587; OLEKSYSZYN J, 1994, METHOD ENZYMOL, V244, P423; Paul S, 1997, J IMMUNOL, V159, P1530; PAUL S, 1991, J BIOL CHEM, V266, P16128; Paul S, 2001, J BIOL CHEM, V276, P28314, DOI 10.1074/jbc.M102530200; SAID SI, 1986, J ENDOCRINOL INVEST, V9, P191, DOI 10.1007/BF03348097; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; Sun JL, 2001, J IMMUNOL, V167, P5775, DOI 10.4049/jimmunol.167.10.5775; Sun M, 1997, J MOL BIOL, V271, P374, DOI 10.1006/jmbi.1997.1196; SUN M, 1991, J BIOL CHEM, V266, P15571; TAWFIK DS, 1995, P NATL ACAD SCI USA, V92, P2145, DOI 10.1073/pnas.92.6.2145; Tramontano A, 2000, CHEM IMMUNOL, V77, P1, DOI 10.1159/000058794; Tyutyulkova S, 1996, BBA-MOL BASIS DIS, V1316, P217, DOI 10.1016/0925-4439(96)00028-2; Vassiliou E, 2001, Arch Physiol Biochem, V109, P365, DOI 10.1076/apab.109.4.365.4245; Voice JK, 2001, FASEB J, V15, P2489, DOI 10.1096/fj.01-0671com; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	36	33	34	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					628	635		10.1096/fj.02-0475com	http://dx.doi.org/10.1096/fj.02-0475com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665475				2022-12-28	WOS:000182580100007
J	Liu, J; Matyakhina, L; Han, ZQ; Sandrini, F; Bei, T; Stratakis, CA; Papasopoulos, V				Liu, J; Matyakhina, L; Han, ZQ; Sandrini, F; Bei, T; Stratakis, CA; Papasopoulos, V			Molecular cloning, chromosomal localization of human peripheral-type benzodiazepine receptor- and protein kinase A regulatory subunit type 1A (PRKAR1A)-associated protein PAP7 and studies in PRKAR1A mutant cells and tissues	FASEB JOURNAL			English	Article						PBR; adrenal cortex; gonads; chromosome 1; steroidogenesis	DIAZEPAM-BINDING INHIBITOR; LEYDIG TUMOR-CELLS; CARNEY COMPLEX; SPOTTY PIGMENTATION; STEROIDOGENESIS; CHOLESTEROL; GENE; IDENTIFICATION; BIOSYNTHESIS; CHORIOGONADOTROPIN	A mouse protein that interacts with the peripheral-type benzodiazepine receptor (PBR) and cAMP-dependent protein kinase A (PKA) regulatory subunit RIalpha. (PRKAR1A), named PBR and PKA-associated protein 7 (PAP7), was identified and shown to be involved in hormone-induced steroid biosynthesis. We report the identification of the human PAP7 gene, its expression pattern, genomic structure, and chromosomal mapping to 1q32-1q41. Human PAP7 is a 60-kDa protein highly homologous to the rodent protein. PAP7 is widely present in human tissues and highly expressed in seminal vesicles, pituitary, thyroid, pancreas, renal cortex, enteric epithelium, muscles, myocardium and in steroidogenic tissues, including the gonads and adrenal cortex. These tissues are also targets of Carney complex (CNC), a multiple neoplasia syndrome caused by germline inactivating PRKAR1A mutations (PRKAR1A-mut) and associated with primary pigmented nodular adrenocortical disease (PPNAD) and increased steroid synthesis. PAP7 and PRKAR1A expression were studied in PPNAD and in lymphoblasts from patients bearing PRKAR1A-mut. Like PRKAR1A, PAP7 was decreased in CNC lymphocytes and PPNAD nodules, but not in the surrounding cortex. These studies showed that, like in the mouse, human PAP7 is highly expressed in steroidogenic tissues, where it follows the pattern of PRKAR1A expression, suggesting that it participates in PRKAR1A-mediated tumorigenesis and hypercortisolism.	Georgetown Univ, Sch Med,Med Ctr, Dept Cell Biol, Div Hormone Res, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA; NICHHD, Sect Genet & Endocrinol, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA	Georgetown University; Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Papasopoulos, V (corresponding author), Georgetown Univ, Sch Med,Med Ctr, Dept Cell Biol, Div Hormone Res, 3900 Reservoir Rd NW, Washington, DC 20057 USA.	papadopv@georgetown.edu	Papadopoulos, Vassilios/AAI-2613-2019	Papadopoulos, Vassilios/0000-0002-1183-8568	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [ZIAHD000642, Z01HD000642] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Amri H, 1996, ENDOCRINOLOGY, V137, P5707, DOI 10.1210/en.137.12.5707; ANHOLT RRH, 1986, J BIOL CHEM, V261, P576; BESMAN MJ, 1989, P NATL ACAD SCI USA, V86, P4897, DOI 10.1073/pnas.86.13.4897; Boujrad N, 1996, ENDOCRINOLOGY, V137, P5727, DOI 10.1210/en.137.12.5727; BOUJRAD N, 1993, P NATL ACAD SCI USA, V90, P5728, DOI 10.1073/pnas.90.12.5728; BOUJRAD N, 1994, ENDOCRINOLOGY, V135, P1576, DOI 10.1210/en.135.4.1576; CARNEY JA, 1995, SEMIN DERMATOL, V14, P90, DOI 10.1016/S1085-5629(05)80003-3; CARNEY JA, 1986, MAYO CLIN PROC, V61, P165, DOI 10.1016/S0025-6196(12)61843-6; Carney JA., 1992, ENDOCRINOLOGIST, V2, P6, DOI DOI 10.1097/00019616-199201000-00003; COSTA E, 1991, LIFE SCI, V49, P325, DOI 10.1016/0024-3205(91)90440-M; GARNIER M, 1994, J BIOL CHEM, V269, P22105; GARNIER M, 1994, MOL PHARMACOL, V45, P201; Hauet T, 2002, ENDOCR RES, V28, P395, DOI 10.1081/ERC-120016814; Jefcoate C, 2002, J CLIN INVEST, V110, P881, DOI 10.1172/JCI200216771; JEFCOATE CR, 1992, J STEROID BIOCHEM, V43, P751, DOI 10.1016/0960-0760(92)90305-3; Kirschner LS, 2000, HUM MOL GENET, V9, P3037, DOI 10.1093/hmg/9.20.3037; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; KNUDSEN J, 1989, BIOCHEM J, V262, P513, DOI 10.1042/bj2620513; KRUEGER KE, 1990, J BIOL CHEM, V265, P15015; Lacapere JJ, 2001, BIOCHEM BIOPH RES CO, V284, P536, DOI 10.1006/bbrc.2001.4975; Li H, 2001, MOL ENDOCRINOL, V15, P2211, DOI 10.1210/me.15.12.2211; Li H, 2001, P NATL ACAD SCI USA, V98, P1267, DOI 10.1073/pnas.031461598; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Mujica AO, 2001, GENE, V280, P175, DOI 10.1016/S0378-1119(01)00780-6; PAPADOPOULOS V, 1993, ENDOCR REV, V14, P222, DOI 10.1210/er.14.2.222; Papadopoulos V, 1997, J BIOL CHEM, V272, P32129, DOI 10.1074/jbc.272.51.32129; PAPADOPOULOS V, 1990, J BIOL CHEM, V265, P3772; PAPADOPOULOS V, 1992, P NATL ACAD SCI USA, V89, P5113, DOI 10.1073/pnas.89.11.5113; PAPADOPOULOS V, 1991, ENDOCRINOLOGY, V129, P1481, DOI 10.1210/endo-129-3-1481; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Sarlis NJ, 1997, J CLIN ENDOCR METAB, V82, P1274, DOI 10.1210/jc.82.4.1274; SIMPSON ER, 1983, CAN J BIOCHEM CELL B, V61, P692, DOI 10.1139/o83-088; Sohda M, 2001, J BIOL CHEM, V276, P45298, DOI 10.1074/jbc.M108961200; Sridaran R, 1999, J MOL ENDOCRINOL, V22, P45, DOI 10.1677/jme.0.0220045; Stocco DM, 1999, BIOESSAYS, V21, P768, DOI 10.1002/(SICI)1521-1878(199909)21:9<768::AID-BIES8>3.3.CO;2-U; Stratakis CA, 2001, J CLIN ENDOCR METAB, V86, P4041, DOI 10.1210/jc.86.9.4041; Stratakis CA, 1996, J CLIN INVEST, V97, P699, DOI 10.1172/JCI118467; Stratakis CA, 1999, ANN INTERN MED, V131, P585, DOI 10.7326/0003-4819-131-8-199910190-00006; Stratakis CA, 2000, FRONT BIOSCI-LANDMRK, V5, pD353, DOI 10.2741/Stratakis; YANAGIBASHI K, 1988, ENDOCRINOLOGY, V123, P2075, DOI 10.1210/endo-123-4-2075; Zilz A, 1999, ENDOCRINOLOGY, V140, P859, DOI 10.1210/en.140.2.859	41	27	30	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1189	+		10.1096/fj.02-1066fje	http://dx.doi.org/10.1096/fj.02-1066fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692076				2022-12-28	WOS:000182580100047
J	Meier, S; Brauer, AU; Heimrich, B; Schwab, ME; Nitsch, R; Savaskan, NE				Meier, S; Brauer, AU; Heimrich, B; Schwab, ME; Nitsch, R; Savaskan, NE			RETRACTED: Molecular analysis of Nogo expression in the hippocampus during development and following lesion and seizure (Retracted article. See vol. 25, pg. 2853, 2011)	FASEB JOURNAL			English	Article; Retracted Publication						axonal growth inhibitors; entorhinal cortex lesion; reticulons; kainic acid-induced seizure; axonal plasticity	NEURITE GROWTH-INHIBITORS; CHONDROITIN SULFATE PROTEOGLYCAN; ENTORHINAL CORTEX LESION; MYELIN-ASSOCIATED GLYCOPROTEIN; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; DENTATE GYRUS; ADULT-RAT; AXONAL REGENERATION; MESSENGER-RNA	The Nogo gene encodes an integral membrane protein mainly responsible for the neurite inhibition properties of myelin. Here, we analyzed the expression pattern of Nogo-A, Nogo-B, and Nogo-C and Nogo-66 receptor (Ng66R) mRNA during hippocampal development and lesion-induced axonal sprouting. Nogo-A and Nogo-B and Ng66R transcripts preceded the progress of myelination and were highly expressed at postnatal day zero (P0) in all principal hippocampal cell layers, with the exception of dentate granule cells. Only a slight Nogo-C expression was found at P0 in the principal cell layers of the hippocampus. During adulthood, all Nogo splice variants and their receptor were expressed in the neuronal cell layers of the hippocampus, in contrast to the myelin basic protein mRNA expression pattern, which revealed a neuronal source of Nogo gene expression in addition to oligodendrocytes. After hippocampal denervation, the Nogo genes showed an isoform-specific temporal regulation. All Nogo genes were strongly regulated in the hippocampal cell layers, whereas the Ng66R transcripts showed a significant increase in the contralateral cortex. These data could be confirmed on protein levels. Furthermore, Nogo-A expression was up-regulated after kainate-induced seizures. Our data show that neurons express Nogo genes with a clearly distinguishable pattern during development. This expression is further dynamically and isoform-specifically altered after lesioning during the early phase of structural rearrengements. Thus, our results indicate a role for Nogo-A, -B, and -C during development and during the stabilization phase of hippocampal reorganization. Taken together with these data, the finding that neurons in a highly plastic brain region express Nogo genes supports the hypothesis that Nogo may function beyond its known neuronal growth inhibition activity in shaping neuronal circuits.	Humboldt Univ, Med Sch Charite, Dept Cell & Neurobiol, Inst Anat, D-10098 Berlin, Germany; Univ Zurich, Dept Neuromorphol, Brain Res Inst, Zurich, Switzerland; Swiss Fed Inst Technol, Dept Biol, Zurich, Switzerland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Zurich; ETH Zurich	Savaskan, NE (corresponding author), Humboldt Univ, Med Sch Charite, Dept Cell & Neurobiol, Inst Anat, Oskar Hertwig House,Philippstr 12, D-10098 Berlin, Germany.	nicolai.savaskan@charite.de	Nitsch, Robert/AAI-9129-2021; Schwab, Martin E/B-6818-2016; Bräuer, Anja/N-3692-2019; Braeuer, Anja/K-8339-2013; Savaskan, Nicolai/D-2923-2018	Savaskan, Nicolai/0000-0003-1348-094X				Alcantara S, 2000, DEVELOPMENT, V127, P1359; Baka ID, 1996, MOL CELL NEUROSCI, V7, P289, DOI 10.1006/mcne.1996.0022; BAYER SA, 1987, PROG NEUROBIOL, V29, P57, DOI 10.1016/0301-0082(87)90015-3; BAYER SA, 1990, EXP NEUROL, V107, P48, DOI 10.1016/0014-4886(90)90062-W; Bendotti C, 1997, EUR J NEUROSCI, V9, P93, DOI 10.1111/j.1460-9568.1997.tb01357.x; BLACKSTAD TW, 1956, J COMP NEUROL, V105, P417, DOI 10.1002/cne.901050305; Bovolenta P, 1997, EUR J NEUROSCI, V9, P977, DOI 10.1111/j.1460-9568.1997.tb01448.x; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Brauer AU, 2001, FASEB J, V15, P2689, DOI 10.1096/fj.01-0235com; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Brittis PA, 2001, NEURON, V30, P11, DOI 10.1016/S0896-6273(01)00258-6; Brosamle C, 2000, J NEUROSCI, V20, P8061; Buffo A, 2000, J NEUROSCI, V20, P2275; CADELLI DS, 1992, EXP NEUROL, V115, P189, DOI 10.1016/0014-4886(92)90246-M; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; COTMAN CW, 1985, ANN NY ACAD SCI, V457, P83, DOI 10.1111/j.1749-6632.1985.tb20800.x; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DELLER T, 1995, J NEUROSCI, V15, P6868; Deller T, 1997, PROG NEUROBIOL, V53, P687, DOI 10.1016/S0301-0082(97)00044-0; DOU CL, 1994, J NEUROSCI, V14, P7616; Forster E, 2001, DEVELOPMENT, V128, P3029; Fournier AE, 2002, PROG BRAIN RES, V137, P361; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Frotscher M, 1997, TRENDS NEUROSCI, V20, P218, DOI 10.1016/S0166-2236(96)01018-1; FROTSCHER M, 1993, P NATL ACAD SCI USA, V90, P10400, DOI 10.1073/pnas.90.21.10400; GALL C, 1979, J COMP NEUROL, V183, P539, DOI 10.1002/cne.901830306; Gao PP, 1999, P NATL ACAD SCI USA, V96, P4073, DOI 10.1073/pnas.96.7.4073; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Grandpre T, 2001, NEUROSCIENTIST, V7, P377, DOI 10.1177/107385840100700507; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Haas CA, 1999, J NEUROSCI, V19, P9953; Hens J, 1998, CELL TISSUE RES, V292, P229, DOI 10.1007/s004410051054; Holder N, 1999, DEVELOPMENT, V126, P2033; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Hu WH, 2002, J NEUROCHEM, V81, P36, DOI 10.1046/j.1471-4159.2002.00788.x; Huber AB, 2002, J NEUROSCI, V22, P3553; HYMAN BT, 1984, SCIENCE, V225, P1168, DOI 10.1126/science.6474172; Josephson A, 2001, EXP NEUROL, V169, P319, DOI 10.1006/exnr.2001.7659; KOVACS A, 2001, SOC NEUR ABSTR, V27, P253; LIU BP, 2002, SCIENCE         0627; MATTHEWS DA, 1976, BRAIN RES, V115, P23, DOI 10.1016/0006-8993(76)90820-9; MATTHEWS DA, 1976, BRAIN RES, V115, P1, DOI 10.1016/0006-8993(76)90819-2; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Niederost BP, 1999, J NEUROSCI, V19, P8979, DOI 10.1523/JNEUROSCI.19-20-08979.1999; OERTLE T, 2000, SOC NEUR ABSTR, V26, P573; PAXINOS G, 1985, J NEUROSCI METH, V13, P139, DOI 10.1016/0165-0270(85)90026-3; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; RUST RS, 1991, NEUROCHEM RES, V16, P991, DOI 10.1007/BF00965842; Savaskan NE, 2002, J NEUROCHEM, V83, P1196, DOI 10.1046/j.1471-4159.2002.01233.x; Savaskan NE, 2001, REV NEUROSCIENCE, V12, P195; Savaskan NE, 1999, EUR J NEUROSCI, V11, P316, DOI 10.1046/j.1460-9568.1999.00430.x; Savaskan NE, 2000, EUR J NEUROSCI, V12, P1024, DOI 10.1046/j.1460-9568.2000.00998.x; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Skaper SD, 2001, PROG NEUROBIOL, V65, P593, DOI 10.1016/S0301-0082(01)00017-X; Skutella T, 2001, TRENDS NEUROSCI, V24, P107, DOI 10.1016/S0166-2236(00)01717-3; Skutella T, 1999, DEV BIOL, V211, P277, DOI 10.1006/dbio.1999.9295; SNYDER DC, 1991, J NEUROBIOL, V22, P897, DOI 10.1002/neu.480220903; Stein E, 1999, J NEUROSCI, V19, P8885, DOI 10.1523/JNEUROSCI.19-20-08885.1999; Steup A, 1999, EUR J NEUROSCI, V11, P729, DOI 10.1046/j.1460-9568.1999.00517.x; Steup A, 2000, MOL CELL NEUROSCI, V15, P141, DOI 10.1006/mcne.1999.0818; STEWARD O, 1993, EXP NEUROL, V124, P167, DOI 10.1006/exnr.1993.1187; STEWARD O, 1976, SCIENCE, V194, P426, DOI 10.1126/science.982024; SUPER H, 1994, J COMP NEUROL, V344, P101, DOI 10.1002/cne.903440108; SUZUKI M, 1994, GLIA, V12, P294, DOI 10.1002/glia.440120406; Tessier-Lavigne M, 2000, SCIENCE, V287, P813, DOI 10.1126/science.287.5454.813; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Thon N, 2000, EUR J NEUROSCI, V12, P2547, DOI 10.1046/j.1460-9568.2000.00109.x; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Wang XX, 2002, J NEUROSCI, V22, P5505; WEIBEL D, 1994, BRAIN RES, V642, P259, DOI 10.1016/0006-8993(94)90930-X; WITTER MP, 1989, PROG NEUROBIOL, V33, P161, DOI 10.1016/0301-0082(89)90009-9; Wu W, 1999, NATURE, V400, P331, DOI 10.1038/22477; Z'Graggen WJ, 1998, J NEUROSCI, V18, P4744; Zagrebelsky M, 1998, J NEUROSCI, V18, P7912	82	57	66	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1153	+		10.1096/fj.02-0453fje	http://dx.doi.org/10.1096/fj.02-0453fje			35	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692091				2022-12-28	WOS:000182580100048
J	Michaud, SE; Menard, C; Guy, LG; Gennaro, G; Rivard, A				Michaud, SE; Menard, C; Guy, LG; Gennaro, G; Rivard, A			Inhibition of hypoxia-induced angiogenesis by cigarette smoke exposure: impairment of the HIF-1-alpha/VEGF pathway	FASEB JOURNAL			English	Article						neovascularization; smoking; ischemia	ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; THERAPEUTIC ANGIOGENESIS; CELL MIGRATION; MOUSE MODEL; DNA-BINDING; FACTOR GENE; TRANSACTIVATION; TRANSCRIPTION; DYSFUNCTION	Smoking is a major risk factor for atherosclerotic diseases. However, the impact of cigarette smoke exposure on neovascularization that develops in response to tissue ischemia is unknown. Here we demonstrate that cigarette smoke extracts inhibit hypoxia-induced in vitro angiogenesis (matrigel assay) in human umbilical vascular endothelial cells. In vivo, mice exposed to cigarette smoke (MES) were shown to have a significant impairment of angiogenesis following surgically induced hindlimb ischemia. The reduced angiogenic response in MES was documented by Laser Doppler flow perfusion studies and capillary density analyses in ischemic hindlimbs. Inhibition of angiogenesis by cigarette smoke in vitro and in vivo was associated with a reduced expression of hypoxia-inducible factor-1alpha, (HIF-1alpha,) and vascular endothelial growth factor (VEGF) in hypoxic conditions. Administration of an adenoviral vector encoding for HIF-1alpha/VP16, a hybrid transcription factor that is stable in hypoxic and normoxic conditions, restored VEGF expression and completely reversed the cigarette smoke inhibition of angiogenesis in hypoxic conditions. Taken together, these results suggest that cigarette smoke exposure impairs angiogenesis by inhibiting VEGF through decreased expression of HIF-1alpha, in hypoxic conditions.	Univ Montreal, Ctr Hosp, Dept Cardiovasc Res, Montreal, PQ H2L 4M1, Canada	Universite de Montreal	Rivard, A (corresponding author), Univ Montreal, Ctr Hosp, Dept Cardiovasc Res, 1560 Sherbrooke Est,Suite Y-3605, Montreal, PQ H2L 4M1, Canada.	rivardal@total.net						Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Couffinhal T, 1998, AM J PATHOL, V152, P1667; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; Emanueli C, 2001, CIRCULATION, V103, P125; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Freedman SB, 2001, J MOL CELL CARDIOL, V33, P379, DOI 10.1006/jmcc.2000.1329; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961; Heitzer T, 1996, CIRCULATION, V93, P1346, DOI 10.1161/01.CIR.93.7.1346; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; JANOFF A, 1977, AM REV RESPIR DIS, V116, P65; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Ma L, 1999, CLIN EXP PHARMACOL P, V26, P828, DOI 10.1046/j.1440-1681.1999.03134.x; MAGERS T, 1995, REPROD TOXICOL, V9, P513, DOI 10.1016/0890-6238(95)02002-0; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Melkonian G, 2000, TOXICOL APPL PHARM, V163, P26, DOI 10.1006/taap.1999.8789; Melkonian G, 2002, TOXICOL SCI, V68, P237, DOI 10.1093/toxsci/68.1.237; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; PETRIK PV, 1995, STROKE, V26, P1409, DOI 10.1161/01.STR.26.8.1409; Pollman MJ, 1999, J CELL PHYSIOL, V178, P359, DOI 10.1002/(SICI)1097-4652(199903)178:3<359::AID-JCP10>3.3.CO;2-F; Powell J T, 1998, Vasc Med, V3, P21, DOI 10.1191/135886398670269973; Raij L, 2001, J HYPERTENS, V19, P891, DOI 10.1097/00004872-200105000-00009; Rivard A, 1999, AM J PATHOL, V154, P355, DOI 10.1016/S0002-9440(10)65282-0; Smith RS, 2002, ARTERIOSCL THROM VAS, V22, P1279, DOI 10.1161/01.ATV.0000026613.18742.67; Snajdar RM, 2001, J SURG RES, V96, P10, DOI 10.1006/jsre.2000.6055; Su YC, 1998, AM J RESP CELL MOL, V19, P819, DOI 10.1165/ajrcmb.19.5.3091; Takeshita S, 1996, BIOCHEM BIOPH RES CO, V227, P628, DOI 10.1006/bbrc.1996.1556; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tsuchiya M, 2002, CIRCULATION, V105, P1155, DOI 10.1161/hc1002.105935; Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Villablanca AC, 2000, CLIN CHEST MED, V21, P159, DOI 10.1016/S0272-5231(05)70015-0; Volm M, 1999, ANTICANCER RES, V19, P333; Wang HJ, 2001, AM J RESP CELL MOL, V25, P772, DOI 10.1165/ajrcmb.25.6.4458; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	43	110	113	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1150	+		10.1096/fj.02-0172fje	http://dx.doi.org/10.1096/fj.02-0172fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709416				2022-12-28	WOS:000182580100014
J	Heiniger, CD; Kostadinova, RM; Rochat, MK; Serra, A; Ferrari, P; Dick, B; Frey, BM; Frey, FJ				Heiniger, CD; Kostadinova, RM; Rochat, MK; Serra, A; Ferrari, P; Dick, B; Frey, BM; Frey, FJ			Hypoxia causes down-regulation of 11 beta-hydroxysteroid dehydrogenase type 2 by induction of Egr-1	FASEB JOURNAL			English	Article						oxygen deprivation; kidney; cortisol; antimycin A; LLC-PK1	OBSTRUCTIVE PULMONARY-DISEASE; SALT-SENSITIVITY; GENE-EXPRESSION; HIGH-ALTITUDE; MINERALOCORTICOID RECEPTORS; LLC-PK1 CELLS; NA+ CHANNEL; HYPERTENSION; ALDOSTERONE; INHIBITION	Hypoxia causes several renal tubular dysfunctions, including abnormal handling of potassium and sodium and increased blood pressure. Therefore, we investigated the impact of hypoxia on 11beta-hydroxysteroid dehydrogenase (11beta-HSD2) enzyme, a crucial prereceptor gatekeeper for renal glucocorticosteroid-mediated mineralocorticoid action. The effect of hypoxia was assessed in vitro by incubating LLC-PK1 cells with antimycin A, an inhibitor of mitochondrial oxidative phosphorylation. Antimycin A induced a dose- and time-dependent reduction of 11beta-HSD2 activity. The early growth response gene, Egr-1, a gene known to be stimulated by hypoxia was investigated because of a potential Egr-1 binding site in the promoter region of 11beta-HSD2. Antimycin A induced Egr-1 protein and Egr-1-regulated luciferase gene expression. This induction was prevented with the MAPKK inhibitor PD 98059. Overexpression of Egr-1 reduced endogenous 11beta-HSD2 activity in LLC-PK1 cells, indicating that MAPK ERK is involved in the regulation of 11beta-HSD2 in vitro. In vivo experiments in rats revealed that Egr-1 protein increases, whereas 11beta-HSD2 mRNA decreases, in kidney tissue after unilateral renal ischemia and in humans the renal activity of 11beta-HSD2 as assessed by the urinary ratio of (tetrahydrocortisol+5alpha-tetrahydrocortisol)/tetrahydrocortisone declined when volunteers were exposed to hypoxemia at high altitude up to 7000 m. Thus, hypoxia decreases 11beta-HSD2 transcription and activity by inducing Egr-1 in vivo and in vitro. This mechanism might account for enhanced renal sodium retention and hypertension associated with hypoxic conditions.	Univ Bern, Div Nephrol & Hypertens, CH-3010 Bern, Switzerland	University of Bern	Frey, FJ (corresponding author), Univ Bern, Inselspital, Div Nephrol Hypertens, Freiburgstr 15, CH-3010 Bern, Switzerland.	felix.frey@insel.ch		Ferrari, Paolo/0000-0002-9619-3104				Agarwal AK, 2000, HYPERTENSION, V36, P187, DOI 10.1161/01.HYP.36.2.187; Agarwal AK, 1996, MOL CELL ENDOCRINOL, V121, P93, DOI 10.1016/0303-7207(96)03855-5; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, P11; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BARTSCH P, 1991, J APPL PHYSIOL, V71, P136; Biller KJ, 2001, AM J PHYSIOL-RENAL, V280, pF172, DOI 10.1152/ajprenal.2001.280.1.F172; BONVENTRE JV, 1991, CELL REGUL, V2, P251, DOI 10.1091/mbc.2.3.251; CHRISTENSEN BM, 1975, AVIAT SPACE ENVIR MD, V46, P16; Dagher PC, 2000, AM J PHYSIOL-CELL PH, V279, pC1270, DOI 10.1152/ajpcell.2000.279.4.C1270; Escher G, 1997, J EXP MED, V186, P189, DOI 10.1084/jem.186.2.189; Ferrari P, 2001, HYPERTENSION, V38, P1330, DOI 10.1161/hy1101.096112; FREY FJ, 1987, ENDOCR REV, V8, P453, DOI 10.1210/edrv-8-4-453; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; Fuster D, 1998, ENDOCRINOLOGY, V139, P3849, DOI 10.1210/en.139.9.3849; GONZALEZ NC, 1994, J APPL PHYSIOL, V77, P1341, DOI 10.1152/jappl.1994.77.3.1341; Hagar H, 1996, KIDNEY INT, V49, P355, DOI 10.1038/ki.1996.52; Heiniger CD, 2001, FEBS LETT, V507, P351, DOI 10.1016/S0014-5793(01)03004-6; Johnson RJ, 2002, NEW ENGL J MED, V346, P913, DOI 10.1056/NEJMra011078; KEYNES RJ, 1982, J ENDOCRINOL, V92, P131, DOI 10.1677/joe.0.0920131; Kinane TB, 1995, J BIOL CHEM, V270, P30760, DOI 10.1074/jbc.270.51.30760; Laghmani K, 2001, J CLIN INVEST, V107, P1563, DOI 10.1172/JCI11234; LECKIE C, 1995, ENDOCRINOLOGY, V136, P5561, DOI 10.1210/en.136.12.5561; Lovati E, 1999, J CLIN ENDOCR METAB, V84, P3745, DOI 10.1210/jc.84.10.3745; MALHOTRA MS, 1975, AVIAT SPACE ENVIR MD, V46, P409; Mazzeo RS, 1998, J APPL PHYSIOL, V84, P1151, DOI 10.1152/jappl.1998.84.4.1151; MOUE Y, 1995, J APPL PHYSIOL, V79, P1657, DOI 10.1152/jappl.1995.79.5.1657; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; Murotsuki J, 1997, AM J PHYSIOL-REG I, V272, pR201, DOI 10.1152/ajpregu.1997.272.1.R201; MUROTSUKI J, 1995, AM J OBSTET GYNECOL, V173, P30, DOI 10.1016/0002-9378(95)90165-5; Murotsuki J, 1998, BIOL REPROD, V58, P234, DOI 10.1095/biolreprod58.1.234; NARAYFEJESTOTH A, 1994, AM J PHYSIOL, V266, pF76, DOI 10.1152/ajprenal.1994.266.1.F76; Narikiyo T, 2002, J CLIN INVEST, V109, P401, DOI 10.1172/JCI13229; Odermatt A, 2001, J BIOL CHEM, V276, P28484, DOI 10.1074/jbc.M100374200; OLSEN NV, 1993, J APPL PHYSIOL, V74, P2166; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; PINES A, 1977, BRIT J DIS CHEST, V71, P203, DOI 10.1016/0007-0971(77)90111-5; Quattropani C, 2001, J CLIN INVEST, V108, P1299, DOI 10.1172/JCI200112745; Raff H, 1996, J APPL PHYSIOL, V81, P604, DOI 10.1152/jappl.1996.81.2.604; RAFF H, 1993, AM JPHYSL, V265, pR8520; RAMIREZ G, 1988, J CLIN ENDOCR METAB, V67, P1162, DOI 10.1210/jcem-67-6-1162; SAHAI A, 1997, AM J PHYSIOL, V272, P809; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; Schoof E, 2001, J CLIN ENDOCR METAB, V86, P1313, DOI 10.1210/jc.86.3.1313; Schumacher M, 2002, TRANSPLANTATION, V74, P66, DOI 10.1097/00007890-200207150-00012; Schwachtgen JL, 1998, J CLIN INVEST, V101, P2540, DOI 10.1172/JCI1404; SHACKLETON CHL, 1993, J STEROID BIOCHEM, V45, P127, DOI 10.1016/0960-0760(93)90132-G; Snyder PM, 2002, ENDOCR REV, V23, P258, DOI 10.1210/er.23.2.258; SOMERS VK, 1991, J CLIN INVEST, V87, P1953, DOI 10.1172/JCI115221; STEWART AG, 1995, THORAX, V50, P838, DOI 10.1136/thx.50.8.838; STEWART AG, 1994, THORAX, V49, P995, DOI 10.1136/thx.49.10.995; Stewart PM, 1999, VITAM HORM, V57, P249; STEWART PM, 1988, J CLIN INVEST, V82, P340, DOI 10.1172/JCI113592; STEWART PM, 1987, LANCET, V2, P821; Sun K, 1997, ENDOCRINOLOGY, V138, P4912, DOI 10.1210/en.138.11.4912; Thottassery JV, 1999, J BIOL CHEM, V274, P3199, DOI 10.1074/jbc.274.5.3199; VENKATACHALAM MA, 1988, J CLIN INVEST, V81, P745, DOI 10.1172/JCI113380; Wang XY, 2001, J CLIN INVEST, V108, P215, DOI 10.1172/JCI200110366; Warnock DG, 2001, AM J MED SCI, V322, P302, DOI 10.1097/00000441-200112000-00002; Wilson RC, 1998, P NATL ACAD SCI USA, V95, P10200, DOI 10.1073/pnas.95.17.10200; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030	60	54	55	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					917	+		10.1096/fj.02-0582fje	http://dx.doi.org/10.1096/fj.02-0582fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626438				2022-12-28	WOS:000181892600019
J	Vincourt, JB; Jullien, D; Amalric, F; Girard, JP				Vincourt, JB; Jullien, D; Amalric, F; Girard, JP			Molecular and functional characterization of SLC26A11, a sodium-independent sulfate transporter from high endothelial venules	FASEB JOURNAL			English	Article						endothelial cells; sulfation; L-selectin; lymphocyte migration; sulfate/anion exchanger	PERIPHERAL LYMPH-NODES; L-SELECTIN; GENE ENCODES; SACCHAROMYCES-CEREVISIAE; EXPRESSION CLONING; PENDRED SYNDROME; MOTOR PROTEIN; CELLS; LIGAND; MUTATIONS	Lymphocyte emigration from the blood into most secondary lymphoid organs and chronically inflamed tissues occurs at the level of high endothelial venules (HEV). A unique characteristic of HEV endothelial cells (HEVEC) is their capacity to incorporate large amounts of sulfate into sialomucin-type counter-receptors for the lymphocyte homing receptor L-selectin. We have previously shown that sulfate uptake into HEVEC is mediated by two distinct functional classes of sulfate transporters: Na+-coupled transporters and sulfate/anion exchangers. Here, we report the molecular characterization from human HEVEC of SLC26A11, a novel member of the SLC26 sulfate/anion exchanger family. Functional expression studies in COS-7 and Sf9 insect cells revealed that SLC26A11 is targeted to the cell membrane and exhibits Na+-independent sulfate transport activity, sensitive to the anion exchanger inhibitor 4,4-diisothiocyanostilbene-2,2-disulfonic acid (DIDS). Northern blot analysis showed the highest SLC26A11 transcript levels in placenta, kidney, and brain. The SLC26A11 gene mapped to human chromosome 17q25, very close to the hereditary hearing loss diseases loci DFNA20, DFNA26, and USH1G. RT-PCR analysis of SLC26 sulfate transporters in human HEVEC revealed coexpression of SLC26A11 with SLC26A2/DTDST and lack of SLC26A1/SAT1, SLC26A3/DRA, and SLC26A8/TAT1. Together, our results indicate that SLC26A11 is a novel Na+-independent sulfate transporter that may cooperate with SLC26A2 to mediate DIDS-sensitive sulfate uptake into HEVEC.	Inst Pharmacol & Biol Struct, Lab Biol Vasc, Inst Pharmacol & Biol Struct, CNRS,UMR 5089, F-31077 Toulouse, France; ENDOCUBE, F-31312 Labege, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Girard, JP (corresponding author), Inst Pharmacol & Biol Struct, Lab Biol Vasc, Inst Pharmacol & Biol Struct, CNRS,UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.	Jean-Philippe.Girard@ipbs.fr	GIRARD, Jean-Philippe/F-5229-2010	GIRARD, Jean-Philippe/0000-0002-9154-1691				ANDREWS P, 1982, J CELL SCI, V57, P277; Baekkevold ES, 1999, LAB INVEST, V79, P327; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BISSIG M, 1994, J BIOL CHEM, V269, P3017; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Byeon MK, 1998, PROTEIN EXPRES PURIF, V12, P67, DOI 10.1006/prep.1997.0809; Cherest H, 1997, GENETICS, V145, P627; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; FREEMONT AJ, 1988, J PATHOL, V155, P225, DOI 10.1002/path.1711550308; Girard JP, 1999, P NATL ACAD SCI USA, V96, P12772, DOI 10.1073/pnas.96.22.12772; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; Girard JP, 1998, FASEB J, V12, P603, DOI 10.1096/fasebj.12.7.603; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; Hemmerich S, 2001, IMMUNITY, V15, P237, DOI 10.1016/S1074-7613(01)00188-1; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Hoglund P, 1996, NAT GENET, V14, P316, DOI 10.1038/ng1196-316; IMAI Y, 1993, NATURE, V361, P555; Knauf F, 2001, P NATL ACAD SCI USA, V98, P9425, DOI 10.1073/pnas.141241098; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; Li XC, 1998, NAT GENET, V18, P215, DOI 10.1038/ng0398-215; Lohi H, 2002, J BIOL CHEM, V277, P14246, DOI 10.1074/jbc.M111802200; Lohi H, 2000, GENOMICS, V70, P102, DOI 10.1006/geno.2000.6355; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morell RJ, 2000, GENOMICS, V63, P1, DOI 10.1006/geno.1999.6058; Mustapha M, 2002, HUM GENET, V110, P348, DOI 10.1007/s00439-002-0690-x; Oliver D, 2001, SCIENCE, V292, P2340, DOI 10.1126/science.1060939; Rossi A, 2001, HUM MUTAT, V17, P159, DOI 10.1002/humu.1; Satoh H, 1998, J BIOL CHEM, V273, P12307, DOI 10.1074/jbc.273.20.12307; Scott DA, 1999, NAT GENET, V21, P440, DOI 10.1038/7783; Shailubhai K, 1997, GLYCOBIOLOGY, V7, P305; SILBERG DG, 1995, J BIOL CHEM, V270, P11897, DOI 10.1074/jbc.270.20.11897; SMITH FW, 1995, MOL GEN GENET, V247, P709, DOI 10.1007/BF00290402; SMITH FW, 1995, P NATL ACAD SCI USA, V92, P9373, DOI 10.1073/pnas.92.20.9373; Soulet F, 2001, BIOCHEM BIOPH RES CO, V289, P591, DOI 10.1006/bbrc.2001.5960; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; SupertiFurga A, 1996, NAT GENET, V12, P100, DOI 10.1038/ng0196-100; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; Toure A, 2001, J BIOL CHEM, V276, P20309, DOI 10.1074/jbc.M011740200; Vincourt JB, 2002, GENOMICS, V79, P249, DOI 10.1006/geno.2002.6689; Waldegger S, 2001, GENOMICS, V72, P43, DOI 10.1006/geno.2000.6445; Yang T, 2000, AM J HUM GENET, V67, P300; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4; Zheng J, 2000, NATURE, V405, P149, DOI 10.1038/35012009	46	64	65	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					890	+		10.1096/fj.02-0787fje	http://dx.doi.org/10.1096/fj.02-0787fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626430				2022-12-28	WOS:000181892600025
J	Petrich, BG; Molkentin, JD; Wang, YB				Petrich, BG; Molkentin, JD; Wang, YB			Temporal activation of c-Jun N-terminal kinase in adult transgenic heart via cre-loxP-mediated DNA recombination	FASEB JOURNAL			English	Article						heart failure; tamoxifen; JNK activation	PROTEIN-KINASES; CARDIAC-HYPERTROPHY; IN-VIVO; EXPRESSION; CARDIOMYOPATHY; STRESSES; DISEASES	Using a cre-loxP-mediated gene-switch approach, we achieved targeted JNK activation in adult hearts. A transgenic model is established carrying a floxed gene-switch construct that directs GFP marker gene expression in the absence of DNA recombination between two loxP sites. A tamoxifen-inducible Cre recombinase was introduced in the transgenic heart by breeding with previously established Mer-Cre-Mer transgenic mice. Upon tamoxifen administration in double transgenic adult animals, cre-loxP-mediated DNA recombination efficiently switches "off" the loxP-flanked GFP expression unit in cardiomyocytes and switches "on" the expression of the target gene, MKK7D, a constitutively activated upstream activator of c-Jun N-terminal kinases (JNK). Expression of MKK7D in adult hearts resulted in significant activation of JNK activities and causes progressive cardiomyopathy in transgenic animals. This unique animal model of cardiac-specific and temporally regulated JNK activation will provide a powerful tool to investigate the functional role of the JNK pathway in the development of heart failure. Our data also demonstrated that the inducible gene-switch approach reported here may also be applicable in other studies to achieve efficient, tissue-specific, and temporally regulated genetic manipulation in intact animals.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA	University System of Maryland; University of Maryland Baltimore; Cincinnati Children's Hospital Medical Center	Wang, YB (corresponding author), Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA.	ywang001@umaryland.edu		Molkentin, Jeffery/0000-0002-3558-6529; Wang, Yibin/0000-0003-0852-0767				BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; Chen J, 1998, DEVELOPMENT, V125, P1943; Chien KR, 2001, CIRC RES, V88, P546, DOI 10.1161/01.RES.88.6.546; Chien KR, 2000, NATURE, V407, P227, DOI 10.1038/35025196; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; Clerk A, 1998, J BIOL CHEM, V273, P7228, DOI 10.1074/jbc.273.13.7228; Fishman GI, 1998, CIRC RES, V82, P837; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Huang Y, 1999, INT J FRACTURE, V100, P1, DOI 10.1023/A:1018313421855; Izumo S, 1998, J Card Fail, V4, P263, DOI 10.1016/S1071-9164(98)90231-7; Liao P, 2001, P NATL ACAD SCI USA, V98, P12283, DOI 10.1073/pnas.211086598; McKinsey TA, 1999, CURR OPIN GENET DEV, V9, P267, DOI 10.1016/S0959-437X(99)80040-9; Palermo J, 1996, CIRC RES, V78, P504, DOI 10.1161/01.RES.78.3.504; Petrich BG, 2002, CIRC RES, V91, P640, DOI 10.1161/01.RES.0000035854.11082.01; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; Redfern CH, 2000, P NATL ACAD SCI USA, V97, P4826, DOI 10.1073/pnas.97.9.4826; Sohal DS, 2001, CIRC RES, V89, P20, DOI 10.1161/hh1301.092687; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Verrou C, 1999, BIOL CHEM, V380, P1435, DOI 10.1515/BC.1999.184; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Wang Yibin, 2001, Current Opinion in Pharmacology, V1, P134, DOI 10.1016/S1471-4892(01)00029-7; Yu ZH, 1996, CIRC RES, V79, P691, DOI 10.1161/01.RES.79.4.691	22	55	59	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					749	+		10.1096/fj.02-0438fje	http://dx.doi.org/10.1096/fj.02-0438fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594183				2022-12-28	WOS:000181456900011
J	Somlyo, AV; Phelps, C; Dipierro, C; Eto, M; Read, P; Barrett, M; Gibson, JJ; Burnitz, MC; Myers, C; Somlyo, AP				Somlyo, AV; Phelps, C; Dipierro, C; Eto, M; Read, P; Barrett, M; Gibson, JJ; Burnitz, MC; Myers, C; Somlyo, AP			Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants	FASEB JOURNAL			English	Article						myosin phosphatase; G-protein; endothelium; tumor necrosis	GTP-BINDING PROTEIN; LIGHT-CHAIN PHOSPHATASE; SMOOTH-MUSCLE; IN-VITRO; TUMOR; BONE; PHOSPHORYLATION; THROMBIN; INVASION; SUBUNIT	The purpose of this study was to determine the effects of inhibitors of Rho kinase (ROK) and matrix metalloproteinases (MMPs) on angiogenesis and tumor growth and to evaluate ROK activity in human prostate cancer PC3 cells and endothelial cells (HUVECs). Vacuolation by endothelial cells and lumen formation, the earliest detectable stages of angiogenesis, were inhibited by the ROK inhibitor Wf-536. Combining Wf-536 with the MMP inhibitor Marimastat greatly enhanced in vitro inhibition of endothelial vacuolation, lumen and cord formation, and VEGF- and HGF-stimulated endothelial sprout formation from aorta. Inhibition of sprout formation by the two inhibitors was synergistic. Both agents inhibited migration of HUVECs. The regulatory subunit (MYPT1) of the myosin phosphatase was phosphorylated in PC3 cells and HUVECs, and phosphorylation of MYPT1 and the myosin regulatory light chain was reduced by Wf-536, providing direct evidence of ROK activity. Early treatment of immuno-incompetent mice bearing xenotransplants of PC3 cells with a combination of Wf-536 plus Marimastat with or without Paclitaxel, significantly inhibited tumor growth, prevented tumor growth escape after discontinuation of Paclitaxel, and increased survival.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Cellular Signaling, Charlottesville, VA 22908 USA; Univ Virginia, Dept Radiat Oncol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Hlth Evaluat Sci, Charlottesville, VA 22908 USA; Amer Inst Dis Prostate, Charlottesville, VA USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia	Somlyo, AP (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, 1300 Jefferson Pk Ave,POB 800736,Jordan Hall, Charlottesville, VA 22908 USA.	avs5u@virginia.edu	Eto, Masumi/ABE-4700-2020	Eto, Masumi/0000-0002-0651-5836	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242, P01HL048807] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL48807, P01 HL19242] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amerongen GPV, 2000, CIRC RES, V87, P335, DOI 10.1161/01.RES.87.4.335; Bayless KJ, 2002, J CELL SCI, V115, P1123; Bissell MJ, 2002, JNCI-J NATL CANCER I, V94, P4; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Carbajal JM, 1999, AM J PHYSIOL-CELL PH, V277, pC955, DOI 10.1152/ajpcell.1999.277.5.C955; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993; Choy M, 2001, CANCER INVEST, V19, P181, DOI 10.1081/CNV-100000152; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; del Peso L, 1997, ONCOGENE, V15, P3047; Diggle P. J., 1996, ANAL LONGITUDINAL DA; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884; Feng JH, 1999, J BIOL CHEM, V274, P37385, DOI 10.1074/jbc.274.52.37385; Figg WD, 2002, INVEST NEW DRUG, V20, P183, DOI 10.1023/A:1015626410273; Folkman J, 2000, NAT REV MOL CELL BIO, V1, P76, DOI 10.1038/35036100; Gelderblom H, 2001, EUR J CANCER, V37, P1590, DOI 10.1016/S0959-8049(01)00171-X; Gelmon KA, 1999, J NATL CANCER I, V91, P1281, DOI 10.1093/jnci/91.15.1281; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Jo M, 2002, J BIOL CHEM, V277, P12479, DOI 10.1074/jbc.M111147200; Kawano Y, 1999, J CELL BIOL, V147, P1023, DOI 10.1083/jcb.147.5.1023; Keller ET, 2001, CANCER METAST REV, V20, P333, DOI 10.1023/A:1015599831232; KRAMER CY, 1956, BIOMETRICS, V12, P307, DOI 10.2307/3001469; Laird AD, 2002, FASEB J, V16, DOI 10.1096/fj.01-0700com; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lawless J.F, 1982, STAT MODELS METHODS; Leung SYL, 2000, PROSTATE, V44, P156, DOI 10.1002/1097-0045(20000701)44:2<156::AID-PROS8>3.0.CO;2-8; Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Nemeth JA, 2002, J NATL CANCER I, V94, P17; Nicholson B, 2001, CANCER METAST REV, V20, P297, DOI 10.1023/A:1015543713485; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191; Polin L, 1997, INVEST NEW DRUG, V15, P99, DOI 10.1023/A:1005856605726; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Richards CT, 2002, J BIOL CHEM, V277, P4422, DOI 10.1074/jbc.M111047200; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Seasholtz TM, 1999, CIRC RES, V84, P1186, DOI 10.1161/01.RES.84.10.1186; Shalinsky DR, 1999, ANN NY ACAD SCI, V878, P236, DOI 10.1111/j.1749-6632.1999.tb07689.x; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Stearns ME, 1996, INVAS METAST, V16, P116; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Thalmann GN, 2000, PROSTATE, V44, P91; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wicki A, 2001, INT J CANCER, V91, P763, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1128>3.0.CO;2-B; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Xin XH, 2001, AM J PATHOL, V158, P1111, DOI 10.1016/S0002-9440(10)64058-8; Yang S, 1999, AM J PATHOL, V155, P887, DOI 10.1016/S0002-9440(10)65188-7; Yoshioka K, 1999, CANCER RES, V59, P2004; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146; ZHANG D, 1995, J CELL SCI, V108, P2285; ZUCKER S, 2002, ANTICANCER DRUG DEV, V6, P91	61	86	93	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					223	234		10.1096/fj.02-0655com	http://dx.doi.org/10.1096/fj.02-0655com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554701				2022-12-28	WOS:000181456900047
J	Gullo, F; Ales, E; Rosati, B; Lecchi, M; Masi, A; Guasti, L; Cano-Abad, MF; Arcangeli, A; Lopez, MG; Wanke, E				Gullo, F; Ales, E; Rosati, B; Lecchi, M; Masi, A; Guasti, L; Cano-Abad, MF; Arcangeli, A; Lopez, MG; Wanke, E			ERG K+ channel blockade enhances firing and epinephrine secretion in rat chromaffin cells: the missing link to LQT2-related sudden death?	FASEB JOURNAL			English	Article						catecholamine release; eag superfamily; erg gene; arrhythmia; adrenal medulla	LONG-QT SYNDROME; CATECHOLAMINE RELEASE; CARDIAC-ARRHYTHMIA; POTASSIUM CHANNELS; HERG; MUTATIONS; EVENTS; CA2+; IDENTIFICATION; EXOCYTOSIS	The ether-a-go-go-related genes (erg) are expressed in tissues other than heart and brain, in which human erg (HERG) K+ channels are known to regulate the repolarization of heart action potentials and neuronal spike-frequency accommodation. We provide evidence that erg1 transcripts and ERG proteins are present in rat chromaffin cells in which we could isolate a K+ current that was biophysically and pharmacologically similar to the ERG current. Firing frequency and catecholamine release were analyzed at the single-cell level by means of perforated patch-clamp and carbon fiber electrochemical detection. It was found that the blocking of ERG, K-ATP, and K-Ca channels led to hyperexcitability and an increase in catecholamine release. Combined immunocytochemical experiments with antibodies directed against phenylethanolamine N-methyltransferase and ERG channels suggested expression of these channels in epinephrine- but not in norepinephrine-containing cells. It is concluded that, in addition to being crucial in regulating the QT period in the heart, ERG channels play a role in modulating epinephrine, a fundamental neurotransmitter shaping cardiac function. This finding suggests that the sudden death phenotype associated with LQT2 syndrome mutations may be the result of an emotionally triggered increase in epinephrine in a long-QT running heart.	Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy; Univ Autonoma Madrid, Dept Farmacol, Inst Teofilo Hernando, E-28029 Madrid, Spain; Univ Florence, Dipartimento Patol & Oncol Sperimentali, I-50134 Florence, Italy	University of Milano-Bicocca; Autonomous University of Madrid; University of Florence	Wanke, E (corresponding author), Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.	enzo.wanke@unimib.it	Ales, Eva/E-6315-2010; Lopez, Manuela G/D-2164-2015; Masi, Alessio/AAB-4884-2022	Ales, Eva/0000-0002-5536-4616; Lopez, Manuela G/0000-0003-4461-8788; GUASTI, LUIGINA/0000-0002-4524-4864; Guasti, Leonardo/0000-0002-4616-6044; Masi, Alessio/0000-0002-0361-0950; Cano-Abad, Maria F./0000-0002-2602-6626	Telethon [1046] Funding Source: Medline	Telethon(Fondazione Telethon)		Akbarali HI, 1999, AM J PHYSIOL-CELL PH, V277, pC1284, DOI 10.1152/ajpcell.1999.277.6.C1284; ALMERS W, 1985, FEBS LETT, V192, P13, DOI 10.1016/0014-5793(85)80033-8; ARTALEJO AR, 1993, PFLUG ARCH EUR J PHY, V423, P97, DOI 10.1007/BF00374966; BELLUZZI O, 1985, J PHYSIOL-LONDON, V358, P109, DOI 10.1113/jphysiol.1985.sp015543; Cherubini A, 2000, BRIT J CANCER, V83, P1722, DOI 10.1054/bjoc.2000.1497; Chiesa N, 1997, J PHYSIOL-LONDON, V501, P313, DOI 10.1111/j.1469-7793.1997.313bn.x; CHOI AY, 1993, J NEUROCHEM, V61, P541; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Corrette BJ, 1996, J MEMBRANE BIOL, V150, P185, DOI 10.1007/s002329900043; Cuchillo-Ibanez I, 1999, FEBS LETT, V459, P22, DOI 10.1016/S0014-5793(99)01115-1; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DIXON JE, 1994, CIRC RES, V75, P252, DOI 10.1161/01.RES.75.2.252; DOUGLAS WW, 1965, NATURE, V208, P1102, DOI 10.1038/2081102a0; ELDAR M, 1987, J AM COLL CARDIOL, V10, P600, DOI 10.1016/S0735-1097(87)80203-6; Faravelli L, 1996, J PHYSIOL-LONDON, V496, P13, DOI 10.1113/jphysiol.1996.sp021661; FINNEGAN JM, 1995, J BIOL CHEM, V270, P5353, DOI 10.1074/jbc.270.10.5353; GANDIA L, 1993, J PHYSIOL-LONDON, V470, P55, DOI 10.1113/jphysiol.1993.sp019847; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gurrola GB, 1999, FASEB J, V13, P953, DOI 10.1096/fasebj.13.8.953; Heath BM, 2000, J PHYSIOL-LONDON, V522, P391, DOI 10.1111/j.1469-7793.2000.t01-2-00391.x; HILLARP NA, 1953, ACTA PHYSIOL SCAND, V30, P55; JERVELL A, 1957, AM HEART J, V54, P59, DOI 10.1016/0002-8703(57)90079-0; LEE K, 1990, J NEUROCHEM, V55, P1131, DOI 10.1111/j.1471-4159.1990.tb03115.x; Magistretti J, 1996, TRENDS NEUROSCI, V19, P530, DOI 10.1016/S0166-2236(96)40004-2; MARTY A, 1985, J PHYSIOL-LONDON, V367, P117, DOI 10.1113/jphysiol.1985.sp015817; MochizukiOda N, 1997, J NEUROCHEM, V69, P377; MONTIEL C, 1995, J PHYSIOL-LONDON, V486, P427, DOI 10.1113/jphysiol.1995.sp020823; Moss AJ, 1999, AM J CARDIOL, V84, P876, DOI 10.1016/S0002-9149(99)00458-0; Nagayama T, 2000, AM J PHYSIOL-REG I, V279, pR448, DOI 10.1152/ajpregu.2000.279.2.R448; Nunez L, 1995, AM J PHYSIOL-CELL PH, V269, pC1540, DOI 10.1152/ajpcell.1995.269.6.C1540; Overholt JL, 2000, J NEUROPHYSIOL, V83, P1150, DOI 10.1152/jn.2000.83.3.1150; Pond AL, 2000, J BIOL CHEM, V275, P5997, DOI 10.1074/jbc.275.8.5997; Rosati B, 2000, FASEB J, V14, P2601, DOI 10.1096/fj.00-0077com; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; Schonherr R, 1999, EUR J NEUROSCI, V11, P753, DOI 10.1046/j.1460-9568.1999.00493.x; Schwartz PJ, 2001, CIRCULATION, V103, P89; SCHWARTZ PJ, 1991, CIRCULATION, V84, P503, DOI 10.1161/01.CIR.84.2.503; SCHWARTZ PJ, 1991, CIRCULATION, V83, P78; Shi WM, 1997, J NEUROSCI, V17, P9423; SPINELLI W, 1993, CARDIOVASC RES, V27, P1580, DOI 10.1093/cvr/27.9.1580; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; STAUDERMAN KA, 1990, J NEUROCHEM, V54, P946, DOI 10.1111/j.1471-4159.1990.tb02342.x; Titus SA, 1997, J NEUROSCI, V17, P875; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Wilde AAM, 1999, J AM COLL CARDIOL, V33, P327, DOI 10.1016/S0735-1097(98)00578-6; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	52	61	63	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					330	+		10.1096/fj.02-0200fje	http://dx.doi.org/10.1096/fj.02-0200fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12490549				2022-12-28	WOS:000180574300029
J	Bantel, H; Schmitz, ML; Raible, A; Gregor, M; Schulze-Osthoff, K				Bantel, H; Schmitz, ML; Raible, A; Gregor, M; Schulze-Osthoff, K			Critical role of nuclear factor-kappa B and stress-activated protein kinases in steroid unresponsiveness	FASEB JOURNAL			English	Article						AP-1; glucocorticoids; chronic inflammation; NF-kappa B; steroid resistance	INFLAMMATORY-BOWEL-DISEASE; TUMOR-NECROSIS-FACTOR; GLUCOCORTICOID RECEPTOR; CROHNS-DISEASE; TRANSCRIPTION FACTOR; ULCERATIVE-COLITIS; EPITHELIAL-CELLS; T-LYMPHOCYTES; RESISTANCE; EXPRESSION	Glucocorticoid resistance is a serious clinical problem in chronic inflammatory diseases, because many patients with rheumatoid arthritis, asthma, or Crohn's disease fail to respond to steroid treatment. The molecular mechanisms underlying this unresponsiveness, however, are completely unknown. The effects of steroids are largely mediated by the interference of the glucocorticoid receptor (GR) with proinflammatory transcription factors. In the present study, we therefore investigated the activation of the transcription factors nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and the upstream kinases p38 and c-Jun N-terminal kinase (JNK) in steroid-sensitive and steroid-resistant patients with Crohn's disease. We demonstrated that steroid-sensitive and steroid-resistant patients reveal a remarkably different cellular activation pattern of these proinflammatory mediators. In steroid-sensitive patients, activation of NF-kappaB, AP-1, p38, and JNK was mainly found in lamina propria macrophages. In contrast, steroid-resistant patients revealed activation of all these mediators mostly in epithelial cells. The functional interference of the proinflammatory mediators with the glucocorticoid response was supported by reporter gene assays. Expression of NF-kappaB and, interestingly, also JNK1 and p38 inhibited the activity of the GR. Thus, our results suggest that steroid resistance is associated with increased epithelial activation of stress-activated protein kinases and NF-kappaB, which might inhibit the anti-inflammatory action of a limited number of GRs.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Univ Munster, Dept Immunol & Cell Biol, D-48149 Munster, Germany; Univ Bern, Inst Chem & Biochem, CH-3012 Bern, Switzerland; Univ Tubingen, Dept Internal Med, D-72076 Tubingen, Germany	Heinrich Heine University Dusseldorf; University of Munster; University of Bern; Eberhard Karls University of Tubingen	Schulze-Osthoff, K (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1, D-40225 Dusseldorf, Germany.	kso@uni-duesseldorf.de	Schmitz, M. Lienhard/D-9328-2017; Schulze-Osthoff, Klaus/N-9025-2013	Schmitz, M. Lienhard/0000-0002-6984-7192; Schulze-Osthoff, Klaus/0000-0003-1443-2720				ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Bantel H, 2000, GASTROENTEROLOGY, V119, P1178, DOI 10.1053/gast.2000.19224; Bantel H, 2000, AM J GASTROENTEROL, V95, P3452; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Da Silva JAP, 1999, ANN NY ACAD SCI, V876, P102; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Dumont A, 1998, TRENDS BIOCHEM SCI, V23, P233, DOI 10.1016/S0968-0004(98)01212-2; Farrell RJ, 2000, GASTROENTEROLOGY, V118, P279, DOI 10.1016/S0016-5085(00)70210-1; Faubion WA, 2001, GASTROENTEROLOGY, V121, P255, DOI 10.1053/gast.2001.26279; Gitter AH, 2001, GASTROENTEROLOGY, V121, P1320, DOI 10.1053/gast.2001.29694; Gitter AH, 2000, FASEB J, V14, P1749, DOI 10.1096/fj.99-0898com; Gonzalez MV, 2000, J CELL BIOL, V150, P1199, DOI 10.1083/jcb.150.5.1199; Hecht K, 1997, J BIOL CHEM, V272, P26659, DOI 10.1074/jbc.272.42.26659; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; Hoffmeyer A, 1999, J BIOL CHEM, V274, P4319, DOI 10.1074/jbc.274.7.4319; Hommes D, 2002, GASTROENTEROLOGY, V122, P7, DOI 10.1053/gast.2002.30770; Honda M, 2000, GASTROENTEROLOGY, V118, P859, DOI 10.1016/S0016-5085(00)70172-7; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2001, J BIOL CHEM, V276, P30208, DOI 10.1074/jbc.M103604200; KALTSCHMIDT C, 1995, BIOL CHEM H-S, V376, P9; Karin M, 2001, J ENDOCRINOL, V169, P447, DOI 10.1677/joe.0.1690447; Lamberts SWJ, 1996, STEROIDS, V61, P157, DOI 10.1016/0039-128X(96)00005-0; Lane SJ, 1998, J CLIN INVEST, V102, P2156, DOI 10.1172/JCI2680; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; McCabe RP, 1996, CURR OPIN GASTROEN, V12, P340, DOI 10.1097/00001574-199607000-00005; MUNKHOLM P, 1994, GUT, V35, P360, DOI 10.1136/gut.35.3.360; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Panwala CM, 1998, J IMMUNOL, V161, P5733; Raddatz D, 2001, INT J COLORECTAL DIS, V16, P377, DOI 10.1007/s003840100331; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; Rogler G, 1999, EUR J CLIN INVEST, V29, P330; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Stange EF, 1999, EUR J CLIN INVEST, V29, P278; Thevenod F, 2000, J BIOL CHEM, V275, P1887, DOI 10.1074/jbc.275.3.1887; Thiele K, 1999, GUT, V45, P693, DOI 10.1136/gut.45.5.693; Urayama S, 1998, J CLIN INVEST, V102, P1860, DOI 10.1172/JCI2235; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Zareie M, 2001, AM J PATHOL, V158, P1101, DOI 10.1016/S0002-9440(10)64057-6; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174; Zhu W, 2000, J IMMUNOL, V164, P6349, DOI 10.4049/jimmunol.164.12.6349	52	93	100	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13	1				1832	+		10.1096/fj.02-0223fje	http://dx.doi.org/10.1096/fj.02-0223fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223450				2022-12-28	WOS:000181189100005
J	Russell, JW; Golovoy, D; Vincent, AM; Mahendru, P; Olzmann, JA; Mentzer, A; Feldman, EL				Russell, JW; Golovoy, D; Vincent, AM; Mahendru, P; Olzmann, JA; Mentzer, A; Feldman, EL			High glucose-induced oxidative stress and mitochondrial dysfunction in neurons	FASEB JOURNAL			English	Article						apoptosis; mitochondria; DRG; glucose; reactive oxygen species	PERMEABILITY TRANSITION PORE; PROGRAMMED CELL-DEATH; BLOOD-FLOW; APOPTOSIS; NERVE; METABOLISM; GANGLION	The current study examines the association between glucose induction of reactive oxygen species (ROS), mitochondrial (Mt) depolarization, and programmed cell death in primary neurons. In primary dorsal root ganglion (DRG) neurons, 45 mM glucose rapidly induces a peak rise in ROS corresponding to a 50% increase in mean Mt size at 6 h (P<0.001). This is coupled with loss of regulation of the Mt membrane potential (Mt membrane hyperpolarization, followed by depolarization, MMD), partial depletion of ATP, and activation of caspase-3 and -9. Glucose-induced activation of ROS, MMD, and caspase-3 and -9 activation is inhibited by myxothiazole and thenoyltrifluoroacetone (P<0.001), which inhibit specific components of the Mt electron transfer chain. Similarly, MMD and caspase-3 activation are inhibited by 100 muM bongkrekic acid (an inhibitor of the adenosine nucleotide translocase ANT). These results indicate that mild increases in glucose induce ROS and Mt swelling that precedes neuronal apoptosis. Glucotoxicity is blocked by inhibiting ROS induction, MMD, or caspase cleavage by specific inhibitors of electron transfer, or by stabilizing the ANT.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; Vet Affairs Med Ctr, Dept Neurol, Ann Arbor, MI USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Russell, JW (corresponding author), Univ Michigan, Dept Neurol, 200 Zina Pitcher Pl,4410 Kresge 3, Ann Arbor, MI 48109 USA.	jruss@umich.edu		Feldman, Eva/0000-0002-9162-2694; Olzmann, James/0000-0001-7751-8316	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001938, R01NS036778, R01NS038849, K02NS042056] Funding Source: NIH RePORTER; NIDDK NIH HHS [5P60DK-20572] Funding Source: Medline; NINDS NIH HHS [NS38849, NS36778, NS01938, NS42056] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bottenstein J.E., 1989, DISSECTION TISSUE CU, P227; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Greene DA, 1999, EUR J PHARMACOL, V375, P217, DOI 10.1016/S0014-2999(99)00356-8; Kishi M, 2002, DIABETES, V51, P819, DOI 10.2337/diabetes.51.3.819; KISHI M, 2001, J PERIPHER NERV SYST, V6, P152; Kogawa S, 2000, NEUROREPORT, V11, P663, DOI 10.1097/00001756-200003200-00003; KORINKOVA P, 1976, ACTA HISTOCHEM, V56, P47; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Russell JW, 1999, NEUROBIOL DIS, V6, P347, DOI 10.1006/nbdi.1999.0254; Russell JW, 1999, HORM METAB RES, V31, P90, DOI 10.1055/s-2007-978704; Sasaki H, 1997, ACTA NEUROPATHOL, V93, P118, DOI 10.1007/s004010050592; Srinivasan S, 2000, DIABETES, V49, P1932, DOI 10.2337/diabetes.49.11.1932; Stevens MJ, 2000, DIABETES, V49, P1006, DOI 10.2337/diabetes.49.6.1006; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vincent AM, 2002, ANN NY ACAD SCI, V959, P368, DOI 10.1111/j.1749-6632.2002.tb02108.x; Wadia JS, 1998, J NEUROSCI, V18, P932; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zochodne DW, 2001, BRAIN, V124, P2319, DOI 10.1093/brain/124.11.2319	25	395	416	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					1738	1748		10.1096/fj.01-1027com	http://dx.doi.org/10.1096/fj.01-1027com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12409316	Green Submitted			2022-12-28	WOS:000180218500006
J	Usui, M; Egashira, K; Ohtani, K; Kataoka, C; Ishibashi, M; Hiasa, K; Katoh, M; Zhao, QW; Kitamoto, S; Takeshita, A				Usui, M; Egashira, K; Ohtani, K; Kataoka, C; Ishibashi, M; Hiasa, K; Katoh, M; Zhao, QW; Kitamoto, S; Takeshita, A			Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys	FASEB JOURNAL			English	Article						MCP-1; inflammation; monocyte; restenosis; neointimal hyperplasia	NITRIC-OXIDE SYNTHESIS; CHRONIC BLOCKADE; ATHEROSCLEROTIC LESIONS; CAROTID ARTERIES; CHEMOKINES; MICE; PATHOGENESIS; RECEPTOR; DISEASE	Prevention of restenosis after coronary intervention is a major clinical challenge, which highlights the need of new therapeutic options. Vascular injury may involve inflammatory responses that accelerate the recruitment and activation of monocytes through the activation of chemotactic factors, including monocyte chemoattractant protein-1 (MCP-1). However, there is no definitive evidence supporting the role of MCP-1 in restenosis. We recently devised a new strategy for anti-MCP-1 gene therapy by transfecting an N-terminal deletion mutant of the MCP-1 gene into skeletal muscles. We demonstrate here that this strategy suppressed monocyte infiltration/activation in the injured site and markedly inhibited restenotic changes (neointimal hyperplasia) after balloon injury of the carotid artery in rats and monkeys. This strategy also suppressed the local production of MCP-1 and inflammatory cytokines. Therefore, monocyte infiltration and activation mediated by MCP-1 are essential in the development of restenotic changes after balloon injury. This strategy may be a useful form of gene therapy against human restenosis.	Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Higashi Ku, Fukuoka 8128582, Japan; Discovery Res Labs, Tokyo, Japan	Kyushu University	Egashira, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	egashira@cardiol.med.kyushu-u.ac.jp		Katoh, Makoto/0000-0002-5216-0271				Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Cipollone F, 2001, ARTERIOSCL THROM VAS, V21, P327, DOI 10.1161/01.ATV.21.3.327; Egashira K, 2000, FASEB J, V14, P1974, DOI 10.1096/fj.00-0141com; Furukawa Y, 1999, CIRC RES, V84, P306, DOI 10.1161/01.RES.84.3.306; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Hayashi S, 2000, CIRCULATION, V102, P1710, DOI 10.1161/01.CIR.102.14.1710; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Horvath C, 2002, CIRC RES, V90, P488, DOI 10.1161/hh0402.105956; Kitamoto S, 2000, CIRCULATION, V102, P806, DOI 10.1161/01.CIR.102.7.806; Koyanagi M, 2000, CIRCULATION, V102, P2243; Libby P, 1997, NEW ENGL J MED, V337, P418, DOI 10.1056/NEJM199708073370608; LIU MW, 1989, CIRCULATION, V79, P1374, DOI 10.1161/01.CIR.79.6.1374; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Mukaida N, 1998, CYTOKINE GROWTH F R, V9, P9, DOI 10.1016/S1359-6101(97)00022-1; Ni WH, 2001, CIRCULATION, V103, P2096; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Takemoto M, 1997, J CLIN INVEST, V99, P278, DOI 10.1172/JCI119156; TAKEYA M, 1993, HUM PATHOL, V24, P534, DOI 10.1016/0046-8177(93)90166-E; TAUBMAN MB, 1992, CIRC RES, V70, P314, DOI 10.1161/01.RES.70.2.314; Topol EJ, 1998, CIRCULATION, V98, P1802, DOI 10.1161/01.CIR.98.17.1802; Usui M, 2000, CIRCULATION, V101, P305, DOI 10.1161/01.CIR.101.3.305; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252	24	80	85	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2002	16	13	1				1838	+		10.1096/fj.02-0094fje	http://dx.doi.org/10.1096/fj.02-0094fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223446				2022-12-28	WOS:000181189100004
J	Park, S; Meyer, M; Jones, AD; Yennawar, HP; Yennawar, NH; Nixon, BT				Park, S; Meyer, M; Jones, AD; Yennawar, HP; Yennawar, NH; Nixon, BT			Two-component signaling in the AAA+ ATPase DctD: binding Mg2+ and BeF3- selects between alternative dimeric states of the receiver domain	FASEB JOURNAL			English	Article						two-component signal transduction; NtrC; sigma 54; enhancer binding protein	NITROGEN-REGULATORY PROTEIN; RHIZOBIUM-MELILOTI DCTD; RESPONSE REGULATOR; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; B-LINKER; NTRC; ACTIVATION; ENHANCER; PHOSPHORYLATION	A crystal structure is described for the Mg2+-BeF3--bound receiver domain of Sinorhizobium meliloti DctD bearing amino acid substitution E121K. Differences between the apo- and ligand-bound active sites are similar to those reported for other receiver domains. However, the off and on states of the DctD receiver domain are characterized by dramatically different dimeric structures, which supports the following hypothesis of signal transduction. In the off state, the receiver domain and coiled-coil linker form a dimer that inhibits oligomerization of the AAA+ ATPase domain. In this conformation, the receiver domain cannot be phosphorylated or bind Mg2+ and BeF3-. Instead, these modifications stabilize an alternative dimeric conformation that repositions the subunits by approximately 20 Angstrom, thus replacing the alpha4-beta5-alpha5 interface with an alpha4-beta5 interface. Reoriented receiver domains permit the ATPase domain to oligomerize and stimulate open complex formation by the sigma(54) form of RNA polymerase. NtrC, which shares 38% sequence identity with DctD, works differently. Its activated receiver domain must facilitate oligomerization of its ATPase domain. Significant differences exist in the signaling surfaces of the DctD and NtrC receiver domains that may help explain how triggering the common two-component switch can variously regulate assembly of a AAA+ ATPase domain.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Nixon, BT (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, 6 Althouse Lab, University Pk, PA 16802 USA.	btn1@psu.edu	Jones, Arthur D/C-2670-2013	Yennawar, Hemant P./0000-0003-2869-1109; Jones, A. Daniel/0000-0002-7408-6690				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Birck C, 1999, STRUCTURE, V7, P1505, DOI 10.1016/S0969-2126(00)88341-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; Chaney M, 2001, GENE DEV, V15, P2282, DOI 10.1101/gad.205501; Dixon R, 1998, ARCH MICROBIOL, V169, P371, DOI 10.1007/s002030050585; Dworkin J, 2000, J BACTERIOL, V182, P311, DOI 10.1128/JB.182.2.311-319.2000; FLASHNER Y, 1995, J MOL BIOL, V249, P700, DOI 10.1006/jmbi.1995.0330; Garmendia J, 2000, MOL MICROBIOL, V38, P401, DOI 10.1046/j.1365-2958.2000.02139.x; GU BH, 1994, MOL MICROBIOL, V13, P51, DOI 10.1111/j.1365-2958.1994.tb00401.x; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Halkides CJ, 2000, BIOCHEMISTRY-US, V39, P5280, DOI 10.1021/bi9925524; HUALA E, 1992, J BACTERIOL, V174, P1428, DOI 10.1128/jb.174.4.1428-1431.1992; IYER PB, 2001, THESIS PENNSYLVANIA; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kern D, 1999, NATURE, V402, P894, DOI 10.1038/47273; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; KLOSE KE, 1993, J MOL BIOL, V232, P67, DOI 10.1006/jmbi.1993.1370; KLOSE KE, 1994, J MOL BIOL, V241, P233, DOI 10.1006/jmbi.1994.1492; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE JH, 1994, J BIOL CHEM, V269, P20401; Lee JH, 2000, J BACTERIOL, V182, P5188, DOI 10.1128/JB.182.18.5188-5195.2000; Lee SY, 2001, J BIOL CHEM, V276, P16425, DOI 10.1074/jbc.M101002200; Lee SY, 2001, NAT STRUCT BIOL, V8, P52; Lewis RJ, 2000, J MOL BIOL, V297, P757, DOI 10.1006/jmbi.2000.3598; Lewis RJ, 1999, J MOL BIOL, V294, P9, DOI 10.1006/jmbi.1999.3261; Meyer MG, 2001, FASEB J, V15, P1326, DOI 10.1096/fj.00-0516fje; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Neuwald AF, 1999, GENOME RES, V9, P27; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; NIXON BT, 1986, P NATL ACAD SCI USA, V83, P7850, DOI 10.1073/pnas.83.20.7850; NIXON BT, 2000, COILED COIL LINKERS; O'Neill E, 2001, EMBO J, V20, P819, DOI 10.1093/emboj/20.4.819; PARK S, 2002, IN PRESS BIOCHEMISTR; Pelton JG, 1999, J MOL BIOL, V292, P1095, DOI 10.1006/jmbi.1999.3140; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; Rippe K, 1998, J MOL BIOL, V278, P915, DOI 10.1006/jmbi.1998.1746; RONSON CW, 1987, NUCLEIC ACIDS RES, V15, P7921, DOI 10.1093/nar/15.19.7921; Scholl D, 1996, J BIOL CHEM, V271, P26435, DOI 10.1074/jbc.271.42.26435; Shingler V, 1996, MOL MICROBIOL, V19, P409, DOI 10.1046/j.1365-2958.1996.388920.x; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; VOLKMAN BF, 1995, BIOCHEMISTRY-US, V34, P1413, DOI 10.1021/bi00004a036; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658; Yan D, 1999, P NATL ACAD SCI USA, V96, P14789, DOI 10.1073/pnas.96.26.14789; Yurgel S, 2000, J BACTERIOL, V182, P4216, DOI 10.1128/JB.182.15.4216-4221.2000	49	38	39	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1964	+		10.1096/fj.02-0395fje	http://dx.doi.org/10.1096/fj.02-0395fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368235				2022-12-28	WOS:000179167600016
J	Krasnova, IN; Mccoy, MT; Ladenheim, B; Cadet, JL				Krasnova, IN; Mccoy, MT; Ladenheim, B; Cadet, JL			CDNA array analysis of gene expression profiles in the striata of wild-type and Cu/Zn superoxide dismutase transgenic mice treated with neurotoxic doses of amphetamine	FASEB JOURNAL			English	Article						amphetamine; neurotoxicity; Cu/Zn SOD; striatum; gene expression analysis	STRESS-INDUCED APOPTOSIS; METHAMPHETAMINE-INDUCED NEUROTOXICITY; PROGRAMMED CELL-DEATH; C-FOS; TRANSCRIPTION FACTORS; RAT STRIATUM; RECEPTOR ACTIVATION; OXIDATIVE STRESS; NERVOUS-SYSTEM; DNA-BINDING	Amphetamine (AMPH) is a drug of abuse that causes the degeneration of striatal dopamine terminals in mammals. Superoxide radicals seem to participate in AMPH-induced damage because its toxicity is attenuated in Cu/Zn superoxide dismutase transgenic (SOD-tg) mice. To provide a detailed analysis of molecular changes associated with AMPH toxicity, we used cDNA arrays consisting of 1176 genes to detect differential changes in gene expression in the striata of wild-type and SOD-tg mice treated with neurotoxic doses of the drug. We found 42 genes that showed >1.8-fold changes in at least two consecutive time points during the course of the study and were differentially affected by AMPH in the two genotypes. Specifically, more transcription factors and genes involved in responses to injury/inflammation were affected in wild-type mice after AMPH administration. Some of these stimulant-induced superoxide-dependent alterations in gene expression might affect neuronal functions and promote neuronal damage. Other changes might help to provide some degree of protection against AMPH toxicity. These results support the view that the use of global array analysis of gene expression will help to identify novel molecular mediators of AMPH-induced neurodegeneration.	NIDA, Mol Neuropsychiat Sect, Intramural Res Program, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Cadet, JL (corresponding author), NIDA, Mol Neuropsychiat Sect, Intramural Res Program, NIH, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.	JCADET@intra.nida.nih.gov			NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000174, Z01DA000388, Z01DA000174] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Asanuma M, 2000, MOL BRAIN RES, V80, P237, DOI 10.1016/S0169-328X(00)00128-5; Barouki R, 2001, BIOCHEM PHARMACOL, V61, P511, DOI 10.1016/S0006-2952(00)00543-8; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BEREZOVSKAYA O, 1995, INT J DEV NEUROSCI, V13, P285, DOI 10.1016/0736-5748(95)00013-7; Cadet JL, 1998, NEUROCHEM INT, V32, P117, DOI 10.1016/S0197-0186(97)00031-4; Cajetan Luna G, 2001, Rev Panam Salud Publica, V9, P114, DOI 10.1590/S1020-49892001000200012; Christians ES, 2002, CRIT CARE MED, V30, pS43, DOI 10.1097/00003246-200201001-00006; COLE AJ, 1992, J NEUROCHEM, V58, P1420, DOI 10.1111/j.1471-4159.1992.tb11358.x; Czerwinski W P, 1998, J La State Med Soc, V150, P491; Dalton TD, 1999, ANNU REV PHARMACOL, V39, P67, DOI 10.1146/annurev.pharmtox.39.1.67; Deng XL, 1999, J NEUROSCI, V19, P10107; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELLISON G, 1978, SCIENCE, V201, P276, DOI 10.1126/science.26975; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Genova LM, 1998, SYNAPSE, V30, P71, DOI 10.1002/(SICI)1098-2396(199809)30:1<71::AID-SYN9>3.0.CO;2-H; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hatayama T, 2001, BIOCHEM BIOPH RES CO, V288, P528, DOI 10.1006/bbrc.2001.5802; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Hirata H, 1998, MOL BRAIN RES, V58, P209, DOI 10.1016/S0169-328X(98)00055-2; Huang NK, 1997, LIFE SCI, V61, P2219, DOI 10.1016/S0024-3205(97)00924-7; Hughes PE, 1999, NEUROSCIENCE, V92, P197, DOI 10.1016/S0306-4522(98)00724-6; Hughes PE, 1999, PROG NEUROBIOL, V57, P421, DOI 10.1016/S0301-0082(98)00057-4; Ito C, 2002, CURR PHARM DESIGN, V8, P147, DOI 10.2174/1381612023396528; Jones SR, 1998, J NEUROSCI, V18, P1979; Kaina B, 1997, CANCER RES, V57, P2721; Krasnova IN, 2001, NEUROSCIENCE, V107, P265, DOI 10.1016/S0306-4522(01)00351-7; KRIEGLSTEIN K, 1995, EMBO J, V14, P736, DOI 10.1002/j.1460-2075.1995.tb07052.x; Lackinger D, 2001, MUTAGENESIS, V16, P233, DOI 10.1093/mutage/16.3.233; Lin HC, 1999, NEUROSCI LETT, V276, P141, DOI 10.1016/S0304-3940(99)00805-8; Luo YQ, 1999, MOL PHARMACOL, V56, P254, DOI 10.1124/mol.56.2.254; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Munz B, 1999, J ENDOCRINOL, V161, P187, DOI 10.1677/joe.0.1610187; Murray JB, 1998, J PSYCHOL, V132, P227, DOI 10.1080/00223989809599162; Nau ME, 2000, J CLIN MICROBIOL, V38, P1901, DOI 10.1128/JCM.38.5.1901-1908.2000; NGUYEN TV, 1992, P NATL ACAD SCI USA, V89, P4270, DOI 10.1073/pnas.89.10.4270; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; PERSICO AM, 1993, MOL BRAIN RES, V20, P91, DOI 10.1016/0169-328X(93)90113-4; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Scheffel U, 1996, SYNAPSE, V23, P61; Sharp FR, 1999, TRENDS NEUROSCI, V22, P97, DOI 10.1016/S0166-2236(98)01392-7; Sheng P, 1996, MOL BRAIN RES, V42, P171, DOI 10.1016/S0169-328X(96)00192-1; SIMPSON JN, 1995, NEUROSCIENCE, V69, P441, DOI 10.1016/0306-4522(95)00274-M; Stumm G, 1999, FASEB J, V13, P1065, DOI 10.1096/fasebj.13.9.1065; Suzuki K, 1999, Nihon Arukoru Yakubutsu Igakkai Zasshi, V34, P465; Takeuchi A, 2001, J NEUROSCI RES, V65, P38, DOI 10.1002/jnr.1125; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; WAGNER GC, 1980, NEUROLOGY, V30, P547; Wang NP, 1999, CIRC RES, V85, P387, DOI 10.1161/01.RES.85.5.387; Wang YM, 1997, NEURON, V19, P1285, DOI 10.1016/S0896-6273(00)80419-5; Woiciechowsky C, 1999, J MOL MED-JMM, V77, P769, DOI 10.1007/s001099900051; Wright JD, 2000, ADDICTION, V95, P1225, DOI 10.1046/j.1360-0443.2000.95812259.x; Yamagishi N, 2000, BIOCHEM BIOPH RES CO, V272, P850, DOI 10.1006/bbrc.2000.2864; Zaman K, 1999, J NEUROSCI, V19, P9821	58	18	18	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2002	16	11					1379	1388		10.1096/fj.01-0796com	http://dx.doi.org/10.1096/fj.01-0796com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12205029				2022-12-28	WOS:000178441800012
J	Guerrero, S; Figueras, A; Casanova, I; Farre, L; Lloveras, B; Capella, G; Trias, M; Mangues, R				Guerrero, S; Figueras, A; Casanova, I; Farre, L; Lloveras, B; Capella, G; Trias, M; Mangues, R			Codon 12 and codon 13 mutations at the K-ras gene induce different soft tissue sarcoma types in nude mice	FASEB JOURNAL			English	Article						tumorogenicity; apoptosis; sarcomas; K-ras	FOCAL ADHESION KINASE; ENCODED P21 PROTEIN; 3-DIMENSIONAL STRUCTURES; PROGNOSTIC IMPLICATIONS; COLORECTAL-CANCER; HUMAN TUMORS; CELL-LINE; H-RAS; APOPTOSIS; OVEREXPRESSION	K-ras codon 12 mutation is more oncogenic in in vitro and in vivo experimental systems than K-ras codon 13 mutation. Moreover, human colorectal tumors bearing a codon 12 mutation are more aggressive, invasive, and metastatic than the same tumor types carrying a codon 13 mutation. However, despite the association between specific sarcoma types and codon 12 or codon 13 mutations, the relationship between the position of the mutated codon at ras genes and tumor aggressiveness has not been studied in this tumor type. Here, we used a nude mice model to evaluate the tumorogenic capacity of stable transfectants of NIH3T3 fibroblasts, expressing K-ras mutated at codon 12 (K12) or 13 (K13), and morphologically, functionally, and molecularly compared these tumors. We found histopathological differences between them, K12-derived tumors showing fibrosarcoma-like features, whereas K13-derived tumors resembled malignant fibrous histiocytomas. Moreover, K12 tumors showed shorter latency of appearance, lower apoptotic and mitotic rates, and higher expression of markers for sarcoma aggressiveness (Ki67, p53 and c-myc) than K13 tumors. They also showed differences in the expression or activation of Ras, Ras downstream pathways [c-Jun N-terminal kinase (JNK), MAPK and AKT], and apoptotic [AKT, Bcl-2, Focal adhesion kinase (FAK)] and mitotic (cyclin B1) regulators, which could explain their functional differences. Most remarkably, the significantly diminished apoptotic rate observed in K12-derived tumors was associated with enhanced antiapoptotic signaling through the AKT pathway. These morphological, functional, and molecular differences demonstrate that codon 12 and codon 13 mutations in the K-ras oncogene can induce two different soft tissue sarcoma types in our in vivo model.	Hosp Santa Creu & Sant Pau, Inst Recerca, Lab Invest Gastrointestinal, Barcelona, Spain; Inst Catala Oncol, Lab Recerca Traslac, Barcelona, Spain; Hosp Santa Creu & Sant Pau, Serv Cirurgia, Barcelona, Spain	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Hospital of Santa Creu i Sant Pau; Catalan Institute of Oncology; Hospital of Santa Creu i Sant Pau	Mangues, R (corresponding author), Hosp Santa Creu & Sant Pau, Inst Recerca, Lab Invest Gastrointestinal, Avda St Antoni M Claret 167, Barcelona, Spain.	rmangues@santpau.es	Mangues, Ramon/J-6396-2014; CASANOVA RIGAT, ISOLDA/I-5393-2014; Capella, Gabriel/I-1879-2015	Mangues, Ramon/0000-0003-2661-9525; CASANOVA RIGAT, ISOLDA/0000-0002-1196-4724; Capella, Gabriel/0000-0002-4669-7320; Farre, Lourdes/0000-0002-3168-1940				BEDI A, 1995, CANCER RES, V55, P1811; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BRANDTRAUF PW, 1988, J PROTEIN CHEM, V7, P349, DOI 10.1007/BF01024884; CAPELLA G, 1991, ENVIRON HEALTH PERSP, V93, P125, DOI 10.2307/3431180; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Coindre JM, 1998, VERHANDLUNGEN DER DEUTSCHEN GESELLSCHAFT FUR PATHOLOGIE 82. TAGUNG, P59; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DEVIVO I, 1994, CANCER CAUSE CONTROL, V5, P273, DOI 10.1007/BF01830248; DROBNJAK M, 1994, J NATL CANCER I, V86, P549, DOI 10.1093/jnci/86.7.549; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FINKELSTEIN SD, 1993, ARCH SURG-CHICAGO, V128, P526; FINKELSTEIN SD, 1993, CANCER, V71, P3827, DOI 10.1002/1097-0142(19930615)71:12<3827::AID-CNCR2820711207>3.0.CO;2-N; FLETCHER CDM, 1992, AM J SURG PATHOL, V16, P213, DOI 10.1097/00000478-199203000-00001; FRANKEN SM, 1993, BIOCHEMISTRY-US, V32, P8411, DOI 10.1021/bi00084a005; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; GILL S, 1991, ONCOGENE, V6, P1651; Guerrero S, 2000, CANCER RES, V60, P6750; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Heslin MJ, 1998, CANCER-AM CANCER SOC, V83, P490, DOI 10.1002/(SICI)1097-0142(19980801)83:3<490::AID-CNCR18>3.0.CO;2-R; Hill MA, 1997, CANCER EPIDEM BIOMAR, V6, P1095; Hong HHL, 2000, TOXICOL PATHOL, V28, P529, DOI 10.1177/019262330002800404; Hoos A, 2001, CANCER, V92, P869, DOI 10.1002/1097-0142(20010815)92:4<869::AID-CNCR1395>3.0.CO;2-U; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; KANTAK SS, 1992, J BIOL CHEM, V73, P16953; Kikuchi Y, 1997, VIRCHOWS ARCH, V431, P111, DOI 10.1007/s004280050076; KLIMPFINGER M, 1990, VIRCHOWS ARCH B, V59, P165, DOI 10.1007/BF02899401; Kornberg LJ, 1998, HEAD NECK-J SCI SPEC, V20, P745, DOI 10.1002/(SICI)1097-0347(199812)20:8<745::AID-HED14>3.0.CO;2-Z; MONACO R, 1995, J PROTEIN CHEM, V14, P457, DOI 10.1007/BF01888140; OWENS LV, 1995, CANCER RES, V55, P2752; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Peluso JJ, 2001, BIOL REPROD, V64, P1183, DOI 10.1095/biolreprod64.4.1183; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; PINCUS MR, 1985, P NATL ACAD SCI USA, V82, P3596, DOI 10.1073/pnas.82.11.3596; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; SLOAN SR, 1990, MOL CELL BIOL, V10, P405, DOI 10.1128/MCB.10.1.405; Sollinger HW, 1999, TRANSPLANTATION, V67, pS543, DOI 10.1097/00007890-199905150-00028; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Szadowska Anna, 1999, Polish Journal of Pathology, V50, P9; TOFFOLI G, 1994, ANN ONCOL, V5, P167, DOI 10.1093/oxfordjournals.annonc.a058771; van Roggen JFG, 1999, J CLIN PATHOL, V52, P481, DOI 10.1136/jcp.52.7.481; Ward RL, 1997, CANCER, V79, P1106, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1106::AID-CNCR8>3.0.CO;2-D; Wilkinson EJ, 1995, J CELL BIOCHEM, P10; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Yoo JY, 1999, MODERN PATHOL, V12, P775	48	31	34	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1642	+		10.1096/fj.02-0050fje	http://dx.doi.org/10.1096/fj.02-0050fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207005				2022-12-28	WOS:000177814000016
J	Pei, M; Solchaga, LA; Seidel, J; Zeng, L; Vunjak-Novakovic, G; Caplan, AI; Freed, LE				Pei, M; Solchaga, LA; Seidel, J; Zeng, L; Vunjak-Novakovic, G; Caplan, AI; Freed, LE			Bioreactors mediate the effectiveness of tissue engineering scaffolds	FASEB JOURNAL			English	Article						chondrocyte; Hyaff-11((R)); polyglycolic acid; cartilage	BIODEGRADABLE POLYMER SCAFFOLDS; ARTICULAR-CARTILAGE; IN-VITRO; REPAIR; COLLAGEN; CHONDROCYTES; ACID; DIFFERENTIATION; DEFECTS; SYSTEM	We hypothesized that the mechanically active environment present in rotating bioreactors mediates the effectiveness of three-dimensional (3D) scaffolds for cartilage tissue engineering. Cartilaginous constructs were engineered by using bovine calf chondrocytes in conjunction with two scaffold materials (SM) (benzylated hyaluronan and polyglycolic acid); three scaffold structures (SS) (sponge, non-woven mesh, and composite woven/non-woven mesh); and two culture systems (CS) (a bioreactor system and petri dishes). Construct size, composition [cells, glycosaminoglycans (GAG), total collagen, and type-specific collagen mRNA expression and protein levels], and mechanical function (compressive modulus) were assessed, and individual and interactive effects of model system parameters (SM, SS, CS, SM*CS and SS*CS) were demonstrated. The CS affected cell seeding (higher yields of more spatially uniform cells were obtained in bioreactor-grown than dish-grown 3-day constructs) and subsequently affected chondrogenesis (higher cell numbers, wet weights, wet weight GAG fractions, and collagen type II levels were obtained in bioreactor-grown than dish-grown 1-month constructs). In bioreactors, mesh-based scaffolds yielded 1-month constructs with lower type I collagen levels and four-fold higher compressive moduli than corresponding sponge-based scaffolds. The data imply that interactions between bioreactors and 3D tissue engineering scaffolds can be utilized to improve the structure, function, and molecular properties of in vitro-generated cartilage.	MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Case Western Reserve Univ, Dept Biol, Skeletal Res Ctr, Cleveland, OH 44106 USA	Massachusetts Institute of Technology (MIT); Case Western Reserve University	Freed, LE (corresponding author), MIT, Div Hlth Sci & Technol, E25-330,77 Massachusetts Ave, Cambridge, MA 02139 USA.	Lfreed@mit.edu	Pei, Ming/N-8175-2017	Freed, Lisa/0000-0002-0720-8432; Vunjak-Novakovic, Gordana/0000-0002-9382-1574; Caplan, Arnold/0000-0002-8677-6621				Aigner J, 1998, J BIOMED MATER RES, V42, P172, DOI 10.1002/(SICI)1097-4636(199811)42:2<172::AID-JBM2>3.3.CO;2-W; AIGNER T, 1993, J CLIN INVEST, V91, P829, DOI 10.1172/JCI116303; Altman GH, 2001, FASEB J, V15, P270, DOI 10.1096/fj.01-0656fje; BALAZS E A, 1973, International Ophthalmology Clinics, V13, P169, DOI 10.1097/00004397-197301330-00014; Bonassar LJ, 2000, ARCH BIOCHEM BIOPHYS, V379, P57, DOI 10.1006/abbi.2000.1820; Brun P, 1999, J BIOMED MATER RES, V46, P337, DOI 10.1002/(SICI)1097-4636(19990905)46:3<337::AID-JBM5>3.0.CO;2-Q; Buckwalter JA, 1997, J BONE JOINT SURG AM, V79A, P612, DOI 10.2106/00004623-199704000-00022; Campoccia D, 1998, BIOMATERIALS, V19, P2101, DOI 10.1016/S0142-9612(98)00042-8; Chen AC, 2001, J BIOMECH, V34, P1, DOI 10.1016/S0021-9290(00)00170-6; Chu CR, 1997, CLIN ORTHOP RELAT R, P220; DUNKELMAN NS, 1995, BIOTECHNOL BIOENG, V46, P299, DOI 10.1002/bit.260460402; Evans CH, 1999, CLIN ORTHOP RELAT R, pS410; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; FRANK EH, 1987, J BIOMECH, V20, P615, DOI 10.1016/0021-9290(87)90282-X; FRAZZA E J, 1971, Journal of Biomedical Materials Research Biomedical Materials Symposium, V1, P43; Freed L. E., 2000, PRINCIPLES TISSUE EN, P143; FREED LE, 1994, BIOTECHNOL BIOENG, V43, P605, DOI 10.1002/bit.260430710; FREED LE, 1994, BIOTECHNOL BIOENG, V43, P597, DOI 10.1002/bit.260430709; FREED LE, 1993, J BIOMED MATER RES, V27, P11, DOI 10.1002/jbm.820270104; FREED LE, 1994, BIO-TECHNOL, V12, P689, DOI 10.1038/nbt0794-689; FREED LE, 1994, J BIOMED MATER RES, V28, P891, DOI 10.1002/jbm.820280808; Freed LE, 1998, EXP CELL RES, V240, P58, DOI 10.1006/excr.1998.4010; Freed LE, 1997, P NATL ACAD SCI USA, V94, P13885, DOI 10.1073/pnas.94.25.13885; Freed LE, 1999, CLIN ORTHOP RELAT R, pS46; FREED LE, 1995, BIOTECHNOL BIOENG, V46, P306, DOI 10.1002/bit.260460403; FREED LE, 2000, BIOMEDICAL ENG HDB, V2, P124; Fukuta S, 1998, MATRIX BIOL, V17, P65, DOI 10.1016/S0945-053X(98)90074-9; Gooch KJ, 2001, BIOCHEM BIOPH RES CO, V286, P909, DOI 10.1006/bbrc.2001.5486; Gooch KJ, 2001, BIOTECHNOL BIOENG, V72, P402, DOI 10.1002/1097-0290(20000220)72:4<402::AID-BIT1002>3.0.CO;2-Q; Grande DA, 1997, J BIOMED MATER RES, V34, P211, DOI 10.1002/(SICI)1097-4636(199702)34:2<211::AID-JBM10>3.0.CO;2-L; HALE JE, 1993, J BIOMECH, V26, P1319, DOI 10.1016/0021-9290(93)90355-I; HOLLANDER AP, 1994, J CLIN INVEST, V93, P1722, DOI 10.1172/JCI117156; HOMMINGA GN, 1993, ACTA ORTHOP SCAND, V64, P441, DOI 10.3109/17453679308993663; KIM YJ, 1988, ANAL BIOCHEM, V174, P168, DOI 10.1016/0003-2697(88)90532-5; KNUDSON CB, 1987, DEV BIOL, V124, P82, DOI 10.1016/0012-1606(87)90462-3; KRAVIS D, 1985, DEV BIOL, V108, P164, DOI 10.1016/0012-1606(85)90018-1; MADRY H, 2001, T ORTHOP RES SOC, V26, P289; Mauck RL, 2000, J BIOMECH ENG-T ASME, V122, P252, DOI 10.1115/1.429656; Milella E, 2000, J BIOMED MATER RES, V52, P695, DOI 10.1002/1097-4636(20001215)52:4<695::AID-JBM14>3.3.CO;2-7; MILLER EJ, 1976, BIOCHEMISTRY-US, V15, P787, DOI 10.1021/bi00649a009; Pazzano D, 2000, BIOTECHNOL PROGR, V16, P893, DOI 10.1021/bp000082v; Pei M, 2002, BIOCHEM BIOPH RES CO, V294, P149, DOI 10.1016/S0006-291X(02)00439-4; Riesle J, 1998, J CELL BIOCHEM, V71, P313, DOI 10.1002/(SICI)1097-4644(19981201)71:3<313::AID-JCB1>3.0.CO;2-C; SAH RLY, 1989, J ORTHOPAED RES, V7, P619, DOI 10.1002/jor.1100070502; SANDBERG M, 1987, J CELL BIOL, V104, P1077, DOI 10.1083/jcb.104.4.1077; Schaefer D, 2002, ARTHRITIS RHEUM-US, V46, P2524, DOI 10.1002/art.10493; Shea LD, 1999, NAT BIOTECHNOL, V17, P551, DOI 10.1038/9853; Smith RL, 1995, J ORTHOPAED RES, V13, P824, DOI 10.1002/jor.1100130604; Solchaga LA, 1999, J ORTHOP RES, V17, P205, DOI 10.1002/jor.1100170209; Vunjak-Novakovic G, 1999, J ORTHOP RES, V17, P130, DOI 10.1002/jor.1100170119; VunjakNovakovic G, 1996, AICHE J, V42, P850, DOI 10.1002/aic.690420323; Wakitani S, 1998, TISSUE ENG, V4, P429, DOI 10.1089/ten.1998.4.429; WAKITANI S, 1994, J BONE JOINT SURG AM, V76A, P579, DOI 10.2106/00004623-199404000-00013; WATT FM, 1988, J CELL SCI, V89, P373; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; WU JJ, 1984, BIOCHEM BIOPH RES CO, V123, P1033, DOI 10.1016/S0006-291X(84)80237-5	56	170	196	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10					1691	+		10.1096/fj.02-0083fje	http://dx.doi.org/10.1096/fj.02-0083fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207008				2022-12-28	WOS:000177814000021
J	Rose, F; Grimminger, F; Appel, J; Heller, M; Pies, V; Weissmann, N; Fink, L; Schmidt, S; Krick, S; Camenisch, G; Gassmann, M; Seeger, W; Hanze, J				Rose, F; Grimminger, F; Appel, J; Heller, M; Pies, V; Weissmann, N; Fink, L; Schmidt, S; Krick, S; Camenisch, G; Gassmann, M; Seeger, W; Hanze, J			Hypoxic pulmonary artery fibroblasts trigger proliferation of vascular smooth muscle cells - role of hypoxia-inducible transcription factors	FASEB JOURNAL			English	Article						pulmonary artery smooth muscle cells; pulmonary artery adventitial fibroblasts; hypoxia-inducible factors	FACTOR 1-ALPHA; ADVENTITIAL FIBROBLASTS; CELLULAR PROLIFERATION; MOLECULAR MECHANISMS; NITRIC-OXIDE; FACTOR-I; HYPERTENSION; FACTOR-1-ALPHA; EXPRESSION; ENDOTHELIN-1	Chronic lung hypoxia causes vascular remodeling with pulmonary artery smooth muscle cell (SMCPA) hyperplasia, resulting in pulmonary hypertension and cor pulmonale. We investigated SMCPA and pulmonary artery adventitial fibroblasts (FBPA) for their proliferative response to hypoxia. Strong SMCPA growth occurred under hypoxic conditions in SMCPA/FBPA co-cultures, but not in SMCPA monocultures. SMCPA growth was fully reproduced by transferring serum-free supernatant from hypoxic cultured FBPA to normoxic SMCPA. Hypoxia-inducible-transcriptionfactor subtypes (HIF-1alpha, HIF-2alpha, HIF-3alpha) and its dependent target genes, carrying the hypoxia-responsive-element as regulatory component, were strongly activated in both hypoxic FBPA and SMCPA. HIF-transcription-factor decoy technique, employed to FBPA during hypoxic culturing, blocked the mitogenic activity of FBPA conditioned medium on SMCPA. The data suggest that hypoxia-driven gene regulation in pulmonary artery fibroblasts results in a mitogenic stimulus on adjacent pulmonary artery smooth muscle cells, and HIF-transcription-decoy may offer a new therapeutic approach to suppress these events.	Univ Giessen, Dept Internal Med Pulm & Crit Care Med, D-35385 Giessen, Germany; Univ Zurich, Inst Vet Physiol, CH-8057 Zurich, Switzerland	Justus Liebig University Giessen; University of Zurich	Hanze, J (corresponding author), Dept Internal Med 2, Klin Str 36, D-35392 Giessen, Germany.	Joerg.Haenze@innere.med.uni-giessen.de		Weissmann, Norbert/0000-0003-2675-3871; Gassmann, Max/0000-0003-2750-8878; Seeger, Werner/0000-0003-1946-0894; Grimminger, Friedrich/0000-0001-8725-6276				Berg JT, 1998, AM J RESP CRIT CARE, V158, P1920, DOI 10.1164/ajrccm.158.6.9804076; Camenisch G, 1999, FASEB J, V13, P81, DOI 10.1096/fasebj.13.1.81; Das M, 2000, AM J RESP CELL MOL, V22, P15, DOI 10.1165/ajrcmb.22.1.3536; Dumas JP, 1999, GEN PHARMACOL, V33, P289, DOI 10.1016/S0306-3623(99)00026-9; Durmowicz A G, 1999, Pediatr Rev, V20, pe91; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Giaid A, 1998, CHEST, V114, p208S, DOI 10.1378/chest.114.3_Supplement.208S; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; Gu YZ, 1998, GENE EXPRESSION, V7, P205; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Maeshima Y, 1998, J CLIN INVEST, V101, P2589, DOI 10.1172/JCI429; MICHIELS C, 1994, EXP CELL RES, V213, P43, DOI 10.1006/excr.1994.1171; Minet E, 2000, INT J MOL MED, V5, P253; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; PERKETT EA, 1992, AM J RESP CELL MOL, V6, P82, DOI 10.1165/ajrcmb/6.1.82; Strauss BH, 2000, AM J RESP CELL MOL, V22, P1; Voelkel NF, 1995, EUR RESPIR J, V8, P2129, DOI 10.1183/09031936.95.08122129; Welsh DJ, 1998, AM J RESP CRIT CARE, V158, P1757, DOI 10.1164/ajrccm.158.6.9706054; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wenger RH, 1997, KIDNEY INT, V51, P560, DOI 10.1038/ki.1997.79; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wort SJ, 2001, AM J RESP CELL MOL, V25, P104, DOI 10.1165/ajrcmb.25.1.4331; Yu AY, 1999, J CLIN INVEST, V103, P691, DOI 10.1172/JCI5912	25	84	86	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1660	+		10.1096/fj.02-0420fje	http://dx.doi.org/10.1096/fj.02-0420fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207001				2022-12-28	WOS:000177814000005
J	Schrauwen, P; Hinderling, V; Hesselink, MKC; Schaart, G; Kornips, E; Saris, WHM; Westerterp-Plantenga, M; Langhans, W				Schrauwen, P; Hinderling, V; Hesselink, MKC; Schaart, G; Kornips, E; Saris, WHM; Westerterp-Plantenga, M; Langhans, W			Etomoxir-induced increase in UCP3 supports a role of uncoupling protein 3 as a mitochondrial fatty acid anion exporter	FASEB JOURNAL			English	Article						fat oxidation; human; GLUT4; translocation	MESSENGER-RNA EXPRESSION; SKELETAL-MUSCLE UCP2; THYROID-HORMONE; METABOLISM; OXIDATION; GENE; THERMOGENESIS; ACCUMULATION; HOMOLOGS; EXERCISE	The physiological function of human uncoupling protein-3 is still unknown. Uncoupling protein-3 is increased during fasting and high-fat feeding. In these situations the availability of fatty acids to the mitochondria exceeds the capacity to metabolize fatty acids, suggesting a role for uncoupling protein-3 in handling of non-metabolizable fatty acids. To test the hypothesis that uncoupling protein-3 acts as a mitochondrial exporter of non-metabolizable fatty acids from the mitochondrial matrix, we gave human subjects Etomoxir (which blocks mitochondrial entry of fatty acids) or placebo in a cross-over design during a 36-h stay in a respiration chamber. Etomoxir inhibited 24-h fat oxidation and fat oxidation during exercise by similar to14-19%. Surprisingly, uncoupling protein-3 content in human vastus lateralis muscle was markedly upregulated within 36 h of Etomoxir administration. Up-regulation of uncoupling protein-3 was accompanied by lowered fasting blood glucose and increased translocation of glucose transporter-4. These data support the hypothesis that the physiological function of uncoupling protein-3 is to facilitate the outward transport of non-metabolizable fatty acids from the mitochondrial matrix and thus prevents mitochondria from the potential deleterious effects of high fatty acid levels. In addition our data show that up-regulation of uncoupling protein-3 can be beneficial in the treatment of type 2 diabetes.	Maastricht Univ, Dept Human Biol, NUTRIM, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, Dept Movement Sci, Maastricht, Netherlands; Swiss Fed Inst Technol, Inst Anim Sci, CH-8092 Zurich, Switzerland	Maastricht University; Maastricht University; Swiss Federal Institutes of Technology Domain; ETH Zurich	Schrauwen, P (corresponding author), Maastricht Univ, Dept Human Biol, NUTRIM, POB 616, NL-6200 MD Maastricht, Netherlands.	p.schrauwen@hb.unimaas.nl	Langhans, Wolfgang/C-4073-2016	schrauwen, patrick/0000-0002-0973-847X				Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Borghouts LB, 2000, PFLUG ARCH EUR J PHY, V441, P351, DOI 10.1007/s004240000431; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Bouchard C, 1997, HUM MOL GENET, V6, P1887, DOI 10.1093/hmg/6.11.1887; BROUWER E, 1957, ACTA PHYSIOL PHARM N, V6, P795; Cabrero A, 2001, BBA-MOL CELL BIOL L, V1532, P195, DOI 10.1016/S1388-1981(01)00131-7; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Dobbins RL, 2001, DIABETES, V50, P123, DOI 10.2337/diabetes.50.1.123; Emilsson V, 2000, METABOLISM, V49, P1610, DOI 10.1053/meta.2000.18692; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Hamilton JA, 1999, DIABETES, V48, P2255, DOI 10.2337/diabetes.48.12.2255; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; HOPPELER H, 1986, INT J SPORTS MED, V7, P187, DOI 10.1055/s-2008-1025758; Huppertz C, 2001, J BIOL CHEM, V276, P12520, DOI 10.1074/jbc.M011708200; JEZEK P, 1994, J BIOL CHEM, V269, P26184; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; Khalfallah Y, 2000, DIABETES, V49, P25, DOI 10.2337/diabetes.49.1.25; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; MOORE JJ, 1982, CLIN CHEM, V28, P702; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; SALTIN B, 1993, AM J CLIN NUTR, V57, P752; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Schoffelen PFM, 1997, J APPL PHYSIOL, V83, P2064, DOI 10.1152/jappl.1997.83.6.2064; Schrauwen P, 2000, DIABETOLOGIA, V43, P1408, DOI 10.1007/s001250051547; Schrauwen P, 1999, INT J OBESITY, V23, P966, DOI 10.1038/sj.ijo.0801026; Schrauwen P, 1999, OBES RES, V7, P97, DOI 10.1002/j.1550-8528.1999.tb00396.x; Schrauwen P, 2001, DIABETES, V50, P2870, DOI 10.2337/diabetes.50.12.2870; Schrauwen P, 2001, FASEB J, V15, P2497, DOI 10.1096/fj.01-0400hyp; Schrauwen P, 2002, AM J PHYSIOL-ENDOC M, V282, pE11, DOI 10.1152/ajpendo.2002.282.1.E11; Schreyer M, 2001, SOLID STATE SCI, V3, P25, DOI 10.1016/S1293-2558(00)01128-6; Stichting Nederlands Voedingsstoffenbestand, 1993, NEVO TAB; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Weigle DS, 1998, DIABETES, V47, P298, DOI 10.2337/diabetes.47.2.298	35	41	43	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1688	+		10.1096/fj.02-0275fje	http://dx.doi.org/10.1096/fj.02-0275fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206997	Green Submitted			2022-12-28	WOS:000177814000001
J	Glosli, H; Tronstad, KJ; Wergedal, H; Muller, F; Svardal, A; Aukrust, P; Berge, RK; Prydz, H				Glosli, H; Tronstad, KJ; Wergedal, H; Muller, F; Svardal, A; Aukrust, P; Berge, RK; Prydz, H			Human TNF-alpha in transgenic mice induces differential changes in redox status and glutathione-regulating enzymes	FASEB JOURNAL			English	Article						redox-balance; oxidative stress; T cells; glutathione reductase; glutathione peroxidase; glutathione transferase	TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION; CD4(+) LYMPHOCYTES; ANTIVIRAL ACTIVITY; OXIDATIVE STRESS; GENE-EXPRESSION; CELL-DEATH; RECEPTORS; ACTIVATION; IMMUNODEFICIENCY	Tumor necrosis factor alpha (TNF-alpha) is a pleiotropic cytokine involved in several diseases. Various effects of TNF-alpha are mediated by the induction of a cellular state consistent with oxidative stress. Glutathione (GSH) is a major redox-buffer of eukaryotic cells and is important in the defense against oxidative stress. We hypothesized that persistent TNF-alpha secretion could induce oxidative stress through modulation of GSH metabolism. This hypothesis was examined in a transgenic mouse model with low, persistent expression of human TNF-alpha in the T cell compartment. Major findings were i) marked tissue-specific changes in GSH redox status and GSH regulating enzymes, with the most pronounced changes in liver; ii) moderate changes in GSH metabolism and up-regulation of GSH-regulating enzymes were observed in lung and kidney from transgenic mice; and iii) liver, lung and kidney from transgenic mice had decreased levels of total glutathione, whereas splenic CD4(+) and CD8(+) T cells had a marked increase in oxidized glutathione as the major change. Oxidative stress induced by persistent low-grade exposure to TNF-alpha in transgenic mice appears to involve marked organ-specific alterations in glutathione redox status and glutathione-regulating enzymes with the most pronounced changes in the liver. These mice constitute a useful model for immunodeficiency syndromes and chronic inflammatory diseases involving pathogenic interaction between TNF-alpha and oxidative stress.	Univ Oslo, Biotechnol Ctr Oslo, N-0317 Oslo, Norway; Univ Bergen, Haukeland Hosp, Dept Clin Biochem, N-5021 Bergen, Norway; Natl Hosp Norway, Internal Med Res Inst, Oslo, Norway; Natl Hosp Norway, Dept Med, Sect Clin Immunol & Infect Dis, Oslo, Norway; Univ Bergen, Dept Pharmacol & Toxicol, Bergen, Norway	University of Oslo; University of Bergen; Haukeland University Hospital; University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; University of Bergen	Prydz, H (corresponding author), Univ Oslo, Biotechnol Ctr Oslo, PB1125, N-0317 Oslo, Norway.	hans.prydz@biotek.uio.no		Tronstad, Karl Johan/0000-0003-3496-3123; Wergedahl, Hege/0000-0003-4614-1960				AEBI H, 1984, METHOD ENZYMOL, V105, P121; Aukrust P, 1996, BLOOD, V88, P2626, DOI 10.1182/blood.V88.7.2626.bloodjournal8872626; AUKRUST P, 1995, BLOOD, V86, P1383, DOI 10.1182/blood.V86.4.1383.bloodjournal8641383; AUKRUST P, 1995, BLOOD, V86, P258, DOI 10.1182/blood.V86.1.258.bloodjournal861258; Avdi NJ, 2001, J BIOL CHEM, V276, P2189, DOI 10.1074/jbc.M007527200; Benveniste EN, 1995, FASEB J, V9, P1577, DOI 10.1096/fasebj.9.15.8529837; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BUTTKE TM, 1995, FREE RADICAL RES, V22, P389, DOI 10.3109/10715769509147548; Chitturi S, 2001, SEMIN LIVER DIS, V21, P27, DOI 10.1055/s-2001-12927; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cope AP, 1997, J EXP MED, V185, P1573, DOI 10.1084/jem.185.9.1573; Driscoll KE, 2000, TOXICOL LETT, V112, P177, DOI 10.1016/S0378-4274(99)00282-9; EKLOW L, 1984, EUR J BIOCHEM, V138, P459, DOI 10.1111/j.1432-1033.1984.tb07938.x; ENGELBERTS I, 1991, LANCET, V338, P515, DOI 10.1016/0140-6736(91)90591-C; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Fernandez-Checa JC, 1998, SEMIN LIVER DIS, V18, P389, DOI 10.1055/s-2007-1007172; Feuerstein GZ, 2000, CARDIOVASC RES, V45, P560, DOI 10.1016/S0008-6363(99)00372-7; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Glosli H, 1999, EUR J HAEMATOL, V63, P50; Goebeler M, 1999, BLOOD, V93, P857, DOI 10.1182/blood.V93.3.857.403k03_857_865; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HELD W, 1990, P NATL ACAD SCI USA, V87, P2239, DOI 10.1073/pnas.87.6.2239; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; Herbein G, 2000, P SOC EXP BIOL MED, V223, P241, DOI 10.1046/j.1525-1373.2000.22335.x; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Jain NC, 1986, SCHALMS VET HEMATOLO; JENKINSON SG, 1994, AM J PHYSIOL, V266, pL125, DOI 10.1152/ajplung.1994.266.2.L125; Kokura S, 2000, CIRC RES, V86, P205, DOI 10.1161/01.RES.86.2.205; Kono H, 2000, J CLIN INVEST, V106, P867, DOI 10.1172/JCI9020; Kumar S, 2001, J CELL PHYSIOL, V187, P294, DOI 10.1002/jcp.1082; LEEDLE RA, 1990, LIPIDS, V25, P241, DOI 10.1007/BF02544382; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Li X, 2000, CIRCULATION, V102, P1690, DOI 10.1161/01.CIR.102.14.1690; LI XY, 1994, LIPIDS, V29, P73, DOI 10.1007/BF02537094; Liu RY, 1999, J BIOL CHEM, V274, P13877, DOI 10.1074/jbc.274.20.13877; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; MANSOOR MA, 1992, ANAL BIOCHEM, V200, P218, DOI 10.1016/0003-2697(92)90456-H; Mechtcheriakova D, 2001, FASEB J, V15, P230, DOI 10.1096/fj.00-0247com; MEISTER A, 1988, J BIOL CHEM, V263, P17205; Morales A, 1997, J BIOL CHEM, V272, P30371, DOI 10.1074/jbc.272.48.30371; Obrador E, 1998, BIOFACTORS, V8, P23, DOI 10.1002/biof.5520080105; Pierce RH, 2000, AM J PATHOL, V157, P221, DOI 10.1016/S0002-9440(10)64533-6; PROBERT L, 1993, J IMMUNOL, V151, P1894; Rahman I, 1999, J BIOL CHEM, V274, P5088, DOI 10.1074/jbc.274.8.5088; ROTH S, 1987, CELL IMMUNOL, V108, P417, DOI 10.1016/0008-8749(87)90224-3; Ruby J, 1997, J EXP MED, V186, P1591, DOI 10.1084/jem.186.9.1591; SAKLATVALA J, 1986, NATURE, V322, P547, DOI 10.1038/322547a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; SVARDAL AM, 1990, ANAL BIOCHEM, V184, P338, DOI 10.1016/0003-2697(90)90691-2; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TAVERNE J, 1994, IMMUNOLOGY, V82, P397; TOBOREK M, 1995, ATHEROSCLEROSIS, V117, P179, DOI 10.1016/0021-9150(95)05568-H; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WAAGE A, 1987, LANCET, V1, P355; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1992, J IMMUNOL, V149, P3350; YANG XD, 1994, J EXP MED, V180, P995, DOI 10.1084/jem.180.3.995; Zinman B, 1999, J CLIN ENDOCR METAB, V84, P272, DOI 10.1210/jc.84.1.272	66	44	47	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1450	+		10.1096/fj.01-0948fje	http://dx.doi.org/10.1096/fj.01-0948fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205044				2022-12-28	WOS:000177813100004
J	Zhang, XP; Graham, SH; Kochanek, PM; Marion, DW; Nathaniel, PD; Watkins, SC; Clark, RSB				Zhang, XP; Graham, SH; Kochanek, PM; Marion, DW; Nathaniel, PD; Watkins, SC; Clark, RSB			Caspase-8 expression and proteolysis in human brain after severe head injury	FASEB JOURNAL			English	Article						apoptosis; cysteine protease; Fas; programmed cell death; traumatic brain injury	TUMOR-NECROSIS-FACTOR; CEREBROSPINAL-FLUID; NEURONAL APOPTOSIS; FAS LIGAND; CELL-DEATH; SIGNALING COMPLEX; ACTIVATION; MICE; CONTUSIONS; INDUCTION	Programmed cell death involves a complex and interrelated cascade of cysteine proteases termed caspases that are synthesized as inactive zymogens, which are proteolytically processed to active enzymes. Caspase-8 is an initiator caspase that becomes activated when Fas death receptor-Fas ligand (FasL) coupling on the cell surface leads to coalescence of a "death complex" perpetuating the programmed cell death cascade. In this study, brain tissue samples removed from adult patients during the surgical management of severe intracranial hypertension after traumatic brain injury (TBI; n=17) were compared with postmortem control brain tissue samples (n=6). Caspase-8 mRNA was measured by semiquantitative reverse transcription and polymerase chain reaction, and caspase-8 protein was examined by Western blot and immunocytochemistry. Fas and FasL were also examined using Western blot. Caspase-8 mRNA and protein were increased in TBI patients vs. controls, and caspase-8 protein was predominately expressed in neurons. Proteolysis of caspase-8 to 20-kDa fragments was seen only in TBI patients. Fas was also increased after TBI vs. control and was associated with relative levels of caspase-8, supporting formation of a death complex. These data identify additional steps in the programmed cell death cascade involving Fas death receptors and caspase-8 after TBI in humans.	Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Safar Ctr Resuscitat Res, Dept Neurol, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Dept Cell Biol & Physiol, Pittsburgh, PA USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA USA; VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System	Clark, RSB (corresponding author), Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Marion, Donald/AAR-5749-2021; Watkins, Simon/ABG-2590-2021; Kochanek, Patrick M/D-2371-2015	Watkins, Simon/0000-0003-4092-1552; Kochanek, Patrick M/0000-0002-2627-913X				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Buki A, 2000, J NEUROSCI, V20, P2825; Cheema ZF, 1999, J NEUROSCI, V19, P1754; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Henshall DC, 2001, NEUROBIOL DIS, V8, P568, DOI 10.1006/nbdi.2001.0415; HOLMIN S, 2000, J NEUROSURG, V92; Jin KL, 2001, J CEREBR BLOOD F MET, V21, P1411, DOI 10.1097/00004647-200112000-00005; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Qiu JH, 2002, J NEUROSCI, V22, P3504; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SEIDBERG N, 2002, IN PRESS J NEUROCHEM; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x	33	45	51	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1367	+		10.1096/fj.02-1067fje	http://dx.doi.org/10.1096/fj.02-1067fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738800				2022-12-28	WOS:000183165000027
J	Asencio, C; Rodriguez-Aguilera, JC; Ruiz-Ferrer, M; Vela, J; Navas, P				Asencio, C; Rodriguez-Aguilera, JC; Ruiz-Ferrer, M; Vela, J; Navas, P			Silencing of ubiquinone biosynthesis genes extends life span in Caenorhabditis elegans	FASEB JOURNAL			English	Article						coenzyme Q; aging; RNAi; superoxide; mitochondria	O-METHYLTRANSFERASE STEPS; LIVED CLK-1 MUTANTS; COENZYME-Q; OXIDATIVE STRESS; SACCHAROMYCES-CEREVISIAE; C-ELEGANS; MITOCHONDRIAL; COMPLEX; PROTEIN; YEAST	Ubiquinone (coenzyme Q; Q) is a key factor in the mitochondria electron transport chain, but it also functions as an antioxidant and as a cofactor of mitochondrial uncoupling proteins. Furthermore, Q isoforms balance in Caenorhabiditis elegans is determined by both dietary intake and endogenous biosynthesis. In the absence of synthesis, withdrawal of dietary Q(8) in adulthood extends life span. Thus, Q plays an important role in the aging process and understanding its synthesis acquires a new impetus. We have identified by RNA interference (RNAi) eight genes, including clk-1, involved in ubiquinone biosynthesis in C. elegans feeding animals with dsRNA-containing Escherichia coli HT115 strains. Silenced C. elegans showed lower levels of both endogenous Q(9) and Q(8) provided by diet, produced less superoxide without a significant modification of mitochondrial electron chain, and extended life span compared with non-interfered animals. E. coli strains harboring dsRNA also interfered with their own Q(8) biosynthesis. These findings suggest that more efficient electron transport between a lower amount of Q and electron transport capacity of the mitochondrial complexes leads to less production of reactive oxygen species that contributes to extension of life span in the nematode C. elegans.	Univ Pablo Olavide, Dept Ciencias Ambientales, Lab Andaluz Biol, E-41013 Seville, Spain	Universidad Pablo de Olavide	Navas, P (corresponding author), Univ Pablo Olavide, Dept Ciencias Ambientales, Lab Andaluz Biol, Ctra Utrera,Km 1, E-41013 Seville, Spain.	pnavas@dex.upo.es	NAVAS, PLACIDO/R-5943-2019; Ruiz-Ferrer, Macarena/M-6168-2015	NAVAS, PLACIDO/0000-0002-4115-7966; Rodriguez Aguilera, Juan Carlos/0000-0002-3371-4128				ASHBY MN, 1992, J BIOL CHEM, V267, P4128; Barja G, 2002, AGEING RES REV, V1, P397, DOI 10.1016/S1568-1637(02)00008-9; Beal MF, 2002, FREE RADICAL RES, V36, P455, DOI 10.1080/10715760290021315; Bolann BJ, 1996, FREE RADICAL RES, V25, P541, DOI 10.3109/10715769609149075; Do TQ, 2001, J BIOL CHEM, V276, P18161, DOI 10.1074/jbc.M100952200; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Feng JL, 2001, DEV CELL, V1, P633, DOI 10.1016/S1534-5807(01)00071-5; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Hihi AK, 2002, J BIOL CHEM, V277, P2202, DOI 10.1074/jbc.M109034200; Hsu AY, 2000, BBA-MOL CELL BIOL L, V1484, P287, DOI 10.1016/S1388-1981(00)00019-6; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; JONASSEN T, 2001, COENZYME Q MOL MECH, P185; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Lenaz G, 1999, BIOFACTORS, V9, P87, DOI 10.1002/biof.5520090202; Levavasseur F, 2001, J BIOL CHEM, V276, P46160, DOI 10.1074/jbc.M108980200; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Miyadera H, 2002, FEBS LETT, V512, P33, DOI 10.1016/S0014-5793(02)02282-2; Miyadera H, 2001, J BIOL CHEM, V276, P7713, DOI 10.1074/jbc.C000889200; Murakami S, 2001, CURR BIOL, V11, P1517, DOI 10.1016/S0960-9822(01)00453-5; Navarro F, 1998, FASEB J, V12, P1665, DOI 10.1096/fasebj.12.15.1665; Okada K, 1997, J BACTERIOL, V179, P3058, DOI 10.1128/jb.179.9.3058-3060.1997; Poon WW, 1999, J BIOL CHEM, V274, P21665, DOI 10.1074/jbc.274.31.21665; Santos-Ocana C, 2002, J BIOL CHEM, V277, P10973, DOI 10.1074/jbc.M112222200; Senoo-Matsuda N, 2001, J BIOL CHEM, V276, P41553, DOI 10.1074/jbc.M104718200; Shults CW, 2001, NEUROLOGY, V57, P375, DOI 10.1212/WNL.57.3.375; Sohal RS, 2002, FREE RADICAL BIO MED, V33, P575, DOI 10.1016/S0891-5849(02)00886-9; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Taub J, 1999, NATURE, V399, P162, DOI 10.1038/20208; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Turunen M, 2002, FREE RADICAL RES, V36, P437, DOI 10.1080/10715760290021298; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; VILLALBA JM, 2001, COENZYME Q MOL MECH, P83; WONG A, 1995, GENETICS, V139, P1247	41	54	65	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1135	+		10.1096/fj.02-1022fje	http://dx.doi.org/10.1096/fj.02-1022fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709403				2022-12-28	WOS:000182580100028
J	Escartin, Q; Lallam-Laroye, C; Baroukh, B; Morvan, FO; Caruelle, JP; Godeau, G; Barritault, D; Saffar, JL				Escartin, Q; Lallam-Laroye, C; Baroukh, B; Morvan, FO; Caruelle, JP; Godeau, G; Barritault, D; Saffar, JL			A new approach to treat tissue destruction in periodontitis with chemically modified dextran polymers	FASEB JOURNAL			English	Article						RGTA; periodontal destruction; gingival inflammation; bone loss; tissue restructuring; osteoprogenitor cells; osteoclasts	SMOOTH-MUSCLE CELLS; MATRIX METALLOPROTEINASES; CRANIOTOMY DEFECTS; GELATINASE-A; EXPRESSION; COLLAGEN; HEPARIN; DISEASE; REGENERATION; GINGIVAL	Periodontitis are diseases of the supportive tissues of the teeth provoked by bacteria and characterized by gingival inflammation and bone destruction. We have developed a new strategy to repair tissues by administrating agents (RGTA) that mimic heparan sulfates by protecting selectively some of the growth factors naturally present within the injured tissue and interfering with inflammation. After periodontitis induction in hamsters, the animals were left untreated or received weekly i.m. injections of RGTA1507 at a dose of 100 mug/kg, 400 mug/kg, 1.5 mg/kg, or 15 mg/kg for 4 wk. RGTA treatment significantly reduced gingival tissue inflammation, thickened the pocket epithelium by increasing cell proliferation, and enhanced collagen accumulation in the gingiva. A marked reduction in bone loss was observed, resulting from depression of osteoclasia and robust stimulation of bone formation at the dose of 1.5 mg/kg. RGTA treatment for 8 wk at this dose reversed macroscopic bone loss, sharply contrasting with the extensive bone destruction in the untreated animals. RGTA treatment decreased gelatinase A (MMP-2) and B (MMP-9) proforms in gingival tissues. Our data indicate that a 4 wk treatment dose-dependently attenuated gingival and bone manifestations of the disease, whereas a longer treatment restored alveolar bone close to controls. By modulating and coordinating host responses, RGTA has unique therapeutic properties and is a promising candidate for the treatment of human periodontitis.	Univ Paris 05, Fac Chirurg Dent, Lab Biol & Physiopathol Craniofaciales, F-92120 Montrouge, France; Univ Paris 12, Fac Sci, CNRS, Lab CRRET, F-94010 Creteil, France	UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Universite Gustave-Eiffel; Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Saffar, JL (corresponding author), Univ Paris 12, CNRS, FRE 2412,Av Gen Gaulle, F-94000 Creteil, France.	saffar@odontologie.univ-paris5.fr		Saffar, Jean-Louis/0000-0001-6288-9325				Albandar JM, 2002, PERIODONTOL 2000, V29, P7, DOI 10.1034/j.1600-0757.2002.290101.x; Albo D, 1996, J CRANIOFAC SURG, V7, P19, DOI 10.1097/00001665-199601000-00007; Alexakis C, 2001, FASEB J, V15, P1546, DOI 10.1096/fj.00-0756com; BARON R, 1978, J PERIODONTAL RES, V13, P309, DOI 10.1111/j.1600-0765.1978.tb00185.x; BERANGER JY, 1994, CELL BIOL INT, V18, P715, DOI 10.1006/cbir.1994.1100; Berton A, 2000, MATRIX BIOL, V19, P139, DOI 10.1016/S0945-053X(00)00057-3; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Blanquaert F, 1995, BONE, V17, P499, DOI 10.1016/8756-3282(95)00402-5; CHANG KM, 1994, J PERIODONTAL RES, V29, P242, DOI 10.1111/j.1600-0765.1994.tb01218.x; Colombier ML, 1999, CELLS TISSUES ORGANS, V164, P131, DOI 10.1159/000016651; Dahan M, 2001, J CLIN PERIODONTOL, V28, P128, DOI 10.1034/j.1600-051x.2001.028002128.x; Desgranges P, 1999, FASEB J, V13, P761, DOI 10.1096/fasebj.13.6.761; FREDJREYGROBELLET D, 1994, OPHTHALMIC RES, V26, P325, DOI 10.1159/000267497; Golub LM, 1997, INFLAMM RES, V46, P310, DOI 10.1007/s000110050193; Ivanovski S, 2001, J PERIODONTAL RES, V36, P131, DOI 10.1034/j.1600-0765.2001.360301.x; Kornman KS, 1997, J CLIN PERIODONTOL, V24, P72, DOI 10.1111/j.1600-051X.1997.tb01187.x; Kusano K, 1998, ENDOCRINOLOGY, V139, P1338, DOI 10.1210/en.139.3.1338; Lafont J, 1998, GROWTH FACTORS, V16, P23, DOI 10.3109/08977199809017489; LAFONT J, 1994, CELL MATER, V4, P219; LASFARGUES JJ, 1983, J PERIODONTAL RES, V18, P110, DOI 10.1111/j.1600-0765.1983.tb00342.x; Ledoux D, 2000, J BIOL CHEM, V275, P29383, DOI 10.1074/jbc.M000837200; Makela M, 1999, EXP CELL RES, V251, P67, DOI 10.1006/excr.1999.4564; MATSUKI Y, 1992, IMMUNOLOGY, V76, P42; Medalion B, 1997, CIRCULATION, V95, P1853; Meddahi A, 1996, J BIOMED MATER RES, V31, P293, DOI 10.1002/(SICI)1097-4636(199607)31:3<293::AID-JBM1>3.0.CO;2-H; Meddahi A, 1996, INT J BIOL MACROMOL, V18, P141, DOI 10.1016/0141-8130(95)01074-2; MEDDAHI A, 1994, PATHOL RES PRACT, V190, P923; Meddahi A, 2002, J BIOMED MATER RES, V62, P525, DOI 10.1002/jbm.10283; Mestries P, 2001, MATRIX BIOL, V20, P171, DOI 10.1016/S0945-053X(01)00131-7; Mestries P, 1998, J BIOMED MATER RES, V42, P286, DOI 10.1002/(SICI)1097-4636(199811)42:2<286::AID-JBM14>3.3.CO;2-F; Okada H, 1998, CRIT REV ORAL BIOL M, V9, P248, DOI 10.1177/10454411980090030101; Paquette DW, 1997, J CLIN PERIODONTOL, V24, P521, DOI 10.1111/j.1600-051X.1997.tb00223.x; REDDY MS, 1993, J CLIN PERIODONTOL, V20, P635, DOI 10.1111/j.1600-051X.1993.tb00708.x; Scannapleco FA, 1999, J PERIODONTAL RES, V34, P340, DOI 10.1111/j.1600-0765.1999.tb02263.x; Seguier S, 2000, J PERIODONTOL, V71, P1079, DOI 10.1902/jop.2000.71.7.1079; TARDIEU M, 1992, J CELL PHYSIOL, V150, P194, DOI 10.1002/jcp.1041500126; TARDIEU M, 1989, Journal of Biomaterials Science Polymer Edition, V1, P63, DOI 10.1163/156856289X00064; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Yamauchi H, 2000, FASEB J, V14, P2133	39	45	50	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					644	651		10.1096/fj.02-0708com	http://dx.doi.org/10.1096/fj.02-0708com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665477				2022-12-28	WOS:000182580100009
J	Eyupoglu, IY; Bechmann, I; Nitsch, R				Eyupoglu, IY; Bechmann, I; Nitsch, R			Modification of microglia function protects from lesion-induced neuronal alterations and promotes sprouting in the hippocampus	FASEB JOURNAL			English	Article						parvalbumin; dendritic arborization; reinnervation	ENTORHINAL CORTEX LESION; TRANSNEURONAL CHANGES; DENTATE GYRUS; AXONAL REGENERATION; ALZHEIMERS-DISEASE; EXPRESSION; GROWTH; CELLS; RECOVERY; ANTIBODY	Primary neuronal destruction in the central nervous system triggers rapid changes in glial morphology and function, after which activated glial cells contribute to secondary neuronal changes. Here we show that, after entorhinal cortex lesion, activation of microglia, but not other glial cells, leads to massive secondary dendritic changes of deafferentiated hippocampal neurons. Blocking of microglial activation in vivo reduced this secondary neuronal damage and enhanced regenerative axonal sprouting. In contrast, abolishing astrocytes or oligodendroglia did not result in specific neuronal changes. Furthermore, primary damage leads to an interleukin 1beta upregulation, which is attenuated by the immuno-modulator transforming growth factor beta1, whereas tumor necrosis factor alpha is not affected. Modification of microglial activity following denervation of the hippocampus protects neurons from secondary dendritic alterations and therefore enables their reinnervation. These data render activated microglia a putative therapeutic target during the course of axonal degeneration.	Humboldt Univ Hosp Charite, Dept Cell & Neurobiol, Inst Anat, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Nitsch, R (corresponding author), Humboldt Univ Hosp Charite, Dept Cell & Neurobiol, Inst Anat, D-10098 Berlin, Germany.	robert.nitsch@charite.de	Nitsch, Robert/AAI-9129-2021	Eyupoglu, Ilker/0000-0002-8185-7764				Amaral David G., 1995, P443; Batchelor PE, 1999, J NEUROSCI, V19, P1708; Bechmann I, 1997, HISTOCHEM CELL BIOL, V107, P391, DOI 10.1007/s004180050125; Bechmann I, 1997, GLIA, V20, P145, DOI 10.1002/(SICI)1098-1136(199706)20:2<145::AID-GLIA6>3.0.CO;2-8; Beyer M, 2000, GLIA, V31, P262, DOI 10.1002/1098-1136(200009)31:3<262::AID-GLIA70>3.0.CO;2-2; Bhat RV, 1996, J NEUROSCI, V16, P4146; BOLOGA L, 1984, DEV NEUROSCI-BASEL, V6, P26, DOI 10.1159/000112329; Bottner M, 2000, J NEUROCHEM, V75, P2227, DOI 10.1046/j.1471-4159.2000.0752227.x; BRAAK H, 1993, HIPPOCAMPUS, V3, P239; BRANN ABZ, 1998, GLIA, V23, P181; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Brown DR, 1998, J NEUROCYTOL, V27, P109, DOI 10.1023/A:1006947322342; CELIO MR, 1988, CELL CALCIUM, V9, P81, DOI 10.1016/0143-4160(88)90027-9; CLUSMANN H, 1994, NEUROSCIENCE, V61, P805, DOI 10.1016/0306-4522(94)90403-0; COTMAN CW, 1985, ANN NY ACAD SCI, V457, P83, DOI 10.1111/j.1749-6632.1985.tb20800.x; Diekmann S, 1996, BRAIN PATHOL, V6, P205, DOI 10.1111/j.1750-3639.1996.tb00846.x; DINARELLO CA, 1984, NEW ENGL J MED, V311, P1413; DINARELLO CA, 1986, J CLIN INVEST, V77, P1734, DOI 10.1172/JCI112495; EINSTEIN G, 1994, J NEUROSCI, V14, P5077; Frotscher M, 1997, TRENDS NEUROSCI, V20, P218, DOI 10.1016/S0166-2236(96)01018-1; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Hailer NP, 1999, EUR J NEUROSCI, V11, P3359, DOI 10.1046/j.1460-9568.1999.00808.x; Hailer NP, 1998, BRAIN PATHOL, V8, P459; Hanisch UK, 2001, EUR J IMMUNOL, V31, P2104, DOI 10.1002/1521-4141(200107)31:7<2104::AID-IMMU2104>3.0.CO;2-3; Heppner FL, 1998, GLIA, V22, P180, DOI 10.1002/(SICI)1098-1136(199802)22:2<180::AID-GLIA9>3.0.CO;2-B; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Keirstead HS, 1999, EXP NEUROL, V159, P225, DOI 10.1006/exnr.1999.7100; Kluge A, 1998, HIPPOCAMPUS, V8, P57, DOI 10.1002/(SICI)1098-1063(1998)8:1<57::AID-HIPO6>3.3.CO;2-I; KRIEGLSTEIN K, 1995, INT J DEV NEUROSCI, V13, P301, DOI 10.1016/0736-5748(94)00062-8; LYNCH G, 1974, BRAIN RES, V69, P1, DOI 10.1016/0006-8993(74)90365-5; Merkler D, 2001, J NEUROSCI, V21, P3665, DOI 10.1523/JNEUROSCI.21-10-03665.2001; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MESULAM MM, 1987, ANN NEUROL, V22, P683, DOI 10.1002/ana.410220603; MIHARA M, 1991, EUR J IMMUNOL, V21, P2327, DOI 10.1002/eji.1830211006; MILLER S, 1995, ANN NY ACAD SCI, V757, P460, DOI 10.1111/j.1749-6632.1995.tb17506.x; NITSCH R, 1992, P NATL ACAD SCI USA, V89, P5197, DOI 10.1073/pnas.89.11.5197; NITSCH R, 1993, HIPPOCAMPUS, V3, P481, DOI 10.1002/hipo.450030409; NITSCH R, 1993, HIPPOCAMPUS, V3, P247; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; OLNEY JW, 1971, EXP BRAIN RES, V14, P61; PAPA M, 1995, J NEUROSCI, V15, P1; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Schilling T, 2001, EUR J NEUROSCI, V14, P463, DOI 10.1046/j.0953-816x.2001.01661.x; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Shrikant P, 1996, J IMMUNOL, V157, P892; SPIEGLER OL, 1999, VISION RES, V39, P169; SPIEGLER OL, 1998, GLIA, V24, P329; SPIEGLER OL, 1996, FASEB J, V10, P1296; Steward O., 1991, CEREB CORTEX, V9, P81; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Ullrich O, 2001, FASEB J, V15, P1460, DOI 10.1096/fj.00-0540fje; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Van Hoesen G W, 1991, Hippocampus, V1, P1, DOI 10.1002/hipo.450010102	53	46	46	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1110	+		10.1096/fj.02-0825fje	http://dx.doi.org/10.1096/fj.02-0825fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692086				2022-12-28	WOS:000182580100046
J	Wiegand, V; Chang, TY; Strauss, JF; Fahrenholz, F; Gimpl, G				Wiegand, V; Chang, TY; Strauss, JF; Fahrenholz, F; Gimpl, G			Transport of plasma membrane-derived cholesterol and the function of Niemann-Pick C1 protein	FASEB JOURNAL			English	Article						lipid droplets; esterification; progesterone; NPC	LIPID DROPLETS; INTRACELLULAR TRAFFICKING; STORAGE DISEASES; CELLS; RICH; ACCUMULATION; COMPARTMENTS; LOCALIZATION; MICRODOMAINS; MOBILIZATION	To visualize the intracellular transport of plasma membrane-derived cholesterol under physiological and pathophysiological conditions, a novel fluorescent cholesterol analog, 6-dansyl cholestanol (DChol), has been synthesized. We present several lines of evidence that DChol mimics cholesterol. The cholesterol probe could be efficiently incorporated into the plasma membrane via cyclodextrin-donor complexes. The itinerary of DChol from the plasma membrane to the cell was studied to determine its dependence on the function of Niemann-Pick C1 (NPC) protein. In all cells, DChol moved from the plasma membrane to the endoplasmic reticulum. Its further transport to the Golgi complex was observed but with marked differences among various cell lines. DChol was finally transported to small (similar to0.5 mum diameter) lipid droplets, a process that required functional acyl-CoA:cholesterol acyltransferase. In human NPC fibroblasts, NPC-like cells, or in cells mimicking the NPC phenotype, DChol was found in enlarged (>1 mum diameter) droplets. When the NPC-phenotype was corrected by transfection with NPC1, DChol was again found in small-sized droplets. Our data show that NPC1 has an essential role in the distribution of plasma membrane-derived cholesterol by maintaining the small size of cholesterol-containing lipid droplets in the cell.	Univ Mainz, Inst Biochem, D-55099 Mainz, Germany; Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; Univ Penn, Ctr Res Reprod Womens Hlth, Philadelphia, PA 19104 USA	Johannes Gutenberg University of Mainz; Dartmouth College; University of Pennsylvania; Pennsylvania Medicine	Gimpl, G (corresponding author), Univ Mainz, Inst Biochem, Becherweg 30, D-55099 Mainz, Germany.	gimpl@mail.uni-mainz.de	Gimpl, Gerald/R-3722-2019	Chang, Ta-Yuan/0000-0002-3249-0468; Gimpl, Gerald/0000-0002-5703-1989				Atshaves BP, 2001, J BIOL CHEM, V276, P25324, DOI 10.1074/jbc.M100560200; Blanchette-Mackie EJ, 2000, BBA-MOL CELL BIOL L, V1486, P171, DOI 10.1016/S1388-1981(00)00055-X; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BURGER K, 2000, THESIS MAINZ; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; COXEY RA, 1993, J LIPID RES, V34, P1165; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Cruz JC, 2000, J BIOL CHEM, V275, P41309, DOI 10.1074/jbc.M008272200; Frolov A, 2000, J BIOL CHEM, V275, P12769, DOI 10.1074/jbc.275.17.12769; Garver WS, 2000, J LIPID RES, V41, P673; Gimpl G, 2000, EUR J BIOCHEM, V267, P2483, DOI 10.1046/j.1432-1327.2000.01280.x; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; Hao MM, 2002, J BIOL CHEM, V277, P609, DOI 10.1074/jbc.M108861200; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Haynes MP, 2000, BIOCHEMISTRY-US, V39, P4508, DOI 10.1021/bi992125q; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; HIGGINS CM, 1999, CURRENT TOP VIROL, V1, P1; KAWASAKI T, 1982, J CHROMATOGR, V233, P61, DOI 10.1016/S0378-4347(00)81731-4; Ko DC, 2001, MOL BIOL CELL, V12, P601, DOI 10.1091/mbc.12.3.601; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; LANGE Y, 1993, J BIOL CHEM, V268, P13838; Lange Y, 1998, J BIOL CHEM, V273, P18915, DOI 10.1074/jbc.273.30.18915; Liscum L, 1999, BBA-MOL CELL BIOL L, V1438, P19, DOI 10.1016/S1388-1981(99)00043-8; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Mintzer EA, 2002, FEBS LETT, V510, P181, DOI 10.1016/S0014-5793(01)03271-9; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; PELLETIER RM, 1994, J HISTOCHEM CYTOCHEM, V42, P1539, DOI 10.1177/42.12.7983355; Prattes S, 2000, J CELL SCI, V113, P2977; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; SCHROEDER F, 1995, MOL MEMBR BIOL, V12, P113, DOI 10.3109/09687689509038505; Simons K, 2000, TRENDS CELL BIOL, V10, P459, DOI 10.1016/S0962-8924(00)01847-X; STEER CJ, 1984, J CELL BIOL, V99, P315, DOI 10.1083/jcb.99.1.315; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Turley SD, 1998, AM J PHYSIOL-ENDOC M, V274, pE1099, DOI 10.1152/ajpendo.1998.274.6.E1099; van Meer G, 2001, J CELL BIOL, V152, pF29, DOI 10.1083/jcb.152.5.F29; Watari H, 1999, P NATL ACAD SCI USA, V96, P805, DOI 10.1073/pnas.96.3.805; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WUSTNER D, 2002, J BIOL CHEM; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5; Zhang M, 2001, P NATL ACAD SCI USA, V98, P4466, DOI 10.1073/pnas.081070898; Zhang M, 2001, J BIOL CHEM, V276, P3417, DOI 10.1074/jbc.M005393200	47	43	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					782	+		10.1096/fj.02-0818fje	http://dx.doi.org/10.1096/fj.02-0818fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594172				2022-12-28	WOS:000181456900012
J	Schluter, SF; Marchalonis, JJ				Schluter, SF; Marchalonis, JJ			Cloning of shark RAG2 and characterization of the RAG1/RAG2 gene locus	FASEB JOURNAL			English	Article						SINE; LINE; RAG gene evolution	RECOMBINATION-ACTIVATING GENES; NON-LTR RETROTRANSPOSONS; SINGLE ACTIVE-SITE; V(D)J RECOMBINATION; LIGHT-CHAIN; MOLECULAR EVOLUTION; SEQUENCE; ELEMENTS; PROTEIN; EMERGENCE	The recombination-activating genes (RAG) encode a site-specific recombinase that is centrally responsible for the rearrangement of genomic V(D)J exons necessary to form functional immunoglobulin and T-cell receptor genes. To help elucidate the origins of the RAG genes, we have cloned the RAG2 gene from the sandbar shark (Carcharhinus plumbeus) and characterized the entire RAG1/RAG2 gene locus. The shark RAG2 protein consists of 520 amino acids, is similar to50% identical with RAG2 proteins from other vertebrates, and contains the same three domains identified in mammalian RAG2. Residues critical for RAG2 function are conserved in the shark sequence. In common with other vertebrate species, the shark RAG2 coding region lacks introns and is closely linked in opposite orientation to the RAG1 gene. The intergenic region is 9.4 kb, which is considerably larger than of teleosts (2-3 kb) and is comparable to that of tetrapods. This length is partially explained by the presence of several SINE and LINE fragments. The ancestors of the sharks were apparently the first vertebrates in phylogeny to have RAG genes, and our results confirm that the RAG genes have been highly conserved during evolution both in terms of sequence and gene organization.	Univ Arizona, Coll Med, Dept Microbiol & Immunol, Tucson, AZ 85724 USA	University of Arizona	Marchalonis, JJ (corresponding author), Univ Arizona, Coll Med, Dept Microbiol & Immunol, POB 24-5049,1501 Nth Campbell Ave, Tucson, AZ 85724 USA.	marchjj@email.arizona.edu						Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Aidinis V, 2000, J IMMUNOL, V164, P5826, DOI 10.4049/jimmunol.164.11.5826; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARTL S, 1994, P NATL ACAD SCI USA, V91, P10769, DOI 10.1073/pnas.91.23.10769; Bernstein RM, 1996, P NATL ACAD SCI USA, V93, P9454, DOI 10.1073/pnas.93.18.9454; Callebaut I, 1998, CELL MOL LIFE SCI, V54, P880, DOI 10.1007/s000180050216; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Capy P, 1996, J MOL EVOL, V42, P359, DOI 10.1007/BF02337546; Capy P, 1997, GENETICA, V100, P63, DOI 10.1023/A:1018300721953; Corneo B, 2000, J BIOL CHEM, V275, P12672, DOI 10.1074/jbc.275.17.12672; Corneo B, 2001, BLOOD, V97, P2772, DOI 10.1182/blood.V97.9.2772; Drew AC, 1997, MOL BIOL EVOL, V14, P602, DOI 10.1093/oxfordjournals.molbev.a025799; Du Pasquier L., 1999, FUNDAMENTAL IMMUNOLO, P605; Fugmann SD, 2000, MOL CELL, V5, P97, DOI 10.1016/S1097-2765(00)80406-2; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Fugmann SD, 2001, MOL CELL, V8, P899, DOI 10.1016/S1097-2765(01)00352-5; Gomez CA, 2000, MOL CELL BIOL, V20, P5653, DOI 10.1128/MCB.20.15.5653-5664.2000; Haas NB, 1997, GENE, V197, P305, DOI 10.1016/S0378-1119(97)00276-X; Haas NB, 2001, GENE, V265, P175, DOI 10.1016/S0378-1119(01)00344-4; Hansen JD, 2000, CURR TOP MICROBIOL, V248, P111; Haren L, 1999, ANNU REV MICROBIOL, V53, P245, DOI 10.1146/annurev.micro.53.1.245; Haren L, 2000, J MOL BIOL, V296, P757, DOI 10.1006/jmbi.1999.3485; Hart DL, 1997, ANNU REV GENET, V31, P337, DOI 10.1146/annurev.genet.31.1.337; HINDS KR, 1986, NATURE, V320, P546, DOI 10.1038/320546a0; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; HOHMAN VS, 1993, P NATL ACAD SCI USA, V90, P9882, DOI 10.1073/pnas.90.21.9882; Kajikawa M, 1997, MOL BIOL EVOL, V14, P1206, DOI 10.1093/oxfordjournals.molbev.a025730; KOKUBU F, 1988, EMBO J, V7, P3413, DOI 10.1002/j.1460-2075.1988.tb03215.x; Landree MA, 1999, GENE DEV, V13, P3059, DOI 10.1101/gad.13.23.3059; Litman GF, 1999, ANNU REV IMMUNOL, V17, P109, DOI 10.1146/annurev.immunol.17.1.109; Lum JK, 2000, MOL BIOL EVOL, V17, P1417, DOI 10.1093/oxfordjournals.molbev.a026242; Malik HS, 2001, GENOME RES, V11, P1187, DOI 10.1101/gr.185101; Marchalonis JJ, 1998, J THEOR BIOL, V193, P429, DOI 10.1006/jtbi.1998.0711; Marchalonis JJ, 1998, IMMUNOL REV, V166, P103, DOI 10.1111/j.1600-065X.1998.tb01256.x; Marchalonis JJ, 1998, ADV IMMUNOL, V70, P417, DOI 10.1016/S0065-2776(08)60392-2; Marchalonis JJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0953hyp; MARCHALONIS JJ, 2002, IN PRESS AM ZOOL; Nikaido M, 1999, P NATL ACAD SCI USA, V96, P10261, DOI 10.1073/pnas.96.18.10261; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ogiwara I, 1999, MOL BIOL EVOL, V16, P1238, DOI 10.1093/oxfordjournals.molbev.a026214; Ogiwara I, 2002, GENOME RES, V12, P316, DOI 10.1101/gr.212302; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Peixoto BR, 2000, GENE, V246, P275, DOI 10.1016/S0378-1119(00)00091-3; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; Plasterk R, 1998, NATURE, V394, P718, DOI 10.1038/29389; PUSTELL J, 1982, NUCLEIC ACIDS RES, V10, P4765, DOI 10.1093/nar/10.15.4765; Qiu JX, 2001, MOL CELL, V7, P77, DOI 10.1016/S1097-2765(01)00156-3; RAST JP, 1994, IMMUNOGENETICS, V40, P83; Rast JP, 1998, IMMUNOL REV, V166, P79, DOI 10.1111/j.1600-065X.1998.tb01254.x; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; Schluter SF, 1999, DEV COMP IMMUNOL, V23, P107; Shedlock AM, 2000, BIOESSAYS, V22, P148, DOI 10.1002/(SICI)1521-1878(200002)22:2&lt;148::AID-BIES6&gt;3.0.CO;2-Z; Swanson PC, 2001, MOL CELL BIOL, V21, P449, DOI 10.1128/MCB.21.2.449-458.2001; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Weiner AM, 2002, CURR OPIN CELL BIOL, V14, P343, DOI 10.1016/S0955-0674(02)00338-1; Willett CE, 1997, IMMUNOGENETICS, V45, P394, DOI 10.1007/s002510050221; [No title captured]	62	24	27	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					470	+		10.1096/fj.02-0565fje	http://dx.doi.org/10.1096/fj.02-0565fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551847				2022-12-28	WOS:000181453700004
J	Zeitz, U; Weber, K; Soegiarto, DW; Wolf, E; Balling, R; Erben, RG				Zeitz, U; Weber, K; Soegiarto, DW; Wolf, E; Balling, R; Erben, RG			Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor	FASEB JOURNAL			English	Article						diabetes; VDR; calcium homeostasis; glucose tolerance; islet neogenesis	GLUCOSE-TOLERANCE; SUSCEPTIBILITY; DEFICIENCY; NORMALIZATION; RICKETS	It was the aim of this study to further explore the functional role of vitamin D in the endocrine pancreas. By gene targeting, we have recently generated mice in which a lacZ reporter gene is driven by the endogenous vitamin D receptor (VDR) promoter. These mice express a functionally inactive mutant VDR. Pancreatic islets but not exocrine pancreas cells showed strong lacZ reporter gene expression in mutant mice. To rule out possible influences of hypocalcemia on pancreatic endocrine function, a rescue diet enriched with calcium, phosphorus, and lactose was fed to wild-type (WT) and VDR mutant mice. The rescue diet normalized body weight and mineral homeostasis in VDR mutants. In glucose tolerance tests, baseline blood glucose levels were unchanged in fasting VDR mutants. However, blood glucose was elevated after oral or subcutaneous glucose loading, and maximum serum insulin levels were reduced by similar to60% in VDR mutants vs. WT mice on either diet. In addition, insulin mRNA levels were decreased in VDR mutant mice on both diets, whereas pancreatic cell mass, islet architecture, and islet neogenesis were normal. These findings clearly establish a molecular role of the VDR in pancreatic insulin synthesis and secretion in vivo.	Univ Munich, Inst Anim Physiol, D-80539 Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Mammalian Genet, D-85758 Neuherberg, Germany; Univ Munich, Inst Mol Anim Breeding, D-81377 Munich, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Erben, RG (corresponding author), Univ Munich, Inst Anim Physiol, Vet Str 13, D-80539 Munich, Germany.	R.Erben@lrz.uni-muenchen.de	Erben, Reinhold/AAG-8007-2020; Weber, Karin/A-6034-2016; Balling, Rudi/E-9680-2010	Erben, Reinhold/0000-0003-0801-6958; Weber, Karin/0000-0002-0541-4355; Balling, Rudi/0000-0003-2902-5650; Wolf, Eckhard/0000-0002-0430-9510				Ayesha I, 2001, DIABETES NUTR METAB, V14, P78; Ayesha I, 2000, J NUTR SCI VITAMINOL, V46, P115, DOI 10.3177/jnsv.46.115; Bonner-Weir S, 2000, ENDOCRINOLOGY, V141, P1926, DOI 10.1210/en.141.6.1926; Bourlon PM, 1999, J ENDOCRINOL, V160, P87, DOI 10.1677/joe.0.1600087; BRINGHURST FR, 1998, WILLIAMS TXB ENDOCRI, P1155; CADE C, 1987, ENDOCRINOLOGY, V120, P1490, DOI 10.1210/endo-120-4-1490; CADE C, 1986, ENDOCRINOLOGY, V119, P84, DOI 10.1210/endo-119-1-84; Chang TJ, 2000, CLIN ENDOCRINOL, V52, P575, DOI 10.1046/j.1365-2265.2000.00985.x; CREUTZFELDT W, 1992, DIABETES METAB REV, V8, P149, DOI 10.1002/dmr.5610080206; Dahlquist G, 1999, DIABETOLOGIA, V42, P51, DOI 10.1007/s001250051112; Erben RG, 2002, MOL ENDOCRINOL, V16, P1524, DOI 10.1210/me.16.7.1524; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GOSSLER A, 1993, GENE TARGETING PRACT, P181; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; HOCHBERG Z, 1985, J CLIN ENDOCR METAB, V60, P57, DOI 10.1210/jcem-60-1-57; Hypponen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140-6736(01)06580-1; JOHNSON JA, 1994, AM J PHYSIOL, V267, pE356, DOI 10.1152/ajpendo.1994.267.3.E356; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Kato S, 2000, J BIOCHEM, V127, P717, DOI 10.1093/oxfordjournals.jbchem.a022662; LEE S, 1994, ENDOCRINOLOGY, V134, P1602, DOI 10.1210/en.134.4.1602; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Li YC, 1998, ENDOCRINOLOGY, V139, P4391, DOI 10.1210/en.139.10.4391; McDermott MF, 1997, DIABETOLOGIA, V40, P971, DOI 10.1007/s001250050776; NORMAN AW, 1980, SCIENCE, V209, P823, DOI 10.1126/science.6250216; Pani MA, 2000, DIABETES, V49, P504, DOI 10.2337/diabetes.49.3.504; Unger R.H., 1998, WILLIAMS TXB ENDOCRI, P973; Xu G, 1999, DIABETES, V48, P2270, DOI 10.2337/diabetes.48.12.2270	27	301	323	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					509	+		10.1096/fj.02-0424fje	http://dx.doi.org/10.1096/fj.02-0424fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12551842				2022-12-28	WOS:000181453700009
J	Wiesener, MS; Jurgensen, JS; Rosenberger, C; Scholze, C; Horstrup, JH; Warnecke, C; Mandriota, S; Bechmann, I; Frei, UA; Pugh, CW; Ratcliffe, PJ; Bachmann, S; Maxwell, PH; Eckardt, KU				Wiesener, MS; Jurgensen, JS; Rosenberger, C; Scholze, C; Horstrup, JH; Warnecke, C; Mandriota, S; Bechmann, I; Frei, UA; Pugh, CW; Ratcliffe, PJ; Bachmann, S; Maxwell, PH; Eckardt, KU			Widespread, hypoxia-inducible expression of HIF-2 alpha in distinct cell populations of different organs	FASEB JOURNAL			English	Article						gene expression; erythropoietin; VEGF; HIF-1; in vivo	PAS DOMAIN PROTEIN-1; ENDOTHELIAL GROWTH-FACTOR; FACTOR-I HIF-1; TRANSCRIPTION FACTOR; PROLYL HYDROXYLATION; FACTOR 1-ALPHA; PROLINE HYDROXYLATION; FACTORS HIF-1-ALPHA; VEGF EXPRESSION; RAT-BRAIN	Cellular responses to oxygen are increasingly recognized as critical in normal development and physiology, and are implicated in pathological processes. Many of these responses are mediated by the transcription factors HIF-1 and HIF-2. Their regulation occurs through oxygen-dependent proteolysis of the alpha subunits HIF-1alpha and HIF-2alpha respectively. Both are stabilized in cell lines exposed to hypoxia, and recently HIF-1alpha was reported to be widely expressed in vivo. In contrast, regulation and sites of HIF-2alpha expression in vivo are unknown, although a specific role in endothelium was suggested. We therefore analyzed HIF-2alpha expression in control and hypoxic rats. Although HIF-2alpha was not detectable under baseline conditions, marked hypoxic induction occurred in all organs investigated, including brain, heart, lung, kidney, liver, pancreas, and intestine. Time course and amplitude of induction varied between organs. Immunohistochemistry revealed nuclear accumulation in distinct cell populations of each tissue, which were exclusively non-parenchymal in some organs (kidney, pancreas, and brain), predominately parenchymal in others (liver and intestine) or equally distributed (myocardium). These data indicate that HIF-2 plays an important role in the transcriptional response to hypoxia in vivo, which is not confined to the vasculature and is complementary to rather than redundant with HIF-1.	Humboldt Univ, Klinikum Charite, Dept Nephrol & Med Intens Care, D-13353 Berlin, Germany; Humboldt Univ, Klinikum Charite, Dept Anat & Cell, D-13353 Berlin, Germany; Humboldt Univ, Klinikum Charite, Dept Neurobiol, D-13353 Berlin, Germany; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Oxford; Wellcome Centre for Human Genetics	Eckardt, KU (corresponding author), Humboldt Univ, Dept Nephrol, Augustenburger Pl 13353, D-13353 Berlin, Germany.	kai-uwe.eckardt@charite.de	Maxwell, Patrick H/C-5557-2008	Maxwell, Patrick H/0000-0002-0338-2679; Ratcliffe, Peter/0000-0002-2853-806X; Pugh, Chris/0000-0002-5170-1662				Akeno N, 2001, ENDOCRINOLOGY, V142, P959, DOI 10.1210/en.142.2.959; Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; ECKARDT KU, 1992, J CLIN INVEST, V89, P753, DOI 10.1172/JCI115652; ECKARDT KU, 1990, AM J PHYSIOL, V258, pF1432, DOI 10.1152/ajprenal.1990.258.5.F1432; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Giatromanolaki A, 2001, BRIT J CANCER, V85, P881, DOI 10.1054/bjoc.2001.2018; Hofbauer KH, 2000, AM J PHYSIOL-REG I, V278, pR513, DOI 10.1152/ajpregu.2000.278.2.R513; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jiang HQ, 2001, P NATL ACAD SCI USA, V98, P7916, DOI 10.1073/pnas.141234698; Jin KL, 2000, NEUROSCIENCE, V99, P577, DOI 10.1016/S0306-4522(00)00207-4; KOURY ST, 1991, BLOOD, V77, P2497; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Lando D, 2000, J BIOL CHEM, V275, P4618, DOI 10.1074/jbc.275.7.4618; Leek RD, 2002, CANCER RES, V62, P1326; Lubbers DW, 1997, KIDNEY INT, V51, P372, DOI 10.1038/ki.1997.49; Maemura K, 1999, J BIOL CHEM, V274, P31565, DOI 10.1074/jbc.274.44.31565; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Onita T, 2002, CLIN CANCER RES, V8, P471; Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wiesener MS, 2001, CANCER RES, V61, P5215; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Xia GB, 2001, CANCER-AM CANCER SOC, V91, P1429, DOI 10.1002/1097-0142(20010415)91:8<1429::AID-CNCR1149>3.0.CO;2-V; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zhu H, 2002, NEPHROL DIAL TRANSPL, V17, P3, DOI 10.1093/ndt/17.suppl_1.3	45	526	565	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					271	+		10.1096/fj.02-0445fje	http://dx.doi.org/10.1096/fj.02-0445fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12490539				2022-12-28	WOS:000180574300030
J	Sellin, L; Huber, TB; Gerke, P; Quack, I; Pavenstadt, H; Walz, G				Sellin, L; Huber, TB; Gerke, P; Quack, I; Pavenstadt, H; Walz, G			NEPH1 defines a novel family of podocin-interacting proteins	FASEB JOURNAL			English	Article						podocyte; slit diaphragm; nephrotic syndrome	GLOMERULAR PROTEIN; SLIT DIAPHRAGM; GENE; ACTIVATION; EXPRESSION; CELLS	Mutations of NPHS1 or NPHS2, the genes encoding for the glomerular podocyte proteins nephrin and podocin, cause steroid-resistant proteinuria. In addition, mice lacking NEPH1 develop a nephrotic syndrome that resembles NPHS mutations, suggesting that all three proteins are essential for the integrity of glomerular podocytes. Podocin interacts with the C-terminal domain of nephrin and facilitates nephrin-dependent signaling. NEPH1, a member of the immunoglobulin superfamily, is structurally related to nephrin. We report now that NEPH1 belongs to a family of three closely related proteins that interact with the C-terminal domain of podocin. All three NEPH proteins share a conserved podocin-binding motif; mutation of a centrally located tyrosine residue dramatically lowers the affinity of NEPH1 for podocin. NEPH1 triggers AP-1 activation similarly to nephrin but requires the presence of Tec family kinases for efficient transactivation. We conclude that NEPH1 defines a new family of podocin-binding molecules that are potential candidates for hereditary nephrotic syndromes not linked to either NPHS1 or NPHS2.	Univ Hosp Freiburg, Dept Internal Med, Div Nephrol, D-79106 Freiburg, Germany	University of Freiburg	Walz, G (corresponding author), Univ Hosp Freiburg, Div Renal, Hugstetterstr 55, D-79106 Freiburg, Germany.	walz@med1.ukl.uni-freiburg.de		Huber, Tobias B./0000-0001-7175-5062				BENZING T, 2000, J BIOL CHEM; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Chamorro M, 2001, BMC Immunol, V2, P3, DOI 10.1186/1471-2172-2-3; Donoviel DB, 2001, MOL CELL BIOL, V21, P4829, DOI 10.1128/MCB.21.14.4829-4836.2001; Greiber S, 1998, KIDNEY INT, V53, P654, DOI 10.1046/j.1523-1755.1998.00796.x; Hamm-Alvarez SF, 2001, AM J PHYSIOL-CELL PH, V280, pC1657, DOI 10.1152/ajpcell.2001.280.6.C1657; Huber TB, 2001, J BIOL CHEM, V276, P41543, DOI 10.1074/jbc.C100452200; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kocher O, 1999, LAB INVEST, V79, P1161; Moeller MJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015614.68893.0B; Putaala H, 2001, HUM MOL GENET, V10, P1, DOI 10.1093/hmg/10.1.1; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI12849; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAKAHASHI T, 1995, BIOCHEM BIOPH RES CO, V209, P218, DOI 10.1006/bbrc.1995.1492; TANAKA N, 1993, FEBS LETT, V324, P1, DOI 10.1016/0014-5793(93)81520-A; Tryggvason K, 2001, CURR OPIN NEPHROL HY, V10, P543, DOI 10.1097/00041552-200107000-00009; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Veri MC, 2001, MOL CELL BIOL, V21, P6939, DOI 10.1128/MCB.21.20.6939-6950.2001	22	162	179	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					115	+		10.1096/fj.02-0242fje	http://dx.doi.org/10.1096/fj.02-0242fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12424224				2022-12-28	WOS:000180218500036
J	Morishita, T; Tsutsui, M; Shimokawa, H; Horiuchi, M; Tanimoto, A; Suda, O; Tasaki, H; Huang, PL; Sasaguri, Y; Yanagihara, N; Nakashima, Y				Morishita, T; Tsutsui, M; Shimokawa, H; Horiuchi, M; Tanimoto, A; Suda, O; Tasaki, H; Huang, PL; Sasaguri, Y; Yanagihara, N; Nakashima, Y			Vasculoprotective roles of neuronal nitric oxide synthase	FASEB JOURNAL			English	Article						arteriosclerosis; neointimal formation; vascular remodeling	SMOOTH-MUSCLE-CELLS; SELECTIVE-INHIBITION; GENETIC DEFICIENCY; LESION FORMATION; VASCULAR LESION; ANGIOTENSIN-II; NO; INJURY; EXPRESSION; INCREASES	Nitric oxide (NO) has multiple important actions that contribute to the maintenance of vascular homeostasis. NO is synthesized by three different isoforms of NO synthase (NOS), all of which have been reported to be expressed in human atherosclerotic vascular lesions. Although the regulatory roles of endothelial NOS (eNOS) and inducible NOS (iNOS) on the development of atherosclerosis have been described, little is known about the role of neuronal NOS (nNOS). Here, we show that nNOS also exerts important vasculoprotective effects in vivo. In a carotid artery ligation model, nNOS gene-deficient (nNOS-KO) mice exhibited accelerated neointimal formation and constrictive vascular remodeling caused by blood flow disruption. In a rat balloon injury model, the selective inhibition of nNOS activity potently enhanced vasoconstrictor responses to a variety of calcium-mobilizing stimuli, suppressed tissue cGMP concentrations, a marker of vascular NO production, and exacerbated neointimal formation. In both models, nNOS was absent before injury and was up-regulated only after the injury, and was predominantly expressed in the neointima and medial smooth muscle cells. These results provide the first direct evidence that nNOS plays important roles in suppressing arteriosclerotic vascular lesion formation in vivo.	Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 2, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Pharmacol, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Pathol & Cell Biol, Kitakyushu, Fukuoka 8078555, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Fukuoka 812, Japan; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02115 USA	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; Kyushu University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Tsutsui, M (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 2, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	mt2498@med.uoeh-u.ac.jp		Huang, Paul/0000-0002-5436-8658				Boulanger CM, 1998, CIRC RES, V83, P1271, DOI 10.1161/01.RES.83.12.1271; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BROCK TA, 1985, HYPERTENSION, V7, pI105, DOI 10.1161/01.HYP.7.3_Pt_2.I105; Chyu KY, 1999, CIRC RES, V85, P1192; DeSanctis GT, 1997, AM J PHYSIOL-LUNG C, V273, pL883, DOI 10.1152/ajplung.1997.273.4.L883; FURFINE ES, 1994, J BIOL CHEM, V269, P26677; Goss SPA, 1997, J BIOL CHEM, V272, P21647, DOI 10.1074/jbc.272.34.21647; GUTHRIE GP, 1995, CLIN CARDIOL S3, V18, P29; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; JOLY GA, 1992, CIRC RES, V71, P331, DOI 10.1161/01.RES.71.2.331; Kawashima S, 2001, ARTERIOSCL THROM VAS, V21, P201, DOI 10.1161/01.ATV.21.2.201; Koglin J, 1998, CIRCULATION, V97, P2059, DOI 10.1161/01.CIR.97.20.2059; Kuhlencordt PJ, 2001, CIRCULATION, V103, P3099, DOI 10.1161/01.CIR.103.25.3099; Kumar A, 1997, CIRCULATION, V96, P4333; LUSCHER TF, 1990, ENDOTHELIUM MODULATO; MAJOR TC, 1995, AM J PHYSIOL-HEART C, V269, pH988, DOI 10.1152/ajpheart.1995.269.3.H988; MISKO TP, 1993, EUR J PHARMACOL, V233, P119, DOI 10.1016/0014-2999(93)90357-N; MITSUHASHI T, 1989, J CLIN INVEST, V84, P635, DOI 10.1172/JCI114209; Miyamoto T, 1997, ATHEROSCLEROSIS, V129, P207, DOI 10.1016/S0021-9150(96)06043-1; Moore MAS, 2002, J CLIN INVEST, V109, P313, DOI 10.1172/JCI200214940; MOORE PK, 1993, BRIT J PHARMACOL, V110, P219, DOI 10.1111/j.1476-5381.1993.tb13795.x; Moroi M, 1998, J CLIN INVEST, V101, P1225, DOI 10.1172/JCI1293; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Ruiz-Ortega M, 2000, CIRC RES, V86, P1266, DOI 10.1161/01.RES.86.12.1266; Saiura A, 2001, NAT MED, V7, P382, DOI 10.1038/86394; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; SCHWARTZ SM, 1995, THROMB HAEMOSTASIS, V74, P541; Shimokawa H, 1999, J MOL CELL CARDIOL, V31, P23, DOI 10.1006/jmcc.1998.0841; THOMAS G, 1991, BIOCHEM BIOPH RES CO, V179, P1677, DOI 10.1016/0006-291X(91)91768-8; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; Wang WH, 2000, J BIOL CHEM, V275, P16899, DOI 10.1074/jbc.M000301200; Wilcox JN, 1997, ARTERIOSCL THROM VAS, V17, P2479, DOI 10.1161/01.ATV.17.11.2479; Yogo K, 2000, ARTERIOSCL THROM VAS, V20, pE96, DOI 10.1161/01.ATV.20.11.e96	36	78	82	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12								10.1096/fj.02-0155fje	http://dx.doi.org/10.1096/fj.02-0155fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397095				2022-12-28	WOS:000179167600014
J	Dittmar, T; Husemann, A; Schewe, Y; Nofer, JR; Niggemann, B; Zanker, KS; Brandt, BH				Dittmar, T; Husemann, A; Schewe, Y; Nofer, JR; Niggemann, B; Zanker, KS; Brandt, BH			Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via epidermal growth factor receptor	FASEB JOURNAL			English	Article						PLC-gamma 1; phosphoinositide kinetics; migration	NEU DIFFERENTIATION FACTOR; ERBB SIGNALING NETWORK; BREAST-CANCER; ACTIVATION; HETERODIMERIZATION; LOCOMOTION; CHANNELS; DOMAINS; KINASES	Induction of tumor cell migration is a key step in invasion and metastasis. Here we report that the epidermal growth factor (EGF)-induced cell migration of breast cancer cells is attributed to a transient, rather than a sustained, activation of phospholipase C (PLC)-gamma1 due to c-erbB-2 signaling. EGF stimulation of EGF receptor (EGFR) overexpressing cells resulted in long-term PLC-gamma1 tyrosine phosphorylation and sustained levels of inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG) producing sinusoidal calcium oscillations. In contrast, c-erbB-2/EGFR expressing cells displayed baseline transient calcium oscillations after EGF treatment due to short-term PLC-gamma1 tyrosine phosphorylation and short-term IP3 and DAG turnover. A third cell line expressing a point-mutated c-erbB-2 receptor that lacks the autophosphorylation Y1248 was generated to investigate whether the different PLC-gamma1 activation was attributed to this structure. Neither PLC-gamma1 tyrosine phosphorylation nor IP3 and DAG turnover and calcium oscillations were observed in this cell line, indicating the modulation of the PLC-gamma1 activation time course by c-erbB-2 signaling. Induction of cell migration was solely observable in the c-erbB-2-positive cell line as proved by the mode of actin reorganization and a cell migration assay, using a 3D-collagen lattice. In summary, c-erbB-2 up-regulation switches on the cell migration program by modulating the time course of PLC-gamma1 activation.	Univ Witten Herdecke, Inst Immunol, D-58448 Witten, Germany; Univ Munster, Inst Clin Chem & Lab Med, D-48129 Munster, Germany	Witten Herdecke University; University of Munster	Dittmar, T (corresponding author), Univ Witten Herdecke, Inst Immunol, Stockumer Str 10, D-58448 Witten, Germany.	thomasd@uni-wh.de	Dittmar, Thomas/X-3691-2019; Dittmar, Thomas/T-6679-2019	Brandt, Burkhard/0000-0003-3681-3049				Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Brandt BH, 1999, FASEB J, V13, P1939, DOI 10.1096/fasebj.13.14.1939; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; Entschladen F, 2000, J CANCER RES CLIN, V126, P671, DOI 10.1007/s004320000143; Feldner JC, 2002, EXP CELL RES, V272, P93, DOI 10.1006/excr.2001.5385; FRIEDL P, 1993, J IMMUNOL METHODS, V165, P157, DOI 10.1016/0022-1759(93)90341-4; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GRUCHALLA RS, 1990, J IMMUNOL, V144, P2334; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kassis J, 1999, CLIN CANCER RES, V5, P2251; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; SUTHERLAND CA, 1982, J BIOL CHEM, V257, P4006; Tang CK, 1998, HORMONES SIGNALING, P113; Tanner B, 1996, GYNECOL ONCOL, V62, P268, DOI 10.1006/gyno.1996.0226; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296	30	104	110	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2002	16	11					1823	+		10.1096/fj.02-0096fje	http://dx.doi.org/10.1096/fj.02-0096fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12354693				2022-12-28	WOS:000178441800002
J	Jover, R; Bort, R; Gomez-Lechon, MJ; Castell, JV				Jover, R; Bort, R; Gomez-Lechon, MJ; Castell, JV			Down-regulation of human CYP3A4 by the inflammatory signal interleukin 6: molecular mechanism and transcription factors involved	FASEB JOURNAL			English	Article						cytochrome P-450; gp130 receptor; JAK/STAT pathway; MAPK; C/EBP transcription factors	ACUTE-PHASE RESPONSE; CCAAT/ENHANCER-BINDING-PROTEIN; ADULT HUMAN HEPATOCYTES; GENE-TRANSCRIPTION; C/EBP ISOFORMS; MESSENGER-RNA; CYTOCHROME-P450 ENZYMES; TRANSDUCTION PATHWAY; ACTIVATED RECEPTOR; INHIBITORY PROTEIN	The hepatic drug-metabolizing cytochrome P-450 (CYP) enzymes are down-regulated during inflammation. In vitro studies with hepatocytes have shown that the cytokines released during inflammatory responses are largely responsible for this CYP repression. However, the signaling pathways and the cytokine-activated factors involved remain to be properly identified. Our research has focused on the negative regulation of CYP3A4 (the major drug-metabolizing human CYP) by interleukin 6 (IL-6) (the principal regulator of the hepatic acute-phase response). CYP3A4 down-regulation by IL-6 requires activation of the glycoprotein receptor gp130; however, it does not proceed through the JAK/STAT pathway, as demonstrated by the overexpression of a dominant-negative STAT3 factor by means of an adenoviral vector. The involvement of IL-6-activated kinases such as extracellular signal-regulated kinase ERK1/2 or p38 is also unlikely, as evidenced by the use of specific chemical inhibitors. It is noteworthy that IL-6 caused a moderated induction in the mRNA of the transcription factor C/EBPbeta (CCAAT-enhancer binding protein beta) and a marked increase in the translation of C/EBPbeta-LIP, a 20-kDa C/EBPbeta isoform lacking a transactivation domain. Adenovirus-mediated expression of C/EBPbeta-LIP caused a dose-dependent repression of CYP3A4 mRNA, whereas overexpression C/EBPalpha and C/EBPbeta-LAP (35 kDa) caused a significant induction. Our results support the idea that IL-6 down-regulates CYP3A4 through translational induction of C/EBPbeta-LIP, which competes with and antagonizes constitutive C/EBP transactivators. From a clinical point of view, these findings could be relevant in the development of therapeutic cytokines with a less repressive effect on hepatic drug-metabolizing enzymes.	Hosp Univ La Fe, Ctr Invest, Unidad Hepatol Expt, E-46009 Valencia, Spain; Univ Valencia, Fac Med, Dept Bioquim, E-46010 Valencia, Spain	Hospital Universitari i Politecnic La Fe; University of Valencia	Castell, JV (corresponding author), Hosp Univ La Fe, Ctr Invest, Unidad Hepatol Expt, Avda Campanar 21, E-46009 Valencia, Spain.	Jose.Castell@uv.es	Bort, Roque/Y-5466-2019; Castell, Jose V/I-9529-2016; Jover, Ramiro/O-9796-2017	Bort, Roque/0000-0002-7285-0536; Castell, Jose V/0000-0003-1179-6430; Jover, Ramiro/0000-0002-4914-5804				ABDELRAZZAK Z, 1993, MOL PHARMACOL, V44, P707; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; An MR, 1996, MOL CELL BIOL, V16, P2295; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; Barclay TB, 1999, J PHARMACOL EXP THER, V290, P1250; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Castell JV, 1997, GENE THER, V4, P455, DOI 10.1038/sj.gt.3300416; CASTELL JV, 1990, HEPATOLOGY, V12, P1179, DOI 10.1002/hep.1840120517; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Gomez-Lechon MJ, 2001, EUR J BIOCHEM, V268, P1448, DOI 10.1046/j.1432-1327.2001.02011.x; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GOMEZLECHON MJ, 1990, IN VITRO CELL DEV B, V26, P67; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; GUENGERICH FP, 1993, AM SCI, V81, P440; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; Guillen MI, 1998, J PHARMACOL EXP THER, V285, P127; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Iber H, 2000, ARCH BIOCHEM BIOPHYS, V377, P187, DOI 10.1006/abbi.2000.1772; Iraburu MJ, 2000, HEPATOLOGY, V31, P1086, DOI 10.1053/he.2000.5981; Jover R, 1998, FEBS LETT, V431, P227, DOI 10.1016/S0014-5793(98)00746-7; Jover R, 2001, HEPATOLOGY, V33, P668, DOI 10.1053/jhep.2001.22176; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Kim H, 1999, MOL CELL BIOL, V19, P5326; Koj A, 1996, BBA-MOL BASIS DIS, V1317, P84, DOI 10.1016/S0925-4439(96)00048-8; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lin JH, 2001, ANNU REV PHARMACOL, V41, P535, DOI 10.1146/annurev.pharmtox.41.1.535; Mazuski JE, 1997, J SURG RES, V68, P161, DOI 10.1006/jsre.1997.4999; Meyer UA, 1997, ANNU REV PHARMACOL, V37, P269, DOI 10.1146/annurev.pharmtox.37.1.269; Morel Y, 1998, J BIOL CHEM, V273, P26969, DOI 10.1074/jbc.273.41.26969; Morgan ET, 1997, DRUG METAB REV, V29, P1129, DOI 10.3109/03602539709002246; Morgan ET, 2001, DRUG METAB DISPOS, V29, P207; MUNTANERELAT J, 1995, HEPATOLOGY, V22, P1143; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NATSUKA S, 1991, FEBS LETT, V291, P58, DOI 10.1016/0014-5793(91)81103-F; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Ourlin JC, 1997, J HEPATOL, V26, P54, DOI 10.1016/S0168-8278(97)80497-7; Pascussi JM, 2000, BIOCHEM BIOPH RES CO, V274, P707, DOI 10.1006/bbrc.2000.3219; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Quattrochi LC, 2001, DRUG METAB DISPOS, V29, P615; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; Rodriguez-Antona C, 2000, ARCH BIOCHEM BIOPHYS, V376, P109, DOI 10.1006/abbi.2000.1697; Runge D, 2000, BIOCHEM BIOPH RES CO, V269, P46, DOI 10.1006/bbrc.2000.2215; Siewert E, 2000, HEPATOLOGY, V32, P49, DOI 10.1053/jhep.2000.8532; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tinel M, 1999, J PHARMACOL EXP THER, V289, P649; Trautwein C, 1996, J BIOL CHEM, V271, P22262, DOI 10.1074/jbc.271.36.22262; Watkins PJ, 1996, CANCER RES, V56, P1063; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Welm AL, 2000, J BIOL CHEM, V275, P27406; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; Wilkinson GR, 1997, ADV DRUG DELIVER REV, V27, P129, DOI 10.1016/S0169-409X(97)00040-9; Zauberman A, 1999, ONCOGENE, V18, P3886, DOI 10.1038/sj.onc.1202738	72	162	171	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2002	16	11					1799	+		10.1096/fj.02-0195fje	http://dx.doi.org/10.1096/fj.02-0195fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12354697				2022-12-28	WOS:000178441800007
J	Quesada, I; Fuentes, E; Viso-Leon, MC; Soria, B; Ripoll, C; Nadal, A				Quesada, I; Fuentes, E; Viso-Leon, MC; Soria, B; Ripoll, C; Nadal, A			Low doses of the endocrine disruptor Bisphenol-A and the native hormone 17 beta-estradiol rapidly activate the transcription factor CREB	FASEB JOURNAL			English	Article						xenoestrogens; estrogen receptors; islets of Langerhans; non-genomic	ELEMENT-BINDING PROTEIN; ESTROGEN-RECEPTOR; MEMBRANE; PHOSPHORYLATION; XENOESTROGENS; CAMP; IDENTIFICATION; NUCLEAR; GROWTH; CELLS	Endocrine-disrupting chemicals (EDCs) are hormone-like agents present in the environment that alter the endocrine system of wildlife and humans. Most EDCs have potencies far below those of the natural hormone 17beta-E2 when acting through the classic estrogen receptors (ERs). Here, we show that the environmental estrogen Bisphenol-A and the native hormone 17beta-E2 activate the transcription factor, cAMP-responsive element binding protein (CREB) with the same potency. Phosphorylated CREB (P-CREB) was increased after only a 5-minute application of either BPA or 17beta-E2 in a calcium-dependent manner. The effect was reproduced by the membrane-impermeable molecule E2 conjugated to horseradish peroxidase (E-HRP). The increase in P-CREB was not modified by the anti-estrogen ICI 182,780. Therefore, low-dose of BPA activates the transcription factor CREB via an alternative mechanism, involving a non-classical membrane estrogen receptor. Because these effects are elicited at concentrations as low as 10(-9) M, this observation is of environmental and public health relevance.	Miguel Hernandez Univ, Inst Bioengn, Alicante 03550, Spain	Universidad Miguel Hernandez de Elche	Nadal, A (corresponding author), Miguel Hernandez Univ, Inst Bioengn, San Juan Campus,Carretera Alicante Valencia Km 87, Alicante 03550, Spain.	nadal@umh.es	Fuentes, Esther/C-7545-2015; , Bernat/AAL-6470-2021; Ivan, Quesada/P-6541-2014; Nadal, Angel/G-6721-2014; Ripoll, Cristina/F-3324-2016	Ivan, Quesada/0000-0002-9808-514X; Nadal, Angel/0000-0003-4178-2152; Ripoll, Cristina/0000-0003-0935-8722; Soria, Bernat/0000-0002-2356-0380; Fuentes, Esther/0000-0002-9113-739X				ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Beyer C, 2000, J NEUROSCI RES, V59, P107, DOI 10.1002/(SICI)1097-4547(20000101)59:1<107::AID-JNR13>3.0.CO;2-W; BROTONS JA, 1995, ENVIRON HEALTH PERSP, V103, P608, DOI 10.2307/3432439; Cagen SZ, 1999, TOXICOL SCI, V50, P36, DOI 10.1093/toxsci/50.1.36; CARLIN L, 2000, CIRC RES, V86, P760; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; DODDS E. C, 1936, NATURE [LONDON], V137, P996, DOI 10.1038/137996a0; Dodds EC, 1938, NATURE, V141, P247, DOI 10.1038/141247b0; Dos Santos EG, 2002, ENDOCRINOLOGY, V143, P930; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Fernandez MF, 2001, ENVIR SCI TECH LIB, V18, P149; Guillette LJ, 1999, GEN COMP ENDOCR, V116, P356, DOI 10.1006/gcen.1999.7375; Idriss SD, 1999, J BIOL CHEM, V274, P9489, DOI 10.1074/jbc.274.14.9489; Kaiser J, 2000, SCIENCE, V290, P695, DOI 10.1126/science.290.5492.695; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279; Loomis AK, 2000, BIOL REPROD, V62, P995, DOI 10.1095/biolreprod62.4.995; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MCLACHLAN JA, 1993, ENVIRON HEALTH PERSP, V101, P386, DOI 10.2307/3431891; McLachlan JA, 2001, ENDOCR REV, V22, P319, DOI 10.1210/er.22.3.319; Nadal A, 2001, NEWS PHYSIOL SCI, V16, P251; Nadal A, 2001, TRENDS PHARMACOL SCI, V22, P597, DOI 10.1016/S0165-6147(00)01846-0; NADAL A, 1994, AM J PHYSIOL-ENDOC M, V267, pE769, DOI 10.1152/ajpendo.1994.267.5.E769; Nadal A, 1998, FASEB J, V12, P1341, DOI 10.1096/fasebj.12.13.1341; Nadal A, 2000, P NATL ACAD SCI USA, V97, P11603, DOI 10.1073/pnas.97.21.11603; Nagel SC, 1997, ENVIRON HEALTH PERSP, V105, P70, DOI 10.2307/3433065; Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888; Petersen DN, 1998, ENDOCRINOLOGY, V139, P1082, DOI 10.1210/en.139.3.1082; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Ropero AB, 2002, MOL ENDOCRINOL, V16, P497, DOI 10.1210/me.16.3.497; Ropero AB, 1999, J PHYSIOL-LONDON, V521, P397, DOI 10.1111/j.1469-7793.1999.00397.x; Ruehlmann DO, 1998, FASEB J, V12, P613, DOI 10.1096/fasebj.12.7.613; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SOTO AM, 1994, ENVIRON HEALTH PERSP, V102, P380, DOI 10.2307/3431626; Steinmetz R, 1998, ENDOCRINOLOGY, V139, P2741, DOI 10.1210/en.139.6.2741; Triendl R, 2001, NATURE, V409, P274, DOI 10.1038/35053303; VALDEOLMILLOS M, 1992, J PHYSIOL-LONDON, V455, P173, DOI 10.1113/jphysiol.1992.sp019295; Watson CS, 1999, EXP PHYSIOL, V84, P1013, DOI 10.1111/j.1469-445X.1999.01903.x; Zhou Y, 1996, ENDOCRINOLOGY, V137, P2163, DOI 10.1210/en.137.5.2163	40	179	187	1	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1671	+		10.1096/fj.02-0313fje	http://dx.doi.org/10.1096/fj.02-0313fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207000	Bronze			2022-12-28	WOS:000177814000002
J	Pang, LH; Nie, M; Corbett, L; Donnelly, R; Gray, S; Knox, AJ				Pang, LH; Nie, M; Corbett, L; Donnelly, R; Gray, S; Knox, AJ			Protein kinase C-epsilon mediates bradykinin-induced cyclooxygenase-2 expression in human airway smooth muscle cells	FASEB JOURNAL			English	Article						prostanoids; inflammation; asthma	PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2; CYTOSOLIC PHOSPHOLIPASE A(2); VASCULAR ENDOTHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; SIGNAL-TRANSDUCTION; PHORBOL ESTER; TRANSCRIPTIONAL REGULATION; EPITHELIAL-CELLS; RESPONSE ELEMENT; NUCLEAR FACTOR	We previously reported that proinflammatory mediator bradykinin (BK) induces cyclooxygenase (COX)-2 expression in human airway smooth muscle (HASM), but the mechanism is unknown in any biological system. Here, we studied the role of specific protein kinase C (PKC) isozyme(s) in COX-2 expression. Among the eight PKC isozymes present in HASM cells, the Ca2+-independent PKC- and - and the Ca2+-dependent PKC-alpha and -betaI were translocated to the nucleus upon BK stimulation. BK-induced COX-2 expression and prostaglandin E-2 (PGE(2)) accumulation were mimicked by the direct PKC activator phorbol 12-myristate 13-acetate (PMA) and inhibited by the broad spectrum PKC inhibitor bisindolylmaleimide I. However, the selective Ca2+-dependent PKC isozyme inhibitor Go 6976 had no effect. Furthermore, the membrane-permeable calcium chelator BAPTA-AM had no effect on BK-induced COX-2 expression and COX activity despite its inhibition of PGE2 accumulation, suggesting the involvement of Ca2+-independent PKC isozymes. Rottlerin, a PKC-delta inhibitor, also had no effect, likely implicating PKC-epsilon. BK-stimulated transcriptional activation of a COX-2 promoter reporter construct was enhanced by overexpression of wildtype PKC-epsilon and abolished by a dominant negative PKC-epsilon, but it was not affected by wild-type or dominant negative PKC-alpha or -delta. Collectively, our results demonstrate that PKC-epsilon mediates BK-induced COX-2 expression in HASM cells.	Univ Nottingham, City Hosp, Div Resp Med, Nottingham NG5 1PB, England; Univ Nottingham, Derbyshire Royal Infirm, Div Vasc Med, Derby DE1 2QY, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham; University of Nottingham	Pang, LH (corresponding author), Univ Nottingham, City Hosp, Div Resp Med, Clin Sci Bldg,Hucknall rd, Nottingham NG5 1PB, England.	linhua.pang@nottingham.ac.uk		Knox, Alan/0000-0002-5906-4143				BARNES PJ, 1992, THORAX, V47, P979, DOI 10.1136/thx.47.11.979; Carlin S, 2000, AM J RESP CELL MOL, V23, P555, DOI 10.1165/ajrcmb.23.4.4197; Carlin S, 1999, AM J PHYSIOL-LUNG C, V276, pL506, DOI 10.1152/ajplung.1999.276.3.L506; Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CLARK KJ, 1995, J BIOL CHEM, V270, P7097, DOI 10.1074/jbc.270.13.7097; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Deszo EL, 2001, J BIOL CHEM, V276, P10212, DOI 10.1074/jbc.M010589200; Giroux M, 2000, J IMMUNOL, V165, P3985, DOI 10.4049/jimmunol.165.7.3985; Graness A, 1997, BIOCHEM J, V327, P147, DOI 10.1042/bj3270147; Graness A, 1998, J BIOL CHEM, V273, P32016, DOI 10.1074/jbc.273.48.32016; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Higaki T, 1999, MICROVASC RES, V58, P144, DOI 10.1006/mvre.1999.2163; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; Kennedy CRJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1605, DOI 10.1152/ajpcell.1997.273.5.C1605; Knox AJ, 2001, FASEB J, V15, P2480, DOI 10.1096/fj.01-0256com; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Lal MA, 1997, AM J PHYSIOL-RENAL, V273, pF907, DOI 10.1152/ajprenal.1997.273.6.F907; Lal MA, 1998, AM J PHYSIOL-RENAL, V274, pF728, DOI 10.1152/ajprenal.1998.274.4.F728; Lin CH, 2000, MOL PHARMACOL, V57, P36; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOMBOULI JV, 1995, ANNU REV PHARMACOL, V35, P679, DOI 10.1146/annurev.pa.35.040195.003335; Nagaki M, 1996, AM J PHYSIOL-LUNG C, V270, pL907, DOI 10.1152/ajplung.1996.270.6.L907; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; Pang LH, 1996, EUR J PHARMACOL, V317, P151, DOI 10.1016/S0014-2999(96)00703-0; Pang LH, 1997, BRIT J PHARMACOL, V121, P579, DOI 10.1038/sj.bjp.0701152; Pang LH, 1997, AM J PHYSIOL-LUNG C, V273, pL1132, DOI 10.1152/ajplung.1997.273.6.L1132; POLOSA R, 1990, AM REV RESPIR DIS, V142, P1367, DOI 10.1164/ajrccm/142.6_Pt_1.1367; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; ROSSETTI M, 1995, AM J PHYSIOL-LUNG C, V268, pL966, DOI 10.1152/ajplung.1995.268.6.L966; SIROIS J, 1993, J BIOL CHEM, V268, P21931; TIPPMER S, 1994, EUR J BIOCHEM, V225, P297, DOI 10.1111/j.1432-1033.1994.00297.x; TRILIVAS I, 1991, J BIOL CHEM, V266, P8431; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wang HQ, 2001, MOL PHARMACOL, V59, P860, DOI 10.1124/mol.59.4.860; WANG LH, 1993, BIOCHEM BIOPH RES CO, V190, P406, DOI 10.1006/bbrc.1993.1062; Webb BLJ, 1997, BIOCHEM PHARMACOL, V54, P199, DOI 10.1016/S0006-2952(97)00165-2; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	50	27	29	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1435	+		10.1096/fj.02-0169fje	http://dx.doi.org/10.1096/fj.02-0169fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205039				2022-12-28	WOS:000177813100007
J	Katoh-Semba, R; Asano, T; Ueda, H; Morishita, R; Takeuchi, IK; Inaguma, Y; Kato, K				Katoh-Semba, R; Asano, T; Ueda, H; Morishita, R; Takeuchi, IK; Inaguma, Y; Kato, K			Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus	FASEB JOURNAL			English	Article						brain-derived neurotrophic factor; proliferation; granule cells; riluzole; neurogenesis	NERVE GROWTH-FACTOR; ADULT-RAT; DENTATE GYRUS; MESSENGER-RNA; NEUROGENESIS; BDNF; INCREASES; INDUCTION; RELEASE; NEURONS	The dentate gyrus of the hippocampus, generating new cells throughout life, is essential for normal recognition memory performance. Reduction of brain-derived neurotrophic factor (BDNF) in this structure impairs its functions. To elucidate the association between BDNF levels and hippocampal neurogenesis, we first conducted a search for compounds that stimulate endogenous BDNF production in hippocampal granule neurons. Among ion channel modulators tested, riluzole, a neuroprotective agent with anticonvulsant properties that is approved for treatment of amyotrophic lateral sclerosis, was highly effective as a single dose by an intraperitoneal injection, causing a rise in BDNF localized in dentate granule neurons, the hilus, and the stratum radiatum of the CA3 region. Repeated, but not single, injections resulted in prolonged elevation of hippocampal BDNF and were associated with increased numbers of newly generated cells in the granule cell layer. This appeared due to promoted proliferation rather than survival of precursor cells, many of which differentiated into neurons. Intraventricular administration of BDNF-specific antibodies blocked such riluzole effects, suggesting that BDNF increase is necessary for the promotion of precursor proliferation. Our results suggest the basis for a new strategy for treatment of memory dysfunction.	Aichi Human Serv Ctr, Inst Dev Res, Dept Perinatol, Aichi 4800392, Japan		Katoh-Semba, R (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Perinatol, Aichi 4800392, Japan.	katohsemba@inst-hsc.pref.aichi.jp						ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Cameron HA, 1999, NAT NEUROSCI, V2, P894, DOI 10.1038/13197; CAMERON HA, 1995, J NEUROSCI, V15, P4687; CASTREN E, 1993, NEUROREPORT, V4, P895, DOI 10.1097/00001756-199307000-00014; Conner JM, 1997, J NEUROSCI, V17, P2295; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fuchs E, 2000, EUR J NEUROSCI, V12, P2211, DOI 10.1046/j.1460-9568.2000.00130.x; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Gray WP, 1998, BRAIN RES, V790, P52, DOI 10.1016/S0006-8993(98)00030-4; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; KATO K, 1985, BIOCHIM BIOPHYS ACTA, V842, P146, DOI 10.1016/0304-4165(85)90196-5; Kato K, 1999, J NEUROCHEM, V73, P229, DOI 10.1046/j.1471-4159.1999.0730229.x; Katoh-Semba R, 1999, NEUROSCI RES, V35, P19, DOI 10.1016/S0168-0102(99)00059-0; Katoh-Semba R, 2001, J NEUROCHEM, V77, P71, DOI 10.1046/j.1471-4159.2001.00138.x; Katoh-Semba R, 1998, NEUROSCI RES, V31, P227, DOI 10.1016/S0168-0102(98)00040-6; KatohSemba R, 1997, J NEUROCHEM, V69, P34; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kinoshita S, 1999, J NEUROSCI, V19, P2122; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; Lee J, 2000, J MOL NEUROSCI, V15, P99, DOI 10.1385/JMN:15:2:99; Li YX, 1998, J NEUROSCI, V18, P10231; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; MARTIN D, 1993, EUR J PHARMACOL, V250, P473, DOI 10.1016/0014-2999(93)90037-I; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; METSIS M, 1993, P NATL ACAD SCI USA, V90, P8802, DOI 10.1073/pnas.90.19.8802; OKADA Y, 1992, NEUROSCI LETT, V142, P233, DOI 10.1016/0304-3940(92)90380-P; Parent JM, 1997, J NEUROSCI, V17, P3727; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; PHILLIPS HS, 1991, NEURON, V7, P695, DOI 10.1016/0896-6273(91)90273-3; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Vicario-Abejon C, 2000, EUR J NEUROSCI, V12, P677, DOI 10.1046/j.1460-9568.2000.00953.x; WIERASZKO A, 1989, BRAIN RES, V491, P356, DOI 10.1016/0006-8993(89)90070-X; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449; Zola SM, 2000, J NEUROSCI, V20, P451, DOI 10.1523/JNEUROSCI.20-01-00451.2000	40	136	143	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1328	+		10.1096/fj.02-0143fje	http://dx.doi.org/10.1096/fj.02-0143fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154010				2022-12-28	WOS:000176683900021
J	Wagner, KD; Wagner, N; Wellmann, S; Schley, G; Bondke, A; Theres, H; Scholz, H				Wagner, KD; Wagner, N; Wellmann, S; Schley, G; Bondke, A; Theres, H; Scholz, H			Oxygen-regulated expression of the Wilms' tumor suppressor Wt1 involves hypoxia-inducible factor-1 (HIF-1)	FASEB JOURNAL			English	Article						gene regulation; promoter; electrophoretic mobility shift assay; immunohistochemistry; apoptosis	ENDOTHELIAL GROWTH-FACTOR; GENE WT1; TRANSCRIPTION FACTOR; KIDNEY DEVELOPMENT; FACTOR 1-ALPHA; SMOOTH-MUSCLE; PROTEIN; APOPTOSIS; BCL-2; QUANTIFICATION	The Wilms' tumor gene Wt1 is unique among tumor suppressors because of its requirement for the development of certain organs. We recently described de novo expression of Wt1 in myocardial blood vessels of ischemic rat hearts. The purpose of this study was to analyze the mechanism(s) of hypoxic/ischemic induction of Wt1. We show here that Wt1 mRNA and protein is up-regulated in the heart and kidneys of rats exposed to normobaric hypoxia (8% O-2). Ectopic Wt1 immunoreactivity was detected in renal tubules of hypoxic rats, which also expressed the antiapoptotic protein Bcl-2 and contained significantly fewer TUNEL-positive cells than in normoxic kidneys. Wt1 expression was enhanced in the osteosarcoma line U-2OS and in Reh lymphoblast cells that were grown either at 1% O-2 or in the presence of CoCl2 and desferrioxamine, respectively. The promoter of the Wt1 gene was capable of mediating expression of a luciferase reporter in response to hypoxia. We identified a hypoxia-responsive element in the Wt1 sequence that bound to hypoxia-inducible factor-1 (HIF-1) and was required for activation of the Wt1 promoter by CoCl2 and HIF-1. These findings demonstrate that Wt1 expression can be stimulated by hypoxia, which involves activation of the Wt1 promoter by HIF-1.	Humboldt Univ, Charite, Johannes Muller Inst Physiol, D-10117 Berlin, Germany; Humboldt Univ, Charite, Klin Padiat Schwerpunkt Onkol & Hamatol, D-10117 Berlin, Germany; Humboldt Univ, Charite, Innere Med Klin 1, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Scholz, H (corresponding author), Humboldt Univ, Charite, Johannes Muller Inst Physiol, Tucholskystr 2, D-10117 Berlin, Germany.	holger.scholz@charite.de	Wellmann, Sven/A-2771-2017; Wagner, Kay-Dietrich/E-6119-2016	Wagner, Kay-Dietrich/0000-0001-5483-7760; Wagner, Nicole/0000-0002-2746-0707; Schley, Gunnar/0000-0001-9929-5854				An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Beckwith JB, 1998, AM J MED GENET, V79, P268, DOI 10.1002/(SICI)1096-8628(19981002)79:4<268::AID-AJMG7>3.0.CO;2-I; Chien CT, 2000, TRANSPLANT P, V32, P1653, DOI 10.1016/S0041-1345(00)01434-2; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Dettman RW, 1998, DEV BIOL, V193, P169, DOI 10.1006/dbio.1997.8801; Dong Z, 2001, J BIOL CHEM, V276, P18702, DOI 10.1074/jbc.M011774200; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; English MA, 1999, J BIOL CHEM, V274, P13258, DOI 10.1074/jbc.274.19.13258; Freeburg Paul B., 2001, Journal of the American Society of Nephrology, V12, p520A; GERALL AA, 1992, HDB BEHAVIORAL NEURO, V11, P1; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRUBB GR, 1994, LAB INVEST, V71, P472; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; HEWITT SM, 1995, CANCER RES, V55, P5386; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Karth J, 2000, J PEDIATR SURG, V35, P1749, DOI 10.1053/jpsu.2000.19241; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Kreuzer KA, 2001, BRIT J HAEMATOL, V114, P313, DOI 10.1046/j.1365-2141.2001.02912.x; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Leuenroth SJ, 2000, SURGERY, V128, P171, DOI 10.1067/msy.2000.107609; LITTLE MH, 1992, ONCOGENE, V7, P635; MALIK KTA, 1994, FEBS LETT, V349, P75, DOI 10.1016/0014-5793(94)00642-3; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Moore AW, 1999, DEVELOPMENT, V126, P1845; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; NOVACK DV, 1994, AM J PATHOL, V145, P61; Peeters MPFMV, 1999, ANAT EMBRYOL, V199, P367, DOI 10.1007/s004290050235; Piret JP, 2002, BIOCHEM PHARMACOL, V64, P889, DOI 10.1016/S0006-2952(02)01155-3; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; Schedl A, 2000, CURR OPIN GENET DEV, V10, P543, DOI 10.1016/S0959-437X(00)00125-8; Scholz F, 1997, J SOLID STATE ELECTR, V1, P1, DOI 10.1007/s100080050017; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Wagner KD, 2002, FASEB J, V16, P1117, DOI 10.1096/fj.01-0986fje; Wagner KD, 2002, EMBO J, V21, P1398, DOI 10.1093/emboj/21.6.1398; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wellmann S, 2001, CLIN CHEM, V47, P654; Wenger RH, 1998, EUR J BIOCHEM, V253, P771, DOI 10.1046/j.1432-1327.1998.2530771.x; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev	44	83	85	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1364	+		10.1096/fj.02-1065fje	http://dx.doi.org/10.1096/fj.02-1065fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738801				2022-12-28	WOS:000183165000036
J	Marvanova, M; Menager, J; Bezard, E; Bontrop, RE; Pradier, L; Wong, G				Marvanova, M; Menager, J; Bezard, E; Bontrop, RE; Pradier, L; Wong, G			Microarray analysis of nonhuman primates: validation of experimental models in neurological disorders	FASEB JOURNAL			English	Article						high-density oligonucleotide array; gene expression; prefrontal cortex (PFC); nonhuman primates (NHPs)	DENSITY OLIGONUCLEOTIDE ARRAYS; DNA HYBRIDIZATION EVIDENCE; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; HOMINOID PHYLOGENY; SQUIRREL-MONKEY; AIDS VACCINE; HUMANS; MPTP; CHIMPANZEES	Nonhuman primates (NHPs) have provided robust experimental animal models for many human-related diseases due to their similar physiologies. Nonetheless, profound differences remain in the acquisition, progression, and outcome of important diseases such as AIDS and Alzheimer's, for which the underlying basis remains obscure. We explored the utility of human high-density oligonucleotide arrays to survey the transcription profile of NHP genomes. Total RNA from prefrontal cortices of human (Homo sapiens), common chimpanzee (Pan troglodytes), cynomolgous macaque (Macaca fascicularis), and common marmoset (Callithrix jacchus) was labeled and hybridized to Affymetrix U95A GeneChip probe arrays. Corresponding data obtained previously from common chimpanzee and orangutan (Pongo pygmaeus) were added for comparison. Qualitative (present or not detected) and quantitative (expression level) analysis indicated that many genes known to be involved in human neurological disorders were present and regulated in NHPs. A gene involved in dopamine metabolism (catechol-O-methyltransferase) was absent in macaque and marmoset. Glutamate receptor 2 was upregulated, and transcription-associated genes were down-regulated in NHPs compared with humans. We demonstrate that transcript profiling of NHPs could provide comparative genomic data to validate and better focus experimental animal models of human neurological disorders.	Univ Kuopio, AI Virtanen Inst, Funct Genom & Bioinformat Lab, Dept Neurobiol, FIN-70211 Kuopio, Finland; Aventis Pharma, Dept Neudegenerat Dis, F-94400 Vitry Sur Seine, France; CNRS, UMR 5543, Dept Neurophysiol, F-33076 Bordeaux, France; Biomed Primate Res Ctr, NL-2280 Rijswijk, Netherlands	University of Eastern Finland; Sanofi-Aventis; Sanofi France; Centre National de la Recherche Scientifique (CNRS)	Wong, G (corresponding author), Univ Kuopio, AI Virtanen Inst, Funct Genom & Bioinformat Lab, Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland.	garry.wong@uku.fi	Bontrop, Ronald E./D-4844-2011; Bezard, Erwan/A-8173-2008; Bezard, Erwan/ABD-5153-2021; Bontrop, Ronald E/J-3628-2012	Bontrop, Ronald E/0000-0003-0874-6467; Bezard, Erwan/0000-0002-0410-4638				Barros M, 2002, NEUROSCI BIOBEHAV R, V26, P187, DOI 10.1016/S0149-7634(01)00064-1; Bezard E, 2001, J NEUROSCI, V21, P6853, DOI 10.1523/JNEUROSCI.21-17-06853.2001; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546; Chen FC, 2001, AM J HUM GENET, V68, P444, DOI 10.1086/318206; Chu L., 2001, GENOME INFO, V12, P227; DOUDET D, 1985, BRAIN RES, V335, P194, DOI 10.1016/0006-8993(85)90294-X; Duyckaerts C, 1997, NEUROBIOL AGING, V18, P267, DOI 10.1016/S0197-4580(97)80306-5; Emerich DF, 1997, NATURE, V386, P395, DOI 10.1038/386395a0; Enard W, 2002, SCIENCE, V296, P340, DOI 10.1126/science.1068996; ERWIN J, 1995, NONHUMAN PRIMATES BI, P117; FERRARI G, 1994, J ACQ IMMUN DEF SYND, V7, P325; Ghosh KK, 2001, J NEUROSCI, V21, P8636, DOI 10.1523/JNEUROSCI.21-21-08636.2001; Goodman M, 1998, MOL PHYLOGENET EVOL, V9, P585, DOI 10.1006/mpev.1998.0495; GOODMAN M, 1990, J MOL EVOL, V30, P260, DOI 10.1007/BF02099995; Hacia JG, 1998, NAT GENET, V18, P155, DOI 10.1038/ng0298-155; Hendrickx AG, 2000, HUM EXP TOXICOL, V19, P219, DOI 10.1191/096032700678815756; HERKENHAM M, 1991, NEUROSCIENCE, V40, P133, DOI 10.1016/0306-4522(91)90180-V; Hof PR, 2002, BRAIN RES, V928, P175, DOI 10.1016/S0006-8993(01)03345-5; IMAI H, 1988, BRAIN RES, V474, P327, DOI 10.1016/0006-8993(88)90446-5; KATZ JL, 1991, PSYCHOPHARMACOLOGY, V103, P33, DOI 10.1007/BF02244070; Kendall AL, 2000, BRAIN, V123, P1442, DOI 10.1093/brain/123.7.1442; Khan J, 1999, BIOCHIM BIOPHYS ACTA, V1423, P17; KING FA, 1988, SCIENCE, V240, P1475, DOI 10.1126/science.3287624; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Lane MA, 2000, EXP GERONTOL, V35, P533, DOI 10.1016/S0531-5565(00)00102-9; LANGSTON JW, 1984, BRAIN RES, V292, P390; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; McMurray DN, 2000, CLIN INFECT DIS, V30, pS210, DOI 10.1086/313885; Nathanson N, 1999, J MED PRIMATOL, V28, P146, DOI 10.1111/j.1600-0684.1999.tb00263.x; Nathanson N, 1999, AIDS, V13, pS113; Ollomo B, 1997, AM J TROP MED HYG, V56, P440, DOI 10.4269/ajtmh.1997.56.440; Osada N, 2001, GENE, V275, P31, DOI 10.1016/S0378-1119(01)00665-5; OSADA N, 2002, GENOME BIOL, V3; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; Price DL, 1991, BRAIN PATHOL, V1, P287, DOI 10.1111/j.1750-3639.1991.tb00672.x; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Sibal L R, 2001, ILAR J, V42, P74; SIBLEY CG, 1990, J MOL EVOL, V30, P202, DOI 10.1007/BF02099992; SIBLEY CG, 1984, J MOL EVOL, V20, P2, DOI 10.1007/BF02101980; SIBLEY CG, 1987, J MOL EVOL, V26, P99, DOI 10.1007/BF02111285; Varki A, 2000, GENOME RES, V10, P1065, DOI 10.1101/gr.10.8.1065; WENK GL, 1993, BEHAV BRAIN RES, V57, P117, DOI 10.1016/0166-4328(93)90127-C; ZOU J, 2002, GENOME BIOL, V3	45	60	62	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					929	+		10.1096/fj.02-0681fje	http://dx.doi.org/10.1096/fj.02-0681fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626435				2022-12-28	WOS:000181892600017
J	Carrillo-Vico, A; Garcia-Maurino, S; Calvo, JR; Guerrero, JM				Carrillo-Vico, A; Garcia-Maurino, S; Calvo, JR; Guerrero, JM			Melatonin counteracts the inhibitory effect of PGE(2) on IL-2 production in human lymphocytes via its mt1 membrane receptor	FASEB JOURNAL			English	Article						neuroimmunomodulation; cytokines; melatonin receptor; immune system	PROTEIN-KINASE-C; PINEAL-GLAND; NUCLEAR RECEPTOR; IMMUNE-SYSTEM; HUMAN INTERLEUKIN-2; HORMONE MELATONIN; ELEVATING AGENTS; GENE-EXPRESSION; HUMAN MONOCYTES; DOWN-REGULATION	It is well known that melatonin plays a fundamental role in human neuro-immunomodulation. Thus, melatonin regulates the production of a large number of cytokines, including interleukin-2 (IL-2) in the human system. Both membrane and nuclear receptors for melatonin are present in lymphoid cells. However, most of these effects have been shown to be mediated by the putative nuclear receptor for the neurohormone. In this paper, we show that prostaglandin E-2 (PGE(2)), a potent inflammatory mediator, inhibits IL-2 production in human lymphocytes by a cyclic AMP (cAMP)-dependent mechanism. In this model, melatonin counteracts the effects of PGE(2) on IL-2 and cAMP production. We propose that the effect of melatonin is mediated by a membrane receptor, since similar results were obtained when cells were cultured in the presence of S 20098, a specific melatonin membrane receptor agonist. No effect was observed by using CGP 52608, a nuclear receptor agonist. Moreover, when cells were stimulated with phorbol myristate acetate (PMA), which has been shown to inhibit mt1 melatonin membrane receptor expression, the neurohormone failed to counteract the effect of PGE(2). Therefore, we postulate, for the first time, a physiological role of the mt1 melatonin membrane receptor in the human immune system.	Univ Seville, Sch Med, Dept Med Biochem & Mol Biol, E-41009 Seville, Spain; Virgen Macarena Hosp, Seville 41009, Spain	University of Sevilla; Hospital Universitario Virgen Macarena	Guerrero, JM (corresponding author), Univ Seville, Sch Med, Dept Med Biochem & Mol Biol, Avda Sanchez Pizjuan 4, E-41009 Seville, Spain.	guerrero@us.es	García-Mauriño, Sofía/E-6707-2010; Guerrero, Josep M./D-5519-2014; Carrillo-Vico, Antonio/K-5265-2014; Guerrero, Josep M./Y-2929-2019; Calvo, Juan R./A-7338-2017; IBIS, NEUROINMUNO/O-9306-2015	García-Mauriño, Sofía/0000-0002-7698-5112; Guerrero, Josep M./0000-0001-5236-4592; Carrillo-Vico, Antonio/0000-0002-8516-0999; Calvo, Juan R./0000-0002-4854-2963; Guerrero, Juan Miguel/0000-0001-7553-0119				ANASTASSIOU ED, 1992, J IMMUNOL, V148, P2845; Barjavel MJ, 1998, J IMMUNOL, V160, P1191; Barrett P, 1998, ENDOCRINOLOGY, V139, P163, DOI 10.1210/en.139.1.163; BENITEZKING G, 1993, LIFE SCI, V53, P201, DOI 10.1016/0024-3205(93)90670-X; Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P77; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOMBO LL, 1992, IMMUNOL LETT, V33, P123, DOI 10.1016/0165-2478(92)90035-M; Cos S, 1998, CANCER RES, V58, P4383; CSABA G, 1975, ENDOCRINOL EXP, V9, P59; DELGOBBO V, 1989, INT J IMMUNOPHARMACO, V11, P567, DOI 10.1016/0192-0561(89)90187-2; DEPREUX P, 1994, J MED CHEM, V37, P3231, DOI 10.1021/jm00046a006; DUBOCOVICH ML, 1995, TRENDS PHARMACOL SCI, V16, P50, DOI 10.1016/S0165-6147(00)88978-6; Fehniger TA, 2002, CYTOKINE GROWTH F R, V13, P169, DOI 10.1016/S1359-6101(01)00021-1; Felli MP, 1996, CELL IMMUNOL, V172, P229, DOI 10.1006/cimm.1996.0237; Garcia-Maurino S, 2000, J PINEAL RES, V29, P129, DOI 10.1034/j.1600-079X.2000.290301.x; Garcia-Maurino S, 1998, J NEUROIMMUNOL, V92, P76, DOI 10.1016/S0165-5728(98)00179-9; Garcia-Maurino S, 1999, LIFE SCI, V65, P2143, DOI 10.1016/S0024-3205(99)00479-8; GarciaMaurino S, 1997, J IMMUNOL, V159, P574; GarciaPerganeda A, 1997, J IMMUNOL, V159, P3774; Gilad E, 1997, ENDOCRINOLOGY, V138, P4255, DOI 10.1210/en.138.10.4255; GIORDANO M, 1991, J PINEAL RES, V10, P117, DOI 10.1111/j.1600-079X.1991.tb00827.x; GONZALEZHABA MG, 1995, FASEB J, V9, P1331, DOI 10.1096/fasebj.9.13.7557023; GOODWIN JS, 1980, CLIN IMMUNOL IMMUNOP, V15, P106, DOI 10.1016/0090-1229(80)90024-0; GOTO T, 1983, J IMMUNOL, V130, P1350; GUERRERO JM, 1992, ENDOCR RES, V18, P91, DOI 10.1080/07435809209035401; Guerrero Juan M., 2002, Current Topics in Medicinal Chemistry, V2, P167, DOI 10.2174/1568026023394335; HILKENS CMU, 1995, EUR J IMMUNOL, V25, P59, DOI 10.1002/eji.1830250112; Kolenko V, 1999, BLOOD, V93, P2308, DOI 10.1182/blood.V93.7.2308.407k16_2308_2318; LEWIS VM, 1978, J CLIN ENDOCR METAB, V47, P145, DOI 10.1210/jcem-47-1-145; MAESTRONI GJM, 1986, J NEUROIMMUNOL, V13, P19, DOI 10.1016/0165-5728(86)90047-0; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; Miller RA, 1996, SCIENCE, V273, P70, DOI 10.1126/science.273.5271.70; MINAKUCHI R, 1990, J IMMUNOL, V145, P2616; MOCCHEGIANI E, 1994, J NEUROIMMUNOL, V53, P189, DOI 10.1016/0165-5728(94)90029-9; Molinero P, 2000, J NEUROIMMUNOL, V103, P180, DOI 10.1016/S0165-5728(99)00237-4; MORREY KM, 1994, J IMMUNOL, V153, P2671; Nelson RJ, 2000, ANN NY ACAD SCI, V917, P404; Nosjean O, 2000, J BIOL CHEM, V275, P31311, DOI 10.1074/jbc.M005141200; Paliogianni F, 1996, CELL IMMUNOL, V171, P95, DOI 10.1006/cimm.1996.0178; PELUS LM, 1977, LIFE SCI, V20, P903, DOI 10.1016/0024-3205(77)90274-0; RAPPAPORT RS, 1982, J EXP MED, V155, P943, DOI 10.1084/jem.155.3.943; Reiter R J, 1997, Adv Pharmacol, V38, P103; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; REITER RJ, 1992, BIOESSAYS, V14, P169, DOI 10.1002/bies.950140307; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; SkwarloSonta K, 1996, ACTA NEUROBIOL EXP, V56, P341; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; Straub RH, 2000, J NEUROIMMUNOL, V109, P10, DOI 10.1016/S0165-5728(00)00296-4; WALDHAUSER F, 1988, J CLIN ENDOCR METAB, V66, P648, DOI 10.1210/jcem-66-3-648; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327	52	94	102	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					755	+		10.1096/fj.02-0501fje	http://dx.doi.org/10.1096/fj.02-0501fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594180				2022-12-28	WOS:000181456900002
J	Zhu, YH; Jin, KL; Mao, XO; Greenberg, DA				Zhu, YH; Jin, KL; Mao, XO; Greenberg, DA			Vascular endothelial growth factor promotes proliferation of cortical neuron precursors by regulating E2F expression	FASEB JOURNAL			English	Article						neurogenesis; VEGF; transcription factors	NEUROGENESIS IN-VITRO; STIMULATES AXONAL OUTGROWTH; GLOBAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; CELL-GROWTH; NEUROTROPHIC FACTOR; HIPPOCAMPAL-NEURONS; PHOSPHATIDYLINOSITOL 3-KINASE; RETINOBLASTOMA PROTEIN; FACTOR RECEPTOR	Neurogenesis, or the production of new neurons, is regulated by physiological and pathological processes including aging, stress, and brain injury. Many mitogenic and trophic factors that regulate proliferation of nonneuronal cells are also involved in neurogenesis. These include vascular endothelial cell growth factor (VEGF), which stimulates the incorporation of bromodeoxyuridine (BrdU) into neuronal precursor cells in vitro and in the adult rat brain in vivo. Using BrdU labeling as an index of cell proliferation, we found that the in vitro neuroproliferative effect of VEGF was associated with up-regulation of E2F family transcription factors, cyclin D1, cyclin E, and cdc25. VEGF also increased nuclear expression of E2F1, E2F2, and E2F3, consistent with regulation of the G(1)/S phase transition of the cell cycle. The proliferative effect of VEGF was inhibited by the extracellular signal-regulated kinase kinase (MEK) inhibitor PD98059, the phospholipase C (PLC) inhibitor U73122, the protein kinase C (PKC) inhibitor GF102390X, and the phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin, indicating involvement of multiple signaling pathways. These findings help to provide a molecular basis for some of the recently identified neuronal effects of VEGF.	Buck Inst Age Res, Novato, CA 94945 USA	Buck Institute for Research on Aging	Greenberg, DA (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	dgreenberg@buckinstitute.org			NINDS NIH HHS [NS-37695] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037695] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Benraiss A, 2001, J NEUROSCI, V21, P6718, DOI 10.1523/JNEUROSCI.21-17-06718.2001; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Cameron HA, 1998, J NEUROBIOL, V36, P287, DOI 10.1002/(SICI)1097-4695(199808)36:2<287::AID-NEU13>3.3.CO;2-E; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; Dolcet X, 1999, J NEUROCHEM, V73, P521, DOI 10.1046/j.1471-4159.1999.0730521.x; Gala S, 2001, BLOOD, V97, P227, DOI 10.1182/blood.V97.1.227; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Hou ST, 2000, J NEUROCHEM, V75, P91, DOI 10.1046/j.1471-4159.2000.0750091.x; Ino H, 2000, MOL BRAIN RES, V78, P163, DOI 10.1016/S0169-328X(00)00092-9; Jin K, 2002, J CLIN INVEST, V110, P311, DOI 10.1172/JCI200215251; Jin KL, 2000, NEUROSCIENCE, V100, P713, DOI 10.1016/S0306-4522(00)00331-6; Jin KL, 2000, J MOL NEUROSCI, V14, P197, DOI 10.1385/JMN:14:3:197; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Jin KL, 2002, J NEUROSCI, V22, P5365; Jin KL, 2002, J NEUROCHEM, V80, P119, DOI 10.1046/j.0022-3042.2001.00678.x; Jin KL, 2001, ANN NEUROL, V50, P93, DOI 10.1002/ana.1073; Jones SM, 2000, ONCOGENE, V19, P5558, DOI 10.1038/sj.onc.1203858; Kawabe T, 2002, ONCOGENE, V21, P1717, DOI 10.1038/sj.onc.1205229; KIRSCHENBAUM B, 1995, P NATL ACAD SCI USA, V92, P210, DOI 10.1073/pnas.92.1.210; Laird AD, 2000, CANCER RES, V60, P4152; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Lee JK, 2000, DEV DYNAM, V217, P361, DOI 10.1002/(SICI)1097-0177(200004)217:4<361::AID-DVDY3>3.0.CO;2-8; Lennmyr F, 1998, J NEUROPATH EXP NEUR, V57, P874, DOI 10.1097/00005072-199809000-00009; Liu JL, 1998, J NEUROSCI, V18, P7768; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; Matsuzaki H, 2001, FASEB J, V15, P1218, DOI 10.1096/fj.00-0495fje; Melder RJ, 1996, NAT MED, V2, P992, DOI 10.1038/nm0996-992; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Nicot A, 2001, P NATL ACAD SCI USA, V98, P4758, DOI 10.1073/pnas.071465398; NOWAKOWSKI RS, 1989, J NEUROCYTOL, V18, P311, DOI 10.1007/BF01190834; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Parent JM, 1997, J NEUROSCI, V17, P3727; PARK JE, 1994, J BIOL CHEM, V269, P25646; Pedram A, 2001, ENDOCRINOLOGY, V142, P1578, DOI 10.1210/en.142.4.1578; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Pencea V, 2001, J NEUROSCI, V21, P6706, DOI 10.1523/JNEUROSCI.21-17-06706.2001; Rakic P, 2002, NAT REV NEUROSCI, V3, P65, DOI 10.1038/nrn700; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Silverman WF, 1999, NEUROSCIENCE, V90, P1529, DOI 10.1016/S0306-4522(98)00540-5; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499; TERMAN BI, 1991, ONCOGENE, V6, P1677; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Wagner JP, 1999, J NEUROSCI, V19, P6006, DOI 10.1523/JNEUROSCI.19-14-06006.1999; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Xiang H, 1996, J NEUROSCI, V16, P6753; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang XJ, 1996, J NEUROSCI, V16, P6089; Yoshikawa K, 2000, NEUROSCI RES, V37, P1, DOI 10.1016/S0168-0102(00)00101-2; Yourey PA, 2000, J NEUROSCI, V20, P6781, DOI 10.1523/JNEUROSCI.20-18-06781.2000; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200; Zigova T, 1998, MOL CELL NEUROSCI, V11, P234, DOI 10.1006/mcne.1998.0684	69	142	151	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					186	193		10.1096/fj.02-0515com	http://dx.doi.org/10.1096/fj.02-0515com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554697				2022-12-28	WOS:000181456900043
J	Joussen, AM; Poulaki, V; Mitsiades, N; Cai, WY; Suzuma, I; Pak, J; Ju, ST; Rook, SL; Esser, P; Mitsiades, C; Kirchhof, B; Adamis, AP; Aiello, LP				Joussen, AM; Poulaki, V; Mitsiades, N; Cai, WY; Suzuma, I; Pak, J; Ju, ST; Rook, SL; Esser, P; Mitsiades, C; Kirchhof, B; Adamis, AP; Aiello, LP			Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes	FASEB JOURNAL			English	Article						diabetic retinopathy; apoptosis; leukocyte adhesion	ADHESION MOLECULE-1; VASCULAR-PERMEABILITY; DOWN-REGULATION; LIGAND; EXPRESSION; DEATH; LEUKOSTASIS; MECHANISM; MEMBER	Diabetic macular edema, resulting from increased microvascular permeability, is the most prevalent cause of vision loss in diabetes. The mechanisms underlying this complication remain poorly understood. In the current study, diabetic vascular permeability (blood-retinal barrier breakdown) is demonstrated to result from a leukocyte-mediated Fas-FasL-dependent apoptosis of the retinal vasculature. Following the onset of streptozotocin-induced diabetes, FasL expression was increased in rat neutrophils (P<0.005) and was accompanied by a simultaneous increase in Fas expression in the retinal vasculature. Static adhesion assays demonstrated that neutrophils from diabetic, but not control, rats induced endothelial cell apoptosis in vitro (P<0.005). The latter was inhibited via an antibody-based FasL blockade (P<0.005). In vivo, the inhibition of FasL potently reduced retinal vascular endothelial cell injury, apoptosis, and blood-retinal barrier breakdown (P<0.0001) but did not diminish leukocyte adhesion to the diabetic retinal vasculature. Taken together, these data are the first to identify leukocyte-mediated Fas-FasL-dependent retinal endothelial cell apoptosis as a major cause of blood-retinal barrier breakdown in early diabetes. These data imply that the targeting of the Fas-FasL pathway may prove beneficial in the treatment of diabetic retinopathy.	Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, D-50931 Cologne, Germany; Univ Cologne, Ctr Mol Med ZMMK, D-50931 Cologne, Germany; Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Res Inst, Boston, MA 02114 USA; Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Surg Res Labs, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02215 USA	University of Cologne; University of Cologne; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Joussen, AM (corresponding author), Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.	JoussenA@aol.com; tony_adamis@meei.harvard.edu	Joussen, Antonia/AAA-6901-2022					Antonetti DA, 1998, DIABETES, V47, P1953, DOI 10.2337/diabetes.47.12.1953; Barber AJ, 1998, J CLIN INVEST, V102, P783, DOI 10.1172/JCI2425; Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153; Cardier JE, 1999, FASEB J, V13, P1950, DOI 10.1096/fasebj.13.14.1950; Carley William W., 1996, Microcirculation (Philadelphia), V3, P359, DOI 10.3109/10739689609148308; Choi C, 1999, J IMMUNOL, V162, P1889; DODGE AB, 1991, COMP BIOCHEM PHYS B, V98, P461, DOI 10.1016/0305-0491(91)90240-E; Gregoli PA, 1999, J CELL PHYSIOL, V178, P133, DOI 10.1002/(SICI)1097-4652(199902)178:2<133::AID-JCP2>3.3.CO;2-X; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Harwood FG, 2000, J BIOL CHEM, V275, P10023, DOI 10.1074/jbc.275.14.10023; Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; KLEIN R, 1984, OPHTHALMOLOGY, V91, P1; Koeplinger KA, 2000, PROTEIN EXPRES PURIF, V18, P378, DOI 10.1006/prep.2000.1205; Kraling BM, 1998, IN VITRO CELL DEV-AN, V34, P308; MCLEOD DS, 1995, AM J PATHOL, V147, P642; Mitsiades N, 1998, J CLIN ENDOCR METAB, V83, P2199, DOI 10.1210/jc.83.6.2199; Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836; Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4; Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746; Nakayama M, 2002, DIABETES, V51, P1391, DOI 10.2337/diabetes.51.5.1391; Ohta N, 1999, J DIABETES COMPLICAT, V13, P151, DOI 10.1016/S1056-8727(99)00040-9; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; POULAKI V, 2002, IN PRESS EXP EYE RES; Rawson RA, 1943, AM J PHYSIOL, V138, P0708, DOI 10.1152/ajplegacy.1943.138.5.708; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; SCHRODER S, 1991, AM J PATHOL, V139, P81; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Walsh K, 1999, MOL MED TODAY, V5, P61, DOI 10.1016/S1357-4310(98)01415-4	29	138	159	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					76	+		10.1096/fj.02-0157fje	http://dx.doi.org/10.1096/fj.02-0157fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475915				2022-12-28	WOS:000180218500021
J	Bernassola, F; Federici, M; Corazzari, M; Terrinoni, A; Hribal, ML; De Laurenzi, V; Ranalli, M; Massa, O; Sesti, G; Mclean, WHI; Citro, G; Barbetti, F; Melino, G				Bernassola, F; Federici, M; Corazzari, M; Terrinoni, A; Hribal, ML; De Laurenzi, V; Ranalli, M; Massa, O; Sesti, G; Mclean, WHI; Citro, G; Barbetti, F; Melino, G			Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MODY patient	FASEB JOURNAL			English	Article						insulin; diabetes; mature; onset diabetes of the young	TYPE-2 DIABETES-MELLITUS; HUMAN PANCREATIC-ISLETS; TISSUE TRANSGLUTAMINASE; INSULIN-SECRETION; BINDING-PROTEINS; BETA-CELLS; APOPTOSIS; RELEASE; YOUNG; GENE	Transglutaminase 2 (TGase 2) is a Ca+2-dependent enzyme that catalyzes both intracellular and extracellular cross-linking reactions by transamidation of specific glutamine residues. TGase 2 is known to be involved in the membrane-mediated events required for glucose-stimulated insulin release from the pancreatic beta cells. Here we show that targeted disruption of TGase 2 impairs glucose-stimulated insulin secretion. TGase 2(-/-) mice show glucose intolerance after intraperitoneal glucose loading. TGase 2(-/-) mice manifest a tendency to develop hypoglycemia after administration of exogenous insulin as a consequence of enhanced insulin receptor substrate 2 (IRS-2) phosphorylation. We suggest that the increased peripheral sensitivity to insulin partially compensates for the defective secretion in this animal model. TGase 2(-/-) mouse phenotype resembles that of the maturity-onset diabetes of young (MODY) patients. In the course of screening for human TGase 2 gene in Italian subjects with the clinical features of MODY, we detected a missense mutation (N333S) in the active site of the enzyme. Collectively, these results identify TGase 2 as a potential candidate gene in type 2 diabetes.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Biochem Lab, IDI IRCCS, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Internal Med, I-00133 Rome, Italy; IBCIT, I-00144 Rome, Italy; Univ Catanzaro Magna Grecia, Dept Clin & Expt Med, I-88100 Catanzaro, Italy; Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Human Genet Unit,Epithelial Genet Grp, Dundee DD1 9SY, Scotland; IFO, Ist Regina Elena Inst, SSD SAFU, Rome, Italy; IRCCS Bambino Gesu Childrens Hosp, I-00165 Rome, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of Rome Tor Vergata; Magna Graecia University of Catanzaro; University of Dundee; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Bambino Gesu	Melino, G (corresponding author), Univ Roma Tor Vergata, Dept Expt Med, Biochem Lab, IDI IRCCS, D26-F153,Via Tor Vergata 135, I-00133 Rome, Italy.	gerry.melino@uniroma2.it	Sesti, Giorgio/B-1509-2012; TERRINONI, Alessandro/J-1533-2012; Barbetti, Fabrizio/AAK-9106-2021; McLean, William HI/C-6352-2009; Corazzari, Marco/B-4631-2019; Corazzari, Marco/K-6422-2016; Corazzari, Marco/J-5825-2019; Barbetti, Fabrizio/I-7351-2018; Federici, Massimo/G-9940-2012; De Laurenzi, Vincenzo/K-7471-2016	TERRINONI, Alessandro/0000-0002-7442-2252; Barbetti, Fabrizio/0000-0003-4687-980X; Corazzari, Marco/0000-0002-6246-5968; Corazzari, Marco/0000-0002-6246-5968; Corazzari, Marco/0000-0002-6246-5968; Barbetti, Fabrizio/0000-0003-4687-980X; Federici, Massimo/0000-0003-4989-5194; McLean, William Henry Irwin/0000-0001-5539-5757; De Laurenzi, Vincenzo/0000-0002-7506-1743; Sesti, Giorgio/0000-0002-1618-7688	Telethon [E.0946, E.1224, E.0872, E.1257] Funding Source: Medline	Telethon(Fondazione Telethon)		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; Almind K, 2001, NAT MED, V7, P277, DOI 10.1038/85405; BALDWIN D, 1980, P NATL ACAD SCI-BIOL, V77, P5975, DOI 10.1073/pnas.77.10.5975; BERNTORP E, 1987, DIABETES RES CLIN EX, V5, P29; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; BUNGAY PJ, 1986, BIOCHEM J, V235, P269, DOI 10.1042/bj2350269; CHRISTESEN HBT, 2002, IN PRESS DIABETES; Clement S, 1998, J BIOL CHEM, V273, P7604, DOI 10.1074/jbc.273.13.7604; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; Driscoll HK, 1997, PANCREAS, V15, P69, DOI 10.1097/00006676-199707000-00010; Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168; Federici M, 2001, FASEB J, V15, P22; Gerich JE, 1998, ENDOCR REV, V19, P491, DOI 10.1210/er.19.4.491; GOMIS R, 1983, BIOCHIM BIOPHYS ACTA, V760, P384, DOI 10.1016/0304-4165(83)90378-1; Gomis R, 1986, Adv Exp Med Biol, V211, P443; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; Hansen L, 2000, J CLIN ENDOCR METAB, V85, P1323, DOI 10.1210/jc.85.3.1323; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; Kahn CR, 1996, ANNU REV MED, V47, P509; Kowluru A, 1996, J CLIN INVEST, V98, P540, DOI 10.1172/JCI118822; Kulkarni RN, 1997, J CLIN INVEST, V100, P2729, DOI 10.1172/JCI119818; Lauro D, 1998, NAT GENET, V20, P294, DOI 10.1038/3112; Massa O, 2001, DIABETOLOGIA, V44, P898; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Melino G, 2000, METHOD ENZYMOL, V322, P433; Nagy L, 1997, CELL DEATH DIFFER, V4, P534, DOI 10.1038/sj.cdd.4400290; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Njolstad PR, 2001, NEW ENGL J MED, V344, P1588, DOI 10.1056/NEJM200105243442104; Piredda L, 1999, FASEB J, V13, P355, DOI 10.1096/fasebj.13.2.355; Porzio O, 1999, J CLIN INVEST, V104, P357, DOI 10.1172/JCI5870; Prisco F, 2000, DIABETOLOGIA, V43, P1331; SENER A, 1985, ENDOCRINOLOGY, V117, P237, DOI 10.1210/endo-117-1-237; TREJOSKALLI AV, 1995, P NATL ACAD SCI USA, V92, P8940, DOI 10.1073/pnas.92.19.8940; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116	39	93	97	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2002	16	11					1371	1378		10.1096/fj.01-0689com	http://dx.doi.org/10.1096/fj.01-0689com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12205028				2022-12-28	WOS:000178441800011
J	Holmuhamedov, E; Lewis, L; Bienengraeber, M; Holmuhamedova, M; Jahangir, A; Terzic, A				Holmuhamedov, E; Lewis, L; Bienengraeber, M; Holmuhamedova, M; Jahangir, A; Terzic, A			Suppression of human tumor cell proliferation through mitochondrial targeting	FASEB JOURNAL			English	Article						mitochondrial DNA; calcium release-activated calcium channels; diazoxide; cancer	OXIDATIVE-PHOSPHORYLATION; CALCIUM; ACTIVATION; CHANNELS; MECHANISMS; RETICULUM; DIAZOXIDE; CYCLE; FLOW	Intracellular calcium signaling plays a central role in cell proliferation. In leukemic cells, the calcium release-activated calcium channels provide a major pathway for calcium entry (I-CRAC) perpetuating progression through the cell cycle. Although I-CRAC is under mitochondrial regulation, targeting mitochondrial function has not been exploited to control malignant cell growth. The benzothiadiazine diazoxide, which depolarized respiration-dependent mitochondrial membrane potential, reduced the rate of proliferation and arrested human acute leukemic T cells in the G0/G1 phase. Diazoxide did not alter cellular energetics, but rather inhibited the mitochondria-controlled I-CRAC and reduced calcium influx into tumor cells. The antiproliferative action of diazoxide was mimicked by removal of extracellular calcium or by the tyrphostin A9, an I-CRAC inhibitor. Deletion of the mitochondrial genome, which encodes essential respiratory chain enzyme subunits, attenuated the inhibitory effect of diazoxide on I-CRAC-mediated calcium influx and cell proliferation. Thus, manipulation of mitochondrial function and associated calcium signaling provides a basis for a novel anticancer strategy.	Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Expt Therapeut, Div Cardiovasc Dis, Rochester, MN 55905 USA; Dartmouth Coll Sch Med, Dept Med, Clin Pharmacol Sect, Lebanon, NH USA; Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Dartmouth College; Dartmouth College	Terzic, A (corresponding author), Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Guggenheim 7, Rochester, MN 55905 USA.	terzic.andre@mayo.edu	Jahangir, Arshad/M-7916-2016; Holmuhamedov, Ekhson L/P-5228-2016	Holmuhamedov, Ekhson L/0000-0002-0809-350X				ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Bonin A, 2000, J LIPID RES, V41, P277; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; CIAPA B, 1994, NATURE, V368, P875, DOI 10.1038/368875a0; DIPPENAAR NG, 1982, BIOCHEM J, V202, P731, DOI 10.1042/bj2020731; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DOLMETSCH RE, 1998, NATURE, V392, P863; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Dzeja PP, 2001, CIRC RES, V89, P744, DOI 10.1161/res.89.9.744; Garlid KD, 1996, J BIOL CHEM, V271, P8796, DOI 10.1074/jbc.271.15.8796; Gilabert JA, 2000, EMBO J, V19, P6401, DOI 10.1093/emboj/19.23.6401; Gross GJ, 2000, CIRC RES, V87, P431; Holmuhamedov EL, 1999, J PHYSIOL-LONDON, V519, P347, DOI 10.1111/j.1469-7793.1999.0347m.x; Holmuhamedov EL, 1998, AM J PHYSIOL-HEART C, V275, pH1567, DOI 10.1152/ajpheart.1998.275.5.H1567; Holmuhamedov EL, 2001, MOL CELL BIOCHEM, V220, P135, DOI 10.1023/A:1010894427373; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Hoth M, 2000, P NATL ACAD SCI USA, V97, P10607, DOI 10.1073/pnas.180143997; Jaconi M, 2000, MOL BIOL CELL, V11, P1845, DOI 10.1091/mbc.11.5.1845; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; Makowska A, 2000, EUR J BIOCHEM, V267, P877, DOI 10.1046/j.1432-1327.2000.01066.x; Morais R, 1996, Methods Enzymol, V264, P296, DOI 10.1016/S0076-6879(96)64028-2; Ozcan C, 2001, J THORAC CARDIOV SUR, V121, P298, DOI 10.1067/mtc.2001.111421; Parekh AB, 1998, J BIOL CHEM, V273, P14925, DOI 10.1074/jbc.273.24.14925; Putney JW, 2001, J CELL SCI, V114, P2223; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; SCHAFER G, 1969, BIOCHEM PHARMACOL, V18, P2678; Sweet S, 1999, J CELL PHYSIOL, V180, P91, DOI 10.1002/(SICI)1097-4652(199907)180:1<91::AID-JCP10>3.0.CO;2-6; Troiano L, 1998, EXP CELL RES, V241, P384, DOI 10.1006/excr.1998.4064; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596	37	59	64	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1010	1016		10.1096/fj.01-0996com	http://dx.doi.org/10.1096/fj.01-0996com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087062				2022-12-28	WOS:000177813100032
J	Linhart, B; Jahn-Schmid, B; Verdino, P; Keller, W; Ebner, C; Kraft, D; Valenta, R				Linhart, B; Jahn-Schmid, B; Verdino, P; Keller, W; Ebner, C; Kraft, D; Valenta, R			Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity	FASEB JOURNAL			English	Article						allergy; recombinant allergen; specific immunotherapy	ANTIGEN-PRESENTING CELLS; PHLEUM-PRATENSE POLLEN; FC-EPSILON-RI; HAPTEN ANTIBODY RESPONSES; HUMAN IMMUNE-RESPONSE; PERENNE RYE POLLEN; GROUP-I ALLERGENS; LOL-P-I; IGE ANTIBODIES; MAJOR ALLERGEN	Most of the 400 million grass pollen-allergic patients worldwide are co-sensitized to several unrelated grass pollen allergens. Based on frequent co-sensitization patterns determined in 200 grass pollen-allergic patients, three recombinant hybrid molecules were developed by polymerase chain reaction-based mending of cDNAs coding for the major timothy grass pollen allergens (Ph1 p 1, Ph1 p 2, Ph1 p 5, Ph1 p 6) for vaccination against grass pollen allergy. The hybrids rP2-P6, rP6-P2, and rP5-P1 contained most of the epitopes of natural grass pollen extract and induced stronger lymphoproliferative responses in cultured mononuclear cells of grass pollen-allergic patients than did equimolar mixtures of the individual allergens. Immunization of mice with the hybrids yielded higher antibody titers than did immunization with the individual allergen components or grass pollen extract, which suggests that the individual components of the hybrids can serve as molecular scaffolds for each other to enhance their immunogenicity. Antibodies induced with the hybrids in mice inhibited the binding of grass pollen-allergic patients' immunoglobulin E to each of the individual allergens and grass pollen extract and may thus represent protective antibodies. The principle of increasing the immunogenicity of antigens by engineering hybrids thereof may be applied not only for the treatment of polysensitized allergic patients but also for general vaccine development.	Univ Vienna, Sch Med, AKH,Mol Immunopathol Grp, Vienna Gen Hosp,Dept Pathophysiol, A-1090 Vienna, Austria; Karl Franzens Univ Graz, Inst Chem, Graz, Austria	University of Vienna; University of Graz	Valenta, R (corresponding author), Univ Vienna, Sch Med, AKH,Mol Immunopathol Grp, Vienna Gen Hosp,Dept Pathophysiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	Rudolf.valenta@akh-wien.ac.at	Keller, Walter/AAW-1501-2021	Keller, Walter/0000-0002-2261-958X; Linhart, Birgit/0000-0001-6857-3049; Valenta, Rudolf/0000-0001-5944-3365				Akdis CA, 1998, EUR J IMMUNOL, V28, P914, DOI 10.1002/(SICI)1521-4141(199803)28:03<914::AID-IMMU914>3.0.CO;2-C; Ball T, 1999, FASEB J, V13, P1277, DOI 10.1096/fasebj.13.11.1277; Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; Bieber T, 1996, CURR OPIN IMMUNOL, V8, P773, DOI 10.1016/S0952-7915(96)80003-3; BITOH S, 1993, CELL IMMUNOL, V150, P168, DOI 10.1006/cimm.1993.1188; BOAK J L, 1971, European Journal of Immunology, V1, P63, DOI 10.1002/eji.1830010202; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK WW, 1975, J EXP MED, V142, P275, DOI 10.1084/jem.142.2.275; De Marino S, 1999, STRUCT FOLD DES, V7, P943; DOLECEK C, 1993, FEBS LETT, V335, P299, DOI 10.1016/0014-5793(93)80406-K; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J IMMUNOL, V154, P1932; FERNANDEZRIVAS M, 2000, REGULATORY CONTROL S, P131; Flicker S, 2000, J IMMUNOL, V165, P3849, DOI 10.4049/jimmunol.165.7.3849; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FOCKE M, 2001, FASEB J; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; FREIDHOFF LR, 1987, J ALLERGY CLIN IMMUN, V80, P646, DOI 10.1016/0091-6749(87)90283-1; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; George-Chandy A, 2001, INFECT IMMUN, V69, P5716, DOI 10.1128/IAI.69.9.5716-5725.2001; Hales BJ, 2000, CLIN EXP ALLERGY, V30, P927, DOI 10.1046/j.1365-2222.2000.00900.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holzinger A, 1996, BIOTECHNIQUES, V20, P804; Hoyne GF, 1999, INT ARCH ALLERGY IMM, V118, P122, DOI 10.1159/000024046; KATZ DH, 1970, J EXP MED, V132, P261, DOI 10.1084/jem.132.2.261; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Laffer S, 1996, J ALLERGY CLIN IMMUN, V98, P652, DOI 10.1016/S0091-6749(96)70099-4; LARSEN JN, 1999, ALLERGENS ALLERGEN I, P297; LECLERC C, 1993, MOL IMMUNOL, V30, P1561, DOI 10.1016/0161-5890(93)90447-J; MITCHISON N A, 1971, European Journal of Immunology, V1, P68, DOI 10.1002/eji.1830010204; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; MYERS KR, 1995, INFECT IMMUN, V63, P168, DOI 10.1128/IAI.63.1.168-174.1995; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258, DOI 10.1016/S0091-6749(98)70391-4; PAUL WE, 1966, J EXP MED, V123, P689, DOI 10.1084/jem.123.4.689; PAUL WE, 1970, J EXP MED, V132, P283, DOI 10.1084/jem.132.2.283; Rossi RE, 2001, ALLERGY, V56, P1180, DOI 10.1034/j.1398-9995.2001.00258.x; Schenk S, 1995, J ALLERGY CLIN IMMUN, V96, P986, DOI 10.1016/S0091-6749(95)70237-7; Stingl G, 1997, INT ARCH ALLERGY IMM, V113, P24, DOI 10.1159/000237499; Suphioglu C, 2000, CLIN EXP ALLERGY, V30, P1335, DOI 10.1046/j.1365-2222.2000.00955.x; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Valenta R, 1999, BIOL CHEM, V380, P815, DOI 10.1515/BC.1999.101; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; VALENTA R, 2001, INFLAMMATORY MECH AL, P495; VANNEERVEN RJJ, 1994, IMMUNOLOGY, V82, P351; VanRee R, 1997, CLIN EXP ALLERGY, V27, P68, DOI 10.1046/j.1365-2222.1997.d01-416.x; VANREE R, 1995, ALLERGY, V50, P281; vanRee R, 1996, ALLERGY, V51, P108, DOI 10.1111/j.1398-9995.1996.tb00043.x; Vrtala S, 1998, J IMMUNOL, V160, P6137; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V98, P913, DOI 10.1016/S0091-6749(96)80007-8; VRTALA S, 1993, J IMMUNOL, V151, P4773; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; Vrtala S, 1999, J IMMUNOL, V163, P5489; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149, DOI 10.1159/000236836	59	60	69	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1301	+		10.1096/fj.01-1012fje	http://dx.doi.org/10.1096/fj.01-1012fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154002				2022-12-28	WOS:000176683900018
J	Lopez-Monteon, A; Ramos-Ligonio, A; Perez-Castillo, L; Talamas-Rohana, P; Rosales-Encina, JL				Lopez-Monteon, A; Ramos-Ligonio, A; Perez-Castillo, L; Talamas-Rohana, P; Rosales-Encina, JL			Specific antibody immune response against the parasitic portion of a glutathione-S-transferase fusion protein	FASEB JOURNAL			English	Article						immunization; antibodies; isotype; induction; humoral response	ALBUMIN-BINDING REGION; CELL-MEDIATED-IMMUNITY; ENTAMOEBA-HISTOLYTICA; RECOMBINANT PROTEIN; ESCHERICHIA-COLI; CYTOKINE PROFILE; IN-VIVO; ANTIGEN; IMMUNIZATION; MICE	The humoral immune response against an Entamoeba histolytica recombinant protein has been investigated. The 628 by Bam HI-Eco RI DNA fragment (L1b) from the M11 cDNA clone, partially coding for a 220 kDa (L220) protein, was ligated in-frame into the pGEX-3X plasmid vector to produce the fusion protein GST-L1b. BALB/c mice were immunized with different doses of the GST-L1b fusion protein (10-500 mug). GST-L1b doses of 100/50/50, 300, or 500 jig induced an antibody response (IgG1 >IgG3, IgG2a>IgG2b) specific for the amoebic part of the fusion protein (L1b). These antibodies were able to recognize the native protein in amoebic total extract. Anti-GST antibodies were not detected. On the other hand, doses of 10/ 10/10 or 200/100/100 mug induced antibodies able to recognize both GST (IgG2a>IgG1>IgG2b) and L1b (IgG1, IgG2a>IgG3>IgG2b). When mice were immunized with GST alone (100/50/50, 300 or 500 jig), antibodies against GST-L1b or GST were not detected. However, GST doses of 10/10/10 or 200/100/100 jig induced an antibody response able to recognize both GST-L1b and GST. We propose that an immunization protocol similar to the one used in this work may allow induction of high antibody titers specific against the parasite segment of a GST-fusion protein.	IPN, CINVESTAV, Dept Expt Pathol, Mexico City 07360, DF, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico	Rosales-Encina, JL (corresponding author), IPN, CINVESTAV, Dept Expt Pathol, Av Inst Politecn Nacl 2508, Mexico City 07360, DF, Mexico.	rosales@mail.cinvestav.mx	Talamás-Rohana, Patricia/AAF-3925-2021	Talamás-Rohana, Patricia/0000-0002-5085-814X; Ramos-Ligonio, Angel/0000-0003-3896-7447				Andersson C, 1999, J IMMUNOL METHODS, V222, P171, DOI 10.1016/S0022-1759(98)00195-1; Andre C I, 1975, Dev Biol Stand, V28, P237; Avramidis N, 2002, VET MICROBIOL, V88, P325, DOI 10.1016/S0378-1135(02)00128-1; BANCROFT AJ, 1994, EUR J IMMUNOL, V24, P3113, DOI 10.1002/eji.1830241230; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; Chaturvedi P, 1996, INT IMMUNOL, V8, P745, DOI 10.1093/intimm/8.5.745; Chowdhury PS, 2001, J IMMUNOL METHODS, V249, P147, DOI 10.1016/S0022-1759(00)00353-7; CONSTANT S, 1995, J IMMUNOL, V154, P4915; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; Daly TM, 1996, INFECT IMMUN, V64, P2602, DOI 10.1128/IAI.64.7.2602-2608.1996; GOLD D, 1990, METHODS ENZYMOLOGY G, V185; HAJISHENGALLIS G, 1995, J IMMUNOL, V154, P4322; HANSSON M, 1994, BIO-TECHNOL, V12, P285, DOI 10.1038/nbt0394-285; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; Jimenez-Delgadillo B, 1997, Arch Med Res, V28 Spec No, P173; KENNEY JS, 1989, J IMMUNOL METHODS, V121, P157, DOI 10.1016/0022-1759(89)90156-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Libon C, 1999, VACCINE, V17, P406, DOI 10.1016/S0264-410X(98)00198-4; Lovgren-Bengtsson K, 1998, METHOD MICROBIOL, V25, P471; MEZA I, 1987, J INFECT DIS, V156, P798, DOI 10.1093/infdis/156.5.798; MURBY M, 1995, EUR J BIOCHEM, V230, P38, DOI 10.1111/j.1432-1033.1995.tb20531.x; MURBY M, 1994, SEPARATIONS BIOTECHN, V3; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; PARISH CR, 1972, J EXP MED, V135, P298, DOI 10.1084/jem.135.2.298; PFEIFFER C, 1991, IMMUNOL REV, V123, P65, DOI 10.1111/j.1600-065X.1991.tb00606.x; PFEIFFER C, 1995, J EXP MED, V181, P1569, DOI 10.1084/jem.181.4.1569; Power CA, 1998, INFECT IMMUN, V66, P5743, DOI 10.1128/IAI.66.12.5743-5750.1998; RENART J, 1979, P NATL ACAD SCI USA, V76, P3116, DOI 10.1073/pnas.76.7.3116; RIGGS P, 1997, CURRENT PROTOCOLS MO, V2; ROSALESENCINA JL, 1987, J INFECT DIS, V156, P790, DOI 10.1093/infdis/156.5.790; Rudolph Rainer, 1996, P283; Sarzotti M, 1996, SCIENCE, V271, P1726, DOI 10.1126/science.271.5256.1726; Sjolander A, 1997, J IMMUNOL METHODS, V201, P115, DOI 10.1016/S0022-1759(96)00217-7; SJOLANDER A, 1993, IMMUNOMETHODS, V2, P79; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITHERS SR, 1989, PARASITE IMMUNOL, V11, P301, DOI 10.1111/j.1365-3024.1989.tb00669.x; TALAMASROHANA P, 1995, INFECT IMMUN, V63, P3953; TEW JG, 1980, IMMUNOL REV, V53, P175; Towbin H, 1992, Biotechnology, V24, P145; TOYE B, 1990, INFECT IMMUN, V58, P3909, DOI 10.1128/IAI.58.12.3909-3913.1990; VARLEY CA, 1992, PARASITE IMMUNOL, V14, P557, DOI 10.1111/j.1365-3024.1992.tb00028.x; Von Seggern DJ, 1999, GENE EXPRESSION SYSTEMS, P111, DOI 10.1016/B978-012253840-7/50006-7; WHITE RG, 1976, ANNU REV MICROBIOL, V30, P579, DOI 10.1146/annurev.mi.30.100176.003051	43	7	8	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					621	627		10.1096/fj.02-0471com	http://dx.doi.org/10.1096/fj.02-0471com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665474				2022-12-28	WOS:000182580100006
J	Harks, EGA; Camina, JP; Peters, PHJ; Ypey, DL; Scheenen, WJJM; van Zoelen, EJJ; Theuvenet, APR				Harks, EGA; Camina, JP; Peters, PHJ; Ypey, DL; Scheenen, WJJM; van Zoelen, EJJ; Theuvenet, APR			Besides affecting intracellular calcium signaling, 2-APB reversibly blocks gap junctional coupling in confluent monolayers, thereby allowing the measurement of single-cell membrane currents in undissociated cells	FASEB JOURNAL			English	Article						patch-clamp; ion channels; IP3 receptor; store-operated calcium entry	INOSITOL TRISPHOSPHATE RECEPTOR; OPERATED CA2+ CHANNELS; SMOOTH-MUSCLE CELLS; RAT-KIDNEY CELLS; 2-AMINOETHOXYDIPHENYL BORATE; GUINEA-PIG; PHENOTYPIC TRANSFORMATION; LYSOPHOSPHATIDIC ACID; NRK FIBROBLASTS; MOLECULAR-BASIS	2-Aminoethoxydiphenyl borate (2-APB) has been widely used as a blocker of the IP3 receptor and TRP channels, including store-operated calcium channels. We now show in monolayers of normal rat kidney cells (NRK/49F) that 2-APB completely and reversibly blocks gap junctional intercellular communication at concentrations similar to that required for inhibition of PGF2alpha-induced increases in intracellular calcium. Gap junctional conductances between NRK cells were estimated with single-electrode patch-clamp measurements and were fully blocked by 2-APB (50 muM), when applied extracellularly but not via the patch pipette. Half maximal inhibition (IC50) of electrical coupling in NRK cells was achieved at 5.7 muM. Similar results were obtained for human embryonic kidney epithelial cells (HEK293/tsA201) with an IC50 of 10.3 muM. Using 2-APB as an electrical uncoupler of monolayer cells, we could thus measure inward rectifier potassium, L-type calcium, and calcium-dependent chloride membrane currents in confluent NRK monolayers, with properties similar to those in dissociated NRK cells in the absence of 2-APB. The electrical uncoupling action described here is a new 2-APB property that promises to provide a powerful pharmacological tool to study single-cell properties in cultured confluent monolayers and intact tissues by electrical and chemical uncoupling of the cells without the need of prior dissociation.	Univ Nijmegen, Dept Cell Biol, Inst Cellular Signaling, Nijmegen, Netherlands; Leiden Univ, Dept Physiol, Med Ctr, NL-2300 RA Leiden, Netherlands; Complejo Hosp Univ Santiago, Dept Med, Mol Endocrinol Lab, Santiago De Compostela, Spain; Univ Nijmegen, Dept Cellular Anim Physiol, Inst Cellular Signaling, Nijmegen, Netherlands	Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Complexo Hospitalario Universitario de Santiago de Compostela; Radboud University Nijmegen	Theuvenet, APR (corresponding author), Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	ATheuv@sci.kun.nl	Scheenen, Wim/E-3674-2012; van Zoelen, Everardus J./D-9192-2012					AFINK GB, 1994, J CELL BIOCHEM, V56, P480, DOI 10.1002/jcb.240560408; Bohmer C, 2001, PFLUG ARCH EUR J PHY, V442, P688; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Braun FJ, 2001, J BIOL CHEM, V276, P1063, DOI 10.1074/jbc.M008348200; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; BULJUBASIC N, 1992, ANESTHESIOLOGY, V76, P990, DOI 10.1097/00000542-199206000-00020; Cornelisse LN, 2002, J NEUROENDOCRINOL, V14, P778, DOI 10.1046/j.1365-2826.2002.00838.x; DEROOS AD, 1997, THESIS U NIJMEGEN; deRoos ADG, 1997, CELL CALCIUM, V22, P195, DOI 10.1016/S0143-4160(97)90013-0; DeRoos ADG, 1997, J CELL PHYSIOL, V170, P166, DOI 10.1002/(SICI)1097-4652(199702)170:2<166::AID-JCP8>3.0.CO;2-M; deRoos ADG, 1996, PFLUG ARCH EUR J PHY, V431, P556, DOI 10.1007/s004240050035; Dobryndeva Y, 2001, MOL PHARMACOL, V60, P541; Fu X, 2000, AM J OBSTET GYNECOL, V182, P582, DOI 10.1067/mob.2000.102707; Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200; Goldberg GS, 1999, NAT CELL BIOL, V1, P457, DOI 10.1038/15693; Gregory RB, 2001, BIOCHEM J, V354, P285, DOI 10.1042/0264-6021:3540285; Gros DB, 1996, BIOESSAYS, V18, P719, DOI 10.1002/bies.950180907; Harks EGA, 2001, J PHARMACOL EXP THER, V298, P1033; HOSSAIN MZ, 2000, SCI STKE, pE1; Imai T, 2002, N-S ARCH PHARMACOL, V366, P282, DOI 10.1007/s00210-002-0596-0; Kukkonen JP, 2001, CELL CALCIUM, V30, P117, DOI 10.1054/ceca.2001.0219; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Lahaye DHTP, 1999, BBA-MOL CELL RES, V1449, P107, DOI 10.1016/S0167-4889(99)00002-6; Lahaye DHTP, 1999, FEBS LETT, V446, P256, DOI 10.1016/S0014-5793(99)00216-1; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Lee YT, 1999, EUR J PHARMACOL, V378, P349, DOI 10.1016/S0014-2999(99)00485-9; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; Li L, 1998, LIFE SCI, V62, pPL289; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2002, J BIOL CHEM, V277, P6915, DOI 10.1074/jbc.M107755200; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Neuhaus J, 2002, WORLD J UROL, V20, P250, DOI 10.1007/s00345-002-0289-9; Neuhaus J, 2002, CELL TISSUE RES, V309, P301, DOI 10.1007/s00441-002-0559-2; NIGGLI E, 1989, AM J PHYSIOL, V256, pC273, DOI 10.1152/ajpcell.1989.256.2.C273; TAKENSKWAK BR, 1992, AM J PHYSIOL, V262, pC1531, DOI 10.1152/ajpcell.1992.262.6.C1531; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; van Zoelen E J, 1991, Crit Rev Oncog, V2, P311; WHITE MM, 1990, MOL PHARMACOL, V37, P720; Wilson HL, 2002, J BIOL CHEM, V277, P34017, DOI 10.1074/jbc.M205120200; Wu J, 2000, MOL PHARMACOL, V58, P1368, DOI 10.1124/mol.58.6.1368; Wu XY, 2002, J BIOL CHEM, V277, P13597, DOI 10.1074/jbc.M110881200; Zhou L, 1999, J CELL BIOL, V144, P1033, DOI 10.1083/jcb.144.5.1033	44	62	67	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					941	+		10.1096/fj.02-0786fje	http://dx.doi.org/10.1096/fj.02-0786fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626431				2022-12-28	WOS:000181892600022
J	Linn, T; Schneider, K; Hammes, HP; Preissner, KT; Brandhorst, H; Morgenstern, E; Kiefer, F; Bretzel, RG				Linn, T; Schneider, K; Hammes, HP; Preissner, KT; Brandhorst, H; Morgenstern, E; Kiefer, F; Bretzel, RG			Angiogenic capacity of endothelial cells in islets of Langerhans	FASEB JOURNAL			English	Article						islet transplantation; vascularization; Tie-2 LacZ	PANCREATIC-ISLETS; GROWTH; RAT; HYPOXIA; EXPRESSION; OXYGEN; MODEL; VEGF	Transplantation of pancreatic islets reconstitutes glucose homeostasis in diabetes mellitus. Before transplantation, islets are disrupted from the surrounding blood vessels by the isolation procedure, with the grafted tissue being subject to ischemic damage. The survival of transplanted islets is assumed to depend on effective revascularization. Perfusion studies suggest that newly formed microvessels supplying the graft with nutrients are exclusively rebuilt by the host. It is generally not known whether isolated islets contain endothelial cells (EC), which potentially participate in the revascularization process. Therefore, we tried to detect immature EC in isolated islets by transformation with polyoma middle T antigen. Endothelioma cells were generated, implicating the presence of de-differentiated EC within isolated islets. When embedded in a fibrin gel, the islets developed cellular cords consisting of EC, whereas FGF-2 and VEGF stimulated the formation of cord-like structures. Furthermore, we studied the presence of donor EC in islet grafts by using transgenic mice with an EC lineage-specific promotor-LacZ reporter construct (Tie-2LacZ). Following islet transplantation, Tie-2LacZ-positive EC of both donor and recipient were identified in the vicinity of or within the graft up to 3 wk after transplantation. In conclusion, EC and/or their progenitors with angiogenic capacity reside within isolated islets of different species, and their proliferative potential can be stimulated by various inducers. These graft-related endothelia persist after islet transplantation and are integrated within newly formed microvessels.	Univ Giessen, Clin Res Unit, Med Clin & Policlin 3, D-35392 Giessen, Germany; Heidelberg Univ, Med Clin 5, Fac Med, Mannheim, Germany; Univ Giessen, Inst Biochem, Fac Med, D-35392 Giessen, Germany; Univ Saarland, Dept Med Biol, Fac Med, D-66421 Homburg, Germany; Max Planck Inst Physiol & Clin Res, Dept Mol Cell Biol, D-61231 Bad Nauheim, Germany	Justus Liebig University Giessen; Ruprecht Karls University Heidelberg; Justus Liebig University Giessen; Saarland University; Max Planck Society	Linn, T (corresponding author), Univ Giessen, Clin Res Unit, Med Clin & Policlin 3, Rodthohl 6, D-35392 Giessen, Germany.	thomas.linn@innere.med.uni-giessen.de	Hammes, Hans-Peter/S-3719-2019	Kiefer, Friedemann/0000-0002-3002-8237				Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Brandhorst H, 1998, CELL TRANSPLANT, V7, P489, DOI 10.1016/S0963-6897(98)00028-1; Brandhorst H, 1999, TRANSPLANTATION, V68, P355, DOI 10.1097/00007890-199908150-00006; Brunicardi FC, 1996, DIABETES, V45, P385, DOI 10.2337/diab.45.4.385; Carlsson PO, 2000, TRANSPLANTATION, V69, P761; Christiani, 1995, Int J Occup Environ Health, V1, P9; Compagni A, 2000, CANCER RES, V60, P7163; Davalli AM, 1996, DIABETES, V45, P1161, DOI 10.2337/diabetes.45.9.1161; DIONNE KE, 1993, DIABETES, V42, P12, DOI 10.2337/diabetes.42.1.12; FOURNIER GA, 1981, INVEST OPHTH VIS SCI, V21, P351; Hammes HP, 1998, DIABETES, V47, P401, DOI 10.2337/diabetes.47.3.401; Hart AW, 2000, NATURE, V408, P864, DOI 10.1038/35048589; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kawakami Y, 2000, CELL TRANSPLANT, V9, P729, DOI 10.1177/096368970000900523; Kenyon BM, 1997, EXP EYE RES, V64, P971, DOI 10.1006/exer.1997.0292; Kroon ME, 2001, J CELL SCI, V114, P825; LINN T, 1989, TRANSPLANT P, V21, P2685; Lou JN, 1999, DIABETES, V48, P1773, DOI 10.2337/diabetes.48.9.1773; Lupia E, 1996, EUR J IMMUNOL, V26, P1690, DOI 10.1002/eji.1830260804; MANDRUPPOULSEN T, 1990, CURR TOP MICROBIOL, V164, P169; Mattsson G, 2002, DIABETES, V51, P1362, DOI 10.2337/diabetes.51.5.1362; MENGER MD, 1992, J CLIN INVEST, V90, P1361, DOI 10.1172/JCI116002; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; PAPACCIO G, 1993, J ANAT, V182, P45; Papas KK, 1996, BBA-GEN SUBJECTS, V1291, P163, DOI 10.1016/0304-4165(96)00062-1; VAJKOCZY P, 1995, AM J PATHOL, V146, P1397; Vasir B, 2001, TRANSPLANTATION, V71, P924, DOI 10.1097/00007890-200104150-00018	27	81	83	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					881	+		10.1096/fj.02-0615fje	http://dx.doi.org/10.1096/fj.02-0615fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670881				2022-12-28	WOS:000181892600008
J	Hofmann, CS; Sonenshein, GE				Hofmann, CS; Sonenshein, GE			Green tea polyphenol epigallocatechin-3 gallate induces apoptosis of proliferating vascular smooth muscle cells via activation of p53	FASEB JOURNAL			English	Article						p21(CIP1); NF-kappa B; p50; p65; I kappa B	NF-KAPPA-B; DEPENDENT KINASE INHIBITOR; TUMOR-SUPPRESSOR GENE; SIGNALING TRANSDUCTION PATHWAY; NUCLEAR-FACTOR; BREAST-CANCER; TRANSCRIPTION FACTORS; NEOINTIMA FORMATION; EXPRESSION; PROMOTER	Green tea polyphenols (GTPs), which possess antioxidant properties, have been shown to inhibit the development of atherosclerotic lesions. Epigallocatechin-3-gallate (EGCG), the most abundant GTP, displays antiproliferative effects in a variety of cell types. Here, we examined the effects of GTPs on aortic smooth muscle cell (SMC) proliferation. Treatment with a GTP mixture or EGCG at a dose of 40 to 50 mug/ml slowed SMC growth, while at a higher dose of 80 mug/ml EGCG also induced cell death as judged by TUNEL assay. Apoptosis was mainly observed in proliferating SMCs in subconfluent cultures; whereas at higher confluency, cell viability was largely unaffected. Treatment with 80 mug/ml EGCG induced the tumor suppressor p53, which was functional as judged by activation of the target cyclin-dependent kinase inhibitor p21(CIP1). Inhibition of p53 activity with a dominant negative mutant reduced cell death. The increase in p53 protein was due to increased stability. EGCG also induced functional nuclear factor-kappaB (NF-kappaB) complexes, and inhibition of this activity reduced the extent of cell death. Thus, EGCG inhibits growth and induces death of SMCs in a p53- and NF-kappaB-dependent manner. These results provide evidence for a new molecular mechanism whereby green tea polyphenols inhibit SMC proliferation and function to prevent the development of atherosclerosis.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	gsonensh@bu.edu						Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Ahn HY, 1999, MOL BIOL CELL, V10, P1093, DOI 10.1091/mbc.10.4.1093; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; ALTERMAN RBM, 1984, MOL CELL BIOL, V4, P123, DOI 10.1128/MCB.4.1.123; Aoki M, 1999, HYPERTENSION, V34, P192, DOI 10.1161/01.HYP.34.2.192; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BENNETT MR, 1995, CIRC RES, V77, P266, DOI 10.1161/01.RES.77.2.266; Benoit V, 2000, ONCOGENE, V19, P4787, DOI 10.1038/sj.onc.1203831; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; Condorelli G, 2001, FASEB J, V15, P2162, DOI 10.1096/fj.01-0032com; Dreosti IE, 1997, CRIT REV FOOD SCI, V37, P761, DOI 10.1080/10408399709527801; Duffy SJ, 2001, CIRCULATION, V104, P151, DOI 10.1161/01.CIR.104.2.151; Dufresne CJ, 2001, J NUTR BIOCHEM, V12, P404, DOI 10.1016/S0955-2863(01)00155-3; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; Hwang KC, 2002, J CARDIOVASC PHARM, V39, P271, DOI 10.1097/00005344-200202000-00014; IMAI K, 1995, BRIT MED J, V310, P693, DOI 10.1136/bmj.310.6981.693; Kavanagh KT, 2001, J CELL BIOCHEM, V82, P387, DOI 10.1002/jcb.1164; KINDY MS, 1988, J BIOL CHEM, V263, P11426; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LAWRENCE R, 1994, J BIOL CHEM, V269, P28913; Lee JS, 1998, EXP CELL RES, V239, P447, DOI 10.1006/excr.1997.3919; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Lu LH, 1998, BRIT J PHARMACOL, V124, P1227, DOI 10.1038/sj.bjp.0701912; Matsushita H, 2000, CIRCULATION, V101, P1447, DOI 10.1161/01.CIR.101.12.1447; Mayr U, 2002, CIRC RES, V90, P197, DOI 10.1161/hh0202.103715; Park JW, 2001, BIOCHEM BIOPH RES CO, V286, P721, DOI 10.1006/bbrc.2001.5415; Pei XH, 1999, J BIOL CHEM, V274, P35240, DOI 10.1074/jbc.274.49.35240; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Pianetti S, 2002, CANCER RES, V62, P652; Pietta PG, 1998, BIOFACTORS, V8, P111, DOI 10.1002/biof.5520080119; Rodriguez-Campos A, 2001, ARTERIOSCL THROM VAS, V21, P214, DOI 10.1161/01.ATV.21.2.214; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; Sriram V, 2001, CIRCULATION, V103, P2414; WAKSMAN R, 1995, CIRCULATION, V92, P3025, DOI 10.1161/01.CIR.92.10.3025; Wu M, 1999, J IMMUNOL, V163, P6530; Wu M, 1998, J EXP MED, V187, P1671, DOI 10.1084/jem.187.10.1671; Yang TTC, 1997, PHARMACOL RES, V35, P505, DOI 10.1006/phrs.1997.0176; Yang ZY, 1996, P NATL ACAD SCI USA, V93, P7905, DOI 10.1073/pnas.93.15.7905; Yonemitsu Y, 1998, CIRC RES, V82, P147; Zhang LH, 2001, J BIOL CHEM, V276, P43534, DOI 10.1074/jbc.M104257200	48	88	93	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					702	+		10.1096/fj.02-0665fje	http://dx.doi.org/10.1096/fj.02-0665fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586742				2022-12-28	WOS:000181456900034
J	Pollock, AS; Turck, J; Lovett, DH				Pollock, AS; Turck, J; Lovett, DH			The prodomain of interleukin 1 alpha interacts with elements of the RNA processing apparatus and induces apoptosis in malignant cells	FASEB JOURNAL			English	Article						IL-1 alpha; nuclear localization signal; RNA processing; Bcl-X	PRE-MESSENGER-RNA; SPLICING FACTORS; SR PROTEINS; BCL-X; NUCLEAR SPECKLES; 2-HYBRID SYSTEM; PRECURSOR; SEQUENCE; GENE; TRANSCRIPTION	Interleukin 1alpha (IL-1alpha), a 33 kDa precursor, is cleaved releasing the 17 kDa carboxyl-terminal cytokine IL-1alpha to which all of the biological properties of IL-1alpha have been attributed. We investigated the potential independent properties of the remaining 16 kDa IL-1alpha amino-terminal propiece by expression in human tumor and primary human cell lines. The IL-1alpha propiece produced apoptosis in malignant but not normal cell lines. A minimal fragment comprised of amino acids 55-108 was required for apoptosis. Deletion and mutation studies identified an extended nuclear localization sequence required for nuclear localization, induction of apoptosis and concentration of the IL-1alpha propiece in interchromatin granule clusters, concentrations of proteins in the RNA splicing and processing pathways. The IL-1alpha propiece interacted with five known components of the RNA splicing/processing pathway, suggesting that the mechanism of action may involve changes in RNA splicing or processing. Expression of the IL-1alpha propiece caused a shift in the ratio of Bcl-X-1/Bcl-X-s toward the apoptotic direction. Our findings indicate that the IL-1alpha propiece induces apoptosis in a range of tumor cells and likely operates through a mechanism involving the RNA processing apparatus and the alternate splicing of apoptosis regulatory proteins.	Univ Calif San Francisco, Vet Adm Med Ctr, No Calif Inst Res & Educ, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA	Northern California Institute for Research & Education; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Pollock, AS (corresponding author), San Francisco VA Med Ctr, Dept Med 111J, 4150 Clement St, San Francisco, CA 94121 USA.	pollock.allan@maelstrom.ucsf.edu			NCI NIH HHS [R55 CA91038] Funding Source: Medline; NIDDK NIH HHS [R01DK31398, R01DK39776] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA091038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031398, R01DK039776] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEASLEY D, 1995, AM J PHYSIOL-CELL PH, V269, pC961, DOI 10.1152/ajpcell.1995.269.4.C961; BEUSCHER HU, 1988, J BIOL CHEM, V263, P4023; Blencowe BJ, 1999, BIOCHEM CELL BIOL, V77, P277, DOI 10.1139/bcb-77-4-277; BOHMANN K, 1995, J CELL BIOL, V131, P817, DOI 10.1083/jcb.131.4.817; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; Bruzik JP, 1996, MICROB PATHOGENESIS, V21, P149, DOI 10.1006/mpat.1996.0050; BUDDE RJA, 1994, CANCER BIOCHEM BIOPH, V14, P171; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; Dye BT, 2001, EXP CELL RES, V263, P131, DOI 10.1006/excr.2000.5097; Eilbracht J, 2001, P NATL ACAD SCI USA, V98, P3849, DOI 10.1073/pnas.071042298; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FINER MH, 1994, BLOOD, V83, P43; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FURUTANI Y, 1986, NUCLEIC ACIDS RES, V14, P3167, DOI 10.1093/nar/14.8.3167; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hanamura A, 1998, RNA, V4, P430; Honma T, 1996, VIRCHOWS ARCH, V428, P165; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; KAVITA U, 1995, J BIOL CHEM, V270, P27758, DOI 10.1074/jbc.270.46.27758; Kobayashi Y, 1997, J BIOCHEM-TOKYO, V121, P896; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Kuhn AN, 1999, MOL CELL, V3, P65, DOI 10.1016/S1097-2765(00)80175-6; KUPPER TS, 1990, J INVEST DERMATOL, V94, pS146, DOI 10.1111/1523-1747.ep12876130; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lewis JD, 2000, SCIENCE, V288, P1385, DOI 10.1126/science.288.5470.1385; Liu ML, 1996, J VIROL, V70, P2497, DOI 10.1128/JVI.70.4.2497-2502.1996; Luo HBR, 1999, RNA, V5, P893, DOI 10.1017/S1355838299990520; MAIER JAM, 1994, MOL CELL BIOL, V14, P1845, DOI 10.1128/MCB.14.3.1845; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Matsunaga K, 2000, PATHOL INT, V50, P206, DOI 10.1046/j.1440-1827.2000.01025.x; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; McMahon GA, 1997, J BIOL CHEM, V272, P28202, DOI 10.1074/jbc.272.45.28202; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; Mintz PJ, 2000, J STRUCT BIOL, V129, P241, DOI 10.1006/jsbi.2000.4213; Pecci A, 2001, J BIOL CHEM, V276, P21062, DOI 10.1074/jbc.M008665200; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Perera LP, 1998, P NATL ACAD SCI USA, V95, P14308, DOI 10.1073/pnas.95.24.14308; Pombo A, 1996, EXP CELL RES, V229, P201, DOI 10.1006/excr.1996.0360; Puvion E, 1996, EXP CELL RES, V229, P217, DOI 10.1006/excr.1996.0363; Sanz C, 1997, BLOOD, V89, P3199, DOI 10.1182/blood.V89.9.3199; Sharma S, 1996, P NATL ACAD SCI USA, V93, P11842, DOI 10.1073/pnas.93.21.11842; Siatecka M, 1999, GENE DEV, V13, P1983, DOI 10.1101/gad.13.15.1983; Sleeman JE, 1999, CURR OPIN CELL BIOL, V11, P372, DOI 10.1016/S0955-0674(99)80052-0; STEVENSON FT, 1992, J CELL PHYSIOL, V152, P223, DOI 10.1002/jcp.1041520202; STEVENSON FT, 1993, P NATL ACAD SCI USA, V90, P7245, DOI 10.1073/pnas.90.15.7245; Tacke R, 1999, P SOC EXP BIOL MED, V220, P59, DOI 10.1046/j.1525-1373.1999.d01-10.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMSON AM, 1995, CLIN EXP METASTAS, V13, P319, DOI 10.1007/BF00121908; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Wei XY, 1999, J CELL BIOL, V146, P543, DOI 10.1083/jcb.146.3.543; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; WESSENDORF JHM, 1993, J BIOL CHEM, V268, P22100; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; Zeng CQ, 1997, EMBO J, V16, P1401, DOI 10.1093/emboj/16.6.1401	62	58	59	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					203	213		10.1096/fj.02-0602com	http://dx.doi.org/10.1096/fj.02-0602com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554699				2022-12-28	WOS:000181456900045
J	La Ferla, K; Reimann, C; Jelkmann, W; Hellwig-Burgel, T				La Ferla, K; Reimann, C; Jelkmann, W; Hellwig-Burgel, T			Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-kappa B	FASEB JOURNAL			English	Article						cytokines; anemia; interleukin 1; tumor necrosis factor alpha; promoter	NECROSIS-FACTOR-ALPHA; NEGATIVE REGULATION; BINDING-PROTEINS; DNA-BINDING; HIF-ALPHA; INTERLEUKIN-1-BETA; SUPPRESSION; HYDROXYLATION; PATHOGENESIS; STIMULATION	The anemia of chronic inflammatory and malignant diseases is partly due to impaired synthesis of the hormone erythropoietin (Epo). The proinflammatory cytokines interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-alpha) suppress in vitro Epo gene expression and Epo protein secretion. However, the molecular mechanisms of this inhibition are poorly understood. The human Epo promoter and the 5' flanking region contain several recognition sequences for transcription factors acting either positively or negatively. Herein, we investigated the roles of the transcription factors GATA-2 and NF-kappaB in the modulation of Epo gene expression by IL-1beta and TNF-alpha in the human hepatoma cell line HepG2. Electrophoretic mobility shift assays revealed increased GATA-2 and NF-kappaB DNA binding in cells treated with IL-1beta or TNF-alpha. Reporter gene assays with a sequence from the Epo promoter in front of the firefly luciferase gene showed that the cytokines reduced Epo reporter gene activity. Functional inactivation of GATA-2 and NF-kappaB by oligo-decoy techniques prevented the inhibition of Epo production by IL-1beta and TNF-alpha. In HepG2 cells stably transfected with a dominant-negative form of IkappaBalpha, the activation of NF-kappaB was inhibited, while Epo mRNA levels and Epo secretion increased. Thus, both GATA-2 and NF-kappaB seem to be involved in the suppression of Epo gene expression by IL-1beta and TNF-alpha in vitro and may be responsible for impaired Epo synthesis in inflammatory diseases in vivo.	Univ Lubeck, Inst Physiol, D-23538 Lubeck, Germany	University of Lubeck	Jelkmann, W (corresponding author), Univ Lubeck, Inst Physiol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	jelkmann@physio.uni-luebeck.de	Hellwig-Bürgel, Thomas/K-6696-2013; Jelkmann, Wolfgang/AAF-8897-2019					ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Ebert BL, 1999, BLOOD, V94, P1864; FANDREY J, 1994, EUR J BIOCHEM, V226, P335, DOI 10.1111/j.1432-1033.1994.tb20057.x; FAQUIN WC, 1992, BLOOD, V79, P1987; Frede S, 1997, AM J PHYSIOL-REG I, V273, pR1067, DOI 10.1152/ajpregu.1997.273.3.R1067; Gires O, 2001, CANCER, V92, P620, DOI 10.1002/1097-0142(20010801)92:3<620::AID-CNCR1362>3.0.CO;2-F; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; Han YQ, 1999, J BIOL CHEM, V274, P939, DOI 10.1074/jbc.274.2.939; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; IMAGAWA S, 1994, J BIOL CHEM, V269, P9038; Imagawa S, 1997, BLOOD, V89, P1430, DOI 10.1182/blood.V89.4.1430; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwase R, 1997, Nucleic Acids Symp Ser, P203; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JELKMANN W, 1992, LIFE SCI, V50, P301, DOI 10.1016/0024-3205(92)90338-P; Jelkmann W, 1998, J INTERF CYTOK RES, V18, P555, DOI 10.1089/jir.1998.18.555; Jelkmann W, 1999, EXP HEMATOL, V27, P224, DOI 10.1016/S0301-472X(98)00054-X; JOHNSON CS, 1989, BLOOD, V73, P678; Ke S, 2001, J BIOL CHEM, V276, P39638, DOI 10.1074/jbc.M106286200; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; LEEHUANG S, 1993, GENE, V128, P227, DOI 10.1016/0378-1119(93)90567-M; MEANS RT, 1992, BLOOD, V80, P1639; SCHOOLEY JC, 1987, BRIT J HAEMATOL, V67, P11, DOI 10.1111/j.1365-2141.1987.tb02289.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0; Tabata M, 2001, J CELL PHYSIOL, V186, P260, DOI 10.1002/1097-4652(200002)186:2<260::AID-JCP1025>3.0.CO;2-K; Tarumoto T, 2000, BLOOD, V96, P1716, DOI 10.1182/blood.V96.5.1716.h8001716_1716_1722; Tsuchiya T, 1997, J BIOCHEM, V121, P193; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	33	117	127	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13	1				1811	+		10.1096/fj.02-0168fje	http://dx.doi.org/10.1096/fj.02-0168fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223449				2022-12-28	WOS:000181189100010
J	Samuel, CS; Zhao, CX; Bathgate, RAD; Bond, CP; Burton, MD; Parry, LJ; Summers, RJ; Tang, MLK; Amento, EP; Tregear, GW				Samuel, CS; Zhao, CX; Bathgate, RAD; Bond, CP; Burton, MD; Parry, LJ; Summers, RJ; Tang, MLK; Amento, EP; Tregear, GW			Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis	FASEB JOURNAL			English	Article						fibrosis; lung phenotypes; lung function; relaxin treatment	PUBIC SYMPHYSIS; MURINE MODEL; COLLAGEN; GENE; RECEPTORS; PREGNANCY; EXPRESSION; ESTROGEN; BINDING	Relaxin (RLX) is a peptide hormone with known antifibrotic properties. However, its significance in the lung and its role as a therapeutic agent against diseases characterized by pulmonary fibrosis are yet to be established. In this study, we examined age-related structural and functional changes in the lung of relaxin-deficient mice. Lung tissues of male and female RLX knockout (-/-) and RLX wild-type (+/+) mice at various ages were analyzed for changes in collagen expression and content. We demonstrate an age-related progression of lung fibrosis in RLX -/- mice with significantly increased tissue wet weight, collagen content and concentration, alveolar congestion, and bronchiole epithelium thickening. The increased fibrosis was associated with significantly altered peak expiratory flow and lung recoil (lung function) in RLX -/- mice. Treatment of RLX -/- mice with relaxin in early and developed stages of fibrosis resulted in the reversal of collagen deposition. Organ bath studies showed that precontracted lung strips relaxed in the presence of relaxin. Together, these data indicate that relaxin may provide a means to regulate excessive collagen deposition in diseased states characterized by pulmonary fibrosis.	Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Zool, Parkville, Vic 3010, Australia; Monash Univ, Dept Pharmacol, Clayton, Vic 3800, Australia; Royal Childrens Hosp, Dept Immunol, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; Mol Med Res Inst, Sunnyvale, CA 94085 USA	Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Melbourne; Monash University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne	Samuel, CS (corresponding author), Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3010, Australia.	c.samuel@hfi.unimelb.edu.au	Bathgate, Ross/ABE-6471-2020; Summers, Roger J/F-6351-2011	Bathgate, Ross/0000-0001-6301-861X; Summers, Roger J/0000-0002-8367-4056; Parry, Laura/0000-0002-6883-3418; Tang, Mimi/0000-0002-3839-5293				BATEMAN JF, 1996, EXTRACELLULAR MATRIX, V2, P22; Bathgate RAD, 2002, J BIOL CHEM, V277, P1148, DOI 10.1074/jbc.M107882200; Coker RK, 1998, EUR RESPIR J, V11, P1218, DOI 10.1183/09031936.98.11061218; Du XJ, 2000, CIRCULATION, V101, P71, DOI 10.1161/01.CIR.101.1.71; DU XJ, 2002, IN PRESS CARDIOVASC; Erikson MS, 2001, RELAXIN 2000, P373; EVANS BA, 1993, J MOL ENDOCRINOL, V10, P15, DOI 10.1677/jme.0.0100015; FERRAIOLO BL, 1989, ENDOCRINOLOGY, V125, P2922, DOI 10.1210/endo-125-6-2922; Fiscus LC, 2001, J ALLERGY CLIN IMMUN, V107, P1019, DOI 10.1067/mai.2001.114703; FLINT MH, 1975, HISTOCHEM J, V7, P529, DOI 10.1007/BF01003791; GALLOP PM, 1975, PHYSIOL REV, V55, P418, DOI 10.1152/physrev.1975.55.3.418; Garber SL, 2001, KIDNEY INT, V59, P876, DOI 10.1046/j.1523-1755.2001.059003876.x; GOLDIE RG, 1982, BRIT J PHARMACOL, V76, P523, DOI 10.1111/j.1476-5381.1982.tb09249.x; Gross TJ, 2001, NEW ENGL J MED, V345, P517, DOI 10.1056/NEJMra003200; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Karsenty G, 1995, Int Rev Immunol, V12, P177, DOI 10.3109/08830189509056711; KNIGHT DP, 2000, J CELL SCI, V113, P4141; LUCAS C, 1989, J ENDOCRINOL, V120, P449, DOI 10.1677/joe.0.1200449; Palejwala S, 2001, ENDOCRINOLOGY, V142, P3405, DOI 10.1210/en.142.8.3405; Samuel CS, 2001, RELAXIN 2000, P221; Samuel CS, 1996, ENDOCRINOLOGY, V137, P3884, DOI 10.1210/en.137.9.3884; SHAHZEIDI S, 1993, THORAX, V48, P622, DOI 10.1136/thx.48.6.622; Sherwood O. David, 1994, P861; SHERWOOD OD, 1980, ENDOCRINOLOGY, V107, P691, DOI 10.1210/endo-107-3-691; Siebel AL, 2002, BIOL REPROD, V66, P1237, DOI 10.1095/biolreprod66.5.1237; Steen V D, 2001, Am J Clin Dermatol, V2, P315, DOI 10.2165/00128071-200102050-00006; Stirling RG, 2000, EUR RESPIR J, V16, P1158, DOI 10.1034/j.1399-3003.2000.16f24.x; Strieter Robert M., 2001, Chest, V120, p77S, DOI 10.1378/chest.120.1_suppl.S77-a; Tan YY, 1999, BRIT J PHARMACOL, V127, P91, DOI 10.1038/sj.bjp.0702517; UNEMORI EN, 1993, J INVEST DERMATOL, V101, P280, DOI 10.1111/1523-1747.ep12365206; UNEMORI EN, 1992, J INVEST DERMATOL, V99, P337, DOI 10.1111/1523-1747.ep12616665; UNEMORI EN, 1990, J BIOL CHEM, V265, P10681; Unemori EN, 1996, J CLIN INVEST, V98, P2739, DOI 10.1172/JCI119099; Williams EJ, 2001, GUT, V49, P577, DOI 10.1136/gut.49.4.577; YANG S, 1992, ENDOCRINOLOGY, V130, P179, DOI 10.1210/en.130.1.179; Zhao L, 2000, BIOL REPROD, V63, P697, DOI 10.1095/biolreprod63.3.697; Zhao L, 1999, ENDOCRINOLOGY, V140, P445, DOI 10.1210/en.140.1.445	38	145	148	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					121	+		10.1096/fj.02-0449fje	http://dx.doi.org/10.1096/fj.02-0449fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12424226				2022-12-28	WOS:000180218500039
J	Cao, RH; Brakenhielm, E; Li, XR; Pietras, K; Widenfalk, J; Ostman, A; Eriksson, U; Cao, YH				Cao, RH; Brakenhielm, E; Li, XR; Pietras, K; Widenfalk, J; Ostman, A; Eriksson, U; Cao, YH			Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alpha alpha and -alpha beta receptors	FASEB JOURNAL			English	Article						VEGF; vascular smooth muscle cells; neovascularization; growth factors	ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; MONOCLONAL-ANTIBODIES; BIOLOGICAL PROPERTIES; DEFICIENT MICE; KNOCKOUT MICE; TUMOR-GROWTH; MOUSE CORNEA; IN-VIVO; GENE	A newly discovered PDGF isoform, PDGF-CC, is expressed in actively angiogenic tissues such as placenta, some embryonic tissues, and tumors. We test the possibility that PDGF-CC promotes angiogenesis in vivo. The core domain (mature form) of human PDGF-CC is sufficiently potent to stimulate neovascularization in the mouse cornea. The corneal angiogenic response induced by PDGF-CC is robust although the area of neovascularization is smaller than those of FGF-2- and VEGF-stimulated angiogenesis. Similarly, PDGF-BB and PDGF-AB induce angiogenic responses virtually indistinguishable from PDGF-CC-stimulated vessels. In contrast, PDGF-AA displays only a weak angiogenic response in the mouse cornea. Although there was no significant difference in incorporation of mural cells to the newly formed blood vessels induced by PDGF-BB and -CC, the percentage of mural cell positive vessels induced by PDGF-AA was greater than those induced by FGF-2, PDGF-BB, and PDGF-CC. In the developing chick embryo, PDGF-CC induced branch sprouts from established blood vessels. In PDGF receptor-transfected endothelial cells, PDGF-CC activated the PDGF receptor alpha subunit (PDGFR-alpha). PDGF-CC, but not PDGF-AA, was able to activate PDGFR-beta receptor in endothelial cells that coexpress both alpha and beta forms of receptors. Thus, the PDGF-CC-mediated angiogenic response is most likely transduced by PDGF-alphaalpha and -alphabeta receptors. These data demonstrate that the PDGF family is a complex and important group of proangiogenic factors.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Ludwig Inst Canc Res, Stockholm Branch, S-17177 Stockholm, Sweden; Ludwig Inst Canc Res, Uppsala Branch, S-75124 Uppsala, Sweden; Karolinska Inst, Inst Neurobiol, S-17177 Stockholm, Sweden	Karolinska Institutet; Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; Karolinska Institutet	Cao, YH (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.	yihai.cao@mtc.ki.se	Brakenhielm, Ebba/E-9758-2011; Pietras, Kristian/ABE-8727-2020; Pietras, Kristian/ABG-2097-2021	Brakenhielm, Ebba/0000-0003-3378-8300; Pietras, Kristian/0000-0001-6738-4705				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BEITZ JG, 1991, P NATL ACAD SCI USA, V88, P2021, DOI 10.1073/pnas.88.5.2021; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Cao YH, 1999, NATURE, V398, P381, DOI 10.1038/18793; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; DEBUS E, 1983, EMBO J, V2, P2305, DOI 10.1002/j.1460-2075.1983.tb01738.x; Ding H, 2000, MECH DEVELOP, V96, P209, DOI 10.1016/S0925-4773(00)00425-1; Dvorak HF, 2000, SEMIN PERINATOL, V24, P75, DOI 10.1016/S0146-0005(00)80061-0; Ekman S, 1999, ONCOGENE, V18, P2481, DOI 10.1038/sj.onc.1202606; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Fruttiger M, 1999, DEVELOPMENT, V126, P457; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; Hamada T, 2000, FEBS LETT, V475, P97, DOI 10.1016/S0014-5793(00)01640-9; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; Karlsson L, 2000, DEVELOPMENT, V127, P3457; Kazlauskas A, 2000, NAT CELL BIOL, V2, pE78, DOI 10.1038/35010508; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; KOYAMA N, 1994, J CELL PHYSIOL, V158, P1, DOI 10.1002/jcp.1041580102; Lao YH, 2001, INT J BIOCHEM CELL B, V33, P357, DOI 10.1016/S1357-2725(01)00023-1; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Lee RJ, 2000, CIRCULATION, V102, P898; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Lindahl P, 1998, CURR OPIN LIPIDOL, V9, P407, DOI 10.1097/00041433-199810000-00004; Lindahl P, 1999, CURR TOPICS PATHOL, V93, P27; Lindahl P, 1998, DEVELOPMENT, V125, P3313; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MARX M, 1994, J CLIN INVEST, V93, P131, DOI 10.1172/JCI116936; MUTHUKKARUPPAN V, 1979, SCIENCE, V205, P1416, DOI 10.1126/science.472760; OIKAWA T, 1994, BIOL PHARM BULL, V17, P1686; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PLATE KH, 1992, LAB INVEST, V67, P529; RESINK TJ, 1990, CELL REGUL, V1, P821, DOI 10.1091/mbc.1.11.821; Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029; Risau W, 1992, GROWTH FACTORS, V7, P261, DOI 10.3109/08977199209046408; RONNSTRAND L, 1988, J BIOL CHEM, V263, P10429; SATO N, 1993, AM J PATHOL, V142, P1119; Smits A, 1989, GROWTH FACTORS, V2, P1, DOI 10.3109/08977198909069076; Soriano P, 1997, DEVELOPMENT, V124, P2691; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Uutela M, 2001, CIRCULATION, V103, P2242; Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091; WANG CY, 1990, MOL CELL BIOL, V10, P6781, DOI 10.1128/MCB.10.12.6781; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	59	174	189	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1575	1583		10.1096/fj.02-0319com	http://dx.doi.org/10.1096/fj.02-0319com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374780				2022-12-28	WOS:000179167600039
J	Huber-Lang, MS; Riedeman, NC; Sarma, JV; Younkin, EM; McGuire, SR; Laudes, IJ; Lu, KT; Guo, RF; Neff, TA; Padgaonkar, VA; Lambris, JD; Spruce, L; Mastellos, D; Zetoune, FS; Ward, PA				Huber-Lang, MS; Riedeman, NC; Sarma, JV; Younkin, EM; McGuire, SR; Laudes, IJ; Lu, KT; Guo, RF; Neff, TA; Padgaonkar, VA; Lambris, JD; Spruce, L; Mastellos, D; Zetoune, FS; Ward, PA			Protection of innate immunity by C5aR antagonist in septic mice	FASEB JOURNAL			English	Article						sepsis; neutrophil; oxidative burst; blood clearance	RECEPTOR ANTAGONIST; COMPLEMENT ACTIVATION; NEUTROPHIL DYSFUNCTION; SEPSIS; MODELS; EXPRESSION; INJURY; SHOCK; AGONISTS; PEPTIDE	Innate immune functions are known to be compromised during sepsis, often with lethal consequences. There is also evidence in rats that sepsis is associated with excessive complement activation and generation of the potent anaphylatoxin C5a. In the presence of a cyclic peptide antagonist (C5aRa) to the C5a receptor (C5aR), the binding of murine I-125-C5a to murine neutrophils was reduced, the in vitro chemotactic responses of mouse neutrophils to mouse C5a were markedly diminished, the acquired defect in hydrogen peroxide (H2O2) production of C5a-exposed neutrophils was reversed, and the lung permeability index (extravascular leakage of albumin) in mice after intrapulmonary deposition of IgG immune complexes was markedly diminished. Mice that developed sepsis after cecal ligation/puncture (CLP) and were treated with C5aRa had greatly improved survival rates. These data suggest that C5aRa interferes with neutrophil responses to C5a, preventing C5a-induced compromise of innate immunity during sepsis, with greatly improved survival rates after CLP.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Michigan System; University of Michigan; University of Pennsylvania	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	pward@umich.edu	Huber-Lang, Markus/AAJ-2209-2020; Lambris, John/Q-5633-2018; Mohammed, Imran/J-8271-2012; Riedemann, Niels C/C-1633-2010	Lambris, John/0000-0002-9370-5776; Mohammed, Imran/0000-0002-8412-0768; Mastellos, Dimitrios/0000-0002-6634-3271	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061656, R01GM029507, R37GM029507] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 61656, GM 29507] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ajuebor MN, 1999, J IMMUNOL, V162, P1685; BARTON PA, 1993, INFECT IMMUN, V61, P1474, DOI 10.1128/IAI.61.4.1474-1481.1993; Bennett GL, 1997, METHOD ENZYMOL, V288, P134; BOTHA AJ, 1995, SHOCK, V3, P157, DOI 10.1097/00024382-199503000-00001; Burg ND, 2001, CLIN IMMUNOL, V99, P7, DOI 10.1006/clim.2001.5007; CHENOWETH DE, 1978, P NATL ACAD SCI USA, V75, P3943, DOI 10.1073/pnas.75.8.3943; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; Deitch EA, 1998, SHOCK, V9, P1, DOI 10.1097/00024382-199801000-00001; DRAPEAU G, 1993, BIOCHEM PHARMACOL, V45, P1289, DOI 10.1016/0006-2952(93)90282-2; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; Ember JA, 1997, IMMUNOPHARMACOLOGY, V38, P3, DOI 10.1016/S0162-3109(97)00088-X; Faist E, 1996, WORLD J SURG, V20, P454, DOI 10.1007/s002689900071; Fildes J, 1998, J TRAUMA, V45, P479, DOI 10.1097/00005373-199809000-00008; Finch AM, 1999, J MED CHEM, V42, P1965, DOI 10.1021/jm9806594; FUREDER W, 1995, J IMMUNOL, V155, P3152; GERARD C, 1992, J IMMUNOL, V149, P2600; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Glauser MP, 2000, CRIT CARE MED, V28, pS4, DOI 10.1097/00003246-200009001-00002; Gommerman JL, 2000, J IMMUNOL, V165, P6915, DOI 10.4049/jimmunol.165.12.6915; GOYA T, 1994, SURGERY, V115, P145; Hecke F, 1997, CRIT CARE MED, V25, P2015, DOI 10.1097/00003246-199712000-00019; Heller T, 1999, J IMMUNOL, V163, P985; Hopken UE, 1997, J EXP MED, V186, P749, DOI 10.1084/jem.186.5.749; Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193; Huber-Lang MS, 2001, FASEB J, V15, P568; KANERVA L, 1995, EUR J DERMATOL, V5, P149; Kildsgaard J, 2000, J IMMUNOL, V165, P5406, DOI 10.4049/jimmunol.165.10.5406; Koch T, 1997, SHOCK, V7, P42, DOI 10.1097/00024382-199701000-00005; KONTEATIS ZD, 1994, J IMMUNOL, V153, P4200; LARSEN GL, 1981, AM REV RESPIR DIS, V123, P434; Matsukawa A, 2001, J EXP MED, V193, P679, DOI 10.1084/jem.193.6.679; Miller CG, 1996, MOL IMMUNOL, V33, P1135, DOI 10.1016/S0161-5890(96)00077-6; MOLLISON KW, 1992, FASEB J, V6, pA2058; Mulligan MS, 1996, J CLIN INVEST, V98, P503, DOI 10.1172/JCI118818; Nishiura H, 1998, LAB INVEST, V78, P1615; Osaka H, 1999, NEUROSCIENCE, V88, P1073, DOI 10.1016/S0306-4522(98)00372-8; Pellas TC, 1998, J IMMUNOL, V160, P5616; Pellas TC, 1999, CURR PHARM DESIGN, V5, P737; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; Riley RD, 2000, J THORAC CARDIOV SUR, V120, P350, DOI 10.1067/mtc.2000.107281; SHARMA SD, 1991, J ORG CHEM, V56, P4981, DOI 10.1021/jo00016a035; Shi FD, 2001, TRENDS IMMUNOL, V22, P97, DOI 10.1016/S1471-4906(00)01821-4; Short A, 1999, BRIT J PHARMACOL, V126, P551, DOI 10.1038/sj.bjp.0702338; Short AJ, 1999, BRIT J PHARMACOL, V128, P511, DOI 10.1038/sj.bjp.0702847; SOLOMKIN JS, 1981, SURGERY, V90, P319; Strachan AJ, 2000, J IMMUNOL, V164, P6560, DOI 10.4049/jimmunol.164.12.6560; TSUJI RF, 1992, BIOSCI BIOTECH BIOCH, V56, P2034, DOI 10.1271/bbb.56.2034; UTOH J, 1989, JPN J SURG, V19, P462, DOI 10.1007/BF02471629; Ward PA, 1996, AM J PATHOL, V149, P1079; WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2; Williams MA, 1999, ARCH SURG-CHICAGO, V134, P1360, DOI 10.1001/archsurg.134.12.1360; Wong AK, 1998, J MED CHEM, V41, P3417, DOI 10.1021/jm9800651; ZIMMERMAN JJ, 1985, CRIT CARE MED, V13, P143, DOI 10.1097/00003246-198503000-00001; Zwirner J, 1999, MOL IMMUNOL, V36, P877, DOI 10.1016/S0161-5890(99)00109-1	54	126	146	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1567	1574		10.1096/fj.02-0209com	http://dx.doi.org/10.1096/fj.02-0209com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374779	Green Submitted			2022-12-28	WOS:000179167600038
J	Papi, A; Papadopoulos, NG; Stanciu, LA; Bellettato, CM; Pinamonti, S; Degitz, K; Holgate, ST; Johnston, SL				Papi, A; Papadopoulos, NG; Stanciu, LA; Bellettato, CM; Pinamonti, S; Degitz, K; Holgate, ST; Johnston, SL			Reducing agents inhibit rhinovirus-induced up-regulation of the rhinovirus receptor intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells	FASEB JOURNAL			English	Article						asthma; rhinitis; oxidants; nuclear factor kappa B	NF-KAPPA-B; OBSTRUCTIVE PULMONARY-DISEASE; TNF-ALPHA; ENDOTHELIAL-CELLS; TRANSCRIPTIONAL REGULATION; OXIDATIVE STRESS; LOWER AIRWAYS; EXPRESSION; ACTIVATION; GLUTATHIONE	Rhinoviruses are the major cause of common colds and of asthma exacerbations. Intercellular adhesion molecule-1 (ICAM-1) has a central role in airway inflammation and is the receptor for 90% of rhinoviruses. Rhinovirus infection of airway epithelium induces ICAM-1. Because redox state is directly implicated in inflammatory responses via molecular signaling mechanisms, here we studied the effects of reducing agents on rhinovirus-induced ICAM-1 expression, mRNA upregulation, promoter activation, and nuclear factor activation. To investigate the effects of rhinovirus infection on the intracellular redox balance, we also studied whether rhinovirus infection triggers the production of reactive oxygen species. We found that reduced (GSH) but not oxidized (GSSG) glutathione (1-100 muM) inhibited in a dose-dependent manner rhinovirus-induced ICAM-1 up-regulation and mRNA induction in primary bronchial and A549 respiratory epithelial cells. GSH but not GSSG also inhibited rhinovirus-induced ICAM-1 promoter activation and rhinovirus-induced NF-kappaB activation. In parallel, we found that rhinovirus infection induced a rapid increase of intracellular superoxide anion that was maximal at the time of NF-kappaB activation. This oxidant generation was completely inhibited by GSH. We conclude that redox-mediated intracellular pathways represent an important target for the therapeutic control of rhinovirus-induced diseases.	Univ Ferrara, Res Ctr Asthma & COPD, I-44100 Ferrara, Italy; Univ Southampton, Southampton, Hants, England; Univ Athens, Allergy Unit, Dept Pediat 2, GR-10679 Athens, Greece; Univ London Imperial Coll Sci Technol & Med, Dept Resp Med, Natl Heart & Lung Inst, London, England; Univ Ferrara, Dept Cell Biol, I-44100 Ferrara, Italy; Univ Munich, Dept Dermatol, D-8000 Munich, Germany	University of Ferrara; University of Southampton; National & Kapodistrian University of Athens; Imperial College London; University of Ferrara; University of Munich	Papi, A (corresponding author), Univ Ferrara, Res Ctr Asthma & COPD, Via Savonarla, I-44100 Ferrara, Italy.	ppa@dns.unife.it	N.G., Papadopoulos/L-8670-2013; Stanciu, Luminita A/B-8384-2012; Papi, alberto/AAC-1888-2019; Papadopoulos, Nikolaos/ABE-1774-2021; Johnston, Sebastian Lennox/I-2423-2012	N.G., Papadopoulos/0000-0002-4448-3468; Papadopoulos, Nikolaos/0000-0002-4448-3468; Johnston, Sebastian Lennox/0000-0003-3009-9200; Papadopoulos, Nikolaos/0000-0002-2508-3872; PAPI, ALBERTO/0000-0002-6924-4500				Atmar RL, 2001, LUNG BIOL HEALTH DIS, V154, P259; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; Chen CC, 2001, CELL SIGNAL, V13, P543, DOI 10.1016/S0898-6568(01)00171-1; Cho S, 1998, BIOCHEM BIOPH RES CO, V253, P104, DOI 10.1006/bbrc.1998.9697; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Doull IJM, 1997, BMJ-BRIT MED J, V315, P858, DOI 10.1136/bmj.315.7112.858; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Grunberg K, 2000, CLIN EXP ALLERGY, V30, P1015; Halliwell B., 1999, FREE RADICAL BIOL ME; Iantomasi T, 1997, BBA-BIOMEMBRANES, V1330, P274; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; JEFFERSON TO, 2001, COCHRANE DATABASE SY, V3; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL., 1997, DIAGNOSTIC PROCEDURE, P553; Krunkosky TM, 2000, AM J RESP CELL MOL, V22, P685, DOI 10.1165/ajrcmb.22.6.3925; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; LOOK DC, 1994, J BIOL CHEM, V269, P8952; MULLER S, 1995, J INVEST DERMATOL, V104, P970, DOI 10.1111/1523-1747.ep12606225; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Papi A, 2000, J ALLERGY CLIN IMMUN, V105, P318, DOI 10.1016/S0091-6749(00)90082-4; Pinamonti S, 1996, FREE RADICAL BIO MED, V21, P147, DOI 10.1016/0891-5849(96)00030-5; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Seemungal T, 2001, AM J RESP CRIT CARE, V164, P1618, DOI 10.1164/ajrccm.164.9.2105011; STANWAY G, 1994, ENCY VIROLOGY, V3, P1253; True AL, 2000, AM J PHYSIOL-LUNG C, V279, pL302, DOI 10.1152/ajplung.2000.279.2.L302; UNCAPHER CR, 1991, VIROLOGY, V180, P814, DOI 10.1016/0042-6822(91)90098-V; Van Klaveren RJ, 1999, FREE RADICAL RES, V30, P371, DOI 10.1080/10715769900300411; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WILSON NM, 1990, ARCH DIS CHILD, V65, P407, DOI 10.1136/adc.65.4.407; Winther B, 1998, AM J RHINOL, V12, P17, DOI 10.2500/105065898782102954	35	38	41	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1934	+		10.1096/fj.02-0118fje	http://dx.doi.org/10.1096/fj.02-0118fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368227				2022-12-28	WOS:000179167600018
J	Endlich, N; Sunohara, M; Nietfeld, W; Wolski, EW; Schiwek, D; Kranzlin, B; Gretz, N; Kriz, W; Eickhoff, H; Endlich, K				Endlich, N; Sunohara, M; Nietfeld, W; Wolski, EW; Schiwek, D; Kranzlin, B; Gretz, N; Kriz, W; Eickhoff, H; Endlich, K			Analysis of differential gene expression in stretched podocytes: osteopontin enhances adaptation of podocytes to mechanical stress	FASEB JOURNAL			English	Article						glomerular hypertension; nephron degeneration; cDNA array; actin cytoskeleton; DOCA-salt	FAWN-HOODED RAT; GLOMERULAR INJURY; HEMODYNAMIC BASIS; GLOMERULOSCLEROSIS; CELLS; TRANSGLUTAMINASE; HYPERTENSION; NEPHROPATHY; CORTACTIN; ADHESION	Glomerular hypertension is a major determinant advancing progression to end-stage renal failure. Podocytes, which are thought to counteract pressure-mediated capillary expansion, are increasingly challenged in glomerular hypertension. Studies in animal models of glomerular hypertension indicate that glomerulosclerosis develops from adhesions of the glomerular tuft to Bowman's capsule due to progressive podocyte loss. However, the molecular alterations of podocytes in glomerular hypertension are unknown. In this study, we determined the changes in gene expression in podocytes induced by mechanical stress in vitro (cyclic biaxial stretch, 0.5 Hz, 5% linear strain, 3 days) using cDNA arrays (6144 clones). Sixteen differentially regulated genes were identified, suggesting alterations of cell-matrix interaction, mitochondrial/metabolic function, and protein synthesis/degradation in stretched podocytes. The transcript for the matricellular protein osteopontin (OPN) was most strongly up-regulated by stretch (approximately threefold). By reverse transcriptase-polymer chain reaction, up-regulation of OPN mRNA was also detected in glomeruli of rats treated for 2.5 wk with desoxycorticosterone acetate-salt, an animal model of glomerular hypertension. In cultured podocytes, OPN coating induced a motile phenotype increasing actin nucleation proteins at cell margins and reducing stress fibers and focal adhesions. Intriguingly, additional OPN coating of collagen IV-coated membranes accelerated stretch-induced actin reorganization and markedly diminished podocyte loss at higher strain. This study delineates the molecular response of podocytes to mechanical stress and identifies OPN as a stretch-adapting molecule in podocytes.	Univ Heidelberg, Inst Anat & Zellbiol 1, Dept Anat & Cell Biol, INF 307, D-69120 Heidelberg, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Univ Heidelberg, Klinikum Mannheim, Med Res Ctr, D-68167 Mannheim, Germany	Ruprecht Karls University Heidelberg; Max Planck Society; Ruprecht Karls University Heidelberg	Endlich, K (corresponding author), Univ Heidelberg, Inst Anat & Zellbiol 1, Dept Anat & Cell Biol, INF 307, D-69120 Heidelberg, Germany.	karlhans.endlich@urz.uni-heidelberg.de	Endlich, Karlhans/G-5485-2013; Sunohara, Masataka/ABA-4095-2020	Endlich, Karlhans/0000-0001-6052-6061				Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; DURVASULA RV, 2001, J AM SOC NEPHROL, V12, pA3514; DWORKIN LD, 1984, J CLIN INVEST, V73, P1448, DOI 10.1172/JCI111349; Eickhoff H, 2000, GENOME RES, V10, P1230, DOI 10.1101/gr.10.8.1230; Endlich N, 2001, J AM SOC NEPHROL, V12, P413, DOI 10.1681/ASN.V123413; Endlich N, 2001, EXP NEPHROL, V9, P436; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; Hartner A, 2001, AM J KIDNEY DIS, V38, P153, DOI 10.1053/ajkd.2001.25209; HAYWARD A, 2001, J AM SOC NEPHROL, V12, pA2402; Holthofer H, 1999, FASEB J, V13, P523, DOI 10.1096/fasebj.13.3.523; Kerjaschki D, 1996, J AM SOC NEPHROL, V7, P2518; KleinNulend J, 1997, J CELL PHYSIOL, V170, P174, DOI 10.1002/(SICI)1097-4652(199702)170:2<174::AID-JCP9>3.0.CO;2-L; KRETZLER M, 1994, VIRCHOWS ARCH, V425, P181; KRIZ W, 1994, KIDNEY INT, V45, P369, DOI 10.1038/ki.1994.47; Kriz W, 1998, KIDNEY INT, V54, P687, DOI 10.1046/j.1523-1755.1998.00044.x; Kriz W, 1998, J AM SOC NEPHROL, V9, P381; Lan HY, 1998, KIDNEY INT, V53, P136, DOI 10.1046/j.1523-1755.1998.00748.x; Meier-Ewert S, 1998, NUCLEIC ACIDS RES, V26, P2216, DOI 10.1093/nar/26.9.2216; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; OBryan GT, 1997, SEMIN NEPHROL, V17, P93; Petermann AT, 2002, KIDNEY INT, V61, P40, DOI 10.1046/j.1523-1755.2002.00102.x; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; Ricardo SD, 2000, AM J PHYSIOL-RENAL, V278, pF708, DOI 10.1152/ajprenal.2000.278.5.F708; Rohrmoser MM, 1996, KIDNEY BLOOD PRESS R, V19, P263, DOI 10.1159/000174086; Schwenger V, 1999, NEPHRON, V83, P202, DOI 10.1159/000045512; SIMONS JL, 1993, J AM SOC NEPHROL, V3, P1775; Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063; Solin ML, 2001, KIDNEY INT, V59, P481, DOI 10.1046/j.1523-1755.2001.059002481.x; TOJO A, 1990, VIRCHOWS ARCH A, V417, P389, DOI 10.1007/BF01606027; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; van Dokkum RPE, 1999, AM J PHYSIOL-REG I, V276, pR855, DOI 10.1152/ajpregu.1999.276.3.R855; van Dokkum RPE, 1999, AM J PHYSIOL-REG I, V276, pR189, DOI 10.1152/ajpregu.1999.276.1.R189; van Rodijnen WF, 2002, HYPERTENSION, V39, P111, DOI 10.1161/hy1201.096817; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Welsch T, 2001, AM J PHYSIOL-RENAL, V281, pF769, DOI 10.1152/ajprenal.2001.281.4.F769; Xie YS, 2001, KIDNEY INT, V60, P1645, DOI 10.1046/j.1523-1755.2001.00032.x; Yaoita E, 2001, CELL TISSUE RES, V304, P339	40	77	78	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2002	16	11					1850	+		10.1096/fj.02-0125fje	http://dx.doi.org/10.1096/fj.02-0125fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12354696				2022-12-28	WOS:000178441800005
J	Huang, JS; Wang, YH; Ling, TY; Chuang, SS; Johnson, FE; Huang, SS				Huang, JS; Wang, YH; Ling, TY; Chuang, SS; Johnson, FE; Huang, SS			Synthetic TGF-beta antagonist accelerates wound healing and reduces scarring	FASEB JOURNAL			English	Article						hypertrophic scarring; tissue fibrosis; peptantagonist	MODEL; MICE	Wound healing consists of re-epithelialization, contraction and formation of granulation and scar tissue. TGF-beta is involved in these events, but its exact roles are not well understood. Here we demonstrate that topical application of a synthetic TGF-beta antagonist accelerates re-epithelialization in pig burn wounds (100% re-epithelialization in antagonist-treated wounds vs. similar to 70% re-epithelialization in control wounds on postburn day 26) and reduces wound contraction and scarring in standard pig skin burn, pig skin excision and rabbit skin excision wounds. These results support the distinct roles of TGF-beta in the complex process of wound healing and demonstrate the feasibility of manipulating wound healing by TGF-beta antagonist.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Surg, St Louis, MO 63104 USA; Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; China Med Coll, Inst Pharmaceut Chem, Taichung, Taiwan; Taiwan Pig Res Inst, Maioli, Taiwan; Chang Gung Mem Hosp, Dept Plast & Reconstruct Surg, Tao Yuan, Taiwan	Saint Louis University; Saint Louis University; Academia Sinica - Taiwan; China Medical University Taiwan; Chang Gung Memorial Hospital	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangjs@slu.edu; huangss@slu.edu		Ling, Thai-Yen/0000-0002-3992-883X				Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Chan JCY, 2001, AM J PATHOL, V159, P1681, DOI 10.1016/S0002-9440(10)63015-5; Huang SS, 1997, J BIOL CHEM, V272, P27155, DOI 10.1074/jbc.272.43.27155; KAUFMAN T, 1984, BURNS, V10, P252, DOI 10.1016/0305-4179(84)90003-2; Kitamura M, 2001, CLIN CARDIOL, V24, P325, DOI 10.1002/clc.4960240413; Knabl JS, 1999, BURNS, V25, P229, DOI 10.1016/S0305-4179(98)00172-7; Liu QJ, 2001, J BIOL CHEM, V276, P46212, DOI 10.1074/jbc.M105177200; MUTOE TA, 1991, J CLIN INVEST, V87, P694; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; Roberts Anita B., 1995, Wound Repair and Regeneration, V3, P408, DOI 10.1046/j.1524-475X.1995.30405.x; SHAH M, 1995, J CELL SCI, V108, P985; SHAH M, 1994, J CELL SCI, V107, P1137; WINTER GD, 1974, BURNS, V1, P191; Xia YP, 1999, J PATHOL, V188, P431, DOI 10.1002/(SICI)1096-9896(199908)188:4<431::AID-PATH362>3.0.CO;2-B; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853	16	83	90	2	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2002	16	8					1269	+		10.1096/fj.02-0103fje	http://dx.doi.org/10.1096/fj.02-0103fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12153996				2022-12-28	WOS:000176683900017
J	Schuh, JM; Power, CA; Proudfoot, AE; Kunkel, SL; Lukacs, NW; Hogaboam, CM				Schuh, JM; Power, CA; Proudfoot, AE; Kunkel, SL; Lukacs, NW; Hogaboam, CM			Airway hyperresponsiveness, but not airway remodeling, is attenuated during chronic pulmonary allergic responses to Aspergillus in CCR4-/- mice	FASEB JOURNAL			English	Article						Aspergillus fumigatus; asthma; allergy; airway hyperreactivity; inflammation	MACROPHAGE-DERIVED CHEMOKINE; GOBLET CELL HYPERPLASIA; CC-CHEMOKINE; PERIBRONCHIAL FIBROSIS; NEUTROPHIL ELASTASE; RECEPTOR EXPRESSION; ANTIFUNGAL ACTIVITY; ANTIGEN CHALLENGE; EPITHELIAL-CELLS; CUTTING EDGE	The role of CC chemokine receptor 4 (CCR4) during the development and maintenance of Th2-type allergic airway disease is controversial. In this study, we examined the role of CCR4 in the chronic allergic airway response to live Aspergillus fumigatus spores, or conidia, in A. fumigatus-sensitized mice. After the conidia challenge, mice lacking CCR4 (CCR4-/- mice) exhibited significantly increased numbers of airway neutrophils and macrophages, and conidia were more rapidly eliminated from these mice compared with control CCR4 wild-type (CCR4+/+) mice. Significant airway hyperresponsiveness to intravenous methacholine was observed at day 3 in CCR4-/- mice, whereas at days 7 and 30, airway hyperresponsiveness was attenuated in these mice compared with control mice. A major reduction in peribronchial and airway eosinophilia was observed in CCR4-/- mice at all times after conidia challenge in contrast to CCR4+/+ mice. Further, whole lung levels of interleukin (IL) 4 and IL-5 were significantly increased in CCR4-/- mice at day 3, whereas these Th2 cytokines and IL-13 were significantly decreased at day 30 in CCR4-/- mice compared with their wild-type counterparts. Peribronchial fibrosis and goblet cell hyperplasia were similar in both groups of mice throughout the course of this model. In summary, CCR4 modulates both innate and acquired immune responses associated with chronic fungal asthma.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Serono Pharmaceut Res Inst, Geneva, Switzerland	University of Michigan System; University of Michigan	Hogaboam, CM (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Room 5214,Med Sci I,1301 Catherine Rd, Ann Arbor, MI 48109 USA.	hogaboam@med.umich.edu	hogaboam, cory/M-3578-2014	Hogaboam, Cory/0000-0003-3366-4850				Agusti C, 1998, AM J RESP CRIT CARE, V158, P1253, DOI 10.1164/ajrccm.158.4.9801041; Berin MC, 2001, AM J RESP CELL MOL, V24, P382, DOI 10.1165/ajrcmb.24.4.4360; Blease K, 2001, J IMMUNOL, V167, P6583, DOI 10.4049/jimmunol.167.11.6583; Blease K, 2002, AM J PATHOL, V160, P481, DOI 10.1016/S0002-9440(10)64867-5; Blease K, 2001, J IMMUNOL, V166, P5219, DOI 10.4049/jimmunol.166.8.5219; Blease K, 2001, J IMMUNOL, V166, P1832, DOI 10.4049/jimmunol.166.3.1832; Blease K, 2000, J IMMUNOL, V165, P2603, DOI 10.4049/jimmunol.165.5.2603; Blease K, 2000, J IMMUNOL, V165, P1564, DOI 10.4049/jimmunol.165.3.1564; Bochner BS, 1999, J ALLERGY CLIN IMMUN, V103, P527, DOI 10.1016/S0091-6749(99)70481-1; Burgel PR, 2000, J ALLERGY CLIN IMMUN, V106, P705, DOI 10.1067/mai.2000.109823; Campbell E, 2000, J IMMUNOL, V164, P1096, DOI 10.4049/jimmunol.164.2.1096; Campbell EM, 1999, J IMMUNOL, V163, P2160; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Chantry D, 1999, BLOOD, V94, P1890; Chvatchko Y, 2000, J EXP MED, V191, P1755, DOI 10.1084/jem.191.10.1755; Clemons KV, 2000, CLIN EXP IMMUNOL, V122, P186, DOI 10.1046/j.1365-2249.2000.01382.x; Cockrill BA, 1999, ANNU REV MED, V50, P303, DOI 10.1146/annurev.med.50.1.303; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Del Sero G, 1999, MICROBES INFECT, V1, P1169, DOI 10.1016/S1286-4579(99)00245-2; Elstad M R, 1991, Semin Respir Infect, V6, P27; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; Gonzalo JA, 1999, J IMMUNOL, V163, P403; GREENBERGER PA, 1987, CHEST, V91, pS165, DOI 10.1378/chest.91.6.165S; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; Gutierrez-Ramos JC, 2000, IMMUNOL REV, V177, P31, DOI 10.1034/j.1600-065X.2000.17713.x; Hamerman JA, 2001, J IMMUNOL, V167, P2227, DOI 10.4049/jimmunol.167.4.2227; Hogaboam CM, 1999, J IMMUNOL, V162, P6071; Hogaboam CM, 2000, AM J PATHOL, V156, P723, DOI 10.1016/S0002-9440(10)64775-X; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1998, J BIOL CHEM, V273, P1764, DOI 10.1074/jbc.273.3.1764; Johnson PRA, 2000, AM J RESP CRIT CARE, V162, P2145, DOI 10.1164/ajrccm.162.6.9909111; KAUFFMAN HF, 1995, AM J RESP CRIT CARE, V151, P2109, DOI 10.1164/ajrccm.151.6.7767565; Kawasaki S, 2001, J IMMUNOL, V166, P2055, DOI 10.4049/jimmunol.166.3.2055; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Lukacs NW, 1999, J CLIN INVEST, V104, P995, DOI 10.1172/JCI8125; Lukacs NW, 2001, CHEST, V120, p5S, DOI 10.1378/chest.120.1_suppl.S5; Mantovani A, 2000, J LEUKOCYTE BIOL, V68, P400; Matsukawa A, 2000, J IMMUNOL, V164, P5362, DOI 10.4049/jimmunol.164.10.5362; Matsukawa A, 2000, Rev Immunogenet, V2, P339; Mehrad B, 1999, J IMMUNOL, V162, P1633; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Murali PS, 1998, J LAB CLIN MED, V131, P228, DOI 10.1016/S0022-2143(98)90094-4; NADEL JA, 1991, RESPIRATION, V58, P3; Nadel JA, 2000, CHEST, V117, p386S, DOI 10.1378/chest.117.5_suppl_2.386S; Nagase H, 2001, J ALLERGY CLIN IMMUN, V108, P563, DOI 10.1067/mai.2001.118292; Nocker RET, 1996, INT ARCH ALLERGY IMM, V109, P183, DOI 10.1159/000237218; Nogami H, 2000, EUR J PHARMACOL, V390, P197, DOI 10.1016/S0014-2999(99)00921-8; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Rodenburg RJT, 1998, J LEUKOCYTE BIOL, V63, P606, DOI 10.1002/jlb.63.5.606; ROILIDES E, 1994, J INFECT DIS, V170, P894, DOI 10.1093/infdis/170.4.894; Roilides E, 1997, J IMMUNOL, V158, P322; Roilides E, 1998, RES IMMUNOL, V149, P454, DOI 10.1016/S0923-2494(98)80769-4; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; Schuh JM, 2002, J IMMUNOL, V168, P1447, DOI 10.4049/jimmunol.168.3.1447; SCHUH JM, 2002, IN PRESS AM J PHYSL; Vestergaard C, 1999, J CLIN INVEST, V104, P1097, DOI 10.1172/JCI7613; Waldorf A R, 1989, Immunol Ser, V47, P243; Warschkau H, 1999, J IMMUNOL, V163, P3409; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wu MT, 2001, J IMMUNOL, V167, P4791, DOI 10.4049/jimmunol.167.9.4791; Yousefi S, 2001, J LEUKOCYTE BIOL, V69, P1045; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	64	107	114	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1313	+		10.1096/fj.02-0193fje	http://dx.doi.org/10.1096/fj.02-0193fje			31	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154006	Green Submitted			2022-12-28	WOS:000176683900028
J	Levine, L				Levine, L			Does the release of arachidonic acid from cells play a role in cancer chemoprevention?	FASEB JOURNAL			English	Article						AA; retinoid; COX-2; antioxidant	RAT-LIVER CELLS; MAMMARY CARCINOGENESIS; SYNTHETIC ANALOGS; EPITHELIAL-CELLS; COLON-CANCER; CYCLOOXYGENASE-2; PREVENTION; INHIBITION; RETINOIDS; GAMMA	COX-2 is overexpressed in cancer cells and has become a major target for cancer preventive drugs. NSAIDs, retinoids, antioxidants, and PPAR agonists, reported to be chemopreventive, suppress COX-2 synthesis. NSAIDs also have been shown to be chemopreventive independent of COX-2 activity. Common to all of these compounds is their ability to release arachidonic acid (AA) from rat liver cells in culture. Most of these compounds inhibit induced PGI(2) production. Vitamin D-3 and tamoxifen, however, not only stimulate the release of AA from cells: they amplify rather than inhibits induced COX activity. In view of the many activities attributable to AA, I propose that its release and accumulation could initiate molecular reactions that lead to apoptosis and eventually to suppression of cancer. Some drugs shown to release AA from cells and affect PGI(2) production e.g., thiazolidinediones and statins are widely used for conditions unrelated to cancer. In vivo studies could reveal whether they can also function as cancer preventive agents.	Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA	Brandeis University	Levine, L (corresponding author), Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA.	llevine@brandeis.edu						Brash AR, 2001, J CLIN INVEST, V107, P1339, DOI 10.1172/JCI13210; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Demetri GD, 1999, P NATL ACAD SCI USA, V96, P3951, DOI 10.1073/pnas.96.7.3951; Fujiki H, 2002, P JPN ACAD B-PHYS, V78, P263, DOI 10.2183/pjab.78.263; Guyton KZ, 2001, ANNU REV PHARMACOL, V41, P421, DOI 10.1146/annurev.pharmtox.41.1.421; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Kelloff GJ, 2000, ADV CANCER RES, V78, P199; LEVINE L, 1978, NATURE, V276, P274, DOI 10.1038/276274a0; Levine L, 1998, CELL SIGNAL, V10, P653, DOI 10.1016/S0898-6568(98)00008-4; Levine L, 2002, PROSTAG LEUKOTR ESS, V67, P453, DOI 10.1054/plef.2002.0456; Levine L, 2001, PROSTAG LEUKOTR ESS, V65, P31, DOI 10.1054/plef.2001.0284; Levine L, 2000, PROSTAG LEUKOTR ESS, V63, P363, DOI 10.1054/plef.2000.0227; LEVINE L, 1986, MANUAL CLIN LABORATO, P685; LEVINE L, 1988, PROGR ALLERGY, V44, P1; Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mestre JR, 1997, CANCER RES, V57, P2890; Michaluart P, 1999, CANCER RES, V59, P2347; RAO CV, 1993, CANCER RES, V53, P4182; Rayyan Y, 2002, CANCER INVEST, V20, P1002, DOI 10.1081/CNV-120005917; Rioux N, 1998, CANCER RES, V58, P5354; Rockwell P, 2000, ARCH BIOCHEM BIOPHYS, V374, P325, DOI 10.1006/abbi.1999.1646; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; SPORN MB, 1976, FED PROC, V35, P1332; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Suh N, 1999, CANCER RES, V59, P5671; THOMPSON HJ, 1995, J NATL CANCER I, V87, P1259; WHATLEY RE, 1994, J CLIN INVEST, V94, P1889, DOI 10.1172/JCI117539; YANG M, 1997, SCIENCE, V275, P218	31	20	24	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					800	802		10.1096/fj.02-0906hyp	http://dx.doi.org/10.1096/fj.02-0906hyp			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724337				2022-12-28	WOS:000183165000004
J	Nebigil, CG; Etienne, N; Messaddeq, N; Maroteaux, L				Nebigil, CG; Etienne, N; Messaddeq, N; Maroteaux, L			Serotonin is a novel survival factor of cardiomyocytes: mitochondria as a target of 5-HT2B-receptor signaling	FASEB JOURNAL			English	Article						PI3 kinase; Akt; Gq; ERK; Bax	ADENINE-NUCLEOTIDE TRANSLOCATOR; NF-KAPPA-B; PERMEABILITY TRANSITION PORE; BCL-2 PROTEIN FAMILY; CARDIAC MYOCYTES; HEART-FAILURE; 2B RECEPTOR; PROMOTES SURVIVAL; CROSS-TALK; IN-VITRO	Identification of factors regulating cardiomyocyte survival and growth is important to understand the pathogenesis of congenital heart diseases. Little is known about the molecular mechanism of cardiac functions triggered by serotonin. The link between signaling circuitry of external stimuli and the mitochondrial apoptotic machinery is of wide interest in cardiac diseases. Using cultured cardiomyocytes and 5-hydroxytryptamine (5-HT)(2B)-receptor knockout mice as an animal model of dilated cardiomyopathy, for the first time we show that serotonin via the Gq-coupled 5-HT2B-receptor protect cardiomyocytes against serum deprivation-induced apoptosis as manifested by DNA fragmentation, nuclear chromatin condensation, and TUNEL labeling. Serotonin prevents cytochrome c release and caspase-9 and -3 activation after serum deprivation via cross-talks between phosphatidylinositol-3 kinase/Akt and extracellular signal-regulated kinase (ERK) 1/2 signaling pathways. Serotonin binding to 5-HT2B-receptor activates ERK kinases to inhibit Bax expression induced by serum deprivation. Serotonin via phosphatidylinositol-3 kinase/Akt can activate NF-kappaB that is required for the regulation of the mitochondrial adenine nucleotide translocator (ANT-1). Parallel to these observations, ultrastructural analysis in the 5-HT2B-receptor knockout mice heart revealed pronounced mitochondrial defects in addition to altered mitochondrial enzyme activities (cytochrome oxidase and succinate dehydrogenase) and ANT-1 and Bax expressions. These findings identify 5-HT as a novel survival factor targeting mitochondria in cardiomyocytes.	Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Maroteaux, L (corresponding author), Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, BP 10142, F-67404 Illkirch Graffenstaden, France.	lucm@igbmc.u-strasbg.fr	Maroteaux, Luc/H-4585-2019; Nebigil, Canan/AAK-7162-2021	Maroteaux, Luc/0000-0002-9499-8603; Nebigil, Canan/0000-0002-2035-5795				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adams JW, 2001, ONCOGENE, V20, P1626, DOI 10.1038/sj.onc.1204275; Adams JW, 2000, CIRC RES, V87, P1180, DOI 10.1161/01.RES.87.12.1180; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0; Bratton SB, 2001, TRENDS PHARMACOL SCI, V22, P306, DOI 10.1016/S0165-6147(00)01718-1; Choi DS, 1997, DEVELOPMENT, V124, P1745; Communal C, 2002, P NATL ACAD SCI USA, V99, P6252, DOI 10.1073/pnas.092022999; Condorelli G, 2002, FASEB J, V16, P1732, DOI 10.1096/fj.02-0419com; Cook SA, 1999, EUR HEART J, V20, P1619, DOI 10.1053/euhj.1999.1548; Craig R, 2001, J BIOL CHEM, V276, P37621, DOI 10.1074/jbc.M103276200; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P6400, DOI 10.1073/pnas.96.11.6400; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Frishman WH, 2000, ANN MED, V32, P195, DOI 10.3109/07853890008998827; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Gill C, 2002, FASEB J, V16, P135, DOI 10.1096/fj.01-0629com; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hoyer D, 2002, PHARMACOL BIOCHEM BE, V71, P533, DOI 10.1016/S0091-3057(01)00746-8; Huang HM, 2000, BLOOD, V96, P1764, DOI 10.1182/blood.V96.5.1764.h8001764_1764_1771; HUANG P, 1992, ANAL BIOCHEM, V207, P163, DOI 10.1016/0003-2697(92)90518-C; Iwai-Kanai E, 1999, CIRCULATION, V100, P305, DOI 10.1161/01.CIR.100.3.305; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; KUBALAK S, 1996, METHODS MOL GENETICS, V8; Maddock HL, 2002, AM J PHYSIOL-HEART C, V283, pH1307, DOI 10.1152/ajpheart.00851.2001; Manivet P, 2000, J BIOL CHEM, V275, P9324, DOI 10.1074/jbc.275.13.9324; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Moretti A, 2002, P NATL ACAD SCI USA, V99, P11860, DOI 10.1073/pnas.182373099; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Narula J, 1999, P NATL ACAD SCI USA, V96, P8144, DOI 10.1073/pnas.96.14.8144; Narula J, 2000, CURR OPIN CARDIOL, V15, P183, DOI 10.1097/00001573-200005000-00011; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P9508, DOI 10.1073/pnas.97.17.9508; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P2591, DOI 10.1073/pnas.050282397; Nebigil CG, 2001, CIRCULATION, V103, P2973, DOI 10.1161/01.CIR.103.24.2973; Portman MA, 2000, MOL GENET METAB, V71, P445, DOI 10.1006/mgme.2000.3030; Reed JC, 1999, P NATL ACAD SCI USA, V96, P7614, DOI 10.1073/pnas.96.14.7614; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Saito S, 2000, J BIOL CHEM, V275, P34528, DOI 10.1074/jbc.M002844200; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; Shi YG, 2001, NAT STRUCT BIOL, V8, P394, DOI 10.1038/87548; Tournois C, 1998, J BIOL CHEM, V273, P17498, DOI 10.1074/jbc.273.28.17498; Villalon CM, 1997, DRUG DISCOV TODAY, V2, P294, DOI 10.1016/S1359-6446(97)01055-6; von Harsdorf R, 1999, CIRC RES, V85, P128, DOI 10.1161/01.RES.85.2.128; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zhu H, 2000, CELL DEATH DIFFER, V7, P773, DOI 10.1038/sj.cdd.4400721	56	113	120	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1373	+		10.1096/fj.02-1122fje	http://dx.doi.org/10.1096/fj.02-1122fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738797	Green Submitted			2022-12-28	WOS:000183165000031
J	Warnecke, C; Griethe, W; Weidemann, A; Jurgensen, JS; Willam, C; Bachmann, S; Ivashchenko, Y; Wagner I; Frei, U; Wiesener, M; Eckardt, KU				Warnecke, C; Griethe, W; Weidemann, A; Jurgensen, JS; Willam, C; Bachmann, S; Ivashchenko, Y; Wagner, I; Frei, U; Wiesener, M; Eckardt, KU			Activation of the hypoxia-inducible factor pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors	FASEB JOURNAL			English	Article						transcription factor; ischemic diseases; neoangiogenesis; pharmacotherapy	TRANSCRIPTION FACTORS; HIF-ALPHA; FACTOR-I; HIF-1-ALPHA/VP16 HYBRID; MYOCARDIAL-INFARCTION; FIBROBLAST-CULTURES; GENE-EXPRESSION; KAPPA-B; 4-HYDROXYLASE; PROTEIN	Hypoxia-inducible transcription factors (HIF) mediate complex adaptations to reduced oxygen supply, including neoangiogenesis. Regulation of HIF occurs mainly through oxygen-dependent destruction of its alpha subunit. In the presence of oxygen, two HIFalpha. prolyl residues undergo enzymatic hydroxylation, which is required for its proteasomal degradation. We therefore tested whether pharmacological activation of HIFalpha. by hydroxylase inhibitors may provide a novel therapeutic strategy for the treatment of ischemic diseases. Three distinct prolyl 4-hydroxylase inhibitors-L-mimosine (L-Mim), ethyl 3,4-dihydroxybenzoate (3,4-DHB), and 6-chlor-3-hydroxychinolin-2-carbonic acid-N-carboxymethylamid (5956711)-demonstrated similar effects to hypoxia (0.5% 02) by inducing HIFalpha. protein in human and rodent cells. L-Mim, 5956711, and, less effectively, 3,4-DHB also induced HIF target genes in cultured cells, including glucose transporter 1 and vascular endothelial growth factor, as well as HIF-dependent reporter gene expression. Systemic administration of L-Mim and 5956711 in rats led to HIFalpha. induction in the kidney. In a sponge model for angiogenesis, repeated local injection of the inhibitors strongly increased invasion of highly vascularized tissue into the sponge centers. In conclusion, structurally distinct inhibitors of prolyl hydroxylation are capable of inducing HIFalpha. and HIF target genes in vitro and in vivo and induce adaptive responses to hypoxia, including angiogenesis.	Humboldt Univ, Dept Nephrol & Med Intens Care, Univ Clin Charite, D-13353 Berlin, Germany; Humboldt Univ, Dept Anat, Univ Clin Charite, D-13353 Berlin, Germany; Aventis Pharma Deutschland GmbH, Dept Cardiovasc Dis, D-65926 Frankfurt, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Sanofi-Aventis	Eckardt, KU (corresponding author), Campus Virchow Clin, Charite, Dept Nephrol & Med Intens Care, Augustenburger Pl 1, D-13353 Berlin, Germany.	uwe.eckardt@charite.de						ABBRUZZESE A, 1991, BIOCHIM BIOPHYS ACTA, V1077, P159, DOI 10.1016/0167-4838(91)90053-3; BAADER E, 1994, BIOCHEM J, V300, P525, DOI 10.1042/bj3000525; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; CUNLIFFE CJ, 1992, J MED CHEM, V35, P2652, DOI 10.1021/jm00092a016; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FLAMME I, 1995, DEV BIOL, V171, P399, DOI 10.1006/dbio.1995.1291; HIROSE Y, 1995, CARCINOGENESIS, V16, P2337, DOI 10.1093/carcin/16.10.2337; HOLMES JHG, 1981, AUST VET J, V57, P257, DOI 10.1111/j.1751-0813.1981.tb05805.x; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Ju HS, 1998, BBA-MOL CELL RES, V1448, P51, DOI 10.1016/S0167-4889(98)00114-1; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KOONG AC, 1994, CANCER RES, V54, P1425; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lee RJ, 2000, CIRCULATION, V102, P898; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; MAJAMAA K, 1987, J INVEST DERMATOL, V89, P405, DOI 10.1111/1523-1747.ep12471775; MAJAMAA K, 1986, J BIOL CHEM, V261, P7819; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MCCAFFREY TA, 1995, J CLIN INVEST, V95, P446, DOI 10.1172/JCI117684; Nwogu JI, 2001, CIRCULATION, V104, P2216, DOI 10.1161/hc4301.097193; Oehme F, 2002, BIOCHEM BIOPH RES CO, V296, P343, DOI 10.1016/S0006-291X(02)00862-8; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; SASAKI T, 1987, J BIOL CHEM, V262, P9397; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Shyu KG, 2002, CARDIOVASC RES, V54, P576, DOI 10.1016/S0008-6363(02)00259-6; SZYSZKA M, 1984, DEUT TIERARZTL WOCH, V91, P262; Vincent KA, 2000, CIRCULATION, V102, P2255; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Willam C, 2002, P NATL ACAD SCI USA, V99, P10423, DOI 10.1073/pnas.162119399; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Wykoff CC, 2000, CANCER RES, V60, P7075; Zaman K, 1999, J NEUROSCI, V19, P9821; Zhu H, 2002, NEPHROL DIAL TRANSPL, V17, P3, DOI 10.1093/ndt/17.suppl_1.3	45	177	201	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1186	+		10.1096/fj.02-1062fje	http://dx.doi.org/10.1096/fj.02-1062fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709400				2022-12-28	WOS:000182580100025
J	Greenwood, J; Walters, CE; Pryce, G; Kanuga, N; Beraud, E; Baker, D; Adamson, P				Greenwood, J; Walters, CE; Pryce, G; Kanuga, N; Beraud, E; Baker, D; Adamson, P			Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis	FASEB JOURNAL			English	Article						statins; blood-brain barrier; leukocyte recruitment; multiple sclerosis	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; COA REDUCTASE INHIBITOR; MYELIN BASIC-PROTEIN; IN-VITRO; BLOOD-BRAIN; TRANSENDOTHELIAL MIGRATION; MULTIPLE-SCLEROSIS; LEWIS RATS; ICAM-1	Neuroinflammatory diseases, such as multiple sclerosis (MS), result from aberrant leukocyte traffic into the central nervous system (CNS). To breach the specialized blood-brain barrier, activated leukocytes interact with CNS endothelial cells (EC) and activate a CD54-mediated signaling pathway controlling the Rho GTPase. To function correctly Rho requires posttranslational prenylation, and this can be inhibited by depleting the supply of isoprenoids through inhibition of the cholesterol synthesis pathway with 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoA reductase) inhibitors (statins). Here we show that treatment of brain EC in vitro with lovastatin inhibits Rho-mediated transendothelial T cell migration. This effect can be reversed by supplementation with mevalonolactone, the downstream product of HMG-CoA reductase, or by ectopic expression of myristoylated Rho, which remains active in the absence of prenylation. In a relapsing-remitting mouse model of MS, lovastatin treatment inhibited leukocyte migration into the CNS and significantly attenuated the development of both acute and relapsing clinical disease. These studies demonstrate that the indirect pharmacological inhibition of Rho proteins in brain EC by statins can inhibit a key stage in the pathogenesis of neuroinflammation, namely leukocyte migration across the blood-brain barrier. These studies demonstrate a novel effect of statins in modulating the immune response in neuroinflammtory diseases and may provide additional rationale for their use in the treatment of MS.	UCL, Div Cell Biol, Inst Ophthalmol, London EC1V 9EL, England; UCL, Dept Neuroinflammat, Inst Neurol, London WC1N 1PJ, England; Univ Aix Marseille 2, Fac Med, Immunol Lab, Marseille, France	University of London; University College London; University of London; University College London; UDICE-French Research Universities; Aix-Marseille Universite	Greenwood, J (corresponding author), UCL, Div Cell Biol, Inst Ophthalmol, Bath St, London EC1V 9EL, England.	j.greenwood@ucl.ac.uk		Greenwood, John/0000-0003-4496-2984	Multiple Sclerosis Society [541, 675] Funding Source: Medline; Wellcome Trust [062403] Funding Source: Medline	Multiple Sclerosis Society(National Multiple Sclerosis Society); Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Adamson P, 2002, FASEB J, V16, DOI 10.1096/fj.02-0035com; ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Adamson P, 1999, J IMMUNOL, V162, P2964; ALLEN SJ, 1993, CELL IMMUNOL, V146, P335, DOI 10.1006/cimm.1993.1031; Amor S, 1996, J IMMUNOL, V156, P3000; Backlund PS, 1997, J BIOL CHEM, V272, P33175, DOI 10.1074/jbc.272.52.33175; BAKER D, 1990, J NEUROIMMUNOL, V28, P261, DOI 10.1016/0165-5728(90)90019-J; BERAUD E, 1986, J IMMUNOL, V136, P511; BERAUD E, 1993, J NEUROIMMUNOL, V47, P41, DOI 10.1016/0165-5728(93)90283-5; CHAKRABARTI R, 1991, J BIOL CHEM, V266, P12216; Etienne S, 1998, J IMMUNOL, V161, P5755; Etienne-Manneville S, 2000, J IMMUNOL, V165, P3375, DOI 10.4049/jimmunol.165.6.3375; Greenwood J, 1996, J NEUROIMMUNOL, V71, P51, DOI 10.1016/S0165-5728(96)00130-0; GREENWOOD J, 1995, IMMUNOLOGY, V86, P408; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lefer AM, 1999, CIRCULATION, V100, P178, DOI 10.1161/01.CIR.100.2.178; MALE D, 1994, IMMUNOLOGY, V81, P366; MCPHERSON R, 1993, J CLIN IMMUNOL, V13, P439, DOI 10.1007/BF00920019; Neuhaus O, 2002, NEUROLOGY, V59, P990, DOI 10.1212/WNL.59.7.990; ONEILL JK, 1992, J NEUROIMMUNOL, V38, P53, DOI 10.1016/0165-5728(92)90090-8; Pryce G, 1997, J NEUROIMMUNOL, V75, P84, DOI 10.1016/S0165-5728(97)00006-4; Reiss Y, 1998, EUR J IMMUNOL, V28, P3086, DOI 10.1002/(SICI)1521-4141(199810)28:10<3086::AID-IMMU3086>3.3.CO;2-Q; Stanislaus R, 1999, NEUROSCI LETT, V269, P71, DOI 10.1016/S0304-3940(99)00414-0; Stanislaus R, 2001, J NEUROSCI RES, V66, P155, DOI 10.1002/jnr.1207; Steinman L, 2001, NAT IMMUNOL, V2, P762, DOI 10.1038/ni0901-762; Walters CE, 2002, J IMMUNOL, V168, P4087, DOI 10.4049/jimmunol.168.8.4087; Weber C, 1997, J AM COLL CARDIOL, V30, P1212, DOI 10.1016/S0735-1097(97)00324-0; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Wong BM, 2001, J LEUKOCYTE BIOL, V69, P959; Yoshida M, 2001, ARTERIOSCL THROM VAS, V21, P1165, DOI 10.1161/hq0701.092143; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	35	185	196	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					905	+		10.1096/fj.02-1014fje	http://dx.doi.org/10.1096/fj.02-1014fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626426	Green Accepted			2022-12-28	WOS:000181892600027
J	Hansson, E; Ronnback, L				Hansson, E; Ronnback, L			Glial neuronal signaling in the central nervous system	FASEB JOURNAL			English	Review						astrocyte; microglia; oligodendrocyte; neuron; network; communication	VASOACTIVE-INTESTINAL-PEPTIDE; NECROSIS-FACTOR-ALPHA; HIPPOCAMPAL ASTROGLIAL CELLS; CALCIUM WAVE-PROPAGATION; ACTIVATED MICROGLIA; CULTURED ASTROCYTES; PRECURSOR PROTEIN; GAP-JUNCTIONS; RAT-BRAIN; IN-SITU	Glial cells are known to interact extensively with neuronal elements in the brain, influencing their activity. Astrocytes associated with synapses integrate neuronal inputs and release transmitters that modulate synaptic sensitivity. Glial cells participate in formation and rebuilding of synapses and play a prominent role in protection and repair of nervous tissue after damage. For glial cells to take an active part in plastic alterations under physiological conditions and pathological disturbances, extensive specific signaling, both within single cells and between cells, is required. In recent years, intensive research has led to our first insight into this signaling. We know there are active connections between astrocytes in the form of networks promoting Ca2+ and ATP signaling; we also know there is intense signaling between astrocytes, microglia, oligodendrocytes, and neurons, with an array of molecules acting as signaling substances. The cells must be functionally integrated to facilitate the enormous dynamics of and capacity for reconstruction within the nervous system. In this paper, we summarize some basic data on glial neuronal signaling to provide insight into synaptic modulation and reconstruction in physiology and protection and repair after damage.	Univ Gothenburg, Inst Clin Neurosci, SE-40530 Gothenburg, Sweden	University of Gothenburg	Hansson, E (corresponding author), Univ Gothenburg, Inst Clin Neurosci, Medicinaregatan 5,POB 420, SE-40530 Gothenburg, Sweden.	elisabeth.hansson@anatcell.gu.se						Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Allansson L, 2001, J NEUROCHEM, V76, P472, DOI 10.1046/j.1471-4159.2001.00097.x; Aloisi F, 1997, J IMMUNOL, V159, P1604; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; ATTWELL D, 1994, NATURE, V369, P707, DOI 10.1038/369707a0; BANATI RB, 1993, GLIA, V9, P199, DOI 10.1002/glia.440090305; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Blomstrand F, 1999, NEUROSCIENCE, V92, P255, DOI 10.1016/S0306-4522(98)00738-6; Blomstrand F, 1999, NEUROSCIENCE, V88, P1241, DOI 10.1016/S0306-4522(98)00351-0; Blomstrand F, 1999, AM J PHYSIOL-CELL PH, V277, pC616, DOI 10.1152/ajpcell.1999.277.4.C616; Blondel O, 2000, J NEUROSCI, V20, P8012; Brenneman DE, 1996, J CLIN INVEST, V97, P2299, DOI 10.1172/JCI118672; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; CARMIGNOTO G, 1999, SOC NEUR ABSTR; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHARLES AC, 1994, DEV NEUROSCI-BASEL, V16, P196, DOI 10.1159/000112107; Ciccarelli R, 2000, GLIA, V29, P202, DOI 10.1002/(SICI)1098-1136(20000201)29:3<202::AID-GLIA2>3.3.CO;2-3; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; DeWitt DA, 1998, EXP NEUROL, V149, P329, DOI 10.1006/exnr.1997.6738; Du YZ, 2002, J NEUROSCI RES, V68, P647, DOI 10.1002/jnr.10245; Eder C, 1999, EUR J NEUROSCI, V11, P4251, DOI 10.1046/j.1460-9568.1999.00852.x; ENKVIST MOK, 1994, J NEUROCHEM, V62, P489; Eugenin EA, 2001, P NATL ACAD SCI USA, V98, P4190, DOI 10.1073/pnas.051634298; Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303; Gegelashvili G, 2000, NEUROCHEM INT, V37, P163, DOI 10.1016/S0197-0186(00)00019-X; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GIULIAN D, 1994, NEUROCHEM INT, V25, P227, DOI 10.1016/0197-0186(94)90066-3; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; Glazner GW, 1999, J NEUROCHEM, V73, P2341, DOI 10.1046/j.1471-4159.1999.0732341.x; Grosche J, 1999, NAT NEUROSCI, V2, P139, DOI 10.1038/5692; Guo ZH, 2000, CEREB CORTEX, V10, P50, DOI 10.1093/cercor/10.1.50; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; Hagberg GB, 1998, NEUROCHEM INT, V32, P153, DOI 10.1016/S0197-0186(97)00087-9; HANSSON E, 1994, J BIOL CHEM, V269, P21955; HANSSON E, 1988, NEUROPHARMACOLOGY, V27, P295, DOI 10.1016/0028-3908(88)90047-0; HANSSON E, 1997, ASTROCYTES GLUTAMATE; HANSSON E, 2003, NONNEURONAL CELLS NE; Hassinger TD, 1996, P NATL ACAD SCI USA, V93, P13268, DOI 10.1073/pnas.93.23.13268; HATTEN ME, 1990, EXPERIENTIA, V46, P907, DOI 10.1007/BF01939383; Hisahara S, 1997, J NEUROCHEM, V69, P10; Illes P, 1996, NEUROCHEM INT, V29, P13; John GR, 1999, P NATL ACAD SCI USA, V96, P11613, DOI 10.1073/pnas.96.20.11613; JURKOWITZALEXANDER MS, 1993, J NEUROCHEM, V61, P1581, DOI 10.1111/j.1471-4159.1993.tb13662.x; KEMPSKI O, 1991, ANN NY ACAD SCI, V633, P306; KETTENMANN H, 1991, ANN NY ACAD SCI, V633, P64; KEYSER DO, 1994, GLIA, V10, P237, DOI 10.1002/glia.440100402; Kim WK, 2000, J NEUROSCI, V20, P3622, DOI 10.1523/JNEUROSCI.20-10-03622.2000; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lascola CD, 1996, J NEUROSCI, V16, P2532; Leybaert L, 1998, GLIA, V24, P398, DOI 10.1002/(SICI)1098-1136(199812)24:4<398::AID-GLIA5>3.0.CO;2-R; Lopez-Redondo F, 2000, MOL BRAIN RES, V76, P429, DOI 10.1016/S0169-328X(00)00022-X; LOUGHLIN AJ, 1992, IMMUNOLOGY, V75, P170; LOUGHLIN AJ, 1993, IMMUNOLOGY, V79, P125; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MITANI Y, 1995, AM J PHYSIOL-CELL PH, V269, pC1228, DOI 10.1152/ajpcell.1995.269.5.C1228; Mongin AA, 1999, AM J PHYSIOL-CELL PH, V277, pC823, DOI 10.1152/ajpcell.1999.277.4.C823; Muyderman H, 1998, BRAIN RES, V793, P127, DOI 10.1016/S0006-8993(98)00151-6; Muyderman H, 2001, J BIOL CHEM, V276, P46504, DOI 10.1074/jbc.M103849200; Nakahama K, 1999, GLIA, V25, P240, DOI 10.1002/(SICI)1098-1136(19990201)25:3<240::AID-GLIA4>3.3.CO;2-3; Neary JT, 1999, J NEUROSCI, V19, P4211, DOI 10.1523/jneurosci.19-11-04211.1999; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; NILSSON M, 1993, NEUROSCIENCE, V54, P605, DOI 10.1016/0306-4522(93)90232-5; O'Neill WC, 1999, AM J PHYSIOL-CELL PH, V276, pC995, DOI 10.1152/ajpcell.1999.276.5.C995; ORKAND RK, 1966, J NEUROPHYSIOL, V29, P788, DOI 10.1152/jn.1966.29.4.788; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pasti L, 2001, J NEUROSCI, V21, P477, DOI 10.1523/JNEUROSCI.21-02-00477.2001; Pasti L, 1997, J NEUROSCI, V17, P7817; Porter JT, 1997, PROG NEUROBIOL, V51, P439, DOI 10.1016/S0301-0082(96)00068-8; Porter JT, 1996, J NEUROSCI, V16, P5073; Pratt Bruce M., 1997, Cytokine and Growth Factor Reviews, V8, P267, DOI 10.1016/S1359-6101(97)00018-X; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; Rathbone MP, 1999, PROG NEUROBIOL, V59, P663, DOI 10.1016/S0301-0082(99)00017-9; Rose CR, 2001, NAT NEUROSCI, V4, P773, DOI 10.1038/90464; Rouach N, 2000, J CELL BIOL, V149, P1513, DOI 10.1083/jcb.149.7.1513; Rutledge EM, 1996, J NEUROSCI, V16, P7803; SAWADA M, 1995, INT J DEV NEUROSCI, V13, P253, DOI 10.1016/0736-5748(94)00076-F; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; Schilling T, 2001, EUR J NEUROSCI, V14, P463, DOI 10.1046/j.0953-816x.2001.01661.x; SELMAJ K, 1991, J NEUROCHEM, V57, P823, DOI 10.1111/j.1471-4159.1991.tb08225.x; Shelton MK, 2000, J NEUROCHEM, V74, P555, DOI 10.1046/j.1471-4159.2000.740555.x; SHIMOJO M, 1991, NEUROSCI LETT, V123, P229, DOI 10.1016/0304-3940(91)90937-O; SNEYD J, 1994, AM J PHYSIOL, V266, pC293, DOI 10.1152/ajpcell.1994.266.1.C293; Soliven B, 2001, MICROSC RES TECHNIQ, V52, P672, DOI 10.1002/jemt.1051; STAUB F, 1993, BRAIN RES, V610, P69, DOI 10.1016/0006-8993(93)91218-H; Stella N, 1997, J NEUROSCI, V17, P2939; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; THERY C, 1993, CLIN NEUROPATHOL, V12, P288; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; VANCALKER D, 1980, P NATL ACAD SCI-BIOL, V77, P6907; VENANCE L, 1995, NATURE, V376, P590, DOI 10.1038/376590a0; Ventura R, 1999, J NEUROSCI, V19, P6897, DOI 10.1523/JNEUROSCI.19-16-06897.1999; Verderio C, 2001, J IMMUNOL, V166, P6383, DOI 10.4049/jimmunol.166.10.6383; Verkhratsky A, 1998, PHYSIOL REV, V78, P99, DOI 10.1152/physrev.1998.78.1.99; Vernadakis A, 1996, PROG NEUROBIOL, V49, P185, DOI 10.1016/S0301-0082(96)00012-3; WALZ W, 1989, PROG NEUROBIOL, V33, P309, DOI 10.1016/0301-0082(89)90005-1; Walz W, 2000, NEUROCHEM INT, V36, P291, DOI 10.1016/S0197-0186(99)00137-0; Watanabe H, 2000, NEUROSCI LETT, V289, P53, DOI 10.1016/S0304-3940(00)01252-0; Yoneda K, 2001, MOL BRAIN RES, V89, P94, DOI 10.1016/S0169-328X(01)00067-5; ZIMMERMANN H, 1994, TRENDS NEUROSCI, V17, P420, DOI 10.1016/0166-2236(94)90016-7	105	228	240	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					341	348		10.1096/fj.02-0429rev	http://dx.doi.org/10.1096/fj.02-0429rev			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12631574				2022-12-28	WOS:000181892600033
J	Ramana, KV; Chandra, D; Srivastava, S; Bhatnagar, A; Srivastava, SK				Ramana, KV; Chandra, D; Srivastava, S; Bhatnagar, A; Srivastava, SK			Nitric oxide regulates the polyol pathway of glucose metabolism in vascular smooth muscle cells	FASEB JOURNAL			English	Article						aldose reductase; glutathiolation; diabetes; nitric oxide and nitrosothiols	ALDOSE REDUCTASE; SIGNALING MECHANISMS; COMPLICATIONS; IDENTIFICATION; PREVENTION; TRANSPORT; STRESS	Increased reduction of glucose via the polyol pathway enzyme aldose reductase (AR) has been linked to the development of secondary diabetic complications. Because AR is a redox-sensitive protein, which in vitro is readily modified by NO donors, we tested the hypothesis that NO may be a physiological regulator of AR. We found that administration of the NO synthase (NOS) inhibitor N-G-nitro-L-arginine methyl ester (L-NAME) increased sorbitol accumulation in the aorta of nondiabetic and diabetic rats, whereas treatment with L-arginine (a precursor of NO) or nitroglycerine patches prevented sorbitol accumulation. When incubated ex vivo with high glucose, sorbitol accumulation was increased by L-NAME and prevented by L-arginine in strips of aorta from rats or wild-type, but not eNOS-deficient, mice. Exposure to NO donors also inhibited AR and prevented sorbitol accumulation in rat aortic vascular smooth muscle cells (VSMC) in culture. The NO donors also increased the incorporation of radioactivity in the AR protein immunoprecipitated from VSMC in which the glutathione pool was prelabeled with [S-35]-cysteine. Based on these observations, we suggest that NO regulates the vascular synthesis of polyols by S-thiolating AR; therefore, increasing NO synthesis or bioavailability may be useful in preventing diabetes-induced changes in the polyol pathway.	Univ Texas, Dept Human Biol Chem & Genet, Med Branch, Galveston, TX 77555 USA; Univ Louisville, Dept Med, Div Cardiol, Louisville, KY 40292 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Louisville	Srivastava, SK (corresponding author), Univ Texas, Dept Human Biol Chem & Genet, Med Branch, Room 6-644,Basic Sci Bldg, Galveston, TX 77555 USA.	ssrivast@utmb.edu	Srivastava, Sanjay/D-3921-2012; Ramana, Kota/C-5460-2012; Bhatnagar, Aruni/H-7791-2013	Ramana, Kota/0000-0001-6502-7800	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065618, R01HL059378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK036118, R01DK036118] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59378, HL65618] Funding Source: Medline; NIDDK NIH HHS [DK 36118] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akaike T, 2000, FREE RADICAL RES, V33, P461, DOI 10.1080/10715760000301001; BHATNAGAR A, 1992, BIOCHEM MED METAB B, V48, P91, DOI 10.1016/0885-4505(92)90055-4; BURG MB, 1995, AM J PHYSIOL, V268, P983; Chandra A, 1997, BIOCHEMISTRY-US, V36, P15801, DOI 10.1021/bi9714722; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Dixit BL, 2000, J BIOL CHEM, V275, P21587, DOI 10.1074/jbc.M909235199; Grant CM, 1999, MOL CELL BIOL, V19, P2650; Henry Y, 1999, CELL MOL LIFE SCI, V55, P1003, DOI 10.1007/s000180050351; Hotta N, 1997, Nagoya J Med Sci, V60, P89; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; KADOR PF, 1985, ANNU REV PHARMACOL, V25, P691, DOI 10.1146/annurev.pa.25.040185.003355; Kassab E, 2001, VASC MED, V6, P249, DOI 10.1177/1358836X0100600409; King GL, 1996, DIABETES, V45, pS105, DOI 10.2337/diab.45.3.S105; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780; Litherland GJ, 2001, MOL MEMBR BIOL, V18, P195; LIU SQ, 1993, BIOCHIM BIOPHYS ACTA, V1164, P268, DOI 10.1016/0167-4838(93)90258-S; Ramana KV, 2000, BIOCHEMISTRY-US, V39, P12172, DOI 10.1021/bi000796e; Recchia Fabio A, 2002, Heart Fail Rev, V7, P141, DOI 10.1023/A:1015324508556; RUDERMAN NB, 1992, FASEB J, V6, P2905, DOI 10.1096/fasebj.6.11.1644256; Seo HG, 2000, MOL PHARMACOL, V57, P709, DOI 10.1124/mol.57.4.709; Srivastava S, 2001, BIOCHEM J, V358, P111, DOI 10.1042/0264-6021:3580111; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P7222, DOI 10.1073/pnas.82.21.7222; Torreilles J, 2001, FRONT BIOSCI-LANDMRK, V6, pD1161, DOI 10.2741/Torreill; Traverse JH, 2002, AM J PHYSIOL-HEART C, V282, pH2278, DOI 10.1152/ajpheart.00504.2001; van Goor H, 2001, NITRIC OXIDE-BIOL CH, V5, P525, DOI 10.1006/niox.2001.0382; West AR, 2002, SYNAPSE, V44, P227, DOI 10.1002/syn.10076; WU JT, 1993, J CLIN LAB ANAL, V7, P293, DOI 10.1002/jcla.1860070510; Yabe-Nishimura C, 1998, PHARMACOL REV, V50, P21	30	72	74	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					417	425		10.1096/fj.02-0722com	http://dx.doi.org/10.1096/fj.02-0722com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12631581				2022-12-28	WOS:000181892600040
J	Behzadian, MA; Windsor, LJ; Ghaly, N; Liou, G; Tsai, NT; Caldwell, RB				Behzadian, MA; Windsor, LJ; Ghaly, N; Liou, G; Tsai, NT; Caldwell, RB			VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor	FASEB JOURNAL			English	Article						vascular endothelial growth factor; endothelial cell junctions; occludin; beta-catenin signaling	PLASMINOGEN-ACTIVATOR RECEPTOR; CELLULAR-BINDING SITE; GROWTH-FACTOR; VASCULAR-PERMEABILITY; BETA-CATENIN; TGF-BETA; TIGHT JUNCTION; EXPRESSION; OCCLUDIN; BARRIER	Vascular endothelial growth factor/vascular permeability factor (VEGF) has been implicated in blood/tissue barrier dysfunctions associated with pathological angiogenesis, but the mechanisms of VEGF-induced permeability increase are poorly understood. Here, the role of VEGF-induced extracellular proteolytic activities on the endothelial cell permeability increase is evaluated. Confluent monolayers of bovine retinal microvascular endothelial (BRE) cells grown on porous membrane were treated with VEGF or urokinase plasminogen activator (uPA), and permeability changes were analyzed. uPA-induced permeability was rapid and sustained, but VEGF-induced permeability showed a biphasic pattern: a rapid and transient phase (1-2 h) followed by delayed and sustained phase (6-24 h). The delayed, but not the early phase of VEGF-induced permeability, was blocked by anti-uPA or anti-uPAR (uPA receptor) antibodies and was accompanied by reduced transendothelial electrical resistance, indicating the paracellular route of permeability. Confocal microscopy and Western blotting showed that VEGF treatment increased free cytosolic beta-catenin, which was followed by beta-catenin nuclear translocation, upregulation of uPAR, and downregulation of occludin. Membrane-bound occludin was released immediately after uPA treatment, but with a long delay after VEGF treatment, suggesting a requirement for uPAR gene expression. In conclusion, VEGF induces a sustained paracellular permeability in capillary endothelial cells that is mediated by activation of the uPA/uPAR system.	Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30809 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA; Indiana Univ, Dept Oral Biol, Indianapolis, IN 46204 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Indiana University System; Indiana University-Purdue University Indianapolis	Behzadian, MA (corresponding author), Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30809 USA.	abehzadi@mail.mcg.edu		Caldwell, Ruth/0000-0003-0168-0354				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Antonetti DA, 1998, DIABETES, V47, P1953, DOI 10.2337/diabetes.47.12.1953; Balcerzak D, 2001, J ANIM SCI, V79, P94; Bates DO, 1999, MICROCIRCULATION, V6, P83, DOI 10.1038/sj.mn.7300054; Behzadian MA, 1995, GLIA, V15, P480, DOI 10.1002/glia.440150411; Behzadian MA, 1998, GLIA, V24, P216, DOI 10.1002/(SICI)1098-1136(199810)24:2<216::AID-GLIA6>3.3.CO;2-D; Behzadian MA, 2001, INVEST OPHTH VIS SCI, V42, P853; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; CLAUDE P, 1978, J MEMBRANE BIOL, V39, P219, DOI 10.1007/BF01870332; Cohen AW, 1999, AM J PHYSIOL-HEART C, V277, pH2038, DOI 10.1152/ajpheart.1999.277.5.H2038; CUBELLIS MV, 1986, J BIOL CHEM, V261, P5819; Dear AE, 1998, EUR J BIOCHEM, V252, P185, DOI 10.1046/j.1432-1327.1998.2520185.x; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; DVORAK HF, 1995, INT ARCH ALLERGY IMM, V107, P233, DOI 10.1159/000236988; DVORAK HF, 1995, AM J PATHOL, V146, P1029; ELLIS V, 1991, J BIOL CHEM, V266, P12752; Ellis V, 1996, J BIOL CHEM, V271, P14779, DOI 10.1074/jbc.271.25.14779; Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Feng D, 1996, J EXP MED, V183, P1981, DOI 10.1084/jem.183.5.1981; Feng YY, 1999, INVEST OPHTH VIS SCI, V40, P157; Giarre M, 1998, ANN NY ACAD SCI, V857, P43, DOI 10.1111/j.1749-6632.1998.tb10106.x; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HADDOCK RC, 1991, J BIOL CHEM, V266, P21466; Hoyer-Hansen G, 2001, BIOCHEM J, V358, P673, DOI 10.1042/0264-6021:3580673; HoyerHansen G, 1997, EUR J BIOCHEM, V243, P21, DOI 10.1111/j.1432-1033.1997.0021a.x; Kawabe H, 2001, J BIOL CHEM, V276, P48350, DOI 10.1074/jbc.M107335200; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Kroon ME, 1999, AM J PATHOL, V154, P1731, DOI 10.1016/S0002-9440(10)65429-6; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Longstaff C, 1999, BLOOD, V93, P3839, DOI 10.1182/blood.V93.11.3839.411k08_3839_3846; Makowski GS, 1998, INFLAMMATION, V22, P287, DOI 10.1023/A:1022300216202; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; McCarthy KM, 1996, J CELL SCI, V109, P2287; Mondino Anna, 1999, Thrombosis and Haemostasis, V82, P19; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NASDALA I, 2002, J BIOL CHEM, V14, P14; NELSON WJ, 1992, COLD SPRING HARB SYM, V57, P621, DOI 10.1101/SQB.1992.057.01.068; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; PALADE GE, 1961, CIRCULATION, V24, P368; Papadopoulos MC, 2001, NEUROPATH APPL NEURO, V27, P384, DOI 10.1046/j.0305-1846.2001.00341.x; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Plesner T, 1997, STEM CELLS, V15, P398, DOI 10.1002/stem.150398; REINARTZ J, 1993, EXP CELL RES, V208, P197, DOI 10.1006/excr.1993.1238; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shih SC, 2001, GROWTH FACTORS, V19, P19, DOI 10.3109/08977190109001073; SOLBERG H, 1994, INT J CANCER, V58, P877, DOI 10.1002/ijc.2910580622; STEVENSON BR, 1988, MOL CELL BIOCHEM, V83, P129; STEVENSON BR, 1988, J CELL BIOL, V107, P2401, DOI 10.1083/jcb.107.6.2401; Stewart PA, 2000, CELL MOL NEUROBIOL, V20, P149, DOI 10.1023/A:1007026504843; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; Tinsley JH, 1999, J BIOL CHEM, V274, P24930, DOI 10.1074/jbc.274.35.24930; TRAWEGER A, 2002, J BIOL CHEM, V8, P8; Vassalli J D, 1992, Curr Top Microbiol Immunol, V181, P65; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; Vines DJ, 2000, J PEPT SCI, V6, P432, DOI 10.1002/1099-1387(200009)6:9<432::AID-PSC279>3.3.CO;2-H; Wang W, 1996, AM J PHYSIOL-CELL PH, V271, pC1973, DOI 10.1152/ajpcell.1996.271.6.C1973; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; Zhou HM, 2000, EMBO J, V19, P4817, DOI 10.1093/emboj/19.17.4817	66	101	113	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					752	+		10.1096/fj.02-0484fje	http://dx.doi.org/10.1096/fj.02-0484fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594181				2022-12-28	WOS:000181456900018
J	Brenner, T; Hamra-Amitay, Y; Evron, T; Boneva, N; Seidman, S; Soreq, H				Brenner, T; Hamra-Amitay, Y; Evron, T; Boneva, N; Seidman, S; Soreq, H			The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis	FASEB JOURNAL			English	Article						neuromuscular function; MG; acetylcholine	NEUROMUSCULAR-JUNCTION; MOLECULAR-FORMS; GENE-EXPRESSION; ANTISENSE; CELLS; DIFFERENTIATION; SUPPRESSION; GENERATION; DEFICIENCY; RESPONSES	Alternative splicing induces, under abnormal cholinergic neurotransmission, overproduction of the rare "readthrough" acetylcholinesterase variant AChE-R. We explored the pathophysiological relevance of this phenomenon in patients with myasthenia gravis (MG) and rats with experimental autoimmune MG (EAMG), neuromuscular junction diseases with depleted acetylcholine receptors. In MG and EAMG, we detected serum AChE-R accumulation. In EAMG, we alleviated electromyographic abnormalities by nanomolar doses of EN101, an antisense oligonucleotide that selectively lowers AChE-R in blood and muscle yet leaves unaffected the synaptic variant AChE-S. Whereas animals treated with placebo or conventional anticholinesterases continued to deteriorate, a 4 wk daily oral administration of EN101 improved survival, neuromuscular strength and clinical status in moribund EAMG rats. The efficacy of targeting only one AChE splicing variant highlights potential advantages of mRNA-targeted therapeutics for chronic cholinergic malfunctioning.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Neurol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Soreq, H (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.	soreq@shum.huji.ac.il		Soreq, Hermona/0000-0002-0955-526X				ANGLISTER L, 1994, J CELL BIOL, V125, P183, DOI 10.1083/jcb.125.1.183; Behra M, 2002, NAT NEUROSCI, V5, P111, DOI 10.1038/nn788; Boneva N, 2000, MUSCLE NERVE, V23, P1204, DOI 10.1002/1097-4598(200008)23:8<1204::AID-MUS7>3.0.CO;2-H; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Carlson CG, 1998, NEUROBIOL DIS, V5, P3, DOI 10.1006/nbdi.1998.0188; Chan RYY, 1998, J BIOL CHEM, V273, P9727, DOI 10.1074/jbc.273.16.9727; CHANGEUX JP, 1992, Q REV BIOPHYS, V25, P395, DOI 10.1017/S0033583500004352; Darboux I, 1996, EMBO J, V15, P4835, DOI 10.1002/j.1460-2075.1996.tb00864.x; Dove A, 2002, NAT BIOTECHNOL, V20, P121, DOI 10.1038/nbt0202-121; DRACHMAN DB, 1994, NEW ENGL J MED, V330, P1797, DOI 10.1056/NEJM199406233302507; Galyam N, 2001, ANTISENSE NUCLEIC A, V11, P51, DOI 10.1089/108729001750072128; Grifman M, 1997, ANTISENSE NUCLEIC A, V7, P351, DOI 10.1089/oli.1.1997.7.351; Haley RW, 1999, TOXICOL APPL PHARM, V157, P227, DOI 10.1006/taap.1999.8703; He FS, 1998, HUM EXP TOXICOL, V17, P40, DOI 10.1191/096032798678907810; Huang DR, 2001, EUR J IMMUNOL, V31, P225, DOI 10.1002/1521-4141(200101)31:1<225::AID-IMMU225>3.3.CO;2-S; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; LEGAY C, 1993, J NEUROCHEM, V60, P337, DOI 10.1111/j.1471-4159.1993.tb05856.x; Lev-Lehman E, 2000, J MOL NEUROSCI, V14, P93, DOI 10.1385/JMN:14:1-2:093; Meshorer E, 2002, SCIENCE, V295, P508, DOI 10.1126/science.1066752; MILLARD CB, 1995, J NEUROCHEM, V64, P1909, DOI 10.1046/j.1471-4159.1995.64051909.x; Monia BP, 1997, CIBA F SYMP, V209, P107; Mor I, 2001, FASEB J, V15, P2039, DOI 10.1096/fj.00-0814fje; Moran D, 1996, J THERM BIOL, V21, P171, DOI 10.1016/0306-4565(95)00042-9; Ohno K, 2000, ANN NEUROL, V47, P162, DOI 10.1002/1531-8249(200002)47:2<162::AID-ANA5>3.0.CO;2-Q; Ostlie NS, 2001, J IMMUNOL, V166, P4853, DOI 10.4049/jimmunol.166.8.4853; Perrier AL, 2002, NEURON, V33, P275, DOI 10.1016/S0896-6273(01)00584-0; PRICE DL, 1993, PROG BRAIN RES, V98, P51; ROSSI SG, 1993, J BIOL CHEM, V268, P19152; ROTUNDO RL, 1990, J CELL BIOL, V110, P715, DOI 10.1083/jcb.110.3.715; SEIDMAN S, 1995, MOL CELL BIOL, V15, P2993; Shapira M, 2000, HUM MOL GENET, V9, P1273, DOI 10.1093/hmg/9.9.1273; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; Sternfeld M, 2000, P NATL ACAD SCI USA, V97, P8647, DOI 10.1073/pnas.140004597; Sternfeld M, 1998, J NEUROSCI, V18, P1240; Tracey KJ, 2001, FASEB J, V15, P1575, DOI 10.1096/fj.01-0148hyp; Vincent A, 1999, CURR OPIN NEUROL, V12, P545, DOI 10.1097/00019052-199910000-00008; WIRGUIN I, 1994, MUSCLE NERVE, V17, P523, DOI 10.1002/mus.880170509; Zhang GX, 1999, J IMMUNOL, V162, P3775	38	100	105	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					214	222		10.1096/fj.02-0609com	http://dx.doi.org/10.1096/fj.02-0609com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554700				2022-12-28	WOS:000181456900046
J	Grandjean, P; Budtz-Jorgensen, E; Steuerwald, U; Heinzow, B; Needham, LL; Jorgensen, PJ; Weihe, P				Grandjean, P; Budtz-Jorgensen, E; Steuerwald, U; Heinzow, B; Needham, LL; Jorgensen, PJ; Weihe, P			Attenuated growth of breast-fed children exposed to increased concentrations of methylmercury and polychlorinated biphenyls	FASEB JOURNAL			English	Article						body weight; eicosapentaenoic acid; diet; postnatal growth; prenatal exposure delayed effects	MATERNAL SEAFOOD DIET; HUMAN-MILK; BIRTH-WEIGHT; FATTY-ACIDS; IN-UTERO; MERCURY; PCBS; SIZE; INFANTS; FOOD	Breast-feeding has been linked to slowed postnatal growth. Although the basis for this "weanling's dilemma" is unclear, environmental contaminants in human milk may be of relevance. We studied a Faroese birth cohort of 182 singleton children, born at term in 1994-95. Concentrations of mercury in cord blood and of polychlorinated biphenyls in maternal milk were measured, and duration of breast-feeding was recorded. At 18 months, children who had been exclusively breast-fed for at least 6 months weighed 0.59 kg less [95% confidence interval (CI) = 0.03, 1.16 kg] and were 1.50 cm [95% CI = 0.52, 2.47 cm] shorter than those not breast-fed. However, calculated transfer of contaminants from human milk fully explained the attenuated growth. Irrespective of duration of breast-feeding, a doubling of the mercury concentration in cord blood was associated with a decrease in weight at 18 months by 0.19 kg (95% CI = 0.03, 0.35 kg) and in height by 0.26 cm (95% CI = 0.02, 0.55 cm). Weight and height at 42 months showed the same tendencies, but the main effect occurred before 18 months of age. Thus, in communities with increased contaminant exposures, risks associated with lactational transfer of toxicants to the infant must be considered when judging the benefits of prolonged breast-feeding.	Boston Univ, Sch Med, Dept Environm Hlth, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA; Univ So Denmark, Inst Publ Hlth, Odense, Denmark; Univ Copenhagen, Panum Inst, Dept Biostat, DK-2200 Copenhagen, Denmark; Faroese Hosp Syst, Dept Occupat & Publ Hlth, Torshavn, Faroe Isl, Denmark; State Agcy Hlth & Occupat Safety Schleswig Holste, Flintbek, Germany; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA; Odense Univ Hosp, Dept Clin Biochem, DK-5000 Odense, Denmark	Boston University; Boston University; Boston University; Boston University; University of Southern Denmark; University of Copenhagen; Centers for Disease Control & Prevention - USA; University of Southern Denmark; Odense University Hospital	Grandjean, P (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA.	pgrandjean@health.sdu.dk	Needham, Larry/E-4930-2011; Grandjean, Philippe/I-2962-2014	Grandjean, Philippe/0000-0003-4046-9658; Budtz-Jorgensen, Esben/0000-0002-5551-0724				ALLEN JR, 1980, J TOXICOL ENV HEALTH, V6, P55, DOI 10.1080/15287398009529830; Armstrong J, 2002, LANCET, V359, P2003, DOI 10.1016/S0140-6736(02)08837-2; Boshuizen HC, 1998, AM J EPIDEMIOL, V147, P117; BREZNER E, 1984, COMP BIOCHEM PHYS C, V77, P65, DOI 10.1016/0742-8413(84)90131-2; Brock JW, 1996, J ANAL TOXICOL, V20, P528, DOI 10.1093/jat/20.7.528; CONTER V, 1995, BRIT MED J, V310, P768, DOI 10.1136/bmj.310.6982.768; Day NL, 1999, ALCOHOL CLIN EXP RES, V23, P863, DOI 10.1097/00000374-199905000-00015; DELEMARREVANDEWAAL HA, 1993, ENVIRON HEALTH PERSP, V101, P39, DOI 10.1289/ehp.93101s239; DEWEY KG, 1995, PEDIATRICS, V96, P495; FEIN GG, 1984, J PEDIATR-US, V105, P315, DOI 10.1016/S0022-3476(84)80139-0; FOLDSPANG A, 1990, AM J EPIDEMIOL, V132, P310, DOI 10.1093/oxfordjournals.aje.a115660; FREDRIKSSON A, 1993, PHARMACOL TOXICOL, V72, P377, DOI 10.1111/j.1600-0773.1993.tb01348.x; Grandjean P, 1995, ENVIRON RES, V71, P29, DOI 10.1006/enrs.1995.1064; GRANDJEAN P, 1993, ENVIRON RES, V61, P176, DOI 10.1006/enrs.1993.1062; GRANDJEAN P, 1992, ARCH ENVIRON HEALTH, V47, P185, DOI 10.1080/00039896.1992.9938348; Grandjean P, 2001, INT J EPIDEMIOL, V30, P1272, DOI 10.1093/ije/30.6.1272; GRANDJEAN P, 1994, ENVIRON HEALTH PERSP, V102, P74, DOI 10.1289/ehp.9410274; GRANDJEAN P, 1988, ENV HLTH, V29; Grandjean P, 2002, BIOMARKERS ENV ASS D, P235; GUO YLL, 1995, ENVIRON HEALTH PERSP, V103, P117, DOI 10.2307/3432359; Haschke F, 2000, J PEDIATR GASTR NUTR, V31, pS60, DOI 10.1097/00005176-200007001-00006; HOVINGA ME, 1992, ARCH ENVIRON CON TOX, V22, P362, DOI 10.1007/BF00212554; JACOBSON JL, 1990, NEUROTOXICOL TERATOL, V12, P319, DOI 10.1016/0892-0362(90)90050-M; Jensen A.A., 1991, CHEM CONTAMINANTS HU; Karlberg J, 2000, ACTA PAEDIATR, V89, P632, DOI 10.1080/080352500750043909; Kaya H, 2002, TOXICOL APPL PHARM, V178, P71, DOI 10.1006/taap.2001.9318; KRAMER MS, 2002, COCHRANE LIB; LAN SJ, 1989, B ENVIRON CONTAM TOX, V42, P931, DOI 10.1007/BF01701638; Lapillonne A, 2001, LIPIDS, V36, P901, DOI 10.1007/s11745-001-0800-y; Larroque B, 1998, ALCOHOL CLIN EXP RES, V22, P295, DOI 10.1111/j.1530-0277.1998.tb03652.x; LEWIS DS, 1986, J CLIN INVEST, V78, P899, DOI 10.1172/JCI112678; Martin RM, 2001, INT J EPIDEMIOL, V30, P481, DOI 10.1093/ije/30.3.481; National Research Council, 2000, TOX EFF METH; Nielsen GA, 1998, ACTA PAEDIATR, V87, P911, DOI 10.1080/080352598750031536; Patandin S, 1998, PEDIATR RES, V44, P538, DOI 10.1203/00006450-199810000-00012; ROGAN WJ, 1987, AM J PUBLIC HEALTH, V77, P1294, DOI 10.2105/AJPH.77.10.1294; ROWLAND IR, 1984, ARCH ENVIRON HEALTH, V39, P401, DOI 10.1080/00039896.1984.10545872; ROWLAND MGM, 1986, ACTA PAEDIATR SCAND, P33; SAUER PJJ, 1994, HUM EXP TOXICOL, V13, P900, DOI 10.1177/096032719401301213; Schade G, 1998, SCI TOTAL ENVIRON, V215, P31, DOI 10.1016/S0048-9697(98)00008-4; Smith JC, 1996, TOXICOL APPL PHARM, V137, P245, DOI 10.1006/taap.1996.0078; Steuerwald U, 2000, J PEDIATR-US, V136, P599, DOI 10.1067/mpd.2000.102774; Strauss RS, 1997, BRIT MED BULL, V53, P81; Turner W, 1997, ORGANOHALOGEN COMPD, V31, P26; VORHEES CV, 1985, NEUROBEH TOXICOL TER, V7, P717	45	64	64	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					699	+		10.1096/fj.02-0661fje	http://dx.doi.org/10.1096/fj.02-0661fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586743	Green Submitted			2022-12-28	WOS:000181456900023
J	Gutwein, P; Mechtersheimer, S; Riedle, S; Stoeck, A; Gast, D; Joumaa, S; Zentgraf, H; Fogel, M; Altevogt, P				Gutwein, P; Mechtersheimer, S; Riedle, S; Stoeck, A; Gast, D; Joumaa, S; Zentgraf, H; Fogel, M; Altevogt, P			ADAM10-mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles	FASEB JOURNAL			English	Article						shedding; cholesterol; methyl-beta-cyclodextrin; Golgi apparatus	AMYLOID PRECURSOR PROTEIN; CHOLESTEROL DEPLETION; MATRIX METALLOPROTEINASES; INTRACELLULAR DOMAIN; MEDIATED RELEASE; BETA-SECRETASE; ECTODOMAIN; BINDING; DISINTEGRIN; ENDOCYTOSIS	Cells can release membrane components in a soluble form and as membrane vesicles. L1, an important molecule for cell migration of neural and tumor cells, is released by membrane-proximal cleavage, and soluble L1 promotes cell migration. Release of L1 is enhanced by shedding inducers such as phorbol ester and pervanadate, but it is also enhanced by depletion of cellular cholesterol with methyl-beta-cyclodextrin (MCD). How such different compounds can induce shedding is presently unknown. We show here that ADAM10 is involved in L1 cleavage, which occurs at the cell surface and in the Golgi apparatus. MCD and pervanadate treatment induced the release of microvesicles containing full-length L1 and the active form of ADAM10. L1 cleavage occurred in isolated vesicles. L1-containing microvesicles could trigger haptotactic cell migration. Only the neural L1 form carrying the RSLE signal for clathrin-dependent endocytosis was recruited and cleaved in vesicles. Phorbol ester treatment activated L1 cleavage predominantly at the cell surface. Our results provide evidence for two pathways of L1 cleavage, based on ADAM10 localization, that can be activated differentially: 1) direct cleavage at the cell surface, and 2) release and cleavage in secretory vesicles most likely derived from the Golgi apparatus. The findings establish a novel role for ADAM10 as a vesicle-based protease.	German Canc Res Ctr, Tumor Immunol Programme, D-69120 Heidelberg, Germany; Kaplan Hosp, Dept Pathol, IL-76100 Rehovot, Israel	Helmholtz Association; German Cancer Research Center (DKFZ); Hebrew University of Jerusalem; Kaplan Medical Center	Altevogt, P (corresponding author), German Canc Res Ctr, Tumor Immunol Programme, G0100,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	P.Altevogt@dkfz.de						Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624; Angelucci A, 2000, CLIN EXP METASTAS, V18, P163, DOI 10.1023/A:1006778000173; Beer S, 1999, J CELL SCI, V112, P2667; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen TT, 1999, MAR BIOTECHNOL, V1, P1; Chubinskaya S, 2001, J HISTOCHEM CYTOCHEM, V49, P1165, DOI 10.1177/002215540104900910; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Denzer K, 2000, J CELL SCI, V113, P3365; Dolo V, 1998, CANCER RES, V58, P4468; Duczmal A, 1997, BIOCHEM BIOPH RES CO, V232, P236, DOI 10.1006/bbrc.1997.6265; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Ginestra A, 1998, ANTICANCER RES, V18, P3433; Grimmer S, 2000, MOL BIOL CELL, V11, P4205, DOI 10.1091/mbc.11.12.4205; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Ilan N, 2001, FASEB J, V15, P362, DOI 10.1096/fj.00-0372com; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kamiguchi H, 1998, J NEUROSCI, V18, P5311, DOI 10.1523/JNEUROSCI.18-14-05311.1998; Kamiguchi H, 2001, J NEUROSCI, V21, P9194, DOI 10.1523/JNEUROSCI.21-23-09194.2001; Kenwrick S, 2000, HUM MOL GENET, V9, P879, DOI 10.1093/hmg/9.6.879; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Long KE, 2001, J BIOL CHEM, V276, P1285, DOI 10.1074/jbc.M006658200; Martinez-Lorenzo MJ, 1999, J IMMUNOL, V163, P1274; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Millichip MI, 1998, BIOCHEM BIOPH RES CO, V245, P594, DOI 10.1006/bbrc.1998.8485; MIURA M, 1991, FEBS LETT, V289, P91, DOI 10.1016/0014-5793(91)80915-P; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Nayeem N, 1999, J CELL SCI, V112, P4739; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Oleszewski M, 1999, J BIOL CHEM, V274, P24602, DOI 10.1074/jbc.274.35.24602; Parvathy S, 1999, BIOCHEMISTRY-US, V38, P9728, DOI 10.1021/bi9906827; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Schachner M, 1997, CURR OPIN CELL BIOL, V9, P627, DOI 10.1016/S0955-0674(97)80115-9; Schaefer AW, 1999, J BIOL CHEM, V274, P37965, DOI 10.1074/jbc.274.53.37965; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schmid RS, 2000, J NEUROSCI, V20, P4177; Silletti S, 2000, J CELL BIOL, V149, P1485, DOI 10.1083/jcb.149.7.1485; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Skovronsky DM, 2000, J BIOL CHEM, V275, P2568, DOI 10.1074/jbc.275.4.2568; Takei K, 2001, TRENDS CELL BIOL, V11, P385, DOI 10.1016/S0962-8924(01)02082-7; Taraboletti G, 2002, AM J PATHOL, V160, P673, DOI 10.1016/S0002-9440(10)64887-0; Turner AJ, 1999, BIOCHEM SOC T, V27, P255, DOI 10.1042/bst0270255; Urban S, 2000, EMBO J, V19, P1217, DOI 10.1093/emboj/19.6.1217; Visconti PE, 1999, J BIOL CHEM, V274, P3235, DOI 10.1074/jbc.274.5.3235; Walev I, 2000, J LEUKOCYTE BIOL, V68, P865; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200	62	185	192	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					292	+		10.1096/fj.02-0430fje	http://dx.doi.org/10.1096/fj.02-0430fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475894				2022-12-28	WOS:000180574300014
J	Kim, HJ; Chae, SC; Lee, DK; Chromy, B; Lee, SC; Park, YC; Klein, WL; Krafft, GA; Hong, ST				Kim, HJ; Chae, SC; Lee, DK; Chromy, B; Lee, SC; Park, YC; Klein, WL; Krafft, GA; Hong, ST			Selective neuronal degeneration induced by soluble oligomeric amyloid beta-protein	FASEB JOURNAL			English	Article						Alzheimer's disease; regiospecific; slice cultures; hippocampal CA1	LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; TRANSGENIC MICE; PRECURSOR-PROTEIN; NEUROTOXICITY; A-BETA(1-42); NEURODEGENERATION; PATHOGENESIS; EXPRESSION; SEVERITY	The prevailing amyloid hypothesis for Alzheimer's disease (AD) holds that amyloid beta-protein (Abeta) causes neuronal degeneration by forming neurotoxic fibrillar structures. Yet, many aspects of AD pathology and symptoms are not well explained by this hypothesis. Here, we present evidence that neurotoxicity of soluble oligomeric Abeta closely corresponds to the selective neurodegeneration so distinctly manifest in AD. Selectivity was first observed in vitro, where only the human central nervous system neuronal cells were susceptible to soluble oligomeric Abeta. Furthermore, in mouse cerebral slice treated with soluble oligomeric Abeta, selective regiospecific toxicity was evident in the hippocampal CA1, a division important for memory, but not in the CA3 subfield. The fibrillar Abeta, however, killed neurons in all regions of the cerebral slice cultures and also in cerebellar slices. Remarkably, even at the highest soluble oligomeric Abeta concentrations, cerebellar neurons were completely spared, consistent with one of the hallmark features of AD pathology. Our observation of the selective neurodegeneration of soluble oligomeric Abeta to neurons involved in cognitive function may provide a new opportunity for the development of an effective AD therapy as well as elucidating the pathological mechanism of AD.	Chonbuk Natl Univ, Inst Cardiovasc Res, Sch Med, Chonju 561712, South Korea; Chonbuk Natl Univ, Dept Microbiol, Sch Med, Chonju 561712, South Korea; Jinis Biopharmacceut Co, Div Res, Chonju, South Korea; Wonkwang Univ, Sch Med, Genom Res Ctr Immune Disorder, Iksan, Chonbuk, South Korea; Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Hanlyo Univ, Dept Adv Mat Engn, Kwangyang, Chonnam, South Korea; HumanBio Co, Res Ctr Biotechnol Human, Iksan, Chonbuk, South Korea; Evanston NW Healthcare Res Inst, Evanston, IL 60201 USA	Jeonbuk National University; Jeonbuk National University; Wonkwang University; Northwestern University	Hong, ST (corresponding author), Chonbuk Natl Univ, Inst Cardiovasc Res, Sch Med, San 2-20,Kumam Dong, Chonju 561712, South Korea.	seonghong@hotmail.com		Hong, Seong-Tshool/0000-0001-8254-6581				Alzheimer A., 1907, Z GESAMTE NEUROL PSY, V18, P177; BAH BA, 1998, J COMP NEURO, V397, P139; Bobinski M, 1998, BRAIN RES, V805, P267, DOI 10.1016/S0006-8993(98)00759-8; Braak H., 1997, CONNECTIONS COGNITIO, P1; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Cummings JL, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.1_Suppl_1.S2; FRAUTSCHY SA, 1991, P NATL ACAD SCI USA, V88, P8362, DOI 10.1073/pnas.88.19.8362; Funato H, 1999, AM J PATHOL, V155, P23, DOI 10.1016/S0002-9440(10)65094-8; Giannakopoulos P, 1997, BRAIN RES REV, V25, P217, DOI 10.1016/S0165-0173(97)00023-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Jen LS, 1998, NATURE, V392, P140, DOI 10.1038/32327; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LI YT, 1994, NEUROBIOL AGING, V15, P1, DOI 10.1016/0197-4580(94)90139-2; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080; Reddy PH, 1999, TRENDS NEUROSCI, V22, P248, DOI 10.1016/S0166-2236(99)01415-0; ROHER AE, 1991, BIOCHEM BIOPH RES CO, V174, P572, DOI 10.1016/0006-291X(91)91455-L; Scorziello A, 1997, NEUROCHEM RES, V22, P257, DOI 10.1023/A:1022430503520; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; Small DH, 2001, NAT REV NEUROSCI, V2, P595, DOI 10.1038/35086072; Soto C, 1999, MOL MED TODAY, V5, P343, DOI 10.1016/S1357-4310(99)01508-7; Stix B, 1998, NEUROSCI LETT, V243, P121, DOI 10.1016/S0304-3940(98)00106-2; SWAAB DF, 1997, CONNECTIONS COGNITIO, P83; Tompkins MM, 1997, BRAIN RES, V775, P24, DOI 10.1016/S0006-8993(97)00874-3; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X; Wernyj RP, 1999, MOL BRAIN RES, V64, P69, DOI 10.1016/S0169-328X(98)00307-6; WEST MJ, 1994, LANCET, V344, P769, DOI 10.1016/S0140-6736(94)92338-8	44	183	191	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					118	+		10.1096/fj.01-0987fje	http://dx.doi.org/10.1096/fj.01-0987fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12424218				2022-12-28	WOS:000180218500031
J	Todorov, AG; Andrade, D; Pesquero, JB; Araujo, RD; Bader, M; Stewart, J; Gera, L; Muller-Esterl, W; Morandi, V; Goldenberg, RCS; Neto, HCF; Scharfstein, J				Todorov, AG; Andrade, D; Pesquero, JB; Araujo, RD; Bader, M; Stewart, J; Gera, L; Muller-Esterl, W; Morandi, V; Goldenberg, RCS; Neto, HCF; Scharfstein, J			Trypanosoma cruzi induces edematogenic responses in mice and invades cardiomyocytes and endothelial cells in vitro by activating distinct kinin receptor subtypes (B-1/B-2)	FASEB JOURNAL			English	Article						Chagas' disease; bradykinin; endothelium; ACE; cruzipain	CHAGAS-DISEASE; BRADYKININ; INVASION; EXPRESSION; CARDIOMYOPATHY; ASSOCIATION; INHIBITION; RELEASE; HEART; CA2+	Trypanosoma cruzi, the protozoan that causes Chagas' heart disease, invades endothelial cells in vitro by activating the B-2 kinin receptor (B2R). Here, we demonstrate that mice infected with trypomastigotes develop potent edema after treatment with the angiotensin-converting enzyme (ACE) (or kininase II) inhibitor captopril. Experiments performed with specific kinin receptor (B2R/B1R) antagonists and knockout mice revealed that the early-phase (3-h) edema is mediated by the constitutive B2R, whereas the late-phase (24-h) response depends on stimulation of the up-regulated B1R. Given previous evidence that parasite invasion of cells expressing B2R is potentiated by captopril, we investigated the prerequisites for in vitro infection of Chinese hamster ovary cells overexpressing either B1R or B2R, human umbilical vein endothelial cells activated by lipopolysaccharide, and neonatal rat cardiomyocytes. Our results indicate that captopril potentiates parasite invasion regardless of the kinin (B-2/B-1) activation pathways, whereas DL-2-mercaptomethyl-3-guanidino-ethylthiopropanoic acid (MGTA), an inhibitor of kininase I (carboxypeptidase M/N), selectively decreases parasite infectivity for B1R-expressing cells. These data suggest that formation of the B1R agonist, i.e., [des-Arg] kinins, critically depends on the processing action of kininase I, here proposed as a potential pathogenesis cofactor. Collectively, our data suggest that fluctuations in the levels of kininases may modulate parasite infectivity and pathological outcome in Chagas' disease.	Univ Brasil, CCS, Inst Biofis Carlos Chagas Filho, BR-21944900 Rio De Janeiro, Brazil; Univ Fed Sao Paulo, Dept Biofis, Escola Paulista Med, Sao Paulo, Brazil; Max Delbruck Ctr Mol Med, Berlin, Germany; Univ Colorado, Sch Med, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Goethe Univ Frankfurt, Sch Med, Inst Biochem 2, D-6000 Frankfurt, Germany; Univ Rio De Janeiro, Dept Biol Celular & Genet, Rio De Janeiro, Brazil; Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Rio De Janeiro, Brazil	Universidade de Brasilia; Universidade Federal de Sao Paulo (UNIFESP); Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Goethe University Frankfurt; Universidade do Grande Rio; Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz	Scharfstein, J (corresponding author), Univ Brasil, CCS, Inst Biofis Carlos Chagas Filho, Bloco G, BR-21944900 Rio De Janeiro, Brazil.	scharf@biof.ufrj.br	Morandi, Verônica/C-5837-2013; Bader, Michael/K-2124-2013; Pesquero, Joao/C-1470-2012; Goldenberg, Regina/ABI-2609-2020	Pesquero, Joao/0000-0002-4507-632X; Goldenberg, Regina/0000-0002-0886-9603; Bader, Michael/0000-0003-4780-4164; Araujo, Ronaldo/0000-0003-0095-4608				Andrade ZA, 1999, MEM I OSWALDO CRUZ, V94, P71, DOI 10.1590/S0074-02761999000700007; Andrade ZA, 1997, AM J TROP MED HYG, V57, P328, DOI 10.4269/ajtmh.1997.57.328; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Brener Z., 1980, Advances in Parasitology, V18, P247, DOI 10.1016/S0065-308X(08)60401-7; Caler EV, 2000, INFECT IMMUN, V68, P6602, DOI 10.1128/IAI.68.12.6602-6610.2000; DelNery E, 1997, J BIOL CHEM, V272, P25713, DOI 10.1074/jbc.272.41.25713; Erdos EG, 1999, TRENDS ENDOCRIN MET, V10, P223, DOI 10.1016/S1043-2760(99)00156-3; Figueroa CD, 2001, HYPERTENSION, V37, P110, DOI 10.1161/01.HYP.37.1.110; Giordano R, 1999, J BIOL CHEM, V274, P3461, DOI 10.1074/jbc.274.6.3461; Higuchi MD, 1999, HEART, V82, P279, DOI 10.1136/hrt.82.3.279; Huang H, 1999, INFECT IMMUN, V67, P5434, DOI 10.1128/IAI.67.10.5434-5440.1999; KAUFMANN J, 1993, J BIOL CHEM, V268, P9079; LARANJA FS, 1956, CIRCULATION, V14, P1035, DOI 10.1161/01.CIR.14.6.1035; Lima APCA, 2002, J BIOL CHEM, V277, P5875, DOI 10.1074/jbc.M108518200; MARCEAU F, 1995, IMMUNOPHARMACOLOGY, V30, P1, DOI 10.1016/0162-3109(95)00011-H; McLean PG, 2000, J EXP MED, V192, P367, DOI 10.1084/jem.192.3.367; MEIRELLES MNL, 1992, MOL BIOCHEM PARASIT, V52, P175, DOI 10.1016/0166-6851(92)90050-T; Michailowsky V, 2001, AM J PATHOL, V159, P1723, DOI 10.1016/S0002-9440(10)63019-2; MING M, 1995, CELL, V82, P287, DOI 10.1016/0092-8674(95)90316-X; Palomino SAP, 2000, ANN TROP MED PARASIT, V94, P571, DOI 10.1080/00034983.2000.11813580; Pesquero JB, 2000, P NATL ACAD SCI USA, V97, P8140, DOI 10.1073/pnas.120035997; QUITTERER U, 1995, J BIOL CHEM, V270, P1992, DOI 10.1074/jbc.270.5.1992; ROSSI MA, 1990, AM HEART J, V120, P233, DOI 10.1016/0002-8703(90)90191-Y; Ruiz RC, 1998, BIOCHEM J, V330, P505; Scharfstein J, 2000, J EXP MED, V192, P1289, DOI 10.1084/jem.192.9.1289; SCHARFSTEIN J, 2002, MOL PATHOGENESIS CHA; Stewart JM, 1999, IMMUNOPHARMACOLOGY, V43, P155, DOI 10.1016/S0162-3109(99)00102-2; TANOWITZ HB, 1990, AM J TROP MED HYG, V43, P274, DOI 10.4269/ajtmh.1990.43.274; TANOWITZ HB, 2002, WORLD CLASS PARASITE, V4; TARDIEUX I, 1992, CELL, V71, P1117, DOI 10.1016/S0092-8674(05)80061-3; Tarleton RL, 1997, P NATL ACAD SCI USA, V94, P3932, DOI 10.1073/pnas.94.8.3932; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Tschope C, 1999, IMMUNOPHARMACOLOGY, V44, P111, DOI 10.1016/S0162-3109(99)00116-2; WITTNER M, 1995, J INFECT DIS, V171, P493, DOI 10.1093/infdis/171.2.493; Yang XP, 2001, CIRC RES, V88, P1072, DOI 10.1161/hh1001.090759; Yayama K, 2000, BBA-MOL CELL RES, V1495, P69, DOI 10.1016/S0167-4889(99)00154-8	36	71	77	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					73	+		10.1096/fj.02-0477fje	http://dx.doi.org/10.1096/fj.02-0477fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12424228				2022-12-28	WOS:000180218500030
J	Wang, R				Wang, R			Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter?	FASEB JOURNAL			English	Article						carbon monoxide; cardiovascular system; gasotransmitter; neuron; nitric oxide	CYSTATHIONINE BETA-SYNTHASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; HYDROGEN-SULFIDE; GAMMA-LYASE; HOMOCYSTEINE METABOLISM; ESCHERICHIA-COLI; NERVOUS-SYSTEM; BRAIN-TISSUE; IN-VITRO; RAT	Bearing the public image of a deadly "gas of rotten eggs," hydrogen sulfide (H2S) can be generated in many types of mammalian cells. Functionally, H2S has been implicated in the induction of hippocampal long-term potentiation, brain development, and blood pressure regulation. By acting specifically on K-ATP channels, H2S can hyperpolarize cell membranes, relax smooth muscle cells, or decrease neuronal excitability. The endogenous metabolism and physiological functions of H2S position this gas well in the novel family of endogenous gaseous transmitters, termed "gasotransmitters." It is hypothesized that H2S is the third endogenous signaling gasotransmitter, besides nitric oxide and carbon monoxide. This positioning of H2S will open an exciting field-H2S physiology-encompassing realization of the interaction of H2S and other gasotransmitters, sulfurating modification of proteins, and the functional role of H2S in multiple systems. It may shed light on the pathogenesis of many diseases related to the abnormal metabolism of H2S.	Univ Saskatchewan, Dept Physiol, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan	Wang, R (corresponding author), Univ Saskatchewan, Dept Physiol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	wangrui@duke.usask.ca	Wang, Rui/C-7824-2012	Wang, Rui/0000-0003-3825-3620				Abe K, 1996, J NEUROSCI, V16, P1066; ARP AJ, 1987, J EXP BIOL, V128, P139; AWATA S, 1995, BIOCHEM MOL BIOL INT, V35, P1331; AWATA S, 1989, ACTA MED OKAYAMA A, V3, P329; Bao LM, 1998, ARCH BIOCHEM BIOPHYS, V350, P95, DOI 10.1006/abbi.1997.0486; BARTHOLOMEW TC, 1980, BIOCHEM PHARMACOL, V29, P2431, DOI 10.1016/0006-2952(80)90346-9; BEAUCHAMP RO, 1984, CRC CR REV TOXICOL, V13, P25, DOI 10.3109/10408448409029321; BERGER PB, 1995, MAYO CLIN PROC, V70, P125, DOI 10.4065/70.2.125; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; Bruno S, 2001, J BIOL CHEM, V276, P16, DOI 10.1074/jbc.C000588200; BUKOVSKA G, 1994, PROTEIN EXPRES PURIF, V5, P442, DOI 10.1006/prep.1994.1063; BUZALEH AM, 1990, GEN PHARMACOL, V21, P27, DOI 10.1016/0306-3623(90)90590-I; CAO K, 2001, CO CARDIOVASCULAR FU, P83; CHADEFAUX B, 1988, LANCET, V2, P741; Chen P, 1999, ADV ENZYME REGUL, V39, P93, DOI 10.1016/S0065-2571(98)00029-6; Dello Russo C, 2000, J NEUROENDOCRINOL, V12, P225; Doughty JM, 1999, AM J PHYSIOL-HEART C, V276, pH1107, DOI 10.1152/ajpheart.1999.276.3.H1107; Eberhardt RT, 2000, J CLIN INVEST, V106, P483, DOI 10.1172/JCI8342; ERICKSON PF, 1990, BIOCHEM J, V269, P335, DOI 10.1042/bj2690335; FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GOODWIN LR, 1989, J ANAL TOXICOL, V13, P105, DOI 10.1093/jat/13.2.105; Guidotti TL, 1996, OCCUP MED-OXFORD, V46, P367, DOI 10.1093/occmed/46.5.367; Hosoki R, 1997, BIOCHEM BIOPH RES CO, V237, P527, DOI 10.1006/bbrc.1997.6878; Kamoun P, 2001, MED HYPOTHESES, V57, P389, DOI 10.1054/mehy.2001.1377; Kimura H, 2000, BIOCHEM BIOPH RES CO, V267, P129, DOI 10.1006/bbrc.1999.1915; KOMBIAN SB, 1988, NEUROTOXICOLOGY, V9, P587; KREDICH NM, 1973, J BIOL CHEM, V248, P6187; KREDICH NM, 1972, J BIOL CHEM, V247, P7157; Levonen AL, 2000, BIOCHEM J, V347, P291, DOI 10.1042/0264-6021:3470291; LU Y, 1992, BIOCHEM BIOPH RES CO, V189, P749, DOI 10.1016/0006-291X(92)92265-Y; MANTEUFFELCYMBOROWSKA M, 1992, BIOCHIM BIOPHYS ACTA, V1116, P166, DOI 10.1016/0304-4165(92)90113-9; Meier M, 2001, EMBO J, V20, P3910, DOI 10.1093/emboj/20.15.3910; MITCHELL TW, 1993, J APPL TOXICOL, V13, P389, DOI 10.1002/jat.2550130605; MUDD SH, 1995, METABOLIC MOL BASES, V1, P1279; NICHOLLS P, 1961, BIOCHEM J, V81, P374, DOI 10.1042/bj0810374; NICHOLLS P, 1981, BIOCHIM BIOPHYS ACTA, V637, P312, DOI 10.1016/0005-2728(81)90170-5; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; REIFFENSTEIN RJ, 1992, ANNU REV PHARMACOL, V32, P109, DOI 10.1146/annurev.pa.32.040192.000545; ROTH SH, 1995, CLIN EXP PHARMACOL P, V22, P379, DOI 10.1111/j.1440-1681.1995.tb02024.x; SAVAGE JC, 1990, J CHROMATOGR-BIOMED, V526, P540, DOI 10.1016/S0378-4347(00)82537-2; Searcy DG, 1998, J EXP ZOOL, V282, P310, DOI 10.1002/(SICI)1097-010X(19981015)282:3<310::AID-JEZ4>3.0.CO;2-P; SIMPSON RC, 1976, J NUTR, V106, P1272, DOI 10.1093/jn/106.9.1272; SKRAJNY B, 1992, CAN J PHYSIOL PHARM, V70, P1515, DOI 10.1139/y92-215; SMITH RP, 1966, TOXICOL APPL PHARM, V9, P209, DOI 10.1016/0041-008X(66)90115-3; STIPANUK MH, 1982, BIOCHEM J, V206, P267, DOI 10.1042/bj2060267; SWAROOP M, 1992, J BIOL CHEM, V267, P11455; VALENTINE WN, 1987, P NATL ACAD SCI USA, V84, P1394, DOI 10.1073/pnas.84.5.1394; vanderMolen EF, 1997, THROMB HAEMOSTASIS, V78, P827; Wang R, 1998, CAN J PHYSIOL PHARM, V76, P1; WARENYCIA MW, 1989, NEUROTOXICOLOGY, V10, P191; WARENYCIA MW, 1989, BIOCHEM PHARMACOL, V38, P973, DOI 10.1016/0006-2952(89)90288-8; WESTLEY AM, 1991, ANAL BIOCHEM, V195, P63, DOI 10.1016/0003-2697(91)90295-5; WOOD JL, 1982, ADV EXP MED BIOL, V148, P327; Yap S, 2000, SEMIN THROMB HEMOST, V26, P335, DOI 10.1055/s-2000-8100; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	56	1448	1678	6	200	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2002	16	13					1792	1798		10.1096/fj.02-0211hyp	http://dx.doi.org/10.1096/fj.02-0211hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12409322				2022-12-28	WOS:000180218500012
J	Alberti, I; Bernard, G; Rouquette-Jadanian, AK; Pelassy, C; Pourtein, M; Aussel, C; Bernard, A				Alberti, I; Bernard, G; Rouquette-Jadanian, AK; Pelassy, C; Pourtein, M; Aussel, C; Bernard, A			CD99 isoform expression dictates T-cell functional outcomes	FASEB JOURNAL			English	Article						adhesion; apoptosis; glycosphingolipidic rafts; sphingomyelin	PROTEIN-KINASE-C; VASCULAR ENDOTHELIUM; E2 MOLECULE; APOPTOSIS; ADHESION; RECEPTOR; DOMAIN; ENGAGEMENT; ANTIBODIES; TRIGGERS	CD99, a unique integral membrane protein present on the surface of all human T cells, has previously been shown to regulate cell function and fate. In peripheral T cells, it triggers immediate activation of alpha4beta1 integrin and cell arrest on inflamed vascular endothelium, whereas it mediates an apoptotic signal in double-positive thymocytes undergoing the selection process. Two isoforms of CD99 exist, a long form corresponding to the full-length protein and a short form harboring a deletion in the intracytoplasmic segment. Here, we show that while peripheral T cells display exclusive expression of the long form, double-positive thymocytes express both isoforms. Moreover, differential expression of these two CD99 molecules can lead to distinct functional outcomes. Expression of the long form in a CD99-deficient Jurkat T cell line is sufficient to promote CD99-induced cell adhesion, whereas coexpression of the two isoforms is required to trigger T-cell death. When coexpressed, the two proteins form covalent heterodimers, which locate within glycosphingolipidic rafts and induce sphingomyelin degradation. Cholesterol depletion experiments show that this localization is required for the induction of apoptosis. Thus, the surface expression pattern of CD99 isoforms determines T-cell functional outcomes.	Univ Nice, Immunol Lab, F-06108 Nice 2, France; Univ Nice, INSERM, U343, F-06108 Nice 2, France	UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Bernard, A (corresponding author), Hop Archet, INSERM, U343, F-06202 Nice 3, France.	u343@unice.fr		ROUQUETTE-JAZDANIAN, Alexandre K./0000-0003-2646-0040				ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; AUBRIT F, 1989, EUR J IMMUNOL, V19, P1431, DOI 10.1002/eji.1830190813; AUSSEL C, 1993, BIOCHEMISTRY-US, V32, P10096, DOI 10.1021/bi00089a027; BERNARD A, 1984, J IMMUNOL, V132, P2338; BERNARD A, 1988, J IMMUNOL, V140, P1802; Bernard G, 2000, EUR J IMMUNOL, V30, P3061, DOI 10.1002/1521-4141(200010)30:10<3061::AID-IMMU3061>3.0.CO;2-M; Bernard G, 1997, J IMMUNOL, V158, P2543; BERNARD G, 1995, J IMMUNOL, V154, P26; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; ELLIS NA, 1994, NAT GENET, V8, P285, DOI 10.1038/ng1194-285; Fouchet C, 2000, BLOOD, V95, P1819, DOI 10.1182/blood.V95.5.1819.005k05_1819_1826; GELIN C, 1991, EUR J IMMUNOL, V21, P715, DOI 10.1002/eji.1830210326; GELIN C, 1989, EMBO J, V8, P3253, DOI 10.1002/j.1460-2075.1989.tb08485.x; Guiter GE, 1999, CANCER CYTOPATHOL, V87, P141; Hahn JH, 1997, J IMMUNOL, V159, P2250; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Lee JY, 2000, J BIOL CHEM, V275, P29290, DOI 10.1074/jbc.M000170200; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Pettersen RD, 1999, J IMMUNOL, V162, P7031; Pettersen RD, 2001, J IMMUNOL, V166, P4931, DOI 10.4049/jimmunol.166.8.4931; Ruggiero G, 1996, J IMMUNOL, V156, P3737; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Scotlandi K, 2000, CANCER RES, V60, P5134; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; Ticchioni M, 2001, FASEB J, V15, P341, DOI 10.1096/fj.99-0833com; Tsuchida M, 2000, J BIOL CHEM, V275, P1344, DOI 10.1074/jbc.275.2.1344; Veldman RJ, 2001, BIOCHEM J, V355, P859, DOI 10.1042/bj3550859; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yonemura S, 1999, J CELL BIOL, V145, P1497, DOI 10.1083/jcb.145.7.1497; Zen K, 1996, IMMUNOBIOLOGY, V195, P323, DOI 10.1016/S0171-2985(96)80049-0; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	32	58	62	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1946	+		10.1096/fj.02-0049fje	http://dx.doi.org/10.1096/fj.02-0049fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368226				2022-12-28	WOS:000179167600020
J	Horn, TFW; Wolf, G; Duffy, S; Weiss, S; Keilhoff, G; MacVicar, BA				Horn, TFW; Wolf, G; Duffy, S; Weiss, S; Keilhoff, G; MacVicar, BA			Nitric oxide promotes intracellular calcium release from mitochondria in striatal neurons	FASEB JOURNAL			English	Article						nitric oxide synthase; NOS isoform; NMDA; NO production	PERMEABILITY TRANSITION PORE; RAT HIPPOCAMPAL-NEURONS; CYTOCHROME-C RELEASE; CYCLIC ADP-RIBOSE; GLUTAMATE EXCITOTOXICITY; FOREBRAIN ISCHEMIA; NMDA RECEPTORS; DEPOLARIZATION; INHIBITION; SYNTHASE	Overproduction of nitric oxide by NMDA receptor stimulation is implicated in calcium deregulation and neurodegeneration of striatal neurons. We investigated the involvement of nitric oxide (NO) in inducing intracellular calcium release and in modifying calcium transients evoked by NMDA. NO application (4-10 muM) reversibly and repeatedly increased the intracellular calcium concentration [Ca2+](i) in Fura-2- or fluo-3-loaded cultured mouse striatal neurons. NO-induced [Ca2+](i) responses persisted in the absence of extracellular calcium, indicating that Ca2+ was released from intracellular stores. The source of calcium was distinct from [Ca2+](i)- activated (ruthenium red and ryanodine sensitive) or IP3-activated (thapsigargin-sensitive) Ca2+ stores and was not dependent on cGMP production because a cell permeant analog, 8-bromo-cGMP, did not increase basal [Ca2+](i). Glucose removal potentiated the NO-induced release of [Ca2+](i). In contrast, pretreatment with either the mitochondrial uncoupler carbonyl cyanide m-chlorophenylhydrazone or cyclosporin A, a blocker of the mitochondrial permeability transition pore, prevented the [Ca2+](i) increase after NO. The rise in [Ca2+](i) during NO exposure was preceded by a decrease in mitochondrial membrane potential that was partly reversible during washout. Repeated applications of NMDA induced irreversible [Ca2+](i) responses in a subpopulation of striatal cells that were greatly reduced by the NOS inhibitor N-omega-nitro-L-arginine. Calcium transients were prolonged by conjoint application of NMDA and NO. We conclude that NMDA-evoked [Ca2+](i) transients are modulated by endogenous NO production, which leads to release of calcium from the mitochondrial pool. An NO-activated mitochondrial permeability transition pore may lead to cell death after overstimulation of NMDA receptors.	Univ Magdeburg, Inst Med Neurobiol, D-39120 Magdeburg, Germany; Univ Alberta, Dept Physiol, Edmonton, AB T6G 2M7, Canada; Univ Calgary, Neurosci Res Grp, Calgary, AB T2N 1N4, Canada	Otto von Guericke University; University of Alberta; University of Calgary	Horn, TFW (corresponding author), Univ Magdeburg, Inst Med Neurobiol, Leipziger Str 44, D-39120 Magdeburg, Germany.	thomas.horn@medizin.uni-magde-burg.de	MacVicar, Brian/P-1553-2015; MacVicar, Brian/AAI-7729-2020	MacVicar, Brian/0000-0003-4596-4623; MacVicar, Brian/0000-0003-4596-4623				AKIRA T, 1994, BRAIN RES, V652, P190, DOI 10.1016/0006-8993(94)90226-7; Bal-Price A, 2000, J NEUROCHEM, V75, P1455, DOI 10.1046/j.1471-4159.2000.0751455.x; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bolanos JP, 1998, BRAIN RES, V787, P117, DOI 10.1016/S0006-8993(97)01530-8; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; Brorson JR, 1999, J NEUROSCI, V19, P147, DOI 10.1523/JNEUROSCI.19-01-00147.1999; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; BUTLER AR, 1995, TRENDS PHARMACOL SCI, V16, P18, DOI 10.1016/S0165-6147(00)88968-3; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; CHEN J, 1991, NEUROREPORT, V2, P121, DOI 10.1097/00001756-199103000-00002; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; DAWSON VL, 1993, J NEUROSCI, V13, P2651; GALIONE A, 1994, MOL CELL ENDOCRINOL, V98, P125, DOI 10.1016/0303-7207(94)90130-9; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Heales SJR, 1999, BBA-BIOENERGETICS, V1410, P215, DOI 10.1016/S0005-2728(98)00168-6; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; Keelan J, 1999, J PHYSIOL-LONDON, V520, P797, DOI 10.1111/j.1469-7793.1999.00797.x; KOLLEGGER H, 1993, BIOCHEM PHARMACOL, V45, P260, DOI 10.1016/0006-2952(93)90401-H; Kozlov AV, 1999, FEBS LETT, V454, P127, DOI 10.1016/S0014-5793(99)00788-7; Kristian T, 1996, LIFE SCI, V59, P357, DOI 10.1016/0024-3205(96)00314-1; Laffranchi R, 1995, BIOCHEM BIOPH RES CO, V217, P584, DOI 10.1006/bbrc.1995.2815; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; MANZONI O, 1992, NEUROREPORT, V3, P77, DOI 10.1097/00001756-199201000-00020; MARIN P, 1993, NEUROPHARMACOLOGY, V32, P29, DOI 10.1016/0028-3908(93)90126-N; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; OKADA D, 1995, J NEUROCHEM, V64, P1298; ONEILL SK, 1993, J PHARMACOL TOXICOL, V29, P217, DOI 10.1016/1056-8719(93)90028-D; Ruiz F, 2000, EUR J PHARMACOL, V404, P29, DOI 10.1016/S0014-2999(00)00584-7; Sarti P, 1999, FASEB J, V13, P191, DOI 10.1096/fasebj.13.1.191; Schinder AF, 1996, J NEUROSCI, V16, P6125; Stadler J, 1996, ADV EXP MED BIOL, V387, P187; STOUT AK, 1994, NEUROPHARMACOLOGY, V33, P1367, DOI 10.1016/0028-3908(94)90038-8; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Vergun O, 1999, J PHYSIOL-LONDON, V519, P451, DOI 10.1111/j.1469-7793.1999.0451m.x; WARD SM, 1994, BRAIN RES, V648, P249, DOI 10.1016/0006-8993(94)91124-X; WEISS S, 1990, J PHARMACOL EXP THER, V252, P380; WEISS S, 1993, BRAIN RES, V627, P63, DOI 10.1016/0006-8993(93)90749-D; WEISSMAN BA, 1992, NEUROSCI LETT, V146, P139, DOI 10.1016/0304-3940(92)90062-C; White RJ, 1996, J NEUROSCI, V16, P5688; Willmott N, 1996, J BIOL CHEM, V271, P3699; Zaidan E, 1999, J NEUROCHEM, V73, P2214	51	62	63	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1611	1622		10.1096/fj.02-0126com	http://dx.doi.org/10.1096/fj.02-0126com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374784				2022-12-28	WOS:000179167600043
J	Koti, RS; Seifalian, AM; McBride, AG; Yang, WX; Davidson, BR				Koti, RS; Seifalian, AM; McBride, AG; Yang, WX; Davidson, BR			The relationship of hepatic tissue oxygenation with nitric oxide metabolism in ischemic preconditioning of the liver	FASEB JOURNAL			English	Article						ischemia reperfusion injury; near-infrared spectroscopy; cytochrome oxidase; hepatoprotection	NEAR-INFRARED SPECTROSCOPY; REPERFUSION INJURY; CYTOCHROME-OXIDASE; ENERGY-METABOLISM; GRAFT FUNCTION; RAT-LIVER; HYPOXIA; TRANSPLANTATION; INHIBITION; SATURATION	Ischemic preconditioning (IPC) may increase the hepatic tolerance of ischemic injury during liver surgery and transplantation via nitric oxide (NO) formation. This study investigates the effect of IPC on hepatic tissue oxygenation and the role of NO stimulation and inhibition on the preconditioning effect in the rat liver. Study groups had 1) sham laparotomy; 2) 45-min lobar liver ischemia and 2-h reperfusion (IR); 3) IPC with 5-min ischemia and 10-min reperfusion before IR; 4) L-arginine before IR; and 5) Nomega-Nitro-L-arginine methyl ester (L-NAME) + IPC before IR. Hepatic tissue oxygenation was monitored by near-infrared spectroscopy. Plasma alanine aminotransferase and plasma nitrite/nitrate were measured. Following IR there was significant decrease in oxyhemoglobin and cytochrome oxidase and an increase in deoxyhemoglobin (P<0.05 vs. Sham). IPC produced a significant increase in intracellular oxygenation at the end of the reperfusion period (cytochrome oxidase Cu(A) redox state, P<0.05 vs IR). NO stimulation with L-arginine did not attenuate the impairment in hepatic tissue oxygenation after IR (P>0.05 vs IR). In contrast, inhibition of NO synthesis blocked the effect of IPC and further impaired tissue oxygenation (decreased cytochrome oxidase CuA redox state and increased deoxyhemoglobin, both P<0.05 vs IR), suggesting an aggravation of ischemia reperfusion injury. Hepatocellular injury was reduced by IPC and L-arginine and increased by NO blockade with L-NAME (Plasma ALT, all P< 0.05 vs IR). Hepatic tissue oxygenation correlated significantly with ALT and plasma nitrite/nitrate. Ischemic preconditioning significantly improved hepatic intra cellular oxygenation and reduced hepatocellular injury. NO stimulation reduced hepatocellular injury, whereas inhibition of nitric oxide synthesis blocked the effect of IPC and reduced tissue oxygenation and increased hepatocellular injury.	Univ London UCL Royal Free Hosp, Royal Free & Univ Coll Med Sch, Dept Surg, London NW3 2QG, England; UCL Royal Free Hosp, Univ Coll London, Royal Free & Univ Coll Med Sch, Liver Transplantat Unit, London NW3 2QG, England	University of London; University College London; University of London; University College London	Davidson, BR (corresponding author), Univ London UCL Royal Free Hosp, Royal Free & Univ Coll Med Sch, Dept Surg, Pond St, London NW3 2QG, England.	b.davidson@rfc.ucl.ac.uk	Seifalian, Alexander M/I-6028-2013	Seifalian, Alexander M/0000-0002-1180-3322				BAUEREISEN B, 1975, GASTROENTEROLOGY, V13, P70; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CHEN SS, 1993, AM J PHYSIOL, V264, pG375, DOI 10.1152/ajpgi.1993.264.2.G375; CHEONG WF, 1990, IEEE J QUANTUM ELECT, V26, P2166, DOI 10.1109/3.64354; Clavien PA, 2000, ANN SURG, V232, P155, DOI 10.1097/00000658-200008000-00001; Cooper CE, 2002, TRENDS BIOCHEM SCI, V27, P33, DOI 10.1016/S0968-0004(01)02035-7; COOPER CE, 1994, BIOCHEM SOC T, V22, P974, DOI 10.1042/bst0220974; COPE M, 1991, THESIS U LONDON; DEGROOT H, 1985, ANESTHESIOLOGY, V62, P44, DOI 10.1097/00000542-198501000-00009; EDWARDS AD, 1991, J APPL PHYSIOL, V71, P1907, DOI 10.1152/jappl.1991.71.5.1907; El-Desoky AE, 2001, LIVER, V21, P37; El-Desoky AEH, 1999, LIVER TRANSPLANT SUR, V5, P219, DOI 10.1002/lt.500050316; El-Desoky AEH, 2000, EUR SURG RES, V32, P207, DOI 10.1159/000008766; Giulivi C, 1998, BIOCHEM J, V332, P673, DOI 10.1042/bj3320673; GOTO M, 1992, HEPATOLOGY, V15, P432, DOI 10.1002/hep.1840150313; GROENLAND THN, 1992, ADV EXP MED BIOL, V317, P835; HARBRECHT BG, 1992, J LEUKOCYTE BIOL, V52, P390, DOI 10.1002/jlb.52.4.390; Harbrecht BG, 1997, SHOCK, V8, P415, DOI 10.1097/00024382-199712000-00004; Hardy KJ, 1996, AUST NZ J SURG, V66, P707, DOI 10.1111/j.1445-2197.1996.tb00722.x; Jaeschke H, 1996, TOXICOL APPL PHARM, V139, P213, DOI 10.1006/taap.1996.0160; JAESCHKE H, 1990, FASEB J, V4, P3355, DOI 10.1096/fasebj.4.15.2253850; Jobsis FF, 1992, QUANTITATIVE SPECTRO, P47; Katsuramaki T, 1997, TRANSPLANTATION, V64, P360, DOI 10.1097/00007890-199707270-00031; Kawachi S, 2000, BIOCHEM BIOPH RES CO, V276, P851, DOI 10.1006/bbrc.2000.3559; KITAI T, 1995, TRANSPLANT INT, V8, P111, DOI 10.1007/BF00344420; Kiuchi T, 1996, TRANSPLANT INT, V9, P90, DOI 10.1111/j.1432-2277.1996.tb00861.x; KOO A, 1992, HEPATOLOGY, V15, P507, DOI 10.1002/hep.1840150325; LEMASTERS JJ, 1983, J CELL BIOL, V97, P778, DOI 10.1083/jcb.97.3.778; LLORISCARSI JM, 1993, TRANSPLANT P, V25, P3303; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; MURRY CE, 1990, CIRC RES, V66, P913, DOI 10.1161/01.RES.66.4.913; Peralta C, 1996, BIOCHEM BIOPH RES CO, V229, P264, DOI 10.1006/bbrc.1996.1790; RIEDER HU, 1994, SURG LIVER BILIARY T, P487; ROCKEY DC, 1995, J CLIN INVEST, V95, P1199, DOI 10.1172/JCI117769; Sankary HN, 1999, TRANSPLANTATION, V68, P958, DOI 10.1097/00007890-199910150-00010; Seifalian AM, 2001, FASEB J, V15, P2642, DOI 10.1096/fj.01-0308com; SHIBAYAMA Y, 1992, LIVER, V12, P84; SUMIMOTO K, 1987, TRANSPL P, V19, P1098; TAKASHIMA S, 1995, BRAIN DEV-JPN, V17, P312, DOI 10.1016/0387-7604(95)00072-J; Taylor D E, 1996, New Horiz, V4, P420; VOLLMAR B, 1994, AM J PATHOL, V145, P1421; WANG Y, 1995, SHOCK, V4, P282, DOI 10.1097/00024382-199510000-00009; Yin DP, 1998, TRANSPLANTATION, V66, P152, DOI 10.1097/00007890-199807270-00002; Yoshizumi T, 1998, BRIT J SURG, V85, P1636; ZEBALLOS GA, 1995, CIRCULATION, V91, P2982, DOI 10.1161/01.CIR.91.12.2982	45	55	55	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10					1654	+		10.1096/fj.01-1034fje	http://dx.doi.org/10.1096/fj.01-1034fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207003				2022-12-28	WOS:000177814000013
J	Barouch, R; Schwartz, M				Barouch, R; Schwartz, M			Autoreactive T cells induce neurotrophin production by immune and neural cells in injured rat optic nerve: Implications for protective autoimmunity	FASEB JOURNAL			English	Article						T and B lymphocytes; macrophages; CNS trauma; protective autoimmunity; neurotrophic factors	MYELIN BASIC-PROTEIN; SPINAL-CORD-INJURY; MESSENGER-RNA EXPRESSION; FACIAL MOTONEURON LOSS; GROWTH-FACTOR; IMMUNOGLOBULIN PRODUCTION; INFLAMMATORY CYTOKINES; PROMOTES RECOVERY; B-CELLS; BRAIN	Accumulating evidence suggests that activation of the immune system in the central nervous system (CNS) after trauma protects the CNS from damage propagation and facilitates regeneration. Studies by our group have shown that passive transfer of autoimmune T cells specific to myelin basic protein (TMBP) can protect injured neurons in the rat CNS from secondary degeneration. In this study, we investigated the effects of TMBP treatment on the local immune response (by B cells and macrophages) and on the expression of neurotrophic factors after crush injury of the rat optic nerve. Systemic injection of activated TMBP caused an increase in the accumulation of macrophages/microglia and B cells in the injured nerve, which was greater than that seen in the injured optic nerves of untreated animals. This accumulation was accompanied by a transient, but massive, increase in the expression of neurotrophic factors. Immunocytochemical analysis demonstrated differential expression of neurotrophins by resident astrocytes and by infiltrating B cells, T cells, and macrophages. Because postinjury neuronal survival and maintenance are known to be affected by neurotrophins, our findings point to a possible contribution of a neurotrophin-related mechanism to the protective effect conferred by T cell-mediated autoimmunity on injured neurons.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	michal.schwartz@weizmann.ac.il						ALOE L, 1977, BRAIN RES, V133, P358, DOI 10.1016/0006-8993(77)90772-7; Aloisi F, 2000, IMMUNOL TODAY, V21, P141, DOI 10.1016/S0167-5699(99)01512-1; Aloisi F, 1999, EUR J IMMUNOL, V29, P2705, DOI 10.1002/(SICI)1521-4141(199909)29:09<2705::AID-IMMU2705>3.0.CO;2-1; Arredondo LR, 2001, EUR J IMMUNOL, V31, P625; BAHR M, 1994, NERVENARZT, V65, P355; Barouch R, 2000, J NEUROIMMUNOL, V103, P112, DOI 10.1016/S0165-5728(99)00233-7; Barouch R, 2001, J LEUKOCYTE BIOL, V69, P1019; Barouch R, 2001, J NEUROIMMUNOL, V112, P72, DOI 10.1016/S0165-5728(00)00408-2; Bell R B, 1991, Semin Immunol, V3, P237; BENNUN A, 1982, J IMMUNOL, V129, P303; BENNUN A, 1981, EUR J IMMUNOL, V11, P195, DOI 10.1002/eji.1830110307; Besser M, 1999, J IMMUNOL, V162, P6303; Braun A, 1998, EUR J IMMUNOL, V28, P3240, DOI 10.1002/(SICI)1521-4141(199810)28:10<3240::AID-IMMU3240>3.0.CO;2-U; BRODIE C, 1994, J NEUROIMMUNOL, V52, P87, DOI 10.1016/0165-5728(94)90166-X; BRODIE C, 1992, J IMMUNOL, V148, P3492; Butovsky Oleg, 2001, FASEB Journal, V15, P1065; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P10984, DOI 10.1073/pnas.90.23.10984; Elkabes S, 1998, J NEUROSCI RES, V54, P117, DOI 10.1002/(SICI)1097-4547(19981001)54:1<117::AID-JNR12>3.0.CO;2-4; Fisher J, 2001, J NEUROSCI, V21, P136, DOI 10.1523/JNEUROSCI.21-01-00136.2001; Hamada A, 1996, BRIT J HAEMATOL, V93, P299, DOI 10.1046/j.1365-2141.1996.5151055.x; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; Hauben E, 2001, P NATL ACAD SCI USA, V98, P15173, DOI 10.1073/pnas.011585298; Hirschberg DL, 1998, J NEUROIMMUNOL, V89, P88, DOI 10.1016/S0165-5728(98)00118-0; HUNIG T, 1989, J EXP MED, V169, P73, DOI 10.1084/jem.169.1.73; KENNEDY MK, 1992, J IMMUNOL, V149, P2496; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; KIMATA H, 1991, CLIN IMMUNOL IMMUNOP, V60, P145, DOI 10.1016/0090-1229(91)90120-Y; Kipnis J, 2000, P NATL ACAD SCI USA, V97, P7446, DOI 10.1073/pnas.97.13.7446; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; KIPNIS J, 2002, IN PRESS J NEUROIMMU; Klocker N, 2000, J NEUROSCI, V20, P6962, DOI 10.1523/JNEUROSCI.20-18-06962.2000; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; LAURENZI MA, 1994, EUR J BIOCHEM, V223, P733, DOI 10.1111/j.1432-1033.1994.tb19047.x; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; LU X, 1991, J NEUROSCI, V11, P972; MANESS LM, 1994, NEUROSCI BIOBEHAV R, V18, P143, DOI 10.1016/0149-7634(94)90043-4; MICERA A, 1995, ARCH ITAL BIOL, V133, P131; Miwa T, 1997, J NEUROSCI RES, V50, P1023; MIZRACHI Y, 1983, PARAPLEGIA, V21, P287, DOI 10.1038/sc.1983.48; Moalem G, 2000, J NEUROIMMUNOL, V106, P189, DOI 10.1016/S0165-5728(00)00240-X; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moalem G, 1999, FASEB J, V13, P1207, DOI 10.1096/fasebj.13.10.1207; Moalem G., 2000, J AUTOIMMUN, V20, P6421; Namiki J, 2000, J NEUROTRAUM, V17, P1219, DOI 10.1089/neu.2000.17.1219; Novikova LN, 2000, EUR J NEUROSCI, V12, P776, DOI 10.1046/j.1460-9568.2000.00978.x; OKUDA Y, 1995, J NEUROIMMUNOL, V62, P103, DOI 10.1016/0165-5728(95)00114-H; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; OTTEN U, 1994, PROG BRAIN RES, V103, P293; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; OWENS T, 1994, IMMUNOL TODAY, V15, P566, DOI 10.1016/0167-5699(94)90218-6; PALLADINI G, 1987, EXP NEUROL, V95, P639, DOI 10.1016/0014-4886(87)90305-0; Patrick CW, 1996, EXP NEUROL, V138, P277, DOI 10.1006/exnr.1996.0066; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; RENNO T, 1995, J IMMUNOL, V154, P944; SCHORI H, 2002, IN PRESS J IMMUNOL; Schwartz M, 2001, TRENDS MOL MED, V7, P252, DOI 10.1016/S1471-4914(01)01993-1; SCHWARTZ M, 1997, CURRENT TOPICS NEURO, V1, P123; Serpe CJ, 2000, J NEUROSCI RES, V62, P273, DOI 10.1002/1097-4547(20001015)62:2<273::AID-JNR11>3.0.CO;2-C; Serpe CJ, 1999, J NEUROSCI, V19; Stefan J, 1971, Cesk Patol, V7, P36; Susaki Y, 1996, BLOOD, V88, P4630, DOI 10.1182/blood.V88.12.4630.bloodjournal88124630; Ullrich O, 2001, FASEB J, V15, P1460, DOI 10.1096/fj.00-0540fje; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001; ZHOU XF, 1994, J NEUROSCI METH, V54, P95, DOI 10.1016/0165-0270(94)90163-5	71	73	78	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1304	+		10.1096/fj.01-0467fje	http://dx.doi.org/10.1096/fj.01-0467fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154003				2022-12-28	WOS:000176683900012
J	Campbell, SJ; Hughes, PM; Iredale, JP; Wilcockson, DC; Waters, S; Docagne, F; Perry, VH; Anthony, DC				Campbell, SJ; Hughes, PM; Iredale, JP; Wilcockson, DC; Waters, S; Docagne, F; Perry, VH; Anthony, DC			CINC-1 is identified as an acute-phase protein induced by focal brain injury causing leukocyte mobilization and liver injury	FASEB JOURNAL			English	Article						MODS; IL-1 beta; cytokine; chemokine; neutrophil	INDUCED NEUTROPHIL CHEMOATTRACTANT; CHEMOKINERGIC NEURONAL PATHWAY; INFLAMMATORY RESPONSE; RAT-LIVER; BLOOD; CYTOKINE; INTERLEUKIN-1-BETA; INDUCTION; EXPRESSION; INJECTION	Following injury or infection, the liver releases acute-phase proteins (APP). After a severe focal injury, this systemic response can be excessive and may lead to multiorgan dysfunction (MODS). CINC-1 is a neutrophil chemoattractant, and we have now established that it also functions as an early APP after injury to the brain or to peripheral tissues. After induction of a focal inflammatory lesion in the brain, there is rapid hepatic and serum CINC-1 induction, which is associated with increases in neutrophil numbers within the liver and within the circulation. CINC-1-mediated recruitment of neutrophils to organs distant from the primary injury site may contribute to MODS. Indeed, we found that enzyme markers of liver tissue injury are increased in the serum following generation of a focal inflammatory lesion in the brain. Neutralization of CINC-1 in the periphery reversed brain-injury-induced neutrophil mobilization and inhibited recruitment of neutrophils to the brain and to the liver. Thus, a significant component of the hepatic acute-phase response is the release of chemokines by the liver, which act to amplify the inflammatory response and modulate the subsequent leukocytosis and secondary tissue damage. Hepatic CINC-1 synthesis following injury presents a novel focus for treatment of inflammation.	Univ Southampton, Sch Biol Sci, Mol Neuropathol Lab, Southampton S016 7PX, Hants, England; Univ Southampton, Sch Biol Sci, CNS, Inflammat Grp, Southampton S016 7PX, Hants, England; Univ Southampton, Sch Med, Southampton SO16 6YD, Hants, England	University of Southampton; University of Southampton; University of Southampton	Campbell, SJ (corresponding author), Univ Southampton, Sch Biol Sci, Mol Neuropathol Lab, Biomed Sci Bldg, Southampton S016 7PX, Hants, England.	s.j.campbell@soton.ac.uk	Perry, V. Hugh/Y-2935-2019; Anthony, Daniel/F-7765-2010; Docagne, Fabian/S-8308-2018	Anthony, Daniel/0000-0003-1380-6655; Docagne, Fabian/0000-0003-1745-0625; Wilcockson, David/0000-0002-5923-4472; Iredale, John/0000-0003-2174-5127				ANDERSSON PB, 1992, NEUROSCIENCE, V48, P169, DOI 10.1016/0306-4522(92)90347-5; Anforth HR, 1998, EUR CYTOKINE NETW, V9, P279; Anthony D, 1998, CURR BIOL, V8, P923, DOI 10.1016/S0960-9822(07)00373-9; Anthony DC, 1997, BRAIN, V120, P435, DOI 10.1093/brain/120.3.435; Banks WA, 1995, NEUROIMMUNOMODULAT, V2, P241, DOI 10.1159/000097202; BANKS WA, 1991, J PHARMACOL EXP THER, V259, P988; Bhatia M, 2000, GUT, V47, P838, DOI 10.1136/gut.47.6.838; Blond D, 2002, BRAIN RES, V958, P89, DOI 10.1016/S0006-8993(02)03473-X; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Calkins CM, 2002, J ENDOTOXIN RES, V8, P59, DOI 10.1179/096805102125000092; Campbell SJ, 2002, J NEUROCHEM, V83, P432, DOI 10.1046/j.1471-4159.2002.01166.x; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; CSERR HF, 1992, BRAIN PATHOL, V2, P269, DOI 10.1111/j.1750-3639.1992.tb00703.x; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; DESIMONI MG, 1993, AM J PHYSIOL, V265, pR739, DOI 10.1152/ajpregu.1993.265.4.R739; DESIMONI MG, 1990, J EXP MED, V171, P1773, DOI 10.1084/jem.171.5.1773; Di Santo E, 1999, NEUROIMMUNOMODULAT, V6, P300, DOI 10.1159/000026388; Ek M, 1998, J NEUROSCI, V18, P9471; Fantuzzi G, 1996, J IMMUNOL, V157, P291; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; GEISTERFER M, 1993, CYTOKINE, V5, P1, DOI 10.1016/1043-4666(93)90017-Y; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559, DOI 10.1002/jlb.56.5.559; Hirata I, 2001, DIGESTION, V63, P73, DOI 10.1159/000051915; Iwamura H, 2002, INFLAMM RES, V51, P160, DOI 10.1007/PL00000288; King AG, 2001, BLOOD, V97, P1534, DOI 10.1182/blood.V97.6.1534; Knopf PM, 1998, J IMMUNOL, V161, P692; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Lawrence CB, 1998, EUR J NEUROSCI, V10, P1188, DOI 10.1046/j.1460-9568.1998.00136.x; Maher JJ, 1997, HEPATOLOGY, V25, P624, DOI 10.1002/hep.510250322; Mercer-Jones MA, 1999, INFLAMMATION, V23, P305; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; Nishimoto N, 1994, Gan To Kagaku Ryoho, V21, P1707; OHehir RE, 1996, CLIN EXP ALLERGY, V26, P20, DOI 10.1111/j.1365-2222.1996.tb00052.x; Ohkubo K, 1998, J GASTROEN HEPATOL, V13, P696, DOI 10.1111/j.1440-1746.1998.tb00716.x; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Pan WH, 2001, J NEUROIMMUNOL, V115, P64, DOI 10.1016/S0165-5728(01)00256-9; Rees GS, 1999, CYTOKINE, V11, P95, DOI 10.1006/cyto.1998.0408; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; RIVEST S, 1992, BRAIN RES, V587, P13, DOI 10.1016/0006-8993(92)91424-D; Saito JM, 2000, GASTROENTEROLOGY, V118, P1157, DOI 10.1016/S0016-5085(00)70369-6; Sakamoto Y, 1996, NEUROSCIENCE, V75, P133, DOI 10.1016/0306-4522(96)00252-7; Sakamoto Y, 1996, ENDOCRINOLOGY, V137, P4503, DOI 10.1210/en.137.10.4503; SAPOLSKY R, 1987, SCIENCE, V238, P522, DOI 10.1126/science.2821621; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; SCHREIBER G, 1989, ANN NY ACAD SCI, V557, P61; Tkalcevic J, 2000, IMMUNITY, V12, P201, DOI 10.1016/S1074-7613(00)80173-9; Tomkinson A, 2001, INT ARCH ALLERGY IMM, V126, P119, DOI 10.1159/000049502; Walters DM, 2001, AM J RESP CRIT CARE, V164, P1438, DOI 10.1164/ajrccm.164.8.2007121; Wiekowski MT, 2001, J IMMUNOL, V167, P7102, DOI 10.4049/jimmunol.167.12.7102; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Xu Y. X., 1999, Hematology, V4, P345; Yamada S, 2000, HEPATOLOGY, V32, P278, DOI 10.1053/jhep.2000.9604; Yamagami S, 1999, J LEUKOCYTE BIOL, V65, P744, DOI 10.1002/jlb.65.6.744; Yamamoto J, 1998, EUR J PHARMACOL, V363, P131, DOI 10.1016/S0014-2999(98)00801-2	55	107	110	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1168	+		10.1096/fj.02-0757fje	http://dx.doi.org/10.1096/fj.02-0757fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709409				2022-12-28	WOS:000182580100017
J	Moreno, M; Lombardi, A; De Lange, P; Silvestri, E; Ragni, M; Lanni, A; Goglia, F				Moreno, M; Lombardi, A; De Lange, P; Silvestri, E; Ragni, M; Lanni, A; Goglia, F			Fasting, lipid metabolism, and triiodothyronine in rat gastrocnemius muscle: interrelated roles of uncoupling protein 3, mitochondrial thioesterase, and coenzyme Q	FASEB JOURNAL			English	Article						mitochondria; UCP3; MTEI; T3	BROWN ADIPOSE-TISSUE; FREE FATTY-ACIDS; SKELETAL-MUSCLE; PROTON CONDUCTANCE; THYROID-HORMONE; YEAST MITOCHONDRIA; GENE-EXPRESSION; MESSENGER-RNA; C-13/P-31 NMR; UCP3 GENE	We investigated the role of uncoupling protein 3 (UCP3) during fasting and examined the effect of triiodothyronine (T3) administration in such a condition. The possible involvement of mitochondrial thioesterase (MTE I) and the role of putative cofactors, such as coenzyme Q (CoQ), was also examined. Here, we report that fasting induced a more than twofold elevation in the expression and activity of MTE I, and an increase in UCP3 expression, without any associated uncoupling activity. Administration of T3 to fasting rats further up-regulated UCP3 as well as MTE I expression, markedly enhanced MTE I enzyme activity and prevented the impairment of the uncoupling activity of UCP3 normally seen during fasting. Indeed, T3-treatment induced an UCP3-dependent decrease in mitochondrial membrane potential, which was abolished by the addition of either GDP or superoxide dismutase (SOD). T3 administration also prevented the marked decrease of CoQ levels observed in fasting rats and this provides evidence that also, in vivo, CoQ represents an essential cofactor for the UCP3-mediated uncoupling. The data also show that MTE I and UCP3 are likely involved in the same biochemical mechanism and that UCP3 postulated functions, such as lipid handling and uncoupling, are not mutually exclusive but may coexist in vivo.	Univ Sannio, Dipartimento Sci Biol & Ambientali, I-82100 Benevento, Italy; Univ Naples Federico II, Dipartimento Fisiol Gen & Ambientale, I-80134 Naples, Italy; Univ Naples 2, Dipartimento Sci Vita, I-81100 Caserta, Italy	University of Sannio; University of Naples Federico II; Universita della Campania Vanvitelli	Goglia, F (corresponding author), Univ Sannio, Dipartimento Sci Biol & Ambientali, Via Port Arsa 1, I-82100 Benevento, Italy.	antonia.lanni@unina2.it; goglia@unisannio.it	de Lange, Pieter/GXA-3052-2022; Ragni, Maurizio/AAB-1527-2020	Ragni, Maurizio/0000-0001-6548-741X; MORENO, Maria/0000-0002-6218-5501; Silvestri, Elena/0000-0002-0592-9033; GOGLIA, Fernando/0000-0003-0468-9645				Acin A, 1999, BIOCHEM BIOPH RES CO, V258, P278, DOI 10.1006/bbrc.1999.0530; ALEXSON SEH, 1988, J BIOL CHEM, V263, P13564; Argyropoulos G, 2002, J APPL PHYSIOL, V92, P2187, DOI 10.1152/japplphysiol.00994.2001; BLAKE NG, 1991, ENDOCRINOLOGY, V129, P2714, DOI 10.1210/endo-129-5-2714; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; Cadenas S, 2000, BIOCHEM J, V348, P209, DOI 10.1042/0264-6021:3480209; Cadenas S, 2002, J BIOL CHEM, V277, P2773, DOI 10.1074/jbc.M109736200; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Clapham JC, 2001, BIOCHEM BIOPH RES CO, V287, P1058, DOI 10.1006/bbrc.2001.5698; Cortright RN, 1999, AM J PHYSIOL-ENDOC M, V276, pE217, DOI 10.1152/ajpendo.1999.276.1.E217; Cusin I, 1998, DIABETES, V47, P1014, DOI 10.2337/diabetes.47.7.1014; de Lange P, 2001, ENDOCRINOLOGY, V142, P3414, DOI 10.1210/en.142.8.3414; DULLOO AG, 2001, BR J NUTR, V86, P1; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Echtay KS, 2001, BIOCHEM SOC T, V29, P763; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Harper JA, 2002, BIOCHEM J, V361, P49, DOI 10.1042/0264-6021:3610049; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; Hwang CS, 1999, BIOCHEM BIOPH RES CO, V258, P464, DOI 10.1006/bbrc.1999.0662; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jucker BM, 2000, P NATL ACAD SCI USA, V97, P6880, DOI 10.1073/pnas.120131997; Jucker BM, 2000, J BIOL CHEM, V275, P39279, DOI 10.1074/jbc.M007760200; Klingenberg M, 2001, BIOCHEM SOC T, V29, P806; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanni A, 1999, FEBS LETT, V444, P250, DOI 10.1016/S0014-5793(99)00061-7; Lanni A, 1996, J PHYSIOL-LONDON, V494, P831, DOI 10.1113/jphysiol.1996.sp021536; Larkin S, 1997, BIOCHEM BIOPH RES CO, V240, P222, DOI 10.1006/bbrc.1997.7636; Lebon V, 2001, J CLIN INVEST, V108, P733, DOI 10.1172/JCI11775; Moore GBT, 2001, BIOCHEM BIOPH RES CO, V283, P785, DOI 10.1006/bbrc.2001.4848; Nohl H, 2001, BIOORG CHEM, V29, P1, DOI 10.1006/bioo.2000.1193; OPPENHEIMER JH, 1991, J CLIN INVEST, V87, P125, DOI 10.1172/JCI114961; RANGANATHAN S, 1975, BIOCHEM J, V148, P35, DOI 10.1042/bj1480035; Samec S, 1998, DIABETES, V47, P1693, DOI 10.2337/diabetes.47.11.1693; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Simonyan RA, 1998, FEBS LETT, V436, P81, DOI 10.1016/S0014-5793(98)01106-5; Stuart JA, 2001, BIOCHEM J, V356, P779, DOI 10.1042/0264-6021:3560779; Stuart JA, 2001, J BIOL CHEM, V276, P18633, DOI 10.1074/jbc.M011566200; TAKADA M, 1982, BIOCHIM BIOPHYS ACTA, V679, P308, DOI 10.1016/0005-2728(82)90301-2; TAKADA M, 1984, METHOD ENZYMOL, V105, P147; Vidal-Puig A, 1999, OBES RES, V7, P133, DOI 10.1002/j.1550-8528.1999.tb00694.x; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Weigle DS, 1998, DIABETES, V47, P298, DOI 10.2337/diabetes.47.2.298; WIMPFHEIMER C, 1979, SCIENCE, V205, P1272, DOI 10.1126/science.224460; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X	49	34	36	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1112	+		10.1096/fj.02-0839fje	http://dx.doi.org/10.1096/fj.02-0839fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692085				2022-12-28	WOS:000182580100035
J	Zernecke, A; Erl, W; Fraemohs, L; Lietz, M; Weber, C				Zernecke, A; Erl, W; Fraemohs, L; Lietz, M; Weber, C			Suppression of endothelial adhesion molecule up-regulation with cyclopentenone prostaglandins is dissociated from I kappa B kinase inhibition and cell death induction	FASEB JOURNAL			English	Article						cell adhesion molecules; endothelium; transcription factors	ACTIVATED RECEPTOR-GAMMA; SMOOTH-MUSCLE CELLS; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); GENE-EXPRESSION; MONOCYTE ADHESION; APOPTOSIS; TRANSCRIPTION; SIGNALS; PATHWAY; VCAM-1	The cyclopentenone prostaglandins (cPG) 15-deoxy-Delta(12,14N)-prostaglandin J(2) (dPGJ(2)) and PGA(1) can inhibit multiple steps in nuclear factor (NF)-kappaB signaling and can induce cell death. Here we characterized the effects of dPGJ(2) and PGA(1) on the inflammatory induction of endothelial cell adhesion molecules (CAM). Pretreatment of endothelial cells with dPGJ(2) or PGA(1) at low concentrations dose dependently inhibited the up-regulation of CAM expression and monocyte arrest by tumor necrosis factor (TNF)-alpha, but not expression of inhibitor of apoptosis proteins. Only at high concentrations, cPG enhanced TNF-alpha-induced cell death and inhibited TNF-alpha-induced IkappaB-alpha kinase (IKK) activation, IkappaB-alpha degradation, and NF-kappaB/p65 translocation, while promoting AP-1/c-jun phosphorylation. Expression of an IKK-beta mutant (C179A) resistant to interaction with cPG impaired cell death induction but not inhibition of CAM up-regulation by cPG. Gel shift and reporter gene analysis revealed that cPG at low concentrations directly impaired DNA binding of NF-kappaB and NF-kappaB-dependent transactivation. The synthetic analogs dPGA(1) or dPGA(2) were ineffective, indicating structural specificity of cPG. Thus, the suppression of endothelial CAM up-regulation with cPG is dissociated from cell death sensitization and IKK inhibition above threshold concentrations and related to interference with NF-kappaB binding. Our findings define distinct mechanisms for anti-inflammatory and proapoptotic effects of cPG in endothelial cells.	Univ Munich, Inst Prophylaxe Kreislaufkrankheiten, D-80336 Munich, Germany; Rhein Westfal TH Aachen, Dept Mol Cardiovasc Res, D-52074 Aachen, Germany	University of Munich; RWTH Aachen University	Weber, C (corresponding author), Univ Klinikum Aachen, Pauwelstr 30, D-52074 Aachen, Germany.	cweber@ukaachen.de	Weber, Christian/AAW-2153-2020	Weber, Christian/0000-0003-4610-8714				Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Chen NG, 2001, BIOCHEM BIOPH RES CO, V282, P717, DOI 10.1006/bbrc.2001.4628; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; Erl W, 1999, CIRC RES, V84, P668, DOI 10.1161/01.RES.84.6.668; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Jackson SM, 1999, ARTERIOSCL THROM VAS, V19, P2094, DOI 10.1161/01.ATV.19.9.2094; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Neuzil J, 2001, BIOCHEMISTRY-US, V40, P4686, DOI 10.1021/bi002498n; Pasceri V, 2000, CIRCULATION, V101, P235, DOI 10.1161/01.CIR.101.3.235; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Spiecker M, 2000, J IMMUNOL, V164, P3316, DOI 10.4049/jimmunol.164.6.3316; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006; Takeda K, 2001, J BIOL CHEM, V276, P48950, DOI 10.1074/jbc.M108722200; VORABERGER G, 1991, J IMMUNOL, V147, P2777; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WEBER C, 1994, ARTERIOSCLER THROMB, V14, P1665, DOI 10.1161/01.ATV.14.10.1665; WEBER C, 1995, CIRCULATION, V91, P1914, DOI 10.1161/01.CIR.91.7.1914; Weber KSC, 1999, EUR J IMMUNOL, V29, P700, DOI 10.1002/(SICI)1521-4141(199902)29:02<700::AID-IMMU700>3.0.CO;2-1; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	37	24	27	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1099	+		10.1096/fj.02-0485fje	http://dx.doi.org/10.1096/fj.02-0485fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692090				2022-12-28	WOS:000182580100038
J	Descamps, FJ; Van den Steen, PE; Martens, E; Ballaux, F; Geboes, K; Opdenakker, G				Descamps, FJ; Van den Steen, PE; Martens, E; Ballaux, F; Geboes, K; Opdenakker, G			Gelatinase B is diabetogenic in acute and chronic pancreatitis by cleaving insulin	FASEB JOURNAL			English	Article						diabetes; inflammation; neutrophil; islets of Langerhans	HUMAN T-LYMPHOCYTES; MATRIX METALLOPROTEINASES; TISSUE INHIBITORS; CELLS; IDENTIFICATION; SPECIFICITIES; GENERATION; ACTIVATION; ANTIBODY; FIBROSIS	Genetic, endocrine, and environmental factors contribute to the development of diabetes. Much information has been gathered on the homeostasis mechanisms of glucose regulation by insulin-producing pancreatic cells. Here we demonstrate high expression levels of gelatinase B (matrix metalloproteinase-9, MMP-9) by neutrophils in acute pancreatitis and by ductular epithelial cells in chronic pancreatitis. Because gelatinase B processes cytokines and chemokines, we investigated whether and how gelatinase B cleaves insulin. Pure human neutrophil gelatinase B was found to destroy insulin by cleavage at 10 sites. Pancreatic islet and ductular cells are relatively spared in comparison with the complete destruction of acinar cells of the exocrine pancreas in chronic pancreatitis. High expression levels of gelatinase B are maintained in the immediate proximity of insulin-secreting cells. Consequently, diabetes may be worsened by enzymatic degradation of insulin by gelatinase B and by the consequent enhancement of the autoimmune process. Gelatinase B is diabetogenic in acute and chronic pancreatitis by cleaving insulin.	Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, B-3000 Louvain, Belgium; Univ Leuven, Dept Morphol & Mol Pathol, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Opdenakker, G (corresponding author), Univ Leuven, Rega Inst Med Res, Lab Mol Immunol, Minderbroedersstr 10, B-3000 Louvain, Belgium.	ghislain.opdenakker@rega.kuleuven.ac.be	Opdenakker, Ghislain/V-8562-2019; Opdenakker, Ghislain/Q-3130-2017; Martens, Erik/F-9214-2015; Van den Steen, Philippe E/K-5132-2012	Opdenakker, Ghislain/0000-0003-1714-2294; Opdenakker, Ghislain/0000-0003-1714-2294; Martens, Erik/0000-0002-7947-6567; Van den Steen, Philippe E/0000-0002-7334-9145				ADAMS MJ, 1969, NATURE, V224, P491, DOI 10.1038/224491a0; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BANKS RE, 1991, CYTOKINE, V3, P12, DOI 10.1016/1043-4666(91)90004-W; CHRISTIE MR, 1990, J EXP MED, V172, P789, DOI 10.1084/jem.172.3.789; Ebihara I, 1998, AM J KIDNEY DIS, V32, P544, DOI 10.1016/S0272-6386(98)70015-0; Fernandez-Patron C, 2001, FASEB J, V15, P2230, DOI 10.1096/fj.01-0178com; Grillet B, 1997, BRIT J RHEUMATOL, V36, P744; Ishihara T, 1998, PANCREAS, V17, P412, DOI 10.1097/00006676-199811000-00013; Kobayashi Y, 1999, J IMMUNOL, V163, P5989; MONTGOMERY AMP, 1993, BIOCHIM BIOPHYS ACTA, V1176, P265, DOI 10.1016/0167-4889(93)90054-S; Muhs BE, 2001, J SURG RES, V101, P21, DOI 10.1006/jsre.2001.6244; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; Ng EK, 2001, J SURG RES, V96, P6, DOI 10.1006/jsre.2000.6048; OPDENAKKER G, 1994, IMMUNOL TODAY, V15, P103, DOI 10.1016/0167-5699(94)90151-1; Opdenakker G, 2001, TRENDS IMMUNOL, V22, P571, DOI 10.1016/S1471-4906(01)02023-3; Paemen L, 1995, EUR J BIOCHEM, V234, P759, DOI 10.1111/j.1432-1033.1995.759_a.x; PROOST P, 1993, J IMMUNOL, V150, P1000; PROOST P, 1993, BIOCHEM BIOPH RES CO, V192, P53; Pu Z, 2002, P NATL ACAD SCI USA, V99, P8844, DOI 10.1073/pnas.092260499; SANJEEVI CB, 2002, ANN NEW YORK ACAD SC, V958; Schonbeck U, 1998, J IMMUNOL, V161, P3340; Smith GD, 2001, ACTA CRYSTALLOGR D, V57, P1091, DOI 10.1107/S0907444901007685; Van Den Steen PE, 2002, FASEB J, V16, DOI 10.1096/fj.01-0688com; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; WEEKS BS, 1993, J CELL PHYSIOL, V157, P644, DOI 10.1002/jcp.1041570326; Wegmann DR, 2000, J AUTOIMMUN, V15, P286, DOI 10.1006/jaut.2000.0444; WEGMANN DR, 1994, EUR J IMMUNOL, V24, P1853, DOI 10.1002/eji.1830240820; Yokota T, 2002, J SURG RES, V104, P106, DOI 10.1006/jsre.2002.6403; ZHOU H, 1993, BIOCHIM BIOPHYS ACTA, V1177, P174, DOI 10.1016/0167-4889(93)90037-P	30	41	43	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					887	+		10.1096/fj.02-0725fje	http://dx.doi.org/10.1096/fj.02-0725fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626433				2022-12-28	WOS:000181892600024
J	Kunduzova, OR; Escourrou, G; Seguelas, MH; Delagrange, P; De La Farge, F; Cambon, C; Parini, A				Kunduzova, OR; Escourrou, G; Seguelas, MH; Delagrange, P; De La Farge, F; Cambon, C; Parini, A			Prevention of apoptotic and necrotic cell death, caspase-3 activation, and renal dysfunction by melatonin after ischemia/reperfusion	FASEB JOURNAL			English	Article						oxidative stress; kidney; rat; acute renal failure; hormone	ISCHEMIA-REPERFUSION; LIPID-PEROXIDATION; ANTIOXIDANT ACTIVITY; OXIDATIVE STRESS; INJURY; INHIBITION; PITUITARY; PROTEINS; NECROSIS; MECHANISM	The pineal hormone melatonin has been reported to protect tissue from oxidative damage. This study was designed to determine whether melatonin could prevent cell events leading to tissue injury and renal dysfunction after ischemia/reperfusion (I/R). Using an in vivo rat model of I/R, we show a significant increase in kidney malondialdehyde concentrations, reflecting lipid peroxidation, and cell apoptosis measured by TUNEL staining. This apoptotic cell death was associated with an increase in the activity of the proapoptotic factor caspase-3, determined by fluorometric protease activity assay. Histomorphological analysis of ischemic kidneys revealed that the most extensive tubular necrosis occurred at 24 and 48 h after reperfusion, which correlated with peak elevations in blood urea nitrogen and creatinine. Rat pretreatment with melatonin prevented lipid peroxidation, cell apoptosis, and necrosis and blocked caspase-3 activity. The prevention of tissue injury was associated with the improvement of renal function as shown by the decrease in blood urea nitrogen and creatinine concentrations. The demonstration that melatonin prevents postreperfusion apoptotic and necrotic cell death and improves renal function suggests that melatonin may represent a novel therapeutic approach for prevention of I/R injury.	CHU Rangueil, INSERM, U388,IFR31, Inst Louis Bugnard, F-31403 Toulouse 4, France; CHU Rangueil, Dept Pathol, F-31403 Toulouse 4, France; Inst Rech Int Servier, F-92415 Courbevoie, France; CHU Rangueil, Biochem Lab, F-31403 Toulouse 4, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Servier; Institut de Recherches Internationales Servier; CHU de Toulouse	Parini, A (corresponding author), CHU Rangueil, INSERM, U388,IFR31, Inst Louis Bugnard, Bat L3, F-31403 Toulouse 4, France.	parini@toulouse.inserm.fr		Kunduzova, Oksana/0000-0003-2503-6555; Parini, Angelo/0000-0002-9848-8838				ARUOMA OI, 1989, BIOCHEM J, V258, P617, DOI 10.1042/bj2580617; Burkitt MJ, 2000, ARCH BIOCHEM BIOPHYS, V381, P253, DOI 10.1006/abbi.2000.1973; Cardinali DP, 2002, NEUROENDOCRINOL LETT, V23, P9; Celebi S, 2002, EUR J OPHTHALMOL, V12, P77, DOI 10.1177/112067210201200201; Chan ASL, 2002, CELL SIGNAL, V14, P249, DOI 10.1016/S0898-6568(01)00240-6; Daemen MARC, 1999, J CLIN INVEST, V104, P541, DOI 10.1172/JCI6974; Dhalla NS, 2000, CARDIOVASC RES, V47, P446, DOI 10.1016/S0008-6363(00)00078-X; Donnahoo KK, 1999, J UROLOGY, V162, P196, DOI 10.1097/00005392-199907000-00068; Eaton P, 1999, AM J PHYSIOL-HEART C, V276, pH935, DOI 10.1152/ajpheart.1999.276.3.H935; Elliott RM, 2000, FREE RADICAL BIO MED, V28, P1438, DOI 10.1016/S0891-5849(00)00271-9; Garcia-Criado FJ, 1998, TRANSPLANTATION, V66, P982, DOI 10.1097/00007890-199810270-00003; Hazlerigg DG, 1996, ENDOCRINOLOGY, V137, P210, DOI 10.1210/en.137.1.210; HORTON JW, 1993, BIOCHEM PHARMACOL, V45, P1721; Ichimura T, 1998, J BIOL CHEM, V273, P4135, DOI 10.1074/jbc.273.7.4135; Kazmers A, 1997, J SURG RES, V67, P62, DOI 10.1006/jsre.1996.4946; KORNBLIHTT LI, 1993, J PINEAL RES, V14, P184, DOI 10.1111/j.1600-079X.1993.tb00501.x; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kunduzova OR, 2002, FASEB J, V16, P1129, DOI 10.1096/fj.01-1008fje; Lagneux C, 2000, LIFE SCI, V66, P503, DOI 10.1016/S0024-3205(99)00620-7; Lankoff A, 2002, ARCH TOXICOL, V76, P158, DOI 10.1007/s00204-001-0310-x; Maier CM, 2002, NEUROSCIENTIST, V8, P323, DOI 10.1177/107385840200800408; Mangano CM, 1998, ANN INTERN MED, V128, P194, DOI 10.7326/0003-4819-128-3-199802010-00005; Martinez-Cruz F, 2002, NEUROSCI LETT, V326, P147, DOI 10.1016/S0304-3940(02)00020-4; Melnikov VY, 2001, J CLIN INVEST, V107, P1145, DOI 10.1172/JCI12089; MORGAN PJ, 1990, J NEUROENDOCRINOL, V2, P773, DOI 10.1111/j.1365-2826.1990.tb00639.x; Naskalski JW, 2001, ADV CLIN CHEM, V35, P161, DOI 10.1016/S0065-2423(01)35017-5; Nava M, 2000, AM J PHYSIOL-RENAL, V279, pF910, DOI 10.1152/ajprenal.2000.279.5.F910; Nosjean O, 2000, J BIOL CHEM, V275, P31311, DOI 10.1074/jbc.M005141200; Ortega-Gutierrez S, 2002, NEUROSCI LETT, V323, P55, DOI 10.1016/S0304-3940(01)02530-7; Peng XX, 2002, PHARMACOL RES, V45, P491, DOI 10.1006/phrs.2002.0991; Pevet P, 2000, BIOL SIGNAL RECEPT, V9, P203; PIERREFICHE G, 1993, RES COMMUN CHEM PATH, V80, P211; Portilla D, 2000, AM J PHYSIOL-RENAL, V278, pF667, DOI 10.1152/ajprenal.2000.278.4.F667; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; Ricardo SD, 1998, SEMIN NEPHROL, V18, P612; Salahudeen AK, 2001, TRANSPLANTATION, V72, P798, DOI 10.1097/00007890-200109150-00010; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schierle GS, 1999, NAT MED, V5, P97, DOI 10.1038/4785; SCHUMER M, 1992, AM J PATHOL, V140, P831; Skwarlo-Sonta K, 2002, NEUROENDOCRINOL LETT, V23, P61; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Sun JZ, 1996, J CLIN INVEST, V97, P562, DOI 10.1172/JCI118449; TANAKA J, 1993, BIOL PHARM BULL, V16, P29, DOI 10.1248/bpb.16.29; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Todor A, 2002, AM J PHYSIOL-HEART C, V283, pH990, DOI 10.1152/ajpheart.01003.2001; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; Ueda N, 2000, AM J MED, V108, P403, DOI 10.1016/S0002-9343(00)00311-9; VANECEK J, 1990, NEUROSCI LETT, V110, P199, DOI 10.1016/0304-3940(90)90811-M; VANECEK J, 1992, ENDOCRINOLOGY, V130, P701, DOI 10.1210/en.130.2.701; Weisberg LS, 1997, ARCH INTERN MED, V157, P1833, DOI 10.1001/archinte.157.16.1833; WITZGALL R, 1994, J CLIN INVEST, V93, P2175, DOI 10.1172/JCI117214; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Yeleswaram K, 1997, J PINEAL RES, V22, P45, DOI 10.1111/j.1600-079X.1997.tb00302.x	55	71	74	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					872	+		10.1096/fj.02-0504fje	http://dx.doi.org/10.1096/fj.02-0504fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670883				2022-12-28	WOS:000181892600003
J	Mochizuki, M; Kadoya, Y; Wakabayashi, Y; Kato, K; Okazaki, I; Yamada, M; Sato, T; Sakairi, N; Nishi, N; Nomizu, M				Mochizuki, M; Kadoya, Y; Wakabayashi, Y; Kato, K; Okazaki, I; Yamada, M; Sato, T; Sakairi, N; Nishi, N; Nomizu, M			Laminin-1 peptide-conjugated chitosan membranes as a novel approach for cell engineering	FASEB JOURNAL			English	Article						basement membrane; cell attachment; integrin; proteoglycan; neurite outgrowth	MOUSE LAMININ; G-DOMAIN; BRANCHING MORPHOGENESIS; BINDING SEQUENCES; GLOBULAR DOMAIN; ALPHA-1; IDENTIFICATION; TISSUE; CHAIN; ADHESION	Laminin, a major component of the basement membrane, has diverse biological activities. Recently, we identified various biologically active sequences on laminin-1 by using a large set of synthetic peptides. Chitosan, a polysaccharide, is biodegradable and has been used as a biomaterial. Here, we conjugated several biologically active laminin peptides onto chitosan membranes and measured the cell attachment activity of peptide-conjugated chitosan membranes with various cell types. The active laminin peptide-conjugated chitosan membranes promoted cell attachment with cell type specificity. A99 (AGTFALRGDNPQG)-chitosan membrane promoted cell attachment with well-organized actin stress fibers. This adhesion was inhibited by EDTA but not by heparin. AG73 (RKRLQVQLSIRT)-chitosan membrane promoted cell attachment with filopodia formation, and this adhesion was inhibited by heparin but not by EDTA. These data suggest that the A99-chitosan membrane interacted with an integrin cellular receptor and that the AG73-chitosan membrane promoted proteoglycan-mediated cell attachment, as previously reported. Furthermore, both AG73-chitosan and A99-chitosan membranes effectively promoted neurite outgrowth with PC12 rat pheochromocytoma cells. We conclude that conjugation on a chitosan membrane is applicable for testing quantitatively the biological activity of synthetic peptides and that these constructs have a potential ability to serve as bioadhesive materials for tissue regeneration and engineering.	Hokkaido Univ, Lab Biomat Chem, Div Biosci, Grad Sch Environm Earth Sci,Kita Ku, Sapporo, Hokkaido 0600810, Japan; Kitasato Univ, Sch Med, Dept Anat, Sagamihara, Kanagawa 2288555, Japan	Hokkaido University; Kitasato University	Nomizu, M (corresponding author), Hokkaido Univ, Lab Biomat Chem, Div Biosci, Grad Sch Environm Earth Sci,Kita Ku, Kita 10 Nishi 5, Sapporo, Hokkaido 0600810, Japan.	nomizu@ees.hokudai.ac.jp	Yamada, Masanori/AAC-7412-2019	Yamada, Masanori/0000-0002-9793-8825				BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CHANDY T, 1990, BIOMATER ARTIF CELL, V18, P1, DOI 10.3109/10731199009117286; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Engbring JA, 2002, CANCER RES, V62, P3549; Fleischmajer R, 1998, J CELL SCI, V111, P1929; Gallaher CM, 2000, J NUTR, V130, P2753, DOI 10.1093/jn/130.11.2753; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Henriksen I, 1996, INT J PHARM, V145, P231, DOI 10.1016/S0378-5173(96)04776-X; Hern DL, 1998, J BIOMED MATER RES, V39, P266, DOI 10.1002/(SICI)1097-4636(199802)39:2<266::AID-JBM14>3.0.CO;2-B; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Hoffman MP, 2001, J BIOL CHEM, V276, P22077, DOI 10.1074/jbc.M100774200; Hosokawa Y, 1999, DEV GROWTH DIFFER, V41, P207; Hubbell JA, 1999, CURR OPIN BIOTECH, V10, P123, DOI 10.1016/S0958-1669(99)80021-4; Iivanainen A, 1999, J BIOL CHEM, V274, P14107, DOI 10.1074/jbc.274.20.14107; Kadoya Y, 1998, DEV DYNAM, V212, P394; Kim WH, 1998, INT J CANCER, V77, P632, DOI 10.1002/(SICI)1097-0215(19980812)77:4<632::AID-IJC25>3.0.CO;2-6; Kumar MNVR, 2000, REACT FUNCT POLYM, V46, P1; Kuratomi Y, 1999, EXP CELL RES, V249, P386, DOI 10.1006/excr.1999.4497; KURITA K, 1977, MAKROMOL CHEM, V178, P3197; Malinda KM, 1999, FASEB J, V13, P53, DOI 10.1096/fasebj.13.1.53; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Nomizu M, 1997, J BIOL CHEM, V272, P32198, DOI 10.1074/jbc.272.51.32198; Nomizu M, 1998, J BIOL CHEM, V273, P32491, DOI 10.1074/jbc.273.49.32491; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Nomizu M, 2000, ARCH BIOCHEM BIOPHYS, V378, P311, DOI 10.1006/abbi.2000.1828; Ponce ML, 1999, CIRC RES, V84, P688, DOI 10.1161/01.RES.84.6.688; Ponce ML, 2001, FASEB J, V15, P1389, DOI 10.1096/fj.00-0736com; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; Richard BL, 1996, EXP CELL RES, V228, P98, DOI 10.1006/excr.1996.0304; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Song SY, 1997, INT J CANCER, V71, P436, DOI 10.1002/(SICI)1097-0215(19970502)71:3<436::AID-IJC22>3.0.CO;2-C; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; Suh JKF, 2000, BIOMATERIALS, V21, P2589; TASHIRO K, 1991, J CELL PHYSIOL, V146, P451, DOI 10.1002/jcp.1041460316; Weeks BS, 1998, EXP CELL RES, V243, P375, DOI 10.1006/excr.1998.4157; YANNAS IV, 1982, SCIENCE, V215, P174, DOI 10.1126/science.7031899	36	88	90	1	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					875	+		10.1096/fj.02-0564fje	http://dx.doi.org/10.1096/fj.02-0564fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12626440				2022-12-28	WOS:000181892600030
J	Zhao, M; Song, B; Pu, J; Forrester, JV; McCaig, CD				Zhao, M; Song, B; Pu, J; Forrester, JV; McCaig, CD			Direct visualization of a stratified epithelium reveals that wounds heal by unified sliding of cell sheets	FASEB JOURNAL			English	Article						wound healing; stratified epithelium; corneal epithelium; corneal organ culture; cell migration	3-DIMENSIONAL CONFOCAL MICROSCOPY; HINDBRAIN NEURAL CREST; TIME-LAPSE ANALYSIS; CORNEA IN-VIVO; ELECTRIC-FIELD; KERATINOCYTE MIGRATION; RABBIT CORNEA; CLOSURE; REEPITHELIALIZATION; FIBRONECTIN	Observing cells in their original niche is a key link between the information gleaned from planar culture and in vivo physiology and pathology. A new approach combining the transparency of the cornea, Hoffman modulation optics, and digital imaging allowed movements of individual corneal cells to be viewed directly in situ. 3-Dimensional time-lapse movies imaging unstained cells within the stratified corneal epithelium during wound healing were made. Tracking cell movements dynamically provided a definitive answer to the long-standing question: does a stratified epithelium heal by "sliding" of cell sheets as a coherent unit or do individual cells "leap frog" each other at the wound margin? A wound in the corneal epithelium healed primarily by sliding of the whole epithelium, with similar to95% of cells moving with similar speed and trajectories and with little change in their relative position. Only 5% of cells changed layers, with equal proportions moving up or down. Epithelial healing in situ occurred in three phases: a latency, migration, and reconstruction phase. This model provides a unique system to study the behaviors of individual cells in their original niche. It shows that cells slide into a wound as a unified unit to heal a stratified epithelium.	Univ Aberdeen, Dept Biomed Sci, Inst Med Sci, Aberdeen AB25 2ZD, Scotland; Univ Aberdeen, Dept Ophthalmol, Inst Med Sci, Aberdeen AB25 2ZD, Scotland	University of Aberdeen; University of Aberdeen	Zhao, M (corresponding author), Univ Aberdeen, Dept Biomed Sci, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.	m.zhao@abdn.ac.uk; c.mccaig@abdn.ac.uk	McCaig, Colin/B-1774-2010; Song, Bing/AAB-4755-2021	Song, Bing/0000-0001-9356-2333	Wellcome Trust [068012] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARLATI S, 1990, EXP EYE RES, V51, P1, DOI 10.1016/0014-4835(90)90162-N; Bohnke M, 1999, PROG RETIN EYE RES, V18, P553, DOI 10.1016/S1350-9462(98)00028-7; BUCK RC, 1979, INVEST OPHTH VIS SCI, V18, P767; CHAN KY, 1986, EXP EYE RES, V42, P417, DOI 10.1016/0014-4835(86)90002-3; CHAN KY, 1989, INVEST OPHTH VIS SCI, V30, P2488; CHIANG MC, 1992, EXP EYE RES, V54, P999, DOI 10.1016/0014-4835(92)90164-N; CROSSON CE, 1986, INVEST OPHTH VIS SCI, V27, P464; Danjo Y, 2002, EXP EYE RES, V74, P199, DOI 10.1006/exer.2001.1115; DONALDSON DJ, 1988, J INVEST DERMATOL, V90, P623, DOI 10.1111/1523-1747.ep12560762; GARLICK JA, 1994, LAB INVEST, V70, P916; GIBBINS JR, 1978, PATHOLOGY, V10, P207, DOI 10.3109/00313027809063503; Gipson I K, 1995, Curr Opin Ophthalmol, V6, P3; HAIK BG, 1977, INVEST OPHTH VIS SCI, V16, P787; HANNA C, 1966, AM J OPHTHALMOL, V61, P55, DOI 10.1016/0002-9394(66)90747-1; HOFFMAN R, 1977, J MICROSC-OXFORD, V110, P205, DOI 10.1111/j.1365-2818.1977.tb00033.x; HOFFMAN R, 1975, NATURE, V254, P586, DOI 10.1038/254586a0; JUMBLATT MM, 1986, INVEST OPHTH VIS SCI, V27, P8; Knight B, 2000, CURR BIOL, V10, P576, DOI 10.1016/S0960-9822(00)00486-3; Koster RW, 2001, CURR BIOL, V11, P1858, DOI 10.1016/S0960-9822(01)00585-1; KRAWCZYK WS, 1971, J CELL BIOL, V49, P247, DOI 10.1083/jcb.49.2.247; Kulesa P, 2000, DEVELOPMENT, V127, P2843; Kulesa PM, 2000, DEVELOPMENT, V127, P1161; KUWABARA T, 1976, INVEST OPHTH VISUAL, V15, P4; Laplante AF, 2001, FASEB J, V15, P2377, DOI 10.1096/fj.01-0250com; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Masters BR, 2001, OPHTHALMIC RES, V33, P125, DOI 10.1159/000055658; Masters BR, 1999, METHOD ENZYMOL, V307, P536; McCaig CD, 2002, TRENDS NEUROSCI, V25, P354, DOI 10.1016/S0166-2236(02)02174-4; Nishida T, 1996, Curr Opin Ophthalmol, V7, P2, DOI 10.1097/00055735-199608000-00002; ORTONNE JP, 1981, VIRCHOWS ARCH A, V392, P217, DOI 10.1007/BF00430822; PFISTER RR, 1975, INVEST OPHTH VISUAL, V14, P648; RADICE GP, 1980, DEV BIOL, V76, P26, DOI 10.1016/0012-1606(80)90360-7; Rorth P, 2002, TRENDS CELL BIOL, V12, P325, DOI 10.1016/S0962-8924(02)02311-5; Rovee D.T., 1972, EPIDERMAL WOUND HEAL, P71; Song B, 2002, P NATL ACAD SCI USA, V99, P13577, DOI 10.1073/pnas.202235299; SRINIVASAN BD, 1977, EXP EYE RES, V25, P343, DOI 10.1016/0014-4835(77)90101-4; Sta Iglesia Drina D., 1998, Wound Repair and Regeneration, V6, P531; Stenn KS., 1992, WOUND HEALING BIOCH, P115; VAUGHAN RB, 1966, J CELL SCI, V1, P407; WEISS PAUL, 1961, P13; Wilson SE, 1999, PROG RETIN EYE RES, V18, P293, DOI 10.1016/S1350-9462(98)00017-2; Wilson SE, 2001, PROG RETIN EYE RES, V20, P625, DOI 10.1016/S1350-9462(01)00008-8; Zhao M, 1999, MOL BIOL CELL, V10, P1259, DOI 10.1091/mbc.10.4.1259; Zhao M, 1996, J CELL SCI, V109, P1405; Zhao M, 1997, CURR EYE RES, V16, P973, DOI 10.1076/ceyr.16.10.973.9014; Zhao M, 1996, INVEST OPHTH VIS SCI, V37, P2548; Zhao M, 1999, P NATL ACAD SCI USA, V96, P4942, DOI 10.1073/pnas.96.9.4942; ZHAO M, 2002, FASEB J, V16; Zieske JD, 2001, CURR OPIN OPHTHALMOL, V12, P237, DOI 10.1097/00055735-200108000-00001	49	61	61	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2003	17	3					397	406		10.1096/fj.02-0610com	http://dx.doi.org/10.1096/fj.02-0610com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12631579	Green Accepted			2022-12-28	WOS:000181892600038
J	Robbesyn, F; Garcia, V; Auge, N; Vieira, O; Frisach, MF; Salvayre, R; Negre-Salvayre, A				Robbesyn, F; Garcia, V; Auge, N; Vieira, O; Frisach, MF; Salvayre, R; Negre-Salvayre, A			HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-kappa B activation in smooth muscle cells	FASEB JOURNAL			English	Article						HDL; oxidized LDL; ROS	LOW-DENSITY-LIPOPROTEIN; CULTURED ENDOTHELIAL-CELLS; TUMOR-NECROSIS-FACTOR; OXIDATIVE STRESS; SIGNALING PATHWAY; SPHINGOSINE KINASE; RECEPTOR PATHWAY; ALPHA-TOCOPHEROL; POTENTIAL ROLE; ATHEROSCLEROSIS	Oxidized low-density lipoproteins (oxLDL) exhibit proinflammatory properties and play a role in atherosclerosis plaque formation, rupture, and subsequent thrombosis. OxLDL alter the activity of the transcription factor NF-kappaB that is involved in the expression of immune and inflammatory genes. In contrast, high-density lipoproteins (HDL) are anti-atherogenic and exhibit anti-inflammatory properties. This work aimed to investigate how oxLDL activate NF-kappaB and whether and how HDL may prevent NF-kappaB activation. In cultured rabbit smooth muscle cells, mitogenic concentrations of mildly oxLDL trigger a rapid and transient NF-kappaB activation, which is strongly inhibited by HDL. Growth factors, phosphatidylinositol 3-kinase/Akt, and sphingosine kinase pathways are not implicated in the oxLDL-induced NF-kappaB activation and are not targets of HDL. OxLDL induce reactive oxygen species (ROS) generation and proteasome activation, which are implicated in NF-kappaB activation, as suggested by the inhibitory effect of the antioxidants N-acetyl-L-cysteine and pyrrolidinedithiocarbamate and the proteasome inhibitor PSI. HDL were able to prevent the intracellular ROS rise triggered by oxLDL or H2O2, thereby inhibiting the subsequent proteasome activation, IkappaB degradation, and NF-kappaB activation. In conclusion, the oxLDL-induced NF-kappaB activation involves ROS generation and proteasome activation, both events being inhibited by HDL. This 'antioxidant' and potentially anti-inflammatory effect of HDL may participate in their general anti-atherogenic properties.	CHU Rangueil, INSERM, U466, Inst Louis Bugnard, F-31403 Toulouse 4, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Negre-Salvayre, A (corresponding author), CHU Rangueil, INSERM, U466, Inst Louis Bugnard, F-31403 Toulouse 4, France.	salvayre@toulouse.inserm.fr	Vieira, O V/C-4860-2013; Vieira, Otilia V/O-8660-2017; GARCIA, Virginie/W-8313-2019	Vieira, Otilia V/0000-0003-4924-1780; GARCIA, Virginie/0000-0002-9761-7036; Auge, Nathalie/0000-0003-2088-7211; Negre-Salvayre, Anne/0000-0003-2136-5706				ANDALIBI A, 1993, BIOCHEM SOC T, V21, P651, DOI 10.1042/bst0210651; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; Auge N, 1999, J BIOL CHEM, V274, P21533, DOI 10.1074/jbc.274.31.21533; Auge N, 2000, PROG LIPID RES, V39, P207, DOI 10.1016/S0163-7827(00)00007-2; Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; Bonnefont-Rousselot D, 1999, CLIN CHEM LAB MED, V37, P939, DOI 10.1515/CCLM.1999.139; Bourcier T, 1997, J BIOL CHEM, V272, P15817, DOI 10.1074/jbc.272.25.15817; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Brand K, 1997, ARTERIOSCL THROM VAS, V17, P1901, DOI 10.1161/01.ATV.17.10.1901; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BURGERING BMT, 1994, CELL GROWTH DIFFER, V5, P341; Caspar-Bauguil S, 1999, BIOCHEM J, V337, P269, DOI 10.1042/0264-6021:3370269; Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1697, DOI 10.1016/S0891-5849(00)00227-6; Cockerill GW, 2001, CIRCULATION, V103, P108; Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373; Cominacini L, 2000, J BIOL CHEM, V275, P12633, DOI 10.1074/jbc.275.17.12633; de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83; Durrington PN, 2001, ARTERIOSCL THROM VAS, V21, P473, DOI 10.1161/01.ATV.21.4.473; Escargueil-Blanc I, 2001, CIRCULATION, V104, P1814, DOI 10.1161/hc4001.097179; FIELDING CJ, 1995, J LIPID RES, V36, P211; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Hajjar DP, 1997, J BIOL CHEM, V272, P22975, DOI 10.1074/jbc.272.37.22975; Han CY, 2000, BIOCHEM J, V350, P829, DOI 10.1042/0264-6021:3500829; Hundal RS, 2001, J LIPID RES, V42, P1483; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Ischiropoulos H, 1999, METHOD ENZYMOL, V301, P367; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Leonarduzzi G, 2000, FREE RADICAL BIO MED, V28, P1370, DOI 10.1016/S0891-5849(00)00216-1; Libby P, 2001, AM J CARDIOL, V88, p3N; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; MABILE L, 1995, FREE RADICAL BIO MED, V19, P177, DOI 10.1016/0891-5849(95)00006-J; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Magnani M., 2000, Current Drug Targets, V1, P387, DOI 10.2174/1389450003349056; MILLER GJ, 1980, ANNU REV MED, V31, P97, DOI 10.1146/annurev.me.31.020180.000525; NEGRESALVAYRE A, 1991, BIOCHIM BIOPHYS ACTA, V1096, P291, DOI 10.1016/0925-4439(91)90065-H; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; Ozes ON, 1999, NATURE, V401, P82; Pajkrt D, 1996, J EXP MED, V184, P1601, DOI 10.1084/jem.184.5.1601; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SCHMITT A, 1995, BBA-LIPID LIPID MET, V1256, P284, DOI 10.1016/0005-2760(95)00032-8; SCHMITT A, 1995, BRIT J PHARMACOL, V116, P1985, DOI 10.1111/j.1476-5381.1995.tb16402.x; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; Shah PK, 2001, CIRCULATION, V104, P2376, DOI 10.1161/hc4401.098467; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Strack PR, 1996, BIOCHEMISTRY-US, V35, P7142, DOI 10.1021/bi9518048; Suc I, 1998, FASEB J, V12, P665, DOI 10.1096/fasebj.12.9.665; Suc I, 1997, ARTERIOSCL THROM VAS, V17, P2158, DOI 10.1161/01.ATV.17.10.2158; Theilmeier G, 2000, FASEB J, V14, P2032, DOI 10.1096/fj.99-1029com; Vacaresse N, 1999, CIRC RES, V85, P892; Van Lenten BJ, 2001, TRENDS CARDIOVAS MED, V11, P155, DOI 10.1016/S1050-1738(01)00095-0; Vieira O, 2000, FASEB J, V14, P532, DOI 10.1096/fasebj.14.3.532; Xia P, 1999, J BIOL CHEM, V274, P33143, DOI 10.1074/jbc.274.46.33143	55	83	87	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					743	+		10.1096/fj.02-0240fje	http://dx.doi.org/10.1096/fj.02-0240fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12586748				2022-12-28	WOS:000181456900028
J	Cho, H; Kozasa, T; Bondjers, C; Betsholtz, C; Kehrl, JH				Cho, H; Kozasa, T; Bondjers, C; Betsholtz, C; Kehrl, JH			Pericyte-specific expression of Rgs5: implications for PDGF and EDG receptor signaling during vascular maturation	FASEB JOURNAL			English	Article						RGS; G-protein signal transduction; blood vessel physiology	PROTEIN-COUPLED RECEPTOR; SMOOTH-MUSCLE CELLS; KINASE ACTIVATION; DEFICIENT MICE; REGULATOR; GENES; ALPHA; SPHINGOSINE-1-PHOSPHATE; G-ALPHA(11); RESPONSES	RGS proteins finely tune heterotrimeric G-protein signaling. Implying the need for such fine-tuning in the developing vascular system, in situ hybridization revealed a striking and extensive expression pattern of Rgs5 in the arterial walls of E12.5-E17.5 mouse embryos. The distribution and location of the Rgs5-positive cells typified that of pericytes and strikingly overlapped the known expression pattern of platelet-derived growth factor receptor (PDGFR)-beta. Both E14.5 PDGFR-beta- and platelet-derived growth factor (PDGF)-B-deficient mice exhibited markedly reduced levels of Rgs5 in their vascular plexa and small arteries. This likely reflects the loss of pericytes in the mutant mice. RGS5 acts as a potent GTPase activating protein for Gialpha and Gqalpha and it attenuated angiotensin II-, endothelin-1-, sphingosine-1-phosphate-, and PDGF-induced ERK-2 phosphorylation. Together these results indicate that RGS5 exerts control over PDGFR-beta and GPCR-mediated signaling pathways active during fetal vascular maturation.	NIAID, B Cell Mol Immunol Sect, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; Univ Illinois, Dept Pharmacol, Chicago, IL USA; Univ Gothenburg, Dept Med Biochem, Gothenburg, Sweden	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Gothenburg	Kehrl, JH (corresponding author), NIAID, B Cell Mol Immunol Sect, Immunoregulat Lab, NIH, Bldg 10,Rm 11B-13,10 Ctr Dr,MSC 1876, Bethesda, MD 20892 USA.	jkehrl@niaid.nih.gov	Kehrl, John/AAE-6292-2019	Cho, Hyeseon/0000-0001-7512-1980; Kehrl, John/0000-0002-6526-159X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000738, ZIAAI000738] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams LD, 2000, CIRC RES, V87, P623, DOI 10.1161/01.RES.87.7.623; Benzing T, 2000, J BIOL CHEM, V275, P28167; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bowman EP, 1998, J BIOL CHEM, V273, P28040, DOI 10.1074/jbc.273.43.28040; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Cho H, 2000, MOL PHARMACOL, V58, P569, DOI 10.1124/mol.58.3.569; CHO HS, 2000, CURR T BIOCHEM RES, V2, P161; Clouthier DE, 1998, DEVELOPMENT, V125, P813; Cunningham ML, 2001, J BIOL CHEM, V276, P5438, DOI 10.1074/jbc.M007699200; Dulin NO, 1999, MOL CELL BIOL, V19, P714; FOX CH, 1993, CURRENT PROTOCOLS IM; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Moratz C, 2000, J IMMUNOL, V164, P1829, DOI 10.4049/jimmunol.164.4.1829; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; Rogers JH, 1999, J CLIN INVEST, V104, P567, DOI 10.1172/JCI6713; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Seki N, 1998, J HUM GENET, V43, P202, DOI 10.1007/s100380050071; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Tsuchida S, 1998, J CLIN INVEST, V101, P755, DOI 10.1172/JCI1899; Wang Q, 2002, J BIOL CHEM, V277, P24949, DOI 10.1074/jbc.M203802200; Zhou J, 2001, LIFE SCI, V68, P1457, DOI 10.1016/S0024-3205(01)00939-0	27	138	145	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					440	+		10.1096/fj.02-0340fje	http://dx.doi.org/10.1096/fj.02-0340fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12514120				2022-12-28	WOS:000181453700020
J	Draghia-Akli, R; Ellis, KM; Hill, LA; Malone, PB; Fiorotto, ML				Draghia-Akli, R; Ellis, KM; Hill, LA; Malone, PB; Fiorotto, ML			High-efficiency growth hormone releasing hormone plasmid vector administration into skeletal muscle mediated by electroporation in pigs	FASEB JOURNAL			English	Article						GHRH; GH; IGF-I; plasmid DNA; body composition	IN-VIVO ELECTROPORATION; HUMAN PANCREATIC TUMOR; GENE-TRANSFER; NAKED DNA; SECRETION; DELIVERY; ELECTROPERMEABILIZATION; ELECTROTRANSFER; THERAPY; MICE	We report here a very efficient method for the in vivo transfer of therapeutic plasmid DNA into porcine muscle fibers by using electric pulses of low field intensity. We evaluated delivery of 0.1-3 mg of plasmid vectors that encode reporter secreted-embryonic alkaline phosphatase (SEAP) or therapeutic growth hormone releasing hormone (GHRH). Reporter gene studies showed that internal needle electrodes give a 25-fold increase in expression levels compared with caliper electrodes in skeletal muscle in swine. Dose and time courses were performed. Pigs injected with 0.1 mg plasmid had significantly greater weight gain than controls over 53 days (22.4 +/- 0.8 kg vs. 19.7 +/- 0.03 kg, respectively; P<0.01). The group treated with GHRH-expressing plasmid at 14 days of age demonstrated greater weight gain than controls at every time point (25.8 +/- 1.5 kg vs. 19.7 +/- 0.03 kg; P<0.01). Body composition studies by dual X-ray absorbitometry showed a 22% decrease in fat deposition (P<0.05) and a 10% increase in bone mineral density (P<0.004). Our studies demonstrate that by optimizing the electroporation method, favorable physiological changes, such as enhanced weight gain and improved body composition, can be obtained at extremely low plasmid doses in a large mammal.	Baylor Coll Med, Ctr Cell & Gene Therapy, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Appl Vet Syst Inc, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, USDA ARS, Children Nutr Res Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; United States Department of Agriculture (USDA)	Draghia-Akli, R (corresponding author), Advisys Inc, 2700 Res Forest Dr,Suite 180, The Woodlands, TX 77381 USA.	ruxandradraghia@advisys.net		Draghia-Akli, Ruxandra/0000-0001-6372-4039				Berneis K, 1996, BAILLIERE CLIN ENDOC, V10, P337, DOI 10.1016/S0950-351X(96)80470-8; BERTHERAT J, 1995, EUR J ENDOCRINOL, V132, P12, DOI 10.1530/eje.0.1320012; BOHLEN P, 1983, BIOCHEM BIOPH RES CO, V116, P726; Bureau MF, 2000, BBA-GEN SUBJECTS, V1474, P353, DOI 10.1016/S0304-4165(00)00028-3; Chevalier RL, 2000, KIDNEY INT, V57, P882, DOI 10.1046/j.1523-1755.2000.057003882.x; DANKO I, 1994, VACCINE, V12, P1499, DOI 10.1016/0264-410X(94)90072-8; Draghia-Akli R, 1999, NAT BIOTECHNOL, V17, P1179, DOI 10.1038/70718; Draghia-Akli R, 1997, NAT BIOTECHNOL, V15, P1285, DOI 10.1038/nbt1197-1285; Draghia-Akli R, 2002, FASEB J, V16, P426, DOI 10.1096/fj.01-0702fje; Drisko JE, 1998, P SOC EXP BIOL MED, V217, P188, DOI 10.3181/00379727-217-44222; DUCK SC, 1992, J CLIN ENDOCR METAB, V75, P1115, DOI 10.1210/jc.75.4.1115; ESCH FS, 1982, BIOCHEM BIOPH RES CO, V109, P152, DOI 10.1016/0006-291X(82)91578-9; FAGLIA G, 1992, ENDOCRIN METAB CLIN, V21, P575, DOI 10.1016/S0889-8529(18)30203-2; Fewell JG, 2001, MOL THER, V3, P574, DOI 10.1006/mthe.2001.0295; FROHMAN LA, 1992, FRONT NEUROENDOCRIN, V13, P344; Gehl J, 1998, ANTI-CANCER DRUG, V9, P319, DOI 10.1097/00001813-199804000-00005; GUILLEMIN R, 1982, SCIENCE, V218, P585, DOI 10.1126/science.6812220; Hartikka J, 2001, MOL THER, V4, P407, DOI 10.1006/mthe.2001.0483; Heller R, 1996, CANCER-AM CANCER SOC, V77, P964, DOI 10.1002/(SICI)1097-0142(19960301)77:5<964::AID-CNCR24>3.0.CO;2-0; Lesbordes JC, 2002, HUM MOL GENET, V11, P1615, DOI 10.1093/hmg/11.14.1615; Li XY, 1999, NAT BIOTECHNOL, V17, P241, DOI 10.1038/6981; Lucas ML, 2002, MOL THER, V5, P668, DOI 10.1006/mthe.2002.0601; Lucas ML, 2001, DNA CELL BIOL, V20, P183, DOI 10.1089/104454901300069040; Mathiesen I, 1999, GENE THER, V6, P508, DOI 10.1038/sj.gt.3300847; Matsubara H, 2001, ANTICANCER RES, V21, P2501; MELMED S, 1991, ENDOCRIN METAB CLIN, V20, P507, DOI 10.1016/S0889-8529(18)30256-1; Muller EE, 1999, PHYSIOL REV, V79, P511, DOI 10.1152/physrev.1999.79.2.511; Murray R D, 2000, Expert Opin Pharmacother, V1, P975, DOI 10.1517/14656566.1.5.975; POMMIER SA, 1990, J ANIM SCI, V68, P1291; Somiari S, 2000, MOL THER, V2, P178, DOI 10.1006/mthe.2000.0124; TANG JQ, 1995, J CLIN ENDOCR METAB, V80, P2381, DOI 10.1210/jc.80.8.2381; Terada Y, 2001, AM J KIDNEY DIS, V38, pS50, DOI 10.1053/ajkd.2001.27398; THORNER MO, 1984, J CLIN ENDOCR METAB, V59, P846, DOI 10.1210/jcem-59-5-846; Toner MS, 1996, J ANIM SCI, V74, P167; Tsurumi Y, 1996, CIRCULATION, V94, P3281, DOI 10.1161/01.CIR.94.12.3281; Vilquin JT, 2001, GENE THER, V8, P1097, DOI 10.1038/sj.gt.3301484; Vittone J, 1997, METABOLISM, V46, P89, DOI 10.1016/S0026-0495(97)90174-8; Yasui A, 2001, INT J MOL MED, V8, P489	38	51	65	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					526	+		10.1096/fj.02-0671fje	http://dx.doi.org/10.1096/fj.02-0671fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12514110				2022-12-28	WOS:000181453700031
J	Rau, T; Nose, M; Remmers, U; Weil, J; Weissmuller, A; Davia, K; Harding, S; Peppel, K; Koch, WJ; Eschenhagen, T				Rau, T; Nose, M; Remmers, U; Weil, J; Weissmuller, A; Davia, K; Harding, S; Peppel, K; Koch, WJ; Eschenhagen, T			Overexpression of wild-type G alpha i-2 suppresses beta-adrenergic signaling in cardiac myocytes	FASEB JOURNAL			English	Article						G protein; heart failure; beta-adrenergic receptors; adenovirus; gene transfer	ENGINEERED HEART-TISSUE; G-PROTEIN; ADENYLATE-CYCLASE; PERTUSSIS-TOXIN; G(I-ALPHA) PROTEINS; RECEPTOR KINASE; ADULT-RAT; GI-ALPHA; EXPRESSION; INCREASE	The role of Galphai-2 overexpression in desensitization of beta-adrenergic signaling in heart failure is controversial. An adenovirus-based approach was used to investigate whether overexpression of Galphai-2 impairs beta-adrenergic stimulation of adenylyl cyclase (AC) activity and cAMP levels in neonatal rat cardiac myocytes (NRCM) and cell shortening of adult rat ventricular myocytes (ARVM). Infection of NRCM with Ad5Galphai-2 increased Galphai-2 by 50-600% in a virus dose-dependent manner. Overexpression was paralleled by suppression of GTP- and isoprenaline-stimulated AC by 10-72% (P<0.001) in a PTX-sensitive manner. Isoprenaline-stimulated shortening of Ad5G alpha i-2-infected ARVM was attenuated by 34% (P<0.01). Ad5Galphai-2/GFP (Galphai-2, green fluorescent protein; bicistronic) was constructed to monitor transfection homogeneity and target Galphai-2 overexpression to levels found in heart failure. At Galphai-2 levels of 93% above control, isoprenaline-stimulated AC activity and cAMP levels were reduced by 17% and 40% (P<0.02), respectively. 1- and 2-adrenergic stimulation was reduced similarly. Our results suggest that (a) the G alpha i-2 system exhibits tonic inhibition of stimulated AC in cardiac myocytes, (b) G alpha i-2-mediated inhibition is concentration-dependent and occurs at G alpha i-2 levels seen in heart failure, and (c) G alpha i-2-mediated inhibition affects both 1- and 2-adrenergic stimulation of AC. The data argue for an important, independent role of the G alpha i-2 increase in heart failure.	Univ Erlangen Nurnberg, Inst Pharmacol & Toxicol, D-91054 Erlangen, Germany; Univ Hamburg Hosp, Inst Pharmacol & Toxicol, D-2000 Hamburg, Germany; Imperial Coll Sch Med, NHLI, London, England; Duke Univ, Sch Med, Durham, NC USA	University of Erlangen Nuremberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Imperial College London; Duke University	Eschenhagen, T (corresponding author), Univ Erlangen Nurnberg, Inst Pharmacol & Toxicol, Fahrstr 17, D-91054 Erlangen, Germany.	eschenhagen@pharmakologie.uni-erlangen.de		Harding, Sian/0000-0002-3651-6354				AbiGerges N, 1997, MOL PHARMACOL, V52, P482, DOI 10.1124/mol.52.3.482; Akaishi Y, 1997, J MOL CELL CARDIOL, V29, P765, DOI 10.1006/jmcc.1996.0315; Akhter SA, 1997, P NATL ACAD SCI USA, V94, P12100, DOI 10.1073/pnas.94.22.12100; AnandSrivastava MB, 1996, MOL CELL BIOCHEM, V157, P163; BOHM M, 1990, CIRCULATION, V82, P1249, DOI 10.1161/01.CIR.82.4.1249; BOHM M, 1988, EUR HEART J, V9, P844; BOHM M, 1992, HYPERTENSION, V20, P103, DOI 10.1161/01.HYP.20.1.103; BRISTOW MR, 1984, J CLIN INVEST, V74, P212, DOI 10.1172/JCI111404; BRISTOW MR, 1991, CIRCULATION, V84, P1024, DOI 10.1161/01.CIR.84.3.1024; BRISTOW MR, 1982, MOL PHARMACOL, V21, P671; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; BRODDE OE, 1991, EUR HEART J, V12, P54, DOI 10.1093/eurheartj/12.suppl_F.54; Brodde OE, 1998, J CARDIOVASC PHARM, V31, P585, DOI 10.1097/00005344-199804000-00018; BROWN LA, 1992, BRIT J PHARMACOL, V106, P115, DOI 10.1111/j.1476-5381.1992.tb14302.x; COLUCCI WS, 1990, CIRCULATION, V82, P44; Davia K, 1999, PHYSIOL GENOMICS, V1, P41, DOI 10.1152/physiolgenomics.1999.1.2.41; Donahue JK, 2000, NAT MED, V6, P1395; Engelhardt S, 1996, J AM COLL CARDIOL, V27, P146, DOI 10.1016/0735-1097(95)00425-4; Eschenhagen T, 1997, FASEB J, V11, P683, DOI 10.1096/fasebj.11.8.9240969; Eschenhagen T, 1996, CIRCULATION, V93, P763, DOI 10.1161/01.CIR.93.4.763; FELDMAN AM, 1988, J CLIN INVEST, V82, P189, DOI 10.1172/JCI113569; Fink C, 2000, FASEB J, V14, P669, DOI 10.1096/fasebj.14.5.669; Gong HB, 2000, BRIT J PHARMACOL, V131, P594, DOI 10.1038/sj.bjp.0703591; Gong HB, 2002, CIRCULATION, V105, P2497, DOI 10.1161/01.CIR.0000017187.61348.95; Grimm M, 1998, J MOL CELL CARDIOL, V30, P1917, DOI 10.1006/jmcc.1998.0769; Hajjar RJ, 1997, CIRCULATION, V95, P423; HANF R, 1993, J PHYSIOL-LONDON, V461, P743, DOI 10.1113/jphysiol.1993.sp019539; HARDING SE, 1988, J MOL CELL CARDIOL, V20, P635, DOI 10.1016/S0022-2828(88)80121-4; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heubach UF, 2002, BRIT J PHARMACOL, V136, P217, DOI 10.1038/sj.bjp.0704700; HILF G, 1989, EUR J BIOCHEM, V186, P725, DOI 10.1111/j.1432-1033.1989.tb15266.x; Huang WY, 2000, NAT MED, V6, P482, DOI 10.1038/74914; Jakubik J, 1995, FEBS LETT, V377, P275, DOI 10.1016/0014-5793(95)01360-1; Janssen PML, 2002, CARDIOVASC RES, V55, P300, DOI 10.1016/S0008-6363(02)00406-6; KATADA T, 1984, J BIOL CHEM, V259, P3568; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; LAUGWITZ KL, 1993, NEURON, V10, P233, DOI 10.1016/0896-6273(93)90314-H; Lutz S, 2002, N-S ARCH PHARMACOL, V365, P50, DOI 10.1007/s00210-001-0500-3; NEUMANN J, 1988, LANCET, V2, P936; NOVOTNY J, 1994, BIOCHEM MOL BIOL INT, V34, P993; O'Donnell JM, 2001, CIRC RES, V88, P415; Redfern CH, 2000, P NATL ACAD SCI USA, V97, P4826, DOI 10.1073/pnas.97.9.4826; RUDOLPH U, 1995, J CLIN IMMUNOL, V15, pS101, DOI 10.1007/BF01540899; SCHMITZ W, 1989, J CARDIOVASC PHARM, V14, pS11, DOI 10.1097/00005344-198914003-00003; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; SCHWINGER RHG, 1990, AM HEART J, V119, P899, DOI 10.1016/S0002-8703(05)80329-1; Sigmund M, 1996, EUR J CLIN PHARMACOL, V51, P127, DOI 10.1007/s002280050172; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; Xiao RP, 1999, CIRC RES, V84, P43; XIAO RP, 1995, MOL PHARMACOL, V47, P322; Yamada M, 1998, PHARMACOL REV, V50, P723; Zimmermann WH, 2000, BIOTECHNOL BIOENG, V68, P106	53	35	36	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					523	+		10.1096/fj.02-0660fje	http://dx.doi.org/10.1096/fj.02-0660fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12631586				2022-12-28	WOS:000181453700016
J	Wartenberg, M; Ling, FC; Muschen, M; Klein, F; Acker, H; Gassmann, M; Petrat, K; Putz, V; Hescheler, J; Sauer, H				Wartenberg, M; Ling, FC; Muschen, M; Klein, F; Acker, H; Gassmann, M; Petrat, K; Putz, V; Hescheler, J; Sauer, H			Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxiainducible factor-1 and reactive oxygen species	FASEB JOURNAL			English	Article						NADPH oxidase; hypoxia	INDUCIBLE FACTOR-I; RECEPTOR NUCLEAR TRANSLOCATOR; EMBRYONIC STEM-CELLS; DRUG-RESISTANCE; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; HAMSTER-CELLS; HYPOXIC CELLS; SOLID TUMORS; MDR1 GENE	Hypoxia in tumors is generally associated with chemoresistance and radioresistance. However, the correlation between the heterodimeric hypoxia-inducible factor-1 (HIF-1) and the multidrug resistance transporter P-glycoprotein (P-gp) has not been investigated. Herein, we demonstrate that with increasing size of DU-145 prostate multicellular tumor spheroids the pericellular oxygen pressure and the generation of reactive oxygen species decreased, whereas the alpha-subunit of HIF-1 (HIF-1alpha) and P-gp were up-regulated. Furthermore, P-gp was up-regulated under experimental physiological hypoxia and chemical hypoxia induced by either cobalt chloride or desferrioxamine. The pro-oxidants H2O2 and buthionine sulfoximine down-regulated HIF-1alpha and P-gp, whereas up-regulation was achieved with the radical scavengers dehydroascorbate, N-acetylcysteine, and vitamin E. The correlation of HIF-1alpha and P-gp expression was validated by the use of hepatoma tumor spheroids that were either wild type (Hepa1) or mutant (Hepa1C4) for aryl hydrocarbon receptor nuclear translocator (ARNT), i.e., HIF-1beta. Chemical hypoxia robustly increased HIF-1alpha as well as P-gp expression in Hepa1 tumor spheroids, whereas no changes were observed in Hepa1C4 spheroids. Hence, our data demonstrate that expression of P-gp in multicellular tumor spheroids is under the control of HIF-1.	Univ Cologne, Dept Neurophysiol, D-50931 Cologne, Germany; Univ Cologne, Inst Genet, D-50931 Cologne, Germany; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; Univ Zurich, Dept Vet Physiol, CH-8006 Zurich, Switzerland	University of Cologne; University of Cologne; Max Planck Society; University of Zurich	Sauer, H (corresponding author), Univ Cologne, Dept Neurophysiol, Robert Koch Str 39, D-50931 Cologne, Germany.	heinrich.sauer@uni-koeln.de	Acker, Helmut Anton Josef/AAS-6841-2020	Acker, Helmut Anton Josef/0000-0001-5589-5508; Gassmann, Max/0000-0003-2750-8878				ACKER H, 1987, BRIT J CANCER, V56, P325, DOI 10.1038/bjc.1987.197; AMELLEM O, 1991, CELL PROLIFERAT, V24, P127, DOI 10.1111/j.1365-2184.1991.tb01144.x; Brown JM, 1998, CANCER RES, V58, P1408; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Bunn HF, 1998, J EXP BIOL, V201, P1197; CARLSSON J, 1988, INT J CANCER, V42, P715, DOI 10.1002/ijc.2910420515; CARLSSON J, 1985, INT J RADIAT ONCOL, V11, P535, DOI 10.1016/0360-3016(85)90185-3; Chilov D, 1999, J CELL SCI, V112, P1203; Du KY, 2000, MOL CELL BIOL, V20, P4320, DOI 10.1128/MCB.20.12.4320-4327.2000; Durand RE, 1998, CANCER RES, V58, P3547; EVANS SM, 1995, BRIT J CANCER, V72, P875, DOI 10.1038/bjc.1995.427; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; Gassmann M, 1996, P NATL ACAD SCI USA, V93, P2867, DOI 10.1073/pnas.93.7.2867; Genius J, 2000, FREE RADICAL BIO MED, V29, P515, DOI 10.1016/S0891-5849(00)00343-9; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GROS P, 1986, P NATL ACAD SCI USA, V83, P337, DOI 10.1073/pnas.83.2.337; GROSSMANN U, 1983, ADV EXP MED BIOL, V159, P477; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Hofer T, 2002, PFLUG ARCH EUR J PHY, V443, P503, DOI 10.1007/s00424-001-0759-8; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Koomagi R, 1999, ANTICANCER RES, V19, P4333; Koukourakis MI, 2001, CANCER RES, V61, P1830; Liang BC, 1996, J NEURO-ONCOL, V29, P149; Matthews NE, 2001, J NATL CANCER I, V93, P1879, DOI 10.1093/jnci/93.24.1879; Muschen M, 2002, P NATL ACAD SCI USA, V99, P10014, DOI 10.1073/pnas.152327399; NumayamaTsuruta K, 1997, EUR J BIOCHEM, V246, P486, DOI 10.1111/j.1432-1033.1997.00486.x; Ogiso Y, 2000, CANCER RES, V60, P2429; Oikawa M, 2001, BIOCHEM BIOPH RES CO, V289, P39, DOI 10.1006/bbrc.2001.5927; Partridge SE, 2001, INT J RADIAT ONCOL, V49, P575, DOI 10.1016/S0360-3016(00)01504-2; ROHLFF C, 1995, CELL SIGNAL, V7, P431, DOI 10.1016/0898-6568(95)00018-K; RONINSON IB, 1984, NATURE, V309, P626, DOI 10.1038/309626a0; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; SAKATA K, 1991, BRIT J CANCER, V64, P809, DOI 10.1038/bjc.1991.405; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; SANNA K, 1994, INT J CANCER, V58, P258, DOI 10.1002/ijc.2910580219; SCHWACHOFER JHM, 1991, ANTICANCER RES, V11, P273; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; SZATROWSKI TP, 1991, CANCER RES, V51, P794; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; Turpaev KT, 2002, BIOCHEMISTRY-MOSCOW+, V67, P281, DOI 10.1023/A:1014819832003; VAUPEL P, 1989, CANCER RES, V49, P6449; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; Volm M, 1996, ANTICANCER RES, V16, P213; WALEH NS, 1995, CANCER RES, V55, P6222; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; Wartenberg M, 2001, FASEB J, V15, P995, DOI 10.1096/fj.00-0350com; Wartenberg M, 1998, INT J CANCER, V75, P855, DOI 10.1002/(SICI)1097-0215(19980316)75:6<855::AID-IJC7>3.3.CO;2-2; Wartenberg M, 2000, INT J CANCER, V85, P267, DOI 10.1002/(SICI)1097-0215(20000115)85:2<267::AID-IJC19>3.0.CO;2-H; Wartenberg M, 2001, J BIOL CHEM, V276, P17420, DOI 10.1074/jbc.M100141200; Weissenberger C, 2000, ANTICANCER RES, V20, P5139; Wenger RH, 1998, CANCER RES, V58, P5678; Wenger RH, 1997, BIOL CHEM, V378, P609; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; WYMANN MP, 1987, ANAL BIOCHEM, V165, P371, DOI 10.1016/0003-2697(87)90284-3; Zhu H, 2001, SCIENCE, V292, P449, DOI 10.1126/science.1060849	65	229	251	1	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					503	+		10.1096/fj.02-0358fje	http://dx.doi.org/10.1096/fj.02-0358fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12514119				2022-12-28	WOS:000181453700029
J	Graeler, M; Goetzl, EJ				Graeler, M; Goetzl, EJ			Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells	FASEB JOURNAL			English	Article						immunity; chemokine; lysophospholipid; receptor; G-protein	MODEL BASEMENT-MEMBRANE; LYSOPHOSPHATIDIC ACID; LYMPHOCYTES; MIGRATION; FTY720	Sphingosine 1-phosphate (S1P) from platelets and macrophages stimulates migration and enhances survival of T cells. Mouse spleen CD4 and CD8 T cells are shown to express predominantly S1P(1) (Edg-1) and S1P(4) (Edg-6) G-protein-coupled receptors with only minimal representation of S1P(2), S1P(3), and S1P(5). At and below plasma concentrations of healthy mammals (1 nM-1 muM), S1P evokes trans-Matrigel chemotaxis of mouse CD4 and CD8 T cells and recruits T cells into subcutaneous air pouches. T cell receptor-mediated activation of CD4 T cells suppresses expression of S1P(1) and S1P(4) receptors and eliminates their chemotactic responses to S1P. The immunoregulator FTY720, a structural homologue of S1P, lacks T cell chemotactic activity and competitively inhibits T cell chemotactic responses to S1P in vitro and in vivo. S1P may be a distinctive contributor to compartmental immunity by attracting naive and memory T cells preferentially over activated effector T cells.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Dept Med, UB8B,UC Box 0711,533 Parnassus & 4th, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu	Gräler, Markus/ABH-1905-2021	Gräler, Markus/0000-0001-6650-7849	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-31809] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2000, TRENDS PHARMACOL SCI, V21, P49, DOI 10.1016/S0165-6147(99)01419-4; Brinkmann V, 2001, TRANSPLANTATION, V72, P764, DOI 10.1097/00007890-200109150-00002; Chun Jerold, 1999, Cell Biochemistry and Biophysics, V30, P213, DOI 10.1007/BF02738068; Gaits F, 1997, FEBS LETT, V410, P54, DOI 10.1016/S0014-5793(97)00411-0; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Goetzl EJ, 2000, J IMMUNOL, V164, P4996, DOI 10.4049/jimmunol.164.10.4996; HLA T, 1990, J BIOL CHEM, V265, P9308; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; Xia MH, 1996, J IMMUNOL, V156, P160; Zheng YH, 2001, J IMMUNOL, V166, P2317, DOI 10.4049/jimmunol.166.4.2317; Zheng YH, 2000, FASEB J, V14, P2387	14	183	187	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2002	16	14					1874	1878		10.1096/fj.02-0548com	http://dx.doi.org/10.1096/fj.02-0548com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12468451				2022-12-28	WOS:000180574300007
J	Steinert, JR; Poston, L; Mann, GE; Jacob, R				Steinert, JR; Poston, L; Mann, GE; Jacob, R			Abnormalities in intracellular Ca2+ regulation in fetal vascular smooth muscle in pre-eclampsia: enhanced sensitivity to arachidonic acid	FASEB JOURNAL			English	Article						calcium; arachidonic acid; pre-eclampsia; cyclooxygenase; smooth muscle cell	ENDOTHELIUM-DEPENDENT RELAXATION; FREE FATTY-ACIDS; RESISTANCE ARTERIES; EPOXYEICOSATRIENOIC ACIDS; UMBILICAL VESSELS; MEMBRANE-FLUIDITY; WOMEN; CELLS; ENTRY; CYTOCHROME-P450	Pre-eclampsia (PE) is a leading cause of maternal and fetal mortality and morbidity. As free fatty acid metabolism is abnormally regulated in PE, we investigated the intracellular Ca2+ ([Ca2+](i)) response to arachidonic acid (AA) in primary cultures of human umbilical artery smooth muscle cells (HUASMC). AA (50 muM) caused a significantly greater [Ca2+](i) elevation in PE than in normal HUASMC, with many cells displaying a delayed secondary increase. The nonmetabolizable AA analog ETYA did not induce a response, suggesting that the augmented PE response depends on an AA metabolite. Inhibition of the AA metabolizing cyclooxygenase or lipoxygenase pathways did not affect the AA response of PE HUASMC but induced in normal cells the secondary rise of [Ca2+](i) observed in PE cells. This potentiated response and the response in PE cells were blocked by inhibitors of the monooxygenase pathway, a third AA metabolizing pathway. We conclude that the [Ca2+](i) response of HUASMC is elevated in PE because of an increased level of a monooxygenase metabolite that stimulates Ca2+ influx and that this can be mimicked in normal cells by blocking cyclooxygenase or lipoxygenase to divert AA to the monooxygenase. This and our work with fetal endothelial cells (FASEB J. 10.1096/fj.010916fje) demonstrate phenotypic changes in the fetal vasculature in PE.	Kings Coll London, GKT Sch Biomed Sci & Med, Ctr Cardiovasc Biol & Med, London SE1 1UL, England	University of London; King's College London	Jacob, R (corresponding author), Kings Coll London, GKT Sch Biomed Sci & Med, Ctr Cardiovasc Biol & Med, Guys Campus, London SE1 1UL, England.	ron.jacob@kcl.ac.uk	Steinert, Joern/A-6678-2008; Steinert, Joern R/AAI-2742-2020; Steinert, Joern/ABB-4561-2020	Steinert, Joern/0000-0003-1640-0845; Steinert, Joern R/0000-0003-1640-0845; Mann, Giovanni/0000-0001-7311-2044				AbdAlla S, 2001, NAT MED, V7, P1003, DOI 10.1038/nm0901-1003; Abou Shouk T, 1999, ANN CLIN BIOCHEM, V36, P62, DOI 10.1177/000456329903600108; AKAR F, 1994, J HYPERTENS, V12, P1235; ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469; Ashworth JR, 1997, BRIT J OBSTET GYNAEC, V104, P1152, DOI 10.1111/j.1471-0528.1997.tb10939.x; Badea M, 1984, Physiologie, V21, P39; Barber A, 2001, FASEB J, V15, P1158, DOI 10.1096/fj.00-0376com; Beck R, 1998, J PHYSIOL-LONDON, V507P, p71P; BODELSSON G, 1995, EARLY HUM DEV, V42, P15, DOI 10.1016/0378-3782(95)01636-H; BROWN M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P285, DOI 10.1016/0005-2736(92)90206-2; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; Cockell AP, 1997, BRIT J OBSTET GYNAEC, V104, P235, DOI 10.1111/j.1471-0528.1997.tb11052.x; Ek BA, 1997, BBA-LIPID LIPID MET, V1346, P75, DOI 10.1016/S0005-2760(97)00021-0; ENDRESEN MJ, 1994, SCAND J CLIN LAB INV, V54, P549, DOI 10.3109/00365519409088567; Fang X, 1999, HYPERTENSION, V34, P1242, DOI 10.1161/01.HYP.34.6.1242; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; Fukao M, 1997, BRIT J PHARMACOL, V120, P439, DOI 10.1038/sj.bjp.0700932; Gailly P, 1998, CELL CALCIUM, V24, P293, DOI 10.1016/S0143-4160(98)90053-7; Godfrey K M, 2001, Public Health Nutr, V4, P611; GRAIER WF, 1995, J PHYSIOL-LONDON, V482, P259, DOI 10.1113/jphysiol.1995.sp020515; Harrington K, 1999, BRIT J OBSTET GYNAEC, V106, P453, DOI 10.1111/j.1471-0528.1999.tb08299.x; Hayman R, 1999, J SOC GYNECOL INVEST, V6, P3, DOI 10.1016/S1071-5576(98)00044-6; HSU CD, 1995, OBSTET GYNECOL, V86, P897, DOI 10.1016/0029-7844(95)00326-M; Hubel CA, 1996, AM J OBSTET GYNECOL, V174, P975, DOI 10.1016/S0002-9378(96)70336-8; Imig JD, 2002, HYPERTENSION, V39, P690, DOI 10.1161/hy0202.103788; JENDRYCZKO A, 1990, ZBL GYNAKOL, V112, P889; Kublickiene KR, 2000, AM J OBSTET GYNECOL, V183, P160, DOI 10.1016/S0002-9378(00)41620-0; LIM KH, 1995, AM J OBSTET GYNECOL, V172, P998, DOI 10.1016/0002-9378(95)90033-0; Liu LW, 2000, J PHYSIOL-LONDON, V525, P391, DOI 10.1111/j.1469-7793.2000.00391.x; LORENTZEN B, 1995, BRIT J OBSTET GYNAEC, V102, P530, DOI 10.1111/j.1471-0528.1995.tb11355.x; LYALL F, 1994, J HYPERTENS, V12, P1339; Mahdy Z, 1998, J PHYSIOL-LONDON, V508, P609, DOI 10.1111/j.1469-7793.1998.00609.x; Matteo R, 1998, AM J OBSTET GYNECOL, V178, P402, DOI 10.1016/S0002-9378(98)80033-1; MCCARTHY AL, 1993, AM J OBSTET GYNECOL, V168, P1323, DOI 10.1016/0002-9378(93)90389-Z; Mignen O, 2000, J BIOL CHEM, V275, P9114, DOI 10.1074/jbc.275.13.9114; Morgan AJ, 1996, BIOCHEM J, V320, P505; Munaron L, 1997, CELL CALCIUM, V22, P179, DOI 10.1016/S0143-4160(97)90011-7; OGBURN PL, 1984, AM J OBSTET GYNECOL, V148, P5, DOI 10.1016/S0002-9378(84)80023-X; Pascoal IF, 1998, J CLIN INVEST, V101, P464, DOI 10.1172/JCI557; Roudbaraki MM, 1996, NEUROENDOCRINOLOGY, V63, P244, DOI 10.1159/000126964; Saijo Y, 2001, BIOCHEM BIOPH RES CO, V286, P964, DOI 10.1006/bbrc.2001.5480; SINGER HA, 1984, BLOOD VESSELS, V21, P223; Steinert JR, 2002, FASEB J, V16, P721, DOI 10.1096/fj.01-0916fje; Suzuki Y, 2000, BRIT J PHARMACOL, V131, P37, DOI 10.1038/sj.bjp.0703529; Velzing-Aarts FV, 1999, AM J CLIN NUTR, V69, P293; Walsh SW, 1996, HYPERTENS PREGNANCY, V15, P101, DOI 10.3109/10641959609015693; Wu XY, 2002, J BIOL CHEM, V277, P13597, DOI 10.1074/jbc.M110881200	48	11	14	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					307	+		10.1096/fj.02-0507fje	http://dx.doi.org/10.1096/fj.02-0507fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12490537				2022-12-28	WOS:000180574300033
J	Feelisch, M; Rassaf, T; Mnaimneh, S; Singh, N; Bryan, NS; Jourd'Heuil, D; Kelm, M				Feelisch, M; Rassaf, T; Mnaimneh, S; Singh, N; Bryan, NS; Jourd'Heuil, D; Kelm, M			Concomitant S-, N-, and heme-nitros(yl)ation in biological tissues and fluids: implications for the fate of NO in vivo	FASEB JOURNAL			English	Article						nitrosothiols; nitrosamines; nitrosylheme; inflammation; plasma; red blood cells	CHROMATOGRAPHY-MASS-SPECTROMETRY; NITRIC-OXIDE; S-NITROSOTHIOLS; BIOCHEMICAL-CHARACTERIZATION; COLORIMETRIC DETERMINATION; SERUM-ALBUMIN; NITROSATION; NITROSYLATION; CYSTEINE; BLOOD	There is growing evidence for the involvement of nitric oxide (NO) -mediated nitrosation in cell signaling and pathology. Although S-nitrosothiols (RSNOs) have been frequently implicated in these processes, it is unclear whether NO forms nitrosyl adducts with moieties other than thiols. A major obstacle in assessing the significance of formation of nitrosated species is the limited reliability of available analytical techniques for measurements in complex biological matrices. Here we report on the presence of nitrosated compounds in plasma and erythrocytes of rats, mice, guinea pigs, and monkeys under basal conditions, in immunologically challenged murine macrophages in vitro and laboratory animals in vivo. Besides RSNOs, all biological samples also contained mercury-stable nitroso species, indicating the additional involvement of amine and heme nitros(yl)ation reactions. Significant differences in the amounts and ratios of RSNOs over N- and heme-nitros(yl)ated compounds were found between species and organs. These observations were made possible by the development of a novel gas-phase chemiluminescence-based technique that allows detection of nitroso species in tissues and biological fluids without prior extraction or deproteinization. The method can quantify as little as 100 fmol bound NO and has been validated extensively for use in different biological matrices. Discrimination between nitrite, RSNOs, and N- nitroso or nitrosylheme compounds is accomplished by use of group-specific reagents. Our findings suggest that NO generation in vivo leads to concomitant formation of RSNOs, nitrosamines, and nitrosylhemes with considerable variation between rodents and primates, highlighting the difficulty in comparing data between different animal models and extrapolating results from experimental animals to human physiology.	LSU Hlth Sci Ctr, Dept Cellular & Mol Physiol, Shreveport, LA 71130 USA; Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA; Univ Dusseldorf, Dept Med, Div Cardiol Pulm Dis & Angiol, D-40225 Dusseldorf, Germany	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Albany Medical College; Heinrich Heine University Dusseldorf	Feelisch, M (corresponding author), LSU Hlth Sci Ctr, Dept Cellular & Mol Physiol, 1501 Kings Hwy, Shreveport, LA 71130 USA.	mfeeli@lsuhsc.edu	Feelisch, Martin/C-3042-2008	Feelisch, Martin/0000-0003-2320-1158; Jourd'heuil, David/0000-0002-6555-5061; Kelm, Malte/0000-0003-0060-1052	NCI NIH HHS [CA89366] Funding Source: Medline; NHLBI NIH HHS [HL69029-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089366] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069029] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alpert C, 1997, ANAL BIOCHEM, V245, P1, DOI 10.1006/abio.1996.9947; BALIGA BT, 1970, J ORG CHEM, V35, P2031, DOI 10.1021/jo00831a072; BEATON ED, 1993, J PHARMACOL TOX MET, V30, P217, DOI 10.1016/1056-8719(93)90020-F; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; CLOUGH PN, 1967, T FARADAY SOC, V63, P915, DOI 10.1039/tf9676300915; COOK HT, 1994, CLIN SCI, V87, P179, DOI 10.1042/cs0870179; COX RD, 1982, J ANAL TOXICOL, V6, P148, DOI 10.1093/jat/6.3.148; DATTA J, 1988, B CHEM SOC JPN, V61, P1735, DOI 10.1246/bcsj.61.1735; EISENBRAND G, 1970, ARZNEI-FORSCHUNG, V20, P1513; Evelyn KA, 1938, J BIOL CHEM, V126, P655; Fang KZ, 1998, BIOCHEM BIOPH RES CO, V252, P535, DOI 10.1006/bbrc.1998.9688; FEELISCH J, 1996, METHODS NITRIC OXIDE, P521; FEELISCH M, 1991, J CARDIOVASC PHARM, V17, pS25, DOI 10.1097/00005344-199117003-00006; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P9943, DOI 10.1073/pnas.180155397; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; Hampl V., 1996, METHODS NITRIC OXIDE, P309; Henry Y.A., 1996, METHODS NITRIC OXIDE, P357; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KHARITONOV VG, 1996, METHODS NITRIC OXIDE, P39; KRUSZYNA R, 1987, J PHARMACOL EXP THER, V241, P307; KUNISAKI N, 1980, J NATL CANCER I, V65, P791, DOI 10.1093/jnci/65.4.791; Kuppusamy P, 2001, MAGNET RESON MED, V45, P700, DOI 10.1002/mrm.1093; Marley R, 2000, FREE RADICAL RES, V32, P1, DOI 10.1080/10715760000300011; MICHEJDA CJ, 1984, IARC SCI PUBL, P365; Mnaimneh S, 1997, J IMMUNOL, V158, P308; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; PIGNATELLI B, 1987, IARC SCI PUBL, V84, P209; Samouilov A, 1998, ANAL BIOCHEM, V258, P322, DOI 10.1006/abio.1998.2609; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Tsikas D, 1997, ANAL BIOCHEM, V244, P208, DOI 10.1006/abio.1996.9880; Tsikas D, 1999, J CHROMATOGR B, V726, P1, DOI 10.1016/S0378-4347(99)00011-0; van der Vliet A, 1998, J BIOL CHEM, V273, P30255, DOI 10.1074/jbc.273.46.30255; Vanin AF, 1998, BIOCHEMISTRY-MOSCOW+, V63, P782; VENTURINI CM, 1993, J PHARMACOL EXP THER, V266, P1497; WALTERS CL, 1978, ANALYST, V103, P1127, DOI 10.1039/an9780301127; Wink DA, 2000, HANDB EXP PHARMACOL, V143, P7; Wolzt M, 1999, J BIOL CHEM, V274, P28983, DOI 10.1074/jbc.274.41.28983; Zhang YY, 1996, J BIOL CHEM, V271, P14271, DOI 10.1074/jbc.271.24.14271	42	337	351	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					1775	1785		10.1096/fj.02-0363com	http://dx.doi.org/10.1096/fj.02-0363com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12409320				2022-12-28	WOS:000180218500010
J	Won, JJ; Yim, JB; Kim, TK				Won, JJ; Yim, JB; Kim, TK			Opposing regulatory roles of E2F in human telomerase reverse transcriptase (hTERT) gene expression in human tumor and normal somatic cells	FASEB JOURNAL			English	Article						E2F-1; Sp1; pRB; repressor; activator	REPRESSES TRANSCRIPTION; CYCLE; PROMOTER; ELEMENTS; SP1; IDENTIFICATION; KERATINOCYTES; INSTABILITY; ACTIVATION; COMPONENT	Telomerase activity is closely correlated with cellular proliferative activity in human tissues. Human cells with high proliferative potential, such as tumor cells or stem cells, exhibit telomerase activity, whereas most normal human somatic cells do not. Telomerase activity is tightly regulated by the expression of its catalytic subunit human telomerase reverse transcriptase (hTERT). Through an expression cloning approach, we identified E2F-1 as a repressor of the hTERT gene in human tumor cells. Ectopic expression of E2F-1 repressed hTERT promoter activity by inhibiting Spl activation of the hTERT promoter. In contrast to the repressor function of E2F-1 in human tumor cells, we demonstrated that E2F-1 is an activator of the hTERT gene in normal human somatic cells. Ectopically expressed E2F-1 activated the hTERT promoter through a noncanonical DNA binding site. E2F-1, E2F-2, and E2F-3 (but not E2F-4 and E2F-5) repressed hTERT promoter activity in human tumor cells, whereas they activated it in normal somatic cells. These contrasting effects of E2F transcription factors on the hTERT promoter could underlie the paradoxical biological activities of E2F, which can both promote and inhibit cellular proliferation and tumorigenesis.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Seoul Natl Univ, Inst Mol Biol & Genet, Natl Creat Res Initiat Ctr Genet Reprogramming, Seoul 151742, South Korea; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Inst Chem & Cell Biol, Boston, MA 02115 USA	Korea Advanced Institute of Science & Technology (KAIST); Seoul National University (SNU); Harvard University; Harvard Medical School	Kim, TK (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	tkkim@mail.kaist.ac.kr						Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Botz J, 1996, MOL CELL BIOL, V16, P3401; CARTWRIGHT P, 2000, J BIOL CHEM, V275, P41219; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; Chou WC, 2001, J CLIN INVEST, V108, P1541, DOI 10.1172/JCI14064; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HIYAMA K, 1995, J IMMUNOL, V155, P3711; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Humbert PO, 2000, GENE DEV, V14, P690; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Johnston A, 2000, STAND, V2, P27; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Klapper W, 2001, MECH AGEING DEV, V122, P695, DOI 10.1016/S0047-6374(01)00223-8; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Kyo S, 1997, CANCER RES, V57, P610; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lee TA, 2000, ONCOGENE, V19, P2257, DOI 10.1038/sj.onc.1203556; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oh S, 1999, BIOCHEM BIOPH RES CO, V263, P361, DOI 10.1006/bbrc.1999.1366; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; Ramirez RD, 1997, J INVEST DERMATOL, V108, P113, DOI 10.1111/1523-1747.ep12285654; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Shin EK, 1996, J BIOL CHEM, V271, P12261, DOI 10.1074/jbc.271.21.12261; Tahara H, 1999, ONCOGENE, V18, P1561, DOI 10.1038/sj.onc.1202458	40	53	58	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1943	+		10.1096/fj.02-0311fje	http://dx.doi.org/10.1096/fj.02-0311fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368233				2022-12-28	WOS:000179167600025
J	Wenger, RH				Wenger, RH			Cellular adaptation to hypoxia: O-2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O-2-regulated gene expression	FASEB JOURNAL			English	Review						environmental adaptation; erythropoietin; oxygen; transcriptional regulation; vascular endothelial growth factor	ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR PROTEIN; FACTOR 1-ALPHA HIF-1-ALPHA; LACTATE-DEHYDROGENASE-A; VASCULAR SMOOTH-MUSCLE; FACTOR-I HIF-1; UBIQUITIN-PROTEASOME PATHWAY; HUMAN ERYTHROPOIETIN GENE; PROSTATE-CANCER CELLS; DNA RECOGNITION SITE	Although it was known for a long time that oxygen deprivation leads to the transcriptional induction of the gene encoding erythropoietin, the molecular mechanisms behind this process remained enigmatic. The cloning of the hypoxia-inducible factors (HIFs), the finding that HIF-1 regulates the expression of many more genes apart from erythropoietin, and the elucidation of the oxygen-dependent mechanisms degrading the HIF alpha subunits recently led to the spectacular discovery of the molecular principles of oxygen sensing. This review aims to summarize our current knowledge of oxygen-regulated gene expression.	Univ Leipzig, Carl Ludwig Inst Physiol, D-04103 Leipzig, Germany	Leipzig University	Wenger, RH (corresponding author), Univ Leipzig, Carl Ludwig Inst Physiol, Liebigstr 27, D-04103 Leipzig, Germany.	wenr@medizin.uni-leipzig.de	Wenger, Roland H./B-7953-2009	Wenger, Roland H./0000-0001-7592-4839				Adelman DM, 2000, GENE DEV, V14, P3191, DOI 10.1101/gad.853700; Agani F, 1998, MOL PHARMACOL, V54, P749, DOI 10.1124/mol.54.5.749; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Berra E, 2001, FEBS LETT, V491, P85, DOI 10.1016/S0014-5793(01)02159-7; Berra E, 2000, BIOCHEM PHARMACOL, V60, P1171, DOI 10.1016/S0006-2952(00)00423-8; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Camenisch G, 2001, PFLUG ARCH EUR J PHY, V443, P240, DOI 10.1007/s004240100679; Caniggia I, 2000, J CLIN INVEST, V105, P577, DOI 10.1172/JCI8316; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chen EY, 2001, CANCER RES, V61, P2429; Cheng KS, 2001, CHINESE J ASTRON AST, V1, P1, DOI 10.1088/1009-9271/1/1/1; Chilov D, 1999, J CELL SCI, V112, P1203; Chilov D, 2001, FASEB J, V15, P2613, DOI 10.1096/fj.01-0092com; Cho S, 2001, FEBS LETT, V498, P62, DOI 10.1016/S0014-5793(01)02499-1; Chun YS, 2002, BIOCHEM J, V362, P71, DOI 10.1042/0264-6021:3620071; Chun YS, 2001, J CELL SCI, V114, P4051; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; Damert A, 1997, BIOCHEM J, V327, P419, DOI 10.1042/bj3270419; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Eckhart AD, 1997, P NATL ACAD SCI USA, V94, P9487, DOI 10.1073/pnas.94.17.9487; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; ESTES SD, 1995, J VIROL, V69, P6335, DOI 10.1128/JVI.69.10.6335-6341.1995; Fatyol K, 2001, J BIOL CHEM, V276, P28421, DOI 10.1074/jbc.M102847200; Feldser D, 1999, CANCER RES, V59, P3915; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Flamme I, 1997, MECH DEVELOP, V63, P51, DOI 10.1016/S0925-4773(97)00674-6; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; Gassmann M, 1997, KIDNEY INT, V51, P567, DOI 10.1038/ki.1997.81; Genbacev O, 1997, SCIENCE, V277, P1669, DOI 10.1126/science.277.5332.1669; Genius J, 2000, FREE RADICAL BIO MED, V29, P515, DOI 10.1016/S0891-5849(00)00343-9; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Gorlach A, 2000, BBA-GENE STRUCT EXPR, V1493, P125, DOI 10.1016/S0167-4781(00)00172-X; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Gradin K, 1996, MOL CELL BIOL, V16, P5221; Graven KK, 1999, BBA-GENE STRUCT EXPR, V1447, P208, DOI 10.1016/S0167-4781(99)00118-9; Grimshaw MJ, 2001, EUR J IMMUNOL, V31, P480, DOI 10.1002/1521-4141(200102)31:2<480::AID-IMMU480>3.0.CO;2-L; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Haddad JJ, 2001, FEBS LETT, V505, P269, DOI 10.1016/S0014-5793(01)02833-2; Haddad JJE, 2000, J BIOL CHEM, V275, P21130, DOI 10.1074/jbc.M000737200; Haddad JJE, 2000, AM J PHYSIOL-LUNG C, V278, pL492, DOI 10.1152/ajplung.2000.278.3.L492; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Hofer T, 2001, FASEB J, V15, P2715, DOI 10.1096/fj.01-0546fje; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Hu B, 1997, MOL CELL BIOL, V17, P851, DOI 10.1128/MCB.17.2.851; Hu J, 1998, BIOCHEM BIOPH RES CO, V245, P894, DOI 10.1006/bbrc.1998.8543; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Katschinski DM, 2002, J BIOL CHEM, V277, P9262, DOI 10.1074/jbc.M110377200; Kietzmann T, 1999, BLOOD, V94, P4177, DOI 10.1182/blood.V94.12.4177.424k14_4177_4185; Kietzmann T, 2001, BIOCHEM J, V354, P531, DOI 10.1042/0264-6021:3540531; Kim CH, 2002, CIRC RES, V90, pE25, DOI 10.1161/hh0202.104923; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; Kline DD, 2002, P NATL ACAD SCI USA, V99, P821, DOI 10.1073/pnas.022634199; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Kvietikova I, 1997, KIDNEY INT, V51, P564, DOI 10.1038/ki.1997.80; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lando D, 2000, J BIOL CHEM, V275, P4618, DOI 10.1074/jbc.275.7.4618; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; Lukashev D, 2001, J BIOL CHEM, V276, P48754, DOI 10.1074/jbc.M104782200; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Marti HH, 2002, MOL ENDOCRINOL, V16, P234, DOI 10.1210/me.16.2.234; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MINCHENKO A, 2001, J BIOL CHEM, V14, P14; Mukhopadhyay CK, 2000, J BIOL CHEM, V275, P21048, DOI 10.1074/jbc.M000636200; Nguyen SV, 1999, BIOCHEM BIOPH RES CO, V265, P382, DOI 10.1006/bbrc.1999.1674; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Oikawa M, 2001, BIOCHEM BIOPH RES CO, V289, P39, DOI 10.1006/bbrc.2001.5927; Okino ST, 1998, J BIOL CHEM, V273, P23837, DOI 10.1074/jbc.273.37.23837; Palmer LA, 2000, MOL PHARMACOL, V58, P1197, DOI 10.1124/mol.58.6.1197; Palmer LA, 1998, AM J PHYSIOL-LUNG C, V274, pL212, DOI 10.1152/ajplung.1998.274.2.L212; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 2000, J BIOL CHEM, V275, P26765; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salceda S, 1997, KIDNEY INT, V51, P556, DOI 10.1038/ki.1997.78; Salceda S, 1996, ARCH BIOCHEM BIOPHYS, V334, P389, DOI 10.1006/abbi.1996.0469; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Sandau KB, 2000, BIOCHEM BIOPH RES CO, V278, P263, DOI 10.1006/bbrc.2000.3789; Sandau KB, 2001, BLOOD, V97, P1009, DOI 10.1182/blood.V97.4.1009; Scheid A, 2002, FASEB J, V16, P411, DOI 10.1096/fj.01-0496fje; Schipani E, 2001, GENE DEV, V15, P2865; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Semenza GL, 2000, GENE DEV, V14, P1983; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Shimoda LA, 2001, AM J PHYSIOL-LUNG C, V281, pL202, DOI 10.1152/ajplung.2001.281.1.L202; Sodhi A, 2000, CANCER RES, V60, P4873; Sogawa K, 1998, P NATL ACAD SCI USA, V95, P7368, DOI 10.1073/pnas.95.13.7368; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Sutter CH, 2000, P NATL ACAD SCI USA, V97, P4748, DOI 10.1073/pnas.080072497; Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142; Tacchini L, 2001, CARCINOGENESIS, V22, P1363, DOI 10.1093/carcin/22.9.1363; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tazuke SI, 1998, P NATL ACAD SCI USA, V95, P10188, DOI 10.1073/pnas.95.17.10188; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; Thrash-Bingham CA, 1999, JNCI-J NATL CANCER I, V91, P143, DOI 10.1093/jnci/91.2.143; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; Vaux EC, 2001, J BIOL CHEM, V276, P44323, DOI 10.1074/jbc.M104678200; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, BIOCHEM BIOPH RES CO, V216, P669, DOI 10.1006/bbrc.1995.2674; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1998, BLOOD, V91, P3471, DOI 10.1182/blood.V91.9.3471.3471_3471_3480; Wenger RH, 2000, J EXP BIOL, V203, P1253; Wenger RH, 1998, EUR J BIOCHEM, V253, P771, DOI 10.1046/j.1432-1327.1998.2530771.x; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Wykoff CC, 2000, CANCER RES, V60, P7075; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yin JH, 2000, BIOCHEM BIOPH RES CO, V279, P30, DOI 10.1006/bbrc.2000.3896; Yu AY, 1999, J CLIN INVEST, V103, P691, DOI 10.1172/JCI5912; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Yu F, 2001, CANCER RES, V61, P4136; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhang W, 1999, J HUM GENET, V44, P293, DOI 10.1007/s100380050163; Zhong H, 2001, BIOCHEM BIOPH RES CO, V284, P352, DOI 10.1006/bbrc.2001.4981; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	178	943	1005	2	74	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1151	10.1096/fj.01-0944rev	http://dx.doi.org/10.1096/fj.01-0944rev			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153983				2022-12-28	WOS:000177814000024
J	Nickenig, G; Baudler, S; Muller, C; Werner, C; Werner, N; Welzel, H; Strehlow, K; Bohm, M				Nickenig, G; Baudler, S; Muller, C; Werner, C; Werner, N; Welzel, H; Strehlow, K; Bohm, M			Redox-sensitive vascular smooth muscle cell proliferation is mediated by GKLF and Id3 in vitro and in vivo	FASEB JOURNAL			English	Article						reactive oxygen species; VSMC; proliferation; gene expression	OXIDATIVE STRESS; INTRACELLULAR CALCIUM; ENDOTHELIAL-CELLS; HYDROGEN-PEROXIDE; SUPEROXIDE ANION; GENE-EXPRESSION; PROTEIN-KINASE; GROWTH; APOPTOSIS; ATHEROSCLEROSIS	Reactive oxygen species such as superoxide and hydroxyl radicals have been implicated in the pathogenic growth of various cell types. The molecular mechanisms involved in redox-sensitive cell growth control are poorly understood. Stimulation of cultured vascular smooth muscle cells (VSMC) with xanthin/xanthin oxidase (X/XO) increases proliferation, whereas stimulation with hydrogen peroxide and Fe(3+)NTA (H-Fe) causes growth arrest of VSMC. Differential Display led to the identification of two novel, differentially regulated redox-sensitive genes. The dominant negative helix-loop- helix protein Id3 is induced by X/XO and down-regulated by H-Fe. The transcription factor gut-enriched Kruppel-like factor (GKLF) is induced by H-Fe but not by X/XO. Induction of GKLF and inhibition of Id3 via transfection experiments leads to growth arrest, whereas overexpression of Id3 and inhibition of GKLF cause cell growth. Id3 down-regulation is induced via binding of GKLF to the Id3 promotor and concomitantly reduced Id3 gene transcription rate. GKLF induction by H-Fe is mediated through hydroxyl radicals, p38MAP kinase-, calcium-, and protein synthesis-dependent pathways. Id3 is induced by X/XO via superoxide, calcium, p38, and p42/44 MAP kinase. GKLF induces and Id3 depresses expression of p21(WAF1/Cip1), p27(KIP1), p53. Induction of Id3 is accomplished by angiotensin II via superoxide release. A vascular injury mouse model revealed that Id3 is overexpressed in proliferating vascular tissue in vivo. These findings reveal novel mechanisms of redox-controlled cellular proliferation involving GKLF and Id3 that may have general implications for our understanding of vascular and nonvascular growth control.	Univ Saarland, Med Klin & Poliklin 3, D-66424 Homburg, Germany	Saarland University	Nickenig, G (corresponding author), Univ Saarland, Med Klin & Poliklin 3, D-66424 Homburg, Germany.	nickenig@med-in.uni-sb.de	Böhm, Michael/C-3638-2011					Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; Berk BC, 1999, THROMB HAEMOSTASIS, V82, P810; DREHER D, 1995, J CELL PHYSIOL, V162, P147, DOI 10.1002/jcp.1041620118; Greene EL, 2000, HYPERTENSION, V35, P942, DOI 10.1161/01.HYP.35.4.942; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griendling KK, 1999, CIRC RES, V85, P562, DOI 10.1161/01.RES.85.6.562; Hensley K, 2000, FREE RADICAL BIO MED, V28, P1456, DOI 10.1016/S0891-5849(00)00252-5; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kanoh S, 2000, EXP LUNG RES, V26, P335, DOI 10.1080/019021400408290; Kawakami M, 1998, MOL PHARMACOL, V53, P497, DOI 10.1124/mol.53.3.497; Kojda G, 1999, CARDIOVASC RES, V43, P562, DOI 10.1016/S0008-6363(99)00169-8; Kunsch C, 1999, CIRC RES, V85, P753, DOI 10.1161/01.RES.85.8.753; Li PF, 1997, FEBS LETT, V404, P249, DOI 10.1016/S0014-5793(97)00093-8; Li PF, 1997, CIRCULATION, V96, P3602; Li PF, 1999, CIRCULATION, V100, P967, DOI 10.1161/01.CIR.100.9.967; Loveys DA, 1996, NUCLEIC ACIDS RES, V24, P2813, DOI 10.1093/nar/24.14.2813; Morel Y, 1999, BIOCHEM J, V342, P481, DOI 10.1042/0264-6021:3420481; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; Okano J, 2000, FEBS LETT, V473, P95, DOI 10.1016/S0014-5793(00)01468-X; Panigada M, 1999, MECH DEVELOP, V81, P103, DOI 10.1016/S0925-4773(98)00237-8; Patel RP, 2000, FREE RADICAL BIO MED, V28, P1780, DOI 10.1016/S0891-5849(00)00235-5; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Tanner FC, 2000, CIRCULATION, V101, P2022, DOI 10.1161/01.CIR.101.17.2022; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200	31	73	75	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2002	16	9					1077	1086		10.1096/fj.01-0570com	http://dx.doi.org/10.1096/fj.01-0570com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087069				2022-12-28	WOS:000177813100039
J	Armstrong, JS; Jones, DP				Armstrong, JS; Jones, DP			Glutathione depletion enforces the mitochondrial permeability transition and causes cell death in HL60 cells that overexpress Bcl-2	FASEB JOURNAL			English	Article						mitochondrial permeability transition; glutathione; respiratory complex III; Bcl-2; reactive oxygen species	CYTOCHROME BC(1) COMPLEX; ADENINE-NUCLEOTIDE TRANSLOCATOR; DEPENDENT ANION CHANNEL; ENDOPLASMIC-RETICULUM; RESPIRATORY-CHAIN; PYRIDINE-NUCLEOTIDES; INNER MITOCHONDRIAL; C RELEASE; APOPTOSIS; PORE	Bcl-2, a protein that blocks apoptosis by inhibiting the mitochondrial permeability transition (MPT) and release of cytochrome c appears to affect normal mitochondrial function by altering electron flow and increasing rates of reactive oxygen species (ROS) production. In this study, we show that glutathione (GSH) depletion induces ROS production and selective toxicity in HL60 cells that overexpress Bcl-2 compared with neomycin vector control cells. Toxicity was mediated by the MPT because it was blocked with the adenine nucleotide translocator (ANT) ligand bongkrekic acid and resulted in mitochondrial cytochrome c release, caspase 3 activation, and DNA fragmentation, indicating the involvement of an apoptotic pathway. Respiratory chain inhibitors stigmatellin and antimycin A, which inhibit Qo and Qi sites of respiratory chain complex III, respectively, blocked ROS production, preserved the redox state of protein thiols, and prevented cell death. These results indicate that in the absence of GSH, endogenous ROS generated at respiratory complex III induce MPT independently of Bcl-2. The results also suggest a new model for MPT in which the central pore protein ANT is regulated by adenine nucleotide and the activity of mitochondrial respiratory complex III.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Armstrong, JS (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd,4123 Rollins Res Ctr, Atlanta, GA 30322 USA.	jeff30322@lycos.com						AKAO Y, 1994, CANCER RES, V54, P2468; Armstrong JS, 2002, CELL DEATH DIFFER, V9, P252, DOI 10.1038/sj.cdd.4400959; Armstrong JS, 2001, EXP CELL RES, V262, P170, DOI 10.1006/excr.2000.5091; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; BASS DA, 1983, J IMMUNOL, V130, P1910; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; CAI J, BIOCH BIOPHYS ACTA, V1366, P139; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Chauvin C, 2001, J BIOL CHEM, V276, P41394, DOI 10.1074/jbc.M106417200; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; COSTANTINI P, 1995, FEBS LETT, V362, P239, DOI 10.1016/0014-5793(95)00256-9; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; Fernandez-Checa JC, 1998, BIOFACTORS, V8, P7, DOI 10.1002/biof.5520080102; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Gotow T, 2000, CELL DEATH DIFFER, V7, P666, DOI 10.1038/sj.cdd.4400694; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; KANG DC, 1983, J BIOCHEM, V94, P1301, DOI 10.1093/oxfordjournals.jbchem.a134475; Kowaltowski A, 2000, CELL DEATH DIFFER, V7, P903, DOI 10.1038/sj.cdd.4400722; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kushnareva YE, 2000, ARCH BIOCHEM BIOPHYS, V376, P377, DOI 10.1006/abbi.2000.1730; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Lee M, 2001, FREE RADICAL BIO MED, V31, P1550, DOI 10.1016/S0891-5849(01)00633-5; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; NOHL H, 1978, EUR J BIOCHEM, V82, P563, DOI 10.1111/j.1432-1033.1978.tb12051.x; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; ROST J, 1964, NATURE, V201, P185, DOI 10.1038/201185a0; Sanchez-Alcazar JA, 2000, J BIOL CHEM, V275, P13353, DOI 10.1074/jbc.275.18.13353; SATO N, 1995, J IMMUNOL, V154, P3194; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Snyder CH, 2000, J BIOL CHEM, V275, P13535, DOI 10.1074/jbc.275.18.13535; Starkov AA, 2001, BIOCHEM BIOPH RES CO, V281, P645, DOI 10.1006/bbrc.2001.4409; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zhang L, 2000, J BIOL CHEM, V275, P7656, DOI 10.1074/jbc.275.11.7656; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	51	192	200	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1263	+		10.1096/fj.02-0097fje	http://dx.doi.org/10.1096/fj.02-0097fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12060676				2022-12-28	WOS:000176683900033
J	Hong, CS; Cho, MC; Kwak, YG; Song, CH; Lee, YH; Lim, JS; Kwon, YK; Chae, SW; Kim, DH				Hong, CS; Cho, MC; Kwak, YG; Song, CH; Lee, YH; Lim, JS; Kwon, YK; Chae, SW; Kim, DH			Cardiac remodeling and atrial fibrillation in transgenic mice overexpressing junctin	FASEB JOURNAL			English	Article						excitation-contraction coupling; sarcoplasmic reticulum; ryanodine receptor; dihydropyridine receptor	SLOW CALCIUM CURRENT; SARCOPLASMIC-RETICULUM; RYANODINE RECEPTOR; CA2+ RELEASE; MOLECULAR-CLONING; SKELETAL; CONTRACTION; CALSEQUESTRIN; HYPERTROPHY; MUSCLE	Junctin is a 26-kDa integral membrane protein, colocalized with the ryanodine receptor (RyR) and calsequestrin at the junctional sarcoplasmic reticulum (SR) membrane in cardiac and skeletal muscles. To elucidate the functional role of junctin in heart, transgenic (TG) mice overexpressing canine junctin (24-29 folds) under the control of mouse alpha-myosin heavy chain promoter were generated. Overexpression of the junctin in mouse heart was associated with heart enlargements, bradycardia, atrial fibrillation, and increased fibrosis. Many ultrastructural alterations were observed in TG atria. The junctional SR cisternae facing transverse-tubules contained a dense matrix of calsequestrin in TG heart. According to echocardiography, TG mice showed enlarged left ventricles, dilated right atriums, and ventricles with paradoxical septal motion and impaired left ventricular systolic function. Overexpression of junctin led to down-regulation of triadin and RyR but to up-regulation of dihydropyridine receptor. The L-type Ca2+ current density and action potential durations increased, which could be the cause for the bradycardia in TG heart. This study provides an important example of pathogenesis leading to substantial cardiac remodeling and atrial fibrillation, which was caused by overexpression of junctin in heart.	Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Chungbuk Natl Univ, Coll Med, Dept Cardiol, Cheongju, South Korea; Chonbuk Natl Univ, Sch Med, Dept Pharmacol, Chonju, South Korea; Chonbuk Natl Univ, Sch Med, Inst Cardiovasc Res, Chonju, South Korea; Chonbuk Natl Univ, Sch Med, Dept Anat, Chonju, South Korea; Kyung Hee Univ, Dept Biol, Seoul, South Korea	Gwangju Institute of Science & Technology (GIST); Chungbuk National University; Jeonbuk National University; Jeonbuk National University; Jeonbuk National University; Kyung Hee University	Kim, DH (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, 1 Oryong Dong, Kwangju 500712, South Korea.	dhkim@kjist.ac.kr						ANDERSON K, 1995, J GEN PHYSIOL, V105, P363, DOI 10.1085/jgp.105.3.363; Ausma J, 1997, CIRCULATION, V96, P3157, DOI 10.1161/01.CIR.96.9.3157; BEAM KG, 1986, NATURE, V320, P168, DOI 10.1038/320168a0; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; Engelhardt S, 2001, FASEB J, V15, P2718, DOI 10.1096/fj.01-0107fje; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; Hong CS, 2001, GENE, V278, P193, DOI 10.1016/S0378-1119(01)00718-1; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; INUI M, 1987, J BIOL CHEM, V262, P1740; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; KATZ EB, 1992, AM J PHYSIOL, V262, pH1867, DOI 10.1152/ajpheart.1992.262.6.H1867; KIM DH, 1994, J MOL CELL CARDIOL, V26, P1505, DOI 10.1006/jmcc.1994.1169; Kirchhefer U, 2001, J BIOL CHEM, V276, P4142, DOI 10.1074/jbc.M006443200; Kiriazis H, 2000, ANNU REV PHYSIOL, V62, P321, DOI 10.1146/annurev.physiol.62.1.321; Kwon MS, 2000, MOL BIOL CELL, V11, P1433, DOI 10.1091/mbc.11.4.1433; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEPPE W, 1977, CIRCULATION, V56, P447, DOI 10.1161/01.CIR.56.3.447; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; Milnes JT, 2001, J MOL CELL CARDIOL, V33, P473, DOI 10.1006/jmcc.2000.1320; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORILLO CA, 1995, CIRCULATION, V91, P1588, DOI 10.1161/01.CIR.91.5.1588; Nakamura K, 2001, J CLIN INVEST, V107, P1245, DOI 10.1172/JCI12412; Ohkura M, 1998, BIOCHEMISTRY-US, V37, P12987, DOI 10.1021/bi972803d; Palermo J, 1996, CIRC RES, V78, P504, DOI 10.1161/01.RES.78.3.504; Paradis P, 2000, P NATL ACAD SCI USA, V97, P931, DOI 10.1073/pnas.97.2.931; POLLAK OJ, 1972, ANIMAL TISSUE TECHNI, P182; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; ROBBINS RJ, 1992, AM J PHYSIOL, V262, pH590, DOI 10.1152/ajpheart.1992.262.2.H590; Sato Y, 1998, J BIOL CHEM, V273, P28470, DOI 10.1074/jbc.273.43.28470; Shin DW, 2000, FEBS LETT, V486, P178, DOI 10.1016/S0014-5793(00)02246-8; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; Thijssen VLJL, 2001, CARDIOVASC RES, V52, P14, DOI 10.1016/S0008-6363(01)00367-4; TIAN Q, 1991, BIOCHIM BIOPHYS ACTA, V1094, P27; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEYMAN AE, 1976, CIRCULATION, V54, P179, DOI 10.1161/01.CIR.54.2.179; YANO K, 1994, MOL CELL BIOCHEM, V135, P61, DOI 10.1007/BF00925961; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389; Zhang L, 2001, J MOL CELL CARDIOL, V33, P233, DOI 10.1006/jmcc.2000.1295	50	63	63	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1310	+		10.1096/fj.01-0908fje	http://dx.doi.org/10.1096/fj.01-0908fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154005				2022-12-28	WOS:000176683900024
J	Zardo, G; Reale, A; Passananti, C; Pradhan, S; Buontempo, S; De Matteis, G; Adams, RLP; Caiafa, P				Zardo, G; Reale, A; Passananti, C; Pradhan, S; Buontempo, S; De Matteis, G; Adams, RLP; Caiafa, P			Inhibition of poly(ADP-ribosyl)ation induces DNA hypermethylation: a possible molecular mechanism	FASEB JOURNAL			English	Article						DNA methylation; DNMT1-PCNA complex; poly(ADP-ribosyl)ation; oncosuppressor gene hypermethylation	MESSENGER-RNA EXPRESSION; CPG ISLANDS; CELL-CYCLE; EUKARYOTIC DNA; HISTONE DEACETYLASE; METHYLATION PATTERN; METHYLTRANSFERASE; GENE; CANCER; TRANSCRIPTION	The pattern of DNA methylation established during embryonic development is necessary for the control of gene expression and is preserved during the replicative process. DNA regions of about 1-2 kb in size, termed CpG islands and located mostly in the promoter regions of housekeeping genes, are protected from methylation, despite being about 6-10 times richer in the dinucleotide CpG than the rest of DNA. Their unmethylated state guarantees the expression of the corresponding housekeeping genes. At present, the mechanism by which CpG islands remain protected from methylation is not clear. However, some results suggest that poly(ADP-ribosyl)ation, an enzymatic process that introduces a postsynthetic modification onto chromatin proteins, might be involved. Here we show in L929 mouse fibroblast cells that inhibition of poly(ADP-ribose) polymerase(s) at different cell-cycle phases increases the mRNA and protein levels of the major maintenance DNA methyltransferase (DNMT1) in G1/S border. Increase of DNMT1 results in a premature PCNA-DNMT1 complex formation, which facilitates robust maintenance, as well as de novo DNA methylation processes during the G1/S border, which leads to abnormal hypermethylation.	Univ Roma La Sapienza, Dipartimento Biotecnol Cellulari & Ematol, Sez Biochim Clin, I-00161 Rome, Italy; CNR, ITBM, Rome, Italy; New England Biolabs Inc, Beverly, MA 01915 USA; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); University of Glasgow	Caiafa, P (corresponding author), Univ Roma La Sapienza, Dipartimento Biotecnol Cellulari & Ematol, Sez Biochim Clin, Vle Regina Elena 324, I-00161 Rome, Italy.	caiafa@bce.med.uniroma1.it	De Matteis, Giovanna/ABD-1479-2020; Passananti, Claudio/K-9593-2016; Reale, Anna/J-5933-2016	Reale, Anna/0000-0001-8988-2342; De Matteis, Giovanna/0000-0003-2963-3365; PASSANANTI, CLAUDIO/0000-0002-9288-5736	Telethon [A.160] Funding Source: Medline	Telethon(Fondazione Telethon)		Adams R. L. P., 1985, MOL BIOL DNA METHYLA; ADAMS RLP, 1995, BIOESSAYS, V17, P139, DOI 10.1002/bies.950170209; Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Baylin SB, 1997, SCIENCE, V277, P1948, DOI 10.1126/science.277.5334.1948; BESTOR TH, 1992, GENET ANAL-BIOMOL E, V9, P48, DOI 10.1016/1050-3862(92)90030-9; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; BIRD A, 1985, CELL, V40, P91, DOI 10.1016/0092-8674(85)90312-5; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; De Capoa A, 1999, FASEB J, V13, P89; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Eads CA, 1999, CANCER RES, V59, P2302; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; GRUENBAUM Y, 1981, FEBS LETT, V124, P67, DOI 10.1016/0014-5793(81)80055-5; Jacobson MK, 1999, TRENDS BIOCHEM SCI, V24, P415, DOI 10.1016/S0968-0004(99)01481-4; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; JOST JP, 1995, J BIOL CHEM, V270, P9734, DOI 10.1074/jbc.270.17.9734; Kanai Y, 2001, INT J CANCER, V91, P205, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1040>3.0.CO;2-2; Karymov MA, 2001, FASEB J, V15, P2631, DOI 10.1096/fj.01-0345com; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10366, DOI 10.1073/pnas.93.19.10366; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Marenzi S, 1999, MOL BIOL REP, V26, P261, DOI 10.1023/A:1007009022336; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Robertson KD, 2000, NUCLEIC ACIDS RES, V28, P2108, DOI 10.1093/nar/28.10.2108; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Schmutte C, 1998, BIOL CHEM, V379, P377; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; SimibulanRosenthal CMG, 1996, PROG NUCLEIC ACID RE, V55, P135; Slack A, 2001, GENE, V268, P87, DOI 10.1016/S0378-1119(01)00427-9; SZYF M, 1985, J BIOL CHEM, V260, P8653; Tsurimoto Toshiki, 1999, Frontiers in Bioscience, V4, pd849, DOI 10.2741/Tsurimoto; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; WOODCOCK DM, 1988, GENE, V74, P151, DOI 10.1016/0378-1119(88)90273-9; YISRAELI J, 1984, DNA METHYLATION BIOL; Zardo G, 1999, FASEB J, V13, P1518, DOI 10.1096/fasebj.13.12.1518; Zardo G, 1998, J BIOL CHEM, V273, P16517, DOI 10.1074/jbc.273.26.16517; Zardo G, 1997, BIOCHEMISTRY-US, V36, P7937, DOI 10.1021/bi970241s	59	23	26	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1319	+		10.1096/fj.01-0827fje	http://dx.doi.org/10.1096/fj.01-0827fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12154007				2022-12-28	WOS:000176683900013
J	Csiszar, A; Ungvari, Z; Koller, A; Edwards, JG; Kaley, G				Csiszar, A; Ungvari, Z; Koller, A; Edwards, JG; Kaley, G			Aging-induced proinflammatory shift in cytokine expression profile in rat coronary arteries	FASEB JOURNAL			English	Article						gene expression; biology of aging; coronary heart disease; biomarkers of aging; inflammation	TUMOR-NECROSIS-FACTOR; VASCULAR SMOOTH-MUSCLE; AORTIC ENDOTHELIAL-CELLS; ALPHA TNF-ALPHA; NITRIC-OXIDE; GENE-EXPRESSION; IL-6 PRODUCTION; MESSENGER-RNA; NO SYNTHASE; AGED RATS	The phenotypic and functional changes of coronary arteries with aging promote ischemic heart disease. We hypothesized that these alterations reflect an aging-induced proinflammatory shift in vascular regulatory mechanisms. Thus, in isolated coronary arteries of young (3-month-old) and aged (25-month-old) male Fischer 344 rats the expression of 96 cytokines, chemokines, and their receptors were screened by a cDNA-based microarray technique. In aged vessels expressions of tumor necrosis factor (TNF)-alpha, (3.3x), interleukin (IL)-1beta (3.0x), IL-6 (2.9x), IL-6Ralpha (2.8x) and IL-17 (6.1x) genes were significantly increased over young vessels. Quantitative reverse transcriptase-polymerase chain reaction confirmed these results. Western blotting demonstrated that protein expressions of TNF-alpha,, IL-1beta, IL-6, and IL-17 were also significantly increased in vessels of aged rats compared with those of young rats. Immunofluorescent double labeling showed that in aged vessels IL-1beta and IL-6 are predominantly localized in the endothelium, whereas TNF-alpha, and IL-17 are localized in smooth muscle. Thus, a proinflammatory shift in the profile of vascular cytokine expression may contribute to the aging-induced phenotypic changes in coronary arteries, promoting the development of ischemic heart disease in the elderly.	New York Med Coll, Dept Physiol, Valhalla, NY 10595 USA	New York Medical College	Kaley, G (corresponding author), New York Med Coll, Dept Physiol, Valhalla, NY 10595 USA.	gabor_kaley@nymc.edu	Ákos, Koller/Q-4672-2019; Ungvari, Zoltan/ADU-0095-2022; Ungvari, Zoltan/GZK-8127-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL043023] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL043023] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aggarwal S, 2002, J LEUKOCYTE BIOL, V71, P1; Agnoletti L, 1999, CIRCULATION, V100, P1983, DOI 10.1161/01.CIR.100.19.1983; BALLIGAND JL, 1995, AM J PHYSIOL-HEART C, V268, pH1293, DOI 10.1152/ajpheart.1995.268.3.H1293; Baumgarten G, 2002, CIRCULATION, V105, P2192, DOI 10.1161/01.CIR.0000015608.37608.18; BELMIN J, 1995, AM J PHYSIOL-HEART C, V268, pH2288, DOI 10.1152/ajpheart.1995.268.6.H2288; Bruunsgaard H, 2000, CLIN EXP IMMUNOL, V121, P255, DOI 10.1046/j.1365-2249.2000.01281.x; Bruunsgaard H, 2001, CURR OPIN HEMATOL, V8, P131, DOI 10.1097/00062752-200105000-00001; Cao CY, 2001, EUR J NEUROSCI, V13, P1781, DOI 10.1046/j.0953-816x.2001.01551.x; Cao SX, 2001, P NATL ACAD SCI USA, V98, P10630, DOI 10.1073/pnas.191313598; Cartford MC, 2002, J NEUROSCI, V22, P5813; Cernadas MR, 1998, CIRC RES, V83, P279, DOI 10.1161/01.RES.83.3.279; Corsini E, 1996, SCAND J IMMUNOL, V44, P506, DOI 10.1046/j.1365-3083.1996.d01-343.x; Csiszar A, 2002, CIRC RES, V90, P1159, DOI 10.1161/01.RES.0000020401.61826.EA; DAYNES RA, 1993, J IMMUNOL, V150, P5219; De Keulenaer GW, 1998, BIOCHEM J, V329, P653; ERSHLER WB, 1993, J AM GERIATR SOC, V41, P176, DOI 10.1111/j.1532-5415.1993.tb02054.x; FABRY Z, 1993, J NEUROIMMUNOL, V47, P23, DOI 10.1016/0165-5728(93)90281-3; Frey RS, 2002, CIRC RES, V90, P1012, DOI 10.1161/01.RES.0000017631.28815.8E; GARFINKEL S, 1994, P NATL ACAD SCI USA, V91, P1559, DOI 10.1073/pnas.91.4.1559; Gerli R, 2000, MECH AGEING DEV, V121, P37; Grammas P, 2001, NEUROBIOL AGING, V22, P837, DOI 10.1016/S0197-4580(01)00276-7; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; Hoffmann J, 2001, CIRC RES, V89, P709, DOI 10.1161/hh2001.097796; Kim F, 2001, AM J PHYSIOL-CELL PH, V280, pC1057, DOI 10.1152/ajpcell.2001.280.5.C1057; Krishnaswamy G, 1998, MICROVASC RES, V55, P189, DOI 10.1006/mvre.1998.2079; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Lee J, 2001, J BIOL CHEM, V276, P1660, DOI 10.1074/jbc.M008289200; Li ZH, 1999, HYPERTENSION, V33, P116, DOI 10.1161/01.HYP.33.1.116; Lundberg MS, 1999, EXP GERONTOL, V34, P549, DOI 10.1016/S0531-5565(99)00036-4; Marin V, 2001, J IMMUNOL, V167, P3435, DOI 10.4049/jimmunol.167.6.3435; McDouall RM, 2001, ENDOTHELIUM-NEW YORK, V8, P25, DOI 10.3109/10623320109063155; MOHAMED F, 1995, ARTERIOSCL THROM VAS, V15, P52, DOI 10.1161/01.ATV.15.1.52; NEREM RM, 1984, BIORHEOLOGY, V21, P565; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; Saito H, 2001, J BIOL CHEM, V276, P29307, DOI 10.1074/jbc.M103740200; SHIMADA Y, 1990, MECH AGEING DEV, V55, P245, DOI 10.1016/0047-6374(90)90152-6; SIREN AL, 1993, STROKE, V24, P880, DOI 10.1161/01.STR.24.6.880; SIRONI M, 1989, J IMMUNOL, V142, P549; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Stralin P, 2000, ATHEROSCLEROSIS, V151, P433, DOI 10.1016/S0021-9150(99)00427-X; Straub RH, 2001, MECH AGEING DEV, V122, P1591, DOI 10.1016/S0047-6374(01)00289-5; SUSCHEK C, 1993, J IMMUNOL, V151, P3283; Tha KK, 2000, BRAIN RES, V885, P25, DOI 10.1016/S0006-8993(00)02883-3; van der Loo B, 2000, J EXP MED, V192, P1731, DOI 10.1084/jem.192.12.1731; Volpato S, 2001, CIRCULATION, V103, P947; WARNER SJC, 1989, J IMMUNOL, V142, P100; Wei YP, 2000, J INTERF CYTOK RES, V20, P403, DOI 10.1089/107999000312342; Weindruch R, 2002, MECH AGEING DEV, V123, P177, DOI 10.1016/S0047-6374(01)00344-X; WONG ML, 1995, NEUROIMMUNOMODULAT, V2, P141, DOI 10.1159/000096884; YAMIN M, 1990, AM J RESP CELL MOL, V2, P207, DOI 10.1165/ajrcmb/2.2.207; Yan ZQ, 1999, ARTERIOSCL THROM VAS, V19, P2854, DOI 10.1161/01.ATV.19.12.2854; Yudkin JS, 2000, ATHEROSCLEROSIS, V148, P209, DOI 10.1016/S0021-9150(99)00463-3; ZEIHER AM, 1993, J CLIN INVEST, V92, P652, DOI 10.1172/JCI116634	53	215	225	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1183	+		10.1096/fj.02-1049fje	http://dx.doi.org/10.1096/fj.02-1049fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709402				2022-12-28	WOS:000182580100020
J	Muzumdar, R; Ma, XH; Yang, XM; Atzmon, G; Bernstein, J; Karkanias, G; Barzilai, N				Muzumdar, R; Ma, XH; Yang, XM; Atzmon, G; Bernstein, J; Karkanias, G; Barzilai, N			Physiologic effect of leptin on insulin secretion is mediated mainly through central mechanisms	FASEB JOURNAL			English	Article						melanocortin; leptin; insulin secretion	PANCREATIC BETA-CELLS; IN-VIVO; MELANOCORTIN SYSTEM; VISCERAL ADIPOSITY; MESSENGER-RNA; ISLETS; RAT; EXPRESSION; INHIBITION; RECEPTOR	Leptin has been shown to decrease glucose-stimulated insulin secretion in both in vivo and in vitro studies. As some of the effects of leptin have been elicited through both peripheral and central mechanisms, we assessed whether leptin modulates insulin secretion also through the central nervous system. We infused leptin or saline through implanted intracerebro-ventricular (ICV) catheters to chronically catheterized, conscious rats (n=15), 2 h after initiation of hyperglycemic (similar to11 mM) clamp. On ICV administration of leptin, there was a gradual and progressive decrease in plasma insulin levels by 52% with 30 ng (P<0.005) and by 28% with 20 ng (P<0.05) of leptin compared with ICV saline. The effect of 20 ng leptin ICV was replicated by intravenous (IV) leptin infusion that achieved physiological leptin levels of similar to17 ng/ml (n=5). When the melanocortin (MC) pathway was blocked with a nonselective MC-3/4 antagonist SHU 9119 administered ICV, and either saline or leptin (n=12) was infused IV, intravenous leptin failed to produce a decrease in glucose-stimulated insulin levels. We conclude that leptin decreases insulin levels by a predominantly central mechanism, probably via the melanocortin receptors; and peripheral leptin receptors on the beta-cells do not play a major role. The physiological features of this response suggest a possible role for leptin in the evolution of diabetes in overweight individuals.	Yeshiva Univ Albert Einstein Coll Med, Inst Aging Res, Dept Med, Montefiore Med Ctr,Div Pediat Endocrinol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Barzilai, N (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Inst Aging Res, Dept Med, Montefiore Med Ctr,Div Pediat Endocrinol, Belfer Bldg 701,1300 Morris Pk Ave, Bronx, NY 10461 USA.	barzilai@aecom.yu.edu	Muzumdar, Radhika/D-9860-2014					Barzilai N, 1999, AM J PHYSIOL-ENDOC M, V277, pE291, DOI 10.1152/ajpendo.1999.277.2.E291; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; Cases JA, 2001, DIABETES, V50, P348, DOI 10.2337/diabetes.50.2.348; Dunbar JC, 1997, DIABETES, V46, P2040, DOI 10.2337/diabetes.46.12.2040; Emilsson V, 1997, DIABETES, V46, P313, DOI 10.2337/diabetes.46.2.313; Fan T, 2000, ENDOCRINOLOGY, V141, P3072; Haynes WG, 1999, HYPERTENSION, V33, P542, DOI 10.1161/01.HYP.33.1.542; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kieffer TJ, 1996, BIOCHEM BIOPH RES CO, V224, P522, DOI 10.1006/bbrc.1996.1059; Kulkarni RN, 1997, J CLIN INVEST, V100, P2729, DOI 10.1172/JCI119818; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Obici S, 2001, J CLIN INVEST, V108, P1079, DOI 10.1172/JCI200112954; Ookuma M, 1998, DIABETES, V47, P219, DOI 10.2337/diabetes.47.2.219; Pallett AL, 1997, BIOCHEM BIOPH RES CO, V238, P267, DOI 10.1006/bbrc.1997.7274; Poitout V, 1998, ENDOCRINOLOGY, V139, P822, DOI 10.1210/en.139.3.822; Roduit R, 1997, FEBS LETT, V415, P179, DOI 10.1016/S0014-5793(97)01115-0; Rossetti L, 1997, J BIOL CHEM, V272, P27758, DOI 10.1074/jbc.272.44.27758; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; Tanizawa Y, 1997, ENDOCRINOLOGY, V138, P4513, DOI 10.1210/en.138.10.4513; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Zhang FM, 1997, NATURE, V387, P206, DOI 10.1038/387206a0	22	57	58	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1130	+		10.1096/fj.02-0991fje	http://dx.doi.org/10.1096/fj.02-0991fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709405				2022-12-28	WOS:000182580100018
J	Escames, G; Leon, J; Macias, M; Khaldy, H; Acuna-Castroviejo, D				Escames, G; Leon, J; Macias, M; Khaldy, H; Acuna-Castroviejo, D			Melatonin counteracts lipopolysaccharide-induced expression and activity of mitochondrial nitric oxide synthase in rats	FASEB JOURNAL			English	Article						melatonin; mtNOS; NO; sepsis; mitochondria; electron transport chain	OXIDATIVE DAMAGE; BRAIN; DYSFUNCTION; RESPIRATION; GLUTATHIONE; DECLINE; KIDNEY; LIVER	Mitochondrial nitric oxide synthase (mtNOS) is expressed constitutively, although it might be induced. Nitric oxide (NO) is a physiological regulator of mitochondrial respiration. Melatonin prevents mitochondrial oxidative damage and inhibits iNOS expression induced by bacterial lipopolysaccharide (LPS). The loss of melatonin with age may be related to the age-dependent mitochondrial damage. Thus, we examined the protective role of melatonin against the effects of LPS on mtNOS and on respiratory complexes activity in liver and lung mitochondria from young and old rats. The activity of mtNOS in control lung was low and did not change with age. LPS administration (10 mg/kg, i.v.) significantly increased mtNOS expression and activity and NO production in lung mitochondria, and the effect was greater in old rats. LPS administration also reduced the age-dependent decrease of the respiratory complexes I and IV. Melatonin administration (60 mg/kg, i.p.) prevented the LPS toxicity, decreasing mitochondrial NOS activity and NO production. Melatonin also counteracted LPS-induced inhibition of complexes I and IV. In general, the actions of melatonin were stronger in older animals than in younger ones. The results suggest that an inducible component of mtNOS, together with mitochondrial damage, occurs during sepsis, and melatonin prevents the mitochondrial failure that occurs during endotoxemia.	Univ Granada, Dept Fisiol, Inst Biotecnol, Granada, Spain	University of Granada	Acuna-Castroviejo, D (corresponding author), Fac Med, Dept Fisiol, Avda Madrid 11, E-18012 Granada, Spain.	dacuna@ugr.es	Leon, Pepi/K-8972-2014; Acuna-Castroviejo, Dario/N-7456-2016; Escames, Germaine/N-7501-2016; Khaldy, Hoda/I-4161-2015	Leon, Pepi/0000-0002-0543-4823; Acuna-Castroviejo, Dario/0000-0002-9680-1560; Escames, Germaine/0000-0003-1256-7656; Khaldy, Hoda/0000-0002-5906-7598				Acuna Castroviejo Dario, 2002, Curr Top Med Chem, V2, P133; Acuna-Castroviejo D, 2001, J PINEAL RES, V30, P65, DOI 10.1034/j.1600-079X.2001.300201.x; Aguilera-Aguirre L, 2002, MITOCHONDRION, V1, P413, DOI 10.1016/S1567-7249(02)00002-8; Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1; BATES TE, 1995, BIOCHEM BIOPH RES CO, V213, P896, DOI 10.1006/bbrc.1995.2213; BENZI G, 1992, NEUROBIOL AGING, V13, P361, DOI 10.1016/0197-4580(92)90109-B; Blanchard B, 2000, J PINEAL RES, V29, P184, DOI 10.1034/j.1600-079X.2000.290308.x; Boczkowski J, 1999, FASEB J, V13, P1637, DOI 10.1096/fasebj.13.12.1637; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3; Bustamante J, 2002, NITRIC OXIDE-BIOL CH, V6, P333, DOI 10.1006/niox.2001.0420; Cadenas E, 2000, FREE RADICAL RES, V33, P747, DOI 10.1080/10715760000301271; Comtois AS, 1999, AM J RESP CRIT CARE, V159, P1975, DOI 10.1164/ajrccm.159.6.9809020; Crespo E, 1999, FASEB J, V13, P1537, DOI 10.1096/fasebj.13.12.1537; DEGREY ADN, 1999, MOL BIOL INTELLIGENC; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Escames G, 1997, NEUROSCI LETT, V230, P147, DOI 10.1016/S0304-3940(97)00498-9; Gitto E, 2001, PEDIATR RES, V50, P756, DOI 10.1203/00006450-200112000-00021; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; GREEN LC, 1981, P NATL ACAD SCI-BIOL, V78, P7764, DOI 10.1073/pnas.78.12.7764; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Heales SJR, 1999, BBA-BIOENERGETICS, V1410, P215, DOI 10.1016/S0005-2728(98)00168-6; Jun T, 1996, J HUM HYPERTENS, V10, P305; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; Kantrow SP, 1997, ARCH BIOCHEM BIOPHYS, V345, P278, DOI 10.1006/abbi.1997.0264; Kozlov AV, 1999, FEBS LETT, V454, P127, DOI 10.1016/S0014-5793(99)00788-7; Lacza Z, 2001, FREE RADICAL BIO MED, V31, P1609, DOI 10.1016/S0891-5849(01)00754-7; LAEMMLI UK, 1970, NATURE, V259, P860; Leach M, 1998, BRIT J PHARMACOL, V125, P817, DOI 10.1038/sj.bjp.0702123; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; Lopez-Figueroa MO, 2000, BIOCHEM BIOPH RES CO, V272, P129, DOI 10.1006/bbrc.2000.2748; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macias M, 1999, J PINEAL RES, V27, P86, DOI 10.1111/j.1600-079X.1999.tb00601.x; Martin M, 2000, FASEB J, V14, P1677; Martin M, 2000, J PINEAL RES, V28, P242, DOI 10.1034/j.1600-079X.2000.280407.x; McCann SM, 1998, EXP GERONTOL, V33, P813, DOI 10.1016/S0531-5565(98)00050-3; Okatani Y, 2002, J PINEAL RES, V32, P143, DOI 10.1034/j.1600-079x.2002.1o106.x; Okatani Y, 2002, NEUROBIOL AGING, V23, P639, DOI 10.1016/S0197-4580(02)00005-2; PAVETO C, 1995, J BIOL CHEM, V270, P16576, DOI 10.1074/jbc.270.28.16576; Poeggeler B, 2002, J PINEAL RES, V33, P20, DOI 10.1034/j.1600-079X.2002.01873.x; Prunet-Marcassus B, 2001, J PINEAL RES, V30, P108, DOI 10.1034/j.1600-079X.2001.300206.x; SCHAPIRA AHV, 1992, MUTAT RES, V275, P133, DOI 10.1016/0921-8734(92)90018-K; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; Tian LQ, 1998, FREE RADICAL BIO MED, V24, P1477, DOI 10.1016/S0891-5849(98)00025-2; Titheradge MA, 1999, BBA-BIOENERGETICS, V1411, P437, DOI 10.1016/S0005-2728(99)00031-6; Wakatsuki A, 2001, J PINEAL RES, V30, P22, DOI 10.1034/j.1600-079X.2001.300103.x; Wei YH, 1998, ANN NY ACAD SCI, V854, P155, DOI 10.1111/j.1749-6632.1998.tb09899.x; Wu CC, 2001, J PINEAL RES, V30, P147, DOI 10.1034/j.1600-079X.2001.300303.x	51	162	171	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					932	+		10.1096/fj.02-0692fje	http://dx.doi.org/10.1096/fj.02-0692fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670878				2022-12-28	WOS:000181892600004
J	Hu, K; Davletov, B				Hu, K; Davletov, B			SNAREs and control of synaptic release probabilities	FASEB JOURNAL			English	Article						neurotransmission; synapse; exocytosis; vesicle; stochastic	TRANSMITTER RELEASE; MEMBRANE-FUSION; VESICLE FUSION; GLUTAMATERGIC SYNAPSES; HIPPOCAMPAL SYNAPSES; QUANTAL SECRETION; CALCIUM; COMPLEX; FACILITATION; SYNAPTOTAGMIN	Since quantal release was first described, it has been clear that release of neurotransmitters is a stochastic process. Modulation of neurotransmitter release probability by regulatory factors likely affects the transfer of information within the nervous system. Although many rules governing release probabilities at the synapse have been discovered, their molecular basis is still under investigation. Here we analyze stimulus-evoked probabilistic assembly of the SNARE fusion machinery and show that a simple SNARE-based mechanism can account quantitatively for the classical binomial behavior of stochastic neurotransmitter release. Our analysis highlights for the first time how the fusion machinery, which is directly responsible for neurotransmitter release, may also contribute to the rich variety of synaptic responses.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Davletov, B (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	baz@mrc-lmb.cam.ac.uk	Davletov, Bazbek/ABA-8569-2021	Davletov, Bazbek/0000-0003-4658-3275				ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; Angleson JK, 2001, J NEUROPHYSIOL, V85, P287, DOI 10.1152/jn.2001.85.1.287; Atwood HL, 2002, NAT REV NEUROSCI, V3, P497, DOI 10.1038/nrn876; Bai JH, 2000, J BIOL CHEM, V275, P25427, DOI 10.1074/jbc.M906729199; BELLEN H, 1999, NEUROTRANSMITTER REL; Bennett MR, 2000, BIOPHYS J, V78, P2201, DOI 10.1016/S0006-3495(00)76769-5; BENNETT MR, 1989, J PHYSIOL-LONDON, V418, P235, DOI 10.1113/jphysiol.1989.sp017837; BLISS TVP, 1990, COLD SPRING HARB SYM, V55, P119; Bollmann JH, 2000, SCIENCE, V289, P953, DOI 10.1126/science.289.5481.953; Chao MV, 2000, J NEUROSCI RES, V59, P353, DOI 10.1002/(SICI)1097-4547(20000201)59:3<353::AID-JNR8>3.3.CO;2-J; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; COOPER RL, 1995, J NEUROSCI, V15, P4209; COWAN WM, 2001, SYNAPSES; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; FERANDEZ I, 2001, NEURON, V32, P1057; Finley MFA, 2002, J NEUROSCI, V22, P1266, DOI 10.1523/JNEUROSCI.22-04-01266.2002; FOGELSON AL, 1985, BIOPHYS J, V48, P1003, DOI 10.1016/S0006-3495(85)83863-7; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Goda Y, 1997, CURR OPIN CELL BIOL, V9, P513, DOI 10.1016/S0955-0674(97)80027-0; Hanse E, 2001, J PHYSIOL-LONDON, V537, P141, DOI 10.1111/j.1469-7793.2001.0141k.x; Hanse E, 2001, J PHYSIOL-LONDON, V531, P481, DOI 10.1111/j.1469-7793.2001.0481i.x; Hu K, 2002, NATURE, V415, P646, DOI 10.1038/415646a; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; Jaffrey SR, 2002, P NATL ACAD SCI USA, V99, P3199, DOI 10.1073/pnas.261705799; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Katz B., 1969, RELEASE NEURAL TRANS; KELLY RB, 1995, CURR BIOL, V5, P257, DOI 10.1016/S0960-9822(95)00054-6; KORN H, 1982, J NEUROPHYSIOL, V48, P679, DOI 10.1152/jn.1982.48.3.679; LLINAS R, 1981, BIOPHYS J, V33, P289, DOI 10.1016/S0006-3495(81)84898-9; MATULSKY H, 1995, INTUITIVE BIOSTATIST; Murthy VN, 1997, NEURON, V18, P599, DOI 10.1016/S0896-6273(00)80301-3; Oertner TG, 2002, NAT NEUROSCI, V5, P657, DOI 10.1038/nn867; Prange O, 1999, J NEUROPHYSIOL, V81, P1810, DOI 10.1152/jn.1999.81.4.1810; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Schikorski T, 1997, J NEUROSCI, V17, P5858; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wittung-Stafshede P, 1999, P NATL ACAD SCI USA, V96, P6587, DOI 10.1073/pnas.96.12.6587; Xu JH, 2002, J NEUROSCI, V22, P53, DOI 10.1523/JNEUROSCI.22-01-00053.2002; Xu-Friedman MA, 2001, J NEUROSCI, V21, P6666, DOI 10.1523/JNEUROSCI.21-17-06666.2001; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247	49	3	4	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					130	135		10.1096/fj.02-0595hyp	http://dx.doi.org/10.1096/fj.02-0595hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554691				2022-12-28	WOS:000181456900037
J	Sonveaux, P; Dessy, C; Brouet, A; Jordan, BF; Gregoire, V; Gallez, B; Balligand, JL; Feron, O				Sonveaux, P; Dessy, C; Brouet, A; Jordan, BF; Gregoire, V; Gallez, B; Balligand, JL; Feron, O			Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery	FASEB JOURNAL			English	Article						nitric oxide; tumor endothelium; oxygenation; irradiation	NITRIC-OXIDE SYNTHASE; ENDOTHELIAL-CELLS; PARTIAL-PRESSURE; MURINE TUMORS; EPR OXIMETRY; SOLID TUMORS; BLOOD-FLOW; OXYGEN; THERAPY; CANCER	The ultimate goal of radiotherapy is to induce irreversible damages in genetically unstable, fast-growing cancer cells while minimizing the cytotoxic effects on host tissues. The satus of the tumor vasculature is particular because it is located within the tumor but mostly arises from host cells. The aim of this study was to characterize the effects of low-dose irradiation on the function of endothelial cells lining tumor vessels. Using isolated arterioles mounted on a pressure myograph, we first documented that the nitric oxide(NO)-mediated vasorelaxation that was defective in tumor vessels was completely restored following local tumor irradiation. Immunoblot analyses revealed that this was attributable to an increase in the abundance of the endothelial NO synthase while the expression of its physiological inhibitor, caveolin-1, was reduced. We further showed that the potentiation of the NO-dependent pathway induced a marked increase in tumor blood flow and oxygenation that determined the higher sensitivity of the tumor to further irradiation. Finally, we documented that the NO-mediated effects of irradiation on the tumor vasculature increased the delivery and expression of a reporter gene into the tumor. Thus, low-dose irradiation of endothelial cells within a tumor is a key determinant of the effectiveness of radiotherapy and may offer a new strategy to increase gene and/or drug delivery to the tumor.	Univ Louvain, Sch Med, Pharmacol & Therapeut Unit, FATH 5349, B-1200 Brussels, Belgium; Univ Louvain, Sch Med, Biomed Magnet Resonance Unit, B-1200 Brussels, Belgium; Univ Louvain, Sch Med, Med Chem & Radiopharm Unit, B-1200 Brussels, Belgium; Univ Louvain, Sch Med, Radiobiol & Radioprotect Unit, B-1200 Brussels, Belgium	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Feron, O (corresponding author), Univ Catholique Louvain, Sch Med, Unit Pharmacol & Therapeut, FATH 5349, 53 Ave E Mounier, B-1200 Brussels, Belgium.	feron@mint.ucl.ac.be	FERON, Olivier/AAM-6395-2020; Balligand, Jean-Luc J/D-7543-2012	FERON, Olivier/0000-0001-5360-0286; BALLIGAND, Jean-Luc/0000-0002-0522-4156; Sonveaux, Pierre/0000-0001-6484-8834				Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Brouet A, 2001, J BIOL CHEM, V276, P32663, DOI 10.1074/jbc.M101371200; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Chaplin DJ, 1998, SEMIN RADIAT ONCOL, V8, P151, DOI 10.1016/S1053-4296(98)80041-6; Denekamp J, 1998, ADV ENZYME REGUL, V38, P281, DOI 10.1016/S0065-2571(97)00015-0; Drummond GR, 2000, CIRC RES, V86, P347, DOI 10.1161/01.RES.86.3.347; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Folkman J, 2001, THROMB HAEMOSTASIS, V86, P23; Folkman J, 2001, SCIENCE, V293, P227, DOI 10.1126/science.1062892; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Gallez B, 1999, MAGN RESON MED, V42, P627, DOI 10.1002/(SICI)1522-2594(199910)42:4<627::AID-MRM2>3.0.CO;2-M; Goda F, 1996, CANCER RES, V56, P3344; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Griffon-Etienne G, 1999, CANCER RES, V59, P3776; Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; JAMES PE, 1995, FREE RADICAL BIO MED, V18, P641, DOI 10.1016/0891-5849(94)00179-N; Jordan BF, 2002, CANCER RES, V62, P3555; Jordan BF, 2000, INT J RADIAT ONCOL, V48, P565, DOI 10.1016/S0360-3016(00)00694-5; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Kong G, 2000, CANCER RES, V60, P4440; Koukourakis MI, 2001, ANTICANCER RES, V21, P4285; Ljungkvist ASE, 2000, INT J RADIAT ONCOL, V48, P1529, DOI 10.1016/S0360-3016(00)00787-2; MILAS L, 1995, CANCER RES, V55, P3564; Navarro-Antolin J, 2000, J BIOL CHEM, V275, P3075, DOI 10.1074/jbc.275.5.3075; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Peters L, 2001, INT J RADIAT ONCOL, V49, P501, DOI 10.1016/S0360-3016(00)01469-3; TAPER HS, 1966, CANCER RES, V26, P143; TEICHER BA, 1992, CANCER RES, V52, P6702; Thews O, 2001, INT J ONCOL, V19, P1243; Thews O, 2000, BRIT J CANCER, V83, P225, DOI 10.1054/bjoc.2000.1229; Thurston G, 1998, J CLIN INVEST, V101, P1401, DOI 10.1172/JCI965; TOZER GM, 1991, INT J RADIAT BIOL, V60, P327, DOI 10.1080/09553009114552081; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; VOLPE JP, 1985, CLIN EXP METASTAS, V3, P281, DOI 10.1007/BF01585082; Zhao DW, 2001, AM J CLIN ONCOL-CANC, V24, P462, DOI 10.1097/00000421-200110000-00010	38	83	88	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1979	+		10.1096/fj.02-0487fje	http://dx.doi.org/10.1096/fj.02-0487fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397083				2022-12-28	WOS:000179167600005
J	Tithof, PK; Elgayyar, M; Cho, Y; Guan, W; Fisher, AB; Peters-Golden, M				Tithof, PK; Elgayyar, M; Cho, Y; Guan, W; Fisher, AB; Peters-Golden, M			Polycyclic aromatic hydrocarbons present in cigarette smoke cause endothelial cell apoptosis by a phospholipase A(2)-dependent mechanism	FASEB JOURNAL			English	Article						phospholipase A(2); arachidonic acid; methylanthracene; benzo(a)pyrene; phenanthrene	TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE CELLS; ARACHIDONIC-ACID; CYTOSOLIC PHOSPHOLIPASE-A(2); A(2); ACTIVATION; RISK; ATHEROSCLEROSIS; MACROPHAGES; INVOLVEMENT	Smoking is a major risk factor for endothelial cell injury and subsequent coronary artery disease. Epidemiological studies implicate the phospholipase A(2)/arachidonic acid cascade in the mechanism by which smoking causes heart disease. However, specific components of cigarette smoke that activate this pathway have not been identified. The purpose of this study was to investigate the effects of polycyclic aromatic hydrocarbons contained in cigarette smoke on phospholipase A(2) (PLA(2)) activity and apoptosis of human coronary artery endothelial cells. 1-methylanthracene (1-MA), phenanthrene (PA), and benzo(a)pyrene (B(a)P) caused significant release of H-3-arachidonate from endothelial cells. 1-MA and PA, but not B(a)P, also caused significant release of H-3-linoleic acid. Release of fatty acids from membrane phospholipids preceded the onset of apoptosis. 3 H-arachidonate release and apoptosis induced by 1-MA, B(a)P, and PA were inhibited by methylarachidonoyl-fluorophosphonate, an inhibitor of Groups IV and VI PLA(2)s. Bromoenol lactone, an inhibitor of Group VI enzymes, inhibited both H-3-arachidonate release and apoptosis induced by 1-MA and PA, but not B(a)P. MJ33, an inhibitor of the acidic calcium-independent PLA(2), attenuated H-3-arachidonate release and apoptosis by PA, but not 1-MA or B(a)P. The presence of Groups IV and VI and the acidic iPLA(2) in endothelial cells was demonstrated by reverse transcriptase-polymerase chain reaction and Western analysis. These data suggest that 1-MA, B(a)P and PA induce apoptosis of endothelial cells by a mechanism that involves activation of these three distinct isoforms of PLA(2).	Univ Tennessee, Dept Comparat Med, Coll Vet Med, Knoxville, TN 37996 USA; Univ Tennessee, Ctr Environm Biotechnol, Knoxville, TN 37996 USA; Univ Penn, Med Ctr, Inst Environm Med, Philadelphia, PA 19104 USA; Univ Michigan, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; University of Tennessee System; University of Tennessee Knoxville; University of Pennsylvania; University of Michigan System; University of Michigan	Tithof, PK (corresponding author), Univ Tennessee, Dept Comparat Med, Coll Vet Med, A205,2407 River Dr, Knoxville, TN 37996 USA.	ptithof@utk.edu		/0000-0002-6224-6685				ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Ahn SG, 1998, BBA-MOL CELL RES, V1448, P115, DOI 10.1016/S0167-4889(98)00113-X; ALMEHDI AB, 1993, BIOCHIM BIOPHYS ACTA, V1167, P56, DOI 10.1016/0005-2760(93)90217-W; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Burchiel SW, 2001, CLIN IMMUNOL, V98, P2, DOI 10.1006/clim.2000.4934; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Capper EA, 2001, PROG LIPID RES, V40, P167, DOI 10.1016/S0163-7827(01)00002-9; CHALOUPKA K, 1995, CHEM-BIOL INTERACT, V96, P207, DOI 10.1016/0009-2797(94)03586-W; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Dimmeler S, 1998, EUR CYTOKINE NETW, V9, P697; Duan L, 2001, J IMMUNOL, V166, P7469, DOI 10.4049/jimmunol.166.12.7469; Fisher AB, 1997, AM J PHYSIOL-LUNG C, V272, pL238, DOI 10.1152/ajplung.1997.272.2.L238; GOODNIGHT SH, 1989, J INVEST DERMATOL, V93, pS102, DOI 10.1111/1523-1747.ep12581218; Harada K, 1997, ATHEROSCLEROSIS, V135, P235, DOI 10.1016/S0021-9150(97)00167-6; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HAZEN SL, 1991, J BIOL CHEM, V266, P5629; Howard G, 1998, JAMA-J AM MED ASSOC, V279, P119, DOI 10.1001/jama.279.2.119; Kerzee JK, 2000, MOL PHARMACOL, V58, P152, DOI 10.1124/mol.58.1.152; Kim TS, 1998, AM J PHYSIOL-LUNG C, V274, pL750, DOI 10.1152/ajplung.1998.274.5.L750; Kockx MM, 2000, CARDIOVASC RES, V45, P736, DOI 10.1016/S0008-6363(99)00235-7; Kuwata H, 1999, ADV EXP MED BIOL, V469, P183; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; Madamanchi NR, 1998, ONCOGENE, V16, P417, DOI 10.1038/sj.onc.1201551; MAOQIANG M, 1995, J LIPID RES, V36, P1925; McCarty MF, 1996, MED HYPOTHESES, V46, P337, DOI 10.1016/S0306-9877(96)90183-8; PENN A, 1988, CARCINOGENESIS, V9, P2185, DOI 10.1093/carcin/9.12.2185; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Revel A, 2001, REPROD TOXICOL, V15, P479, DOI 10.1016/S0890-6238(01)00149-6; Rice SQJ, 1998, BIOCHEM J, V330, P1309; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Rodriguez BL, 1996, CIRCULATION, V94, P952, DOI 10.1161/01.CIR.94.5.952; SBARBATI R, 1991, BLOOD, V77, P764; SEVERSON RF, 1976, CARCINOGENESIS, V1, P269; Shinozaki K, 1999, BIOCHEMISTRY-US, V38, P1669, DOI 10.1021/bi982123q; Song CZ, 1999, J BIOL CHEM, V274, P17063, DOI 10.1074/jbc.274.24.17063; Surette ME, 1999, CARCINOGENESIS, V20, P757, DOI 10.1093/carcin/20.5.757; TAI HH, 1990, ADV EXP MED BIOL, V273, P211; Tew DG, 1996, ARTERIOSCL THROM VAS, V16, P591, DOI 10.1161/01.ATV.16.4.591; Tithof PK, 1998, J IMMUNOL, V160, P953; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; Zhuang JG, 1998, J BIOL CHEM, V273, P15628, DOI 10.1074/jbc.273.25.15628	46	60	60	2	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1463	+		10.1096/fj.02-0092fje	http://dx.doi.org/10.1096/fj.02-0092fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205049	Bronze, Green Submitted			2022-12-28	WOS:000177813100013
J	Devchand, PR; Arita, M; Hong, S; Bannenberg, G; Moussignac, RL; Gronert, K; Serhan, CN				Devchand, PR; Arita, M; Hong, S; Bannenberg, G; Moussignac, RL; Gronert, K; Serhan, CN			Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense	FASEB JOURNAL			English	Article						eicosanoids; lipoxin A(4); resolution of inflammation; inhibition of NF kappa B; G-protein-coupled receptor	ASPIRIN-TRIGGERED LIPOXINS	Signaling pathways instrumental in the temporal and spatial progression of acute inflammation toward resolution are of wide interest. Here a transgenic mouse with myeloid-selective expression of human lipoxin A(4) receptor (hALX) was prepared and used to evaluate in vivo the effect of hALX expression. hALX-transfected HEK293 cells transmitted LXA(4) signals that inhibit TNFalpha-induced NFkappaB activation. Transgenic FvB mice were generated by DNA injections of a 3.8 kb transgene consisting of the full-length hALX cDNA driven by a fragment of the hCD11b promoter. When topically challenged via dermal ear skin, hALX transgenic mice gave attenuated neutrophil infiltration (similar to80% reduction) in response to leukotriene B-4 (LTB4) plus prostaglandin E-2 (PGE(2)) as well as similar to50% reduction in PMN infiltrates (P<0.02) to receptor-bypass inflammation evoked by phorbol ester. The hALX transgenic mice gave markedly decreased PMN infiltrates to the peritoneum with zymosan and altered the dynamics of this response. Transgenic hALX mice displayed increased sensitivity with >50% reduction in PMN infiltrates to suboptimal doses (10 ng/mouse) of the ligand lipoxin A(4) stable analog compared with < 10% reduction of PMN in nontransgenic littermates. Soluble mediators generated within the local inflammatory milieu of hALX mice showed diminished ability to activate the proinflammatory transcription factor NF kappa B. Analyses of the lipid-derived mediators from exudates using LC-MS tandem mass spectroscopy indicated an altered profile in hALX transgenic mice that included lower levels of LTB4 and increased amounts of lipoxin A(4) compared with nontransgenic littermates. Together these results demonstrate a gain-of-function with hALX transgenic mouse and indicate that ALX is a key receptor and sensor in formation of acute exudates and their resolution.	Harvard Univ, Sch Med,Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Serhan, CN (corresponding author), Harvard Univ, Sch Med,Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Thorn Bldg Med Res,7th Floor,75 Francis St, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu	Bannenberg, Gerard/AAF-6216-2020	Arita, Makoto/0000-0001-9902-0463; Bannenberg, Gerard/0000-0001-7763-6224	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305, K01DK060583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038765, R37GM038765, R29GM038765] Funding Source: NIH RePORTER; NIAMS NIH HHS [K01-AR02219] Funding Source: Medline; NIDDK NIH HHS [DK50305, K01 DK060583-03] Funding Source: Medline; NIGMS NIH HHS [GM38765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aliberti J, 2002, NAT IMMUNOL, V3, P76, DOI 10.1038/ni745; Chiang N, 2000, J EXP MED, V191, P1197, DOI 10.1084/jem.191.7.1197; Chiang N, 1999, J CLIN INVEST, V104, P309, DOI 10.1172/JCI7016; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Collard CD, 2001, ANESTHESIOLOGY, V94, P1133, DOI 10.1097/00000542-200106000-00030; Cotran R., 1999, ROBBINS PATHOLOGIC B, P1; Cotran R. S., 1999, ROBBINS PATHOLOGIC B, V6th; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DZIENNIS S, 1995, BLOOD, V85, P319; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gallin J.I., 1999, INFLAMMATION BASIC P; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Kang Y, 2000, BIOCHEMISTRY-US, V39, P13551, DOI 10.1021/bi001196i; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; McMahon B, 2001, TRENDS PHARMACOL SCI, V22, P391, DOI 10.1016/S0165-6147(00)01771-5; Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897; Narumiya S, 2001, J CLIN INVEST, V108, P25, DOI 10.1172/JCI200113455; Perez H D, 1994, Curr Opin Hematol, V1, P40; QIU FH, 2001, FASEB J, DOI DOI 10.1096/FJ.1001-0576FJE; RAUD J, 1988, P NATL ACAD SCI USA, V85, P2315, DOI 10.1073/pnas.85.7.2315; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; Serhan Charles N, 2002, ScientificWorldJournal, V2, P169; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693	27	152	162	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					652	659		10.1096/fj.02-0770com	http://dx.doi.org/10.1096/fj.02-0770com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665478				2022-12-28	WOS:000182580100010
J	Kalabis, J; Patterson, MJ; Enders, GH; Marian, B; Iozzo, RV; Rogler, G; Gimotty, PA; Herlyn, M				Kalabis, J; Patterson, MJ; Enders, GH; Marian, B; Iozzo, RV; Rogler, G; Gimotty, PA; Herlyn, M			Stimulation of human colonic epithelial cells by leukemia inhibitory factor is dependent on collagen-embedded fibroblasts in organotypic culture	FASEB JOURNAL			English	Article						colon; organotypic culture; LIF	DIFFERENTIATION; GROWTH; EXPRESSION; LINES; PROLIFERATION; INTESTINE; MYOFIBROBLASTS; ESTABLISHMENT; RECEPTORS; PHENOTYPE	The colonic epithelium undergoes a continuous cycle of proliferation, differentiation, and apoptosis. To characterize factors important for colonic homeostasis and its dysregulation, human fetal colonic epithelial cells were isolated and seeded on a collagen type I matrix with embedded colonic fibroblasts. The epithelial cells rapidly spread from clusters and proliferated, and within 3 days, a columnar layer of polarized epithelium surrounded the surface of the constricted collagen matrix. The polarized enterocytes developed brush borders, tight junctions and desmosomes, and goblet and enteroendocrine cells were present. A balance of growth and differentiation was maintained for several weeks in the presence of collagen-embedded fibroblasts and a complex mixture of growth factors. Leukemia inhibitory factor (LIF) was critical for proliferation of enterocytes and inhibited expression of the differentiation marker carbonic anhydrase II. In the presence of LIF, the relative number of goblet cells remained stable, whereas enteroendocrine relative cell number declined. LIF-stimulated epithelial cells remained dependent on the presence of fibroblasts in the matrix. In combination with stem cell factor and endothelin 3, LIF induced formation of disorganized structures of stratified and semi-stratified cells, suggesting that the homeostatic balance in the normal human colon requires cooperation with differentiation-inducing factors.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Vienna, Inst Canc Res, Vienna, Austria; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Regensburg, Dept Internal Med 1, D-8400 Regensburg, Germany; Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Vienna; Jefferson University; University of Regensburg; University of Pennsylvania; Pennsylvania Medicine	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.upenn.edu	Gimotty, Phyllis/GWZ-4136-2022; Rogler, Gerhard/O-5308-2015; Iozzo, Renato/AAS-1980-2020	Gimotty, Phyllis/0000-0002-3850-9799; Rogler, Gerhard/0000-0002-1733-9188; Iozzo, Renato/0000-0002-5908-5112				Bach SP, 2000, CARCINOGENESIS, V21, P469, DOI 10.1093/carcin/21.3.469; BAIBAKOV BA, 1994, IN VITRO CELL DEV-AN, V30A, P490, DOI 10.1007/BF02631321; BARTEK J, 1986, HISTOCHEM J, V18, P565, DOI 10.1007/BF01675198; Bekku S, 1998, RES EXP MED, V198, P175, DOI 10.1007/s004330050101; Berking C, 2001, CANCER RES, V61, P8306; CAESAR PA, 1988, BIOCHEM J, V253, P451, DOI 10.1042/bj2530451; DAHLQVIST A, 1966, CLIN SCI, V30, P517; Dai CY, 2000, GASTROENTEROLOGY, V119, P929, DOI 10.1053/gast.2000.17952; Dignass AU, 2001, INFLAMM BOWEL DIS, V7, P68, DOI 10.1097/00054725-200102000-00014; EVANS GS, 1994, ANNU REV PHYSIOL, V56, P399; FOSTER HM, 1990, GASTROENTEROLOGY, V99, P1710, DOI 10.1016/0016-5085(90)90477-I; Guimbaud R, 1998, EUR CYTOKINE NETW, V9, P607; Halttunen T, 1996, GASTROENTEROLOGY, V111, P1252, DOI 10.1053/gast.1996.v111.pm8898639; HO SB, 1992, J CELL BIOCHEM, P119; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Jobson TM, 1998, J CLIN INVEST, V101, P2650, DOI 10.1172/JCI1876; KAMOHARA H, 1994, RES COMMUN MOL PATH, V85, P131; Karamuk E, 1999, ARTIF ORGANS, V23, P881, DOI 10.1046/j.1525-1594.1999.06308.x; KAYE GI, 1968, GASTROENTEROLOGY, V54, P852; Kedinger M, 1998, ANN NY ACAD SCI, V859, P1, DOI 10.1111/j.1749-6632.1998.tb11107.x; KEDINGER M, 1987, DIFFERENTIATION, V36, P71, DOI 10.1111/j.1432-0436.1987.tb00182.x; Kermorgant S, 2001, AM J PHYSIOL-GASTR L, V281, pG1068, DOI 10.1152/ajpgi.2001.281.4.G1068; Menard D., 1994, MEMBRANE PHYSIOPATHO, P319; MOYER MP, 1995, METHOD ENZYMOL, V254, P153; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; Oda D, 1998, IN VITRO CELL DEV-AN, V34, P211; Oda D, 1998, IN VITRO CELL DEV-AN, V34, P46; Oda DP, 1995, EXP MOL PATHOL, V63, P16, DOI 10.1006/exmp.1995.1026; Pageot LP, 2000, MICROSC RES TECHNIQ, V49, P394; PARENTEAU NL, 1991, J CELL BIOCHEM, V45, P245, DOI 10.1002/jcb.240450304; Pedersen G, 2000, SCAND J GASTROENTERO, V35, P772, DOI 10.1080/003655200750023471; Perreault N, 1996, EXP CELL RES, V224, P354, DOI 10.1006/excr.1996.0145; Perreault N, 1998, EXP CELL RES, V245, P34, DOI 10.1006/excr.1998.4221; Perreault N, 1998, BIOCHEM BIOPH RES CO, V248, P121, DOI 10.1006/bbrc.1998.8919; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Quaroni A, 1997, GASTROENTEROLOGY, V113, P1198, DOI 10.1053/gast.1997.v113.pm9322515; Quaroni A, 1980, Methods Cell Biol, V21B, P403; Rockman SP, 2001, J GASTROEN HEPATOL, V16, P991, DOI 10.1046/j.1440-1746.2001.02588.x; Rogler G, 1998, LAB INVEST, V78, P889; ROUSSET M, 1986, BIOCHIMIE, V68, P1035, DOI 10.1016/S0300-9084(86)80177-8; Schorkhuber M, 1998, CELL BIOL TOXICOL, V14, P211, DOI 10.1023/A:1007418811589; SORGER T, 1995, IN VITRO CELL DEV-AN, V31, P671; WHITEHEAD RH, 1987, IN VITRO CELL DEV B, V23, P436; Whitehead RH, 1999, GASTROENTEROLOGY, V117, P858, DOI 10.1016/S0016-5085(99)70344-6; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718	47	32	36	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1115	+		10.1096/fj.02-0852fje	http://dx.doi.org/10.1096/fj.02-0852fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692084				2022-12-28	WOS:000182580100043
J	Lee, S; Kim, H; Ryu, S; Kim, H; Kim, B; Kim, D; Lim, C; Jung, H; Lee, D; Kim, H				Lee, S; Kim, H; Ryu, S; Kim, H; Kim, B; Kim, D; Lim, C; Jung, H; Lee, D; Kim, H			Effects of chronic polyphenol or vitamin ingestion on antioxidative activity during exercise in rats	FASEB JOURNAL			English	Meeting Abstract	Experimental Biology 2003 Meeting	APR 11-15, 2003	SAN DIEGO, CALIFORNIA						Lab Exercise Nutr, Taegu 702701, South Korea										0	61	62	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 14	2003	17	4	1	S			A326	A326		10.1096/fj.02-0570fje	http://dx.doi.org/10.1096/fj.02-0570fje			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	658QZ	12475887				2022-12-28	WOS:000181733101552
J	Agarwal, S; Long, P; Seyedain, A; Piesco, N; Shree, A; Gassner, R				Agarwal, S; Long, P; Seyedain, A; Piesco, N; Shree, A; Gassner, R			A central role for nuclear factor-kappa B pathway in the antiinflammatory and proinflammatory actions of mechanical strain	FASEB JOURNAL			English	Article						NF-kappa B; signal transduction; osteoblastic cells; mechanical strain	HUMAN PERIODONTAL-LIGAMENT; SIGNAL-TRANSDUCTION; TENSILE STRAIN; EXPRESSION; CELLS; INDUCTION; STRESS; ALPHA; GENE; OSTEOGENESIS	Mechanical signals play an integral role in bone homeostasis. These signals are observed at the interface of bone and teeth, where osteoblast-like periodontal ligament (PDL) cells constantly take part in bone formation and resorption in response to applied mechanical forces. Earlier, we reported that signals generated by tensile strain of low magnitude (TENS-L) are antiinflammatory, whereas tensile strain of high magnitude (TENS-H) is proinflammatory and catabolic. In this study, we examined the mechanisms of intracellular actions of the antiinflammatory and proinflammatory signals generated by TENS of various magnitudes. We show that both low and high magnitudes of mechanical strain exploit nuclear factor (NF)-kappaB as a common pathway for transcriptional inhibition/activation of proinflammatory genes and catabolic processes. TENS-L is a potent inhibitor of interleukin (IL)-1beta-induced I-kappaBbeta degradation and prevents dissociation of NF-kappaB from cytoplasmic complexes and thus its nuclear translocation. This leads to sustained suppression of IL-1beta-induced NF-kappaB transcriptional regulation of proinflammatory genes. In contrast, TENS-H is a proinflammatory signal that induces I-kappaBbeta degradation, nuclear translocation of NF-kappaB, and transcriptional activation of proinflammatory genes. These findings are the first to describe the largely unknown intracellular mechanism of action of applied tensile forces in osteoblast-like cells and have critical implications in bone remodeling.	Univ Pittsburgh, McGowen Inst Regenerat Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Agarwal, S (corresponding author), Univ Pittsburgh, McGowen Inst Regenerat Med, 589 Salk Hall,3501 Terrace St, Pittsburgh, PA 15261 USA.	sagar@pitt.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015399] Funding Source: NIH RePORTER; NCCIH NIH HHS [R01 AT000646] Funding Source: Medline; NIDCR NIH HHS [R01 DE015399] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Agarwal S, 1998, INFECT IMMUN, V66, P932, DOI 10.1128/IAI.66.3.932-937.1998; Bolcato-Bellemin AL, 2000, J DENT RES, V79, P1712, DOI 10.1177/00220345000790091201; BURGER EH, 1992, J BONE MINER RES, V7, pS397, DOI 10.1002/jbmr.5650071406; Chaturvedi MM, 1997, J BIOL CHEM, V272, P30129, DOI 10.1074/jbc.272.48.30129; CHIBA M, 1993, J BIOMECH, V26, P561, DOI 10.1016/0021-9290(93)90017-9; Chien HH, 1999, CALCIFIED TISSUE INT, V64, P402, DOI 10.1007/PL00005822; DAVIDOVITCH Z, 1996, BIOL MECH TOOTH MOVE, P255; Donnelly RP, 1999, J INTERF CYTOK RES, V19, P563, DOI 10.1089/107999099313695; Du W, 1995, J BIOMECH, V28, P1485, DOI 10.1016/0021-9290(95)00096-8; Fermor B, 1998, BONE, V22, P637, DOI 10.1016/S8756-3282(98)00047-7; Gassner R, 1999, J IMMUNOL, V163, P2187; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Howard PS, 1998, J PERIODONTAL RES, V33, P500; Ikegame M, 2001, J BONE MINER RES, V16, P24, DOI 10.1359/jbmr.2001.16.1.24; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Inoh H, 2002, FASEB J, V16, P405, DOI 10.1096/fj.01-0354fje; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Klein-Nulend J, 2002, OSTEOPOROSIS INT, V13, P137, DOI 10.1007/s001980200005; KLEINNULEND J, 1995, FASEB J, V9, P441, DOI 10.1096/fasebj.9.5.7896017; Ko KS, 2001, BIOCHEM BIOPH RES CO, V285, P1077, DOI 10.1006/bbrc.2001.5177; Long P, 2002, BONE, V30, P547, DOI 10.1016/S8756-3282(02)00673-7; Long P, 2001, J DENT RES, V80, P1416, DOI 10.1177/00220345010800050601; Long P, 2001, ARTHRITIS RHEUM, V44, P2311, DOI 10.1002/1529-0131(200110)44:10<2311::AID-ART393>3.0.CO;2-Q; McCulloch CAG, 2000, PERIODONTOL 2000, V24, P56, DOI 10.1034/j.1600-0757.2000.2240104.x; Rubin J, 2000, AM J PHYSIOL-CELL PH, V278, pC1126, DOI 10.1152/ajpcell.2000.278.6.C1126; Salter DM, 2001, CLIN ORTHOP RELAT R, pS49; Shimizu N, 1998, J PERIODONTOL, V69, P670, DOI 10.1902/jop.1998.69.6.670; Toma CD, 1997, J BONE MINER RES, V12, P1626, DOI 10.1359/jbmr.1997.12.10.1626; Yamaguchi M, 1997, J PERIODONTAL RES, V32, P308, DOI 10.1111/j.1600-0765.1997.tb00539.x; Yang JH, 1998, J BIOL CHEM, V273, P6550, DOI 10.1074/jbc.273.11.6550	30	57	71	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					899	+		10.1096/fj.02-0901fje	http://dx.doi.org/10.1096/fj.02-0901fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670873	Green Accepted			2022-12-28	WOS:000181892600005
J	Smit, JJ; van Loveren, H; Hoekstra, MO; Nijkamp, FP; Bloksma, N				Smit, JJ; van Loveren, H; Hoekstra, MO; Nijkamp, FP; Bloksma, N			Influence of the macrophage bacterial resistance gene Nramp1 (Slc11a1) on the induction of allergic asthma in the mouse	FASEB JOURNAL			English	Article						Th1/Th2 cells; allergy; natural-resistance-associated macrophage protein 1	MAST-CELLS; NATURAL-RESISTANCE; AIRWAY HYPERRESPONSIVENESS; EOSINOPHILIC INFLAMMATION; INTRACELLULAR PARASITES; EPITHELIAL-CELLS; BCG VACCINATION; MURINE MODEL; IN-VITRO; MICE	Based on the hygiene hypothesis that lack of early childhood bacterial infections would favor development of allergic disease, we hypothesize that genes controlling antibacterial resistance may be important as well. We, therefore, studied whether Nramp1 alleles that determine resistance (Nramp1(r)) or susceptibility (Nramp1(s)) to intracellular bacteria at the macrophage level affect sensitivity to induction of allergic asthma. Nramp1(s) and congenic Nramp1(r) mice were sensitized with ovalbumin/alum on days 0 and 14 and challenged with ovalbumin or saline aerosols on days 42, 45, and 48. On day 49, airway responsiveness was assessed, blood was withdrawn, and lung lavage was performed. We demonstrated that ovalbumin sensitization and challenge of Nramp1(s) and Nramp1(r) mice caused comparable airway hyperreactivity and airway eosinophilia and a similar increase in serum levels of ovalbumin-specific IgG1 and IgG2a. Ovalbumin challenge, however, induced significantly lower serum levels of total and ovalbumin-specific IgE and significantly lower mast cell degranulation in Nramp1(r) mice as compared with Nramp1(s) mice. In addition, ovalbumin challenge of Nramp1(r) mice led to significantly less release of Th2 cytokines into the airways. Results show that Nramp1 can affect the development of allergy but not the development of airway hyperresponsiveness in the mouse.	Univ Utrecht, Dept Pharmacol & Pathophysiol, Utrecht Inst Pharmaceut Sci, NL-3508 TB Utrecht, Netherlands; Univ Utrecht, Fac Biol, NL-3508 TB Utrecht, Netherlands; Natl Inst Publ Hlth & Environm, Lab Pathol & Immunobiol, Bilthoven, Netherlands; Maastricht Univ, Dept Hlth Risk Anal & Toxicol, Maastricht, Netherlands; UMC, Dept Gen Pediat, Wilhelmina Childrens Hosp, Utrecht, Netherlands	Utrecht University; Utrecht University; Netherlands National Institute for Public Health & the Environment; Maastricht University; Wilhelmina Kinderziekenhuis	Bloksma, N (corresponding author), Univ Utrecht, Dept Pharmacol & Pathophysiol, Utrecht Inst Pharmaceut Sci, POB 80082, NL-3508 TB Utrecht, Netherlands.	M.A.Bloksma@pharm.uu.nl		Smit, Joost/0000-0003-4612-4036				Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Araujo LMM, 1998, EUR J IMMUNOL, V28, P2913, DOI 10.1002/(SICI)1521-4141(199809)28:09&lt;2913::AID-IMMU2913&gt;3.0.CO;2-3; Bellamy R, 1999, MICROBES INFECT, V1, P23, DOI 10.1016/S1286-4579(99)80010-0; Bingisser RM, 2001, SWISS MED WKLY, V131, P171; BIOZZI G, 1984, ADV IMMUNOL, V36, P189, DOI 10.1016/S0065-2776(08)60902-5; Blackwell JM, 1999, IMMUNOL LETT, V65, P73, DOI 10.1016/S0165-2478(98)00127-8; Blackwell JM, 1996, MOL MED TODAY, V2, P205, DOI 10.1016/1357-4310(96)88773-9; Blackwell JM, 1996, PARASITOLOGY, V112, pS67, DOI 10.1017/S0031182000076678; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425, DOI 10.1165/ajrcmb.14.5.8624247; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Chu SJ, 2000, J IMMUNOL, V165, P4640, DOI 10.4049/jimmunol.165.8.4640; COLEMAN JW, 2000, MAST CELLS BASOPHILS, P221; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Corry DB, 1999, NATURE, V402, pB18; de Bie JJ, 2000, EXP LUNG RES, V26, P491; Eastmond NC, 1997, J IMMUNOL, V159, P1444; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Faquim-Mauro EL, 1999, J IMMUNOL, V163, P3572; GHILDYAL N, 1992, J IMMUNOL, V149, P2123; Govoni G, 1997, J LEUKOCYTE BIOL, V62, P277, DOI 10.1002/jlb.62.2.277; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Herz U, 1998, J ALLERGY CLIN IMMUN, V102, P867, DOI 10.1016/S0091-6749(98)70030-2; HESSEL EM, 1995, EUR J PHARM-ENVIRON, V293, P401, DOI 10.1016/0926-6917(95)90061-6; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; Hogan SP, 1998, J IMMUNOL, V161, P1501; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; Houtman R, 2001, J IMMUNOL, V166, P861, DOI 10.4049/jimmunol.166.2.861; Karupiah G, 2000, Rev Immunogenet, V2, P387; Kay AB, 2001, NEW ENGL J MED, V344, P109, DOI 10.1056/NEJM200101113440206; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lalmanach AC, 1999, MICROBES INFECT, V1, P719, DOI 10.1016/S1286-4579(99)80073-2; Lang T, 1997, INFECT IMMUN, V65, P380, DOI 10.1128/IAI.65.2.380-386.1997; Lin TJ, 1997, J IMMUNOL, V159, P4015; MOCK BA, 1994, INFECT IMMUN, V62, P325, DOI 10.1128/IAI.62.1.325-328.1994; Olivier M, 1998, EUR J BIOCHEM, V251, P734, DOI 10.1046/j.1432-1327.1998.2510734.x; Postma DS, 1998, AM J RESP CRIT CARE, V158, pS187, DOI 10.1164/ajrccm.158.supplement_2.13tac170; Rojas M, 1999, J IMMUNOL, V162, P6122; Rook GAW, 2000, IMMUNOL TODAY, V21, P249, DOI 10.1016/S0167-5699(00)01630-3; Sears MR, 1997, LANCET, V350, P1; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Skamene E, 1998, ANNU REV MED, V49, P275, DOI 10.1146/annurev.med.49.1.275; Soo SS, 1998, INFECT IMMUN, V66, P1910, DOI 10.1128/IAI.66.5.1910-1917.1998; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Strannegard O, 2001, ALLERGY, V56, P91, DOI 10.1034/j.1398-9995.2001.056002091.x; Thomason MJ, 2000, THORAX, V55, P785, DOI 10.1136/thorax.55.9.785; van Scott MR, 2000, AM J PHYSIOL-LUNG C, V278, pL667, DOI 10.1152/ajplung.2000.278.4.L667; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; von Hertzen LC, 2000, ANN MED, V32, P397, DOI 10.3109/07853890008995946; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	54	16	16	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2003	17	3					958	+		10.1096/fj.02-0985fje	http://dx.doi.org/10.1096/fj.02-0985fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	661LT	12670871				2022-12-28	WOS:000181892600002
J	Hidaka, K; Lee, JK; Kim, HS; Ihm, CH; Iio, A; Ogawa, M; Nishikawa, SI; Kodama, I; Morisaki, T				Hidaka, K; Lee, JK; Kim, HS; Ihm, CH; Iio, A; Ogawa, M; Nishikawa, SI; Kodama, I; Morisaki, T			Chamber-specific differentiation of Nkx2.5-positive cardiac precursor cells from murine embryonic stem cells	FASEB JOURNAL			English	Article						cardiomyocyte; green fluorescent protein; embryoid body; diversification; retinoic acid	IN-VITRO; RETINOIC ACID; TRANSCRIPTION FACTORS; HEART DEVELOPMENT; FUNCTIONAL-PROPERTIES; IONIC CURRENTS; GENE NKX2-5; MOUSE HEART; ES CELLS; EXPRESSION	Embryonic stem (ES) cells are a useful system to study cardiac differentiation in vitro. It has been difficult, however, to track the fates of chamber-specific cardiac lineages, since differentiation is induced within the embryoid body. We have established an in vitro culture system to track Nkx2.5(+) cell lineages during mouse ES cell differentiation by using green fluorescent protein (GFP) as a reporter. Nkx2.5/GFP(+) cardiomyocytes purified from embryoid bodies express sarcomeric tropomyosin and myosin heavy chain and heterogeneously express cardiac troponin I (cTnI), myosin light chain 2v (MLC2v) and atrial natriuretic peptide (ANP). After 4-week culture, GFP(+) cells exhibited electrophysiological characteristics specific to sinoatrial (SA) node, atrial, or ventricular type. Furthermore, we found that administration of 10 7 M retinoic acid (RA) to embryoid bodies increased the percentage of MLC2v(-)ANP(+) cells; this also increased the expression of atrial-specific genes in the Nkx2.5/GFP(+) fraction, in a time- and dose-dependent fashion. These results suggest that Nkx2.5(+) lineage cells possess the potential to differentiate into various cardiomyocyte cell types and that RA can modify the differentiation potential of Nkx2.5(+) cardiomyocytes at an early stage.	Osaka Univ, Grad Sch Pharmaceut Sci, Dept Mol Pathophysiol, Suita, Osaka 5658565, Japan; Osaka Univ, Natl Cardiovasc Ctr, Res Inst, Dept Biosci, Suita, Osaka 5658565, Japan; Nagoya Univ, Environm Med Res Inst, Dept Circulat, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Kyoto Univ, Grad Sch Med, Dept Mol Genet, Sakyo Ku, Kyoto 6068507, Japan	Osaka University; National Cerebral & Cardiovascular Center - Japan; Osaka University; Nagoya University; Kyoto University	Morisaki, T (corresponding author), 5-7-1 Fujishiro Dai, Osaka 5658565, Japan.	morisaki@ri.ncvc.go.jp						ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Biben C, 2000, CIRC RES, V87, P888, DOI 10.1161/01.RES.87.10.888; Boheler KR, 2002, CIRC RES, V91, P189, DOI 10.1161/01.RES.0000027865.61704.32; Bruneau BG, 2000, DEV BIOL, V217, P266, DOI 10.1006/dbio.1999.9548; Chazaud C, 1999, DEVELOPMENT, V126, P2589; Christoffels VM, 2000, DEV BIOL, V223, P266, DOI 10.1006/dbio.2000.9753; Doevendans PA, 2000, J MOL CELL CARDIOL, V32, P839, DOI 10.1006/jmcc.2000.1128; Durocher D, 1996, MOL CELL BIOL, V16, P4648, DOI 10.1128/mcb.16.9.4648; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Fujimoto T, 2001, GENES CELLS, V6, P1113, DOI 10.1046/j.1365-2443.2001.00490.x; Hescheler J, 1997, CARDIOVASC RES, V36, P149, DOI 10.1016/S0008-6363(97)00193-4; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Huang XP, 1999, CIRC RES, V84, P1; Kasahara H, 1998, CIRC RES, V82, P936, DOI 10.1161/01.RES.82.9.936; Kataoka H, 1997, DEV GROWTH DIFFER, V39, P729; Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131; Klug MG, 1995, AM J PHYSIOL-HEART C, V269, pH1913, DOI 10.1152/ajpheart.1995.269.6.H1913; Kolossov E, 1998, J CELL BIOL, V143, P2045, DOI 10.1083/jcb.143.7.2045; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Kupershmidt S, 1999, CIRC RES, V84, P146, DOI 10.1161/01.RES.84.2.146; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P; MCCARRICK JW, 1993, TRANSGENIC RES, V2, P183, DOI 10.1007/BF01977348; METZGER JM, 1995, CIRC RES, V76, P710, DOI 10.1161/01.RES.76.5.710; Meyer N, 2000, FEBS LETT, V478, P151, DOI 10.1016/S0014-5793(00)01839-1; MILLERHANCE WC, 1993, J BIOL CHEM, V268, P25244; Min JY, 2002, J APPL PHYSIOL, V92, P288, DOI 10.1152/jappl.2002.92.1.288; Molkentin JD, 2000, DEV BIOL, V217, P301, DOI 10.1006/dbio.1999.9544; Muller M, 2000, FASEB J, V14, P2540, DOI 10.1096/fj.00-0002com; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; Niederreither K, 2001, DEVELOPMENT, V128, P1019; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Pereira FA, 1999, GENE DEV, V13, P1037, DOI 10.1101/gad.13.8.1037; ROHWEDEL J, 1994, DEV BIOL, V164, P87, DOI 10.1006/dbio.1994.1182; SAGGIN L, 1989, J BIOL CHEM, V264, P16299; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Tanaka M, 1999, DEVELOPMENT, V126, P1269; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wang GF, 1996, J BIOL CHEM, V271, P19836, DOI 10.1074/jbc.271.33.19836; Westfall MV, 1996, DEV DYNAM, V206, P24, DOI 10.1002/(SICI)1097-0177(199605)206:1<24::AID-AJA3>3.0.CO;2-2; Wobus AM, 1997, J MOL CELL CARDIOL, V29, P1525, DOI 10.1006/jmcc.1997.0433; Xavier-Neto J, 1999, DEVELOPMENT, V126, P2677; YUTZEY KE, 1995, CIRC RES, V77, P216, DOI 10.1161/01.RES.77.2.216; YUTZEY KE, 1994, DEVELOPMENT, V120, P871; YUTZEY KE, 1995, DEV BIOL, V170, P531, DOI 10.1006/dbio.1995.1234; Zammit PS, 2000, DEV DYNAM, V217, P75, DOI 10.1002/(SICI)1097-0177(200001)217:1<75::AID-DVDY7>3.0.CO;2-L; Zou YM, 1997, DEVELOPMENT, V124, P793	49	114	119	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					740	+		10.1096/fj.02-0104fje	http://dx.doi.org/10.1096/fj.02-0104fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594186				2022-12-28	WOS:000181456900006
J	Schafer, M; Ewald, N; Schafer, C; Stapler, A; Piper, HM; Noll, T				Schafer, M; Ewald, N; Schafer, C; Stapler, A; Piper, HM; Noll, T			Signaling of hypoxia-induced autonomous proliferation of endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; extracellular signal-regulated kinase; inositol-3-phosphate-sensitive Ca2+ release	GROWTH-FACTOR; KINASE; MECHANISMS; CALCIUM; PROTEIN; CARDIOMYOCYTES; ANGIOGENESIS; INVOLVEMENT; ACTIVATION; DEPLETION	Endothelial cells exhibit an autonomous proliferative response to hypoxia, independent of paracrine effectors. In cultured endothelial cells of porcine aorta, we analyzed the signaling and compared hypoxia with mitochondrial inhibition by rotenone. Particularly, roles of the mitogen-activated protein kinase (MAPK) kinase (MEK)/MAPK pathway and cytosolic Ca2+ were studied. Hypoxia resulted in increased proliferation by 65+/-2%. Hypoxia induced transient activation of p42 MAPK (phosphorylation rose from 11+/-5 to 51+/-7%), followed by translocation of p42 MAPK into the nucleus. The proliferative response was diminished after inhibition of the MEK/MAPK pathway by PD 98059 (20 muM) or UO 126 (10 muM) but not sensitive to 8-phenyltheophillin (10 muM), an adenosine receptor blocker, nor to a neutralizing antibody for vascular endothelial growth factor (VEGF). Inhibition of intracellular Ca2+ release, capacitive Ca2+ influx, or removal of extracellular Ca2+ prevented hypoxic Ca2+ overload and the proliferative response. Suppression of cytosolic Ca2+ rise did not interfere with activation of p42 MAPK but abolished its nuclear translocation. Effects of hypoxia were mimicked by rotenone (10 muM). Transient hypoxic inhibition of mitochondria induces a proliferative endothelial response mediated through Ca2+-independent activation and Ca2+-dependent nuclear translocation of p42 MAPK. This proliferative response is independent of adenosine or VEGF.	Univ Giessen, Inst Physiol, D-35392 Giessen, Germany	Justus Liebig University Giessen	Piper, HM (corresponding author), Univ Giessen, Inst Physiol, Aulweg 129, D-35392 Giessen, Germany.	Michael.Piper@physiologie.med.uni-giessen.de						Bustamante JO, 2000, PFLUG ARCH EUR J PHY, V439, P433, DOI 10.1007/s004240050960; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; GODFREY K, 1985, NEW ENGL J MED, V313, P1450, DOI 10.1056/NEJM198512053132305; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; LI QA, 1987, BIOCHEM BIOPH RES CO, V147, P120; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; MEININGER CJ, 1990, AM J PHYSIOL, V258, pH198, DOI 10.1152/ajpheart.1990.258.1.H198; MEININGER CJ, 1988, AM J PHYSIOL, V255, P554; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Muller JN, 1997, J BIOL CHEM, V272, P23435, DOI 10.1074/jbc.272.37.23435; NOLL T, 1995, AM J PHYSIOL-HEART C, V268, pH1462, DOI 10.1152/ajpheart.1995.268.4.H1462; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schafer M, 2001, AM J PHYSIOL-HEART C, V280, pH1002, DOI 10.1152/ajpheart.2001.280.3.H1002; Schluter KD, 1999, AM J PHYSIOL-HEART C, V276, pH1655, DOI 10.1152/ajpheart.1999.276.5.H1655; Spahr R., 1990, CELL CULTURE TECHNIQ, P220; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; Suzuki E, 2000, J BIOL CHEM, V275, P3637, DOI 10.1074/jbc.275.5.3637	22	23	23	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					449	+		10.1096/fj.02-0398fje	http://dx.doi.org/10.1096/fj.02-0398fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12631583				2022-12-28	WOS:000181453700014
J	Tanaka, SM; Alam, I; Turner, CH				Tanaka, SM; Alam, I; Turner, CH			Stochastic resonance in osteogenic response to mechanical loading	FASEB JOURNAL			English	Article						biomechanics; bone formation; osteoporosis; mechanotransduction	SIGNAL-TRANSDUCTION; BONE; STRAIN; ENHANCEMENT; VIBRATION	Stochastic resonance, in which noise enhances the response of a nonlinear system to a weak signal, has been observed in various biological sensory systems. We speculated that bone formation in response to mechanical loading could be enhanced by adding noise (vibration) to a standard exercise regimen. To test this hypothesis, three different loading regimens were applied to the ulnae of mice: (1) high amplitude, low frequency sinusoidal loading at 2 Hz with an amplitude of 3 N to simulate exercise; (2) low amplitude, broad frequency vibration with frequency components 0-50 Hz and 0.3 N of mean amplitude; (3) the sinusoidal wave combined with vibration (S+V) to invoke stochastic resonance. The simulated exercise regimen induced new bone formation on the periosteal surface of the ulna, however the addition of vibration noise with exercise enhanced the osteogenic response by almost 4-fold. Vibration by itself had no effect on bone formation. It was concluded that adding low magnitude vibration greatly enhanced bone formation in response to loading, suggesting a contribution of stochastic resonance in the osteogenic response.	Indiana Univ, Sch Med, Dept Orthoped Surg, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Turner, CH (corresponding author), Indiana Univ, Sch Med, Dept Orthoped Surg, 541 Clin Dr,Room 600, Indianapolis, IN 46202 USA.	turnerch@iupui.edu	Tanaka, Shigeo/E-7098-2015	Tanaka, Shigeo/0000-0002-1262-3876				BENZI R, 1982, TELLUS, V34, P10, DOI 10.1111/j.2153-3490.1982.tb01787.x; BENZI R, 1981, J PHYS A-MATH GEN, V14, pL453, DOI 10.1088/0305-4470/14/11/006; BEZRUKOV SM, 1995, NATURE, V378, P362, DOI 10.1038/378362a0; BRAUN HA, 1994, NATURE, V367, P270, DOI 10.1038/367270a0; Collins JJ, 1997, PHYS REV E, V56, P923, DOI 10.1103/PhysRevE.56.923; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; Duncan RL, 1998, SEMIN NEPHROL, V18, P178; Fritton SP, 2000, J BIOMECH, V33, P317, DOI 10.1016/S0021-9290(99)00210-9; Huang RP, 1999, J GERONTOL A-BIOL, V54, pB352, DOI 10.1093/gerona/54.8.B352; Khan K, 2000, J Sci Med Sport, V3, P150, DOI 10.1016/S1440-2440(00)80077-8; Rubin C, 2002, J BONE MINER RES, V17, P349, DOI 10.1359/jbmr.2002.17.2.349; Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122; Rubin C, 2002, BONE, V30, P445, DOI 10.1016/S8756-3282(01)00689-5; RUBIN CT, 1990, J BIOMECH, V23, P43, DOI 10.1016/0021-9290(90)90040-A; Tanaka S, 2001, J BONE MINER RES, V16, pS481; TURNER CH, 1995, J BIOMECH, V28, P39, DOI 10.1016/0021-9290(95)80005-0; TURNER CH, 1995, J BONE MINER RES, V10, P1544; USUI Y, 1989, J ORTHOPAED RES, V7, P559, DOI 10.1002/jor.1100070414	21	52	60	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2002	16	14					313	+		10.1096/fj.02-0561fje	http://dx.doi.org/10.1096/fj.02-0561fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12475888				2022-12-28	WOS:000180574300017
J	Nakayama, H; Otsu, K; Yamaguchi, O; Nishida, K; Date, MO; Hongo, K; Kusakari, Y; Toyofuku, T; Hikoso, S; Kashiwase, K; Takeda, T; Matsumura, Y; Kurihara, S; Hori, M; Tada, M				Nakayama, H; Otsu, K; Yamaguchi, O; Nishida, K; Date, MO; Hongo, K; Kusakari, Y; Toyofuku, T; Hikoso, S; Kashiwase, K; Takeda, T; Matsumura, Y; Kurihara, S; Hori, M; Tada, M			Cardiac-specific overexpression of a high Ca2+ affinity mutant of SERCA2a attenuates in vivo pressure overload cardiac hypertrophy	FASEB JOURNAL			English	Article						phospholamban; calcium signaling; PKC	PROTEIN-KINASE-C; LEFT-VENTRICULAR HYPERTROPHY; SARCOPLASMIC-RETICULUM; EXPRESSION; HEART; MYOCYTES; GENE; CONTRACTILITY; TRANSCRIPTION; STIMULATION	In cardiomyocytes, calcium plays important roles as a signal in cardiac hypertrophy and contraction-relaxation cycling. Elevation of Ca2+ concentration in myoplasm is associated with the onset and progression of hypertrophy as well as the enhancement of contractility. The cardiac Ca2+ ATPase (SERCA2a) of the sarcoplasmic reticulum plays a dominant role in lowering cytoplasmic calcium levels during relaxation and is regulated by phospholamban (PLN). To examine whether the modulation of SERCA2a activity results in the attenuation of cardiac hypertrophy and enhancement of contractility, we generated transgenic mice (TG) overexpressing a high calcium affinity SERCA2a mutant (K397/400E), lacking a functional association with PLN. In the TG hearts, the apparent affinity of SERCA2a for Ca2+ significantly increased compared with their nontransgenic littermate controls. The TG showed increased contraction and relaxation, with increases in the amplitude of Ca2+ transient and rapid Ca2+ decay. Upon induction of pressure overload by transverse aortic constriction, the TG developed less cardiac hypertrophy than littermate controls did. The activation of Ca2+-sensitive protein kinase C by pressure overload was significantly attenuated in the TG hearts. Our findings indicate an association of SERCA2a activity with cardiac hypertrophy and thus a new therapeutic target for the prevention and treatment of cardiac hypertrophy.	Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Med Informat Sci, Suita, Osaka 5650871, Japan; Jikei Univ, Sch Med, Dept Physiol, Tokyo, Japan	Osaka University; Osaka University; Jikei University	Otsu, K (corresponding author), Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Box A8,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kotsu@medone.med.osaka-u.ac.jp	Hikoso, Shungo/R-4281-2018	Yamaguchi, Osamu/0000-0002-7461-369X; Hikoso, Shungo/0000-0003-2284-1970				ALLO SN, 1991, J BIOL CHEM, V266, P22003; Baker DL, 1998, CIRC RES, V83, P1205, DOI 10.1161/01.RES.83.12.1205; CHIEN KR, 1999, MOL CELLULAR BIOL CA; Date M, 2002, J AM COLL CARDIOL, V39, P907, DOI 10.1016/S0735-1097(01)01826-5; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; GU X, 1994, CIRC RES, V75, P926, DOI 10.1161/01.RES.75.5.926; GULICK J, 1991, J BIOL CHEM, V266, P9180; Hajjar RJ, 1997, CIRC RES, V81, P145, DOI 10.1161/01.RES.81.2.145; Harjai KJ, 1999, ANN INTERN MED, V131, P376, DOI 10.7326/0003-4819-131-5-199909070-00009; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; IMAGAWA T, 1989, J BIOCHEM-TOKYO, V106, P342, DOI 10.1093/oxfordjournals.jbchem.a122855; Ito K, 2001, CIRC RES, V89, P422, DOI 10.1161/hh1701.095522; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; Kiriazis H, 2002, CARDIOVASC RES, V53, P372, DOI 10.1016/S0008-6363(01)00487-4; LAPOINTE MC, 1990, HYPERTENSION, V15, P20, DOI 10.1161/01.HYP.15.1.20; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; SADOSHIMA J, 1995, CIRC RES, V76, P1; SEI CA, 1991, J BIOL CHEM, V266, P15910; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; TADA M, 2001, CARDIAC SARCOPLASMIC; TAKEISHI Y, 1999, AM J PHYSIOL, V45, pH53; TOYOFUKU T, 1994, J BIOL CHEM, V269, P22929; van Zwieten PA, 2000, CARDIOVASC RES, V45, P82, DOI 10.1016/S0008-6363(99)00291-6; WINDT LJD, 2000, J BIOL CHEM, V275, P13571, DOI DOI 10.1074/JBC.275.18.13571; Wolska BM, 1996, AM J PHYSIOL-HEART C, V271, pH1250, DOI 10.1152/ajpheart.1996.271.3.H1250; Zhai J, 2000, J BIOL CHEM, V275, P10538, DOI 10.1074/jbc.275.14.10538	31	42	46	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					61	+		10.1096/fj.02-0474fje	http://dx.doi.org/10.1096/fj.02-0474fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12424227				2022-12-28	WOS:000180218500032
J	Ceddia, RB; Koistinen, HA; Zierath, JR; Sweeney, G				Ceddia, RB; Koistinen, HA; Zierath, JR; Sweeney, G			Analysis of paradoxical observations on the association between leptin and insulin resistance	FASEB JOURNAL			English	Review						obesity; lipoatrophy; lipodystrophy; diabetes mellitus; glucose metabolism	PANCREATIC BETA-CELLS; ISOLATED RAT ADIPOCYTES; SYMPATHETIC NERVOUS-SYSTEM; MESSENGER-RNA EXPRESSION; HUMAN SKELETAL-MUSCLE; DIABETIC FATTY RATS; OBESE ZUCKER RATS; LOW PLASMA LEPTIN; GLUCOSE-METABOLISM; IN-VIVO	Obesity is commonly associated with the development of insulin resistance and diabetes in humans and rodents. Insulin resistance and diabetes are observed in lipoatrophic individuals or rodent models of lipoatrophy. Here we focus on the role of leptin, the product of the obesity (ob) gene, in the development of insulin resistance and diabetes associated with obesity and lipoatrophy. We review the reported effects of leptin on whole body glucose metabolism and compare and contrast these with direct effects on skeletal muscle, fat and liver. This summary of paradoxical observations on the effects of leptin on glucose homeostasis and the ability of leptin to induce or improve insulin resistance suggests that a complex interplay exists between direct peripheral and centrally mediated effects of the hormone. Evidence suggesting that leptin acts as a mediator of insulin release from pancreatic beta cells is reviewed. Finally, intracellular signaling mechanisms stimulated by both leptin and insulin are discussed, with potential points of cross-talk suggested.	York Univ, Dept Biol, Toronto, ON M3J 1P3, Canada; Karolinska Inst, Stockholm, Sweden; Univ Helsinki, Cent Hosp, Dept Med, Div Cardiol, Helsinki, Finland	York University - Canada; Karolinska Institutet; University of Helsinki; Helsinki University Central Hospital	Sweeney, G (corresponding author), York Univ, Dept Biol, 4700 Keele St, Toronto, ON M3J 1P3, Canada.	gsweeney@yorku.ca		Zierath, Juleen/0000-0001-6891-7497				Ahima RS, 2000, FRONT NEUROENDOCRIN, V21, P263, DOI 10.1006/frne.2000.0197; Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Ahren B, 1999, AM J PHYSIOL-REG I, V277, pR959, DOI 10.1152/ajpregu.1999.277.4.R959; AlBarazanji KA, 1997, OBES RES, V5, P387, DOI 10.1002/j.1550-8528.1997.tb00660.x; Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; Berti L, 1997, DIABETOLOGIA, V40, P606, DOI 10.1007/s001250050722; BEUTTNER R, 2000, AM J PHYSIOL, V278, pE563; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Boden G, 1997, J CLIN INVEST, V100, P1107, DOI 10.1172/JCI119621; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caprio M, 2001, TRENDS ENDOCRIN MET, V12, P65, DOI 10.1016/S1043-2760(00)00352-0; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; CARPINELLI AR, 1980, J ENDOCRINOL INVEST, V3, P365, DOI 10.1007/BF03349372; Cases JA, 2001, DIABETES, V50, P348, DOI 10.2337/diabetes.50.2.348; Ceddia RB, 2000, EUR J BIOCHEM, V267, P5952, DOI 10.1046/j.1432-1327.2000.01664.x; Ceddia RB, 1998, J ENDOCRINOL, V158, pR7, DOI 10.1677/joe.0.158R007; Ceddia RB, 1999, GEN PHARMACOL-VASC S, V32, P233, DOI 10.1016/S0306-3623(98)00185-2; Ceddia RB, 1999, INT J OBESITY, V23, P1207, DOI 10.1038/sj.ijo.0801095; Ceddia RB, 1999, INT J OBESITY, V23, P75, DOI 10.1038/sj.ijo.0800762; Ceddia RB, 1998, GEN PHARMACOL-VASC S, V31, P799, DOI 10.1016/S0306-3623(98)00086-X; Chen NG, 1997, J CLIN INVEST, V100, P1174, DOI 10.1172/JCI119629; Chinookoswong N, 1999, DIABETES, V48, P1487, DOI 10.2337/diabetes.48.7.1487; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Cohen SM, 1998, P NATL ACAD SCI USA, V95, P7385, DOI 10.1073/pnas.95.13.7385; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Das K, 2001, BIOCHEM BIOPH RES CO, V280, P1120, DOI 10.1006/bbrc.2001.4217; Dukes ID, 1996, DIABETES, V45, P845, DOI 10.2337/diabetes.45.7.845; Ebihara K, 2001, DIABETES, V50, P1440, DOI 10.2337/diabetes.50.6.1440; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Emanuelli B, 2001, J BIOL CHEM, V276, P47944, DOI 10.1074/jbc.M104602200; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Farooqi IS, 2001, NATURE, V414, P34, DOI 10.1038/35102112; Fehmann HC, 1997, HORM METAB RES, V29, P572, DOI 10.1055/s-2007-979103; Fehmann HC, 1997, PEPTIDES, V18, P1267, DOI 10.1016/S0196-9781(97)00135-6; Friedman JE, 1997, AM J PHYSIOL-ENDOC M, V273, pE1014, DOI 10.1152/ajpendo.1997.273.5.E1014; Friedman JM, 1998, NUTR REV, V56, pS38; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Furnsinn C, 1998, DIABETOLOGIA, V41, P524, DOI 10.1007/s001250050941; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; Greco AV, 2002, DIABETES, V51, P144, DOI 10.2337/diabetes.51.1.144; Guan XM, 1998, MOL BRAIN RES, V59, P273, DOI 10.1016/S0169-328X(98)00150-8; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Haque MS, 1999, DIABETES, V48, P1706, DOI 10.2337/diabetes.48.9.1706; Harris RBS, 1998, BIOCHEM BIOPH RES CO, V245, P502, DOI 10.1006/bbrc.1998.8468; Harvey J, 1997, J PHYSIOL-LONDON, V504, P527, DOI 10.1111/j.1469-7793.1997.527bd.x; Harvey JA, 2000, J HIGH ENERGY PHYS; Havel PJ, 1998, AM J PHYSIOL-REG I, V274, pR1482, DOI 10.1152/ajpregu.1998.274.5.R1482; Hegele RA, 2000, MOL GENET METAB, V71, P539, DOI 10.1006/mgme.2000.3092; Hegele RA, 2001, TRENDS MOL MED, V7, P121, DOI 10.1016/S1471-4914(01)01930-X; HERVEY GR, 1959, J PHYSIOL-LONDON, V145, P336, DOI 10.1113/jphysiol.1959.sp006145; Heymsfield SB, 1999, JAMA-J AM MED ASSOC, V282, P1568, DOI 10.1001/jama.282.16.1568; Ingalls AM, 1996, OBES RES, V4, P101, DOI 10.1002/j.1550-8528.1996.tb00519.x; Ishizuka T, 1998, J NUTR, V128, P2299, DOI 10.1093/jn/128.12.2299; Islam MS, 2000, INT J OBESITY, V24, P1246, DOI 10.1038/sj.ijo.0801370; Kahn BB, 1996, DIABETES, V45, P1644, DOI 10.2337/diabetes.45.11.1644; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kamohara S, 1997, NATURE, V389, P374, DOI 10.1038/38717; Kellerer M, 1997, DIABETOLOGIA, V40, P1358, DOI 10.1007/s001250050832; Kellerer M, 2001, DIABETOLOGIA, V44, P1125, DOI 10.1007/s001250100614; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Kieffer TJ, 2000, AM J PHYSIOL-ENDOC M, V278, pE1, DOI 10.1152/ajpendo.2000.278.1.E1; Kieffer TJ, 1996, BIOCHEM BIOPH RES CO, V224, P522, DOI 10.1006/bbrc.1996.1059; Kieffer TJ, 1997, DIABETES, V46, P1087, DOI 10.2337/diabetes.46.6.1087; Kielar D, 1998, METABOLISM, V47, P844, DOI 10.1016/S0026-0495(98)90124-X; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; KRODER G, 1996, EXP CLIN ENDOCR S2, V104, P66; Larcher F, 2001, FASEB J, V15, P1529, DOI 10.1096/fj.01-0082com; Leclercq-Meyer V, 1998, MOL CELL ENDOCRINOL, V141, P111, DOI 10.1016/S0303-7207(98)00087-2; LeclercqMeyer V, 1996, BIOCHEM BIOPH RES CO, V229, P794, DOI 10.1006/bbrc.1996.1882; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; Liu YL, 1997, FEBS LETT, V411, P351, DOI 10.1016/S0014-5793(97)00732-1; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Mantzoros CS, 1999, ANN INTERN MED, V130, P671, DOI 10.7326/0003-4819-130-8-199904200-00014; Marti A, 1999, J PHYSIOL BIOCHEM, V55, P43; Mick G, 1998, METABOLISM, V47, P1360, DOI 10.1016/S0026-0495(98)90305-5; Ming MC, 1998, J LIPID RES, V39, P1655; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Minokoshi Y, 1999, DIABETES, V48, P287, DOI 10.2337/diabetes.48.2.287; Mizuno A, 1998, ENDOCRINOLOGY, V139, P3863, DOI 10.1210/en.139.9.3863; Mizuno A, 2001, REGUL PEPTIDES, V99, P41, DOI 10.1016/S0167-0115(01)00215-4; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Muller G, 1997, J BIOL CHEM, V272, P10585, DOI 10.1074/jbc.272.16.10585; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; Muoio DM, 1999, AM J PHYSIOL-ENDOC M, V276, pE913, DOI 10.1152/ajpendo.1999.276.5.E913; Muzzin P, 1996, P NATL ACAD SCI USA, V93, P14804, DOI 10.1073/pnas.93.25.14804; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Nemecz M, 1999, HEPATOLOGY, V29, P166, DOI 10.1002/hep.510290110; O'Rourke L, 2001, DIABETES, V50, P955, DOI 10.2337/diabetes.50.5.955; Ookuma M, 1998, DIABETES, V47, P219, DOI 10.2337/diabetes.47.2.219; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Ramsay TG, 2000, J ANIM SCI, V78, P1497; Ranganathan S, 1998, ENDOCRINOLOGY, V139, P2509, DOI 10.1210/en.139.5.2509; Ravussin E, 1997, NAT MED, V3, P238, DOI 10.1038/nm0297-238; Reitman ML, 2000, TRENDS ENDOCRIN MET, V11, P410, DOI 10.1016/S1043-2760(00)00309-X; Reitman ML, 2000, INT J OBESITY, V24, pS11, DOI 10.1038/sj.ijo.0801493; Reue K, 2000, Curr Atheroscler Rep, V2, P390, DOI 10.1007/s11883-000-0077-1; Rossetti L, 1997, J BIOL CHEM, V272, P27758, DOI 10.1074/jbc.272.44.27758; Rutter GA, 2000, CURR BIOL, V10, pR736, DOI 10.1016/S0960-9822(00)00737-5; Seeley RJ, 1996, HORM METAB RES, V28, P664, DOI 10.1055/s-2007-979874; Segal KR, 1996, DIABETES, V45, P988, DOI 10.2337/diabetes.45.7.988; SEIP M, 1959, ACTA PAEDIATR SCAND, V413, P2; Seufert J, 1999, J CLIN ENDOCR METAB, V84, P670, DOI 10.1210/jc.84.2.670; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimizu H, 1997, PEPTIDES, V18, P1263, DOI 10.1016/S0196-9781(97)00137-X; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Sivitz WI, 1997, ENDOCRINOLOGY, V138, P3395, DOI 10.1210/en.138.8.3395; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213; Strosberg AD, 1999, TRENDS PHARMACOL SCI, V20, P227, DOI 10.1016/S0165-6147(99)01313-9; Surwit RS, 1997, DIABETES, V46, P1516, DOI 10.2337/diabetes.46.9.1516; Surwit RS, 2000, DIABETES, V49, P1203, DOI 10.2337/diabetes.49.7.1203; Sweeney G, 2002, CELL SIGNAL, V14, P655, DOI 10.1016/S0898-6568(02)00006-2; Sweeney G, 2001, ENDOCRINOLOGY, V142, P4806, DOI 10.1210/en.142.11.4806; Sweeney G, 2000, ENDOCRINOLOGY, V141, P1277, DOI 10.1210/en.141.3.1277; Szanto I, 2000, P NATL ACAD SCI USA, V97, P2355, DOI 10.1073/pnas.050580497; Takaya K, 1996, NAT GENET, V14, P130, DOI 10.1038/ng1096-130; Tanizawa Y, 1997, ENDOCRINOLOGY, V138, P4513, DOI 10.1210/en.138.10.4513; Taylor SI, 1996, SCIENCE, V274, P1151, DOI 10.1126/science.274.5290.1151; Unger RH, 1997, TRENDS ENDOCRIN MET, V8, P276, DOI 10.1016/S1043-2760(97)00094-5; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; Walder K, 1997, J ENDOCRINOL, V155, pR5, DOI 10.1677/joe.0.155R005; Wang JL, 1999, ENDOCRINOLOGY, V140, P2117, DOI 10.1210/en.140.5.2117; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; Wang MY, 1998, P NATL ACAD SCI USA, V95, P714, DOI 10.1073/pnas.95.2.714; Wang MY, 1998, P NATL ACAD SCI USA, V95, P11921, DOI 10.1073/pnas.95.20.11921; Wang YP, 1997, J BIOL CHEM, V272, P16216, DOI 10.1074/jbc.272.26.16216; Widdowson PS, 1998, HORM METAB RES, V30, P259, DOI 10.1055/s-2007-978879; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yaspelkis BB, 2001, AM J PHYSIOL-ENDOC M, V280, pE130, DOI 10.1152/ajpendo.2001.280.1.E130; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao AZ, 2000, J BIOL CHEM, V275, P11348, DOI 10.1074/jbc.275.15.11348; Zierath JR, 1998, DIABETES, V47, P1, DOI 10.2337/diabetes.47.1.1; Zierath JR, 2000, DIABETOLOGIA, V43, P821, DOI 10.1007/s001250051457	143	202	214	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1163	10.1096/fj.02-0158rev	http://dx.doi.org/10.1096/fj.02-0158rev			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153984				2022-12-28	WOS:000177814000025
J	Walther, T; Siems, WE; Hauke, D; Spillmann, F; Dendorfer, A; Krause, W; Schultheiss, HP; Tschope, C				Walther, T; Siems, WE; Hauke, D; Spillmann, F; Dendorfer, A; Krause, W; Schultheiss, HP; Tschope, C			AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats	FASEB JOURNAL			English	Article						bradykinin; enzymes; hemodynamics; inhibitors; neutral endopeptidase; renin-angiotensin system	ANGIOTENSIN-CONVERTING ENZYME; KININ SYSTEM; INHIBITION; EXPRESSION; OMAPATRILAT; HEART	ACE inhibition protects the heart against ischemic injury by reducing angiotensin II and promoting bradykinin (BK) accumulation. Since neutral endopeptidase (NEP) metabolizes BK, we determined its activity after induction of myocardial infarction (MI) and examined whether it is influenced by treatment with an ACE inhibitor or AT1 receptor blocker. Rats were studied 6 days and 3 wk after coronary occlusion. Starting 48 h after MI induction, additional animals were treated with the ACE inhibitor quinapril (2 mg.kg(-1).day(-1)) or the AT1 blocker irbesartan (50 mg.kg(-1).day(-1)). Animals were hemodynamically characterized. Finally, NEP-specific activity and BK concentrations were detected in homogenates of heart compartments. Quinapril and irbesartan treatment improved left ventricular function 6 days and 3 wk after MI induction, and NEP activity was elevated only in the infarcted area of untreated compared with sham-operated rats. After 6 days, irbesartan reversed this increase by 80% and quinapril by 35%. Quinapril had no effect after 3 wk, whereas irbesartan almost completely blocked the increased NEP activity in the infarcted area and concomitantly induced a further rise in the BK concentrations. These results indicate mechanisms of NEP regulation influenced by the AT1 receptor. Our data suggest that NEP is more decisive than ACE in mediating BK degradation and may indicate BK involvement in the cardioprotective effects of AT1 antagonists.	Free Univ Berlin, Dept Cardiol & Pneumol, D-1000 Berlin, Germany; Inst Mol Pharmacol, Berlin, Germany; Med Univ Lubeck, Inst Pharmacol, Lubeck, Germany	Free University of Berlin; University of Lubeck	Walther, T (corresponding author), Free Univ Berlin, Univ Hosp Benjamin Franklin, Dept Cardiol & Pneumol, Hindenburgdamm 30, D-12200 Berlin, Germany.	thomas.walther@ukbf.fu-berlin.de		Spillmann, Frank/0000-0003-0002-5745; Tschope, Carsten/0000-0001-5243-8985				Bischoff A, 1999, PFLUG ARCH EUR J PHY, V438, P797, DOI 10.1007/s004240051109; Blais C, 2001, PEPTIDES, V22, P953, DOI 10.1016/S0196-9781(01)00401-6; HASHIMOTO K, 1978, AM HEART J, V95, P619, DOI 10.1016/0002-8703(78)90304-6; Jalowy A, 1998, J AM COLL CARDIOL, V32, P1787, DOI 10.1016/S0735-1097(98)00441-0; Kokkonen JO, 1999, CIRCULATION, V99, P1984, DOI 10.1161/01.CIR.99.15.1984; Liu YH, 1997, J CLIN INVEST, V99, P1926, DOI 10.1172/JCI119360; Maeda K, 2000, J APPL PHYSIOL, V89, P458, DOI 10.1152/jappl.2000.89.2.458; Marie C, 1996, CARDIOVASC DRUG THER, V10, P593, DOI 10.1007/BF00051002; NIO Y, 1995, J CLIN INVEST, V95, P46, DOI 10.1172/JCI117675; Trippodo NC, 1999, J CARDIOVASC PHARM, V34, P782, DOI 10.1097/00005344-199912000-00003; Tschope C, 2002, J CARDIOVASC PHARM, V39, P478, DOI 10.1097/00005344-200204000-00003; Tschope C, 2000, J HYPERTENS, V18, P223, DOI 10.1097/00004872-200018020-00014; Tschope C, 1997, J Card Fail, V3, P133, DOI 10.1016/S1071-9164(97)90047-6; Tschope C, 2000, BRIT J PHARMACOL, V129, P1537, DOI 10.1038/sj.bjp.0703239; Tsutsumi Y, 1999, J CLIN INVEST, V104, P925, DOI 10.1172/JCI7886; Turner AJ, 1997, FASEB J, V11, P355, DOI 10.1096/fasebj.11.5.9141502; Winkler A, 1998, ALCOHOL CLIN EXP RES, V22, P1262, DOI 10.1097/00000374-199809000-00011; Yang XP, 1997, J CARDIOVASC PHARM, V29, P250, DOI 10.1097/00005344-199702000-00014	18	21	24	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1237	10.1096/fj.01-0641com	http://dx.doi.org/10.1096/fj.01-0641com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153991				2022-12-28	WOS:000177814000032
J	Wayman, NS; Hattori, Y; Mcdonald, MC; Mota-Filipe, H; Cuzzocrea, S; Pisano, B; Chatterjee, PK; Thiemermann, C				Wayman, NS; Hattori, Y; Mcdonald, MC; Mota-Filipe, H; Cuzzocrea, S; Pisano, B; Chatterjee, PK; Thiemermann, C			Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size	FASEB JOURNAL			English	Article						ischemia-reperfusion; infarction; PPAR; heart; adhesion molecules; inducible nitric oxide synthase; reperfusion injury	NF-KAPPA-B; ISCHEMIA-REPERFUSION; INJURY; INTERLEUKIN-1-BETA; PROSTAGLANDINS; IDENTIFICATION; INFLAMMATION; INHIBITOR; REGULATOR; KINASE	This study was designed to investigate the effects of various chemically distinct activators of PPAR-gamma and PPAR-alpha in a rat model of acute myocardial infarction. Using Northern blot analysis and RT-PCR in samples of rat heart, we document the expression of the mRNA for PPAR-gamma (isoform 1 but not isoform 2) as well as PPAR-beta and PPAR-alpha in freshly isolated cardiac myocytes and cardiac fibroblasts and in the left and right ventricles of the heart. Using a rat model of regional myocardial ischemia and reperfusion (in vivo), we have discovered that various chemically distinct ligands of PPAR-gamma (including the TZDs rosiglitazone, ciglitazone, and pioglitazone, as well as the cyclopentanone prostaglandins 15D-PGJ(2) and PGA(1)) cause a substantial reduction of myocardial infarct size in the rat. We demonstrate that two distinct ligands of PPAR-gamma (including clofibrate and WY 14643) also cause a substantial reduction of myocardial infarct size in the rat. The most pronounced reduction in infarct size was observed with the endogenous PPAR-gamma ligand, 15-deoxyDelta(12,14)-prostagalndin J(2) (15D- PGJ(2)). The mechanisms of the cardioprotective effects of 15D- PGJ(2) may include 1) activation of PPAR-alpha, 2) activation of PPAR-gamma, 3) expression of HO-1, and 4) inhibition of the activation of NF-kappaB in the ischemic-reperfused heart. Inhibition by 15D- PGJ2 of the activation of NF-kappaB in turn results in a reduction of the 1) expression of inducible nitric oxide synthase and the nitration of proteins by peroxynitrite, 2) formation of the chemokine MCP-1, and 3) expression of the adhesion molecule ICAM-1. We speculate that ligands of PPAR-gamma and PPAR-alpha may be useful in the therapy of conditions associated with ischemia-reperfusion of the heart and other organs. Our findings also imply that TZDs and fibrates may help protect the heart against ischemia-reperfusion injury. This beneficial effect of 15D- PGJ(2) was associated with a reduction in the expression of the 1) adhesion molecules ICAM-1 and P-selectin, 2) chemokine macrophage chemotactic protein 1, and 3) inducible isoform of nitric oxide synthase. 15D- PGJ(2) reduced the nitration of proteins (immunohistological analysis of nitrotyrosine formation) caused by ischemia-reperfusion, likely due to the generation of peroxynitrite. Not all of the effects of 15D-PGJ(2), however, are due to the activation of PPAR-gamma. For instance, exposure of rat cardiac myocytes to 15D-PGJ(2), but not to rosiglitazone, results in an up-regulation of the expression of the mRNA for heme-oxygenase-1 (HO-1). Taken together, these results provide convincing evidence that several, chemically distinct ligands of PPAR-gamma reduce the tissue necrosis associated with acute myocardial infarction.	St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Dept Expt Med & Nephrol, London EC1M 6BQ, England; Dokkyo Univ, Sch Med, Dept Endocrinol, Mibu, Tochigi 32102, Japan; Univ Lisbon, Fac Pharm, Pharmacol Lab, P-1699 Lisbon, Portugal; Univ Messina, Sch Med, Inst Pharmacol, I-98123 Messina, Italy; Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy	University of London; Queen Mary University London; Dokkyo Medical University; Universidade de Lisboa; University of Messina; University of Naples Federico II	Thiemermann, C (corresponding author), St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Dept Expt Med & Nephrol, Charterhouse Sq, London EC1M 6BQ, England.	c.thiemermann@mds.qmw.ac.uk	Mota-Filipe, Helder/M-6199-2019; Mota-Filipe, Helder/M-6298-2013; Mota-Filipe, Helder/GSE-1539-2022	Mota-Filipe, Helder/0000-0003-3045-2553; Mota-Filipe, Helder/0000-0003-3045-2553; Mota-Filipe, Helder/0000-0003-3045-2553; Thiemermann, Christoph/0000-0003-4228-9722				ADAMS JE, 1993, CIRCULATION, V88, P750, DOI 10.1161/01.CIR.88.2.750; Behr TM, 2000, CIRCULATION, V102, P1315, DOI 10.1161/01.CIR.102.11.1315; Bishop-Bailey D, 2000, BRIT J PHARMACOL, V129, P823, DOI 10.1038/sj.bjp.0703149; Chandrasekar B, 2001, CIRCULATION, V103, P2296; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; Cuzzocrea S, 1997, BRIT J PHARMACOL, V121, P1065, DOI 10.1038/sj.bjp.0701234; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; GAUTHIER TW, 1994, AM J PHYSIOL-GASTR L, V267, pG562, DOI 10.1152/ajpgi.1994.267.4.G562; HATTORI Y, 1993, BIOCHEM BIOPH RES CO, V195, P435, DOI 10.1006/bbrc.1993.2062; Horio T, 1998, ENDOCRINOLOGY, V139, P4576, DOI 10.1210/en.139.11.4576; Izumi T, 2001, J CLIN INVEST, V108, P203, DOI 10.1172/JCI12088; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Manning AM, 1995, J INFLAMM, V45, P283; MARBER MS, 1993, CIRCULATION, V88, P1264, DOI 10.1161/01.CIR.88.3.1264; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Murphy GJ, 2000, TRENDS PHARMACOL SCI, V21, P469, DOI 10.1016/S0165-6147(00)01559-5; NACHLAS MM, 1963, AM J PATHOL, V42, P379; Nakajima A, 2001, GASTROENTEROLOGY, V120, P460, DOI 10.1053/gast.2001.21191; REMPPIS A, 1994, BRIT HEART J, V71, P242; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Roberts ML, 1998, BIOCHEM BIOPH RES CO, V251, P166, DOI 10.1006/bbrc.1998.9434; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Telek G, 2001, J SURG RES, V96, P56, DOI 10.1006/jsre.2000.6052; Thiemermann C, 2000, PHARMACOL THERAPEUT, V87, P61, DOI 10.1016/S0163-7258(00)00069-3; TIYUE TL, 2001, CIRCULATION, V104, P2588; VILLARREAL FJ, 1993, CIRCULATION, V88, P2849, DOI 10.1161/01.CIR.88.6.2849; Wayman N, 2001, EUR J PHARMACOL, V430, P93, DOI 10.1016/S0014-2999(01)01359-0; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Young PW, 1998, J PHARMACOL EXP THER, V284, P751	33	338	363	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2002	16	9					1027	1040		10.1096/fj.01-0793com	http://dx.doi.org/10.1096/fj.01-0793com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087064				2022-12-28	WOS:000177813100034
J	Wiemann, SU; Satyanarayana, A; Tsahuridu, M; Tillmann, HL; Zender, L; Klempnauer, J; Flemming, P; Franco, S; Blasco, MA; Manns, MP; Rudolph, KL				Wiemann, SU; Satyanarayana, A; Tsahuridu, M; Tillmann, HL; Zender, L; Klempnauer, J; Flemming, P; Franco, S; Blasco, MA; Manns, MP; Rudolph, KL			Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis	FASEB JOURNAL			English	Article						telomerase; regeneration; chronic disease; fibrosis; stellate cell activation	IN-VIVO; HEPATOCELLULAR CARCINOMAS; REPLICATIVE SENESCENCE; PROLIFERATIVE ACTIVITY; HEPATIC REGENERATION; MICE; CARCINOGENESIS; TUMORIGENESIS; DYSFUNCTION; FIBROBLASTS	Telomere shortening limits the number of cell divisions of primary human cells and might affect the regenerative capacity of organ systems during aging and chronic disease. To test whether the telomere hypothesis applies to human cirrhosis, the telomere length was monitored in cirrhosis induced by a broad variety of different etiologies. Telomeres were significantly shorter in cirrhosis compared with noncirrhotic samples independent of the primary etiology and independent of the age of the patients. Quantitative fluorescence in situ hybridization showed that telomere shortening was restricted to hepatocytes whereas lymphocytes and stellate cells in areas of fibrosis had significantly longer telomere reserves. Hepatocyte-specific telomere shortening correlated with senescence-associated beta-galactosidase staining in 84% of the cirrhosis samples, specifically in hepatocytes, but not in stellate cells or lymphocytes. Hepatocyte telomere shortening and senescence correlated with progression of fibrosis in cirrhosis samples. This study demonstrates for the first time that cell type-specific telomere shortening and senescence are linked to progression of human cirrhosis. These findings give a novel explanation for the pathophysiology of cirrhosis, indicating that fibrotic scarring at the cirrhosis stage is a consequence of hepatocyte telomere shortening and senescence. The data imply that future therapies aiming to restore regenerative capacity during aging and chronic diseases will have to ensure efficient targeting of specific cell types within the affected organs.	Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Visceral Surg, D-30625 Hannover, Germany; Hannover Med Sch, Dept Pathol, D-30625 Hannover, Germany; CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid, Spain	Hannover Medical School; Hannover Medical School; Hannover Medical School; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Rudolph, KL (corresponding author), Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Rudolph.Lenhard@MH-Hannover.de	Blasco, Maria A./M-1694-2014	Blasco, Maria A./0000-0002-4211-233X; Rudolph, Karl Lenhard/0000-0002-4839-2862				Aikata H, 2000, EXP CELL RES, V256, P578, DOI 10.1006/excr.2000.4862; Albrecht JH, 1997, HEPATOLOGY, V25, P557, DOI 10.1002/hep.510250311; Alcolado R, 1997, CLIN SCI, V92, P103, DOI 10.1042/cs0920103; ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; Ball SE, 1998, BLOOD, V91, P3582; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bond J, 1996, ONCOGENE, V13, P2097; Boultwood J, 2000, BLOOD, V96, P358, DOI 10.1182/blood.V96.1.358.013k16_358_361; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Delhaye M, 1996, HEPATOLOGY, V23, P1003, DOI 10.1002/hep.510230510; Delhaye M, 1999, J HEPATOL, V30, P461, DOI 10.1016/S0168-8278(99)80106-8; DIMRI GP, 1994, COLD SPRING HARB SYM, V59, P67, DOI 10.1101/SQB.1994.059.01.010; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Effros RB, 2000, MICROBES INFECT, V2, P69, DOI 10.1016/S1286-4579(00)00283-5; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Kaita KDE, 1997, LIVER, V17, P13; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KITADA T, 1995, BIOCHEM BIOPH RES CO, V211, P33, DOI 10.1006/bbrc.1995.1774; LIVNI N, 1995, CANCER, V75, P2420, DOI 10.1002/1097-0142(19950515)75:10<2420::AID-CNCR2820751006>3.0.CO;2-6; Miura N, 1997, CANCER GENET CYTOGEN, V93, P56, DOI 10.1016/S0165-4608(96)00329-9; Nakayama JI, 1998, NAT GENET, V18, P65, DOI 10.1038/ng0198-65; Paradis V, 2001, HUM PATHOL, V32, P327, DOI 10.1053/hupa.2001.22747; POON SSS, 2001, CURRENT PROTOCOLS CE; RUDI J, 1995, J HEPATOL, V22, P43, DOI 10.1016/0168-8278(95)80258-4; Rudolph KL, 2000, SCIENCE, V287, P1253, DOI 10.1126/science.287.5456.1253; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; RUDOLPH KL, 2001, LIVER BIOL PATHOBIOL, P1000; Severino J, 2000, EXP CELL RES, V257, P162, DOI 10.1006/excr.2000.4875; Urabe Y, 1996, LIVER, V16, P293; Vaziri H, 1996, EXP GERONTOL, V31, P295, DOI 10.1016/0531-5565(95)02025-X; Williams EJ, 1998, POSTGRAD MED J, V74, P193, DOI 10.1136/pgmj.74.870.193	35	377	400	1	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2002	16	9					935	942		10.1096/fj.01-0977com	http://dx.doi.org/10.1096/fj.01-0977com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12087054				2022-12-28	WOS:000177813100024
J	Flynn, CR; Komalavilas, P; Tessier, D; Thresher, J; Niederkofler, EE; Dreiza, CM; Nelson, RW; Panitch, A; Joshi, L; Brophy, CM				Flynn, CR; Komalavilas, P; Tessier, D; Thresher, J; Niederkofler, EE; Dreiza, CM; Nelson, RW; Panitch, A; Joshi, L; Brophy, CM			Transduction of biologically active motifs of the small heat shock-related protein, HSP20, leads to relaxation of vascular smooth muscle	FASEB JOURNAL			English	Article						protein transduction; mass spectrometric immunoassay (MSIA) phospho-peptide analogs	SIGNAL-TRANSDUCTION; RAT SKELETAL; IN-VIVO; PHOSPHORYLATION; DELIVERY; INSULIN; INHIBITION; SERINE-16; ARTERY; P20	Activation of cyclic nucleotide-dependent signaling pathways leads to phosphorylation of the small heat shock-related protein, HSP20, on serine 16, and relaxation of vascular smooth muscle. In this study, we used an enhanced protein transduction domain (PTD) sequence to deliver HSP20 phosphopeptide analogs into porcine coronary artery. The transduction of phosphoHSP20 analogs led to dose-dependent relaxation of coronary artery smooth muscle. Peptides containing the protein transduction domain coupled to a random orientation of the same amino acids did not. Direct fluorescence microscopy of arterial rings incubated with fluorescein isothiocyanate (FITC)-PTD or FITC-PTD-HSP20 peptides showed a diffuse peptide uptake. Mass spectrometric immunoassays (MSIAs) of smooth muscle homogenates were used to determine whether the phosphopeptide analogs affected the phosphorylation of endogenous HSP20. Treatment with the phosphodiesterase inhibitor papaverine led to a mass shift of 80 Da. However, there was no mass shift of HSP20 in muscles treated with phosphoHSP20 analogs. This suggests that the PTD-phosphoHSP20 peptide alone is sufficient to inhibit force maintenance and likely has a direct effect on the target of phosphorylated HSP20. These results suggest that transduction of phosphopeptide analogs of HSP20 directly alters physiological responses of intact muscles. The data also support a direct role for phosphorylated HSP20 in mediating vasorelaxation.	Arizona State Univ, Dept Bioengn, Tempe, AZ 85287 USA; Carl T Hayden Vet Affairs Med Ctr, Phoenix, AZ USA; Mayo Clin Jacksonville, Dept Surg, Scottsdale, AZ 85259 USA; Arizona State Univ, Dept Kinesiol, Tempe, AZ 85287 USA; Intrins Bioprobes Inc, Tempe, AZ 85281 USA; Arizona State Univ, Dept Plant Biol, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Mayo Clinic; Mayo Clinic Phoenix; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Brophy, CM (corresponding author), Arizona State Univ, Dept Bioengn, Tempe, AZ 85287 USA.	colleen.brophy@asu.edu	Panitch, Alyssa/F-4413-2012; Flynn, Charles/M-3895-2015	Flynn, Charles/0000-0002-3749-0598; Joshi, Lokesh/0000-0002-3612-0747				Beall A, 1999, J BIOL CHEM, V274, P11344, DOI 10.1074/jbc.274.16.11344; Beall AC, 1997, J BIOL CHEM, V272, P11283; BERGH CM, 1995, AM J PHYSIOL-HEART C, V268, pH202, DOI 10.1152/ajpheart.1995.268.1.H202; Brophy CM, 1997, BIOL REPROD, V57, P1354, DOI 10.1095/biolreprod57.6.1354; Brophy CM, 2000, AM J PHYSIOL-HEART C, V278, pH991, DOI 10.1152/ajpheart.2000.278.3.H991; Brophy CM, 1999, J VASC SURG, V29, P326, DOI 10.1016/S0741-5214(99)70385-X; Brophy CM, 1999, J BIOL CHEM, V274, P6324, DOI 10.1074/jbc.274.10.6324; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; DOGRUEL D, 1995, ANAL CHEM, V67, P4343, DOI 10.1021/ac00119a022; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Fuchs LC, 2000, AM J PHYSIOL-REG I, V279, pR492, DOI 10.1152/ajpregu.2000.279.2.R492; Ho A, 2001, CANCER RES, V61, P474; Jerius H, 1999, J VASC SURG, V29, P678, DOI 10.1016/S0741-5214(99)70314-9; KATO K, 1994, J BIOL CHEM, V269, P15302; Knoepp L, 2000, J VASC SURG, V31, P343, DOI 10.1016/S0741-5214(00)90164-2; Pipkin W, 2003, CIRCULATION, V107, P469, DOI 10.1161/01.CIR.0000044386.27444.5A; Rembold CM, 2001, J APPL PHYSIOL, V91, P1460, DOI 10.1152/jappl.2001.91.3.1460; Rembold CM, 2000, J PHYSIOL-LONDON, V524, P865, DOI 10.1111/j.1469-7793.2000.00865.x; Sandu OA, 2001, J APPL PHYSIOL, V91, P1475, DOI 10.1152/jappl.2001.91.3.1475; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Tubbs KA, 2001, ANAL BIOCHEM, V289, P26, DOI 10.1006/abio.2000.4921; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Wang Y, 1999, BIOCHEM J, V344, P971, DOI 10.1042/0264-6021:3440971; Wang Y, 1999, FEBS LETT, V462, P25, DOI 10.1016/S0014-5793(99)01496-9; Woodrum DA, 1999, AM J PHYSIOL-HEART C, V277, pH931, DOI 10.1152/ajpheart.1999.277.3.H931	27	53	57	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1358	+		10.1096/fj.02-1028fje	http://dx.doi.org/10.1096/fj.02-1028fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738803				2022-12-28	WOS:000183165000025
J	Schafer, T; Scheuer, C; Roemer, K; Menger, MD; Vollmar, B				Schafer, T; Scheuer, C; Roemer, K; Menger, MD; Vollmar, B			Inhibition of p53 protects liver tissue against endotoxin-induced apoptotic and necrotic cell death	FASEB JOURNAL			English	Article						apoptosis; necrosis; pifithrin-alpha; LPS; microcirculation; caspase 3; NF-kappa B; ICAM-1; intravital fluorescence microscopy; bisbenzimide	TUMOR-NECROSIS-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; MULTIPLE ORGAN FAILURE; NF-KAPPA-B; IN-VIVO; HEPATOCELLULAR APOPTOSIS; HEPATOCYTE APOPTOSIS; PERFUSION FAILURE; MURINE MODEL; SHOCK MODEL	There is increasing evidence that apoptotic and necrotic hepatocyte death following endotoxin-induced liver injury act as signals for leukocyte sequestration in the liver vasculature. p53 has been implicated to promote apoptosis through traps-activation and down-regulation of specific pro- and antiapoptotic genes. Here, we report that inhibition of p53 decreases apoptotic and necrotic tissue injury as well as inflammatory cell response. Sprague-Dawley rats were injected intraperitoneally with 2.2 mg/kg pifithrin-a (PFT), a p53-inactivating agent, or the vehicle DMSO 30 min before intravenous exposure to lipopolysaccharide (LPS). In vehicle-pretreated animals, LPS induced significant apoptosis and necrosis of hepatocytes, which was associated with intrahepatic leukocyte recruitment, microvascular dysfunction, and enzyme release. Inhibition of p53 effectively attenuated (P<0.05) hepatocellular apoptosis and necrosis, but also reduced leukocyte recruitment and microvascular dysfunction. Western blot analysis revealed that PFT lowered the nuclear-to-cytoplasmic p53 ratio and reduced both activation of NF-kappa B and cleavage of procaspase 3 (P<0.05). In parallel, immunohistochemistry of PFT-pretreated, but not vehicle-pretreated, endotoxic animals exhibited nuclear p53 exclusion and reduced NF-kappaB p65 staining. This indicates that p53 mediates, at least in part, LPS-associated apoptosis and contributes to inflammatory endotoxic tissue injury through leukocyte activation and intraorgan sequestration.	Univ Rostock, Dept Expt Surg, D-18055 Rostock, Germany; Univ Saarland, Inst Clin & Expt Surg, D-66421 Homburg, Germany; Univ Saarland, Dept Virol, D-66421 Homburg, Germany	University of Rostock; Saarland University; Saarland University	Vollmar, B (corresponding author), Univ Rostock, Dept Expt Surg, D-18055 Rostock, Germany.	brigitte.vollmar@med.uni-rostock.de						BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BAUE AE, 1994, SHOCK, V2, P385, DOI 10.1097/00024382-199412000-00001; Burns M, 1999, WESTERN HUM REV, V53, P239; CLEMENS MG, 1985, AM J PHYSIOL, V248, pH804, DOI 10.1152/ajpheart.1985.248.6.H804; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; Essani NA, 1996, J IMMUNOL, V156, P2956; Gantner F, 1995, EUR J PHARMACOL, V294, P353, DOI 10.1016/0014-2999(95)00724-5; Haendeler J, 1996, SHOCK, V6, P405, DOI 10.1097/00024382-199612000-00004; HARRIS NR, 1994, CIRC SHOCK, V43, P155; Jaeschke H, 1996, SHOCK, V6, P351, DOI 10.1097/00024382-199611000-00009; Jaeschke H, 1997, J LEUKOCYTE BIOL, V61, P647, DOI 10.1002/jlb.61.6.647; Jaeschke H, 1997, AM J PHYSIOL-GASTR L, V273, pG602, DOI 10.1152/ajpgi.1997.273.3.G602; Jaeschke H, 1998, J IMMUNOL, V160, P3480; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lawson JA, 1998, HEPATOLOGY, V28, P761, DOI 10.1002/hep.510280324; LEIST M, 1995, J IMMUNOL, V154, P1307; LEIST M, 1995, AM J PATHOL, V146, P1220; LIVINGSTON DH, 1995, ANN MED, V27, P13, DOI 10.3109/07853899509031931; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Menger MD, 2000, MICROCIRCULATION, V7, P291, DOI 10.1038/sj.mn.7300117; Morikawa A, 1996, INFECT IMMUN, V64, P734, DOI 10.1128/IAI.64.3.734-738.1996; Rogers HW, 1996, J IMMUNOL, V156, P679; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Tsuji H, 1997, INFECT IMMUN, V65, P1892, DOI 10.1128/IAI.65.5.1892-1898.1997; VOLLMAR B, 1994, AM J PHYSIOL-GASTR L, V267, pG786, DOI 10.1152/ajpgi.1994.267.5.G786; VOLLMAR B, 1995, J HEPATOL, V23, P613, DOI 10.1016/0168-8278(95)80070-0; VOLLMAR B, 1994, AM J PATHOL, V145, P1421; Wanner GA, 1999, FASEB J, V13, P1239, DOI 10.1096/fasebj.13.10.1239; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	33	90	94	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					660	667		10.1096/fj.02-0774com	http://dx.doi.org/10.1096/fj.02-0774com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665479				2022-12-28	WOS:000182580100011
J	Umeda, J; Sano, S; Kogawa, K; Motoyama, N; Yoshikawa, K; Itami, S; Kondoh, G; Watanabe, T; Takeda, J				Umeda, J; Sano, S; Kogawa, K; Motoyama, N; Yoshikawa, K; Itami, S; Kondoh, G; Watanabe, T; Takeda, J			In vivo cooperation between Bcl-x(L) and the phosphoinositide 3-kinase-Akt signaling pathway for the protection of epidermal keratinocytes from apoptosis	FASEB JOURNAL			English	Article						Cre-LoxP; UVB irradiation; sunburn cells	GROWTH-FACTOR RECEPTOR; BCL-X EXPRESSION; CELL-DEATH; IN-VIVO; PROTEIN FAMILY; CYTOCHROME-C; SURVIVAL; STAT3; MICE; MITOCHONDRIA	To investigate the function of Bcl-x(L) in the skin, we established keratinocyte-specific Bcl-x gene-targeted mice under the keratin 5 promoter (K5). K5.Bcl-x(L)-/- mice were viable, devoid of alteration in the development of skin or appendages. However, they harbored spontaneous apoptotic keratinocytes in the epidermis. Bcl-x(L)-deficient keratinocytes cultured in vitro readily underwent apoptosis in the absence of growth factors, but the addition of HGF or EGF resulted in restoration of cell survival, which was reversed by treatment with wortmannin, an inhibitor of phosphoinositide-3 kinase (PI3K). Topical treatment of K5.Bcl-x(L)-/- mice with wortmannin sensitized the skin for apoptosis induced by UV (UV) B, although wild-type epidermis was only marginally affected by this treatment, suggesting that the resistance to UVB largely depended on PI3KAkt signaling in Bcl-xL deficient mice but not in wild-type mice. Furthermore, UVB irradiation resulted in redistribution of phosphorylated Akt from the basal layer to the suprabasal layer, indicating that Akt could spatially cooperate with Bcl-xL upon UVB exposure in the upper epidermis where Bcl-xL is normally localized. These results suggest that Bcl-xL and the PI3KAkt pathway form a cooperative, intercompensatory axis for the protection of epidermal keratinocytes from apoptosis in vivo.	Osaka Univ, Grad Sch Med, Dept Dermatol, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Social & Environm Med, Osaka 5650871, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol Immunol, Fukuoka 8128582, Japan	Osaka University; Osaka University; Kyushu University	Sano, S (corresponding author), Osaka Univ, Grad Sch Med, Dept Dermatol, 2-2 Yamadaoka, Osaka 5650871, Japan.	sano@derma.med.osaka-u.ac						Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grillot DAM, 1997, J IMMUNOL, V158, P4750; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Jost M, 1999, J INVEST DERMATOL, V112, P443, DOI 10.1046/j.1523-1747.1999.00543.x; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kondo S, 1996, INT J CANCER, V68, P727, DOI 10.1002/(SICI)1097-0215(19961211)68:6<727::AID-IJC6>3.0.CO;2-5; Krajewska M, 1996, CANCER RES, V56, P2422; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Kulms D, 2000, PHOTODERMATOL PHOTO, V16, P195, DOI 10.1034/j.1600-0781.2000.160501.x; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Pena JC, 1999, EMBO J, V18, P3596, DOI 10.1093/emboj/18.13.3596; Pena JC, 1997, CELL GROWTH DIFFER, V8, P619; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; Rodeck U, 1997, J CELL SCI, V110, P113; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; Sano S, 2000, P NATL ACAD SCI USA, V97, P13824, DOI 10.1073/pnas.240303097; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schwarz T, 1998, J PHOTOCH PHOTOBIO B, V44, P91, DOI 10.1016/S1011-1344(98)00126-2; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Taylor JK, 1999, ONCOGENE, V18, P4495, DOI 10.1038/sj.onc.1202836; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	49	42	42	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					610	620		10.1096/fj.02-0597com	http://dx.doi.org/10.1096/fj.02-0597com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12665473				2022-12-28	WOS:000182580100005
J	Bek, MJ; Wahle, S; Muller, B; Benzing, T; Huber, TB; Kretzler, M; Cohen, C; Busse-Grawitz, A; Pavenstadt, H				Bek, MJ; Wahle, S; Muller, B; Benzing, T; Huber, TB; Kretzler, M; Cohen, C; Busse-Grawitz, A; Pavenstadt, H			Stra13, a prostaglandin E-2-induced gene, regulates the cellular redox state of podocytes	FASEB JOURNAL			English	Article						retinoic acid; oxidative stress; heme oxygenase 1; cytoprotection	RETINOID-X-RECEPTORS; HEME OXYGENASE-1; PROSTANOID RECEPTORS; NAD(P)H OXIDASE; MESANGIAL CELLS; EXPRESSION; INDUCTION; ROLES; ACID; DIFFERENTIATION	Podocyte injury is a central mechanism in the pathogenesis of proteinuria. Prostaglandin E-2 (PGE(2)) has been suggested to protect podocytes from cellular injury. Here we investigated whether PGE(2)-induced gene expression accounts for the protective role of PGE(2) in podocytes. Using a suppressive-subtractive hybridization method, we isolated a differentially expressed clone that was identified as Stra13, a recently described retinoic acid-inducible gene. PGE(2), forskolin, and retinoic acid induced a time-dependent up-regulation of Stra13 mRNA and protein expression in podocytes. To test the function of Stra13 in podocytes, Stra13 was overexpressed by using retroviral gene transfer. Compared with control cells, cells overexpressing Stra13 showed markedly reduced NADPH-dependent superoxid anion generation. Furthermore, expression of heme oxygenase 1 (HO-1) was increased in podocytes overexpressing Stra13. HO-1 plays an important protective role in the defense against reactive oxygen species (ROS). After stimulation with exogenous ROS, Stra13-overexpressing podocytes were more resistant to oxidative stress than were control cells. Our data indicate that Stra13 may play an important protective role against oxidative stress in podocytes. ROS are involved in the pathogenesis of glomerular inflammation in several forms of glomerulonephritis. Therefore, knowledge about protective mechanisms may provide insight into new therapeutic strategies for glomerulopathies.	Freiburg Univ Hosp, Div Nephrol, Dept Med, Freiburg, Germany; Univ Munich, Med Poliklin, D-8000 Munich, Germany	University of Freiburg; University of Munich	Pavenstadt, H (corresponding author), Freiburg Univ Clin, Dept Internal Med, Div Nephrol, Hugstetter Str 55, D-79106 Freiburg, Germany.	paven@med1.ukl.uni-freiburg.de	Benzing, Thomas/X-5476-2019	Huber, Tobias B./0000-0001-7175-5062				Agarwal A, 2000, J AM SOC NEPHROL, V11, P965, DOI 10.1681/ASN.V115965; Baranano DE, 2001, P NATL ACAD SCI USA, V98, P10996, DOI 10.1073/pnas.191351298; Bek M, 1999, J AM SOC NEPHROL, V10, P2084; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Datta PK, 1999, J AM SOC NEPHROL, V10, P2540; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; Greiber S, 1998, KIDNEY INT, V53, P654, DOI 10.1046/j.1523-1755.1998.00796.x; Greiber S, 2002, J AM SOC NEPHROL, V13, P86, DOI 10.1681/ASN.V13186; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Gwinner W, 2000, NEPHROL DIAL TRANSPL, V15, P1127, DOI 10.1093/ndt/15.8.1127; HEIFETS M, 1987, KIDNEY INT, V32, P335, DOI 10.1038/ki.1987.214; Kanwar YS, 2001, KIDNEY INT, V59, P378, DOI 10.1046/j.1523-1755.2001.00505.x; KERJASCHKI D, 1994, KIDNEY INT, V45, P300, DOI 10.1038/ki.1994.39; Konta T, 2001, J BIOL CHEM, V276, P12697, DOI 10.1074/jbc.M011000200; Lucio-Cazana J, 2001, J AM SOC NEPHROL, V12, P688, DOI 10.1681/ASN.V124688; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Manzano VM, 2000, BRIT J PHARMACOL, V131, P1673, DOI 10.1038/sj.bjp.0703728; Morath R, 1999, J AM SOC NEPHROL, V10, P1851; Mosley K, 1998, KIDNEY INT, V53, P672, DOI 10.1046/j.1523-1755.1998.00798.x; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; NEALE TJ, 1993, P NATL ACAD SCI USA, V90, P3645, DOI 10.1073/pnas.90.8.3645; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; Pavenstadt H, 2000, AM J PHYSIOL-RENAL, V278, pF173, DOI 10.1152/ajprenal.2000.278.2.F173; RODEWALD R, 1974, J CELL BIOL, V60, P423, DOI 10.1083/jcb.60.2.423; Shen M, 2001, EUR J CELL BIOL, V80, P329, DOI 10.1078/0171-9335-00167; SRAER JD, 1982, KIDNEY INT, V21, pS63; STAHL RAK, 1987, KIDNEY INT, V31, P1126, DOI 10.1038/ki.1987.118; Sugawara A, 1997, ENDOCRINOLOGY, V138, P3175, DOI 10.1210/en.138.8.3175; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; Wagner J, 2001, NEPHROL DIAL TRANSPL, V16, P441, DOI 10.1093/ndt/16.3.441; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF966, DOI 10.1152/ajprenal.1999.277.6.F966	35	25	26	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					682	+		10.1096/fj.02-0250fje	http://dx.doi.org/10.1096/fj.02-0250fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594185				2022-12-28	WOS:000181456900014
J	El-Armouche, A; Rau, T; Zolk, O; Ditz, D; Pamminger, T; Zimmermann, WH; Jackel, E; Harding, SE; Boknik, P; Neumann, J; Eschenhagen, T				El-Armouche, A; Rau, T; Zolk, O; Ditz, D; Pamminger, T; Zimmermann, WH; Jackel, E; Harding, SE; Boknik, P; Neumann, J; Eschenhagen, T			Evidence for protein phosphatase inhibitor-1 playing an amplifier role in beta-adrenergic signaling in cardiac myocytes	FASEB JOURNAL			English	Article						adenoviral gene transfer; gene expression; heart failure; beta-adrenergic signaling; phospholamban	GLYCOGEN-SYNTHASE; PHOSPHORYLATION; RAT; EXPRESSION; MUSCLE; ISOPROTERENOL; DARPP-32; RECEPTOR; CLONING; TISSUE	The protein phosphatase inhibitor-1 (PPI-1) inhibits phosphatase type-1 (PP1) only when phosphorylated by protein kinase A and could play a pivotal role in the phosphorylation/dephosphorylation balance. Rat cardiac PPI-1 was cloned by reverse transcriptase-polymerase chain reaction, expressed in Eschericia coli, evaluated in phosphatase assays, and used to generate an antiserum. An adenovirus was constructed encoding PPI-1 and green fluorescent protein (GFP) under separate cytomegalovirus promotors (AdPPI-1/GFP). A GFP-only virus (AdGFP) served as control. Engineered heart tissue (EHT) from neonatal rat cardiomyocytes and adult rat cardiac myocytes (ARCMs) were used as model systems. PPI-1 expression was determined in human ventricular samples by Northern blots. Compared with AdGFP, AdPPI-1/GFP-infected neonatal rat cardiomyocytes displayed a 73% reduction in PP1 activity. EHTs infected with AdPPI-1/GFP exhibited a fivefold increase in isoprenaline sensitivity. AdPPI-1/GFP-infected ARCMs displayed enhanced cell shortening as well as enhanced phospholamban phosphorylation when stimulated with 1 nM isoprenaline. PPI-1 mRNA levels were reduced by 57+/-12% in failing hearts with dilated and ischemic cardiomyopathy (n=8 each) compared with nonfailing hearts (n=8). In summary, increased PPI-1 expression enhances myocyte sensitivity to isoprenaline, indicating that PPI-1 acts as an amplifier in beta-adrenergic signaling. Decreased PPI-1 in failing human hearts could participate in desensitization of the cAMP pathway.	Univ Hamburg, Hosp Eppendorf, Inst Expt & Klin Pharmakol & Toxikol, D-20246 Hamburg, Germany; Univ Erlangen Nurnberg, Inst Expt & Klin Pharmakol & Toxikol, Erlangen, Germany; Dana Farber Canc Inst, Boston, MA 02115 USA; Univ London Imperial Coll Sci Technol & Med, Sch Med, NHLI, London, England; Univ Munster, Inst Pharmakol & Toxikol, D-4400 Munster, Germany	University of Hamburg; University of Erlangen Nuremberg; Harvard University; Dana-Farber Cancer Institute; Imperial College London; University of Munster	Eschenhagen, T (corresponding author), Univ Hamburg, Hosp Eppendorf, Inst Expt & Klin Pharmakol & Toxikol, Martinistr 52, D-20246 Hamburg, Germany.	t.eschenhagen@uke.uni-hamburg.de	El-Armouche, Ali/H-3161-2018; Zimmermann, Wolfram-Hubertus H/I-6838-2012	El-Armouche, Ali/0000-0003-2514-9429; Zimmermann, Wolfram-Hubertus H/0000-0003-1190-4040; Zolk, Oliver/0000-0002-8220-3834; Harding, Sian/0000-0002-3651-6354				AHMAD Z, 1989, J BIOL CHEM, V264, P3859; AITKEN A, 1982, EUR J BIOCHEM, V126, P235, DOI 10.1111/j.1432-1033.1982.tb06771.x; ALEMANY S, 1986, EUR J BIOCHEM, V156, P101, DOI 10.1111/j.1432-1033.1986.tb09554.x; Allen PB, 2000, J NEUROSCI, V20, P3537, DOI 10.1523/JNEUROSCI.20-10-03537.2000; Bartel S, 1996, MOL CELL BIOCHEM, V157, P171; Carr AN, 2002, MOL CELL BIOL, V22, P4124, DOI 10.1128/MCB.22.12.4124-4135.2002; Carr AN, 2001, J PHYSIOL-LONDON, V534, P357, DOI 10.1111/j.1469-7793.2001.00357.x; Dubell WH, 2002, AM J PHYSIOL-HEART C, V282, pH38, DOI 10.1152/ajpheart.00536.2001; ELBRECHT A, 1990, J BIOL CHEM, V265, P13415; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; FOULKES JG, 1983, EUR J BIOCHEM, V132, P309, DOI 10.1111/j.1432-1033.1983.tb07363.x; Gupta RC, 1996, AM J PHYSIOL-HEART C, V270, pH1159, DOI 10.1152/ajpheart.1996.270.4.H1159; HARDING SE, 1988, J MOL CELL CARDIOL, V20, P635, DOI 10.1016/S0022-2828(88)80121-4; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herzig S, 2000, PHYSIOL REV, V80, P173, DOI 10.1152/physrev.2000.80.1.173; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; IhlVahl R, 1996, J MOL CELL CARDIOL, V28, P1, DOI 10.1006/jmcc.1996.0001; KURIHARA T, 1988, J NEUROSCI, V8, P508; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MACDOUGALL LK, 1991, EUR J BIOCHEM, V196, P725, DOI 10.1111/j.1432-1033.1991.tb15871.x; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NAKIELNY S, 1991, EUR J BIOCHEM, V199, P713, DOI 10.1111/j.1432-1033.1991.tb16175.x; NEUMANN J, 1994, J PHARMACOL EXP THER, V271, P535; NEUMANN J, 1991, CIRC RES, V69, P1450, DOI 10.1161/01.RES.69.6.1450; Neumann J, 1997, J MOL CELL CARDIOL, V29, P265, DOI 10.1006/jmcc.1996.0271; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; Port JD, 2001, J MOL CELL CARDIOL, V33, P887, DOI 10.1006/jmcc.2001.1358; POULTER L, 1988, EUR J BIOCHEM, V175, P497, DOI 10.1111/j.1432-1033.1988.tb14222.x; Schmidt U, 1999, AM J PHYSIOL-HEART C, V277, pH474, DOI 10.1152/ajpheart.1999.277.2.H474; Schwinger RHG, 1999, J MOL CELL CARDIOL, V31, P479, DOI 10.1006/jmcc.1998.0897; SNYDER GL, 1992, J NEUROSCI, V12, P3071, DOI 10.1523/JNEUROSCI.12-08-03071.1992; SOLARO RJ, 1986, PROTEIN PHOSPHORYLAT, P129; Zakhary DR, 1999, CIRCULATION, V99, P505, DOI 10.1161/01.CIR.99.4.505; Zimmermann WH, 2002, CIRC RES, V90, P223, DOI 10.1161/hh0202.103644; Zimmermann WH, 2000, BIOTECHNOL BIOENG, V68, P106; Zolk O, 2000, CIRCULATION, V101, P2674, DOI 10.1161/01.CIR.101.23.2674	38	93	94	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					437	+		10.1096/fj.02-0057fje	http://dx.doi.org/10.1096/fj.02-0057fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12514122				2022-12-28	WOS:000181453700021
J	Masmoudi, O; Gandolfo, P; Leprince, J; Vaudry, D; Fournier, A; Patte-MEnsah, C; Vaudry, H; Tonon, MC				Masmoudi, O; Gandolfo, P; Leprince, J; Vaudry, D; Fournier, A; Patte-MEnsah, C; Vaudry, H; Tonon, MC			Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates endozepine release from cultured rat astrocytes via a PKA-dependent mechanism	FASEB JOURNAL			English	Article						endozepines; PAC1 receptor; PKA/PKC; intracellular Ca2+; astroglial cells	DIAZEPAM-BINDING INHIBITOR; VASOACTIVE-INTESTINAL-PEPTIDE; INTRACELLULAR FREE CALCIUM; CENTRAL-NERVOUS-SYSTEM; HUMAN BRAIN-TUMORS; OCTADECANEUROPEPTIDE ODN; BENZODIAZEPINE RECEPTORS; FUNCTIONAL EXPRESSION; GLIAL-CELLS; CASSETTE TRANSPORTER	Astroglial cells synthesize and release endozepines, neuropeptides that are related to the octadecaneuropeptide ODN. Glial cells also express PACAP/VIP receptors. We have investigated the possible effect of PACAP on the release of ODN-like immunoreactivity (ODN-LI) by cultured rat astrocytes. Administration of PACAP27 and PACAP38 induced a concentration-dependent increase in secretion of ODN-LI whereas VIP was similar to1000-fold less potent. The maximum effect of PACAP38 occurred after 5 min, then gradually declined during the next 10 min. The stimulatory effects of PACAP and VIP were abrogated by the PACAP antagonist PACAP6-38. PACAP38 stimulated cAMP formation, activated polyphosphoinositide turnover, and provoked calcium mobilization from IP3-sensitive pools. The PKA inhibitor H89 suppressed PACAP-induced secretion of ODN-LI, whereas PLC inhibitor U73122 and the PKC inhibitor chelerythrine had no effect. In contrast, U73122 restored the stimulatory action of PACAP on ODN-LI release and cAMP formation during prolonged (15 min) incubation with the peptide, and this effect was prevented by PMA. The present results demonstrate that PACAP stimulates endozepine release through activation of PAC1 receptors coupled to the AC/PKA pathway. Our data also show that activation of the PLC/PKC pathway downregulates the effect of PACAP on endozepine release.	Univ Rouen, European Inst Peptide Res IFRMP 23, Lab Cellular & Mol Neuroendocrinol, UA CNRS,INSERM,U413, F-76821 Mont St Aignan, France; Univ Quebec, INRS, Inst Armand Frappier, Pointe Claire, PQ H9R 1G6, Canada	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie; University of Quebec; Institut national de la recherche scientifique (INRS)	Vaudry, H (corresponding author), Univ Rouen, European Inst Peptide Res IFRMP 23, Lab Cellular & Mol Neuroendocrinol, UA CNRS,INSERM,U413, F-76821 Mont St Aignan, France.	hubert.vaudry@univ-rouen.fr	VAUDRY, David/M-1454-2018; Leprince, Jerome/N-9083-2017; Patte-Mensah, Christine/D-5961-2011	VAUDRY, David/0000-0003-3567-7452; Patte-Mensah, Christine/0000-0002-9970-8214; Leprince, Jerome/0000-0002-7814-9927				ALHO H, 1995, CELL GROWTH DIFFER, V6, P309; ALHO H, 1991, NEUROPHARMACOLOGY, V30, P1381, DOI 10.1016/S0028-3908(11)80005-5; Arimura A, 1998, JPN J PHYSIOL, V48, P301, DOI 10.2170/jjphysiol.48.301; Ashur-Fabian O, 1997, J MOL NEUROSCI, V9, P211, DOI 10.1007/BF02800503; Becq F, 1997, J BIOL CHEM, V272, P2695, DOI 10.1074/jbc.272.5.2695; Burgi B, 1999, J NEUROENDOCRINOL, V11, P85; Calegari F, 1999, J BIOL CHEM, V274, P22539, DOI 10.1074/jbc.274.32.22539; Cosentino M, 2000, J LEUKOCYTE BIOL, V67, P637, DOI 10.1002/jlb.67.5.637; Dautzenberg FM, 2001, NEUROPHARMACOLOGY, V40, P394, DOI 10.1016/S0028-3908(00)00167-2; De Mateos-Verchere JG, 1998, PEPTIDES, V19, P841; de Mateos-Verchere JG, 2001, EUR J PHARMACOL, V414, P225; Decleves X, 2000, J NEUROSCI RES, V60, P594, DOI 10.1002/(SICI)1097-4547(20000601)60:5<594::AID-JNR4>3.0.CO;2-6; Deschepper CF, 1998, FRONT NEUROENDOCRIN, V19, P20, DOI 10.1006/frne.1997.0161; Do-Rego JL, 2001, J NEUROCHEM, V76, P128, DOI 10.1046/j.1471-4159.2001.00053.x; FERRERO P, 1984, NEUROPHARMACOLOGY, V23, P1359, DOI 10.1016/0028-3908(84)90061-3; Gaillard PJ, 2000, PHARMACEUT RES, V17, P1198, DOI 10.1023/A:1026406528530; Gandolfo P, 1997, EUR J PHARMACOL, V322, P275, DOI 10.1016/S0014-2999(97)00012-5; Gonzalez BJ, 1998, ANN ENDOCRINOL-PARIS, V59, P364; GRAY PW, 1987, NEUROPHARMACOLOGY, V26, P863, DOI 10.1016/0028-3908(87)90063-3; Grimaldi M, 1999, EUR J NEUROSCI, V11, P2767, DOI 10.1046/j.1460-9568.1999.00693.x; Grimaldi M, 2000, ANN NY ACAD SCI, V921, P312; GUIDOTTI A, 1983, P NATL ACAD SCI-BIOL, V80, P3531, DOI 10.1073/pnas.80.11.3531; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; Jaworski DM, 2000, CELL TISSUE RES, V300, P219, DOI 10.1007/s004410000184; Jeremic A, 2001, J NEUROCHEM, V77, P664, DOI 10.1046/j.1471-4159.2001.00272.x; Lamacz M, 1996, MOL BRAIN RES, V37, P290, DOI 10.1016/0169-328X(95)00330-U; Leprince J, 1998, J MED CHEM, V41, P4433, DOI 10.1021/jm980275d; Leprince J, 2001, EUR J BIOCHEM, V268, P6045, DOI 10.1046/j.0014-2956.2001.02533.x; LIHRMANN I, 1994, P NATL ACAD SCI USA, V91, P6899, DOI 10.1073/pnas.91.15.6899; LUCIUS R, 1991, J BIOL CHEM, V266, P18907; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; MALAGON M, 1993, NEUROSCIENCE, V57, P777, DOI 10.1016/0306-4522(93)90023-9; McArdle CA, 1997, J NEUROENDOCRINOL, V9, P893, DOI 10.1046/j.1365-2826.1997.00657.x; MENTLEIN R, 1994, J NEUROCHEM, V62, P27; MENTLEIN R, 1990, BRAIN RES, V527, P159, DOI 10.1016/0006-8993(90)91076-S; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; PAPADOPOULOS V, 1991, ENDOCRINOLOGY, V129, P1481, DOI 10.1210/endo-129-3-1481; Patte C, 1999, GLIA, V25, P404, DOI 10.1002/(SICI)1098-1136(19990215)25:4<404::AID-GLIA9>3.3.CO;2-H; PATTE C, 1995, FEBS LETT, V362, P106, DOI 10.1016/0014-5793(95)00209-R; Seibert FS, 1999, BBA-BIOMEMBRANES, V1461, P275, DOI 10.1016/S0005-2736(99)00163-7; SHIVERS BD, 1991, ENDOCRINOLOGY, V128, P3055, DOI 10.1210/endo-128-6-3055; SLOBODYANSKY E, 1994, REGUL PEPTIDES, V50, P29, DOI 10.1016/0167-0115(94)90188-0; SLOBODYANSKY E, 1989, J NEUROCHEM, V53, P1276, DOI 10.1111/j.1471-4159.1989.tb07425.x; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; TATSUNO I, 1994, BRAIN RES, V662, P1, DOI 10.1016/0006-8993(94)90790-0; TATSUNO I, 1991, PEPTIDES, V12, P617, DOI 10.1016/0196-9781(91)90110-B; TATSUNO I, 1990, BIOCHEM BIOPH RES CO, V168, P1027, DOI 10.1016/0006-291X(90)91132-C; Tatsuno I, 1996, ANN NY ACAD SCI, V805, P482; Tatsuno I, 1996, ANN NY ACAD SCI, V805, P613; TONG Y, 1991, NEUROPEPTIDES, V20, P33, DOI 10.1016/0143-4179(91)90037-J; TONON MC, 1990, NEUROPEPTIDES, V15, P17, DOI 10.1016/0143-4179(90)90155-R; Vaudry D, 2000, PHARMACOL REV, V52, P269; VAUDRY H, 1978, NEUROENDOCRINOLOGY, V27, P9, DOI 10.1159/000122796; VIDNYANSZKY Z, 1994, GLIA, V10, P132, DOI 10.1002/glia.440100207; Yin YZ, 2000, BRIT J HAEMATOL, V108, P565, DOI 10.1046/j.1365-2141.2000.01903.x	58	41	42	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2003	17	1					17	27		10.1096/fj.02-0317com	http://dx.doi.org/10.1096/fj.02-0317com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12522108				2022-12-28	WOS:000181453700035
J	Bodennec, J; Pelled, D; Riebeling, C; Trajkovic, S; Futerman, AH				Bodennec, J; Pelled, D; Riebeling, C; Trajkovic, S; Futerman, AH			Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP : phosphocholine cytidylyltransferase by glucosylceramide	FASEB JOURNAL			English	Article						sphingolipid; phospholipid; conduritol-B-epoxide; glucocerebrosidase; lysosomal storage disease	FIBROBLAST-GROWTH-FACTOR; RAT SYMPATHETIC NEURONS; BILAYER-FORMING LIPIDS; AXONAL GROWTH; ENDOPLASMIC-RETICULUM; PHOSPHOLIPID BIOSYNTHESIS; HIPPOCAMPAL-NEURONS; LIVER; MEMBRANE; METABOLISM	Glucosylceramide (GlcCer) accumulates in the inherited metabolic disorder, Gaucher disease, because of the defective activity of lysosomal glucocerebrosidase. We previously demonstrated that upon GlcCer accumulation, cultured hippocampal neurons exhibit modified growth patterns, altered endoplasmic reticulum density, and altered calcium release from intracellular stores. We here examined the relationship between GlcCer accumulation and phospholipid synthesis. After treatment of neurons with an active site-directed inhibitor of glucocerebrosidase, or in neurons obtained from a mouse model of Gaucher disease, [C-14]methyl choline incorporation into [C-14]phosphatidylcholine ([C-14]PC) and [C-14]sphingomyelin was elevated, as were [C-14]CDPcholine levels, suggesting that CTP:phosphocholine cytidylyltransferase (CCT) is activated. Indeed, CCT activity was elevated in neurons that had accumulated GlcCer. GlcCer, but not galactosylceramide (GalCer), stimulated CCT activity in rat brain homogenates, and significantly higher levels of CCT were membrane associated in cortical homogenates from a mouse model of Gaucher disease compared with wild-type mice. Because CCT mRNA and protein levels were unaltered in either neurons or brain tissue that had accumulated GlcCer, it appeared likely that GlcCer activates CCT by a post-translational mechanism. This was verified by examination of the effect of GlcCer on CCT purified about 1200-fold from rat brain. GlcCer stimulated CCT activity, with stimulation observed at levels as low as 2.5 mol% and with maximal activation reached at 10 mol%. In contrast, GalCer had no effect. Together, these data demonstrate that GlcCer directly activates CCT, which results in elevated PC synthesis, which may account for some of the changes in growth rates observed upon neuronal GlcCer accumulation.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Futerman, AH (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	tony.futerman@weizmann.ac.il		Futerman, Anthony/0000-0003-0013-0115; Riebeling, Christian/0000-0003-1991-0170				ADACHI M, 1967, ARCH PATHOL, V83, P513; ADACHI M, 1977, ARCH PATHOL LAB MED, V101, P255; Araki W, 1998, J NEUROSCI RES, V51, P667, DOI 10.1002/(SICI)1097-4547(19980315)51:6<667::AID-JNR1>3.3.CO;2-L; Ardail D, 2001, FEBS LETT, V488, P160, DOI 10.1016/S0014-5793(00)02332-2; Arnold RS, 1996, BIOCHEMISTRY-US, V35, P9917, DOI 10.1021/bi960397c; BEUTLER E, 2001, METABOLIC MOL BASES, P3635; Bodennec J, 2000, J LIPID RES, V41, P1524; Boldin S, 1997, J NEUROCHEM, V68, P882; Boldin SA, 2000, J BIOL CHEM, V275, P9905, DOI 10.1074/jbc.275.14.9905; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Campbell HA, 2001, BBA-MOL CELL BIOL L, V1534, P85, DOI 10.1016/S1388-1981(01)00174-3; CORNELL R, 1989, J BIOL CHEM, V264, P9077; Cornell RB, 1996, CHEM PHYS LIPIDS, V81, P215, DOI 10.1016/0009-3084(96)02584-4; Cornell RB, 1998, BIOCHEM SOC T, V26, P539, DOI 10.1042/bst0260539; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; Cox TM, 2001, J INHERIT METAB DIS, V24, P106; DATTA SC, 1986, LIPIDS, V21, P702, DOI 10.1007/BF02537244; DATTA SC, 1988, LIPIDS, V23, P508, DOI 10.1007/BF02535529; DECHAVES EP, 1995, J CELL BIOL, V128, P913, DOI 10.1083/jcb.128.5.913; DITTMER JC, 1964, J LIPID RES, V5, P126; Erikson A, 1997, BAILLIERE CLIN HAEM, V10, P711, DOI 10.1016/S0950-3536(97)80035-2; FOLCH J, 1957, J BIOL CHEM, V226, P497; Futerman AH, 1998, ANN NY ACAD SCI, V845, P176, DOI 10.1111/j.1749-6632.1998.tb09670.x; Futerman AH, 1996, TRENDS NEUROSCI, V19, P144, DOI 10.1016/S0166-2236(96)80025-7; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; Goslin K., 1998, CULTURING NERVE CELL, P339; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; HARA A, 1979, BIOCHIM BIOPHYS ACTA, V582, P423, DOI 10.1016/0304-4165(79)90134-X; Hirschberg K, 1996, J BIOL CHEM, V271, P14876, DOI 10.1074/jbc.271.25.14876; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; Ichikawa S, 1998, TRENDS CELL BIOL, V8, P198, DOI 10.1016/S0962-8924(98)01249-5; JAMIL H, 1993, BIOCHEM J, V291, P419, DOI 10.1042/bj2910419; JENSEN JW, 1988, BIOCHEMISTRY-US, V27, P6315, DOI 10.1021/bi00417a017; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; Korkotian E, 1999, J BIOL CHEM, V274, P21673, DOI 10.1074/jbc.274.31.21673; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGLER G, 1988, ARCH BIOCHEM BIOPHYS, V260, P437, DOI 10.1016/0003-9861(88)90467-5; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Lykidis A, 2001, BIOCHEMISTRY-US, V40, P494, DOI 10.1021/bi002140r; MACDONALD JIS, 1993, PROTEIN EXPRES PURIF, V4, P1, DOI 10.1006/prep.1993.1001; Marchell NL, 1998, J INVEST DERMATOL, V110, P383, DOI 10.1046/j.1523-1747.1998.00145.x; NAVARRO JC, 1990, CLIN NEUROPATHOL, V9, P310; NILSSON O, 1982, J NEUROCHEM, V39, P709, DOI 10.1111/j.1471-4159.1982.tb07950.x; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; Orvisky E, 2000, PEDIATR RES, V48, P233, DOI 10.1203/00006450-200008000-00018; Pelled D, 2000, J INHERIT METAB DIS, V23, P175, DOI 10.1023/A:1005622001239; Pelled D, 2002, J BIOL CHEM, V277, P1957, DOI 10.1074/jbc.M104677200; Radin NS, 1999, BIOCHEM PHARMACOL, V57, P589; Radin NS, 2001, EUR J BIOCHEM, V268, P193, DOI 10.1046/j.1432-1033.2001.01845.x; RENKONEN O, 1966, LIPIDS, V1, P160, DOI 10.1007/BF02533012; SANGHERA JS, 1989, J BIOL CHEM, V264, P1215; SANGO K, 1995, NAT GENET, V11, P170, DOI 10.1038/ng1095-170; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; Schwarz A, 1997, J NEUROSCI, V17, P2929; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; Shayman JA, 2000, METHOD ENZYMOL, V311, P373; Suzuki K, 1998, NEUROCHEM RES, V23, P251, DOI 10.1023/A:1022436928925; TYBULEWICZ VLJ, 1992, NATURE, V357, P407, DOI 10.1038/357407a0; van Meer G, 2000, BBA-MOL CELL BIOL L, V1486, P145, DOI 10.1016/S1388-1981(00)00054-8; VANCE DE, 1980, J BIOL CHEM, V255, P1064; VANCE JE, 1994, J NEUROCHEM, V62, P329; Vance JE, 2000, BBA-MOL CELL BIOL L, V1486, P84, DOI 10.1016/S1388-1981(00)00050-0; Vielhaber G, 2001, J INVEST DERMATOL, V117, P1126, DOI 10.1046/j.0022-202x.2001.01527.x; WARREN KR, 1976, J LIPID RES, V17, P132; WEINHOLD PA, 1992, METHOD ENZYMOL, V209, P248; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; Xiong Y, 2000, NEUROSCI LETT, V283, P129, DOI 10.1016/S0304-3940(00)00929-0	70	67	68	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13	1				1814	+		10.1096/fj.02-0149fje	http://dx.doi.org/10.1096/fj.02-0149fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223447				2022-12-28	WOS:000181189100009
J	Nanthakumar, NN; Dai, DW; Newburg, DS; Walker, WA				Nanthakumar, NN; Dai, DW; Newburg, DS; Walker, WA			The role of indigenous microflora in the development of murine intestinal fucosyl- and sialyltransferases	FASEB JOURNAL			English	Article						luminal bacteria; germ-free mice; postnatal development; brush border membrane glycoconjugates; extrinsic regulation	BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; GERM-FREE; BACTERIAL-COLONIZATION; FUCOSYL-TRANSFERASE; EPITHELIAL-CELLS; EXPRESSION; ONTOGENY; ADULT; FETAL; GLYCOSYLATION	Most enteric bacteria use intestinal brushborder glycoconjugates as their target host cell receptors. It has been postulated that resident microbes regulate specific glycosyltransferases that are responsible for synthesizing brushborder glycoconjugates. To investigate this hypothesis, we measured glycosyltransferase enzyme activities in intestine from different regions of maturing conventional (CONV), germ-free (GF), and ex-germ-free (XGF) mice and compared them to general enzyme markers of gut development, for example, disaccharidases. High alpha2,3/6-Sialyltransferase (ST) activity and low alpha1,2-fucosyltransferase (FT) activities were detected from duodenum to colon in suckling CONV mice, but the relative levels of these activities reversed during the third postnatal wk, rapidly reaching adult levels by the fourth wk. These age-related enzyme changes were significantly attenuated in GF mice, maintaining an immature pattern well past 3 wk. Introduction of gut microflora in GF mice rapidly initiated maturation of glycosyltransferase activity but had no significant affect on developmental programming of dissacharidases. Therefore, in mice, intestinal glycosyltransferase activities are under tissue and developmental control and microflora play a major role in their specific ontogeny but not in overall development. These findings may help explain the regional specificity of commensal bacteria and of enteric pathogens and may also relate age-related changes in microflora to susceptibility to enteropathogens.	Massachusetts Gen Hosp, Dev Gastroenterol Lab, Combined Program Pediat Gastroenterol & Nutr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Xinhua Hosp, Shanghai Inst Pediat Res, Shanghai, Peoples R China; Shanghai Med Univ 2, Shanghai, Peoples R China; Eunice Kennedy Shriver Ctr Mental Retardat Inc, Program Glycobiol, Waltham, MA 02254 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Shanghai Jiao Tong University	Walker, WA (corresponding author), Massachusetts Gen Hosp, Dev Gastroenterol Lab, Combined Program Pediat Gastroenterol & Nutr, 114 16th St 114-3503, Charlestown, MA 02129 USA.	wwalker@partners.org		Dai, Dingwei/0000-0001-9385-0992				Berg RD, 1996, TRENDS MICROBIOL, V4, P430, DOI 10.1016/0966-842X(96)10057-3; Bry L, 1996, SCIENCE, V273, P1380, DOI 10.1126/science.273.5280.1380; Bry L, 1996, P NATL ACAD SCI USA, V93, P1161, DOI 10.1073/pnas.93.3.1161; BUGAUT M, 1987, COMP BIOCHEM PHYS B, V86, P439, DOI 10.1016/0305-0491(87)90433-0; BULLER HA, 1990, GASTROENTEROLOGY, V98, P667; CHU SHW, 1986, BIOCHIM BIOPHYS ACTA, V883, P496, DOI 10.1016/0304-4165(86)90289-8; Claud EC, 2001, FASEB J, V15, P1398, DOI 10.1096/fj.00-0833hyp; Dai D, 1999, Adv Pediatr, V46, P353; Dai DW, 2000, J PEDIATR GASTR NUTR, V30, pS23, DOI 10.1097/00005176-200003002-00005; Dai DW, 2002, AM J PHYSIOL-GASTR L, V282, pG480, DOI 10.1152/ajpgi.00531.2000; DALLOLIO F, 1990, BIOCHEM J, V270, P519, DOI 10.1042/bj2700519; Etzioni A, 1996, PEDIATR RES, V39, P191, DOI 10.1203/00006450-199602000-00001; Falk PG, 1998, MICROBIOL MOL BIOL R, V62, P1157, DOI 10.1128/MMBR.62.4.1157-1170.1998; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; Henning J. C. M., 1987, Semiconductor Science and Technology, V2, P1, DOI 10.1088/0268-1242/2/1/001; Hooper LV, 1998, BIOESSAYS, V20, P336, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;336::AID-BIES10&gt;3.0.CO;2-3; Hooper LV, 1999, P NATL ACAD SCI USA, V96, P9833, DOI 10.1073/pnas.96.17.9833; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; KARLSSON KA, 1995, CURR OPIN STRUC BIOL, V5, P622, DOI 10.1016/0959-440X(95)80054-9; KLEIN RM, 1983, J PEDIATR GASTR NUTR, V2, P10, DOI 10.1097/00005176-198302010-00004; KOTTGEN E, 1976, BIOCHEM BIOPH RES CO, V72, P61; LARSON G, 1988, J BIOL CHEM, V263, P10790; MIDTVEDT T, 1987, APPL ENVIRON MICROB, V53, P2866, DOI 10.1128/AEM.53.12.2866-2871.1987; MORITA A, 1996, BIOCHIM BIOPHYS ACTA, V883, P506; MULIVOR RA, 1978, P NATL ACAD SCI USA, V75, P3909, DOI 10.1073/pnas.75.8.3909; NANTHAKUMAR NN, 1993, AM J PHYSIOL, V264, pG306, DOI 10.1152/ajpgi.1993.264.2.G306; REDDY BS, 1966, ARCH BIOCHEM BIOPHYS, V113, P609, DOI 10.1016/0003-9861(66)90238-4; SCHIFFRIN EJ, 1993, J PEDIATR GASTR NUTR, V17, P271; SHAH S, 1992, J BIOL CHEM, V267, P10652; SRIVASTAVA OP, 1987, BIOCHIM BIOPHYS ACTA, V914, P143, DOI 10.1016/0167-4838(87)90057-4; SURAWICZ CM, 1989, GASTROENTEROLOGY, V96, P981, DOI 10.1016/0016-5085(89)91613-2; Takashima S, 1999, BIOCHEM BIOPH RES CO, V260, P23, DOI 10.1006/bbrc.1999.0794; UMESAKI Y, 1982, BIOCHEM BIOPH RES CO, V105, P439, DOI 10.1016/0006-291X(82)91453-X; UMESAKI Y, 1995, MICROBIOL IMMUNOL, V39, P555, DOI 10.1111/j.1348-0421.1995.tb02242.x; UMESAKI Y, 1984, J HISTOCHEM CYTOCHEM, V32, P299, DOI 10.1177/32.3.6693758; Vanderhoof JA, 1998, J PEDIATR GASTR NUTR, V27, P323, DOI 10.1097/00005176-199809000-00011; VANDERWAAIJ D, 1989, ANNU REV MICROBIOL, V43, P69, DOI 10.1146/annurev.micro.43.1.69; VERTINOBELL A, 1994, DEV BIOL, V165, P126, DOI 10.1006/dbio.1994.1240; VOCKLEY J, 1984, P NATL ACAD SCI-BIOL, V81, P6120, DOI 10.1073/pnas.81.19.6120; Walker WA, 1998, J NUTR BIOCHEM, V9, P668, DOI 10.1016/S0955-2863(98)00058-8	40	51	55	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					44	+		10.1096/fj.02-0031fje	http://dx.doi.org/10.1096/fj.02-0031fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475916				2022-12-28	WOS:000180218500024
J	Behfar, A; Zingman, LV; Hodgson, DM; Rauzier, JM; Kane, GC; Terzic, A; Puceat, M				Behfar, A; Zingman, LV; Hodgson, DM; Rauzier, JM; Kane, GC; Terzic, A; Puceat, M			Stem cell differentiation requires a paracrine pathway in the heart	FASEB JOURNAL			English	Article						TGF-beta; ischemic heart disease; cardiomyocytes; cardioblasts	GROWTH-FACTOR-BETA; NEONATAL CARDIAC MYOCYTES; IN-VITRO; MYOCARDIAL-INFARCTION; TGF-BETA; CARDIOMYOCYTES; PROTEIN; RAT; EXPRESSION; FAILURE	Members of the transforming growth factor beta1 (TGF-beta) superfamily-namely, TGF-beta and BMP2-applied to undifferentiated murine embryonic stem cells up-regulated mRNA of mesodermal (Brachyury) and cardiac specific transcription factors (Nkx2.5, MEF2C). Embryoid bodies generated from stem cells primed with these growth factors demonstrated an increased potential for cardiac differentiation with a significant increase in beating areas and enhanced myofibrillogenesis. In an environment of postmitotic cardiomyocytes, stem cells engineered to express a fluorescent protein under the control of a cardiac promoter differentiated into fluorescent ventricular myocytes beating in synchrony with host cells, a process significantly enhanced by TGF-beta or BMP2. In vitro, disruption of the TGF-beta/BMP signaling pathways by latency-associated peptide and/or noggin prevented differentiation of stem cells. In fact, only host cells that secrete a TGF-beta family member induced a cardiac phenotype in stem cells. In vivo, transplantation of stem cells into heart also resulted in cardiac differentiation provided that TGF-beta/BMP2 signaling was intact. In infarcted myocardium, grafted stem cells differentiated into functional cardiomyocytes integrated with surrounding tissue, improving contractile performance. Thus, embryonic stem cells are directed to differentiate into cardiomyocytes by signaling mediated through TGF-beta/BMP2, a cardiac paracrine pathway required for therapeutic benefit of stem cell transplantation in diseased heart.	CRBM, CNRS, UPR 1086, F-34293 Montpellier, France; INSERM, U390, Lab Physiopathol Cardiovasc, Montpellier, France; Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Div Cardiovasc Dis, Rochester, MN 55905 USA	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Mayo Clinic; Mayo Clinic	Puceat, M (corresponding author), CRBM, CNRS, UPR 1086, 1919 Route Mende, F-34293 Montpellier, France.	puceat@crbm.cnrs-mop.fr	Zingman, Leonid V/GXG-0136-2022; PUCEAT, michel/R-6140-2017	Zingman, Leonid V/0000-0002-7566-4616; Behfar, Atta/0000-0003-3775-5784; PUCEAT, michel/0000-0001-9055-7563	NHLBI NIH HHS [HL-07111, HL-64822] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064822] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aimond F, 1999, CARDIOVASC RES, V42, P402, DOI 10.1016/S0008-6363(99)00070-X; AKHURST RJ, 1990, DEVELOPMENT, V108, P645; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; BRAND T, 1993, J BIOL CHEM, V268, P11500; Braunwald E, 2000, CIRCULATION, V102, P14; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; BURNETT JC, 1986, SCIENCE, V231, P1145, DOI 10.1126/science.2935937; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARROW BJ, 1995, CIRC RES, V76, P381, DOI 10.1161/01.RES.76.3.381; FLANDERS KC, 1995, J MOL CELL CARDIOL, V27, P805, DOI 10.1016/0022-2828(95)90087-X; Flink IL, 1998, J MOL CELL CARDIOL, V30, P563, DOI 10.1006/jmcc.1997.0620; FRANDRICH F, 2002, NAT MED, V8, P171; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; Hao JM, 2000, AM J PHYSIOL-HEART C, V279, pH3020, DOI 10.1152/ajpheart.2000.279.6.H3020; Hao JM, 1999, J MOL CELL CARDIOL, V31, P667, DOI 10.1006/jmcc.1998.0902; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Izumi M, 2001, J BIOL CHEM, V276, P31133, DOI 10.1074/jbc.M101463200; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kessler PD, 1999, ANNU REV PHYSIOL, V61, P219, DOI 10.1146/annurev.physiol.61.1.219; KLUG MG, 1996, J CLIN INVEST, V98, P216; KOH GY, 1993, J CLIN INVEST, V92, P1548, DOI 10.1172/JCI116734; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Leor J, 1996, CIRCULATION, V94, P332; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Meyer N, 2000, FEBS LETT, V478, P151, DOI 10.1016/S0014-5793(00)01839-1; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Moutsatsos IK, 2001, MOL THER, V3, P449, DOI 10.1006/mthe.2001.0291; Olson EN, 2001, SCIENCE, V291, P2327, DOI 10.1126/science.1060063; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Oyamada Y, 1996, EXP CELL RES, V229, P318, DOI 10.1006/excr.1996.0377; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; ROBERTS AB, 1992, J CLIN INVEST, V90, P2056, DOI 10.1172/JCI116087; Roell W, 2002, CIRCULATION, V105, P2435, DOI 10.1161/01.CIR.0000016063.66513.BB; Ruwhof C, 2000, MOL CELL BIOCHEM, V208, P89, DOI 10.1023/A:1007046105745; Schlange T, 2000, MECH DEVELOP, V91, P259, DOI 10.1016/S0925-4773(99)00311-1; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Scorsin M, 1996, CIRCULATION, V94, P337; Scorsin M, 2000, J THORAC CARDIOV SUR, V119, P1169, DOI 10.1067/mtc.2000.104865; Sharma M, 1999, J CELL PHYSIOL, V180, P1; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; SOONPAA MH, 1994, SCIENCE, V264, P98, DOI 10.1126/science.8140423; Strom TB, 2001, TRANSPL P, V33, P3044, DOI 10.1016/S0041-1345(01)02303-X; SUN JZ, 1993, J MOL CELL CARDIOL, V25, P379, DOI 10.1006/jmcc.1993.1044; Sun Y, 2000, CARDIOVASC RES, V46, P250, DOI 10.1016/S0008-6363(00)00032-8; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zhang M, 2001, J MOL CELL CARDIOL, V33, P907, DOI 10.1006/jmcc.2001.1367; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	51	368	414	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1558	1566		10.1096/fj.02-0072com	http://dx.doi.org/10.1096/fj.02-0072com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12374778				2022-12-28	WOS:000179167600037
J	Schubert, SY; Neeman, I; Resnick, N				Schubert, SY; Neeman, I; Resnick, N			A novel mechanism for the inhibition of NF kappa B activation in vascular endothelial cells by natural antioxidants	FASEB JOURNAL			English	Article						inflammation; cytokines; biomechanical forces; inhibitor of kappa B; phosphorylation	TPA-INDUCED EXPRESSION; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; RED WINE; C-JUN; KINASE; CURCUMIN; PATHWAY; PROTOONCOGENES; APOPTOSIS	The activation of Nuclear Factor kappa B (NF-kappaB) in vascular endothelial cells, in response to biochemical or biomechanical stimuli, is associated with vascular pathologies such as atherosclerosis. The present manuscript studies the ability of the natural antioxidant-pomegranate wine (PW), to inhibit tumor necrosis factor alpha (TNF-alpha) or shear stress-mediated-NF-kappaB activation in vascular endothelial cells and compares it to that of red wine (RW) and N-acetyl cysteine (NAC). PW and RW act as potent antioxidants in vascular endothelial cells, inhibiting the oxidation of 2',7'-dichloroflurescin diacetate in TNF-alpha, treated cells. PW (as well as RW and NAC) acted as potent inhibitors of NF-kappaB activation (migration into the nucleus and DNA binding activity) in vascular endothelial cells. Nevertheless, PW and NAC failed to inhibit TNF-alpha, induced serine 32/36 phosphorylation and IkappaBalpha degradation. Surprisingly, these antioxidants alone induced enhanced IkappaB serine phosphorylation, which was not accompanied by IkappaBalpha degradation, or NF-kappaB nuclear translocation. This phosphorylation did not involve serine 32/36. Furthermore, we show for the first time that NAC inhibited TNF-alpha, mediated phosphorylation of p65 (ser536), whereas PW had no effect on this phosphorylation. Thus, natural antioxidants may serve as potent NF-kappaB inhibitors in vascular endothelial cells, yet act through unique and divergent pathways.	Technion Israel Inst Technol, Dept Anat & Cell Biol, Bruce Rappaport Res Inst, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Interdept Program Biotechnol, Bruce Rappaport Res Inst, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Food Engn & Biotechnol, Bruce Rappaport Res Inst, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Technion Israel Institute of Technology	Resnick, N (corresponding author), Technion Israel Inst Technol, Dept Anat & Cell Biol, Bruce Rappaport Res Inst, Bruce Rappaport Fac Med, Efron St,POB 9697,Bat Galim, IL-31096 Haifa, Israel.	nitzanr@tx.technion.ac.il						Aviram M, 1997, BIOFACTORS, V6, P415, DOI 10.1002/biof.5520060408; Aviram M, 2000, AM J CLIN NUTR, V71, P1062; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Blanco-Colio LM, 2000, CIRCULATION, V102, P1020, DOI 10.1161/01.CIR.102.9.1020; CHAN MMY, 1995, BIOCHEM PHARMACOL, V49, P1551, DOI 10.1016/0006-2952(95)00171-U; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; DEWEY CF, 1981, J BIOMECH ENG-T ASME, V103, P177, DOI 10.1115/1.3138276; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; Frei B, 1999, FASEB J, V13, P963, DOI 10.1096/fasebj.13.9.963; GIMBRONE MA, 1995, ANN NY ACAD SCI, V748, P122; GIMBRONE MA, 1995, MOL CARDIOVASCULAR M, P49; Hajra L, 2000, P NATL ACAD SCI USA, V97, P9052, DOI 10.1073/pnas.97.16.9052; Hsu JD, 1999, ANTICANCER RES, V19, P4221; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; IWASAKI T, 1992, FEBS LETT, V298, P240, DOI 10.1016/0014-5793(92)80067-Q; KAKAR SS, 1994, CANCER LETT, V87, P85, DOI 10.1016/0304-3835(94)90413-8; Lee S, 1997, J IMMUNOL, V158, P3401; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; Murase T, 1999, ARTERIOSCL THROM VAS, V19, P1412, DOI 10.1161/01.ATV.19.6.1412; Musonda CA, 1998, CARCINOGENESIS, V19, P1583, DOI 10.1093/carcin/19.9.1583; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Pierce JW, 1996, J IMMUNOL, V156, P3961; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; Rice-Evans C, 2001, CURR MED CHEM, V8, P797, DOI 10.2174/0929867013373011; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; Schubert SY, 1999, J ETHNOPHARMACOL, V66, P11, DOI 10.1016/S0378-8741(98)00222-0; SHIMIZU S, 1994, RES COMMUN CHEM PATH, V84, P301; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Thurberg BL, 1998, CURR OPIN LIPIDOL, V9, P387, DOI 10.1097/00041433-199810000-00002; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	41	102	110	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1931	+		10.1096/fj.02-0147fje	http://dx.doi.org/10.1096/fj.02-0147fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368228				2022-12-28	WOS:000179167600019
J	Tureci, O; Bian, HJ; Nestle, FO; Raddrizzani, L; Rosinski, JA; Tassis, A; Hilton, H; Walstead, M; Sahin, U; Hammer, J				Tureci, O; Bian, HJ; Nestle, FO; Raddrizzani, L; Rosinski, JA; Tassis, A; Hilton, H; Walstead, M; Sahin, U; Hammer, J			Cascades of transcriptional induction during dendritic cell maturation revealed by genome-wide expression analysis	FASEB JOURNAL			English	Article						DC; B cells; apoptotic death	CLUSTERIN GENE-EXPRESSION; T-CELLS; TNF-RECEPTOR; B-CELLS; IN-VIVO; APOPTOSIS; VACCINATION; CHEMOKINES; RESISTANCE; IMMATURE	Dendritic cells (DC) are central regulators of immunity. Signal-induced maturation of DCs is assumed to be the starting point for specific immune responses. To further understand this process, we analyzed the alteration of transcript profiles along the time course of CD40 ligand-induced maturation of human myeloid DCs by Affymetrix GeneChip(R) microarrays covering >6800 genes. Besides rediscovery of genes already described as associated with DC maturation proving reliability of the methods used, we identified clusterin as novel maturation marker. Looking across the time course, we observed synchronized kinetics of distinct functional groups of molecules whose temporal coregulation underscores known cellular events during dendritic cell maturation. For example, an early-peaking wave of inflammatory chemokines was followed by a sustained increase of constitutive chemokines and accompanied by slow but continuous induction of survival proteins. After an immediate but transient induction of cytokine-responsive transcripts, there was an increased expression of a group of genes involved in not only the regulation of cytokine effects, but also of transcription in general. Our results demonstrate that microarray studies along time courses combined with real-time PCR not only discover new marker molecules with functional implications, but also dissect the molecular kinetics of biological processes identifying complex pathways of regulation.	Univ Mainz, Med Klin & Poliklin 3, Dept Internal Med 3, D-55131 Mainz, Germany; Hoffmann La Roche Inc, Genom & Informat Sci, Nutley, NJ 07110 USA; Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; Affymetrix, Santa Clara, CA USA	Johannes Gutenberg University of Mainz; Roche Holding; University of Zurich; University Zurich Hospital; Affymetrix	Tureci, O (corresponding author), Univ Mainz, Med Klin & Poliklin 3, Dept Internal Med 3, Obere Zahlbacherstr 63, D-55131 Mainz, Germany.	Tureci@mail.uni-mainz.de	Sahin, Ugur/L-4818-2017	Sahin, Ugur/0000-0003-0363-1564				Aicher A, 1999, J IMMUNOL, V163, P5786; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; ASHANASY D, 1999, J IMMUNOL, V163, P5503; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bjorck P, 1997, INT IMMUNOL, V9, P365, DOI 10.1093/intimm/9.3.365; Cyster JG, 1999, J EXP MED, V189, P447, DOI 10.1084/jem.189.3.447; Dhodapkar MV, 2002, BLOOD, V100, P174, DOI 10.1182/blood.V100.1.174; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; FRENCH LE, 1994, J CLIN INVEST, V93, P877, DOI 10.1172/JCI117043; Granucci F, 2001, NAT IMMUNOL, V2, P882, DOI 10.1038/ni0901-882; Gupta S, 1998, J IMMUNOL, V161, P5997; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Hartgers FC, 2000, IMMUNOL TODAY, V21, P542, DOI 10.1016/S0167-5699(00)01736-9; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Josien R, 2000, J EXP MED, V191, P495, DOI 10.1084/jem.191.3.495; Koch-Brandt C, 1996, Prog Mol Subcell Biol, V16, P130; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Morse MA, 1999, CANCER RES, V59, P56; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Nestle FO, 2001, NAT MED, V7, P761, DOI 10.1038/89863; Perlman H, 1999, J EXP MED, V190, P1679, DOI 10.1084/jem.190.11.1679; Poon S, 2000, BIOCHEMISTRY-US, V39, P15953, DOI 10.1021/bi002189x; ROSENBERG ME, 1995, INT J BIOCHEM CELL B, V27, P633, DOI 10.1016/1357-2725(95)00027-M; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Sozzani S, 1998, J IMMUNOL, V161, P1083; Steinman RM, 2001, INT J CANCER, V94, P459, DOI 10.1002/ijc.1503; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; vanKooten C, 1997, CURR OPIN IMMUNOL, V9, P330, DOI 10.1016/S0952-7915(97)80078-7; Viard I, 1999, J INVEST DERMATOL, V112, P290, DOI 10.1046/j.1523-1747.1999.00531.x; Wellmann A, 2000, BLOOD, V96, P398; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yamagata T, 1996, MOL CELL BIOL, V16, P1283	34	72	73	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					836	847		10.1096/fj.02-0724com	http://dx.doi.org/10.1096/fj.02-0724com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724343				2022-12-28	WOS:000183165000010
J	Izzotti, A; Balansky, RM; Cartiglia, C; Camoirano, A; Longobardi, M; De Flora, S				Izzotti, A; Balansky, RM; Cartiglia, C; Camoirano, A; Longobardi, M; De Flora, S			Genomic and transcriptional alterations in mouse fetus liver after transplacental exposure to cigarette smoke	FASEB JOURNAL			English	Article						mouse liver development; transplacental cigarette smoke; N-acetylcysteine; genomic alterations; multigene expression analysis	TOBACCO-SPECIFIC NITROSAMINE; SISTER-CHROMATID EXCHANGES; N-ACETYLCYSTEINE; OXIDATIVE STRESS; GENE-EXPRESSION; INTERCELLULAR COMMUNICATION; CHILDHOOD EXPOSURE; MATERNAL EXPOSURE; ADDUCT FORMATION; CANCER-RISK	The transplacental exposure of fetuses to maternal cigarette smoke may increase the risk of developmental impairments, congenital diseases, and childhood cancer. The whole-body exposure of Swiss mice to environmental cigarette smoke (ECS) during pregnancy decreased the number of fetuses per dam, placenta weight, and fetus weight. ECS increased DNA adducts, oxidative nucleotide alterations, and cytogenetic damage in fetus liver. Evaluation by cDNA array of 746 genes showed that 61 of them were expressed in fetus liver under basal conditions. The oral administration of N-acetylcysteine (NAC) during pregnancy enhanced the expression of three genes only, including two glutathione S-transferases and alpha1-antitrypsin precursor, whose deficiency plays a pathogenetic role in congenital emphysema. Transplacental ECS upregulated the expression of 116 genes involved in metabolism, response to oxidative stress, DNA and protein repair, and signal transduction. NAC inhibited the ECS-related genetic damage and upregulation of most genes. ECS stimulated pro-apoptotic genes and genes downregulating the cell cycle, which may justify growth impairments in the developing fetus. Thus, both genetic and epigenetic mechanisms were modulated by ECS. Moreover, hypoxia-related genes and several oncogenes and receptors involved in proliferation and differentiation of leukocytes were induced in the fetal liver, which also bears hematopoietic functions.	Univ Genoa, Dept Hlth Sci, I-16132 Genoa, Italy; Natl Oncol Ctr, BU-1157 Sofia, Bulgaria	University of Genoa; National Oncology Center - Bulgaria	De Flora, S (corresponding author), Univ Genoa, Dept Hlth Sci, Via A Pastore 1, I-16132 Genoa, Italy.	sdf@unige.it		izzotti, alberto/0000-0002-8588-0347				Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; ANDERSON LM, 1989, CANCER RES, V49, P3770; ARDITO G, 1980, MUTAT RES, V78, P209, DOI 10.1016/0165-1218(80)90100-7; BALANSKY RB, 1992, CANCER LETT, V64, P123, DOI 10.1016/0304-3835(92)90072-4; BALANSKY RM, 1989, MUTAT RES, V223, P1, DOI 10.1016/0165-1218(89)90056-6; BALANSKY RM, 1991, IARC SCI PUBL, V105, P535; BIALKOWSKA A, 2003, IN PRESS ARCH ENV RE; Boffetta P, 2000, ENVIRON HEALTH PERSP, V108, P73, DOI 10.2307/3454298; Bosio A, 2002, CARCINOGENESIS, V23, P741, DOI 10.1093/carcin/23.5.741; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; BULAY OM, 1971, JNCI-J NATL CANCER I, V46, P397; Bush PG, 2000, PLACENTA, V21, P824, DOI 10.1053/plac.2000.0571; CORREA E, 1990, CANCER RES, V50, P3435; De Flora S, 2003, MUTAT RES-FUND MOL M, V523, P237, DOI 10.1016/S0027-5107(02)00340-8; De Flora S, 2001, CARCINOGENESIS, V22, P999, DOI 10.1093/carcin/22.7.999; DEFLORA S, 1986, ANTICANCER RES, V6, P1009; DEFLORA S, 1985, CARCINOGENESIS, V6, P1735; DEFLORA S, 1986, CANCER LETT, V32, P235, DOI 10.1016/0304-3835(86)90175-8; Devanaboyina U, 1996, CARCINOGENESIS, V17, P917, DOI 10.1093/carcin/17.5.917; EVERSON RB, 1980, LANCET, V2, P123; Finette BA, 1998, NAT MED, V4, P1144, DOI 10.1038/2640; Freed BM, 2001, TOXICOL SCI, V59, P1, DOI 10.1093/toxsci/59.1.1; GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943; GUPTA RC, 1985, CANCER RES, V45, P5656; HANSEN C, 1992, TERATOGEN CARCIN MUT, V12, P51, DOI 10.1002/tcm.1770120202; HAYES JA, 1977, LAB ANIM SCI, V27, P762; Horowitz RS, 1997, J TOXICOL-CLIN TOXIC, V35, P447, DOI 10.3109/15563659709001226; IDELL S, 1983, CLIN CHEST MED, V4, P359; *INT AG RES CANC, 1986, IARC MON EV CARC RIS, V96; Izzotti A, 1999, CARCINOGENESIS, V20, P1499, DOI 10.1093/carcin/20.8.1499; Izzotti A, 1999, MUTAT RES-GEN TOX EN, V446, P215, DOI 10.1016/S1383-5718(99)00189-8; IZZOTTI A, 1992, CARCINOGENESIS, V13, P2187, DOI 10.1093/carcin/13.11.2187; Izzotti A, 1998, FREE RADICAL RES, V28, P165, DOI 10.3109/10715769809065802; KARUBE T, 1989, CANCER RES, V49, P3550; LEICHTER J, 1995, GROWTH DEVELOP AGING, V59, P63; Lin LH, 2000, J NEUROCHEM, V74, P1098; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; McKarns SC, 2000, TOXICOL IN VITRO, V14, P41, DOI 10.1016/S0887-2333(99)00081-8; Nelson E, 1999, HUM EXP TOXICOL, V18, P257, DOI 10.1191/096032799678840011; NICOLOV IG, 1979, J CANCER RES CLIN, V94, P249, DOI 10.1007/BF00419284; Perera FP, 1999, ENVIRON HEALTH PERSP, V107, P451, DOI 10.1289/ehp.99107s3451; PinoriniGodly MT, 1996, TOXICOLOGY, V107, P209, DOI 10.1016/0300-483X(95)03263-F; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; RANDERATH K, 1989, IARC SCI PUBL, V96, P189; Rappa G, 1997, CANCER RES, V57, P5232; REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543; Repine JE, 1997, AM J RESP CRIT CARE, V156, P341, DOI 10.1164/ajrccm.156.2.9611013; SALHAB AS, 1987, CHEM-BIOL INTERACT, V61, P203, DOI 10.1016/0009-2797(87)90001-9; SANDLER DP, 1985, AM J PUBLIC HEALTH, V75, P487, DOI 10.2105/AJPH.75.5.487; SARDAS S, 1995, MUTAT RES-GENET TOX, V341, P249; Sasco AJ, 1999, HUM EXP TOXICOL, V18, P192, DOI 10.1191/096032799678839905; SATOH K, 1988, AM J HUM GENET, V42, P77; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; Sipowicz MA, 1997, CANCER LETT, V117, P87, DOI 10.1016/S0304-3835(97)00208-5; TEAGUE SV, 1994, INHAL TOXICOL, V6, P79, DOI 10.3109/08958379409029697; Tomatis L, 1989, IARC Sci Publ, P1; Trosko JE, 1998, ENVIRON HEALTH PERSP, V106, P331, DOI 10.2307/3433935; Upham BL, 1998, ENVIRON HEALTH PERSP, V106, P975, DOI 10.2307/3434140; Villard PH, 1998, TOXICOL APPL PHARM, V148, P195, DOI 10.1006/taap.1997.8332; Vinson RK, 2001, MUTAT RES-DNA REPAIR, V486, P113, DOI 10.1016/S0921-8777(01)00087-8; Wani G, 1998, CANCER LETT, V125, P123, DOI 10.1016/S0304-3835(97)00507-7; Wilson MR, 2000, EXP CELL RES, V254, P257, DOI 10.1006/excr.1999.4771	62	64	67	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2003	17	6					1127	+		10.1096/fj.02-0967fje	http://dx.doi.org/10.1096/fj.02-0967fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709406				2022-12-28	WOS:000182580100021
J	Yuen, BSJ; Owens, PC; Muhlhausler, BS; Roberts, CT; Symonds, ME; Keisler, DH; McFarlane, JR; Kauter, KG; Evens, Y; McMillen, IC				Yuen, BSJ; Owens, PC; Muhlhausler, BS; Roberts, CT; Symonds, ME; Keisler, DH; McFarlane, JR; Kauter, KG; Evens, Y; McMillen, IC			Leptin alters the structural and functional characteristics of adipose tissue before birth	FASEB JOURNAL			English	Article						fetus; lipid; UCP1	MAINTENANCE ENERGY-REQUIREMENTS; MESSENGER-RNA EXPRESSION; FETAL SHEEP; PLASMA LEPTIN; INTRAUTERINE GROWTH; GENE-EXPRESSION; LATE-GESTATION; CORD-BLOOD; UNCOUPLING PROTEIN; MATERNAL NUTRITION	This study aimed to determine for the first time whether leptin can act to alter the structural and functional characteristics of adipose tissue before birth. Leptin (0.48 mg/kg/day) or saline was infused intravenously into fetal sheep for 4 days from either 136 or 137 days of gestation (term=147+/-3 days). Circulating leptin concentrations were increased approximately four- to fivefold by leptin infusion. Leptin infusion resulted in a significant increase in the proportion of smaller lipid locules present within fetal perirenal adipose tissue (PAT), and this was associated with a significant increase in the proportion of multilocular tissue and a significant decrease in the proportion and relative mass of unilocular tissue in fetal PAT. The relative abundance of leptin mRNA in fetal PAT was significantly lower in the leptin-infused group, and there was a positive correlation between the relative abundance of leptin mRNA and the proportion of unilocular adipose tissue in fetal PAT. The amount of uncoupling protein 1 tended to be higher (P=0.06) in leptin-infused compared with saline-infused fetuses. This is the first demonstration that leptin can act to regulate the lipid storage characteristics, leptin synthetic capacity, and potential thermogenic functions of fat before birth.	Univ Adelaide, Dept Physiol, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Obstet & Gynecol, Adelaide, SA 5005, Australia; Univ Nottingham Hosp, Sch Human Dev, Acad Div Child Hlth, Nottingham NG7 2UH, England; Univ Missouri, Dept Anim Sci, Columbia, MO USA; Univ New England, Dept Physiol, Armidale, NSW 2350, Australia	University of Adelaide; University of Adelaide; University of Nottingham; University of Missouri System; University of Missouri Columbia; University of New England	McMillen, IC (corresponding author), Univ Adelaide, Dept Physiol, Adelaide, SA 5005, Australia.	caroline.mcmillen@adelaide.edu.au	McFarlane, James/F-9277-2010; Keisler, Duane H/C-2746-2011; McMillen, Isabella Caroline/N-5540-2019; Roberts, Claire/A-1205-2007	McFarlane, James/0000-0003-4429-5384; Keisler, Duane H/0000-0002-8792-7030; Symonds, Michael/0000-0001-9649-8963; Kauter, Kate/0000-0003-2470-9172; Muhlhausler, Beverly/0000-0002-9021-6790; Roberts, Claire/0000-0002-9250-2192				Adams MB, 1999, J NEUROENDOCRINOL, V11, P569; Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; ALEXANDER G, 1978, AUST J BIOL SCI, V31, P489, DOI 10.1071/BI9780489; Aprath-Husmann I, 2001, INT J OBESITY, V25, P1465, DOI 10.1038/sj.ijo.0801737; Bassett JM, 1998, AM J PHYSIOL-REG I, V275, pR112, DOI 10.1152/ajpregu.1998.275.1.R112; Blache D, 2000, J ENDOCRINOL, V165, P625, DOI 10.1677/joe.0.1650625; BOUILLAUD F, 1986, J BIOL CHEM, V261, P1487; Bray GA, 1997, J CLIN ENDOCR METAB, V82, P2771, DOI 10.1210/jc.82.9.2771; CASTEILLA L, 1994, BIOCHEM J, V297, P93, DOI 10.1042/bj2970093; Cetin I, 2000, PEDIATR RES, V48, P646, DOI 10.1203/00006450-200011000-00016; CHAN YL, 1984, J BIOL CHEM, V259, P224; Chilliard Y, 2001, DOMEST ANIM ENDOCRIN, V21, P271, DOI 10.1016/S0739-7240(01)00124-2; Cinti S, 1997, ENDOCRINOLOGY, V138, P797, DOI 10.1210/en.138.2.797; Commins SP, 2000, J BIOL CHEM, V275, P33059, DOI 10.1074/jbc.M006328200; Commins SP, 1999, ENDOCRINOLOGY, V140, P4772, DOI 10.1210/en.140.10.4772; Delavaud C, 2000, J ENDOCRINOL, V165, P519, DOI 10.1677/joe.0.1650519; Devaskar SU, 2002, AM J PHYSIOL-REG I, V282, pR431, DOI 10.1152/ajpregu.2002.282.2.R431; Edwards LJ, 2001, ENDOCRINOLOGY, V142, P1778, DOI 10.1210/en.142.5.1778; Ehrhardt RA, 2002, AM J PHYSIOL-REG I, V282, pR1628, DOI 10.1152/ajpregu.00750.2001; Forhead AJ, 2002, ENDOCRINOLOGY, V143, P1166, DOI 10.1210/en.143.4.1166; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fruhbeck G, 1997, BIOCHEM BIOPH RES CO, V240, P590, DOI 10.1006/bbrc.1997.7716; GEMMELL RT, 1978, AUST J BIOL SCI, V31, P505, DOI 10.1071/BI9780505; Gertler A, 1998, FEBS LETT, V422, P137, DOI 10.1016/S0014-5793(97)01613-X; Havel PJ, 1996, J CLIN ENDOCR METAB, V81, P4406, DOI 10.1210/jc.81.12.4406; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; Hoggard N, 1997, P NATL ACAD SCI USA, V94, P11073, DOI 10.1073/pnas.94.20.11073; Jaquet D, 1998, J CLIN ENDOCR METAB, V83, P1243, DOI 10.1210/jc.83.4.1243; Kauter K, 2000, J ENDOCRINOL, V166, P127, DOI 10.1677/joe.0.1660127; Koistinen HA, 1997, J CLIN ENDOCR METAB, V82, P3328, DOI 10.1210/jc.82.10.3328; Lonnqvist F, 1997, J CLIN INVEST, V99, P2398, DOI 10.1172/JCI119422; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; Mizuno A, 1998, ENDOCRINOLOGY, V139, P3863, DOI 10.1210/en.139.9.3863; Mostyn A, 2002, FASEB J, V16, P1438, DOI 10.1096/fj.02-0077fje; Moulin K, 2001, BIOCHEM J, V356, P659, DOI 10.1042/bj3560659; Muhlhausler BS, 2002, BIOL REPROD, V67, P493, DOI 10.1095/biolreprod67.2.493; Muller G, 1997, J BIOL CHEM, V272, P10585, DOI 10.1074/jbc.272.16.10585; Newby D, 2001, J ANIM SCI, V79, P445; Roberts CT, 2001, PLACENTA, V22, P177, DOI 10.1053/plac.2000.0602; Scarpace PJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE259, DOI 10.1152/ajpendo.1998.275.2.E259; Schermer SJ, 1996, REPROD FERT DEVELOP, V8, P995, DOI 10.1071/RD9960995; Schubring C, 1997, J CLIN ENDOCR METAB, V82, P1480, DOI 10.1210/jc.82.5.1480; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Shekhawat PS, 1998, PEDIATR RES, V43, P338, DOI 10.1203/00006450-199803000-00005; Siegrist-Kaiser CA, 1997, J CLIN INVEST, V100, P2858, DOI 10.1172/JCI119834; SYMONDS ME, 1992, J PHYSIOL-LONDON, V455, P487, DOI 10.1113/jphysiol.1992.sp019313; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Thomas L, 2001, J ENDOCRINOL, V169, P465, DOI 10.1677/joe.0.1690465; Wiznitzer A, 2000, OBSTET GYNECOL, V96, P707, DOI 10.1016/S0029-7844(00)00992-3; Yaspelkis BB, 1999, METABOLISM, V48, P671, DOI 10.1016/S0026-0495(99)90070-7; Yuen BSJ, 2002, BIOL REPROD, V67, P911, DOI 10.1095/biolreprod.101.002931; Yuen BSJ, 1999, J ENDOCRINOL, V163, pR11, DOI 10.1677/joe.0.163R011; Zhang YY, 2002, AM J PHYSIOL-REG I, V282, pR226, DOI 10.1152/ajpregu.00392.2001	53	64	65	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1102	+		10.1096/fj.02-0756fje	http://dx.doi.org/10.1096/fj.02-0756fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12709410				2022-12-28	WOS:000182580100031
J	Choi, KS; Fogg, KD; Yoon, CS; Waisman, DM				Choi, KS; Fogg, KD; Yoon, CS; Waisman, DM			p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells	FASEB JOURNAL			English	Article						annexin; S100A10; p11; plasminogen; plasmin; urokinase; cancer	ANNEXIN-II TETRAMER; BREAST-CANCER CELLS; T-PA; BOUND REACTANTS; HUMAN LEUKEMIA; PRO-UROKINASE; SARCOMA-CELLS; ALPHA-ENOLASE; ACTIVATION; RECEPTOR	The defining characteristic of a tumor cell is its ability to escape the constraints imposed by neighboring cells, invade the surrounding tissue, and metastasize to distant sites. This invasive property of tumor cells is dependent on activation of proteases at the cell surface. Most cancer cells secrete the urokinase-type plasminogen activator, which converts cell-bound plasminogen to plasmin. Here we address the issue of whether the plasminogen binding protein, p11, plays a significant role in this process. Transfection of human HT1080 fibrosarcoma cells with the human p11 gene in the antisense orientation resulted in a loss of p11 protein from the cell surface and concomitant decreases in cellular plasmin production, ECM degradation, and cellular invasiveness. The transfected cells demonstrated reduced development of lung metastatic foci in SCID mice. In contrast, HT1080 cells transfected with the p11 gene in the sense orientation displayed increased cell surface p11 protein and concomitant increases in cellular plasmin production, as well as enhanced ECM degradation and enhanced cellular invasiveness. The p11 overexpressing cells showed enhanced development of lung metastatic foci. These data establish that changes in the extracellular expression of the plasminogen receptor protein, p11, dramatically affect tumor cell-mediated pericellular proteolysis.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Med Sci, Calgary, AB T2N 4N1, Canada; Univ Calgary, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Waisman, DM (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	waisman@ucalgary.ca		Waisman, David/0000-0002-5097-9662	NCI NIH HHS [CA78639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andronicos NM, 2001, BRIT J CANCER, V85, P909, DOI 10.1054/bjoc.2001.2022; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHOI KS, 2002, IN PRESS ANNEXINS BI; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DeClerck YA, 1997, ADV EXP MED BIOL, V425, P89; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1993, J BIOL CHEM, V268, P4806; Ellis V, 1996, J BIOL CHEM, V271, P14779, DOI 10.1074/jbc.271.25.14779; Felez J, 1998, FIBRINOLYSIS PROTEOL, V12, P183, DOI 10.1016/S0268-9499(98)80012-X; Fitzpatrick SL, 2000, BIOCHEMISTRY-US, V39, P1021, DOI 10.1021/bi991411z; Fogg DK, 2002, BIOCHEMISTRY-US, V41, P4953, DOI 10.1021/bi012045y; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hawley SB, 2001, J BIOL CHEM, V276, P179, DOI 10.1074/jbc.M004919200; HEMBROUGH TA, 1995, J CELL SCI, V108, P1071; Hembrough TA, 1996, J BIOL CHEM, V271, P25684, DOI 10.1074/jbc.271.41.25684; JONES PA, 1979, P NATL ACAD SCI USA, V76, P353, DOI 10.1073/pnas.76.1.353; Kang HM, 1999, TRENDS CARDIOVAS MED, V9, P92, DOI 10.1016/S1050-1738(99)00012-2; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; Kralovich KR, 1998, J PROTEIN CHEM, V17, P845, DOI 10.1023/A:1020738620817; LAUG WE, 1992, INT J CANCER, V52, P298, DOI 10.1002/ijc.2910520224; Lijnen HR, 1998, THROMB HAEMOSTASIS, V79, P1171; Ma JX, 2000, J BIOL CHEM, V275, P12806, DOI 10.1074/jbc.275.17.12806; Mai JX, 2000, BBA-PROTEIN STRUCT M, V1477, P215, DOI 10.1016/S0167-4838(99)00274-5; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; Mustjoki S, 1999, APMIS, V107, P144, DOI 10.1111/j.1699-0463.1999.tb01537.x; NAMIRANIAN S, 1995, BIOCHEM J, V309, P977, DOI 10.1042/bj3090977; Pancholi V, 2001, CELL MOL LIFE SCI, V58, P902, DOI 10.1007/PL00000910; Pepper MS, 2001, THROMB HAEMOSTASIS, V86, P346; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; Rabbani S A, 2001, Surg Oncol Clin N Am, V10, P393; REDLITZ A, 1995, BAILLIERE CLIN HAEM, V8, P313, DOI 10.1016/S0950-3536(05)80270-7; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; SUENSON E, 1988, BIOCHEMISTRY-US, V27, P2435, DOI 10.1021/bi00407a029; Tapiovaara H, 1996, ADV CANCER RES, V69, P101, DOI 10.1016/S0065-230X(08)60861-1; Tibbles LA, 2002, J VIROL, V76, P1559, DOI 10.1128/JVI.76.4.1559-1568.2002; YEATMAN TJ, 1993, CLIN EXP METASTAS, V11, P37, DOI 10.1007/BF00880064	39	59	65	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					235	246		10.1096/fj.02-0697com	http://dx.doi.org/10.1096/fj.02-0697com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554702				2022-12-28	WOS:000181456900048
J	Plackett, TP; Schilling, EM; Douglas, DE; Choudhry, MA; Witte, PL; Kovacs, EJ				Plackett, TP; Schilling, EM; Douglas, DE; Choudhry, MA; Witte, PL; Kovacs, EJ			Aging enhances lymphocyte cytokine defects after injury	FASEB JOURNAL			English	Article						burns; trauma; IL-4; IL-10; IFN gamma	AGE-RELATED-CHANGES; FLOW CYTOMETRIC ANALYSIS; TRAUMA-HEMORRHAGE; THERMAL-INJURY; T-CELLS; INTERFERON-GAMMA; IMMUNE-RESPONSES; INTERLEUKIN-6-DEFICIENT MICE; MEDIATED-IMMUNITY; ETHANOL EXPOSURE	Mortality and sepsis after a traumatic injury is greater in the elderly than in young individuals. The altered lymphocyte response observed to occur in healthy aged individuals is proposed to be a contributing factor to increased mortality. The immune response associated with the increased mortality was explored using a murine scald injury model. In the absence of injury, aged mice had depressed delayed-type hypersensitivity (DTH) and splenocyte proliferative responses relative to young mice. There was also an increase with age in the production of the TH2 cytokines interleukin (IL)-4 and IL-10 by splenocytes. There was no change in the TH1 cytokines IFNgamma or IL-12 with age. However, IL-2 production was significantly lower. Following injury, there was a further decrease in the DTH response of aged injured mice, compared with aged sham mice. In addition, there was a decrease in all of the cytokines examined, regardless of age. In contrast, IFNgamma and IL-2 were significantly lower in the aged injured animals compared with the young injured animals. These results suggest that the lack of an adequate amount of TH1 cytokines shortly after injury in the aged mice may parallel the increased incidence of sepsis and death that occurs in aged burn patients.	Loyola Univ, Stritch Sch Med, Dept Cell Biol Neurobiol & Anat, Maywood, IL 60513 USA; Loyola Univ, Stritch Sch Med, Dept Surg, Maywood, IL 60513 USA; Loyola Univ, Immunol & Aging Program, Maywood, IL 60153 USA; Loyola Univ, Burn & Shock Trauma Inst, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; Loyola University Chicago	Kovacs, EJ (corresponding author), Loyola Univ, Stritch Sch Med, Dept Cell Biol Neurobiol & Anat, Bldg 110,Room 4237,2160 S 1st Ave, Maywood, IL 60513 USA.	ekovacs@lumc.edu		Plackett, Timothy/0000-0002-0580-6287				Adolfsson O, 2001, J IMMUNOL, V167, P3809, DOI 10.4049/jimmunol.167.7.3809; ALEXANDER JW, 1996, ARCH SURG-CHICAGO, V93, P75; Billiau A, 1998, ANN NY ACAD SCI, V856, P22, DOI 10.1111/j.1749-6632.1998.tb08309.x; Bruunsgaard H, 2000, CLIN EXP IMMUNOL, V119, P433, DOI 10.1046/j.1365-2249.2000.01146.x; Cumming J, 2001, J TRAUMA, V50, P510, DOI 10.1097/00005373-200103000-00016; DALRYMPLE SA, 1995, INFECT IMMUN, V63, P2262, DOI 10.1128/IAI.63.6.2262-2268.1995; De AK, 2000, CLIN IMMUNOL, V96, P52, DOI 10.1006/clim.2000.4879; Decker D, 1996, SURGERY, V119, P316, DOI 10.1016/S0039-6060(96)80118-8; Dhabhar FS, 2000, ANN NY ACAD SCI, V917, P876, DOI 10.1111/j.1749-6632.2000.tb05454.x; DORIA G, 1994, ANN NY ACAD SCI, V741, P299, DOI 10.1111/j.1749-6632.1994.tb23113.x; Durbin EA, 2000, CYTOKINE, V12, P1669, DOI 10.1006/cyto.2000.0768; Ershler WB, 2000, ANNU REV MED, V51, P245, DOI 10.1146/annurev.med.51.1.245; Ertel W, 1996, ARCH SURG-CHICAGO, V131, P51; Faunce DE, 1997, J LEUKOCYTE BIOL, V62, P733, DOI 10.1002/jlb.62.6.733; Ferrari E, 2001, EUR J ENDOCRINOL, V144, P319, DOI 10.1530/eje.0.1440319; FRANKLIN RA, 1993, MECH AGEING DEV, V67, P33, DOI 10.1016/0047-6374(93)90110-D; Ginaldi L, 2001, AM J HEMATOL, V67, P63, DOI 10.1002/ajh.1082; Glaser R, 2001, J GERONTOL A-BIOL, V56, pM477, DOI 10.1093/gerona/56.8.M477; Gregory MS, 2000, J LEUKOCYTE BIOL, V67, P319, DOI 10.1002/jlb.67.3.319; GRIFFITHS RW, 1981, BURNS, V7, P365, DOI 10.1016/0305-4179(81)90012-7; Han SN, 2000, J INFECT DIS, V182, pS74, DOI 10.1086/315915; Haynes L, 1999, J EXP MED, V190, P1013, DOI 10.1084/jem.190.7.1013; Hensler T, 1997, INFECT IMMUN, V65, P2283, DOI 10.1128/IAI.65.6.2283-2291.1997; Hobden JA, 1997, INFECT IMMUN, V65, P2754, DOI 10.1128/IAI.65.7.2754-2758.1997; Kahlke V, 2000, AM J PHYSIOL-CELL PH, V278, pC509, DOI 10.1152/ajpcell.2000.278.3.C509; Kahlke V, 2000, CYTOKINE, V12, P69, DOI 10.1006/cyto.1999.0511; Kelly JL, 1997, SURGERY, V122, P146, DOI 10.1016/S0039-6060(97)90003-9; Kernacki KA, 2000, INVEST OPHTH VIS SCI, V41, P3019; Knoferl MW, 2001, AM J PHYSIOL-CELL PH, V281, pC1131, DOI 10.1152/ajpcell.2001.281.4.C1131; KOERNER TJ, 1987, CELL IMMUNOL, V109, P437, DOI 10.1016/0008-8749(87)90326-1; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kovacs EJ, 2002, J AM AGING ASSOC, V25, P3, DOI 10.1007/s11357-002-0001-4; KUBO M, 1990, EUR J IMMUNOL, V20, P1289, DOI 10.1002/eji.1830200614; LINN BS, 1980, J AM GERIATR SOC, V28, P118, DOI 10.1111/j.1532-5415.1980.tb00244.x; Mascarucci P, 2001, AGING-CLIN EXP RES, V13, P85, DOI 10.1007/BF03351530; MCIRVINE AJ, 1982, ANN SURG, V196, P297; Messingham KAN, 2002, ALCOHOL CLIN EXP RES, V26, P519, DOI 10.1097/00000374-200204000-00013; MEYERS BR, 1989, AM J MED, V86, P379, DOI 10.1016/0002-9343(89)90333-1; Miller RA, 1996, SCIENCE, V273, P70, DOI 10.1126/science.273.5271.70; MILLER RA, 1991, INT REV CYTOL, V124, P187; NAGELKERKEN L, 1991, EUR J IMMUNOL, V21, P273, DOI 10.1002/eji.1830210206; Newton C, 2000, INFECT IMMUN, V68, P5234, DOI 10.1128/IAI.68.9.5234-5240.2000; O'Sullivan ST, 1997, BRIT J PLAST SURG, V50, P615, DOI 10.1016/S0007-1226(97)90507-5; Oberholzer A, 2000, CRIT CARE MED, V28, pN3, DOI 10.1097/00003246-200004001-00002; PRUITT BA, 1990, BRIT J SURG, V77, P1081, DOI 10.1002/bjs.1800771002; PRUITT BA, 1964, ANN SURG, V159, P396; Puyana JC, 1998, J TRAUMA, V44, P1037, DOI 10.1097/00005373-199806000-00017; Ramzy PI, 1999, CRIT CARE CLIN, V15, P333, DOI 10.1016/S0749-0704(05)70058-0; Rittenbury M S, 1965, J Trauma, V5, P587; Schneider CP, 2000, SHOCK, V14, P347, DOI 10.1097/00024382-200014030-00019; Song C, 1999, PSYCHIAT RES, V85, P71, DOI 10.1016/S0165-1781(98)00130-9; SONG LJ, 1993, EXP GERONTOL, V28, P313, DOI 10.1016/0531-5565(93)90058-L; Spector WS, 1956, HDB BIOL DATA; Spellberg B, 2001, CLIN INFECT DIS, V32, P76, DOI 10.1086/317537; Straub RH, 2000, J NEUROIMMUNOL, V109, P10, DOI 10.1016/S0165-5728(00)00296-4; TEJERINA C, 1992, BURNS, V18, P149, DOI 10.1016/0305-4179(92)90015-M; TRAN DD, 1990, CRIT CARE MED, V18, P474, DOI 10.1097/00003246-199005000-00002; Wakikawa A, 1997, MECH AGEING DEV, V94, P113, DOI 10.1016/S0047-6374(97)01880-0; WEIGLE WO, 1989, HOSP PRACT, V24, P112; Ye SM, 1999, J NEUROIMMUNOL, V93, P139, DOI 10.1016/S0165-5728(98)00217-3	60	46	49	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					688	+		10.1096/fj.02-0452fje	http://dx.doi.org/10.1096/fj.02-0452fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594182				2022-12-28	WOS:000181456900001
J	Nakamura, M; Matzuk, MM; Gerstmayer, B; Bosio, A; Lauster, R; Miyachi, Y; Werner, S; Paus, R				Nakamura, M; Matzuk, MM; Gerstmayer, B; Bosio, A; Lauster, R; Miyachi, Y; Werner, S; Paus, R			Control of pelage hair follicle development and cycling by complex interactions between follistatin and activin	FASEB JOURNAL			English	Article						BMP-2; MGP, morphogenesis; TGF-beta	MATRIX GLA PROTEIN; COMPREHENSIVE GUIDE; GENE-EXPRESSION; GROWTH-FACTOR; RECEPTOR; INVOLVEMENT; OVEREXPRESSION; REVEALS; NOGGIN; DIFFERENTIATION	Members of the transforming growth factor beta/bone morphogenetic protein (TGF-beta/BMP) family are involved in the control of hair follicle (HF) morphogenesis and cycling. The activities of several members of this family (activins and BMP-2, -4, -7, and -11) are controlled by antagonists such as follistatin. Because follistatin-deficient mice show abnormalities in vibrissae development, we explored the role of follistatin and activin in pelage HF development and cycling. We show here that during HF development follistatin mRNA was prominently expressed by hair matrix and outer root sheath keratinocytes as well as by interfollicular epidermal cells, whereas activin betaA mRNA was mainly expressed in dermal papilla cells. Compared with age-matched wild-type controls, both follistatin knockout mice and activin betaA transgenic mice showed a significant retardation of HF morphogenesis. Treatment of wild-type embryonic skin explants with follistatin protein stimulated HF development. This effect was inhibited by addition of recombinant activin A protein. Activin betaA transgenic mice demonstrated retardation of catagen entry, down-regulation of BMP-2, and up-regulation of expression of its antagonist matrix GLA protein. These observations suggest that follistatin and activin interaction plays an important role in both HF development and cycling, possibly in part by regulating expression of BMP-2 and its antagonist.	Univ Hamburg, Univ Hosp Eppendorf, Dept Dermatol, D-20246 Hamburg, Germany; Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Memorec Stoffel Gmbh, D-50829 Cologne, Germany; Deutsch Rheumaforschungszentrum, Berlin, Germany; Swiss Fed Inst Technol, Inst Cell Biol, Zurich, Switzerland	University of Hamburg; University Medical Center Hamburg-Eppendorf; Kyoto University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Deutsches Rheuma-Forschungszentrum (DRFZ); Swiss Federal Institutes of Technology Domain; ETH Zurich	Paus, R (corresponding author), Univ Hamburg, Univ Hosp Eppendorf, Dept Dermatol, Martinistr 52, D-20246 Hamburg, Germany.	paus@uke.uni-hamburg.de	Paus, Ralf/F-6243-2011	Bosio, Andreas/0000-0001-9776-2535; Werner, Sabine/0000-0001-7397-8710				Bosio A, 2002, CARCINOGENESIS, V23, P741, DOI 10.1093/carcin/23.5.741; Bostrom K, 2001, J BIOL CHEM, V276, P14044, DOI 10.1074/jbc.M008103200; Botchkarev VA, 2002, J INVEST DERMATOL, V118, P3, DOI 10.1046/j.1523-1747.2002.01645.x; Botchkarev VA, 1999, NAT CELL BIOL, V1, P158, DOI 10.1038/11078; Botchkarev VA, 1998, AM J PATHOL, V153, P785, DOI 10.1016/S0002-9440(10)65621-0; Botchkarev VA, 1998, J INVEST DERMATOL, V111, P279, DOI 10.1046/j.1523-1747.1998.00277.x; Botchkarev VA, 2001, FASEB J, V15, P2205, DOI 10.1096/fj.01-0207com; Botchkareva NV, 1999, DEV BIOL, V216, P135, DOI 10.1006/dbio.1999.9464; Botchkareva NV, 2000, J INVEST DERMATOL, V114, P314, DOI 10.1046/j.1523-1747.2000.00864.x; Brown CW, 2000, NAT GENET, V25, P453, DOI 10.1038/78140; Cotsarelis G, 2001, TRENDS MOL MED, V7, P293, DOI 10.1016/S1471-4914(01)02027-5; de Berker D, 2000, BRIT J DERMATOL, V142, P89, DOI 10.1046/j.1365-2133.2000.03246.x; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; FEIJEN A, 1994, DEVELOPMENT, V120, P3621; Ferguson CA, 1998, GENE DEV, V12, P2636, DOI 10.1101/gad.12.16.2636; Ferguson CA, 2001, DEVELOPMENT, V128, P4605; Foitzik K, 1999, DEV BIOL, V212, P278, DOI 10.1006/dbio.1999.9325; Gamer LW, 1999, DEV BIOL, V208, P222, DOI 10.1006/dbio.1998.9191; Guo QX, 1998, MOL ENDOCRINOL, V12, P96, DOI 10.1210/mend.12.1.0053; HANDJISKI BK, 1994, BRIT J DERMATOL, V131, P303, DOI 10.1111/j.1365-2133.1994.tb08515.x; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; IEMURA S, 1998, P NATL ACAD SCI USA, V77, P649; Ito Y, 2001, DEV BIOL, V236, P181, DOI 10.1006/dbio.2001.0332; Kim SK, 2000, GENE DEV, V14, P1866; Kulessa H, 2000, EMBO J, V19, P6664, DOI 10.1093/emboj/19.24.6664; Lindner G, 2000, FASEB J, V14, P319, DOI 10.1096/fasebj.14.2.319; Magerl M, 2001, J INVEST DERMATOL, V116, P947, DOI 10.1046/j.0022-202x.2001.01368.x; Massague J, 2000, GENE DEV, V14, P627; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1993, RECEPTOR, V3, P173; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; MCLEAN WHI, 1995, NAT GENET, V9, P273, DOI 10.1038/ng0395-273; Merino R, 1999, DEVELOPMENT, V126, P2161; Millar SE, 2002, J INVEST DERMATOL, V118, P216, DOI 10.1046/j.0022-202x.2001.01670.x; Miralles F, 1998, DEVELOPMENT, V125, P1017; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; Nakamura M, 2001, EXP DERMATOL, V10, P369, DOI 10.1034/j.1600-0625.2001.100601.x; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Patel K, 1998, INT J BIOCHEM CELL B, V30, P1087, DOI 10.1016/S1357-2725(98)00064-8; Patel K, 1999, MECH DEVELOP, V86, P51, DOI 10.1016/S0925-4773(99)00107-0; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PAUS R, 1996, CURR OPIN DERMATOL, V3, P248; ROBERTS VJ, 1991, ENDOCRINOLOGY, V128, P3122, DOI 10.1210/endo-128-6-3122; Smith M, 1998, JNMS-J NEUROMUSC SYS, V6, P17; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Tomiuk S, 2001, Brief Bioinform, V2, P329, DOI 10.1093/bib/2.4.329; UENO N, 1987, P NATL ACAD SCI USA, V84, P8282, DOI 10.1073/pnas.84.23.8282; Wankell M, 2001, J ENDOCRINOL, V171, P385, DOI 10.1677/joe.0.1710385; Wankell M, 2001, EMBO J, V20, P5361, DOI 10.1093/emboj/20.19.5361; YASUDA H, 1993, J CLIN INVEST, V92, P1491, DOI 10.1172/JCI116727; Zebboudj AF, 2002, J BIOL CHEM, V277, P4388, DOI 10.1074/jbc.M109683200	55	59	64	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					497	+		10.1096/fj.02-0247fje	http://dx.doi.org/10.1096/fj.02-0247fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12514121				2022-12-28	WOS:000181453700028
J	Okada, M; Yan, SF; Pinsky, DJ				Okada, M; Yan, SF; Pinsky, DJ			Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets	FASEB JOURNAL			English	Article						ischemia; reperfusion; early growth response-1; troglitazone	RENAL ISCHEMIA/REPERFUSION INJURY; TRANSCRIPTION FACTOR; VITAMIN-E; REPERFUSION; ADIPOGENESIS; CHEMOKINES; EXPRESSION; CYTOKINES; REGULATOR; HYPOXIA	The peroxisome proliferator-activated receptor (PPAR) is a nuclear receptor whose activation regulates metabolism and inflammation. Recent data indicate that the zinc finger transcription factor early growth response gene-1 (Egr-1) acts as a master switch for the inflammatory response in ischemic vessels. Experiments tested the hypothesis that activation of endogenous PPAR-gamma inhibits induction of Egr-1. Egr-1 is rapidly induced in murine lungs after ischemia-reperfusion, as well as in alveolar mononuclear phagocytes deprived of oxygen as an ischemic model. In vitro, the natural PPAR-gamma ligand (15-deoxy-Delta(12,14)-prostaglandin J(2)) and a PPAR-gamma activator (troglitazone), but not a PPAR-gamma activator (bezafibrate), strikingly diminished Egr-1 mRNA and protein expression and nuclear DNA binding activity corresponding to Egr-1. In vivo, treatment with troglitazone before ischemia prevented induction of Egr-1 and its target genes such as interleukin-1beta, monocyte chemotactic protein-1, and macrophage inflammatory protein-2. As a consequence of PPAR-gamma activation, pulmonary leukostasis was decreased and oxygenation and overall survival were improved. Activation of PPAR-gamma suppresses activation of Egr-1 and its inflammatory gene targets and provides potent protection against ischemic pulmonary injury. These data reveal a new mechanism whereby PPAR-gamma activation may decrease tissue inflammation in response to an ischemic insult.	Columbia Univ Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Pinsky, DJ (corresponding author), Columbia Univ Coll Phys & Surg, PH 10 Stem,630 W 168th St, New York, NY 10032 USA.	djp5@columbia.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060900, R01HL059488, R01HL055397] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55397, HL60900, HL59488] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams DH, 1997, LANCET, V349, P490, DOI 10.1016/S0140-6736(96)07524-1; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FURIE MB, 1995, AM J PATHOL, V146, P1287; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GOLDBLUM SE, 1985, J APPL PHYSIOL, V59, P1978, DOI 10.1152/jappl.1985.59.6.1978; Heemann U, 2000, AM J PATHOL, V156, P287, DOI 10.1016/S0002-9440(10)64729-3; HERSKOWITZ A, 1995, AM J PATHOL, V146, P419; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Miura M, 2001, AM J PATHOL, V159, P2137, DOI 10.1016/S0002-9440(10)63065-9; Nakajima A, 2001, GASTROENTEROLOGY, V120, P460, DOI 10.1053/gast.2001.21191; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Okada M, 2001, FASEB J, V15, P2757, DOI 10.1096/fj.01-0490fje; Ricote M, 1999, J LEUKOCYTE BIOL, V66, P733, DOI 10.1002/jlb.66.5.733; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Venditti P, 1999, ARCH PHYSIOL BIOCHEM, V107, P27, DOI 10.1076/apab.107.1.27.4355; Venditti P, 2000, LIFE SCI, V66, P697, DOI 10.1016/S0024-3205(99)00641-4; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030	25	101	110	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2002	16	14					1861	1868		10.1096/fj.02-0503com	http://dx.doi.org/10.1096/fj.02-0503com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	638MG	12468449				2022-12-28	WOS:000180574300005
J	Delgado, M; Leceta, J; Ganea, D				Delgado, M; Leceta, J; Ganea, D			Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells	FASEB JOURNAL			English	Article						VIP; PACAP; neuroimmunomodulation; memory T cells; apoptosis	T-CELLS; FAS LIGAND; INDUCED APOPTOSIS; VIP; EXPRESSION; LYMPHOCYTES; DEATH; NEUROPEPTIDES; TRANSCRIPTION; MACROPHAGES	Functionally active effector T cells are generated through clonal expansion. Most effector T cells are later eliminated, whereas a small number survive and differentiate into memory T cells. The mechanisms by which some effector T cells escape apoptosis and become memory T cells are not understood. Neuropeptides such as the vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) inhibit antigen-induced apoptosis of CD4 T cells. By using an in vivo long-term experimental model, in which CD4 T cells from TRC-transgenic mice were transferred into hosts, we demonstrate that VIP and PACAP induce the survival and/or generation of antigen-specific CD4 T cells with a memory Th2 phenotype. This was confirmed by the fact that transgenic CD4 T cells were recovered only from mice that received Th2, but not Th1 effector cells, in the presence of VIP or PACAP. In vitro, VIP/PACAP support the survival of Th2, but not Th1, cell lines through an inhibition of antigen-induced apoptosis. The role of neuropeptides in the biased development of Th2 memory cells is particularly relevant in view of the immune deviation existing in immune-privileged sites such as the brain and eye, where Th2, but not Th1, responses occur in nonpathological conditions.	Univ Complutense, Fac Biol, Dept Biol Celular, E-28040 Madrid, Spain; Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA	Complutense University of Madrid; Rutgers State University Newark; Rutgers State University New Brunswick	Delgado, M (corresponding author), Univ Complutense, Sch Biol, Dept Cell Biol, E-28040 Madrid, Spain.	mariodm@bio.ucm.es	Leceta, Javier/H-6940-2017; Delgado, Mario/P-1524-2016	Leceta, Javier/0000-0003-4845-0046; Delgado, Mario/0000-0003-1893-5982				Bellinger DL, 1996, ADV NEUROIMMUNOL, V6, P5, DOI 10.1016/S0960-5428(96)00008-3; Cerwenka A, 1996, J IMMUNOL, V156, P459; Delgado M, 2000, J IMMUNOL, V164, P1200, DOI 10.4049/jimmunol.164.3.1200; Delgado M, 1999, ANN NY ACAD SCI, V897, P401, DOI 10.1111/j.1749-6632.1999.tb07909.x; Delgado M, 1999, J NEUROIMMUNOL, V96, P167, DOI 10.1016/S0165-5728(99)00023-5; Delgado M, 2001, J IMMUNOL, V166, P2907, DOI 10.4049/jimmunol.166.5.2907; Delgado M, 1999, J IMMUNOL, V163, P3629; Delgado M, 2001, J IMMUNOL, V166, P1028, DOI 10.4049/jimmunol.166.2.1028; Delgado M, 2000, J IMMUNOL, V165, P114, DOI 10.4049/jimmunol.165.1.114; EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25; Ganea D, 2001, ARCH IMMUNOL THER EX, V49, P101; Genestier L, 1999, J EXP MED, V189, P231, DOI 10.1084/jem.189.2.231; Gomariz RP, 2001, CURR PHARM DESIGN, V7, P89, DOI 10.2174/1381612013398374; Harling-Berg CJ, 1999, J NEUROIMMUNOL, V101, P111, DOI 10.1016/S0165-5728(99)00130-7; Harmar AJ, 1998, PHARMACOL REV, V50, P265; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; Leceta J, 1996, ADV NEUROIMMUNOL, V6, P29, DOI 10.1016/S0960-5428(96)00001-0; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Martinez C, 1999, J NEUROIMMUNOL, V93, P126, DOI 10.1016/S0165-5728(98)00216-1; MCCORMACK JE, 1993, J IMMUNOL, V150, P3785; POWERS GD, 1988, J IMMUNOL, V140, P3352; Pozo D, 2000, IMMUNOL TODAY, V21, P7, DOI 10.1016/S0167-5699(99)01525-X; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; Streilein JW, 2000, ANN NY ACAD SCI, V917, P297; SWAIN SL, 1994, IMMUNITY, V1, P543, DOI 10.1016/1074-7613(94)90044-2; Takahashi M, 1999, CLIN EXP IMMUNOL, V116, P231; Wang HY, 2000, J NEUROIMMUNOL, V104, P68, DOI 10.1016/S0165-5728(99)00244-1; WEINBERG AD, 1990, J IMMUNOL, V144, P1800; ZHANG XH, 1995, J EXP MED, V182, P699, DOI 10.1084/jem.182.3.699; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837; Zheng LX, 1998, J IMMUNOL, V160, P763	34	57	63	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13	1				1844	+		10.1096/fj.02-0248fje	http://dx.doi.org/10.1096/fj.02-0248fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	649CJ	12223451				2022-12-28	WOS:000181189100002
J	Inui, S; Fukuzato, Y; Nakajima, T; Yoshikawa, K; Itami, S				Inui, S; Fukuzato, Y; Nakajima, T; Yoshikawa, K; Itami, S			Androgen-inducible TGF-beta 1 from balding dermal papilla cells inhibits epithelial cell growth: a clue to understanding paradoxical effects of androgen on human hair growth	FASEB JOURNAL			English	Article						androgenetic alopecia; androgen receptor; growth factor	IN-VITRO; RECEPTOR; 5-ALPHA-REDUCTASE; EXPRESSION; BETA; CONTAIN; BEARD; DIFFERENTIATION; KERATINOCYTES; TESTOSTERONE	We attempted establishing an in vitro coculture system by using human dermal papilla cells (DPCs) from androgenetic alopecia (AGA) and keratinocytes (KCs) to explore the role of androgens in hair growth regulation. Androgen showed no significant effect on the growth of KCs when they were cocultured with DPCs from AGA. Because the expressions of mRNA of androgen receptor (AR) decreased during subcultivation of DPCs in vitro, we transiently transfected the AR expression vector into the DPCs and cocultured them with KCs. In this modified coculture, androgen significantly suppressed the growth of KCs by similar to50%, indicating that overexpression of AR can restore the responsiveness of the DPCs to androgen in vivo. We found that androgen stimulated the expression of TGF-beta1 mRNA in the cocultured DPCs. ELISA assays demonstrated that androgen treatment increased the secretion of both total and active TGF-beta1 in the conditioned medium. Moreover, the neutralizing anti-TGF-beta1 antibody reversed the androgen-elicited growth inhibition of KCs in a dose-dependent manner. These findings suggest that androgen-inducible TGF-beta1 derived from DPCs of AGA is involved in epithelial cell growth suppression in our coculture system, providing the clue to understand the paradoxical effects of androgens for human hair growth.	Osaka Univ, Dept Dermatol, Course Mol Med, Grad Sch Med, Suita, Osaka 5650871, Japan	Osaka University	Itami, S (corresponding author), Osaka Univ, Dept Dermatol, Course Mol Med, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	itami@derma.med.osaka-u.ac.jp						Ando Y, 1999, BRIT J DERMATOL, V141, P840, DOI 10.1046/j.1365-2133.1999.03156.x; Asada Y, 2001, J CLIN ENDOCR METAB, V86, P2875, DOI 10.1210/jc.86.6.2875; CHOUDHRY R, 1992, J ENDOCRINOL, V133, P467, DOI 10.1677/joe.0.1330467; EBILING FJG, 1986, J CLIN ENDOCR METAB, V15, P319; Foitzik K, 2000, FASEB J, V14, P752, DOI 10.1096/fasebj.14.5.752; Hamilton JB, 1942, AM J ANAT, V71, P451, DOI 10.1002/aja.1000710306; HEINLEIN CA, 2002, ENDOCR REV, V23, P175, DOI DOI 10.1210/ER.23.2.175; Hibberts NA, 1998, J ENDOCRINOL, V156, P59, DOI 10.1677/joe.0.1560059; Inui S, 2000, J DERMATOL SCI, V23, P87, DOI 10.1016/S0923-1811(99)00091-2; ITAMI S, 1991, ANN NY ACAD SCI, V642, P385; ITAMI S, 1995, BRIT J DERMATOL, V132, P527; ITAMI S, 1995, BIOCHEM BIOPH RES CO, V212, P988, DOI 10.1006/bbrc.1995.2067; ITAMI S, 1990, J INVEST DERMATOL, V94, P150, DOI 10.1111/1523-1747.ep12874003; ITAMI S, 1991, J INVEST DERMATOL, V96, P57, DOI 10.1111/1523-1747.ep12514729; Kamimura J, 1997, J INVEST DERMATOL, V109, P534, DOI 10.1111/1523-1747.ep12336704; Khalil N, 1999, MICROBES INFECT, V1, P1255, DOI 10.1016/S1286-4579(99)00259-2; LINK RE, 1990, J INVEST DERMATOL, V95, P202, DOI 10.1111/1523-1747.ep12478002; Liu X, 2001, P NATL ACAD SCI USA, V98, P9139, DOI 10.1073/pnas.161016098; MATSUMOTO K, 1990, J CELL PHYSIOL, V145, P95, DOI 10.1002/jcp.1041450114; Obana N, 1997, ENDOCRINOLOGY, V138, P356, DOI 10.1210/en.138.1.356; Pan HJ, 1999, ENDOCRINE, V11, P321, DOI 10.1385/ENDO:11:3:321; Parrelli JM, 1998, INT J BIOCHEM CELL B, V30, P623, DOI 10.1016/S1357-2725(98)00005-3; Paus R, 1997, J INVEST DERMATOL, V109, P518, DOI 10.1111/1523-1747.ep12336635; Pentyala SN, 1998, CANCER LETT, V130, P121, DOI 10.1016/S0304-3835(98)00120-7; RANDALL VA, 1992, J ENDOCRINOL, V133, P141, DOI 10.1677/joe.0.1330141; SHIPLEY GD, 1986, CANCER RES, V46, P2068; Soma T, 1998, J INVEST DERMATOL, V111, P948, DOI 10.1046/j.1523-1747.1998.00408.x; Sonoda Tadashige, 1993, Journal of Dermatological Science, V6, P214, DOI 10.1016/0923-1811(93)90041-M; UNO H, 1967, J INVEST DERMATOL, V49, P288, DOI 10.1038/jid.1967.138; Xing RHM, 1999, ENDOCRINOLOGY, V140, P4056, DOI 10.1210/en.140.9.4056; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	31	147	164	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1967	+		10.1096/fj.02-0043fje	http://dx.doi.org/10.1096/fj.02-0043fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397096				2022-12-28	WOS:000179167600010
J	Jacobs, EH; Spijker, S; Verhoog, CW; Kamprath, K; de Vries, TJ; Smit, AB; Schoffelmeer, ANM				Jacobs, EH; Spijker, S; Verhoog, CW; Kamprath, K; de Vries, TJ; Smit, AB; Schoffelmeer, ANM			Active heroin administration induces specific genomic responses in the nucleus accumbens shell	FASEB JOURNAL			English	Article						addiction; instrumental learning; long-term gene expression; subtractive hybridization; quantitative real-time PCR	MESSENGER-RNA; INDEPENDENT COCAINE; SEEKING BEHAVIOR; DENDRITIC SPINES; MORPHINE; DOPAMINE; EXPRESSION; RECEPTOR; RELAPSE; NEURONS	Long-term drug-induced alterations in gene expression underlying neuroplasticity in the nucleus accumbens (NAc) may play a crucial role in relapse behavior in abstinent drug addicts. In this respect, stimulus-induced relapse behavior is considered as the retrieval of stored drug-related information. Because the NAc shell may determine the impact of external and internal stimuli on goal-directed behavior, we compared long-term gene expression in this brain region after active and passive administration of different drugs of abuse. We made use of a preselected set of transcripts that were down-regulated 3 wk after active i.v. heroin self-administration. We found that most of these transcripts were not down-regulated long after passive exposure to the opiate. Most of the active heroin administration-regulated transcripts were also down-regulated in the NAc shell following active cocaine administration (common denominators). As observed with passive administration of heroin, passive exposure to cocaine was found to be relatively ineffective in reducing the expression of these transcripts. This work reveals that active drug consumption during self-administration (instrumental learning) is a crucial psychological factor directing long-term genomic responses in the brain.	Vrije Univ Amsterdam, Neurosci Res Inst, Dept Med Pharmacol, Med Ctr,Drug Abuse Program, NL-1081 BT Amsterdam, Netherlands; Fac Earth & Life Sci, Dept Mol & Cellular Neurobiol, NL-1081 HV Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Schoffelmeer, ANM (corresponding author), Vrije Univ Amsterdam, Neurosci Res Inst, Dept Med Pharmacol, Med Ctr,Drug Abuse Program, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	anm.schoffelmeer.pharm@med.vu.nl	De Vries, Taco J/B-2831-2014; Spijker, Sabine/F-2300-2011; Smit, August B/E-8410-2011	Spijker, Sabine/0000-0002-6814-2019; De Vries, Taco/0000-0002-0340-4946				Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Berry MD, 2000, J NEUROSCI RES, V60, P150, DOI 10.1002/(SICI)1097-4547(20000415)60:2<150::AID-JNR3>3.0.CO;2-4; Boronat MA, 2001, BRIT J PHARMACOL, V134, P1263, DOI 10.1038/sj.bjp.0704364; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Caporaso GL, 2000, NEUROPHARMACOLOGY, V39, P1637, DOI 10.1016/S0028-3908(99)00230-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; De Vries TJ, 2001, NAT MED, V7, P1151, DOI 10.1038/nm1001-1151; De Vries TJ, 1998, EUR J NEUROSCI, V10, P3565, DOI 10.1046/j.1460-9568.1998.00368.x; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DiCiano P, 1996, BEHAV PHARMACOL, V7, P714; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Ghasemzadeh MB, 1999, J NEUROCHEM, V72, P157, DOI 10.1046/j.1471-4159.1999.0720157.x; Harlan RE, 1998, MOL NEUROBIOL, V16, P221, DOI 10.1007/BF02741385; Hemby SE, 1997, PSYCHOPHARMACOLOGY, V133, P7, DOI 10.1007/s002130050365; HOUK JC, 1995, CEREB CORTEX, V5, P95, DOI 10.1093/cercor/5.2.95; Houk JC, 1995, MODELS INFORMATION P, P249; Hu SX, 2002, NEUROPHARMACOLOGY, V42, P829, DOI 10.1016/S0028-3908(02)00030-8; Kelley AE, 1997, P NATL ACAD SCI USA, V94, P12174, DOI 10.1073/pnas.94.22.12174; Kelley AE, 1999, PSYCHOBIOLOGY, V27, P198; Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7; Kuzmin A, 1999, EUR J NEUROSCI, V11, P3694, DOI 10.1046/j.1460-9568.1999.00795.x; Lecuona E, 2000, FEBS LETT, V481, P217, DOI 10.1016/S0014-5793(00)02009-3; Lee RS, 1999, SYNAPSE, V33, P49, DOI 10.1002/(SICI)1098-2396(199907)33:1<49::AID-SYN5>3.3.CO;2-F; Mark GP, 1999, PSYCHOPHARMACOLOGY, V143, P47, DOI 10.1007/s002130050918; Matus A, 2000, SCIENCE, V290, P754, DOI 10.1126/science.290.5492.754; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Nestby P, 1997, PSYCHOPHARMACOLOGY, V133, P69, DOI 10.1007/s002130050373; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Parkinson JA, 1999, J NEUROSCI, V19, P2401; Robbins TW, 1996, CURR OPIN NEUROBIOL, V6, P228, DOI 10.1016/S0959-4388(96)80077-8; Robinson TE, 1999, SYNAPSE, V33, P160; Robinson TE, 2001, SYNAPSE, V39, P257; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Schoffelmeer ANM, 2001, SYNAPSE, V42, P87, DOI 10.1002/syn.1104; Shaham Y, 1996, J NEUROSCI, V16, P1957; Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1; SPANAGEL R, 1993, SYNAPSE, V14, P243, DOI 10.1002/syn.890140307; SPANAKIS E, 1993, NUCLEIC ACIDS RES, V21, P3809, DOI 10.1093/nar/21.16.3809; Stefanski R, 1999, EUR J PHARMACOL, V371, P123, DOI 10.1016/S0014-2999(99)00094-1; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; van Rossum D, 1999, TRENDS NEUROSCI, V22, P290, DOI 10.1016/S0166-2236(99)01404-6; Wang XB, 1997, J NEUROSCI, V17, P5993; Wise Roy A., 2000, Neuron, V26, P27, DOI 10.1016/S0896-6273(00)81134-4; Yoshida T, 1999, FEBS LETT, V457, P251, DOI 10.1016/S0014-5793(99)01048-0; ZAHM DS, 1992, NEUROSCIENCE, V50, P751, DOI 10.1016/0306-4522(92)90202-D; Zahm DS, 2000, NEUROSCI BIOBEHAV R, V24, P85, DOI 10.1016/S0149-7634(99)00065-2	47	45	46	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1961	+		10.1096/fj.02-0272fje	http://dx.doi.org/10.1096/fj.02-0272fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397092				2022-12-28	WOS:000179167600003
J	Hohaus, A; Person, V; Behlke, J; Schaper, J; Morano, I; Haase, H				Hohaus, A; Person, V; Behlke, J; Schaper, J; Morano, I; Haase, H			The carboxyl-terminal region of ahnak provides a link between cardiac L-type Ca2+ channels and the actin-based cytoskeleton	FASEB JOURNAL			English	Article						L-type calcium channel; beta subunit; protein-protein interaction; cardiomyocytes	PROTEIN-KINASE-A; CALCIUM-CHANNEL; BETA-SUBUNIT; DESMOYOKIN/AHNAK PROTEIN; GENE AHNAK; PLASMA-MEMBRANE; EXPRESSION; BINDING; IDENTIFICATION; TRANSLOCATION	Ahnak is a ubiquitously expressed giant protein of 5643 amino acids implicated in cell differentiation and signal transduction. In a recent study, we demonstrated the association of ahnak with the regulatory beta2 subunit of the cardiac L-type Ca2+ channel. Here we identify the most carboxyl-terminal ahnak region (aa 5262-5643) to interact with recombinant beta2a as well as with beta2 and beta1a isoforms of native muscle Ca2+ channels using a panel of GST fusion proteins. Equilibrium sedimentation analysis revealed K-d values of 55 +/- 11 nM and 328 +/- 24 nM for carboxyl- terminal (aa 195- 606) and amino-terminal (aa 1-200) truncates of the beta2a subunit, respectively. The same carboxyl-terminal ahnak region (aa 5262-5643) bound to G-actin and cosedimented with F-actin. Confocal microscopy of human left ventricular tissue localized the carboxyl-terminal ahnak portion to the sarcolemma including the T-tubular system and the intercalated disks of cardiomyocytes. These results suggest that ahnak provides a structural basis for the subsarcolemmal cytoarchitecture and confers the regulatory role of the actin-based cytoskeleton to the L-type Ca2+ channel.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Max Planck Inst Physiol & Clin Res, D-61231 Bad Nauheim, Germany; Humboldt Univ, Charite, Inst Physiol, D-10117 Berlin, Germany; Humboldt Univ, Charite, Franz Volhard Clin, D-13125 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Haase, H (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	haase@mdc-berlin.de						Behlke J, 1997, EUR BIOPHYS J BIOPHY, V25, P325, DOI 10.1007/s002490050046; Behlke J, 1999, PROG COLL POL SCI S, V113, P182; Behlke J, 1997, BIOCHEMISTRY-US, V36, P5149, DOI 10.1021/bi962755h; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Bredt DS, 1999, NAT CELL BIOL, V1, pE89, DOI 10.1038/12085; Caldwell JH, 2000, MICROSC RES TECHNIQ, V49, P84, DOI 10.1002/(SICI)1097-0029(20000401)49:1<84::AID-JEMT9>3.0.CO;2-E; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; Gentil BJ, 2001, J BIOL CHEM, V276, P23253, DOI 10.1074/jbc.M010655200; Gerster U, 1999, J PHYSIOL-LONDON, V517, P353, DOI 10.1111/j.1469-7793.1999.0353t.x; Gomez AM, 2000, CIRC RES, V86, P30, DOI 10.1161/01.RES.86.1.30; HAASE H, 1991, EUR J PHARM-MOLEC PH, V207, P51, DOI 10.1016/S0922-4106(05)80037-9; Haase H, 2000, J CELL BIOCHEM, V76, P695, DOI 10.1002/(SICI)1097-4644(20000315)76:4<695::AID-JCB17>3.0.CO;2-Q; HAASE H, 1993, FEBS LETT, V335, P217, DOI 10.1016/0014-5793(93)80733-B; Haase H, 1999, FASEB J, V13, P2161, DOI 10.1096/fasebj.13.15.2161; HAASE H, 1994, RECEPTOR CHANNEL, V2, P41; HASHIMOTO T, 1993, J CELL SCI, V105, P275; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; HIEDA Y, 1989, J CELL BIOL, V109, P1511, DOI 10.1083/jcb.109.4.1511; Hohaus A, 2000, BIOCHEM J, V348, P657, DOI 10.1042/0264-6021:3480657; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Kamp TJ, 2000, CIRC RES, V87, P1095, DOI 10.1161/01.RES.87.12.1095; Kingsley PD, 2001, DEV GROWTH DIFFER, V43, P133; Kostin S, 1998, CELL TISSUE RES, V294, P449, DOI 10.1007/s004410051196; Krafft C, 2000, FEBS LETT, V471, P128, DOI 10.1016/S0014-5793(00)01377-6; KUDOH J, 1995, CYTOGENET CELL GENET, V70, P218, DOI 10.1159/000134037; Lader AS, 1999, AM J PHYSIOL-CELL PH, V277, pC1277, DOI 10.1152/ajpcell.1999.277.6.C1277; MASUNAGA T, 1995, J INVEST DERMATOL, V104, P941, DOI 10.1111/1523-1747.ep12606213; MELTZER NM, 1987, ANAL BIOCHEM, V160, P356, DOI 10.1016/0003-2697(87)90060-1; Morano I, 1997, FEBS LETT, V408, P71, DOI 10.1016/S0014-5793(97)00390-6; Nakamura M, 2000, AM J PHYSIOL-CELL PH, V279, pC480, DOI 10.1152/ajpcell.2000.279.2.C480; Nie ZZ, 2000, J INVEST DERMATOL, V114, P1044, DOI 10.1046/j.1523-1747.2000.00949.x; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; Prat AG, 1999, AM J PHYSIOL-CELL PH, V277, pC1160, DOI 10.1152/ajpcell.1999.277.6.C1160; Schade M, 1999, FEBS LETT, V458, P27, DOI 10.1016/S0014-5793(99)01119-9; Schwartz T, 2001, NAT STRUCT BIOL, V8, P761, DOI 10.1038/nsb0901-761; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; Sussman J, 2001, J CELL BIOL, V154, P1019, DOI 10.1083/jcb.200105121; Wyman J., 1990, BINDING LINKAGE; Xu H, 2000, FEBS LETT, V482, P180, DOI 10.1016/S0014-5793(00)02026-3	44	107	107	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1205	10.1096/fj.01-0855com	http://dx.doi.org/10.1096/fj.01-0855com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12153988				2022-12-28	WOS:000177814000029
J	Wu, CG; Forgues, M; Siddique, S; Farnsworth, J; Velerie, K; Wang, XW				Wu, CG; Forgues, M; Siddique, S; Farnsworth, J; Velerie, K; Wang, XW			SAGE transcript profiles of normal primary human hepatocytes expressing oncogenic hepatitis B virus X protein	FASEB JOURNAL			English	Article						liver cancer; Megarray; nuclear export signal	GENE-EXPRESSION; HEPATOCELLULAR-CARCINOMA; TRANSGENIC MICE; SERIAL ANALYSIS; LIVER-CANCER; HEPATOCARCINOGENESIS; INFECTION; LOCALIZATION; ETIOLOGY; COMPLEX	Hepatitis B virus (HBV) is a major risk factor for hepatocellular carcinoma (HCC). HBV encodes an oncogenic HBx gene that functions as a transcriptional coactivator of multiple cellular genes. To understand the role(s) of HBx in the early genesis of HCC, we systematically analyzed gene expression profiles by serial analysis of gene expression (SAGE) in freshly isolated human primary hepatocytes infected with a replication-defective adenovirus containing HBx. A total of 19,501 sequence tags (representing 1443 unique transcripts) were analyzed, which provide a distribution of a transcriptome characteristic of normal hepatocytes and a profile associated with HBx expression. Examples of the targeted genes were confirmed by the Megarray analysis with a significant correlation between quantitative SAGE and Megarray (r = 0.8, P < 0.005). In HBx-expressing hepatocytes, a total of 57 transcripts (3.9%) were induced, and 46 transcripts (3.3%) were repressed by more than fivefold. Interestingly, most of the HBx-up-regulated transcripts can be clustered into three major classes, including genes that encode ribosomal proteins, transcription factors with zinc-finger motifs, and proteins associated with protein degradation pathways. These results suggest that HBx may function as a major regulator in common cellular pathways that, in turn, regulate protein synthesis, gene transcription, and protein degradation.	NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; US FDA, Div Hematol, Ctr Biol Evaluat & Res, Bethesda, MD 20014 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); Virginia Commonwealth University	Wang, XW (corresponding author), NCI, Human Carcinogenesis Lab, Ctr Canc Res, NIH, 37 Convent Dr,MSC 4255,Bldg 37,Room 2C25, Bethesda, MD 20892 USA.	xin_wei_wang@nih.gov	Wang, Xin Wei/B-6162-2009	Wang, Xin Wei/0000-0001-9735-606X				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Andrisani OM, 1999, INT J ONCOL, V15, P373; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bradley DW, 1999, P ASSOC AM PHYSICIAN, V111, P588, DOI 10.1046/j.1525-1381.1999.t01-1-99240.x; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; CASELMANN WH, 1995, J HEPATOL, V22, P34; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Feitelson MA, 1999, J CELL PHYSIOL, V181, P188; Forgues M, 2001, J BIOL CHEM, V276, P22797, DOI 10.1074/jbc.M101259200; Heinrich JM, 2001, J IMMUNOL, V167, P1624, DOI 10.4049/jimmunol.167.3.1624; Hoare J, 2001, J MED VIROL, V64, P419, DOI 10.1002/jmv.1067; Hough CD, 2000, CANCER RES, V60, P6281; KAWAMATA H, 1995, INT J CANCER, V63, P680, DOI 10.1002/ijc.2910630513; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; LAI WS, 1995, J BIOL CHEM, V270, P25266, DOI 10.1074/jbc.270.42.25266; Maddrey WC, 2000, J MED VIROL, V61, P362, DOI 10.1002/1096-9071(200007)61:3&lt;362::AID-JMV14&gt;3.0.CO;2-I; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; Robinson WS, 1999, MICROBES AND MALIGNANCY, P232; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Shilatifard A, 1997, P NATL ACAD SCI USA, V94, P3639, DOI 10.1073/pnas.94.8.3639; Song J, 2001, J BIOL CHEM, V276, P19897, DOI 10.1074/jbc.M010658200; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Vernon E, 2001, MOL CELL NEUROSCI, V17, P637, DOI 10.1006/mcne.2000.0960; Wu CG, 1996, BBA-MOL BASIS DIS, V1315, P169, DOI 10.1016/0925-4439(95)00117-4; Wu CG, 1997, CARCINOGENESIS, V18, P47, DOI 10.1093/carcin/18.1.47; Wu CG, 2001, ONCOGENE, V20, P3674, DOI 10.1038/sj.onc.1204481; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V269, P110, DOI 10.1006/bbrc.2000.2272; Yeh CT, 2000, J GASTROEN HEPATOL, V15, P339, DOI 10.1046/j.1440-1746.2000.02166.x; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Zhang ZS, 2000, J BIOL CHEM, V275, P15157, DOI 10.1074/jbc.M910378199; Zhou W, 1998, CANCER EPIDEM BIOMAR, V7, P109; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	39	26	29	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2002	16	10					1665	+		10.1096/fj.02-0074fje	http://dx.doi.org/10.1096/fj.02-0074fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12207007				2022-12-28	WOS:000177814000019
J	Rebuffat, AG; Nawrocki, AR; Nielsen, PE; Bernasconi, AG; Bernal-Mendez, E; Frey, BM; Frey, FJ				Rebuffat, AG; Nawrocki, AR; Nielsen, PE; Bernasconi, AG; Bernal-Mendez, E; Frey, BM; Frey, FJ			Gene delivery by a steroid-peptide nucleic acid conjugate	FASEB JOURNAL			English	Article						nonviral; peptide nucleic acid; glucocorticosteroid; glucocorticoid receptor	ESTROGEN-RECEPTOR-BETA; PLASMID DNA; GLUCOCORTICOID RECEPTOR; STRAND DISPLACEMENT; PROSTATE-CANCER; BREAST-CANCER; LIVING CELLS; EXPRESSION; PNA; BINDING	We previously introduced a method called steroid-mediated gene delivery (SMGD), which uses steroid receptors as shuttles to facilitate the nuclear uptake of transfected DNA. Here, we describe a SMGD strategy with peptide nucleic acids (PNAs) that allowed linkage of a steroid molecule to a defined position in a plasmid without disturbing its gene expression. We synthesized and tested several bifunctional steroid derivatives [patent in process of nationalization] and finally selected the compound named DEX-bisPNA, a molecule consisting of a dexamethasone moiety linked to a PNA clamp (bisPNA) through a 30-atom chemical spacer. Dex-bisPNA binds to the glucocorticoid receptor (GR) as well as to reporter plasmids containing the corresponding PNA binding sites, translocates the GR from the cytoplasm into the nucleus, and increases the delivery of plasmid to the nucleus, resulting in enhanced GR-dependent expression of the reporter gene. The SMGD effect was more pronounced in growth-arrested cells than in proliferating cells. The specificity for the GR was shown by the reversion of the SMGD effect in the presence of dexamethasone as well as an enhanced expression in GR-positive cells but not in GR-negative cells. Thus, SMGD with PNA is a promising strategy for nonviral gene delivery into target tissues expressing specific steroid receptors.	Univ Bern, Div Nephrol & Hypertens, Dept Med, CH-3010 Bern, Switzerland; Univ Bern, Div Nephrol & Hypertens, Dept Clin Res, CH-3010 Bern, Switzerland; Univ Bern, Dept Chem, CH-3010 Bern, Switzerland; Univ Copenhagen, Panum Inst, Dept B, Ctr Biomol Recognit,IMBG, DK-2200 Copenhagen N, Denmark	University of Bern; University of Bern; University of Bern; University of Copenhagen	Frey, FJ (corresponding author), Univ Bern, Div Nephrol & Hypertens, Dept Med, Freiburgstr 15, CH-3010 Bern, Switzerland.	felix.frey@insel.ch						ACEDO M, 1995, BIOORG MED CHEM LETT, V5, P1577, DOI 10.1016/0960-894X(95)00274-W; AKNER G, 1995, J STEROID BIOCHEM, V52, P1, DOI 10.1016/0960-0760(94)00155-F; Becker K, 1999, HUM GENE THER, V10, P2559, DOI 10.1089/10430349950016898; Bernasconi A, 2001, TETRAHEDRON LETT, V42, P6511, DOI 10.1016/S0040-4039(01)01291-6; BERNASCONI AG, 2001, THESIS U BERN, P1; Boulikas T., 1998, GENE THER MOL BIOL, V1, P713; Branden LJ, 1999, NAT BIOTECHNOL, V17, P784, DOI 10.1038/11726; Brinkmann AO, 2000, NAT MED, V6, P628, DOI 10.1038/76194; Brunner S, 2000, GENE THER, V7, P401, DOI 10.1038/sj.gt.3301102; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; Cheng PW, 1996, HUM GENE THER, V7, P275, DOI 10.1089/hum.1996.7.3-275; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHRISTENSEN L, 1995, J PEPT SCI, V1, P175, DOI DOI 10.1002/PSC.310010304; Coward P, 1998, P NATL ACAD SCI USA, V95, P352, DOI 10.1073/pnas.95.1.352; DEMIDOV VV, 1995, P NATL ACAD SCI USA, V92, P2637, DOI 10.1073/pnas.92.7.2637; DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; EGHOLM M, 1995, NUCLEIC ACIDS RES, V23, P217, DOI 10.1093/nar/23.2.217; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; EGHOLM M, 1992, J AM CHEM SOC, V114, P9677, DOI 10.1021/ja00050a068; FUNDER JW, 1973, ENDOCRINOLOGY, V92, P1005, DOI 10.1210/endo-92-4-1005; FUNDER JW, 1992, SEMIN NEPHROL, V12, P6; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GREENBERG ME, 1997, CURR PROT MOL BIOL, V1; Hager GL, 2000, J STEROID BIOCHEM, V74, P249, DOI 10.1016/S0960-0760(00)00100-X; HOUSLEY PR, 1989, BIOCHEM BIOPH RES CO, V164, P480, DOI 10.1016/0006-291X(89)91745-2; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Kersten S, 2001, FASEB J, V15, P1971, DOI 10.1096/fj.01-0147com; Kuhn H, 1998, NUCLEIC ACIDS RES, V26, P582, DOI 10.1093/nar/26.2.582; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Lechardeur D, 1999, GENE THER, V6, P482, DOI 10.1038/sj.gt.3300867; Liang KW, 2000, MOL THER, V1, P236, DOI 10.1006/mthe.2000.0043; Ma Haiching, 2001, Current Pharmaceutical Biotechnology, V2, P1, DOI 10.2174/1389201013378770; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mesika A, 2001, MOL THER, V3, P653, DOI 10.1006/mthe.2001.0312; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MONDER C, 1991, FASEB J, V5, P3047, DOI 10.1096/fasebj.5.15.1743437; Mortimer I, 1999, GENE THER, V6, P403, DOI 10.1038/sj.gt.3300837; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NIELSEN PE, 1999, PEPTIDE NUCL ACIDS P, P253; Nielsen Peter E., 1994, Journal of Molecular Recognition, V7, P165, DOI 10.1002/jmr.300070303; Nishikawa M, 2001, HUM GENE THER, V12, P861, DOI 10.1089/104303401750195836; Odermatt A, 2001, J BIOL CHEM, V276, P28484, DOI 10.1074/jbc.M100374200; Pampinella F, 2002, MOL THER, V5, P161, DOI 10.1006/mthe.2002.0528; Perales JC, 1997, J BIOL CHEM, V272, P7398, DOI 10.1074/jbc.272.11.7398; Pratt WB, 2001, TRENDS PLANT SCI, V6, P54, DOI 10.1016/S1360-1385(00)01843-4; Rebuffat A, 2001, NAT BIOTECHNOL, V19, P1155, DOI 10.1038/nbt1201-1155; Reid P, 1999, INVEST NEW DRUG, V17, P271, DOI 10.1023/A:1006344807086; Sebestyen MG, 1998, NAT BIOTECHNOL, V16, P80, DOI 10.1038/nbt0198-80; Speirs V, 1999, CANCER RES, V59, P5421; Vacik J, 1999, GENE THER, V6, P1006, DOI 10.1038/sj.gt.3300924; Veselkov AG, 1996, NUCLEIC ACIDS RES, V24, P2483, DOI 10.1093/nar/24.13.2483; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; Ward CM, 2000, CURR OPIN MOL THER, V2, P182; Wei P, 1998, J STEROID BIOCHEM, V64, P1, DOI 10.1016/S0022-1759(97)89907-3; Zelphati O, 1999, HUM GENE THER, V10, P15, DOI 10.1089/10430349950019156; Zelphati O, 2000, BIOTECHNIQUES, V28, P304, DOI 10.2144/00282rr01	58	46	53	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2002	16	9					1426	+		10.1096/fj.01-0706fje	http://dx.doi.org/10.1096/fj.01-0706fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205036				2022-12-28	WOS:000177813100019
J	Werz, O; Burkert, E; Fischer, L; Szellas, D; Dishart, D; Samuelsson, B; Radmark, O; Steinhilber, D				Werz, O; Burkert, E; Fischer, L; Szellas, D; Dishart, D; Samuelsson, B; Radmark, O; Steinhilber, D			Extracellular signal-regulated kinases phosphorylate 5-lipoxygenase and stimulate 5-lipoxygenase product formation in leukocytes	FASEB JOURNAL			English	Article						arachidonic acid; leukotriene; p38 MAP kinase	ACTIVATED PROTEIN-KINASE; CYTOSOLIC PHOSPHOLIPASE A(2); ARACHIDONIC-ACID RELEASE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; MYELIN BASIC-PROTEIN; HUMAN-NEUTROPHILS; LEUKOTRIENE SYNTHESIS; SUBSTRATE RECOGNITION; CHEMOTACTIC FACTOR; HUMAN EOSINOPHILS	5-Lipoxygenase (5-LO) is the key enzyme in the biosynthesis of proinflammatory leukotrienes. Here, we demonstrate that extracellular signal-regulated kinases (ERKs) can phosphorylate 5-LO in vitro. Efficient phosphorylation required the presence of unsaturated fatty acids and was abolished when Ser-663 was mutated to alanine. In intact HeLa cells stimulated with arachidonic acid (AA), impaired 5-LO product formation was evident in cells expressing the S663A-5-LO mutant compared with cells expressing wild-type 5-LO. For Mono Mac 6 cells, priming with phorbol myristate acetate (PMA) before stimulation with ionophore was required for ERK1/2 activation and efficient 5-LO phosphorylation, in parallel with substantial AA release and 5-LO product formation. Inhibition of PKC by GF109203x or MEK1/2 by U0126 (or PD98059) abolished the 5-LO up-regulation effects of PMA. In contrast, these inhibitors failed to suppress 5-LO product formation induced by stimuli such as AA plus ionophore, which apparently do not involve the ERK1/2 pathway. Based on inhibitor studies, ERKs are also involved in AA-stimulated 5-LO product formation in PMNL, whereas a role for ERKs is not apparent in 5-LO activation induced by ionophore or cell stress. Finally, the data suggest that ERKs and p38 MAPK-regulated MAPKAPKs can act in conjunction to stimulate 5-LO by phosphorylation.	Goethe Univ Frankfurt, Inst Pharmaceut Chem, D-60439 Frankfurt, Germany; Karolinska Inst, Div Physiol Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Goethe University Frankfurt; Karolinska Institutet	Werz, O (corresponding author), Goethe Univ Frankfurt, Inst Pharmaceut Chem, Marie Curie Str 9, D-60439 Frankfurt, Germany.	o.werz@pharmchem.uni-frankfurt.de	Steinhilber, Dieter/J-3221-2012					Ahamed J, 2002, J BIOL CHEM, V277, P22685, DOI 10.1074/jbc.M110210200; Bates ME, 2000, J BIOL CHEM, V275, P10968, DOI 10.1074/jbc.275.15.10968; Boden SE, 2000, INT J BIOCHEM CELL B, V32, P1069, DOI 10.1016/S1357-2725(00)00049-2; Boden SE, 2001, MOL PHARMACOL, V60, P267, DOI 10.1124/mol.60.2.267; BRUNGS M, 1995, P NATL ACAD SCI USA, V92, P107, DOI 10.1073/pnas.92.1.107; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; Caporale T, 1998, APPL ECON LETT, V5, P165, DOI 10.1080/758521375; Chang LC, 2001, J LEUKOCYTE BIOL, V69, P659; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Elzi DJ, 2001, AM J PHYSIOL-CELL PH, V281, pC350; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; HAMMARBERG T, 1995, EUR J BIOCHEM, V230, P401; Hammarberg T, 1999, BIOCHEMISTRY-US, V38, P4441, DOI 10.1021/bi9824700; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Hazan-Halevy I, 2000, J BIOL CHEM, V275, P12416, DOI 10.1074/jbc.275.17.12416; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; Lepley RA, 1998, ARCH BIOCHEM BIOPHYS, V356, P71, DOI 10.1006/abbi.1998.0744; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; Lepley RA, 1996, ARCH BIOCHEM BIOPHYS, V331, P141, DOI 10.1006/abbi.1996.0292; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; NACCACHE PH, 1989, BRIT J PHARMACOL, V97, P461, DOI 10.1111/j.1476-5381.1989.tb11973.x; NACCACHE PH, 1979, SCIENCE, V203, P461, DOI 10.1126/science.760200; Peters-Golden M, 2000, AM J RESP CRIT CARE, V161, pS36, DOI 10.1164/ajrccm.161.supplement_1.ltta-8; Provost P, 2001, J BIOL CHEM, V276, P16520, DOI 10.1074/jbc.M011205200; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; Radmark OP, 2000, AM J RESP CRIT CARE, V161, pS11, DOI 10.1164/ajrccm.161.supplement_1.ltta-3; ROUZER CA, 1986, FEBS LETT, V204, P293, DOI 10.1016/0014-5793(86)80831-6; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHATZMUNDING M, 1991, EUR J BIOCHEM, V197, P487, DOI 10.1111/j.1432-1033.1991.tb15936.x; Surette ME, 1999, MOL PHARMACOL, V56, P1055, DOI 10.1124/mol.56.5.1055; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Werz O, 1996, EUR J BIOCHEM, V242, P90, DOI 10.1111/j.1432-1033.1996.0090r.x; Werz O, 2002, J BIOL CHEM, V277, P14793, DOI 10.1074/jbc.M111945200; Werz O, 2002, BLOOD, V99, P1044, DOI 10.1182/blood.V99.3.1044; Werz O, 2001, BLOOD, V97, P2487, DOI 10.1182/blood.V97.8.2487; Werz O, 2001, J LEUKOCYTE BIOL, V70, P830; Werz O, 1996, PHARMAZIE, V51, P893; WHITE JR, 1983, BIOCHEM BIOPH RES CO, V113, P44, DOI 10.1016/0006-291X(83)90429-1; Zhu XD, 2001, J IMMUNOL, V167, P461, DOI 10.4049/jimmunol.167.1.461	52	114	117	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1441	+		10.1096/fj.01-0909fje	http://dx.doi.org/10.1096/fj.01-0909fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205041				2022-12-28	WOS:000177813100018
J	Ramsauer, M; Krause, D; Dermietzel, R				Ramsauer, M; Krause, D; Dermietzel, R			Angiogenesis of the blood-brain barrier in vitro and the function of cerebral pericytes	FASEB JOURNAL			English	Article						astrocyte; coculture; endothelial cell; TGF-beta 1	TRANSFORMING-GROWTH-FACTOR; IMMUNOREACTIVE GLUTAMYL AMINOPEPTIDASE; CAPILLARY-LIKE STRUCTURES; SMOOTH-MUSCLE-CELLS; FACTOR TYPE-BETA; ENDOTHELIAL-CELLS; RAT-BRAIN; SPROUT FORMATION; TGF-BETA; CULTURE	Cerebral pericytes constitute an essential component of the blood-brain barrier (BBB) and are involved in blood vessel assembly. Recently, we reported on the induction of a BBB-specific enzyme expressed by cerebral pericytes (pericytic aminopeptidase N/pAPN) in coculture with cerebral endothelial cells. We completed this in vitro BBB system by adding astrocytes to these mixed cultures of endothelial cells and pericytes. Under these triculture conditions, endothelial cells and pericytes reorganize into capillary-like structures (CLSs). Capillary formation can also be achieved by the application of transforming growth factor beta 1 (TGF-beta1) in the culture medium of endothelial-pericyte cultures lacking astrocytes. In contrast to the effect achieved by astrocytes, pericytes did not assemble with endothelial cells. In both cases (application of astrocytes or TGF-beta1), endothelial cells underwent apoptosis. However, endothelial cells that form CLSs in the presence of pericytes appeared to be resistant to induction of apoptosis. On the basis of these observations, we concluded that astrocytes have a profound influence on the morphogenetic events underlying the organization of the vessel wall; that the effect of TGF-beta1 is different from the astrocytic effect because it lacks induction of endothelial-pericyte association; and that pericytes stabilize CLSs formed by endothelial cells in coculture with astrocytes.	Ruhr Univ Bochum, Dept Neuroanat & Mol Brain Res, D-44801 Bochum, Germany	Ruhr University Bochum	Dermietzel, R (corresponding author), Ruhr Univ Bochum, Dept Neuroanat & Mol Brain Res, Univ Str 150, D-44801 Bochum, Germany.	rolf.dermietzel@ruhr-uni-bochum.de						ABBOTT NJ, 1992, J CELL SCI, V103, P23; ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; AUDUS KL, 1987, ANN NY ACAD SCI, V507, P9, DOI 10.1111/j.1749-6632.1987.tb45787.x; Balabanov R, 1998, J NEUROSCI RES, V53, P637, DOI 10.1002/(SICI)1097-4547(19980915)53:6<637::AID-JNR1>3.0.CO;2-6; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BAUSBACK HH, 1988, BIOCHEM PHARMACOL, V37, P155, DOI 10.1016/0006-2952(88)90712-5; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; Crone C., 1984, HDB PHYSL CARDIOVASC, P411; DERMIETZEL R, 1991, INT REV CYTOL, V127, P57; DERMIETZEL R, 1975, CELL TISSUE RES, V164, P45; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; FARRELL CR, 1987, ANAT REC, V218, P466, DOI 10.1002/ar.1092180416; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1986, CANCER RES, V46, P467; FREY A, 1991, EUR J BIOCHEM, V202, P421, DOI 10.1111/j.1432-1033.1991.tb16391.x; GEHRMANN J, 1991, J COMP NEUROL, V313, P409, DOI 10.1002/cne.903130302; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GREENWOOD J, 1991, ANN NY ACAD SCI, V633, P426; HEALY DP, 1993, BRAIN RES, V606, P295, DOI 10.1016/0006-8993(93)90997-2; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; IMAYAMA S, 1984, ANAT EMBRYOL, V169, P271, DOI 10.1007/BF00315632; IRUELAARISPE ML, 1993, J CELL BIOCHEM, V52, P414, DOI 10.1002/jcb.240520406; JOO F, 1992, J NEUROCHEM, V58, P1, DOI 10.1111/j.1471-4159.1992.tb09272.x; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KRAUSE D, 1988, CELL TISSUE RES, V252, P543, DOI 10.1007/BF00216641; KUNZ J, 1995, J NEUROIMMUNOL, V59, P41, DOI 10.1016/0165-5728(95)00024-V; KUNZ J, 1994, J NEUROCHEM, V62, P2375; LATERRA J, 1990, J CELL PHYSIOL, V144, P204, DOI 10.1002/jcp.1041440205; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MAXWELL K, 1989, J NEUROPATH EXP NEUR, V48, P69, DOI 10.1097/00005072-198901000-00006; MAXWELL K, 1987, BRAIN RES, V410, P309, DOI 10.1016/0006-8993(87)90329-5; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEYER J, 1991, J NEUROCHEM, V57, P1971, DOI 10.1111/j.1471-4159.1991.tb06411.x; MEYER J, 1990, BRAIN RES, V514, P305, DOI 10.1016/0006-8993(90)91425-G; MINAKAWA T, 1991, LAB INVEST, V65, P32; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; NEHLS V, 1994, MICROVASC RES, V48, P349, DOI 10.1006/mvre.1994.1061; NEHLS V, 1993, HISTOCHEMISTRY, V99, P1, DOI 10.1007/BF00268014; NEHLS V, 1992, CELL TISSUE RES, V270, P469, DOI 10.1007/BF00645048; ORLIDGE A, 1987, J CELL BIOL, V105, P1455, DOI 10.1083/jcb.105.3.1455; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; PEPPER MS, 1991, J CELL PHYSIOL, V146, P170, DOI 10.1002/jcp.1041460122; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; Ramsauer M, 1998, J CEREBR BLOOD F MET, V18, P1270, DOI 10.1097/00004647-199811000-00014; RAYCHAUDHURY A, 1991, J CELL BIOCHEM, V47, P224, DOI 10.1002/jcb.240470307; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; RISAU W, 1992, J NEUROCHEM, V58, P667, DOI 10.1111/j.1471-4159.1992.tb09769.x; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SONG L, 1993, BRAIN RES, V606, P286, DOI 10.1016/0006-8993(93)90996-Z; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; SUZUMURA A, 1993, J IMMUNOL, V151, P2150; VERHOEVEN D, 1988, VIRCHOWS ARCH B, V54, P263; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WISEMAN DM, 1988, BIOCHEM BIOPH RES CO, V157, P793, DOI 10.1016/S0006-291X(88)80319-X; YANG EY, 1990, J CELL BIOL, V111, P731, DOI 10.1083/jcb.111.2.731	63	119	120	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1274	+		10.1096/fj.01-0814fje	http://dx.doi.org/10.1096/fj.01-0814fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12153997				2022-12-28	WOS:000176683900026
J	Cardoso, I; Merlini, G; Saraiva, MJ				Cardoso, I; Merlini, G; Saraiva, MJ			4 '-iodo-4 '-Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters	FASEB JOURNAL			English	Article						familial amyloidotic polyneuropathy; transthyretin; I-DOX; tetracyclines; amyloid disruption	CARDIAC TOXICITY; POLYNEUROPATHY; CARDIOTOXICITY; INHIBITION; DEPOSITION; RECEPTOR	Transthyretin Leu55Pro is one of the most aggressive mutations in familial amyloidotic polyneuropathy, an autosomal dominant disorder characterized by extracellular deposition of fibrillar amyloid protein. This variant has the ability to form fibrils in vitro under physiological conditions (PBS, pH 7.4). We studied by transmission electron microscopy the effect of the drug 4'-iodo-4'-deoxydoxorubicin (I-DOX) on the in vitro assembly of TTR Leu55Pro fibrils by following fibril growth over a 15 day period. Our results showed that I-DOX at a concentration of 10(-5) M/100 mug fibrils does not inhibit fibril formation in up to 10 days since fibrils identical to the ones present in the untreated sample were observed. However, after 15 days of treatment, only round particles, resembling soluble native TTR, were observed. We also tested the ability of tetracyclines and nitrophenols to interfere with amyloid fibril formation for 17 days; the group of compounds tested showed fibril disruption activity to different extents: doxycycline and 2,4-dinitrophenol resulted in complete disaggregation of fibrils. The species generated upon I-DOX and tetracyclines treatments were nontoxic, as revealed by the lack of significant caspase-3 activation on a Schwannoma cell line, making them potential therapeutic drugs in TTR-related and other amyloidosis.	Univ Porto, IBMC, Amyloid Unit, P-4150180 Oporto, Portugal; Univ Porto, ICBAS, P-4150180 Oporto, Portugal; Policlin San Matteo, IRCCS, Univ Hosp, Biotechnol Res Labs, Pavia, Italy; Univ Pavia, Dept Biochem, I-27100 Pavia, Italy	Universidade do Porto; Universidade do Porto; IRCCS Fondazione San Matteo; University of Pavia; University of Pavia	Saraiva, MJ (corresponding author), Univ Porto, IBMC, Amyloid Unit, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	mjsaraiv@ibmc.up.pt	Cardoso, Isabel/K-3903-2013; Merlini, Giampaolo/A-3817-2008; Saraiva, Maria João/K-3907-2013	Cardoso, Isabel/0000-0003-2472-7055; Merlini, Giampaolo/0000-0001-7680-3254; Saraiva, Maria João/0000-0002-3360-6899				Almeida MR, 1997, ENDOCRINE, V6, P309, DOI 10.1007/BF02820508; Bendeck MP, 2002, AM J PATHOL, V160, P1089, DOI 10.1016/S0002-9440(10)64929-2; Cardoso I, 2002, J MOL BIOL, V317, P683, DOI 10.1006/jmbi.2002.5441; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; COIMBRA A, 1971, BRAIN, V94, P199, DOI 10.1093/brain/94.2.199; DANESI R, 1990, CANCER CHEMOTH PHARM, V26, P403, DOI 10.1007/BF02994089; De Felice FG, 2001, FASEB J, V15, P1297, DOI 10.1096/fj.00-0676fje; Forloni G, 2001, FEBS LETT, V487, P404, DOI 10.1016/S0014-5793(00)02380-2; FURUYA H, 1991, BIOCHEMISTRY-US, V30, P2415, DOI 10.1021/bi00223a017; Gertz MA, 2002, AMYLOID, V9, P24, DOI 10.3109/13506120209072441; GIANNI L, 1995, BLOOD, V86, P855; Howlett DR, 1999, BIOCHEM J, V343, P419, DOI 10.1042/0264-6021:3430419; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERLINI G, 1995, P NATL ACAD SCI USA, V92, P2959, DOI 10.1073/pnas.92.7.2959; Merlini G, 1999, BLOOD, V93, P1112, DOI 10.1182/blood.V93.3.1112; MROSS K, 1990, EUR J CLIN PHARMACOL, V39, P507; Palha JA, 2000, AM J PATHOL, V156, P1919, DOI 10.1016/S0002-9440(10)65065-1; PODESTA A, 1994, TOXICOL PATHOL, V22, P68, DOI 10.1177/019262339402200109; Saraiva MJM, 2001, FEBS LETT, V498, P201, DOI 10.1016/S0014-5793(01)02480-2; Sebastiao MP, 2000, BIOCHEM J, V351, P273, DOI 10.1042/0264-6021:3510273; Sousa MM, 2001, AM J PATHOL, V159, P1993; Sousa MM, 2001, J NEUROSCI, V21, P7576, DOI 10.1523/JNEUROSCI.21-19-07576.2001; Sousa MM, 2000, LAB INVEST, V80, P1101, DOI 10.1038/labinvest.3780116; Suhr OB, 2000, LIVER TRANSPLANT, V6, P263, DOI 10.1053/lv.2000.6145; Tagliavini F, 2000, J MOL BIOL, V300, P1309, DOI 10.1006/jmbi.2000.3840; VILLANI F, 1991, EUR J CANCER, V27, P1601, DOI 10.1016/0277-5379(91)90423-B; VILLANI F, 1988, INVEST NEW DRUG, V6, P173; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	29	97	102	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					803	809		10.1096/fj.02-0764com	http://dx.doi.org/10.1096/fj.02-0764com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724338				2022-12-28	WOS:000183165000005
J	Jiang, Q; Ames, BN				Jiang, Q; Ames, BN			gamma-Tocopherol, but not alpha-tocopherol, decreases proinflammatory eicosanoids and inflammation damage in rats	FASEB JOURNAL			English	Article						vitamin E; gamma-tocopherol metabolite; prostaglandin E-2; leukotriene B-4; TNF-alpha	CORONARY HEART-DISEASE; CYCLOOXYGENASE ACTIVITY; ANTIINFLAMMATORY DRUGS; VITAMIN-E; KAPPA-B; IN-VIVO; CANCER; INHIBITION; MECHANISM; ASPIRIN	gamma-Tocopherol (gammaT), the major form of vitamin E in U.S. diets, and its physiological metabolite 2, 7, 8-trimethyl-2-(beta-carboxyethyl)-6-hydroxychroman (gamma-CEHC), in contrast to alpha-tocopherol (alphaT), the primary vitamin E in supplements, inhibit cyclooxygenase-catalyzed synthesis of prostaglandin E-2 (PGE(2)) in activated macrophages and epithelial cells. Here we report that in carrageenan-induced inflammation in male Wistar rats, administration of gammaT (33 or 100 mg/kg) and gamma-CEHC (2 mg/pouch), but not alphaT (33 mg/kg), significantly reduced PGE(2) synthesis at the site of inflammation. gammaT, but not alphaT, significantly inhibited the formation of leukotriene B-4, a potent chemotactic agent synthesized by the 5-lipoxygenase of neutrophils. Although gammaT had no effect on neutrophil infiltration, it significantly attenuated the partial loss of food consumption caused by inflammation-associated discomfort. Administration of gammaT led consistently to a significant reduction of inflammation-mediated increase in 8-isoprostane, a biomarker of lipid peroxidation. gammaT at 100 mg/kg reduced TNF-alpha (65%; P=0.069), total nitrate/nitrite (40%; P=0.1), and lactate dehydrogenase activity (30%; P=0.067). Collectively, gammaT inhibits proinflammatory PGE(2) and LTB4, decreases TNF-alpha, and attenuates inflammation-mediated damage. These findings provide strong evidence that gammaT shows anti-inflammatory activities in vivo that may be important for human disease prevention and therapy.	Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; Univ Calif Berkeley, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of California System; University of California Berkeley	Ames, BN (corresponding author), Childrens Hosp Oakland, Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	bnames@uclink4.berkeley.edu			NIEHS NIH HHS [ES01896] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Beharka AA, 2002, FREE RADICAL BIO MED, V32, P503, DOI 10.1016/S0891-5849(01)00817-6; BELARDELLI F, 1995, APMIS, V103, P161, DOI 10.1111/j.1699-0463.1995.tb01092.x; Christen S, 1997, P NATL ACAD SCI USA, V94, P3217, DOI 10.1073/pnas.94.7.3217; COONEY RV, 1995, FREE RADICAL BIO MED, V19, P259, DOI 10.1016/0891-5849(95)00019-T; COONEY RV, 1993, P NATL ACAD SCI USA, V90, P1771, DOI 10.1073/pnas.90.5.1771; Criscione LG, 2002, CURR OPIN RHEUMATOL, V14, P204, DOI 10.1097/00002281-200205000-00002; Cronstein BN, 1999, P NATL ACAD SCI USA, V96, P6377, DOI 10.1073/pnas.96.11.6377; Helzlsouer KJ, 2000, J NATL CANCER I, V92, P2018, DOI 10.1093/jnci/92.24.2018; Jiang Q, 2001, AM J CLIN NUTR, V74, P714; Jiang Q, 2002, FREE RADICAL BIO MED, V33, P1534, DOI 10.1016/S0891-5849(02)01091-2; Jiang Q, 2000, P NATL ACAD SCI USA, V97, P11494, DOI 10.1073/pnas.200357097; Kirchner T, 1997, J PHARMACOL EXP THER, V282, P1094; Kristenson M, 1997, BRIT MED J, V314, P629, DOI 10.1136/bmj.314.7081.629; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Lorenz HM, 2002, ARTHRITIS RES THER, V4, pS17, DOI 10.1186/ar564; MARNETT LJ, 1992, CANCER RES, V52, P5575; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; McGeer PL, 2001, NEUROBIOL AGING, V22, P799, DOI 10.1016/S0197-4580(01)00289-5; Morrow JD, 2000, DRUG METAB REV, V32, P377, DOI 10.1081/DMR-100102340; Murray ED, 1997, J PHARMACOL EXP THER, V282, P657; Ohrvall M, 1996, J INTERN MED, V239, P111, DOI 10.1046/j.1365-2796.1996.410753000.x; Plutzky J, 2001, AM J CARDIOL, V88, p10K; Sabate J, 1999, AM J CLIN NUTR, V70, p500S, DOI 10.1093/ajcn/70.3.500s; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; SEDGWICK AD, 1983, J PATHOL, V141, P483, DOI 10.1002/path.1711410406; SEDGWICK AD, 1986, AGENTS ACTIONS, V18, P429, DOI 10.1007/BF01965008; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; Stahl W, 1999, ANAL BIOCHEM, V275, P254, DOI 10.1006/abio.1999.4312; Swanson JE, 1999, J LIPID RES, V40, P665; THUN MJ, 1993, CANCER RES, V53, P1322; Vane JR, 1998, INT J TISSUE REACT, V20, P3; VANE JR, 1976, ADV PROSTAG THROMB R, V2, P791; Williams R O 3rd, 1997, Pharm Dev Technol, V2, P1, DOI 10.3109/10837459709022604; Williamson KS, 2002, NITRIC OXIDE-BIOL CH, V6, P221, DOI 10.1006/niox.2001.0399; Wynne H A, 1993, Pharmacoeconomics, V3, P107, DOI 10.2165/00019053-199303020-00004; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yokomizo T, 2001, ARCH BIOCHEM BIOPHYS, V385, P231, DOI 10.1006/abbi.2000.2168	39	255	271	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					816	822		10.1096/fj.02-0877com	http://dx.doi.org/10.1096/fj.02-0877com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12724340				2022-12-28	WOS:000183165000007
J	Hiltunen, MO; Ruuskanen, M; Huuskonen, J; Mahonen, AJ; Ahonen, M; Rutanen, J; Kosma, VM; Mahonen, A; Kroger, H; Yla-Herttuala, S				Hiltunen, MO; Ruuskanen, M; Huuskonen, J; Mahonen, AJ; Ahonen, M; Rutanen, J; Kosma, VM; Mahonen, A; Kroger, H; Yla-Herttuala, S			Adenovirus-mediated VEGF-A gene transfer induces bone formation in vivo	FASEB JOURNAL			English	Article						osteogenesis; gene therapy; osteoporosis	ENDOTHELIAL GROWTH-FACTOR; LOWER-LIMB ARTERY; ANGIOGENESIS; EXPRESSION; ISCHEMIA; DIFFERENTIATION; INJECTION; THERAPY; HYPERPLASIA; PHVEGF(165)	Osteoporosis is a major problem in elderly population. We tested the hypothesis whether vascular endothelial growth factor (VEGF-A) gene transfer is an appropriate way to enhance bone formation and recruitment of osteoblasts in vivo. Adenovirus vectors containing VEGF-A or lacZ cDNAs (1.4x10(10) pfu) were injected locally into right distal femurs of New Zealand White rabbits. Saline was injected into all contralateral distal femurs. One and three weeks after the gene transfers femurs were collected for analyses. X-Gal staining showed that up to 20% of the bone marrow cells were transfected although gene transfer also resulted in biodistribution of the vector and expression of the transgene in liver and spleen. Trabecular bone hard tissue histomorphometry of the distal femurs was performed to analyze the effect of gene transfer on bone turnover. When compared with unilateral lacZ transfected trabecular bone at one-week and three-week time points, VEGF-A gene transfer significantly increased bone formation parameters, such as osteoblast number, osteoid volume, and bone volume. Also, bone resorption surface was greatly reduced. It is concluded that injection of adenovirus vector can transfect bone marrow cells in vivo with a relatively high efficiency. Our results suggest that adenovirus-mediated VEGF-A gene transfer induces bone formation via increasing osteoblast activity and may be useful for the treatment of osteoporosis and other diseases that require efficient osteogenic therapy.	Univ Kuopio, AI Virtanen Inst, Dept Mol Med, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Surg, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Pathol & Forens Med, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Pathol, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland; Univ Kuopio, Gene Therapy Unit, FIN-70211 Kuopio, Finland; Tampere Univ Hosp, Tampere, Finland	Finland National Institute for Health & Welfare; University of Eastern Finland; University of Eastern Finland; University of Eastern Finland; University of Eastern Finland; Finland National Institute for Health & Welfare; University of Eastern Finland; University of Eastern Finland; Tampere University; Tampere University Hospital	Yla-Herttuala, S (corresponding author), Univ Kuopio, AI Virtanen Inst, Dept Mol Med, POB 1627, FIN-70211 Kuopio, Finland.	Seppo.Ylaherttuala@uku.fi		Yla-Herttuala, Seppo/0000-0001-7593-2708				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; ASAHARA T, 1995, CIRCULATION, V91, P2793, DOI 10.1161/01.CIR.91.11.2793; Baron R, 1983, PROCESSING UNDECALCI, P13; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; Baylink DJ, 1999, MOL MED TODAY, V5, P133, DOI 10.1016/S1357-4310(98)01426-9; BOLANDER ME, 1992, P SOC EXP BIOL MED, V200, P165; BREIER G, 1992, DEVELOPMENT, V114, P521; BRIGHTON CT, 1991, J BONE JOINT SURG AM, V73A, P832, DOI 10.2106/00004623-199173060-00006; Carlevaro MF, 2000, J CELL SCI, V113, P59; Clesham GJ, 1998, GENE THER, V5, P174, DOI 10.1038/sj.gt.3300576; Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667; Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Hiltunen MO, 2000, FASEB J, V14, P2230, DOI 10.1096/fj.00-0145com; Hiltunen MO, 2000, CIRCULATION, V102, P2262; Huuskonen J, 2001, ANN CHIR GYNAECOL, V90, P37; Laitinen M, 1998, HUM GENE THER, V9, P1481, DOI 10.1089/hum.1998.9.10-1481; Laitinen M, 1997, HUM GENE THER, V8, P1737, DOI 10.1089/hum.1997.8.15-1737; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Makinen K, 2002, MOL THER, V6, P127, DOI 10.1006/mthe.2002.0638; MALLUCHE HH, 1982, CALCIFIED TISSUE INT, V34, P439, DOI 10.1007/BF02411282; Mayr-Wohlfart U, 2002, BONE, V30, P472, DOI 10.1016/S8756-3282(01)00690-1; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Newman KD, 1995, J CLIN INVEST, V96, P2955, DOI 10.1172/JCI118367; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303; Puumalainen AM, 1998, HUM GENE THER, V9, P1769, DOI 10.1089/hum.1998.9.12-1769; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468; Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; Tsurumi Y, 1997, CIRCULATION, V96, P382; Yla-Herttuala S, 2000, LANCET, V355, P213, DOI 10.1016/S0140-6736(99)04180-X	37	65	84	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2003	17	6					1147	+		10.1096/fj.02-0514fje	http://dx.doi.org/10.1096/fj.02-0514fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	673KL	12692089				2022-12-28	WOS:000182580100039
J	Fiorotto, M; Khan, A; Cummings, K; Draghia, R				Fiorotto, M; Khan, A; Cummings, K; Draghia, R			Administration of a plasmid expressing growth hormone-releasing hormone (GHRH) augments lean mass gain in pigs	FASEB JOURNAL			English	Meeting Abstract	Experimental Biology 2003 Meeting	APR 11-15, 2003	SAN DIEGO, CALIFORNIA						Baylor Coll Med, Houston, TX 77030 USA; ADViSYS Inc, Pediat, The Woodlands, TX USA	Baylor College of Medicine; Advisys									0	52	56	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 14	2003	17	4	1	S			A700	A700		10.1096/fj.02-0289fje	http://dx.doi.org/10.1096/fj.02-0289fje			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	658QZ	12528713				2022-12-28	WOS:000181733103295
J	Mund, T; Gewies, A; Schoenfeld, N; Bauer, MKA; Grimm, S				Mund, T; Gewies, A; Schoenfeld, N; Bauer, MKA; Grimm, S			Spike, a novel BH3-only protein, regulates apoptosis at the endoplasmic reticulum	FASEB JOURNAL			English	Article						cell death; caspase-8; BH3 domain; tumors; Bap31	CYTOCHROME-C; CELL-DEATH; BH3 DOMAIN; INDUCE APOPTOSIS; MITOCHONDRIAL-MEMBRANE; BCL-2 FAMILY; ELEGANS; COMPLEX; ACTIVATION; RELEASE	We have isolated Spike, a novel and evolutionary conserved BH3-only protein. BH3-only proteins constitute a family of apoptosis inducers that mediate proapoptotic signals. In contrast to most proteins of this family, Spike was not found to be associated with mitochondria. Furthermore, unlike the known BH3-only proteins, Spike could not interact with all tested Bcl-2 family members, despite its BH3 domain being necessary for cell killing. Our findings indicate that Spike is localized to the endoplasmic reticulum. The endoplasmic reticulum is an organelle that has only recently been implicated in regulation of apoptosis. At this locale, Spike interacts with Bap31, an adaptor protein for pro-caspase-8 and Bcl-XL. In doing so, Spike is able to inhibit the formation of a complex between Bap31 and the antiapoptotic Bcl-XL protein. Furthermore, Spike transmits the signal of specific death receptors. Its down-regulation in certain tumors suggests that Spike may also play a role in tumorigenesis. Our findings add new insight for how BH3-only and antiapoptotic Bcl-2 proteins regulate cell death.	Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Grimm, S (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	sgrimm@biochem.mpg.de		Mund, Thomas/0000-0002-3957-1105; Gewies, Andreas/0000-0002-7606-6482				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Bitzer M, 1999, J VIROL, V73, P702, DOI 10.1128/JVI.73.1.702-708.1999; Bratton SB, 2001, TRENDS PHARMACOL SCI, V22, P306, DOI 10.1016/S0165-6147(00)01718-1; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Cizeau J, 2000, ONCOGENE, V19, P5453, DOI 10.1038/sj.onc.1203929; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Conus S, 2000, CELL DEATH DIFFER, V7, P947, DOI 10.1038/sj.cdd.4400729; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200; Ghosh C, 2000, ANTISENSE NUCLEIC A, V10, P263, DOI 10.1089/108729000421448; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grimm S, 1997, J EXP MED, V185, P1137, DOI 10.1084/jem.185.6.1137; Grimm S, 1996, P NATL ACAD SCI USA, V93, P10923, DOI 10.1073/pnas.93.20.10923; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Neudecker F, 2000, BIOTECHNIQUES, V28, P107; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tan KO, 2001, J BIOL CHEM, V276, P2802, DOI 10.1074/jbc.M008955200; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	49	54	57	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					696	+		10.1096/fj.02-0657fje	http://dx.doi.org/10.1096/fj.02-0657fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12594175				2022-12-28	WOS:000181456900016
J	Ou, BX; Huang, DJ; Hampschl-Woodill, M; Flanagan, JA				Ou, BX; Huang, DJ; Hampschl-Woodill, M; Flanagan, JA			When east meets west: the relationship between yin-yang and antioxidation-oxidation	FASEB JOURNAL			English	Article						traditional Chinese medicine; herbs; polyphenolics; oxygen radical absorbance capacity	CAPACITY; FLAVONOIDS; STRESS	Ancient traditional Chinese medicine (TCM) has effectively relied on the theory of yin-yang balance in diagnoses and treatments of diseases and disorders for more than 2000 years. However, in eastern society, yin-yang is regarded as an incomprehensible ideology without definite physical meaning. Consequently, the yin-yang balance in medicine has not been studied by modern scientific means. In the western world, yin-yang balance is often misunderstood as a religious belief or a principle of lifestyle. Herein, we attempted to define the physical meaning of yin-yang in TCM by correlating it with biochemical processes. We propose that yin-yang balance is antioxidation-oxidation balance with yin representing antioxidation and yang as oxidation. Our proposal is partially supported by the fact that the yin-tonic traditional Chinese herbs have, on average, about six times more antioxidant activity and polyphenolic contents than the yang-tonic herbs. Our hypothesis opens an avenue to systematically study the yin-yang balance and its health implications with the use of modern biochemical tools.	Brunswick Labs, Wareham, MA 02571 USA		Huang, DJ (corresponding author), Brunswick Labs, 6 Thatcher Lane, Wareham, MA 02571 USA.	dejian@brunswicklabs.com	Huang, Dejian/A-7439-2010	Huang, Dejian/0000-0002-2305-3960				Chau PL, 2000, NATURE, V404, P431, DOI 10.1038/35006734; *COMM ZHONGH BENC, 1998, ZHONGHUA BENCAO, V1; Davies KJA, 2000, IUBMB LIFE, V50, P279, DOI 10.1080/15216540051081010; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Huang DJ, 2002, J AGR FOOD CHEM, V50, P1815, DOI 10.1021/jf0113732; LEHNINGER AL, 1990, PRINCIPLES BIOCH, P359; Ni M., 1995, YELLOW EMPERORS CLAS; Ou BX, 2001, J AGR FOOD CHEM, V49, P4619, DOI 10.1021/jf010586o; Ou BX, 2002, J AGR FOOD CHEM, V50, P3122, DOI 10.1021/jf0116606; Pietta PG, 2000, J NAT PROD, V63, P1035, DOI 10.1021/np9904509; Prior RL, 2000, J AOAC INT, V83, P950; SIES H, 1982, OXIDATIVE STRESS, P1; SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144; Theoharides TC, 2001, INT J IMMUNOPATH PH, V14, P119	14	88	95	3	38	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2003	17	2					127	129		10.1096/fj.02-0527hyp	http://dx.doi.org/10.1096/fj.02-0527hyp			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653VC	12554690				2022-12-28	WOS:000181456900036
J	Kovjazin, R; Eldar, T; Patya, M; Vanichkin, A; Lander, HM; Novogrodsky, A				Kovjazin, R; Eldar, T; Patya, M; Vanichkin, A; Lander, HM; Novogrodsky, A			Ferrocene-induced lymphocyte activation and antitumor activity is mediated by redox-sensitive signaling	FASEB JOURNAL			English	Article						ERK 1/2; free radicals; cancer immunotherapy	STIMULATORY PROPERTIES; TYROSINE KINASE; FREE-RADICALS; P21(RAS); INTERLEUKIN-2; RECRUITMENT; COMPLEXES; ANTIBODY; PROTEINS; THERAPY	Ferrocene, a stable, synthetic, iron-containing compound induces in vitro and in vivo activation of mouse lymphocytes and macrophages. Ferrocene also has a marked antitumor effect in mice, upon its administration intraperitoneally and in drinking water. Ferrocene's antitumor activity is attributed to its immune-stimulatory property. This conclusion is supported by adoptive transfer experiments demonstrating that immune cells from ferrocene-treated tumor-bearing mice elicit an antitumor effect in mice not treated with ferrocene. We postulate that the immune stimulatory effect of ferrocene is mediated by redox-sensitive signaling such as activation of p21(ras). This postulation is supported by the following findings: Ferrocene generates H2O2 by autooxidation; N-acetylcysteine, a free-radical scavenger, reduces its antitumor effect; and it stimulates GTPase activity catalyzed by pure recombinant p21(ras) and activates ERK 1/2 in wild Jurkat T cells but fails to do so in the Jurkat T cells expressing p21(ras) in which cysteine 118 was replaced by serine. Lastly, ferrocene activates and translocates NF-kB in human PBM, a pathway which is mediated by ras. It is most plausible that additional redox-sensitive signaling proteins mediate the biological effects of ferrocene.	Tel Aviv Univ, Rabin Med Ctr, Sackler Fac Med, Felsenstein Med Res Ctr, IL-49100 Petah Tiqwa, Israel; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Cornell University	Novogrodsky, A (corresponding author), Tel Aviv Univ, Rabin Med Ctr, Sackler Fac Med, Felsenstein Med Res Ctr, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.	novog@post.tau.ac.il						Deora AA, 2000, BIOCHEMISTRY-US, V39, P9901, DOI 10.1021/bi992954b; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Dutcher JP, 1997, CANCER J, V3, pS73; Galandrini R, 1996, J EXP MED, V183, P179, DOI 10.1084/jem.183.1.179; Gasiorwski K, 1999, BIOMETALS, V12, P19, DOI 10.1023/A:1009238611562; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; GRAVES JD, 1992, J IMMUNOL, V148, P2417; Hall IH, 1998, ANTICANCER RES, V18, P951; Hank JA, 1995, CLIN CANCER RES, V1, P481; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; Keilholz U, 1997, CANCER J SCI AM, V3, pS22; KOPFMAIER P, 1984, ANGEW CHEM INT EDIT, V23, P456, DOI 10.1002/anie.198404561; KOPFMAIER P, 1989, ARZNEIMITTEL-FORSCH, V39-1, P369; LANDER HM, 1993, BIOCHEM J, V291, P281, DOI 10.1042/bj2910281; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LANDER HM, 1993, J IMMUNOL, V151, P7182; LANDER HM, 1993, J IMMUNOL, V150, P1509; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; MARGOLIASH E, 1958, BIOCHEM J, V68, P468, DOI 10.1042/bj0680468; Margolin KA, 2000, SEMIN ONCOL, V27, P194; Mungan NA, 1998, BRIT J UROL, V82, P213; NOVOGRODSKY A, 1991, CELL IMMUNOL, V133, P295, DOI 10.1016/0008-8749(91)90105-K; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; NOVOGRODSKY A, 1989, J IMMUNOL, V143, P3981; PORTER AG, 1991, TRENDS BIOTECHNOL, V9, P158, DOI 10.1016/0167-7799(91)90053-K; Queirolo P, 1999, ANN SURG ONCOL, V6, P272, DOI 10.1007/s10434-999-0272-4; SCANNONE H, 1964, BIOCHEMISTRY-US, V3, P1742, DOI 10.1021/bi00899a027; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; TSUJI A, 1993, CLIN EXP IMMUNOL, V93, P308, DOI 10.1111/j.1365-2249.1993.tb08177.x	32	51	54	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2003	17	1					467	+		10.1096/fj.02-0558fje	http://dx.doi.org/10.1096/fj.02-0558fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	653TT	12514114				2022-12-28	WOS:000181453700022
J	Fotia, AB; Dinudom, A; Shearwin, KE; Koch, JP; Korbmacher, C; Cook, DI; Kumar, S				Fotia, AB; Dinudom, A; Shearwin, KE; Koch, JP; Korbmacher, C; Cook, DI; Kumar, S			The role of individual Nedd4-2 (KIAA0439) WW domains in binding and regulating epithelial sodium channels	FASEB JOURNAL			English	Article						Nedd4; far-Western analysis; PY motif; ENaC; surface plasmon resonance	SUBUNIT MESSENGER-RNAS; NA+-CHANNEL; LIDDLES-SYNDROME; BETA-SUBUNIT; GAMMA-SUBUNIT; MISSENSE MUTATION; DUCT CELLS; PY MOTIF; EXPRESSION; PROTEIN	The amiloride-sensitive epithelial sodium channel (ENaC) is essential for fluid and electrolyte homeostasis. ENaC consists of alpha, beta, and gamma subunits, each of which contains a PPxY motif that interacts with the WW domains of the ubiquitin-protein ligases Nedd4 and Nedd4-2. Disruption of this interaction, as in Liddle's syndrome in which mutations delete or alter the PPxY motif of either the beta or the gamma subunits, results in increased ENaC activity. We report here that Nedd4-2 has two major isoforms that show tissue-specific expression; however, both isoforms can inhibit ENaC in Xenopus oocytes. Because there are four WW domains in Nedd4-2, we analyzed binding kinetics and affinity between individual WW domains and ENaC subunits. Using whole cell patch-clamp techniques, we studied the role of individual WW domains in the regulation of ENaC in mammalian cells. We report here that unlike Nedd4, only two of the Nedd4-2 WW domains, WW3 and WW4, are required for both the binding to ENaC subunits and the regulation of Na+ feedback control of ENaC. Although both WW3 and WW4 individually can interact with all three ENaC subunits in vitro, both domains together are essential for in vivo function of Nedd4-2 in ENaC regulation. These data suggest that Nedd4-2 WW3 and WW4 interact with distinct, noninterchangeable sites in ENaC and that to prevent Na+ feedback control of ENaC it is necessary to occlude both sites.	Hanson Inst, IMVS, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Med, Adelaide, SA 5000, Australia; Univ Sydney, Dept Physiol, Sydney, NSW 2006, Australia; Univ Adelaide, Dept Mol Biosci, Adelaide, SA 5000, Australia; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Univ Erlangen Nurnberg, Inst Zellulare & Mol Physiol, D-91054 Erlangen, Germany	Hanson Institute; Institute Medical & Veterinary Science Australia; University of Adelaide; University of Sydney; University of Adelaide; University of Oxford; University of Erlangen Nuremberg	Kumar, S (corresponding author), Hanson Inst, IMVS, POB14,Rundle Mall, Adelaide, SA 5000, Australia.	sharad.kumar@imvs.sa.gov.au	Kumar, Sharad/AAX-7787-2020; Shearwin, Keith/AAS-1247-2021	Kumar, Sharad/0000-0001-7126-9814; Shearwin, Keith/0000-0002-7736-2742				Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Asher C, 2001, BIOCHEM BIOPH RES CO, V286, P1228, DOI 10.1006/bbrc.2001.5508; Awayda MS, 1997, AM J PHYSIOL-CELL PH, V273, pC1889; Bowles MR, 1997, ANAL BIOCHEM, V244, P133, DOI 10.1006/abio.1996.9888; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; DINUDOM A, 1995, J PHYSIOL-LONDON, V487, P549, DOI 10.1113/jphysiol.1995.sp020899; Dinudom A, 2001, J BIOL CHEM, V276, P13744, DOI 10.1074/jbc.M011273200; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; DINUDOM A, 1993, J MEMBRANE BIOL, V135, P289; DUC C, 1994, J CELL BIOL, V127, P1907, DOI 10.1083/jcb.127.6.1907; Eskandari S, 1999, J BIOL CHEM, V274, P27281, DOI 10.1074/jbc.274.38.27281; Farman N, 1997, AM J PHYSIOL-CELL PH, V272, pC131, DOI 10.1152/ajpcell.1997.272.1.C131; Farr TJ, 2000, BIOCHEM J, V345, P503, DOI 10.1042/0264-6021:3450503; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Harvey KF, 2001, J BIOL CHEM, V276, P8597, DOI 10.1074/jbc.C000906200; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Jeunemaitre X, 1997, J HYPERTENS, V15, P1091, DOI 10.1097/00004872-199715100-00007; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kamynina E, 2001, KIDNEY INT, V60, P466, DOI 10.1046/j.1523-1755.2001.060002466.x; Kamynina E, 2001, AM J PHYSIOL-RENAL, V281, pF469, DOI 10.1152/ajprenal.2001.281.3.F469; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Komwatana P, 1996, P NATL ACAD SCI USA, V93, P8107, DOI 10.1073/pnas.93.15.8107; Konstas AA, 2002, J BIOL CHEM, V277, P29406, DOI 10.1074/jbc.M203018200; Konstas AA, 2001, PFLUG ARCH EUR J PHY, V442, P752, DOI 10.1007/s004240100597; Konstas AA, 2000, PFLUG ARCH EUR J PHY, V441, P341, DOI 10.1007/s004240000430; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kumar S, 1997, CELL DEATH DIFFER, V4, P378, DOI 10.1038/sj.cdd.4400251; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; Lott JS, 2002, BIOCHEM J, V361, P481, DOI 10.1042/0264-6021:3610481; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Matsushita K, 1996, AM J PHYSIOL-LUNG C, V271, pL332, DOI 10.1152/ajplung.1996.271.2.L332; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 2001, J BIOL CHEM, V276, P28321, DOI 10.1074/jbc.M011487200; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; WARD LD, 1995, BIOCHEMISTRY-US, V34, P2901, DOI 10.1021/bi00009a021	54	83	88	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					70	+		10.1096/fj.02-0497fje	http://dx.doi.org/10.1096/fj.02-0497fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12424229				2022-12-28	WOS:000180218500038
J	Rabinovsky, ED; Gelir, E; Gelir, S; Lui, H; Kattash, M; DeMayo, FJ; Shenaq, SM; Schwartz, RJ				Rabinovsky, ED; Gelir, E; Gelir, S; Lui, H; Kattash, M; DeMayo, FJ; Shenaq, SM; Schwartz, RJ			Targeted expression of IGF-1 transgene to skeletal muscle accelerates muscle and motor neuron regeneration	FASEB JOURNAL			English	Article						transgenic mice; peripheral nerve injury; insulin-like growth factor; muscle regulatory factors; MyoD; myogenin; IGF-1	GROWTH-FACTOR-I; SATELLITE CELL-PROLIFERATION; ACETYLCHOLINE-RECEPTOR; SCIATIC-NERVE; TEMPORAL EXPRESSION; GENE-EXPRESSION; MESSENGER-RNA; SUBUNIT GENE; INSULIN; MYOGENIN	Currently, there is no known medical treatment that hastens the repair of damaged nerve and muscle. Using IGF-1 transgenic mice that specifically express human recombinant IGF-1 in skeletal muscle, we test the hypotheses that targeted gene expression of IGF-1 in skeletal muscle enhances motor nerve regeneration after a nerve crush injury. The IGF-1 transgene affects the initiation of the muscle repair process after nerve injury as shown by increased activation of SCA-1positive myogenic stem cells. Increased satellite cell differentiation and proliferation are observed in IGF-1 transgenic mice, shown by increased expression of Cyclin D1, MyoD, and myogenin. Expression of myogenin and nicotinic acetylcholine receptor subunits, initially increased in both wild-type and IGF-1 transgenic mice, are restored to normal levels at a faster rate in IGF-1 transgenic mice, which indicates a rescue of nerve-evoked muscle activity. Expression of the IGF-1 transgene in skeletal muscle results in accelerated recovery of saltatory nerve conduction, increased innervation as detected by neurofilament expression, and faster recovery of muscle mass. These studies demonstrate that local expression of IGF-1 augments the repair of injured nerve and muscle.	Baylor Coll Med, Michael E DeBakey Dept Surg, Div Plast Surg, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Rabinovsky, ED (corresponding author), Baylor Coll Med, Michael E DeBakey Dept Surg, Div Plast Surg, 1 Baylor Plaza, Houston, TX 77030 USA.	ericr@bcm.tmc.edu	DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336				ADAMS L, 1995, J CELL BIOL, V131, P1341, DOI 10.1083/jcb.131.5.1341; ALLEN DL, 1995, J APPL PHYSIOL, V78, P1969, DOI 10.1152/jappl.1995.78.5.1969; ALLEN RE, 1989, J CELL PHYSIOL, V138, P311, DOI 10.1002/jcp.1041380213; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; Barton-Davis ER, 1999, ACTA PHYSIOL SCAND, V167, P301; BISCHOFF R, 1994, MYOGENESIS, V2, P97; CARONI P, 1990, J CELL BIOL, V110, P1307, DOI 10.1083/jcb.110.4.1307; CARONI P, 1993, ANN NY ACAD SCI, V692, P209; CARONI P, 1994, J CELL BIOL, V125, P893, DOI 10.1083/jcb.125.4.893; CARONI P, 1992, J NEUROSCI, V12, P3849; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; Cornelison DDW, 1997, DEV BIOL, V191, P270, DOI 10.1006/dbio.1997.8721; DUTTON EK, 1993, P NATL ACAD SCI USA, V90, P2040, DOI 10.1073/pnas.90.5.2040; EFTIMIE R, 1991, P NATL ACAD SCI USA, V88, P1349, DOI 10.1073/pnas.88.4.1349; FERNYHOUGH P, 1989, MOL BRAIN RES, V6, P109, DOI 10.1016/0169-328X(89)90044-2; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; GLAZNER GW, 1993, NEUROSCIENCE, V54, P791, DOI 10.1016/0306-4522(93)90248-E; GROUNDS MD, 1991, PATHOL RES PRACT, V187, P1; HANSSON HA, 1987, CELL TISSUE RES, V247, P241; Hsu HH, 1997, BIOCHEM MOL MED, V60, P142, DOI 10.1006/bmme.1997.2570; ISHII DN, 1995, J NEUROSCI RES, V40, P138, DOI 10.1002/jnr.490400116; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; JENNISCHE E, 1987, ACTA PHYSIOL SCAND, V129, P9, DOI 10.1111/j.1748-1716.1987.tb08034.x; JENNISCHE E, 1987, ACTA PHYSIOL SCAND, V130, P327, DOI 10.1111/j.1748-1716.1987.tb08144.x; KANJE M, 1989, BRAIN RES, V486, P396, DOI 10.1016/0006-8993(89)90531-3; Kurek JB, 1996, MUSCLE NERVE, V19, P1291, DOI 10.1002/(SICI)1097-4598(199610)19:10<1291::AID-MUS6>3.0.CO;2-9; LEWIS ME, 1993, ANN NY ACAD SCI, V692, P201; LI LX, 1994, J NEUROBIOL, V25, P759, DOI 10.1002/neu.480250702; Lindon C, 1998, J CELL BIOL, V140, P111, DOI 10.1083/jcb.140.1.111; MA JX, 1994, SYNAPSE, V17, P225, DOI 10.1002/syn.890170403; MERLIE JP, 1994, J BIOL CHEM, V269, P2461; Miller JB, 1999, CURR TOP DEV BIOL, V43, P191; MONTARRAS D, 1991, NEW BIOL, V3, P592; NEAR SL, 1992, P NATL ACAD SCI USA, V89, P11716, DOI 10.1073/pnas.89.24.11716; NEFF NT, 1993, J NEUROBIOL, V24, P1578, DOI 10.1002/neu.480241203; NUMBERGER M, 1991, EMBO J, V10, P2957, DOI 10.1002/j.1460-2075.1991.tb07846.x; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; RANTANEN J, 1995, LAB INVEST, V72, P341; RECIOPINTO E, 1986, J NEUROSCI, V6, P1211; ROSENBLATT JD, 1994, MUSCLE NERVE, V17, P608, DOI 10.1002/mus.880170607; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; Sheehan SM, 1999, J CELL PHYSIOL, V181, P499, DOI 10.1002/(SICI)1097-4652(199912)181:3<499::AID-JCP14>3.0.CO;2-1; SJOBERG J, 1989, BRAIN RES, V485, P102, DOI 10.1016/0006-8993(89)90671-9; SKOTTNER A, 1987, J CLIN INVEST S4, V10, P25; SMITH CK, 1994, J CELL PHYSIOL, V159, P379, DOI 10.1002/jcp.1041590222; Stewart HJS, 1996, EUR J NEUROSCI, V8, P553, DOI 10.1111/j.1460-9568.1996.tb01240.x; Svenningsen AF, 1996, GLIA, V18, P68, DOI 10.1002/(SICI)1098-1136(199609)18:1<68::AID-GLIA7>3.0.CO;2-#; VANDERIJN M, 1989, P NATL ACAD SCI USA, V86, P4634; WANG C, 1992, MOL BRAIN RES, V13, P289, DOI 10.1016/0169-328X(92)90212-T; WITZEMANN V, 1991, FEBS LETT, V282, P259, DOI 10.1016/0014-5793(91)80490-T; YABLONKAREUVENI Z, 1994, DEV BIOL, V164, P588, DOI 10.1006/dbio.1994.1226	55	91	100	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					53	+		10.1096/fj.02-0183fje	http://dx.doi.org/10.1096/fj.02-0183fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12424223				2022-12-28	WOS:000180218500040
J	Soderdahl, T; Enoksson, M; Lundberg, M; Holmgren, A; Ottersen, OP; Orrenius, S; Bolcsfoldi, G; Cotgreave, IA				Soderdahl, T; Enoksson, M; Lundberg, M; Holmgren, A; Ottersen, OP; Orrenius, S; Bolcsfoldi, G; Cotgreave, IA			Visualization of the compartmentalization of glutathione and protein-glutathione mixed disulfides in cultured cells	FASEB JOURNAL			English	Article						confocal microscopy; FACS; mitochondria; nucleus; diamide	S-THIOLATION; OXIDATIVE STRESS; HEPATOCYTES; MITOCHONDRIAL; SULFHYDRYLS; MENADIONE; DEPLETION	Fluorescence microscopy of A549 cells stained with a glutathione (L-gamma-glutamyl-L-cysteinylglycine, GSH)-specific polyclonal antibody displayed uniform staining of the perinuclear cytosol, with the nuclear region apparently lacking GSH staining. This discontinuous staining was confirmed in other cell types and also corroborated in A549 cells stained with the thiol-reactive dye mercury orange. The selectivity of antibody binding was confirmed by buthionine sulfoximine (BSO)-dependent inhibition of GSH synthesis. However, confocal visualization of antibody-stained A549 cells in the z-plane revealed the majority of the perinuclear staining intensity in the upper half of the cell to be associated with mitochondria, as confirmed by double staining for cytochrome oxidase. Integration of the confocal signals from the nuclear and cytosolic regions halfway down the z-plane showed that the GSH concentrations of these compartments are close to equilibrium. Confirmation of the relatively high levels of mitochondrial glutathione was provided in cells treated with BSO and visualized in z-section, revealing the mitochondrial GSH content of these cells to be well preserved in apposition to near-complete depletion of cytosolic/nuclear GSH. Localized gradients within the cytosolic compartment were also visible, particularly in the z-plane. The antibody also provided initial visualization of the compartmentalization of protein-GSH mixed disulfides formed in A549 cells exposed to diamide. Discontinuous staining was again evident, with heavy staining in membrane blebs and in the nuclear region. Using FACS analysis of anti-GSH antibody-stained Jurkat T lymhocytes, we also demonstrated population variations in the cellular compliment of GSH and protein-GSH mixed disulfides, formed in response to diamide. In addition, we showed cell-cycle variation in GSH content of the cells, with the highest levels of GSH associated with the G2/M mitotic phase of the cell cycle, using double staining with propidium iodide. Similar FACS analyses performed in isolated mitochondria presented a considerable variation in GSH content within mitochondria of uniform granularity from the same preparation.	Karolinska Inst, Inst Environm Med, Div Biochem Toxicol, S-17177 Stockholm, Sweden; Karolinska Inst, Inst Environm Med, Div Toxicol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, Div Biochem, S-17177 Stockholm, Sweden; Univ Oslo, Inst Basic Med Sci, Dept Anat, N-0317 Oslo, Norway; AstraZeneca R&D Sodertalje, Safety Assessment, Dept Genet Toxicol, S-15185 Sodertalje, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Oslo; AstraZeneca	Cotgreave, IA (corresponding author), Karolinska Inst, Inst Environm Med, Div Biochem Toxicol, Box 210, S-17177 Stockholm, Sweden.	Ian.Cotgreave@Imm.ki.se						ATZORI L, 1990, J CELL PHYSIOL, V143, P165, DOI 10.1002/jcp.1041430123; BELLOMO G, 1992, P NATL ACAD SCI USA, V89, P4412, DOI 10.1073/pnas.89.10.4412; BRITTEN RA, 1991, BIOCHEM PHARMACOL, V41, P647, DOI 10.1016/0006-2952(91)90642-I; BRIVIBA K, 1993, BIOCHEM J, V294, P631, DOI 10.1042/bj2940631; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P264, DOI 10.1006/abbi.1994.1166; CHAI YC, 1991, ARCH BIOCHEM BIOPHYS, V284, P270, DOI 10.1016/0003-9861(91)90295-T; COTGREAVE IA, 1986, J BIOCHEM BIOPH METH, V13, P231, DOI 10.1016/0165-022X(86)90102-8; Cotgreave IA, 2002, FASEB J, V16, P435, DOI 10.1096/fj.01-0685fje; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; Herzenberg LA, 1997, P NATL ACAD SCI USA, V94, P1967, DOI 10.1073/pnas.94.5.1967; HJELLE OP, 1994, EUR J NEUROSCI, V6, P793, DOI 10.1111/j.1460-9568.1994.tb00990.x; Huster D, 1998, ANAT EMBRYOL, V198, P277, DOI 10.1007/s004290050184; JEVTOVICTODOROVIC V, 1992, BIOCHEM PHARMACOL, V44, P1383, DOI 10.1016/0006-2952(92)90540-Y; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEREDITH MJ, 1982, J BIOL CHEM, V257, P3747; MIRABELLI F, 1988, ARCH BIOCHEM BIOPHYS, V264, P261, DOI 10.1016/0003-9861(88)90593-0; Ramirez-Leon V, 1999, EUR J NEUROSCI, V11, P2935, DOI 10.1046/j.1460-9568.1999.00710.x; ROKUTAN K, 1994, AM J PHYSIOL, V266, pG247, DOI 10.1152/ajpgi.1994.266.2.G247; ROMERO FJ, 1984, EXPERIENTIA, V40, P365, DOI 10.1007/BF01952555; ROMERO FJ, 1984, BIOCHEM BIOPH RES CO, V123, P1116, DOI 10.1016/S0006-291X(84)80248-X; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; SCHUPPEKOISTINE.I, 1995, ENDOTHELIUM, V3, P301; SCHUPPEKOISTINEN I, 1994, EUR J BIOCHEM, V221, P1033, DOI 10.1111/j.1432-1033.1994.tb18821.x; TAYLOR CW, 1973, EXP CELL RES, V82, P215, DOI 10.1016/0014-4827(73)90264-4; THOMAS M, 1995, BRIT J CANCER, V72, P45, DOI 10.1038/bjc.1995.275; TIRMENSTEIN MA, 1988, BIOCHEM BIOPH RES CO, V155, P956, DOI 10.1016/S0006-291X(88)80589-8; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956	29	86	88	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2002	16	13					124	+		10.1096/fj.02-0259fje	http://dx.doi.org/10.1096/fj.02-0259fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	632HU	12475911				2022-12-28	WOS:000180218500016
J	Kang, KW; Kim, YG; Cho, MK; Bae, SK; Kim, CW; Lee, MG; Kim, SG				Kang, KW; Kim, YG; Cho, MK; Bae, SK; Kim, CW; Lee, MG; Kim, SG			Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation	FASEB JOURNAL			English	Article						liver cirrhosis; C/EBP; TGF-beta 1	PRIMARY BILIARY-CIRRHOSIS; URSODEOXYCHOLIC-ACID THERAPY; HEPATOCYTE GROWTH-FACTOR; REPUBLIC-OF-CHINA; RAT-LIVER; 5-(2-PYRAZINYL)-4-METHYL-1,2-DITHIOL-3-THIONE OLTIPRAZ; TRANSFORMING GROWTH-FACTOR-BETA-1; HEPATIC-FIBROSIS; GENE-EXPRESSION; COLLAGEN GENE	Liver cirrhosis (LC) is a chronic disease with high mortality rate. In the United States and Western world as well as Asian countries, LC is the major leading cause of death by disease. Yet, no effective therapeutic agent is available for LC treatment. Laboratory cirrhotic rats produced by dimethylnitrosamine administrations simulate the clinical features of human LC such as mortality, ascites, hepatic parenchymal cell destruction, and formation of connective tissue and nodular regeneration, providing a preclinical model to evaluate therapeutic efficacy of drugs and the underlying mechanisms. Oltipraz [5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione] has been used clinically and is of little toxicity. Comprehensive mechanistic and phase IIa clinical studies supported the notion that oltipraz exerts chemopreventive effects against chemical carcinogenesis. We report here that oltipraz within the clinical dose range regenerates cirrhotic liver in the established LC rats as a result of reduction of the intensities of cirrhotic nodules, elimination of accumulated extracellular matrix, and inactivation of stellate cells, thereby improving survival rate. We also reveal that activation of CCAAT/enhancer binding protein by oltipraz inhibits transforming growth factor beta1 gene expression in stellate cells, which provides a molecular target for pharmacological treatment of LC. Oltipraz is the first therapeutic agent that regenerates cirrhotic liver.	Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; Seoul Natl Univ, Natl Res Lab, Seoul 151742, South Korea; Hanyang Univ, Sch Med, Dept Clin Pathol, Seoul 133791, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Hanyang University	Kim, SG (corresponding author), Seoul Natl Univ, Coll Pharm, Sillim Dong,Kwanak Gu, Seoul 151742, South Korea.	sgk@snu.ac.kr						Albanis E, 2001, Clin Liver Dis, V5, P315, DOI 10.1016/S1089-3261(05)70168-9; ANSHER SS, 1983, HEPATOLOGY, V3, P932; Baroni GS, 1996, HEPATOLOGY, V23, P1189; BOLTON MG, 1993, CANCER RES, V53, P3499; Chi WJ, 1998, CARCINOGENESIS, V19, P2133, DOI 10.1093/carcin/19.12.2133; CLAPPER ML, 1995, CARCINOGENESIS, V16, P2159, DOI 10.1093/carcin/16.9.2159; Clouthier DE, 1997, J CLIN INVEST, V100, P2697, DOI 10.1172/JCI119815; Corpechot C, 2000, HEPATOLOGY, V32, P1196, DOI 10.1053/jhep.2000.20240; Crowell JA, 1997, FUND APPL TOXICOL, V35, P9, DOI 10.1006/faat.1996.2256; DEBAKEY SF, 1996, 41 NAT I ALC AB ALC; ELTAYEB M, 1988, ANN TROP MED PARASIT, V82, P53; FREIDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1992, HEPATOLOGY, V15, P234, DOI 10.1002/hep.1840150211; George J, 1996, BBA-PROTEIN STRUCT M, V1292, P215, DOI 10.1016/0167-4838(95)00202-2; Goulis J, 1999, LANCET, V354, P1053, DOI 10.1016/S0140-6736(98)11293-X; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; Hautekeete ML, 1997, VIRCHOWS ARCH, V430, P195, DOI 10.1007/BF01324802; HENRIKSEN JH, 1980, SCAND J CLIN LAB INV, V40, P493, DOI 10.3109/00365518009091956; Inagaki Y, 2001, J BIOL CHEM, V276, P16573, DOI 10.1074/jbc.M010485200; Inagaki Y, 2001, J CELL PHYSIOL, V187, P117, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1059>3.0.CO;2-S; Iraburu MJ, 2000, HEPATOLOGY, V31, P1086, DOI 10.1053/he.2000.5981; Jacobson LP, 1997, CANCER EPIDEM BIOMAR, V6, P257; KAKIZOE T, 1999, CANC STAT JAPAN 1999; Kang KW, 2000, MOL PHARMACOL, V58, P1017, DOI 10.1124/mol.58.5.1017; Kang KW, 2002, CHEM-BIOL INTERACT, V139, P61, DOI 10.1016/S0009-2797(01)00286-1; Kensler T W, 1995, J Cell Biochem Suppl, V22, P101; KENSLER TW, 1987, CANCER RES, V47, P4271; Kiiasov A P, 1998, Tsitologiia, V40, P876; Kim SG, 1997, MOL PHARMACOL, V51, P225, DOI 10.1124/mol.51.2.225; Kruse JJM, 1999, CYTOKINE, V11, P179, DOI 10.1006/cyto.1998.0413; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langouet S, 1997, CARCINOGENESIS, V18, P1343, DOI 10.1093/carcin/18.7.1343; Luo JC, 1998, J GASTROEN HEPATOL, V13, P685, DOI 10.1111/j.1440-1746.1998.tb00714.x; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; MATSUZAKI Y, 1990, AM J GASTROENTEROL, V85, P15; Mizuno S, 2000, KIDNEY INT, V57, P937; Moragas A, 1998, ANAL QUANT CYTOL, V20, P169; Nancy V, 1999, J BIOL CHEM, V274, P8737, DOI 10.1074/jbc.274.13.8737; Neuberger J, 2000, HEPATOLOGY, V31, P1027; NOMURA F, 1990, J HEPATOL, V11, P65, DOI 10.1016/0168-8278(90)90273-T; Pares A, 1998, J HEPATOL, V28, P615, DOI 10.1016/S0168-8278(98)80285-7; Pares A, 2000, J HEPATOL, V32, P561, DOI 10.1016/S0168-8278(00)80216-0; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; Pinzani M, 1998, LIVER, V18, P2; PROCHASKA HJ, 1995, MOL PHARMACOL, V48, P15; Qi Z, 1999, P NATL ACAD SCI USA, V96, P2345, DOI 10.1073/pnas.96.5.2345; RAO CV, 1993, CANCER RES, V53, P2502; Skrtic S, 2001, HORM RES, V55, P1, DOI 10.1159/000063454; TSUKAMOTO H, 1990, SEMIN LIVER DIS, V10, P56, DOI 10.1055/s-2008-1040457; Tsukamoto H, 1999, ALCOHOL CLIN EXP RES, V23, P911, DOI 10.1111/j.1530-0277.1999.tb04202.x; Ueki T, 1999, NAT MED, V5, P226, DOI 10.1038/5593; VYBERG M, 1987, ACTA PATH MICRO IM A, V95, P11; Wagner AH, 2000, MOL PHARMACOL, V58, P1333, DOI 10.1124/mol.58.6.1333; Wang JS, 1999, JNCI-J NATL CANCER I, V91, P347, DOI 10.1093/jnci/91.4.347; WATTENBERG LW, 1986, CARCINOGENESIS, V7, P1379, DOI 10.1093/carcin/7.8.1379; YAMAZAKI H, 1992, CARCINOGENESIS, V13, P979, DOI 10.1093/carcin/13.6.979; YAMAZAKI H, 1992, CARCINOGENESIS, V13, P1789, DOI 10.1093/carcin/13.10.1789; Yao FY, 2001, HEPATOLOGY, V34, P411, DOI 10.1053/jhep.2001.26512; YOON G, 2000, AF249327 GENB; YOON YH, 2001, 57 NAT I ALC AB ALC; Zauberman A, 2001, J BIOL CHEM, V276, P24719, DOI 10.1074/jbc.M005813200	61	74	75	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1988	+		10.1096/fj.02-0406fje	http://dx.doi.org/10.1096/fj.02-0406fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12397085				2022-12-28	WOS:000179167600009
J	Grazide, S; Maestre, N; Veldman, RJ; Bezombes, C; Maddens, S; Levade, T; Laurent, G; Jaffrezou, JP				Grazide, S; Maestre, N; Veldman, RJ; Bezombes, C; Maddens, S; Levade, T; Laurent, G; Jaffrezou, JP			Ara-C- and daunorubicin-induced recruitment of Lyn in sphingomyelinase-enriched membrane rafts	FASEB JOURNAL			English	Article						1-beta-D-arabinofuranosylcytosine; ceramide; apoptosis; Lyn kinase	INTERNUCLEOSOMAL DNA FRAGMENTATION; NEUTRAL SPHINGOMYELINASE; TYROSINE PHOSPHORYLATION; CERAMIDE GENERATION; INDUCED APOPTOSIS; PROTEIN; 1-BETA-D-ARABINOFURANOSYLCYTOSINE; KINASE; ASSOCIATION; HYDROLYSIS	Induction of apoptosis by DNA-damaging agents such as 1-beta-D-arabinofuranosylcytosine (AraC) includes the activation of Lyn protein tyrosine kinase. We have previously established that Ara-C-induced activation of Lyn results in its binding to a neutral sphingomyelinase (SMase) and is requisite for its stimulation and the induction of apoptosis in U937 cells. However, the spacio-temporal organization of these events is unclear. This study demonstrates that part of the total cellular SMase activity is sequestered in sphingomyelin-enriched plasma membrane microdomains (rafts). Under Ara-C and daunorubicin (DNR) treatment, Lyn is rapidly activated and translocated into rafts. The compartmentalization of Lyn (as well as neutral SMase activation and apoptosis) induced by these drugs was blocked by the tyrosine kinase inhibitor herbimycin A and raft disruption. In conclusion, this study establishes that DNA-damaging agents such as AraC and DNR rapidly induce Lyn activation and its translocation into membrane rafts. This in turn leads to neutral SMase activation and raft-associated sphingomyelin hydrolysis with the concomitant generation of the proapoptotic lipid second messenger, ceramide. The apparent topological partitioning between DNA damage and apoptosis signaling (integrated into specialized plasma membrane domains) is discussed.	Inst Claudius Regaud, INSERM, E9910, F-31052 Toulouse, France; CHU Rangueil, INSERM, U466, Lab Biochim Med, F-31403 Toulouse, France; CHU Purpan, Hematol Serv, F-31059 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Jaffrezou, JP (corresponding author), Inst Claudius Regaud, INSERM, E9910, 20 Rue Pont St Pierre, F-31052 Toulouse, France.	jaffrezou@icr.fnclcc.fr	Levade, Thierry/O-8948-2014; Bezombes, christine/X-8479-2019; Bezombes, Christine/AAC-1724-2020; Bezombes, Christine/G-2743-2017	Bezombes, christine/0000-0003-4079-4872; 				Andrieu N, 1996, EUR J BIOCHEM, V236, P738, DOI 10.1111/j.1432-1033.1996.00738.x; Bettaieb A, 1996, BLOOD, V88, P1465, DOI 10.1182/blood.V88.4.1465.bloodjournal8841465; Bezombes C, 2001, FASEB J, V15, P1583, DOI 10.1096/fj.00-0787fje; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Bodin S, 2001, BIOCHEMISTRY-US, V40, P15290, DOI 10.1021/bi0109313; Bradshaw CD, 1996, BIOCHEM MOL BIOL INT, V40, P709; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHABNER BA, 1989, CANC PRINCIPALS PRAC, P154; CHENG HC, 1991, J BIOL CHEM, V266, P17919; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; FRAM RJ, 1982, CANCER RES, V42, P4050; Genini D, 2000, J BIOL CHEM, V275, P29, DOI 10.1074/jbc.275.1.29; GUNJI H, 1991, CANCER RES, V51, P741; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JAFFREZOU JP, 2002, PHOSPHOLID METABOLIS, V36, P269; Laurent G, 2001, BLOOD, V98, P913, DOI 10.1182/blood.V98.4.913; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; MYERS CE, 1990, CANC CHEMOTHERAPY PR, P356; QuilletMary A, 1996, LEUKEMIA, V10, P417; Sampath D, 2000, CANCER RES, V60, P6408; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; STRUM JC, 1994, J BIOL CHEM, V269, P15493; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; Usami I, 1998, BIOCHEM PHARMACOL, V55, P185, DOI 10.1016/S0006-2952(97)00429-2; Veldman RJ, 2001, BIOCHEM J, V355, P859, DOI 10.1042/bj3550859; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Yoshida K, 2000, MOL CELL BIOL, V20, P5370, DOI 10.1128/MCB.20.15.5370-5380.2000; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P1058, DOI 10.1021/bi00003a041	40	37	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1685	+		10.1096/fj.01-0794fje	http://dx.doi.org/10.1096/fj.01-0794fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206990				2022-12-28	WOS:000177814000006
J	Yogev-Falach, M; Amit, T; Bar-Am, O; Weinstock, M; Youdim, MBH				Yogev-Falach, M; Amit, T; Bar-Am, O; Weinstock, M; Youdim, MBH			The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline	FASEB JOURNAL			English	Article						alpha-secretase; acetylcholinesterase inhibitors; signal transduction; Alzheimer's disease	ALPHA-SECRETASE CLEAVAGE; OXIDASE-B INHIBITOR; ANTI-PARKINSON DRUG; CLOSED-HEAD INJURY; ALZHEIMERS-DISEASE; BETA-PROTEIN; CONVERTING-ENZYME; BRAIN; PHOSPHORYLATION; RIVASTIGMINE	Two novel neuroprotective cholinesterase (ChE) inhibitors, TV3326, (N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate, and TV3279, (N-propargyl-(3S) aminoindan-5-yl)ethyl methyl carbamate, were derived from rasagiline for the treatment of Alzheimer's disease (AD). TV3326 also inhibits monoamine oxidase (MAO)-A and -B, whereas its S-isomer, TV3279, lacks MAO inhibitory activity. The action of these drugs in the regulation of amyloid precursor protein (APP) processing, using rat PC12 and human SH-SY5Y neuroblastoma cells, was examined. Both isomers stimulated the release of the non-amyloidogenic alpha-secretase form of soluble APP (sAPP) from these cell lines. The increases in sAPP induced by TV3326 and TV3279, were dose-dependent (0.1-100 muM) and blocked by the hydroxamic acid-based metalloprotease inhibitor, Ro31-9790, suggesting mediation via alpha-secretase activity. Using several signal transduction inhibitors, we identified the involvement of protein kinase C (PKC), mitogen-activated protein (MAP) kinase, and tyrosine kinase-dependent pathways in the enhancement of sAPP release by TV3326 and TV3279. In addition, both drugs directly induced the phosphorylation of p44 and p42 MAP kinase, which was abolished by the specific inhibitors of MAP kinase activation, PD98059 and U0126. These data suggest a novel pharmacological mechanism whereby these ChE inhibitors regulate the secretory processes of APP via activation of the MAP kinase pathway.	Technion Israel Inst Technol, Fac Med, Dept Pharmacol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Eve Topf Ctr Neurodegenerat Dis, Haifa, Israel; Technion Israel Inst Technol, Fac Med, NPF Ctr Neurodegenerat Dis, Haifa, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, IL-91010 Jerusalem, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Hebrew University of Jerusalem	Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Pharmacol, POB 9697, IL-31096 Haifa, Israel.	Youdim@tx.technion.ac.il						Abu-Raya S, 1999, J NEUROSCI RES, V58, P456, DOI 10.1002/(SICI)1097-4547(19991101)58:3<456::AID-JNR12>3.0.CO;2-S; ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Bejar C, 1999, EUR J PHARMACOL, V383, P231, DOI 10.1016/S0014-2999(99)00643-3; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DAVIES B, 1993, CANCER RES, V53, P2087; DAVISSALINAS J, 1994, J BIOL CHEM, V269, P22623; Desai A, 2001, Expert Opin Pharmacother, V2, P653, DOI 10.1517/14656566.2.4.653; Desdouits-Magnen J, 1998, J NEUROCHEM, V70, P524; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Finberg J P, 1999, Adv Neurol, V80, P495; Finberg JPM, 1998, NEUROREPORT, V9, P703; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Giacobini E, 1998, NEUROCHEM INT, V32, P413, DOI 10.1016/S0197-0186(97)00124-1; Giacobini E, 1996, ANN NY ACAD SCI, V777, P393, DOI 10.1111/j.1749-6632.1996.tb34451.x; Gouras GK, 2000, P NATL ACAD SCI USA, V97, P1202, DOI 10.1073/pnas.97.3.1202; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; HUNG AY, 1993, J BIOL CHEM, V268, P22959; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Krall WJ, 1999, ANN PHARMACOTHER, V33, P441, DOI 10.1345/aph.18211; Lamb HM, 2001, PHARMACOECONOMICS, V19, P303, DOI 10.2165/00019053-200119030-00008; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LeBlanc AC, 1998, J NEUROSCI, V18, P2907; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; Maruyama W, 2001, ANN NY ACAD SCI, V939, P320; Maruyama W, 2001, J NEUROCHEM, V78, P727, DOI 10.1046/j.1471-4159.2001.00448.x; MARUYAMA W, 2002, IN PRESS NEUROSCI LE; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Meziane H, 1998, P NATL ACAD SCI USA, V95, P12683, DOI 10.1073/pnas.95.21.12683; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Mills J, 1997, J NEUROSCI, V17, P9415; MORI F, 1995, NEUROREPORT, V6, P633, DOI 10.1097/00001756-199503000-00012; Morimoto T, 1998, J NEUROSCI RES, V51, P185, DOI 10.1002/(SICI)1097-4547(19980115)51:2<185::AID-JNR7>3.0.CO;2-9; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; NITSCH RM, 1993, ANN NY ACAD SCI, V695, P122, DOI 10.1111/j.1749-6632.1993.tb23039.x; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Pakaski M, 2001, NEUROCHEM INT, V38, P219, DOI 10.1016/S0197-0186(00)00091-7; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; Racchi M, 1999, J NEUROCHEM, V72, P2464, DOI 10.1046/j.1471-4159.1999.0722464.x; Racchi M, 2001, MOL PSYCHIATR, V6, P520, DOI 10.1038/sj.mp.4000878; Rossner S, 2000, EUR J NEUROSCI, V12, P3191, DOI 10.1046/j.1460-9568.2000.00211.x; Savage MJ, 1998, J NEUROSCI, V18, P1743; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMALL DH, 1994, J NEUROSCI, V14, P2117; Solano DC, 2000, FASEB J, V14, P1015, DOI 10.1096/fasebj.14.7.1015; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Vincent B, 2001, J BIOL CHEM, V276, P37743; Weinstock M, 1999, CNS DRUGS, V12, P307, DOI 10.2165/00023210-199912040-00005; Weinstock M, 2000, DRUG DEVELOP RES, V50, P216, DOI 10.1002/1098-2299(200007/08)50:3/4<216::AID-DDR4>3.3.CO;2-Q; Weinstock M, 2001, ANN NY ACAD SCI, V939, P148; WEINSTOCK M, 2000, J NEURAL TRANSM-SUPP, V60, pS157; WOLF BA, 1995, J BIOL CHEM, V270, P4916, DOI 10.1074/jbc.270.9.4916; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243; Youdim MBH, 2001, CELL MOL NEUROBIOL, V21, P555, DOI 10.1023/A:1015131516649; Youdim MBH, 2001, BRIT J PHARMACOL, V132, P500, DOI 10.1038/sj.bjp.0703826; Youdim MBH, 2001, ANN NY ACAD SCI, V939, P450; YOUDIM MBH, 1999, NEUROSCI LETT, V54, pS45	80	107	111	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10					1674	+		10.1096/fj.02-0198fje	http://dx.doi.org/10.1096/fj.02-0198fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	12206996				2022-12-28	WOS:000177814000010
J	Ishizaka, S; Shiroi, A; Kanda, S; Yoshikawa, M; Tsujinoue, H; Kuriyama, S; Hasuma, T; Nakatani, K; Takahashi, K				Ishizaka, S; Shiroi, A; Kanda, S; Yoshikawa, M; Tsujinoue, H; Kuriyama, S; Hasuma, T; Nakatani, K; Takahashi, K			Development of hepatocytes from embryonic stem cells after transfection with the HNF-3 beta gene	FASEB JOURNAL			English	Article						ES cells; differentiation	LONG-TERM CULTURE; RAT HEPATOCYTES; IN-VITRO; GROWTH-FACTOR; LIVER; TRANSCRIPTION; EXPRESSION; DIFFERENTIATION; ORGANIZATION; MAINTENANCE	We have attempted to generate embryonic stem (ES) cell-derived hepatocytes expressing liver-specific functional properties by use of ES cell technology. It was found that ES cells are allowed to differentiate into hepatocytes possessing high metabolic activities when hepatocyte nuclear factor (HNF)-3beta-transfected ES cells are cultured in alpha-MEM medium supplemented with 10% fetal bovine serum (FBS) and fibroblast growth factor (FGF)-2 in the three-dimensional cell culture system at 5% CO2. The differentiated cells induced albumin, triacylglycerol, urea, and glycogen synthesis as well as further expression of metabolic proteins and serum factors as markers of hepatocytic differentiation for at least 4 months. The cells differentiated from HNF-3beta-transfected ES cells also had hepatocyte-like ultrastructural characteristics, including several endoplasmic reticula, mitochondrion, and glycogen. Our findings indicate that generation of hepatocytes maintaining high metabolic functions developed from mouse ES cells will facilitate the study of the basic mechanism for hepatogenesis and will certainly provide new opportunities for tissue transplantation.	Nara Med Univ, Program Tissue Engn, Kashihara, Nara 6348521, Japan; Nara Med Univ, Dept Parasitol, Kashihara, Nara 6348521, Japan; Nara Med Univ, Dept Internal Med 3, Kashihara, Nara 6348521, Japan; Osaka City Univ, Sch Med, Dept Biochem 2, Osaka 558, Japan; Osaka City Univ, Sch Med, Dept Anat, Osaka 558, Japan; Osaka Prefecture Coll Hlth Sci, Dept Anat & Physiol, Osaka, Japan	Nara Medical University; Nara Medical University; Nara Medical University; Osaka Metropolitan University; Osaka Metropolitan University	Ishizaka, S (corresponding author), Nara Med Univ, Program Tissue Engn, 840 Shijo Cho, Kashihara, Nara 6348521, Japan.	ishizaka@naramed-u.ac.jp						Abe K, 1996, EXP CELL RES, V229, P27, DOI 10.1006/excr.1996.0340; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Chen HL, 1998, J BIOMED SCI, V5, P435, DOI 10.1007/BF02255932; CHEN LH, 1989, ANTICANCER RES, V9, P1069; CHIST B, BIOL CHEM HOPPE SEYL, V371, P395; DEJUAN C, 1992, EXP CELL RES, V202, P495, DOI 10.1016/0014-4827(92)90104-G; DEJUAN C, 1992, J CELL PHYSIOL, V152, P95, DOI 10.1002/jcp.1041520113; DIAMANTSTEIN T, 1982, INT ARCH ALLER A IMM, V68, P377, DOI 10.1159/000233129; DUERDEN JM, 1989, BIOCHEM J, V263, P937, DOI 10.1042/bj2630937; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Funatsu K, 2001, ARTIF ORGANS, V25, P194, DOI 10.1046/j.1525-1594.2001.025003194.x; Glicklis R, 2000, BIOTECHNOL BIOENG, V67, P344, DOI 10.1002/(SICI)1097-0290(20000205)67:3<344::AID-BIT11>3.0.CO;2-2; GUIGUET M, 1987, IN VITRO CELL DEV B, V23, P821; HALLETT CJ, 1971, CLIN CHIM ACTA, V35, P33, DOI 10.1016/0009-8981(71)90289-0; Halpner AD, 1998, ARCH BIOCHEM BIOPHYS, V359, P305, DOI 10.1006/abbi.1998.0914; Hamazaki T, 2001, FEBS LETT, V497, P15, DOI 10.1016/S0014-5793(01)02423-1; Holzinger A, 1998, FEBS LETT, V433, P179, DOI 10.1016/S0014-5793(98)00873-4; INOUE C, 1989, J BIOL CHEM, V264, P4747; Jover R, 1996, MOL PHARMACOL, V50, P474; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Kaibori M, 1998, HEPATOLOGY, V27, P1354, DOI 10.1002/hep.510270523; LANDRY J, 1985, J CELL BIOL, V101, P914, DOI 10.1083/jcb.101.3.914; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; LevinsonDushnik M, 1997, MOL CELL BIOL, V17, P3817, DOI 10.1128/MCB.17.7.3817; Li JX, 2000, GENE DEV, V14, P464; Marc N, 2000, EUR J BIOCHEM, V267, P963, DOI 10.1046/j.1432-1327.2000.01083.x; Mori T, 1997, BIOMATERIALS, V18, P947, DOI 10.1016/S0142-9612(97)00017-3; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Overturf K, 1999, AM J PATHOL, V155, P2135, DOI 10.1016/S0002-9440(10)65531-9; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PRUDDEN JF, 1970, AM J SURG, V119, P560, DOI 10.1016/0002-9610(70)90175-3; Puviani AC, 1999, INT J ARTIF ORGANS, V22, P778, DOI 10.1177/039139889902201112; Ranucci CS, 1999, TISSUE ENG, V5, P407, DOI 10.1089/ten.1999.5.407; ROSENBERG MR, 1982, IN VITRO CELL DEV B, V18, P775; Sakai Y, 1996, CELL TRANSPLANT, V5, pS41, DOI 10.1016/0963-6897(96)00037-1; SCHUDT C, 1979, EUR J BIOCHEM, V97, P155, DOI 10.1111/j.1432-1033.1979.tb13097.x; Shibata Y, 1998, J IMMUNOL, V161, P4283; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SPAYD RW, 1978, CLIN CHEM, V24, P1343; STEWARD AR, 1985, MOL PHARMACOL, V27, P125; TONG JZ, 1992, EXP CELL RES, V200, P326, DOI 10.1016/0014-4827(92)90179-C; VANHARKEN DR, 1969, J BIOL CHEM, V244, P2278; Wang Q, 1998, AM J PHYSIOL-REG I, V275, pR1584, DOI 10.1152/ajpregu.1998.275.5.R1584; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Yanagi K, 1998, ASAIO J, V44, pM436, DOI 10.1097/00002480-199809000-00022; Zaret KS, 2000, MECH DEVELOP, V92, P83, DOI 10.1016/S0925-4773(99)00326-3; ZHENG Q, 1990, PEDIATR RES, V32, P714	49	100	117	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1444	+		10.1096/fj.01-0806fje	http://dx.doi.org/10.1096/fj.01-0806fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205042	Bronze			2022-12-28	WOS:000177813100017
J	Piccioni, F; Pinton, P; Simeoni, S; Pozzi, P; Fascio, U; Vismara, G; Martini, L; Rizzuto, R; Poletti, A				Piccioni, F; Pinton, P; Simeoni, S; Pozzi, P; Fascio, U; Vismara, G; Martini, L; Rizzuto, R; Poletti, A			Androgen receptor with elongated polyglutamine tract forms aggregates that alter axonal trafficking and mitochondrial distribution in motoneuronal processes	FASEB JOURNAL			English	Article						triplet repeats; fast axonal transport; kinesin; neurodegeneration; spinal bulbar muscular atrophy	BULBAR MUSCULAR-ATROPHY; NEURONAL INTRANUCLEAR INCLUSIONS; EXPANDED-POLYGLUTAMINE; HUNTINGTONS-DISEASE; TRANSGENIC MICE; NUCLEAR INCLUSIONS; CAG REPEAT; CELL-DEATH; NEURODEGENERATIVE DISEASES; 5-ALPHA-REDUCTASE TYPE-2	The CAG/polyglutamine (polyGln)-related diseases include nine different members that together form the most common class of inherited neurodegenerative disorders; neurodegeneration is linked to the same type of mutation, found in unrelated genes, consisting of an abnormal expansion of a polyGln tract normally present in the wild-type proteins. Nuclear, cytoplasmic, or neuropil aggregates are detectable in CAG/polyGln-related diseases, but their role is still debated. Alteration of the androgen receptor (AR), one of these proteins, has been linked to spinal and bulbar muscular atrophy, an X-linked recessive disease characterized by motoneuronal death. By using immortalized motoneuronal cells (the neuroblastoma-spinal cord cell line NSC34), we analyzed neuropil aggregate formation and toxicity: green fluorescent protein-tagged wild-type or mutated ARs were cotransfected into NSC34 cells with a blue fluorescent protein tagged to mitochondria. Altered mitochondrial distribution was observed in neuronal processes containing aggregates; occasionally, neuropil aggregates and mitochondrial concentration corresponded to axonal swelling. Neuropil aggregates also impaired the distribution of the motor protein kinesin. These data suggest that neuropil aggregates may physically alter neurite transport and thus deprive neuronal processes of factors or components that are important for axonal and dendritic functions. The soma may then be affected, leading to neuronal dysfunctions and possibly to cell death.	Univ Milan, Ctr Excellence Study Treatment Neurodegenerat Dis, Ist Endocrinol, I-20133 Milan, Italy; Univ Ferrara, ICSI, I-44100 Ferrara, Italy; Univ Ferrara, TCCI, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Univ Milan, Dept Biol, Sect Zool, I-20133 Milan, Italy; Univ Milan, Interdisciplinary Ctr Adv Microscopy, I-20133 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Milan; University of Ferrara; University of Ferrara; University of Milan; University of Milan	Poletti, A (corresponding author), Univ Milan, Ctr Excellence Study Treatment Neurodegenerat Dis, Ist Endocrinol, Via Balzaretti 9, I-20133 Milan, Italy.	Angelo.Poletti@unimi.it	Poletti, Angelo/A-9016-2011; Pinton, Paolo/J-8025-2012; Rizzuto, Rosario/B-6312-2008	Poletti, Angelo/0000-0002-8883-0468; Pinton, Paolo/0000-0001-7108-6508; Rizzuto, Rosario/0000-0001-7044-5097	Telethon [1283] Funding Source: Medline	Telethon(Fondazione Telethon)		Abdullah AAR, 1998, HUM MOL GENET, V7, P379, DOI 10.1093/hmg/7.3.379; Adachi H, 2001, HUM MOL GENET, V10, P1039, DOI 10.1093/hmg/10.10.1039; Altschuler EL, 1997, J PEPT RES, V50, P73; Andrew SE, 1997, HUM MOL GENET, V6, P2005, DOI 10.1093/hmg/6.12.2005; Brooks BP, 1997, NEUROBIOL DIS, V3, P313, DOI 10.1006/nbdi.1997.0126; Butler R, 1998, HUM MOL GENET, V7, P121, DOI 10.1093/hmg/7.1.121; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; Cattaneo E, 2001, TRENDS NEUROSCI, V24, P182, DOI 10.1016/S0166-2236(00)01721-5; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; Choong CS, 1998, J MOL ENDOCRINOL, V21, P235, DOI 10.1677/jme.0.0210235; Cooper JK, 1998, HUM MOL GENET, V7, P783, DOI 10.1093/hmg/7.5.783; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Davies SW, 1998, LANCET, V351, P131, DOI 10.1016/S0140-6736(97)08360-8; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DURHAM HD, 1993, NEUROTOXICOLOGY, V14, P387; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Fischbeck KH, 2001, BRAIN RES BULL, V56, P161, DOI 10.1016/S0361-9230(01)00577-9; Fischbeck KH, 1997, J INHERIT METAB DIS, V20, P152, DOI 10.1023/A:1005344403603; Gallo JM, 2001, BRAIN RES BULL, V56, P209, DOI 10.1016/S0361-9230(01)00575-5; Gao TS, 1996, J STEROID BIOCHEM, V59, P9, DOI 10.1016/S0960-0760(96)00097-0; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; HARRY GJ, 1992, MOL NEUROBIOL, V6, P203; Hirakura Y, 2000, J NEUROSCI RES, V60, P490, DOI 10.1002/(SICI)1097-4547(20000515)60:4<490::AID-JNR7>3.0.CO;2-9; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hurd DD, 1996, GENETICS, V144, P1075; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Jones AL, 1997, J INHERIT METAB DIS, V20, P125, DOI 10.1023/A:1005340302695; KAZEMIESFARJANI P, 1995, HUM MOL GENET, V4, P523, DOI 10.1093/hmg/4.4.523; KENNEDY WR, 1968, NEUROLOGY, V18, P671, DOI 10.1212/WNL.18.7.671; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; LASPADA AR, 1992, NAT GENET, V2, P301, DOI 10.1038/ng1292-301; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; Li H, 1999, HUM MOL GENET, V8, P1227, DOI 10.1093/hmg/8.7.1227; Li I, 1998, AM J PATHOL, V153, P695, DOI 10.1016/S0002-9440(10)65612-X; Li M, 1998, ANN NEUROL, V44, P249, DOI 10.1002/ana.410440216; Lieberman AP, 1998, LANCET, V351, P884, DOI 10.1016/S0140-6736(05)70296-8; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Merry DE, 2001, BRAIN RES BULL, V56, P203, DOI 10.1016/S0361-9230(01)00594-9; Merry DE, 1998, HUM MOL GENET, V7, P693, DOI 10.1093/hmg/7.4.693; MHATRE AN, 1993, NAT GENET, V5, P184, DOI 10.1038/ng1093-184; Monoi H, 2000, BIOPHYS J, V78, P2892, DOI 10.1016/S0006-3495(00)76830-5; Morrison PJ, 1998, CLIN GENET, V53, P276; Moulder KL, 1999, J NEUROSCI, V19, P705; Nagai Y, 1999, ANN NY ACAD SCI, V893, P192, DOI 10.1111/j.1749-6632.1999.tb07826.x; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; Onodera O, 1997, BIOCHEM BIOPH RES CO, V238, P599, DOI 10.1006/bbrc.1997.7337; Ordway JM, 1997, CELL, V91, P753, DOI 10.1016/S0092-8674(00)80464-X; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Paulson HL, 1999, AM J HUM GENET, V64, P339, DOI 10.1086/302269; PERUTZ M, 1994, PROTEIN SCI, V3, P1629, DOI 10.1002/pro.5560031002; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Piccioni F, 2001, BRAIN RES BULL, V56, P215, DOI 10.1016/S0361-9230(01)00652-9; Poletti A, 1998, ENDOCRINOLOGY, V139, P2171, DOI 10.1210/en.139.4.2171; Poletti A, 2001, J NEUROENDOCRINOL, V13, P353, DOI 10.1046/j.1365-2826.2001.00635.x; POLETTI A, 1999, RRD NEUROCHEMISTRY 2, V2, P507; Rigamonti D, 2001, J BIOL CHEM, V276, P14545, DOI 10.1074/jbc.C100044200; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Sculptoreanu A, 2000, MOL CELL BIOCHEM, V203, P23, DOI 10.1023/A:1007010020228; Simeoni S, 2000, HUM MOL GENET, V9, P133, DOI 10.1093/hmg/9.1.133; Singhrao SK, 1998, EXP NEUROL, V150, P213, DOI 10.1006/exnr.1998.6778; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; SOBUE G, 1989, BRAIN, V112, P209, DOI 10.1093/brain/112.1.209; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Toyoshima I, 1998, J NEUROL SCI, V159, P38, DOI 10.1016/S0022-510X(98)00137-3; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553; Yagishita S, 1997, PATHOL INT, V47, P1, DOI 10.1111/j.1440-1827.1997.tb04429.x; Zhang B, 1997, J CELL BIOL, V139, P1307, DOI 10.1083/jcb.139.5.1307; Zhao C, 2001, CELL, V105, P587, DOI 10.1016/S0092-8674(01)00363-4; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	79	88	91	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2002	16	9					1418	+		10.1096/fj.01-1035fje	http://dx.doi.org/10.1096/fj.01-1035fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HH	12205033	Bronze			2022-12-28	WOS:000177813100010
J	Martinez-Chantar, ML; Corrales, FJ; Martinez-Cruz, LA; Garcia-Trevijano, ER; Huang, ZZ; Chen, LX; Kanel, G; Avila, MA; Mato, JM; Lu, SC				Martinez-Chantar, ML; Corrales, FJ; Martinez-Cruz, LA; Garcia-Trevijano, ER; Huang, ZZ; Chen, LX; Kanel, G; Avila, MA; Mato, JM; Lu, SC			Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A	FASEB JOURNAL			English	Article						S-adenosylmethionine; cytochrome P450 2E1; hepatocellular carcinoma; CCl4-induced hepatotoxicity	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; S-ADENOSYLMETHIONINE; RAT-LIVER; GLUTATHIONE SYNTHESIS; UNCOUPLING PROTEIN-2; CYTOCHROME-P450 2E1; GENE-EXPRESSION; HEPG2 CELLS; CYP2E1; HEPATOCYTES	In mammals, methionine metabolism occurs mainly in the liver via methionine adenosyltransferase-catalyzed conversion to S-adenosylmethionine. Of the two genes that encode methionine adenosyltransferase(MAT1A and MAT2A), MAT1A is mainly expressed in adult liver whereas MAT2A is expressed in all extrahepatic tissues. Mice lacking MAT1A have reduced hepatic S-adenosylmethionine content and hyperplasia and spontaneously develop nonalcoholic steatohepatitis. In this study, we examined whether chronic hepatic S-adenosylmethionine deficiency generates oxidative stress and predisposes to injury and malignant transformation. Differential gene expression in MAT1A knockout mice was analyzed following the criteria of the Gene Ontology Consortium. Susceptibility of MAT1A knockout mice to CCl4-induced hepatotoxicity and malignant transformation was determined in 3- and 18-month-old mice, respectively. Analysis of gene expression profiles revealed an abnormal expression of genes involved in the metabolism of lipids and carbohydrates in MAT1A knockout mice, a situation that is reminiscent of that found in diabetes, obesity, and other conditions associated with nonalcoholic steatohepatitis. This aberrant expression of metabolic genes in the knockout mice was associated with hyperglycemia, increased hepatic CYP2E1 and UCP2 expression and triglyceride levels, and reduced hepatic glutathione content. The knockout animals have increased lipid peroxidation and enhanced sensitivity to CCl4-induced liver damage, which was largely due to increased CYP2E1 expression because diallyl sulfide, an inhibitor of CYP2E1, prevented CCl4-induced liver injury. Hepatocellular carcinoma developed in more than half of the knockout mice by 18 months of age. Taken together, our findings define a critical role for S-adenosylmethionine in maintaining normal hepatic function and tumorigenesis of the liver.	Univ Navarra, Fac Med, Sch Med,Dept Med, Div Hepatol & Gene Therapy, Pamplona 31008, Spain; Univ So Calif, UCLA Res Ctr Alcohol Liver & Pancreat Dis, USC Liver Dis Res Ctr,USC Sch Med, Div Gastroenterol & Liver Dis, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA	University of Navarra; University of Southern California; University of Southern California	Mato, JM (corresponding author), Univ Navarra, Fac Med, Sch Med,Dept Med, Div Hepatol & Gene Therapy, Edificio Los Castanos, Pamplona 31008, Spain.	jmmato@unav.es; shellylu@hsc.usc.edu	Ruiz García-Trevijano, Elena R./ABE-1014-2021; Avila, Matias A/Y-6342-2019; Martinez-Cruz, Luis Alfonso/G-2285-2011; Mato, Jose/A-5187-2011; Martinez Chantar, Maria Luz/F-5190-2011	Ruiz García-Trevijano, Elena R./0000-0002-3985-1270; Avila, Matias A/0000-0001-6570-3557; Martinez-Cruz, Luis Alfonso/0000-0002-5856-9377; Mato, Jose/0000-0003-1264-3153; Lu, Shelly/0000-0003-2128-5407; Martinez Chantar, Maria Luz/0000-0002-6446-9911; Corrales, Fernando/0000-0002-0231-5159				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Avila MA, 2000, J HEPATOL, V33, P907, DOI 10.1016/S0168-8278(00)80122-1; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cai JX, 1998, CANCER RES, V58, P1444; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; Carrington DB, 1998, ENVIRON ST, V2, P55; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; CHEN LS, 1994, BIOCHEM PHARMACOL, V48, P2199, DOI 10.1016/0006-2952(94)00435-8; CORRALES F, 1992, HEPATOLOGY, V16, P1022, DOI 10.1002/hep.1840160427; Cortez-Pinto H, 1999, GASTROENTEROLOGY, V116, P1184, DOI 10.1016/S0016-5085(99)70022-3; DAVIS JF, 1993, J BIOL CHEM, V268, P16584; Enriquez A, 1999, BIOCHEM BIOPH RES CO, V255, P300, DOI 10.1006/bbrc.1999.0202; GARCEA R, 1989, CANCER RES, V49, P1850; Garcia-Trevijano ER, 2000, FASEB J, V14, P2511, DOI 10.1096/fj.00-0121com; Garcia-Trevijano ER, 2002, GASTROENTEROLOGY, V122, P1355, DOI 10.1053/gast.2002.33020; Gerard-Monnier D, 1998, CHEM RES TOXICOL, V11, P1176, DOI 10.1021/tx9701790; Huang ZZ, 2000, BBA-GENE STRUCT EXPR, V1493, P48, DOI 10.1016/S0167-4781(00)00156-1; Huang ZZ, 2001, FASEB J, V15, P19, DOI 10.1096/fj.00-0445fje; Kim ND, 1997, BIOCHEM PHARMACOL, V53, P261, DOI 10.1016/S0006-2952(96)00647-8; KINSELL LW, 1947, SCIENCE, V106, P589, DOI 10.1126/science.106.2763.589; LATASA MU, 2001, FASEB J, DOI DOI 10.1096/FJ.00-0056FJE; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; LU SC, 1994, BIOCHEM PHARMACOL, V47, P859, DOI 10.1016/0006-2952(94)90486-3; Lu SC, 1999, HEPATOLOGY, V30, P209, DOI 10.1002/hep.510300134; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Lu SC, 2001, P NATL ACAD SCI USA, V98, P5560, DOI 10.1073/pnas.091016398; Majano PL, 2001, J HEPATOL, V35, P692, DOI 10.1016/S0168-8278(01)00208-2; Mari M, 2001, J BIOMED SCI, V8, P52, DOI 10.1159/000054013; Mari R, 2000, J BIOL CHEM, V275, P15563; MARTINDUCE C, 1988, HEPATOLOGY, V8, P65; Mato JM, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P47; Newberne P M, 1986, Adv Exp Med Biol, V206, P223; REINKE LA, 1985, DRUG METAB DISPOS, V13, P548; Robertson Graham, 2001, American Journal of Physiology, V281, pG1135; SHIVAPURKAR N, 1983, CARCINOGENESIS, V4, P1051, DOI 10.1093/carcin/4.8.1051; Weltman MD, 1996, GASTROENTEROLOGY, V111, P1645, DOI 10.1016/S0016-5085(96)70028-8; Wu CC, 2001, FOOD CHEM TOXICOL, V39, P563, DOI 10.1016/S0278-6915(00)00171-X; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799	38	207	216	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2002	16	8					1292	+		10.1096/fj.02-0078fje	http://dx.doi.org/10.1096/fj.02-0078fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	570WR	12060674				2022-12-28	WOS:000176683900036
J	Varani, K; Abbracchio, MP; Cannella, M; Cislaghi, G; Giallonardo, P; Mariotti, C; Cattabriga, E; Cattabeni, F; Borea, PA; Squitieri, F; Cattaneo, E				Varani, K; Abbracchio, MP; Cannella, M; Cislaghi, G; Giallonardo, P; Mariotti, C; Cattabriga, E; Cattabeni, F; Borea, PA; Squitieri, F; Cattaneo, E			Aberrant A(2A) receptor function in peripheral blood cells in Huntington's disease	FASEB JOURNAL			English	Article						A(2A) adenosine receptor; blood circulating cells; Huntington's disease; biomarker	ADENOSINE RECEPTORS; LIGAND-BINDING; BIOCHEMICAL-CHARACTERIZATION; NEURODEGENERATIVE DISEASE; MEMBRANES; LYMPHOCYTES; MECHANISM; STRIATUM; SYSTEMS; MODELS	A(2A) adenosine receptors specifically found on striatal medium spiny neurons play a major role in sensory motor function and may also be involved in neuropsychiatric and neurodegenerative disorders. One hypothesis concerning Huntington's disease (HD) proposes that an imbalance of the cortico-striatal pathway, due to the mutation in the HD gene, leads to striatal vulnerability. An A(2A) receptor dysfunction has been previously demonstrated in striatal cells engineered to express mutant huntingtin. Here we tested whether a similar dysfunction (i.e., the binding and functional parameters of A(2A) adenosine receptors) is present in peripheral blood cells (platelets, lymphocytes, and neutrophils) of subjects carrying the mutant gene. This study involved 48 heterozygous and three homozygous patients compared with 58 healthy subjects. Moreover, we selected seven at-risk mutation carriers. A(2A) receptor density and function are substantially increased in peripheral blood cells from both patients and subjects at the presymptomatic stage. In the neutrophils of the three homozygous HD subjects receptor dysfunction was higher than in heterozygotes. These data indicate the existence of an aberrant A(2A) receptor phenotype in the peripheral blood cells of subjects carrying the HD mutation. Future studies will assess whether this parameter can be exploited as a peripheral biomarker of Huntington's disease.	IRCCS Neuromed, Neurogenet Unit, I-86077 Pozzilli, IS, Italy; Univ Ferrara, Dept Clin & Expt Med, Pharmacol Unit, I-44100 Ferrara, Italy; Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy; Fornaroli Hosp, Neurol Sect, Magenta, MI, Italy; IRCCS C Besta, Neurogenet Sect, Milan, Italy	IRCCS Neuromed; University of Ferrara; University of Milan; University of Milan	Squitieri, F (corresponding author), IRCCS Neuromed, Neurogenet Unit, Local Camerelle, I-86077 Pozzilli, IS, Italy.	neurogen@neuromed.it; elena.cattaneo@unimi.it	Squitieri, Ferdinando/N-1852-2019; Cannella, Milena/G-8291-2011; Mariotti, Caterina/AAP-9425-2021; Abbracchio, Maria Pia/B-9342-2014	Squitieri, Ferdinando/0000-0002-7397-1727; Mariotti, Caterina/0000-0003-2405-3564; Abbracchio, Maria Pia/0000-0002-7833-3388; CANNELLA, Milena/0000-0001-6284-9374; CATTANEO, ELENA/0000-0002-0755-4917	Telethon [GGP02185] Funding Source: Medline	Telethon(Fondazione Telethon)		Abbracchio MP, 1999, ANN NY ACAD SCI, V890, P79, DOI 10.1111/j.1749-6632.1999.tb07983.x; Barbanti P, 2000, CEPHALALGIA, V20, P15, DOI 10.1046/j.1468-2982.2000.00001.x; BENJAMIN CM, 1994, AM J HUM GENET, V55, P606; BLUM D, 2003, LANCET, V362, P366; Cannella M, 2001, NEUROL SCI, V22, P55, DOI 10.1007/s100720170044; Cattaneo E, 2001, TRENDS NEUROSCI, V24, P182, DOI 10.1016/S0166-2236(00)01721-5; Cha JHJ, 1999, PHILOS T R SOC B, V354, P981, DOI 10.1098/rstb.1999.0449; Di Luca M, 1998, ARCH NEUROL-CHICAGO, V55, P1195, DOI 10.1001/archneur.55.9.1195; Draper N.R., 1998, APPL REGRESSION ANAL, P79; FERRE S, 1993, J NEUROSCI, V13, P5402, DOI 10.1523/JNEUROSCI.13-12-05402.1993; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; Gusella JF, 2000, NAT REV NEUROSCI, V1, P109, DOI 10.1038/35039051; Ilani T, 2001, P NATL ACAD SCI USA, V98, P625, DOI 10.1073/pnas.021535398; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P456, DOI 10.1016/S0165-6147(97)90683-0; Kieburtz K, 1996, MOVEMENT DISORD, V11, P136, DOI 10.1002/mds.870110204; Lawrence AD, 1998, BRAIN, V121, P1343, DOI 10.1093/brain/121.7.1343; Lin CH, 2001, HUM MOL GENET, V10, P137, DOI 10.1093/hmg/10.2.137; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MAGGI R, 1993, PHARMACOL RES, V28, P351, DOI 10.1006/phrs.1993.1137; MARTINEZMIR MI, 1991, NEUROSCIENCE, V42, P697, DOI 10.1016/0306-4522(91)90038-P; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PARSONS B, 1995, J NEUROCHEM, V65, P2057; Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002; Rovati GE, 1998, TRENDS PHARMACOL SCI, V19, P365; Rubinsztein DC, 2002, TRENDS GENET, V18, P202, DOI 10.1016/S0168-9525(01)02625-7; Seubert CN, 2000, ANESTHESIOLOGY, V92, P567, DOI 10.1097/00000542-200002000-00041; Sipione S, 2001, MOL NEUROBIOL, V23, P21; Squitieri F, 2001, BRAIN RES BULL, V56, P233, DOI 10.1016/S0361-9230(01)00648-7; SQUITIERI F, 1994, HUM MOL GENET, V3, P2103, DOI 10.1093/hmg/3.12.2103; Squitieri F, 2003, BRAIN, V126, P946, DOI 10.1093/brain/awg077; Ujfalusi A, 1998, LIFE SCI, V64, pPL19, DOI 10.1016/S0024-3205(98)00547-5; Varani K, 2000, MOL PHARMACOL, V57, P968; Varani K, 1998, BRIT J PHARMACOL, V123, P1723, DOI 10.1038/sj.bjp.0701758; Varani K, 1996, BRIT J PHARMACOL, V117, P1693, DOI 10.1111/j.1476-5381.1996.tb15341.x; Varani K, 1999, BRIT J CLIN PHARMACO, V47, P167, DOI 10.1046/j.1365-2125.1999.00866.x; Varani K, 2003, FASEB J, V17, P2148, DOI 10.1096/fj.03-0079fje; Varani K, 2001, FASEB J, V15, P1245, DOI 10.1096/fj.00-0730fje; Varani K, 1997, BRIT J PHARMACOL, V122, P386, DOI 10.1038/sj.bjp.0701378; Vonsattel JPG, 1998, J NEUROPATH EXP NEUR, V57, P369	39	122	126	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2148	+		10.1096/fj.03-0079fje	http://dx.doi.org/10.1096/fj.03-0079fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958155				2022-12-28	WOS:000185925100018
J	Nahoum, V; Gangloff, A; Shi, R; Lin, SX				Nahoum, V; Gangloff, A; Shi, R; Lin, SX			How estrogen-specific proteins discriminate estrogens from androgens: A common steroid-binding site architecture	FASEB JOURNAL			English	Article						"sandwich-like" structure; estrogen-specific; estrogen receptor; 17 beta-HSD1; estrogen sulfotransferase; convergent evolution	HUMAN 17-BETA-HYDROXYSTEROID DEHYDROGENASE; CRYSTAL-STRUCTURE; HUMAN-BREAST; ESTRADIOL; RECEPTOR; CANCER; C-19-DELTA-5-STEROIDS; 17-BETA-ESTRADIOL; SULFOTRANSFERASE; INTRACRINOLOGY	Steroid hormones play an essential role in a wide range of physiological and pathological processes, such as growth, metabolism, aging, and hormone-sensitive cancers. Estrogens are no exception and influence growth, differentiation, and functioning of many target tissues, such as the mammary gland, uterus, hypothalamus, pituitary, bone, and liver. Although very similar in structure, each steroid class (i.e., estrogens, androgens, progestins, mineral corticoids, or glucocorticoids) is responsible for distinct physiological processes. To permit specific biological responses for a given steroid class, specific proteins are responsible for steroid bioactivation, action, and inactivation, yet they have low or no affinity to other classes. Estrogens make no exception and possess their own set of related proteins. To understand the molecular basis underlying estrogen recognition from other steroids, structural features of estrogen-specific proteins were analyzed along with their ability to discriminate between steroid hormones belonging to different classes. Hence, the study of all estrogen-specific proteins for which an atomic structure has been determined demonstrated that a common steroid-binding pocket architecture is shared by these proteins. This architecture is composed of the following elements: i) a glutamate residue acting as a proton acceptor coupled with a proton donor that interact with the steroid O3; ii) a proton donor (His or Ser) that interacts with O17; iii) a highly conserved sandwich-like structure providing steric hindrance and preventing C19 steroid from binding; and iv) several amino acid residues interacting with the C18. As these different estrogen-specific proteins are not related in overall sequence, the inference is that the steroid binding site in these proteins has originated by convergent evolution.	CHU Laval, Res Ctr, Oncol & Mol Endocrinol Res Ctr, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Quebec City, PQ, Canada	Laval University; Laval University	Lin, SX (corresponding author), CHU Laval, Res Ctr, Oncol & Mol Endocrinol Res Ctr, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	sxlin@crchul.ulaval.ca		Gangloff, Anne/0000-0002-6848-6559; Nahoum, Virginie/0000-0003-3125-6618; Lin, Sheng-Xiang/0000-0001-9149-375X				AAKVAAG A, 1990, CANCER RES, V50, P7806; ADAMS JB, 1985, MOL CELL ENDOCRINOL, V41, P1, DOI 10.1016/0303-7207(85)90138-8; Azzi A, 1996, NAT STRUCT BIOL, V3, P665, DOI 10.1038/nsb0896-665; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622; Ekena K, 1998, J BIOL CHEM, V273, P693, DOI 10.1074/jbc.273.2.693; Gangloff A, 2002, FASEB J, V16, P274, DOI 10.1096/fj.02-0397fje; Gangloff A, 2001, BIOCHEM J, V356, P269, DOI 10.1042/0264-6021:3560269; Han Q, 2000, J BIOL CHEM, V275, P1105, DOI 10.1074/jbc.275.2.1105; Huang YW, 2001, MOL ENDOCRINOL, V15, P2010, DOI 10.1210/me.15.11.2010; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Katzenellenbogen B S, 1979, Recent Prog Horm Res, V35, P259; KATZENELLENBOGEN BS, 1980, ANNU REV PHYSIOL, V42, P17, DOI 10.1146/annurev.ph.42.030180.000313; LABRIE F, 1991, MOL CELL ENDOCRINOL, V78, pC113, DOI 10.1016/0303-7207(91)90116-A; Lamminmaki U, 2001, J BIOL CHEM, V276, P36687, DOI 10.1074/jbc.M102367200; Mazza C, 1998, J BIOL CHEM, V273, P8145, DOI 10.1074/jbc.273.14.8145; Monnet C, 2002, J MOL BIOL, V315, P699, DOI 10.1006/jmbi.2001.5284; MURDOCK GL, 1988, BIOCHEMISTRY-US, V27, P4452, DOI 10.1021/bi00412a036; Petrotchenko EV, 1999, J BIOL CHEM, V274, P30019, DOI 10.1074/jbc.274.42.30019; POULIN R, 1986, CANCER RES, V46, P4933; Puranen T, 1997, MOL ENDOCRINOL, V11, P77, DOI 10.1210/me.11.1.77; READ LD, 1991, CHARACTERIZATION REG; Sarrel P.M., 1994, SCI MED, V1, P44; Sasano H, 2000, ONCOLOGY-BASEL, V59, P5, DOI 10.1159/000055281; SIMARD J, 1988, MOL CELL ENDOCRINOL, V55, P233, DOI 10.1016/0303-7207(88)90138-4; SIMARD J, 1987, J STEROID BIOCHEM, V26, P539, DOI 10.1016/0022-4731(87)90005-7; Suzuki T, 2000, BRIT J CANCER, V82, P518; Trinh CH, 1997, STRUCTURE, V5, P937, DOI 10.1016/S0969-2126(97)00247-5; Yue W, 1998, CANCER RES, V58, P927	31	36	36	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1334	+		10.1096/fj.02-0524fje	http://dx.doi.org/10.1096/fj.02-0524fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759331				2022-12-28	WOS:000183165000013
J	Plat, J; Mensink, RP				Plat, J; Mensink, RP			Increased intestinal ABCA1 expression contributes to the decrease in cholesterol absorption after plant stanol consumption	FASEB JOURNAL			English	Article						sitostanol; intestine; LXR; cholesterol transport	BETA-SITOSTEROL; METABOLISM; STEROL; MARGARINES; PATHWAY; MICE; ACCUMULATION; MUTATIONS; EFFLUX	The hypocholesterolemic effect of plant stanols is explained by a decreased intestinal cholesterol absorption due to a competition between plant stanols and cholesterol for incorporation into mixed micelles. Earlier we had suggested that plant stanols have a so far unknown action inside the enterocytes. The recent discovery of the involvement of ATP binding cassette (ABC) transporters in cholesterol absorption was a lead to further explore the hypocholesterolemic mechanism of plant stanols. We found that mixed micelles enriched with sitostanol or with cholesterol plus sitostanol were potent inducers of ABCA1 expression in caco-2 cells, an accepted model to study human intestinal lipoprotein metabolism. Based on these findings, we now hypothesize that plant stanols- and possibly plant sterols-increase ABCA1-mediated cholesterol efflux back into the intestinal lumen. We further hypothesize that intracellular levels of plant stanols are monitored by the same sensors (SREBP-2 and LXR) as those that monitor cholesterol. Consequently, increased plant stanol levels within the enterocyte activate cholesterol efflux through ABCA1- but not SREBP-2-mediated endogenous cholesterol synthesis even if intracellular cholesterol concentrations are lowered through consumption of plant stanols. If our hypothesis is correct, then the LXR pathway may be a target for dietary regulation of intestinal lipid metabolism.	Maastricht Univ, Dept Human Biol, NL-6200 MD Maastricht, Netherlands	Maastricht University	Plat, J (corresponding author), Maastricht Univ, Dept Human Biol, POB 616, NL-6200 MD Maastricht, Netherlands.	J.Plat@HB.UNIMAAS.NL						Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Christiansen-Weber TA, 2000, AM J PATHOL, V157, P1017, DOI 10.1016/S0002-9440(10)64614-7; Costet P, 2000, J BIOL CHEM, V275, P28240; Dean M, 2001, J LIPID RES, V42, P1007; Drobnik W, 2001, GASTROENTEROLOGY, V120, P1203, DOI 10.1053/gast.2001.23250; Field FJ, 1997, J LIPID RES, V38, P348; FIELD FJ, 1983, J LIPID RES, V24, P409; IKEDA I, 1989, J NUTR SCI VITAMINOL, V35, P361, DOI 10.3177/jnsv.35.361; IKEDA I, 1988, J LIPID RES, V29, P1573; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Law M, 2000, BMJ-BRIT MED J, V320, P861, DOI 10.1136/bmj.320.7238.861; Le Lay S, 2001, J BIOL CHEM, V276, P16904, DOI 10.1074/jbc.M010955200; Lee MH, 2001, CURR OPIN LIPIDOL, V12, P141, DOI 10.1097/00041433-200104000-00007; LEVY E, 1995, FASEB J, V9, P626, DOI 10.1096/fasebj.9.8.7768354; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; PETERSON DW, 1951, P SOC EXP BIOL MED, V78, P143, DOI 10.3181/00379727-78-19002; Plat J, 2000, EUR J CLIN NUTR, V54, P671, DOI 10.1038/sj.ejcn.1601071; Plat J, 2001, METABOLISM, V50, P520, DOI 10.1053/meta.2001.22509; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sierksma A, 1999, BRIT J NUTR, V82, P273, DOI 10.1017/S0007114599001476; SYLVEN C, 1970, SCAND J GASTROENTERO, V5, P57; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Weststrate JA, 1998, EUR J CLIN NUTR, V52, P334, DOI 10.1038/sj.ejcn.1600559	29	176	187	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2002	16	10							UNSP 0892-6638/02/0016-1248	10.1096/fj.01-0718hyp	http://dx.doi.org/10.1096/fj.01-0718hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	590HQ	11772951				2022-12-28	WOS:000177814000034
